PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Ondruschka, B; Pohlers, D; Sommer, G; Schober, K; Teupser, D; Franke, H; Dressler, J				Ondruschka, Benjamin; Pohlers, Dirk; Sommer, Gerald; Schober, Kristin; Teupser, Daniel; Franke, Heike; Dressler, Jan			S100B and NSE as Useful Postmortem Biochemical Markers of Traumatic Brain Injury in Autopsy Cases	JOURNAL OF NEUROTRAUMA			English	Article						NSE; postmortem biochemistry; S100B; survival time; traumatic brain injury	NEURON-SPECIFIC ENOLASE; FIBRILLARY ACIDIC PROTEIN; SERUM S-100B PROTEIN; MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; CHEMISTRY UPDATE; HEAD-INJURY; NEUROENDOCRINE CELLS; MOLECULAR MARKER; DAMAGE	Postmortem analysis of relevant biomarkers might aid in characterizing causes of death and survival times in legal medicine. However, there are still no sufficiently established results of practical postmortem biochemical investigations in cases of traumatic brain injury (TBI). The two biomarkersS100 protein subunit B (S100B) and neuronal specific enolase (NSE)could be of special interest. Therefore, the aim of the present study was to investigate changes in their postmortem levels for further determination of brain damage in TBI. In 17 cases of TBI (average age, 58 years) and in 23 controls with different causes of death (average age, 59 years), serum and cerebrospinal fluid (CSF) samples were analyzed with a chemiluminescence immunoassay for marker expression. An increase in serum S100B, as well as a subsequent decrease after survival times>4 days, were detected in TBI cases (p<0.01). CSF NSE values >6,000ng/mL and CSF S100B levels >10,000ng/mL seem to indicate a TBI survival time of at least 15min (p<0.01). It is of particular interest that CSF S100B levels (p<0.01) and serum S100B levels (p<0.05) as well as CSF NSE values (p<0.01) were significantly higher in TBI cases in comparison to the controls, especially when compared with fatal non-head injuries. In conclusion, the present findings emphasize that S100B and NSE are useful markers in postmortem biochemistry in cases of suspected TBI. Further, S100B may be helpful to estimate the survival time of fatal injuries in legal medicine.	[Ondruschka, Benjamin; Schober, Kristin; Dressler, Jan] Univ Leipzig, Inst Legal Med, D-04109 Leipzig, Germany; [Sommer, Gerald] Univ Leipzig, Innovat Ctr Comp Assisted Surg, D-04109 Leipzig, Germany; [Franke, Heike] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, Fac Med, D-04109 Leipzig, Germany; [Pohlers, Dirk] Klinikum Chemnitz, Ctr Diagnost GmbH, Chemnitz, Germany; [Schober, Kristin] German Airforce Inst Aviat Med, Furstenfeldbruck, Germany; [Teupser, Daniel] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany; [Teupser, Daniel] Univ Munich, Inst Lab Med, Munich, Germany		Ondruschka, B (corresponding author), Univ Leipzig, Inst Legal Med, D-04109 Leipzig, Germany.	benjamin.ondruschka@medizin.uni-leipzig.de					Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BARGER SW, 1992, J BIOL CHEM, V267, P9689; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baydas G, 2003, FREE RADICAL BIO MED, V35, P797, DOI 10.1016/S0891-5849(03)00408-8; Beaudeux JL, 2000, CLIN CHEM, V46, P989; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Casmiro M, 2005, EUR J NEUROL, V12, P369, DOI 10.1111/j.1468-1331.2004.01021.x; COE JI, 1993, AM J FOREN MED PATH, V14, P91, DOI 10.1097/00000433-199306000-00001; Cooper E. H., 1987, LUNG CANCER, V3, P61, DOI DOI 10.1016/S0169-5002(87)80001-6; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAIMOTO H, 1985, LAB INVEST, V52, P257; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Janeczko K., 1991, BRAIN RES, V565, P86; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Li D. R., 2006, LEGAL MED, V8, P78; Li Dong-Ri, 2006, Legal Medicine, V8, P71, DOI 10.1016/j.legalmed.2005.07.004; Li Dong-Ri, 2009, Leg Med (Tokyo), V11 Suppl 1, pS273, DOI 10.1016/j.legalmed.2009.02.042; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; Maeda H, 2011, LEGAL MED-TOKYO, V13, P55, DOI 10.1016/j.legalmed.2010.12.005; Maeda Hitoshi, 2009, Leg Med (Tokyo), V11 Suppl 1, pS46, DOI 10.1016/j.legalmed.2009.01.048; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; MURRAY GI, 1993, J CLIN PATHOL, V46, P993, DOI 10.1136/jcp.46.11.993; Nogami M, 1999, Leg Med (Tokyo), V1, P76, DOI 10.1016/S1344-6223(99)80016-9; Oehmichen Manfred, 2003, Leg Med (Tokyo), V5, P190, DOI 10.1016/S1344-6223(03)00077-4; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; Ohrt-Nissen S, 2011, EMERG MED J, V28, P941, DOI 10.1136/emj.2010.091363; OSUNA E, 1992, FORENSIC SCI INT, V52, P193, DOI 10.1016/0379-0738(92)90107-8; Palmiere C, 2012, INT J LEGAL MED, V126, P199, DOI 10.1007/s00414-011-0614-1; Palmiere C, 2012, INT J LEGAL MED, V126, P187, DOI 10.1007/s00414-011-0625-y; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Raabe A, 2003, CLIN CHEM LAB MED, V41, P700, DOI 10.1515/CCLM.2003.106; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Reali C, 2005, J NEUROSCI RES, V81, P677, DOI 10.1002/jnr.20584; Romero-Aleman MD, 2003, J NEUROBIOL, V57, P54, DOI 10.1002/neu.10258; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schiavi Paolo, 2012, Acta Biomed, V83, P5; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Sen J, 2007, J NEUROSCI RES, V85, P1373, DOI 10.1002/jnr.21211; Sorci G, 2004, J CELL PHYSIOL, V199, P274, DOI 10.1002/jcp.10462; Staffa K, 2012, J NEUROTRAUM, V29, P2716, DOI 10.1089/neu.2011.2246; STEINBERG R, 1983, NEUROCHEM INT, V5, P145, DOI 10.1016/0197-0186(83)90021-9; Steiner J, 2006, J NEUROL NEUROSUR PS, V77, P1284, DOI 10.1136/jnnp.2006.093427; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; SUZUKI F, 1983, J BIOCHEM-TOKYO, V94, P1707; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vasquez M. D., 1995, AM J FOREN MED PATH, V16, P210; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Wojtczak-Soska K, 2010, CARDIOL J, V17, P532; WYLER D, 1994, INT J LEGAL MED, V106, P194, DOI 10.1007/BF01371336; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	81	29	39	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2013	30	22					1862	1871		10.1089/neu.2013.2895			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	243PH	WOS:000326328400004	23796187				2022-02-06	
J	Kellogg, RG; Fontes, RBV; Lopes, DK				Kellogg, Robert G.; Fontes, Ricardo B. V.; Lopes, Demetrius K.			Massive cerebral involvement in fat embolism syndrome and intracranial pressure management Case report	JOURNAL OF NEUROSURGERY			English	Article						cerebral fat embolism; fat embolism syndrome; decompressive hemicraniectomy; traumatic brain injury	DIFFUSION-WEIGHTED MRI; COMPUTED-TOMOGRAPHY; BRAIN; DIAGNOSIS; INJURY; ARTHROPLASTY; FRACTURE; COMA	Fat embolism syndrome (FES) is a common clinical entity that can occasionally have significant neurological sequelae. The authors report a case of cerebral fat embolism and FES that required surgical management of intracranial pressure (ICP). They also discuss the literature as well as the potential need for neurosurgical management of this disease entity in select patients. A 58-year-old woman presented with a seizure episode and altered mental status after suffering a right femur fracture. Head CT studies demonstrated hypointense areas consistent with fat globules at the gray-white matter junction predominantly in the right hemisphere. This CT finding is unique in the literature, as other reports have not included imaging performed early enough to capture this finding. Brain MR images obtained 3 days later revealed T2-hyperintense areas with restricted diffusion within the same hemisphere, along with midline shift and subfalcine herniation. These findings steered the patient to the operating room for decompressive hemicraniectomy. A review of the literature from 1980 to 2012 disclosed 54 cases in 38 reports concerning cerebral fat embolism and FES. Analysis of all the cases revealed that 98% of the patients presented with mental status changes, whereas only 22% had focal signs and/or seizures. A good outcome was seen in 57.6% of patients with coma and/or abnormal posturing on presentation and in 90.5% of patients presenting with mild mental status changes, focal deficits, or seizure. In the majority of cases ICP was managed conservatively with no surgical intervention. One case featured the use of an ICP monitor, while none featured the use of hemicraniectomy.	[Kellogg, Robert G.; Fontes, Ricardo B. V.; Lopes, Demetrius K.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA		Kellogg, RG (corresponding author), 1725 W Harrison St,Ste 855, Chicago, IL 60612 USA.	Robert_Kellogg@Rush.edu	Lopes, Demetrius/AAD-7334-2020	Lopes, Demetrius/0000-0002-6280-0113			ALLARDYCE DB, 1974, J TRAUMA, V14, P955, DOI 10.1097/00005373-197411000-00008; ANEGAWA S, 1991, Neurologia Medico-Chirurgica, V31, P359, DOI 10.2176/nmc.31.359; Babikian VL, 2000, NEUROLOGY, V54, P797, DOI 10.1212/WNL.54.4.797; Barak M, 2008, ANESTH ANALG, V107, P221, DOI 10.1213/ane.0b013e3181770abb; Beretta Luigi, 2008, J Trauma, V65, pE46, DOI 10.1097/01.ta.0000221368.79241.bd; BROOKS RA, 1977, J COMPUT ASSIST TOMO, V1, P487, DOI 10.1097/00004728-197710000-00016; Bulger EM, 1997, ARCH SURG-CHICAGO, V132, P435; Buskens CJ, 2008, MED SCI MONITOR, V14, pCS125; Butteriss DJA, 2006, AM J NEURORADIOL, V27, P620; Chen JJS, 2008, EMERG RADIOL, V15, P187, DOI 10.1007/s10140-007-0664-3; Chrysikopoulos H, 1996, CLIN RADIOL, V51, P728, DOI 10.1016/S0009-9260(96)80248-0; CITERIO G, 1995, INTENS CARE MED, V21, P679, DOI 10.1007/BF01711549; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cox G, 2011, INJURY, V42, pS6, DOI 10.1016/S0020-1383(11)70005-5; Dive AM, 2002, ANESTHESIOLOGY, V96, P1029, DOI 10.1097/00000542-200204000-00037; Duja CM, 2010, BMC EMERG MED, V10, DOI 10.1186/1471-227X-10-18; Eguia P, 2007, J NEUROIMAGING, V17, P78, DOI 10.1111/j.1552-6569.2006.00068.x; ERDEM E, 1993, NEURORADIOLOGY, V35, P199, DOI 10.1007/BF00588493; FABIAN TC, 1993, NEW ENGL J MED, V329, P961, DOI 10.1056/NEJM199309233291313; FINDLAY JM, 1984, CAN MED ASSOC J, V131, P755; Gombar S, 2005, ACTA ANAESTH SCAND, V49, P723, DOI 10.1111/j.1399-6576.2005.00588.x; GOSSLING HR, 1982, CLIN ORTHOP RELAT R, P68; Gregorakos L, 2000, J ACCID EMERG MED, V17, P144; Guillevin R, 2005, ANN NEUROL, V57, P434, DOI 10.1002/ana.20388; GURD AR, 1974, J BONE JOINT SURG BR, VB 56, P408, DOI 10.1302/0301-620X.56B3.408; JACOBSON DM, 1986, NEUROLOGY, V36, P847, DOI 10.1212/WNL.36.6.847; Kamano M, 2001, CLIN ORTHOP RELAT R, P206; KAMENAR E, 1980, STROKE, V11, P477, DOI 10.1161/01.STR.11.5.477; KAWANO Y, 1991, NEURORADIOLOGY, V33, P72, DOI 10.1007/BF00593341; Kim Kyung-Cheon, 2008, Orthopedics, V31, P170, DOI 10.3928/01477447-20080201-15; Kumar S, 2012, NEUROL INDIA, V60, P100, DOI 10.4103/0028-3886.93597; Lee SC, 2012, J ARTHROPLASTY, V27, P409, DOI 10.1016/j.arth.2011.06.013; LEVY D, 1990, CLIN ORTHOP RELAT R, P281; Marshall GB, 2004, CAN J NEUROL SCI, V31, P417, DOI 10.1017/S0317167100003565; Metting Z, 2009, CLIN NEUROL NEUROSUR, V111, P597, DOI 10.1016/j.clineuro.2009.03.005; Meyer N, 2007, J TRAUMA, V63, P1395, DOI 10.1097/01.ta.0000223953.05151.96; Nastanski F, 2005, J TRAUMA, V58, P372, DOI 10.1097/01.TA.0000108996.10785.0B; Parizel PM, 2001, STROKE, V32, P2942, DOI 10.1161/str.32.12.2942; PELL ACH, 1993, J BONE JOINT SURG BR, V75, P921, DOI 10.1302/0301-620X.75B6.8245083; Pfeffer G, 2010, CAN J NEUROL SCI, V37, P128, DOI 10.1017/S0317167100009793; Rughani AI, 2011, NEUROCRIT CARE, V15, P190, DOI 10.1007/s12028-010-9388-4; SAITO A, 1990, NEUROSURGERY, V26, P882, DOI 10.1227/00006123-199005000-00027; SAKAMOTO T, 1983, NEURORADIOLOGY, V24, P283, DOI 10.1007/BF00333182; Sasano N, 2004, CAN J ANAESTH, V51, P875, DOI 10.1007/BF03018883; Satoh H, 1997, J TRAUMA, V43, P345, DOI 10.1097/00005373-199708000-00023; SCHNEIDER RC, 1952, J NEUROSURG, V9, P1, DOI 10.3171/jns.1952.9.1.0001; SCOPA M, 1994, J TRAUMA, V36, P906, DOI 10.1097/00005373-199406000-00030; Simon AD, 2003, AM J NEURORADIOL, V24, P97; Stienen MN, 2012, AM J EMERG MED, V30, DOI 10.1016/j.ajem.2011.02.021; Takahashi M, 1999, J TRAUMA, V46, P324, DOI 10.1097/00005373-199902000-00021; Thaunat O, 2004, PLAST RECONSTR SURG, V113, P2235, DOI 10.1097/01.PRS.0000123627.33690.9E; Ammon JT, 2007, J ARTHROPLASTY, V22, P477, DOI 10.1016/j.arth.2006.03.005; Walshe Criona M, 2007, Crit Care Resusc, V9, P184; Yeon HB, 2003, J ARTHROPLASTY, V18, P113, DOI 10.1054/arth.2003.50003; Yoshida A, 1996, J TRAUMA, V40, P437, DOI 10.1097/00005373-199603000-00019; Zenker FA, 1862, BEITRAIGE NORMALEN P	56	29	31	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2013	119	5					1263	1270		10.3171/2013.7.JNS13363			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	238OB	WOS:000325956200033	23952720				2022-02-06	
J	Lam, TI; Bingham, D; Chang, TJ; Lee, CC; Shi, J; Wang, DM; Massa, S; Swanson, RA; Liu, JL				Lam, Tina I.; Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.; Liu, Jialing			Beneficial Effects of Minocycline and Botulinum Toxin-Induced Constraint Physical Therapy Following Experimental Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						controlled cortical impact; constraint-induced movement therapy (CIMT); botox; rehabilitation; microglia; glial fibrillary acidic protein (GFAP)	INDUCED MOVEMENT THERAPY; MICROGLIAL ACTIVATION; ANIMAL-MODELS; STROKE; METAANALYSIS; CHILDREN; RECOVERY; TARGETS; ADULT; LIMB	Background. Effective recovery from functional impairments caused by traumatic brain injury (TBI) requires appropriate rehabilitation therapy. Multiple pathways are involved in secondary injury and recovery suggesting a role for multimodal approaches. Objective. Here, we examined the efficacy of the anti-inflammatory agent minocycline and botulinum toxin (botox)-induced limb constraint with structured physical therapy, delivered alone or in combination, after a severe TBI produced by a controlled cortical impact in rats. Methods. Minocycline was administered at 25 mg/kg daily for 2 weeks beginning 1 day after TBI or sham surgery. For constraint/physical therapy, botox-type A was injected into the nonaffected forearm muscle 1 day after injury and 2 weeks of physical therapy commenced at 5 days after injury. Functional evaluations were conducted 8 weeks after injury. Results. Minocycline, either as a monotherapy or as combination treatment with botox/physical therapy significantly reduced impairments of spatial learning and memory in the water maze test, whereas botox/physical therapy reduced forelimb motor asymmetry and improved manual dexterity in the cylinder and vermicelli handling tests, A synergistic effect between the 2 treatments was observed when rats performed tasks requiring dexterity. Inflammation was attenuated in the peri-contusion cortex and hippocampus in all TBI groups receiving mono or combination therapies, though there was no significant difference in lesion size among groups. Conclusion. These data provide a rationale for incorporating anti-inflammatory treatment during rehabilitation therapy.	[Lam, Tina I.; Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA USA; [Lam, Tina I.; Shi, Jian; Wang, Dongmin; Massa, Stephen; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Lam, Tina I.] USDA, Foodborne Contaminants Res Unit, Western Reg Res Ctr, Res Serv, Albany, CA USA; [Bingham, Deborah; Chang, Ting Ju; Lee, Chih Cheng; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA		Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382; Swanson, Raymond/0000-0002-3664-5359	Veterans Affairs Research Enhancement Award; Veterans Affairs merit awardsUS Department of Veterans Affairs	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Veterans Affairs Research Enhancement Award (RAS), and Veterans Affairs merit awards (JL, SM).].	Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cimolin V, 2012, J HEAD TRAUMA REHAB, V27, P177, DOI 10.1097/HTR.0b013e3182172276; Corbetta D, 2010, EUR J PHYS REHAB MED, V46, P537; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Gauthier LV, 2008, STROKE, V39, P1520, DOI 10.1161/STROKEAHA.107.502229; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Janssen H, 2013, NEUROREHAB NEURAL RE, V27, P3, DOI 10.1177/1545968312449696; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; McIntosh TK, 1996, LAB INVEST, V74, P315; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nijland R, 2011, INT J STROKE, V6, P425, DOI 10.1111/j.1747-4949.2011.00646.x; Orsucci D, 2009, CNS NEUROL DISORD-DR, V8, P222; Peurala SH, 2012, CLIN REHABIL, V26, P209, DOI 10.1177/0269215511420306; Ramchand R, 2008, PREVALENCE PTSD DEPR; Reiss AP, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/159391; Reitmeir R, 2011, BRAIN, V134, P84, DOI 10.1093/brain/awq344; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Shaw SE, 2005, J REHABIL RES DEV, V42, P769, DOI 10.1682/JRRD.2005.06.0094; Sirtori V, 2010, STROKE, V41, pE57, DOI 10.1161/STROKEAHA.109.569665; Smania N, 2009, EUR J PHYS REHAB MED, V45, P493; Sun SF, 2010, NEUROREHAB NEURAL RE, V24, P34, DOI 10.1177/1545968309341060; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Ulgen Berkin O, 2011, Recent Pat Cardiovasc Drug Discov, V6, P123; Wittenberg GF, 2009, CURR OPIN NEUROL, V22, P582, DOI 10.1097/WCO.0b013e3283320229; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	41	29	29	1	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV	2013	27	9					889	899		10.1177/1545968313491003			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	229IL	WOS:000325256000013	23778701				2022-02-06	
J	Smith, DW; Myer, GD; Currie, DW; Comstock, RD; Clark, JF; Bailes, JE				Smith, David W.; Myer, Gregory D.; Currie, Dustin W.; Comstock, R. Dawn; Clark, Joseph F.; Bailes, Julian E.			Altitude Modulates Concussion Incidence Implications for Optimizing Brain Compliance to Prevent Brain Injury in Athletes	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						concussion; athletes; sports-related concussion; prevention; football; elevation; Slosh theory	STATES HIGH-SCHOOL; EPIDEMIOLOGY; EXPECTATIONS; PRESSURE; PLACEBO; VOLUME; PAIN	Background: Recent research indicates that the volume and/or pressure of intracranial fluid, a physiology affected by one's altitude (ie, elevation above sea level), may be associated with the likelihood and/or severity of a concussion. The objective was to employ an epidemiological field investigation to evaluate the relationship between altitude and concussion rate in high school sports. Hypothesis: Because of the physiologies that occur during acclimatization, including a decline in intracranial compliance (a "tighter fit"), increased altitude may be related to a reduction in concussion rates in high school athletes. Study Design: Cohort study; Level of evidence, 3. Methods: Data on concussions and athlete exposures (AEs) between 2005-2006 and 2011-2012 were obtained from a large national sample of high schools (National High School Sports-Related Injury Surveillance System [High School RIO]) and were used to calculate total, competition, and practice concussion rates for aggregated sports and for football only. Results: Altitude of participating schools ranged from 7 to 6903 ft (median, 600 ft), and a total of 5936 concussions occurred in 20,618,915 exposures (2.88 per 10,000AEs). When concussion rates were dichotomized by altitude using the median, elevated altitude was associated with a reduction in concussion rates overall (rate ratio [RR], 1.31; P < .001), in competition (RR, 1.31; P < .001), and in practice (RR, 1.29; P < .001). Specifically, high school sports played at higher altitude demonstrated a 31% reduction (95% confidence interval [CI], 25%-38%) in the incidence of total reported concussions. Likewise, concussion rates at increased altitude were reduced 30% for overall exposures, 27% for competition exposures, and 28% for practice exposures in football players (P < .001). Conclusion: The results of this epidemiological investigation indicate increased physiological responses to altitude may be associated with a reduction in sports-related concussion rates, especially in collision sports. Future research that focuses on the potential prophylactic effect of optimizing outflow impedance and thus reduction of intracranial compliance (a "tighter fit") in humans is warranted to determine the most effective approaches to mitigate sport-related concussion, especially in football players.	[Smith, David W.; Myer, Gregory D.; Currie, Dustin W.] Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA; [Smith, David W.; Myer, Gregory D.; Currie, Dustin W.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH USA; [Smith, David W.; Bailes, Julian E.] NorthShore Univ Healthsyst, Dept Neurosurg, Evanston, IL USA; [Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Orthopaed Surg, Cincinnati, OH USA; [Myer, Gregory D.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Currie, Dustin W.; Comstock, R. Dawn] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Clark, Joseph F.] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA		Myer, GD (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA.	greg.myer@cchmc.org	Myer, Gregory/H-6572-2016	Myer, Gregory/0000-0002-9983-8422	Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; NOCSAE; DonJoy Orthotics; Eyeblack	The content of this report was funded in part by the Centers for Disease Control and Prevention (CDC grants R49/CE000674-01 and R49/CE001172-01). The authors also acknowledge the generous research funding contributions of the National Federation of State High School Associations, NOCSAE, DonJoy Orthotics, and Eyeblack.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Benz LN, 2013, J ORTHOP SPORT PHYS, V43, P439, DOI 10.2519/jospt.2013.0105; Bishop MD, 2013, J ORTHOP SPORT PHYS, V43, P457, DOI 10.2519/jospt.2013.4492; CHASIS JA, 1986, J CELL BIOL, V103, P343, DOI 10.1083/jcb.103.2.343; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Glickman T. S., 2000, GLOSSARY METEOROLOGY; Gonzalez-Iglesias J, 2009, J ORTHOP SPORT PHYS, V39, P515, DOI 10.2519/jospt.2009.3072; Hackett PH, 1998, JAMA-J AM MED ASSOC, V280, P1920, DOI 10.1001/jama.280.22.1920; High School RIO, REP INF ONL PED INJ; Higher Peak Altitude Training, EFF AM OXYG DIFF ALT; Ito H, 2003, J CEREBR BLOOD F MET, V23, P665, DOI 10.1097/01.WCB.0000067721.64998.F5; Kim HS, 2008, J MECH SCI TECHNOL, V22, P25, DOI 10.1007/s12206-007-1003-z; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P575; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marmarou Christina R., 2009, P393, DOI 10.1007/978-1-60327-185-1_34; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McSharry PE, 2007, BMJ-BRIT MED J, V335, P1278, DOI 10.1136/bmj.39393.451516.AD; Oken BS, 2008, BRAIN, V131, P2812, DOI 10.1093/brain/awn116; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; Reilly P, 1997, HEAD INJURY PATHOPHY; Roach RC, 2001, J EXP BIOL, V204, P3161; ROSS RT, 1985, LANCET, V1, P990; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Saks V A, 1992, Biokhimiia, V57, P1763; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Tokarska-Schlattner M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043178; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; United States Census Bureau, 2009, CENS REG US; WATTS RG, 1990, KEEP YOUR EYE BALL S; Wilson MH, 2008, NEUROSURGERY, V63, P970, DOI 10.1227/01.NEU.0000327885.15132.CA; Wilson MH, 2013, ANN NEUROL, V73, P381, DOI 10.1002/ana.23796; Wilson MH, 2011, J CEREBR BLOOD F MET, V31, P2019, DOI 10.1038/jcbfm.2011.81; Young A.J., 2002, HUMAN ADAPTATION HIG	39	29	29	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		2325-9671		ORTHOP J SPORTS MED	Orthop. J. Sports Med.	NOV	2013	1	6							2325967113511588	10.1177/2325967113511588			7	Orthopedics; Sport Sciences	Emerging Sources Citation Index (ESCI)	Orthopedics; Sport Sciences	V0Q9J	WOS:000216477800002	26535254	Green Published, gold			2022-02-06	
J	Inoue, T; Lin, A; Ma, XK; McKenna, SL; Creasey, GH; Manley, GT; Ferguson, AR; Bresnahan, JC; Beattie, MS				Inoue, Tomoo; Lin, Amity; Ma, Xiaokui; McKenna, Stephen L.; Creasey, Graham H.; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.			Combined SCI and TBI: Recovery of forelimb function after unilateral cervical spinal cord injury (SCI) is retarded by contralateral traumatic brain injury (TBI), and ipsilateral TBI balances the effects of SCI on paw placement	EXPERIMENTAL NEUROLOGY			English	Article						Behavioral analysis; Neuronal plasticity; Spinal cord injury; Traumatic brain injury; 'Dual diagnosis'	CLOSED HEAD-INJURY; LESS-AFFECTED FORELIMB; ADULT MALE RATS; SENSORIMOTOR CORTEX; CORTICAL INFARCTS; CONTUSION INJURY; RISK-FACTORS; FORCED USE; PLASTICITY; STROKE	A significant proportion (estimates range from 16 to 74%) of patients with spinal cord injury (SCI) have concomitant traumatic brain injury (TBI), and the combination often produces difficulties in planning and implementing rehabilitation strategies and drug therapies. For example, many of the drugs used to treat SCI may interfere with cognitive rehabilitation, and conversely drugs that are used to control seizures in TBI patients may undermine locomotor recovery after SCI. The current paper presents an experimental animal model for combined SCI and TBI to help drive mechanistic studies of dual diagnosis. Rats received a unilateral SCI (75 kdyn) at C5 vertebral level, a unilateral TBI (2.0 mm depth, 4.0 m/s velocity impact on the forelimb sensori-motor cortex), or both SCI + TBI. TBI was placed either contralateral or ipsilateral to the SCI. Behavioral recovery was examined using paw placement in a cylinder, grooming, open field locomotion, and the IBB cereal eating test. Over 6 weeks, in the paw placement test, SCI + contralateral TBI produced a profound deficit that failed to recover, but SCI + ipsilateral TBI increased the relative use of the paw on the SCI side. In the grooming test, SCI + contralateral TBI produced worse recovery than either lesion alone even though contralateral TBI alone produced no observable deficit. In the IBB forelimb test, SCI + contralateral TBI revealed a severe deficit that recovered in 3 weeks. For open field locomotion, SCI alone or in combination with TBI resulted in an initial deficit that recovered in 2 weeks. Thus, TBI and SCI affected forelimb function differently depending upon the test, reflecting different neural substrates underlying, for example, exploratory paw placement and stereotyped grooming. Concurrent SCI and TBI had significantly different effects on outcomes and recovery, depending upon laterality of the two lesions. Recovery of function after cervical SCI was retarded by the addition of a moderate TBI in the contralateral hemisphere in all tests, but forepaw placements were relatively increased by an ipsilateral TBI relative to SCI alone, perhaps due to the dual competing injuries influencing the use of both forelimbs. These findings emphasize the complexity of recovery from combined CNS injuries, and the possible role of plasticity and laterality in rehabilitation, and provide a start towards a useful preclinical model for evaluating effective therapies for combine SCI and TBI. (C) 2013 Elsevier Inc. All rights reserved.	[Inoue, Tomoo; Lin, Amity; Ma, Xiaokui; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; [Inoue, Tomoo; Lin, Amity; Ma, Xiaokui; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Inoue, Tomoo; Lin, Amity; Ma, Xiaokui; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [McKenna, Stephen L.] Santa Clara Valley Med Ctr, Rehabil Trauma Ctr, San Jose, CA 95128 USA; [Creasey, Graham H.] Palo Alto Hlth Care Syst, Dept Vet Affairs, Spinal Cord Injury & Disorders Serv, Palo Alto, CA USA		Beattie, MS (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94110 USA.	inouet@neurosurg.ucsf.edu; Amity.Lin@ucsf.edu; MaX@neurosurg.ucsf.edu; Stephen.McKenna@hhs.sccgov.org; Graham.Creasey@va.gov; manleyg@neurosurg.ucsf.edu; adam.ferguson@ucsf.edu; jacqueline.bresnahan@ucsf.edu; michael.beattie@ucsf.edu		Ferguson, Adam/0000-0001-7102-1608	DoD/CDMRP SCIRP [W81XWH-10-1-0910]; Uehara Memorial Foundation Research fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038079] Funding Source: NIH RePORTER	This work was supported by DoD/CDMRP SCIRP Translational Partnership Award #W81XWH-10-1-0910. T. Inoue was supported by the Uehara Memorial Foundation Research fellowship. The authors would like to acknowledge Ms. Ellie Stuck and Yvette Nout, DVM, PhD for help with some of the behavioral testing, and Jeffrey Sacramento and Jinghua Yao for help with the histological preparations and analysis.	Allred RP, 2010, BEHAV NEUROSCI, V124, P124, DOI 10.1037/a0018457; Arzaga Deborah, 2003, SCI Nurs, V20, P86; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; BERTELLI JA, 1993, J NEUROSCI METH, V46, P203, DOI 10.1016/0165-0270(93)90068-3; Blanco JE, 2007, EXP NEUROL, V203, P333, DOI 10.1016/j.expneurol.2006.08.017; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS77, DOI 10.1016/j.apmr.2008.07.008; Bury SD, 2004, BEHAV BRAIN RES, V150, P43, DOI 10.1016/S0166-4328(03)00253-5; Cooper D J, 2005, Crit Care Resusc, V7, P181; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1986, PARAPLEGIA, V24, P97, DOI 10.1038/sc.1986.13; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Dunham KA, 2010, J NEUROTRAUM, V27, P2091, DOI 10.1089/neu.2010.1424; Ferguson AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059712; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hagen EM, 2010, ACTA NEUROL SCAND, V122, P51, DOI 10.1111/j.1600-0404.2010.01376.x; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Hsu JE, 2006, EXP NEUROL, V201, P479, DOI 10.1016/j.expneurol.2006.05.003; Hsu JE, 2005, EUR J NEUROSCI, V22, P2069, DOI 10.1111/j.1460-9568.2005.04370.x; Huie JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039751; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; Irvine K. A., 2010, J VIS EXP, V46; Jones TA, 1996, BRAIN RES, V733, P142, DOI 10.1016/S0006-8993(96)00792-5; Jones TA, 2012, J NEUROTRAUM, V29, P1455, DOI 10.1089/neu.2011.2207; Jones TA, 2009, STROKE, V40, pS136, DOI 10.1161/STROKEAHA.108.533653; Keppel G., 2004, DESIGN ANAL RES HDB, V4th ed.; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Lu D.C., 2013, J NEUROTRAU IN PRESS, DOI DOI 10.1089/NEU; Luke LM, 2004, SYNAPSE, V54, P187, DOI 10.1002/syn.20080; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Martinez M, 2009, J NEUROTRAUM, V26, P1043, DOI 10.1089/neu.2008.0717; McKenna JE, 2000, J COMP NEUROL, V419, P286, DOI 10.1002/(SICI)1096-9861(20000410)419:3<286::AID-CNE2>3.0.CO;2-3; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; Mihai G, 2008, J NEUROTRAUM, V25, P1, DOI 10.1089/neu.2007.0338; Nishimura Y, 2012, EXP NEUROL, V235, P152, DOI 10.1016/j.expneurol.2011.08.013; Nishimura Y, 2009, NEUROSCIENTIST, V15, P436, DOI 10.1177/1073858408331375; Nout YS, 2009, CRIT CARE MED, V37, P2160, DOI 10.1097/CCM.0b013e3181a05d41; OMALLEY KF, 1988, J TRAUMA, V28, P1476, DOI 10.1097/00005373-198810000-00013; POVOLNY MA, 1993, J REHABIL, V59, P23; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; Ricker JH, 1999, TOP SPINAL CORD INJ, V5, P76; Rosenzweig ES, 2010, NAT NEUROSCI, V13, P1505, DOI 10.1038/nn.2691; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T, 2003, J REHABIL RES DEV, V40, P9, DOI 10.1682/JRRD.2003.08.0009; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SOICHER E, 1991, BRIT J SURG, V78, P1013, DOI 10.1002/bjs.1800780837; Sommer JL, 2004, BRAIN INJURY, V18, P1297, DOI 10.1080/02699050410001672288; SPRAGUE JM, 1966, SCIENCE, V153, P1544, DOI 10.1126/science.153.3743.1544; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; Strong MK, 2009, EXP NEUROL, V217, P96, DOI 10.1016/j.expneurol.2009.01.020; Tian HL, 2009, J TRAUMA, V67, P1305, DOI 10.1097/TA.0b013e31819db57c; Watanabe T, 1999, TOP SPINAL CORD INJ, V5, P83; Wei CW, 2008, ARCH PHYS MED REHAB, V89, pS85, DOI 10.1016/j.apmr.2008.07.005; Willis JK, 2002, PEDIATRICS, V110, P94, DOI 10.1542/peds.110.1.94; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	61	29	29	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2013	248						136	147		10.1016/j.expneurol.2013.06.006			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	261SJ	WOS:000327684600013	23770071	Green Accepted			2022-02-06	
J	Li, Q; Yang, CH; Xu, JG; Li, H; You, C				Li, Q.; Yang, C. H.; Xu, J. G.; Li, H.; You, C.			Surgical treatment for large spontaneous basal ganglia hemorrhage: retrospective analysis of 253 cases	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cerebral hemorrhage; intracranial pressure; decompressive craniectomy (DC); mortality	TRAUMATIC BRAIN-INJURY; SUPRATENTORIAL INTRACEREBRAL HEMORRHAGE; DECOMPRESSIVE CRANIECTOMY; CONSERVATIVE TREATMENT; CEREBRAL EDEMA; MANAGEMENT; EVACUATION; HEMATOMAS; THERAPY; IMPACT	Objectives. Spontaneous intracerebral hemorrhage (ICH) is a challenge to both neurologists and neurosurgeons. We aim to summarize the surgical treatment of ICH based on retrospective analysis of our patients. Methods. Two hundred and fifty-three patients with spontaneous ICH from August 2008 to August 2011 were retrospectively analyzed. Clinical data, including preoperative ICH score, pre- and postoperative GCS score, hematoma volume, postoperative brain infarction, 30-day mortality, and GOS 3 months postictus, were collected. One hundred and fifty patients had their intracranial pressure (ICP) monitored, and data were recorded and analyzed. All patients underwent craniotomy and clot removal under general anesthesia. Outcome analysis was stratified using hematoma volume, ICH score, preoperative GCS score, and decompressive craniectomy (DC). Results. The mean hematoma volume was 70.8 mL, and 68 patients (26.9%) underwent DC. The mean postoperative ICP was 28.8 +/- 6.7 mmHg for patients without DC, and only 17.5 +/- 8.6 mmHg for patients with DC. Twenty-five patients (9.9%) died within 30 days of operation, and 88 patients (34.8%, GOS >= 4) had good outcome 3 months after surgery. ICH volume > 50 mL, preoperative GCS score <= 8, and ICH score >= 3 are risk factors for unfavorable outcomes. Conclusions. DC can be used for patients with low preoperative GCS score, and it effectively reduces ICP and 30-day mortality. Hematoma volume, preoperative GCS score, and ICH score are of predictive value for surgical outcome of large basal ganglia hemorrhage.	[Li, Q.; Yang, C. H.; Xu, J. G.; Li, H.; You, C.] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Peoples R China		You, C (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, 37 Guoxue Rd, Chengdu 610041, Peoples R China.	chaoy12345@gmail.com			China National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81172411]	This work is supported by grant No. 81172411 from China National Natural Science Foundation. The authors report no declarations of interest. The authors alone are responsible for the content and writing of the paper.	Albert R, 2004, J CLIN NEUROSCI, V11, P259, DOI 10.1016/S0967-5868(03)00154-1; Andaluz N, 2009, J NEUROSURG, V110, P403, DOI 10.3171/2008.5.17559; Arac A, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0958; Ariesen MJ, 2003, STROKE, V34, P2060, DOI 10.1161/01.STR.0000080678.09344.8D; Barlas O, 2009, MINIM INVAS NEUROSUR, V52, P62, DOI 10.1055/s-0028-1104610; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Castellanos M, 2005, J NEUROL NEUROSUR PS, V76, P691, DOI 10.1136/jnnp.2004.044347; Cho DY, 2008, SURG NEUROL, V70, P628, DOI 10.1016/j.surneu.2007.08.006; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Gazzeri R, 2009, J NEUROSURG, V110, P939, DOI 10.3171/2008.8.JNS17642; Hemphill JC, 2009, NEUROLOGY, V73, P1088, DOI 10.1212/WNL.0b013e3181b8b332; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hoff JT, 2003, ACT NEUR S, V86, P11; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kim KT, 2009, ACTA NEUROCHIR, V151, P21, DOI 10.1007/s00701-008-0164-6; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kuo JR, 2006, J CLIN NEUROSCI, V13, P218, DOI 10.1016/j.jocn.2005.01.012; Marion DW, 2006, NEUROSURGERY, V58, P655; Mendelow AD, 2005, LANCET, V365, P387; Murthy JMK, 2005, NEUROCRIT CARE, V2, P258, DOI 10.1385/NCC:2:3:258; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Orakcioglu B, 2008, NEUROCRIT CARE, V8, P448, DOI 10.1007/s12028-007-9047-6; Pantazis G, 2006, SURG NEUROL, V66, P492, DOI 10.1016/j.surneu.2006.05.054; Rincon F, 2008, CRIT CARE, V12, DOI 10.1186/cc7092; Schorl M, 2009, CENT EUR NEUROSURG, V70, P68, DOI 10.1055/s-0028-1093355; Siddique MS, 2000, BRIT MED BULL, V56, P444, DOI 10.1258/0007142001903085; Testai FD, 2008, NEUROL CLIN, V26, P963, DOI 10.1016/j.ncl.2008.06.001; Wang WZ, 2009, INT J STROKE, V4, P11, DOI 10.1111/j.1747-4949.2009.00239.x; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833	32	29	31	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2013	27	5					617	621		10.3109/02688697.2013.765938			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	216FG	WOS:000324266800012	23406426				2022-02-06	
J	Tolan, NV; Vidal-Folch, N; Algeciras-Schimnich, A; Singh, RJ; Grebe, SKG				Tolan, Nicole V.; Vidal-Folch, Noemi; Algeciras-Schimnich, Alicia; Singh, Ravinder J.; Grebe, Stefan K. G.			Individualized correction of neuron-specific enolase (NSE) measurement in hemolyzed serum samples	CLINICA CHIMICA ACTA			English	Article						Neuron-specific enolase; Ischemic brain injury; Therapeutic hypothermia; Neurological prognosis; Individualized hemolysis correction	TRAUMATIC BRAIN-INJURY; CREUTZFELDT-JAKOB-DISEASE; MILD THERAPEUTIC HYPOTHERMIA; CELL LUNG-CANCER; CARDIAC-ARREST; PROGNOSTIC VALUE; TUMOR-MARKERS; BIOMARKERS; DIAGNOSIS; CSF	Background: Accuracy of serum neuron-specific enolase (NSE) measurement is paramount, particularly in the context of neurological outcome prognostication. However, NSE measurements are compromised by even slight hemolysis, as it is abundant in red blood cells (RBCs). We derived and validated an individualized hemolysis correction equation in an attempt to reduce the current rejection rate of 14% at our institution. Methods: Intracellular NSE was measured in RBC lysates to determine concentration variability. A correction equation was derived, accounting for both RBC-derived NSE false-elevation and hemoglobin-derived signal quenching. The performance of this individualized correction was evaluated in intentionally hemolyzed samples and accuracy was compared to a generalized correction. Results: Significant inter-individual variability of RBC NSE was observed, with an almost two-fold range (15.7-28.5 ng NSE/mg Hb, p < 0.001); intra-individual variability was insignificant. The individualized hemolysis correction equation derived: NSEcorr = NSEmeas - (Hb(serum))(NSERBCs/Hb) + 0.0844(Hb(serum)) + 1.1 corrected 95% of the intentionally hemolyzed samples to within +/- 5 ng/ml of corresponding baseline NSE concentrations, compared to 74% using a generalized formula. Conclusions: The individualized hemolysis correction provides increased accuracy in the estimation of true serum NSE concentrations for hemolyzed samples, compared to a generalized approach, by accounting for inter-individual RBC NSE variability. Incorporating this correction should reduce sample rejection rates and overall health care costs. (c) 2013 Elsevier B.V. All rights reserved.	[Tolan, Nicole V.; Vidal-Folch, Noemi; Algeciras-Schimnich, Alicia; Singh, Ravinder J.; Grebe, Stefan K. G.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA		Grebe, SKG (corresponding author), Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	grebe.stefan@mayo.edu		Tolan, Nicole/0000-0002-7239-1843			Aksamit AJ, 2001, NEUROLOGY, V57, P728, DOI 10.1212/WNL.57.4.728; Auer Johann, 2006, CJEM, V8, P13; Bahl JMC, 2009, NEUROBIOL AGING, V30, P1834, DOI 10.1016/j.neurobiolaging.2008.01.013; Berger R, 2009, PEDIATR CRIT CARE ME, V10, P260, DOI 10.1097/PCC.0b013e31819a376d; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; BURGHUBER OC, 1990, CANCER, V65, P1386, DOI 10.1002/1097-0142(19900315)65:6<1386::AID-CNCR2820650623>3.0.CO;2-9; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Cho WCS, 2007, BIOMED PHARMACOTHER, V61, P515, DOI 10.1016/j.biopha.2007.08.005; Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Einav S, 2012, J AM COLL CARDIOL, V60, P304, DOI 10.1016/j.jacc.2012.04.020; FAIRBANKS VF, 1992, CLIN CHEM, V38, P132; Fugate JE, 2010, ANN NEUROL, V68, P907, DOI 10.1002/ana.22133; Gonzalez-Garcia S, 2012, CLIN BIOCHEM, V45, P1302, DOI 10.1016/j.clinbiochem.2012.07.094; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Green AJE, 2001, J NEUROL NEUROSUR PS, V70, P744, DOI 10.1136/jnnp.70.6.744; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Holdenrieder S, 2008, CLIN CANCER RES, V14, P7813, DOI 10.1158/1078-0432.CCR-08-0678; Holzer M, 2002, NEW ENGL J MED, V346, P549; MARANGOS PJ, 1980, J NEUROCHEM, V34, P1254, DOI 10.1111/j.1471-4159.1980.tb09967.x; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; NIKLINSKI J, 1995, EUR J CANCER PREV, V4, P129, DOI 10.1097/00008469-199504000-00002; Oddo M, 2011, CURR OPIN CRIT CARE, V17, P254, DOI 10.1097/MCC.0b013e328344f2ae; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; Samaniego EA, 2011, NEUROCRIT CARE, V15, P113, DOI 10.1007/s12028-010-9412-8; Samaniego EA, 2011, CURR NEUROL NEUROSCI, V11, P111, DOI 10.1007/s11910-010-0148-9; Sanchez-Juan P, 2006, NEUROLOGY, V67, P637, DOI 10.1212/01.wnl.0000230159.67128.00; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Steffen IG, 2010, CRIT CARE, V14, DOI 10.1186/cc8975; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Storm C, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-6; Tolan NV, 2009, ANAL CHEM, V81, P3102, DOI 10.1021/ac900084g; Verfaillie CJ, 2010, CLIN CHEM LAB MED, V48, P891, DOI 10.1515/CCLM.2010.159; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; WOLD F, 1957, J BIOL CHEM, V227, P313; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88	38	29	31	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	SEP 23	2013	424						216	221		10.1016/j.cca.2013.06.009			6	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	226NH	WOS:000325042600041	23778024				2022-02-06	
J	Forslund, MV; Roe, C; Arango-Lasprilla, JC; Sigurdardottir, S; Andelic, N				Forslund, Marit V.; Roe, Cecilie; Arango-Lasprilla, Juan C.; Sigurdardottir, Solrun; Andelic, Nada			IMPACT OF PERSONAL AND ENVIRONMENTAL FACTORS ON EMPLOYMENT OUTCOME TWO YEARS AFTER MODERATE-TO-SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; environmental factors; employment; prospective study	COMMUNITY INTEGRATION QUESTIONNAIRE; FOLLOW-UP; EARLY REHABILITATION; RACIAL-DIFFERENCES; PREDICTING RETURN; WORK; POPULATION; TBI; INDIVIDUALS; PERSPECTIVE	Objectives: To describe employment outcomes and assess the impact of personal and environmental factors on employment outcomes 2 years after moderate-to-severe traumatic brain injury. Design/subjects: A prospective cohort of 100 patients with moderate-to-severe traumatic brain injury, aged 16-55 years, hospitalized in a Trauma Referral Centre during the period 2005-2007 and followed up at 1 and 2 years post-injury. Methods: Variables of interest were divided into personal and environmental factors. Personal factors include sociodemographics (age, gender, education, work demands, marital status and child-care). Environmental factors included social (support by friends), institutional (number of rehabilitation services, need for well-coordinated healthcare services), and physical (access to own transportation) factors. A multivariate logistic regression analysis was conducted with employment (working part-/full-time or studying) at 2-year follow-up as the dependent variable, and including independent variables based on significance from a univariate analysis, adjusting for injury severity. Results: At the 2-year follow-up, 44% of patients were employed. Patients with less severe injuries (odds ratio (OR)=1.2, p=0.03), those supported by friends (OR=3.5, p=0.07), those not in need of well-coordinated health services (OR-=4.1, p=0.04), and patients driving a vehicle at the 1-year follow-up (OR=8.4, p<0.001) were more likely to be employed at the 2-year follow-up. Conclusion: Rehabilitation professionals should be aware of the role of environmental factors when planning vocational rehabilitation services after traumatic brain injury.	[Forslund, Marit V.; Roe, Cecilie; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Forslund, Marit V.; Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway; [Sigurdardottir, Solrun; Andelic, Nada] Univ Oslo, Fac Med, CHARM Res Ctr Habilitat & Rehabil Models & Serv, Oslo, Norway; [Arango-Lasprilla, Juan C.] Univ Deusto, IKERBASQUE Basque Fdn Sci, Bilbao, Spain; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp Trust, Akershus, Norway		Forslund, MV (corresponding author), Olav M Troviks Vei 28 H505, NO-0864 Oslo, Norway.	mvforslund@gmail.com		Andelic, Nada/0000-0002-3719-4406	Norwegian Health South-East Authority; Research Council of NorwayResearch Council of Norway	The authors would like to thank all the patients for their participation. Special thanks to Nini Hammergren for assistance with patient registrations. This study was funded by grants from the Norwegian Health South-East Authority and The Research Council of Norway.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fleming J, 1999, BRAIN INJURY, V13, P417; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hoffmann B, 2002, ACT NEUR S, V79, P33; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johansson U, 2001, DISABIL REHABIL, V23, P474; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Schanke AK, 2008, J REHABIL MED, V40, P733, DOI 10.2340/16501977-0256; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Stergiou-Kita M, 2011, J OCCUP REHABIL, V21, P374, DOI 10.1007/s10926-010-9282-0; TEASDALE G, 1974, LANCET, V2, P81; Tingvoll WA, 2010, J NURS MANAGE, V18, P767, DOI 10.1111/j.1365-2834.2010.01112.x; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 2007, INT CLASS FUNCT DIS	41	29	30	0	16	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					801	807		10.2340/16501977-1168			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500016	24002317	Green Submitted, gold			2022-02-06	
J	Max, JE; Pardo, D; Hanten, G; Schachar, RJ; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Wilde, EA; Bigler, ED; Thompson, WK; Yang, TT; Levin, HS				Max, Jeffrey E.; Pardo, David; Hanten, Gerri; Schachar, Russell J.; Saunders, Ann E.; Ewing-Cobbs, Linda; Chapman, Sandra B.; Dennis, Maureen; Wilde, Elisabeth A.; Bigler, Erin D.; Thompson, Wesley K.; Yang, Tony T.; Levin, Harvey S.			Psychiatric Disorders in Children and Adolescents Six-to-Twelve Months After Mild Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; POST-CONCUSSIVE SYMPTOMS; 1ST 6 MONTHS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; PERSONALITY-CHANGE; COGNITIVE RESERVE; PREDICTORS; RELIABILITY; VALIDITY	The objective of this study was to understand how novel psychiatric disorders (NPD) in children with mild traumatic brain injury (MTBI) are related to pre-injury variables, injury-related variables, and concurrent neurocognitive outcome. A group of 79 children, ages 5 to 14 years, who had experienced MTBI, were studied from consecutive hospital admissions with semistructured psychiatric interviews soon after injury (baseline); 60 children were reassessed 12 months post-injury. Standardized instruments were used to assess injury severity; lesion characteristics; pre-injury variables, including psychiatric disorder, family psychiatric history, family functioning, socioeconomic status, psychosocial adversity, adaptive functioning, and post-injury neurocognitive and adaptive functioning. NPD occurred in 17 of 60 participants (28%) in the 6-12-month interval after injury, with disorders that were significantly associated with socioeconomic status, psychosocial adversity, estimated pre-injury academic functioning, and concurrent deficits in adaptive functioning, academic performance, processing speed, memory, and expressive language. NPD was not significantly associated with pre-injury adaptive functioning, injury severity, family psychiatric history, pre-injury psychiatric disorder, lesion location, gender, or age at injury. These findings suggest that the short-term psychiatric morbidity associated with MTBI in children occurs more commonly than previously reported and is related to both pre-injury social factors and concurrent neurocognitive functioning.	[Max, Jeffrey E.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Rady Childrens Hosp, San Diego, CA USA		Max, JE (corresponding author), Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH085734, K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National Institute of Mental Health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Cohen J., 2013, STAT POWER ANAL BEHA; Delis D.C., 1994, CVLT C CALIFORNIA VE; DENCKLA M B, 1974, Cortex, V10, P186; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 2010, NEUROPSYCHOLOGICAL P; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Semel E., 1995, CLIN EVALUATION LANG, VThird; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	50	29	29	1	13	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2013	25	4					272	282		10.1176/appi.neuropsych.12040078			11	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	286TN	WOS:000329491700035	24247854	Green Accepted			2022-02-06	
J	Nelson, PA; Sage, JR; Wood, SC; Davenport, CM; Anagnostaras, SG; Boulanger, LM				Nelson, P. Austin; Sage, Jennifer R.; Wood, Suzanne C.; Davenport, Christopher M.; Anagnostaras, Stephan G.; Boulanger, Lisa M.			MHC class I immune proteins are critical for hippocampus-dependent memory and gate NMDAR-dependent hippocampal long-term depression	LEARNING & MEMORY			English	Article							LOW-FREQUENCY STIMULATION; BIDIRECTIONAL SYNAPTIC PLASTICITY; NEURODEVELOPMENTAL ANIMAL-MODEL; RAT HIPPOCAMPUS; CA1 REGION; COGNITIVE DYSFUNCTION; DEVELOPMENTAL SWITCH; RECEPTOR ANTAGONIST; PRENATAL INFECTION; BRAIN-DEVELOPMENT	Memory impairment is a common feature of conditions that involve changes in inflammatory signaling in the brain, including traumatic brain injury, infection, neurodegenerative disorders, and normal aging. However, the causal importance of inflammatory mediators in cognitive impairments in these conditions remains unclear. Here we show that specific immune proteins, members of the major histocompatibility complex class I (MHC class I), are essential for normal hippocampus-dependent memory, and are specifically required for NMDAR-dependent forms of long-term depression (LTD) in the healthy adult hippocampus. In beta 2m(-/-)TAP(-/-) mice, which lack stable cell-surface expression of most MHC class I proteins, NMDAR-dependent LTD in area CA1 of adult hippocampus is abolished, while NMDAR-independent forms of potentiation, facilitation, and depression are unaffected. Altered NMDAR-dependent synaptic plasticity in the hippocampus of beta 2m(-/-)TAP(-/-) mice is accompanied by pervasive deficits in hippocampus-dependent memory, including contextual fear memory, object recognition memory, and social recognition memory. Thus normal MHC class I expression is essential for NMDAR-dependent hippocampal synaptic depression and hippocampus-dependent memory. These results suggest that changes in MHC class I expression could be an unexpected cause of disrupted synaptic plasticity and cognitive deficits in the aging, damaged, and diseased brain.	[Nelson, P. Austin; Anagnostaras, Stephan G.; Boulanger, Lisa M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Sage, Jennifer R.; Wood, Suzanne C.; Anagnostaras, Stephan G.] Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA; [Davenport, Christopher M.; Boulanger, Lisa M.] Univ Calif San Diego, Neurobiol Sect, La Jolla, CA 92093 USA		Boulanger, LM (corresponding author), Princeton Univ, 123 Lewis Thomas Labs, Princeton, NJ 08544 USA.	lboulang@princeton.edu		Davenport, Christopher/0000-0003-2639-6392; Wood, Suzanne/0000-0003-3734-8927; Boulanger, Lisa/0000-0002-6578-7890	Alfred P. Sloan FoundationAlfred P. Sloan Foundation; Silvio Varon Chair in Neuroregeneration; Whitehall Foundation; Cure Autism Now; Autism Speaks; Hellman Fellowship;  [MH071666]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH071666, T32MH018870] Funding Source: NIH RePORTER	We thank P. Riquelme, N. Colaco, J. Kim, S. Carmack, and T. Czech for expert technical assistance, D. Feldman for lending equipment and expertise for the cortical LTD experiments, M. Scanziani for helpful discussions, and D. Raulet for providing TAP<SUP>-/-</SUP> mice. We are grateful for the support and guidance of C. J. Shatz, who was instrumental in initiating these experiments at Harvard Medical School, supported in part by MH071666 (C. J. Shatz). Additional support for these studies was provided by The Alfred P. Sloan Foundation, the Silvio Varon Chair in Neuroregeneration, and grants from the Whitehall Foundation, Cure Autism Now, and Autism Speaks (L. M. B), and a Hellman Fellowship (S.G.A.).	Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ADAMS W, 1993, BRIT J PSYCHIAT, V163, P522, DOI 10.1192/bjp.163.4.522; Allen CB, 2003, NAT NEUROSCI, V6, P291, DOI 10.1038/nn1012; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; Anagnostaras SG, 2003, NAT NEUROSCI, V6, P51, DOI 10.1038/nn992; Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Anagnostaras SG, 2000, LEARN MEMORY, V7, P58, DOI 10.1101/lm.7.1.58; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Banks WA, 2001, J PHARMACOL EXP THER, V299, P536; Barch DM, 2012, TRENDS COGN SCI, V16, P27, DOI 10.1016/j.tics.2011.11.015; Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Bear MF, 1996, P NATL ACAD SCI USA, V93, P13453, DOI 10.1073/pnas.93.24.13453; Ben Shalom D, 2003, CORTEX, V39, P1129; Bender VA, 2006, J NEUROSCI, V26, P4166, DOI 10.1523/JNEUROSCI.0176-06.2006; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Bilousova T, 2012, J NEUROIMMUNOL, V247, P1, DOI 10.1016/j.jneuroim.2012.03.008; Bitanihirwe BKY, 2010, INT J NEUROPSYCHOPH, V13, P981, DOI 10.1017/S1461145710000192; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Boulanger LM, 2009, NEURON, V64, P93, DOI 10.1016/j.neuron.2009.09.001; Boulanger LM, 2004, NAT REV NEUROSCI, V5, P521, DOI 10.1038/nrn1428; Boulanger LM, 2001, CURR OPIN NEUROBIOL, V11, P568, DOI 10.1016/S0959-4388(00)00251-8; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Brown AS, 2006, SCHIZOPHRENIA BULL, V32, P200, DOI 10.1093/schbul/sbj052; Chacon MA, 2013, MOL CELL NEUROSCI, V52, P117, DOI 10.1016/j.mcn.2012.11.004; COAN EJ, 1987, NEUROSCI LETT, V80, P111, DOI 10.1016/0304-3940(87)90505-2; Collingridge GL, 2013, NEUROPHARMACOLOGY, V64, P13, DOI 10.1016/j.neuropharm.2012.06.051; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; Datwani A, 2009, NEURON, V64, P463, DOI 10.1016/j.neuron.2009.10.015; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dorfman JR, 1997, J IMMUNOL, V159, P5219; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; Elmer BM, 2012, TRENDS NEUROSCI, V35, P660, DOI 10.1016/j.tins.2012.08.001; Feldman DE, 1998, NEURON, V21, P347, DOI 10.1016/S0896-6273(00)80544-9; Feldman DE, 2000, NEURON, V27, P45, DOI 10.1016/S0896-6273(00)00008-8; Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040; Fitzjohn SM, 1999, NEUROPHARMACOLOGY, V38, P1577, DOI 10.1016/S0028-3908(99)00123-9; Fitzjohn SM, 2001, J PHYSIOL-LONDON, V537, P421, DOI 10.1111/j.1469-7793.2001.00421.x; Fitzjohn SM, 1998, NEUROPHARMACOLOGY, V37, P1445, DOI 10.1016/S0028-3908(98)00145-2; Fourgeaud L, 2010, P NATL ACAD SCI USA, V107, P22278, DOI 10.1073/pnas.0914064107; Fourgeaud L, 2010, EUR J NEUROSCI, V32, P207, DOI 10.1111/j.1460-9568.2010.07342.x; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; Gibertini M, 1996, ADV EXP MED BIOL, V402, P207; Glynn MW, 2011, NAT NEUROSCI, V14, P442, DOI 10.1038/nn.2764; Goddard CA, 2007, P NATL ACAD SCI USA, V104, P6828, DOI 10.1073/pnas.0702023104; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; He HY, 2006, J NEUROSCI, V26, P2951, DOI 10.1523/JNEUROSCI.5554-05.2006; Hilsabeck RC, 2002, HEPATOLOGY, V35, P440, DOI 10.1053/jhep.2002.31257; Huang CC, 2001, J BIOL CHEM, V276, P48108, DOI 10.1074/jbc.M106388200; Huber KM, 2001, J NEUROPHYSIOL, V86, P321, DOI 10.1152/jn.2001.86.1.321; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Ibi D, 2009, NEUROSCI RES, V64, P297, DOI 10.1016/j.neures.2009.03.015; Ireland DR, 2009, J NEUROPHYSIOL, V101, P1375, DOI 10.1152/jn.90643.2008; Ito HT, 2010, BRAIN BEHAV IMMUN, V24, P930, DOI 10.1016/j.bbi.2010.03.004; Jo J, 2006, NAT NEUROSCI, V9, P170, DOI 10.1038/nn1637; Kipnis J, 2004, P NATL ACAD SCI USA, V101, P8180, DOI 10.1073/pnas.0402268101; Kipnis J, 2012, NAT REV IMMUNOL, V12, P662, DOI 10.1038/nri3280; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Leinders-Zufall T, 2004, SCIENCE, V306, P1033, DOI 10.1126/science.1102818; Li R, 2004, NEUROSCI LETT, V357, P87, DOI 10.1016/j.neulet.2003.11.004; Lidman O, 1999, EUR J NEUROSCI, V11, P4468, DOI 10.1046/j.1460-9568.1999.00904.x; Lin YX, 2008, NATURE, V455, P1198, DOI 10.1038/nature07319; Linda H, 1999, J NEUROIMMUNOL, V101, P76, DOI 10.1016/S0165-5728(99)00135-6; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LJUNGGREN HG, 1995, INT IMMUNOL, V7, P975, DOI 10.1093/intimm/7.6.975; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Maren S, 1999, TRENDS NEUROSCI, V22, P561, DOI 10.1016/S0166-2236(99)01465-4; Maren S, 1998, TRENDS COGN SCI, V2, P39, DOI 10.1016/S1364-6613(98)01123-1; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; Matynia A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002121; McAllister AK, 2009, NEURON, V64, P9, DOI 10.1016/j.neuron.2009.09.038; McConnell MJ, 2009, P NATL ACAD SCI USA, V106, P6784, DOI 10.1073/pnas.0902018106; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; Meyer U, 2005, NEUROSCI BIOBEHAV R, V29, P913, DOI 10.1016/j.neubiorev.2004.10.012; Meyer U, 2008, BRAIN BEHAV IMMUN, V22, P469, DOI 10.1016/j.bbi.2007.09.012; Meyer U, 2010, PSYCHOPHARMACOLOGY, V208, P531, DOI 10.1007/s00213-009-1754-6; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; Miralves J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001354; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Nabavi S, 2013, P NATL ACAD SCI USA, V110, P4027, DOI 10.1073/pnas.1219454110; Needleman LA, 2010, P NATL ACAD SCI USA, V107, P16999, DOI 10.1073/pnas.1006087107; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Nicoll RA, 1998, NEUROBIOL LEARN MEM, V70, P62, DOI 10.1006/nlme.1998.3838; Nosyreva ED, 2005, J NEUROSCI, V25, P2992, DOI 10.1523/JNEUROSCI.3652-04.2005; O'Connor DH, 2005, J NEUROPHYSIOL, V94, P1565, DOI 10.1152/jn.00047.2005; O'Connor DH, 2005, P NATL ACAD SCI USA, V102, P9679, DOI 10.1073/pnas.0502332102; O'Dell T J, 1994, Learn Mem, V1, P129; OITZL MS, 1993, BRAIN RES, V613, P160, DOI 10.1016/0006-8993(93)90468-3; Oliet SHR, 1997, NEURON, V18, P969, DOI 10.1016/S0896-6273(00)80336-0; Ozawa K, 2006, BIOL PSYCHIAT, V59, P546, DOI 10.1016/j.biopsych.2005.07.031; Palmer MJ, 1997, NEUROPHARMACOLOGY, V36, P1517, DOI 10.1016/S0028-3908(97)00181-0; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Patterson PH, 2009, BEHAV BRAIN RES, V204, P313, DOI 10.1016/j.bbr.2008.12.016; Peineau S, 2007, NEURON, V53, P703, DOI 10.1016/j.neuron.2007.01.029; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Radjavi A, 2014, MOL PSYCHIATR, V19, P531, DOI 10.1038/mp.2013.79; RALL GF, 1995, J EXP MED, V182, P1201, DOI 10.1084/jem.182.5.1201; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Sanchez-Andrade G, 2005, J REPROD DEVELOP, V51, P547, DOI 10.1262/jrd.17031; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schmidt H, 2006, BRAIN, V129, P333, DOI 10.1093/brain/awh711; Shatz CJ, 2009, NEURON, V64, P40, DOI 10.1016/j.neuron.2009.09.044; Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Torres AR, 2001, FRONT BIOSCI, V6, pD936, DOI 10.2741/Torres; ULLAL GR, 1989, EPILEPSY RES, V3, P232, DOI 10.1016/0920-1211(89)90029-6; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; Vugmeyster Y, 1998, P NATL ACAD SCI USA, V95, P12492, DOI 10.1073/pnas.95.21.12492; Washburn LR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018439; Watabe AM, 2002, J NEUROPHYSIOL, V87, P1395, DOI 10.1152/jn.00723.2001; Wood S, 2009, PSYCHOPHARMACOLOGY, V202, P197, DOI 10.1007/s00213-008-1185-9; Yasuda H, 2003, NAT NEUROSCI, V6, P15, DOI 10.1038/nn985; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zelcer I, 2006, CEREB CORTEX, V16, P460, DOI 10.1093/cercor/bhi125; Zhang L, 2009, EUR J NEUROSCI, V29, P2137, DOI 10.1111/j.1460-9568.2009.06783.x; Zhong J, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-17; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629; Ziv Y, 2008, BRAIN BEHAV IMMUN, V22, P167, DOI 10.1016/j.bbi.2007.08.006; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	136	29	30	0	18	COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT	COLD SPRING HARBOR	1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	1072-0502	1549-5485		LEARN MEMORY	Learn. Mem.	SEP	2013	20	9					505	517		10.1101/lm.031351.113			13	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	220KC	WOS:000324581100008	23959708	Green Published, gold			2022-02-06	
J	Wright, MJ; McArthur, DL; Alger, JR; Van Horn, J; Irimia, A; Filippou, M; Glenn, TC; Hovda, DA; Vespa, P				Wright, Matthew J.; McArthur, David L.; Alger, Jeffry R.; Van Horn, Jack; Irimia, Andrei; Filippou, Maria; Glenn, Thomas C.; Hovda, David A.; Vespa, Paul			Early metabolic crisis-related brain atrophy and cognition in traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Metabolic crisis; Neuropsychology; Brain atrophy; Neuroimaging	HEAD-INJURY; WHITE-MATTER; MEMORY; MODERATE; DYSFUNCTION; MICRODIALYSIS; GLUCOSE; CONSOLIDATION; RETRIEVAL; IMPACT	Traumatic brain injury often results in acute metabolic crisis. We recently demonstrated that this is associated with chronic brain atrophy, which is most prominent in the frontal and temporal lobes. Interestingly, the neuropsychological profile of traumatic brain injury is often characterized as 'frontal-temporal' in nature, suggesting a possible link between acute metabolic crisis-related brain atrophy and neurocognitive impairment in this population. While focal lesions and diffuse axonal injury have a well-established role in the neuropsychological deficits observed following traumatic brain injury, no studies to date have examined the possible contribution of acute metabolic crisis-related atrophy in the neuropsychological sequelae of traumatic brain injury. In the current study we employed positron emission tomography, magnetic resonance imaging, and neuropsychological assessments to ascertain the relationship between acute metabolic crisis-related brain atrophy and neurocognitive outcome in a sample of 14 right-handed traumatic brain injury survivors. We found that acute metabolic crisisaEurorelated atrophy in the frontal and temporal lobes was associated with poorer attention, executive functioning, and psychomotor abilities at 12 months post-injury. Furthermore, participants with gross frontal and/or temporal lobe atrophy exhibited numerous clinically significant neuropsychological deficits in contrast to participants with other patterns of brain atrophy. Our findings suggest that interventions that reduce acute metabolic crisis may lead to improved functional outcomes for traumatic brain injury survivors.	[Wright, Matthew J.] Harbor Univ Calif, Los Angeles Med Ctr, Los Angeles Biomed Res Inst, Psychol Div, Torrance, CA 90502 USA; [Wright, Matthew J.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [McArthur, David L.; Filippou, Maria; Glenn, Thomas C.; Hovda, David A.; Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Van Horn, Jack; Irimia, Andrei; Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA		Wright, MJ (corresponding author), Harbor Univ Calif, Los Angeles Med Ctr, Los Angeles Biomed Res Inst, Psychol Div, 1124 W Carson St,B 4 South Box 490, Torrance, CA 90502 USA.	mwright@labiomed.org	Irimia, Andrei/B-8275-2008	Irimia, Andrei/0000-0002-9254-9388; Glenn, Thomas/0000-0003-4273-3408; Filippou-Frye, Maria/0000-0001-5516-0384	California State Neurotrauma Initiative;  [NS049471];  [NS02089];  [P01-NS058489]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049471, K08NS002089, P01NS058489] Funding Source: NIH RePORTER	This research was supported by NS049471, NS02089, P01-NS058489 and the California State Neurotrauma Initiative.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Army Individual Test Battery, 1944, MAN DIR SCOR; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bentourkia M, 2000, J NEUROL SCI, V181, P19, DOI 10.1016/S0022-510X(00)00396-8; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bor D, 2004, EUR J NEUROSCI, V19, P3365, DOI 10.1111/j.1460-9568.2004.03438.x; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Dinov Ivo D, 2009, Front Neuroinform, V3, P22, DOI 10.3389/neuro.11.022.2009; Fahy JF., 1993, NEUROPSYCHOLOGY, V7, P136, DOI [10.1037/0894-4105.7.2.136, DOI 10.1037/0894-4105.7.2.136]; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Gleissner U, 1997, NEUROREPORT, V8, P2893, DOI 10.1097/00001756-199709080-00018; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Habib R, 2003, TRENDS COGN SCI, V7, P241, DOI 10.1016/S1364-6613(03)00110-4; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hattori N, 2003, J NUCL MED, V44, P1709; Hayman LA, 1992, CLIN BRAIN IMAGING N, P130; Head D, 2004, CEREB CORTEX, V14, P410, DOI 10.1093/cercor/bhh003; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lezak M, 2004, NEUROPSYCHOLOGICAL A, P158; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Matthews CG., 1964, INSTRUCTION MANUAL A; Mitrushina M, 2005, HDB NORMATIVE DATA N, P648; NIELSENBOHLMAN L, 1994, NEUROREPORT, V5, P1517, DOI 10.1097/00001756-199407000-00027; Nixon S.J., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [DOI 10.1037/10198-001, https://doi.org/10.1037/10198-001]; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P179, DOI 10.1038/jcbfm.1992.28; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raz N, 2000, HDB AGING COGNITION, P1; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P104, DOI 10.1037/0894-4105.18.1.104; Schmitter-Edgecombe M, 2003, J CLIN EXP NEUROPSYC, V25, P933, DOI 10.1076/jcen.25.7.933.16493; Shattuck DW, 2002, MED IMAGE ANAL, V6, P129, DOI 10.1016/S1361-8415(02)00054-3; Smith A., 1991, SYMBOL DIGIT MODALIT; SQUIRE LR, 1994, INT REV NEUROBIOL, V37, P243; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; SQUIRE LR, 1980, NEUROPSYCHOLOGIA, V18, P369, DOI 10.1016/0028-3932(80)90134-7; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2004, BRAIN PATHOL, V14, P210, DOI 10.1111/j.1750-3639.2004.tb00055.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Wright MJ, 2011, J HEAD TRAUMA REHAB, V26, P182, DOI 10.1097/HTR.0b013e318218dcf9; Wright MJ, 2010, J CLIN EXP NEUROPSYC, V32, P728, DOI 10.1080/13803390903512652; Wright MJ, 2009, J CLIN EXP NEUROPSYC, V31, P790, DOI 10.1080/13803390802508918; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	56	29	30	1	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2013	7	3					307	315		10.1007/s11682-013-9231-6			9	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	253GG	WOS:000327071400009	23636971	Green Accepted			2022-02-06	
J	Kim, J; Yang, M; Kim, SH; Kim, JC; Wang, HB; Shin, T; Moon, C				Kim, Juhwan; Yang, Miyoung; Kim, Sung-Ho; Kim, Jong-Choon; Wang, Hongbing; Shin, Taekyun; Moon, Changjong			Possible Role of the Glycogen Synthase Kinase-3 Signaling Pathway in Trimethyltin-Induced Hippocampal Neurodegeneration in Mice	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; NEUROTOXICITY IN-VIVO; PROTEIN-KINASE; NEURONAL DEGENERATION; RAT HIPPOCAMPUS; POTENTIAL ROLE; BETA-CATENIN; LITHIUM; ACTIVATION	Trimethyltin (TMT) is an organotin compound with potent neurotoxic effects characterized by neuronal destruction in selective regions, including the hippocampus. Glycogen synthase kinase-3 (GSK-3) regulates many cellular processes, and is implicated in several neurodegenerative disorders. In this study, we evaluated the therapeutic effect of lithium, a selective GSK-3 inhibitor, on the hippocampus of adult C57BL/6 mice with TMT treatment (2.6 mg/kg, intraperitoneal [i.p.]) and on cultured hippocampal neurons (12 days in vitro) with TMT treatment (5 mM). Lithium (50 mg/kg, i.p., 0 and 24 h after TMT injection) significantly attenuated TMT-induced hippocampal cell degeneration, seizure, and memory deficits in mice. In cultured hippocampal neurons, lithium treatment (0-10 mM; 1 h before TMT application) significantly reduced TMT-induced cytotoxicity in a dose-dependent manner. Additionally, the dynamic changes in GSK-3/beta-catenin signaling were observed in the mouse hippocampus and cultured hippocampal neurons after TMT treatment with or without lithium. Therefore, lithium inhibited the detrimental effects of TMT on the hippocampal neurons in vivo and in vitro, suggesting involvement of the GSK-3/beta-catenin signaling pathway in TMT-induced hippocampal cell degeneration and dysfunction.	[Kim, Juhwan; Yang, Miyoung; Kim, Sung-Ho; Kim, Jong-Choon; Moon, Changjong] Chonnam Natl Univ, Coll Vet Med, Dept Vet Anat, Kwangju, South Korea; [Kim, Juhwan; Yang, Miyoung; Kim, Sung-Ho; Kim, Jong-Choon; Moon, Changjong] Chonnam Natl Univ, Coll Vet Med, Dept Vet Toxicol, Kwangju, South Korea; [Kim, Juhwan; Yang, Miyoung; Kim, Sung-Ho; Kim, Jong-Choon; Moon, Changjong] Chonnam Natl Univ, Anim Med Inst, Kwangju, South Korea; [Yang, Miyoung; Wang, Hongbing] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Yang, Miyoung; Wang, Hongbing] Michigan State Univ, Neurosci Program, E Lansing, MI 48824 USA; [Shin, Taekyun] Jeju Natl Univ, Coll Vet Med, Dept Vet Anat, Cheju, South Korea		Shin, T (corresponding author), Jeju Natl Univ, Coll Vet Med, Dept Vet Anat, Cheju, South Korea.	shint@jejunu.ac.kr; moonc@chonnam.ac.kr	Moon, Changjong/AAI-2005-2020	Moon, Changjong/0000-0003-2451-0374; SHIN, Taekyun/0000-0002-9851-4354	Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2012R1A1B4001262]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1B4001262). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7; Avila J, 2010, EXPERT REV NEUROTHER, V10, P703, DOI 10.1586/ERN.10.40; Bahremand A, 2011, EUR J PHARMACOL, V666, P93, DOI 10.1016/j.ejphar.2011.05.043; BESSER R, 1987, NEUROLOGY, V37, P945, DOI 10.1212/WNL.37.6.945; Bian QM, 2007, BRAIN RES, V1184, P270, DOI 10.1016/j.brainres.2007.09.054; Casalbore P, 2010, J CELL PHYSIOL, V224, P710, DOI 10.1002/jcp.22170; Chang L W, 1990, J Toxicol Sci, V15 Suppl 4, P125; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chong ZZ, 2004, HISTOL HISTOPATHOL, V19, P495, DOI 10.14670/HH-19.495; Chuang DM, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00015; Crespo-Biel N, 2010, BIPOLAR DISORD, V12, P425, DOI 10.1111/j.1399-5618.2010.00825.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; EARLEY B, 1992, NEUROCHEM INT, V21, P351, DOI 10.1016/0197-0186(92)90186-U; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Eom TY, 2009, BIOL PSYCHIAT, V66, P494, DOI 10.1016/j.biopsych.2009.04.015; Fabrizi C, 2012, J NEURAL TRANSM, V119, P1295, DOI 10.1007/s00702-012-0785-z; FELDMAN RG, 1993, ARCH NEUROL-CHICAGO, V50, P1320, DOI 10.1001/archneur.1993.00540120035010; Fiedorowicz A, 2001, BRAIN RES, V912, P116, DOI 10.1016/S0006-8993(01)02675-0; Fiorentini A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014382; Geloso MC, 2011, NEUROCHEM INT, V58, P729, DOI 10.1016/j.neuint.2011.03.009; Ghasemi M, 2010, EPILEPSY BEHAV, V18, P171, DOI 10.1016/j.yebeh.2010.04.002; Gold AB, 2011, CURR DRUG TARGETS, V12, P243; Goodenough S, 2004, BRAIN RES, V1026, P116, DOI 10.1016/j.brainres.2004.08.021; Harry GJ, 2008, BRAIN RES, V1194, P8, DOI 10.1016/j.brainres.2007.11.076; Harry GJ, 2002, TOXICOL APPL PHARM, V180, P205, DOI 10.1006/taap.2002.9390; Tran HYP, 2012, FREE RADICAL BIO MED, V52, P1159, DOI 10.1016/j.freeradbiomed.2011.12.008; Jope RS, 2006, CURR DRUG TARGETS, V7, P1421, DOI 10.2174/1389450110607011421; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Jope RS, 2002, MOL PSYCHIATR, V7, pS35, DOI 10.1038/sj.mp.4001017; Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kim JS, 2008, J RADIAT RES, V49, P517, DOI 10.1269/jrr.08020; Kuramoto N, 2011, J NEUROSCI RES, V89, P552, DOI 10.1002/jnr.22588; Lai JS, 2006, EUR J PHARMACOL, V539, P18, DOI 10.1016/j.ejphar.2006.03.076; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Little AR, 2012, NEUROTOXICOL TERATOL, V34, P72, DOI 10.1016/j.ntt.2011.09.012; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Ogita K, 2004, NEUROPHARMACOLOGY, V47, P619, DOI 10.1016/j.neuropharm.2004.06.012; Perez-Costas E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008911; Ponce-Lopez T, 2011, BRAIN RES, V1426, P73, DOI 10.1016/j.brainres.2011.09.056; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sereno L, 2009, NEUROBIOL DIS, V35, P359, DOI 10.1016/j.nbd.2009.05.025; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shin EJ, 2005, NEUROSCIENCE, V133, P715, DOI 10.1016/j.neuroscience.2005.02.030; Shirakawa T, 2007, NEUROSCI RES, V59, P117, DOI 10.1016/j.neures.2007.06.1468; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takashima A, 1996, NEUROSCI LETT, V203, P33, DOI 10.1016/0304-3940(95)12257-5; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Wang Z, 2012, NEUROSCIENCE, V206, P190, DOI 10.1016/j.neuroscience.2011.12.043; Wine RN, 2009, NEUROTOX RES, V16, P280, DOI 10.1007/s12640-009-9060-y; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yan XB, 2007, BEHAV BRAIN RES, V177, P282, DOI 10.1016/j.bbr.2006.11.021; Yang M, 2012, NEUROCHEM INT, V61, P955, DOI 10.1016/j.neuint.2012.09.015; Yang M, 2011, BIOCHEM PHARMACOL, V82, P72, DOI 10.1016/j.bcp.2011.03.020; Yang M, 2010, NEUROBIOL LEARN MEM, V93, P487, DOI 10.1016/j.nlm.2010.01.006; Yao HB, 2002, J CHEM NEUROANAT, V23, P291, DOI 10.1016/S0891-0618(02)00014-5; Yoneyama M, 2008, NEUROCHEM INT, V52, P761, DOI 10.1016/j.neuint.2007.09.003; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang M, 2008, J NEUROSCI, V28, P4736, DOI 10.1523/JNEUROSCI.1177-08.2008	73	29	29	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e70356	10.1371/journal.pone.0070356			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218XC	WOS:000324465000061	23940567	Green Published, gold, Green Submitted			2022-02-06	
J	Kumar, S; Rao, SL; Chandramouli, BA; Pillai, S				Kumar, Sanjay; Rao, Shobini L.; Chandramouli, Bangalore A.; Pillai, Shibu			Reduced contribution of executive functions in impaired working memory performance in mild traumatic brain injury patients	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Brain injury; Working memory; Executive function; Neuropsychology	CLOSED-HEAD-INJURY; DIVIDED ATTENTION; DYSFUNCTION; IMPAIRMENTS; SEQUELAE; DEFICITS; LESIONS	Aim: Mild traumatic brain injury (MTBI) is associated with often selective impairment of both working memory (WM) and the executive functions (EFs). Research indicates that one of the commonest deficits present in MTBI patients falls in the domain of WM. We aimed to investigate the role of EFs in WM impairment following MTBI. Methods: Performance on the tests of EFs and the verbal and visuo-spatial WM of 30 consecutive MTBI patients were compared with age/education/IQ matched 30 normal healthy control participants. Correlation between EFs and WM was studied separately for the MTBI and the control group. Results: The MTBI and control group were tested on a range of EF tests and WM. The MTBI group was demonstrated impairment on verbal and visuo-spatial WM and category fluency tests only. Furthermore, the MTBI group had fewer significant correlations between the WM and EFs (5 out of 54 possible correlations) than in the control group (13 out of 54 possible correlations). Conclusions: We suggest that MTBI may lead to WM deficits as the contribution of executive processes to support the WM is diminished following MTBI. Such an understanding of the poor WM performance in MTBI patients will be helpful when planning appropriate strategies for cognitive rehabilitation. (C) 2013 Elsevier B.V. All rights reserved.	[Kumar, Sanjay] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; [Kumar, Sanjay; Rao, Shobini L.] Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Bangalore 560029, Karnataka, India; [Chandramouli, Bangalore A.; Pillai, Shibu] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India		Kumar, S (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	sanjay.kumar@psy.ox.ac.uk		Kumar, Sanjay/0000-0001-5018-4184	NIMHANS fellowship; Department of Biotechnology, Ministry of Science and Technology (Government of India)Department of Biotechnology (DBT) IndiaMinistry of Science and Technology, Government of India	This work was supported by an NIMHANS fellowship for Ph.D. to S. Kumar and a Department of Biotechnology, Ministry of Science and Technology (Government of India) grant to S.L. Rao.	ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; BADDELEY A, 1984, J EXP PSYCHOL GEN, V113, P518, DOI 10.1037/0096-3445.113.4.518; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blanchet S, 2009, BRAIN INJURY, V23, P111, DOI 10.1080/02699050802649688; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; de Oliveira FF, 2011, ARQ NEURO-PSIQUIAT, V69, P790, DOI 10.1590/S0004-282X2011000600013; DeHaan A, 2007, NEUROPSYCHOLOGIA, V45, P406, DOI 10.1016/j.neuropsychologia.2006.06.008; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Fossati P, 1999, PSYCHIAT RES, V89, P171, DOI 10.1016/S0165-1781(99)00110-9; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geary E. K., 2011, J INT NEUROPSYCH SOC, P1; Gilhooly K.J., 2002, THINK REASONING, V8, P165, DOI 10.1080/13546780244000006; Goldberg D., 1988, USERS GUIDE GEN HLTH; Hartman M, 2003, SCHIZOPHR RES, V63, P201, DOI 10.1016/S0920-9964(02)00353-5; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mayer A. R., 2011, HUMAN BRAIN MAPPING; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Miotto EC, 2012, CLIN NEUROLOGY NEURO; MORRIS RG, 1990, Q J EXP PSYCHOL-A, V42, P67, DOI 10.1080/14640749008401208; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Proctor A, 2000, BRAIN INJURY, V14, P633; Raven JC, 1939, PROGR MATRICES PERCE; Roca M, 2010, BRAIN, V133, P234, DOI 10.1093/brain/awp269; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Salthouse TA, 2003, J EXP PSYCHOL GEN, V132, P566, DOI 10.1037/0096-3445.132.4.566; Schelstraete MA, 2002, EXP AGING RES, V28, P269, DOI 10.1080/03610730290080326; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Vitali P, 2005, BRAIN LANG, V93, P32, DOI 10.1016/j.bandl.2004.08.005; Was Christopher A, 2008, Adv Cogn Psychol, V3, P399, DOI 10.2478/v10053-008-0004-5; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	49	29	29	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	AUG	2013	115	8					1326	1332		10.1016/j.clineuro.2012.12.038			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	198NJ	WOS:000322929300024	23374237				2022-02-06	
J	Wang, JQ; Fox, MA; Povlishock, JT				Wang, Jiaqiong; Fox, Michael A.; Povlishock, John T.			Diffuse Traumatic Axonal Injury in the Optic Nerve Does Not Elicit Retinal Ganglion Cell Loss	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Microglia/macrophage; Retinal ganglion cell survival; Traumatic axonal injury; Traumatic brain injury; Visual system; YFP-16 transgenic mice	C-JUN EXPRESSION; BRAIN-INJURY; NEURITE TRANSECTION; NEUROTROPHIC FACTOR; NEURONAL SURVIVAL; CALCIUM-CHANNEL; STRETCH-INJURY; MOUSE MODEL; TIME-COURSE; ADULT-RAT	Much of the morbidity after traumatic brain injury (TBI) is associated with traumatic axonal injury (TAI). Although most TAI studies focus on corpus callosum white matter, the visual system has received increased interest. To assess visual system TAI, we developed a mouse model of optic nerve TAI. It is unknown, however, whether this TAI causes retinal ganglion cell (RGC) death. To address this issue, YFP (yellow fluorescent protein)-16 transgenic mice were subjected to mild TBI and followed from 2 to 28 days. Neither TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling)-positive or cleaved caspase-3Yimmunoreactive RGCs were observed from 2 to 28 days after TBI. Quantification of immunoreactivity of Brn3a, an RGC marker, demonstrated no RGC loss; parallel electron microscopic analysis confirmed RGC viability. Persistent RGC survival was also consistent with the finding of reorganization in the proximal axonal segments after TAI, wherein microglia/macrophages remained inactive. In contrast, activated microglia/macrophages closely enveloped the distal disconnected, degenerating axonal segments at 7 to 28 days after injury, thereby confirming that this model consistently evoked TAI followed by disconnection. Collectively, these data provide novel insight into the evolving pathobiology associated with TAI that will form a foundation for future studies exploring TAI therapy and its downstream consequences.	[Wang, Jiaqiong; Fox, Michael A.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, 1101 E Marshall St,Sanger Hall,Room 12-048, Richmond, VA 23298 USA.	jtpovlis@vcu.edu		Fox, Michael/0000-0002-1649-7782	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD055813, NS047463]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grants HD055813 and NS047463.	Agudo M, 2008, MOL VIS, V14, P1050; Alarcon-Martinez L, 2010, VISION RES, V50, P2176, DOI 10.1016/j.visres.2010.08.014; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BRUCK W, 1995, ACTA NEUROPATHOL, V89, P363; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Catrinescu MM, 2012, EXP EYE RES, V97, P31, DOI 10.1016/j.exer.2012.02.006; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Comley LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017639; DALE SM, 1995, EXP NEUROL, V135, P67, DOI 10.1006/exnr.1995.1066; Dibas A, 2010, MOL VIS, V16, P330; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EMERY DG, 1991, EXP BRAIN RES, V86, P60; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Galindo-Romero C, 2011, EXP EYE RES, V92, P377, DOI 10.1016/j.exer.2011.02.008; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; Gown AM, 2002, J HISTOCHEM CYTOCHEM, V50, P449, DOI 10.1177/002215540205000401; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; HERDEGEN T, 1993, J NEUROBIOL, V24, P528, DOI 10.1002/neu.480240410; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Hu Y, 2012, NEURON, V73, P445, DOI 10.1016/j.neuron.2011.11.026; HULL M, 1994, NEUROSCI LETT, V178, P39, DOI 10.1016/0304-3940(94)90284-4; HULL M, 1994, J NEUROBIOL, V25, P92, DOI 10.1002/neu.480250109; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kielczewski JL, 2005, INVEST OPHTH VIS SCI, V46, P3188, DOI 10.1167/iovs.05-0321; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lefebvre JL, 2008, DEVELOPMENT, V135, P4141, DOI 10.1242/dev.027912; Leybaert L, 1996, EXP BRAIN RES, V112, P392, DOI 10.1007/BF00227945; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Liu PH, 2004, ANAT EMBRYOL, V207, P439, DOI 10.1007/s00429-003-0361-2; Liu PH, 2003, EXP NEUROL, V179, P111, DOI 10.1006/exnr.2002.8057; Lu Q, 2003, INVEST OPHTH VIS SCI, V44, P5342, DOI 10.1167/iovs.03-0444; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; Lukas TJ, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-5; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; MEIRI H, 1983, BRAIN RES, V263, P1, DOI 10.1016/0006-8993(83)91195-2; Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267; Nehrt A, 2007, NEUROSCIENCE, V146, P1504, DOI 10.1016/j.neuroscience.2007.02.015; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Palmer HS, 2010, J NEUROTRAUM, V27, P853, DOI 10.1089/neu.2009.1225; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; ROBINSON GA, 1994, MOL BRAIN RES, V24, P43, DOI 10.1016/0169-328X(94)90116-3; ROBINSON GA, 1995, MOL BRAIN RES, V30, P61, DOI 10.1016/0169-328X(94)00277-L; Rosenberg LJ, 2001, J NEUROPATH EXP NEUR, V60, P33, DOI 10.1093/jnen/60.1.33; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Smith PD, 2013, ANN THORAC SURG, V95, P1647, DOI 10.1016/j.athoracsur.2012.11.075; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; STRAUTMAN AF, 1990, J NEUROSCI, V10, P3564; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Viana LC, 2013, NEUROSCIENCE, V238, P280, DOI 10.1016/j.neuroscience.2013.02.019; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; XIANG MQ, 1995, J NEUROSCI, V15, P4762; XIE XY, 1991, J NEUROSCI, V11, P3257; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	72	29	29	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	2013	72	8					768	781		10.1097/NEN.0b013e31829d8d9d			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	299GI	WOS:000330383600006	23860030	Bronze, Green Accepted			2022-02-06	
J	Bali, N; Arimoto, JM; Morgan, TE; Finch, CE				Bali, N.; Arimoto, J. M.; Morgan, T. E.; Finch, C. E.			Progesterone Antagonism of Neurite Outgrowth Depends on Microglial Activation via Pgrmc1/S2R	ENDOCRINOLOGY			English	Article							MEMBRANE COMPONENT 1; BRAIN-INJURY; GENE-EXPRESSION; GRANULOSA-CELLS; ESTROUS-CYCLE; UP-REGULATION; PROTEIN; NEUROPROTECTION; RECEPTORS; ESTRADIOL	Neuronal plasticity is regulated by the ovarian steroids estradiol (E2) and progesterone (P4) in many normal brain functions, as well as in acute response to injury and chronic neurodegenerative disease. In a female rat model of axotomy, the E2-dependent compensatory neuronal sprouting is antagonized by P4. To resolve complex glial-neuronal cell interactions, we used the "wounding in-a-dish" model of neurons cocultured with astrocytes or mixed glia (microglia to astrocytes, 1: 3). Although both astrocytes and mixed glia supported E2-enhanced neurite outgrowth, P4 antagonized E2-induced neurite outgrowth only with mixed glia, but not astrocytes alone. We now show that P4-E2 antagonism of neurite outgrowth is mediated by microglial expression of progesterone receptor (Pgr) membrane component 1 (Pgrmc1)/S2R, a putative nonclassical Pgr mediator with multiple functions. The P4-E2 antagonism of neurite outgrowth was restored by add-back of microglia to astrocyte-neuron cocultures. Because microglia do not express the classical Pgr, we examined the role of Pgrmc1, which is expressed in microglia in vitro and in vivo. Knockdown by siRNA-Pgrmc1 in microglia before add-back to astrocyte-neuron cocultures suppressed the P4-E2 antagonism of neurite outgrowth. Conditioned media from microglia restored the P4-E2 activity, but only if microglia were activated by lipopolysaccharide or by wounding. Moreover, the microglial activation was blocked by Pgmrc1-siRNA knockdown. These findings explain why non-wounded cultures without microglial activation lack P4 antagonism of E2-induced neurite outgrowth. We suggest that microglial activation may influence brain responses to exogenous P4, which is a prospective therapy in traumatic brain injury. (Endocrinology 154: 2468-2480, 2013)	[Bali, N.; Arimoto, J. M.; Finch, C. E.] Univ So Calif, Dornsife Coll Letters Arts & Sci, Program Mol Biol, Los Angeles, CA 90089 USA; [Morgan, T. E.; Finch, C. E.] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA 90089 USA		Finch, CE (corresponding author), Univ So Calif, Davis Sch Gerontol, 3715 McClintock Ave,GER 336A, Los Angeles, CA 90089 USA.	cefinch@usc.edu	Finch, Caleb/AAA-7250-2022		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2P01 AG026572-06]; Project 2; Animal Core; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG026572] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant 2P01 AG026572-06 (to R.D.B.); Project 2 (to C.E.F and T.E.M); and Animal Core (to T.E.M.).	Aguirre CC, 2009, EUR J NEUROSCI, V29, P447, DOI 10.1111/j.1460-9568.2008.06591.x; Bali N, 2012, ENDOCRINOLOGY, V153, P759, DOI 10.1210/en.2011-1699; Bashour NM, 2012, ENDOCRINOLOGY, V153, P4457, DOI 10.1210/en.2012-1122; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Cahill MA, 2007, J STEROID BIOCHEM, V105, P16, DOI 10.1016/j.jsbmb.2007.02.002; Carroll JC, 2007, J NEUROSCI, V27, P13357, DOI 10.1523/JNEUROSCI.2718-07.2007; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009; Cuevas J, 2011, J PHARMACOL EXP THER, V339, P161, DOI 10.1124/jpet.111.182816; Gatson JW, 2011, ENDOCRINOLOGY, V152, P207, DOI 10.1210/en.2010-0724; Gerdes D, 1998, BIOL CHEM, V379, P907; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Intlekofer KA, 2011, NEUROSCIENCE, V176, P86, DOI 10.1016/j.neuroscience.2010.12.033; Jeon H, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-149; Johannessen M, 2011, AM J PHYSIOL-CELL PH, V300, pC328, DOI 10.1152/ajpcell.00383.2010; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Lefrancois T, 1997, J NEUROSCI, V17, P4121; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu LF, 2009, ENDOCRINOLOGY, V150, P3186, DOI 10.1210/en.2008-1447; Mir SUR, 2012, INT J CANCER, V131, pE1, DOI 10.1002/ijc.26432; Mir SUR, 2012, J BIOL CHEM, V287, P14494, DOI 10.1074/jbc.M111.324921; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Morgan TE, 1999, NEUROSCIENCE, V89, P687, DOI 10.1016/S0306-4522(98)00334-0; Ndiaye K, 2012, J REPROD IMMUNOL, V95, P15, DOI 10.1016/j.jri.2012.04.004; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Noreen M, 2012, INFLAMM RES, V61, P177, DOI 10.1007/s00011-011-0427-1; Oda S, 2011, DRUG METAB DISPOS, V39, P2057, DOI 10.1124/dmd.111.040907; Peluso JJ, 2010, MOL CELL ENDOCRINOL, V320, P153, DOI 10.1016/j.mce.2010.02.005; Peluso JJ, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.103036; Peluso JJ, 2012, ENDOCRINOLOGY, V153, P3929, DOI 10.1210/en.2011-2096; Peluso JJ, 2012, STEROIDS, V77, P1007, DOI 10.1016/j.steroids.2012.01.013; Peluso JJ, 2009, J CLIN ENDOCR METAB, V94, P2644, DOI 10.1210/jc.2009-0147; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Qin LY, 2005, GLIA, V52, P78, DOI 10.1002/glia.20225; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Rohe HJ, 2009, PHARMACOL THERAPEUT, V121, P14, DOI 10.1016/j.pharmthera.2008.09.006; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roy AA, 2006, J BIOL CHEM, V281, P32684, DOI 10.1074/jbc.M604416200; Runko E, 2004, J NEUROSCI, V24, P9015, DOI 10.1523/JNEUROSCI.2385-04.2004; Runko E, 1999, MOL CELL NEUROSCI, V14, P428, DOI 10.1006/mcne.1999.0794; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Shao R, 2003, BIOL REPROD, V68, P914, DOI 10.1095/biolreprod.102.009035; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Singer CA, 1999, J NEUROSCI, V19, P2455; Stone DJ, 2000, EXP NEUROL, V165, P46, DOI 10.1006/exnr.2000.7455; Su C, 2012, ENDOCRINOLOGY, V153, P4389, DOI 10.1210/en.2011-2177; Szczesna-Skorupa E, 2011, MOL PHARMACOL, V79, P340, DOI 10.1124/mol.110.068478; Wendler A, 2012, STEROIDS, V77, P1002, DOI 10.1016/j.steroids.2011.12.023; Wise PM, 2000, BIOL REPROD, V63, P982, DOI 10.1095/biolreprod63.4.982; Wong AM, 2009, ENDOCRINOLOGY, V150, P324, DOI 10.1210/en.2008-0988; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Xu JB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1386	58	29	30	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	JUL	2013	154	7					2468	2480		10.1210/en.2012-2109			13	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	169EL	WOS:000320760700024	23653459	Green Published, Bronze			2022-02-06	
J	Bennett, TD; Niedzwecki, CM; Korgenski, EK; Bratton, SL				Bennett, Tellen D.; Niedzwecki, Christian M.; Korgenski, E. Kent; Bratton, Susan L.			Initiation of Physical, Occupational, and Speech Therapy in Children With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Annual Assembly of the American-Academy-for-Physical-Medicine-and-Rehabilitation	NOV 18, 2011	Orlando, FL	Amer Acad Phys Med & Rehabil		Craniocerebral trauma; Occupational therapy; Pediatrics; Rehabilitation; Speech therapy	CRITICALLY-ILL PATIENTS; OF-CARE INDICATORS; UNITED-STATES; HEALTH-CARE; REHABILITATION; OUTCOMES	Objectives: (1) To determine factors associated with physical therapy (PT) or occupational therapy (OT) evaluation and speech or swallow therapy evaluation in hospitalized children with traumatic brain injury (TBI); (2) to describe when during the hospital stay the initial therapy evaluations typically occur; and (3) to quantify any between-hospital variation in therapy evaluation. Design: Retrospective cohort study. Setting: Children's hospitals participating in the Pediatric Health Information System database (January 2001 June 2011). Participants: Children (age <18y) with TBI (N=21,399) who were admitted to the intensive care unit and survived to hospital discharge. Interventions: Not applicable. Main Outcome Measures: PT or OT evaluation and speech or swallow therapy evaluation. A propensity score was calculated to allow comparison of expected with observed rates of therapy evaluations by the hospital. Results: The median hospital length of stay was 5 days (interquartile range, 3-10d). Overall, 8748 (41%) of 21,399 children received either a PT or OT evaluation, and 5490 (26%) out of 21,399 children received either a speech or swallow evaluation. Older children and those with higher energy injury mechanisms, more severe injuries, extremity fractures, more treatment with neuromuscular blocking agents or pentobarbital, and admission to a hospital with an American College of Surgeons Level I pediatric trauma designation were more likely to receive therapy evaluations. The median time until the first therapy evaluation was 5 (PT or OT) and 7 days (speech or swallow). Expected hospital evaluation rates were 25% to 54% (PT or OT) and 16% to 35% (speech or swallow), while observed hospital evaluation rates were 11% to 74% (PT or OT) and 4% to 55% (speech or swallow). Conclusions: There is wide between-hospital variation in provision of rehabilitation therapies for children with TBI. Evidence-based criteria for initiation of routine therapy evaluations after TBI are needed. (C) 2013 by the American Congress of Rehabilitation Medicine	[Bennett, Tellen D.; Bratton, Susan L.] Univ Utah, Sch Med, Salt Lake City, UT 84158 USA; [Niedzwecki, Christian M.] Baylor Coll Med, Houston, TX 77030 USA; [Korgenski, E. Kent] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA		Bennett, TD (corresponding author), Univ Utah, Sch Med, POB 581289, Salt Lake City, UT 84158 USA.	tell.bennett@hsc.utah.edu	Bratton, Susan L./O-2353-2013; Guenat, Heather/H-6528-2014	Bratton, Susan L./0000-0002-4605-8078; Bennett, Tellen/0000-0003-1483-4236	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [KM1CA156723] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001067] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001067] Funding Source: Medline; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [KM1 CA156723, 1KM1CA156723] Funding Source: Medline		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; American College of Surgeons Trauma Programs, 2012, VER TRAUM CTR; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Beaulieu CL, 2002, SURG CLIN N AM, V82, P393, DOI 10.1016/S0039-6109(02)00009-9; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Bennett TD, 2012, CRIT CARE MED, V40, P208, DOI 10.1097/CCM.0b013e31822e9d31; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Carroll Christopher P, 2010, Ann Adv Automot Med, V54, P233; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Conway PH, 2009, J PEDIATR-US, V154, P789, DOI 10.1016/j.jpeds.2009.01.010; Dumas HM, 2002, AM J PHYS MED REHAB, V81, P661, DOI 10.1097/00002060-200209000-00005; Fan E, 2012, RESP CARE, V57, P933, DOI 10.4187/respcare.01634; Gerber JS, 2010, PEDIATRICS, V126, P1067, DOI 10.1542/peds.2010-1275; Goldin AB, 2007, PEDIATRICS, V119, P905, DOI 10.1542/peds.2006-2040; Goodman DC, 2009, PEDIATR CLIN N AM, V56, P745, DOI 10.1016/j.pcl.2009.05.007; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KRAUS JF, 1987, PEDIATRICS, V79, P501; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Medicare Learning Network, 2011, INP REH THER SERV CO; Needham DM, 2010, ARCH PHYS MED REHAB, V91, P536, DOI 10.1016/j.apmr.2010.01.002; Rivara FP, 2012, ARCH PHYS MED REHAB, V93, P381, DOI 10.1016/j.apmr.2011.08.015; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rivara FP, 2012, ARCH PHYS MED REHAB, V93, P1371, DOI 10.1016/j.apmr.2012.02.031; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089; Tri-Analytics Inc. and The Johns Hopkins University, 1997, ICDMAP 90 SOFTW US G; US Health Care Financing Administration, 2007, INT CLASS DIS; Weiss PF, 2009, J PEDIAT, V155; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	33	29	29	1	42	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2013	94	7					1268	1276		10.1016/j.apmr.2013.02.021			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	182GG	WOS:000321729100007	23473704	Green Accepted			2022-02-06	
J	Kuo, JR; Cheng, YH; Chen, YS; Chio, CC; Gean, PW				Kuo, Jinn-Rung; Cheng, Yi-Hsuan; Chen, Yi-Shion; Chio, Chung-Ching; Gean, Po-Wu			Involvement of Extracellular Signal Regulated Kinases in Traumatic Brain Injury-Induced Depression in Rodents	JOURNAL OF NEUROTRAUMA			English	Article						antidepressant; depression; extracellular signal regulated kinases (ERK); hippocampus; traumatic brain injury	MAP KINASE; FLUOXETINE; DISORDER; BEHAVIOR; MODEL; RATES	Traumatic brain injury (TBI) is the most common cause of death and acquired disability among children and young adults in the developed countries. In clinical studies, the incidence of depression is high after TBI, and the mechanisms behind TBI-induced depression remain unclear. In the present study, we subjected rats to a moderate fluid percussion into the closed cranial cavity to induce TBI. After 3 days of recovery, injured rats were given a forced swim test (FST) and novelty-suppressed feeding tests. We found that TBI rats exhibited increased duration of immobility and longer latency to begin chewing food in a new environment compared with sham-operated rats. Western blot analysis showed that TBI led to a decrease in the phosphorylated levels of extracellular signal regulated kinases (ERK1/2) and p38 mitogen-activated protein kinase (p38 MAPK). Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), significantly reduced the duration of immobility when administered once per day for 14 days. Consistent with behavioral tests, fluoxetine treatment reversed TBI-induced decrease in p-ERK1/2 and p-p38 MAPK levels. Pre-treatment with a selective tryptophan hydroxylase inhibitor para-chlorophenylalanine (PCPA) blocked the antidepressant effect of fluoxetine. PCPA also prevented the effect of fluoxetine on ERK1/2 phosphorylation without affecting p38 MAPK phosphorylation. Pre-treatment with ERK inhibitor SL327 but not p38 MAPK inhibitor SB203580 prevented the antidepressant effect of fluoxetine. These results suggest that ERK1/2 plays a critical role in TBI-induced depression.	[Kuo, Jinn-Rung; Chio, Chung-Ching] Taiwan Univ Sci & Technol, Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan; [Kuo, Jinn-Rung] Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Cheng, Yi-Hsuan; Chen, Yi-Shion; Gean, Po-Wu] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan		Gean, PW (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.	Chiocc@ms28.hinet.net; powu@mail.ncku.edu.tw			National Health Research InstituteNational Health Research Institutes - Taiwan [NHRI-EX101-10117NI]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC101-2321-B-006-025]; Aim for the Top University Project of the National Cheng-Kung University	This study was supported by grants NHRI-EX101-10117NI from the National Health Research Institute, NSC101-2321-B-006-025 from the National Science Council and Aim for the Top University Project of the National Cheng-Kung University. We thank Dr Min-Der Lai for critical comments on thearticle.	Adachi M, 2008, BIOL PSYCHIAT, V63, P642, DOI 10.1016/j.biopsych.2007.09.019; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; CLIFTON PG, 1989, PSYCHOPHARMACOLOGY, V97, P89, DOI 10.1007/BF00443419; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Duman CH, 2007, BIOL PSYCHIAT, V61, P661, DOI 10.1016/j.biopsych.2006.05.047; Duric V, 2010, NAT MED, V16, P1328, DOI 10.1038/nm.2219; Dwivedi Y, 2001, J NEUROCHEM, V77, P916, DOI 10.1046/j.1471-4159.2001.00300.x; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Feng PF, 2003, BRAIN RES, V991, P195, DOI 10.1016/j.brainres.2003.08.018; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Fumagalli F, 2005, J NEUROCHEM, V93, P1551, DOI 10.1111/j.1471-4159.2005.03149.x; Harrison PJ, 2002, BRAIN, V125, P1428, DOI 10.1093/brain/awf149; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber D, 2008, NATURE, V451, P61, DOI 10.1038/nature06445; Iversen L, 2003, BRAIN, V126, P1252, DOI 10.1093/brain/awg143; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; KOE BK, 1966, J PHARMACOL EXP THER, V154, P499; MacQueen GM, 2008, BIOL PSYCHIAT, V64, P880, DOI 10.1016/j.biopsych.2008.06.027; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; Nielsen CK, 2000, BEHAV BRAIN RES, V107, P21; Page ME, 1999, PSYCHOPHARMACOLOGY, V147, P162, DOI 10.1007/s002130051156; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Rajkowska G, 2003, NEUROSCIENTIST, V9, P273, DOI 10.1177/1073858403252773; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Savitz J, 2009, NEUROSCI BIOBEHAV R, V33, P699, DOI 10.1016/j.neubiorev.2009.01.004; Sheline YI, 2003, BIOL PSYCHIAT, V54, P338, DOI 10.1016/S0006-3223(03)00347-0; Stedenfeld KA, 2011, PHYSIOL BEHAV, V103, P210, DOI 10.1016/j.physbeh.2011.02.001; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Yin HQ, 2008, INFLAMMATION, V31, P65, DOI 10.1007/s10753-007-9050-2; Zheng SQ, 2004, MOL PHARMACOL, V65, P1172, DOI 10.1124/mol.65.5.1172	37	29	29	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1223	1231		10.1089/neu.2012.2689			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100002	23360216	Green Published			2022-02-06	
J	Failla, MD; Burkhardt, JN; Miller, MA; Scanlon, JM; Conley, YP; Ferrell, RE; Wagner, AK				Failla, Michelle D.; Burkhardt, Josh N.; Miller, Megan A.; Scanlon, Joelle M.; Conley, Yvette P.; Ferrell, Robert E.; Wagner, Amy K.			Variants of SLC6A4 in depression risk following severe TBI	BRAIN INJURY			English	Article						5-HTTLPR; depression; gene variation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEROTONIN TRANSPORTER GENE; STRESSFUL LIFE EVENTS; TRANSCRIPTION FACTOR AP-2; MESSENGER-RNA LEVELS; MAJOR DEPRESSION; PROMOTER REGION; 5-HTTLPR; POLYMORPHISM; ASSOCIATION	Background: Post-traumatic depression (PTD) may be a result of several factors like secondary injury chemical cascades as well as psycho-social factors following traumatic brain injury (TBI). While the role of serotonin in the pathology and treatment of idiopathic major depression may be somewhat controversial, it is unclear what role serotonin may play in PTD following a TBI. Objective: To assess serotonergic function and genetic risk for PTD development over 1 year following TBI. Research design: Examination of variation in the serotonin transporter gene [SLC6A4 (5-HTTLPR, rs25331, and a variable number of tandem repeats variant in Intron 2)] in 109 subjects with moderate-severe injury. Depression was assessed using the Patient Health Questionnaire (PHQ-9) at 6 and/or 12 months post-injury. Main outcomes and results: At 6 months post-injury, subjects with a history of pre-morbid mood disorders and 5-HTTLPR L-homozygotes were at greater risk for PTD. Contrary to major depression, subjects without pre-morbid mood disorders (n = 80) and S-carriers were 2.803-times less likely to be depressed compared to L-homozygotes. At 12 months postinjury, LG-carriers were also less likely to experience PTD. Temporal analysis also showed 5-HTTLPR associations in PTD development across recovery. Conclusions: This study suggests a unique injury-and temporally-specific interaction between TBI and genetic risk for depression.	[Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Burkhardt, Josh N.; Miller, Megan A.; Scanlon, Joelle M.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15213 USA; [Ferrell, Robert E.] Univ Pittsburgh, Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, 3471 5th Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067	CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR323155]; DODUnited States Department of Defense [W81XWH-071-0701]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR008424, R01 HD048162]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424] Funding Source: NIH RePORTER	Sources of Support: CDC: R49 CCR323155; DOD: W81XWH-071-0701; NIH R01NR008424, and R01 HD048162.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Damberg M, 2005, J NEURAL TRANSM, V112, P1281, DOI 10.1007/s00702-005-0325-1; Edenberg HJ, 1998, PSYCHIATR GENET, V8, P193, DOI 10.1097/00041444-199800830-00011; Erritzoe D, 2010, J NEUROSCI, V30, P3391, DOI 10.1523/JNEUROSCI.2852-09.2010; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Faraone SV, 2005, BIOL PSYCHIAT, V57, P1313, DOI 10.1016/j.biopsych.2004.11.024; Faul M, 2010, TRAUMATIC BRAIN INJU; Frodl T, 2008, MOL PSYCHIATR, V13, P1093, DOI 10.1038/mp.2008.62; Frodl T, 2004, ARCH GEN PSYCHIAT, V61, P177, DOI 10.1001/archpsyc.61.2.177; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Garcia MA, 1996, J NEUROSCI, V16, P7550; Gelernter J, 1999, AM J MED GENET, V88, P61, DOI 10.1002/(SICI)1096-8628(19990205)88:1<61::AID-AJMG11>3.0.CO;2-K; Gould KR, PSYCHOL MED, V201, P1; Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829; Heils A, 1996, J NEUROCHEM, V66, P2621; Ho P-S, PSYCHIAT RES NEUROIM; Homberg JR, 2011, BIOL PSYCHIAT, V69, P513, DOI 10.1016/j.biopsych.2010.09.024; Hranilovic D, 2004, BIOL PSYCHIAT, V55, P1090, DOI 10.1016/j.biopsych.2004.01.029; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Karg K, 2011, ARCH GEN PSYCHIAT, V68, P444, DOI 10.1001/archgenpsychiatry.2010.189; Kenna GA, 2012, PHARMACOGN PERS MED, V5, P19, DOI 10.2147/PGPM.S23462; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kobiella A., 2011, TRANSL PSYCHIAT, V1, P1; Krishnan V, 2008, NATURE, V455, P894, DOI 10.1038/nature07455; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Little KY, 1998, AM J PSYCHIAT, V155, P207; Lotrich Francis E, 2003, Am J Pharmacogenomics, V3, P145, DOI 10.2165/00129785-200303020-00007; Mak KK, 2013, J NEUROL NEUROSUR PS, V84, P322, DOI 10.1136/jnnp-2012-303791; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; Ogilvie AD, 1996, LANCET, V347, P731, DOI 10.1016/S0140-6736(96)90079-3; Parsey RV, 2006, AM J PSYCHIAT, V163, P48, DOI 10.1176/appi.ajp.163.1.48; Philibert R, 2007, AM J MED GENET B, V144B, P101, DOI 10.1002/ajmg.b.30414; Praschak-Rieder N, 2007, BIOL PSYCHIAT, V62, P327, DOI 10.1016/j.biopsych.2006.09.022; Rees M, 1997, MOL PSYCHIATR, V2, P398, DOI 10.1038/sj.mp.4000256; Reimold M, 2007, J NEURAL TRANSM, V114, P635, DOI 10.1007/s00702-006-0609-0; Risch N, 2009, JAMA-J AM MED ASSOC, V301, P2462, DOI 10.1001/jama.2009.878; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1974, LANCET, V2, P81; Van Dyck CH, 2004, AM J PSYCHIAT, V161, P525, DOI 10.1176/appi.ajp.161.3.525; van Ijzendoorn MH, 2010, BIOL PSYCHIAT, V68, P405, DOI 10.1016/j.biopsych.2010.05.008; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; Wendland JR, 2006, MOL PSYCHIATR, V11, P224, DOI 10.1038/sj.mp.4001789; Wozniak G, 2010, NEUROSURG QUART, V20, P297, DOI 10.1097/WNQ.0b013e3181732399; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006; Zalsman G, 2006, AM J PSYCHIAT, V163, P1588, DOI 10.1176/appi.ajp.163.9.1588	60	29	29	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2013	27	6					696	706		10.3109/02699052.2013.775481			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	143QO	WOS:000318882500009	23672445				2022-02-06	
J	Clavisi, O; Bragge, P; Tavender, E; Turner, T; Gruen, RL				Clavisi, Ornella; Bragge, Peter; Tavender, Emma; Turner, Tari; Gruen, Russell L.			Effective stakeholder participation in setting research priorities using a Global Evidence Mapping approach	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Prioritization; Traumatic brain injury; Research funding; Evidence mapping; Research gaps; Rehabilitation	TRAUMATIC BRAIN-INJURY; HEALTH; REHABILITATION	Objective: We present a multistep process for identifying priority research areas in rehabilitation and long-term care of traumatic brain-injured (TBI) patients. In particular, we aimed to (1) identify which stakeholders should be involved; (2) identify what methods are appropriate; (3) examine different criteria for the generation of research priority areas; and (4) test the feasibility of linkage and exchange among researchers, decision makers, and other potential users of the research. Study Design and Setting: Potential research questions were identified and developed using an initial scoping meeting and preliminary literature search, followed by a facilitated mapping workshop and an online survey. Identified research questions were then prioritized against specific criteria (clinical importance, novelty, and controversy). Existing evidence was then mapped to the high-priority questions using usual processes for search, screening, and selection. A broad range of stakeholders were then brought together at a forum to identify priority research themes for future research investment. Using clinical and research leaders, smaller targeted planning workshops prioritized specific research projects for each of the identified themes. Results: Twenty-six specific questions about TBI rehabilitation were generated, 14 of which were high priority. No one method identified all high-priority questions. Methods that relied solely on the views of clinicians and researchers identified fewer high-priority questions compared with methods that used broader stakeholder engagement. Evidence maps of these high-priority questions yielded a number of evidence gaps. Priority questions and evidence maps were then used to inform a research forum, which identified 12 priority themes for future research. Conclusion: Our research demonstrates the value of a multistep and multimethod process involving many different types of stakeholders for prioritizing research to improve the rehabilitation outcomes of people who have suffered TBI. Enhancing stakeholder representation can be augmented using a combination of methods and a process of linkage and exchange. This process can inform decisions about prioritization of research areas. (C) 2013 Elsevier Inc. All rights reserved.	[Clavisi, Ornella; Bragge, Peter; Tavender, Emma; Gruen, Russell L.] Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Clavisi, Ornella; Bragge, Peter; Tavender, Emma; Gruen, Russell L.] Monash Univ, Melbourne, Vic 3004, Australia; [Turner, Tari] Monash Univ, Australasian Cochrane Ctr, Dept Epidemiol & Preventat Med, Melbourne, Vic 3004, Australia		Gruen, RL (corresponding author), Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Level 4,89 Commercial Rd, Melbourne, Vic 3004, Australia.	russell.gruen@monash.edu		Tavender, Emma/0000-0002-7230-712X; Turner, Tari/0000-0002-7990-1623; Bragge, Peter/0000-0003-0745-5131	Victorian Transport Accident Commission; Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	The Global Evidence Mapping Initiative is supported by the Victorian Transport Accident Commission. The authors thank Jason Wasiak, Loyal Pattuwage, Marisa Chau, Marion Cincotta, Haifa Sekkouah, and Anne Parkhill for their valuable input to this work. R.L.G. is supported by a Practitioner Fellowship from the Australian National Health and Medical Research Council.	Anderson Stuart, 2008, Health Res Policy Syst, V6, P7, DOI 10.1186/1478-4505-6-7; [Anonymous], 2000, Health Policy Plan, V15, P130; Arvidsson E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-71; BATTISTA RN, 1995, CAN MED ASSOC J, V153, P1233; BOWLING A, 1993, SOC SCI MED, V37, P851, DOI 10.1016/0277-9536(93)90138-T; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Doyle J, 2005, J EPIDEMIOL COMMUN H, V59, P193, DOI 10.1136/jech.2003.019547; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Institute of Medicine, 2008, KNOW WHAT WORKS HLTH; Kapiriri Lydia, 2002, Health Expect, V5, P55; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Lomas J, 2003, MILBANK Q, V81, P363, DOI 10.1111/1468-0009.t01-1-00060; McKinlay E, 2001, CLIN PRACTICE GUIDEI; Noorani HZ, 2007, INT J TECHNOL ASSESS, V23, P310, DOI 10.1017/S026646230707050X; Oliver S, 2006, EVALUATION PUBLIC IN; Oxman Andrew D, 2006, Health Res Policy Syst, V4, P14, DOI 10.1186/1478-4505-4-14; Sassi F, 2003, HEALTH POLICY, V63, P141, DOI 10.1016/S0168-8510(02)00061-1; Sibbald SL, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-43; SitthiAmorn C, 1995, INT J TECHNOL ASSESS, V11, P663, DOI 10.1017/S0266462300009090; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; VANDEVEN A, 1971, ACAD MANAGE J, V14, P203, DOI 10.2307/255307; World Health Organization, 2002, COMM LANG FUNCT DIS; World Health Organization, 2008, ICF BROWS; YANG J M, 1987, Yonsei Medical Journal, V28, P60	24	29	29	1	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	MAY	2013	66	5					496	502		10.1016/j.jclinepi.2012.04.002			7	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	125QW	WOS:000317557400007	22819249				2022-02-06	
J	Nishijima, DK; Haukoos, JS; Newgard, CD; Staudenmayer, K; White, N; Slattery, D; Maxim, PC; Gee, CA; Hsia, RY; Melnikow, JA; Holmes, JF				Nishijima, Daniel K.; Haukoos, Jason S.; Newgard, Craig D.; Staudenmayer, Kristan; White, Nathan; Slattery, David; Maxim, Preston C.; Gee, Christopher A.; Hsia, Renee Y.; Melnikow, Joy A.; Holmes, James F.			Variability of ICU Use in Adult Patients With Minor Traumatic Intracranial Hemorrhage	ANNALS OF EMERGENCY MEDICINE			English	Article							BRAIN-INJURY; EMERGENCY-DEPARTMENT; AMERICAN-COLLEGE; ADMISSION; TOMOGRAPHY; UTILITY; RULE	Study objective: Patients with minor traumatic intracranial hemorrhage are frequently admitted to the ICU, although many never require critical care interventions. To describe ICU resource use in minor traumatic intracranial hemorrhage, we assess (1) the variability of ICU use in a cohort of patients with minor traumatic intracranial hemorrhage across multiple trauma centers, and (2) the proportion of adult patients with traumatic intracranial hemorrhage who are admitted to the ICU and never receive a critical care intervention during hospitalization. In addition, we evaluate the association between ICU admission and key independent variables. Methods: A structured, historical cohort study of adult patients (aged 18 years and older) with minor traumatic intracranial hemorrhage was conducted within a consortium of 8 Level I trauma centers in the western United States from January 2005 to June 2010. The study population included patients with minor traumatic intracranial hemorrhage, defined as an emergency department (ED) Glasgow Coma Scale (GCS) score of 15 (normal mental status) and an Injury Severity Score less than 16 (no other major organ injury). The primary outcome measure was initial ICU admission. The secondary outcome measure was a critical care intervention during hospitalization. Critical care interventions included mechanical ventilation, neurosurgical intervention, transfusion of blood products, vasopressor or inotrope administration, and invasive hemodynamic monitoring. ED disposition and the proportion of ICU patients not receiving a critical care intervention were compared across sites with descriptive statistics. The association between ICU admission and predetermined independent variables was analyzed with multivariable regression. Results: Among 11,240 adult patients with traumatic intracranial hemorrhage, 1,412 (13%) had minor traumatic intracranial hemorrhage and complete ED disposition data (mean age 48 years; SD 20 years). ICU use within this cohort across sites ranged from 50% to 97%. Overall, 847 of 888 patients (95%) with minor traumatic intracranial hemorrhage who were admitted to the ICU did not receive a critical care intervention during hospitalization (range between sites 80% to 100%). Three of 524 (0.6%) patients discharged home or admitted to the observation unit or ward received a critical care intervention. After controlling for severity of injury (age, blood pressure, and Injury Severity Score), study site was independently associated with ICU admission (odds ratios ranged from 1.5 to 30; overall effect P<.001). Conclusion: Across a consortium of trauma centers in the western United States, there was wide variability in ICU use within a cohort of patients with minor traumatic intracranial hemorrhage. Moreover, a large proportion of patients admitted to the ICU never required a critical care intervention, indicating the potential to improve use of critical care resources in patients with minor traumatic intracranial hemorrhage.	[Nishijima, Daniel K.; Holmes, James F.] UC Davis Sch Med, Dept Emergency Med, Sacramento, CA USA; [Melnikow, Joy A.] UC Davis Sch Med, Dept Family & Community Med, Sacramento, CA USA; [Haukoos, Jason S.] Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO USA; [Newgard, Craig D.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; [Staudenmayer, Kristan] Stanford Univ, Sch Med, Dept Surg, Palo Alto, CA 94304 USA; [White, Nathan] Univ Washington, Sch Med, Div Emergency Med, Seattle, WA USA; [Slattery, David] Univ Nevada, Sch Med, Dept Emergency Med, Las Vegas, NV 89154 USA; [Maxim, Preston C.; Hsia, Renee Y.] UCSF Sch Med, Dept Emergency Med, San Francisco, CA USA; [Gee, Christopher A.] Univ Utah, Sch Med, Div Emergency Med, Salt Lake City, UT USA		Nishijima, DK (corresponding author), UC Davis Sch Med, Dept Emergency Med, Sacramento, CA USA.	daniel.nishijima@ucdmc.ucdavis.edu		White, Nathan/0000-0002-3752-310X	UC Davis Clinical and Translational Science Center [UL1 RR024146]; Colorado Clinical and Translational Science Institute [UL1 RR025780]; Oregon Clinical and Translational Research Institute [UL1 RR024140]; Stanford Center for Clinical and Translational Education and Research [1UL1 RR025744]; Institute of Translational Health Sciences at the University of Washington [UL1 RR025014]; University of Utah Center for Clinical and Translational Science [UL1-RR025764, C06-RR11234]; UCSF Clinical and Translational Science Institute [UL1 RR024131]; Robert Wood Johnson Foundation (RWJF) Physician Faculty Scholars ProgramRobert Wood Johnson Foundation (RWJF); National Center for Advancing Translational Sciences [NCATS], a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000421] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025744, UL1RR024140, UL1RR024131, UL1RR025764, UL1RR025014, UL1RR025780, C06RR011234, UL1RR024146] Funding Source: NIH RePORTER	Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. This project was supported by the UC Davis Clinical and Translational Science Center (grant UL1 RR024146), Colorado Clinical and Translational Science Institute (grant UL1 RR025780), Oregon Clinical and Translational Research Institute (grant UL1 RR024140), Stanford Center for Clinical and Translational Education and Research (grant 1UL1 RR025744), Institute of Translational Health Sciences at the University of Washington (grant UL1 RR025014), University of Utah Center for Clinical and Translational Science (grants UL1-RR025764 and C06-RR11234), UCSF Clinical and Translational Science Institute (grant UL1 RR024131), and the Robert Wood Johnson Foundation (RWJF) Physician Faculty Scholars Program. All Clinical and Translational Science Awards are from the National Center for Research Resources (now National Center for Advancing Translational Sciences [NCATS]), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The NIH and the RWJF had no role in the design and conduct of the study, in the analysis or interpretation of the data, or in the preparation of the data. Dr. Nishijima had full access to all the data and had final responsibility for the decision to submit for publication. The views expressed in this article are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH. Information on NCATS is available at http://www.ncats.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translationalasp.	[Anonymous], HEAD INJ TRIAG ASS I; Baker N, 2010, REDUCING COSTS APPRO; Barker DE, 2006, AM SURGEON, V72, P1166; Bolorunduro OB, 2011, J SURG RES, V166, P40, DOI 10.1016/j.jss.2010.04.012; BONE RC, 1993, CHEST, V104, P1806, DOI 10.1378/chest.104.6.1806; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Egol A, 1999, CRIT CARE MED, V27, P633; Escher M, 2004, BRIT MED J, V329, P425, DOI 10.1136/bmj.329.7463.425; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Huynh T, 2006, AM SURGEON, V72, P1162; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; Newgard CD, 2011, J AM COLL SURGEONS, V213, P709, DOI 10.1016/j.jamcollsurg.2011.09.012; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; Robert R, 2012, AM J RESP CRIT CARE, V185, P1081, DOI 10.1164/rccm.201104-0729OC; Salottolo K, 2009, INJURY, V40, P999, DOI 10.1016/j.injury.2009.05.013; Schaller B, 2010, EMERG MED J, V27, P537, DOI 10.1136/emj.2009.073031; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; U.S. Department of Health and Human Services, 1997, INT CLASS DIS 9 REV; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; Viera AJ, 2005, FAM MED, V37, P360; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Welch RD, 2001, EMERG MED CLIN N AM, V19, P137, DOI 10.1016/S0733-8627(05)70172-3; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021; Zehtabchi S, 2011, ACAD EMERG MED, V18, P637, DOI 10.1111/j.1553-2712.2011.01083.x	36	29	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAY	2013	61	5					509	517		10.1016/j.annemergmed.2012.08.024			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	145OW	WOS:000319027500003	23021347	hybrid, Green Accepted			2022-02-06	
J	Bolorunduro, OB; Haider, AH; Oyetunji, TA; Khoury, A; Cubangbang, M; Haut, ER; Greene, WR; Chang, DC; Cornwell, EE; Siram, SM				Bolorunduro, Oluwaseyi B.; Haider, Adil H.; Oyetunji, Tolulope A.; Khoury, Amal; Cubangbang, Maricel; Haut, Elliot R.; Greene, Wendy R.; Chang, David C.; Cornwell, Edward E., III; Siram, Suryanarayana M.			Disparities in trauma care: are fewer diagnostic tests conducted for uninsured patients with pelvic fracture?	AMERICAN JOURNAL OF SURGERY			English	Article						Pelvic fracture; Disparities; Uninsured; Procedures; Trauma; Diagnostic tests	INSURANCE STATUS; MASSACHUSETTS; MORTALITY; ASSOCIATION; OUTCOMES; CHILDREN; ACCESS	BACKGROUND: Research from other medical specialties suggests that uninsured patients experience treatment delays, receive fewer diagnostic tests, and have reduced health literacy when compared with their insured counterparts. We hypothesized that these disparities in interventions would not be present among patients experiencing trauma. Our objective was to examine differences in diagnostic and therapeutic procedures administered to patients undergoing trauma with pelvic fractures using a national database. METHODS: A retrospective analysis was conducted using the National Trauma Data Bank (NTDB), 2002 to 2006. Patients aged 18 to 64 years who experienced blunt injuries with pelvic fractures were analyzed. Patients who were dead on arrival, those with an injury severity score (ISS) less than 9, those with traumatic brain injury, and patients with burns were excluded. The likelihood of the uninsured receiving select diagnostic and therapeutic procedures was compared with the same likelihood in the insured. Multivariate analysis for mortality was conducted, adjusting for age, sex, race, ISS, presence of shock, Glasgow Coma Scale (GCS) motor score, and mechanism of injury. RESULTS: Twenty-one thousand patients met the inclusion criteria: 82% of these patients were insured and 18% were uninsured. There was no clinical difference in ISSs (21 vs 20), but the uninsured were more likely to present in shock (P < .001). The mortality rate in the uninsured was 11.6% vs 5.0% in the insured (P < .001). The uninsured were less likely to receive vascular ultrasonography (P - .01) and computed tomography (CT) of the abdomen (P < .005). There was no difference in the rates of CT of the thorax and abdominal ultrasonography, but the uninsured were more likely to receive radiographs. There was no difference in exploratory laparotomy and fracture reduction, but uninsured patients were less likely to receive transfusions, central venous pressure (CVP) monitoring, or arterial catheterization for embolization. Insurance-based disparities were less evident in level 1 trauma centers. CONCLUSIONS: Uninsured patients with pelvic fractures get fewer diagnostic procedures compared with their insured counterparts; this disparity is much greater for more invasive and resource-intensive tests and is less apparent in level 1 trauma centers. Differences in care that patients receive after trauma may be 1 of the mechanisms that leads to insurance disparities in outcomes after trauma. (C) 2013 Elsevier Inc. All rights reserved.	[Bolorunduro, Oluwaseyi B.; Oyetunji, Tolulope A.; Khoury, Amal; Cubangbang, Maricel; Greene, Wendy R.; Chang, David C.; Cornwell, Edward E., III; Siram, Suryanarayana M.] Howard Univ, Coll Med, Howard Hopkins Ctr Outcomes Res, Dept Surg, Washington, DC 20060 USA; [Haider, Adil H.; Haut, Elliot R.] Johns Hopkins Sch Med, Ctr Surg Trials & Outcomes Res, Baltimore, MD USA		Bolorunduro, OB (corresponding author), Howard Univ, Coll Med, Howard Hopkins Ctr Outcomes Res, Dept Surg, 2041 Georgia Ave Northwest, Washington, DC 20060 USA.	obolorun@gmail.com	Haut, Elliott R./J-3948-2019	Oyetunji, Tolulope/0000-0003-3039-7195; Haut, Elliott/0000-0001-7075-771X			Center for American Progress, MOR AM LOS HLTH INS; Downing SR, 2011, J TRAUMA, V70, P130, DOI 10.1097/TA.0b013e3182032b34; Fowler RA, 2010, AM J RESP CRIT CARE, V181, P1003, DOI 10.1164/rccm.200902-0281ST; Greene WR, 2010, AM J SURG, V199, P554, DOI 10.1016/j.amjsurg.2009.11.005; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Hadley J, 2007, JAMA-J AM MED ASSOC, V297, P1774; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Halpern MT, 2009, ANN SURG ONCOL, V16, P562, DOI 10.1245/s10434-008-0205-7; *IOM, 2002, CAR COV TOO LITTL TO; Oyetunji TA, 2011, J SURG RES, V165, pE37, DOI 10.1016/j.jss.2010.09.025; Pierce CA, 2008, J TRAUMA, V64, P932, DOI 10.1097/TA.0b013e318166b808; Quintana JM, 1997, INT J QUAL HEALTH C, V9, P419, DOI 10.1093/intqhc/9.6.419; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; U. S. Census Bureau, 2008, INC POV HLTH INS COV; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; Zhu J, 2010, J GEN INTERN MED, V25, P1356, DOI 10.1007/s11606-010-1482-y	17	29	29	0	2	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610			AM J SURG	Am. J. Surg.	APR	2013	205	4					365	370		10.1016/j.amjsurg.2012.10.026			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Surgery	123UV	WOS:000317417600001	23375757				2022-02-06	
J	Balan, IS; Saladino, AJ; Aarabi, B; Castellani, RJ; Wade, C; Stein, DM; Eisenberg, HM; Chen, HGH; Fiskum, G				Balan, Irina S.; Saladino, Andrew J.; Aarabi, Bizhan; Castellani, Rudolf J.; Wade, Christine; Stein, Deborah M.; Eisenberg, Howard M.; Chen, Hegang H.; Fiskum, Gary			Cellular Alterations in Human Traumatic Brain Injury: Changes in Mitochondrial Morphology Reflect Regional Levels of Injury Severity	JOURNAL OF NEUROTRAUMA			English	Article						cristae; electron microscopy; matrix; penumbra	RAT LIVER MITOCHONDRIA; LINKED MECHANICAL ACTIVITY; CYCLOSPORINE-A; ULTRASTRUCTURAL-CHANGES; AXONAL INJURY; ISCHEMIA; DYNAMICS; DAMAGE; DEATH; TRANSITION	Mitochondrial dysfunction may be central to the pathophysiology of traumatic brain injury (TBI) and often can be recognized cytologically by changes in mitochondrial ultrastructure. This study is the first to broadly characterize and quantify mitochondrial morphologic alterations in surgically resected human TBI tissues from three contiguous cortical injury zones. These zones were designated as injury center (Near), periphery (Far), and Penumbra. Tissues from 22 patients with TBI with varying degrees of damage and time intervals from TBI to surgical tissue collection within the first week post-injury were rapidly fixed in the surgical suite and processed for electron microscopy. A large number of mitochondrial structural patterns were identified and divided into four survival categories: normal, normal reactive, reactive degenerating, and end-stage degenerating profiles. A tissue sample acquired at 38 hours post-injury was selected for detailed mitochondrial quantification, because it best exhibited the wide variation in cellular and mitochondrial changes consistently noted in all the other cases. The distribution of mitochondrial morphologic phenotypes varied significantly between the three injury zones and when compared with control cortical tissue obtained from an epilepsy lobectomy. This study is unique in its comparative quantification of the mitochondrial ultrastructural alterations at progressive distances from the center of injury in surviving TBI patients and in relation to control human cortex. These quantitative observations may be useful in guiding the translation of mitochondrial-based neuroprotective interventions to clinical implementation.	[Balan, Irina S.; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Balan, Irina S.; Wade, Christine; Stein, Deborah M.; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA; [Saladino, Andrew J.; Castellani, Rudolf J.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Stein, Deborah M.] Univ Maryland, Sch Med, Dept Surg, Program Trauma, Baltimore, MD 21201 USA; [Aarabi, Bizhan; Eisenberg, Howard M.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Chen, Hegang H.] Univ Maryland, Sch Med, Div Biostat & Bioinformat, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Saladino, Andrew J.] Vet Affairs Med Ctr, Pathol Serv, Baltimore, MD USA		Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 W Baltimore St MSTF 5-34, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu		Balan, Irina/0000-0002-2299-6115; Stein, Deborah/0000-0003-3683-3963	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM075776, P01 HD16596]; Paragon Bioservices, Inc.; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM075776] Funding Source: NIH RePORTER	This work was supported by NIH grants T32 GM075776 and P01 HD16596 and a grant from Paragon Bioservices, Inc.	Ahn ES, 2008, J NEUROSURG, V108, P124, DOI 10.3171/JNS/2008/108/01/0124; Balan I.S., 2012, ANIMAL MODELS ACUTE, P29; Balan IS, 2010, BRAIN RES, V1316, P112, DOI 10.1016/j.brainres.2009.12.042; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Benani A, 2009, J NEUROSCI METH, V178, P301, DOI 10.1016/j.jneumeth.2008.12.023; Bereiter-Hahn J, 2010, INT REV CEL MOL BIO, V284, P1, DOI 10.1016/S1937-6448(10)84001-8; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Castejon O.J., 2004, STRUCTURAL PATTERNS; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Colbourne F, 1999, J NEUROSCI, V19, P4200; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; CRAGG BG, 1976, J ANAT, V121, P331; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; GREENAWALT JW, 1964, J CELL BIOL, V23, P21, DOI 10.1083/jcb.23.1.21; Gunawardena S, 2004, J NEUROBIOL, V58, P258, DOI 10.1002/neu.10319; HACKENBROCK CR, 1968, J CELL BIOL, V37, P345, DOI 10.1083/jcb.37.2.345; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HACKENBROCK CR, 1971, J CELL BIOL, V51, P123, DOI 10.1083/jcb.51.1.123; Harris Kristen M., 2008, P1, DOI 10.1007/978-0-387-77232-5_1; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155; Johannessen J.V., 1978, ELECT MICROSCOPY HUM, P1; Kristian T, 1996, LIFE SCI, V59, P357, DOI 10.1016/0024-3205(96)00314-1; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lai Y, 2008, J NEUROCHEM, V104, P1700, DOI 10.1111/j.1471-4159.2007.05114.x; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu CL, 2010, J NEUROCHEM, V115, P68, DOI 10.1111/j.1471-4159.2010.06905.x; Liu X, 2011, CELL DEATH DIFFER, V18, P1561, DOI 10.1038/cdd.2011.13; Lyamzaev KG, 2008, BBA-BIOENERGETICS, V1777, P817, DOI 10.1016/j.bbabio.2008.03.027; Mannella CA, 2006, BBA-MOL BASIS DIS, V1762, P140, DOI 10.1016/j.bbadis.2005.07.001; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Mishchenko Y, 2010, NEURON, V67, P1009, DOI 10.1016/j.neuron.2010.08.014; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; MYRON DR, 1971, J CELL BIOL, V48, P291, DOI 10.1083/jcb.48.2.291; Neuspiel M, 2008, CURR BIOL, V18, P102, DOI 10.1016/j.cub.2007.12.038; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; ONG WY, 1991, J ANAT, V175, P79; PACKER L, 1970, FED PROC, V29, P1533; Perez-Pinzon MA, 2012, J CEREBR BLOOD F MET, V32, P1362, DOI 10.1038/jcbfm.2012.32; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Popov V, 2005, J COMP NEUROL, V492, P50, DOI 10.1002/cne.20682; Sanchez V, 2011, ANESTHESIOLOGY, V115, P992, DOI 10.1097/ALN.0b013e3182303a63; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Skulachev VP, 2004, MOL CELL BIOCHEM, V256, P341, DOI 10.1023/B:MCBI.0000009880.94044.49; SLOPER JJ, 1979, PHILOS T R SOC B, V285, P141, DOI 10.1098/rstb.1979.0003; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Taiushev K G, 1999, Morfologiia, V116, P7; Taiushev K G, 1990, Arkh Anat Gistol Embriol, V99, P26; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; TRUMP BF, 1976, CIRCULATION, V53, P17; TRUMP BF, 1965, LAB INVEST, V14, P343; Ugriumov V M, 1977, Zh Vopr Neirokhir Im N N Burdenko, P3; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114; Zick M, 2009, BBA-MOL CELL RES, V1793, P5, DOI 10.1016/j.bbamcr.2008.06.013	66	29	31	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2013	30	5					367	381		10.1089/neu.2012.2339			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	103CI	WOS:000315891600007	23131111	Green Published			2022-02-06	
J	Titus, DJ; Furones, C; Kang, Y; Atkins, CM				Titus, D. J.; Furones, C.; Kang, Y.; Atkins, C. M.			AGE-DEPENDENT ALTERATIONS IN CAMP SIGNALING CONTRIBUTE TO SYNAPTIC PLASTICITY DEFICITS FOLLOWING TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						cAMP; fluid-percussion; long-term potentiation; phosphodiesterase; rolipram; traumatic brain injury	LONG-TERM POTENTIATION; AMP-SELECTIVE PHOSPHODIESTERASE; PROTEIN-KINASE ACTIVITY; HIPPOCAMPAL AREA CA1; RAT-BRAIN; CREB PHOSPHORYLATION; FLUID-PERCUSSION; SPATIAL MEMORY; MIDDLE-AGE; ROLIPRAM	The elderly have comparatively worse cognitive impairments from traumatic brain injury (TBI) relative to younger adults, but the molecular mechanisms that underlie this exacerbation of cognitive deficits are unknown. Experimental models of TBI have demonstrated that the cyclic AMP-protein kinase A (cAMP-PKA) signaling pathway is downregulated after brain trauma. Since the cAMP-PKA signaling pathway is a key mediator of long-term memory formation, we investigated whether the TBI-induced decrease in cAMP levels is exacerbated in aged animals. Aged (19 months) and young adult (3 months) male Fischer 344 rats received sham surgery or mild (1.4-1.6 atmospheres, atm) or moderate (1.7-2.1 atm) parasagittal fluid-percussion brain injury. At various time points after surgery, the ipsilateral parietal cortex, hippocampus, and thalamus were assayed for cAMP levels. Mild TBI lowered cAMP levels in the hippocampus of aged, but not young adult animals. Moderate TBI lowered cAMP levels in the hippocampus and parietal cortex of both age groups. In the thalamus, cAMP levels were significantly lowered after moderate, but not mild TBI. To determine if the TBI-induced decreases in cAMP had physiological consequences in aged animals, hippocampal long-term potentiation (LTP) in the Schaffer collateral pathway of the CA1 region was assessed. LTP was significantly decreased in both young adult and aged animals after mild and moderate TBI as compared to sham surgery animals. Rolipram rescued the LTP deficits after mild TBI for young adult animals and caused a partial recovery for aged animals. However, rolipram did not rescue LTP deficits after moderate TBI in either young adult or aged animals. These results indicate that the exacerbation of cognitive impairments in aged animals with TBI may be due to decreased cAMP levels and deficits in hippocampal LTP. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Atkins, C. M.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Atkins, C. M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA		Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Post Box 016960,R-48, Miami, FL 33136 USA.	catkins@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493; Titus, David/0000-0001-7819-734X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG033266, NS069721, NS056072]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069721, R01NS056072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG033266] Funding Source: NIH RePORTER	The authors thank Dayaris Morffi for technical assistance and Drs. W. Dalton Dietrich, H.M. Bramlett, I. Hentall, and Kaming Lo for critical reading of the manuscript. We thank the University of Miami Biostatistics Collaboration and Consulting Core for statistical support. This work was supported by NIH Grants AG033266, NS069721, NS056072 and The Miami Project to Cure Paralysis.	Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI 10.1089/neu.2008-0765; Anderson WW, 2007, J NEUROSCI METH, V162, P346, DOI 10.1016/j.jneumeth.2006.12.018; ASANUMA M, 1993, ARCH GERONTOL GERIAT, V16, P191, DOI 10.1016/0167-4943(93)90009-7; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Bach ME, 1999, P NATL ACAD SCI USA, V96, P5280, DOI 10.1073/pnas.96.9.5280; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; Barnes CA, 1997, NEUROBIOL AGING, V18, P445, DOI 10.1016/S0197-4580(97)00044-4; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; BICKFORDWIMER PC, 1987, NEUROPHARMACOLOGY, V26, P597, DOI 10.1016/0028-3908(87)90153-5; Bodhinathan K, 2010, J NEUROSCI, V30, P1914, DOI 10.1523/JNEUROSCI.5485-09.2010; Boric K, 2008, J NEUROSCI, V28, P8034, DOI 10.1523/JNEUROSCI.2036-08.2008; Davare MA, 2003, P NATL ACAD SCI USA, V100, P16018, DOI 10.1073/pnas.2236970100; Faul M, 2010, TRAUMATIC BRAIN INJU; Foster TC, 2001, J NEUROSCI, V21, P4066, DOI 10.1523/JNEUROSCI.21-11-04066.2001; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Godbout JP, 2006, NEUROL CLIN, V24, P521, DOI 10.1016/j.ncl.2006.03.010; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hattiangady B, 2005, EXP NEUROL, V195, P353, DOI 10.1016/j.expneurol.2005.05.014; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hsu KS, 2002, HIPPOCAMPUS, V12, P787, DOI 10.1002/hipo.10032; Itoh T, 2012, BRAIN STRUC IN PRESS; Karege F, 2001, BRAIN RES, V903, P86, DOI 10.1016/S0006-8993(01)02409-X; Karege F, 2001, NEUROSCI LETT, V315, P89, DOI 10.1016/S0304-3940(01)02358-8; Kato H, 1997, J NEURAL TRANSM, V104, P269, DOI 10.1007/BF01273187; Kato H, 1998, METHOD FIND EXP CLIN, V20, P403, DOI 10.1358/mf.1998.20.5.485701; Kudo K, 2005, BRAIN RES, V1054, P30, DOI 10.1016/j.brainres.2005.06.045; Lin SL, 2003, J NEUROCHEM, V87, P1076, DOI 10.1046/j.1471-4159.2003.02076.x; Martinez M, 2001, BRAIN RES, V922, P148, DOI 10.1016/S0006-8993(01)03009-8; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; Mawhinney LJ, 2012, BRAIN RES, V1431, P23, DOI 10.1016/j.brainres.2011.11.004; Mons N, 2004, NEUROBIOL AGING, V25, P1095, DOI 10.1016/j.neurobiolaging.2003.10.014; Monti B, 2005, HIPPOCAMPUS, V15, P1041, DOI 10.1002/hipo.20099; Murray CA, 1998, J NEUROSCI, V18, P2974; Navakkode S, 2004, J NEUROSCI, V24, P7740, DOI 10.1523/JNEUROSCI.1796-04.2004; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PARFITT KD, 1990, NEUROBIOL AGING, V11, P591, DOI 10.1016/0197-4580(90)90022-R; Porte Y, 2008, NEUROBIOL AGING, V29, P1533, DOI 10.1016/j.neurobiolaging.2007.03.023; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; Reis GF, 2005, J NEUROPHYSIOL, V93, P3381, DOI 10.1152/jn.00827.2004; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Shankar S, 1998, J NEUROPHYSIOL, V79, P334, DOI 10.1152/jn.1998.79.1.334; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tohda M, 1996, BIOL PHARM BULL, V19, P300; Vincent G. K., 2010, CURR POPULATION REP, P1125; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; Watabe AM, 2003, NEUROBIOL AGING, V24, P267, DOI 10.1016/S0197-4580(02)00082-9; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Zhang GR, 2009, HIPPOCAMPUS, V19, P413, DOI 10.1002/hipo.20506	59	29	31	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	FEB 12	2013	231						182	194		10.1016/j.neuroscience.2012.12.002			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	087EN	WOS:000314744200017	23238576	Green Accepted			2022-02-06	
J	Pomschar, A; Koerte, I; Lee, S; Laubender, RP; Straube, A; Heinen, F; Ertl-Wagner, B; Alperin, N				Pomschar, Andreas; Koerte, Inga; Lee, Sang; Laubender, Ruediger P.; Straube, Andreas; Heinen, Florian; Ertl-Wagner, Birgit; Alperin, Noam			MRI Evidence for Altered Venous Drainage and Intracranial Compliance in Mild Traumatic Brain Injury	PLOS ONE			English	Article							PHASE-CONTRAST MRI; HEAD-INJURY; BLOOD-FLOW; PHYSIOLOGY; OUTFLOW; HUMANS; SYSTEM; ICP	Purpose: To compare venous drainage patterns and associated intracranial hydrodynamics between subjects who experienced mild traumatic brain injury (mTBI) and age-and gender-matched controls. Methods: Thirty adult subjects (15 with mTBI and 15 age- and gender-matched controls) were investigated using a 3T MR scanner. Time since trauma was 0.5 to 29 years (mean 11.4 years). A 2D-time-of-flight MR-venography of the upper neck was performed to visualize the cervical venous vasculature. Cerebral venous drainage through primary and secondary channels, and intracranial compliance index and pressure were derived using cine-phase contrast imaging of the cerebral arterial inflow, venous outflow, and the craniospinal CSF flow. The intracranial compliance index is the defined as the ratio of maximal intracranial volume and pressure changes during the cardiac cycle. MR estimated ICP was then obtained through the inverse relationship between compliance and ICP. Results: Compared to the controls, subjects with mTBI demonstrated a significantly smaller percentage of venous outflow through internal jugular veins (60.9+/-21% vs. controls: 76.8+/-10%; p=0.01) compensated by an increased drainage through secondary veins (12.3+/-10.9% vs. 5.5+/-3.3%; p<0.03). Mean intracranial compliance index was significantly lower in the mTBI cohort (5.8+/-1.4 vs. controls 8.4+/-1.9; p<0.0007). Consequently, MR estimate of intracranial pressure was significantly higher in the mTBI cohort (12.5+/-2.9 mmHg vs. 8.8+/-2.0 mmHg; p<0.0007). Conclusions: mTBI is associated with increased venous drainage through secondary pathways. This reflects higher outflow impedance, which may explain the finding of reduced intracranial compliance. These results suggest that hemodynamic and hydrodynamic changes following mTBI persist even in the absence of clinical symptoms and abnormal findings in conventional MR imaging.	[Pomschar, Andreas; Koerte, Inga; Ertl-Wagner, Birgit] Univ Munich, Inst Clin Radiol, Munich, Germany; [Lee, Sang; Alperin, Noam] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA; [Laubender, Ruediger P.] Univ Munich, Inst Med Informat Biometry & Epidemiol IBE, Munich, Germany; [Straube, Andreas] Univ Munich, Dept Neurol, D-80539 Munich, Germany; [Heinen, Florian] Univ Munich, Dept Pediat Neurol Dev Med, Dr von Hauners Childrens Hosp, Munich, Germany		Alperin, N (corresponding author), Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA.	nalperin@med.miami.edu	Ertl-Wagner, Birgit/AAD-5708-2020; Heinen, Florian/B-6594-2015; Koerte, Inga Katharina/AAW-3031-2021	Heinen, Florian/0000-0002-3872-6136; Ertl-Wagner, Birgit/0000-0002-7896-7049	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS05212]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052122] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health award R01 NS05212. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alperin N, 2005, ACTA NEUROCHIR SUPPL, V95, P191; Alperin N, 2005, ACT NEUR S, V95, P129; Alperin N, 2005, J MAGN RESON IMAGING, V22, P591, DOI 10.1002/jmri.20427; Alperin N, 2003, MAGNET RESON MED, V49, P934, DOI 10.1002/mrm.10455; Alperin N, 2002, P INT SOC MAG RESON, P2; Alperin NJ, 2000, RADIOLOGY, V217, P877, DOI 10.1148/radiology.217.3.r00dc42877; Bailey DM, 2012, CLIN SCI LOND; BATSON OV, 1957, AMER J ROENTGENOL RA, V78, P195; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Doepp F, 2004, NEURORADIOLOGY, V46, P565, DOI 10.1007/s00234-004-1213-3; Ertl-Wagner B, 2012, MULT SCLER J, V18, P1000, DOI 10.1177/1352458511432742; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kivioja J, 2001, J CLIN IMMUNOL, V21, P272, DOI 10.1023/A:1010931309088; Koerte IK, 2011, INVEST RADIOL; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Miyati T, 2007, J MAGN RESON IMAGING, V26, P274, DOI 10.1002/jmri.20999; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Piccio L, 2005, J IMMUNOL, V174, P5805, DOI 10.4049/jimmunol.174.9.5805; Piechnik SK, 2001, NEUROSURGERY, V49, P1214, DOI 10.1097/00006123-200111000-00034; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schaller B, 2004, BRAIN RES REV, V46, P243, DOI 10.1016/j.brainresrev.2004.04.005; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Stoquart-ElSankari S, 2009, J CEREBR BLOOD F MET, V29, P1208, DOI [10.1038/jcbfm.2009.29, 10.1038/sj.jcbfm.jcbfm200929]; Tain RW, 2009, J MAGN RESON IMAGING, V30, P878, DOI 10.1002/jmri.21925; Tain RW, 2009, IEEE T BIO-MED ENG, V56, P544, DOI 10.1109/TBME.2008.2006010; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Zhang K, 2010, EXP BRAIN RES	37	29	31	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2013	8	2							e55447	10.1371/journal.pone.0055447			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092WJ	WOS:000315153400096	23405151	Green Published, gold, Green Submitted			2022-02-06	
J	Hennelly, KE; Mannix, R; Nigrovic, LE; Lee, LK; Thompson, KM; Monuteaux, MC; Proctor, M; Schutzman, S				Hennelly, Kara E.; Mannix, Rebekah; Nigrovic, Lise E.; Lee, Lois K.; Thompson, Kimberly M.; Monuteaux, Michael C.; Proctor, Mark; Schutzman, Sara			Pediatric Traumatic Brain Injury and Radiation Risks: A Clinical Decision Analysis	JOURNAL OF PEDIATRICS			English	Article							QUALITY-OF-LIFE; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; INTRACRANIAL INJURY; UNITED-STATES; EMERGENCY-DEPARTMENTS; IDENTIFYING CHILDREN; BREAST-CANCER; HEALTH; CT	Objective To determine the optimal imaging strategy for young children with minor head injury considering health-related quality of life and radiation risk. In children with minor head trauma, the risk of missing a clinically important traumatic brain injury (ciTBI) must be weighed against the risk of radiation-induced malignancy from computed tomography (CT) to assess impact on public health. Study design We included children <2 years old with minor blunt head trauma defined by a Glasgow Coma Scale score of 14-15. We used decision analysis to model a CT-all versus no-CT strategy and assigned values to clinical outcomes based on a validated health-related quality of life scale: (1) baseline health; (2) non-ciTBI; (3) ciTBI without neurosurgery, death, or intubation; and (4) ciTBI with neurosurgery, death, or intubation >24 hours with probabilities from a prospective study of 10 000 children. Sensitivity analysis determined the optimal management strategy over a range of ciTBI risk. Results The no-CT strategy resulted in less risk with the expected probability of a ciTBI of 0.9%. Sensitivity analysis for the probability of ciTBI identified 4.8% as the threshold above which CT all becomes the preferred strategy and shows that the threshold decreases with less radiation. The CT all strategy represents the preferred approach for children identified as high-risk. Conclusion Among children <2 years old with minor head trauma, the no-CT strategy is preferable for those at low risk, reserving CT for children at higher risk. (J Pediatr 2013;162:392-7).	[Hennelly, Kara E.; Mannix, Rebekah; Nigrovic, Lise E.; Lee, Lois K.; Monuteaux, Michael C.; Schutzman, Sara] Childrens Hosp Boston, Div Emergency Med, Boston, MA 02115 USA; [Proctor, Mark] Childrens Hosp Boston, Div Neurosurg, Boston, MA 02115 USA; [Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL USA		Hennelly, KE (corresponding author), Childrens Hosp Boston, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	kara.hennelly@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Monuteaux, Michael C/O-5032-2018	Nigrovic, Lise/0000-0002-6369-3997; Thompson, Kimberly/0000-0002-0849-9147			Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Callahan Michael J, 2011, Pediatr Radiol, V41 Suppl 2, P488, DOI 10.1007/s00247-011-2099-y; Calonge N, 2009, ANN INTERN MED, V151, P716, DOI 10.7326/0003-4819-151-10-200911170-00008; Centers for Disease Control National Center for Injury Prevention and Control, 2006, TRAUM BRAIN INJ US A; Da Dalt L, 2006, EUR J PEDIATR, V165, P142, DOI 10.1007/s00431-005-0019-6; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Frush Donald P, 2011, Pediatr Radiol, V41 Suppl 2, P483, DOI 10.1007/s00247-011-2098-z; Frush DP, 2003, RADIOLOGY, V229, P289, DOI 10.1148/radiol.2291030373; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Gordon JB, 2010, J AM COLL RADIOL, V7, P243, DOI 10.1016/j.jacr.2010.01.010; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Huda W, 1997, RADIOLOGY, V203, P417, DOI 10.1148/radiology.203.2.9114097; Kanal KM, 2011, J AM COLL RADIOL, V8, P242, DOI 10.1016/j.jacr.2010.11.005; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Korley FK, 2010, JAMA-J AM MED ASSOC, V304, P1465, DOI 10.1001/jama.2010.1408; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Luchette F, 2010, J TRAUMA, V69, P530; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Palchak MJ, 2009, PEDIATR EMERG CARE, V25, P61, DOI 10.1097/PEC.0b013e318196e9c0; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Petersen C, 2008, BUNDESGESUNDHEITSBLA, V51, P629, DOI 10.1007/s00103-008-0536-3; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Seidenwurm D, 2010, J AM COLL RADIOL, V7, P265, DOI 10.1016/j.jacr.2010.01.001; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Stein SC, 2008, PEDIATR NEUROSURG, V44, P448, DOI 10.1159/000172967; Sun BC, 2007, ANN EMERG MED, V49; Woolf SH, 2010, JAMA-J AM MED ASSOC, V303, P162, DOI 10.1001/jama.2009.1989	47	29	30	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	FEB	2013	162	2					392	397		10.1016/j.jpeds.2012.07.018			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	071GX	WOS:000313579900034	22921827				2022-02-06	
J	Berryhill, ME; Wiener, M; Stephens, JA; Lohoff, FW; Coslett, HB				Berryhill, Marian E.; Wiener, Martin; Stephens, Jaclyn A.; Lohoff, Falk W.; Coslett, H. Branch			COMT and ANKK1-Taq-Ia Genetic Polymorphisms Influence Visual Working Memory	PLOS ONE			English	Article							CATECHOL-O-METHYLTRANSFERASE; D2 RECEPTOR GENE; TRAUMATIC BRAIN-INJURY; RIGHT PARIETAL LOBE; VAL(158)MET POLYMORPHISM; PREFRONTAL CORTEX; BASAL GANGLIA; HEALTHY-VOLUNTEERS; EXECUTIVE FUNCTION; MESSENGER-RNA	Complex cognitive tasks such as visual working memory (WM) involve networks of interacting brain regions. Several neurotransmitters, including an appropriate dopamine concentration, are important for WM performance. A number of gene polymorphisms are associated with individual differences in cognitive task performance. COMT, for example, encodes catechol-o-methyl transferase the enzyme primarily responsible for catabolizing dopamine in the prefrontal cortex. Striatal dopamine function, linked with cognitive tasks as well as habit learning, is influenced by the Taq-Ia polymorphism of the DRD2/ANKK1 gene complex; this gene influences the density of dopamine receptors in the striatum. Here, we investigated the effects of these polymorphisms on a WM task requiring the maintenance of 4 or 6 items over delay durations of 1 or 5 seconds. We explored main effects and interactions between the COMT and DRD2/ANKK1-Taq-Ia polymorphisms on WM performance. Participants were genotyped for COMT (Val(158) Met) and DRD2/ANKK1-Taq-Ia (A1+, A1-) polymorphisms. There was a significant main effect of both polymorphisms. Participants' WM reaction times slowed with increased Val loading such that the Val/Val homozygotes made the slowest responses and the Met/Met homozygotes were the fastest. Similarly, WM reaction times were slower and more variable for the DRD2/ANKK1-Taq-Ia A1+ group than the A1- group. The main effect of COMT was only apparent in the DRD2/ANKK1-Taq-Ia A1- group. These findings link WM performance with slower dopaminergic metabolism in the prefrontal cortex as well as a greater density of dopamine receptors in the striatum.	[Berryhill, Marian E.; Stephens, Jaclyn A.] Univ Nevada, Dept Psychol, Memory & Brain Lab, Reno, NV 89557 USA; [Wiener, Martin; Coslett, H. Branch] Univ Penn, Dept Neurol, Perelman Sch Med, Lab Cognit & Neural Stimulat, Philadelphia, PA 19104 USA; [Lohoff, Falk W.] Univ Penn, Dept Psychiat, Perelman Sch Med, Translat Res Lab,Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA		Berryhill, ME (corresponding author), Univ Nevada, Dept Psychol, Memory & Brain Lab, Reno, NV 89557 USA.	mberryhill@unr.edu	Lohoff, Falk W/M-7951-2016	Berryhill, Marian/0000-0002-8218-6587	University of Nevada; COBRE [1P20GM103650-01, R15EY022775]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R15EY022775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103650] Funding Source: NIH RePORTER	This work was supported by faculty start-up funds generously provided by the University of Nevada to MB and by COBRE 1P20GM103650-01 (PI M. Webster, project PI MB) and R15EY022775 to MB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilera M, 2008, AM J MED GENET B, V147B, P898, DOI 10.1002/ajmg.b.30705; Allen RJ, 2012, Q J EXP PSYCHOL, V65, P2369, DOI 10.1080/17470218.2012.687384; Anderson DE, 2012, J COGNITIVE NEUROSCI, V24, P1069, DOI 10.1162/jocn_a_00207; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; Backman L, 2011, SCIENCE, V333, P718, DOI 10.1126/science.1204978; Baier B, 2010, J NEUROSCI, V30, P9788, DOI 10.1523/JNEUROSCI.1513-10.2010; Barnett JH, 2007, MOL PSYCHIATR, V12, P502, DOI 10.1038/sj.mp.4001973; Barnett JH, 2008, BIOL PSYCHIAT, V64, P137, DOI 10.1016/j.biopsych.2008.01.005; Berryhill ME, 2008, NEUROPSYCHOLOGIA, V46, P1775, DOI 10.1016/j.neuropsychologia.2008.03.005; Berryhill ME, 2008, NEUROPSYCHOLOGIA, V46, P1767, DOI 10.1016/j.neuropsychologia.2008.01.009; Berryhill ME, 2010, NEUROSCI LETT, V479, P312, DOI 10.1016/j.neulet.2010.05.087; Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542; Bogacz R, 2010, TRENDS NEUROSCI, V33, P10, DOI 10.1016/j.tins.2009.09.002; Boscarino JA, 2012, NEUROPSYCH DIS TREAT, V8, P131, DOI 10.2147/NDT.S29508; Bruder GE, 2005, BIOL PSYCHIAT, V58, P901, DOI 10.1016/j.biopsych.2005.05.010; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Colzato LS, 2010, NEUROPSYCHOLOGIA, V48, P2764, DOI 10.1016/j.neuropsychologia.2010.04.023; Cools R, 2008, J NEUROSCI, V28, P1208, DOI 10.1523/JNEUROSCI.4475-07.2008; Cools R, 2011, CURR OPIN NEUROBIOL, V21, P402, DOI 10.1016/j.conb.2011.04.002; Cools R, 2011, BIOL PSYCHIAT, V69, pE113, DOI 10.1016/j.biopsych.2011.03.028; de Frias CM, 2005, J COGNITIVE NEUROSCI, V17, P1018, DOI 10.1162/0898929054475136; Diamond A, 2007, CEREB CORTEX, V17, pI161, DOI 10.1093/cercor/blini082; Diaz-Asper CM, 2008, BIOL PSYCHIAT, V63, P72, DOI 10.1016/j.biopsych.2007.03.031; Dickinson D, 2009, NEUROSCIENCE, V164, P72, DOI 10.1016/j.neuroscience.2009.05.014; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Forstmann BU, 2010, P NATL ACAD SCI USA, V107, P15916, DOI 10.1073/pnas.1004932107; Frank MJ, 2011, NEUROPSYCHOPHARMACOL, V36, P133, DOI 10.1038/npp.2010.96; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Goldberg TE, 2003, ARCH GEN PSYCHIAT, V60, P889, DOI 10.1001/archpsyc.60.9.889; Gruber AJ, 2006, J COMPUT NEUROSCI, V20, P153, DOI 10.1007/s10827-005-5705-x; Hazy TE, 2006, NEUROSCIENCE, V139, P105, DOI 10.1016/j.neuroscience.2005.04.067; Hirvonen MM, 2009, PROG NEURO-PSYCHOPH, V33, P630, DOI 10.1016/j.pnpbp.2009.02.021; Ho T, 2012, J NEUROSCI, V32, P7992, DOI 10.1523/JNEUROSCI.0340-12.2012; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Matsumoto M, 2003, NEUROSCIENCE, V116, P127, DOI 10.1016/S0306-4522(02)00556-0; Mattay VS, 2003, P NATL ACAD SCI USA, V100, P6186, DOI 10.1073/pnas.0931309100; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P594, DOI 10.1038/nn1438; Mier D, 2010, MOL PSYCHIATR, V15, P918, DOI 10.1038/mp.2009.36; Nagel IE, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.001.2008; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Noble E P, 2000, Pharmacogenomics, V1, P309, DOI 10.1517/14622416.1.3.309; Nolan KA, 2004, AM J PSYCHIAT, V161, P359, DOI 10.1176/appi.ajp.161.2.359; O'Reilly RC, 2006, NEURAL COMPUT, V18, P283, DOI 10.1162/089976606775093909; Oroszi G, 2004, PHARMACOGENOMICS, V5, P1037, DOI 10.1517/14622416.5.8.1037; Pohjalainen T, 1998, MOL PSYCHIATR, V3, P256, DOI 10.1038/sj.mp.4000350; Savitz J, 2006, GENES BRAIN BEHAV, V5, P311, DOI 10.1111/j.1601-183X.2005.00163.x; Schellekens AF, 2012, ADDICTION BIOL; Slifstein M, 2008, MOL PSYCHIATR, V13, P821, DOI 10.1038/mp.2008.19; Stefanis NC, 2005, AM J PSYCHIAT, V162, P1752, DOI 10.1176/appi.ajp.162.9.1752; Stelzel C, 2009, EUR J NEUROSCI, V29, P1056, DOI 10.1111/j.1460-9568.2009.06647.x; Stormer VS, 2012, DEV PSYCHOL, V48, P875, DOI 10.1037/a0026198; Tammimaki AE, 2010, PHARMACOGENET GENOM, V20, P717, DOI 10.1097/FPC.0b013e328340bdf2; Tunbridge EM, 2006, BIOL PSYCHIAT, V60, P141, DOI 10.1016/j.biopsych.2005.10.024; Tunbridge EM, 2012, CNS NEUROLOGICAL DIS; Wiener M, 2011, J COGNITIVE NEUROSCI, V23, P2811, DOI 10.1162/jocn.2011.21626; Williams GV, 2006, NEUROSCIENCE, V139, P263, DOI 10.1016/j.neuroscience.2005.09.028; Wishart HA, 2011, J INT NEUROPSYCH SOC, V17, P174, DOI 10.1017/S1355617710001402	62	29	29	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2013	8	1							e55862	10.1371/journal.pone.0055862			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	085JH	WOS:000314610600166	23383291	gold, Green Published, Green Submitted			2022-02-06	
J	Cohen, SI; Suri, P; Amick, MM; Yan, K				Cohen, Sara I.; Suri, Pradeep; Amick, Melissa M.; Yan, Kun			Clinical and demographic factors associated with employment status in US military veterans returning from Iraq and Afghanistan	WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION			English	Article						Depression; OIF/OEF; pain; Polytrauma; posttraumatic stress disorder	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; WORK; DEPRESSION; OUTCOMES; SERVICE; REHABILITATION; INTEGRATION; PREDICTION	OBJECTIVE: To determine the association between clinical and demographic factors with employment status in post-deployment US military veterans returning from Iraq and Afghanistan. PARTICIPANTS: 169 OIF/OEF veterans seen at a post-deployment clinic between December of 2009 and May of 2010. METHODS: Data was collected retrospectively on employment status, age, marital status, gender, pre-deployment education, ratings of sleep disturbance, pain, and depression, and mild traumatic brain injury (mTBI) or PTSD diagnosis. RESULTS: Unemployment was highly prevalent in this sample (45%). Of the demographic and clinical factors examined, only a self-report of global depression severity was significantly associated with a higher prevalence of unemployment in multivariate analysis (odds ratio [OR] 0.21, 95% confidence interval [CI] 0.10-0.47). Age greater than 40 demonstrated a positive association with employment status that was of borderline statistical significance ([OR] 2.8, 95% confidence interval [CI] 1.0-8.1). Prior diagnoses of mTBI or PTSD, and current sleep or pain symptoms, were not associated with employment status. CONCLUSIONS: Individuals with more severe self-reported depression had a higher prevalence of unemployment. Future prospective studies are needed to better understand which factors determine employment status in returning veterans.	[Cohen, Sara I.] Braintree Rehabil Hosp, Braintree, MA USA; [Suri, Pradeep; Amick, Melissa M.; Yan, Kun] VA Boston Healthcare Syst, W Roxbury, MA USA; [Suri, Pradeep] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Suri, Pradeep] Spaulding Rehabil Hosp, Boston, MA USA; [Amick, Melissa M.; Yan, Kun] Def & Vet Brain Injury Ctr, Boston, MA USA; [Amick, Melissa M.] Boston Univ, Dept Psychiat, Sch Med, Medford, MA USA; [Yan, Kun] Tufts Univ, Medford, MA USA		Suri, P (corresponding author), PMR Serv, 1400 VFW Pkwy,MC 117, W Roxbury, MA 01232 USA.	Pradeep.Suri@va.gov	Suri, Pradeep/AAH-9572-2020				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bureau of Labor Statistics, 2010, NEW ENGL STAT UN; Catalano D, 2006, NEUROREHABILITATION, V21, P279; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen SP, 2010, LANCET, V375, P301, DOI 10.1016/S0140-6736(09)61797-9; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Economics T., 2011, US UN RAT; Fleming J, 1999, BRAIN INJURY, V13, P417; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Kissinger DB, 2008, WORK, V31, P309; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Latham J, 1994, Disabil Rehabil, V16, P39; Lerner D, 2004, PSYCHIAT SERV, V55, P1371, DOI 10.1176/appi.ps.55.12.1371; Leung K L, 2005, Work, V25, P333; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Patten SB, 2009, CAN J PSYCHIAT, V54, P841, DOI 10.1177/070674370905401207; Prigerson HG, 2002, AM J PUBLIC HEALTH, V92, P59, DOI 10.2105/AJPH.92.1.59; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Semuels Alana, 2011, LOS ANGELES TIMES; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Tanielian T., 2008, INVISIBLE WOUNDS WAR; US Government Accountability Office, 2008, VA HLTH CAR MILD TRA; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Washington Post Editors, 2010, WASHINGTON POST; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8	36	29	29	0	18	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1051-9815			WORK	Work		2013	44	2					213	219		10.3233/WOR-2012-1417			7	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	087ZC	WOS:000314802300011	22927609				2022-02-06	
J	Maki-Marttunen, V; Diez, I; Cortes, JM; Chialvo, DR; Villarreal, M				Maeki-Marttunen, Veronica; Diez, Ibai; Cortes, Jesus M.; Chialvo, Dante R.; Villarreal, Mirta			Disruption of transfer entropy and inter-hemispheric brain functional connectivity in patients with disorder of consciousness	FRONTIERS IN NEUROINFORMATICS			English	Article						disorder of consciousness; resting state; functional magnetic resonance imaging; BOLD signal; transfer entropy; partial correlation; functional connectivity; brain networks		Severe traumatic brain injury can lead to disorders of consciousness (DOC) characterized by deficit in conscious awareness and cognitive impairment including coma, vegetative state, minimally consciousness, and lock-in syndrome. Of crucial importance is to find objective markers that can account for the large-scale disturbances of brain function to help the diagnosis and prognosis of DOC patients and eventually the prediction of the coma outcome. Following recent studies suggesting that the functional organization of brain networks can be altered in comatose patients, this work analyzes brain functional connectivity (FC) networks obtained from resting-state functional magnetic resonance imaging (rs-fMRI). Two approaches are used to estimate the FC: the Partial Correlation (PC) and the Transfer Entropy (TE). Both the PC and the TE show significant statistical differences between the group of patients and control subjects; in brief, the inter-hemispheric PC and the intra-hemispheric TE account for such differences. Overall, these results suggest two possible rs-fMRI markers useful to design new strategies for the management and neuropsychological rehabilitation of DOC patients.	[Maeki-Marttunen, Veronica; Villarreal, Mirta] FLENI, Neurol Res Inst, Dept Cognit Neurosci, Buenos Aires, DF, Argentina; [Maeki-Marttunen, Veronica; Cortes, Jesus M.; Chialvo, Dante R.] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina; [Diez, Ibai; Cortes, Jesus M.] Hosp Univ Cruces, Biocruces Hlth Res Inst, Baracaldo, Spain; [Cortes, Jesus M.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain		Villarreal, M (corresponding author), FLENI, Neurol Res Inst, Dept Cognit Neurosci, Montaneses 2325,C1428AQK, Buenos Aires, DF, Argentina.	mvillarreal@fleni.org.ar	Chialvo, Dante R./P-5279-2019; Chialvo, Dante R/A-4658-2009; Maki-Marttunen, Veronica/AAA-5157-2022; Cortes, Jesus/D-9949-2012	Chialvo, Dante R./0000-0002-1038-3637; Chialvo, Dante R/0000-0002-1038-3637; Cortes, Jesus/0000-0002-9059-8194; Diez, Ibai/0000-0001-5769-0178	Ikerbasque: The Basque Foundation for Science; Junta de AndaluciaJunta de Andalucia [P09-FQM-4682]; CONICET (National Council of Scientific and Technological Research) of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Department of Neurology; Department of Teaching and Research of FLENI, Buenos Aires, Argentina	Jesus M. Cortes is supported by Ikerbasque: The Basque Foundation for Science. Jesus M. Cortes acknowledges financial support from Junta de Andalucia, grant P09-FQM-4682. Veronica Maki-Marttunen, Mirta Villarreal, and Dante R. Chialvo are partially supported by CONICET (National Council of Scientific and Technological Research) of Argentina. Additional support was provided by the Department of Neurology, and Department of Teaching and Research of FLENI, Buenos Aires, Argentina.	Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Barnett L, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.238701; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bonachela JA, 2008, J PHYS A-MATH THEOR, V41, DOI 10.1088/1751-8113/41/20/202001; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; de Pasquale F, 2012, NEURON, V74, P753, DOI 10.1016/j.neuron.2012.03.031; de Pasquale F, 2010, P NATL ACAD SCI USA, V107, P6040, DOI 10.1073/pnas.0913863107; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Gaillard R, 2009, PLOS BIOL, V7, P472, DOI 10.1371/journal.pbio.1000061; Ganzetti M, 2013, NEUROSCIENCE, V240, P297, DOI 10.1016/j.neuroscience.2013.02.032; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Heine L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00295; Hudetz AG, 2012, BRAIN CONNECT, V2, P291, DOI 10.1089/brain.2012.0107; JAYNES ET, 1957, PHYS REV, V106, P620, DOI 10.1103/PhysRev.106.620; Nir Y, 2008, NAT NEUROSCI, V11, P1100, DOI 10.1038/nn.2177; Noirhomme Q, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00160; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ovadia-Caro S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037238; Paninski L, 2003, NEURAL COMPUT, V15, P1191, DOI 10.1162/089976603321780272; Panzeri S, 1996, NETWORK-COMP NEURAL, V7, P87, DOI 10.1080/0954898X.1996.11978656; Peng H., MUTUAL INFORM TOOLBO; Perri C. D., 2013, EPILEPSY BEHAV, DOI [10.1016/j.yebeh.2013.09.014, DOI 10.1016/J.YEBEH.2013.09.014]; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Schreiber T, 2000, PHYS REV LETT, V85, P461, DOI 10.1103/PhysRevLett.85.461; Seth AK, 2006, P NATL ACAD SCI USA, V103, P10799, DOI 10.1073/pnas.0604347103; TEASDALE G, 1974, LANCET, V2, P81; Thomas M., 2006, ELEMENTS INFORM THEO, V2nd ed.; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Vidal JR, 2012, J NEUROSCI, V32, P6421, DOI 10.1523/JNEUROSCI.4363-11.2012	34	29	30	1	12	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5196			FRONT NEUROINFORM	Front. Neuroinformatics		2013	7								UNSP 24	10.3389/fninf.2013.00024			11	Mathematical & Computational Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Mathematical & Computational Biology; Neurosciences & Neurology	V36JA	WOS:000209207300023	24312048	Green Published, gold, Green Submitted			2022-02-06	
J	Sultan, S; Gebara, E; Toni, N				Sultan, Sebastien; Gebara, Elias; Toni, Nicolas			Doxycycline increases neurogenesis and reduces microglia in the adult hippocampus	FRONTIERS IN NEUROSCIENCE			English	Article						dentate gyrus; hippocampus; adult neurogenesis; doxycycline; tetracycline; gene expression regulation	NEURAL STEM-CELLS; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; GFP TRANSGENIC MICE; DENTATE GYRUS; HYPOXIA-ISCHEMIA; MATRIX METALLOPROTEINASES; SYNAPTIC PLASTICITY; PARKINSONS-DISEASE	Adult hippocampal neurogenesis results in the continuous formation of new neurons and is a process of brain plasticity involved in learning and memory. Although inducible-reversible transgenic mouse models are increasingly being used to investigate adult neurogenesis, transgene control requires the administration of an activator, doxycycline (Dox), with unknown effects on adult neurogenesis. Here, we tested the effect of Dox administration on adult neurogenesis in vivo. We found that 4 weeks of Dox treatment at doses commonly used for gene expression control, resulted in increased neurogenesis. Furthermore, the dendrites of new neurons displayed increased spine density. Concomitantly, lba1-expressing microglia was reduced by Dox treatment. These results indicate that Dox treatment may interfere with parameters of relevance for the use of inducible transgenic mice in studies of adult neurogenesis or brain inflammation.	[Sultan, Sebastien; Gebara, Elias; Toni, Nicolas] Univ Lausanne, Dept Fundamental Neurosci, CH-1005 Lausanne, Switzerland		Toni, N (corresponding author), Univ Lausanne, Dept Fundamental Neurosci, 9 Rue Bugnon, CH-1005 Lausanne, Switzerland.	nicolas.toni@unil.ch	Toni, Nicolas/M-2057-2014	Toni, Nicolas/0000-0001-5585-268X; Gebara, Elias/0000-0003-4389-6604	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission	The authors wish to thank Romain Gosselin (Department of Fundamental Neurosciences, University of Lausanne, Switzerland) for critical insight on in vitro experiments and Coralie Rummel and Florian Udry for technical assistance. Images acquisition was performed at the Cellular Imaging Facility of the university of Lausanne (Lausanne, Switzerland). This work was supported by the Swiss National Science Foundation.	ALTMAN J, 1969, J COMP NEUROL, V136, P269, DOI 10.1002/cne.901360303; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Beckervordersandforth R, 2010, CELL STEM CELL, V7, P744, DOI 10.1016/j.stem.2010.11.017; Bozdagi O, 2007, J NEUROPHYSIOL, V98, P334, DOI 10.1152/jn.00202.2007; Buller KM, 2009, J NEUROSCI RES, V87, P599, DOI 10.1002/jnr.21890; Burggraf D, 2007, NEUROBIOL DIS, V25, P506, DOI 10.1016/j.nbd.2006.10.013; Cho Y, 2009, NEUROTOX RES, V16, P361, DOI 10.1007/s12640-009-9078-1; Chow JDY, 2012, TRANSGENIC RES, V21, P415, DOI 10.1007/s11248-011-9525-7; Clark WM, 1997, J MOL NEUROSCI, V9, P103, DOI 10.1007/BF02736854; Dupret D, 2007, PLOS BIOL, V5, P1683, DOI 10.1371/journal.pbio.0050214; Ehninger D, 2008, CELL TISSUE RES, V331, P243, DOI 10.1007/s00441-007-0478-3; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Encinas JM, 2011, CELL STEM CELL, V8, P566, DOI 10.1016/j.stem.2011.03.010; Ethell IM, 2007, J NEUROSCI RES, V85, P2813, DOI 10.1002/jnr.21273; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Ge SY, 2008, J PHYSIOL-LONDON, V586, P3759, DOI 10.1113/jphysiol.2008.155655; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu Y, 2012, NAT NEUROSCI, V15, P1700, DOI 10.1038/nn.3260; Hodge RD, 2008, J NEUROSCI, V28, P3707, DOI 10.1523/JNEUROSCI.4280-07.2008; Huntley GW, 2012, NAT REV NEUROSCI, V13, P743, DOI 10.1038/nrn3320; Huttmann K, 2003, EUR J NEUROSCI, V18, P2769, DOI 10.1111/j.1460-9568.2003.03002.x; Jantzie LL, 2010, J PSYCHIATR NEUROSCI, V35, P20, DOI 10.1503/jpn.090061; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kohman RA, 2013, BEHAV BRAIN RES, V242, P17, DOI 10.1016/j.bbr.2012.12.032; Kohman RA, 2012, BRAIN BEHAV IMMUN, V26, P803, DOI 10.1016/j.bbi.2011.10.006; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Krzisch M, 2013, ANESTHESIOLOGY, V118, P602, DOI 10.1097/ALN.0b013e3182815948; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Lee H, 2009, NEUROBIOL DIS, V34, P189, DOI 10.1016/j.nbd.2008.12.012; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Lu L, 2010, CNS NEUROL DISORD-DR, V9, P232, DOI 10.2174/187152710791012035; Ma DK, 2009, CELL RES, V19, P672, DOI 10.1038/cr.2009.56; Mandyam CD, 2007, NEUROSCIENCE, V146, P108, DOI 10.1016/j.neuroscience.2006.12.064; Massa F, 2011, P NATL ACAD SCI USA, V108, P6644, DOI 10.1073/pnas.1016928108; McIver SR, 2012, EXP BIOL MED, V237, P1129, DOI 10.1258/ebm.2012.012029; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Nolte C, 2001, GLIA, V33, P72; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Peixoto RT, 2012, NEURON, V76, P396, DOI 10.1016/j.neuron.2012.07.006; Richter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062621; Romero-Grimaldi C, 2011, STEM CELLS, V29, P1628, DOI 10.1002/stem.710; Samuels BA, 2011, EUR J NEUROSCI, V33, P1152, DOI 10.1111/j.1460-9568.2011.07614.x; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Saxe MD, 2007, P NATL ACAD SCI USA, V104, P4642, DOI 10.1073/pnas.0611718104; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Shors TJ, 2012, BEHAV BRAIN RES, V227, P450, DOI 10.1016/j.bbr.2011.04.023; Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Thomas M, 2003, CLIN NEUROPHARMACOL, V26, P18, DOI 10.1097/00002826-200301000-00005; Thuret S, 2009, HIPPOCAMPUS, V19, P658, DOI 10.1002/hipo.20550; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; Toni N, 2007, NAT NEUROSCI, V10, P727, DOI 10.1038/nn1908; Toni N, 2011, EUR J NEUROSCI, V33, P1062, DOI 10.1111/j.1460-9568.2011.07604.x; Tronel S, 2012, HIPPOCAMPUS, V22, P292, DOI 10.1002/hipo.20895; Trouche S, 2009, P NATL ACAD SCI USA, V106, P5919, DOI 10.1073/pnas.0811054106; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vukovic J, 2012, J NEUROSCI, V32, P6435, DOI 10.1523/JNEUROSCI.5925-11.2012; Wang XB, 2008, P NATL ACAD SCI USA, V105, P19520, DOI 10.1073/pnas.0807248105; Wideroe M, 2012, EUR J NEUROSCI, V36, P2006, DOI 10.1111/j.1460-9568.2012.08114.x; Yamaguchi M, 2000, NEUROREPORT, V11, P1991, DOI 10.1097/00001756-200006260-00037; Yang CP, 2011, DEVELOPMENT, V138, P4351, DOI 10.1242/dev.065540; Yao J, 2012, PROTEIN CELL, V3, P251, DOI 10.1007/s13238-012-2033-6; Yoon SY, 2012, NEUROSCIENCE, V221, P214, DOI 10.1016/j.neuroscience.2012.06.024; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhou X, 2006, GENE THER, V13, P1382, DOI 10.1038/sj.gt.3302780	74	29	31	0	1	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.		2013	7								131	10.3389/fnins.2013.00131			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AW9HF	WOS:000346567300130	23898238	Green Published, gold			2022-02-06	
J	VanItallie, TB				VanItallie, Theodore B.			Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention	METABOLISM-CLINICAL AND EXPERIMENTAL			English	Article						Neuroimaging biomarkers; Apolipoprotein E epsilon 4; Fluorodeoxyglucose-positron emission tomography; Cerebral metabolic rate of glucose; Personalized medicine	POSITRON-EMISSION-TOMOGRAPHY; APOE EPSILON-4 ALLELE; FAMILY-HISTORY; MOUSE MODEL; CLEARANCE; DEMENTIA; DEFICIT	The most opportune time for preventive intervention in sporadic Alzheimer's disease (spAD) is early in its preclinical stage (pcAD), when the odds of preventing or minimizing later disabling neurodegeneration are most favorable. The efficacy of promising preventive interventions should be assessed in patients in the earliest discernible phase of pcAD. This will require application of personalized medicine techniques, with use of suitable biomarkers to detect pcAD in individuals believed to be spAD-prone. This review focuses on the genetic biomarker, apolipoprotein E (apoE) epsilon 4, and on certain neuroimaging biomarkers, such as structural MRI (sMRI), fluorodeoxyglucose-positron emission tomography (FDG-PET), and PET-amyloid tracers capable of delineating the extent and distribution of amyloid-beta (A beta) deposits in the brain, that can be useful in identifying cognitively normal people who are at enhanced risk of developing spAD. Many years before AD symptoms appear, such neuroimaging procedures can disclose signature abnormalities of brain structure, function, and amyloid levels in cognitively normal apoE epsilon 4 allele carriers and/or individuals with a family history of spAD. Although no effective treatment for spAD is yet available, there is evidence that, by taking a proactive personalized-medicine approach, the practicing physician may be able to reduce risk in AD-prone patients by attending to such modifiable AD risk factors as hypertension, obesity, type 2 diabetes, insulin resistance, hypercholesterolemia, sedentary lifestyle, and current cigarette smoking. Young patients who are epsilon 4 positive should be advised to avoid participation in contact sports or other activities that expose them to risk of traumatic brain injury. (C) 2013 Elsevier Inc. All rights reserved.	Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Dept Med, Div Endocrinol Diabet & Nutr, New York, NY 10025 USA		VanItallie, TB (corresponding author), Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Dept Med, Div Endocrinol Diabet & Nutr, New York, NY 10025 USA.				College International de Recherche Servier (CIRS)	Publication of this article was supported by the College International de Recherche Servier (CIRS).	Alzheimers Assoc, 2011, ALZHEIMERS DEMENT, V7, P208, DOI 10.1016/j.jalz.2011.02.004; Berti V, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2011.01.001; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697; de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198; Dickerson BC, 2011, NEUROLOGY, V76, P1395, DOI 10.1212/WNL.0b013e3182166e96; Fan JJ, 2009, BIOFACTORS, V35, P239, DOI 10.1002/biof.37; Fennema-Notestine C, 2011, J ALZHEIMERS DIS, V26, P49, DOI 10.3233/JAD-2011-0002; Fleisher AS, 2011, ARCH NEUROL-CHICAGO, V68, P1404, DOI 10.1001/archneurol.2011.150; Fleisher AS, 2012, NEUROBIOL A IN PRESS; Gandy S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004274; Knopman DS, 2012, NEUROLOGY, V78, P1576, DOI 10.1212/WNL.0b013e3182563bbe; Lee CYD, 2012, J BIOL CHEM, V287, P2032, DOI 10.1074/jbc.M111.295451; Lee SH, 2012, J NEUROSCI, V32, P5953, DOI 10.1523/JNEUROSCI.0465-12.2012; Liu Y, 2008, FEBS LETT, V582, P359, DOI 10.1016/j.febslet.2007.12.035; Martin LJ, 2012, PROG MOL BIOL TRANSL, V107, P355, DOI 10.1016/B978-0-12-385883-2.00005-9; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; Mosconi L, 2007, P NATL ACAD SCI USA, V104, P19067, DOI 10.1073/pnas.0705036104; Mosconi Lisa, 2005, Eur J Nucl Med Mol Imaging, V32, P486, DOI 10.1007/s00259-005-1762-7; Mosconi L, 2011, ADV ALZH DIS, V2, P219, DOI 10.3233/978-1-60750-793-2-219; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Sabuncu MR, 2011, ARCH NEUROL-CHICAGO, V68, P1040, DOI 10.1001/archneurol.2011.167; Sadowsky CH, 2012, J AM BOARD FAM MED, V25, P350, DOI 10.3122/jabfm.2012.03.100183; Talbot K, 2012, J CLIN INVEST, V122, P1316, DOI 10.1172/JCI59903; Tondelli M, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.05.018; Valla J, 2010, J ALZHEIMERS DIS, V22, P307, DOI 10.3233/JAD-2010-100129; Varghese M, 2011, TRANSL NEUROSCI, V2, P1, DOI 10.2478/s13380-011-0011-8; Veech RL, 2012, IUBMB LIFE, V64, P203, DOI 10.1002/iub.590; Vlassenko AG, 2011, ANN NEUROL, V70, P857, DOI 10.1002/ana.22608; Westman E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022506; Wu Z, 1998, ALZ DIS ASSOC DIS, V12, P190, DOI 10.1097/00002093-199809000-00011; Xiong CJ, 2011, ARCH NEUROL-CHICAGO, V68, P1313, DOI 10.1001/archneurol.2011.208; Yao J, 2009, P NATL ACAD SCI USA, V106, P14670, DOI 10.1073/pnas.0903563106	33	29	29	0	53	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0026-0495	1532-8600		METABOLISM	Metab.-Clin. Exp.	JAN	2013	62	1		1			S30	S33		10.1016/j.metabol.2012.08.024			4	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	056PZ	WOS:000312504700008	23021038				2022-02-06	
J	Ruban, A; Berkutzki, T; Cooper, I; Mohar, B; Teichberg, VI				Ruban, Angela; Berkutzki, Tamara; Cooper, Itzik; Mohar, Boaz; Teichberg, Vivian I.			Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas	INVESTIGATIONAL NEW DRUGS			English	Article						Blood glutamate scavengers; Gliomas; Glutamate-oxaloacetate transferase	CLOSED-HEAD INJURY; HUMAN GLIOBLASTOMA; MALIGNANT GLIOMAS; AMINO-ACID; GROWTH; CELLS; NEUROPROTECTION; MICRODIALYSIS; COTRANSPORTER; TRANSPORTERS	L-Glutamate (Glu) plays a crucial role in the growth of malignant gliomas. We have established the feasibility of accelerating a naturally occurring brain to-blood Glu efflux by decreasing blood Glu levels with intravenous oxaloacetate, the respective Glu co-substrate of the blood resident enzyme humane glutamate-oxaloacetate transaminase (hGOT). We wished to demonstrate that blood Glu scavenging provides neuroprotection in the case of glioma. We now describe the neuroprotective effects of blood Glu scavenging in a fatal condition such as brain-implanted C6 glioma in rats and brain-implanted human U87 MG glioma in nude mice. Rat (C-6) or human (U87) glioma cells were grafted stereotactically in the brain of rats or mice. After development of tumors, the animals were drinking oxaloacetate with or without injections of hGOT. In addition, mice were treated with combination treatment, which included drinking oxaloacetate with intracutaneous injections of hGOT and intraperitoneal injection of Temozolomide. Animals drinking oxaloacetate with or without injections of hGOT displayed a smaller tumor volume, reduced invasiveness and prolonged survival than control animals drinking saline. These effects were significantly enhanced by Temozolomide in mice, which increased survival by 237%. This is the first demonstration of blood Glu scavenging in brain cancer, and because of its safety, is likely to be of clinical significance for the future treatment of human gliomas. As we demonstrated, the blood glutamate scavenging treatment in combination with TMZ could be a good candidate or as an alternative treatment to the patients that do not respond to TMZ.	[Ruban, Angela; Cooper, Itzik; Mohar, Boaz; Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Berkutzki, Tamara] Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel		Ruban, A (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	Angela.matuzani@weizmann.ac.il	Mohar, Boaz/H-6398-2011	Mohar, Boaz/0000-0002-8613-2869; cooper, itzik/0000-0003-0723-5542; Ruban, Angela/0000-0003-1091-8854	Bio-Med Morasha ISF [1898/08]; NISF-Legacy-Bio-Med [1162]; Nella and Leon Benoziyo Center for Neurological Diseases; Irwin Green Fund for Studying the Development of the Brain; Carl and Micaela Einhorn-Dominic Institute for Brain Research; estate of Lola Asseof	This work was supported by grants to VIT from the Bio-Med Morasha ISF program no. 1898/08, the NISF-Legacy-Bio-Med 1162, the Nella and Leon Benoziyo Center for Neurological Diseases; the Irwin Green Fund for Studying the Development of the Brain, the Carl and Micaela Einhorn-Dominic Institute for Brain Research and the estate of Lola Asseof. VIT is the incumbent of the Louis and Florence Katz-Cohen Chair of Neuropharmacology.	Arcella A, 2005, NEURO-ONCOLOGY, V7, P236, DOI 10.1215/S1152851704000961; Augustine CK, 2009, CLIN CANCER RES, V15, P502, DOI 10.1158/1078-0432.CCR-08-1916; Behrens PF, 2000, J NEURO-ONCOL, V47, P11, DOI 10.1023/A:1006426917654; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; Burckhardt BC, 2005, AM J PHYSIOL-RENAL, V288, pF792, DOI 10.1152/ajprenal.00360.2004; Campos F, 2011, J CEREB BLOOD FLOW M; Campos F, J CEREB BLOOD FLOW M; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Cohen-Kashi-Malina K, J CEREB BLOOD FLOW M; de Groot J, 2011, GLIA, V59, P1181, DOI 10.1002/glia.21113; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; HAUSSINGER D, 1989, EUR J BIOCHEM, V185, P189, DOI 10.1111/j.1432-1033.1989.tb15101.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Ishiuchi S, 2007, J NEUROSCI, V27, P7987, DOI 10.1523/JNEUROSCI.2180-07.2007; Kollareddy M, 2008, BIOMED PAP, V152, P27, DOI 10.5507/bp.2008.004; Loh JK, BMC CANC, V10, P268; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Ma DQ, 2004, BRIT MED BULL, V71, P77, DOI 10.1093/bmb/ldh036; OKA A, 1993, J NEUROSCI, V13, P1441; Pajor AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1215, DOI 10.1152/ajpcell.2001.280.5.C1215; Philip M, 2009, STROKE, V40, P577, DOI 10.1161/STROKEAHA.108.524330; Rich JN, 2004, NAT REV DRUG DISCOV, V3, P430, DOI 10.1038/nrd1380; Rijpkema M, 2003, NMR BIOMED, V16, P12, DOI 10.1002/nbm.807; Roslin M, 2003, J NEURO-ONCOL, V61, P151, DOI 10.1023/A:1022106910017; Sontheimer H, 2004, MOL NEUROBIOL, V29, P61, DOI 10.1385/MN:29:1:61; Sontheimer H, 2003, TRENDS NEUROSCI, V26, P543, DOI 10.1016/j.tins.2003.08.007; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Ye ZC, 1999, CANCER RES, V59, P4383; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2009, J NEUROSURG ANESTH, V21, P235, DOI 10.1097/ANA.0b013e3181a2bf0b	35	29	29	0	9	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0167-6997			INVEST NEW DRUG	Invest. New Drugs	DEC	2012	30	6					2226	2235		10.1007/s10637-012-9794-x			10	Oncology; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Pharmacology & Pharmacy	029BP	WOS:000310470100015	22392507	Green Published, hybrid			2022-02-06	
J	Schnieders, J; Willemsen, D; de Boer, H				Schnieders, Jessica; Willemsen, Dennis; de Boer, Hans			Factors Contributing to Chronic Fatigue After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						pituitary hormone deficiency; sleep disorders; traumatic brain injury; vitamin D deficiency	QUALITY-OF-LIFE; POSTTRAUMATIC HYPOPITUITARISM; SLEEP DISORDERS; PREVALENCE; MILD; DYSFUNCTION; INSTRUMENT; RECOVERY; INSOMNIA; INDEX	Background: The annual incidence of traumatic brain injury in Europe amounts to 235 per 100 000 persons. About two-thirds will develop posttraumatic brain injury chronic fatigue (pTBI-CF). Aim: To identify the reversible hormonal and nonhormonal causes of pTBI-CF. Patients and Methods: Ninety patients with varying degrees of pTBI-CF underwent endocrine testing and an evaluation of sleep, attention, coping style, daily activity and dependency, physical performance, emotional well-being, and quality of life. Results: Vitamin D deficiency was found in 65%, poor sleep quality in 54%, anxiety disorders in 36%, growth hormone deficiency in 16%, and gonadal hormone deficiencies in 9%. Fatigue severity was correlated with poor sleep (R = +0.65, P < .0001), serum 25-hydroxy vitamin D levels (R = -0.50, P < .0001), and anxiety (R = +0.50, P < .0001) but not with growth hormone deficiency or gonadal hormone deficiencies. The first 3 factors together explained 59% of the fatigue score variance. Conclusions: Poor sleep, vitamin D deficiency, and anxiety were the most important factors associated with pTBI-CF. Appropriate treatment of these disorders may help to reduce fatigue in these patients.	[Schnieders, Jessica] Waterland Hosp, Dept Rehabil, NL-1441 RN Purmerend, Netherlands; [Willemsen, Dennis; de Boer, Hans] Rijnstate Hosp, Dept Internal Med, Arnhem, Netherlands		Schnieders, J (corresponding author), Waterland Hosp, Dept Rehabil Med, Waterlandlaan 250, NL-1441 RN Purmerend, Netherlands.	j_schnieders@hotmail.com					Aaronson L S, 1999, Image J Nurs Sch, V31, P45; ASTRAND PO, 1986, TXB WORK PHYSL PHYSL, P354; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Blair JC, 2010, BRIT J NEUROSURG, V24, P10, DOI 10.3109/02688690903536637; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; Eskes SA, 2009, NETH J MED, V67, P127; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hayes SC, 2004, PSYCHOL REC, V54, P553, DOI 10.1007/BF03395492; Hintzpeter B, 2008, EUR J CLIN NUTR, V62, P1079, DOI 10.1038/sj.ejcn.1602825; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Molitch ME, 2006, J CLIN ENDOCR METAB, V91, P1621, DOI 10.1210/jc.2005-2227; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Valsamis HA, 2006, NUTR METABOLISM, V3, DOI 10.1186/1743-7075-3-36; Van Cauter E, 1998, SLEEP, V21, P553; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; van Groningen L, 2010, EUR J ENDOCRINOL, V162, P805, DOI 10.1530/EJE-09-0932; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	48	29	29	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					404	412		10.1097/HTR.0b013e3182306341			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200011	22190008				2022-02-06	
J	Cooper, DB; Chau, PM; Armistead-Jehle, P; Vanderploeg, RD; Bowles, AO				Cooper, Douglas B.; Chau, Phuong M.; Armistead-Jehle, Patrick; Vanderploeg, Rodney D.; Bowles, Amy O.			Relationship Between Mechanism of Injury and Neurocognitive Functioning in OEF/OIF Service Members With Mild Traumatic Brain Injuries	MILITARY MEDICINE			English	Article								Military personnel deployed to combat theaters in Iraq and Afghanistan are at risk of sustaining mild traumatic brain injuries (mTBI) from causes such as improvised explosive devices, motor vehicle accidents, and falls. Despite the high incidence of mTBI in deployed personnel, questions remain about the effects of blast-related vs. non-blast-related mTBI on acute and long-term sequelae. This investigation is a retrospective review of service members who presented for evaluation of suspected mTBI and underwent neurocognitive screening evaluation. mTBI diagnosis was made by semistructured clinical interview. Only individuals in whom mechanism of injury could be determined (blast vs. non-blast) were included. Sixty individuals were included in the final sample: 32 with blast mTBI and 28 with non-blast mTBI. There were no differences between the blast-related and non-blast-related mTBI groups on age, time since injury, combat stress symptoms, or headache. Analysis of variance showed no significant between-group differences on any of the neurocognitive performance domains. Although speculation remains that the effects of primary blast exposure are unique, the results of this study are consistent with prior research suggesting that blast-related mTBI does not differ from other mechanisms of injury with respect to cognitive sequelae in the postacute phase.	[Cooper, Douglas B.; Chau, Phuong M.; Bowles, Amy O.] San Antonio Mil Med Ctr, Dept Orthoped & Rehabil, Traumat Brain Injury Serv, Ft Sam Houston, TX 78234 USA; [Cooper, Douglas B.; Vanderploeg, Rodney D.] San Antonio Mil Med Ctr, DVBIC, Ft Sam Houston, TX 78234 USA; [Armistead-Jehle, Patrick] Munson Army Hlth Ctr, Concuss Clin, Fort Leavenworth, KS 66027 USA; [Vanderploeg, Rodney D.] James A Haley VA Med Ctr, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Neurosci, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA		Cooper, DB (corresponding author), San Antonio Mil Med Ctr, Dept Orthoped & Rehabil, Traumat Brain Injury Serv, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.		Armistead-Jehle, Patrick/AAU-5741-2020	Armistead-Jehle, Patrick/0000-0002-6784-1432			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Casscells S., 2007, HLTH AFFAIRS MEMORAN; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cohen J., 1983, APPL MULTIPLE REGRES; Friedl KE, 2009, P INT STAT SCI M NON; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mckay C, 2008, CLIN NEUROPSYCHOL, V22, P228, DOI 10.1080/13854040701260370; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Randolph C., 1998, REPEATABLE BATTERY A; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Ware JE, 2000, NEUROLOGY, V54, pA336; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	19	29	29	0	5	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	OCT	2012	177	10					1157	1160		10.7205/MILMED-D-12-00098			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V33OE	WOS:000209027300011	23113441	Bronze			2022-02-06	
J	de Jongh, MAC; van Stel, HF; Schrijvers, AJP; Leenen, LPH; Verhofstad, MHJ				de Jongh, Mariska A. C.; van Stel, Henk F.; Schrijvers, Augustinus J. P.; Leenen, Luke P. H.; Verhofstad, Michael H. J.			The effect of Helicopter Emergency Medical Services on trauma patient mortality in the Netherlands	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Trauma; Mortality; Prehospital care; HEMS	INJURY SEVERITY SCORE; ON-SCENE TIMES; BRAIN-INJURY; ENDOTRACHEAL INTUBATION; GOLDEN HOUR; CARE; SURVIVAL; SCALE; IMPACT; COHORT	Introduction: Object of this study was to evaluate the effect of the Helicopter Emergency Medical Services (HEMS) on trauma patient mortality and the effect of prehospital time on the association between HEMS and mortality. Materials and methods: Trauma patients admitted to a level 1 trauma centre and treated on-scene by the HEMS and Emergency Medical Services (EMS) between 2003 and 2008 were included (n = 186). A control group treated by EMS only (n = 186) was created by matching on ISS, age and severe traumatic brain injury (TBI). Mortality was compared by calculating odds ratios (OR) and numbers needed to treat (NNT), with adjustment for prehospital coded Revised Trauma Score. The effect of prehospital time mortality was tested by a logistic regression. Analyses were made for patients with and without TBI. Results: The OR of early trauma fatality for the HEMS/EMS versus EMS-only groups was 0.8 for patients both with TBI (95% CI 0.4-1.7; NNT: 22) and without TBI (95% CI 0.2-3.3; NNT: 273). The risk of in-hospital mortality was non-significantly higher for patients with TBI in the HEMS/EMS group (OR = 1.3; 95% CI 0.6-2.7; NNT: -15) compared to the EMS-only group and non-significantly lower for patients without TBI (OR = 0.9; 95% CI 0.3-2.5; NNT: 129). After adjustment for prehospital time, the risk of early trauma fatality for patients with TBI treated by the HEMS decreased (OR = 0.6; 95% CI 0.3-1.6). The risk of in-hospital mortality for these patients decreased from 1.3 to 0.8 (95% CI 0.4-2.0). The effect of the HEMS on patients without TBI did not change after adjustment for prehospital time. Discussion: HEMS treatment is associated with a non-significantly higher risk of in-hospital mortality for patients with TBI and a non-significantly lower risk for patients without TBI. This increased risk of mortality in TBI patients is attributable to the increased prehospital time. These results indicate that HEMS does not have a positive impact on survival. (C) 2012 Elsevier Ltd. All rights reserved.	[de Jongh, Mariska A. C.; Verhofstad, Michael H. J.] St Elizabeth Hosp, Trauma Ctr Brabant, NL-5000 LC Tilburg, Netherlands; [van Stel, Henk F.; Schrijvers, Augustinus J. P.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Leenen, Luke P. H.] Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands; [Verhofstad, Michael H. J.] St Elizabeth Hosp, Dept Surg, NL-5000 LC Tilburg, Netherlands		de Jongh, MAC (corresponding author), St Elizabeth Hosp, Trauma Ctr Brabant, POB 90151, NL-5000 LC Tilburg, Netherlands.	m.d.jongh@elisabeth.nl		Leenen, Luke/0000-0001-8385-1801; van Stel, Henk/0000-0002-3475-9846			[Anonymous], 2011, NUMB NEED TREAT; [Anonymous], 2011, KERNC PROV 2010; Association for the Advancement of Automotive Medicine (AAAM), 1998, COMM INJ SCAL ABBR I; Aydin S, 2010, J TRAUMA, V69, P589, DOI 10.1097/TA.0b013e3181e74858; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berlot G, 2009, EUR J EMERG MED, V16, P312, DOI 10.1097/MEJ.0b013e32832d3aa1; Carr BG, 2008, PREHOSP EMERG CARE, V12, P327, DOI 10.1080/10903120802096928; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; de Jongh MAC, 2010, BRIT J SURG, V97, P1805, DOI 10.1002/bjs.7216; de Jongh MAC, 2008, INJURY, V39, P1007, DOI 10.1016/j.injury.2008.03.026; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Iirola TT, 2006, EUR J EMERG MED, V13, P335, DOI 10.1097/01.mej.0000224429.51623.fb; Lee A, 2003, INJURY, V34, P815, DOI 10.1016/S0020-1383(02)00395-9; Lemeshow S, 2000, APPL LOGISTIC REGRES; Lemson J, 2008, Ned Tijdschr Geneeskd, V152, P1106; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Mitchell AD, 2007, CAN J SURG, V50, P129; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Osler T, 2008, ANN SURG, V247, P1041, DOI 10.1097/SLA.0b013e31816ffb3f; Ringburg Akkie N, 2005, Air Med J, V24, P248, DOI 10.1016/j.amj.2005.08.002; Ringburg AN, 2007, J TRAUMA, V63, P258, DOI 10.1097/01.ta.0000240449.23201.57; Ringburg Akkie N, 2009, Air Med J, V28, P298, DOI 10.1016/j.amj.2009.03.007; Rothman K.J., 2008, Modern epidemiology, V3rd; Spaite DW, 2003, ANN EMERG MED, V42, P729, DOI 10.1016/S0196-0644(03)00822-9; van der Velden MWA, 2008, EMERG MED J, V25, P444, DOI 10.1136/emj.2007.052662; Zink BJ, 2004, ANN EMERG MED, V44, P451, DOI 10.1016/j.annemergmed.2004.05.001	29	29	29	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1362	1367		10.1016/j.injury.2012.01.009			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100005	22305588				2022-02-06	
J	Kolbe, S; Bajraszewski, C; Chapman, C; Nguyen, T; Mitchell, P; Paine, M; Butzkueven, H; Johnston, L; Kilpatrick, T; Egan, G				Kolbe, Scott; Bajraszewski, Clare; Chapman, Caron; Tan Nguyen; Mitchell, Peter; Paine, Mark; Butzkueven, Helmut; Johnston, Leigh; Kilpatrick, Trevor; Egan, Gary			Diffusion tensor imaging of the optic radiations after optic neuritis	HUMAN BRAIN MAPPING			English	Article						diffusion tensor imaging; multiple sclerosis; optic radiations	TRAUMATIC AXONAL INJURY; MULTIPLE-SCLEROSIS; WHITE-MATTER; RETROGRADE DEGENERATION; MAGNETIZATION-TRANSFER; CORPUS-CALLOSUM; MRI; ATROPHY; LESIONS; NERVE	Trans-synaptic degeneration could exacerbate neurodegeneration in multiple sclerosis (MS). We aimed to assess whether anterograde trans-synaptic degeneration could be identified in the primary visual pathway in vivo. Diffusion tensor imaging (DTI) was used to assess the optic radiations in 15 patients with previous optic nerve inflammation and 9 healthy volunteers. A probabilistic atlas of the optic radiations was created from healthy diffusion tractography data. Lengthwise profiles for DTI parameters (axial [gimel vertical bar vertical bar|], radial [gimel perpendicular to] and mean diffusivity [MD], fractional anisotropy [FA] and the angle of deviation of the principal eigenvector [alpha]) were analyzed for patients and controls. Patients also underwent multifocal visual evoked potential (mfVEP) assessments to characterize the latency and amplitude of cortical potentials. Correlations were performed between mfVEP latency and amplitude in the left and right visual hemi-fields and DTI parameters in the contra-lateral optic radiations. Patients displayed a significant decrease in lambda vertical bar vertical bar within the body of both optic radiations, which significantly correlated with loss of mfVEP amplitude. Abnormal gimel perpendicular to and FA were detected bilaterally throughout the optic radiations in patients but the abnormality was not associated with amplitude reduction or latency prolongation of the mfVEP. An abnormal a value was observed in the left optic radiations of patients, and the a value in the body of the optic radiations also correlated with mfVEP amplitude loss. The assocation between bilateral DTI abnormalities within the optic radiations and loss of afferent electrical activity could indicate anterograde trans-synaptic degeneration occurs following optic neuritis. Hum Brain Mapp 33:20472061, 2012. (c) 2011 Wiley Periodicals, Inc.	[Kolbe, Scott; Butzkueven, Helmut; Johnston, Leigh; Kilpatrick, Trevor; Egan, Gary] Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic, Australia; [Kolbe, Scott; Bajraszewski, Clare; Chapman, Caron; Butzkueven, Helmut; Kilpatrick, Trevor; Egan, Gary] Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; [Tan Nguyen; Paine, Mark] Royal Victorian Eye & Ear Hosp, Neuroophthalmol Unit, Melbourne, Vic 3002, Australia; [Mitchell, Peter] Royal Melbourne Hosp, Dept Radiol, Melbourne, Vic, Australia; [Butzkueven, Helmut; Kilpatrick, Trevor] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia; [Johnston, Leigh] Univ Melbourne, Dept Elect & Elect Engn, Melbourne, Vic, Australia; [Johnston, Leigh] Univ Melbourne, NICTA Victorian Res Lab, Melbourne, Vic, Australia		Kolbe, S (corresponding author), Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic, Australia.	scott.kolbe@florey.edu.au	Egan, Gary F./A-1381-2013; Johnston, Leigh A/D-7102-2014	Johnston, Leigh A/0000-0002-5032-4674; Egan, Gary/0000-0002-3186-4026; Kilpatrick, Trevor/0000-0003-3999-085X; Kolbe, Scott/0000-0003-4685-1380; Butzkueven, Helmut/0000-0003-3940-8727	Australian National Health and Medical Research Council (NHMRC) Principal Research Fellowship, AustraliaNational Health and Medical Research Council of Australia [400317]; Joint MS Research Australia/Trish MS Foundation/NHMRC Betty Cuthbert FellowshipNational Health and Medical Research Council of Australia [400476]; Joint MS Research Australia/Australian Financial Advisors Association Postgraduate Scholarship; Charityworks for MS, Melbourne; Neurosciences Victoria Neuro-Informatics Platform	Contract grant sponsor: Australian National Health and Medical Research Council (NHMRC) Principal Research Fellowship, Australia; Contract grant number: 400317; Contract grant sponsor: Joint MS Research Australia/Trish MS Foundation/NHMRC Betty Cuthbert Fellowship; Contract grant number: 400476; Contract grant sponsors: The Joint MS Research Australia/Australian Financial Advisors Association Postgraduate Scholarship; Charityworks for MS, Melbourne; Neurosciences Victoria Neuro-Informatics Platform.	Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; Audoin B, 2006, BRAIN, V129, P1031, DOI 10.1093/brain/awl039; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Chard DT, 2003, J NEUROL NEUROSUR PS, V74, P1551, DOI 10.1136/jnnp.74.11.1551; Ciccarelli O, 2005, HUM BRAIN MAPP, V25, P308, DOI 10.1002/hbm.20101; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Costello F, 2006, ANN NEUROL, V59, P963, DOI 10.1002/ana.20851; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Evangelou N, 2001, BRAIN, V124, P1813, DOI 10.1093/brain/124.9.1813; Geurts JJG, 2005, RADIOLOGY, V236, P254, DOI 10.1148/radiol.2361040450; GHETTI B, 1972, BRAIN RES, V45, P31, DOI 10.1016/0006-8993(72)90214-4; Ginsberg SD, 2002, J NEUROTRAUM, V19, P99, DOI 10.1089/089771502753460277; GLEES P, 1967, ACTA NEUROPATHOL, V7, P361, DOI 10.1007/BF00688092; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Inglese M, 2001, J NEUROL SCI, V188, P33, DOI 10.1016/S0022-510X(01)00542-1; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnson H, 2000, EXP BRAIN RES, V132, P269, DOI 10.1007/s002210000384; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Klistorner A, 2008, ANN NEUROL, V64, P325, DOI 10.1002/ana.21474; Klistorner A, 2007, INVEST OPHTH VIS SCI, V48, P4549, DOI 10.1167/iovs.07-0381; Kolbe S, 2009, NEUROIMAGE, V45, P679, DOI 10.1016/j.neuroimage.2008.12.047; Korsholm K, 2007, BRAIN, V130, P1244, DOI 10.1093/brain/awm045; LeVay S, 1971, CELL TISSUE RES, V113, P396; Lin F, 2007, AM J NEURORADIOL, V28, P278; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Naismith RT, 2009, NEUROLOGY, V72, P589, DOI 10.1212/01.wnl.0000335766.22758.cd; Pagani E, 2005, NEUROIMAGE, V26, P258, DOI 10.1016/j.neuroimage.2005.01.008; Peltier J, 2006, J NEUROSURG, V105, P294, DOI 10.3171/jns.2006.105.2.294; Reich DS, 2010, NEUROIMAGE, V49, P3047, DOI 10.1016/j.neuroimage.2009.11.043; Reich DS, 2009, ARCH NEUROL-CHICAGO, V66, P1; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rovaris M, 2005, NEUROLOGY, V65, P1526, DOI 10.1212/01.wnl.0000184471.83948.e0; Rovaris M, 2007, J NEUROIMAGING, V17, p27S, DOI 10.1111/j.1552-6569.2007.00133.x; Shimony JS, 2006, CEREB CORTEX, V16, P1653, DOI 10.1093/cercor/bhj102; Shu N, 2009, HUM BRAIN MAPP, V30, P220, DOI 10.1002/hbm.20507; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trip SA, 2006, NEUROIMAGE, V31, P286, DOI 10.1016/j.neuroimage.2005.11.051; Trip SA, 2006, NEUROIMAGE, V30, P498, DOI 10.1016/j.neuroimage.2005.09.024; Ueki S, 2006, AM J OPHTHALMOL, V142, P591, DOI 10.1016/j.ajo.2006.05.042; VANBUREN JM, 1963, J NEUROL NEUROSUR PS, V26, P402; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wu QZ, 2008, J MAGN RESON IMAGING, V27, P446, DOI 10.1002/jmri.21111; Wu QZ, 2007, NEUROIMAGE, V37, P1138, DOI 10.1016/j.neuroimage.2007.06.029; Xie S, 2007, AM J OPHTHALMOL, V143, P642, DOI 10.1016/j.ajo.2006.12.009; Zhang H, 2006, MED IMAGE ANAL, V10, P764, DOI 10.1016/j.media.2006.06.004; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	57	29	33	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	SEP	2012	33	9					2047	2061		10.1002/hbm.21343			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	989XB	WOS:000307593400003	21915943	Green Published			2022-02-06	
J	Tallus, J; Lioumis, P; Hamalainen, H; Kahkonen, S; Tenovuo, O				Tallus, J.; Lioumis, P.; Hamalainen, H.; Kahkonen, S.; Tenovuo, O.			Long-lasting TMS motor threshold elevation in mild traumatic brain injury	ACTA NEUROLOGICA SCANDINAVICA			English	Article						head injury; electromyography; neurophysiology; neurotraumatology; transcranial magnetic stimulation	TRANSCRANIAL MAGNETIC STIMULATION; CORTICOMOTOR THRESHOLD; CORTICAL EXCITABILITY; SLEEP-DEPRIVATION; SPORTS CONCUSSION; CORTEX DISTANCE; HEAD-INJURY; REPEATABILITY; IMPAIRMENT; RESPONSES	Tallus J, Lioumis P, Hamalainen H, Kahkonen S, Tenovuo O. Long-lasting TMS motor threshold elevation in mild traumatic brain injury. ?Acta Neurol Scand: 2012: 126: 178182.(C) 2011 John Wiley & Sons A/S. Objectives Mild traumatic brain injury (mTBI) is very common, and part of the patients experience persistent symptoms. These may be caused by diffuse neuronal damage and could therefore affect cortical excitability. The motor threshold (MT), measured by transcranial magnetic stimulation (TMS), is a measure of cortical excitability and cortico-spinal tract integrity. Materials and methods We used navigated TMS (nTMS) and electromyography to determine subjects left hemisphere MTs. Nineteen subjects with mTBI (11 with persistent symptoms and eight fully recovered) and nine healthy controls were tested. The injuries had occurred on average 5 years earlier. All participants had normal brain MRIs, that is, no signs of injury. None used centrally acting medication. Results The mean MT in controls was 43.0% (SD 2.5) of maximum stimulator output. The mTBI subjects mean MT was 53.4% (SD 9.7), being higher than the controls threshold. Subjective recovery did not correlate with MT. Conclusions The results show chronic MT elevation in a sample of subjects with symptomatic or recovered mTBI. This suggests that mTBI may be compensated, although not fully recovered, years after the injury. While the cause for MT elevation cannot be concluded from these preliminary observations, possible explanations include decreased cortical excitability and impaired subcortical conduction.	[Tallus, J.; Hamalainen, H.] Univ Turku, Ctr Cognit Neurosci, Dept Psychol, Turku 20014, Finland; [Lioumis, P.] Univ Helsinki, BioMag Lab, HUSLAB, Cent Hosp, Helsinki, Finland; [Kahkonen, S.] Univ Helsinki, Cent Hosp, BioMag Lab & Pain Clin, Helsinki, Finland; [Tenovuo, O.] Hosp Dist SW Finland, Turku, Finland		Tallus, J (corresponding author), Univ Turku, Ctr Cognit Neurosci, Dept Psychol, Assistentinkatu 7, Turku 20014, Finland.	jptall@utu.fi	Lioumis, Pantelis/A-3801-2019	Lioumis, Pantelis/0000-0003-2016-9199			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARKER AT, 1985, LANCET, V1, P1106; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Civardi C, 2001, J NEUROL NEUROSUR PS, V71, P809, DOI 10.1136/jnnp.71.6.809; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Di Lazzaro V, 2003, J PHYSIOL-LONDON, V547, P485, DOI 10.1113/jphysiol.2002.030486; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Herbsman T, 2009, HUM BRAIN MAPP, V30, P2044, DOI 10.1002/hbm.20649; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Kahkonen S, 2004, J PSYCHOPHARMACOL, V18, P257, DOI 10.1177/0269881104042631; Kimiskidis VK, 2004, NEUROPHYSIOL CLIN, V34, P259, DOI 10.1016/j.neucli.2004.10.002; Lioumis P, 2009, HUM BRAIN MAPP, V30, P1387, DOI 10.1002/hbm.20608; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Manganotti P, 2006, J NEUROL NEUROSUR PS, V77, P56, DOI 10.1136/jnnp.2004.041137; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mills KR, 1997, MUSCLE NERVE, V20, P570, DOI 10.1002/(SICI)1097-4598(199705)20:5<570::AID-MUS5>3.0.CO;2-6; Petersen NC, 2010, ACTA PHYSIOL, V198, P403, DOI 10.1111/j.1748-1716.2009.02066.x; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Ruohonen J., 2002, HDB TRANSCRANIAL MAG, P18; Saisanen L, 2008, J CLIN NEUROPHYSIOL, V25, P367, DOI 10.1097/WNP.0b013e31818e7944; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Stokes MG, 2005, J NEUROPHYSIOL, V94, P4520, DOI 10.1152/jn.00067.2005; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	30	29	29	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	SEP	2012	126	3					178	182		10.1111/j.1600-0404.2011.01623.x			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	983DX	WOS:000307099800006	22103909				2022-02-06	
J	Wagner, AK; Brett, CA; McCullough, EH; Niyonkuru, C; Loucks, TL; Dixon, CE; Ricker, J; Arenth, P; Berga, SL				Wagner, Amy K.; Brett, Christopher A.; McCullough, Emily H.; Niyonkuru, Christian; Loucks, Tammy L.; Dixon, C. Edward; Ricker, Joseph; Arenth, Patricia; Berga, Sarah L.			Persistent hypogonadism influences estradiol synthesis, cognition and outcome in males after severe TBI	BRAIN INJURY			English	Article						Traumatic brain injury; testosterone; estradiol; cognitive outcome	TRAUMATIC BRAIN-INJURY; SYNAPTIC PLASTICITY; ANTIPITUITARY ANTIBODIES; GENDER-DIFFERENCES; BINDING GLOBULIN; CRITICALLY-ILL; ACUTE-PHASE; TESTOSTERONE; ESTROGEN; RECOVERY	Objective: Acute hypogonadotropic hypogonadism (AHH) occurs frequently after TBI, as does chronic hypogonadotropic hypogonadism. However, AHH and persistent hypogonadotropic hypogonadism (PHH) after TBI are not well studied. The objective of this study was to characterize longitudinal hormone profiles and the impact of AHH and PHH on outcome. Methods: In this prospective cohort study, men with severe TBI (n=38) had serum gonadal and gonadotropic hormones measured during weeks 1-52 post-injury. AHH, PHH and/or early resolving hypogonadotropic hypogonadism (ERHH) were based on temporal hormone assessments. PHH and hormone profiles were then compared to multiple outcome measures 6-12 months post-TBI. Results: AHH affected 100% of the population, while 37% subsequently developed PHH. Acute testosterone (TEST) and estradiol/testosterone (E2/TEST) ratios were associated with PHH and outcome. Over time, post-acute TEST and E2 levels for the ERHH group approached normal range, while levels for the PHH group remained low. Post-acute gonadotrophin levels were within the normal range for both groups. PHH, along with lower post-acute TEST and E2 profiles, was associated with worse functional and cognitive outcomes at 6 and 12 months post-injury. Conclusions: These results support screening for post-acute secondary hypogonadism and further research to assess the mechanisms underlying PHH and associated functional and cognitive deficits.	[Wagner, Amy K.; McCullough, Emily H.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Brett, Christopher A.; McCullough, Emily H.; Niyonkuru, Christian; Dixon, C. Edward; Ricker, Joseph; Arenth, Patricia] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Loucks, Tammy L.; Berga, Sarah L.] Emory Univ, Dept Obstet & Gynecol, Atlanta, GA 30322 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Loucks, Tammy/N-8223-2019	Loucks, Tammy/0000-0001-7651-7602; Ricker, Joseph/0000-0003-3415-991X	CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR323155]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318-16]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	This work was supported by CDC grant # R49/CCR323155 (AKW, SB) and NIH 5P01NS030318-16 to (CED). The authors report no conflicts of interest.	Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; [Anonymous], 1998, REH PERS TRAUM BRAIN, P1; Bain J, 2010, MATURITAS, V66, P16, DOI 10.1016/j.maturitas.2010.01.009; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bassil N, 2005, J THERAPEUTICS CLIN, V5, P427; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Beauchet O, 2006, EUR J ENDOCRINOL, V155, P773, DOI 10.1530/eje.1.02306; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Carlson NE, 2009, BRAIN INJURY, V23, P336, DOI 10.1080/02699050902788535; Cherrier MM, 2003, J ANDROL, V24, P568; Cherrier MM, 2009, FRONT HORM RES, V37, P150, DOI 10.1159/000176051; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Dawson JD, 2010, J AM GERIATR SOC, V58, P1090, DOI 10.1111/j.1532-5415.2010.02872.x; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Dossett LA, 2008, SURG INFECT, V9, P41, DOI 10.1089/sur.2007.037; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; Estes Susie M, 2005, Pituitary, V8, P267, DOI 10.1007/s11102-006-6053-1; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M, 2010, TRAUMATIC BRAIN INJU; Foy MR, 2011, NEUROBIOL LEARN MEM, V95, P134, DOI 10.1016/j.nlm.2010.11.003; Foy MR, 2010, VITAM HORM, V82, P219, DOI 10.1016/S0083-6729(10)82012-6; Garringer J, 2010, AM J PHYS MED REH  S, V89, pS6; Gillies GE, 2010, PHARMACOL REV, V62, P155, DOI 10.1124/pr.109.002071; Green RE, 2008, ARCH PHYS ME S12 S60, V89; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Hohl A, 2009, ARQ BRAS ENDOCRINOL, V53, P908, DOI 10.1590/S0004-27302009000800003; JENNETT B, 1975, LANCET, V1, P480; Kalantaridou SN, 2004, J REPROD IMMUNOL, V62, P61, DOI 10.1016/j.jri.2003.09.004; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klein M. J., 2009, POSTHEAD INJURY ENDO; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; Klose M, 2008, PITUITARY, V11, P255, DOI 10.1007/s11102-008-0102-x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kramar EA, 2012, NEUROBIOL AGING, V33, P708, DOI 10.1016/j.neurobiolaging.2010.06.008; Kronenberg HM, 2011, WILLIAMS TXB ENDOCRI; Lanfranco F, 2004, LANCET, V364, P273, DOI 10.1016/S0140-6736(04)16678-6; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mastorakos G, 2005, HORM METAB RES, V37, P577, DOI 10.1055/s-2005-870426; Matousek RH, 2010, HORM BEHAV, V57, P352, DOI 10.1016/j.yhbeh.2010.01.004; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; Menon SK, 2009, SINGAP MED J, V50, P1080; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moura PJ, 2010, REV NEUROSCIENCE, V21, P363; O'Kelly P, 2006, TBI FACTS STATS; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Pallais JC, 2007, GENEREVIEWS; Peck-Palmer O, 2010, ADULT PEDIAT REFEREN; Reitan R., 1985, NEUROPSYCHOLOGICAL T; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schulz K, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00187; Seidman SN, 1999, AM J GERIAT PSYCHIAT, V7, P18; Shang XL, 2010, NEUROSCI BULL, V26, P133, DOI 10.1007/s12264-010-0913-4; Sheridan LK, 2006, ARCH CLIN NEUROPSYCH, V21, P23, DOI 10.1016/j.acn.2005.07.003; Shores MM, 2009, J CLIN PSYCHIAT, V70, P1009, DOI 10.4088/JCP.08m04478; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith A., 1982, SYMBOL DIGITS MODALI; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Spritzer MD, 2007, DEV NEUROBIOL, V67, P1321, DOI 10.1002/dneu.20457; Spritzer MD, 2011, HORM BEHAV, V59, P484, DOI 10.1016/j.yhbeh.2011.01.009; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Sutton-Tyrrell K, 2005, CIRCULATION, V111, P1242, DOI 10.1161/01.CIR.0000157697.54255.CE; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; TEASDALE G, 1974, LANCET, V2, P81; ter Horst GJ, 2010, VITAM HORM, V82, P319, DOI 10.1016/S0083-6729(10)82017-5; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; van Veelen NMJ, 2010, SCHIZOPHR RES, V120, P191, DOI 10.1016/j.schres.2010.04.011; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2000, ARCH PHYS MED REHAB, V81, P1267; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; Williams GP, 2010, EUR J CANCER PREV, V19, P256, DOI 10.1097/CEJ.0b013e328338f7d2; WINTERS SJ, 1994, ENDOCRIN METAB CLIN, V23, P709, DOI 10.1016/S0889-8529(18)30063-X; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zarrour FA, 2009, J PSYCHIATR PRACT, V15, P289, DOI 10.1097/01.pra.0000358315.88931.fc; Zhao Y, 1996, MOL ENDOCRINOL, V10, P1350, DOI 10.1210/me.10.11.1350	109	29	29	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2012	26	10					1226	1242		10.3109/02699052.2012.667594			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	984GR	WOS:000307178600008	22571223				2022-02-06	
J	Bajor, M; Michaluk, P; Gulyassy, P; Kekesi, AK; Juhasz, G; Kaczmarek, L				Bajor, Malgorzata; Michaluk, Piotr; Gulyassy, Peter; Kekesi, Adrienna Katalin; Juhasz, Gabor; Kaczmarek, Leszek			Synaptic cell adhesion molecule-2 and collapsin response mediator protein-2 are novel members of the matrix metalloproteinase-9 degradome	JOURNAL OF NEUROCHEMISTRY			English	Article						CRMP-2; degradome; MMP-9; proteolysis; synaptoneurosomes; SynCAM-2	LONG-TERM POTENTIATION; MATRIX METALLOPROTEINASE-2 AND-9; GENE KNOCK-OUT; RAT-BRAIN; EPILEPTIC SEIZURES; NEURONAL DEATH; RECEPTOR; CRMP-2; MMP-9; PHOSPHORYLATION	J. Neurochem. (2012) 122, 775788. Abstract The elucidation of entire sets of protease substrates (proteodegradomes) is important for understanding proteolytic pathways, their networks, and their role in the regulation of cell function. Matrix metalloproteinase-9 (MMP-9) is an extracellularly operating protease that is expressed and released in the brain in response to enhanced neuronal activity. Under physiological conditions, MMP-9 is involved in neuronal plasticity, including long-term potentiation, learning, and memory. This function may be related to its activity at the synapse. Under pathological conditions (e.g., during excitotoxicity, stroke, and traumatic brain injury), when the concentration of glutamate is persistently increased, MMP-9 is detrimental to brain tissue. To assess the MMP-9 degradome, we used synaptoneurosomal fractions isolated from the hippocampus of wildtype and MMP-9 knockout mice. To induce MMP-9 activity, the synaptoneurosomal fractions were treated with 50 mu M glutamate for 30 min at 37 degrees C. To investigate MMP-9 targets, two-dimensional fluorescence difference gel electrophoresis was performed. This approach enabled the accurate analysis of differences in protein abundance between samples. The differential spots that contained potential MMP-9 substrates were excised from the gel, and proteins of interest were identified using mass spectrometry. Two novel MMP-9 targets were identified: synaptic cell adhesion molecule-2 and collapsin response mediator protein-2. The MMP-9-driven processing of the newly identified substrates was confirmed by western blot in primary hippocampal neurons after stimulation with either N-methyl-D-aspartate or glutamate or incubation with recombinant autoactivating MMP-9 and use of a specific inhibitor.	[Bajor, Malgorzata; Michaluk, Piotr; Kaczmarek, Leszek] Nencki Inst, Neurobiol Lab, Warsaw, Poland; [Gulyassy, Peter; Kekesi, Adrienna Katalin; Juhasz, Gabor] Eotvos Lorand Univ, Lab Prote, Budapest, Hungary		Bajor, M (corresponding author), Nencki Inst, Neurobiol Lab, Warsaw, Poland.	m.bajor@nencki.gov.pl; l.kaczmarek@nencki.gov.pl	Michaluk, Piotr/AAR-5238-2021; Kekesi, Katalin Adrienna A/H-3484-2017; Kaczmarek, Leszek/B-6171-2008; Juhasz, Gabor/I-7781-2017	Michaluk, Piotr/0000-0003-2306-3314; Kekesi, Katalin Adrienna A/0000-0003-3042-4878; Kaczmarek, Leszek/0000-0002-7207-3490; Juhasz, Gabor/0000-0002-0849-6931; Bajor, Malgorzata/0000-0001-5778-0165	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [HEALTH-F2-2009-223524]; International Brain Research Organization	We thank Adam Gorlewicz for help preparing the electron microscopy specimens, Attila Simor and Jewgeni Nikolaev for help with the statistical analysis, and Emilia Rejmak for help with synaptoneurosome preparation. We also thank Prof. Czeslaw Cierniewski who provided substantial support during the initial stage of the project. This work was supported by the European Commission's Seventh Framework Programme (FP7) through project "Plasticise: Promotion of plasticity as a treatment for neurodegenerative conditions'' (grant agreement HEALTH-F2-2009-223524) to L. K. and an InEurope Short Stay Grant from the International Brain Research Organization to M. B. The authors have no conflict of interest to declare.	Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Backstrom JR, 1996, J NEUROSCI, V16, P7910; Bayes A, 2011, NAT NEUROSCI, V14, P19, DOI 10.1038/nn.2719; BENAVIDES J, 1988, J NEUROSCI, V8, P3607; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Bilousova TV, 2009, J MED GENET, V46, P94, DOI 10.1136/jmg.2008.061796; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Butler GS, 2009, BIOCHEMISTRY-US, V48, P10830, DOI 10.1021/bi901656f; Cauwe B, 2010, CRIT REV BIOCHEM MOL, V45, P351, DOI 10.3109/10409238.2010.501783; Cauwe B, 2009, INTEGR BIOL-UK, V1, P404, DOI 10.1039/b904701h; Conant K, 2010, NEUROSCIENCE, V166, P508, DOI 10.1016/j.neuroscience.2009.12.061; Conant K, 2011, J NEUROCHEM, V118, P521, DOI 10.1111/j.1471-4159.2010.07153.x; Czech T, 2004, NEUROCHEM RES, V29, P2189, DOI 10.1007/s11064-004-7025-3; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; Dominguez R, 2007, J NEUROCHEM, V101, P232, DOI 10.1111/j.1471-4159.2006.04360.x; Emes RD, 2008, NAT NEUROSCI, V11, P799, DOI 10.1038/nn.2135; Emes RD, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00044; Fogel AI, 2007, J NEUROSCI, V27, P12516, DOI 10.1523/JNEUROSCI.2739-07.2007; Franken S, 2003, J BIOL CHEM, V278, P3241, DOI 10.1074/jbc.M210181200; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Gerrow K, 2006, NEURON, V49, P547, DOI 10.1016/j.neuron.2006.01.015; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Hinkle CL, 2006, J NEUROBIOL, V66, P1378, DOI 10.1002/neu.20257; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Jiang SX, 2007, EUR J NEUROSCI, V26, P801, DOI 10.1111/j.1460-9568.2007.05715.x; Kim J, 2010, J BIOL CHEM, V285, P22917, DOI 10.1074/jbc.M110.126649; Kim SH, 2010, J NEUROSCI, V30, P3870, DOI 10.1523/JNEUROSCI.4717-09.2010; Klemmer P, 2009, J PROTEOMICS, V72, P82, DOI 10.1016/j.jprot.2008.10.005; Kovacs Z, 2011, NEUROCHEM INT, V59, P563, DOI 10.1016/j.neuint.2011.06.016; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Lim ST, 2012, J NEUROCHEM, V120, P741, DOI 10.1111/j.1471-4159.2011.07592.x; Lin KT, 2008, J BIOL CHEM, V283, P28969, DOI 10.1074/jbc.M804401200; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Marouga R, 2005, ANAL BIOANAL CHEM, V382, P669, DOI 10.1007/s00216-005-3126-3; Meighan SE, 2006, J NEUROCHEM, V96, P1227, DOI 10.1111/j.1471-4159.2005.03565.x; Michaluk P, 2007, CELL DEATH DIFFER, V14, P1255, DOI 10.1038/sj.cdd.4402141; Michaluk P, 2007, J BIOL CHEM, V282, P16036, DOI 10.1074/jbc.M700641200; Michaluk P, 2011, J CELL SCI, V124, P3369, DOI 10.1242/jcs.090852; Micheva KD, 2010, NEURON, V68, P639, DOI 10.1016/j.neuron.2010.09.024; Mizoguchi H, 2008, J PHARMACOL SCI, V106, P9, DOI 10.1254/jphs.FM0070139; Muddashetty RS, 2007, J NEUROSCI, V27, P5338, DOI 10.1523/JNEUROSCI.0937-07.2007; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Noble LJ, 2002, J NEUROSCI, V22, P7526; Okulski P, 2007, BIOL PSYCHIAT, V62, P359, DOI 10.1016/j.biopsych.2006.09.012; PIMENTA AF, 1995, NEURON, V15, P287, DOI 10.1016/0896-6273(95)90034-9; Planas AM, 2001, NEUROBIOL DIS, V8, P834, DOI 10.1006/nbdi.2001.0435; Prudova A, 2010, MOL CELL PROTEOMICS, V9, P894, DOI 10.1074/mcp.M000050-MCP201; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; Rivera S, 2010, J NEUROSCI, V30, P15337, DOI 10.1523/JNEUROSCI.3467-10.2010; Rogemond V, 2008, J BIOL CHEM, V283, P14751, DOI 10.1074/jbc.M708480200; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Sara Y, 2005, J NEUROSCI, V25, P260, DOI 10.1523/JNEUROSCI.3165-04.2005; Sbai O, 2010, GLIA, V58, P344, DOI 10.1002/glia.20927; Shinomura T, 1999, ANESTH ANALG, V88, P1401, DOI 10.1097/00000539-199906000-00037; Takacs E, 2010, NEUROCHEM INT, V56, P799, DOI 10.1016/j.neuint.2010.03.003; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Tian L, 2007, J CELL BIOL, V178, P687, DOI 10.1083/jcb.200612097; Troca-Marin JA, 2010, MOL CELL NEUROSCI, V43, P308, DOI 10.1016/j.mcn.2009.12.004; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Villasana LE, 2006, J NEUROSCI METH, V158, P30, DOI 10.1016/j.jneumeth.2006.05.008; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang XB, 2008, P NATL ACAD SCI USA, V105, P19520, DOI 10.1073/pnas.0807248105; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wilczynski GM, 2008, J CELL BIOL, V180, P1021, DOI 10.1083/jcb.200708213; Wright JW, 2009, BEHAV BRAIN RES, V203, P27, DOI 10.1016/j.bbr.2009.04.014; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078; Zhou N, 2011, MICROVASC RES, V82, P113, DOI 10.1016/j.mvr.2011.06.005	79	29	30	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2012	122	4					775	788		10.1111/j.1471-4159.2012.07829.x			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	974ZH	WOS:000306475700012	22694054	Bronze			2022-02-06	
J	Elias, PZ; Spector, M				Elias, Paul Z.; Spector, Myron			Implantation of a collagen scaffold seeded with adult rat hippocampal progenitors in a rat model of penetrating brain injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Penetrating brain injury; Traumatic brain injury; Collagen scaffold; Brain tissue engineering; Stem cells; Adult hippocampal neural progenitors	NEURAL STEM-CELLS; MAJOR HISTOCOMPATIBILITY COMPLEX; STEM/PROGENITOR CELLS; IN-VITRO; PERINEURONAL OLIGODENDROCYTES; NEURONAL DIFFERENTIATION; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; COGNITIVE FUNCTION; MHC EXPRESSION	Penetrating brain injury (PBI) is a complex central nervous system injury in which mechanical damage to brain parenchyma results in hemorrhage, ischemia, broad areas of necrosis, and eventually cavitation. The permanent loss of brain tissue affords the possibility of treatment using a biomaterial scaffold to fill the lesion site and potentially deliver pharmacological or cellular therapeutic agents. The administration of cellular therapy may be of benefit in both mitigating the secondary injury process and promoting regeneration through replacement of certain cell populations. This study investigated the survival and differentiation of adult rat hippocampal neural progenitor cells delivered by a collagen scaffold in a rat model of PBI. The cell-scaffold construct was implanted 1 week after injury and was observed to remain intact with open pores upon analysis 4 weeks later. Implanted neural progenitors were found to have survived within the scaffold, and also to have migrated into the surrounding brain. Differentiated phenotypes included astrocytes, oligodendrocytes, vascular endothelial cells, and possibly macrophages. The demonstrated multipotency of this cell population in vivo in the context of traumatic brain injury has implications for regenerative therapies, but additional stimulation appears necessary to promote neuronal differentiation outside normally neurogenic regions. (c) 2012 Elsevier B.V. All rights reserved.	[Elias, Paul Z.; Spector, Myron] VA Boston Healthcare Syst, Tissue Engn Labs, Boston, MA 02130 USA; [Elias, Paul Z.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Spector, Myron] Harvard Univ, Sch Med, Dept Orthoped Surg, Brigham & Womens Hosp, Boston, MA 02115 USA		Elias, PZ (corresponding author), VA Boston Healthcare Syst, Tissue Engn Labs, Mail Stop 151,150 S Huntington Ave, Boston, MA 02130 USA.	pzelias@alum.mit.edu; mspector@rics.bwh.harvard.edu		Spector, Myron/0000-0003-3328-4858	U.S. Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs	This research was supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service.	Aberg MAI, 2003, MOL CELL NEUROSCI, V24, P23, DOI 10.1016/S1044-7431(03)00082-4; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Andres RH, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E15; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Astradsson A, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E5; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Baschong W, 2001, J HISTOCHEM CYTOCHEM, V49, P1565, DOI 10.1177/002215540104901210; Ben-Hur T, 2008, ANN NY ACAD SCI, V1142, P218, DOI 10.1196/annals.1444.014; Ben-Shaanan TL, 2008, MOL PSYCHIATR, V13, P222, DOI 10.1038/sj.mp.4002084; Bifari Francesco, 2010, World J Stem Cells, V2, P50, DOI 10.4252/wjsc.v2.i3.50; Bolliet C, 2008, TISSUE ENG PART C-ME, V14, P207, DOI 10.1089/ten.tec.2008.0168; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Capetian P, 2011, SEMIN IMMUNOPATHOL, V33, P619, DOI 10.1007/s00281-011-0272-x; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Chen ZG, 2008, HUM MOL GENET, V17, pR84, DOI 10.1093/hmg/ddn104; Chen ZG, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014787, 10.1371/journal.pone.0028618]; Chen ZY, 2011, BRAIN RES, V1368, P71, DOI 10.1016/j.brainres.2010.10.028; Chiba S, 2004, J NEUROL SCI, V219, P107, DOI 10.1016/j.jns.2004.01.006; Chopp M, 2008, ACTA NEUROCHIR SUPPL, V105, P79; Clelland CD, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E8; Compton CC, 1998, J INVEST DERMATOL, V110, P908, DOI 10.1046/j.1523-1747.1998.00200.x; Coras R, 2010, BRAIN, V133, P3359, DOI 10.1093/brain/awq215; Cromey DW, 2010, SCI ENG ETHICS, V16, P639, DOI 10.1007/s11948-010-9201-y; Dayer AG, 2007, BRAIN, V130, P2962, DOI 10.1093/brain/awm200; Delcroix GJR, 2010, BIOMATERIALS, V31, P2105, DOI 10.1016/j.biomaterials.2009.11.084; Dziewczapolski G, 2003, EXP NEUROL, V183, P653, DOI 10.1016/S0014-4886(03)00212-7; Elias PZ, 2012, J MECH BEHAV BIOMED, V12, P63, DOI 10.1016/j.jmbbm.2012.03.014; Elias PZ, 2012, J NEUROTRAU IN PRESS; Faijerson J, 2006, J NEUROSCI RES, V84, P1415, DOI 10.1002/jnr.21044; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Goya RL, 2011, NEUROBIOL DIS, V41, P407, DOI 10.1016/j.nbd.2010.10.008; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Harley BA, 2004, CELLS TISSUES ORGANS, V176, P153, DOI 10.1159/000075035; Harley BA, 2007, ACTA BIOMATER, V3, P463, DOI 10.1016/j.actbio.2006.12.009; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hermann A, 2006, J NEUROCHEM, V98, P629, DOI 10.1111/j.1471-4159.2006.03916.x; Hori J, 2003, STEM CELLS, V21, P405, DOI 10.1634/stemcells.21-4-405; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hsu WC, 2000, INVEST OPHTH VIS SCI, V41, P2404; Jain KK, 2009, MOL BIOTECHNOL, V42, P367, DOI 10.1007/s12033-009-9166-8; Jessberger S, 2008, NAT NEUROSCI, V11, P888, DOI 10.1038/nn.2148; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johansson S, 2008, STEM CELLS, V26, P2444, DOI 10.1634/stemcells.2008-0116; Klassen H, 2003, VISION RES, V43, P947, DOI 10.1016/S0042-6989(03)00094-4; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; LUDWIN SK, 1984, NEUROPATH APPL NEURO, V10, P143, DOI 10.1111/j.1365-2990.1984.tb00345.x; LUDWIN SK, 1979, ACTA NEUROPATHOL, V47, P49, DOI 10.1007/BF00698272; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Naegele JR, 2010, NEUROPHARMACOLOGY, V58, P855, DOI 10.1016/j.neuropharm.2010.01.019; Nakada A, 2009, CELLS TISSUES ORGANS, V190, P326, DOI 10.1159/000223233; Nehlin JO, 2009, BIOGERONTOLOGY, V10, P339, DOI 10.1007/s10522-009-9213-7; Odeberg J, 2005, J NEUROIMMUNOL, V161, P1, DOI 10.1016/j.jneuroim.2004.11.016; Oishi K, 2004, J PHARMACOL SCI, V96, P208, DOI 10.1254/jphs.FP0040373; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Pagani L, 2008, NEUROL RES, V30, P244, DOI 10.1179/016164107X230667; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Prajerova I, 2010, CELL MOL NEUROBIOL, V30, P199, DOI 10.1007/s10571-009-9443-x; Ricci-Vitiani L, 2006, NEUROL RES, V28, P488, DOI 10.1179/016164106X115134; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Roshal LM, 2009, B EXP BIOL MED+, V148, P140, DOI 10.1007/s10517-009-0642-8; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sapsford W, 2003, J R Army Med Corps, V149, P5; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Spilker MH, 2001, RESTOR NEUROL NEUROS, V18, P23; Sun JQ, 2010, DEV DYNAM, V239, P2345, DOI 10.1002/dvdy.22377; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Takasaki C, 2010, EUR J NEUROSCI, V32, P1326, DOI 10.1111/j.1460-9568.2010.07377.x; Taniike M, 2002, J NEUROSCI, V22, P4885, DOI 10.1523/JNEUROSCI.22-12-04885.2002; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Teng FYH, 2009, DIFFERENTIATION, V77, P121, DOI 10.1016/j.diff.2008.09.013; Ubiali F, 2007, INT IMMUNOL, V19, P1063, DOI 10.1093/intimm/dxm079; Walker PA, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/369578; Wang TW, 2009, ACTA BIOMATER, V5, P2371, DOI 10.1016/j.actbio.2009.03.033; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Wong DY, 2008, J NEUROSURG, V109, P715, DOI 10.3171/JNS/2008/109/10/0715; Wong DY, 2007, TISSUE ENG, V13, P2515, DOI 10.1089/ten.2006.0440; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Yin L, 2008, STEM CELLS DEV, V17, P53, DOI 10.1089/scd.2007.0063	97	29	32	0	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUL 30	2012	209	1					199	211		10.1016/j.jneumeth.2012.06.003			13	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	983QB	WOS:000307132700024	22698665				2022-02-06	
J	Jacobowitz, DM; Cole, JT; McDaniel, DP; Pollard, HB; Watson, WD				Jacobowitz, David M.; Cole, Jeffrey T.; McDaniel, Dennis P.; Pollard, Harvey B.; Watson, William D.			Microglia activation along the corticospinal tract following traumatic brain injury in the rat: A neuroanatomical study	BRAIN RESEARCH			English	Article						Microglia; Traumatic brain injury; Corticospinal neuron; Electron microscopy; Light microscopy; Rat	CLOSED-HEAD INJURY; NERVOUS-SYSTEM; MICE; INTERLEUKIN-1-BETA; RECEPTORS; RECOVERY; PROTEIN	Traumatic injury to the brain often manifests itself symptomatically and structurally long after the traumatic event. The cellular basis of this complex response is not completely understood. However, we hypothesized that microglia might contribute to the brain-wide process. To test this hypothesis, we employed optical and electron microscopy to study the microglia in rat brains up to 2 months after digitally controlled cortical impact (CCI) to produce traumatic brain injury (TBI). We also used antibodies against ED-1 and Iba-1, respectively, as markers for activated and resting microglia. ED-1 positive microglial cells are observed accompanying the entire corticospinal tract (CST) on the injured side, but not the control, contralateral side of the brain at 2 months. In this case, ED-1 and Iba-1 were observed to co-localize uniquely on the injured side of the brain. At earlier times following CCI, ultrastructural studies reveal that microglial cells have very irregular shapes and have many processes that intermingle with degenerating nerve axons of the CST in the hindbrain pyramids. These cells appear to be engulfing degenerating myelinated axons. The debris within the cells is converted to lipofuscin, the antigen for the ED-1 antibody, and remains in the cell cytoplasm throughout the life of the cell. We conclude, as hypothesized, that microglia are critical cellular components. Based on observed close association with myelin degeneration, interdigitating activated microglia may be contributing to damage control. Finally, based on the close neuroanatomical relationship between the lesioned corticospinal tract and the wide distribution of activated microglia, primary signals from CST neurons per se, may be directing microglial responses along the entire damaged rat neuroaxis. The role of persistent activation of microglia has not been determined. Published by Elsevier B.V.	[Jacobowitz, David M.; Pollard, Harvey B.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Cole, Jeffrey T.; Watson, William D.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [McDaniel, Dennis P.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Biomed Instrumentat Ctr, Bethesda, MD 20814 USA		Jacobowitz, DM (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA.	djacobowitz@usuhs.mil			Comprehensive National Neuroscience Program (CNNP) [W81XWH-07-0679]	This work was supported in part by the Comprehensive National Neuroscience Program (CNNP, award number W81XWH-07-0679). Additionally, the authors would like to thank Mr. William Kean for the preparation of the animals, Ms. Xiuying Zhang for her expert help in preparing this manuscript and the excellent technical assistance of Ms. Tinghua Chen.	Basiri M, 2010, BRAIN RES BULL, V81, P43, DOI 10.1016/j.brainresbull.2009.11.002; Benveniste E.N., 1994, IMMUNOLOGY NERVOUS S; Del Rio-Hortega R., 1965, CYTOLOGY CELLULAR PA, P483; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1988, J NEUROSCI, V8, P4707; Gomes-Leal W, 2005, BRAIN RES, V1066, P57, DOI 10.1016/j.brainres.2005.10.069; Harting MT, 2010, J SURG RES, V159, P557, DOI 10.1016/j.jss.2008.10.014; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hoge CW, 2011, JAMA-J AM MED ASSOC, V306, P549, DOI 10.1001/jama.2011.1096; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; JACOBOWITZ DM, 1974, BRAIN RES, V80, P111, DOI 10.1016/0006-8993(74)90726-4; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEENEN LPH, 1985, BRAIN RES, V359, P65, DOI 10.1016/0006-8993(85)91413-1; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; RAIVICH G, 1994, GLIA, V11, P129, DOI 10.1002/glia.440110208; SAMORAJSKI T, 1965, J CELL BIOL, V26, P779, DOI 10.1083/jcb.26.3.779; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thiel A, 2011, STROKE, V42, P507, DOI 10.1161/STROKEAHA.110.598821; Thiel A, 2010, J NUCL MED, V51, P1404, DOI 10.2967/jnumed.110.076612; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; VAUGHN JE, 1970, J COMP NEUROL, V140, P175, DOI 10.1002/cne.901400204; Yamamoto S, 2010, J NEUROCHEM, V115, P1057, DOI 10.1111/j.1471-4159.2010.06996.x; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	33	29	29	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 17	2012	1465						80	89		10.1016/j.brainres.2012.05.008			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	974PI	WOS:000306448300009	22617376				2022-02-06	
J	Lehto, LJ; Sierra, A; Corum, CA; Zhang, JJ; Idiyatullin, D; Pitkanen, A; Garwood, M; Grohn, O				Lehto, Lauri Juhani; Sierra, Alejandra; Corum, Curtis Andrew; Zhang, Jinjin; Idiyatullin, Djaudat; Pitkanen, Asla; Garwood, Michael; Grohn, Olli			Detection of calcifications in vivo and ex vivo after brain injury in rat using SWIFT	NEUROIMAGE			English	Article						SWIFT; Phase contrast; Brain calcification; Ultra short echo-time	LATERAL FLUID-PERCUSSION; MAGNETIC-RESONANCE; INTRACRANIAL CALCIFICATION; MRI; ACCUMULATION; LESIONS; IMAGES; DIFFERENTIATION; RECONSTRUCTION; MICROBLEEDS	Calcifications represent one component of pathology in many brain diseases. With MRI, they are most often detected by exploiting negative contrast in magnitude images. Calcifications are more diamagnetic than tissue, leading to a magnetic field disturbance that can be seen in phase MR images. Most phase imaging studies use gradient recalled echo based pulse sequences. Here, the phase component of SWIFT, a virtually zero acquisition delay sequence, was used to detect calcifications ex vivo and in vivo in rat models of status epilepticus and traumatic brain injury. Calcifications were detected in phase and imaginary SWIFT images based on their dipole like magnetic field disturbances. In magnitude SWIFT images, calcifications were distinguished as hypointense and hyperintense. Hypointense calcifications showed large crystallized granules with few surrounding inflammatory cells, while hyperintense calcifications contained small granules with the presence of more inflammatory cells. The size of the calcifications in SWIFT magnitude images correlated with that in Alizarin stained histological sections. Our data indicate that SWIFT is likely to better preserve signal in the proximity of a calcification or other field perturber in comparison to gradient echo due to its short acquisition delay and broad excitation bandwidth. Furthermore, a quantitative description for the phase contrast near dipole magnetic field inhomogeneities for the SWIFT pulse sequence is given. In vivo detection of calcifications provides a tool to probe the progression of pathology in neurodegenerative diseases. In particular, it appears to provide a surrogate marker for inflammatory cells around the calcifications after brain injury. (C) 2012 Elsevier Inc. All rights reserved.	[Corum, Curtis Andrew; Zhang, Jinjin; Idiyatullin, Djaudat; Garwood, Michael] Univ Minnesota, Dept Radiol, Ctr Magnet Resonance Res, Sch Med, Minneapolis, MN 55455 USA; [Lehto, Lauri Juhani; Sierra, Alejandra; Pitkanen, Asla; Grohn, Olli] Univ Eastern Finland, Dept Neurobiol, Biomed Imaging Unit, AI Virtanen Inst Mol Sci, Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Corum, CA (corresponding author), Univ Minnesota, Dept Radiol, Ctr Magnet Resonance Res, Sch Med, 2021 6th St SE, Minneapolis, MN 55455 USA.	corum@cmrr.umn.edu	Idiyatullin, Djaudat/J-5994-2012; Corum, Curtis/A-7520-2016	Idiyatullin, Djaudat/0000-0002-0942-3208; Sierra Lopez, Alejandra/0000-0001-5399-2056; Corum, Curtis/0000-0002-4994-6206	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41 RR008079, P30 NS057091, R21 CA139688, S10 RR023730]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA139688] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR008079, S10RR023730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057091] Funding Source: NIH RePORTER	We thank Maarit Pulkkinen for her invaluable help in handling the histology, Jarmo Hartikainen for his help with the disease models, and Ryan Chamberlain and Rajesh Venkataraman for the use of high performance gridding code for image reconstruction. We would also like to thank Doctoral Program in Molecular Medicine at University of Eastern Finland, Emil Aaltonen Foundation, Academy of Finland and the strategic funding of the University of Eastern Finland (UEF-Brain). Additional funds were provided by NIH grants, P41 RR008079, P30 NS057091, R21 CA139688, and S10 RR023730.	ANSARI MQ, 1990, PEDIATR NEUROL, V6, P94, DOI 10.1016/0887-8994(90)90041-X; ARNOLD MM, 1991, POSTGRAD MED J, V67, P147, DOI 10.1136/pgmj.67.784.147; AVRAHAMI E, 1994, J NEUROL, V241, P381, DOI 10.1007/BF02033355; Beatty PJ, 2005, IEEE T MED IMAGING, V24, P799, DOI 10.1109/TMI.2005.848376; BERGIN CJ, 1991, RADIOLOGY, V179, P777, DOI 10.1148/radiology.179.3.2027991; Caldemeyer KS, 1997, AM J NEURORADIOL, V18, P107; Carl M, 2012, MAGN RESON MED, V67, P991, DOI 10.1002/mrm.23075; Cervos-Navarro J., 1991, J NEUROL SCI, V103, P3; Chan CF, 2010, J CARDIOVASC MAGN R, V12, DOI 10.1186/1532-429X-12-17; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Cordonnier C, 2011, BRAIN, V134, P335, DOI 10.1093/brain/awq321; Corum C.A., 2005, NUCL MAGNETIC RESONA; Corum C.A., 2010, P 18 ANN M ISMRM STO, P5113; DEMER LL, 1994, TRENDS CARDIOVAS MED, V4, P45, DOI 10.1016/1050-1738(94)90025-6; Du JA, 2011, MAGN RESON MED, V65, P1013, DOI 10.1002/mrm.22682; Gayoso MJ, 2003, HISTOL HISTOPATHOL, V18, P855, DOI 10.14670/HH-18.855; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Gupta RK, 2001, J COMPUT ASSIST TOMO, V25, P698, DOI 10.1097/00004728-200109000-00006; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HAFNER S, 1994, MAGN RESON IMAGING, V12, P1047, DOI 10.1016/0730-725X(94)91236-P; HENKELMAN RM, 1991, RADIOLOGY, V179, P199, DOI 10.1148/radiology.179.1.1848714; Idiyatullin D, 2008, J MAGN RESON, V193, P267, DOI 10.1016/j.jmr.2008.05.009; Idiyatullin D, 2006, J MAGN RESON, V181, P342, DOI 10.1016/j.jmr.2006.05.014; Idiyatullin D, 2011, J ENDODONT, V37, P745, DOI 10.1016/j.joen.2011.02.022; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; LAFRENIERE GF, 1992, BRAIN RES BULL, V28, P825, DOI 10.1016/0361-9230(92)90268-3; Lauzon ML, 1996, MAGNET RESON MED, V36, P940, DOI 10.1002/mrm.1910360617; LEWIS DA, 1986, J COMP NEUROL, V248, P1, DOI 10.1002/cne.902480102; MACDONALD HL, 1986, BRIT J RADIOL, V59, P355, DOI 10.1259/0007-1285-59-700-355; Makinen S, 2008, J CEREBR BLOOD F MET, V28, P263, DOI 10.1038/sj.jcbfm.9600529; Marques JP, 2005, CONCEPT MAGN RESON B, V25B, P65, DOI 10.1002/cmr.b.20034; Nissi M., 2010, P 18 ANN M ISMRM STO, P5113; NITSCH C, 1992, ACTA NEUROPATHOL, V85, P55, DOI 10.1007/BF00304634; OKUCHI K, 1992, NEURORADIOLOGY, V34, P328, DOI 10.1007/BF00588194; Oliveira A, 2003, EXP NEUROL, V179, P127, DOI 10.1016/S0014-4886(02)00012-2; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PARISI J, 1988, CAN J NEUROL SCI, V15, P152, DOI 10.1017/S0317167100027530; Park JY, 2012, MAGN RESON MED, V67, P428, DOI 10.1002/mrm.23026; Park JY, 2009, MAGN RESON MED, V61, P175, DOI 10.1002/mrm.21822; Park JY, 2006, MAGN RESON MED, V55, P848, DOI 10.1002/mrm.20821; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Rahmer J, 2006, MAGN RESON MED, V55, P1075, DOI 10.1002/mrm.20868; Rauscher A, 2003, J MAGN RESON IMAGING, V18, P175, DOI 10.1002/jmri.10346; Rodriguez MJ, 2001, NEUROBIOL DIS, V8, P59, DOI 10.1006/nbdi.2000.0332; Saam T, 2005, ARTERIOSCL THROM VAS, V25, P234, DOI 10.1161/01.ATV.0000149867.61851.31; Sandner G, 2010, NEUROIMAGE, V53, P44, DOI 10.1016/j.neuroimage.2010.06.007; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Seevinck PR, 2011, MAGN RESON MED, V65, P146, DOI 10.1002/mrm.22594; SHIROTANI T, 1994, J CEREBR BLOOD F MET, V14, P831, DOI 10.1038/jcbfm.1994.104; Shmueli K, 2009, MAGN RESON MED, V62, P1510, DOI 10.1002/mrm.22135; SILVER MS, 1985, PHYS REV A, V31, P2753, DOI 10.1103/PhysRevA.31.2753; Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs; Watanabe H, 1998, J CEREBR BLOOD F MET, V18, P686, DOI 10.1097/00004647-199806000-00011; Wu Z, 2009, J MAGN RESON IMAGING, V29, P177, DOI 10.1002/jmri.21617; Yamada N, 1996, RADIOLOGY, V198, P171, DOI 10.1148/radiology.198.1.8539373; Zhou R, 2010, MAGN RESON MED, V63, P1154, DOI 10.1002/mrm.22378; Zhu WZ, 2008, CHINESE MED J-PEKING, V121, P2021, DOI 10.1097/00029330-200810020-00014	59	29	29	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JUL 16	2012	61	4					761	772		10.1016/j.neuroimage.2012.03.002			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	967PP	WOS:000305920600002	22425671	Green Accepted			2022-02-06	
J	Lucca, JJD; Chavko, M; Dubick, MA; Adeeb, S; Falabella, MJ; Slack, JL; McCarron, R; Li, YS				Lucca, Jurandir J. Dalle; Chavko, Mikulas; Dubick, Michael A.; Adeeb, Saleena; Falabella, Michael J.; Slack, Jessica L.; McCarron, Richard; Li, Yansong			Blast-induced moderate neurotrauma (BINT) elicits early complement activation and tumor necrosis factor alpha (TNF alpha) release in a rat brain	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Blast overpressure; Blast-induced neurotrauma; Complement activation; Edema; Inflammatory cytokine; Leukocyte infiltration	MEMBRANE ATTACK; INJURY; EXPRESSION; CONTUSION; INCREASE; EDEMA; CELLS; FLUID; C3	Blast-induced neurotrauma (BINT) is a major medical concern yet its etiology is largely undefined. Complement activation may play a role in the development of secondary injury following traumatic brain injury; however, its role in BINT is still undefined. The present study was designed to characterize the complement system and adaptive immune-inflammatory responses in a rat model of moderate BINT. Anesthetized rats were exposed to a moderate blast (120 kPa) using an air-driven shock tube. Brain tissue injury, systemic and local complement, cerebral edema, inflammatory cell infiltration, and pro-inflammatory cytokine production were measured at 0.5, 3, 48, 72, 120, and 168 h. Injury to brain tissue was evaluated by histological evaluation. Systemic complement was measured via ELSIA. The remaining measurements were determined by immunohistoflourescent staining. Moderate blast triggers moderate brain injuries, elevated levels of local brain C3/C5b-9 and systemic C5b-9, increased leukocyte infiltration, unregulated tumor necrosis factor alpha (TNF alpha), and aquaporin-4 in rat brain cortex at 3- and 48-hour post blast. Early immune-inflammatory response to BINT involves complement and TNF alpha, which correlates with hippocampus and cerebral cortex damage. Complement and TNF alpha activation may be a novel therapeutic target for reducing the damaging effects of BINT inflammation. Published by Elsevier B.V.	[Lucca, Jurandir J. Dalle; Dubick, Michael A.; Falabella, Michael J.; Slack, Jessica L.; Li, Yansong] USA, Inst Surg Res, Immunomodulat Trauma Program, Ft Sam Houston, TX 78234 USA; [Chavko, Mikulas; Adeeb, Saleena; McCarron, Richard] USN, Dept Trauma & Resuscitat Med, Med Res Ctr, Silver Spring, MD 20910 USA		Lucca, JJD (corresponding author), USA, Inst Surg Res, Immunomodulat Trauma Program, 3650 Chambers Pass,BHT2,Bldg 3610, Ft Sam Houston, TX 78234 USA.	Jurandir.dallelucca@us.army.mil			Defense Medical Research and Development Program (DMRDP); US Army Medical Research and Materiel Command Combat Casualty Care Research ProgramU.S. Army Medical Research & Materiel Command (USAMRMC); Office of Naval ResearchOffice of Naval Research	This study was funded by the Defense Medical Research and Development Program (DMRDP) and US Army Medical Research and Materiel Command Combat Casualty Care Research Program and the Office of Naval Research.	Alexander JJ, 2003, BBA-MOL BASIS DIS, V1639, P169, DOI 10.1016/j.bbadis.2003.09.005; Anderson AJ, 2004, J NEUROTRAUM, V21, P1831, DOI 10.1089/0897715042664894; Arumugam TV, 2009, NEUROSCIENCE, V158, P1074, DOI 10.1016/j.neuroscience.2008.07.015; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Defense Manpower Data Center [internet], 2008, GLOB WAR TERR CAS RE; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139; Ingersoll SA, 2010, MOL IMMUNOL, V48, P219, DOI 10.1016/j.molimm.2010.08.007; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mellor SG, 1998, BR J HOSP MED, V39, P536; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Schmidt O.I., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Surbatovic M, 2007, MIL MED, V172, P190, DOI 10.7205/MILMED.172.2.190; Tenuta Joachim J, 2006, J Am Acad Orthop Surg, V14, pS45; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang Y, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-24; Weeks C, 2007, CLIN IMMUNOL, V124, P311, DOI 10.1016/j.clim.2007.05.010; WOOD A, 1993, J NEUROSCI, V13, P3319	35	29	29	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	JUL 15	2012	318	1-2					146	154		10.1016/j.jns.2012.02.002			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	964BK	WOS:000305668500025					2022-02-06	
J	Faruqui, S; Stern, PJ; Kiefhaber, TR				Faruqui, Safi; Stern, Peter J.; Kiefhaber, Thomas R.			Percutaneous Pinning of Fractures in the Proximal Third of the Proximal Phalanx: Complications and Outcomes	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						Complication; percutaneous; phalanx; proximal; outcome	CLOSED REDUCTION; FIXATION	Purpose Two common techniques for fixation of extra-articular fractures at the proximal phalanx base are transarticular (across the metacarpophalangeal joint) and extra-articular cross-pinning. The aim of this study was to assess the complications and outcomes of these 2 techniques. Our hypothesis was that transarticular and extra-articular closed reduction and percutaneous pinning of base of proximal phalanx fractures have similar complication rates and outcomes. Methods A retrospective chart review identified 338 patients with base of proximal phalanx fractures. We treated 50 isolated fractures with closed reduction and percutaneous pinning using 1 of 2 techniques: transarticular (25 fractures through the metacarpal head) or extra-articular (25 fractures cross-pinned through the base of the proximal phalanx). Outcome measures included total active motion and complications. Results We found a substantial overall complication rate in both groups. The mean total active motion for the transarticular group and cross-pinning group was 201 degrees and 198 degrees, respectively. Proximal interphalangeal joint motion was notably affected; nearly half of the patients in each group had flexion loss greater than 20 degrees (average, 27 degrees) at the proximal interphalangeal joint. Nearly a third of patients in both groups had fixed flexion contracture greater than 15 degrees at the proximal interphalangeal joint. There were more secondary procedures in the transarticular group (6) than in the cross-pinning group (2). There was no statistical significance between groups in any of the outcome parameters used. Conclusions Closed pinning minimizes additional soft tissue injury and allows for early motion, but neither fixation method was superior in terms of the measured parameters. In addition, overall results were not as good as what has been reported in the literature. (J Hand Surg 2012;37A:1342-1348. Copyright (c) 2012 by the American Society for Surgery of the Hand All rights reserved)	[Faruqui, Safi] Naval Med Ctr Portsmouth, Dept Orthoped Surg, Div Hand Surg, Portsmouth, VA 23700 USA; Univ Cincinnati, Coll Med, Dept Orthoped Surg & Hand Surg, Cincinnati, OH USA; Hand Surg Spedalists Inc, Cincinnati, OH USA		Faruqui, S (corresponding author), Naval Med Ctr Portsmouth, Dept Orthoped Surg, Div Hand Surg, 620 John Paul Jones Circle, Portsmouth, VA 23700 USA.	safi.faruqui@med.navy.mil					AGEE J, 1992, ORTHOP CLIN N AM, V23, P35; BELSKY MR, 1984, J HAND SURG-AM, V9A, P725, DOI 10.1016/S0363-5023(84)80023-4; Chung KC, 2001, J HAND SURG-AM, V26A, P908, DOI 10.1053/jhsu.2001.26322; COONRAD RW, 1969, J BONE JOINT SURG AM, VA 51, P1291, DOI 10.2106/00004623-196951070-00006; Day CS, 2011, OPERATIVE HAND SURG, V1, P695; Elmaraghy MW, 1998, ANN PLAS SURG, V41, P125; GREEN DP, 1986, HAND CLIN, V2, P307; GREEN DP, 1973, J BONE JOINT SURG AM, VA 55, P1651, DOI 10.2106/00004623-197355080-00009; Hornbach EE, 2001, J HAND SURG-BRIT EUR, V26, P45, DOI 10.1054/jhsb.2000.0524; Joshi BB, 1976, HAND, V8, P85; Vahey JW, 1998, J HAND SURG-AM, V23A, P673, DOI 10.1016/S0363-5023(98)80054-3	11	29	30	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023			J HAND SURG-AM	J. Hand Surg.-Am. Vol.	JUL	2012	37A	7					1342	1348		10.1016/j.jhsa.2012.04.019			7	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	031VN	WOS:000310670700007	22721457				2022-02-06	
J	Hoarau, X; Richer, E; Dehail, P; Cuny, E				Hoarau, Xavier; Richer, Edwige; Dehail, Patrick; Cuny, Emmanuel			A 10-year follow-up study of patients with severe traumatic brain injury and dysautonomia treated with intrathecal baclofen therapy	BRAIN INJURY			English	Article						Severe traumatic brain injury; dysautonomia; spasticity; hypertonia; consciousness; intrathecal baclofen therapy	ALLEVIATES AUTONOMIC DYSFUNCTION; SUPRASPINAL SPASTICITY; DIENCEPHALIC SEIZURES; VEGETATIVE STATE; INFUSION; RECOVERY; RELIABILITY; HYPERTONIA; PREDICTION; DYSTONIA	Primary objective: To describe the long-term disorders of consciousness in patients with dysautonomia and hypertonia treated with intrathecal baclofen therapy (IBT). Methods and procedures: Forty-three patients with severe traumatic brain injuries who were previously implanted with an intrathecal baclofen pump were included to be evaluated in the long-term with the Coma Recovery Scale-Revised. The Barthel Index, the Glasgow Outcome Scale, the Ashworth scale, the scores of hypertonic attacks, of sweating episodes and of voluntary motor responses were used to describe functional abilities and residual impairments. A retrospective analysis highlighted patients' characteristics at admission, before surgery and their complications. Main outcomes and results: After a mean follow-up of 10 years, nine of 43 (20.9%) patients had died, 13/43 (30.2%) patients were severely disabled or in an unresponsive wakefulness syndrome and 21/43 (48.8%) patients had good recovery of consciousness. The latter patients tended to receive IBT later, suggesting a later development of uncontrolled symptoms of dysautonomia and hypertonia. They needed lower doses of baclofen, suggesting that they had less severe symptoms. Their dysautonomia, limb hypertonia and voluntary motor responses improved significantly compared to patients with poor outcome. Conclusions: Recovery of good long-term consciousness is possible. A low level of consciousness recovery and the early development of severe and persistent symptoms of dysautonomia associated with hypertonia could be linked to poor long-term outcome.	[Cuny, Emmanuel] Univ Bordeaux Segalen, CHU Bordeaux, Hop Pellegrin, Serv Neurochirurg B, F-33076 Bordeaux, France; [Hoarau, Xavier; Cuny, Emmanuel] Hop Pellegrin, Serv Neurochirurg, F-33076 Bordeaux, France; [Richer, Edwige] LADAPT, Ctr Reeducat, Cenac, France; [Dehail, Patrick] Hop Pellegrin, Serv Med Phys & Readaptat, F-33076 Bordeaux, France		Cuny, E (corresponding author), Univ Bordeaux Segalen, CHU Bordeaux, Hop Pellegrin, Serv Neurochirurg B, Pl Amelie Raba Leon, F-33076 Bordeaux, France.	emmanuel.cuny@chu-bordeaux.fr	Dehail, Patrick/T-5081-2019				Ahmadi SA, 2010, BRAIN INJURY, V24, P1539, DOI 10.3109/02699052.2010.523049; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Atzema C, 2006, J TRAUMA, V60, P1010, DOI 10.1097/01.ta.0000218038.28064.9d; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Becker R, 1999, J NEUROL NEUROSUR PS, V66, P114, DOI 10.1136/jnnp.66.1.114; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; COHADON F, 1993, NEUROCHIRURGIE, V39, P281; Condouret JPM, 1988, HEMIPLEGIE VASCULAIR, P45; Corral L, 2009, BRAIN INJURY, V23, P403, DOI 10.1080/02699050902788477; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Dario A, 2002, ACTA NEUROL SCAND, V105, P83, DOI 10.1034/j.1600-0404.2002.1o042.x; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Francois B, 2001, J TRAUMA, V50, P158, DOI 10.1097/00005373-200101000-00035; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lippert-Gruener M, 2007, BRAIN INJURY, V21, P1001, DOI 10.1080/02699050701468933; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MAHONEY F I, 1965, Md State Med J, V14, P61; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; Richard I, 2007, ACTA NEUROCHIR SUPPL, V97, P213; Rifici C, 1994, Funct Neurol, V9, P29; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Taira T, 2009, PROG BRAIN RES, V177, P317, DOI 10.1016/S0079-6123(09)17721-X; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188	51	29	30	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2012	26	7-8					927	940		10.3109/02699052.2012.661913			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	957CB	WOS:000305135100004	22668125				2022-02-06	
J	Mioni, G; Stablum, F; McClintock, SM; Cantagallo, A				Mioni, Giovanna; Stablum, Franca; McClintock, Shawn M.; Cantagallo, Anna			Time-Based Prospective Memory in Severe Traumatic Brain Injury Patients: The Involvement of Executive Functions and Time Perception	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Time monitoring; Time reproduction; Inhibition; Updating; Patients study; Cognitive disorder	WORKING-MEMORY; PROCESSING SPEED; EVENT; ATTENTION; ADULTS; DAMAGE; TASKS	Prospective memory (PM) is the ability to remember to perform a future action at a specified later time, which is investigated through the use of event-based and time-based tasks. Prior investigations have found that PM is impaired following traumatic brain injury (TB!). However, there is limited information regarding the cognitive functions that mediate TB! and PM performance. Thus, this study investigated time-based PM in TBI patients, and the relationship among time-based PM, time perception, and executive functions. To accomplish this objective, 18 severe TBI patients and 18 healthy matched controls performed a time-based PM task, a time reproduction task, and two executive functions (Stroop and n-back) tasks. While both groups increased their monitoring frequency close to the target time, TB! patients monitored more and were less accurate than healthy controls at the target time confirming the time-based PM dysfunction in these patients. Importantly, executive functions, particularly inhibition and updating abilities, were strongly related to time-based PM performance; both time perception and executive functions are involved in time-based prospective memory in controls, whereas, only executive functions appear to be involved in TBI time-based prospective memory performance. (JINS, 2012, 18, 697-705)	[Mioni, Giovanna; Stablum, Franca] Univ Padua, Dipartimento Psicol Gen, I-35131 Padua, Italy; [McClintock, Shawn M.] UT SW Med Ctr, Dept Psychiat, Dallas, TX USA; [McClintock, Shawn M.] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY USA; [Cantagallo, Anna] Univ Ferrara, Riabilitaz Azienda Osped, Dipartimento Neurosci, UMR, I-44100 Ferrara, Italy		Mioni, G (corresponding author), Univ Padua, Dipartimento Psicol Gen, Via Venezia 8, I-35131 Padua, Italy.	giovanna.mioni@unipd.it	McClintock, Shawn/N-1526-2017	mioni, Giovanna/0000-0002-1212-4591; Stablum, Franca/0000-0003-0123-5090			Baudouin A, 2006, BRAIN COGNITION, V62, P17, DOI 10.1016/j.bandc.2006.03.003; Block RA, 1998, PSYCHOL AGING, V13, P584, DOI 10.1037/0882-7974.13.4.584; Block RA, 2006, TIMING THE FUTURE: THE CASE FOR A TIME-BASED PROSPECTIVE MEMORY, P25, DOI 10.1142/9789812707123_0002; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Burgess P, 1996, BEHAV ASSESSMENT DYS; Carlesimo G.A., 2004, BEHAV NEUROL, V22, P101; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Del Missier F, 2010, THINK REASONING, V16, P69, DOI 10.1080/13546781003630117; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; ELLIS J, 2000, APPL COGNITIVE PSYCH, V14, P1, DOI DOI 10.1002/ACP.767; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Glicksohn J, 2006, TIMING THE FUTURE: THE CASE FOR A TIME-BASED PROSPECTIVE MEMORY, P1; Gonneaud J, 2011, MEMORY, V19, P360, DOI 10.1080/09658211.2011.570765; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hagen C, 1979, REHABILITATION HEAD; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Henry J.D., 2007, J CLIN EXPT NEUROPSY, V1, P1; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Kliegel M., 2008, PROSPECTIVE MEMORY C; Kopp UA, 2003, INT J PSYCHOL, V38, P229, DOI 10.1080/00207590344000150; Labelle MA, 2009, EUR J COGN PSYCHOL, V21, P501, DOI 10.1080/09541440802031000; Laiacona M, 2000, NEUROL SCI, V21, P279, DOI 10.1007/s100720070065; Mantyla T, 2006, TIMING THE FUTURE: THE CASE FOR A TIME-BASED PROSPECTIVE MEMORY, P191, DOI 10.1142/9789812707123_0008; Mantyla T, 2007, J EXP CHILD PSYCHOL, V96, P1, DOI 10.1016/j.jecp.2006.08.003; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McDaniel M A, 1993, Memory, V1, P23, DOI 10.1080/09658219308258223; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McFarland CP, 2009, NEUROPSYCHOLOGIA, V47, P1660, DOI 10.1016/j.neuropsychologia.2009.02.023; McQueen, 2003, BRAIN IMPAIR, V4, P135, DOI [10.1375/brim.4.2.135.270, DOI 10.1375/BRIM.4.2.135.27024]; MEYERS CA, 1992, NEUROPSY NEUROPSY BE, V5, P28; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nichelli P, 1995, ANN NY ACAD SCI, V769, P183, DOI 10.1111/j.1749-6632.1995.tb38139.x; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Schmitter-Edgecombe M, 2008, J CLIN EXP NEUROPSYC, V30, P212, DOI 10.1080/13803390701363803; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D, 2011, NEUROPSYCHOLOGIA, V49, P2156, DOI 10.1016/j.neuropsychologia.2011.02.006; TEASDALE G, 1974, LANCET, V2, P81; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; ZAKAY D, 1993, PERCEPTION, V22, P91, DOI 10.1068/p220091; Zakay D., 1996, ADV PSYCHOL, V115, P143, DOI [10.1016/S0166-4115(96), DOI 10.1016/S0166-4115(96)80057-4, 10.1016/S0166-4115(96)80057-4]; Zimmermann P., 2002, BATTERIA TEST ESAME	46	29	32	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2012	18	4					697	705		10.1017/S1355617712000306			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	978BN	WOS:000306714600008	22433779				2022-02-06	
J	Kim, JH; Nam, YP; Jeon, SM; Han, HS; Suk, K				Kim, Jong-Heon; Nam, Young-Pyo; Jeon, Sang-Min; Han, Hyung-Soo; Suk, Kyoungho			Amyloid neurotoxicity is attenuated by metallothionein: dual mechanisms at work	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; beta-amyloid; glia; metallothionein; neurodegenerative disease; neuroinflammation	CENTRAL-NERVOUS-SYSTEM; ENDOPLASMIC-RETICULUM STRESS; GROWTH-INHIBITORY FACTOR; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; GENE-EXPRESSION; MICROGLIAL ACTIVATION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; METAL CHELATORS	J. Neurochem. (2012) 121, 751762. Abstract Alzheimers disease (AD) is a neurodegenerative disorder characterized by a progressive loss of memory and cognition. One of the hallmarks of AD is the accumulation of beta-amyloid (A beta). Although endoplasmic reticulum stress, mitochondrial dysfunction, and oxidative stress have been implicated in A beta toxicity, the molecular mechanism(s) of A beta-induced neurotoxicity are not fully understood. In this study, we present evidence that the glia-derived stress protein metallothionein (MT) attenuates A beta-induced neurotoxicity by unique mechanisms. MT expression was increased in brain astrocytes of a NSE-APPsw transgenic mouse model of AD. Astrocyte-derived MT protected N2a neuroblastoma cells and primary cortical neurons against A beta toxicity with concurrent reduction of reactive oxygen species levels. MT reversed A beta-induced down-regulation of Bcl-2 and survival signaling in neuroblastoma cells. Moreover, MT inhibited A beta-induced proinflammatory cytokine production from microglia. The neurotoxicity of A beta-stimulated microglia was significantly attenuated by MT-I. The results indicate that MT released from reactive astrocytes may antagonize A beta neurotoxicity by direct inhibition of A beta neurotoxicity and indirect suppression of neurotoxic microglial activation. These findings broaden the understanding of neurotoxic mechanisms of A beta and the crosstalk between A beta and MT in AD.	[Kim, Jong-Heon; Nam, Young-Pyo; Jeon, Sang-Min; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, CMRI, Taegu 700422, South Korea; [Han, Hyung-Soo] Kyungpook Natl Univ, Sch Med, Dept Physiol, CMRI, Taegu 700422, South Korea; [Kim, Jong-Heon; Nam, Young-Pyo; Jeon, Sang-Min; Han, Hyung-Soo; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, Brain Sci & Engn Inst, Taegu 700422, South Korea		Suk, K (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Pharmacol, CMRI, 101 Dong In, Taegu 700422, South Korea.	hshan@knu.ac.kr; ksuk@knu.ac.kr			Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [A100870, A111345]; Ministry of Knowledge Economy (MKE, Korea)Ministry of Knowledge Economy, Republic of Korea [10035197]; National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST) of Korean governmentMinistry of Education, Science and Technology, Republic of Korea [2011-0028240]	This work was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100870, A111345), and by a grant of the Industrial Strategic Technology Development Program (10035197) funded by the Ministry of Knowledge Economy (MKE, Korea). This work was also supported by the National Research Foundation (NRF) grants funded by the Ministry of Education, Science and Technology (MEST) of Korean government (2011-0028240). The authors declare no conflict of interest.	Ambjorn M, 2008, J NEUROCHEM, V104, P21, DOI 10.1111/j.1471-4159.2007.05036.x; AOKI Y, 1991, J BIOCHEM BIOPH METH, V23, P207, DOI 10.1016/0165-022X(91)90013-M; AOKI Y, 1986, ANAL BIOCHEM, V157, P117, DOI 10.1016/0003-2697(86)90204-6; Asmussen JW, 2009, J NEUROSCI RES, V87, P2926, DOI 10.1002/jnr.22118; Blaauwgeers H. G. T., 1994, Biological Signals, V3, P181; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Carrasco J, 2006, NEUROSCIENCE, V143, P911, DOI 10.1016/j.neuroscience.2006.08.054; Cherian MG, 2000, CELL MOL BIOL, V46, P347; Chung RS, 2008, J NEUROCHEM, V104, P14, DOI 10.1111/j.1171-4159.2007.05026.x; Chung RS, 2007, CELL MOL LIFE SCI, V64, P2716, DOI 10.1007/s00018-007-7267-8; Chung RS, 2009, NEUROTOX RES, V15, P381, DOI 10.1007/s12640-009-9044-y; Chung RS, 2008, J BIOL CHEM, V283, P15349, DOI 10.1074/jbc.M708446200; Chung RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012030; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; Ebadi M, 1987, Experientia Suppl, V52, P289; El Ghazi I, 2010, INT J ALZHEIMERS DIS, V2011, DOI DOI 10.4061/2011/20863421234102; Fitzgerald M, 2007, EXP BRAIN RES, V183, P171, DOI 10.1007/s00221-007-1032-y; Floden AM, 2005, J NEUROSCI, V25, P2566, DOI 10.1523/JNEUROSCI.4998-04.2005; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Hao QA, 2007, J CELL PHYSIOL, V210, P428, DOI 10.1002/jcp.20874; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; Hidalgo J, 2002, METHOD ENZYMOL, V348, P238, DOI 10.1016/S0076-6879(02)48642-9; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Hidalgo J, 2006, EXP BIOL MED, V231, P1450, DOI 10.1177/153537020623100902; Hwang DY, 2004, EXP NEUROL, V186, P20, DOI 10.1016/j.expneurol.2003.09.021; Irie Y, 2003, BRAIN RES, V960, P228, DOI 10.1016/S0006-8993(02)03891-X; Irie Y, 2001, BIOCHEM BIOPH RES CO, V282, P416, DOI 10.1006/bbrc.2001.4594; Jana A, 2010, J NEUROSCI, V30, P12676, DOI 10.1523/JNEUROSCI.1243-10.2010; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kay CJ, 1997, FEBS LETT, V403, P230, DOI 10.1016/S0014-5793(97)00076-8; Kobayakawa Mutsutaka, 2010, Brain and Nerve (Tokyo), V62, P737; Kondo Y, 1997, MOL PHARMACOL, V52, P195, DOI 10.1124/mol.52.2.195; Leung YKJ, 2010, EXP NEUROL, V221, P98, DOI 10.1016/j.expneurol.2009.10.006; Manso Y, 2011, J BIOL INORG CHEM, V16, P1103, DOI 10.1007/s00775-011-0802-y; Marchesi VT, 2011, FASEB J, V25, P5, DOI 10.1096/fj.11-0102ufm; Maret W, 2003, J NUTR, V133, p1460S, DOI 10.1093/jn/133.5.1460S; Maret W, 2011, J BIOL INORG CHEM, V16, P1079, DOI 10.1007/s00775-011-0800-0; Martin BL, 2006, MOL CELL BIOCHEM, V283, P129, DOI 10.1007/s11010-006-2390-7; Martinho A, 2010, FEBS J, V277, P3427, DOI 10.1111/j.1742-4658.2010.07749.x; MASTERS BA, 1994, J NEUROSCI, V14, P5844; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meloni G, 2008, NAT CHEM BIOL, V4, P366, DOI 10.1038/nchembio.89; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Ock J, 2010, BRIT J PHARMACOL, V159, P1646, DOI 10.1111/j.1476-5381.2010.00659.x; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Penkowa M, 2005, J NEUROSCI RES, V79, P522, DOI 10.1002/jnr.20387; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T; Penkowa M, 2006, J NEUROSCI RES, V84, P1452, DOI 10.1002/jnr.21043; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Sakono M, 2010, FEBS J, V277, P1348, DOI 10.1111/j.1742-4658.2010.07568.x; Sawada Jun-Ichi, 1994, Biological Signals, V3, P157; Tabner BJ, 2005, BIOCHEM SOC T, V33, P548, DOI 10.1042/BST0330548; Tabner BJ, 2005, J BIOL CHEM, V280, P35789, DOI 10.1074/jbc.C500238200; Tougu V, 2011, METALLOMICS, V3, P250, DOI 10.1039/c0mt00073f; Tougu V, 2009, J NEUROCHEM, V110, P1784, DOI 10.1111/j.1471-4159.2009.06269.x; Trayhurn P, 2000, HORM METAB RES, V32, P542, DOI 10.1055/s-2007-978683; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Y, 2002, J BIOL CHEM, V277, P32353, DOI 10.1074/jbc.M111263200; Vallee B L, 1987, Experientia Suppl, V52, P5; VARSHNEY U, 1986, MOL CELL BIOL, V6, P26, DOI 10.1128/MCB.6.1.26; Vasak M, 2005, J TRACE ELEM MED BIO, V19, P13, DOI 10.1016/j.jtemb.2005.03.003; Vasak M, 2011, J BIOL INORG CHEM, V16, P1067, DOI 10.1007/s00775-011-0799-2; West AK, 2004, REV NEUROSCIENCE, V15, P157; Ye B, 2001, P NATL ACAD SCI USA, V98, P2317, DOI 10.1073/pnas.041619198; Yin XY, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-21; Zambenedetti P, 1998, J CHEM NEUROANAT, V15, P21, DOI 10.1016/S0891-0618(98)00024-6	75	29	30	1	8	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	2012	121	5					751	762		10.1111/j.1471-4159.2012.07725.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	933UE	WOS:000303387800008	22404335	Bronze			2022-02-06	
J	von Reyn, CR; Mott, RE; Siman, R; Smith, DH; Meaney, DF				von Reyn, Catherine R.; Mott, Rosalind E.; Siman, Robert; Smith, Douglas H.; Meaney, David F.			Mechanisms of calpain mediated proteolysis of voltage gated sodium channel alpha-subunits following in vitro dynamic stretch injury	JOURNAL OF NEUROCHEMISTRY			English	Article						axon; calpain; NMDA receptor; proteolysis; sodium channel; traumatic brain injury	TRAUMATIC BRAIN-INJURY; EXCITATORY AMINO-ACIDS; D-ASPARTATE RECEPTORS; NMDA RECEPTOR; CORTICAL-NEURONS; CYTOSKELETAL PROTEOLYSIS; CALCIUM INFLUX; CNS INJURY; MU-CALPAIN; RAT	J. Neurochem. (2012) 121, 793805. Abstract Although enhanced calpain activity is well documented after traumatic brain injury (TBI), the pathways targeting specific substrate proteolysis are less defined. Our past work demonstrated that calpain cleaves voltage gated sodium channel (NaCh) a-subunits in an in vitro TBI model. In this study, we investigated the pathways leading to NaCh cleavage utilizing our previously characterized in vitro TBI model, and determined the location of calpain activation within neuronal regions following stretch injury to micropatterned cultures. Calpain specific breakdown products of a-spectrin appeared within axonal, dendritic, and somatic regions 6 h after injury, concurrent with the appearance of NaCh a-subunit proteolysis in both whole cell or enriched axonal preparations. Direct pharmacological activation of either NMDA receptors (NMDArs) or NaChs resulted in NaCh proteolysis. Likewise, a chronic (6 h) dual inhibition of NMDArs/NaChs but not L-type voltage gated calcium channels significantly reduced NaCh proteolysis 6 h after mechanical injury. Interestingly, an early, transient (30 min) inhibition of NMDArs alone significantly reduced NaCh proteolysis. Although a chronic inhibition of calpain significantly reduced proteolysis, a transient inhibition of calpain immediately after injury failed to significantly attenuate NaCh proteolysis. These data suggest that both NMDArs and NaChs are key contributors to calpain activation after mechanical injury, and that a larger temporal window of sustained calpain activation needs consideration in developing effective treatments for TBI.	[von Reyn, Catherine R.; Mott, Rosalind E.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Siman, Robert; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Meaney, David/0000-0002-0954-4122; von Reyn, Catherine/0000-0002-5753-2134	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS-015202, NS 35712, HD41699]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202, R01NS035712] Funding Source: NIH RePORTER	Funds were provided by grants from the National Institutes of Health, P01-NS-015202, NS 35712 and HD41699.	Araujo IM, 2004, J NEUROCHEM, V91, P1322, DOI 10.1111/j.1471-4159.2004.02811.x; Araujo IM, 2010, NEUROCHEM RES, V35, P1966, DOI 10.1007/s11064-010-0323-z; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; BENKE TA, 1993, P NATL ACAD SCI USA, V90, P7819, DOI 10.1073/pnas.90.16.7819; BERMUDEZRATTONI F, 1991, P NATL ACAD SCI USA, V88, P5379, DOI 10.1073/pnas.88.12.5379; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Christie JM, 2008, NEURON, V60, P298, DOI 10.1016/j.neuron.2008.08.028; Cochilla AJ, 1999, J NEUROSCI, V19, P193, DOI 10.1523/JNEUROSCI.19-01-00193.1999; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Garcia M, 2005, BIOCHEM BIOPH RES CO, V338, P1241, DOI 10.1016/j.bbrc.2005.10.081; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Golshani P, 1998, J NEUROPHYSIOL, V80, P143, DOI 10.1152/jn.1998.80.1.143; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jette N, 2006, J CEREBR BLOOD F MET, V26, P777, DOI 10.1038/sj.jcbfm.9600226; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Nguyen TH, 1999, J NEUROCHEM, V73, P1995; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Papadia S, 2007, NEUROSCIENTIST, V13, P572, DOI 10.1177/1073858407305833; Peng TI, 1998, MOL PHARMACOL, V53, P974; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; Prakriya M, 2000, NEURON, V26, P671, DOI 10.1016/S0896-6273(00)81203-9; Rasband MN, 1999, J NEUROSCI, V19, P7516, DOI 10.1523/JNEUROSCI.19-17-07516.1999; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; Smith DH, 1999, J NEUROSCI, V19, P4263; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Vanderklish P, 1996, LEARN MEMORY, V3, P209, DOI 10.1101/lm.3.2-3.209; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WESTENBROEK RE, 1989, NEURON, V3, P695, DOI 10.1016/0896-6273(89)90238-9; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xu J, 2009, J NEUROSCI, V29, P9330, DOI 10.1523/JNEUROSCI.2212-09.2009; Yuen EY, 2007, J PHYSIOL-LONDON, V580, P241, DOI 10.1113/jphysiol.2006.122754; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	65	29	29	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	2012	121	5					793	805		10.1111/j.1471-4159.2012.07735.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	933UE	WOS:000303387800012	22428606	Bronze, Green Accepted			2022-02-06	
J	Sun, CY; Ou, XM; Farley, JM; Stockmeier, C; Bigler, S; Brinton, RD; Wang, JM				Sun, Chenyou; Ou, Xiaoming; Farley, Jerry M.; Stockmeier, Craig; Bigler, Steven; Brinton, Roberta Diaz; Wang, Jun Ming			Allopregnanolone Increases the Number of Dopaminergic Neurons in Substantia Nigra of a Triple Transgenic Mouse Model of Alzheimer's Disease	CURRENT ALZHEIMER RESEARCH			English	Article						Allopregnanolone; neurogenesis; tyrosine hydroxylase (TH); substantia nigra; dopaminergic neurons	GAMMA-AMINOBUTYRIC-ACID; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; LOCUS-COERULEUS; LEWY BODIES; CELL-DEATH; NEUROSTEROID ALLOPREGNANOLONE; PRESENILIN-1 MUTATION; TYROSINE-HYDROXYLASE; TANGLE FORMATION	More than a third of Alzheimer's disease (AD) patients show nigrostriatal pathway disturbances, resulting in akinesia (inability to initiate movement) and bradykinesia (slowness of movement). The high prevalence of this dysfunction of dopaminergic neuron in the nigrostriatal pathway in AD suggests that the risk factors for AD appear also significant risk factors for substantia nigra pars compacta (SNpc) lesions. Previously, we have demonstrated that allopregnanolone (AP alpha) promotes neurogenesis and improves the cognitive function in a triple transgenic mouse model of AD (3xTgAD). In this study, we sought to exam 1) the SNpc lesions in 3xTgAD mice and 2) the impact of AP alpha on promoting the regeneration of new dopaminergic neurons in SNpc of the 3xTgAD mice. The number of Nissl-stained total neurons, tyrosine hydroxylase (TH) positive neurons, and BrdU/TH double positive newly formed neurons were analyzed with unbiased stereology. In the SNpc of 3xTgAD mice, TH positive neurons was 47 +/- 18 % (p = 0.007), total neurons was 62 +/- 11.6 % (p = 0.016), of those in the SNpc of non-Tg mice, respectively. APa treatment increased the TH positive neurons in the SNpc of 3xTgAD mice to 93.2 +/- 18.5 % (p = 0.021 vs. 3xTgAD vehicle) and the total neurons to 84.9 +/- 6.6 (p = 0.046 vs. 3xTgAD vehicle) of non-Tg mice. These findings indicate that there is a loss of neurons, specifically the TH positive neurons in SNpc of 3xTgAD mice, and that AP alpha reverses the lesion in SNpc of 3xTgAD by increasing the formation of new TH neurons.	[Sun, Chenyou; Bigler, Steven; Wang, Jun Ming] Univ Mississippi, Med Ctr, Dept Pathol, Jackson, MS 39216 USA; [Ou, Xiaoming; Stockmeier, Craig; Wang, Jun Ming] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA; [Farley, Jerry M.; Wang, Jun Ming] Univ Mississippi, Med Ctr, Dept Pharmacol & Toxicol, Jackson, MS 39216 USA; [Sun, Chenyou] Wenzhou Medial Coll, Dept Anat, Wenzhou 325035, Zhejiang, Peoples R China; [Brinton, Roberta Diaz] Univ So Calif, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA		Wang, JM (corresponding author), Univ Mississippi, Med Ctr, Dept Pathol, 2500 N State St, Jackson, MS 39208 USA.	jwang@umc.edu		Brinton, Roberta/0000-0001-8450-772X	Michael J FOX RRIA; Carryway foundation; NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR17701]; IIRG from the Alzheimer's Association; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR017701] Funding Source: NIH RePORTER	The authors thank Dr. Frank LaFerla for his gift of 3xTgAD mice. This study was supported by Michael J FOX RRIA grant, a Carryway foundation grant, a small grant of NCRR RR17701 and a IIRG grant from the Alzheimer's Association. All experiments conformed to the Animal Welfare Act, Guide to Use and Care of Laboratory Animals, and the U. S. Government Principles of the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training guidelines on the ethical use of animals. In addition, the minimal number of required animals was used for these experiments and pain was minimized.	Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Arias-Carrion O, 2009, J NEURAL TRANSM-SUPP, P279, DOI 10.1007/978-3-211-92660-4_23; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Baulieu EE, 2000, STEROIDS, V65, P605, DOI 10.1016/S0039-128X(00)00173-2; Bittner T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015477; Bjugstad KB, 2008, EXP NEUROL, V211, P362, DOI 10.1016/j.expneurol.2008.01.025; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Burns JM, 2005, NEUROLOGY, V64, P1397, DOI 10.1212/01.WNL.0000158423.05224.7F; Chen S, 2011, PLOS ONE UNPUB; Chen SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024293; CHUI HC, 1986, ARCH NEUROL-CHICAGO, V43, P991, DOI 10.1001/archneur.1986.00520100013007; Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; DAHLSTROM A, 1964, EXPERIENTIA, V20, P398, DOI 10.1007/BF02147990; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; German DC, 2005, J COMP NEUROL, V492, P469, DOI 10.1002/cne.20744; Gomez-Tortosa E, 1998, J AM GERIATR SOC, V46, P1449, DOI 10.1111/j.1532-5415.1998.tb06016.x; Gong CX, 2008, CURR MED CHEM, V15, P2321, DOI 10.2174/092986708785909111; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Iqbal K, 2006, J ALZHEIMERS DIS, V9, P219; JELLINGER K, 1987, J NEURAL TRANSM, P109; Jellinger KA, 2003, ACTA NEUROPATHOL, V106, P191, DOI 10.1007/s00401-003-0725-y; Jimenez-Escrig A, 2004, EUR J NEUROL, V11, P663, DOI 10.1111/j.1468-1331.2004.00865.x; KASTNER A, 1993, J NEUROCHEM, V61, P1024, DOI 10.1111/j.1471-4159.1993.tb03616.x; KAZEE AM, 1995, ARCH PATHOL LAB MED, V119, P448; KAZEE AM, 1995, ALZ DIS ASSOC DIS, V9, P61, DOI 10.1097/00002093-199509020-00001; Keller EA, 2004, DEV BRAIN RES, V153, P13, DOI 10.1016/j.devbrainres.2004.07.009; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536; Luchetti S, 2010, BRAIN PATHOL, V20, P945, DOI 10.1111/j.1750-3639.2010.00396.x; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; MAYEUX R, 1985, NEUROLOGY, V35, P453, DOI 10.1212/WNL.35.4.453; McCormack AL, 2006, NEUROSCIENCE, V141, P929, DOI 10.1016/j.neuroscience.2006.03.069; McMillan PJ, 2011, BRAIN RES, V1373, P240, DOI 10.1016/j.brainres.2010.12.015; Mellon SH, 2002, ENDOCR RES, V28, P463, DOI 10.1081/ERC-120016823; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; MITSUYAMA Y, 1993, DEMENTIA, V4, P137, DOI 10.1159/000107312; MORRIS JC, 1989, ARCH NEUROL-CHICAGO, V46, P651, DOI 10.1001/archneur.1989.00520420071025; Mudher A, 2004, MOL PSYCHIATR, V9, P522, DOI 10.1038/sj.mp.4001483; Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166-2236(00)02031-2; Naylor JC, 2010, BBA-MOL CELL BIOL L, V1801, P951, DOI 10.1016/j.bbalip.2010.05.006; Nelson EL, 1996, J COMP NEUROL, V369, P361, DOI 10.1002/(SICI)1096-9861(19960603)369:3<361::AID-CNE3>3.0.CO;2-3; O'Neil JN, 2007, J CHEM NEUROANAT, V34, P102, DOI 10.1016/j.jchemneu.2007.05.008; Oberto A, 2002, J NEUROCHEM, V82, P1272, DOI 10.1046/j.1471-4159.2002.01079.x; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Perez SE, 2005, J NEUROSCI, V25, P10220, DOI 10.1523/JNEUROSCI.2773-05.2005; Ramsden M, 2005, J NEUROSCI, V25, P10637, DOI 10.1523/JNEUROSCI.3279-05.2005; Rey NL, 2012, NEUROBIOL AGING, V33; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Schmitz C, 2004, AM J PATHOL, V164, P1495, DOI 10.1016/S0002-9440(10)63235-X; Singh C, 2011, NEUROBIOLOG IN PRESS; Snider BJ, 2005, ARCH NEUROL-CHICAGO, V62, P1821, DOI 10.1001/archneur.62.12.1821; Szot P, 2009, NEUROSCI LETT, V463, P93, DOI 10.1016/j.neulet.2009.07.055; TORACK RM, 1992, J NEURAL TRANSM-PARK, V4, P165, DOI 10.1007/BF02251479; Verny M, 1998, ANN MED INTERNE, V149, P209; Wang Doris D, 2008, Epilepsy Curr, V8, P137, DOI 10.1111/j.1535-7511.2008.00270.x; Wang J, 2010, HIPPOCAMPAL NEURAL P; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2007, ALLOPREGNANOLONE REV; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Wang JM, 2007, CURR ALZHEIMER RES, V4, P510, DOI 10.2174/156720507783018262; Wang JM, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00194; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wang JM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S11; Yang SY, 2005, TRENDS ENDOCRIN MET, V16, P167, DOI 10.1016/j.tem.2005.03.006; Zarow C, 2003, ARCH NEUROL-CHICAGO, V60, P337, DOI 10.1001/archneur.60.3.337; Zhao M, 2003, P NATL ACAD SCI USA, V100, P7925, DOI 10.1073/pnas.1131955100	73	29	39	0	6	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	MAY	2012	9	4					473	480		10.2174/156720512800492567			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	944HF	WOS:000304189200009	22272610	Green Accepted			2022-02-06	
J	Laskowitz, DT; Lei, BL; Dawson, HN; Wang, HC; Bellows, ST; Christensen, DJ; Vitek, MP; James, ML				Laskowitz, Daniel T.; Lei, Beilei; Dawson, Hana N.; Wang, Haichen; Bellows, Steven T.; Christensen, Dale J.; Vitek, Michael P.; James, Michael L.			The apoE-mimetic Peptide, COG1410, Improves Functional Recovery in a Murine Model of Intracerebral Hemorrhage	NEUROCRITICAL CARE			English	Article						Intracerebral hemorrhage; Murine model; Apolipoprotein E; Therapeutic; Outcome	PROTEIN PHOSPHATASE 2A; SYSTEM INFLAMMATORY RESPONSE; TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E; SERINE/THREONINE PHOSPHATASE; KINASE PATHWAYS; MOUSE MODEL; ACTIVATION; RAT; EXCITOTOXICITY	Background Apolipoprotein E has previously been demonstrated to modulate acute brain injury responses, and administration of COG1410, an apoE-mimetic peptide derived from the receptor-binding region of apoE, improves outcome in preclinical models of acute neurological injury. In the current study, we sought to establish the optimal dose and timing of peptide administration associated with improved functional outcome in a murine model of intracerebral hemorrhage (ICH). Methods Ten to twelve-week-old C57/BL6 male mice were injured by collagenase-induced ICH and randomly selected to receive either vehicle or one of four doses of COG1410 (0.5, 1, 2, or 4 mg/kg) via tail vein injection at 30 min after injury and then daily for 5 days. The injured mice were euthanized at various time points to assess inflammatory mediators, cerebral edema, and hematoma volume. Over the first 5 days following injury, vestibulomotor function was tested via Rotorod (RR) latency. After an optimal dose was demonstrated, a final cohort of animals was injured with ICH and randomly assigned to receive the first dose of COG1410 or vehicle at increasingly longer treatment initiation times after injury. The mice were then assessed for functional deficit via RR testing over the first 5 days following injury. Results The mice receiving 2 mg/kg of COG1410 after injury demonstrated reduced functional deficit, decreased brain concentrations of inflammatory proteins, and less cerebral edema, although hematoma volume did not vary. The improved RR performance was maintained when peptide administration was delayed for up to 2 h after ICH. Conclusions COG1410 administered at a dose of 2 mg/kg within 2 h after injury improves functional recovery in a murine model of ICH.	[Laskowitz, Daniel T.; Lei, Beilei; James, Michael L.] Duke Univ, Multidisciplinary Neuroprotect Labs, Dept Anesthesiol, Durham, NC 27710 USA; [Laskowitz, Daniel T.; Dawson, Hana N.; Wang, Haichen; James, Michael L.] Duke Univ, Multidisciplinary Neuroprotect Labs, Dept Med Neurol, Durham, NC 27710 USA; [Laskowitz, Daniel T.] Duke Univ, Multidisciplinary Neuroprotect Labs, Dept Neurobiol, Durham, NC 27710 USA; [Christensen, Dale J.] Duke Univ, Dept Med Hematol, Durham, NC 27710 USA; [Christensen, Dale J.; Vitek, Michael P.] Cognosci Inc, Res Triangle Pk, NC USA		James, ML (corresponding author), Duke Univ, Multidisciplinary Neuroprotect Labs, Dept Anesthesiol, DUMC 3094, Durham, NC 27710 USA.	Daniel.laskowitz@duke.edu; beilei.lei@duke.edu; hana.dawson@duke.edu; haichen.wang@duke.edu; steven.bellows@gmail.com; dchristensen@cognosci.com; mvitek@cognosci.com; Michael.james@duke.edu	James, Michael L./AAJ-5592-2020; tao, li/G-7956-2011	James, Michael L./0000-0002-8715-5210; Vitek, Michael/0000-0001-8140-8048	American Heart AssociationAmerican Heart Association; Foundation of Anesthesia Education and Research;  [R43NS064651-01A1]	The authors would like to thank Jessica Oddo for technical assistance. This research was made possible through grants from R43NS064651-01A1 (DJC), the American Heart Association Scientist Development Grant (MLJ), and Foundation of Anesthesia Education and Research Mentored Research Training Grant (MLJ). COG1410 was provided by Cognosci, Inc. (Research Triangle Park, NC, USA).	Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x; Dawson HN, 2010, NEUROSCIENCE, V169, P516, DOI 10.1016/j.neuroscience.2010.04.037; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; Fujimoto S, 2007, NEUROSCIENCE, V144, P694, DOI 10.1016/j.neuroscience.2006.09.049; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; James ML, 2010, J NEUROTRAUM, V27, P217, DOI 10.1089/neu.2009.1022; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; Lomnitski L, 1999, J NEUROSCI RES, V58, P586; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2010, STROKE, V41, pS95, DOI 10.1161/STROKEAHA.110.594457; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; Mendelow AD, 2005, LANCET, V365, P387; Mesis Rachel G, 2006, Neurosurg Focus, V21, pE4; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Ohnishi M, 2007, EXP NEUROL, V206, P43, DOI 10.1016/j.expneurol.2007.03.030; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966; Singh K, 2008, J BIOL CHEM, V283, P16752, DOI 10.1074/jbc.M710530200; Singh K, 2011, J BIOL CHEM, V286, P3839, DOI 10.1074/jbc.M110.176719; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Tukhovskaya EA, 2009, J NEUROSCI RES, V87, P677, DOI 10.1002/jnr.21874; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	52	29	35	1	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2012	16	2					316	326		10.1007/s12028-011-9641-5			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	949ZS	WOS:000304618500018	21989844				2022-02-06	
J	Medeiros, FA; Weinreb, RN; Boer, ER; Rosen, PN				Medeiros, Felipe A.; Weinreb, Robert N.; Boer, Erwin R.; Rosen, Peter N.			Driving Simulation as a Performance-based Test of Visual Impairment in Glaucoma	JOURNAL OF GLAUCOMA			English	Article						driving; simulation; glaucoma; functional impairment; quality of life	OPEN-ANGLE GLAUCOMA; QUALITY-OF-LIFE; VEHICLE COLLISION INVOLVEMENT; INCREASED DEPRESSIVE SYMPTOMS; LATERAL GENICULATE-NUCLEUS; TRAUMATIC BRAIN-INJURY; OLDER DRIVERS; ALZHEIMER-DISEASE; RISK-FACTORS; FIELD LOSS	The fundamental goal of glaucoma management is to prevent patients from developing visual impairments sufficient to produce disability in their daily lives and impair their quality of life. Ultimately, patients are interested in how their vision will impact their ability to perform daily activities, such as driving. Although technologic advancements such as automated perimetry and devices for optic nerve imaging have resulted in great improvement in our ability to quantify structural and functional damage in glaucoma, the impact on vision-related quality of life of some of the information acquired from these tests remain elusive. In contrast, performance-based measures may be better correlated to traditional measures of vision health and, more importantly, they provide a more direct measure of disability. Driving simulators can be used as a performance-based test for evaluation of functional impairment in glaucoma. Their use can potentially help in the evaluation of driving safety and performance of diseased subjects and provide insight into the different mechanisms involved in causing driving impairment in this disease. The ability to do this in an experimentally controlled and standardized setting enables testing of a much larger number of hypotheses compared with on-road evaluations. Besides evaluating driver fitness, simulators could also potentially be used as a sophisticated test to evaluate cognitive impairment in the context of an everyday task (driving) that has not been available through traditional neuropsychologic assessment.	[Medeiros, Felipe A.; Weinreb, Robert N.; Boer, Erwin R.; Rosen, Peter N.] Univ Calif San Diego, Dept Ophthalmol, Hamilton Glaucoma Ctr, La Jolla, CA 92093 USA		Medeiros, FA (corresponding author), Univ Calif San Diego, Dept Ophthalmol, Hamilton Glaucoma Ctr, 9500 Gilman Dr, La Jolla, CA 92093 USA.	fmedeiros@glaucoma.ucsd.edu			National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY08208]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY008208, R01EY021818] Funding Source: NIH RePORTER	Supported in part by the National Eye Institute grant EY08208 (F.A.M.).	Akinwuntan AE, 2005, NEUROLOGY, V65, P843, DOI 10.1212/01.wnl.0000171749.71919.fa; Aspinall PA, 2008, INVEST OPHTH VIS SCI, V49, P1907, DOI 10.1167/iovs.07-0559; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; Bedard M, 2010, AM J OCCUP THER, V64, P336, DOI 10.5014/ajot.64.2.336; Biederman Joseph, 2007, Ann Gen Psychiatry, V6, P4, DOI 10.1186/1744-859X-6-4; BLAAUW GJ, 1982, HUM FACTORS, V24, P473, DOI 10.1177/001872088202400408; BOYDSTUN LE, 1980, P HUM FACT SOC 24 AN, P111; Brooks JO, 2010, ACCIDENT ANAL PREV, V42, P788, DOI 10.1016/j.aap.2009.04.013; Chisholm CM, 2008, BRIT J OPHTHALMOL, V92, P225, DOI 10.1136/bjo.2007.129726; Coeckelbergh TRM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1509, DOI 10.1001/archopht.120.11.1509; Crabb DP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009710; Crabb DP, 2004, BRIT J OPHTHALMOL, V88, P1191, DOI 10.1136/bjo.2003.035949; Cross JM, 2009, BRIT J OPHTHALMOL, V93, P400, DOI 10.1136/bjo.2008.144584; de Winter JCF, 2009, ERGONOMICS, V52, P137, DOI 10.1080/00140130802277521; DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010; DECINA LE, 1993, ACCIDENT ANAL PREV, V25, P267, DOI 10.1016/0001-4575(93)90021-N; Devos H, 2007, NEUROLOGY, V69, P1434, DOI 10.1212/01.wnl.0000277640.58685.fc; DRANCE SM, 1981, ARCH OPHTHALMOL-CHIC, V99, P829, DOI 10.1001/archopht.1981.03930010829007; Fildes Brian, 2007, Annu Proc Assoc Adv Automot Med, V51, P559; Fonda SJ, 2001, J GERONTOL B-PSYCHOL, V56, pS343, DOI 10.1093/geronb/56.6.S343; Freeman EE, 2006, AM J PUBLIC HEALTH, V96, P1254, DOI 10.2105/AJPH.2005.069146; Freund B., 2006, ADV TRANSPORTATION S, P71; Garway-Heath DF, 2008, PROG BRAIN RES, V173, P47, DOI 10.1016/S0079-6123(08)01105-9; GAWRON VJ, 1988, ERGONOMICS, V31, P1219, DOI 10.1080/00140138808966764; Gilhotra JS, 2001, CLIN EXP OPHTHALMOL, V29, P104, DOI 10.1046/j.1442-9071.2001.00411.x; Girkin CA, 2004, INVEST OPHTH VIS SCI, V45, P2272, DOI 10.1167/iovs.03-0996; Girkin CA, 2010, ARCH OPHTHALMOL-CHIC, V128, P541, DOI 10.1001/archophthalmol.2010.49; Godley ST, 2002, ACCIDENT ANAL PREV, V34, P589, DOI 10.1016/S0001-4575(01)00056-2; Gupta N, 2009, BRIT J OPHTHALMOL, V93, P56, DOI 10.1136/bjo.2008.138172; Gupta N, 2007, SURV OPHTHALMOL, V52, pS122, DOI 10.1016/j.survophthal.2007.08.006; Gupta N, 2007, CURR OPIN OPHTHALMOL, V18, P110, DOI 10.1097/ICU.0b013e3280895aea; Haymes SA, 2008, INVEST OPHTH VIS SCI, V49, P3035, DOI 10.1167/iovs.07-1609; Haymes SA, 2007, INVEST OPHTH VIS SCI, V48, P1149, DOI 10.1167/iovs.06-0886; Hills BL, 1977, REANALYSIS CALIFORNI, P1; Horswill MS, 2008, PERCEPTION, V37, P1269, DOI 10.1068/p5821; HUGHES DTD, 1967, MED SCI LAW, V7, P200, DOI 10.1177/002580246700700407; Janz NK, 2009, INVEST OPHTH VIS SCI, V50, P1718, DOI 10.1167/iovs.08-2575; JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371; Klimkeit EI, 2009, NEUROSCI BIOBEHAV R, V33, P223, DOI 10.1016/j.neubiorev.2008.08.005; Lee GCH, 1997, COMPUT IND ENG, V33, P533, DOI 10.1016/S0360-8352(97)00186-1; Lee H. C., 2003, T ENG AUST, V8, P89, DOI [10.3389/fnhum.2014.00772, DOI 10.3389/FNHUM.2014.00772]; Lee HC, 2005, AM J OCCUP THER, V59, P97, DOI 10.5014/ajot.59.1.97; Lee HC, 2003, J SAFETY RES, V34, P453, DOI 10.1016/j.jsr.2003.09.007; Lee HC, 2003, AM J OCCUP THER, V57, P324, DOI 10.5014/ajot.57.3.324; Lee JD, 2002, HUM FACTORS, V44, P314, DOI 10.1518/0018720024497844; LEE JD, 2004, SIMULATOR FIDELITY L; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Lew HL, 2009, J HEAD TRAUMA REHAB, V24, P51, DOI 10.1097/HTR.0b013e3181956fe3; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lorenzana L, 2009, OPHTHAL EPIDEMIOL, V16, P107, DOI 10.1080/09286580902738142; Loughman J, 2007, BRIT J OPHTHALMOL, V91, P1493, DOI 10.1136/bjo.2006.108084; Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x; MCCLOSKEY LW, 1994, AGE AGEING, V23, P267, DOI 10.1093/ageing/23.4.267; McGwin G, 2005, ARCH OPHTHALMOL-CHIC, V123, P89, DOI 10.1001/archopht.123.1.89; McGwin G, 2005, INVEST OPHTH VIS SCI, V46, P4437, DOI 10.1167/iovs.05-0750; McGwin G, 2004, INVEST OPHTH VIS SCI, V45, P3934, DOI 10.1167/iovs.04-0524; McGwin G, 1998, ACCIDENT ANAL PREV, V30, P781, DOI 10.1016/S0001-4575(98)00031-1; McKendrick AM, 2007, INVEST OPHTH VIS SCI, V48, P2115, DOI 10.1167/iovs.06-1208; McKendrick AM, 2005, INVEST OPHTH VIS SCI, V46, P3693, DOI 10.1167/iovs.04-1406; Medeiros FA, 2004, ARCH OPHTHALMOL-CHIC, V122, P827, DOI 10.1001/archopht.122.6.827; Medeiros FA, 2004, AM J OPHTHALMOL, V137, P863, DOI 10.1016/j.ajo.2003.12.009; Medeiros FA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1250, DOI 10.1001/archophthalmol.2009.276; Owen VMF, 2008, INVEST OPHTH VIS SCI, V49, P2449, DOI 10.1167/iovs.07-0877; Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1; Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574; Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Owsley C, 2001, OPTOMETRY VISION SCI, V78, P350, DOI 10.1097/00006324-200105000-00019; Owsley C, 2010, VISION RES, V50, P2348, DOI 10.1016/j.visres.2010.05.021; Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224; Ragland DR, 2005, J GERONTOL A-BIOL, V60, P399, DOI 10.1093/gerona/60.3.399; Ramulu P, 2009, CURR OPIN OPHTHALMOL, V20, P92, DOI 10.1097/ICU.0b013e32832401a9; Ramulu PY, 2009, OPHTHALMOLOGY, V116, P1846, DOI 10.1016/j.ophtha.2009.03.033; Reed MP, 1999, ERGONOMICS, V42, P1015, DOI 10.1080/001401399185117; Reimer B, 2007, J SAFETY RES, V38, P563, DOI 10.1016/j.jsr.2007.07.002; Reimer B, 2006, BEHAV RES METHODS, V38, P314, DOI 10.3758/BF03192783; Reinach SJ, 1997, ALZ DIS ASSOC DIS, V11, P21, DOI 10.1097/00002093-199706001-00006; Richman J, 2010, OPHTHAL EPIDEMIOL, V17, P144, DOI 10.3109/09286581003734878; Rizzo M, 2001, ALZ DIS ASSOC DIS, V15, P10, DOI 10.1097/00002093-200101000-00002; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; Rizzo M, 2004, ARCH OPHTHALMOL-CHIC, V122, P641, DOI 10.1001/archopht.122.4.641; Rubin GS, 2007, INVEST OPHTH VIS SCI, V48, P1483, DOI 10.1167/iovs.06-0474; SAMPLE PA, 1990, INVEST OPHTH VIS SCI, V31, P1869; Sample PA, 2000, INVEST OPHTH VIS SCI, V41, P1783; Schappert S. M., 1995, ADV DATA, V262, p[1, 1991]; Shechtman O, 2009, TRAFFIC INJ PREV, V10, P379, DOI 10.1080/15389580902894989; SILVERMAN SE, 1990, INVEST OPHTH VIS SCI, V31, P722; Strayer DL, 2006, HUM FACTORS, V48, P381, DOI 10.1518/001872006777724471; Szlyk JP, 2005, J GLAUCOMA, V14, P145, DOI 10.1097/01.ijg.0000151686.89162.28; Szlyk JP, 2002, J REHABIL RES DEV, V39, P467; Thibos LN, 1998, OPTOMETRY VISION SCI, V75, P399, DOI 10.1097/00006324-199806000-00024; Uc EY, 2009, NEUROLOGY, V73, P1103, DOI 10.1212/WNL.0b013e3181bacf6e; Warrian KJ, 2010, SURV OPHTHALMOL, V55, P146, DOI 10.1016/j.survophthal.2009.06.006; Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0; Yan X, 2008, ACCIDENT ANAL PREV, V40, P274, DOI 10.1016/j.aap.2007.06.007; Yucel YH, 2003, PROG RETIN EYE RES, V22, P465, DOI 10.1016/S1350-9462(03)00026-0; Yucel Y, 2008, PROG BRAIN RES, V173, P465, DOI 10.1016/S0079-6123(08)01132-1	98	29	29	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1057-0829	1536-481X		J GLAUCOMA	J. Glaucoma	APR-MAY	2012	21	4					221	227		10.1097/IJG.0b013e3182071832			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Ophthalmology	920DK	WOS:000302382100003	21467952	Green Accepted			2022-02-06	
J	Hart, T; Vaccaro, MJ; Hays, C; Maiuro, RD				Hart, Tessa; Vaccaro, Monica J.; Hays, Christina; Maiuro, Roland D.			Anger Self-Management Training for People With Traumatic Brain Injury: A Preliminary Investigation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anger management; emotional regulation; traumatic brain injury	CAREGIVER BURDEN; AGGRESSION; DEFICITS; PROGRAM; PSYCHOTHERAPY; IRRITABILITY; GUIDELINES; SYMPTOMS; THERAPY; PATIENT	Objective: To examine the feasibility and gather preliminary data on the efficacy of a fully manualized, 8-session, psychoeducational treatment for irritability and anger after traumatic brain injury (TBI), called anger self-management training (ASMT). Participants: A total of 10 persons with moderate to severe, chronic TBI with significant cognitive impairment and elevated levels of anger and irritability participated in the study; 8 had significant others (SOs) who participated in portions of the treatment and provided pre- and posttreatment measures; 1 SO provided only data. Main Outcome Measure: Two subscales of the State-Trait Anger Expression Scale-Revised and Brief Anger-Aggression Questionnaire. Design: Pre- to posttreatment pilot study. Results: There was significant improvement on all 3 measures of self-reported anger, with large effect sizes (>1.0), and on 1 of 3 SO-reported scales. Qualitative feedback from participants was positive and dropout rate was low (1 of 11). Conclusions: The treatment model represented by the ASMT appears worthy of further study in persons with TBI who have both problematic anger and cognitive impairment.	[Hart, Tessa; Vaccaro, Monica J.; Hays, Christina; Maiuro, Roland D.] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA		Hart, T (corresponding author), Moss Rehabil Res Inst, Med Arts Bldg,50 Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu			Moss Rehabilitation Research Institute; TBI Clinical Trials Network, National Institutes of Health [UO1 HD042738]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042738] Funding Source: NIH RePORTER	This research was supported by a seed grant from the Moss Rehabilitation Research Institute and by the TBI Clinical Trials Network, National Institutes of Health grant UO1 HD042738. Jo Ann Brockway, PhD, contributed to the development of the treatment manual described in this project. Christianne Hopwood, PsyD, served as a research therapist and Megan Bartlett, MA, assisted with manuscript preparation. We thank the clinicians at the Drucker Brain Injury Center, Moss Rehabilitation Hospital for referring participants. We also owe a debt of gratitude to the people with TBI and their friends and family members who participated in this study.	Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Beck R, 1998, COGNITIVE THER RES, V22, P63, DOI 10.1023/A:1018763902991; Blanco J. M., 2001, ANSIEDAD ESTRES, V7, P247; Burgess PW, 1996, BRIXTON SPATIAL ANTI; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Deffenbacher JL, 2002, COUNS PSYCHOL, V30, P262, DOI 10.1177/0011000002302004; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Eames P., 1990, NEUROBEHAVIORAL SEQU, P410; Eames PG, 2001, BRAIN DAM B, P29; Fassino S, 2002, EUR NEUROPSYCHOPHARM, V12, P453, DOI 10.1016/S0924-977X(02)00058-5; Greve KW, 2001, BRAIN INJURY, V15, P255; Gualtieri T, 1990, J HEAD TRAUMA REHAB, V5, P32; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hart T, 2010, J VOCAT REHABIL, V32, P135, DOI 10.3233/JVR-2010-0505; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Levy M, 2005, NEUROREHABILITATION, V20, P279; LIRA FT, 1983, INT J CLIN NEUROPSYC, V5, P159; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Novaco RW., 1975, ANGER CONTROL DEV EV; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Schnurr PR, 2007, J TRAUMA STRESS, V20, P779, DOI 10.1002/jts.20292; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silver J, 2007, BRAIN INJURY MED PRI, P963; Spielberger C. D., 1999, STATE TRAIT ANGER EX; Stevenson CS, 2002, AUST NZ J PSYCHIAT, V36, P610, DOI 10.1046/j.1440-1614.2002.01052.x; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Vaccaro M, 2007, DISABIL REHABIL-ASSI, V2, P85, DOI 10.1080/17483100601167586; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wechsler D., 2011, WECHSLER ABBREVIATED; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J., 2004, REHABILITATION MED P, P1677; Whyte J, 2009, ARCH PHYS MED REHAB, V90, pS3, DOI 10.1016/j.apmr.2009.07.008; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; [No title captured], DOI DOI 10.1177/088626087002002003	49	29	29	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2012	27	2					113	122		10.1097/HTR.0b013e31820e686c			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	912LI	WOS:000301799100004	21407088				2022-02-06	
J	Kaloostian, P; Robertson, C; Gopinath, SP; Stippler, M; King, CC; Qualls, C; Yonas, H; Nemoto, EM				Kaloostian, Paul; Robertson, Claudia; Gopinath, Shankar P.; Stippler, Martina; King, C. Christopher; Qualls, Clifford; Yonas, Howard; Nemoto, Edwin M.			Outcome Prediction within Twelve Hours after Severe Traumatic Brain Injury by Quantitative Cerebral Blood Flow	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; Glasgow Outcome Scale; outcome prediction; quantitative stable xenon CT; traumatic brain injury	GLASGOW COMA SCALE; PROGNOSTIC ANALYSIS; CLINICAL-TRIALS; HEAD-INJURY; ISCHEMIA; NEUROPROTECTION; HYPEROXIA; IMPACT; TISSUE; EPIDEMIOLOGY	We measured quantitative cortical mantle cerebral blood flow (CBF) by stable xenon computed tomography (CT) within the first 12 h after severe traumatic brain injury (TBI) to determine whether neurologic outcome can be predicted by CBF stratification early after injury. Stable xenon CT was used for quantitative measurement of CBF (mL/100g/min) in 22 cortical mantle regions stratified as follows: low (0-8), intermediate (9-30), normal (31-70), and hyperemic (>70) in 120 patients suffering severe (Glasgow Coma Scale [GCS] score <= 8) TBI. For each of these CBF strata, percentages of total cortical mantle volume were calculated. Outcomes were assessed by Glasgow Outcome Scale (GOS) score at discharge (DC), and 1, 3, and 6 months after discharge. Quantitative cortical mantle CBF differentiated GOS 1 and GOS 2 (dead or vegetative state) from GOS 3-5 (severely disabled to good recovery; p < 0.001). Receiver operating characteristic (ROC) curve analysis for percent total normal plus hyperemic flow volume (TNHV) predicting GOS 3-5 outcome at 6 months for CBF measured < 6 and < 12 h after injury showed ROC area under the curve (AUC) cut-scores of 0.92 and 0.77, respectively. In multivariate analysis, percent TNHV is an independent predictor of GOS 3-5, with an odds ratio of 1.460 per 10 percentage point increase, as is initial GCS score (OR = 1.090). The binary version of the Marshall CT score was an independent predictor of 6-month outcome, whereas age was not. These results suggest that quantitative cerebral cortical CBF measured within the first 6 and 12 h after TBI predicts 6-month outcome, which may be useful in guiding patient care and identifying patients for randomized clinical trials. A larger multicenter randomized clinical trial is indicated.	[Kaloostian, Paul; Stippler, Martina; Yonas, Howard; Nemoto, Edwin M.] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; [Robertson, Claudia; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [King, C. Christopher] AMC Emergency Med Grp, Dept Emergency Med, Albany, NY USA		Nemoto, EM (corresponding author), Univ New Mexico, Dept Neurosurg, 1 Univ New Mexico, Albuquerque, NM 87131 USA.	enemoto@salud.unm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061216, NS051639, P01-NS38660]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS061216, R01NS051639, P01NS038660] Funding Source: NIH RePORTER	We wish to acknowledge the xenon CT technicians at Baylor College of Medicine as well as the nursing staff for their dedication to this project. This work was supported in part by National Institutes of Health grants no. NS061216, NS051639, and P01-NS38660.	ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; Bandera E, 2006, STROKE, V37, P1334, DOI 10.1161/01.STR.0000217418.29609.22; Baron JC, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000049119; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Hattori N, 2003, J NUCL MED, V44, P1709; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; JENNETT B, 1976, LANCET, V1, P1031; Jovin TG, 2003, STROKE, V34, P2426, DOI 10.1161/01.STR.0000091232.81947.C9; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Marchal G, 1996, STROKE, V27, P599, DOI 10.1161/01.STR.27.4.599; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mazzeo AT, 2006, J NEUROSURG ANESTH, V18, P170, DOI 10.1097/01.ana.0000210999.18033.f6; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Menon DK, 2006, CURR OPIN CRIT CARE, V12, P85, DOI 10.1097/01.ccx.0000216572.19062.8f; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Symon L., 1997, J CLIN PATHOL S, V11, P149; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; YONAS H, 1991, J CEREBR BLOOD F MET, V11, P716, DOI 10.1038/jcbfm.1991.128; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	53	29	31	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					727	734		10.1089/neu.2011.2147			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900003	22111910	Green Published			2022-02-06	
J	Shah, S; Yallampalli, R; Merkley, TL; McCauley, SR; Bigler, ED; MacLeod, M; Chu, ZL; Li, XQ; Troyanskaya, M; Hunter, JV; Levin, HS; Wilde, EA				Shah, Sanjeev; Yallampalli, Ragini; Merkley, Tricia L.; McCauley, Stephen R.; Bigler, Erin D.; MacLeod, Marianne; Chu, Zili; Li, Xiaoqi; Troyanskaya, Maya; Hunter, Jill V.; Levin, Harvey S.; Wilde, Elisabeth A.			Diffusion tensor imaging and volumetric analysis of the ventral striatum in adults with traumatic brain injury	BRAIN INJURY			English	Article						Neuroimaging; MRI; DTI; TBI; executive functioning	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; NUCLEUS-ACCUMBENS; DECISION-MAKING; PREFRONTAL CORTEX; AXONAL INJURY; HEAD-INJURY; MODERATE; SCALE; IMPULSIVITY; MORPHOMETRY	Objectives: The aim was to determine if there are changes in the integrity and volume of the ventral striatum following severe traumatic brain injury (TBI) and if these changes relate to executive functioning. Methods: This study recruited 14 participants with severe TBI (mean age: 22 years) and 15 demographically-matched controls. All participants underwent magnetic resonance imaging with diffusion tensor imaging (DTI) and volumetric analysis at 6 months post-injury. Participants with TBI underwent neuropsychological testing and the relation between imaging data and cognitive performance was examined. Results: Differences in DTI parameters (fractional anisotropy (FA) and apparent diffusion coefficient (ADC)) were found between participants with TBI and controls. Correlations between right and left ventral striatum ADC and the executive functioning factor of the Neurobehavioural Rating Scale-Revised (NRS-R) were found. Correlations between right ventral striatum FA and the Controlled Oral Word Association Test, Trails Making Test Part B (TMT-B) time and NRS-R executive functioning factor were also found. Volumetric analysis showed a difference only in left nucleus accumbens between TBI and control groups. Conclusions: The integrity of the ventral striatum is affected following severe TBI. Decreases in executive functioning are related to damage to the ventral striatum and its associated structures.	[Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Shah, Sanjeev] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Shah, Sanjeev; Yallampalli, Ragini; Merkley, Tricia L.; McCauley, Stephen R.; MacLeod, Marianne; Li, Xiaoqi; Troyanskaya, Maya; Levin, Harvey S.; Wilde, Elisabeth A.] Univ Texas Houston Med Sch, Houston, TX USA; [Yallampalli, Ragini; McCauley, Stephen R.; Troyanskaya, Maya; Levin, Harvey S.; Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Merkley, Tricia L.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [McCauley, Stephen R.; Levin, Harvey S.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Chu, Zili; Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA		Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia L./AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	Dana Foundation	The authors report no conflicts of interest. Funding for this project was provided by a grant from the Dana Foundation (PI: Wilde).	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Basar K, 2010, PROG NEUROBIOL, V92, P533, DOI 10.1016/j.pneurobio.2010.08.007; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bolla KI, 2004, CEREB CORTEX, V14, P1226, DOI 10.1093/cercor/bhh083; Buchel C, 2011, NEUROIMAGE, V57, P1124, DOI 10.1016/j.neuroimage.2011.05.031; Cardinal RN, 2001, SCIENCE, V292, P2499, DOI 10.1126/science.1060818; Carmona S, 2009, BIOL PSYCHIAT, V66, P972, DOI 10.1016/j.biopsych.2009.05.013; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Cohen J, 1988, POWER ANAL BEHAV SCI; Faul M, 2010, TRAUMATIC BRAIN INJU; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002; Goldenberg G, 1999, J NEUROL NEUROSUR PS, V67, P163, DOI 10.1136/jnnp.67.2.163; Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003; Haber SN, 1999, ANN NY ACAD SCI, V877, P33, DOI 10.1111/j.1749-6632.1999.tb09259.x; Heimer L, 2006, NEUROSCI BIOBEHAV R, V30, P126, DOI 10.1016/j.neubiorev.2005.06.006; Heimer L, 1975, PERSPECTIVES NEUROBI, P177; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; MacDonald P.A., 2011, PARKINSONS DIS-US, V2011, DOI DOI 10.4061/2011/572743; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Martinaud O, 2009, EUR J NEUROL, V16, P595, DOI 10.1111/j.1468-1331.2009.02546.x; Martinez D, 2005, BIOL PSYCHIAT, V58, P779, DOI 10.1016/j.biopsych.2005.04.044; Matthews SC, 2004, NEUROREPORT, V15, P2123, DOI 10.1097/00001756-200409150-00025; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Salat DH, 2009, NEUROIMAGE, V48, P21, DOI 10.1016/j.neuroimage.2009.06.074; Scheres A, 2007, BIOL PSYCHIAT, V61, P720, DOI 10.1016/j.biopsych.2006.04.042; Slawik H, 2009, J NEUROTRAUM, V26, P1891, DOI 10.1089/neu.2009.0942; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; Volkow ND, 2007, J NEUROSCI, V27, P12700, DOI 10.1523/JNEUROSCI.3371-07.2007; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333	42	29	29	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2012	26	3					201	210		10.3109/02699052.2012.654591			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	899XD	WOS:000300849100001	22372408				2022-02-06	
J	Cui, X; Chopp, M; Shehadah, A; Zacharek, A; Kuzmin-Nichols, N; Sanberg, CD; Dai, JH; Zhang, CL; Ueno, Y; Roberts, C; Chen, JL				Cui, Xu; Chopp, Michael; Shehadah, Amjad; Zacharek, Alex; Kuzmin-Nichols, Nicole; Sanberg, Cyndy Davis; Dai, Junhao; Zhang, Chunling; Ueno, Yuji; Roberts, Cynthia; Chen, Jieli			Therapeutic Benefit of Treatment of Stroke With Simvastatin and Human Umbilical Cord Blood Cells: Neurogenesis, Synaptic Plasticity, and Axon Growth	CELL TRANSPLANTATION			English	Article						Simvastatin; Human umbilical cord blood cells (HUCBCs); Neurogenesis; Synaptic plasticity; Stroke	TRAUMATIC BRAIN-INJURY; ISCHEMIA-INDUCED NEUROGENESIS; STEM-CELLS; VASCULAR STABILIZATION; BEHAVIORAL DEFICITS; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; INFARCT VOLUME; UP-REGULATION; RAT MODEL	The therapeutic efficacy of cell-based therapy after stroke can be enhanced by making the host brain tissue more receptive to the administered cells, which thereby facilitates brain plasticity. We hypothesized that simvastatin increases human umbilical cord blood cell (HUCBC) migration into the ischemic brain and promotes brain plasticity and neurological functional outcome after stroke. Rats were subjected to 2-h middle cerebral artery occlusion (MCAo) and administered subtherapeutic doses of simvastatin (0.5 mg/kg, gavaged daily for 7 days), HUCBCs (1 x 10(6), one time injection via tail vein), or combination simvastatin with HUCBCs starting at 24 h after stroke. Combination treatment of stroke showed an interactive effect in improvement of neurological outcome compared with simvastatin or HUCBC monotherapy groups. In addition, combination treatment significantly increased brain-derived neurotrophic factor/TrkB expression and the number of engrafted HUCBCs in the ischemic brain compared with HUCBC monotherapy. The number of engrafted HUCBCs was significantly correlated with functional outcome (modified neurological severity score). Combination treatment significantly increased neurogenesis and synaptic plasticity in the ischemic brain, and promoted neuroblast migration in cultured subventricular zone explants. Using primary cultured neurons (PCNs), we found that combination treatment enhanced neurite outgrowth compared with nontreatment control, simvastatin or HUCBC supernatant monotherapy. Inhibition of TrkB significantly attenuated combination treatment-induced neurite outgrowth. Our data indicate that combination simvastatin and HUCBC treatment of stroke increases BDNF/TrkB expression, enhances HUCBC migration into the ischemic brain, amplifies endogenous neurogenesis, synaptic plasticity and axonal growth, and thereby improves functional outcome after stroke.	[Cui, Xu; Chopp, Michael; Shehadah, Amjad; Zacharek, Alex; Dai, Junhao; Zhang, Chunling; Ueno, Yuji; Roberts, Cynthia; Chen, Jieli] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Kuzmin-Nichols, Nicole; Sanberg, Cyndy Davis] Saneron CCEL Therapeut Inc, Tampa, FL USA		Chen, JL (corresponding author), Henry Ford Hosp, Dept Neurol, E&R Bldg,Room 3091,2799 W Grand Blvd, Detroit, MI 48202 USA.	jieli@neuro.hfh.edu	Ueno, Yuji/ABB-2492-2020	Cui, Xu/0000-0002-6937-6191; Shehadah, Amjad/0000-0001-8679-3774	National Institute of Neurological Disorder and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R41NS064708]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RO1 AG031811]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [PO1 NS23393]; American Heart Association grantAmerican Heart Association [09GRNT2300151]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393, R41NS064708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031811] Funding Source: NIH RePORTER	The authors thank Qinge Lu and Supata Santra for technical assistance. This work was supported by National Institute of Neurological Disorder and Stroke (NINDS) 1R41NS064708 (J.C.), National Institute on Aging RO1 AG031811 (J.C.), NINDS PO1 NS23393 (M.C.), and American Heart Association grant 09GRNT2300151 (J.C.). J. Chen is a consultant for Saneron CCEL Therapeutics, Inc.	Arboix A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-47; Buga AM, 2009, ROM J MORPHOL EMBRYO, V50, P559; Chen JL, 2009, J CELL MOL MED, V13, P1348, DOI 10.1111/j.1582-4934.2008.00380.x; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Cui X, 2010, STROKE, V41, P2044, DOI 10.1161/STROKEAHA.110.589333; Cui X, 2009, NEUROBIOL DIS, V36, P35, DOI 10.1016/j.nbd.2009.06.012; Daadi MM, 2001, BRAIN RES BULL, V56, P147, DOI 10.1016/S0361-9230(01)00621-9; Gordon Tessa, 2009, Neurosurg Focus, V26, pE3, DOI 10.3171/FOC.2009.26.2.E3; Gorski JA, 2003, J NEUROSCI, V23, P6856; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gustafsson E, 2003, STROKE, V34, P2710, DOI 10.1161/01.STR.0000096025.35225.36; Halterman MW, 2009, J NEUROSCI METH, V177, P348, DOI 10.1016/j.jneumeth.2008.10.023; Huang GP, 2007, CELL TRANSPLANT, V16, P579, DOI 10.3727/000000007783465073; Iwai M, 2010, STROKE, V41, P1032, DOI 10.1161/STROKEAHA.109.570325; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Kadam SD, 2008, BRAIN RES, V1208, P35, DOI 10.1016/j.brainres.2008.02.037; Karnezis T, 2004, NAT NEUROSCI, V7, P736, DOI 10.1038/nn1261; Knowles DW, 2006, P NATL ACAD SCI USA, V103, P4445, DOI 10.1073/PNAS.0509944102; Koestenbauer S, 2009, CELL TRANSPLANT, V18, P1059, DOI 10.3727/096368909X471288; Kozlowska H, 2007, STEM CELLS DEV, V16, P481, DOI 10.1089/scd.2007.9993; Liu YP, 2009, ACTA NEUROPATHOL, V117, P469, DOI 10.1007/s00401-009-0516-1; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Markus A, 2002, NEURON, V35, P65, DOI 10.1016/S0896-6273(02)00752-3; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Meng QX, 2010, NEUROSCI LETT, V480, P25, DOI 10.1016/j.neulet.2010.05.067; Neuhoff S, 2007, EXP HEMATOL, V35, P1119, DOI 10.1016/j.exphem.2007.03.019; Park DH, 2009, CELL TRANSPLANT, V18, P985, DOI 10.3727/096368909X471279; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reimann, 2009, DTSCH ARZTEBL INT, V106, P831, DOI 10.3238/arztebl.2009.0831; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tang YM, 2007, CELL TRANSPLANT, V16, P159; Ujike H, 2002, ANN NY ACAD SCI, V965, P55; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Wagner JE, 2010, SEMIN HEMATOL, V47, P3, DOI 10.1053/j.seminhematol.2009.10.011; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yamauchi A, 2005, CELL MOL NEUROBIOL, V25, P923, DOI 10.1007/s10571-005-4956-5; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zacharek A, 2009, STROKE, V40, P254, DOI 10.1161/STROKEAHA.108.524116; Zhang RL, 2011, J CEREBR BLOOD F MET, V31, P614, DOI 10.1038/jcbfm.2010.134; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	44	29	32	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2012	21	5					845	856		10.3727/096368911X627417			12	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	974SB	WOS:000306455600005	22405262	Green Accepted			2022-02-06	
J	Lundberg, J; Sodersten, E; Sundstrom, E; Le Blanc, K; Andersson, T; Hermanson, O; Holmin, S				Lundberg, Johan; Sodersten, Erik; Sundstrom, Erik; Le Blanc, Katarina; Andersson, Tommy; Hermanson, Ola; Holmin, Staffan			Targeted Intra-arterial Transplantation of Stem Cells to the Injured CNS Is More Effective Than Intravenous Administration: Engraftment Is Dependent on Cell Type and Adhesion Molecule Expression	CELL TRANSPLANTATION			English	Article						Endovascular; Transplantation; Human mesenchymal stem cells (hMSCs); Rat neural progenitor cells (rNPCs); Human neural progenitor cells (hNPCs); Vascular cell adhesion molecule-1 (VCAM-1)	TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM; IN-VITRO; STROKE; RAT; THERAPY; MODEL; NEUROPROTECTION; INJECTION; MIGRATION	Stem cell transplantation procedures using intraparenchymal injections cause tissue injury in addition to associated surgical risks. Intravenous cell administration give engraftment in parenchymal lesions although the method has low efficacy and specificity. In pathological conditions with inflammation, such as traumatic brain injury, there is a transient up-regulation of ICAM-I and VCAM-1 which might provide environmental cues for migration of stem cells from blood to parenchyma. The aim of this study was to i) analyze the effect of intra-arterial administration on cellular engraftment, ii) compare engraftment and side effects between three different stem cell systems, and iii) analyze gene expression in these three systems. We performed specific intra-arterial transplantations with human mesenchymal stem cells (hMSCs), human neural progenitor cells (hNPCs), and rat neural progenitor cells (rNPCs) in a rat model of traumatic brain injury. These results were compared to the intravenous route for each cell type, respectively. Analysis of engraftment and recipient characterization was performed by immunohistochemistry. We further characterized the different types of cells by microarray and RT-qPCR analysis. Specific intra-arterial transplantations produced significantly higher engraftment compared to intravenous transplantation with hMSCs and rNPCs. No engraftment was detected after intra-arterial or intravenous administration of hNPCs. Characterization of integrin expression indicated that CD49dVCAM-1 and possibly ICAM-1 interactions through CD18 and CD11a, respectively, are important for engraftment after intravascular cell administration. No side effects, such as thromboembolic complications, were detected. When translating stem cell therapies to clinical practice, the route of transplantation and the properties of the cell lines (homing, diapedesis, and migration) become important. This study supports the use of selective intra-arterial transplantation for improving engraftment after traumatic brain injury. In addition, we conclude that careful analysis of cells intended for local, intra-arterial transplantation with respect to integrin expression is important.	[Lundberg, Johan; Andersson, Tommy; Holmin, Staffan] Karolinska Univ Hosp, Dept Neuroradiol, S-17176 Stockholm, Sweden; [Lundberg, Johan; Andersson, Tommy; Holmin, Staffan] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Sodersten, Erik; Hermanson, Ola] Karolinska Inst, Dept Neurosci, DBRM, Stockholm, Sweden; [Sundstrom, Erik] Karolinska Inst, Div Neurodegenerat, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [Sundstrom, Erik] Stiftelsen Stockholms Sjukhem, Stockholm, Sweden; [Le Blanc, Katarina] Karolinska Inst, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden; [Le Blanc, Katarina] Karolinska Univ Hosp, Hematol Ctr, S-17176 Stockholm, Sweden		Holmin, S (corresponding author), Karolinska Univ Hosp, Dept Neuroradiol, S-17176 Stockholm, Sweden.	staffan.holmin@karolinska.se	Le Blanc, Katarina/L-4631-2019; , Ola/AAF-5126-2021	Hermanson, Ola/0000-0001-9320-7921; Holmin, Staffan/0000-0002-1628-1615; Sodersten, Erik/0000-0002-2998-4889	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Karolinska InstitutetKarolinska Institutet; Swedish Society of Medicine and Strokefonden	The authors wish to thank BEA, Karolinska for excellent technical assistance with the microarray analysis. This study was supported by grants from the Swedish Research Council, Karolinska Institutet funds, the Swedish Society of Medicine and Strokefonden. The authors declare no conflict of interest.	Akesson E, 2007, PHYSIOL BEHAV, V92, P60, DOI 10.1016/j.physbeh.2007.05.056; Amar AP, 2003, NEUROSURGERY, V52, P402, DOI 10.1227/01.NEU.0000043698.86548.A0; Andersson T, 2009, J BIOL CHEM, V284, P3672, DOI 10.1074/jbc.M808119200; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Ben-Haim S, 2009, NEUROSURGERY, V64, P754, DOI 10.1227/01.NEU.0000339173.77240.34; Bliss TM, 2010, NEUROBIOL DIS, V37, P275, DOI 10.1016/j.nbd.2009.10.003; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Field P, 2001, J NEUROSURG, V94, P545, DOI 10.3171/jns.2001.94.4.0545; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gordon PH, 2004, ARCH NEUROL-CHICAGO, V61, P858, DOI 10.1001/archneur.61.6.858; Grinnemo KH, 2006, ANN MED, V38, P144, DOI 10.1080/07853890500422982; Guzman R, 2008, STROKE, V39, P1300, DOI 10.1161/STROKEAHA.107.500470; Heng BC, 2009, CELL TRANSPLANT, V18, P1111, DOI 10.3727/096368909X12483162197006; Jackson JS, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt17; Jin KL, 2005, NEUROBIOL DIS, V18, P366, DOI 10.1016/j.nbd.2004.10.010; Kamiya N, 2008, LIFE SCI, V83, P433, DOI 10.1016/j.lfs.2008.07.018; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Lundberg J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010449; Lundberg J, 2009, NEURORADIOLOGY, V51, P661, DOI 10.1007/s00234-009-0551-6; Piao JH, 2006, J NEUROSCI RES, V84, P471, DOI 10.1002/jnr.20955; RYCHLIK W, 1990, NUCLEIC ACIDS RES, V18, P6409, DOI 10.1093/nar/18.21.6409; Savitz SI, 2005, CEREBROVASC DIS, V20, P101, DOI 10.1159/000086518; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Stuve O, 2008, J NEUROL, V255, P58, DOI 10.1007/s00415-008-6011-0; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Yu SJ, 2009, CELL TRANSPLANT, V18, P111, DOI 10.3727/096368909788341243	31	29	34	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2012	21	1					333	343		10.3727/096368911X576036			11	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	932KS	WOS:000303290600024	21669035				2022-02-06	
J	Petrov, IY; Petrov, Y; Prough, DS; Deyo, DJ; Cicenaite, I; Esenaliev, RO				Petrov, I. Y.; Petrov, Y.; Prough, D. S.; Deyo, D. J.; Cicenaite, I.; Esenaliev, R. O.			Optoacoustic monitoring of cerebral venous blood oxygenation through extracerebral blood	BIOMEDICAL OPTICS EXPRESS			English	Article							HEMOGLOBIN CONCENTRATION; OPTICAL-PROPERTIES; IN-VIVO; REAL-TIME; BRAIN; SPECTROSCOPY; INCREASE; HYPOXIA	There is strong clinical evidence that controlling cerebral venous oxygenation (oxyhemoglobin saturation) is critically important for patients with severe traumatic brain injury as well as for patients undergoing cardiac surgery. However, the only available method for cerebral venous blood oxygenation monitoring is invasive and requires catheterization of the internal jugular vein. We designed and built a novel optoacoustic monitor of cerebral venous oxygenation as measured in the superior sagittal sinus (SSS), the large midline cerebral vein. To the best of our knowledge, optical monitoring of cerebral venous blood oxygenation through overlying extracerebral blood is reported for the first time in this paper. The system was capable of detecting SSS signals in vivo at 700, 800, and 1064 nm through the thick (5-6 mm) sheep skull containing the circulating blood. The high (submillimeter) in-depth resolution of the system provided identification of the SSS peaks in the optoacoustic signals. The SSS peak amplitude closely followed the actual SSS blood oxygenation measured invasively using catheterization, blood sampling, and "gold standard" CO-Oximetry. Our data indicate the system may provide accurate measurement of the SSS blood oxygenation in patients with extracerebral blood over the SSS. (C) 2011 Optical Society of America	[Petrov, I. Y.; Petrov, Y.; Cicenaite, I.; Esenaliev, R. O.] Univ Texas Galveston, Med Branch, Ctr Biomed Engn, Lab Opt Sensing & Monitoring, Galveston, TX 77555 USA; [Prough, D. S.; Deyo, D. J.; Esenaliev, R. O.] Univ Texas Galveston, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Esenaliev, R. O.] Univ Texas Galveston, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA		Petrov, IY (corresponding author), Univ Texas Galveston, Med Branch, Ctr Biomed Engn, Lab Opt Sensing & Monitoring, 301 Univ Blvd, Galveston, TX 77555 USA.	riesenal@utmb.edu	Esenaliev, Rinat/Y-4361-2019; Prough, Donald S/G-5793-2013	Esenaliev, Rinat/0000-0002-2848-5906; Prough, Donald S/0000-0001-7994-532X	National Institutes of Health from the National Institute of Biomedical Imaging and Bioengineering [R01 EB00763, U54EB007954]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS044345]; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R41HL10309501]; Moody Center for Brain and Spinal Cord Injury Research/Mission Connect of UTMB; Texas Emerging Technology Fund; UTMB	This work is supported in part by the National Institutes of Health (Grants R01 EB00763 and U54EB007954 from the National Institute of Biomedical Imaging and Bioengineering, Grant R01 NS044345 from the National Institute of Neurological Disorders and Stroke, Grant R41HL10309501 from the National Heart, Lung and Blood Institute), the Moody Center for Brain and Spinal Cord Injury Research/Mission Connect of UTMB, Texas Emerging Technology Fund, and UTMB Seed Grant Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIBIB or NIH. Drs. Prough and Esenaliev are co-owners of Noninvasix, Inc., a UTMB-based startup that has licensed the rights to optoacoustic monitoring technology.	Andreev VG, 2009, PROC SPIE, V7177, DOI 10.1117/12.816043; Brecht HP, 2007, OPT EXPRESS, V15, P16261, DOI 10.1364/OE.15.016261; CHEONG WF, 1990, IEEE J QUANTUM ELECT, V26, P2166, DOI 10.1109/3.64354; Choi J, 2004, J BIOMED OPT, V9, P221, DOI 10.1117/1.1628242; Enderle J., 2000, INTRO BIOMEDICAL ENG; Esenaliev RO, 2000, OSA TRENDS OPT PHOTO, V38, P272; Esenaliev RO, 2002, APPL OPTICS, V41, P4722, DOI 10.1364/AO.41.004722; FRY FJ, 1978, J ACOUST SOC AM, V63, P1576, DOI 10.1121/1.381852; HALE GM, 1973, APPL OPTICS, V12, P555, DOI 10.1364/AO.12.000555; Horecker BL, 1943, J BIOL CHEM, V148, P173; Jacques S, OPTICAL ABSORPTION M; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Jose J, 2011, OPT EXPRESS, V19, P2093, DOI 10.1364/OE.19.002093; Kuwahira I, 1999, J APPL PHYSIOL, V86, P181, DOI 10.1152/jappl.1999.86.1.181; Laser Institute of America, 2000, AM NAT STAND SAF US; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; Murkin John M, 2004, Semin Cardiothorac Vasc Anesth, V8, P13, DOI 10.1177/108925320400800104; Oka T, 2007, PEDIATR INT, V49, P898, DOI 10.1111/j.1442-200X.2007.02481.x; Passler K, 2011, BIOMED OPT EXPRESS, V2, P2655, DOI 10.1364/BOE.2.002655; Petrov YY, 2006, OPT LETT, V31, P1827, DOI 10.1364/OL.31.001827; Petrov YY, 2004, P ANN INT IEEE EMBS, V26, P2052; Petrov YY, 2005, ANESTHESIOLOGY, V102, P69, DOI 10.1097/00000542-200501000-00014; Petrova IY, 2009, OPT EXPRESS, V17, P7285, DOI 10.1364/OE.17.007285; Prahl S., OPTICAL ABSORPTION H; Richardson MX, 2009, EUR J APPL PHYSIOL, V105, P63, DOI 10.1007/s00421-008-0873-9; Simpson CR, 1998, PHYS MED BIOL, V43, P2465, DOI 10.1088/0031-9155/43/9/003; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Stevens Wendy J, 2004, J Neurosci Nurs, V36, P332; Taroni P, 2007, OPT EXPRESS, V15, P3301, DOI 10.1364/OE.15.003301; Taruttis A, 2010, OPT EXPRESS, V18, P19592, DOI 10.1364/OE.18.019592; TUCHIN V, 2000, TISSUE OPTICS LIGHT; Wang XD, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192804	32	29	29	1	3	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2156-7085			BIOMED OPT EXPRESS	Biomed. Opt. Express	JAN 1	2012	3	1					125	136		10.1364/BOE.3.000125			12	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	886WM	WOS:000299884600011	22254173	Green Published, Green Submitted, gold			2022-02-06	
J	Ruff, RL; Riechers, RG; Wang, XF; Piero, T; Ruff, SS				Ruff, Robert L.; Riechers, Ronald G., II; Wang, Xiao-Feng; Piero, Traci; Ruff, Suzanne S.			For veterans with mild traumatic brain injury, improved posttraumatic stress disorder severity and sleep correlated with symptomatic improvement	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						combat; concussion; headache; mild traumatic brain injury; OIF/OEF; olfaction; pain; prazosin; PTSD; sleep	OPERATIONS ENDURING FREEDOM; MONTREAL COGNITIVE ASSESSMENT; OLFACTORY DYSFUNCTION; PRAZOSIN TREATMENT; NIGHTMARES; IRAQ; DISTURBANCE; POLYTRAUMA; HEADACHES; HEALTH	This was an observational study of a cohort of 63 Operation Iraqi Freedom/Operation Enduring Freedom veterans with mild traumatic brain injury (mTBI) associated with an explosion. They had headaches, residual neurological deficits (NDs) on neurological examination, and posttraumatic stress disorder (PTSD) and were seen on average 2.5 years after their last mTBI. We treated them with sleep hygiene counseling and oral prazosin. We monitored headache severity, daytime sleepiness using the Epworth Sleepiness Scale, cognitive performance using the Montreal Cognitive Assessment test, and the presence of NDs. We quantitatively measured olfaction and assessed PTSD severity using the PTSD Checklist-Military Version. Nine weeks after starting sleep counseling and bedtime prazosin, the veterans' headache severity decreased, cognitive function as assayed with a brief screening tool improved, and daytime sleepiness diminished. Six months after completing treatment, the veterans demonstrated additional improvement in headache severity and daytime sleepiness and their improvements in cognitive function persisted. There were no changes in the prevalence of NDs or olfaction scores. Clinical improvements correlated with reduced PTSD severity and daytime sleepiness. The data suggested that reduced clinical manifestations following mTBI correlated with PTSD severity and improvement in sleep, but not the presence of NDs or olfaction impairment.	[Ruff, Robert L.; Riechers, Ronald G., II] Louis Stokes Cleveland Dept Vet Affairs Med Ctr C, Neurol Serv, Cleveland, OH USA; [Ruff, Robert L.; Riechers, Ronald G., II; Piero, Traci] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Robert L.; Riechers, Ronald G., II; Ruff, Suzanne S.] CVAMC, Polytrauma Syst Care, Cleveland, OH USA; [Wang, Xiao-Feng] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Ruff, Suzanne S.] CVAMC, Psychol Serv, Cleveland, OH USA		Ruff, RL (corresponding author), Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Neurol Serv, 127 W,10701 East Blvd, Cleveland, OH 44106 USA.	robert.ruff1@va.gov			Department of Veterans AffairsUS Department of Veterans Affairs; Office of Research and Development; Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; Functional Electrical Stimulation Center of Excellence. Award	This material is based on work supported by Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service, 2010 Magnuson Award (R. L. Ruff) and Functional Electrical Stimulation Center of Excellence. Award (R. L Ruff, Co-Principal Investigator).	Agresti A., 2019, INTRO CATEGORICAL DA; Agresti A., 1992, STAT SCI, V7, P131, DOI [DOI 10.1214/SS/1177011454, https://doi.org/10.1214/ss/1177011454]; Alhola Paula, 2007, Neuropsychiatr Dis Treat, V3, P553; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belle G, 2004, BIOSTATISTICS METHOD; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boehnlein James K, 2007, J Psychiatr Pract, V13, P72, DOI 10.1097/01.pra.0000265763.79753.c1; Boynton L, 2009, J PSYCHIATR PRACT, V15, P454, DOI 10.1097/01.pra.0000364287.63210.92; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Calohan J, 2010, J TRAUMA STRESS, V23, P645, DOI 10.1002/jts.20570; Carlson K, 2009, ASSESSMENT TREATMENT, P72; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; COGGON D, 2003, STAT CLIN PRACTICE; Costanzo RM, 2006, ADV OTO-RHINO-LARYNG, V63, P99, DOI 10.1159/000093753; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; Department of Veterans Affairs, 2010, NAT CTR PTSD US PTSD; Dierks MR, 2007, ANN PHARMACOTHER, V41, P1013, DOI 10.1345/aph.1H588; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Gurvits TV, 2006, ARCH GEN PSYCHIAT, V63, P571, DOI 10.1001/archpsyc.63.5.571; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Molenberghs G., 2000, LINEAR MIXED MODELS; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pietrzak RH, 2010, J PSYCHOSOM RES, V69, P441, DOI 10.1016/j.jpsychores.2010.07.002; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Roberts RJ, 2008, SCI AM MIND, V19, P51, DOI DOI 10.1038/SCIENTIFICAMERICANMIND1208-50; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sailer U, 2008, NEUROPSYCHOLOGIA, V46, P2836, DOI 10.1016/j.neuropsychologia.2008.05.022; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor FB, 2008, BIOL PSYCHIAT, V63, P629, DOI 10.1016/j.biopsych.2007.07.001; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whalley MG, 2009, BRAIN COGNITION, V69, P98, DOI 10.1016/j.bandc.2008.05.008; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zadikoff C, 2008, MOVEMENT DISORD, V23, P297, DOI 10.1002/mds.21837	57	29	29	0	20	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	9					1305	1320		10.1682/JRRD.2011.12.0251			16	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	149FB	WOS:000319303300003	23408213	Bronze			2022-02-06	
J	Weckbach, S; Perl, M; Heiland, T; Braumuller, S; Stahel, PF; Flierl, MA; Ignatius, A; Gebhard, F; Huber-Lang, M				Weckbach, Sebastian; Perl, Mario; Heiland, Tim; Braumueller, Sonja; Stahel, Philip F.; Flierl, Michael A.; Ignatius, Anita; Gebhard, Florian; Huber-Lang, Markus			A New Experimental Polytrauma Model in Rats: Molecular Characterization of the Early Inflammatory Response	MEDIATORS OF INFLAMMATION			English	Article							INJURY SEVERITY; COMPLEMENT ACTIVATION; TRAUMA; SEPSIS; C5A; CARDIOPULMONARY; INTERLEUKIN-6; APOPTOSIS; FAILURE; BLOOD	Background. The molecular mechanisms of the immune response after polytrauma are highly complex and far from fully understood. In this paper, we characterize a new standardized polytrauma model in rats based on the early molecular inflammatory and apoptotic response. Methods. Male Wistar rats (250 g, 6-10/group) were anesthetized and exposed to chest trauma (ChT), closed head injury (CHI), or Tib/Fib fracture including a soft tissue trauma (Fx + STT) or to the following combination of injuries: (1) ChT; (2) ChT + Fx + STT; (3) ChT + CHI; (4) CHI; (5) polytrauma (PT = ChT + CHI + Fx+ STT). Sham-operated rats served as negative controls. The inflammatory response was quantified at 2 hours and 4 hours after trauma by analysis of "key" inflammatory mediators, including selected cytokines and complement components, in serum and bronchoalveolar (BAL) fluid samples. Results. Polytraumatized (PT) rats showed a significant systemic and intrapulmonary release of cytokines, chemokines, and complement anaphylatoxins, compared to rats with isolated injuries or selected combinations of injuries. Conclusion. This new rat model appears to closely mimic the early immunological response of polytrauma observed in humans and may provide a valid basis for evaluation of the complex pathophysiology and future therapeutic immune modulatory approaches in experimental polytrauma.	[Weckbach, Sebastian; Perl, Mario; Heiland, Tim; Braumueller, Sonja; Gebhard, Florian; Huber-Lang, Markus] Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, D-89075 Ulm, Germany; [Stahel, Philip F.; Flierl, Michael A.] Univ Colorado, Dept Orthopaed Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA; [Ignatius, Anita] Univ Ulm, Ctr Musculoskeletal Res Ulm, Inst Orthopaed Res & Biomech, D-89075 Ulm, Germany		Gebhard, F (corresponding author), Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, D-89075 Ulm, Germany.	florian.gebhard@uniklinik-ulm.de; markus.huber-lang@uniklinik-ulm.de	Heiland, Tim/J-7306-2019; Ignatius, Anita/M-6012-2013; Huber-Lang, Markus/AAJ-2209-2020	Ignatius, Anita/0000-0002-4782-1979; 	German Research Foundation DFGGerman Research Foundation (DFG) [(KFO-200) HU 823/3-1, PE EN 908/2-1]	The authors thank Barbara Acker, Stephanie Denk, Ralf Reuter, and Christoph Hohmann for outstanding technical support. They especially thank Assistant Professor Dr. Lutz Duerselen for his excellent biomechanic assistance. They also want to express our gratitude to Justin Losacco for cross-reading the paper and correcting the language. This study was supported by Grants from the German Research Foundation DFG (KFO-200) HU 823/3-1 and PE EN 908/2-1.	BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Bryan SA, 2002, AM J RESP CRIT CARE, V165, P1602, DOI 10.1164/rccm.200111-059OC; Claes L, 2006, J ORTHOP RES, V24, P1178, DOI 10.1002/jor.20173; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Efstathopoulos N, 2006, CLIN EXP IMMUNOL, V145, P139, DOI 10.1111/j.1365-2249.2006.03112.x; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Flach R, 1999, CYTOKINE, V11, P173, DOI 10.1006/cyto.1998.0412; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fremont RD, 2010, J TRAUMA, V68, P1121, DOI 10.1097/TA.0b013e3181c40728; Ganter MT, 2007, SHOCK, V28, P29, DOI 10.1097/shk.0b013e3180342439; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Gebhard F., 2000, UNTERSUCHUNGEN SYSTE; Guo RF, 2006, J LEUKOCYTE BIOL, V80, P1575, DOI 10.1189/jlb.0106065; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang M, 2005, J IMMUNOL, V174, P1104, DOI 10.4049/jimmunol.174.2.1104; Irwin R J, 1998, J Okla State Med Assoc, V91, P387; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Knoferl MW, 2004, SHOCK, V22, P51, DOI 10.1097/01.shk.0000127684.64611.5c; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Liener UC, 2002, SHOCK, V17, P169, DOI 10.1097/00024382-200203000-00002; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; MCCABE WR, 1973, NEW ENGL J MED, V288, P21, DOI 10.1056/NEJM197301042880105; Mkhoian G G, 2009, Anesteziol Reanimatol, P60; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Perl M, 2006, CRIT CARE MED, V34, P1152, DOI 10.1097/01.CCM.0000207343.53990.A8; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schreiber H, 2006, ADV EXP MED BIOL, V586, P217; Spolarics Z, 2001, CRIT CARE MED, V29, P728, DOI 10.1097/00003246-200104000-00005; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Stiletto RJ, 2001, CRIT CARE MED, V29, P1690, DOI 10.1097/00003246-200109000-00006; Strecker W, 2002, EUR J TRAUMA, V28, P75; Trupka A, 1998, UNFALLCHIRURG, V101, P244, DOI 10.1007/s001130050265	36	29	29	0	2	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2012	2012								890816	10.1155/2012/890816			9	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	923YI	WOS:000302656300001	22481866	gold, Green Submitted, Green Published			2022-02-06	
J	Sackellares, JC; Shiau, DS; Halford, JJ; LaRoche, SM; Kelly, KM				Sackellares, J. Chris; Shiau, Deng-Shan; Halford, Jonathon J.; LaRoche, Suzette M.; Kelly, Kevin M.			Quantitative EEG analysis for automated detection of nonconvulsive seizures in intensive care units	EPILEPSY & BEHAVIOR			English	Article						Intensive care unit; Nonconvulsive seizures; Continuous electroencephalographic monitoring; Seizure detection; Quantitative EEG trending	TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; ELECTROGRAPHIC SEIZURES; ICU	Because of increased awareness of the high prevalence of nonconvulsive seizures in critically ill patients, use of continuous EEG (cEEG) monitoring is rapidly increasing in ICUs. However, cEEG monitoring is labor intensive, and manual review and interpretation of the EEG are impractical in most ICUs. Effective methods to assist in rapid and accurate detection of nonconvulsive seizures would greatly reduce the cost of cEEG monitoring and enhance the quality of patient care. In this study, we report a preliminary investigation of a novel ICU EEG analysis and seizure detection algorithm. Twenty-four prolonged cEEG recordings were included in this study. Seizure detection sensitivity and specificity were assessed for the new algorithm and for the two commercial seizure detection software systems. The new algorithm performed with a mean sensitivity of 90.4% and a mean false detection rate of 0.066/hour. The two commercial detection products performed with low sensitivities (12.9 and 10.1%) and false detection rates of 1.036/hour and 0.013/hour, respectively. These findings suggest that the novel algorithm has potential to be the basis of clinically useful software that can assist ICU staff in timely identification of nonconvulsive seizures. This study also suggests that currently available seizure detection software does not perform sufficiently in detection of nonconvulsive seizures in critically ill patients. This article is part of a Supplemental Special Issue entitled The Future of Automated Seizure Detection and Prediction. (C) 2011 Elsevier Inc. All rights reserved.	[Sackellares, J. Chris; Shiau, Deng-Shan] Optima Neurosci Inc, Alachua, FL 32615 USA; [Halford, Jonathon J.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA; [LaRoche, Suzette M.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Kelly, Kevin M.] Allegheny Gen Hosp, Allegheny Singer Res Inst, Ctr Neurosci Res, Pittsburgh, PA 15212 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurol, Philadelphia, PA 19104 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurobiol, Philadelphia, PA 19104 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Anat, Philadelphia, PA 19104 USA		Sackellares, JC (corresponding author), Optima Neurosci Inc, 13420 Progress Blvd,Suite 200, Alachua, FL 32615 USA.	csackellares@optimaneuro.com		Halford, Jonathan/0000-0003-1681-6744	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43 NS064647, R44 NS064647, R43 NS076045] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43NS076045, R44NS064647, R43NS064647] Funding Source: NIH RePORTER		American Clinical Neurophysiology Society, 1994, J CLIN NEUROPHYSIOL, V11, P114; Bearden Scott, 2008, Am J Electroneurodiagnostic Technol, V48, P11; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Halford Jonathan J, 2010, Am J Electroneurodiagnostic Technol, V50, P133; Hirsch Lawrence J, 2004, Am J Electroneurodiagnostic Technol, V44, P137; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P305; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Kaplan PW, 2006, J CLIN NEUROPHYSIOL, V23, P221, DOI 10.1097/01.wnp.0000220837.99490.66; Kelly KM, 2010, CLIN NEUROPHYSIOL, V121, P1832, DOI 10.1016/j.clinph.2010.04.016; Kull LL, 2005, J CLIN NEUROPHYSIOL, V22, P107, DOI 10.1097/01.WNP.0000158361.24544.2D; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Shiau DS, 2010, CYBERN SYST ANAL+, V46, P922, DOI 10.1007/s10559-010-9273-3; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Young GB, 1996, NEUROLOGY, V47, P83; Zhang J, 2009, EPILEPSIA, V51, P243	31	29	29	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	DEC	2011	22			1			S69	S73		10.1016/j.yebeh.2011.08.028			5	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	862CQ	WOS:000298067800011	22078521	Green Accepted			2022-02-06	
J	Wood, RL; McCabe, M; Dawkins, J				Wood, Rodger Ll.; McCabe, Michael; Dawkins, Jayne			The role of anxiety sensitivity in symptom perception after minor head injury: An exploratory study	BRAIN INJURY			English	Article						Mild traumatic brain injury; somatization; belief systems; cognition; perception; personality trait	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYMPTOMS; COLLABORATING-CENTER; TASK-FORCE; PAIN; STRESS; ALEXITHYMIA; DISORDER; MODERATE	Primary objective: This exploratory study examined the role of anxiety sensitivity (AS) as a factor contributing to outcome following minor head injury (MHI). Recent research has implicated AS in perception of pain intensity after orthopaedic trauma. AS, therefore, has the potential to mediate perception of and reaction to post-concussion symptoms at an early stage of recovery, increasing the risk of a protracted and incomplete recovery. Research design: A case series analysis. Methods and procedures: Sixty-three head trauma patients referred from an accident and emergency unit to an acute minor head injury service were compared to 58 patients who had suffered recent orthopaedic injury. Participants completed the Rivermead Post-Concussion Questionnaire (RPQ), to determine the number and severity of head injury-related symptoms, and the Anxiety Sensitivity Index (ASI), to measure their emotional reaction to symptoms. Main outcomes and results: Significant between-group differences were found for both RPQ and ASI measures. The MHI group reported more serious symptoms. Both groups also recorded significant positive correlations between the RPQ and ASI measures, with a stronger relationship recorded for the MHI group. Conclusions: The results support the impression that anxiety sensitivity may be an important factor mediating perception of symptoms after injury, potentially influencing speed and quality of recovery.	[Wood, Rodger Ll.] Swansea Univ, Sch Human & Hlth Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales; [Wood, Rodger Ll.] Morriston Hosp Swansea, Dept Accid & Emergency, Swansea, W Glam, Wales		Wood, RL (corresponding author), Swansea Univ, Sch Human & Hlth Sci, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk					Asmundson GJG, 2001, EUR J PAIN, V5, P23, DOI 10.1053/eujp.2000.0211; ASMUNDSON GJG, 1995, BEHAV RES THER, V33, P771, DOI 10.1016/0005-7967(95)00012-M; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Jenewein J, 2009, J PSYCHOSOM RES, V66, P119, DOI 10.1016/j.jpsychores.2008.07.011; Keogh E, 2001, EUR J PAIN, V5, P11, DOI 10.1053/eujp.2000.0210; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; MALLER RG, 1992, J ANXIETY DISORD, V6, P241, DOI 10.1016/0887-6185(92)90036-7; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M., 2008, MILD TRAUMATIC BRAIN; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Meares S, 2010, J NEUROL NEUROSUR PS, V79, P300; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mueller J, 2006, COMPR PSYCHIAT, V47, P489, DOI 10.1016/j.comppsych.2006.03.001; Muris P, 2001, BEHAV RES THER, V39, P1357, DOI 10.1016/S0005-7967(01)00018-3; Peterson R. A., 1987, ANXIETY SENSITIVITY; Peterson RA, 1999, LEA SER PER CLIN PSY, P61; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reiss S., 1985, THEORETICAL ISSUES B, P107; Taylor S., 1999, ANXIETY SENSITIVITY; Thompson T, 2008, PAIN, V134, P187, DOI 10.1016/j.pain.2007.04.018; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wood RLL, 2009, BRAIN INJURY, V23, P649, DOI 10.1080/02699050902970786; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518; Wood RL, 2011, INJURY, V42, P1214, DOI 10.1016/j.injury.2010.07.245	33	29	29	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2011	25	13-14					1296	1299		10.3109/02699052.2011.624569			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	847MI	WOS:000296976600004	22077534				2022-02-06	
J	Haddad, S; Aldawood, AS; Alferayan, A; Russell, NA; Tamim, HM; Arabi, YM				Haddad, S.; Aldawood, A. S.; Alferayan, A.; Russell, N. A.; Tamim, H. M.; Arabi, Y. M.			Relationship between intracranial pressure monitoring and outcomes in severe traumatic brain injury patients	ANAESTHESIA AND INTENSIVE CARE			English	Article						trauma; brain injury; intracranial pressure monitoring; outcomes	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; CEREBRAL PERFUSION-PRESSURE; INTENSIVE-CARE-UNIT; DECOMPRESSIVE CRANIECTOMY; HEMORRHAGIC COMPLICATIONS; RISK-FACTORS; MANAGEMENT; EPIDEMIOLOGY; HYPERTENSION	Intracranial pressure (ICP) monitoring is recommended in patients with a severe traumatic brain injury (TBI) and an abnormal computed tomography (CT) scan. However, there is contradicting evidence about whether ICP monitoring improves outcome. The purpose of this study was to examine the relationship between ICP monitoring and outcomes in patients with severe TBI. From February 2001 to December 2008, a total of 477 consecutive adult (>= 18 years) patients with severe TBI were included retrospectively in the study. Patients who underwent ICP monitoring (n=52) were compared with those who did not (n=425). The primary outcome was hospital mortality. Secondary outcomes were ICU mortality, mechanical ventilation duration, the need for tracheostomy, and ICU and hospital length of stay (LOS). After adjustment for multiple potential confounding factors, ICP monitoring was not associated with significant difference in hospital or ICU mortality (odds ratio [OR]=1.71, 95% confidence interval [CI]=0.79 to 3.70, P=0.17; OR=1.01, 95% CI=0.41 to 2.45, P=0.99, respectively). ICP monitoring was associated with a significant increase in mechanical ventilation duration (coefficient=5.66, 95% CI=3.45 to 7.88, P <0.0001), need for tracheostomy (OR=2.02, 95% CI=1.02 to 4.03, P=0.04), and ICU LOS (coefficient=5.62, 95% CI=3.27 to 7.98, P <0.0001), with no significant difference in hospital LOS (coefficient=8.32, 95% CI=-82.6 to 99.25, P=0.86). Stratified by the Glasgow Coma Scale score, ICP monitoring was associated with a significant increase in hospital mortality in the group of patients with Glasgow Coma Scale 7 to 8 (adjusted OR=12.89, 95% CI=3.14 to 52.95, P=0.0004). In patients with severe TBI, ICP monitoring was not associated with reduced hospital mortality, however, with a significant increase in mechanical ventilation duration, need for tracheostomy, and ICU LOS.	[Haddad, S.] King Fahad Natl Guard Hosp, Dept Intens Care, Surg Intens Care Unit, Riyadh 11426, Saudi Arabia; [Alferayan, A.; Russell, N. A.] King Fahad Natl Guard Hosp, Dept Neurosurg, Riyadh 11426, Saudi Arabia		Haddad, S (corresponding author), King Fahad Natl Guard Hosp, Dept Intens Care, Surg Intens Care Unit, MC 1425,POB 22490, Riyadh 11426, Saudi Arabia.			Arabi, Yaseen/0000-0001-5735-6241			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Arabi Y, 2006, CRIT CARE MED, V34, P605, DOI 10.1097/01.CCM.0000203947.60552.DD; Arabi Y, 2005, AM J INFECT CONTROL, V33, P137, DOI 10.1016/j.ajic.2004.11.008; Arabi YM, 2010, J CRIT CARE, V25, P190, DOI 10.1016/j.jcrc.2009.05.004; AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; Blaha M, 2005, J NEUROL NEUROSUR PS, V76, P147, DOI 10.1136/jnnp.2003.030817; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, GUID MAN SEV TRAUM B; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Cremer OL, 2004, ANESTH ANALG, V99, P1211, DOI 10.1213/01.ANE.0000133917.67728.2A; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Demetriades D, 1998, J AM COLL SURGEONS, V187, P373, DOI 10.1016/S1072-7515(98)00209-9; Dings J, 1996, ZBL NEUROCHIR, V57, P177; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Forsyth RJ, 2010, COCHRANE DB SYST REV, V3; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lane PL, 2000, CAN J SURG, V43, P442; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; Meyer AA, 1998, J TRAUMA, V44, P1, DOI 10.1097/00005373-199801000-00001; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Mortifee PRS, 1996, ARCH PHYS MED REHAB, V77, P436, DOI 10.1016/S0003-9993(96)90030-1; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SAUL TG, 1982, AM SURGEON, V48, P477; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	62	29	32	0	4	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	NOV	2011	39	6					1043	1050		10.1177/0310057X1103900610			8	Anesthesiology; Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; General & Internal Medicine	853LV	WOS:000297428700009	22165356	Bronze			2022-02-06	
J	Cantu, RC; Register-Mihalik, JK				Cantu, Robert C.; Register-Mihalik, Johna K.			Considerations for Return-to-Play and Retirement Decisions After Concussion	PM&R			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL; RECURRENT CONCUSSION; SEX-DIFFERENCES; EPIDEMIOLOGY; ASSOCIATION; INJURY; SPORTS; IMPACT; RISK	Return-to-play and retirement decisions after concussion are often difficult and complex. The complexity of these decisions may be influenced by many factors, including the number, proximity, and severity of previous concussions; gender; age; sport played; exposure to head impacts; and predisposing or pre-existing conditions. These circumstances and conditions can confound the decisions concerning return to play and retirement. Clinicians should carefully weigh how these circumstances and conditions influence quality of life and how they interact with the effects of concussion. Furthermore, clinicians should consider past and potential exposures to both subconcussive and concussive impacts during the athlete's lifetime when deliberating a return to play or retirement. The purpose of this overview is to highlight and discuss these issues as they factor into the return-to-play and retirement decisions after a concussive injury in an effort to provide clinicians with evidence-based information that can be used in the decision-making process. PM R 2011;3:S440-S444	[Cantu, Robert C.] Emerson Hosp, Dept Surg, Concord, MA 01742 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Cantu, Robert C.; Register-Mihalik, Johna K.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Register-Mihalik, Johna K.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC USA		Cantu, RC (corresponding author), Emerson Hosp, Dept Surg, 131 ORNAC,Suite 820, Concord, MA 01742 USA.	rcantu@emersonhosp.org		Register-Mihalik, Johna/0000-0002-4229-4743			Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; FARMER JE, 1995, HEALTH PSYCHOL, V14, P325, DOI 10.1037/0278-6133.14.4.325; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920	27	29	29	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S440	S444		10.1016/j.pmrj.2011.07.013			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	966YK	WOS:000305873100012	22035687				2022-02-06	
J	Hannon, MJ; Sherlock, M; Thompson, CJ				Hannon, M. J.; Sherlock, M.; Thompson, C. J.			Pituitary dysfunction following traumatic brain injury or subarachnoid haemorrhage - In "Endocrine Management in the Intensive Care Unit"	BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article						pituitary; TBI; subarachnoid haemorrhage; glucocorticoid insufficiency; DI; SIADH	LEYDIG-CELL STEROIDOGENESIS; CRITICALLY-ILL PATIENTS; ANTI-DIURETIC HORMONE; SPECIAL WRITING GROUP; HUMAN GROWTH-HORMONE; ANTIDIURETIC-HORMONE; NEUROENDOCRINE DYSFUNCTION; INAPPROPRIATE SECRETION; ADRENAL INSUFFICIENCY; DIABETES-INSIPIDUS	Traumatic brain injury and subarachnoid haemorrhage are important causes of morbidity and mortality in the developed world. There is a large body of evidence that demonstrates that both conditions may adversely affect pituitary function in both the acute and chronic phases of recovery. Diagnosis of hypopituitarism and accurate treatment of pituitary disorders offers the opportunity to improve mortality and outcome in both traumatic brain injury and subarachnoid haemorrhage. In this article, we will review the history and pathophysiology of pituitary function in the acute phase following traumatic brain injury and subarachnoid haemorrhage, and we will discuss in detail three key aspects of pituitary dysfunction which occur in the early course of TBI; acute cortisol deficiency, diabetes insipidus and SIAD. (C) 2011 Elsevier Ltd. All rights reserved.	[Hannon, M. J.; Sherlock, M.; Thompson, C. J.] Beaumont Hosp RCSI Med Sch, Acad Dept Endocrinol, Dublin 9, Ireland		Thompson, CJ (corresponding author), Beaumont Hosp RCSI Med Sch, Acad Dept Endocrinol, Beaumont Rd, Dublin 9, Ireland.	christhompson@beaumont.ie					Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; [Anonymous], 1998, NIH CONSENS STATEMEN, V16, P1; Audibert G, 2009, ANESTH ANALG, V108, P1922, DOI 10.1213/ane.0b013e31819a85ae; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Berendes E, 1997, LANCET, V349, P245, DOI 10.1016/S0140-6736(96)08093-2; Berl T, 2010, J AM SOC NEPHROL, V21, P705, DOI 10.1681/ASN.2009080857; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Bornstein SR, 2008, TRENDS ENDOCRIN MET, V19, P175, DOI 10.1016/j.tem.2008.01.009; Boughey JC, 2004, AM SURGEON, V70, P500; Brandt L, 2004, ACTA NEUROL SCAND, V109, P91, DOI 10.1046/j.0001-6314.2003.00189.x; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; CALKINS JH, 1988, ENDOCRINOLOGY, V123, P1605, DOI 10.1210/endo-123-3-1605; Carlson NE, 2009, BRAIN INJURY, V23, P336, DOI 10.1080/02699050902788535; CARTLIDGE NE, 1972, J NEUROSURG, V36, P640, DOI 10.3171/jns.1972.36.5.0640; CATALANO RD, 1984, ARCH SURG-CHICAGO, V119, P145; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; CROMPTON MR, 1963, BRAIN, V86, P301, DOI 10.1093/brain/86.2.301; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Crowley RK, 2007, CLIN ENDOCRINOL, V66, P475, DOI 10.1111/j.1365-2265.2007.02754.x; CYRAN E, 1918, DEUT MED WOCHENSCHR, P1; DEJONG FH, 1984, J CLIN ENDOCR METAB, V59, P1143, DOI 10.1210/jcem-59-6-1143; Della Corte F, 1998, CRIT CARE MED, V26, P1419; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; DONG Q, 1992, CLIN ENDOCRINOL, V36, P399, DOI 10.1111/j.1365-2265.1992.tb01466.x; EDWARDS OM, 1986, MEDICINE, V65, P281; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; GUO H, 1990, ENDOCRINOLOGY, V127, P1234, DOI 10.1210/endo-127-3-1234; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HANNON MJ, 2011, AM END SOC ANN M JUN; HANNON MJ, 2011, AM END SOC ANN M; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; Hoff R, 2009, STROKE, V40, P2575, DOI 10.1161/STROKEAHA.108.538116; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingall T, 2000, STROKE, V31, P1054, DOI 10.1161/01.STR.31.5.1054; ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198; JEEVANANDAM M, 1995, JPEN-PARENTER ENTER, V19, P137, DOI 10.1177/0148607195019002137; Jovanovic V, 2010, HORM-INT J ENDOCRINO, V9, P235, DOI 10.14310/horm.2002.1273; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kao L, 2009, PITUITARY, V12, P347, DOI 10.1007/s11102-009-0188-9; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; KNOX J, 1995, J TRAUMA, V39, P526; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Koo DJ, 2001, CRIT CARE MED, V29, P618, DOI 10.1097/00003246-200103000-00026; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Kurokawa Y, 1996, SURG NEUROL, V46, P500, DOI 10.1016/S0090-3019(96)00034-1; LEVITAN D, 1984, AM J NEPHROL, V4, P99, DOI 10.1159/000166785; Ligtenberg JJM, 2001, INTENS CARE MED, V27, P1567, DOI 10.1007/s001340101050; Maggiore U, 2009, CRIT CARE, V13, DOI 10.1186/cc7953; Marik PE, 2002, CRIT CARE MED, V30, P1267, DOI 10.1097/00003246-200206000-00018; Mauduit C, 1998, ENDOCRINOLOGY, V139, P2863, DOI 10.1210/en.139.6.2863; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; MCIVER B, 1991, BRIT MED J, V303, P1465, DOI 10.1136/bmj.303.6815.1465; Mebis L, 2006, ENDOCRIN METAB CLIN, V35, P807, DOI 10.1016/j.ecl.2006.09.009; Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014; Michalaki M, 2001, J CLIN ENDOCR METAB, V86, P4198, DOI 10.1210/jc.86.9.4198; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Oh MS, 1999, NEPHRON, V82, P110, DOI 10.1159/000045385; OSTERMAN PO, 1975, ACTA NEUROL SCAND, V52, P56, DOI 10.1111/j.1600-0404.1975.tb02827.x; Palmer BF, 2000, NEPHROL DIAL TRANSPL, V15, P262, DOI 10.1093/ndt/15.2.262; PARENTI G, 2010, J ENDOCRINOLOGI 0831; Peeters RP, 2005, J CLIN ENDOCR METAB, V90, P4559, DOI 10.1210/jc.2005-0535; Peeters RP, 2003, J CLIN ENDOCR METAB, V88, P3202, DOI 10.1210/jc.2002-022013; PERLMUTTER D, 1976, J NEUROSURG, V45, P259, DOI 10.3171/jns.1976.45.3.0259; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.physiol.54.1.885; Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012; RAO RH, 1987, METABOLISM, V36, P658, DOI 10.1016/0026-0495(87)90150-8; Rap Z, 1971, Pol Med J, V10, P188; Rinkel GJ, 2004, COCHRANE DB SYST REV, V4; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schrier RW, 2006, NEW ENGL J MED, V355, P2099, DOI 10.1056/NEJMoa065181; SECKL J, 1998, BMJ-BRIT MED J, V298, P2; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Sherlock M, 2006, CLIN ENDOCRINOL, V64, P250, DOI 10.1111/j.1365-2265.2006.02432.x; Sherlock M, 2010, EUR J ENDOCRINOL, V162, pS13, DOI 10.1530/EJE-09-1057; Sobey CG, 1998, CLIN EXP PHARMACOL P, V25, P867, DOI 10.1111/j.1440-1681.1998.tb02337.x; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; SPRATT DI, 1993, J CLIN ENDOCR METAB, V76, P1548, DOI 10.1210/jc.76.6.1548; SPRATT DI, 1992, J CLIN ENDOCR METAB, V75, P1562, DOI 10.1210/jc.75.6.1562; TAKAKU A, 1979, SURG NEUROL, V11, P349; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Tanriverdi F, 2007, BRAIN INJURY, V21, P433, DOI 10.1080/02699050701311083; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; THOMPSON CJ, 1986, CLIN SCI, V71, P651, DOI 10.1042/cs0710651; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; Van den Berghe G H, 1998, Verh K Acad Geneeskd Belg, V60, P487; VandenBerghe G, 1997, J CLIN ENDOCR METAB, V82, P590, DOI 10.1210/jc.82.2.590; VANDENBERGHE GH, 1998, VERHANDELINGEN KONIN, V60, P520; Vanhorebeek I, 2006, CRIT CARE CLIN, V22, P1, DOI 10.1016/j.ccc.2005.09.004; VANTHOFF W, 1961, BMJ-BRIT MED J, V2, P1190, DOI 10.1136/bmj.2.5261.1190; Vermes I, 2001, BEST PRACT RES CL EN, V15, P495, DOI 10.1053/beem.2001.0166; VOERMAN HJ, 1992, NETH J MED, V41, P229; Wagner J, 2010, J NEUROTRAUM, V27, P1007, DOI 10.1089/neu.2009.1092; WAGNER RL, 1984, NEW ENGL J MED, V310, P1415, DOI 10.1056/NEJM198405313102202; WANG C, 1978, CLIN ENDOCRINOL, V9, P249, DOI 10.1111/j.1365-2265.1978.tb02207.x; WEBSTER J E, 1960, Arch Neurol, V2, P19; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3; WIJDICKS EFM, 1985, ANN NEUROL, V17, P137, DOI 10.1002/ana.410170206; Wijesurendra RS, 2009, NEUROCRIT CARE, V11, P158, DOI 10.1007/s12028-009-9217-9; Witkowska AM, 2009, ARCH IMMUNOL THER EX, V57, P137, DOI 10.1007/s00005-009-0010-4; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083	126	29	29	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1521-690X	1532-1908		BEST PRACT RES CL EN	Best Pract. Res. Clin. Endoc. Metab.	OCT	2011	25	5					783	798		10.1016/j.beem.2011.06.001			16	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	833CQ	WOS:000295859800008	21925078				2022-02-06	
J	Choi, S; Cunningham, DT; Aguila, F; Corrigan, JD; Bogner, J; Mysiw, WJ; Knopp, MV; Schmalbrock, P				Choi, Seongjin; Cunningham, Dustin T.; Aguila, Francisco; Corrigan, John D.; Bogner, Jennifer; Mysiw, W. Jerry; Knopp, Michael V.; Schmalbrock, Petra			DTI at 7 and 3 T: systematic comparison of SNR and its influence on quantitative metrics	MAGNETIC RESONANCE IMAGING			English	Article						DTI; 7 T; SNR; Partial volume effects	TRAUMATIC BRAIN-INJURY; DIFFUSION-TENSOR MRI; WHITE-MATTER; MAGNETIC-RESONANCE; ANISOTROPY; QUANTIFICATION; TRACTOGRAPHY; SCHEMES; TRACTS; SENSE	Diffusion tensor imaging (DTI) and advanced related methods such as diffusion spectrum and kurtosis imaging are limited by low signal-to-noise ratio (SNR) at conventional field strengths. DTI at 7 T can provide increased SNR; however, B0 and B1 inhomogeneity and shorter T2* still pose formidable challenges. The purpose of this study was to quantify and compare SNR at 7 and 3 T for different parallel imaging reduction factors, R, and TE, and to evaluate SNRs influences on fractional anisotropy (FA) and apparent diffusion coefficient (ADC). We found that R>4 at 7 T and R >= 2 at 3 T were needed to reduce geometric distortions due to B0 inhomogeneity. For these R at 7 T, SNR was 70-90 for b=0 s/mm(2) and 22-28 for b=1000s/mm(2) in central brain regions. SNR was lower at 3 T (40 for b=0 s/mm(2) and 15 for b=1000 s/mm(2)) and in lateral brain regions at 7 T due to B1 inhomogeneity. FA and ADC did not change with MRI field strength, SENSE factor or TE in the tested range. However, the coefficient of variation for FA increased for SNR <15 and for SNR <10 in ADC, consistent with published theoretical studies. Our study demonstrates that 7 T is advantageous for DTI and lays the groundwork for further development. Foremost, future work should further address challenges with B0 and B1 inhomogencity to take full advantage for the increased SNR at 7 T. (C) 2011 Elsevier Inc. All rights reserved.	[Choi, Seongjin; Cunningham, Dustin T.; Aguila, Francisco; Knopp, Michael V.; Schmalbrock, Petra] Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; [Corrigan, John D.; Bogner, Jennifer; Mysiw, W. Jerry] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Schmalbrock, P (corresponding author), Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA.	schmalbrock.1@osu.edu	Bogner, Jennifer/E-2773-2011; Corrigan, John D./E-2921-2011; Choi, Seongjin/E-2889-2011	Choi, Seongjin/0000-0002-7949-3359	Wright Center of Innovation in Biomedical Imaging at The Ohio State University, Ohio Department of Development [AGMT TECH 03-051]	This work was supported by The Wright Center of Innovation in Biomedical Imaging at The Ohio State University, Ohio Department of Development (AGMT TECH 03-051).	Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Alexander AL, 2006, NEUROIMAGING CLIN N; Bernstein MA, 2004, HDB MRI PULSE SEQUEN, P620; Brunner DO, 2009, NATURE, V457, P994, DOI 10.1038/nature07752; Choi S, 2010, P 18 ANN M INT SOC M, P1602; Cruz L Celso Hygino Jr, 2006, Magn Reson Imaging Clin N Am, V14, P183, DOI 10.1016/j.mric.2006.06.003; Dhital B, 2010, P 18 ANN M INT SOC M, V13, P3994; Finsterbusch J, 2010, J MAGN RESON IMAGING, V31, P1530, DOI 10.1002/jmri.22196; Heidemann RM, 2010, MAGN RESON MED, V64, P9, DOI 10.1002/mrm.22480; Thierry AGM, 2006, EUR RADIOL, V16, P1651, DOI 10.1007/s00330-006-0175-8; Ibrahim TS, 2005, MAGN RESON MED, V54, P683, DOI 10.1002/mrm.20596; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jaermann T, 2006, MAGN RESON MED, V55, P335, DOI 10.1002/mrm.20769; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jeong HK, 2010, P 18 ANN M INT SOC M, P1616; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kezele IB, 2008, MULT SCLER, V14, P779, DOI 10.1177/1352458507088106; Koay CG, 2006, J MAGN RESON, V179, P317, DOI 10.1016/j.jmr.2006.01.016; Koay CG, 2006, J MAGN RESON, V182, P115, DOI 10.1016/j.jmr.2006.06.020; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kristoffersen A, 2009, J MAGN RESON IMAGING, V29, P237, DOI 10.1002/jmri.21589; Kumazawa S, 2010, P 18 ANN M INT SOC M, P3126; Landman BA, 2008, MAGN RESON IMAGING, V26, P790, DOI 10.1016/j.mri.2008.01.034; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Metcalf M, 2007, P 15 ANN M INT SOC M, P2180; Mihai G, 2007, THESIS OHIO STATE U; Morgan PS, 2009, P 17 ANN M INT SOC M, P1807; Mukherjee P, 2005, NEUROIMAG CLIN N AM, V15, P655, DOI 10.1016/j.nic.2005.08.010; Mukherjee P, 2008, MAGN RESON IMAGING, V26, P171, DOI 10.1016/j.mri.2007.05.011; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Oouchi H, 2007, AM J NEURORADIOL, V28, P1102, DOI 10.3174/ajnr.A0488; Pfefferbaum A, 2003, MAGNET RESON MED, V49, P953, DOI 10.1002/mrm.10452; Piatkowski J, 2010, P 18 ANN M INT SOC M, P1574; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pierpaoli C, 2010, P 18 ANN M INT SOC M, P1616; Polders D, 2009, P 17 ANN M INT SOC M, P1406; Polders DL, 2010, P 18 ANN M INT SOC M, P1641; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.3.CO;2-J; Qin W, 2009, MAGN RESON MED, V61, P755, DOI 10.1002/mrm.21920; Sammet S, 2007, P 15 ANN M INT SOC M; Sarlis JE, 2010, P 18 ANN M INT SOC M, P1612; Taoka T, 2006, AM J NEURORADIOL, V27, P1040; Tsao S, 2010, P 18 ANN M INT SOC M, P1647; Von Morze J, 2010, P 18 ANN M INT SOC M, P3993; Vos SB, 2010, P 18 ANN M INT SOC M, P113; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Yarnykh VL, 2007, MAGN RESON MED, V57, P192, DOI 10.1002/mrm.21120	50	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	JUL	2011	29	6					739	751		10.1016/j.mri.2011.02.009			13	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	787EG	WOS:000292358800001	21571473				2022-02-06	
J	Heuer, JF; Pelosi, P; Hermann, P; Perske, C; Crozier, TA; Bruck, W; Quintel, M				Heuer, Jan Florian; Pelosi, Paolo; Hermann, Peter; Perske, Christina; Crozier, Thomas A.; Brueck, Wolfgang; Quintel, Michael			Acute effects of intracranial hypertension and ARDS on pulmonary and neuronal damage: a randomized experimental study in pigs	INTENSIVE CARE MEDICINE			English	Article						ABI; ARDS; ELWI; CT scan; Organ dysfunction	RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; ACUTE LUNG INJURY; SEVERE HEAD-INJURY; HIGH TIDAL VOLUME; CRITICALLY-ILL PATIENTS; NSE SERUM MEASUREMENTS; S-100 PROTEIN; S100B PROTEIN; SERIAL S-100	To determine reciprocal and synergistic effects of acute intracranial hypertension and ARDS on neuronal and pulmonary damage and to define possible mechanisms. Twenty-eight mechanically ventilated pigs were randomized to four groups of seven each: control; acute intracranial hypertension (AICH); acute respiratory distress syndrome (ARDS); acute respiratory distress syndrome in combination with acute intracranial hypertension (ARDS + AICH). AICH was induced with an intracranial balloon catheter and the inflation volume was adjusted to keep intracranial pressure (ICP) at 30-40 cmH(2)O. ARDS was induced by oleic acid infusion. Respiratory function, hemodynamics, extravascular lung water index (ELWI), lung and brain computed tomography (CT) scans, as well as inflammatory mediators, S100B, and neuronal serum enolase (NSE) were measured over a 4-h period. Lung and brain tissue were collected and examined at the end of the experiment. In both healthy and injured lungs, AICH caused increases in NSE and TNF-alpha plasma concentrations, extravascular lung water, and lung density in CT, the extent of poorly aerated (dystelectatic) and atelectatic lung regions, and an increase in the brain tissue water content. ARDS and AICH in combination induced damage in the hippocampus and decreased density in brain CT. AICH induces lung injury and also exacerbates pre-existing damage. Increased extravascular lung water is an early marker. ARDS has a detrimental effect on the brain and acts synergistically with intracranial hypertension to cause histological hippocampal damage.	[Heuer, Jan Florian; Hermann, Peter; Crozier, Thomas A.; Quintel, Michael] Univ Gottingen, Med Ctr, Dept Anaesthesiol Emergency & Intens Care Med, Gottingen, Germany; [Pelosi, Paolo] Univ Genoa, Dipartimento Sci Chirurg & Diagnost Integrate, Genoa, Italy; [Perske, Christina] Univ Gottingen, Dept Pathol, Med Ctr, D-3400 Gottingen, Germany; [Brueck, Wolfgang] Univ Gottingen, Med Ctr, Dept Neuropathol, Gottingen, Germany		Heuer, JF (corresponding author), Univ Gottingen, Med Ctr, Dept Anaesthesiol Emergency & Intens Care Med, Gottingen, Germany.	jheuer@med.uni-goettingen.de; ppelosi@hotmail.com; phermann@med.uni-goettingen.de; tinaperske@med.uni-goettingen.de; tcrozier@med.uni-goettingen.de; wbrueck@med.uni-goettingen.de; mquintel@med.uni-goettingen.de	Rocco, Patricia/I-7460-2012	Rocco, Patricia/0000-0003-1412-7136; Pelosi, Paolo/0000-0001-5055-3023			Appelberg J, 2010, CLIN PHYSIOL FUNCT I, V30, P301, DOI 10.1111/j.1475-097X.2010.00941.x; Avlonitis VS, 2005, AM J TRANSPLANT, V5, P684, DOI 10.1111/j.1600-6143.2005.00755.x; Beaudeux JL, 2000, CLIN CHEM, V46, P989; Beilin B, 2007, BRIT J ANAESTH, V99, P522, DOI 10.1093/bja/aem218; Bickenbach J, 2009, ANESTH ANALG, V109, P847, DOI 10.1213/ane.0b013e3181ad5769; BIGGER JT, 1992, CIRCULATION, V85, P164, DOI 10.1161/01.CIR.85.1.164; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Broccard AF, 1997, CRIT CARE MED, V25, P16, DOI 10.1097/00003246-199701000-00007; DAUBER IM, 1983, J CLIN INVEST, V72, P1977, DOI 10.1172/JCI111162; de Oliveira RP, 2010, CRIT CARE, V14, DOI 10.1186/cc8919; Florio P, 2006, PEDIATRICS, V118, pE747, DOI 10.1542/peds.2005-2875; Fries M, 2005, ANESTHESIOLOGY, V102, P761, DOI 10.1097/00000542-200504000-00011; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gazzolo D, 2005, PEDIATR RES, V58, P1170, DOI 10.1203/01.pdr.0000185131.22985.30; GOLDMAN G, 1992, J APPL PHYSIOL, V73, P571, DOI 10.1152/jappl.1992.73.2.571; Gonzalvo R, 2007, CRIT CARE, V11, DOI 10.1186/cc5930; Haitsma JJ, 2009, ACTA ANAESTH SCAND, V53, P176, DOI 10.1111/j.1399-6576.2008.01844.x; HALPERIN BD, 1985, CHEST, V88, P649, DOI 10.1378/chest.88.5.649; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2006, BRAIN INJURY, V20, P263, DOI 10.1080/02699050500488199; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; HORN M, 1995, STROKE, V26, P296; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; KOWALSKI ML, 1989, AM REV RESPIR DIS, V140, P101, DOI 10.1164/ajrccm/140.1.101; Lopez-Aguilar J, 2005, CRIT CARE MED, V33, P1077, DOI 10.1097/01.CCM.0000162913.72479.F7; Lopez-Aguilar J, 2010, INTENS CARE MED, V36, P347, DOI 10.1007/s00134-009-1695-x; Lou JN, 1997, AM J PATHOL, V151, P1397; Lowe GJ, 2006, CURR OPIN CRIT CARE, V12, P3, DOI 10.1097/01.ccx.0000198055.29600.4b; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; PELOSI P, 1994, AM J RESP CRIT CARE, V149, P8, DOI 10.1164/ajrccm.149.1.8111603; Rassler B, 2003, RESP PHYSIOL NEUROBI, V135, P25, DOI 10.1016/S1569-9048(03)00062-4; Rohde V, 2002, J NEUROSURG, V97, P954, DOI 10.3171/jns.2002.97.4.0954; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486; Rylander C, 2005, CRIT CARE, V9, pR165, DOI 10.1186/cc3058; Sakka SG, 2002, CHEST, V122, P2080, DOI 10.1378/chest.122.6.2080; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SIBILLE Y, 1993, EUR RESPIR J, V6, P1529; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; STRIETER RM, 1994, J INVEST MED, V42, P640; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; Takahashi N, 2010, JPN J RADIOL, V28, P349, DOI 10.1007/s11604-010-0430-4; TOUHO H, 1989, NEUROSURGERY, V25, P762, DOI 10.1227/00006123-198911000-00011; Unden J, 2007, NEUROCRIT CARE, V6, P94, DOI 10.1007/s12028-007-0005-0; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valenza F, 2005, CRIT CARE MED, V33, P361, DOI 10.1097/01.CCM.0000150660.45376.7C; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Vlahakis NE, 1999, AM J PHYSIOL-LUNG C, V277, pL167, DOI 10.1152/ajplung.1999.277.1.L167; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1165; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	66	29	30	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUL	2011	37	7					1182	1191		10.1007/s00134-011-2232-2			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	786ET	WOS:000292286800020	21544692	Green Published, hybrid			2022-02-06	
J	van Veldhoven, LM; Sander, AM; Struchen, MA; Sherer, M; Clark, AN; Hudnall, GE; Hannay, HJ				van Veldhoven, L. M.; Sander, A. M.; Struchen, M. A.; Sherer, M.; Clark, A. N.; Hudnall, Gina Evans; Hannay, H. J.			Predictive ability of preinjury stressful life events and post-traumatic stress symptoms for outcomes following mild traumatic brain injury: analysis in a prospective emergency room sample	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEAD-INJURY; POSTCONCUSSIONAL-SYNDROME; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; DISORDER; CRITERIA; DEPRESSION	Background A subset of persons with mild traumatic brain injury (mTBI) experience long-term difficulties. Preinjury stress has been hypothesised to play a role in long-term maintenance of symptoms. Objective To investigate the predictive ability of preinjury stressful life events and post-traumatic stress symptoms to health-related quality of life and emotional distress after mTBI. Methods Within 2 weeks of injury, 186 participants with mTBI who were admitted to an emergency centre completed an interview and questionnaires regarding preinjury functioning, including the Stressful Life Events Questionnaire and the Post-Traumatic Stress Disorder Checklist. Outcomes were assessed at 3 months after injury and included the depression and anxiety subscales of the Brief Symptom Inventory, and the physical and mental component scores of the 36-item Short-Form Health Survey (SF-36). The incidence and type of stressful life events were reported. Hierarchical regression analyses were used to determine the predictive utility of Stressful Life Events Questionnaire and Post-Traumatic Stress Disorder Checklist after controlling for age, injury severity (complicated versus uncomplicated mild) and preinjury depression. Results Several potentially life-altering stressful events were endorsed by at least 25% of participants as having been experienced prior to injury. The incidence of stressful life events was a significant predictor of all four outcome variables. History of post-traumatic stress symptoms was predictive of scores on the SF-36 mental health component. Conclusions A history of stressful events may predispose persons with mTBI to have poor outcomes. History of stress should be assessed during the early stages after mTBI to help identify those who could benefit from therapies to assist with adjustment and maximise recovery.	[van Veldhoven, L. M.; Sander, A. M.; Sherer, M.; Clark, A. N.] Brain Injury Res Ctr, TIRR Mem Hermann, Houston, TX 77019 USA; [van Veldhoven, L. M.; Sander, A. M.; Struchen, M. A.; Sherer, M.; Clark, A. N.; Hudnall, Gina Evans; Hannay, H. J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, A. M.; Hannay, H. J.] Harris Cty Hosp Dist, Houston, TX USA; [Hudnall, Gina Evans] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Hannay, H. J.] Univ Houston, Dept Psychol, Houston, TX USA		Sander, AM (corresponding author), Brain Injury Res Ctr, TIRR Mem Hermann, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu		Hannay, H. Julia/0000-0001-7023-912X	National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133B990014, H133B090023, H133A070043]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant nos H133B990014, H133B090023 and H133A070043).	American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU, V4th, P427; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cutrona CE, 2005, J ABNORM PSYCHOL, V114, P3, DOI 10.1037/0021-843X.114.1.3; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; Derogatis L.R., 1975, BRIEF SYMPTOM INVENT; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Goodman LA, 1998, J TRAUMA STRESS, V11, P521, DOI 10.1023/A:1024456713321; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lynch JW, 1997, NEW ENGL J MED, V337, P1889, DOI 10.1056/NEJM199712253372606; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; ORSILLO SM, 2001, PRACTITIONERS GUIDE, P287; Ponniah K, 2009, DEPRESS ANXIETY, V26, P1086, DOI 10.1002/da.20635; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Symonds C. P, 1937, P ROY SOC MED, V30, P33; United States Department of Health and Human Services, 2001, MENT HLTH REP SURG G; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Ware J.E., 1994, SF 36 PHYS MENTAL SU; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weathers F. W., 1994, PTSD CHECKLIST CIVIL; Weathers F.W., 1993, PTSD CHECKLIST RELIA; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	40	29	29	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2011	82	7					782	787		10.1136/jnnp.2010.228254			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	775AR	WOS:000291429200018	21242288				2022-02-06	
J	Davidson, JRT; Crawford, C; Ives, JA; Jonas, WB				Davidson, Jonathan R. T.; Crawford, Cindy; Ives, John A.; Jonas, Wayne B.			Homeopathic Treatments in Psychiatry: A Systematic Review of Randomized Placebo-Controlled Studies	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							MAJOR DEPRESSIVE DISORDER; CONTROLLED-TRIALS; DOUBLE-BLIND; FIBROMYALGIA SYNDROME; ALTERNATIVE MEDICINE; CLINICAL-TRIAL; METAANALYSIS; COMPLEMENTARY; EFFICACY; FIBROSITIS	Objective: To systematically review placebo-controlled randomized trials of homeopathy for psychiatric conditions. Data Sources: Eligible studies were identified using the following databases from database inception to April 2010: PubMed, CINAHL, PsycINFO, Horn-Inform, Cochrane CENTRAL, National Center for Complementary and Alternative Medicine grantee publications database, and ClinicalTrials.gov. Gray literature was also searched using Google, Google Scholar, the European Committee for Homeopathy, inquiries with homeopathic experts and manufacturers, and the bibliographic lists of included published studies and reviews. Search terms were as follows: (homeopath* or homoeopath*) and (placebo or sham) and (anxiety or panic or phobia or post-traumatic stress or PTSD or obsessive-compulsive disorder or fear or depress* or dysthym* or attention deficit hyperactivity or premenstrual syndrome or premenstrual disorder or premenstrual dysphoric disorder or traumatic brain injury or fibromyalgia or chronic fatigue syndrome or myalgic encephalitis or insomnia or sleep disturbance). Searches included only English-language literature that reported randomized controlled trials in humans. Study Selection: Trials were included if they met 7 criteria and were assessed for possible bias using the Scottish Intercollegiate Guidelines Network (SIGN) 50 guidelines. Overall assessments were made using the Grading of Recommendations Assessment, Development and Evaluation procedure. Identified studies were grouped into anxiety or stress, sleep or circadian rhythm complaints, premenstrual problems, attention-deficit/hyperactivity disorder, mild traumatic brain injury, and functional somatic syndromes. Results: Twenty-five eligible studies were identified from an initial pool of 1,431. Study quality according to SIGN 50 criteria varied, with 6 assessed as good, 9 as fair, and 10 as poor. Outcome was unrelated to SIGN quality. Effect size could be calculated in 16 studies, and number needed to treat, in 10 studies. Efficacy was found for the functional somatic syndromes group (fibromyalgia and chronic fatigue syndrome), but not for anxiety or stress. For other disorders, homeopathy produced mixed effects. No placebo-controlled studies of depression were identified. Meaningful safety data were lacking in the reports, but the superficial findings suggested good tolerability of homeopathy. A funnel plot in 13 studies did not support publication bias (chi(2)(1)=1.923, P=.166). Conclusions: The database on studies of homeopathy and placebo in psychiatry is very limited, but results do not preclude the possibility of some benefit. J Clin Psychiatry 2011;72(6):795-805 (C) Copyright 2011 Physicians Postgraduate Press, Inc.	[Davidson, Jonathan R. T.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Crawford, Cindy; Ives, John A.; Jonas, Wayne B.] Samueli Inst, Alexandria, VA USA		Davidson, JRT (corresponding author), 3068 Baywood Dr, Seabrook Isl, SC 29455 USA.	jonathan.davidson@duke.edu	Crawford, Cindy/AAI-3891-2021		AstraZenecaAstraZeneca; Euthymics Bioscience; United States Army Medical Research Acquisition Activity [W81XWH-08-1-0615-P00001]	In the last 12 months, Dr Davidson has received consulting fees from AstraZeneca and Euthymics Bioscience and royalties from the Davidson Trauma Scale, Social Phobia Inventory, Connor-Davidson Resilience Scale, Guilford Publications, and American Psychiatric Press. Ms Crawford and Drs Ives and Jonas report no potential conflict of interest.; This project was partially supported by award number W81XWH-08-1-0615-P00001 (United States Army Medical Research Acquisition Activity).	Aaron LA, 2001, ANN INTERN MED, V134, P868, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00011; AWDRY R, 1996, INT J ALTERN COMPLEM, V14, P12; Baker DG, 2003, COMPLEMENT THER MED, V11, P65, DOI 10.1016/S0965-2299(03)00059-1; Bell IR, 2004, INT J NEUROSCI, V114, P1195, DOI 10.1080/00207450490475724; Bell IR, 2004, RHEUMATOLOGY, V43, P577, DOI 10.1093/rheumatology/keh111; Bell IR, 2004, J ALTERN COMPLEM MED, V10, P285, DOI 10.1089/107555304323062275; BELL IR, SLEEP MED; Bonne O, 2003, J CLIN PSYCHIAT, V64, P282, DOI 10.4088/JCP.v64n0309; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; Chapman EH., 1994, J AM I HOMEOPATH, V87, P14; COLE CL, 1998, THESIS TECHNIKON WIT, P1; COLQUHOUN D, 1990, LANCET, V336, P441, DOI 10.1016/0140-6736(90)91989-N; Cooper KL, 2010, SLEEP MED REV, V14, P329, DOI 10.1016/j.smrv.2009.11.005; Cucherat M, 2000, EUR J CLIN PHARMACOL, V56, P27, DOI 10.1007/s002280050716; Davidson JRT, 1998, COMPR PSYCHIAT, V39, P16, DOI 10.1016/S0010-440X(98)90027-X; De Silva V, 2010, RHEUMATOLOGY, V49, P1063, DOI 10.1093/rheumatology/keq025; Ernst E, 2010, MED J AUSTRALIA, V192, P458, DOI 10.5694/j.1326-5377.2010.tb03585.x; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; FISHER P, 1990, LANCET, V336, P954, DOI 10.1016/0140-6736(90)92334-E; Fisher P., 1986, BR HOM J, V75, P142; Freeman MP, 2010, J CLIN PSYCHIAT, V71, P669, DOI 10.4088/JCP.10cs05959blu; Freeman MP, 2010, J CLIN PSYCHIAT, V71, P682, DOI 10.4088/JCP.10r05976blu; Frei H, 2005, EUR J PEDIATR, V164, P758, DOI 10.1007/s00431-005-1735-7; Grabia S, 2003, HOMEOPATHY, V92, P92, DOI 10.1016/S1475-4916(03)00007-9; Hauser W, 2009, PAIN, V145, P69, DOI 10.1016/j.pain.2009.05.014; Hauser W, 2009, JAMA-J AM MED ASSOC, V301, P198, DOI 10.1001/jama.2008.944; Hedges L.V., 1985, STAT METHODS META AN; HEIRS M, 2007, COCHRANE DB SYST REV, V4; Jacobs BP, 2009, ACP EVIDENCE BASED G; Jacobs J, 2005, J ALTERN COMPLEM MED, V11, P799, DOI 10.1089/acm.2005.11.799; JACOBS J, 1991, BR HOMEOPATH J, V80, P57; Jonas WB, 2003, ANN INTERN MED, V138, P393, DOI 10.7326/0003-4819-138-5-200303040-00009; KIRTLAND KA, 1994, THESIS TECHNIKON NAT; Kolia-Adam N, 2008, SIMILLIMUM, VXXI, P91; KOLIAADAM N, 2010, EFFICACY COFFEA CRUD; KUMAR K, NO JET LAG SCI TEST; La Pine MP, 2006, DIMENS CRIT CARE NUR, V25, P130, DOI 10.1097/00003465-200605000-00015; LAISTER CA, EFFICACY HOMOEOPATHI; Lewith G, 2009, J EVAL CLIN PRACT, V15, P1236, DOI 10.1111/j.1365-2753.2009.01261.x; Linde K, 1998, J ALTERN COMPLEM MED, V4, P371, DOI 10.1089/acm.1998.4.371; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Lipman Derek, 1999, Sleep Breath, V3, P53, DOI 10.1007/s11325-999-0053-0; Ludtke R, 2008, J CLIN EPIDEMIOL, V61, P1197, DOI 10.1016/j.jclinepi.2008.06.015; MAHARAJ A, 2005, THESIS DURBAN I TECH; McCarney RW, 2003, COCHRANE DB SYST REV; McCutcheon LE., 1996, J APPL NUTR, V48, P2; Naude DF, 2010, HOMEOPATHY, V99, P63, DOI 10.1016/j.homp.2009.11.001; NGOBESE JC, 2006, THEIS DURBAN U TECHN; Perry R, 2010, CLIN RHEUMATOL, V29, P457, DOI 10.1007/s10067-009-1361-2; Pilkington K, 2006, HOMEOPATHY, V95, P151, DOI 10.1016/j.homp.2006.05.005; Relton C, 2009, HOMEOPATHY, V98, P77, DOI 10.1016/j.homp.2008.12.004; SAUL W, 2005, THESIS TECHNIKON NAT; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; *SIGN NETW, 2001, GUID DEV HDB; STRAUSS LC, 2000, BIOMED THER, V18, P197; TRAUB G, 2000, THESIS TECHNIKON WIT; VAITHILINGAM H, 2005, THESIS DURBAN U TECH; Weatherley-Jones E, 2004, J PSYCHOSOM RES, V56, P189, DOI 10.1016/S0022-3999(03)00377-5; Yakir M, 2001, Br Homeopath J, V90, P148, DOI 10.1054/homp.1999.0491	59	29	29	0	46	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry	JUN	2011	72	6					795	805		10.4088/JCP.10r06580			11	Psychology, Clinical; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	786XJ	WOS:000292340900009	21733480				2022-02-06	
J	Honeybul, S				Honeybul, Stephen			Sudden death following cranioplasty: a complication of decompressive craniectomy for head injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						Decompressive craniectomy; complications; neurotrauma		This report details three cases of massive post-operative cerebral swelling following autologous cranioplasty. All three patients had a bifrontal decompressive craniectomy for intractably raised intracranial pressure following severe neurotrauma, developed hydrocephalus necessitating shunt insertion and were making a poor neurological recovery.	Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au					Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	3	29	30	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2011	25	3					343	345		10.3109/02688697.2011.568643			3	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	769QR	WOS:000291033800012	21501058				2022-02-06	
J	Parenti, G; Cecchi, PC; Ragghianti, B; Schwarz, A; Ammannati, F; Mennonna, P; Di Rita, A; Gallina, P; Di Lorenzo, N; Innocenti, P; Forti, G; Peri, A				Parenti, G.; Cecchi, P. C.; Ragghianti, B.; Schwarz, A.; Ammannati, F.; Mennonna, P.; Di Rita, A.; Gallina, P.; Di Lorenzo, N.; Innocenti, P.; Forti, G.; Peri, A.			Evaluation of the anterior pituitary function in the acute phase after spontaneous subarachnoid hemorrhage	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						Hypopituitarism; subarachnoid hemorrhage; pituitary; hypocortisolism; cerebral aneurysm	TRAUMATIC BRAIN-INJURY; LONG-TERM; HIGH-RISK; HYPOPITUITARISM; DEFICIENCY; DYSFUNCTION; PREVALENCE; DIAGNOSIS	Background: Subarachnoid hemorrhage (SAH) is a potential cause of hypopituitarism. Most of the studies regarding the relationship between SAH and anterior pituitary function were retrospective and hormonal assessment was performed several months after SAH. Aim: To prospectively evaluate the prevalence of anterior pituitary hormone deficiencies in the acute phase after spontaneous SAH and their possible correlation with clinical and radiological parameters. Methods: Pituitary function was tested in 60 patients within 72 h after spontaneous SAH. Results: 56.9% of the patients showed at least one anterior pituitary hormone deficiency: gonadotropin and GH secretion failure represented the most prevalent hormonal deficiencies (33.3 and 22.0%, respectively), whereas ACTH and TSH deficiency was less frequent (7.1 and 1.8%, respectively). With the exception of secondary hypogonadism, the prevalence of other pituitary hormone deficiencies is in agreement with previous studies, which evaluated pituitary function on long-term follow up after SAH. No correlation was found between hypopituitarism and clinical status, as assessed with Hunt-Hess and Glascow Coma Scales. Moreover, no correlation was found between hypopituitarism and bleeding severity evaluated with Fisher's scale. Conclusions: We demonstrated a high prevalence of anterior pituitary hormone deficiencies acutely after SAH. Although part of GH and gonadotropin deficiencies might be a consequence of functional alteration due to SAH itself, the finding of low cortisol levels in this stressful condition strongly suggests the presence of true hypocortisolism. Therefore, an evaluation of pituitary function shortly after SAH might be useful to identify a subset of patients who deserve a more accurate follow-up. (J. Endocrinol. Invest. 34: 361-365, 2011) (c) 2011, Editrice Kurtis	[Parenti, G.; Ragghianti, B.; Forti, G.; Peri, A.] Univ Florence, Dept Clin Physiopathol, Endocrine Unit, I-50139 Florence, Italy; [Cecchi, P. C.; Schwarz, A.] Reg Gen Hosp, Operat Unit Neurosurg, Bolzano, Italy; [Ammannati, F.; Mennonna, P.] Careggi Univ Hosp, Operat Unit Neurosurg, Florence, Italy; [Di Rita, A.; Gallina, P.; Di Lorenzo, N.] Univ Florence, Dept Neurosurg, I-50139 Florence, Italy; [Innocenti, P.] Univ Florence, Dept Neurol & Psychiat Sci, I-50139 Florence, Italy		Peri, A (corresponding author), Univ Florence, Dept Clin Physiopathol, Endocrine Unit, Via Pieraccini 6, I-50139 Florence, Italy.	a.peri@dfc.unifi.it	Peri, Alessandro/AAR-9664-2021; Parenti, Gabriele/AAX-9932-2020				Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Brandt L, 2004, ACTA NEUROL SCAND, V109, P91, DOI 10.1046/j.0001-6314.2003.00189.x; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fisher LA, 2006, NEUROCRIT CARE, V5, P180, DOI 10.1385/NCC:5:3:180; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Kreitschmann-Andermahr I, 2003, J NEUROL NEUROSUR PS, V74, P1133, DOI 10.1136/jnnp.74.8.1133; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Mangieri P, 2003, ARQ NEURO-PSIQUIAT, V61, P14, DOI 10.1590/S0004-282X2003000100003; Mesotten D, 2008, NAT CLIN PRACT ENDOC, V4, P496, DOI 10.1038/ncpendmet0921; Nieschlag E, 2005, EUR UROL, V48, P1, DOI 10.1016/j.eururo.2005.04.027; SCHNEIDER HJ, 2007, JAMA-J AM MED ASSOC, V12, P1429; STRATAKIS CA, 1995, ANN NY ACAD SCI, V29, P1; Tanriverdi F, 2007, CLIN ENDOCRINOL, V67, P931, DOI 10.1111/j.1365-2265.2007.02989.x; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Young R, 2004, Crit Care Resusc, V6, P295	22	29	31	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0391-4097	1720-8386		J ENDOCRINOL INVEST	J. Endocrinol. Invest.	MAY	2011	34	5					361	365		10.1007/BF03347460			5	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	784QD	WOS:000292172400006	20811167				2022-02-06	
J	Waldron-Perrine, B; Rapport, LJ; Hanks, RA; Lumley, M; Meachen, SJ; Hubbarth, P				Waldron-Perrine, Brigid; Rapport, Lisa J.; Hanks, Robin A.; Lumley, Mark; Meachen, Sarah-Jane; Hubbarth, Paul			Religion and Spirituality in Rehabilitation Outcomes Among Individuals With Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article							QUALITY-OF-LIFE; MENTAL-HEALTH; CONGREGATIONAL SUPPORT; OVARIAN-CANCER; HEAD-INJURY; SATISFACTION; INVOLVEMENT; DISABILITY; ADJUSTMENT; BELIEFS	Objective: The long-term consequences of traumatic brain injury affect millions of Americans, many of whom report using religion and spirituality to cope. Little research, however, has investigated how various elements of the religious and spiritual belief systems affect rehabilitation outcomes. The present study sought to assess the use of specifically defined elements of religion and spirituality as psychosocial resources in a sample of traumatically brain injured adults. Participants: The sample included 88 adults with brain injury from 1 to 20 years post injury and their knowledgeable significant others (SOs). The majority of the participants with brain injury were male (76%), African American (75%) and Christian (76%). Measures: Participants subjectively reported on their religious/spiritual beliefs and psychosocial resources as well as their current physical and psychological status. Significant others reported objective rehabilitation outcomes. Analyses: Hierarchical multiple regression analyses were used to determine the proportion of variance in outcomes accounted for by demographic, injury related, psychosocial and religious/spiritual variables. Results: The results indicate that religious well-being (a sense of connection to a higher power) was a unique predictor for life satisfaction, distress and functional ability whereas public religious practice and existential well-being were not. Conclusions: The findings of this project indicate that specific facets of religious and spiritual belief systems do play direct and unique roles in predicting rehabilitation outcomes whereas religious activity does not. Notably, a self-reported individual connection to a higher power was an extremely robust predictor of both subjective and objective outcome.	[Waldron-Perrine, Brigid; Rapport, Lisa J.; Lumley, Mark; Meachen, Sarah-Jane; Hubbarth, Paul] Wayne State Univ, Dept Psychol, Detroit, MI 48201 USA; [Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48201 USA		Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, Detroit, MI 48201 USA.	rapport@sun.science.wayne.edu		Rapport, Lisa/0000-0001-8014-9523			Brillhart Barbara, 2005, Rehabil Nurs, V30, P31; BUFFORD RK, 1991, J PSYCHOL THEOL, V19, P56, DOI 10.1177/009164719101900106; Canada AL, 2006, GYNECOL ONCOL, V101, P102, DOI 10.1016/j.ygyno.2005.09.045; Canada AL, 2005, GYNECOL ONCOL, V99, pS125, DOI 10.1016/j.ygyno.2005.07.057; Carone DA, 2001, CLIN PSYCHOL REV, V21, P989, DOI 10.1016/S0272-7358(00)00078-7; *CDC INJ CTR, 2006, TRAUM BRAIN INJ US E; Chally PS, 2004, ARCH PHYS MED REHAB, V85, pS60, DOI 10.1016/j.apmr.2004.03.013; Cohen D, 2009, INT J PSYCHOL RELIG, V19, P121, DOI 10.1080/10508610802711335; Contrada RJ, 2004, HEALTH PSYCHOL, V23, P227, DOI 10.1037/0278-6133.23.3.227; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Ellison CG, 2001, SOC FORCES, V80, P215, DOI 10.1353/sof.2001.0063; ELLISON CG, 1994, J SCI STUD RELIG, V33, P46, DOI 10.2307/1386636; ELLISON CW, 1983, J PSYCHOL THEOL, V11, P330, DOI 10.1177/009164718301100406; Faul M, 2010, TRAUMATIC BRAIN INJU; Fetzer Institute, 1999, MULT MEAS REL SPIR U; Finkelstein E., 2006, INCIDENCE EC BURDEN; Fitchett G, 1999, REHABIL PSYCHOL, V44, P333, DOI 10.1037//0090-5550.44.4.333; George LK, 2002, PSYCHOL INQ, V13, P190, DOI 10.1207/S15327965PLI1303_04; Herrmann M, 2000, DISABIL REHABIL, V22, P539, DOI 10.1080/096382800416788; Hill PC, 2003, AM PSYCHOL, V58, P64, DOI 10.1037/0003-066X.58.1.64; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; Ironson G, 2002, ANN BEHAV MED, V24, P34, DOI 10.1207/S15324796ABM2401_05; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Johnstone B, 2007, DISABIL REHABIL, V29, P1153, DOI 10.1080/09638280600955693; Johnstone B, 2009, REHABIL PSYCHOL, V54, P422, DOI 10.1037/a0017758; Johnstone B, 2009, BRAIN INJURY, V23, P411, DOI 10.1080/02699050902788501; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Karademas EC, 2010, J HEALTH PSYCHOL, V15, P239, DOI 10.1177/1359105309347585; Keefe FJ, 2001, J PAIN, V2, P101, DOI 10.1054/jpai.2001.19296; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Koenig H. G., 2002, LINK RELIG HLTH PSYC; Koenig HaroldG., 2001, HDB RELIG HLTH; Koenig HG, 1998, J NERV MENT DIS, V186, P513, DOI 10.1097/00005053-199809000-00001; Landis B J, 1996, Issues Ment Health Nurs, V17, P217, DOI 10.3109/01612849609049916; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Makros J, 2003, J RELIG HEALTH, V42, P143, DOI 10.1023/A:1023681830716; Matheis EN, 2006, REHABIL PSYCHOL, V51, P265, DOI 10.1037/0090-5550.51.3.265; MATON KI, 1989, J SCI STUD RELIG, V28, P310, DOI 10.2307/1386742; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1016/S0003-9993(00)90117-5; Pargament K., 1997, PSYCHOL RELIG COPING; Prigatano G., 1986, PATIENT COMPETENCY R; Ray O, 2004, AM PSYCHOL, V59, P29, DOI 10.1037/0003-066X.59.1.29; Riley BB, 1998, ARCH PHYS MED REHAB, V79, P258, DOI 10.1016/S0003-9993(98)90004-1; Rippentrop AE, 2005, REHABIL PSYCHOL, V50, P278, DOI 10.1037/0090-5550.50.3.278; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; Saunders SM, 2010, PROF PSYCHOL-RES PR, V41, P355, DOI 10.1037/a0020953; Sheldon KM, 2001, AM PSYCHOL, V56, P216, DOI 10.1037//0003-066X.56.3.216; Smith A., 1973, SYMBOL DIGITS MODALI; Soderback I, 1992, Disabil Rehabil, V14, P30; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tabachnick B. G., 2006, USING MULTIVARIATE S, V5th; Tate DG, 2002, AM J PHYS MED REHAB, V81, P400, DOI 10.1097/00002060-200206000-00002; Thoresen CE, 2002, ANN BEHAV MED, V24, P3, DOI 10.1207/S15324796ABM2401_02; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	58	29	29	0	12	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2011	56	2					107	116		10.1037/a0023552			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	769KL	WOS:000291011800004	21574729				2022-02-06	
J	Oda, Y; Gao, GY; Wei, EP; Povlishock, JT				Oda, Yasutaka; Gao, Guoyi; Wei, Enoch P.; Povlishock, John T.			Combinational therapy using hypothermia and the immunophilin ligand FK506 to target altered pial arteriolar reactivity, axonal damage, and blood-brain barrier dysfunction after traumatic brain injury in rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						amyloid precursor protein; blood-brain barrier; brain arteriolar reactivity; diffuse axonal injury; hypothermia; immunosuppressant	POSTTRAUMATIC HYPOTHERMIA; HEAD-INJURY; ISCHEMIA; MODEL; CONSEQUENCES; ENDOTHELIUM; TACROLIMUS; CHILDREN; PROTECTS; SYSTEM	This study evaluated the utility of combinational therapy, coupling delayed posttraumatic hypothermia with delayed FK506 administration, on altered cerebral vascular reactivity, axonal injury, and blood-brain barrier (BBB) disruption seen following traumatic brain injury (TBI). Animals were injured, subjected to various combinations of hypothermic/FK506 intervention, and equipped with cranial windows to assess pial vascular reactivity to acetylcholine. Animals were then processed with antibodies to the amyloid precursor protein and immunoglobulin G to assess axonal injury and BBB disruption, respectively. Animals were assigned to five groups: (1) sham injury plus delayed FK506, (2) TBI, (3) TBI plus delayed hypothermia, (4) TBI plus delayed FK506, and (5) TBI plus delayed hypothermia with FK506. Sham injury plus FK506 had no impact on vascular reactivity, axonal injury, or BBB disruption. Traumatic brain injury induced dramatic axonal injury and altered pial vascular reactivity, while triggering local BBB disruption. Delayed hypothermia or FK506 after TBI provided limited protection. However, TBI with combinational therapy achieved significantly enhanced vascular and axonal protection, with no BBB protection. This study shows the benefits of combinational therapy, using posttraumatic hypothermia with FK506 to attenuate important features of TBI. This suggests that hypothermia not only protects but also extends the therapeutic window for improved FK506 efficacy. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1143-1154; doi: 10.1038/jcbfm.2010.208; published online 15 December 2010	[Oda, Yasutaka; Gao, Guoyi; Wei, Enoch P.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Oda, Yasutaka] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan; [Gao, Guoyi] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200030, Peoples R China		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD 055813, NS 057175]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS057175] Funding Source: NIH RePORTER	This study is supported by NIH grants HD 055813 and NS 057175.	Bacher A, 1998, ANESTHESIOLOGY, V88, P403, DOI 10.1097/00000542-199802000-00019; Baranova AI, 2008, J NEUROSURG, V109, P502, DOI 10.3171/JNS/2008/109/9/0502; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; ELLISON MD, 1990, J NEUROIMMUNOL, V28, P249, DOI 10.1016/0165-5728(90)90018-I; Furuichi Y, 2003, J CEREBR BLOOD F MET, V23, P1183, DOI 10.1097/01.WCB.0000088761.02615.EB; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HUTCHISON JS, N ENGL J MED, V358, P2447; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KONTOS HA, 1988, AM J PHYSIOL, V255, pH1259, DOI 10.1152/ajpheart.1988.255.5.H1259; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Namgaladze D, 2005, BIOCHEM BIOPH RES CO, V334, P1061, DOI 10.1016/j.bbrc.2005.07.003; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nito C, 2004, BRAIN RES, V1008, P179, DOI 10.1016/j.brainres.2004.02.031; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Sasakawa T, 2005, CYTOKINE, V29, P67, DOI 10.1016/j.cyto.2004.04.006; Sasaki T, 2004, BRAIN RES, V1009, P34, DOI 10.1016/j.brainres.2004.01.088; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Thomale UW, 2007, IMMUNOBIOLOGY, V212, P567, DOI 10.1016/j.imbio.2007.01.007; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	37	29	32	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2011	31	4					1143	1154		10.1038/jcbfm.2010.208			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	744AQ	WOS:000289064500017	21157473	Green Published, Bronze			2022-02-06	
J	Fitzgerald, PB; Hoy, KE; Maller, JJ; Herring, S; Segrave, R; McQueen, S; Peachey, A; Hollander, Y; Anderson, JF; Daskalakis, ZJ				Fitzgerald, Paul B.; Hoy, Kate E.; Maller, Jerome J.; Herring, Sally; Segrave, Rebecca; McQueen, Susan; Peachey, Amy; Hollander, Yitzchak; Anderson, Jacqueline F.; Daskalakis, Zafiris J.			Transcranial Magnetic Stimulation for Depression After a Traumatic Brain Injury A Case Study	JOURNAL OF ECT			English	Article						transcranial magnetic stimulation; major depression; traumatic brain injury		Depression after a traumatic brain injury (TBI) is very common, yet there is a lack of evidence-based treatment options for people who experience depression after a TBI. Traditionally, a history of TBI has been considered an exclusion criterion for transcranial magnetic stimulation trials because of the increased risk of seizure after a TBI. We present what we believe to be the first case of a patient with depression after a TBI treated with transcranial magnetic stimulation.	[Fitzgerald, Paul B.] Monash Univ, Monash Alfred Psychiat Res Ctr, Dept Psychiat, Alfred Hosp, Prahran, Vic 3181, Australia; [Fitzgerald, Paul B.; Hoy, Kate E.; Maller, Jerome J.; Herring, Sally; Segrave, Rebecca; McQueen, Susan; Peachey, Amy] Monash Univ, Sch Psychol & Psychiat, Prahran, Vic 3181, Australia; [Hollander, Yitzchak] Alfred Hosp, Dept Psychiat, Melbourne, Vic, Australia; [Anderson, Jacqueline F.] Univ Melbourne, Melbourne, Vic, Australia; [Daskalakis, Zafiris J.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada		Fitzgerald, PB (corresponding author), Monash Univ, Monash Alfred Psychiat Res Ctr, Dept Psychiat, Alfred Hosp, Commercial Rd, Prahran, Vic 3181, Australia.	Paul.fitzgerald@alfred.org.au	Segrave, Rebecca/H-4554-2014; Daskalakis, Zafiris J/J-5503-2013; Maller, Jerome J/H-4963-2014; Fitzgerald, Paul B/A-1225-2008	Segrave, Rebecca/0000-0002-1839-0794; Daskalakis, Zafiris J/0000-0001-9502-0538; Maller, Jerome J/0000-0003-4685-1508; Fitzgerald, Paul B/0000-0003-4217-8096; Anderson, Jacqueline/0000-0003-4996-8189; Herring, Sally/0000-0003-0996-7413; Hoy, Kate/0000-0003-0694-9674			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Fava M, 2003, BIOL PSYCHIAT, V53, P649, DOI 10.1016/S0006-3223(03)00231-2; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676	4	29	30	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1095-0680			J ECT	J. ECT	MAR	2011	27	1					38	40		10.1097/YCT.0b013e3181eb30c6			3	Behavioral Sciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Psychiatry	726CU	WOS:000287697100026	20938348				2022-02-06	
J	Luo, JA; Bo, XN; Wu, DS; Yeh, J; Richardson, PM; Zhang, Y				Luo, Juan; Bo, Xuenong; Wu, Dongsheng; Yeh, John; Richardson, Peter M.; Zhang, Yi			Promoting Survival, Migration, and Integration of Transplanted Schwann Cells by Over-Expressing Polysialic Acid	GLIA			English	Article						polysialyltransferase; astrocyte; cell therapy; spinal cord injury; neurotrauma; lentiviral vector	CENTRAL-NERVOUS-SYSTEM; OLFACTORY ENSHEATHING CELLS; ADHESION MOLECULE NCAM; SPINAL-CORD-INJURY; IN-VITRO; AXONAL REGENERATION; FUNCTIONAL RECOVERY; PERIPHERAL-NERVE; SENSORY AXONS; PSA-NCAM	The poor survival and migration of transplanted Schwann cells (SCs) are major drawbacks for their clinical application in cell therapy for neurotrauma. To overcome such drawbacks we genetically modified SCs to over-express polysialic acid (PSA) by lentiviral delivery of polysialyltransferase (PST) to study whether over-expression of PSA could enhance their survival, migration, and integration when transplanted into the spinal cord. It was found that more PSA-expressing SCs (PST/SCs) survived than GFP-expressing SCs (GFP/SCs) after transplantation, although cell loss was still quite significant. PSA expression did not enhance the motility of transplanted SCs in uninjured spinal cord. However, in a spinal cord crush injury model PST/SCs transplanted caudal to the lesion showed that increased number of PST/SCs migrated to the injury site compared with that of GFP/SCs. Induced expression of PSA in spinal cord can further facilitate the infiltration of PST/SCs into the lesion site. PST/SCs were also shown to intermingle well with host spinal cells while GFP/SCs formed boundaries with host tissue. This was confirmed by an in vitro confrontation assay showing that more PST/SCs crossed over to astrocyte territory than GFP/SCs. Furthermore, PST/SCs induced much less expression of glial fibrillary acidic protein and chondroitin sulfate proteoglycan in the surrounding tissues than GFP/SCs, indicating that expression of PSA on SCs do not cause significant stress response of astrocytes. These results demonstrate that expression of PSA on SCs significantly changes their biological properties and makes them more feasible for neural repair after neurotrauma. (C)2010 Wiley-Liss, Inc.	[Luo, Juan; Bo, Xuenong; Wu, Dongsheng; Zhang, Yi] Univ London, Ctr Neurosci & Trauma, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, London E1 2AT, England; [Yeh, John; Richardson, Peter M.] Univ London, Barts & London Sch Med & Dent, Dept Neurosurg, London E1 2AT, England		Zhang, Y (corresponding author), Univ London, Ctr Neurosci & Trauma, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, 4 Newark St, London E1 2AT, England.	yi.zhang@qmul.ac.uk	Bo, Xuenong/E-9845-2012	Bo, Xuenong/0000-0002-9202-3562	International Spinal Research Trust	Grant sponsor: Nathalie Rose Barr PhD Studentship from International Spinal Research Trust.	ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; Afshari FT, 2010, GLIA, V58, P857, DOI 10.1002/glia.20970; Afshari FT, 2010, J NEUROSCI, V30, P4246, DOI 10.1523/JNEUROSCI.3351-09.2010; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Angata K, 2007, MOL CELL BIOL, V27, P6659, DOI 10.1128/MCB.00205-07; Bachelin C, 2010, BRAIN, V133, P406, DOI 10.1093/brain/awp256; Barral-Moran MJ, 2003, J NEUROSCI RES, V72, P679, DOI 10.1002/jnr.10627; Biernaskie JA, 2006, NAT PROTOC, V1, P2803, DOI 10.1038/nprot.2006.422; Boyle K, 2005, NEUROBIOL DIS, V20, P412, DOI 10.1016/j.nbd.2005.03.022; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Decker L, 2000, MOL CELL NEUROSCI, V16, P422, DOI 10.1006/mcne.2000.0885; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; El Maarouf A, 2006, P NATL ACAD SCI USA, V103, P16989, DOI 10.1073/pnas.0608036103; Fairless R, 2005, INT J BIOCHEM CELL B, V37, P693, DOI 10.1016/j.biocel.2004.10.010; Fairless R, 2005, MOL CELL NEUROSCI, V28, P253, DOI 10.1016/j.mcn.2004.09.009; Fewou SN, 2007, J BIOL CHEM, V282, P16700, DOI 10.1074/jbc.M610797200; Franceschini I, 2004, MOL CELL NEUROSCI, V27, P151, DOI 10.1016/j.mcn.2004.05.006; Franssen EHP, 2007, BRAIN RES REV, V56, P236, DOI 10.1016/j.brainresrev.2007.07.013; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; Gascon E, 2007, DEVELOPMENT, V134, P1181, DOI 10.1242/dev.02808; Gregoriadis G, 2000, CELL MOL LIFE SCI, V57, P1964, DOI 10.1007/PL00000676; HEKMAT A, 1990, J COMP NEUROL, V291, P457, DOI 10.1002/cne.902910311; Hill CE, 2007, EUR J NEUROSCI, V26, P1433, DOI 10.1111/j.1460-9568.2007.05771.x; Hill CE, 2006, GLIA, V53, P338, DOI 10.1002/glia.20287; JANCIK JM, 1978, CELL TISSUE RES, V186, P209, DOI 10.1007/BF00225532; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Kiss JZ, 1998, MOL CELL ENDOCRINOL, V140, P89; Lakatos A, 2000, GLIA, V32, P214, DOI 10.1002/1098-1136(200012)32:3<214::AID-GLIA20>3.0.CO;2-7; Lakatos A, 2003, EXP NEUROL, V184, P237, DOI 10.1016/S0014-4886(03)00270-X; Lavdas AA, 2008, CURR MED CHEM, V15, P151; Lavdas AA, 2006, GLIA, V53, P868, DOI 10.1002/glia.20340; Levi ADO, 1996, J NEUROSCI METH, V68, P21, DOI 10.1016/0165-0270(96)00055-6; Li YW, 2003, J BIOL CHEM, V278, P9585, DOI 10.1074/jbc.M213244200; Mackay-Sim A, 2008, BRAIN, V131, P2376, DOI 10.1093/brain/awn173; McKenzie IA, 2006, J NEUROSCI, V26, P6651, DOI 10.1523/JNEUROSCI.1007-06.2006; NOBLE M, 1984, EMBO J, V3, P2243, DOI 10.1002/j.1460-2075.1984.tb02122.x; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Oudega M, 2006, J NEUROTRAUM, V23, P453, DOI 10.1089/neu.2006.23.453; Papastefanaki F, 2007, BRAIN, V130, P2159, DOI 10.1093/brain/awm155; Park HW, 2010, GLIA, V58, P1118, DOI 10.1002/glia.20992; Pearse DD, 2007, GLIA, V55, P976, DOI 10.1002/glia.20490; Plant GW, 2001, MOL CELL NEUROSCI, V17, P471, DOI 10.1006/mcne.2000.0948; RAISMAN G, EXP NEUROL IN PRESS; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Santos-Silva A, 2007, J NEUROSCI, V27, P7154, DOI 10.1523/JNEUROSCI.1184-07.2007; Seidenfaden R, 2001, J NEUROBIOL, V46, P11, DOI 10.1002/1097-4695(200101)46:1<11::AID-NEU2>3.0.CO;2-#; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; TETZLAFF W, 2010, J NEUROTRAU IN PRESS; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Vutskits L, 2006, NEUROCHEM RES, V31, P215, DOI 10.1007/s11064-005-9021-7; YANG PF, 1994, J BIOL CHEM, V269, P23039; Yoshida K, 1999, J NEUROSCI, V19, P794; Zhang H, 2004, J CELL SCI, V117, P93, DOI 10.1242/jcs.00827; Zhang Y, 2008, RESTOR NEUROL NEUROS, V26, P81; Zhang Y, 2007, MOL THER, V15, P1796, DOI 10.1038/sj.mt.6300220; Zhang Y, 2007, MOL CELL NEUROSCI, V35, P109, DOI 10.1016/j.mcn.2007.02.011; Zhang Y, 2007, EUR J NEUROSCI, V25, P351, DOI 10.1111/j.1460-9568.2007.05311.x	61	29	34	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	2011	59	3					424	434		10.1002/glia.21111			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	718ZT	WOS:000287166500007	21264949				2022-02-06	
J	Steel, JL; Dunlavy, AC; Stillman, J; Pape, HC				Steel, Jennifer L.; Dunlavy, Andrea C.; Stillman, Jessica; Pape, Hans Christoph			Measuring depression and PTSD after trauma: Common scales and checklists	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic injury; Depression; PTSD; Measurement	POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; BRAIN-INJURY; MAJOR DEPRESSION; PSYCHOMETRIC PROPERTIES; MENTAL-HEALTH; SELF-REPORT; CULTURAL-DIFFERENCES; OUTCOMES MEASUREMENT; CIVILIAN VERSION	Traumatic injury is an important public health problem secondary to high levels of morbidity and mortality. Injured survivors face several physical, emotional, and financial repercussions that can significantly impact their lives as well as their family. Depression and posttraumatic stress disorder ( PTSD) are the most common psychiatric sequelae associated with traumatic injury. Factors affecting the prevalence of these psychiatric symptoms include: concomitant TBI, the timing of assessment of depression and PTSD, the type of injury, premorbid, sociodemographic, and cultural factors, and comorbid medical conditions and medication side effects. The appropriate assessment of depression and PTSD is critical to an understanding of the potential consequences of these disorders as well as the development of appropriate behavioural and pharmacological treatments. The reliability and validity of screening instruments and structured clinical interviews used to assess depression and PTSD must be considered. Common self-report instruments and structured clinical interviews used to assess depression and PTSD and their reliability and validity are described. Future changes in diagnostic criteria for depression and PTSD and recent initiatives by the National Institute of Health regarding patient-reported outcomes may result in new methods of assessing these psychiatric sequelae of traumatic injury. (C) 2010 Elsevier Ltd. All rights reserved.	[Steel, Jennifer L.] Univ Pittsburgh, Sch Med, Starzl E Transplantat Inst, Dept Surg & Psychiat,Liver Canc Ctr, Pittsburgh, PA 15213 USA; [Dunlavy, Andrea C.; Stillman, Jessica] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA		Steel, JL (corresponding author), Univ Pittsburgh, Sch Med, Starzl E Transplantat Inst, Dept Surg & Psychiat,Liver Canc Ctr, 3459 5th Ave,Montefiore 7S, Pittsburgh, PA 15213 USA.	steeljl@upmc.edu		Pape, Hans-Christoph/0000-0002-2059-4980	 [NCI-5K07CA118576];  [NCI-R21CA127046-01A1];  [3K07CA118576-04S1]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [K07CA118576, R21CA127046] Funding Source: NIH RePORTER	The following is the corresponding author's support and financial disclosure declaration: NCI-5K07CA118576; NCI-R21CA127046-01A1; 3K07CA118576-04S1.	Aben I, 2002, PSYCHOSOMATICS, V43, P386, DOI 10.1176/appi.psy.43.5.386; Akdemir A, 2001, COMPR PSYCHIAT, V42, P161, DOI 10.1053/comp.2001.19756; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; American Psychiatric Association Task Force for the Handbook of Psychiatric Measures, 2000, HDB PSYCH MEAS; ANTONY MM, 2001, PRACTITIONERS GUIDE; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bagby RM, 2004, AM J PSYCHIAT, V161, P2163, DOI 10.1176/appi.ajp.161.12.2163; Basco MR, 2000, AM J PSYCHIAT, V157, P1599, DOI 10.1176/appi.ajp.157.10.1599; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Beck JG, 2008, J ANXIETY DISORD, V22, P187, DOI 10.1016/j.janxdis.2007.02.007; Beck JG, 2009, J ANXIETY DISORD, V23, P443, DOI 10.1016/j.janxdis.2008.09.001; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BLANCHARD EB, 1995, J NERVOUS MENTAL DIS; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; BREWIN CR, 2009, J TRAUMATIC STRESS; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2003, J TRAUMA STRESS, V16, P439, DOI 10.1023/A:1025750209553; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Caspi Y, 2005, J LOSS TRAUMA, V10, P319, DOI 10.1080/15325020590956756; Cella D, 2007, QUAL LIFE RES, V16, P133, DOI 10.1007/s11136-007-9204-6; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Centers for Disease Control, 2006, CDC INJ FACT BOOK; COMPTON WM, 2004, DIAGNOSTIC INTERVIEW; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; Darnall BD, 2005, ARCH PHYS MED REHAB, V86, P650, DOI 10.1016/j.apmr.2004.10.028; DAVIDSON J, 1989, J NERV MENT DIS, V177, P336, DOI 10.1097/00005053-198906000-00003; Davidson J R, 1997, Depress Anxiety, V5, P127, DOI 10.1002/(SICI)1520-6394(1997)5:3<127::AID-DA3>3.0.CO;2-B; Davidson JRT, 1990, BIOL ASSESSMENT TREA, P205; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Ehring T, 2008, PSYCHIAT RES, V161, P67, DOI 10.1016/j.psychres.2007.08.014; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First MB., 2004, STRUCTURED CLIN INTE; Foa EB, 1997, PSYCHOL ASSESSMENT; Fullerton CS, 2001, AM J PSYCHIAT, V158, P1486, DOI 10.1176/appi.ajp.158.9.1486; GABRYS JB, 1985, PSYCHOL REP, V57, P1091, DOI 10.2466/pr0.1985.57.3f.1091; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Gray LB, 2009, CURR PSYCHIAT REP, V11, P106, DOI 10.1007/s11920-009-0017-x; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hammaiberg M., 1992, PSYCHOL ASSESSMENT, V4, P67, DOI [10.1037/1040-3590.4.1.67, DOI 10.1037/1040-3590.4.1.67]; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Jobson L, 2008, BRIT J CLIN PSYCHOL, V47, P95, DOI 10.1348/014466507X235953; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Karasz A, 2005, SOC SCI MED, V60, P1625, DOI 10.1016/j.socscimed.2004.08.011; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Klein E, 2003, CAN J PSYCHIAT, V48, P28, DOI 10.1177/070674370304800106; Kulka R., 1988, CONTRACTUAL REPORT F, V1; Lauterbach D, 1997, J TRAUMA STRESS, V10, P499, DOI 10.1002/jts.2490100313; Lauterbach D., 1996, ASSESSMENT, V3, P17, DOI DOI 10.1177/107319119600300102; Lee PW, 2007, J AFFECT DISORDERS, V99, P139, DOI 10.1016/j.jad.2006.09.002; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Lowe B, 2005, J PSYCHOSOM RES, V58, P163, DOI 10.1016/j.jpsychores.2004.09.006; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Mellman TA, 2001, DEPRESS ANXIETY, V14, P226, DOI 10.1002/da.1071; Mendlowicz MV, 2000, AM J PSYCHIAT, V157, P669, DOI 10.1176/appi.ajp.157.5.669; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; Mollica RF, 2002, BRIT J PSYCHIAT, V181, P339, DOI 10.1192/bjp.181.4.339; Morris DW, 2007, J CLIN PSYCHIAT, V68, P1339, DOI 10.4088/JCP.v68n0903; *NORTH CENTR REG T, 2006, NAT TRAUM STAT; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Olatunji BO, 2007, CLIN PSYCHOL REV, V27, P572, DOI 10.1016/j.cpr.2007.01.015; Ouellet MC, 2009, J REHABIL MED, V41, P179, DOI 10.2340/16501977-0306; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Pies RW, 2009, J AFFECT DISORDERS, V116, P1, DOI 10.1016/j.jad.2008.11.009; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Richter JC, 2006, PSYCHOSOMATICS, V47, P223, DOI 10.1176/appi.psy.47.3.223; Romans SE, 2008, J NERV MENT DIS, V196, P237, DOI 10.1097/NMD.0b013e318166350f; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; RYDER AG, 2005, CROSS CULTURAL DIFFE; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Schotte CKW, 1996, PSYCHOL MED, V26, P1161, DOI 10.1017/S0033291700035881; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shalev AY, 1997, BRIT J PSYCHIAT, V170, P558, DOI 10.1192/bjp.170.6.558; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Snyder JJ, 2009, PSYCHIAT RES, V170, P256, DOI 10.1016/j.psychres.2008.11.008; Spitzer RL, 2007, J ANXIETY DISORD, V21, P233, DOI 10.1016/j.janxdis.2006.09.006; Stahl S.M, 2000, ESSENTIAL PSYCHOPHAR; Strik JJMH, 2001, PSYCHOSOMATICS, V42, P423, DOI 10.1176/appi.psy.42.5.423; Turner-Stokes L, 2005, J NEUROL NEUROSUR PS, V76, P1273, DOI 10.1136/jnnp.2004.050096; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; VREVEN DL, 1995, J TRAUMA STRESS, V8, P91, DOI 10.1007/BF02105409; WATSON CG, 1994, J TRAUMA STRESS, V7, P75, DOI 10.1007/BF02111913; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; Weathers F., 1994, PTSD RES Q, V5, P2, DOI [DOI 10.1037/E572192010-003, DOI 10.1037/PAS0000486]; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; WHO, 2010, DEPR; *WHO, 2010, INJ; WILSON JP, 2007, LENS CULTURE THEORET; World Health Organization, 1993, ICD 10 CLASS MENT BE; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	120	29	30	2	27	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAR	2011	42	3					288	300		10.1016/j.injury.2010.11.045			13	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	717CJ	WOS:000287019700012	21216400	Green Accepted			2022-02-06	
J	Tate, DF; Khedraki, R; Neeley, ES; Ryser, DK; Bigler, ED				Tate, David F.; Khedraki, Rola; Neeley, E. Shannon; Ryser, David K.; Bigler, Erin D.			Cerebral Volume Loss, Cognitive Deficit, and Neuropsychological Performance: Comparative Measures of Brain Atrophy: II. Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						MRI; TBI; Cognition; Atrophy; Brain/behavior relationships; CNS	ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; MRI; MEMORY; SCHIZOPHRENIA; IMPAIRMENT; DEMENTIA; MODERATE; CORTEX; AD	Traumatic brain injury (TB!) results in a variable degree of cerebral atrophy that is not always related to cognitive measures across studies. However, the use of different methods for examining atrophy may be a reason why differences exist. The purpose of this manuscript was to examine the predictive utility of seven magnetic resonance imaging (MRI) - derived brain volume or indices of atrophy for a large cohort of TBI patients (n = 65). The seven quantitative MRI (qMRI) measures included uncorrected whole brain volume, brain volume corrected by total intracranial volume, brain volume corrected by the ratio of the individual TICV by group TICV, a ventricle to brain ratio, total ventricular volume, ventricular volume corrected by TICV, and a direct measure of parenchymal volume loss. Results demonstrated that the various qMRI measures were highly interrelated and that corrected measures proved to be the most robust measures related to neuropsychological performance. Similar to an earlier study that examined cerebral atrophy in aging and dementia, these results suggest that a single corrected brain volume measure is all that is necessary in studies examining global MRI indicators of cerebral atrophy in relationship to cognitive function making additional measures of global atrophy redundant and unnecessary. (JINS, 2011, 17, 308-316)	[Tate, David F.] Boston Univ, Med Ctr, Alzheimers Dis Ctr, Boston, MA USA; [Tate, David F.; Neeley, E. Shannon] Brigham Young Univ, Dept Stat, Provo, UT 84602 USA; [Ryser, David K.] Intermt Med Ctr, Dept Phys Med & Rehabil, Murray, UT USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Tate, David F.; Khedraki, Rola] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Imaging, Boston, MA 02115 USA		Tate, DF (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Imaging, 1249 Boylston St,Room 345, Boston, MA 02115 USA.	dftatephd@mac.com	Tate, David/G-5166-2011; Tate, David F/I-3963-2013	Tate, David/0000-0003-0213-1920; Tate, David F/0000-0003-0213-1920; Khedraki, Rola/0000-0002-6334-923X	Deseret Foundation at LDS Hospital; Ira Fulton Foundation; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH073416] Funding Source: NIH RePORTER	Support for this study was provided by grants from the Deseret Foundation at LDS Hospital and the Ira Fulton Foundation. There are no financial and/or relationship conflicts of interest to disclose.	ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Balthazar MLF, 2010, J INT NEUROPSYCH SOC, V16, P205, DOI 10.1017/S1355617709990956; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P442, DOI 10.1017/S1355617704103111; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, INVEST RADIOL, V36, P539, DOI 10.1097/00004424-200109000-00006; Bigler ED, 2000, AM J NEURORADIOL, V21, P1857; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Blinkov SM., 1968, HUMAN BRAIN FIGURES; BRADLEY WG, 2000, NEUROIMAGING, P704; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.1155/2009/616581, 10.3233/BEN-2009-0226]; Cahn DA, 1998, J INT NEUROPSYCH SOC, V4, P106, DOI 10.1017/S1355617798001064; Carne RP, 2006, J CLIN NEUROSCI, V13, P60, DOI 10.1016/j.jocn.2005.02.013; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; Fama R, 2000, NEUROPSYCHOLOGY, V14, P29, DOI 10.1037/0894-4105.14.1.29; Fjell AM, 2009, J NEUROSCI, V29, P15223, DOI 10.1523/JNEUROSCI.3252-09.2009; Forstl H, 1996, BRIT J PSYCHIAT, V168, P280, DOI 10.1192/bjp.168.3.280; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Gur RE, 2000, ARCH GEN PSYCHIAT, V57, P769, DOI 10.1001/archpsyc.57.8.769; HAUG JO, 1962, ACTA PSYCHIAT SCAND, V165, P1; He J, 2009, ARCH NEUROL-CHICAGO, V66, P1393, DOI 10.1001/archneurol.2009.252; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Jack CR, 1998, NEUROLOGY, V51, P993, DOI 10.1212/WNL.51.4.993; Jack CR, 1999, NEUROLOGY, V52, P1397, DOI 10.1212/WNL.52.7.1397; JACK CR, 1995, MAGN RESON IMAGING, V13, P1057, DOI 10.1016/0730-725X(95)02013-J; Killiany RJ, 2000, ANN NEUROL, V47, P430, DOI 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Loewenstein DA, 2009, AM J GERIAT PSYCHIAT, V17, P1050, DOI 10.1097/JGP.0b013e3181b7ef42; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; NELLHAUS G, 1968, PEDIATRICS, V41, P106; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Penna S, 2010, J HEAD TRAUMA REHAB, V25, P52, DOI 10.1097/HTR.0b013e3181c29952; Perry ME, 2009, NEUROPSYCHOLOGIA, V47, P2835, DOI 10.1016/j.neuropsychologia.2009.06.008; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; RAZ N, 1988, PSYCHIAT RES, V26, P245, DOI 10.1016/0165-1781(88)90079-0; RAZ S, 1988, PSYCHIAT RES, V24, P71, DOI 10.1016/0165-1781(88)90142-4; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; ROBB R, 1995, ANALYZE 3 DIMENSIONA; Robb RA, 2001, IEEE T MED IMAGING, V20, P854, DOI 10.1109/42.952724; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; SHEAR PK, 1995, ARCH NEUROL-CHICAGO, V52, P392, DOI 10.1001/archneur.1995.00540280078021; Smith CD, 2000, NEUROLOGY, V54, P838, DOI 10.1212/WNL.54.4.838; Tanabe JL, 1997, AM J NEURORADIOL, V18, P115; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Wilson RS, 1996, NEUROPSYCHOLOGY, V10, P459; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zar, 1996, BIOSTAT ANAL	52	29	29	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					308	316		10.1017/S1355617710001670			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900011	21352625				2022-02-06	
J	Suhr, JA; Sullivan, BK; Rodriguez, JL				Suhr, Julie A.; Sullivan, Brian K.; Rodriguez, Jose Luis			The Relationship of Noncredible Performance to Continuous Performance Test Scores in Adults Referred for Attention-Deficit/Hyperactivity Disorder Evaluation	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; Attention deficit disorder with hyperactivity; Neuropsychological assessment; Continuous performance tests	DEFICIT HYPERACTIVITY DISORDER; WORD MEMORY TEST; TRAUMATIC BRAIN-INJURY; COLLEGE-STUDENTS; SELF-REPORT; PRESCRIPTION STIMULANTS; SYMPTOM EXAGGERATION; ILLICIT USE; ADHD; PREVALENCE	Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults is complicated by the fact that neither symptom report nor neuropsychological findings are specific to the diagnosis. Few studies have addressed the possibility that noncredible performance influences the effectiveness of neuropsychological test findings in ADHD assessment. The present study utilized archival data on Conner's Continuous Performance Test (CPT) scores from young adults referred for concerns about ADHD at two different universities, who were divided into three groups: (1) those who failed a measure of noncredible performance (the Word Memory Test; WMT), (2) those who met diagnostic criteria for ADHD, and (3) controls with psychological symptoms who did not meet the diagnostic criteria for ADHD. More individuals who failed the WMT were also clinically impaired on the CPT than individuals diagnosed with ADHD and individuals with psychological symptoms, who could not be distinguished from each other. Results demonstrate the importance of assessing for noncredible performance before interpreting neuropsychological test scores in ADHD assessment. Results also emphasize the importance of considering other disorders that can impact CPT performance prior to interpreting CPT impairment as indicative of ADHD.	[Suhr, Julie A.] Ohio Univ, Dept Psychol, Athens, OH 45701 USA; [Sullivan, Brian K.; Rodriguez, Jose Luis] Coll Charleston, Counseling Serv, Charleston, SC 29401 USA; [Sullivan, Brian K.; Rodriguez, Jose Luis] Coll Charleston, Substance Abuse Serv, Charleston, SC 29401 USA		Suhr, JA (corresponding author), Ohio Univ, Dept Psychol, Athens, OH 45701 USA.	suhr@ohio.edu					Advokat Claire, 2007, J Atten Disord, V10, P253, DOI 10.1177/1087054706292106; ALFANO K, 2007, ASSESSMENT FEIGNED C; Barkley R. A., 2006, ATTENTION DEFICIT HY; Booksh RL, 2010, J ATTEN DISORD, V13, P325, DOI 10.1177/1087054708329927; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Cohen Andrew L, 2007, J Atten Disord, V11, P49, DOI 10.1177/1087054706292162; Conners C. K., 2000, CONNERS CONTINUOUS P; Conners CK., 1998, CONNERS ADULT ATTENT; Conti RP, 2004, PSYCHOL REP, V94, P987; DuPaul GJ, 2001, J LEARN DISABIL-US, V34, P370, DOI 10.1177/002221940103400412; Egeland J, 2007, ARCH CLIN NEUROPSYCH, V22, P763, DOI 10.1016/j.acn.2007.06.004; Epstein JN, 1998, CLIN NEUROPSYCHOL, V12, P155, DOI 10.1076/clin.12.2.155.2000; Faraone Stephen V, 2005, J Atten Disord, V9, P384, DOI 10.1177/1087054705281478; Frazier TW, 2008, ARCH CLIN NEUROPSYCH, V23, P501, DOI 10.1016/j.acn.2008.04.001; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2005, GREENS WORD MEMORY T, Vrev. ed.; GROTE CL, 2007, ASSESSMENT MALINGERE; Hall KM, 2005, J AM COLL HEALTH, V53, P167, DOI 10.3200/JACH.53.4.167-174; Harrison A. G., 2004, ADHD REPORT, V12, P8, DOI [10.1521/adhd.12.6.8.55256, DOI 10.1521/ADHD.12.6.8.55256]; Harrison AG, 2007, ARCH CLIN NEUROPSYCH, V22, P577, DOI 10.1016/j.acn.2007.03.008; Harrison AG, 2010, APPL NEUROPSYCHOL, V17, P135, DOI 10.1080/09084281003715642; Heiligenstein E, 1998, J AM COLL HEALTH, V46, P185, DOI 10.1080/07448489809595609; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jachimowicz G., 2004, COGNITIVE SCI ONLINE, V2, P6; Leark RA, 2002, ARCH CLIN NEUROPSYCH, V17, P335, DOI 10.1016/S0887-6177(01)00118-4; Lewandowski LJ, 2008, J ATTEN DISORD, V12, P156, DOI 10.1177/1087054707310882; Mannuzza S, 2002, AM J PSYCHIAT, V159, P1882, DOI 10.1176/appi.ajp.159.11.1882; McCabe SE, 2005, ADDICTION, V100, P96, DOI 10.1111/j.1360-0443.2005.00944.x; McCann BS, 2004, COMPR PSYCHIAT, V45, P175, DOI 10.1016/j.comppsych.2004.02.006; Murphy K., 1996, J ATTEN DISORD, DOI [10.1177/108705479600100303, DOI 10.1177/108705479600100303]; MURPHY K, 1994, ADHD REPORT, V2, P3; Murphy P, 2000, AM J PSYCHIAT, V157, P1156, DOI 10.1176/appi.ajp.157.7.1156; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1424, DOI 10.1016/j.biopsych.2004.11.011; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Quinn CA, 2003, ARCH CLIN NEUROPSYCH, V18, P379, DOI 10.1016/S0887-6177(02)00150-6; Riccio C.A., 2001, CLIN APPL CONTINUOUS; ROYBYRNE R, 1997, COMPR PSYCHIAT, V38, P133, DOI DOI 10.1016/S0010-440X(97)90065-1; Solanto MV, 2004, CNS SPECTRUMS, V9, P649, DOI 10.1017/S1092852900001929; Stefanatos GA, 2007, NEUROPSYCHOL REV, V17, P5, DOI 10.1007/s11065-007-9020-3; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teter CJ, 2005, J AM COLL HEALTH, V53, P253, DOI 10.3200/JACH.53.6.253-262; *US DEP ED, 1999, STUD DIS POSTS ED PR; WEYANDT LL, 1995, J PSYCHOPATHOL BEHAV, V17, P293, DOI 10.1007/BF02229304; White BP, 2006, J AM COLL HEALTH, V54, P261, DOI 10.3200/JACH.54.5.261-268	49	29	29	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2011	26	1					1	7		10.1093/arclin/acq094			7	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	709SU	WOS:000286462500001	21159792	Bronze, Green Published			2022-02-06	
J	Walson, KH; Tang, MK; Glumac, A; Alexander, H; Manole, MD; Ma, L; Hsia, CJ; Clark, RS; Kochanek, PM; Kagan, VE; Bayir, H				Walson, Karen H.; Tang, Minke; Glumac, Ashley; Alexander, Henry; Manole, Mioara D.; Ma, Li; Hsia, Carelton J.; Clark, Robert S.; Kochanek, Patrick M.; Kagan, Valerian E.; Bayir, Huelya			Normoxic versus hyperoxic resuscitation in pediatric asphyxial cardiac arrest: Effects on oxidative stress	CRITICAL CARE MEDICINE			English	Article						oxidant injury; cardiac arrest; immature brain; cardiopulmonary resuscitation; brain hypoxia-ischemia; hyperoxia	TRANSIENT FOCAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; INTERNATIONAL LIAISON COMMITTEE; PROTEIN-TYROSINE NITRATION; ADVANCED LIFE-SUPPORT; REDUCES INFARCT SIZE; CEREBRAL-ISCHEMIA; POLYNITROXYL-ALBUMIN; SUPEROXIDE-DISMUTASE	Objective: To determine the effects of normoxic vs. hyperoxic resuscitation on oxidative stress in a model of pediatric asphyxial cardiac arrest. Design: Prospective, interventional study. Setting: University research laboratory. Subjects: Postnatal day 16-18 rats (n = 5 per group). Interventions: Rats underwent asphyxial cardiac arrest for 9 min. Rats were randomized to receive 100% oxygen, room air, or 100% oxygen with polynitroxyl albumin (10 mL.kg(-1) intravenously, 0 and 30 min after resuscitation) for 1 hr from the start of cardiopulmonary resuscitation. Shams recovered in 100% oxygen or room air after surgery. Measurements and Main Results: Physiological variables were recorded at baseline to 1 hr after resuscitation. At 6 hrs after asphyxial cardiac arrest, levels of reduced glutathione and protein-thiols (fluorescent assay), activities of total superoxide dismutase and mitochondrial manganese superoxide dismutase (cytochrome c reduction method), manganese superoxide dismutase expression (Western blot), and lipid peroxidation (4-hydroxynonenal Michael adducts) were evaluated in brain tissue homogenates. Hippocampal 3-nitrotyrosine levels were determined by immunohistochemistry 72 hrs after asphyxial cardiac arrest. Survival did not differ among groups. At 1 hr after resuscitation, PaO2, pH, and mean arterial pressure were decreased in room air vs. 100% oxygen rats (59 +/- 3 vs. 465 +/- 46 mm Hg, 7.36 +/- 0.05 vs. 7.42 +/- 0.03, 35 +/- 4 vs. 45 +/- 5 mm Hg; p<.05). Rats resuscitated with 100% oxygen had decreased hippocampal reduced glutathione levels vs. sham (15.3 +/- 0.4 vs. 20.9 +/- 4.1 nmol.mgprotein(-1); p<.01). Hippocampal manganese superoxide dismutase activity was significantly increased in 100% oxygen rats vs. sham (14 +/- 2.4 vs. 9.5 +/- 1.6 units.mg protein(-1), p<.01), with no difference in protein expression of manganese superoxide dismutase. Room air and 100% oxygen plus polynitroxyl albumin groups had hippocampal reduced glutathione and manganese superoxide dismutase activity levels comparable with sham. Protein thiol levels were unchanged across groups. Compared with all other groups, rats receiving 100% oxygen had increased immunopositivity for 3-nitrotyrosine in the hippocampus and increased lipid peroxidation in the cortex. Conclusions: Resuscitation with 100% oxygen leads to increased oxidative stress in a model that mimics pediatric cardiac arrest. This may be prevented by using room air or giving an antioxidant with 100% oxygen resuscitation. (Crit Care Med 2011; 39: 335-343)	[Walson, Karen H.; Clark, Robert S.; Kochanek, Patrick M.; Bayir, Huelya] Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Glumac, Ashley; Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Tang, Minke; Alexander, Henry; Manole, Mioara D.; Clark, Robert S.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Grad Sch Publ Hlth, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA USA; [Ma, Li; Hsia, Carelton J.] SynZyme Technol, Irvine, CA USA		Walson, KH (corresponding author), Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA.	karen.walson@choa.org; bayihx@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885	Department of Defense, Washington, DCUnited States Department of Defense [PR054755 W81XWH0610247]; National Institutes of Health, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061817, HD057587, HD045968]; Laerdal Foundation, Stavanger, Norway; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD058798] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045968, R21HD057587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817] Funding Source: NIH RePORTER	Supported, in part, by grants from the Department of Defense, Washington, DC (PR054755 W81XWH0610247), National Institutes of Health, Bethesda, MD (NS061817, HD057587, and HD045968), and the Laerdal Foundation, Stavanger, Norway.	Alvarez-Diaz A, 2007, NEONATOLOGY, V92, P227, DOI 10.1159/000103741; Atkins DL, 2006, PEDIATRICS, V117, pE955, DOI 10.1542/peds.2006-0206; Atkins DL, 2006, PEDIATRICS, V117, pE1005, DOI 10.1542/peds.2006-0346; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; Balan IS, 2006, STROKE, V37, P3008, DOI 10.1161/01.STR.0000248455.73785.b1; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Beaulieu C, 1998, J CEREBR BLOOD F MET, V18, P1022, DOI 10.1097/00004647-199809000-00012; Behringer W, 2002, J CEREBR BLOOD F MET, V22, P105, DOI 10.1097/00004647-200201000-00013; Bostek C C, 1989, AANA J, V57, P231; Buonocore G, 2007, SEMIN FETAL NEONAT M, V12, P287, DOI 10.1016/j.siny.2007.01.020; Candelario-Jalil E, 2001, NEUROSCI RES, V41, P233, DOI 10.1016/S0168-0102(01)00282-6; CERCHIARI EL, 1993, RESUSCITATION, V25, P9, DOI 10.1016/0300-9572(93)90003-9; Chaudhari T, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006817.pub2; Chen Patrick, 2005, Air Med J, V24, P244, DOI 10.1016/j.amj.2005.08.003; CHEVION M, 1988, FREE RADICAL BIO MED, V5, P27, DOI 10.1016/0891-5849(88)90059-7; Deguchi K, 2008, BRAIN RES, V1188, P1, DOI 10.1016/j.brainres.2007.07.104; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dohi K, 2003, ACT NEUR S, V86, P87; Donoghue AJ, 2005, ANN EMERG MED, V46, P512, DOI 10.1016/j.annemergmed.2005.05.028; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fink Ericka L, 2004, Pediatr Crit Care Med, V5, P139, DOI 10.1097/01.PCC.0000112376.29903.8F; GUTTERIDGE JMC, 1994, CHEM-BIOL INTERACT, V91, P133, DOI 10.1016/0009-2797(94)90033-7; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hayashi T, 2004, NEUROBIOL DIS, V15, P229, DOI 10.1016/j.nbd.2003.10.005; Hou ST, 2002, INT REV CYTOL, V221, P93; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Ischiropoulos H, 2009, ARCH BIOCHEM BIOPHYS, V484, P117, DOI 10.1016/j.abb.2008.10.034; Ishibashi N, 2002, J IMMUNOL, V168, P1926, DOI 10.4049/jimmunol.168.4.1926; IZUMI Y, 1995, SYNAPSE, V20, P19, DOI 10.1002/syn.890200104; JACKSON PS, 1993, J NEUROPHYSIOL, V70, P1412, DOI 10.1152/jn.1993.70.4.1412; Kentner R, 2002, J TRAUMA, V53, P968, DOI 10.1097/00005373-200211000-00025; Kilgannon JH, 2008, RESUSCITATION, V79, P410, DOI 10.1016/j.resuscitation.2008.07.019; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; KIRSCH JR, 1992, J NEUROTRAUM, V9, pS157; Klaus S, 2003, RESUSCITATION, V56, P299, DOI 10.1016/S0300-9572(02)00342-8; Kliegman R. M., 2007, NELSON TXB PEDIAT, V18th; Kondo T, 1997, J NEUROSCI, V17, P4180; Kuisma M, 2006, RESUSCITATION, V69, P199, DOI 10.1016/j.resuscitation.2005.08.010; Kuppusamy P, 1996, BIOCHEMISTRY-US, V35, P7051, DOI 10.1021/bi952857s; Kutzsche S, 2001, PEDIATR RES, V49, P834, DOI 10.1203/00006450-200106000-00020; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li HQ, 2002, FREE RADICAL BIO MED, V32, P712, DOI 10.1016/S0891-5849(02)00762-1; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; Liu YB, 1998, STROKE, V29, P1679, DOI 10.1161/01.STR.29.8.1679; Love S, 1999, BRAIN PATHOL, V9, P119; Lukic-Panin V, 2007, BRAIN RES, V1176, P143, DOI 10.1016/j.brainres.2007.07.038; Macdonald RL, 1998, NEUROL MED-CHIR, V38, P1, DOI 10.2176/nmc.38.1; MacLean DA, 1998, CIRCULATION, V98, P1990, DOI 10.1161/01.CIR.98.19.1990; Margaill I, 2005, FREE RADICAL BIO MED, V39, P429, DOI 10.1016/j.freeradbiomed.2005.05.003; Martin RJ, 2008, SEMIN PERINATOL, V32, P355, DOI 10.1053/j.semperi.2008.08.002; Matchett GA, 2009, NEUROL RES, V31, P128, DOI 10.1179/174313209X393546; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; McCracken E, 2001, BRAIN PATHOL, V11, P414, DOI 10.1111/j.1750-3639.2001.tb00409.x; Mullner M, 1996, STROKE, V27, P59, DOI 10.1161/01.STR.27.1.59; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; Nicole A, 1998, BIOMED PHARMACOTHER, V52, P349, DOI 10.1016/S0753-3322(99)80001-8; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ramji S, 2003, Indian Pediatr, V40, P510; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Safar P, 2002, CRIT CARE MED, V30, pS140, DOI 10.1097/00003246-200204001-00004; Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; Saugstad OD, 2005, BIOL NEONATE, V87, P27, DOI 10.1159/000080950; Saugstad OD, 2003, PEDIATRICS, V112, P296, DOI 10.1542/peds.112.2.296; Sirbaugh PE, 1999, ANN EMERG MED, V33, P174, DOI 10.1016/S0196-0644(99)70391-4; Skinner MR, 1996, J PHYSIOL-LONDON, V495, P553, DOI 10.1113/jphysiol.1996.sp021615; Solas A B, 2001, Pediatr Crit Care Med, V2, P340; Solberg R, 2007, PEDIATR RES, V62, P559, DOI 10.1203/PDR.0b013e318156e8aa; Soule BP, 2007, FREE RADICAL BIO MED, V42, P1632, DOI 10.1016/j.freeradbiomed.2007.02.030; Sugawara T, 2003, ANTIOXID REDOX SIGN, V5, P597, DOI 10.1089/152308603770310266; Sugawara T, 2001, NEUROREPORT, V12, P3609, DOI 10.1097/00001756-200111160-00047; Sugawara Taku, 2004, NeuroRx, V1, P17, DOI 10.1602/neurorx.1.1.17; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Ullegaddi R, 2005, EUR J CLIN NUTR, V59, P1367, DOI 10.1038/sj.ejcn.1602248; VAAGENES P, 1984, CRIT CARE MED, V12, P846, DOI 10.1097/00003246-198410000-00002; Vento M, 2002, SEMIN PERINATOL, V26, P406, DOI 10.1053/sper.2002.37312; Vento M, 2003, J PEDIATR-US, V142, P240, DOI 10.1067/mpd.2003.91; Vento M, 2001, PEDIATRICS, V107, P642, DOI 10.1542/peds.107.4.642; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; Vos GD, 2003, EUR J EMERG MED, V10, P195, DOI 10.1097/00063110-200309000-00007; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06; Zhang S, 2000, FREE RADICAL BIO MED, V29, P42, DOI 10.1016/S0891-5849(00)00295-1; ZWEMER CF, 1994, RESUSCITATION, V27, P159, DOI 10.1016/0300-9572(94)90009-4	89	29	29	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2011	39	2					335	343		10.1097/CCM.0b013e3181ffda0e			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709GN	WOS:000286426400014	21057313				2022-02-06	
J	Kramer, AH; Diringer, MN; Suarez, JI; Naidech, AM; Macdonald, LR; Le Roux, PD				Kramer, Andreas H.; Diringer, Michael N.; Suarez, Jose I.; Naidech, Andrew M.; Macdonald, Loch R.; Le Roux, Peter D.			Red blood cell transfusion in patients with subarachnoid hemorrhage: a multidisciplinary North American survey	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL OXYGENATION; INTENSIVE-CARE; COMPLICATIONS; METABOLISM; PRESSURE; DELIVERY; TENSION; FLOW	Introduction: Anemia is associated with poor outcomes in patients with aneurysmal subarachnoid hemorrhage (SAH). It remains unclear whether this association can be modified with more aggressive use of red blood cell (RBC) transfusions. The degree to which restrictive thresholds have been adopted in neurocritical care patients remains unknown. Methods: We performed a survey of North American academic neurointensivists, vascular neurosurgeons and multidisciplinary intensivists who regularly care for patients with SAH to determine hemoglobin (Hb) concentrations which commonly trigger a decision to initiate transfusion. We also assessed minimum and maximum acceptable Hb goals in the context of a clinical trial and how decision-making is influenced by advanced neurological monitoring, clinician characteristics and patient-specific factors. Results: The survey was sent to 531 clinicians, of whom 282 (53%) responded. In a hypothetical patient with high-grade SAH (WFNS 4), the mean Hb concentration at which clinicians administered RBCs was 8.19 g/dL (95% CI, 8.07 to 8.30 g/dL). Transfusion practices were comparatively more restrictive in patients with low-grade SAH (mean Hb 7.85 g/dL (95% CI, 7.73 to 7.97 g/dL)) (P < 0.0001) and more liberal in patients with delayed cerebral ischemia (DCI) (mean Hb 8.58 g/dL (95% CI, 8.45 to 8.72 g/dL)) (P < 0.0001). In each setting, there was a broad range of opinions. The majority of respondents expressed a willingness to study a restrictive threshold of = 8 g/dL (92%) and a liberal goal of = 10 g/dl (75%); in both cases, the preferred transfusion thresholds were significantly higher for patients with DCI (P < 0.0001). Neurosurgeons expressed higher minimum Hb goals than intensivists, especially for patients with high-grade SAH (b = 0.46, P = 0.003), and were more likely to administer two rather than one unit of RBCs (56% vs. 19%; P < 0.0001). Institutional use of transfusion protocols was associated with more restrictive practices. More senior clinicians preferred higher Hb goals in the context of a clinical trial. Respondents were more likely to transfuse patients with brain tissue oxygen tension values < 15 mmHg and lactate-to-pyruvate ratios > 40. Conclusions: There is widespread variation in the use of RBC transfusions in SAH patients. Practices are heavily influenced by the specific dynamic clinical characteristics of patients and may be further modified by clinician specialty and seniority, the use of protocols and advanced neurological monitoring.	[Kramer, Andreas H.] Univ Calgary, Dept Crit Care Med, Hotchkiss Brain Inst, Foothills Med Ctr, Calgary, AB T2N 2T9, Canada; [Kramer, Andreas H.] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Foothills Med Ctr, Calgary, AB T2N 2T9, Canada; [Diringer, Michael N.] Washington Univ, Sch Med, Dept Neurol & Neurol Surg, Neurol Neurosurg Intens Care Unit, St Louis, MO 63110 USA; [Suarez, Jose I.] Baylor Coll Med, Dept Neurol, Div Vasc Neurol, Houston, TX 77030 USA; [Suarez, Jose I.] Baylor Coll Med, Dept Neurol, Div Neurocrit Care, Houston, TX 77030 USA; [Naidech, Andrew M.] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA; [Macdonald, Loch R.] Univ Toronto, Div Neurosurg, Dept Surg, St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Le Roux, Peter D.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19106 USA		Kramer, AH (corresponding author), Univ Calgary, Dept Crit Care Med, Hotchkiss Brain Inst, Foothills Med Ctr, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.	andreas.kramer@calgaryhealthregion.ca	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537			Bendel P, 2008, RADIOLOGY, V246, P543, DOI 10.1148/radiol.2461061915; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Cummings SM, 2001, HEALTH SERV RES, V35, P1347; Deans KJ, 2007, CRIT CARE MED, V35, P1509, DOI 10.1097/01.CCM.0000266584.40715.A6; Dhar R, 2009, STROKE, V40, P3039, DOI 10.1161/STROKEAHA.109.556159; Ekelund A, 2002, ACTA NEUROCHIR, V144, P703, DOI 10.1007/s00701-002-0959-9; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kahn JM, 2006, CRIT CARE MED, V34, P196, DOI 10.1097/01.CCM.0000194540.44020.8E; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Kramer AH, 2008, CRIT CARE MED, V36, P2070, DOI 10.1097/CCM.0b013e31817c1095; Kramer AH, 2009, NEUROCRIT CARE, V10, P20, DOI 10.1007/s12028-008-9137-0; Kramer AH, 2009, CRIT CARE, V13, DOI 10.1186/cc7916; KURTZ P, 2010, CRITICAL CARE, V14, P341; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Leece P, 2004, J MED INTERNET RES, V6, P26, DOI 10.2196/jmir.6.3.e30; Levine J, 2010, NEUROSURGERY, V66, P312, DOI 10.1227/01.NEU.0000363747.47587.6C; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Naidech AM, 2006, NEUROSURGERY, V59, P775, DOI 10.1227/01.NEU.0000232662.86771.A9; Ramakrishna R, 2008, J NEUROSURG, V109, P1075, DOI 10.3171/JNS.2008.109.12.1075; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stevens RD, 2009, INTENS CARE MED, V35, P1556, DOI 10.1007/s00134-009-1533-1; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22; BRAIN TISSUE OXYGEN	31	29	31	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	1							R30	10.1186/cc9977			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742RJ	WOS:000288961900030	21244675	gold, Green Published			2022-02-06	
J	Mogensen, J				Mogensen, Jesper			Reorganization of the injured brain: implications for studies of the neural substrate of cognition	FRONTIERS IN PSYCHOLOGY			English	Article						neural plasticity; reorganization; brain injury; localization of function; recovery; recovery of function; consciousness; neural organization	TRANSCRANIAL MAGNETIC STIMULATION; FORNIX AND/OR ABLATION; SPATIAL DELAYED ALTERNATION; GENE-EXPRESSION; SOMATOSENSORY CORTEX; PRISM ADAPTATION; NEURONAL REPLACEMENT; CORTICAL PLASTICITY; CEREBRAL PLASTICITY; FUNCTIONAL RECOVERY	In the search for a neural substrate of cognitive processes, a frequently utilized method is the scrutiny of post-traumatic symptoms exhibited by individuals suffering focal injury to the brain. For instance, the presence or absence of conscious awareness within a particular domain may, combined with knowledge of which regions of the brain have been injured, provide important data in the search for neural correlates of consciousness. Like all studies addressing the consequences of brain injury, however, such research has to face the fact that in most cases, post-traumatic impairments are accompanied by a "functional recovery" during which symptoms are reduced or eliminated. The apparent contradiction between localization and recovery, respectively, of functions constitutes a problem to almost all aspects of cognitive neuroscience. Several lines of investigation indicate that although the brain remains highly plastic throughout life, the post-traumatic plasticity does not recreate a copy of the neural mechanisms lost to injury. Instead, the uninjured parts of the brain are functionally reorganized in a manner which - in spite of not recreating the basic information processing lost to injury - is able to allow a more or less complete return of the surface phenomena (including manifestations of consciousness) originally impaired by the trauma. A novel model [the Reorganization of Elementary Functions-model] of these processes is presented - and some of its implications discussed relative to studies of the neural substrates of cognition and consciousness.	Univ Copenhagen, Dept Psychol, Unit Cognit Neurosci, DK-1353 Copenhagen K, Denmark		Mogensen, J (corresponding author), Univ Copenhagen, Dept Psychol, Unit Cognit Neurosci, Oester Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.	jesper.mogensen@psy.ku.dk		Mogensen, Jesper/0000-0003-1959-581X			Ansaldo AI, 2003, BRAIN LANG, V87, P177, DOI 10.1016/S0093-934X(03)00258-X; Ansaldo AN, 2002, BRAIN LANG, V82, P206, DOI 10.1016/S0093-934X(02)00017-2; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Banks C., 2010, J STROKE CEREBROVASC, P1; Barrett HC, 2006, PSYCHOL REV, V113, P628, DOI 10.1037/0033-295X.113.3.628; Bartolomeo P, 2007, CURR OPIN NEUROL, V20, P381, DOI 10.1097/WCO.0b013e32816aa3a3; Baumgaertner A, 2005, BRAIN LANG, V95, P211, DOI 10.1016/j.bandl.2005.07.110; Berardi N, 2004, NEURON, V44, P905, DOI 10.1016/j.neuron.2004.12.008; Berry M, 1982, Bibl Anat, P1; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Buller D. J., 2000, BRAIN MIND, V1, P307, DOI [10.1023/A:1011573226794, DOI 10.1023/A:1011573226794]; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Choi JY, 2007, J NUCL MED, V48, P194; Coltheart M., 2001, HDB COGNITIVE NEUROP, P3; Danckert J, 2000, CURR BIOL, V10, pR64, DOI 10.1016/S0960-9822(00)00284-0; Del Rio JA, 2007, CURR PHARM DESIGN, V13, P2485; DELFS JM, 1995, J NEUROSCI, V15, P6562; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; FAWCETT JW, 1989, DEV BIOL, V135, P449, DOI 10.1016/0012-1606(89)90193-0; Fodor J., 2000, MIND DOESNT WORK WAY; Fodor J.A., 1983, MODULARITY MIND; Frassinetti F, 2002, BRAIN, V125, P608, DOI 10.1093/brain/awf056; Friston KJ, 2003, TRENDS COGN SCI, V7, P151, DOI 10.1016/S1364-6613(03)00054-8; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Funk J, 2010, NEUROPSYCHOLOGIA, V48, P298, DOI 10.1016/j.neuropsychologia.2009.09.018; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; Hagemann G, 1998, ANN NEUROL, V44, P255, DOI 10.1002/ana.410440217; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; Hiramoto M, 2000, NATURE, V406, P886, DOI 10.1038/35022571; Irvine DRF, 2007, HEARING RES, V229, P158, DOI 10.1016/j.heares.2007.01.006; Karl A, 2001, J NEUROSCI, V21, P3609, DOI 10.1523/JNEUROSCI.21-10-03609.2001; Kentridge RW, 1999, P ROY SOC B-BIOL SCI, V266, P1805, DOI 10.1098/rspb.1999.0850; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Koeberle PD, 2004, J NEUROBIOL, V59, P162, DOI 10.1002/neu.10345; Krechevsky I, 1933, J COMP PSYCHOL, V16, P99, DOI 10.1037/h0072223; Krechevsky I, 1932, PSYCHOL REV, V39, P516, DOI 10.1037/h0073500; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Lane RD, 1997, BIOL PSYCHIAT, V42, P834, DOI 10.1016/S0006-3223(97)00050-4; Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982; Leon-Carrion J., 2001, REV ESPANOLA NEUROPS, V3, P58; Lepore F., 1985, CAN J PSYCHOL, V37, P527; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Marcel AJ, 1998, BRAIN, V121, P1565, DOI 10.1093/brain/121.8.1565; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; Meinzer M, 2008, NEUROIMAGE, V39, P2038, DOI 10.1016/j.neuroimage.2007.10.008; Merzenich M M, 1993, J Hand Ther, V6, P89; Mogensen J, 2005, BRAIN RES BULL, V65, P41, DOI 10.1016/j.brainresbull.2004.11.010; Mogensen J, 2004, BRAIN RES BULL, V63, P217, DOI 10.1016/j.brainresbull.2004.02.008; Mogensen J, 2003, PHARMACOL BIOCHEM BE, V75, P381, DOI 10.1016/S0091-3057(03)00107-2; MOGENSEN J, 1987, ACTA NEUROBIOL EXP, V47, P45; Mogensen J, 2002, NEUROBIOL LEARN MEM, V78, P139, DOI 10.1006/nlme.2001.4055; Mogensen J., 2011, FRONT CONSC IN PRESS; Mogensen J., 2011, HDB LAB ANI IN PRESS, VII; Mogensen J., 2003, HDB LAB ANIMAL SCI, VII, P95; Mogensen J, 2008, BRAIN RES BULL, V77, P1, DOI 10.1016/j.brainresbull.2008.05.005; Mogensen J, 2007, BRAIN RES BULL, V73, P86, DOI 10.1016/j.brainresbull.2007.02.006; Mogensen J, 2009, SCAND J PSYCHOL, V50, P561, DOI 10.1111/j.1467-9450.2009.00781.x; Monakow C, 1914, LOKALISATION GROSSHI; Munte TF, 2002, NAT REV NEUROSCI, V3, P473, DOI 10.1038/nrn843; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Natsoulas T, 1997, AM J PSYCHOL, V110, P1, DOI 10.2307/1423698; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; OLTON DS, 1978, CIBA F S, V58, P327; PANKSEPP J, 2000, EVOLUTION COGNITION, V6, P108, DOI DOI 10.1146/ANNUREV.AN.18.100189.0; Pascual-Leone A, 1999, PHILOS T R SOC B, V354, P1229, DOI 10.1098/rstb.1999.0476; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; Perani D, 2003, BRAIN LANG, V85, P357, DOI 10.1016/S0093-934X(02)00561-8; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Price CJ, 2002, TRENDS COGN SCI, V6, P416, DOI 10.1016/S1364-6613(02)01976-9; Ptito M, 2005, BRAIN, V128, P606, DOI 10.1093/brain/awh380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Ramachandran V., 1998, PHANTOMS BRAIN PROBI; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; RECANZONE GH, 1993, J NEUROSCI, V13, P87; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; Rumelhart DE., 1986, PARALLEL DISTRIBUTED, P318, DOI 10.7551/mitpress/5236.001.0001; Sarri M, 2008, NEUROPSYCHOLOGIA, V46, P1069, DOI 10.1016/j.neuropsychologia.2007.11.005; Schafer R, 2008, NEUROSCI LETT, V439, P61, DOI 10.1016/j.neulet.2008.04.098; Scharff C, 2000, NEURON, V25, P481, DOI 10.1016/S0896-6273(00)80910-1; Scheich H, 1991, Curr Opin Neurobiol, V1, P236, DOI 10.1016/0959-4388(91)90084-K; Schindler I, 2006, NEUROPSYCHOLOGIA, V44, P1444, DOI 10.1016/j.neuropsychologia.2005.12.003; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Selnes OA., 2001, HDB COGNITIVE NEUROP, P23; Serino A, 2007, NEUROPSYCHOL REHABIL, V17, P657, DOI 10.1080/09602010601052006; Serino A, 2006, NEUROPSYCHOLOGIA, V44, P1068, DOI 10.1016/j.neuropsychologia.2005.10.024; Silvanto J, 2008, CURR BIOL, V18, pR950, DOI 10.1016/j.cub.2008.08.016; Specht K, 2009, NEUROIMAGE, V47, P2057, DOI 10.1016/j.neuroimage.2009.06.011; Thai-Van H, 2007, HEARING RES, V233, P14, DOI 10.1016/j.heares.2007.06.003; Thomas C, 1997, ELECTROEN CLIN NEURO, V102, P86, DOI 10.1016/S0921-884X(96)95653-2; Thulborn KR, 1999, STROKE, V30, P749, DOI 10.1161/01.STR.30.4.749; Walsh V, 2000, NAT REV NEUROSCI, V1, P73, DOI 10.1038/35036239; Weiss T, 2000, EXP BRAIN RES, V134, P199, DOI 10.1007/s002210000456; Werbos P. J., 1994, ROOTS BACKPROPAGATIO; Wilms I, 2010, NEUROPSYCHOL REHABIL, V20, P830, DOI 10.1080/09602011.2010.492711; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Xerri C, 1996, J PHYSIOLOGY-PARIS, V90, P277, DOI 10.1016/S0928-4257(97)81438-6; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010; [No title captured]	108	29	29	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.		2011	2								7	10.3389/fpsyg.2011.00007			10	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	V31DG	WOS:000208863700019	21713186	Green Published, gold			2022-02-06	
J	Pervin, F; Chen, WNW				Pervin, Farhana; Chen, Weinong W.			Effect of inter-species, gender, and breeding on the mechanical behavior of brain tissue	NEUROIMAGE			English	Article						Brain tissues; Species; Strain rates; Stress-strain; Kolsky Bar	HOPKINSON PRESSURE BAR	Mechanical response of brain tissue deforming at high rates are needed to build high-fidelity computer models for traumatic brain injury (TBI) studies. Different types of mammalian brains have been used to obtain the constitutive behavior of tissue. It is necessary to examine how these different brains compare to each other in order to determine which animal might be the best surrogate for human brain tissue. In this experimental study, fresh brain tissue from three different mammals, two types of porcine breeds, and genders were loaded under uniaxial compression over a wide range of strain rates. The experiments at higher rates were conducted with a Kolsky bar modified for soft tissue characterization, whereas lower rate experiments were performed on a conventional hydraulic material test frame. Experimental results did not show any significant difference in high-rate compressive response of the brain tissue of different animals, different breeds, and different genders. However, there was significant rate dependence for all tissues tested, especially in the Kolsky bar range. Further investigation is necessary to identify the source of the rate effects. (C) 2010 Elsevier Inc. All rights reserved.	[Chen, Weinong W.] Purdue Univ, Sch Aeronaut Astronaut, W Lafayette, IN 47907 USA; Purdue Univ, Sch Mat Engn, W Lafayette, IN 47907 USA		Chen, WNW (corresponding author), Purdue Univ, Sch Aeronaut Astronaut, 3323 Neil Armstrong Hall Engn,701 W Stadium Ave, W Lafayette, IN 47907 USA.	wchen@purdue.edu			US Army Research Office (ARO); Joint Improvised Explosive Device Defeat Organization (JIEDDO) through Massachusetts Institute of Technology (MIT)	This research was financially supported by US Army Research Office (ARO) and Joint Improvised Explosive Device Defeat Organization (JIEDDO) through Massachusetts Institute of Technology (MIT).	Atay SM, 2008, J BIOMECH ENG, V130, P1; BRANDS D. W. A., 2000, P STAPP CAR CRASH C, V44, P249; Brands D.W.A., 2002, THESIS U EINDHOVEN E; Casem D, 2005, EXP MECH, V45, P368, DOI 10.1177/0014485105056090; Chen W, 1999, EXP MECH, V39, P81, DOI 10.1007/BF02331109; Chen W, 2000, EXP MECH, V40, P1, DOI 10.1007/BF02327540; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; ESTES M, 1970, P 4 ASME BIOM C, P1; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Frew DJ, 2001, EXP MECH, V41, P40, DOI 10.1007/BF02323102; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gray III GT., 2000, ASM HDB, V8, P488; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange M T, 2000, Stapp Car Crash J, V44, P205; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P79; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]	23	29	29	1	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	JAN	2011	54			1			S98	S102		10.1016/j.neuroimage.2010.03.077			5	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600014	20362684				2022-02-06	
J	Sedney, CL; Orphanos, J; Bailes, JE				Sedney, Cara L.; Orphanos, John; Bailes, Julian E.			When to Consider Retiring an Athlete After Sports-Related Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Mild traumatic brain injury; Athletes	CHRONIC TRAUMATIC ENCEPHALOPATHY; BRAIN-INJURY; RECURRENT CONCUSSION; ASSOCIATION; TAU	The pathophysiology of concussion may lead to a variety of both short-and long-term effects, which may lead to a decision to retire from contact sports. These effects follow a recognizable progression and may cause an athlete to opt out of play at any point along this progression. To elucidate the effect of concussion or mild traumatic brain injury and weigh in on a decision to retire, the treating physician needs to take into account the history, neurologic examination, brain imaging, and neuropsychological testing. In addition, myriad social factors surrounding play must be taken into consideration.	[Sedney, Cara L.] W Virginia Univ, Dept Neurosurg, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; [Orphanos, John; Bailes, Julian E.] W Virginia Univ, Dept Neurosurg, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26505 USA		Sedney, CL (corresponding author), W Virginia Univ, Dept Neurosurg, Robert C Byrd Hlth Sci Ctr, POB 9183, Morgantown, WV 26506 USA.	csedney@hsc.wvu.edu		Sedney, Cara/0000-0003-1290-7083			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Callaway GH, 1996, MED SCI SPORT EXER, V28, P1218, DOI 10.1097/00005768-199610000-00002; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldberg DS, 2008, HEC FORUM, V20, P337, DOI 10.1007/s10730-008-9079-0; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; ILKONOMOVIC M, 2004, EXP NEUROL, V190, P192; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Miele Vincent J, 2006, Neurosurg Focus, V21, pE9; OMALU B, J NEUROSURG IN PRESS; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Osborne B, 2001, J ATHL TRAINING, V36, P316; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Schneider RC., 1973, HEAD NECK INJURIES F; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Torg JS, 1991, ATHLETIC INJURIES HE, Vsecond; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	32	29	30	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					189	+		10.1016/j.csm.2010.08.005			13	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	691XR	WOS:000285114800017	21074092				2022-02-06	
J	Powers, WJ				Powers, William J.			Intracerebral Hemorrhage and Head Trauma Common Effects and Common Mechanisms of Injury	STROKE			English	Article; Proceedings Paper	27th Princeton Conference 2010	APR 22-24, 2010	Boston, MA			intracerebral hemorrhage; traumatic brain injury; cerebral oxygen metabolism; cerebral glucose metabolism	BRAIN-INJURY; CEREBRAL METABOLISM; DYSFUNCTION; HYPERVENTILATION; GLUCOSE	Nontraumatic intracerebral hemorrhage (ICH) remains a devastating condition with 30-day mortality rates of 35% to 52%. Until the pathophysiology of this condition is better understood, it will not be possible to develop effective therapies. Studies of cerebral blood flow and metabolism in patients with acute ICH show similar abnormalities to those that occur in patients with traumatic brain injury, thus raising the question of whether there are common mechanisms of injury shared by the 2 conditions. In both ICH and traumatic brain injury, there is an early reduction in the cerebral metabolic rate of oxygen without ischemia, mitochondrial dysfunction, and transient focal increases in regional glucose metabolism that occur after a few days. ICH and traumatic brain injury share barotrauma from pressure waves that propagate through the intracranial contents as a common mechanism of brain injury. Recent data demonstrating contralateral hemispheric damage in patients with acute ICH provide further support for this theory of common injury mechanisms. (Stroke. 2010;41[suppl 1]:S107-S110.)	Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA		Powers, WJ (corresponding author), Univ N Carolina, Dept Neurol, CB 7025,Room 2131,170 Manning Dr, Chapel Hill, NC 27599 USA.	powersw@neurology.unc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS044885, P01NS035966, P50NS055977, P50NS035966] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35966, P01 NS035966, NS044885, P50 NS055977, K23 NS044885] Funding Source: Medline		Adams RE, 1998, NEUROLOGY, V50, P519, DOI 10.1212/WNL.50.2.519; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERING EA, 1956, SURG GYNECOL OBSTET, V102, P134; Bolanos JP, 2009, ADV DRUG DELIVER REV, V61, P1299, DOI 10.1016/j.addr.2009.05.009; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Hattori N, 2004, J NUCL MED, V45, P775; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; Kim-Han JS, 2006, STROKE, V37, P2457, DOI 10.1161/01.STR.0000240674.99945.4e; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; PAPO I, 1979, NEUROSURGERY, V4, P504, DOI 10.1227/00006123-197906000-00002; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; Sarrafzadeh A, 2005, J NEURORADIOLOGY, V32, P348, DOI 10.1016/S0150-9861(05)83168-2; SETTE G, 1989, BRAIN, V112, P931, DOI 10.1093/brain/112.4.931; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WISE RJS, 1983, ANN NEUROL, V14, P627, DOI 10.1002/ana.410140605; Xing L, 2010, STROKE, V41, pE212; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zazulia AR, 2010, STROKE, V41, pE211; Zazulia AR, 2009, STROKE, V40, P1638, DOI 10.1161/STROKEAHA.108.536037; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	26	29	30	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	2010	41	10		1			S107	S110		10.1161/STROKEAHA.110.595058			4	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Cardiovascular System & Cardiology	655DR	WOS:000282224300029	20876480	Green Accepted, Bronze, Green Submitted			2022-02-06	
J	Siegel, JA; Craytor, MJ; Raber, J				Siegel, Jessica A.; Craytor, Michael J.; Raber, Jacob			Long-term effects of methamphetamine exposure on cognitive function and muscarinic acetylcholine receptor levels in mice	BEHAVIOURAL PHARMACOLOGY			English	Article						acetylcholine; apolipoprotein E; cognition; hippocampus; methamphetamine; mouse	VENTRAL TEGMENTAL AREA; TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E GENE; BASAL FOREBRAIN; ALZHEIMERS-DISEASE; CHOLINERGIC RECEPTORS; PREPULSE INHIBITION; OBJECT RECOGNITION; SPATIAL NAVIGATION; BENZILATE BINDING	Exposure to methamphetamine during brain development impairs cognition in humans and rodents. In mice, these impairments are more severe in females than males. Genetic factors, such as apolipoprotein E genotype, may modulate the cognitive effects of methamphetamine. Methamphetamine-induced alterations in the brain acetylcholine system may contribute to the cognitive effects of methamphetamine and may also be modulated by apolipoprotein E isoform. We assessed the long-term effects of methamphetamine exposure during brain development on cognitive function and muscarinic acetylcholine receptors in mice, and whether apolipoprotein E isoform modulates these effects. Mice expressing human apolipoprotein E3 or E4 were exposed to methamphetamine (5 mg/kg) or saline once a day from postnatal days 11-20 and behaviorally tested in adulthood. Muscarinic acetylcholine receptor binding was measured in the hippocampus and cortex. Methamphetamine exposure impaired novel location recognition in female, but not male, mice. Methamphetamine-exposed male and female mice	[Siegel, Jessica A.; Craytor, Michael J.; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Div Neurosci ONPRC, Portland, OR 97239 USA		Raber, J (corresponding author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 8131 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	raberj@ohsu.edu			NIH, NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 MH77647, T32-DA007262]; NASANational Aeronautics & Space Administration (NASA) [NNJ05HE63G]; Alzheimer's AssociationAlzheimer's Association [IIRG-05-14021]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH077647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007262] Funding Source: NIH RePORTER	The authors would like to acknowledge Ted Benice, Laura Villasana, Jenna Rosenberg, Tim Pfankuch, and Anthony Bader for their help with injections and behavioral testing of mice for this study. This study was supported by NIH R01 MH77647, T32-DA007262 NIDA Institutional Training Grant, NASA NNJ05HE63G, and Alzheimer's Association IIRG-05-14021.	ACEVEDO S, 2008, NEUR ANN M WASH DC U; Acevedo SF, 2008, J NEUROCHEM, V107, P976, DOI 10.1111/j.1471-4159.2008.05673.x; Acevedo SF, 2007, NEUROPSYCHOPHARMACOL, V32, P665, DOI 10.1038/sj.npp.1301091; Acevedo SF, 2010, PEDIATR RES, V67, P293, DOI 10.1203/PDR.0b013e3181cb8e68; Alexander MP, 2007, NEUROLOGY, V68, P1515, DOI 10.1212/01.wnl.0000261482.99569.fb; Allen SJ, 1997, NEUROSCI LETT, V239, P33, DOI 10.1016/S0304-3940(97)00872-0; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; Arendt T, 1997, J NEUROSCI, V17, P516; Arnold HM, 2002, NEUROSCIENCE, V114, P451, DOI 10.1016/S0306-4522(02)00292-0; Arters J, 1998, J NEUROBIOL, V37, P582, DOI 10.1002/(SICI)1097-4695(199812)37:4<582::AID-NEU7>3.0.CO;2-5; Aubert I, 1996, J COMP NEUROL, V369, P31; Bacciottini L, 2001, BEHAV BRAIN RES, V124, P183, DOI 10.1016/S0166-4328(01)00230-3; Ballmaier M, 2002, NEUROSCIENCE, V114, P91, DOI 10.1016/S0306-4522(02)00234-8; Bartres-Faz D, 2002, ADDICT BIOL, V7, P227, DOI 10.1080/135562102200120451; BAYER SA, 1982, SCIENCE, V216, P890, DOI 10.1126/science.7079742; Bechtholt AJ, 2004, PHARMACOL BIOCHEM BE, V77, P783, DOI 10.1016/j.pbb.2004.02.002; Benice TS, 2008, J NEUROSCI METH, V168, P422, DOI 10.1016/j.jneumeth.2007.11.002; Berlanga ML, 2005, J COMP NEUROL, V492, P34, DOI 10.1002/cne.20684; Bitner RS, 2002, BRAIN RES, V938, P45, DOI 10.1016/S0006-8993(02)02485-X; Bleich S, 2003, J NEURAL TRANSM, V110, P401, DOI 10.1007/s00702-002-0789-1; Bredy TW, 2004, HORM BEHAV, V46, P30, DOI 10.1016/j.yhbeh.2003.09.017; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; Bussey TJ, 1999, J NEUROSCI, V19, P495, DOI 10.1523/JNEUROSCI.19-01-00495.1999; Buttini M, 1999, J NEUROSCI, V19, P4867; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Chang L, 2004, PSYCHIAT RES-NEUROIM, V132, P95, DOI 10.1016/j.pscychresns.2004.06.004; Chang L, 2009, NEUROIMAGE, V48, P391, DOI 10.1016/j.neuroimage.2009.06.062; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; Clancy B, 2007, NEUROTOXICOLOGY, V28, P931, DOI 10.1016/j.neuro.2007.01.014; Clancy B, 2007, NEUROINFORMATICS, V5, P79, DOI 10.1385/NI:5:1:79; Crawford CA, 2003, SYNAPSE, V48, P131, DOI 10.1002/syn.10197; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DAY J, 1992, SYNAPSE, V12, P281, DOI 10.1002/syn.890120405; Deacon RMJ, 2002, BEHAV BRAIN RES, V133, P57, DOI 10.1016/S0166-4328(01)00451-X; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Dobbs LK, 2008, NEUROSCIENCE, V156, P700, DOI 10.1016/j.neuroscience.2008.07.052; Forrester MB, 2007, J TOXICOL ENV HEAL A, V70, P7, DOI 10.1080/15287390600748799; Garcia-Rates S, 2007, TOXICOL APPL PHARM, V223, P195, DOI 10.1016/j.taap.2007.05.015; Gaykema RP, 1996, J COMP NEUROL, V374, P555; Gill TM, 2000, J NEUROSCI, V20, P4745, DOI 10.1523/JNEUROSCI.20-12-04745.2000; Guangda Xiang, 1999, Atherosclerosis, V147, P293, DOI 10.1016/S0021-9150(99)00198-7; Heller A, 2001, J PHARMACOL EXP THER, V298, P769; Heller A, 2001, DEV BRAIN RES, V130, P139, DOI 10.1016/S0165-3806(01)00222-X; HOLSON RR, 1992, NEUROTOXICOL TERATOL, V14, P221, DOI 10.1016/0892-0362(92)90020-B; HORTNAGL H, 1993, BRAIN RES BULL, V31, P129, DOI 10.1016/0361-9230(93)90019-8; Hruba L, 2010, DEV PSYCHOBIOL, V52, P71, DOI 10.1002/dev.20414; Jones CK, 2000, J PHARMACOL EXP THER, V294, P1017; Kenny PJ, 2000, J NEUROCHEM, V75, P2409, DOI 10.1046/j.1471-4159.2000.0752409.x; Kish SJ, 1999, MOL PSYCHIATR, V4, P26, DOI 10.1038/sj.mp.4000462; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Lai MKP, 2006, NEUROBIOL DIS, V22, P555, DOI 10.1016/j.nbd.2005.12.016; Lin L, 1998, NEUROREPORT, V9, P547, DOI 10.1097/00001756-199802160-00030; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Masuda J, 2005, NEUROSCIENCE, V132, P537, DOI 10.1016/j.neuroscience.2005.01.010; MCCABE RT, 1987, BRAIN RES BULL, V19, P551; Mirza NR, 2000, PSYCHOPHARMACOLOGY, V148, P243, DOI 10.1007/s002130050048; MUIR JL, 1994, J NEUROSCI, V14, P2313; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Murai T, 2007, PHYSIOL BEHAV, V90, P116, DOI 10.1016/j.physbeh.2006.09.013; Muramatsu T, 1997, J NEURAL TRANSM, V104, P913, DOI 10.1007/BF01285559; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Pike CJ, 2001, BRAIN RES, V919, P160, DOI 10.1016/S0006-8993(01)03024-4; PIPER BJ, 2010, PSYCHOPHARM IN PRESS; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2002, J NEUROSCI, V22, P5204, DOI 10.1523/JNEUROSCI.22-12-05204.2002; Raber Jacob, 2004, Sci Aging Knowledge Environ, V2004, pre2, DOI 10.1126/sageke.2004.11.re2; RAVIKUMAR BV, 1985, J NEUROCHEM, V44, P240, DOI 10.1111/j.1471-4159.1985.tb07136.x; Ricceri L, 2002, BRAIN RES, V954, P160, DOI 10.1016/S0006-8993(02)03172-4; Rice CJ, 2008, ENDOCRINOLOGY, V149, P4892, DOI 10.1210/en.2008-0633; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Salehi A, 1998, P NATL ACAD SCI USA, V95, P11445, DOI 10.1073/pnas.95.19.11445; Sambeth A, 2007, EUR J PHARMACOL, V572, P151, DOI 10.1016/j.ejphar.2007.06.018; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SAVE E, 1992, BEHAV NEUROSCI, V106, P447, DOI 10.1037/0735-7044.106.3.447; Schaefer TL, 2008, J NEUROCHEM, V104, P1674, DOI 10.1111/j.1471-4159.2007.05112.x; Siegal D, 2004, SYNAPSE, V52, P223, DOI 10.1002/syn.20020; SIEGEL JA, 2009, NEUROBIOL AGING; Skelton MR, 2007, PSYCHONEUROENDOCRINO, V32, P734, DOI 10.1016/j.psyneuen.2007.05.004; Smith LM, 2008, NEUROTOXICOL TERATOL, V30, P20, DOI 10.1016/j.ntt.2007.09.005; Smith LM, 2006, PEDIATRICS, V118, P1149, DOI 10.1542/peds.2005-2564; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; STRUTHERS JM, 1992, J DEV BEHAV PEDIATR, V13, P108, DOI 10.1097/00004703-199204000-00005; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Terplan M, 2009, OBSTET GYNECOL, V113, P1285, DOI 10.1097/AOG.0b013e3181a5ec6f; Timofeeva OA, 2008, NEUROTOXICOL TERATOL, V30, P38, DOI 10.1016/j.ntt.2007.10.002; van Meer P, 2007, BEHAV BRAIN RES, V176, P372, DOI 10.1016/j.bbr.2006.10.024; VANHEST A, 1990, PHARMACOL BIOCHEM BE, V35, P903, DOI 10.1016/0091-3057(90)90378-U; Vaucher E, 2002, NEUROBIOL AGING, V23, P87, DOI 10.1016/S0197-4580(01)00250-0; Vorhees CV, 2007, BEHAV PHARMACOL, V18, P549, DOI 10.1097/FBP.0b013e3282ee2abe; Vorhees CV, 2000, J NEUROSCI, V20, P4732, DOI 10.1523/JNEUROSCI.20-12-04732.2000; VOYTKO ML, 1994, J NEUROSCI, V14, P167; WATSON M, 1986, J PHARMACOL EXP THER, V237, P419; WEISSMAN AD, 1993, SYNAPSE, V13, P241, DOI 10.1002/syn.890130307; Whiteaker P, 2000, BRIT J PHARMACOL, V131, P729, DOI 10.1038/sj.bjp.0703616; Wilhelm J, 2007, J PSYCHIATR RES, V41, P871, DOI 10.1016/j.jpsychires.2006.07.011; Williams MT, 2004, EUR J NEUROSCI, V19, P3165, DOI 10.1111/j.0953-816X.2004.03405.x; Williams MT, 2003, PSYCHOPHARMACOLOGY, V168, P329, DOI 10.1007/s00213-003-1433-y; Williams MT, 2003, SYNAPSE, V48, P138, DOI 10.1002/syn.10159; Williams MT, 2002, BRAIN RES, V958, P312, DOI 10.1016/S0006-8993(02)03620-X; Winzer-Serhan UH, 2008, FRONT BIOSCI-LANDMRK, V13, P636, DOI 10.2741/2708; Won L, 2002, SYNAPSE, V43, P139, DOI 10.1002/syn.10026; WON L, 1992, BRAIN RES, V575, P6, DOI 10.1016/0006-8993(92)90416-7	106	29	29	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0955-8810	1473-5849		BEHAV PHARMACOL	Behav. Pharmacol.	OCT	2010	21	7					602	614		10.1097/FBP.0b013e32833e7e44			13	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	650AG	WOS:000281817900002	20729719	Green Accepted			2022-02-06	
J	Booth-Kewley, S; Larson, GE; Highfill-McRoy, RM; Garland, CF; Gaskin, TA				Booth-Kewley, Stephanie; Larson, Gerald E.; Highfill-McRoy, Robyn M.; Garland, Cedric F.; Gaskin, Thomas A.			Factors Associated With Antisocial Behavior in Combat Veterans	AGGRESSIVE BEHAVIOR			English	Article						antisocial behavior; post-traumatic stress disorder; combat deployment; mental health	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; WAR ZONE STRESSORS; VIETNAM VETERANS; MENTAL-HEALTH; INTERNALIZING SUBTYPES; SYMPTOMS; IRAQ; DEPLOYMENT; EXPOSURE	The objective of this study was to identify factors associated with antisocial behavior in 1,543 Marines who deployed to combat zones in support of conflicts in Iraq and Afghanistan during 2002-2007. Five factors were associated with antisocial behavior in multivariate analyses: post-traumatic stress disorder (PTSD) symptoms, deployment-related stressors, combat exposure, younger age, and being divorced. PTSD symptoms had a stronger association with antisocial behavior than any other variable. A unique and important finding of this study was the association between deployment-related stressors and a higher incidence of antisocial behavior. Because deployment-related stressors are potentially modifiable, the military may be able to address them in concrete ways such as by shortening deployments and improving communication with home. Aggr. Behav. 36:330-337, 2010. Published 2010 by Wiley-Liss, Inc.(dagger)	[Booth-Kewley, Stephanie] USN, Hlth Res Ctr, Behav Sci & Epidemiol Dept, San Diego, CA 92106 USA; [Garland, Cedric F.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; [Garland, Cedric F.] Moores UCSD Canc Ctr, La Jolla, CA USA; [Gaskin, Thomas A.] US Marine Corps, Combat Operat Stress Control, Headquarters, Quantico, VA USA		Booth-Kewley, S (corresponding author), USN, Hlth Res Ctr, Behav Sci & Epidemiol Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.	stephanie.kewley@med.navy.mil			Headquarters, Marine Corps (Combat Operational Stress Control)	Grant sponsor: Headquarters, Marine Corps (Combat Operational Stress Control).; This study was funded by Headquarters, Marine Corps (Combat Operational Stress Control), under Work Unit 60518 at Naval Health Research Center.	Barrett DH, 1996, J ABNORM PSYCHOL, V105, P575, DOI 10.1037/0021-843X.105.4.575; Bartone PT, 1998, MIL MED, V163, P587, DOI 10.1093/milmed/163.9.587; Beckham JC, 1997, J CLIN PSYCHOL, V53, P859, DOI 10.1002/(SICI)1097-4679(199712)53:8<859::AID-JCLP11>3.3.CO;2-U; Booth-Kewley S, 2010, J TRAUMA STRESS, V23, P69, DOI 10.1002/jts.20485; Bray RM, 2006, RTI7841106FR; Engelhard IM, 2007, CAN J PSYCHIAT, V52, P505, DOI 10.1177/070674370705200808; Fontana A, 2005, J NERV MENT DIS, V193, P203, DOI 10.1097/01.nmd.0000154835.92962.e5; Fontana A, 1999, J TRAUMA STRESS, V12, P111, DOI 10.1023/A:1024750417154; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; KING DW, 1995, J ABNORM PSYCHOL, V104, P184, DOI 10.1037/0021-843X.104.1.184; KURDEK LA, 1993, J PERS SOC PSYCHOL, V64, P221, DOI 10.1037/0022-3514.64.2.221; Litz BT, 1997, J CONSULT CLIN PSYCH, V65, P1001, DOI 10.1037/0022-006X.65.6.1001; Litz BT, 1997, AM J PSYCHIAT, V154, P178; MHAT, 2008, MENT HLTH ADV TEAM M MENT HLTH ADV TEAM M; Miller MW, 2004, J ABNORM PSYCHOL, V113, P636, DOI 10.1037/0021-843X.113.4.636; Miller MW, 2003, PSYCHOL ASSESSMENT, V15, P205, DOI 10.1037/1040-3590.15.2.205; RESNICK HS, 1989, J CLIN PSYCHOL, V45, P860, DOI 10.1002/1097-4679(198911)45:6<860::AID-JCLP2270450605>3.0.CO;2-5; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shiner RL, 2002, J PERS SOC PSYCHOL, V83, P1165, DOI 10.1037//0022-3514.83.5.1165; Simon RW, 2002, AM J SOCIOL, V107, P1065, DOI 10.1086/339225; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Taft CT, 2007, J TRAUMA STRESS, V20, P135, DOI 10.1002/jts.20197; Vaughan D, 2006, TODAYS OFFICER FALL, P20; Vogt DS, 2005, J TRAUMA STRESS, V18, P115, DOI 10.1002/jts.20018; Weathers F.W., 1993, ANN CONV INT SOC TRA; WRIGHT KM, 1995, OPERATION DESERT CHI; YAGER T, 1984, ARCH GEN PSYCHIAT, V41, P327	30	29	30	0	11	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0096-140X			AGGRESSIVE BEHAV	Aggressive Behav.	SEP-OCT	2010	36	5					330	337		10.1002/ab.20355			8	Behavioral Sciences; Psychology, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Psychology	641MS	WOS:000281131500006	20626042				2022-02-06	
J	Kanjwal, K; Karabin, B; Kanjwal, Y; Grubb, BP				Kanjwal, Khalil; Karabin, Beverly; Kanjwal, Yousuf; Grubb, Blair P.			Autonomic dysfunction presenting as postural tachycardia syndrome following traumatic brain injury	CARDIOLOGY JOURNAL			English	Article						postural tachycardia syndrome; trauma; brain injury	SEVERE HEAD-INJURY; MANAGEMENT; DIAGNOSIS; DYSAUTONOMIA	Background Autonomic dysregulation (also called diencephalic epilepsy) has been reported following traumatic brain injuries (TBI) However, until now, postural tachycardia syndrome (POTS) has not been reported as a long-term complication in patients who have suffered a TBI We report on a series of patients who developed POTS after suffering TBI Methods Eight patients who were referred to our center had suffered TBI and developed features of orthostatic intolerance following head trauma The patients' neurological, neurosurgical and autonomic data (charts and/or physician letters) were then carefully reviewed for demographic characteristics, comorbid conditions, symptoms of orthostatic intolerance, medications and response to medication These patients were diagnosed as having POTS, primarily based on their clinical features and findings from the head-up tilt test (HUTT) The data presented is observational and descriptive (percentages or means) Results Eight patients (seven of them women) aged 21-41 years had suffered from TBI and had developed features of POTS All had been normal with no symptoms prior to their TBI All patients experienced orthostatic dizziness, fatigue, palpitations and near syncope Six patients suffered from frank syncope Six patients developed significant cognitive dysfunction, and three developed a chronic pain syndrome following trauma All of the patients reported severe limitations to their daily activities and had been unable to keep their jobs, and two were housebound Six patients demonstrated a good response to therapy with various combinations of medication The symptoms of orthostatic intolerance and syncope improved with the initiation of medical therapy, as well as their reported quality of life Two patients failed to show any improvement with various combinations of medications and tilt training, and continued to experience orthostatic difficulties Conclusions Postural tachycardia syndrome may, in some cases, be a late complication of traumatic brain injury (Cardiol J 2010, 17, 5 482-487)	[Grubb, Blair P.] Univ Toledo, Med Ctr, Electrophysiol Serv, Div Cardiol,Dept Med,Sect Electrophysiol, Toledo, OH 43614 USA		Grubb, BP (corresponding author), Univ Toledo, Med Ctr, Electrophysiol Serv, Div Cardiol,Dept Med,Sect Electrophysiol, Hlth Sci Campus,Mail Stop 1118,3000 Arlington ave, Toledo, OH 43614 USA.		Kanjwal, Khalil/AAO-5841-2021				Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P113, DOI 10.1007/BF01406331; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Grubb BP, 2008, CIRCULATION, V117, P2814, DOI 10.1161/CIRCULATIONAHA.107.761643; Grubb BP, 2001, MED CLIN N AM, V85, P457, DOI 10.1016/S0025-7125(05)70322-9; Grubb BP, 2006, J CARDIOVASC ELECTR, V17, P108, DOI 10.1111/j.1540-8167.2005.00318.x; Grubb BP, 2001, J INTERV CARD ELECTR, V5, P9, DOI 10.1023/A:1009845521949; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Kanjwal Y, 2003, PACE, V26, P1747, DOI 10.1046/j.1460-9592.2003.t01-1-00262.x; KISHNER S, POSTHEAD INJURY AUTO; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Metz SA, 1978, ANNS INT MED, V88, P89; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Sandroni P, 1999, MAYO CLIN PROC, V74, P1106, DOI 10.4065/74.11.1106; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	19	29	30	0	5	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1897-5593	1898-018X		CARDIOL J	Cardiol. J.	SEP	2010	17	5					482	487					6	Cardiac & Cardiovascular Systems	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	681TI	WOS:000284341800009	20865679				2022-02-06	
J	Kamali, A; Kramer, LA; Hasan, KM				Kamali, Arash; Kramer, Larry A.; Hasan, Khader M.			Feasibility of prefronto-caudate pathway tractography using high resolution diffusion tensor tractography data at 3 T	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Diffusion tensor imaging; High spatial resolution; Frontostriatal; Caudate; Tractography	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; INTERNAL CAPSULE; FIBER TRACKING; CONNECTIONS; ANISOTROPY; METRICS; GRAY	Mapping the human brain frontostriatal pathways using noninvasive diffusion tensor imaging (DTI) has been hampered by the inadequate imaging sensitivity, poor spatial resolution, lower tensor anisotropy within gray matter, increased partial volume averaging effects and poor signal-to-noise ratio. We investigated for the first time the utility of high spatial resolution DTI-based fiber-tractography using the fiber assignment by continuous tracking (FACT) to reconstruct and quantify bilaterally the prefronto-caudothalamic connections within the human brain at 3 T. Five healthy right-handed men (age range 24-37 years) were studied. We traced the anterior thalamic radiation and prefronto-caudo-thalamic pathways bilaterally and measured the volume of each tract and the corresponding diffusion tensor metrics in all subjects. The anterior thalamic radiation tract volume and corresponding fractional anisotropy (FA) were significantly larger bilaterally than prefronto-caudate pathway, whereas the mean diffusivity (D,) values were similar (p> 0.7). For both anterior thalamic radiation and prefronto-caudate pathway the tract volume and corresponding DTI metrics (FA, D) were not significantly different between the two hemispheres (p > 0.2). Our DTI acquisition protocol and analysis permitted the reconstruction of the connectivity of the caudate with the thalamus as well as with the prefrontal cortex and allowed tracking of the whole trajectory of the prefronto-caudo-thalamic pathway. (C) 2010 Elsevier B.V. All rights reserved.	[Kamali, Arash; Kramer, Larry A.; Hasan, Khader M.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA		Hasan, KM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St,MSB 2-100, Houston, TX 77030 USA.	HKhader.M.Hasan@uth.tmc.edu	kamali, Arash/AAG-5803-2020; Hasan, Khader M./ABB-5767-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052505] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052505, R01 NS052505-04] Funding Source: Medline		AFIFI AK, 1998, TEXT ATLAS; Alexander AL, 2001, MAGN RESON MED, V45, P770, DOI 10.1002/mrm.1105; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Casey BJ, 2007, AM J PSYCHIAT, V164, P1729, DOI 10.1176/appi.ajp.2007.06101754; Casey BJ, 2002, DEV PSYCHOBIOL, V40, P237, DOI 10.1002/dev.10030; Cowan FM, 2005, SEMIN FETAL NEONAT M, V10, P461, DOI 10.1016/j.siny.2005.05.007; Hagler DJ, 2009, HUM BRAIN MAPP, V30, P1535, DOI 10.1002/hbm.20619; Hasan KM, 2008, MAGN RESON MED, V59, P7, DOI 10.1002/mrm.21434; Hasan KM, 2007, MAGN RESON IMAGING, V25, P1196, DOI 10.1016/j.mri.2007.02.011; Hasan KM, 2011, HUM BRAIN MAPP, V32, P107, DOI 10.1002/hbm.21004; Hasan KM, 2009, MAGN RESON IMAGING, V27, P631, DOI 10.1016/j.mri.2008.10.007; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Haznedar MM, 2005, BIOL PSYCHIAT, V57, P733, DOI 10.1016/j.biopsych.2005.01.002; Henry RG, 2009, J NEUROL SCI, V282, P61, DOI 10.1016/j.jns.2009.02.379; Jaermann T, 2008, AM J NEURORADIOL, V29, P146, DOI 10.3174/ajnr.A0742; Jones DK, 2005, MAGNET RESON MED, V53, P1143, DOI 10.1002/mrm.20466; KAMALI A, 2009, EUR RADIAL, V19, P1408; Kim M, 2006, NEUROIMAGE, V32, P1243, DOI 10.1016/j.neuroimage.2006.06.006; Kloppel S, 2008, BRAIN, V131, P196, DOI 10.1093/brain/awm275; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; LANDMAN BA, 2010, P SOC PHOTO OPT INST, V7623; Lawes INC, 2008, NEUROIMAGE, V39, P62, DOI 10.1016/j.neuroimage.2007.06.041; Leh SE, 2007, NEUROSCI LETT, V419, P113, DOI 10.1016/j.neulet.2007.04.049; Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Oouchi H, 2007, AM J NEURORADIOL, V28, P1102, DOI 10.3174/ajnr.A0488; Papadakis NG, 2002, MAGNET RESON MED, V48, P394, DOI 10.1002/mrm.10204; Poonawalla AH, 2004, J MAGN RESON IMAGING, V19, P489, DOI 10.1002/jmri.20020; Rose SE, 2006, NEUROIMAGE, V32, P16, DOI 10.1016/j.neuroimage.2006.03.003; Santiago O, 2007, ARCH CLIN NEUROPSYCH, V22, P623, DOI 10.1016/j.acn.2007.04.003; Suzuki M, 2004, PSYCHIAT RES-NEUROIM, V130, P213, DOI 10.1016/j.pscychresns.2004.01.001; TAYLOR AE, 1990, BRAIN COGNITION, V13, P211, DOI 10.1016/0278-2626(90)90051-O; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Valente AA, 2005, BIOL PSYCHIAT, V58, P479, DOI 10.1016/j.biopsych.2005.04.021; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Yamada K, 2009, P NATL ACAD SCI USA, V106, pE14, DOI 10.1073/pnas.0812352106; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	40	29	29	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	AUG 30	2010	191	2					249	254		10.1016/j.jneumeth.2010.06.026			6	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	651KR	WOS:000281927100015	20600311	Green Accepted			2022-02-06	
J	Ibrahim, NG; Margulies, SS				Ibrahim, Nicole G.; Margulies, Susan S.			Biomechanics of the toddler head during low-height falls: an anthropomorphic dummy analysis Laboratory investigation	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						anthropomorphic surrogate; low-height fall; toddler; head impact; pediatric head injury	PEDIATRIC INJURY RISK; SHORT-DISTANCE FALLS; FETAL CRANIAL BONE; CHILDHOOD FALLS; CERVICAL-SPINE; INFANT SKULL; BRAIN-INJURY; CHILDREN; CONCUSSION; IMPACTS	Object. Falls are the most common environmental setting for closed head injuries in children between 2 and 4 years of age. The authors previously found that toddlers had fewer skull fractures and scalp/facial soft-tissue injuries, and more frequent altered mental status than infants for the same low-height falls (<= 3 ft). Methods. To identify potential age-dependent mechanical load factors that may be responsible for these clinical findings, the authors created an instrumented dummy representing an 18-month-old child using published toddler anthropometry and mechanical properties of the skull and neck, and they measured peak angular acceleration during low-height falls (1,2, and 3 ft) onto carpet pad and concrete. They compared these results from occiput-first impacts to previously obtained values measured in a 6-week-old infant dummy. Results. Peak angular acceleration of the toddler dummy head was largest in the sagittal and horizontal directions and increased significantly (around 2-fold) with fall height between I and 2 ft. Impacts onto concrete produced larger peak angular accelerations and smaller impact durations than those onto carpet pad. When compared with previously measured infant drops, toddler head accelerations were more than double those of the infant from the same height onto the same surface, likely contributing to the higher incidence of loss of consciousness reported in toddlers. Furthermore, the toddler impact forces were larger than those in the infant, but because of the thicker toddler skull, the risk of skull fracture from low-height falls is likely lower in toddlers compared with infants. Conclusions. If similar fracture limits and brain tissue injury thresholds between infants and toddlers are assumed, it is expected that for impact events, the toddler is likely less vulnerable to skull fracture but more vulnerable to neurological impairment compared with the infant. (DOI: 10.3171/2010.3.PEDS09357)	[Ibrahim, Nicole G.; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS-39679, T32-NS-043126] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126, R01NS039679] Funding Source: NIH RePORTER		ADELOYE A, 1975, AM J PHYS ANTHROPOL, V43, P23, DOI 10.1002/ajpa.1330430105; Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; AISENSON MR, 1950, PEDIATRICS, V6, P223; ANDERSON RN, 2004, DEATHS INJURIES 2001, V52; BAGNALL KM, 1977, J ANAT, V124, P791; BAGNALL KM, 1977, J ANAT, V123, P777; Bertocci GE, 2004, INJURY, V35, P417, DOI 10.1016/S0020-1383(03)00062-7; Bertocci GE, 2003, ARCH PEDIAT ADOL MED, V157, P480, DOI 10.1001/archpedi.157.5.480; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Chang LT, 2007, J TRAUMA, V63, P70, DOI 10.1097/01.ta.0000219142.15584.b8; Coats B., 2007, THESIS U PENNSYLVANI; Coats B, 2008, J NEUROSURG-PEDIATR, V2, P321, DOI 10.3171/PED.2008.2.11.321; Coats B, 2006, J NEUROTRAUM, V23, P1222, DOI 10.1089/neu.2006.23.1222; Cory CZ, 2006, FORENSIC SCI INT, V163, P102, DOI 10.1016/j.forsciint.2005.11.014; Deemer E, 2005, MED ENG PHYS, V27, P31, DOI 10.1016/j.medengphy.2004.09.005; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; Demetriades D, 2005, J TRAUMA, V58, P342, DOI 10.1097/01.TA.0000135161.44100.D8; Egan J.P., 1975, SIGNAL DETECTION THE; EPPINGER R, 2000, DEV IMPROVED INJURY; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; HALL JR, 1989, J TRAUMA, V29, P1273, DOI 10.1097/00005373-198909000-00015; Hennrikus WL, 2003, CLIN ORTHOP RELAT R, P148, DOI 10.1097/01.blo.0000043059.62337.97; Holsti M, 2005, PEDIATR EMERG CARE, V21, P639, DOI 10.1097/01.pec.0000181426.25342.a9; HUBBARD RP, 1971, J BIOMECH, V4, P491, DOI 10.1016/0021-9290(71)90039-X; IBRAHIM NG, 2009, THESIS U PENNSYLVANI; Irwin AL, 1997, P 41 STAPP CAR CRASH; Johnson K, 2005, CLIN RADIOL, V60, P464, DOI 10.1016/j.crad.2004.09.013; Jun OY, 2005, SPINE, V30, pE716, DOI 10.1097/01.brs.0000192280.53831.70; Kapoor T, 2008, ACCIDENT ANAL PREV, V40, P1880, DOI 10.1016/j.aap.2008.07.008; Kim K A, 2000, Neurosurg Focus, V8, pe3; Kleinberger M, 1998, DEV IMPROVED INJURY; KOENIG WJ, 1995, PLAST RECONSTR SURG, V95, P1; KRIEWALL TJ, 1981, J BIOMECH, V14, P73, DOI 10.1016/0021-9290(81)90166-4; Lallier M, 1999, J PEDIATR SURG, V34, P1060, DOI 10.1016/S0022-3468(99)90564-X; LEHMAN D, 1993, PEDIATRICS, V92, P121; LEVENE S, 1991, ARCH DIS CHILD, V66, P1047, DOI 10.1136/adc.66.9.1047; LYONS TJ, 1993, PEDIATRICS, V92, P125; Macgregor D M, 2000, Inj Prev, V6, P291, DOI 10.1136/ip.6.4.291; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; Murray JA, 2000, AM SURGEON, V66, P863; *NHTSA, 2000, NHTSA PUBL; Nightingale RW, 2002, J BIOMECH, V35, P725, DOI 10.1016/S0021-9290(02)00037-4; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; Nuckley DJ, 2006, J BIOMECH, V39, P3045, DOI 10.1016/j.jbiomech.2005.10.014; Nuckley DJ, 2004, BONE, V35, P720, DOI 10.1016/j.bone.2004.04.015; Nyquist G. W., 1986, P 30 STAPP CAR CRASH; Oehmichen M, 2005, NEUROPEDIATRICS, V36, P240, DOI 10.1055/s-2005-872812; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1966, P 10 STAPP CAR CRASH, P191; OMMAYA AK, 1967, P 11 STAPP CAR CRASH, P73; Park SH, 2004, YONSEI MED J, V45, P229, DOI 10.3349/ymj.2004.45.2.229; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Phelan KJ, 2001, AMBUL PEDIATR, V1, P227, DOI 10.1367/1539-4409(2001)001<0227:TAPOPI>2.0.CO;2; Pincemaille Y., 1988, INVESTIGATION RELATI; Pintar F A, 2000, Stapp Car Crash J, V44, P77; Pitone ML, 2006, PEDIATR EMERG CARE, V22, P470, DOI 10.1097/01.pec.0000226869.41803.50; PRANGE M, 2002, THESIS U PENNSYLVANI; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Reed MP, 2009, ACCIDENT ANAL PREV, V41, P598, DOI 10.1016/j.aap.2009.02.009; RIVARA FP, 1993, PEDIATRICS, V92, P61; ROOT I, 1992, AM J FOREN MED PATH, V13, P85, DOI 10.1097/00000433-199203000-00017; Sances A, 2000, CRIT REV BIOMED ENG, V28, P213; Schneider LW, 1986, SIZE SHAPE HEAD NECK; Sherwood C P, 2003, Traffic Inj Prev, V4, P206, DOI 10.1080/15389580309885; Smith GA, 1996, PEDIATRICS, V97, P161; Snyder RG, 1977, ANTHROPOMETRY INFANT; Timoshenko S., 1940, THEORY PLATES SHELLS; Vilke GM, 2004, PEDIATR EMERG CARE, V20, P660, DOI 10.1097/01.pec.0000142949.81135.3d; Wang MY, 2001, J PEDIATR SURG, V36, P1528, DOI 10.1053/jpsu.2001.27037; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; ZITELLI BJ, 1992, ATLAS PEDIAT PHYS DI	78	29	29	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUL	2010	6	1					57	68		10.3171/2010.3.PEDS09357			12	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	615BV	WOS:000279107100010	20593989				2022-02-06	
J	Piland, SG; Ferrara, MS; Macciocchi, SN; Broglio, SP; Gould, TE				Piland, Scott G.; Ferrara, Michael S.; Macciocchi, Stephen N.; Broglio, Steven P.; Gould, Trenton E.			Investigation of Baseline Self-Report Concussion Symptom Scores	JOURNAL OF ATHLETIC TRAINING			English	Article						baseline evaluation; factorial validity; Postconcussion Symptom Scale	POSTCONCUSSION-LIKE SYMPTOMS; COLLEGIATE FOOTBALL PLAYERS; MILD HEAD-INJURY; CEREBRAL CONCUSSION; SPORTS; MANAGEMENT; STATEMENT; VALIDITY; RETURN	Context: Self-reported symptoms (SRS) scales comprise one aspect of a multifaceted assessment of sport-related concussion. Obtaining SRS assessments before a concussion occurs assists in determining when the injury is resolved. However, athletes may present with concussion-related symptoms at baseline. Thus, it is important to evaluate such reports to determine if the variables that are common to many athletic environments are influencing them. Objective: To evaluate the influence of a history of concussion, sex, acute fatigue, physical illness, and orthopaedic injury on baseline responses to 2 summative symptom scales; to investigate the psychometric properties of all responses; and to assess the factorial validity of responses to both scales in the absence of influential variables. Design: Cross-sectional study. Setting: Athletic training facilities of 6 National Collegiate Athletic Association institutions. Patients or Other Participants: The sample of 1065 was predominately male (n = 805) collegiate athletes with a mean age of 19.81 +/- 1.53 years. Main Outcome Measure(s): Participants completed baseline measures for duration and severity of concussion-related SRS and a brief health questionnaire. Results: At baseline, respondents reporting a previous concussion had higher composite scores on both scales (P <= .01), but no sex differences were found for concussion-related symptoms. Acute fatigue, physical illness, and orthopaedic injury increased composite SRS scores on both duration and severity measures (P <= .01). Responses to both scales were stable and internally consistent. Confirmatory factor analysis provided strong evidence for the factorial validity of the responses of participants reporting no fatigue, physical illness, or orthopaedic injury on each instrument. Conclusions: A history of concussion, acute fatigue, physical illness, and orthopaedic injury increased baseline SRS scores. These conditions need to be thoroughly investigated and controlled by clinicians before baseline SRS measures are collected.	[Piland, Scott G.; Gould, Trenton E.] Univ So Mississippi, Hattiesburg, MS 39406 USA; [Ferrara, Michael S.] Univ Georgia, Athens, GA 30602 USA; [Macciocchi, Stephen N.] Shepherd Spinal Inst, Atlanta, GA USA; [Broglio, Steven P.] Univ Illinois, Champaign, IL 61820 USA		Piland, SG (corresponding author), Univ So Mississippi, 118 Coll Dr,Box 5142, Hattiesburg, MS 39406 USA.	scott.piland@usm.edu	, scott/ABB-2057-2021		National Athletic Trainers' Association Research & Education Foundation [303DGP0007]; Department of Kinesiology, The University of Georgia	This project was funded by a National Athletic Trainers' Association Research & Education Foundation Doctoral Dissertation Grant (303DGP0007) and the Kindig Research Award from the Department of Kinesiology, The University of Georgia.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bollen K. A., 1989, STRUCTURAL EQUATIONS, DOI 10.1002/9781118619179; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Cantu RC, 2000, NEUROSURGERY, V47, P669; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Joreskog K. G., 1993, TESTING STRUCTURAL E, P294, DOI DOI 10.1093/SF/73.3.1161; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; STEIGER JH, 1990, MULTIVAR BEHAV RES, V25, P173, DOI 10.1207/s15327906mbr2502_4; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	40	29	29	0	9	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAY-JUN	2010	45	3					273	278		10.4085/1062-6050-45.3.273			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	599PI	WOS:000277925200010	20446841	Green Submitted, Green Published			2022-02-06	
J	Stancin, T; Wade, SL; Walz, NC; Yeates, KO; Taylor, HG				Stancin, Terry; Wade, Shari L.; Walz, Nicolay C.; Yeates, Keith Owen; Taylor, H. Gerry			Family Adaptation 18 Months After Traumatic Brain Injury in Early Childhood	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						traumatic brain injury; family impact; parent coping; early childhood	OUTCOME 30 MONTHS; FUNCTIONAL RECOVERY; INITIAL YEAR; SHORT-TERM; PREDICTORS; CHILDREN; RELIABILITY; BURDEN; CAREGIVER; SEVERITY	Objective: The purpose of this study was to examine family adaptation to a traumatic brain injury (TBI) in young children during the first 18-month postinjury, when compared with children who had an orthopedic injury. Methods: A concurrent cohort/prospective research design was used with repeated assessments of children aged 3 to 6 years with TBI or orthopedic injury requiring hospitalization and their families. Shortly after injury and at 6-, 12-, and 18-month postinjury, parents of 99 children with TBI (20 severe, 64 moderate, 15 mild) and 117 with orthopedic injury completed standardized assessments of family functioning, parental distress and coping, injury-related burden, and noninjury-related parent stressors and resources. Mixed models analyses examined group differences in parental burden and distress adjusted for race and social demographic factors. Results: Both moderate and severe TBI were associated with higher levels of injury-related stress than orthopedic injury, with stress levels diminishing over time in all groups. Severe TBI was also associated with greater psychological distress on the Brief Symptom Inventory but not with more depressive symptoms. Family functioning and social resources moderated the relationship of TBI severity to injury-related burden and caregiver distress, respectively. Lower child adaptive skills were associated with poorer family outcome but group differences remained even when controlling for this effect. Conclusions: Severe TBI in young children has adverse consequences for parents and families during the first 18-month postinjury. The consequences lessen over time for many families and vary as a function of social resources.	[Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Div Pediat Psychol, Cleveland, OH 44109 USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Rehabil, Cincinnati, OH USA; [Wade, Shari L.; Walz, Nicolay C.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Walz, Nicolay C.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Behav Med & Clin Psychol, Cincinnati, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA		Stancin, T (corresponding author), Metrohlth Med Ctr, Dept Psychiat, Div Pediat Psychol, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.	tstancin@metrohealth.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; USPHS NIHUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [M01 RR 08084]; State of Ohio Emergency Medical Services; NIH/NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1UL1RR026314]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084, UL1RR026314] Funding Source: NIH RePORTER	Supported by grant R01 HD42729 from NICHD, in part by USPHS NIH Grant M01 RR 08084, and by Trauma Research grants from the State of Ohio Emergency Medical Services (to S. L. W.).; This publication was supported by an Institutional Clinical and Translational Science Award, NIH/NCRR Grant Number 1UL1RR026314.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Derogatis LR., 1982, BRIEF SYMPTOM INVENT; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HARRISON PL, 2003, MANUAL ADAPTIVE BEHA, V2; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos RH, 1994, LIFE STRESSORS SOCIA; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; SAS Institute, 1990, SAS STAT US GUID VER; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 2008, J INT NEUROPSYCH SOC, V14, P1; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WADE SL, 2006, TREATING NEURODEVELO, P170; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	38	29	30	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-206X	1536-7312		J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	MAY	2010	31	4					317	325		10.1097/DBP.0b013e3181dbaf32			9	Behavioral Sciences; Psychology, Developmental; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Psychology; Pediatrics	597PE	WOS:000277769600007	20431399	Green Accepted			2022-02-06	
J	Lange, RT; Sullivan, KA; Scott, C				Lange, Rae T.; Sullivan, Karen A.; Scott, Clinton			Comparison of MMPI-2 and PAI validity indicators to detect feigned depression and PTSD symptom reporting	PSYCHIATRY RESEARCH			English	Article						MMPI-2; PAI; Symptom exaggeration; PTSD; Depression; Malingering	POSTTRAUMATIC-STRESS-DISORDER; PERSONALITY-ASSESSMENT INVENTORY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; MENTAL-DISORDERS; TEST USAGE; SCALE; VALIDATION; SPECIFICITY; SENSITIVITY	The purpose of this study was to compare the clinical utility of PAI and MMPI-2 validity indicators to detect exaggeration of psychological symptoms. Participants were 49 (75.5% female) Australian university students who completed the MMPI-2 and PAI under one of three conditions: Control [i.e., honest responding (n = 20)], Feign Post Traumatic Stress Disorder [PTSD (n 15)], or Feign Depression (n = 14). Participants instructed to feign depression or feign PTSD had significantly higher scores on the majority of MMPI-2 and PAI validity indicators compared with controls. The Meyers Validity Index, the Obvious-Subtle index, and the Response Bias Scale were the most accurate MMPI-2 validity indicators. Diagnostic-specific MMPI-2 validity indicators, such as the Infrequency-PSTD scales and Malingered Depression scale, were not effective at detecting participants instructed to feign those conditions. For the PAI, the most accurate validity indicator was the MAL index: however, the detection rate using this validity indicator was modest at best. The MMPI-2 validity indicators were clearly superior to those on the PAI at identifying feigned versus honest responding in this sample. Crown Copyright (C) 2009 Published by Elsevier Ireland Ltd. All rights reserved.	[Lange, Rae T.] BC Mental Hlth & Addict Serv, PHSA Res & Networks, Dept Res, Vancouver, BC V5Z 4C2, Canada; [Lange, Rae T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Sullivan, Karen A.] Queensland Univ Technol, Sch Psychol & Counseling, Brisbane, Qld 4001, Australia; [Scott, Clinton] Queensland Univ Technol, Dept Psychol, Brisbane, Qld 4001, Australia; [Sullivan, Karen A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia		Lange, RT (corresponding author), BC Mental Hlth & Addict Serv, PHSA Res & Networks, Dept Res, Suite 201,601 W Broadway, Vancouver, BC V5Z 4C2, Canada.	rlange@bcmhs.bc.ca			Queensland University of Technology (QUT), Brisbane, Australia	This study was supported in part by a research grant from the Queensland University of Technology (QUT), Brisbane, Australia.	Allen L., 1997, CARB 97 MANUAL COMPU; Arbisi PA, 1997, PSYCHOL ASSESSMENT, V9, P102, DOI 10.1037/1040-3590.9.2.102; Bagby RM, 2002, J PERS ASSESS, V78, P69, DOI 10.1207/S15327752JPA7801_05; Bagby RM, 1997, J PERS ASSESS, V68, P650, DOI 10.1207/s15327752jpa6803_11; BARRON F, 1956, J CONSULT PSYCHOL, V19, P239; Blanchard DD, 2003, J PERS ASSESS, V80, P197, DOI 10.1207/S15327752JPA8002_08; Calhoun PS, 2000, J PERS ASSESS, V75, P338, DOI 10.1207/S15327752JPA7502_11; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Cohen J., 2013, STAT POWER ANAL BEHA; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Eakin DE, 2006, J PSYCHOPATHOL BEHAV, V28, P145, DOI 10.1007/s10862-005-9006-5; Elhai JD, 2004, ASSESSMENT, V11, P139, DOI 10.1177/1073191104264965; Elhai JD, 2002, J PERS ASSESS, V79, P531, DOI 10.1207/S15327752JPA7903_08; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; GOUGH HG, 1947, J ABNORM SOC PSYCH, V42, P215, DOI 10.1037/h0063295; Gough HG, 1957, CALIFORNIA PSYCHOL I; GOUGH HG, 1950, J CONSULT PSYCHOL, V14, P408; GREENE RL, 1999, MMPI 2 INTERPRETIVE; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Hathaway S.R., 1989, MINNESOTA MULTIPHASI; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Kaemmer, 1989, MINNESOTA MULTIPHASI; Lees-Haley PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Liljequist L, 1998, J PERS ASSESS, V71, P322, DOI 10.1207/s15327752jpa7103_3; Marshall MB, 2006, ASSESSMENT, V13, P417, DOI 10.1177/1073191106290842; Martin-Cannici C, 1995, ASSESSMENT, V2, P333, DOI [10.1177/1073191195002004004, DOI 10.1177/1073191195002004004]; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Morey, 1991, PERSONALITY ASSESSME; Morey L. C., 1996, INTERPRETIVE GUIDE P; Morey LC, 1998, ASSESSMENT, V5, P203, DOI 10.1177/107319119800500301; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; ROGERS R, 1993, J PERS ASSESS, V60, P554, DOI 10.1207/s15327752jpa6003_12; Rogers R, 1996, J PERS ASSESS, V67, P629, DOI 10.1207/s15327752jpa6703_15; SILVERTON L, 1998, MALINGERING PROBABIL; Slick DJ, 2006, COMPENDIUM NEUROPSYC, P3; Smith GP, 1997, J AM ACAD PSYCHIATRY, V25, P183; Steffan JS, 2003, ASSESSMENT, V10, P382, DOI 10.1177/1073191103259548; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P541, DOI 10.1080/13854040590967135; Tombaugh T.N., 1996, TEST MEMORY MALINGER; WIENER D, 1946, SUBTLE OBVIOUS KEYS; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594; [No title captured]	45	29	29	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	APR 30	2010	176	2-3					229	235		10.1016/j.psychres.2009.03.004			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	585MP	WOS:000276830000024	20207423	Green Published			2022-02-06	
J	Cadosch, D; Toffoli, AM; Gautschi, OP; Frey, SP; Zellweger, R; Skirving, AP; Filgueira, L				Cadosch, Dieter; Toffoli, Andrew M.; Gautschi, Oliver P.; Frey, Soenke P.; Zellweger, Rene; Skirving, Allan P.; Filgueira, Luis			Serum After Traumatic Brain Injury Increases Proliferation and Supports Expression of Osteoblast Markers in Muscle Cells	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							BONE MORPHOGENETIC PROTEIN-2; TRANSCRIPTION FACTOR OSTERIX; SKELETAL-MUSCLE; STEM-CELLS; HETEROTOPIC OSSIFICATION; HEAD-INJURY; TISSUE; DIFFERENTIATION; OSTEOINDUCTION; PHOSPHATASE	Background: Traumatic brain injury is associated with an increased rate of heterotopic ossification within skeletal muscle, possibly as a result of humoral factors. In this study, we investigated whether cells from skeletal muscle adopt an osteoblastic phenotype in response to serum from patients with traumatic brain injury. Methods: Serum was collected from thirteen patients with severe traumatic brain injury, fourteen patients with a long-bone fracture, and ten control subjects. Primary cultures of skeletal muscle cells isolated from patients undergoing orthopaedic surgery were performed and characterized with use of immunofluorescence microscopy, reverse transcription-polymerase chain reaction, and Western blot analysis. Proliferation and osteoblastic differentiation were assessed with use of commercial cell assays, Western blot analysis (for Osterix protein), and the Villanueva bone stain. Results: All serum-treated cell populations expressed the osteoblast marker Osterix after one week in culture. Cells treated with serum from all study groups in mineralization medium had increased alkaline phosphatase activity and mineralized nodules within the mesenchymal cell subpopulation after three weeks in culture. Serum from patients with traumatic brain injury induced a significant increase (p = 0.02) in the rate of proliferation of primary skeletal muscle cells (1.87 [95% confidence interval, 1.66 to 2.09]) compared with the rate induced by serum from patients with a fracture (1.42 [95% confidence interval, 1.21 to 1.58]) or by serum from controls (1.35 [95% confidence interval, 1.15 to 1.54]). Conclusions: Human serum supports the osteoblastic differentiation of cells derived from human skeletal muscle, and serum from patients with severe traumatic brain injury accelerates proliferation of these cells. These findings suggest the early presence of humoral factors following traumatic brain injury that stimulate the expansion of mesenchymal cells and osteoprogenitors within skeletal muscle.	[Cadosch, Dieter] Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009, Australia; Royal Perth Hosp, Perth, WA, Australia		Cadosch, D (corresponding author), Univ Western Australia, Sch Anat & Human Biol, 35 Stirling Highway, Crawley, WA 6009, Australia.	dcadosch@gmx.net	Filgueira, Luis/B-6492-2008	Filgueira, Luis/0000-0002-2266-6650			Alessandri G, 2004, LANCET, V364, P1872, DOI 10.1016/S0140-6736(04)17443-6; *ASS ADV AUT MED, 1998, ABBR INJ SCAL AIS 19; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Bosse A, 1997, Veroff Pathol, V146, P1; Bujan J, 2005, HISTOL HISTOPATHOL, V20, P891, DOI 10.14670/HH-20.891; CADOSCH D, 2010, ANZ J SURG IN PRESS; Cadosch D, 2009, J BONE JOINT SURG AM, V91A, P938; Cadosch D, 2009, J BONE JOINT SURG AM, V91A, P282, DOI 10.2106/JBJS.G.01613; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; Cohly HHP, 2003, BIOMED SCI INSTRUM, V39, P446; COLLICOTT PE, 1980, JAMA-J AM MED ASSOC, V243, P1156; COPE R, 1990, SOUTH MED J, V83, P1058, DOI 10.1097/00007611-199009000-00020; Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932; EKELUND A, 1991, CLIN ORTHOP RELAT R, P102; Flin C., 2002, Annales de Readaptation et de Medecine Physique, V45, P517, DOI 10.1016/S0168-6054(02)00305-7; Fujimura K, 2001, BRIT J ORAL MAX SURG, V39, P294, DOI 10.1054/bjom.2001.0647; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; GRIM M, 1990, J HISTOCHEM CYTOCHEM, V38, P1907, DOI 10.1177/38.12.1701462; Huggins CB, 1931, BIOCHEM J, V25, P728, DOI 10.1042/bj0250728; Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635-200403000-00007; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Le Du MH, 2002, J BIOL CHEM, V277, P49808, DOI 10.1074/jbc.M207394200; Lecoeur L, 1997, BIOMATERIALS, V18, P989, DOI 10.1016/S0142-9612(97)00025-2; Levy MM, 2001, BONE, V29, P317, DOI 10.1016/S8756-3282(01)00585-3; Marusic A, 1999, BONE, V25, P25, DOI 10.1016/S8756-3282(99)00095-2; Mastrogiacomo M, 2005, J CELL PHYSIOL, V204, P594, DOI 10.1002/jcp.20325; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; Musgrave DS, 2002, J BONE JOINT SURG BR, V84B, P120, DOI 10.1302/0301-620X.84B1.11708; Musgrave DS, 2000, CLIN ORTHOP RELAT R, P290; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; Okubo Y, 2000, INT J ORAL MAX SURG, V29, P62, DOI 10.1034/j.1399-0020.2000.290114.x; Pape HC, 2001, J ORTHOP TRAUMA, V15, P229, DOI 10.1097/00005131-200105000-00001; Purpura KA, 2003, J CELL BIOCHEM, V90, P109, DOI 10.1002/jcb.10596; PUZAS JE, 1989, CLIN ORTHOP RELAT R, V245, P269; Sakaguchi Y, 2005, ARTHRITIS RHEUM-US, V52, P2521, DOI 10.1002/art.21212; SAWYER JR, 1991, CALCIFIED TISSUE INT, V49, P208, DOI 10.1007/BF02556120; SOREN A, 1983, Zentralblatt fuer Allgemeine Pathologie und Pathologische Anatomie, V127, P91; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Sun JS, 2005, BIOMATERIALS, V26, P3953, DOI 10.1016/j.biomaterials.2004.10.016; Tai GP, 2005, BIOCHEM BIOPH RES CO, V333, P1116, DOI 10.1016/j.bbrc.2005.05.195; TEASDALE G, 1974, LANCET, V2, P81; URIST MR, 1973, P NATL ACAD SCI USA, V70, P3511, DOI 10.1073/pnas.70.12.3511; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; WHARTON GW, 1970, J BONE JOINT SURG AM, VA 52, P105, DOI 10.2106/00004623-197052010-00010; Williams JT, 1999, AM SURGEON, V65, P22; Yoshida K, 1998, J CRANIO MAXILL SURG, V26, P112, DOI 10.1016/S1010-5182(98)80050-4	51	29	31	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	MAR	2010	92A	3					645	653		10.2106/JBJS.I.00097			9	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	564KT	WOS:000275213800015	20194323	Green Accepted			2022-02-06	
J	Diestel, A; Troeller, S; Billecke, N; Sauer, IM; Berger, F; Schmitt, KRL				Diestel, Antje; Troeller, Silke; Billecke, Nils; Sauer, Igor M.; Berger, Felix; Schmitt, Katharina R. L.			Mechanisms of hypothermia-induced cell protection mediated by microglial cells in vitro	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						cytokines; IkappaB-alpha; microglia; morphology; phagocytosis	PRO-INFLAMMATORY CYTOKINES; TRAUMATIC BRAIN-INJURY; FACTOR-KAPPA-B; CEREBRAL-ISCHEMIA; SIGNALING PATHWAY; AMEBOID MICROGLIA; TNF-ALPHA; DISEASE; IL-10; SLIDEREACTOR	Despite the widespread interest in the clinical applications of hypothermia, the cellular mechanisms of hypothermia-induced neuroprotection have not yet been clearly understood. Therefore, the aim of this study was to elucidate the cellular effects of clinically relevant hypothermia and rewarming on the morphological and functional characteristics of microglia. Microglial cells were exposed to a dynamic cooling and rewarming protocol. For stimulation, microglial cells were treated with 1 mu g/mL lipopolysaccharide (LPS). We found that hypothermia led to morphological changes from ramified to ameboid cell shapes. At 2 h after hypothermia and rewarming, microglial cells were again ramified with extended branches. Moreover, we found enhanced cell activation after rewarming, accompanied by increased phagocytosis and adenosine triphosphate consumption. Interestingly, hypothermia and rewarming led to a time-dependent significant up-regulation of the anti-inflammatory cytokines interleukin-10 and interleukin-1 receptor antagonist in stimulated microglial cells. This is in line with the reduced proliferation and time-dependent down-regulation of the pro-inflammatory cytokines tumor necrosis factor-alpha and monocyte chemotactic protein-1 in comparison to normothermic control cells after LPS stimulation. Furthermore, degradation of the inhibitor of the nuclear transcription factor-kappaB (IkappaB-alpha) was diminished and delayed under conditions of cooling and rewarming in LPS-stimulated microglial cells. Thus, our results show that hypothermia and rewarming activate microglial cells, increase phagocytosis and shift the balance of cytokine release in stimulated microglial cells towards the anti-inflammatory cytokines. This could be a new cellular mechanism of hypothermia-induced neuroprotection mediated by activated microglial cells.	[Troeller, Silke; Berger, Felix; Schmitt, Katharina R. L.] Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis Pediat Cardiol, D-13353 Berlin, Germany; [Diestel, Antje; Berger, Felix] Charite, Dept Pediat Cardiol, D-13353 Berlin, Germany		Schmitt, KRL (corresponding author), Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis Pediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	katharina.schmitt@charite.de	Billecke, Nils/E-9276-2013; Sauer, Igor/AAM-4217-2021	Billecke, Nils/0000-0002-2343-8684; Sauer, Igor/0000-0001-9355-937X; Berger, Felix/0000-0001-7881-1557	European Foundation (efre); Fordergemeinschaft Deutsche Kinderherzzentren e.V.; Deutsche Stiftung fur Herzforschung	The authors wish to thank Chantel Spencer Haensch and Franka Brey for excellent technical assistance and Anne Gale for editing the manuscript. The sources of financial support were the European Foundation (efre), Fordergemeinschaft Deutsche Kinderherzzentren e.V. and Deutsche Stiftung fur Herzforschung.	Acarin L, 2001, Prog Brain Res, V132, P375; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Brabers NACH, 2006, EUR J CLIN INVEST, V36, P447, DOI 10.1111/j.1365-2362.2006.01657.x; Brasier AR, 2006, CARDIOVASC TOXICOL, V6, P111, DOI 10.1385/CT:6:2:111; Christian E, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E9; Christov A, 2004, NEUROL RES, V26, P540, DOI 10.1179/016164104225016218; Dawson J, 2003, EXPERT OPIN THER TAR, V7, P35; Deng YY, 2009, GLIA, V57, P604, DOI 10.1002/glia.20790; Diestel A, 2009, J HEART LUNG TRANSPL, V28, P718, DOI 10.1016/j.healun.2009.04.003; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DINARELLO CA, 1997, SEMIN ONCOL, V24; Froen JF, 2002, BRAIN RES, V942, P87, DOI 10.1016/S0006-8993(02)02700-2; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Hsieh CL, 2009, J NEUROCHEM, V109, P1144, DOI 10.1111/j.1471-4159.2009.06042.x; Hu SX, 1999, J LEUKOCYTE BIOL, V65, P815, DOI 10.1002/jlb.65.6.815; Koller H, 1997, J NEUROIMMUNOL, V76, P185, DOI 10.1016/S0165-5728(97)00056-8; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lucas R, 1997, INFECT IMMUN, V65, P2006, DOI 10.1128/IAI.65.6.2006-2010.1997; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Molina-Holgado E, 2001, EUR J NEUROSCI, V13, P493, DOI 10.1046/j.0953-816x.2000.01412.x; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Nomura F, 1996, ANN THORAC SURG, V62, P115, DOI 10.1016/0003-4975(96)00331-1; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Petersen MA, 2004, GLIA, V46, P195, DOI 10.1002/glia.10362; Pinteaux E, 2006, GLIA, V53, P551, DOI 10.1002/glia.20308; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Sauer IM, 2005, ARTIF ORGANS, V29, P264, DOI 10.1111/j.1525-1594.2005.29049.x; Schilling M, 2009, BRAIN RES, V1289, P79, DOI 10.1016/j.brainres.2009.06.054; Schmitt KRL, 2007, J NEUROIMMUNOL, V189, P7, DOI 10.1016/j.jneuroim.2007.06.010; Schwartlander R, 2007, TISSUE ENG, V13, P187, DOI 10.1089/ten.2006.0071; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001	43	29	29	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAR	2010	31	5					779	787		10.1111/j.1460-9568.2010.07128.x			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	563AC	WOS:000275096500001	20374279				2022-02-06	
J	Griesdale, DEG; McEwen, J; Kurth, T; Chittock, DR				Griesdale, Donald E. G.; McEwen, Jonathan; Kurth, Tobias; Chittock, Dean R.			External Ventricular Drains and Mortality in Patients with Severe Traumatic Brain Injury	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							PULMONARY-ARTERY CATHETER; INTRACRANIAL-PRESSURE; LOGISTIC-REGRESSION; INTENSIVE-CARE; HYPERTENSION; EXPERIENCE; MANAGEMENT; PROTOCOL; EVENTS; NUMBER	Purpose: To determine our institutional adherence to the Brain Trauma Foundation guidelines with respect to intracranial pressure (ICP) monitoring, and examine the relationship between external ventricular drain (EVD) use and mortality. Materials & Methods: Retrospective cohort study of 171 patients with severe traumatic brain injury (TBI). Propensity score adjusted logistic regression was used to model the association between EVD use and mortality. Results: EVDs were inserted in 98 of 171 patients. Of the 73 patients without an EVD, 63 (86%) would have qualified for ICP monitoring under the current guidelines. EVDs were in situ for a median of 8 days (SD 6). In adjusted analyses, EVD use was associated with hospital mortality (OR 2.8, 95% CI: 1.1 - 7.1, p=0.04) and 28-day mortality (OR 2.1, 95% CI: 0.80 - 5.6, p=0.13). We observed significant modification of the association between EVD and 28-day mortality by GCS within 12 hours (p-interaction = 0.04), indicating strong association only among those patients with GCS score of at least 6 (OR 5.0, 95% CI: 1.5 - 16.7, p<0.01). Conclusions: The association of EVD with 28-day mortality was only apparent among patients with GCS score of >= 6. Further research is warranted to further refine which patients may benefit from ICP monitoring.	[Griesdale, Donald E. G.] Vancouver Gen Hosp, Program Crit Care Med, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; McEwen, Jonathan] Univ British Columbia, Dept Anesthesiol, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; McEwen, Jonathan] Univ British Columbia, Dept Anesthesia, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.; Chittock, Dean R.] Univ British Columbia, Dept Med, Div Crit Care Med, Vancouver, BC, Canada; [Kurth, Tobias] Univ Paris 06, INSERM, Neuroepidemiol U708, Paris, France; [Kurth, Tobias] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Kurth, Tobias] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA		Griesdale, DEG (corresponding author), Vancouver Gen Hosp, Program Crit Care Med, Room 2438,Jim Pattison Pavil,2nd Floor,855 W 12th, Vancouver, BC V5Z 1M9, Canada.		Kurth, Tobias/A-9243-2012	Kurth, Tobias/0000-0001-7169-2620; Griesdale, Donald/0000-0001-5985-8624			*AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS37; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; Chittock DR, 2006, CRIT CARE MED, V34, P1820, DOI 10.1097/01.CCM.0000221151.44489.E3; Chittock DR, 2004, CRIT CARE MED, V32, P911, DOI 10.1097/01.CCM.0000119423.38610.65; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213	22	29	29	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	JAN	2010	37	1					43	48		10.1017/S031716710000963X			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	549HT	WOS:000274039200008	20169772	Bronze			2022-02-06	
J	Langley, J; Johnson, S; Slatyer, M; Skilbeck, CE; Thomas, M				Langley, J.; Johnson, S.; Slatyer, M.; Skilbeck, C. E.; Thomas, M.			Issues of loss to follow-up in a population study of traumatic brain injury (TBI) followed to 3 years post-trauma	BRAIN INJURY			English	Article						Traumatic brain injury; loss to follow up; mild traumatic brain injury	HEAD-INJURY; COMMUNITY INTEGRATION; LIFE SATISFACTION; SILENT EPIDEMIC; SYSTEMATIC BIAS; RETURN; WORK; PREDICTORS; COMPLAINTS; SYMPTOMS	Primary objective: To examine loss to follow-up (LTFU) using a population with traumatic brain injury (TBI) to include a range of severity and to follow participants to 3 years post-injury. Also investigated were cause of TBI and employment status. Research design: The research included 947 adults from a TBI population study. Data were obtained on severity, cause of TBI and employment status and participants were followed up at 1, 3, 6, 12, 24 and 36 months after injury. Chi-squared analyses were used to examine rates of loss to follow-up. Main outcome and results: Overall LTFU increased from 22% at 1 month post-injury to 81% at 3-year follow-up. Most participants (52%) were employed at the time of their TBI, with 39% of TBIs being motor vehicle related. Lower LTFU at 2 and 3 years post-TBI was significantly associated with severe TBI. Within the mTBI sub-group significantly higher LTFU at 1 and 6 months after injury and at 2 and 3 years post-injury was associated with TBI from assault. Those sustaining mTBI from a fall or sport-related injury showed significantly lower LTFU at the 6-month, 12-month and 2-year follow-up points. The highest LTFU was noted for unemployed participants, with retired participants showing the lowest rate.	[Langley, J.] Community Rehabil Royal Hobart Hosp, Hobart, Tas, Australia; [Langley, J.; Johnson, S.; Slatyer, M.; Skilbeck, C. E.; Thomas, M.] Royal Hobart Hosp, Sch Med, Hobart, Tas, Australia; [Slatyer, M.] Royal Hobart Hosp, Sch Med, Hobart, Tas, Australia; [Skilbeck, C. E.] Univ Tasmania, Sch Psychol, Hobart, Tas 7001, Australia; [Thomas, M.] Charles Sturt Univ, Bathurst, NSW 2795, Australia		Langley, J (corresponding author), Community Rehabil Unit, 90 Davey St, Hobart, Tas 7001, Australia.	jenny.langley@dhhs.tas.gov.au			Motor Accident Insurance Board of Tasmania	The Tasmanian Neurotrauma Register was funded by the Motor Accident Insurance Board of Tasmania.	Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORTUNE N, 1999, DIS15 AIHW; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hillier SL, 1997, BRAIN INJURY, V11, P649; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Labi MLC, 2003, BRAIN INJURY, V17, P265, DOI 10.1080/0269905021000038410; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; RIBISL JM, MINIMIZING PARTICIPA; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SILVER JM, 2005, TXB TRAUMATIC BRAIN, P279; SLATYER M, 2004, BRAIN INJ ASS TASM C; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stuart M, 2004, J HEAD TRAUMA REHAB, V19, P329, DOI 10.1097/00001199-200407000-00007; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; TABCHNICK BG, 1995, USING MULTIVARIANTE; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thomas MD, 2009, BRAIN INJURY, V23, P516, DOI 10.1080/02699050902926333; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207	36	29	29	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	7-8					939	947		10.3109/02699052.2010.491494			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	620MW	WOS:000279505000003	20545449				2022-02-06	
J	McAuley, G; Schrag, M; Sipos, P; Sun, SW; Obenaus, A; Neelavalli, J; Haacke, EM; Holshouser, B; Madacsi, R; Kirsch, W				McAuley, Grant; Schrag, Matthew; Sipos, Pal; Sun, Shu-Wei; Obenaus, Andre; Neelavalli, Jaladhar; Haacke, E. Mark; Holshouser, Barbara; Madacsi, Ramona; Kirsch, Wolff			Quantification of Punctate Iron Sources Using Magnetic Resonance Phase	MAGNETIC RESONANCE IN MEDICINE			English	Article						iron quantification; phase images; susceptibility weighted imaging; brain microbleeds; blooming effect	DIFFUSE AXONAL INJURY; TRANSVERSE RELAXATION RATES; BRAIN IRON; ALZHEIMERS-DISEASE; LABELED CELLS; MR-IMAGES; SUSCEPTIBILITY; MICROBLEEDS; ARTIFACTS; FERRITIN	Iron-mediated tissue damage is present in cerebrovascular and neurodegenerative diseases and neurotrauma. Brain microbleeds are often present in these maladies and are assuming increasing clinical importance. Because brain microbleeds present a source of pathologic iron to the brain, the noninvasive quantification of this iron pool is potentially valuable. Past efforts to quantify brain iron have focused on content estimation within distributed brain regions. In addition, conventional approaches using "magnitude" images have met significant limitations. In this study, a technique is presented to quantify the iron content of punctate samples using phase images. Samples are modeled as magnetic dipoles and phase shifts due to local dipole field perturbations are mathematically related to sample iron content and radius using easily recognized geometric features in phase images. Phantoms containing samples of a chitosan-ferric oxyhydroxide composite (which serves as a mimic for hemosiderin) were scanned with a susceptibility-weighted imaging sequence at 11.7 T. Plots relating sample iron content and radius to phase image features were compared to theoretical predictions. The primary result is the validation of the technique by the excellent agreement between theory and the iron content plot. This research is a potential first step toward quantification of punctate brain iron sources such as brain microbleeds. Magn Reson Med 63:106-115, 2010. (C) 2009 Wiley-Liss, Inc.	[McAuley, Grant; Schrag, Matthew; Kirsch, Wolff] Loma Linda Univ, Neurosurg Ctr Res Training & Educ, Loma Linda, CA 92354 USA; [Sipos, Pal; Madacsi, Ramona] Univ Szeged, Dept Inorgan & Analyt Chem, Szeged, Hungary; [Sun, Shu-Wei; Obenaus, Andre] Loma Linda Univ, Sch Sci & Technol, Loma Linda, CA 92354 USA; [Obenaus, Andre] Loma Linda Univ, Noninvas Imaging Lab, Radiobiol Program, Loma Linda, CA 92354 USA; [Obenaus, Andre; Haacke, E. Mark; Holshouser, Barbara] Loma Linda Univ, Med Ctr, Loma Linda, CA 92354 USA; [Neelavalli, Jaladhar; Haacke, E. Mark] Magnet Resonance Inst Biomed Res, Detroit, MI USA; [Neelavalli, Jaladhar] Univ Oxford, ONNRU, Nuffield Dept Surg, Oxford OX1 2JD, England; [Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI USA		Kirsch, W (corresponding author), Loma Linda Univ, Neurosurg Ctr Res Training & Educ, 11175 Campus St,CPA11113, Loma Linda, CA 92354 USA.	wkirsch@llu.edu	McAuley, Grant/I-2497-2013; Sipos, Pal/B-8505-2018; NEELAVALLI, JALADHAR/C-6904-2014	McAuley, Grant/0000-0002-4083-5825; Sipos, Pal/0000-0003-1407-0950; NEELAVALLI, JALADHAR/0000-0002-9513-337X			Akter M, 2007, ACAD RADIOL, V14, P1011, DOI 10.1016/j.acra.2007.05.013; Andersen JK, 2004, J ALZHEIMERS DIS, V6, pS47; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; BARTZOKIS G, 1993, MAGN RESON MED, V29, P459, DOI 10.1002/mrm.1910290406; BIZZI A, 1990, RADIOLOGY, V177, P59, DOI 10.1148/radiology.177.1.2399339; Bos C, 2003, MAGNET RESON MED, V50, P400, DOI 10.1002/mrm.10505; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Cheng YCN, 2007, MAGN RESON IMAGING, V25, P1171, DOI 10.1016/j.mri.2007.01.008; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Dixon WT, 2009, MAGN RESON MED, V61, P1132, DOI 10.1002/mrm.21930; Duyn JH, 2007, P NATL ACAD SCI USA, V104, P11796, DOI 10.1073/pnas.0610821104; Gaasch JA, 2007, NEUROCHEM RES, V32, P1196, DOI 10.1007/s11064-007-9290-4; Gelman N, 1999, RADIOLOGY, V210, P759, DOI 10.1148/radiology.210.3.r99fe41759; Gilissen EP, 1999, J NEUROL SCI, V168, P21, DOI 10.1016/S0022-510X(99)00162-8; Gossuin Y, 2007, NMR BIOMED, V20, P749, DOI 10.1002/nbm.1140; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Haacke EM, 2007, J MAGN RESON IMAGING, V26, P256, DOI 10.1002/jmri.22987; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Helmer OM, 1934, J BIOL CHEM, V104, P157; House MJ, 2007, MAGN RESON MED, V57, P172, DOI 10.1002/mrm.21118; Jara Hernan, 2006, Top Magn Reson Imaging, V17, P19, DOI 10.1097/01.rmr.0000245460.82782.69; Jensen JH, 2009, MAGN RESON MED, V61, P481, DOI 10.1002/mrm.21823; KIM JK, 1993, RADIOLOGY, V187, P735, DOI 10.1148/radiology.187.3.8497623; MacKay A, 2006, MAGN RESON IMAGING, V24, P515, DOI 10.1016/j.mri.2005.12.037; Mills PH, 2008, MAGN RESON IMAGING, V26, P618, DOI 10.1016/j.mri.2008.01.007; Neelavalli J, 2009, J MAGN RESON IMAGING, V29, P937, DOI 10.1002/jmri.21693; Neema M, 2009, J NEUROIMAGING, V19, P3, DOI 10.1111/j.1552-6569.2008.00296.x; Nighoghossian N, 2002, STROKE, V33, P735, DOI 10.1161/hs0302.104615; Ogg RJ, 1999, MAGN RESON IMAGING, V17, P1141, DOI 10.1016/S0730-725X(99)00017-X; ORDIDGE RJ, 1994, MAGNET RESON MED, V32, P335, DOI 10.1002/mrm.1910320309; Pintaske J, 2006, PHYS MED BIOL, V51, P4707, DOI 10.1088/0031-9155/51/18/016; Pintaske J, 2006, MAGN RESON MATER PHY, V19, P46, DOI 10.1007/s10334-006-0026-2; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robson P, 2005, AICHE J, V51, P1633, DOI 10.1002/aic.10408; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schenck JF, 2004, NMR BIOMED, V17, P433, DOI 10.1002/nbm.922; Sipos P, 2003, J INORG BIOCHEM, V95, P55, DOI 10.1016/S0162-0134(03)00068-0; Smirnov P, 2006, CONTRAST MEDIA MOL I, V1, P165, DOI 10.1002/cmmi.104; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Venkatesan, 1999, MAGNETIC RESONANCE I; Viswanathan A, 2006, STROKE, V37, P550, DOI 10.1161/01.STR.0000199847.96188.12; Vymazal J, 2007, J NEUROL SCI, V263, P20, DOI 10.1016/j.jns.2007.05.018; Wang Y, 2000, J MAGN RESON IMAGING, V12, P661, DOI 10.1002/1522-2586(200011)12:5<661::AID-JMRI2>3.0.CO;2-L; Wang ZYJ, 2005, RADIOLOGY, V234, P749, DOI 10.1148/radiol.2343031084; Yakushiji Y, 2008, STROKE, V39, P3323, DOI 10.1161/STROKEAHA.108.516112; Yamada N, 1996, RADIOLOGY, V198, P171, DOI 10.1148/radiology.198.1.8539373	48	29	30	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	JAN	2010	63	1					106	115		10.1002/mrm.22185			10	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	543LI	WOS:000273578600012	19953510	Bronze			2022-02-06	
J	Moore, DW; Ashman, TA; Cantor, JB; Krinick, RJ; Spielman, LA				Moore, Dana W.; Ashman, Teresa A.; Cantor, Joshua B.; Krinick, Ren Jolie; Spielman, Lisa A.			Does gender influence cognitive outcome after traumatic brain injury?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Gender; Cognitive; Memory; Executive functioning	SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; CONCUSSION SYMPTOMS; FUNCTIONAL RECOVERY; MENSTRUAL-CYCLE; NEURONAL LOSS; PROGESTERONE; MEMORY; TESTOSTERONE; PERFORMANCE	The aim of this study was to determine whether males and females differ in post-acute cognitive outcome following traumatic brain injury (TBI). Performances of 83 men and 75 women with mild to severe TBI were compared on measures of cognitive functions typically impacted by TBI (i.e., processing speed, executive functioning, and memory). Participants completed selected subtests of the Cambridge Neuropsychological Test Automated Battery (CANTAB). Among the participants with mild TBI, women scored significantly higher than men on a test of visual memory. There were no other significant gender differences in cognitive outcomes. These findings overall suggest that cognitive outcome after TBI does not differ according to gender, with the possible exception of memory functioning. Further research is needed to replicate this finding and determine which moderating variables may impact on the relationship between gender and cognitive outcome after TBI.	[Moore, Dana W.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Ashman, Teresa A.; Cantor, Joshua B.; Krinick, Ren Jolie; Spielman, Lisa A.] Mt Sinai Sch Med, New York, NY USA		Moore, DW (corresponding author), Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Neurol & Neurosci, 428 E 72nd St,Suite 500, New York, NY 10021 USA.	dwm2003@med.cornell.edu	Ashman, Teresa/B-1621-2013	Ashman, Teresa/0000-0003-2401-7192	National Institute on Disability and Rehabilitation Research (NIDRR) [H133A020501, H133P050004]	This study was funded by grant numbers H133A020501 and H133P050004 from the National Institute on Disability and Rehabilitation Research (NIDRR).	ALDERMAN N, 1996, BEHAV ASSESSMENT DYS; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Axelrod BN, 1996, J CLIN EXP NEUROPSYC, V18, P338, DOI 10.1080/01688639608408991; Barnfield AMC, 1999, PERCEPT MOTOR SKILL, V89, P339, DOI 10.2466/pms.1999.89.1.339; Basso MR, 2000, CLIN NEUROPSYCHOL, V14, P231, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT231; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Crawford JR, 2001, PSYCHOL MED, V31, P451, DOI 10.1017/S0033291701003634; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; DELUCA CR, 2008, J CLIN EXPT NEUROPSY, V25, P242; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; FEINGOLD A, 1988, AM PSYCHOL, V43, P95, DOI 10.1037/0003-066X.43.2.95; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; GORDON WA, 1998, LIVING LIFE TBI; Greendale GA, 2009, NEUROLOGY, V72, P1850, DOI 10.1212/WNL.0b013e3181a71193; Halari R, 2005, BEHAV NEUROSCI, V119, P104, DOI 10.1037/0735-7044.119.1.104; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Janowsky JS, 1998, DEV NEUROPSYCHOL, V14, P421, DOI 10.1080/87565649809540719; Jeppesen LL, 1996, ARTERIOSCL THROM VAS, V16, P749, DOI 10.1161/01.ATV.16.6.749; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Lewin C, 2001, NEUROPSYCHOLOGY, V15, P165, DOI 10.1037//0894-4105.15.2.165; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Maki PM, 2002, NEUROPSYCHOLOGIA, V40, P518, DOI 10.1016/S0028-3932(01)00126-9; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Mehta MA, 2000, J NEUROSCI, V20; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mordecai KL, 2008, HORM BEHAV, V54, P286, DOI 10.1016/j.yhbeh.2008.03.006; MORRIS RG, 1986, COGNITIVE NEUROCHEMI, P21; Nelson H.E., 1982, NATL ADULT READING T; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Pan Y, 2005, BRAIN RES, V1043, P195, DOI 10.1016/j.brainres.2005.02.078; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P497, DOI 10.1016/0306-4530(92)90008-U; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; *RES TRAIN CTR COM, 1997, BRAIN INJ SCREEN QUE; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; SMITH D, 1998, COGNITIVE NEUROPSYCH, V3, P71, DOI DOI 10.1080/135468098396251; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Wechsler D., 1997, WECHSLER ADULT MEMOR; Wechsler D, 1987, MANUAL WECHSLER MEMO; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195	50	29	29	0	14	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	3					340	354	PII 916210592	10.1080/09602010903250928			15	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	598RZ	WOS:000277857200002	19859853				2022-02-06	
J	Murillo-Cabezas, F; Munoz-Sanchez, MA; Rincon-Ferrari, MD; Martin-Rodriguez, JF; Amaya-Villar, R; Garcia-Gomez, S; Leon-Carrion, J				Murillo-Cabezas, Francisco; Angeles Munoz-Sanchez, Maria; Dolores Rincon-Ferrari, Maria; Francisco Martin-Rodriguez, Juan; Amaya-Villar, Rosario; Garcia-Gomez, Susana; Leon-Carrion, Jose			The prognostic value of the temporal course of S100 beta protein in post-acute severe brain injury: A prospective and observational study	BRAIN INJURY			English	Article						Acute brain injury; traumatic brain injury; serum S100 beta; brain injury biomarker; brain injury outcome	SERUM S-100B PROTEIN; SEVERE HEAD-INJURY; TRAUMATIC BRAIN; S100B; DAMAGE; MULTICENTER; TOMOGRAPHY; BIOMARKERS; PRESSURE; ADULTS	Methods and procedures: Eighty-seven patients with severe TBI were studied. Clinical and CT scan were taken at admission. S100 beta concentration was quantified at admission and 24, 48 and 72 hours post-TBI (days 0, 1, 2 and 3). Outcome was assessed 12 months after discharge using Glasgow Outcome Score (GOS). Results: Significant negative correlations were found between 1-year GOS and S100 beta concentrations on days 1-3, but not on day 0. Deceased patients showed higher S100 beta concentration than survivors on days 1-3. Good (GOS = 4-5) vs poor outcome (GOS = 1-3) differed significantly on day 3. Death outcome was independently predicted by day 2 (> 2.37 mu g l<SU-1</SU), day 3 (> 1.41 mu g l<SU-1</SU) samples and absence of pupillary reaction. Poor outcome was predicted independently only by pupillary reaction and the 72-hour sample (> 1.1 mu g l<SU-1</SU), but this predictive model was less satisfactory than the predictive model for death. Conclusions: A temporal profile of S100 beta release from admission to 72 hours post-TBI is strongly recommended for use in identifying patients at risk of developing a worse outcome. The S100 beta protein might be an early biomarker for predicting long-term outcome in patients with acute severe TBI.	[Murillo-Cabezas, Francisco; Angeles Munoz-Sanchez, Maria; Dolores Rincon-Ferrari, Maria; Amaya-Villar, Rosario; Garcia-Gomez, Susana] Univ Hosp Virgen del Rocio, Intens Care Unit, Seville, Spain; [Francisco Martin-Rodriguez, Juan; Leon-Carrion, Jose] Univ Seville, Human Neuropsychol Lab, Ctr Brain Injury Rehabil CRECER, Seville, Spain		Murillo-Cabezas, F (corresponding author), HHUU Virgen del Rocio, Dept Emergency & Crit Care, Avda Manuel Siurot S-N, Seville 41013, Spain.	murillomunoz@telefonica.net	IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021	Martin Rodriguez, Juan Francisco/0000-0003-1392-8775			Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bishop Y.M., 1975, DISCRETE MULTIVARIAT; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; JENNETT B, 1975, LANCET, V1, P480; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Korfias S, 2006, CURR MED CHEM, V13, P3719, DOI 10.2174/092986706779026129; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McKeating EG, 1998, ACT NEUR S, V71, P117; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	31	29	31	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	4					609	619		10.3109/02699051003652823			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	570ML	WOS:000275682300005	20235763				2022-02-06	
J	Sullivan, JR; Riccio, CA				Sullivan, Jeremy R.; Riccio, Cynthia A.			Language Functioning and Deficits Following Pediatric Traumatic Brain Injury	APPLIED NEUROPSYCHOLOGY			English	Article						children; language; TBI; traumatic brain injury	CLOSED-HEAD INJURY; CHILDREN; COMPREHENSION; ADOLESCENTS; DISCOURSE; CHILDHOOD; FLUENCY; MEMORY; SKILLS; MILD	The purpose of this article is to provide a current review of language functioning and deficits following traumatic brain injury (TBI), specifically among the pediatric population. This paper will: (a) outline the manner in which these deficits may impede functioning across environments; (b) review methods of assessing language functioning within this population; and (c) discuss empirically supported interventions to address noted language deficits as they present in pediatric TBI.	[Sullivan, Jeremy R.] Univ Texas San Antonio, Dept Educ Psychol, San Antonio, TX 78207 USA; [Riccio, Cynthia A.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA		Sullivan, JR (corresponding author), Univ Texas San Antonio, Dept Educ Psychol, 501 W Durango Blvd, San Antonio, TX 78207 USA.	jeremy.sullivan@utsa.edu					Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bowen JM, 2005, PREV SCH FAIL, V49, P34, DOI 10.3200/PSFL.49.4.34-41; Carrow-Woolfolk E., 1999, TEST AUDITORY COMPRE, VThird; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SS, 2005, BEHAV INTERVENT, V20, P37, DOI 10.1002/bin.168; Delis DC., 1994, CALIFORNIA VERBAL LE; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Dunn, 2007, PPVT 4 PEABODY PICTU; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; Gardner M. F., 2000, EXPRESSIVE ONE WORD; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; HAMMILL DD, 2007, TEST ADOLESCENT ADUL; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Hay E, 2005, AM J SPEECH-LANG PAT, V14, P324, DOI 10.1044/1058-0360(2005/031); Hotz G, 2001, J HEAD TRAUMA REHAB, V16, P426, DOI 10.1097/00001199-200110000-00003; Huisingh R, 2005, WORD TEST; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Moran C, 2004, BRAIN INJURY, V18, P273, DOI 10.1080/02699050310001617415; Morse S, 1999, Pediatr Rehabil, V3, P139; Oberg L, 1998, J HEAD TRAUMA REHAB, V13, P44, DOI 10.1097/00001199-199806000-00005; Phelps-Terasaki D, 2007, TEST PRAGMATIC LANGU; RICCIO CA, 1999, MILD BRAIN INJURY CL, P77; Semel E., 2003, CLIN EVALUATION LANG; Shinn M, 1989, CURRICULUM BASED MEA; Sohlberg M. M., 1992, IMPROVING PRAGMATIC; Thomas-Stonell N, 1994, J HEAD TRAUMA REHAB, V9, P25, DOI DOI 10.1097/00001199-199412000-00005; Wagner RK., 1999, COMPREHENSIVE TEST P; Wallace G., 2002, COMPREHENSIVE RECEPT; Wetherington C. E., 2006, EXCEPTIONALITY, V14, P155, DOI [10.1207/s15327035-x1403_4, DOI 10.1207/S15327035-X1403_4]; Wiig E. H., 1989, TEST LANGUAGE COMPET; Wilkinson G., 1993, WIDE RANGE ACHIEVEME, V3; Williams, 2007, EXPRESSIVE VOCABULAR; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005; Woodcock R. W., 2001, WOODCOCKJOHNSON 3 TE	42	29	29	1	18	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	2					93	98	PII 922162312	10.1080/09084281003708852			6	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	596CX	WOS:000277662800003	20467948				2022-02-06	
J	Zhang, J; Mitsis, EM; Chu, K; Newmark, RE; Hazlett, EA; Buchsbaum, MS				Zhang, Jing; Mitsis, Effie M.; Chu, Kingwai; Newmark, Randall E.; Hazlett, Erin A.; Buchsbaum, Monte S.			Statistical Parametric Mapping and Cluster Counting Analysis of [F-18] FDG-PET Imaging in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral metabolism; head injury; spatial pattern; voxel statistics	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; HEAD-INJURY; IMAGES; CONSCIOUSNESS; ACTIVATION; IMPAIRMENT; MEMORY; SPECT; SCALE	In this study we investigated regional cerebral glucose metabolism abnormalities of [F-18] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in traumatic brain injury (TBI). PET images of 81 TBI patients and 68 normal controls were acquired and a word list learning task was administered during the uptake period. The TBI group included 35 patients with positive structural imaging (CT or MRI) findings soon after injury, 40 patients with negative findings, and 6 cases without structural imaging. Statistical parametric mapping (SPM) analysis was applied with several levels of spatial smoothing. Cluster counting analysis was performed for each subject to identify abnormal clusters with contiguous voxel values that deviated by two standard deviations or more from the mean of the normal controls, and to count the number of clusters in 10 size categories. SPM maps demonstrated that the 81 patients had significantly lower FDG uptake than normal controls, widely across the cortex (including bilateral frontal and temporal regions), and in the thalamus. Cluster counting results indicated that TBI patients had a higher proportion of larger clusters than controls. These large low-FDG-uptake clusters of the TBI patients were closer to the brain edge than those of controls. These results suggest that deficits of cerebral metabolism in TBI are spread over multiple brain areas, that they are closer to the cortical surface than clusters in controls, and that group spatial patterns of abnormal cerebral metabolism may be similar in TBI patients with cognitive deficits with and without obvious acute abnormalities identified on structural imaging.	[Buchsbaum, Monte S.] Univ Calif San Diego, Ctr Mol Imaging, Mt Sinai Sch Med, San Diego, CA 92121 USA		Buchsbaum, MS (corresponding author), Univ Calif San Diego, Ctr Mol Imaging, Mt Sinai Sch Med, 11388 Sorrento Valley Rd, San Diego, CA 92121 USA.	mbuchsbaum@ucsd.edu					Allman JM, 2001, ANN NY ACAD SCI, V935, P107, DOI 10.1111/j.1749-6632.2001.tb03476.x; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Buchsbaum MS, 2007, SCHIZOPHR RES, V94, P293, DOI 10.1016/j.schres.2007.04.027; Choo IH, 2007, ALZ DIS ASSOC DIS, V21, P77, DOI 10.1097/WAD.0b013e3180687418; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; FEDIO P, 1970, EXP NEUROL, V29, P84, DOI 10.1016/0014-4886(70)90039-7; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; Hattori N, 2003, J NUCL MED, V44, P1709; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Hazlett EA, 1999, AM J PSYCHIAT, V156, P1190; Hazlett EA, 1998, NEUROBIOL AGING, V19, P437, DOI 10.1016/S0197-4580(98)00075-X; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jeong Y, 2005, J NUCL MED, V46, P233; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lovell MK FM, 1994, NEUROPSYCHIATRY TRAU, P152; MARKLUND N, 2009, J NEUROTRAUMA   0408; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Newberg AB, 2003, SEMIN NUCL MED, V33, P136, DOI 10.1053/snuc.2003.127299; POLINE JB, 1993, J CEREBR BLOOD F MET, V13, P425, DOI 10.1038/jcbfm.1993.57; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Reimold M, 2006, J CEREBR BLOOD F MET, V26, P751, DOI 10.1038/sj.jcbfm.9600231; Roland P. E., 1993, Human Brain Mapping, V1, P3, DOI 10.1002/hbm.460010103; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; SINGH M, 2009, MAGN RESON IMAG 0714; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stamatakis EA, 2002, J NUCL MED, V43, P476; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; TEASDALE G, 1974, LANCET, V2, P81; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Van Heertum RL, 2004, SEMIN NUCL MED, V34, P300, DOI 10.1053/j.semnuclmed.2004.03.003; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P74, DOI 10.1002/(SICI)1097-0193(1996)4:1<74::AID-HBM5>3.0.CO;2-M; Ziolko SK, 2006, NEUROIMAGE, V33, P94, DOI 10.1016/j.neuroimage.2006.05.063	47	29	30	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					35	49		10.1089/neu.2009.1049			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200003	19715400				2022-02-06	
J	Bernabeu, M; Demirtas-Tatlidede, A; Opisso, E; Lopez, R; Tormos, JM; Pascual-Leone, A				Bernabeu, Montse; Demirtas-Tatlidede, Asli; Opisso, Eloy; Lopez, Raquel; Ma Tormos, Jose; Pascual-Leone, Alvaro			Abnormal Corticospinal Excitability in Traumatic Diffuse Axonal Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						corticospinal excitability; diffuse axonal injury; transcranial magnetic stimulation; traumatic brain injury	TRANSCRANIAL MAGNETIC STIMULATION; SILENT PERIOD; MOTOR CORTEX; HEAD-INJURY; INHIBITION; RECOVERY; POTENTIALS; MODERATE	This study aimed to investigate the cortical motor excitability characteristics in diffuse axonal injury (DAI) due to severe traumatic brain injury (TBI). A variety of excitatory and inhibitory transcranial magnetic stimulation (TMS) paradigms were applied to primary motor cortices of 17 patients and 11 healthy controls. The parameters of testing included resting motor threshold (MT), motor evoked potential (MEP) area under the curve, input-output curves, MEP variability, and silent period (SP) duration. The patient group overall revealed a higher MT, smaller MEP areas, and narrower recruitment curves compared to normal controls (p<0.05). The alterations in excitability were more pronounced with an increase in DAI severity (p<0.005) and the presence of motor impairment (p<0.05), while co-existence of focal lesions did not affect the degree of MEP changes. MEP variability was significantly lower in the group with motor impairment only (p<0.05). The intracortical inhibition, as revealed by SP duration, did not exhibit any significant differences in any of the patient groups. In conclusion, our findings expand the concept that impairment of the excitatory and inhibitory phenomena in the motor cortex does not proceed in parallel and demonstrate distinct patterns of aberrations in TBI. Furthermore, these data suggest that alterations in the corticospinal excitatory mechanisms are determined predominantly by the severity of DAI, and show a significant relationship with clinical motor dysfunction following severe trauma diffusely affecting the motor cortical connections. In severe TBI, motor and functional recovery might be linked to restitution of normal corticospinal mechanisms, indexed by normalization of the cortical excitability parameters.	[Demirtas-Tatlidede, Asli; Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA; [Bernabeu, Montse; Opisso, Eloy; Lopez, Raquel; Ma Tormos, Jose] Guttmann Univ, Inst Neurorehabil UAB, Badalona, Spain		Pascual-Leone, A (corresponding author), Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, 330 Brookline Ave KS 158, Boston, MA 02215 USA.	apleone@bidmc.harvard.edu	Pascual-Leone, Alvaro/G-6566-2011; Pascual-Leone, Alvaro/AAC-5101-2019	Pascual-Leone, Alvaro/0000-0001-8975-0382; Opisso, Eloy/0000-0002-6868-6737; Tormos Munoz, Jose Maria/0000-0002-8764-2289; Demirtas-Tatlidede, MD, PhD, Asli/0000-0003-2050-5674	BBVA Translational Research Chair in BiomedicineBBVA Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K 24 RR018875]; Instituto de Salud Carlos III ResearchInstituto de Salud Carlos III; Non-Invasive Brain Stimulation; Robot-Assisted Rehabilitation to Improve TBI [PI082004]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K24RR018875] Funding Source: NIH RePORTER	Supported in part by a BBVA Translational Research Chair in Biomedicine, and a mentoring grant form the National Institutes of Health (K 24 RR018875), and the Instituto de Salud Carlos III Research Grant, Non-Invasive Brain Stimulation and Robot-Assisted Rehabilitation to Improve TBI recovery (PI082004). Special thanks go to Dr. Felip Orient, who assisted in collecting part of the data. We would also like to take this opportunity to thank the anonymous peer reviewers, whose reviews greatly helped to improve the manuscript.	Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Catano A, 1997, ELECTROMYOGR MOTOR C, V105, P290, DOI 10.1016/S0924-980X(97)00021-0; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; Damron LA, 2008, J NEUROSCI METH, V173, P121, DOI 10.1016/j.jneumeth.2008.06.001; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; HALLETT M, 1995, ADV NEUROL, V67, P107; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KIERS L, 1993, ELECTROEN CLIN NEURO, V89, P415, DOI 10.1016/0168-5597(93)90115-6; KIERS L, 1995, ELECTROMYOGR MOTOR C, V97, P131, DOI 10.1016/0924-980X(94)00325-2; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lopantsev V, 1999, J NEUROPHYSIOL, V82, P1218, DOI 10.1152/jn.1999.82.3.1218; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; Moosavi SH, 1999, J NEUROL SCI, V164, P179, DOI 10.1016/S0022-510X(99)00065-9; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Pena-Casanova J, 1997, Neurologia, V12, P99; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; REID AE, 2002, HDB TRANSCRANIAL MAG, P97; ROICK H, 1993, EXP BRAIN RES, V94, P489, DOI 10.1007/BF00230207; Rossini P M, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P171; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.0.CO;2-M; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; STERIADE M, 1990, ELECTROEN CLIN NEURO, V76, P481, DOI 10.1016/0013-4694(90)90001-Z; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Weber HK, 1997, J MOL CATAL B-ENZYM, V3, P131, DOI 10.1016/S1381-1177(96)00045-8; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073	43	29	29	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2185	2193		10.1089/neu.2008.0859			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200006	19604100	Green Published			2022-02-06	
J	DeJong, J; Donders, J				DeJong, Joy; Donders, Jacobus			A Confirmatory Factor Analysis of the California Verbal Learning Test-Second Edition (CVLT-II) in a Traumatic Brain Injury Sample	ASSESSMENT			English	Article						learning; memory; construct validity; factor analysis; traumatic brain injury	WAIS-III; RECALL DISCRIMINABILITY; CONSTRUCT-VALIDITY; CRITERION VALIDITY; 2ND EDITION; WMS-III; MEMORY; PERFORMANCE; INDEXES; DISCREPANCIES	The latent structure of the California Verbal Learning Test-Second Edition (CVLT-II) was examined in a clinical sample of 223 persons with traumatic brain injury that had been screened to remove individuals with complicating premorbid (e. g., psychiatric) or comorbid (e. g., financial compensation seeking) histories. Analyses incorporated the z scores from 12 CVLT-II variables. Maximum-likelihood confirmatory analyses were performed to test the fit and parsimony of four hypothetical models. A four-factor model, consisting of Attention Span, Learning Efficiency, Delayed Memory, and Inaccurate Memory, met all the a priori specified criteria for model fit and parsimony. This model was consistent with that identified previously in a confirmatory factor analysis of the CVLT-II standardization sample. The results support the construct validity of the CVLT-II in individuals with traumatic brain injury and indicate that a multifactorial interpretation is appropriate for clinical practice.	[Donders, Jacobus] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA		Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bell BD, 2004, CLIN NEUROPSYCHOL, V18, P303, DOI 10.1080/13854040490501646; Burton DB, 2003, ARCH CLIN NEUROPSYCH, V18, P629, DOI 10.1093/arclin/18.6.629; Caruso JC, 1999, PSYCHOL ASSESSMENT, V11, P198, DOI 10.1037/1040-3590.11.2.198; Cliff N, 1998, PSYCHOL METHODS, V3, P291, DOI 10.1037/1082-989X.3.3.291; Crawford JR, 2008, J INT NEUROPSYCH SOC, V14, P1069, DOI 10.1017/S1355617708081228; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 2003, J INT NEUROPSYCH SOC, V9, P936, DOI 10.1017/S1355617703960139; Delis DC, 2005, J INT NEUROPSYCH SOC, V11, P708, DOI 10.1017/S1355617705050812; Dodson CS, 2007, PSYCHOL AGING, V22, P122, DOI 10.1037/0882-7974.22.1.122; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2008, J CLIN EXP NEUROPSYC, V30, P741, DOI 10.1080/13803390701689595; Donders J, 2008, ASSESSMENT, V15, P123, DOI 10.1177/1073191107310926; Donders J, 2007, J INT NEUROPSYCH SOC, V13, P354, DOI 10.1017/S1355617707070439; Donders J, 2006, PSYCHOL ASSESSMENT, V18, P458, DOI 10.1037/1040-3590.18.4.458; Eslinger PJ, 2007, BRAIN INJURY MED PRI, P779; FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312; Hanks RA, 2004, DIFFERENTIAL DIAGNOSIS IN ADULT NEUROPSYCHOLOGICAL ASSESSMENT, P218; Hatcher L, 1994, STEP BY STEP APPROAC, P325; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; KAUFMAN AS, 1999, ESSENTIALS WAIS 3 AS; Lange RT, 2006, PSYCHOL ASSESSMENT, V18, P174, DOI 10.1037/1040-3590.18.2.174; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; McCabe DP, 2007, MEM COGNITION, V35, P231, DOI 10.3758/BF03193444; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Mottram L, 2005, PSYCHOL ASSESSMENT, V17, P212, DOI 10.1037/1040-3590.17.2.212; *NAT COUNC MEAS ED, 1999, STAND ED PSYCH TESTS; Roebuck-Spencer T, 2008, TXB CLIN NEUROPSYCHO, P411; *SAS I, 1990, SAS STAT US GUID VER, V0001; SHESLOW D, 1999, WIDE RANGE ASSESSMEN; Stricker JL, 2002, J INT NEUROPSYCH SOC, V8, P425, DOI 10.1017/S1355617702813224; Thompson B., 2004, EXPLORATORY CONFIRMA; Tulsky DS, 2004, J CLIN EXP NEUROPSYC, V26, P563, DOI 10.1080/13803390490490782; van der Heijden P, 2003, J CLIN EXP NEUROPSYC, V25, P59, DOI 10.1076/jcen.25.1.59.13627; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	38	29	29	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2009	16	4					328	336		10.1177/1073191109336989			9	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	519QC	WOS:000271781100002	19546480				2022-02-06	
J	Markianos, M; Tripodianakis, J; Istikoglou, C; Rouvali, O; Christopoulos, M; Papageorgopoulos, P; Seretis, A				Markianos, Manolis; Tripodianakis, John; Istikoglou, Christos; Rouvali, Olga; Christopoulos, Markos; Papageorgopoulos, Pavlos; Seretis, Andreas			Suicide attempt by jumping: A study of gonadal axis hormones in male suicide attempters versus men who fell by accident	PSYCHIATRY RESEARCH			English	Article						Suicide attempt; Jumping; Accident; Fall from heights; Testosterone; LH; FSH; Cortisol; Prolactin	TRAUMATIC BRAIN-INJURY; TESTOSTERONE; STRESS; PROLACTIN; PLASMA; SUPPRESSION; DYSFUNCTION; DEPRESSION; SEVERITY; DOPAMINE	Low plasma total testosterone (T) levels may influence the sense of well-being and produce depressive symptomatology, increasing the risk of suicide. In a previous study, we reported reduced serum T levels in male psychiatric patients after a suicide attempt. The reduction was more pronounced in subjects who used violent attempt methods, and we discussed the possible influence of stress of hospitalization, serious medical condition and treatment In order to minimize the influence of such factors, we compared in this study the levels of plasma sex hormones of 15 psychiatric patients (10 suffering from schizophrenia and 5 from depression) who had attempted suicide by jumping with those of a group of 18 male subjects who were hospitalized after accidentally falling from a high height. Compared with a healthy control group of 40 males, both accident and attempt groups had lower T levels. The attempt group showed a trend toward lower T levels compared with levels in the accident group. In the accident group, luteinizing hormone (LH) levels were elevated compared with levels in healthy controls, indicating a normal function of the hypothalamic-pituitary-gonadal (HPG) axis. This was not the case for the attempt group, where low T levels were not accompanied by increases in LH. Cortisol and prolactin were similarly elevated in both patient groups, but were not related to the low T levels. The results indicate that male psychiatric patients who attempt suicide by violent methods may have low total plasma T levels, possibly due to a dysfunction of the HPG axis at the hypothalamic-pituitary level. Monitoring HPG axis function in future studies could prove to be a predictor of suicide at least for male psychiatric attempters, and could lead to preventive strategies. (c) 2008 Elsevier Ireland Ltd. All rights reserved.	[Markianos, Manolis] Univ Athens, Eginit Hosp, Sch Med, Lab Clin Neurochem, GR-11528 Athens, Greece; [Tripodianakis, John; Rouvali, Olga] Evangelismos Gen Hosp, Dept Psychiat, Athens 10676, Greece; [Istikoglou, Christos] Asclepe Hosp, Dept Psychiat, Voula Athens, Greece; [Christopoulos, Markos; Papageorgopoulos, Pavlos; Seretis, Andreas] Thriass Gen Hosp, Dept Neurosurg, Eleusis, Greece		Markianos, M (corresponding author), Univ Athens, Eginit Hosp, Sch Med, Lab Clin Neurochem, Vas Sophias 74, GR-11528 Athens, Greece.	markian@otenet.gr		Markianos, Manolis/0000-0002-4751-1014			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ARCHER J, 1991, BRIT J PSYCHOL, V82, P1, DOI 10.1111/j.2044-8295.1991.tb02379.x; BECK AT, 1975, AM J PSYCHIAT, V132, P182; Cernak I, 1997, WORLD J SURG, V21, P240, DOI 10.1007/s002689900223; Elman I, 1997, LIFE SCI, V61, P1705, DOI 10.1016/S0024-3205(97)00776-5; Gustavsson G, 2003, EUR NEUROPSYCHOPHARM, V13, P105, DOI 10.1016/S0924-977X(02)00131-1; HANDA RJ, 1994, PHYSIOL BEHAV, V55, P117, DOI 10.1016/0031-9384(94)90018-3; HASKINS JT, 1981, ENDOCRINOLOGY, V108, P767, DOI 10.1210/endo-108-3-767; Jokinen J, 2007, PSYCHIAT RES, V150, P297, DOI 10.1016/j.psychres.2006.12.001; JURCOVICOVA J, 1990, ENDOCRINOLOGY, V126, P2527, DOI 10.1210/endo-126-5-2527; LEE SC, 1994, BRAIN INJURY, V8, P571; Pope HG, 2003, AM J PSYCHIAT, V160, P105, DOI 10.1176/appi.ajp.160.1.105; REYMOND MJ, 1983, BRAIN RES, V262, P253, DOI 10.1016/0006-8993(83)91015-6; RIVIER C, 1991, BIOL REPROD, V45, P523, DOI 10.1095/biolreprod45.4.523; ROY A, 1992, BIOL PSYCHIAT, V32, P812, DOI 10.1016/0006-3223(92)90084-D; Shores MM, 2004, ARCH GEN PSYCHIAT, V61, P162, DOI 10.1001/archpsyc.61.2.162; SPRATT DI, 1993, J CLIN ENDOCR METAB, V76, P1548, DOI 10.1210/jc.76.6.1548; TRIPODIANAKIS J, 2007, EUROPEAN ARCH PSYCHI, V101, P255; van Heeringen K, 2000, J AFFECT DISORDERS, V60, P181, DOI 10.1016/S0165-0327(99)00180-9; Viau V, 2002, J NEUROENDOCRINOL, V14, P506, DOI 10.1046/j.1365-2826.2002.00798.x; Viau V, 1996, J NEUROSCI, V16, P1866; Zitzmann M, 2001, EUR J ENDOCRINOL, V144, P183, DOI 10.1530/eje.0.1440183	22	29	30	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	NOV 30	2009	170	1					82	85		10.1016/j.psychres.2008.08.001			4	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	522TY	WOS:000272023000013	19781790				2022-02-06	
J	Sugiyama, K; Kondo, T; Oouchida, Y; Suzukamo, Y; Higano, S; Endo, M; Watanabe, H; Shindo, K; Izumi, SI				Sugiyama, Ken; Kondo, Takeo; Oouchida, Yutaka; Suzukamo, Yoshimi; Higano, Shuichi; Endo, Minoru; Watanabe, Hiroshi; Shindo, Keiichiro; Izumi, Shin-Ichi			Clinical Utility of Diffusion Tensor Imaging for Evaluating Patients with Diffuse Axonal Injury and Cognitive Disorders in the Chronic Stage	JOURNAL OF NEUROTRAUMA			English	Article						cognitive disorder; diffuse axonal injury; diffusion tensor imaging	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; LESIONS; HIPPOCAMPUS; AMYGDALA; MONKEYS; MEMORY; DAMAGE; TRAIL; MRI	Although diffuse axonal injury (DAI) usually ellicits cognitive disorders, abnormal brain findings are generally undetected by conventional imaging techniques. The aim of this study was to evaluate the feasibility of using diffusion tensor imaging (DTI) to detect lesions in DAI patients and to investigate the correlation between DAI lesions and cognitive disorders. We examined 16 healthy controls and 11 patients with DAI. Using voxel-based analysis, we found that there were significantly more brain regions with decreased fractional anisotropy (FA) in the brain but DAI patients compared to healthy controls (p < 0.001), whereas few lesions were detected via conventional magnetic resonance imaging. There was a significant relationship between the results of the Wechsler Adult Intelligence Scale-Revised, Trail Making Test, and some indices of the Wechsler Memory Scale-Revised and the decreased FA observed in various areas of the brain (p < 0.001). The total cognitive scores on the functional independence and functional assessment measures, which represent behavioral problems, were correlated with the cluster (number of DAI lesions, p = 0.007) and voxel numbers (total size of all DAI lesions, p = 0.001). In the fiber tractography-based analysis, DAI patients with memory disorders showed an interruption of fibers within the fornix compared to healthy controls. These results indicate that DTI is a useful technique not only for detecting DAI lesions but also for examining cognitive disorders in DAI patients.	[Sugiyama, Ken] Tohoku Univ, Grad Sch Med, Dept Phys Med & Rehabil, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Higano, Shuichi] Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Sendai, Miyagi 9808575, Japan; [Endo, Minoru] Tohoku Employees Pens Welf Hosp, Div Neurol, Sendai, Miyagi, Japan; [Watanabe, Hiroshi] Tohoku Employees Pens Welf Hosp, Div Phys Med & Rehabil, Sendai, Miyagi, Japan		Sugiyama, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Phys Med & Rehabil, Aoba Ku, 2-1 Seiryocho, Sendai, Miyagi 9808575, Japan.	s-ken@mail.tains.tohoku.ac.jp	Suzukamo, Yoshimi/T-6500-2019; oocuhida, yutaka/H-8686-2019	Suzukamo, Yoshimi/0000-0001-7162-4871; Oouchida, Yutaka/0000-0002-6367-7081			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Burgess P, 1996, BEHAV ASSESSMENT DYS; Ezaki Y, 2006, ACTA NEUROCHIR, V148, P547, DOI 10.1007/s00701-005-0692-2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; FUJIWARA T, 2001, JPN J REHABIL MED, V38, P253; Furutani K, 2005, J MED INVESTIG, V52, P186, DOI 10.2152/jmi.52.186; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, P854; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hashimoto K, 2007, J REHABIL MED, V39, P418, DOI 10.2340/16501977-0065; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; KADO Y, 2004, TO HATTATSU, V36, P475; Kashima H, 1995, BRAIN SCI MENT DISOR, V6, P209; KENNEDY KJ, 1981, PERCEPT MOTOR SKILL, V52, P671, DOI 10.2466/pms.1981.52.2.671; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Masutani Y, 2003, EUR J RADIOL, V46, P53, DOI 10.1016/S0720-048X(02)00328-5; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Murakami K, 1996, BRAIN SCI MENT DISOR, V7, P401; Murray EA, 1998, J NEUROSCI, V18, P6568; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Seel RT, 2007, J HEAD TRAUMA REHAB, V22, P267, DOI 10.1097/01.HTR.0000290971.56130.c8; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Takeda Takahiro, 2007, Rinsho Shinkeigaku, V47, P135; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler, 1997, WECHSLER ADULT INTEL; WECHSLER D, 1984, MANUAL WECHSLER MEMO; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	51	29	37	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1879	1890		10.1089/neu.2008.0839			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600003	19514848				2022-02-06	
J	Zemlyak, I; Sapolsky, R; Gozes, I				Zemlyak, Ilona; Sapolsky, Robert; Gozes, Illana			NAP protects against cytochrome c release: Inhibition of the initiation of apoptosis	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Neuroprotection; Microtubule; Oxygen-glucose deprivation; Cytochrome c; Cortical neuron; Neuroprotective peptide	DEPENDENT NEUROPROTECTIVE PROTEIN; FETAL ALCOHOL SYNDROME; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; MOUSE MODEL; ENDOPLASMIC-RETICULUM; HIPPOCAMPAL-NEURONS; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; DRUG CANDIDATE	NAPVSIPQ (NAP), an 8 amino acid peptide derived from activity-dependent neuroprotective protein (ADNP), provides neuroprotection through interaction with microtubules. Previous results have demonstrated NAP protection against oxygen-glucose deprivation in hippocampal cells in culture. Furthermore, in vivo studies have shown that NAP reduces caspase 3 activation in rats subjected to permanent mid-cerebral artery occlusion (a rat model of stroke). Oxygen-glucose deprivation (ischemia) has been associated with microtubule breakdown and cytochrome c release from mitochondria leading to apoptosis. Here, NAP in concentrations ranging from 10(-14) M to 10(-8) M Completely blocked cytochrome c release in cortical neurons subjected to oxygen-glucose deprivation. Furthermore, quantitative microscopy coupled to microtubule immunocytochemistry suggested that NAP prevented microtubule degradation under oxidative stress. As cytochrome c release is a known initiator of the apoptotic pathway, it is suggested that NAP inhibits the early events of apoptosis. (C) 2009 Elsevier B.V. All rights reserved.	[Sapolsky, Robert; Gozes, Illana] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Zemlyak, Ilona; Sapolsky, Robert] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA		Gozes, I (corresponding author), Lily & Avraham Gildor Chair Invest Growth Factors, Tel Aviv, Israel.	igozes@post.tau.ac.il					Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brooke S, 1997, P NATL ACAD SCI USA, V94, P9457, DOI 10.1073/pnas.94.17.9457; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carre M, 2002, J BIOL CHEM, V277, P33664, DOI 10.1074/jbc.M203834200; Cattano D, 2008, NEUROSCI LETT, V440, P217, DOI 10.1016/j.neulet.2008.05.086; CHEN S, 2008, P NATL ACAD SCI US; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cosgrave AS, 2008, NEUROBIOL DIS, V30, P281, DOI 10.1016/j.nbd.2008.02.005; Divinski I, 2004, J BIOL CHEM, V279, P28531, DOI 10.1074/jbc.M403197200; Divinski I, 2006, J NEUROCHEM, V98, P973, DOI 10.1111/j.1471-4159.2006.03936.x; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Furman S, 2004, NEURON GLIA BIOL, V1, P193, DOI 10.1017/S1740925X05000013; Gozes I, 2007, PHARMACOL THERAPEUT, V114, P146, DOI 10.1016/j.pharmthera.2007.01.004; Gozes I, 2007, CURR ALZHEIMER RES, V4, P507, DOI 10.2174/156720507783018208; Gozes I, 2005, CNS DRUG REV, V11, P353; Gozes Illana, 2005, Current Alzheimer Research, V2, P149, DOI 10.2174/1567205053585873; Gozes I, 2009, CURR ALZHEIMER RES, V6, P455, DOI 10.2174/156720509789207895; Gozes Illana, 2006, Current Alzheimer Research, V3, P197; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; Jin HW, 2008, EXP NEUROL, V210, P229, DOI 10.1016/j.expneurol.2007.11.001; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Longuet M, 2004, INT J ONCOL, V25, P309; Mandel S, 2008, J MOL NEUROSCI, V35, P127, DOI 10.1007/s12031-007-9013-y; Matsuoka Y, 2008, J PHARMACOL EXP THER, V325, P146, DOI 10.1124/jpet.107.130526; Mironov SL, 2005, J BIOL CHEM, V280, P715, DOI 10.1074/jbc.M409819200; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; Olney JW, 2002, NEUROBIOL DIS, V9, P205, DOI 10.1006/nbdi.2001.0475; Pascual M, 2007, J NEUROCHEM, V103, P557, DOI 10.1111/j.1471-4159.2007.04761.x; Poggi SH, 2003, AM J OBSTET GYNECOL, V189, P790, DOI 10.1067/S0002-9378(03)00834-2; Rotstein M, 2006, J PHARMACOL EXP THER, V319, P332, DOI 10.1124/jpet.106.106898; Santa-Maria I, 2005, BBA-MOL BASIS DIS, V1740, P472, DOI 10.1016/j.bbadis.2004.11.024; Sari Y, 2006, BRAIN RES REV, V52, P107, DOI 10.1016/j.brainresrev.2006.01.004; SCHMECHEL DE, 2008, J ALZHEIMERS ASS, V4, pT483; Seyb KI, 2006, J MOL NEUROSCI, V28, P111, DOI 10.1385/JMN:28:2:111; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; Steingart RA, 2000, J MOL NEUROSCI, V15, P137, DOI 10.1385/JMN:15:3:137; Stewart AJ, 2007, EXPERT OPIN INV DRUG, V16, P1183, DOI 10.1517/13543784.16.8.1183; Valleggi S, 2008, J NEUROSURG ANESTH, V20, P226, DOI 10.1097/ANA.0b013e31817da878; Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005; Vulih-Shultzman I, 2007, J PHARMACOL EXP THER, V323, P438, DOI 10.1124/jpet.107.129551; Zaltzman R, 2005, PEPTIDES, V26, P1520, DOI 10.1016/j.peptides.2005.03.014; Zaltzman R, 2004, J MOL NEUROSCI, V24, P181, DOI 10.1385/JMN:24:2:181; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1; Zemlyak I, 2007, PEPTIDES, V28, P2004, DOI 10.1016/j.peptides.2007.08.004; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	29	30	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	SEP 15	2009	618	1-3					9	14		10.1016/j.ejphar.2009.07.013			6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	498BN	WOS:000270110500002	19619522				2022-02-06	
J	Ortolano, F; Colombo, A; Zanier, ER; Sclip, A; Longhi, L; Perego, C; Stocchetti, N; Borsello, T; De Simoni, MG				Ortolano, Fabrizio; Colombo, Alessio; Zanier, Elisa Roncati; Sclip, Allessandra; Longhi, Luca; Perego, Carlo; Stocchetti, Nino; Borsello, Tiziana; De Simoni, Maria Grazia			c-Jun N-Terminal Kinase Pathway Activation in Human and Experimental Cerebral Contusion	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Brain contusion; c-Jun N-terminal kinase pathway; D-JNKI1; Neuroprotection; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; CELL-DEATH; PEPTIDE INHIBITOR; HEAD-INJURY; SELECTIVE VULNERABILITY; SIGNAL-TRANSDUCTION; NEURONAL APOPTOSIS; COGNITIVE DEFICITS; ACOUSTIC TRAUMA	The c-Jun N-terminal kinase (JNK) pathway is involved in cell stress and apoptosis. We tested the hypothesis that this pathway plays a role in traumatic brain injury (TBI) by assessing JNK activation in human brain tissues and in brains of mice subjected to controlled cortical impact brain injury. We also assessed the effects of specific inhibition of the JNK pathway by the cell-permeable JNK inhibitor peptide, D-JNKI1, on neurobehavioral function and posttraumatic cell loss in mice. The inhibitor was administered intraperitoneally 10 minutes after injury. The JNK pathway showed robust activation both in human contusion specimens and in injured cortex and hippocampi of TBI-injured mice, 1, 4, and 48 hours after injury. D-JNKI1 treatment significantly improved motor performance at 48 hours and 7 days after injury and reduced the contusion volume compared with saline treatment; the numbers of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells were significantly decreased in the hippocampi of injured mice 48 hours after treatment. Thus, because the JNK pathway is activated after human and experimental TBI and the inhibitor peptide D-JNKI1 affords significant neuroprotection and amelioration of neurobehavioral deficits after experimental TBI, therapeutic targeting of the JNK activation pathway may hold promise for future clinical applications.	[De Simoni, Maria Grazia] Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst Dis, Dept Neurosci, I-20156 Milan, Italy; [Ortolano, Fabrizio; Zanier, Elisa Roncati; Longhi, Luca; Stocchetti, Nino] Univ Milan, Neurosurg Intens Care Unit, Dept Anesthesia & Crit Care Med, Fdn IRCCS,Osped Maggiore Policlin, Milan, Italy		De Simoni, MG (corresponding author), Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst Dis, Dept Neurosci, I-20156 Milan, Italy.	desimoni@marionegri.it	De Simoni, Maria Grazia/I-6021-2012; Perego, Carlo/AAA-6513-2020; Borsello, Tiziana/ABG-7759-2020; Zanier, Elisa/AAA-8095-2020; Longhi, Luca/AAF-9903-2021; Stocchetti, Nino/O-7444-2017; Borsello, Tiziana/J-8232-2016	De Simoni, Maria Grazia/0000-0001-6695-5297; Perego, Carlo/0000-0002-0259-0003; Zanier, Elisa/0000-0002-3011-8718; Longhi, Luca/0000-0001-9894-8788; Stocchetti, Nino/0000-0003-3250-6834; Ortolano, Fabrizio/0000-0003-1996-948X; Borsello, Tiziana/0000-0002-9729-7642	Botnar Foundation FNRS (Swiss National Science Foundation)Swiss National Science Foundation (SNSF) [310000-107888]	Tiziana Borsello was supported by Grant No. 310000-107888 from the Botnar Foundation FNRS (Swiss National Science Foundation).	Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Assimakopoulou M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-202; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Beckham JD, 2007, J VIROL, V81, P6984, DOI 10.1128/JVI.00467-07; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Centeno C, 2007, CELL DEATH DIFFER, V14, P240, DOI 10.1038/sj.cdd.4401988; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang LF, 2003, DEV CELL, V4, P521, DOI 10.1016/S1534-5807(03)00094-7; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Milano G, 2007, AM J PHYSIOL-HEART C, V292, pH1828, DOI 10.1152/ajpheart.01117.2006; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Repici M, 2007, NEUROSCIENCE, V150, P40, DOI 10.1016/j.neuroscience.2007.08.021; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Suckfuell M, 2007, ACTA OTO-LARYNGOL, V127, P938, DOI 10.1080/00016480601110212; TEASDALE G, 1974, LANCET, V2, P81; Wang J, 2003, J NEUROSCI, V23, P8596; Yao MZ, 2005, J NEUROSCI, V25, P1149, DOI 10.1523/JNEUROSCI.4736-04.2005; Yoshida H, 2004, J NEUROCHEM, V90, P352, DOI 10.1111/j.1471-4159.2004.02479.x; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006	43	29	29	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	SEP	2009	68	9					964	971		10.1097/NEN.0b013e3181b20670			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	491LV	WOS:000269581300002	19680147	Bronze			2022-02-06	
J	Stein, SC; Ganguly, K; Belfield, CM; Xu, XS; Swanson, EW; Chen, XH; Browne, KD; Johnson, VE; Smith, DH; LeBold, DG; Cines, DB; Muzykhantov, VR				Stein, Sherman C.; Ganguly, Kumkum; Belfield, Caitlin M.; Xu, Xiangsheng; Swanson, Edward W.; Chen, Xiao-Han; Browne, Kevin D.; Johnson, Victoria E.; Smith, Douglas H.; LeBold, David G.; Cines, Douglas B.; Muzykhantov, Vladimir R.			Erythrocyte-Bound Tissue Plasminogen Activator is Neuroprotective in Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Conference of the International-Neurotrauma-Society	2006	Rotterdam, NETHERLANDS	Int Neurotrauma Soc		blood-brain barrier; microclots; tissue plasminogen activator; traumatic brain injury	FIBRINOLYSIS; CLEARANCE; AFFINITY; DAMAGE; RAT	The purpose of this study was to test the effects of exogenous tissue plasminogen activator (tPA) in traumatic brain injury (TBI). We tested two different tPA formulations, free tPA and tPA bound to erythrocytes (RBC/tPA). Vehicle and each of the tPA treatments were injected intravenously into anesthetized rats 15 min after moderate lateral fluid percussion injury. The animals were sacrificed at 2 days for calculating microclot burden (n = 13) and IgG staining area (n = 13) in the brain sections as indicators of post-traumatic thrombosis and blood-brain barrier (BBB) breakdown, respectively. Another set of injured animals treated in the same way were sacrificed at 7 days to compare cortical lesion volumes (n = 28) and CA3 hippocampal cell loss (n = 24). All evaluations were done blinded with respect to treatment. No significant differences were found with respect to microclot burden or IgG staining volume. Injection of wild-type tPA caused significantly (p < 0.05) larger cortical injuries and greater cerebral hemorrhage. In contrast, there was significantly less cortical injury (p < 0.01) and hippocampal cell loss (p < 0.01) in the RBC/tPA group than in all other groups. These results reveal that RBC/tPA is more neuroprotective in experimental TBI than is unbound tPA.	[Stein, Sherman C.; Belfield, Caitlin M.; Xu, Xiangsheng; Swanson, Edward W.; Chen, Xiao-Han; Browne, Kevin D.; Johnson, Victoria E.; Smith, Douglas H.; LeBold, David G.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19106 USA; [Cines, Douglas B.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19106 USA; [Muzykhantov, Vladimir R.] Univ Penn, Sch Med, Inst Environm Med, Inst Translat Med, Philadelphia, PA 19106 USA; [Muzykhantov, Vladimir R.] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19106 USA; [Ganguly, Kumkum] Los Alamos Natl Lab, Div B, Los Alamos, NM USA		Stein, SC (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 310 Spruce St, Philadelphia, PA 19106 USA.	sherman.stein@uphs.upenn.edu	smith, douglas/A-1321-2007	Ganguly, Kumkum/0000-0002-2255-8940; Swanson, Edward/0000-0001-5689-4419	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA83121] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL077760-01A2, R01 HL76406, R01 HL090697-01A1, R01 HL76206, R01 HL07971, R01 HL81864, R01 HL090697] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS053410] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA083121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL090697, R01HL076206, R01HL077760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053410] Funding Source: NIH RePORTER		Armstead WM, 2006, NAT NEUROSCI, V9, P1150, DOI 10.1038/nn1757; ARMSTEAD WM, 2008, STOKE, V30, P165; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; Danielyan K, 2008, CIRCULATION, V118, P1442, DOI 10.1161/CIRCULATIONAHA.107.750257; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Ganguly K, 2006, J PHARMACOL EXP THER, V316, P1130, DOI 10.1124/jpet.105.093450; Ganguly K, 2005, J PHARMACOL EXP THER, V312, P1106, DOI 10.1124/jpet.104.075770; Ganguly K, 2007, J PHARMACOL EXP THER, V321, P158, DOI 10.1124/jpet.106.114405; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846; Muzykantov VR, 1996, BIOTECHNOL APPL BIOC, V24, P41; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; Polavarapu R, 2007, BLOOD, V109, P3270, DOI 10.1182/blood-2006-08-043125; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Yepes M, 2004, EXP BIOL MED, V229, P1097, DOI 10.1177/153537020422901103; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Zaitsev S, 2006, BLOOD, V108, P1895, DOI 10.1182/blood-2005-11-012336	27	29	31	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1585	1592		10.1089/neu.2008.0720			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200015	19331516	Green Accepted, Green Published			2022-02-06	
J	Kelso, ML; Scheff, SW; Pauly, JR; Loftin, CD				Kelso, Matthew L.; Scheff, Stephen W.; Pauly, James R.; Loftin, Charles D.			Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice	BMC NEUROSCIENCE			English	Article							CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; CELL-DEATH; INDUCIBLE CYCLOOXYGENASE; BENZODIAZEPINE-RECEPTORS; PERSISTENT ACCUMULATION; INFLAMMATORY RESPONSE; ACTIVATED MICROGLIA; UP-REGULATION; RAT	Background: Neuroinflammation contributes to the pathophysiology of acute CNS injury, including traumatic brain injury (TBI). Although prostaglandin lipid mediators of inflammation contribute to a variety of inflammatory responses, their importance in neuroinflammation is not clear. There are conflicting reports as to the efficacy of inhibiting the enzymes required for prostaglandin formation, cyclooxygenase (COX)-1 and COX-2, for improving outcomes following TBI. The purpose of the current study was to determine the role of the COX isoforms in contributing to pathological processes resulting from TBI by utilizing mice deficient in COX-1 or COX-2. Results: Following a mild controlled cortical impact injury, the amount of cortical tissue loss, the level of microglial activation, and the capacity for functional recovery was compared between COX-1-deficient mice or COX-2-deficient mice, and their matching wild-type controls. The deficiency of COX-2 resulted in a minor (6%), although statistically significant, increase in the sparing of cortical tissue following TBI. The deficiency of COX-1 resulted in no detectable effect on cortical tissue loss following TBI. As determined by (3)[H]-PK11195 autoradiography, TBI produced a similar increase in microglial activation in multiple brain regions of both COX-1 wildtype and COX-1-deficient mice. In COX-2 wild-type and COX-2-deficient mice, TBI increased (3)[H]-PK11195 binding in all brain regions that were analyzed. Following injury, (3)[H]-PK11195 binding in the dentate gyrus and CA1 region of the hippocampus was greater in COX-2-deficient mice, as compared to COX-2 wild-type mice. Cognitive assessment was performed in the wildtype, COX-1-deficient and COX-2-deficient mice following 4 days of recovery from TBI. There was no significant cognitive effect that resulted from the deficiency of either COX-1 or COX-2, as determined by acquisition and spatial memory retention testing in a Morris water maze. Conclusion: These findings suggest that the deficiency of neither COX-1 nor COX-2 is sufficient to alter cognitive outcomes following TBI in mice.	[Kelso, Matthew L.; Pauly, James R.; Loftin, Charles D.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Kelso, Matthew L.; Scheff, Stephen W.; Pauly, James R.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA		Loftin, CD (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.	mlkels2@email.uky.edu; sscheff@email.uky.edu; jim.pauly@uky.edu; cdloft2@email.uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL083122]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL083122] Funding Source: NIH RePORTER	The authors acknowledge the technical assistance of Deann Hopkins, Nicole Scheff, Kelly Roberts, and Alex McFarland-Watts. C. D. L is supported by the National Institutes of Health [HL083122].	Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Aid S, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-17; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Candelario-Jalil E, 2007, J NEUROCHEM, V100, P1108, DOI 10.1111/j.1471-4159.2006.04280.x; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; Choi SH, 2008, FASEB J, V22, P1491, DOI 10.1096/fj.07-9411com; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Giusti L, 2004, CLIN BIOCHEM, V37, P61, DOI 10.1016/j.clinbiochem.2003.10.004; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kelso ML, 2006, BRAIN RES, V1083, P204, DOI 10.1016/j.brainres.2006.01.127; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schwab JM, 2000, ACTA NEUROPATHOL, V99, P609, DOI 10.1007/s004010051170; Schwab JM, 2000, J NEUROIMMUNOL, V111, P122, DOI 10.1016/S0165-5728(00)00372-6; Schwab JM, 2002, J NEUROSURG, V96, P892, DOI 10.3171/jns.2002.96.5.0892; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Venneti S, 2007, NEUROSCI LETT, V426, P117, DOI 10.1016/j.neulet.2007.08.053; Venneti S, 2009, NEUROBIOL AGING, V30, P1217, DOI 10.1016/j.neurobiolaging.2007.11.005; Vijitruth R, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-6; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	41	29	29	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	AUG 31	2009	10								108	10.1186/1471-2202-10-108			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	503SB	WOS:000270558800001	19719848	Green Published, gold			2022-02-06	
J	Gaetz, MB; Iverson, GL				Gaetz, M. B.; Iverson, G. L.			Sex differences in self-reported symptoms after aerobic exercise in non-injured athletes: implications for concussion management programmes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							BINDING-SITE POLYMORPHISM; ANTERIOR CRUCIATE LIGAMENT; ACHILLES-TENDON INJURIES; OSTEOPOROTIC FRACTURE; SP1 POLYMORPHISM; COL5A1 GENE; RISK; PARTICIPANTS; DENSITY; WOMEN	Background: After a concussion, when symptoms have decreased substantially at rest, it is recommended that athletes begin light aerobic exercise before progressing to sport specific exercise. The British Columbia Concussion Rehabilitation Programme (BC-CRP) uses a standardized cognitive and exercise test protocol designed to indicate when an athlete should progress to sport-specific exercise after a concussion. Objective: To document the effects of exercise on symptom reporting in healthy, uninjured, male and female amateur athletes. Design: Quasi-experimental, pretest-post-test, nonequivalent groups design. Methods: Before the exercise protocol, 45 female and 30 male young amateur athletes completed computerized cognitive testing, symptom ratings and balance testing. The 15-minute cycle ergometry protocol, conducted at 90 revolutions/minute, was as follows: 0-2 minutes at 0 W tension, 2-5 minutes at 50 W, 5-8 minutes at 100 W, 8-11 minutes at 150 W and 11-14 minutes at 200 W tension followed by a 1-minute cooling-down period. After exercise, participants completed symptom ratings, balance testing and perceived exertion ratings. Self-reported symptoms were assessed using an abbreviated version of the Post-Concussion Scale. Results: Significant increases in self-reported balance problems, numbness and tingling were seen for both genders after aerobic exercise. For women, emotional symptoms such as irritability, sadness, nervousness and feeling more emotional decreased significantly after aerobic exercise. Headache also decreased in the women, but no significant change was seen in the men. Conclusions: Sex differences exist for symptom reporting after aerobic exercise. Both genders report increases in somatic symptoms, but only women report decreases in emotional symptoms. The concept of being "asymptomatic'' after exercise should be reconsidered to include expected mild increases and decreases in certain symptoms.	[Gaetz, M. B.] Univ Fraser Valley, Dept Kinesiol & Phys Educ, Abbotsford, BC V2S 7M8, Canada; [Iverson, G. L.] Univ British Columbia, Fac Med, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada		Gaetz, MB (corresponding author), Univ Fraser Valley, Dept Kinesiol & Phys Educ, 33844 King Rd, Abbotsford, BC V2S 7M8, Canada.	michael.gaetz@ufv.ca		Iverson, Grant/0000-0001-7348-9570			Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Collins M, 2010, BRIT J SPORT MED, V44, P1063, DOI 10.1136/bjsm.2008.056184; de Loes M, 2000, SCAND J MED SCI SPOR, V10, P90, DOI 10.1034/j.1600-0838.2000.010002090.x; Flynn RK, 2005, AM J SPORT MED, V33, P23, DOI 10.1177/0363546504265678; Frank C. B., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P199; Griffin LY, 2006, AM J SPORT MED, V34, P1512, DOI 10.1177/0363546506286866; Hoffmann A, 2007, INT ORTHOP, V31, P791, DOI 10.1007/s00264-007-0395-9; Khoschnau S, 2008, AM J SPORT MED, V36, P2432, DOI 10.1177/0363546508320805; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; Lian K, 2005, ARTHRITIS RHEUM-US, V52, P1431, DOI 10.1002/art.21011; Lo IKY, 2003, CLIN ORTHOP RELAT R, P249, DOI 10.1097/01.blo.0000037442.23683.35; Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347; Mann V, 2003, BONE, V32, P711, DOI 10.1016/S8756-3282(03)00087-5; Marshall S., 2007, UNDERSTANDING PREVEN, P5; Meeuwisse WH., 1994, CLIN J SPORT MED, V4, P166, DOI [10.1097/00042752-199407000-00004, DOI 10.1097/00042752-199407000-00004]; Mokone GG, 2006, SCAND J MED SCI SPOR, V16, P19, DOI 10.1111/j.1600-0838.2005.00439.x; Mokone GG, 2005, AM J SPORT MED, V33, P1016, DOI 10.1177/0363546504271986; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Parkkari J, 2008, BRIT J SPORT MED, V42, P422, DOI 10.1136/bjsm.2008.046185; Posthumus M, 2009, J SCI MED SPORT, V12, P184, DOI 10.1016/j.jsams.2007.12.006; Raleigh SM, 2009, BRIT J SPORT MED, V43, P514, DOI 10.1136/bjsm.2008.053892; September AV, 2009, BRIT J SPORT MED, V43, P357, DOI 10.1136/bjsm.2008.048793; Skorupski P, 2006, AM J OBSTET GYNECOL, V194, P346, DOI 10.1016/j.ajog.2005.07.034; Speer G, 2006, ACTA CARDIOL, V61, P321, DOI 10.2143/AC.61.3.2014835; Tilkeridis C, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.033225	25	29	29	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	JUL	2009	43	7					508	513		10.1136/bjsm.2008.051748			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	467FS	WOS:000267724100008	19139034				2022-02-06	
J	Liu, W; Zhou, XW; Liu, SJ; Hu, KH; Wang, C; He, QY; Li, MT				Liu, Wei; Zhou, Xing-wang; Liu, Shaojun; Hu, Kunhua; Wang, Chong; He, Qingyu; Li, Mingtao			Calpain-truncated CRMP-3 and-4 contribute to potassium deprivation-induced apoptosis of cerebellar granule neurons	PROTEOMICS			English	Article						Apoptosis; Calpain substrates; CRMPs; Neuron	RESPONSE MEDIATOR PROTEINS; TRAUMATIC BRAIN-INJURY; FAS-INDUCED APOPTOSIS; PROTEOME ANALYSIS; CELL-DEATH; ALZHEIMERS-DISEASE; PROTEASE FAMILIES; NERVOUS-SYSTEM; GROWTH CONES; CROSS-TALK	Increasing evidence shows that calpain-mediated proteolytic processing of a selective number of proteins plays an important role in neuronal apoptosis. Study of calpain-mediated cleavage events and related functions may contribute to a better understanding of neuronal apoptosis and neurodegenerative diseases. We, therefore, investigated the role of calpain substrates in potassium deprivation-induced apoptosis of cerebellar granule neurons (CGNs). Twelve previously known and seven novel candidates of calpain substrates were identified by 2-D DIGE and MALDI-TOF/TOF MS analysis. Further, the identified novel calpain substrates were validated by Western blot analysis. Moreover, we focused on the collapsin response mediator proteins (CRMP-1, -2, -3 and -4 isoforms) and found that CRMPs were proteolytically processed by calpain but not by caspase, both in vivo and in vitro. To clarify the properties of the calpain-mediated proteolysis of CRMPs, we constructed the deletion mutants of CRMPs for additional biochemical studies. In vitro cleavage assays revealed that CRMP-1, -2 and -4 were truncated by calpain at the C-terminus, whereas CRMP-3 was cleaved at the N-terminus. Finally, we assessed the role of CRMPs in the process of potassium deprivation-triggered neuronal apoptosis by overexpressing the truncated CRMPs in CGNs. Our data clearly showed that the truncated CRMP-3 and -4, but not CRMP-1 and -2, significantly induced neuronal apoptosis. These findings demonstrated that calpain-truncated CRMP-3 and -4 act as pro-apoptotic players when CGNs undergo apoptosis.	[Liu, Wei; Zhou, Xing-wang; Liu, Shaojun; Hu, Kunhua; Wang, Chong; Li, Mingtao] Sun Yat Sen Univ, Prote Ctr, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China; [Liu, Shaojun; Hu, Kunhua; Wang, Chong; Li, Mingtao] Sun Yat Sen Univ, Dept Pharmacol, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China; [He, Qingyu] Jinan Univ, Inst Life & Hlth Engn, Guangzhou, Guangdong, Peoples R China		Li, MT (corresponding author), Sun Yat Sen Univ, Prote Ctr, Zhongshan Sch Med, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	limt@mail.sysu.edu.cn	Liu, Wei/AAH-5037-2020; He, Qing-Yu/H-7078-2014	Liu, Wei/0000-0002-4935-7591; He, Qing-Yu/0000-0003-0503-9492	NSFCNational Natural Science Foundation of China (NSFC) [U0632006, 30629002, 30870786, 30870988]	This work was supported by grants from NSFC (No. U0632006, No. 30629002 and No. 30870786 to M-T Li, and No. 30870988 to X-W Zhou). The authors thank Dr. Joachim Kappler for generously providing anti-CRMPs sera and pQE-80-CRMps constructions, and Dr. Bjorn Kafsack for critically reading the manuscript.	Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; AUTH D, 1992, P NATL ACAD SCI USA, V89, P4368, DOI 10.1073/pnas.89.10.4368; Bachis A, 2003, J NEUROSCI, V23, P5715; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Boehmerle W, 2007, P NATL ACAD SCI USA, V104, P11103, DOI 10.1073/pnas.0701546104; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Cadel S, 1997, P NATL ACAD SCI USA, V94, P2963, DOI 10.1073/pnas.94.7.2963; Canals F, 2006, PROTEOMICS, V6, pS28, DOI 10.1002/pmic.200500446; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Canu N, 1998, J NEUROSCI, V18, P7061; Chan SO, 1998, NEUROCHEM RES, V23, P393, DOI 10.1023/A:1022417819356; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; COOK JC, 1992, J BIOL CHEM, V267, P24315; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Fifre A, 2006, J BIOL CHEM, V281, P229, DOI 10.1074/jbc.M507378200; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200; Gerner C, 2000, J BIOL CHEM, V275, P39018, DOI 10.1074/jbc.M006495200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; Hou ST, 2006, J NEUROSCI, V26, P2241, DOI 10.1523/JNEUROSCI.4485-05.2006; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Jiang SX, 2007, EUR J NEUROSCI, V26, P801, DOI 10.1111/j.1460-9568.2007.05715.x; Kaneda Y, 1998, CELL DEATH DIFFER, V5, P20, DOI 10.1038/sj.cdd.4400315; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kimura E, 2003, BIOSCI BIOTECH BIOCH, V67, P1786, DOI 10.1271/bbb.67.1786; Kito S, 2005, J ORAL PATHOL MED, V34, P478, DOI 10.1111/j.1600-0714.2005.00346.x; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kowara R, 2005, J NEUROCHEM, V95, P466, DOI 10.1111/j.1471-4159.2005.03383.x; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; Lee AY, 2004, PROTEOMICS, V4, P3429, DOI 10.1002/pmic.200400979; Lee MH, 1996, J BIOL CHEM, V271, P3420; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Ma C, 2007, J BIOL CHEM, V282, P30901, DOI 10.1074/jbc.M608694200; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McCollum AT, 2002, J NEUROCHEM, V82, P1208, DOI 10.1046/j.1471-4159.2002.01057.x; Mori K, 2004, NEUROSCI RES, V48, P439, DOI 10.1016/j.neures.2003.12.012; Movsesyan VA, 2004, CELL DEATH DIFFER, V11, P1121, DOI 10.1038/sj.cdd.4401442; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura TY, 2006, J CELL BIOL, V172, P1081, DOI 10.1083/jcb.200508156; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NELSON WJ, 1983, MOL CELL BIOL, V3, P1146, DOI 10.1128/MCB.3.6.1146; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Quach TT, 2004, MOL CELL NEUROSCI, V25, P433, DOI 10.1016/j.mcn.2003.11.006; Raynaud F, 2006, FEBS J, V273, P3437, DOI 10.1111/j.1742-4658.2006.05352.x; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Rosslenbroich V, 2005, EXP CELL RES, V310, P434, DOI 10.1016/j.yexcr.2005.08.005; Saric T, 2004, J BIOL CHEM, V279, P46723, DOI 10.1074/jbc.M406537200; Shaw G, 2004, BIOCHEM BIOPH RES CO, V325, P619, DOI 10.1016/j.bbrc.2004.09.223; SIMAN R, 1990, J NEUROSCI, V10, P2400; Singh R, 2002, J BIOL CHEM, V277, P37630, DOI 10.1074/jbc.M203648200; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Tahimic CGT, 2006, BIOCHEM BIOPH RES CO, V340, P1244, DOI 10.1016/j.bbrc.2005.12.132; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; Thiede B, 2004, MASS SPECTROM REV, V23, P333, DOI 10.1002/mas.10079; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Volbracht C, 2001, NEUROREPORT, V12, P3645, DOI 10.1097/00001756-200112040-00008; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang LH, 1996, J NEUROSCI, V16, P6197; Xie M, 2007, J BIOL CHEM, V282, P23275, DOI 10.1074/jbc.M610779200; Yoshimura T, 2006, BIOCHEM BIOPH RES CO, V340, P62, DOI 10.1016/j.bbrc.2005.11.147; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yuasa-Kawada J, 2003, EUR J NEUROSCI, V17, P2329, DOI 10.1046/j.1460-9568.2003.02664.x; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078; Zhou FQ, 2004, J NEUROBIOL, V58, P84, DOI 10.1002/neu.10278	81	29	31	2	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1615-9853	1615-9861		PROTEOMICS	Proteomics	JUL	2009	9	14					3712	3728		10.1002/pmic.200800979			17	Biochemical Research Methods; Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	483MN	WOS:000268971000008	19639589				2022-02-06	
J	Wilson, C; Huston, T; Koval, J; Gordon, SA; Schwebel, A; Gassaway, J				Wilson, Catherine; Huston, Toby; Koval, Jill; Gordon, Samuel A.; Schwebel, Andrea; Gassaway, Julie			SCIRehab Project Series: The Psychology Taxonomy	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries; Rehabilitation, physical; Psychology; Classification; Taxonomy; Practice-based evidence; Health services research	SPINAL-CORD-INJURY; THERAPEUTIC WORKING ALLIANCE; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; DEPRESSION; OUTCOMES; TEAM; CARE; SATISFACTION; AWARENESS	Context: The integration of psychologists as members of the rehabilitation team has occurred in conjunction with the evolution and adoption of interdisciplinary teams as the standard of care in spinal cord injury (SCI) rehabilitation. Although the value of psychological services during rehabilitation is endorsed widely, specific interventions and their association with patient outcomes have not been examined adequately. Objective: To address this shortcoming, psychologists from 6 SCI centers collaborated to develop a psychology intervention taxonomy and documentation framework. Methods: Utilizing an interactive process, the lead psychologists from 6 centers compiled an inclusive list of patient characteristics assessed and interventions delivered in routine psychological practice at the participating rehabilitation facilities. These were systematically grouped, defined, and compared. Results: The resulting taxonomy became the basis of a documentation framework utilized by psychologists for the study. The psychology taxonomy includes 4 major clinical categories (assessment, psychotherapeutic interventions, psychoeducational interventions, and consultation) with 5 to 10 specific activities in each category. Conclusions: Examination of psychological interventions and their potential association with positive outcomes for persons who sustain SCI requires the development of a taxonomy. Results of these efforts illustrate similarities and differences in psychological practice among SCI centers and offer the opportunity to blend research and clinical practice in an innovative approach to evidence-based practice improvement. The established taxonomy provides a basic framework for future studies on the effect of psychological interventions.	[Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA; [Wilson, Catherine] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Huston, Toby] Craig Hosp, Englewood, CO USA; [Koval, Jill] Shepherd Ctr, Atlanta, GA USA; [Gordon, Samuel A.] Natl Rehabil Hosp, Washington, DC USA; [Schwebel, Andrea] Carolinas Rehabil, Charlotte, NC USA		Gassaway, J (corresponding author), Inst Clin Outcomes Res, 699 E S Temple, Salt Lake City, UT 84102 USA.	jgassaway@isisicor.com			Department of EducationUS Department of Education; NIDRR [H133A060103, H133N060005, H133N060028, H133A21943-16, H133N060009, H133N060027, H133N060014]	The contents of this article were developed under grants from the Department of Education, NIDRR grant numbers H133A060103 and H133N060005 to Craig Hospital, H133N060028 to National Rehabilitation Hospital, H133A21943-16 to Carolinas Rehabilitation, H133N060009 to Shepherd Center, H133N060027 to Mount Sinai School of Medicine, and H133N060014 to Rehabilitation Institute of Chicago. However, these contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the federal government.	AGICH G, 1982, HIST VIEW HLTH CARE; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; CRAIG AR, 1994, BRIT J CLIN PSYCHOL, V33, P221, DOI 10.1111/j.2044-8260.1994.tb01116.x; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; Derogatis LR, 2000, BSI 18 ADM SCORING P; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; Fenton L R, 2001, J Psychother Pract Res, V10, P262; FRANK RG, 1985, AM J PSYCHIAT, V142, P252; GANS JS, 1983, ARCH PHYS MED REHAB, V64, P176; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; GASTON L, 1988, WORKING ALLIANCE THE, P85; Hammell KW, 2007, SPINAL CORD, V45, P260, DOI 10.1038/sj.sc.3102034; Hartman D., 2004, J HEART CTR THERAPIE, V7, P3; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Kazdin AE, 2008, AM PSYCHOL, V63, P146, DOI 10.1037/0003-066X.63.3.146; Keith MS, 1998, BRAIN INJURY, V12, P1037, DOI 10.1080/026990598121945; KEITH RA, 1991, ARCH PHYS MED REHAB, V72, P269; Kennedy P, 2000, ARCH PHYS MED REHAB, V81, P932, DOI 10.1053/apmr.2000.5580; Lenze EJ, 2004, ARCH PHYS MED REHAB, V85, P380, DOI 10.1016/j.apmr.2003.06.001; *NAT SPIN CORD INJ, 2006, ANN STAT REP; Pegg PO, 2005, REHABIL PSYCHOL, V50, P366, DOI 10.1037/0090-5550.50.4.366; Richards JS, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P11, DOI 10.1037/10361-001; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; ROHE D, 1998, REHABILITATION MED P; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Strasser DC, 2008, ARCH PHYS MED REHAB, V89, P10, DOI 10.1016/j.apmr.2007.08.127; STRASSER DC, 1997, TOP STROKE REHABIL, V4, P34; Verhoef J, 2008, CLIN REHABIL, V22, P23, DOI 10.1177/0269215507079845; Whitford DL, 2009, DIABETES CARE, V32, P251, DOI 10.2337/dc08-1200	34	29	29	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	JUN	2009	32	3					319	328		10.1080/10790268.2009.11760785			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	474NF	WOS:000268290100012	19810633	Green Published			2022-02-06	
J	Avramescu, S; Nita, DA; Timofeev, I				Avramescu, Sinziana; Nita, Dragos A.; Timofeev, Igor			Neocortical Post-Traumatic Epileptogenesis Is Associated with Loss of GABAergic Neurons	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cortical deafferentation; epilepsy; GABA; GAD	TEMPORAL-LOBE EPILEPSY; GABA-IMMUNOREACTIVE NEURONS; PARTIAL CORTICAL DEAFFERENTATION; PILOCARPINE-INDUCED SEIZURES; V PYRAMIDAL NEURONS; STATUS EPILEPTICUS; VISUAL-CORTEX; DENTATE GYRUS; IN-VITRO; DEVELOPMENTAL NEUROPATHOLOGY	The subtle mechanisms of post-traumatic epileptogenesis remain unknown, although the incidence of chronic epilepsy after penetrating cortical wounds is high. Here, we investigated whether the increased frequency of seizures occurring within 6 weeks following partial deafferentation of the suprasylvian gyrus in cats is accompanied with a change in the ratio between the number of excitatory and inhibitory neurons. Immunohistochemical labeling of all neurons with neuronal-specific nuclear protein (NeuN) antibody, and of the GABAergic inhibitory neurons with either gamma-aminobutyric acid (GABA) or glutamic acid decarboxylase (GAD 65&67) antibodies, was performed on sections obtained from control and epileptic animals with chronically deafferented suprasylvian gyrus. Quantification of the labeled neurons was performed in control animals and at 2, 4, and 6 weeks following cortical deafferentation, in the suprasylvian and marginal gyri, both ipsi- and contra-lateral to the cortical trauma. In all epileptic animals, the neuronal loss was circumscribed to the deafferented suprasylvian gyrus. Inhibitory GABAergic neurons were particularly more sensitive to cortical deafferentation than excitatory ones, leading to a progressively increasing ratio between excitation and inhibition towards excitation, potentially explaining the increased propensity to seizures in chronic undercut cortex.	[Avramescu, Sinziana; Nita, Dragos A.; Timofeev, Igor] Univ Laval Robert Giffard, Ctr Rech, Univ Laval, Sch Med, Quebec City, PQ G1J 2G3, Canada		Timofeev, I (corresponding author), Univ Laval Robert Giffard, Ctr Rech, Univ Laval, Sch Med, 2601 Canardiere, Quebec City, PQ G1J 2G3, Canada.	igor.timofeev@phs.ulaval.ca	Timofeev, Igor/E-8828-2012; Timofeev, Igor/AAP-7529-2021; Nita, Dragos A/C-6445-2008	Timofeev, Igor/0000-0002-1389-5857	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-67175, MOP-93611]; Natural Science and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC) [298475]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS060870-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060870] Funding Source: NIH RePORTER	This research was supported by grants (MOP-67175 and MOP-93611) from the Canadian Institutes of Health Research, Natural Science and Engineering Research Council of Canada ( grant 298475), and National Institute of Neurological Disorders and Stroke (1R01NS060870-01). I. T. is a scholar of Fonds de la Recherche en Sante du Quebec, and S. A. is a Savoy Foundation fellow.	AVRAMESCU S, 2007, NEUR M PLANN SOC NEU; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Baillarger JGF, 1840, MEM ACAD ROY MED, V8, P149; Bernard C, 2000, EPILEPSIA, V41, pS90, DOI 10.1111/j.1528-1157.2000.tb01564.x; Bianchi MT, 2002, J NEUROSCI, V22, P5321; BLOOM FE, 1971, NATURE, V229, P628, DOI 10.1038/229628a0; Boucetta S, 2008, EPILEPSIA, V49, P1925, DOI 10.1111/j.1528-1167.2008.01707.x; Bouilleret V, 2000, NEUROSCIENCE, V97, P47, DOI 10.1016/S0306-4522(00)00017-8; BROMAN J, 1988, J COMP NEUROL, V274, P467, DOI 10.1002/cne.902740402; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748, DOI 10.1152/jn.1999.82.4.1748; Cendes F, 2005, CURR OPIN NEUROL, V18, P173, DOI 10.1097/01.wco.0000162860.49842.90; Chen R, 1998, J NEUROSCI, V18, P3443; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Ebert U, 2002, EPILEPSIA, V43, P86, DOI 10.1046/j.1528-1157.43.s.5.39.x; ESPLIN MS, 1994, EPILEPSIA, V35, P911, DOI 10.1111/j.1528-1157.1994.tb02533.x; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; Fueta Y, 2005, NEUROSCIENCE, V132, P335, DOI 10.1016/j.neuroscience.2004.12.044; GABBOTT PLA, 1986, EXP BRAIN RES, V61, P323; Gorter JA, 2003, EPILEPSIA, V44, P647, DOI 10.1046/j.1528-1157.2003.53902.x; HENDRY SHC, 1990, J NEUROSCI, V10, P2438; HENDRY SHC, 1986, NATURE, V320, P750, DOI 10.1038/320750a0; HENDRY SHC, 1988, NEURON, V1, P701, DOI 10.1016/0896-6273(88)90169-9; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; Jacobs KM, 1999, J NEUROPHYSIOL, V81, P159, DOI 10.1152/jn.1999.81.1.159; Jacobs KM, 1999, CEREB CORTEX, V9, P733, DOI 10.1093/cercor/9.7.733; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; KARLSSON G, 1992, NEUROSCIENCE, V47, P63, DOI 10.1016/0306-4522(92)90120-Q; Lin JJ, 2007, CEREB CORTEX, V17, P2007, DOI 10.1093/cercor/bhl109; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marcikic M, 1998, INJURY, V29, P613, DOI 10.1016/S0020-1383(98)00146-6; Marin-Padilla M, 1999, J NEUROPATH EXP NEUR, V58, P407, DOI 10.1097/00005072-199905000-00001; Marin-Padilla M, 2002, ACTA NEUROPATHOL, V103, P321, DOI 10.1007/s00401-001-0470-z; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MICHEVA KD, 1995, J COMP NEUROL, V361, P574, DOI 10.1002/cne.903610403; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NIEDERMEYER E, 1969, DTSCH Z NERVENHEILKD, V195, P263; NISHIMURA Y, 1986, NATURE, V320, P753, DOI 10.1038/320753a0; Nita DA, 2006, J NEUROPHYSIOL, V95, P902, DOI 10.1152/jn.00742.2005; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; OBENAUS A, 1993, J NEUROSCI, V13, P4470; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; ROBBINS RJ, 1991, ANN NEUROL, V29, P325, DOI 10.1002/ana.410290316; ROMIJN HJ, 1988, EXP NEUROL, V100, P332, DOI 10.1016/0014-4886(88)90112-4; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Sanabria ERG, 2006, NEUROSCIENCE, V142, P871, DOI 10.1016/j.neuroscience.2006.06.057; Schwenkreis P, 2000, NEUROSCI LETT, V293, P143, DOI 10.1016/S0304-3940(00)01517-2; SLOPER JJ, 1980, BRAIN RES, V198, P204, DOI 10.1016/0006-8993(80)90356-X; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Spreafico R, 1998, EPILEPSY RES, V32, P34, DOI 10.1016/S0920-1211(98)00038-2; Spreafico R, 1998, NEUROLOGY, V50, P27, DOI 10.1212/WNL.50.1.27; Steriade M, 1998, J NEUROPHYSIOL, V80, P1456, DOI 10.1152/jn.1998.80.3.1456; STERIADE M, 1995, J NEUROSCI, V15, P623; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Takase K, 2008, EPILEPSIA, V49, P997, DOI 10.1111/j.1528-1167.2008.01558.x; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; WEISS JH, 1990, NEUROLOGY, V40, P1288, DOI 10.1212/WNL.40.8.1288; WELKER E, 1989, EXP BRAIN RES, V78, P659, DOI 10.1007/BF00230256; White HS, 1999, EPILEPSIA, V40, pS2, DOI 10.1111/j.1528-1157.1999.tb00913.x; WHITTINGTON MA, 1994, J PHYSIOL-LONDON, V481, P593, DOI 10.1113/jphysiol.1994.sp020466; Yamauchi T, 2006, PSYCHIAT CLIN NEUROS, V60, P507, DOI 10.1111/j.1440-1819.2006.01553.x; Ziemann U, 1998, J NEUROSCI, V18, P7000	76	29	30	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					799	812		10.1089/neu.2008.0739			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500014	19422294	Green Accepted, Green Published			2022-02-06	
J	Zweckberger, K; Plesnila, N				Zweckberger, Klaus; Plesnila, Nikolaus			Anatibant (R), a selective non-peptide bradykinin B-2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Bradykinin; Bradykinin B-2 receptor antagonist; Contusion volume; Intracranial pressure	CONTROLLED CORTICAL IMPACT; CLOSED-HEAD TRAUMA; CEREBRAL BLOOD-VOLUME; LF 16-0687 MS; KININ RECEPTORS; RAT MODEL; EDEMA; KALLIKREIN; NEURONS; SYSTEM	Bradykinin, the main metabolite of the kallikrein-kinin system and one of the first mediators released during inflammation, is well known to increase the permeability of the blood brain barrier (BBB) by activation of kinin B-2 receptors and hence promote brain edema formation following traumatic brain injury (TBI). Anatibant (R) (LF 16-0687), a selective non-peptide bradykinin B-2 receptor antagonist, reduces brain edema after experimental TBI, however, so far no data are available if Anatibant (R) reduces also the sequels of brain edema formation, i.e. morphological brain damage. Therefore, we investigated the effect of Anatibant (3.0 mg/kg b.w.) on intracranial pressure (ICP) and contusion volume after experimental TBI. Male C57/BI6 mice (25-28 g) were subjected to Controlled Cortical Impact trauma (CCI). Anatibant (R) was administrated as a subcutaneous bolus 15 min and 8 h after TBI. ICP was measured 3, 6, and 10 h after injury and contusion volume was quantified 24 h after trauma. Our data demonstrate a significant reduction of ICP (16.6 +/- 1.67 mmHg vs. 24.40 +/- 3.58 mmHg; n=6; p=0.002) and of contusion volume 24 h after trauma (28.28 +/- 5.18 mm(3) vs. 35.0 +/- 3.32 mm(3) n=7; p=0.003) in treated mice. Therefore we conclude, that inhibition of bradykinin B-2 receptors seems to be a promising treatment option, and might therefore be investigated in clinical trails for the treatment of TBI. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Zweckberger, Klaus; Plesnila, Nikolaus] Univ Munich, Inst Surg Res, Med Ctr Grosshadern, D-8000 Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany		Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, 123 St,Stephens Green, Dublin 2, Ireland.	klaus.zweckberger@med.uni-heidelberg.de; nikolausplesnila@rcsi.ie	Plesnila, Nikolaus/T-7522-2019				BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BAETHMANN A, 1982, MUNCHEN MED WOCHEN, V124, P941; Bouma GJ, 1998, ACT NEUR S, V71, P272; BULLOCK R, 1990, BRIT MED J, V300, P1515, DOI 10.1136/bmj.300.6738.1515; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lee YJ, 2002, MOL CELL NEUROSCI, V19, P186, DOI 10.1006/mcne.2001.1073; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Mahabeer R, 2000, METAB BRAIN DIS, V15, P325, DOI 10.1023/A:1011131510491; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Mayhan WG, 1996, BRAIN RES, V738, P337, DOI 10.1016/S0006-8993(96)01000-1; Murone C, 1997, J COMP NEUROL, V381, P203, DOI 10.1002/(SICI)1096-9861(19970505)381:2<203::AID-CNE7>3.0.CO;2-7; Pela IR, 1996, BRIT J PHARMACOL, V118, P1488, DOI 10.1111/j.1476-5381.1996.tb15564.x; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; Rachinsky M, 2001, J TRAUMA, V51, P944, DOI 10.1097/00005373-200111000-00020; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; REGOLI D, 1984, J CARDIOVASC PHARM, V6, pS401, DOI 10.1097/00005344-198406002-00015; REILLY PL, 1975, LANCET, V2, P375; Schulz J, 2000, ACT NEUR S, V76, P137; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 2000, ACTA NEUROCHIR SUPPL, V76, P171; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; Wahl M., 1999, Acta Physiologica Hungarica, V86, P155; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; Zausinger S, 2002, BRAIN RES, V950, P268, DOI 10.1016/S0006-8993(02)03053-6; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	33	29	31	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 24	2009	454	2					115	117		10.1016/j.neulet.2009.02.014			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	435MH	WOS:000265347500002	19429066				2022-02-06	
J	Manders, JE; Stoneman, Z				Manders, Jeanette E.; Stoneman, Zolinda			Children with disabilities in the child protective services system: An analog study of investigation and case management	CHILD ABUSE & NEGLECT			English	Article						Disability; Child abuse; Investigation; Services	DEVELOPMENTAL-DISABILITIES; MALTREATMENT; ABUSE	Objective: The study used a series of vignettes to investigate how the presence of three disabilities (cerebral palsy, intellectual disabilities, emotional/behavioral disabilities) affects the processes and Outcomes of child abuse investigations at two levels of child injury severity (moderate, severe). Method: Seventy-five CPS case workers completed study surveys and answered questions in response to a series of eight vignettes. Results: This study revealed differences in the responses of CPS case workers when the alleged victim of physical abuse had a disability. Children with disabilities were more likely than children without disabilities to be seen as having characteristics that contributed to their abuse. Most CPS workers felt at least some empathy with abusive parents; empathy was highest when the children had emotional/behavioral disabilities. Services recommended for families of children with disabilities were more likely to be child-focused. Parent-focused services, such as individual counseling and adult anger management, were more likely to be recommended for families of children without disabilities. In general, differences among disability groups and between cases involving children with and without disabilities were more pronounced when the children's injuries were less severe. Even with more severe injuries, such as a concussion or broken bones, the CPS workers still responded differently depending on the disability status of the child victims. Conclusions: Recommendations are made concerning the utilization of investigation teams that include disability specialists and the need for further disability-related training for CPS case workers. Practice implications: There is a strong need for training related to disability, with an emphasis on attitudes as well as knowledge and skills. The training should include examples of healthy family functioning and positive aspects of parenting a child with a disability to counteract the prevailing perception of disability as a cause of chronic stress and dysfunction; identification of broader ecological contexts in which these families live, including social response to disability and the disability-related service system and; strategies for disentangling the signs of abuse from characteristics of the disability. Interdisciplinary teams should include members from disability-related fields to share expertise and increase communication between systems. (c) 2009 Published by Elsevier Ltd.	[Manders, Jeanette E.; Stoneman, Zolinda] Univ Georgia, Inst Human Dev & Disabil, Athens, GA 30602 USA		Manders, JE (corresponding author), Univ Georgia, Inst Human Dev & Disabil, Rivers Crossing Bldg,850 Coll Stn Rd, Athens, GA 30602 USA.						ALTER CF, 1985, CHILD WELFARE, V64, P99; AMMERMAN RT, 1989, CHILD ABUSE NEGLECT, V13, P335, DOI 10.1016/0145-2134(89)90073-2; AMMERMAN RT, 1988, J FAMILY VIOLENCE, V3, P53; ANDRE CE, 1985, DISS ABSTR INT A, V46, P792; Baron R. A., 1991, SOCIAL PSYCHOL UNDER; BENEDICT MI, 1990, CHILD ABUSE NEGLECT, V14, P207, DOI 10.1016/0145-2134(90)90031-N; BENEDICT MI, 1992, CHILD ABUSE NEGLECT, V16, P155, DOI 10.1016/0145-2134(92)90024-L; Bonner B., 1997, CHILD MALTREATMENT, V2, P52; BUCHELEASH A, 1995, MENTAL PHYSICAL DISA, V19, P115; CICCHINELLI LF, 1991, S RISK ASS CHILD PRO; CRAFT JL, 1980, J SOCIAL SERVICE RES, V4, P31; CROSSE SB, 1993, REPORT MALTREATMENT; ELMER E, 1967, PEDIATRICS, V40, P596; FRIEDRICH WN, 1978, HOSP COMMUNITY PSYCH, V29, P248; GARBARINO J, 1987, SPECIAL CHILDREN SPE; *GEORG DEP FAM CHI, 1994, GEORG CHILD AB CENTR; Goldson E, 1998, CHILD ABUSE NEGLECT, V22, P663; HERRENKOHL EC, 1981, NAT C FAM VIOL RES; JACKSON D, 1994, REV UTILITY RI UNPUB; Kvam MH, 2000, CHILD ABUSE NEGLECT, V24, P1073, DOI 10.1016/S0145-2134(00)00159-9; LUJAN C, 1989, CHILD ABUSE NEGLECT, V13, P449, DOI 10.1016/0145-2134(89)90049-5; MANDERS J, 1995, CPS NEEDS ASSESSMENT; Mitchell L. M., 2000, J DISABIL POLICY STU, V10, P225, DOI DOI 10.1177/104420730001000206; MULLINS JB, 1986, J SCHOOL HEALTH, V56, P134, DOI 10.1111/j.1746-1561.1986.tb05720.x; OATES K, 1984, Australia and New Zealand Journal of Developmental Disabilities, V10, P27; Orelove FP, 2000, CHILD ABUSE NEGLECT, V24, P185, DOI 10.1016/S0145-2134(99)00134-9; RICHARDSON M, 1989, CHILD WELFARE, V68, P605; RINDFLEISCH N, 1984, CHILD ABUSE NEGLECT, V8, P33, DOI 10.1016/0145-2134(84)90047-4; ROSEN H, 1981, SOC WORK RES ABSTR, V17, P27; SHAPIRA M, 1993, SOC WORK RES ABSTR, V29, P14, DOI 10.1093/swra/29.2.14; Sobsey D, 1997, CHILD ABUSE NEGLECT, V21, P707, DOI 10.1016/S0145-2134(97)00033-1; Sobsey D., 2002, EXCEPTIONALITY, V10, P29; Sobsey D., 1994, VIOLENCE ABUSE LIVES; Standen, 2002, CHILD ABUSE REV, V11, P1, DOI [DOI 10.1002/CAR.710, 10.1002/(ISSN)1099-085210.1002/car.v11:110.1002/car.710]; Sullivan P. M., 1998, DEV DISABILITIES B, V26, P59; Sullivan PM, 2000, CHILD ABUSE NEGLECT, V24, P1257, DOI 10.1016/S0145-2134(00)00190-3; Sullivan PM, 1998, CHILD ABUSE NEGLECT, V22, P271, DOI 10.1016/S0145-2134(97)00175-0; VERDUGO MA, 1995, CHILD ABUSE NEGLECT, V19, P205, DOI 10.1016/0145-2134(94)00117-D; Vig S, 2002, J DEV PHYS DISABIL, V14, P371, DOI 10.1023/A:1020334903216; von Hentig H, 1948, CRIMINAL HIS VICTIM; Von Hentig H., 1940, J CRIM LAW CRIM, V31, P303, DOI [10.2307/1137415, DOI 10.2307/1137415]; WEST MA, 1992, MENT RETARD, V30, P221	42	29	29	1	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	APR	2009	33	4					229	237		10.1016/j.chiabu.2008.10.001			9	Family Studies; Psychology, Social; Social Work	Social Science Citation Index (SSCI)	Family Studies; Psychology; Social Work	435CO	WOS:000265321200005	19348941				2022-02-06	
J	Adelson, PD				Adelson, P. David			Hypothermia following Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			children; clinical trial; hypothermia; pediatric; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; INTRACRANIAL-PRESSURE; CARDIAC-ARREST; PHASE-II; CHILDREN; METABOLISM; OUTCOMES	Preclinical as well as clinical studies in traumatic brain injury (TBI) have established the likely association of secondary injury and outcome in adults in children following severe injury. Similarly, there is growing evidence in experimental laboratory studies that moderate hypothermia has a beneficial effect on outcome, though the exact mechanisms remain to be absolutely defined. The Pediatric TBI Guidelines provided the knowledge and background for standard management of children following severe TBI and highlighted that there are very few clinical studies to date. In particular with respect to temperature regulation and the use of hypothermia, initial findings of case series of small numbers were promising. Further preliminary randomized clinical trials, both single institution and multicenter, have provided the initial data on safety and efficacy, though larger, Phase III studies are necessary to ensure both the safety and efficacy of hypothermia in pediatric TBI prior to implementation as part of the standard of care. It is expected that hypothermia initiated early after severe TBI will have a protective effect on the pediatric brain and can be done safely, but this still remains to be definitively tested.	Phoenix Childrens Hosp, Childrens Neurosci Inst, Phoenix, AZ 85016 USA		Adelson, PD (corresponding author), Phoenix Childrens Hosp, Childrens Neurosci Inst, 1919 E Thomas Rd Bldg B,4th Floor, Phoenix, AZ 85016 USA.	dadelson@phoenixchildrens.com	Adelson, David/W-2083-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS052478, R01NS042298] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS42298, R01 NS052478, U01 NS052478-01A2, U01 NS052478] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; ADELSON PD, 1996, J NEUROTRAUM, V13, P607; ADELSON PD, 1995, J NEUROTRAUM, V12, P984; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Bayir H, 2003, CRIT CARE MED, V31, pA92; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BIJUR PE, 1990, PEDIATRICS, V86, P337; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; *BRAIN TRUAM FDN, 2007, J NEUROTRAUMA S, V24; Bruce D. A., 1995, TRAUMATIC HEAD INJUR, P40; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Bruce DA, 1996, J NEUROSURG, V84, P726; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COHADON F, 1991, J NEUROL SCI, V103, pS27; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DRAKE CG, 1962, CAN MED ASSOC J, V87, P887; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Gruszkiewicz J, 1973, Surg Neurol, V1, P197; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; KLONOFF H, 1977, J TRAUMA, V63, P1271; Kochanek Patrick M, 2005, Curr Treat Options Neurol, V7, P441, DOI 10.1007/s11940-005-0044-9; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kraus JF, 1987, HEAD INJURY, V2, P1; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; Shafi NI, 2006, PEDIATR CRIT CARE ME, V7, P468, DOI 10.1097/01.PCC.0000235258.79253.8C; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHORE PM, 2003, PEDIATR CRIT CARE ME, V4, pA143; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; Strachan R D, 1989, Brain Inj, V3, P51, DOI 10.3109/02699058909008073; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Teasdale G, 1991, J Neurotrauma, V8 Suppl 1, pS53; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	70	29	30	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					429	436		10.1089/neu.2008.0571			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900018	19271965	Green Published, Green Accepted			2022-02-06	
J	Hemmen, TM; Lyden, PD				Hemmen, Thomas M.; Lyden, Patrick D.			Hypothermia after Acute Ischemic Stroke	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	2nd International Brain Hypothermia Symposium	OCT, 2007	Miami Beach, FL			cerebral vascular disease; hypothermia; regeneration; stem cells; stroke; traumatic brain injury; traumatic spinal cord injury	CEREBRAL-ARTERY OCCLUSION; DELAYED POSTISCHEMIC HYPOTHERMIA; DAMAGE COOL AID; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; SHIVERING THRESHOLD; FOCAL ISCHEMIA; CARDIAC-ARREST; INFARCT SIZE	Induced hypothermia after ischemic stroke is a promising neuroprotective therapy and is the most potent in preclinical models. Technological limitations and homeostatic mechanisms that maintain core body temperature, however, have limited the clinical application of hypothermia. Advances in intravascular cooling and successful trials of hypothermia after global cerebral ischemia, such as in cardiac arrest and neonatal asphyxia, have renewed interest in hypothermia for stroke.	[Hemmen, Thomas M.; Lyden, Patrick D.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Lyden, Patrick D.] Dept Vet Affairs, San Diego, CA USA		Hemmen, TM (corresponding author), Univ Calif San Diego, Dept Neurosci, 200 W Arbor Dr,MC 8466 OPC 3rd Floor,Suite 3, San Diego, CA 92103 USA.	themmen@ucsd.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS044148] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS044148-06, P50 NS044148, P50 NS044148-02S2] Funding Source: Medline		Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; Alfonsi P, 1998, ANESTHESIOLOGY, V89, P43, DOI 10.1097/00000542-199807000-00009; BAKER CJ, 1991, SURG NEUROL, V36, P175, DOI 10.1016/0090-3019(91)90109-M; Baumgardner JE, 1999, ANESTH ANALG, V89, P163, DOI 10.1097/00000539-199907000-00029; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BURKS LC, 1980, ARCH INTERN MED, V140, P483, DOI 10.1001/archinte.140.4.483; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; CHENG C, 1995, ANESTHESIOLOGY, V82, P1160, DOI 10.1097/00000542-199505000-00011; Cheng Yu Dennis, 2004, NeuroRx, V1, P36, DOI 10.1602/neurorx.1.1.36; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; CORREIA M, 2001, COOLING THERAPY ACUT; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; DELAUNAY L, 1993, ANESTHESIOLOGY, V79, P470, DOI 10.1097/00000542-199309000-00009; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Eberspacher E, 2005, ACTA ANAESTH SCAND, V49, P477, DOI 10.1111/j.1399-6576.2005.00649.x; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; Hemmen TM, 2006, STROKE, V37, P706; Holzer M, 2002, NEW ENGL J MED, V346, P549; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; IKONOMIDOU C, 1989, BRAIN RES, V487, P184, DOI 10.1016/0006-8993(89)90956-6; Inamasu J, 2001, NEUROL RES, V23, P105, DOI 10.1179/016164101101198217; JESSEN K, 1980, ACTA ANAESTH SCAND, V24, P138, DOI 10.1111/j.1399-6576.1980.tb01522.x; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; KURZ M, 1993, ANESTHESIOLOGY, V79, P1193, DOI 10.1097/00000542-199312000-00009; Lyden Patrick D, 2005, J Stroke Cerebrovasc Dis, V14, P107, DOI 10.1016/j.jstrokecerebrovasdis.2005.01.001; Lyden PD, 2006, INT J STROKE, V1, P9, DOI 10.1111/j.1747-4949.2005.00011.x; Mack WJ, 2003, STROKE, V34, P1994, DOI 10.1161/01.STR.0000079813.31539.6D; Mahmood MA, 2007, J NEUROL SCI, V261, P47, DOI 10.1016/j.jns.2007.04.038; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Martin-Schild S, 2008, STROKE, V39, P532; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Roelfsema V, 2004, J CEREBR BLOOD F MET, V24, P877, DOI 10.1097/01.WCB.0000123904.17746.92; Rogalewski A, 2006, STROKE, V37, P1129, DOI 10.1161/01.STR.0000209330.73175.34; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Takata T, 1997, NEUROSCI LETT, V227, P41, DOI 10.1016/S0304-3940(97)00296-6; TREKOVA NA, 2004, ANESTEZIOL REANIMAT, V5, P86; van Breda Eric J, 2005, BMC Cardiovasc Disord, V5, P24, DOI 10.1186/1471-2261-5-24; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; Wang LM, 2005, CELL RES, V15, P387, DOI 10.1038/sj.cr.7290306; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; Yenari MA, 2002, J CEREBR BLOOD F MET, V22, P29, DOI 10.1097/00004647-200201000-00004; YENARI MA, 1995, THROMB RES, V77, P475, DOI 10.1016/0049-3848(95)93883-2; YOUNG RSK, 1980, JAMA-J AM MED ASSOC, V244, P1233, DOI 10.1001/jama.244.11.1233; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zausinger S, 2003, STROKE, V34, P2246, DOI 10.1161/01.STR.0000083622.65684.21; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; Zweifler Richard M, 2003, J Stroke Cerebrovasc Dis, V12, P237, DOI 10.1016/j.jstrokecerebrovasdis.2003.09.006	68	29	30	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2009	26	3					387	391		10.1089/neu.2008.0574			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	420ZO	WOS:000264327900012	19231919	Green Published, Green Accepted			2022-02-06	
J	Ruff, R				Ruff, Ronald			Best Practice Guidelines for Forensic Neuropsychological Examinations of Patients With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						forensic neuropsychology; guidelines; traumatic brain injury		Forensic examiners generally agree that their contributions to the forensic process have to be based on scientific principles, high ethical values, and sound clinical skills and judgment. In part I, the challenges of maintaining high ethical standards as a scientist-practitioner are addressed. In part II, the scientific strengths and weaknesses of our neuropsychological assessments are explored within the context of the 4 articles published in this issue. Specifically, Wood points out that while most traumatic brain injuries (TBIs) compromise the prefrontal cortex (PFC), traditional neuropsychological examinations do not fully capture to what extent PFC damage disrupts cognitive, emotional, and social regulation. New advances in clinical neuroscience are presented to facilitate a more detailed understanding of PFC functioning. Schwarz et al examine how clinical neuropsychology services can adequately handle forensic consultations. Frederick and Bowden, meanwhile, identify the persistent weaknesses of various Symptom Validity Tests in reliably classifying poor effort and malingering. Bailey et al conclude that the findings from sport concussion studies cannot be generalized to clinical populations, who, as a rule, have more premorbid and comorbid vulnerabilities. Finally, part III provides guidelines based on the introductory article by Bigler and Brooks, as well as a synopsis of the main conclusions offered by the contributors in this journal issue. Guidelines for both the diagnosis of mild TBI and the diagnosis of postconcussional disorder are included.	[Ruff, Ronald] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA		Ruff, R (corresponding author), 909 Hyde St, San Francisco, CA 94109 USA.	ronruff@mindspring.com					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Aronson E., 1969, ADV EXP SOC PSYCHOL, V4, P1, DOI [10.1016/S0065-2601(08)60075-1, DOI 10.1016/S0065-2601(08)60075-1]; Bailey CM, 2009, J HEAD TRAUMA REHAB, V24, P123, DOI 10.1097/HTR.0b013e31819c1caa; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bigler ED, 2009, J HEAD TRAUMA REHAB, V24, P76, DOI 10.1097/HTR.0b013e31819c2190; Blair RJR, 2004, BRAIN COGNITION, V55, P198, DOI 10.1016/s0278-2626(03)00276-8; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P997, DOI 10.1016/j.acn.2005.06.003; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Festinger L., 1957, THEORY COGNITIVE DIS; Frederick RI, 2009, J HEAD TRAUMA REHAB, V24, P105, DOI 10.1097/HTR.0b013e31819b1210; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Green P., 1996, WORD MEMORY TEST USE; Harmon-Jones E., 1999, COGNITIVE DISSONANCE; Hegel G. W. F., 1967, PHENOMENOLOGY MIND; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; HOWIESON DB, 1993, NEUROLOGY, V43, P1882, DOI 10.1212/WNL.43.10.1882; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; KOSS E, 1991, DEV NEUROPSYCHOL, V7, P99, DOI 10.1080/87565649109540479; MARKOWITSCH HJ, 2003, HDB CLIN NEUROPSYCHO; McCrea M., 2008, MILD TRAUMATIC BRAIN; MILNER B, 1970, BIOL MEMORY; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUFF RM, ARCH CLIN N IN PRESS; Seidenberg M, 1998, NEUROPSYCHOLOGY, V12, P303, DOI 10.1037/0894-4105.12.2.303; Squire LR., 1987, MEMORY BRAIN; SWEET JJ, 1999, J FORENSIC NEUROPSYC, V1, P73; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; *WHO, 2003, MULT PRES ICD 10 US; Wood RL, 2009, J HEAD TRAUMA REHAB, V24, P88, DOI 10.1097/HTR.0b013e31819b118a	33	29	30	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2009	24	2					131	140		10.1097/01.HTR.0000348755.42649.e9			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	427WF	WOS:000264809100007	19333068				2022-02-06	
J	Mate, M; Janos, F; David, N; Gabriella, R; Zsolt, K; Laszlo, V; Jozsef, T; Ruban-Matuzani, A; Teichberg, VI; Farkas, T				Mate Marosi; Janos Fuzik; David Nagy; Gabriella Rakos; Zsolt Kis; Laszlo Vecsei; Jozsef Toldi; Ruban-Matuzani, Angela; Teichberg, Vivian I.; Farkas, Tamas			Oxaloacetate restores the long-term potentiation impaired in rat hippocampus CA1 region by 2-vessel occlusion	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Glutamate neurotoxicity; Hypoperfusion; 2-vessel occlusion; Oxaloacetate; Glutamate-scavenging; LTP	D-ASPARTATE RECEPTOR; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN-INJURY; TRANSIENT FOREBRAIN ISCHEMIA; TYROSINE PHOSPHORYLATION; GLUTAMATE TRANSPORTERS; CEREBROSPINAL-FLUID; GERBIL HIPPOCAMPUS; CEREBRAL-ISCHEMIA; ARTERY OCCLUSION	Various acute brain pathological conditions are characterized by the presence of elevated glutamate concentrations in the brain interstitial fluids. It has been established that a decrease in the blood glutamate level enhances the brain-to-blood efflux of glutamate, removal of which from the brain may prevent glutamate excitotoxicity and its contribution to the long-lasting neurological deficits seen in stroke. A decrease in blood glutamate level can be achieved by exploiting the glutamate-scavenging properties of the blood-resident enzyme glutamate-oxaloacetate transaminase, which transforms glutamate into 2-ketoglutarate in the presence of the glutamate co-substrate oxaloacetate. The present study had the aim of an evaluation of the effects of the blood glutamate scavenger oxaloacetate on the impaired long-term potentiation (LTP) induced in the 2-vessel occlusion ischaemic model in rat. Transient (30-min) incomplete forebrain ischaemia was produced 72 h before LTP induction. Although the short transient brain hypoperfusion did not induce histologically identifiable injuries in the CA1 region (Fluoro-jade B, S-100 and cresyl violet), it resulted in an impaired LTP function in the hippocampal CA1 region without damaging the basal synaptic transmission between the Schaffer collaterals and the pyramidal neurons. This impairment could be fended off in a dose-dependent manner by the intravenous administration of oxaloacetate in saline (at doses between 1.5 mmol and 0.1 mu mol) immediately after the transient hypoperfusion. Our results suggest that oxaloacetate-mediated blood and brain glutamate scavenging contributes to the restoration of the LTP after its impairment by brain ischaemia. (C) 2008 Elsevier B.V. All rights reserved.	[Mate Marosi; Janos Fuzik; David Nagy; Gabriella Rakos; Zsolt Kis; Jozsef Toldi; Farkas, Tamas] Univ Szeged, Dept Physiol Anat & Neurosci, H-6726 Szeged, Hungary; [Laszlo Vecsei] Univ Szeged, Dept Neurol, H-6701 Szeged, Hungary; [Ruban-Matuzani, Angela; Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel		Jozsef, T (corresponding author), Univ Szeged, Dept Physiol Anat & Neurosci, Kozep Fasor 52, H-6726 Szeged, Hungary.	toldi@bio.u-szeged.hu	Marosi, Mate/B-1807-2009; Kis, Zsolt/A-4583-2009; Toldi, Jozsef/M-4858-2018; Vecsei, Laszlo/B-2066-2010; Farkas, Tamas/B-7193-2008; Vecsei, Laszlo/ABA-6137-2021	Kis, Zsolt/0000-0002-6896-5883; Toldi, Jozsef/0000-0001-7355-0503; Vecsei, Laszlo/0000-0001-8037-3672; Ruban, Angela/0000-0003-1091-8854	Hungarian National Bureau of Research and DevelopmentNational Office for Research and Technology [NKTH RET 08/2004];  [OTKA K 75628];  [GVOP-3.2.1-2004-04-0357/3.0]	This work was supported by the Hungarian National Bureau of Research and Development (NKTH RET 08/2004). OTKA K 75628 and GVOP-3.2.1-2004-04-0357/3.0. T.F. was a Bolyai Fellow of the Hungarian Academy of Sciences.	Asano T, 2005, CNS NEUROL DISORD-DR, V4, P127, DOI 10.2174/1568007053544084; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Cavaglia M, 2001, BRAIN RES, V910, P81, DOI 10.1016/S0006-8993(01)02637-3; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chen XM, 1999, J CLIN INVEST, V103, P1159, DOI 10.1172/JCI5392; Cheung HH, 2003, J NEUROCHEM, V86, P1441, DOI 10.1046/j.1471-4159.2003.01951.x; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davalos A, 2000, J Stroke Cerebrovasc Dis, V9, P2, DOI 10.1053/jscd.2000.18908; DREWES LR, 1977, AM J PHYSIOL, V233, pE320, DOI 10.1152/ajpendo.1977.233.4.E320; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Ishiuchi S, 2007, J NEUROSCI, V27, P7987, DOI 10.1523/JNEUROSCI.2180-07.2007; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Kalia LV, 2004, ONCOGENE, V23, P8007, DOI 10.1038/sj.onc.1208158; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Martinez G, 1998, INT J DEV NEUROSCI, V16, P519, DOI 10.1016/S0736-5748(98)00035-5; Matsui T, 2002, J CEREBR BLOOD F MET, V22, P711, DOI 10.1097/00004647-200206000-00010; MITANI A, 1992, NEUROSCIENCE, V48, P307, DOI 10.1016/0306-4522(92)90492-K; Mori K, 1998, BRAIN RES, V795, P221, DOI 10.1016/S0006-8993(98)00295-9; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OLDENDORF WH, 1976, AM J PHYSIOL, V230, P94, DOI 10.1152/ajplegacy.1976.230.1.94; Pei L, 2000, ACTA PHARMACOL SIN, V21, P695; Rao VLR, 2000, NEUROCHEM INT, V36, P531, DOI 10.1016/S0197-0186(99)00153-9; Rong YQ, 2001, J NEUROCHEM, V79, P382, DOI 10.1046/j.1471-4159.2001.00565.x; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sas K, 2008, NEUROBIOL DIS, V32, P302, DOI 10.1016/j.nbd.2008.07.013; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Takagi N, 1999, J CEREBR BLOOD F MET, V19, P880, DOI 10.1097/00004647-199908000-00007; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; TODD NV, 1984, STROKE, V15, P579, DOI 10.1161/str.15.3.579a; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wahl AS, 2009, NEUROSCIENCE, V158, P344, DOI 10.1016/j.neuroscience.2008.06.018; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zalewska T, 2005, BRAIN RES, V1042, P214, DOI 10.1016/j.brainres.2005.02.025; ZIOTNIK A, 2008, NEUROCHEM RES, V33, P1044; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	55	29	29	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	FEB 14	2009	604	1-3					51	57		10.1016/j.ejphar.2008.12.022			7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	412XE	WOS:000263756700007	19135048				2022-02-06	
J	Cyr, AA; Stinchcombe, A; Gagnon, S; Marshall, S; Hing, MMS; Finestone, H				Cyr, Andree-Ann; Stinchcombe, Arne; Gagnon, Sylvain; Marshall, Shawn; Hing, Malcolm Man-Son; Finestone, Hillel			Driving difficulties of brain-injured drivers in reaction to high-crash-risk simulated road events: A question of impaired divided attention?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Brain injury; Driving; Simulation; Cognitive load; Unexpected driving events	CLOSED-HEAD-INJURY; OF-THE-LITERATURE; OLDER DRIVERS; PERFORMANCE; DEFICITS; PREDICTORS; DEMENTIA; METAANALYSIS; DISEASE; FITNESS	This study examined the role of impaired divided attention and speed of processing in traumatic brain injury (TBI) drivers in high-crash-risk simulated road events. A total of 17 TBI drivers and 16 healthy participants were exposed to four challenging simulated roadway events to which behavioral reactions were recorded. Participants were also asked to perform a dual task during portions of the driving task, and TBI individuals were administered standard measures of divided attention and reaction time. Results indicated that the TBI group crashed significantly more than controls (p <.05) and that dual-task performance correlated significantly with crash rate (r = .58, p = .05).	[Gagnon, Sylvain] Univ Ottawa, Sch Psychol, Ottawa, ON K1N 6N5, Canada; [Gagnon, Sylvain; Marshall, Shawn; Hing, Malcolm Man-Son; Finestone, Hillel] Elisabeth Bruyere Res Inst, Ottawa, ON, Canada; [Marshall, Shawn] Ottawa Gen Hosp, Rehabil Ctr, Ottawa, ON K1H 8L6, Canada		Gagnon, S (corresponding author), Univ Ottawa, Sch Psychol, Pavillon Montpetit 410A,CP 450,Succ A, Ottawa, ON K1N 6N5, Canada.	sgagnon@uottawa.ca		Cyr, Andree-Ann/0000-0001-9036-2889			Akinwuntan AE, 2005, NEUROLOGY, V65, P843, DOI 10.1212/01.wnl.0000171749.71919.fa; Ball K., 1992, J AM OPTOM ASSOC, V64, P71; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; BROUWER WH, 1991, HUM FACTORS, V33, P573, DOI 10.1177/001872089103300508; Brown LB, 2004, J GERIATR PSYCH NEUR, V17, P232, DOI 10.1177/0891988704269825; Byers J.C., 1989, ADV IND ERFONOMICS S, VI, P481; CANTAGALLO A, 1995, J INT NEUROPSYCH SOC, V1, P198; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CYR AA, 2006, ADV TRANSPORTATION S, P31; Dobbs AR, 1998, ACCIDENT ANAL PREV, V30, P363, DOI 10.1016/S0001-4575(97)00110-3; FINKELMAN JM, 1977, J APPL PSYCHOL, V62, P713, DOI 10.1037/0021-9010.62.6.713; Fisk GD, 1998, BRAIN INJURY, V12, P683; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Grace J, 2005, J INT NEUROPSYCH SOC, V11, P766, DOI 10.1017/S135561770505848; HILL SG, 1992, HUM FACTORS, V34, P429, DOI 10.1177/001872089203400405; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Hunt LA, 1997, ARCH NEUROL-CHICAGO, V54, P707, DOI 10.1001/archneur.1997.00550180029008; Kennedy RS, 1993, INT J AVIAT PSYCHOL, V3, P203, DOI [10.1207/s15327108ijap0303_3, DOI 10.1207/S15327108IJAP0303_3]; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Marshall SC, 2007, TOP STROKE REHABIL, V14, P98, DOI 10.1310/tsr1401-98; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Mills J., 2004, THEOR ISS ERGON SCI, V5, P385, DOI 10.1080/14639220412331298938; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; OTT BR, 2003, J GERIATR PSYCHIAT, V18, P85; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Reger MA, 2004, NEUROPSYCHOLOGY, V18, P85, DOI 10.1037/0894-4105.18.1.85; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; VANZOMEREN AH, 1994, NEUROPSYCHOLOGY ATTE; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; WITHAAR FK, 2000, THESIS RIJSKUNIVERSI	43	29	30	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	4					472	482	PII 901408923	10.1080/13803390802255627			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	435HH	WOS:000265334200010	18686115				2022-02-06	
J	Linnman, C; Appel, L; Soderlund, A; Frans, O; Engler, H; Furmark, T; Gordh, T; Langstrom, B; Fredrikson, M				Linnman, Clas; Appel, Lieuwe; Soderlund, Anne; Frans, Orjan; Engler, Henry; Furmark, Tomas; Gordh, Torsten; Langstrom, Bengt; Fredrikson, Mats			Chronic whiplash symptoms are related to altered regional cerebral blood flow in the resting state	EUROPEAN JOURNAL OF PAIN			English	Article						Whiplash; Positron emission tomography; Neuroimaging; Chronic pain; Post traumatic stress	POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; NECK DISABILITY INDEX; MUSCLE PAIN; HUMAN BRAIN; CENTRAL REPRESENTATION; FUNCTIONAL MRI; STIMULATION; ACTIVATION; INJURY	The neural pathogenic mechanisms involved in mediating chronic pain and whiplash associated disorders (WAD) after rear impact car collisions are largely unknown. This study's first objective was to compare resting state regional cerebral blood flow (rCBF) by means of positron emission tomography with (15)O labelled water in 21 WAD patients with 18 healthy, pain-free controls. A second objective was to investigate the relations between brain areas with altered rCBF to pain experience, somatic symptoms, posttraumatic stress symptoms and personality traits in the patient group. Patients had heightened resting rCBF bilaterally in the posterior parahippocampal and the posterior cingulate gyri, in the right thalamus and the right medial prefrontal gyrus as well as lowered tempero-occipital blood flow compared with healthy controls. The altered rCBF in the patient group was correlated to neck disability ratings. We thus suggest an involvement of the posterior cingulate, parahippocampal and medial prefrontal gyri in WAD and speculate that alterations in the resting state are linked to an increased self-relevant evaluation of pain and stress. (C) 2008 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.	[Linnman, Clas; Frans, Orjan; Furmark, Tomas; Fredrikson, Mats] Uppsala Univ, Dept Psychol, SE-75142 Uppsala, Sweden; [Appel, Lieuwe; Engler, Henry; Langstrom, Bengt] GE Healthcare, Uppsala Imanet AB, Uppsala, Sweden; [Soderlund, Anne] Uppsala Univ, Dept Publ Hlth & Caring Sci, Sect Caring Sci, SE-75142 Uppsala, Sweden; [Gordh, Torsten] Univ Uppsala Hosp, Div Anaesthesiol & Intens Care Med, Dept Surg Sci, Lab Pain Res, Uppsala, Sweden		Linnman, C (corresponding author), Uppsala Univ, Dept Psychol, Box 1225, SE-75142 Uppsala, Sweden.	clas.linnman@psyk.uu.se	Engler, Henry/ABD-8950-2020	Engler, Henry/0000-0002-8966-3788; Gordh, Torsten/0000-0003-1454-3148; Soderlund, Anne/0000-0002-4537-030X; Linnman, Clas/0000-0001-8449-894X; Furmark, Tomas/0000-0001-6821-9058	LF insurance research foundation; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Amersham Fund; Uppsala Imanet AB	The authors would like to thank two anonymous rewievers and Dr Stephen Butler for valuable comments, Anna Hillered Hultman for assistance in recruiting patients, Anna Pissiota, Fredrik Ahs and Asa Michelgard for assistance during data collection and the staff at Uppsala Imanet AB for providing an excellent research environment.; This work was supported by LF insurance research foundation, the Swedish Research Council, the Uppsala University Amersham Fund and Uppsala Imanet AB.	Ackelman BH, 2002, J REHABIL MED, V34, P284, DOI 10.1080/165019702760390383; Alexander Michael P, 2003, Pain Res Manag, V8, P19; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Baciu MV, 1999, AM J NEURORADIOL, V20, P1920; Bantick SJ, 2002, BRAIN, V125, P310, DOI 10.1093/brain/awf022; BERGMAN H, 2003, NEO PI R SVENSK VERS; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Brett M, 2002, NEUROIMAGE, V16; Buitenhuis J, 2006, J PSYCHOSOM RES, V61, P681, DOI 10.1016/j.jpsychores.2006.07.008; Costa P. T., 1992, REVISED NEO PERSONAL; Creac'h C, 2000, AM J NEURORADIOL, V21, P1402; Curatolo M, 2001, CLIN J PAIN, V17, P306, DOI 10.1097/00002508-200112000-00004; Derbyshire SWG, 1997, PAIN, V73, P431, DOI 10.1016/S0304-3959(97)00138-3; Dickerson BC, 2004, ANN NEUROL, V56, P27, DOI 10.1002/ana.20163; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Frans O, 2005, ACTA PSYCHIAT SCAND, V111, P291, DOI 10.1111/j.1600-0447.2004.00463.x; Freitag P, 2001, NEUROREHAB NEURAL RE, V15, P31, DOI 10.1177/154596830101500105; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Gelnar PA, 1999, NEUROIMAGE, V10, P460, DOI 10.1006/nimg.1999.0482; Hsieh JC, 1996, PAIN, V67, P59, DOI 10.1016/0304-3959(96)03066-7; HSIEH JC, 1995, PAIN, V63, P225, DOI 10.1016/0304-3959(95)00048-W; Iadarola MJ, 1998, BRAIN, V121, P931, DOI 10.1093/brain/121.5.931; Johansen MK, 1999, PAIN, V83, P229, DOI 10.1016/S0304-3959(99)00106-2; Kuchinad A, 2007, J NEUROSCI, V27, P4004, DOI 10.1523/JNEUROSCI.0098-07.2007; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Lorberboym M, 2002, J TRAUMA, V52, P521, DOI 10.1097/00005373-200203000-00017; Maddock RJ, 1999, TRENDS NEUROSCI, V22, P310, DOI 10.1016/S0166-2236(98)01374-5; Mai JK, 1997, ATLAS HUMAN BRAIN; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Naliboff BD, 2001, PSYCHOSOM MED, V63, P365, DOI 10.1097/00006842-200105000-00006; Niddam DM, 2002, NEUROIMAGE, V17, P1437, DOI 10.1006/nimg.2002.1270; Nygren A., 2000, NACKSKADOR EFTER BIL; Otte A, 1998, EUR J NUCL MED, V25, P306; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; OTTE A, 1995, LANCET, V345, P1513, DOI 10.1016/S0140-6736(95)91075-1; Otte A, 1997, J NEUROL NEUROSUR PS, V63, P368, DOI 10.1136/jnnp.63.3.368; Otte A, 1997, J NUCL MED, V38, P1002; Otte A, 1995, J VASC INVEST, V1, P157; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; Pissiota A, 2002, EUR ARCH PSY CLIN N, V252, P68, DOI 10.1007/s004060200014; Ploghaus A, 2001, J NEUROSCI, V21, P9896, DOI 10.1523/JNEUROSCI.21-24-09896.2001; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rodriquez AA, 2004, MUSCLE NERVE, V29, P768, DOI 10.1002/mus.20060; SCHALLING D, 1987, ACTA PSYCHIAT SCAND, V76, P172, DOI 10.1111/j.1600-0447.1987.tb02881.x; Seminowicz DA, 2006, PAIN, V120, P297, DOI 10.1016/j.pain.2005.11.008; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Soderlund A, 2006, EUR J PAIN, V10, P113, DOI 10.1016/j.ejpain.2005.01.015; Spielberger CD., 1970, STATE TRAIT ANXIETY; SPITZER WO, 1995, SPINE, V20, pS1; Sterling M, 2006, PAIN, V122, P102, DOI 10.1016/j.pain.2006.01.014; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Sundstrom T, 2006, EUR SPINE J, V15, P1189, DOI 10.1007/s00586-005-0040-5; Svensson P, 1997, J NEUROPHYSIOL, V78, P450, DOI 10.1152/jn.1997.78.1.450; Talairach J., 1988, COPLANAR STEREOTAXIC; Thunberg J, 2005, EUR J PAIN, V9, P185, DOI 10.1016/j.ejpain.2004.05.003; Tolle TR, 1999, ANN NEUROL, V45, P40, DOI 10.1002/1531-8249(199901)45:1<40::AID-ART8>3.0.CO;2-L; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Wik G, 2006, INT J NEUROSCI, V116, P1, DOI 10.1080/00207450690962208; Wik G, 2003, NEUROREPORT, V14, P619, DOI 10.1097/00001756-200303240-00019	64	29	29	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3801			EUR J PAIN	Eur. J. Pain	JAN	2009	13	1					65	70		10.1016/j.ejpain.2008.03.001			6	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	402KL	WOS:000263012500011	18486506				2022-02-06	
J	McAllister, TW				McAllister, Thomas W.			Polymorphisms in Genes Modulating the Dopamine System: Do They Influence Outcome and Response to Medication After Traumatic Brain Injury?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							RECEPTOR-BINDING; WORKING-MEMORY; SCHIZOPHRENIA; TRANSPORTER; DRD2; PERFORMANCE; MECHANISMS; TOLCAPONE; GENOTYPE; ALLELE		[McAllister, Thomas W.] Dartmouth Med Sch, Sect Neuropsychiat, Hanover, NH USA		McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu			NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176]; NIDRR [H133G70031, H133000136]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS40472-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER	This work was supported in part by NICHD grant R01 HD048176, NIDRR grant; H133G70031 and H133000136, and NIH grant RO1 NS40472-01.	Bilder RM, 2002, BIOL PSYCHIAT, V52, P701, DOI 10.1016/S0006-3223(02)01416-6; Comings DE, 1998, ALCOHOL, V16, P61, DOI 10.1016/S0741-8329(97)00178-X; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dulawa SC, 1999, J NEUROSCI, V19, P9550; Ebstein RP, 1998, MOL PSYCHIATR, V3, P238, DOI 10.1038/sj.mp.4000363; Ebstein RP, 2000, EUR J PHARMACOL, V410, P205, DOI 10.1016/S0014-2999(00)00852-9; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Gainetdinov RR, 1998, BRAIN RES REV, V26, P148, DOI 10.1016/S0165-0173(97)00063-5; Gasparini M, 1997, J NEURAL TRANSM, V104, P887, DOI 10.1007/BF01285556; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Goldberg TE, 2003, ARCH GEN PSYCHIAT, V60, P889, DOI 10.1001/archpsyc.60.9.889; Guillin O, 2004, INT REV NEUROBIOL, V59, P425; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jovanovic V, 1999, PHARMACOGENETICS, V9, P561, DOI 10.1097/01213011-199910000-00003; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Liljequist R, 1997, BEHAV BRAIN RES, V82, P195, DOI 10.1016/S0166-4328(97)80989-8; LIPSKY RH, 2005, J NEUROPSYCHIATRY CL, V17; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Martinsson L, 2004, DRUG AGING, V21, P67, DOI 10.2165/00002512-200421020-00001; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Miller GM, 2002, MOL PSYCHIATR, V7, P44, DOI 10.1038/sj/mp/4000921; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Watts VJ, 1999, PSYCHOPHARMACOLOGY, V141, P83, DOI 10.1007/s002130050810; Weinberger DR, 2001, BIOL PSYCHIAT, V50, P825, DOI 10.1016/S0006-3223(01)01252-5; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Wong AHC, 2000, EUR J PHARMACOL, V410, P183	31	29	30	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					65	68		10.1097/HTR.0b013e3181996e6b			4	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500010	19158598	Green Accepted			2022-02-06	
J	Mowery, NT; Gunter, OL; Guillamondegui, O; Dossett, LA; Dortch, MJ; Morris, JA; May, AK				Mowery, Nathan T.; Gunter, Oliver L.; Guillamondegui, Oscor; Dossett, Lesly A.; Dortch, Marcus J.; Morris, John A., Jr.; May, Addison K.			Stress Insulin Resistance is a Marker for Mortality in Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Stress hyperglycemia; Insulin resistance; Intensive insulin therapy; Trauma; Intensive care; Traumatic brain injury	ADMISSION HYPERGLYCEMIA; ACUTE STROKE; GLUCOSE-METABOLISM; THERAPY; SURGERY; SYSTEM; MICRODIALYSIS; INFARCTION; TOLERANCE; PROTOCOL	Background: Both hyper- and hypo-glycemia have been associated with poor outcome in traumatic brain injury (TBI). Neither the risks nor benefit of tight glucose control (goal range, 80-110 mg/dL) have been documented in the TBI population. Objective: To analyze whether densely collected blood glucose data, using a computerized algorithm, to maintain tight glycemic control will reveal significant differences in blood glucose control between survivors and nonsurvivors in patients with TBI. Methods: From October 2005 to April 2006, all ventilated, critically ill surgical patients with TBI Abbreviated Injury Scale score of >= 3 were placed on an automated, euglycemia protocol with every 2-hour blood glucose sampling. Mortalities within 24 hours were excluded. The protocol calculates the insulin rate using a linear equation (rate = blood glucose - 60[M]). M is an adapting multiplier and used here as a marker for insulin resistance (111). Results: Of 1,636 trauma intensive care unit admissions 160 patients, (median Injury Severity Score 34, mortality 13.1%) had 10,071 samples collected. Median glucose 115.6 mg/dL, with 41% of values between 80 and 110 mg/dL, 81% between 80 and 150 mg/dL, and 0.3% <40 mg/dL. The median blood glucose was statistically different but not clinically different among the patients who lived and died (114; interquartile range, 109-132 vs. 118; 111-136, p = 0.01). The median insulin dose was a unit per hour higher among the patient who died (4.2; 2.7-5.9 vs. 3.2; 2.4-5.0, p = 0.006). A logistic regression model demonstrated insulin rate (odds ratio 0.736, 95% confidence interval, 0.549-0.985, p = 0.039) to be the only independent predictor of mortality among the measures of blood glucose control. Conclusion: Nonsurvivors with TBI have significantly higher markers of IR (insulin rate and multiplier). Markers of glucose control (median glucose, hypoglycemic episodes, and the percentage of values in range) did not differ clinically among groups. Despite this stress IR, tight glycemic control appears possible and safe with low levels of hypoglycemic episodes in the TBI population.	[Mowery, Nathan T.] Wake Forest Univ, Dept Surg, Winston Salem, NC 27109 USA; [Gunter, Oliver L.; Guillamondegui, Oscor; Dossett, Lesly A.; Dortch, Marcus J.; Morris, John A., Jr.; May, Addison K.] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA		Mowery, NT (corresponding author), Med Ctr Blvd, Winston Salem, NC 27157 USA.	nmowery@wfubmc.edu	Dossett, Lesly/I-8881-2019	Dossett, Lesly/0000-0001-8060-1073			AARIMAA M, 1974, ANN SURG, V179, P926, DOI 10.1097/00000658-197406000-00019; Auer RN, 2004, METAB BRAIN DIS, V19, P169, DOI 10.1023/B:MEBR.0000043967.78763.5b; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Boord JB, 2007, J AM MED INFORM ASSN, V14, P278, DOI 10.1197/jamia.M2292; CANDELISE L, 1985, ARCH NEUROL-CHICAGO, V42, P661, DOI 10.1001/archneur.1985.04060070051014; Carlson GL, 2003, BRIT J SURG, V90, P259, DOI 10.1002/bjs.4081; CLARKE RSJ, 1970, BRIT J ANAESTH, V42, P295, DOI 10.1093/bja/42.4.295; Davidson PC, 2005, DIABETES CARE, V28, P2418, DOI 10.2337/diacare.28.10.2418; Dhindsa S, 2005, J CLIN ENDOCR METAB, V90, P5058, DOI 10.1210/jc.2005-0223; Dortch MJ, 2008, JPEN-PARENTER ENTER, V32, P18, DOI 10.1177/014860710803200118; FIETSAM R, 1991, AM SURGEON, V57, P551; Ghanim H, 2007, DIABETOLOGIA, V50, P278, DOI 10.1007/s00125-006-0508-9; HILL MR, 1986, J IMMUNOL, V137, P858; KEHLET H, 1979, BRIT J SURG, V66, P543, DOI 10.1002/bjs.1800660807; Kwoun MO, 1997, JPEN-PARENTER ENTER, V21, P91, DOI 10.1177/014860719702100291; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; Lattermann R, 2001, ANESTH ANALG, V93, P121; Ljungqvist O, 2000, SURGERY, V128, P757, DOI 10.1067/msy.2000.107166; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Mowery NT, 2006, CRIT CARE MED, V34, pA11, DOI 10.1097/00003246-200612002-00044; Nygren J, 1998, CLIN NUTR, V17, P65, DOI 10.1016/S0261-5614(98)80307-5; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; ONEILL PA, 1991, STROKE, V22, P842, DOI 10.1161/01.STR.22.7.842; Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6; ROSS H, 1966, LANCET, V2, P563; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; Souba WW, 1997, NEW ENGL J MED, V336, P41, DOI 10.1056/NEJM199701023360107; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANKOOTEN F, 1993, STROKE, V24, P1129, DOI 10.1161/01.STR.24.8.1129; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303; WERB MR, 1989, J CLIN ENDOCR METAB, V69, P1010, DOI 10.1210/jcem-69-5-1010; WHITE NH, 1982, ANN INTERN MED, V97, P210, DOI 10.7326/0003-4819-97-2-210; WOLFE RR, 1979, METABOLISM, V28, P1031, DOI 10.1016/0026-0495(79)90007-6; WOLFE RR, 1987, NEW ENGL J MED, V317, P403, DOI 10.1056/NEJM198708133170702; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zhu CZ, 2004, J NEUROSURG, V101, P664, DOI 10.3171/jns.2004.101.4.0664	44	29	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					145	153		10.1097/TA.0b013e3181938c5e			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	395SJ	WOS:000262543500019	19131817				2022-02-06	
J	Pare, N; Rabin, L; Fogel, J; Pepin, M				Pare, Nadia; Rabin, Laura A.; Fogel, Joshua; Pepin, Michel			Mild traumatic brain injury and its sequelae: Characterisation of divided attention deficits	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Attention; Brain injuries; Neuropsychological tests	MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; REACTION-TIME; POSTCONCUSSION SYNDROME; MODERATE; PERFORMANCE; MEMORY; PREDICTION; LONG; PATHOPHYSIOLOGY	Deficits in divided attention occur after a mild traumatic brain injury (MTBI) but many extant tasks lack sensitivity for detecting subtle cognitive difficulties. We use the Test d'Attention Partagee Informatise (TAPI), a novel dual-task paradigm, to investigate the impact of MTBI on the ability to divide attention between two stimuli sources. Individuals with MTBI (n = 37) were evaluated within the first week following head trauma and at three months post-injury. A healthy control (HC) group (n = 79) was also assessed. The primary outcome was reaction time and there were three different conditions that included visual target detection and auditory digit span tasks. Analyses utilised repeated measures ANOVA and ANCOVA models that adjusted for relevant variables including post-concussive and affective symptoms. Results indicated that at both baseline and follow-up, the MTBI group had significantly slower reaction time than the HC group. Also, both the MTBI and HC groups had slower reaction times as participants progressed through each of the more challenging TAPI conditions. This study supports the usefulness of this novel instrument and allows clinicians and researchers to assess for subtle divided attention deficits that may persist in those with MTBI even three months post-injury.	[Pare, Nadia] Kaiser Fdn Rehabil Ctr, Vallejo, CA USA; [Rabin, Laura A.; Fogel, Joshua] Brooklyn Coll, City Univ New York, Brooklyn, NY USA; [Pare, Nadia] Kaiser Fdn Rehabil Ctr, Vallejo, CA 94589 USA; [Pare, Nadia; Pepin, Michel] Univ Laval, Quebec City, PQ, Canada; [Rabin, Laura A.; Fogel, Joshua] CUNY Brooklyn Coll, Brooklyn, NY 11210 USA		Pare, N (corresponding author), Kaiser Fdn Rehabil Ctr, 975 Sereno Dr, Vallejo, CA 94589 USA.	nad.pare@gmail.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alfano MS, 2000, J CLIN PSYCHOL, V56, P975, DOI 10.1002/1097-4679(200007)56:7<975::AID-JCLP13>3.0.CO;2-Z; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Andres P, 2000, J GERONTOL B-PSYCHOL, V55, pP373, DOI 10.1093/geronb/55.6.P373; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beck A. T., 1996, MANUAL BECK DEPRESSI, VII; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2000, BRAIN COGNITION, V44, P50, DOI 10.1006/brcg.1999.1209; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DIKMEN SS, 1989, MILD HEAD INJURY, P229; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GENTILINI M, 1989, MILD HEAD INJURY, P163; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GRONWALL D, 1974, LANCET, V2, P605; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jagoda A, 2000, EMERG MED CLIN N AM, V18, P355, DOI 10.1016/S0733-8627(05)70130-9; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Keller M, 2000, J NEUROL NEUROSUR PS, V68, P761, DOI 10.1136/jnnp.68.6.761; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; PARE N, 2003, DISS ABSTR INT, V65, P478; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P315; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; SPIELBERGER CD, 1970, MANUAL STAI; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; *SPSS, 2006, VERS 15 01; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; VANZOMEREN AH, 2002, 30 ANN CONV INT NEUR; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	71	29	30	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	1					110	137	PII 794347145	10.1080/09602010802106486			28	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	386HX	WOS:000261874300007	18609010				2022-02-06	
J	Parsons, TD; Notebaert, AJ; Shields, EW; Guskiewicz, KM				Parsons, Thomas D.; Notebaert, Andrew J.; Shields, Edgar W.; Guskiewicz, Kevin M.			Application of Reliable Change Indices to Computerized Neuropsychological Measures of Concussion	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						neurocognitive; reliable change; sports-related concussion; statistical assessment	COLLEGIATE FOOTBALL PLAYERS; COGNITIVE CHANGE; POSTURAL STABILITY; SPORTS; IMPAIRMENT; FREQUENCY; STATEMENT; RECOVERY; DEFICITS	Serial assessments of neurocognitive functioning in athletes with concussion are commonly used for return to play decisions. This study provides reliable change indices (RCIs) for computerized tests from 40 NCAA Division I collegiate athletes that suffered a sports-related concussion. The normative data that resulted from the RCIs and subsequent analyses of differences between improved and not improved athletes may aid both clinicians and researchers to assess whether observed change on neuropsychological measures is reliable change or change due simply to practice effects. Hence, the RCIs presented herein provide information that may be used judiciously by a clinician for assessing meaningful change.	[Parsons, Thomas D.] Univ So Calif, VRPSYCH Lab, Inst Creat Technol, Marina Del Rey, CA 90292 USA; [Parsons, Thomas D.] Univ So Calif, Sch Gerontol, Marina Del Rey, CA 90292 USA; [Notebaert, Andrew J.] Univ Iowa, Iowa City, IA 52242 USA; [Shields, Edgar W.; Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC 27515 USA		Parsons, TD (corresponding author), Univ So Calif, VRPSYCH Lab, Inst Creat Technol, 13274 Fiji Way, Marina Del Rey, CA 90292 USA.	tparsons@usc.edu		Parsons, Thomas/0000-0003-0331-5019; Guskiewicz, Kevin/0000-0002-8682-2130			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; CHELUNE GJ, 1991, NEUROLOGY, V41, P399, DOI 10.1212/WNL.41.3.399; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Ferrara Michael S., 2001, J Athl Train, V36, P145; Frerichs RJ, 2005, ARCH CLIN NEUROPSYCH, V20, P321, DOI 10.1016/j.acn.2004.08.002; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; MEAD AD, 1993, PSYCHOL BULL, V114, P449, DOI 10.1037/0033-2909.114.3.449; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Reeves DL., 1997, NEUROPSYCHOLOGY HDB, V1, P423; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Wilson BA, 2000, J INT NEUROPSYCH SOC, V6, P469, DOI 10.1017/S1355617700644053; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P83, DOI 10.1016/j.acn.2005.07.008; Zillmer EA, 2003, APPL NEUROPSYCHOL, V10, P1, DOI 10.1207/S15324826AN1001_1	39	29	30	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.		2009	119	4					492	507	PII 908857710	10.1080/00207450802330876			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	410CO	WOS:000263553900005	19229718	Green Submitted			2022-02-06	
J	Rubiano, AM; Villarreal, W; Hakim, EJ; Aristizabal, J; Hakim, F; Diez, JC; Pena, G; Puyana, JC				Rubiano, Andres Mariano; Villarreal, Wilson; Hakim, Enrique Jimenez; Aristizabal, Jorge; Hakim, Fernando; Diez, Juan Carlos; Pena, German; Puyana, Juan Carlos			Early decompressive craniectomy for neurotrauma: an institutional experience	ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY			English	Article						Decompressive craniectomy; neurotrauma severe head trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL BLOOD-FLOW; SUBTEMPORAL DECOMPRESSION; SECONDARY INSULTS; SINGLE-CENTER; MANAGEMENT; CHILDREN; EDEMA	BACKGROUND Neurotrauma centers have developed management protocols on the basis of evidence obtained from literature analysis and institutional experience. This article reviews our institutional experience in the management of severe traumatic brain injury (TBI) at Simon Bolivar Hospital, the district trauma center for Bogota's north zone. METHODS This is a case control study comparing a group of patients (n: 16) operated for severe TBI between January 2002 and July 2004 according to an institutional management protocol characterized by an early decompressive craniectomy (DC) approach versus a historical control group (n: 20) managed before the implementation of such protocol. Mortality and Glasgow Outcome Score (GOS) at 6 months were used as the main outcome variables. RESULTS An early DC protocol implemented within 12 hours from injury in 16 patients with severe isolated TBI and a Marshall score between III or IV was associated with a lesser mortality than the conventional approach with ventriculostomy and Intensive Care Unit (ICU) management alone. The GOS was significantly better in the DC group (p=0.0002) than in the control group. CONCLUSION The use of an early DC protocol for severe TBI patients (Glasgow Coma Scale <9) had a significantly improved outcome compared with the conventional approach with ventriculostomy and ICU management in Simon Bolivar Hospital in Bogotd, Colombia.	[Rubiano, Andres Mariano; Villarreal, Wilson] Univ Simon Bolivar, Neurol Surg Serv, Bogota, Colombia; [Hakim, Enrique Jimenez; Hakim, Fernando; Pena, German] Fdn Santa Fe Bogota, Bogota, Colombia; [Aristizabal, Jorge; Diez, Juan Carlos] Clin El Bosque, Bogota, Colombia; [Puyana, Juan Carlos] Univ Pittsburgh, Trauma & Crit Care Dept, Pittsburgh, PA 15260 USA		Rubiano, AM (corresponding author), Cra 5A, 16-29 Ap 301 El Triunfo, Neiva, Huila, Colombia.	andresrubiano@hispavista.com	RUBIANO, ANDRES M/K-6704-2012	RUBIANO, ANDRES M/0000-0001-8931-3254	FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW007560] Funding Source: NIH RePORTER; FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43 TW007560-05] Funding Source: Medline		Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; *BRAIN TRAUM FDN, 2006, NEUROSURGERY, V58, pS2; *BRAIN TRAUM FDN S, 2003, PEDIATR CRIT CARE ME, V4, P1; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock MR, 2000, NEUROSURGERY, V47, P322; Burkert W, 1989, Zentralbl Neurochir, V50, P106; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chestnut RM, 2000, J NEUROTRAUM, V17, P614; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Compagnone C, 2005, NEUROSURGERY, V57, P1183; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; CRONE KR, 1985, NEUROSURGERY, V16, P726; *EUR BRAIN INJ CON, 1997, ACTA NEUROCHIR WIEN, V139, P286; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GAAB MR, 1990, ACT NEUR S, V51, P326; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Hlatky Roman, 2003, Neurosurg Focus, V14, pe2; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; IBANEZ J, 2000, EST MULT CENTR MULT, V1, P179; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; KARLEN J, 1987, NEUROCHIRURGIA, V30, P35; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Meier U, 2005, ACT NEUR S, V95, P55; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reithmeier T, 2005, CHILD NERV SYST, V21, P249, DOI 10.1007/s00381-004-1044-x; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; RUBIANO A, 2004, SURG MANAGEMENT HEAD, P1; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Spagnuolo E, 2004, NEUROCIRUGIA, V15, P36; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; ZAPATA GDP, 2003, PREHOSPITAL DISAST M, V18, P80; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	68	29	29	0	0	TURKISH ASSOC TRAUMA EMERGENCY SURGERY	ISTANBUL	KOPRULU MEHMET PASA SOC, DENIZ ABDAL MAH, DADASOGLU AP, 25-1 SEHREMINI, ISTANBUL, 00000, TURKEY	1306-696X			ULUS TRAVMA ACIL CER	Ulus. Travma Acil Cerrahi Derg.	JAN	2009	15	1					28	38					11	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	388QM	WOS:000262034300007	19130336				2022-02-06	
J	Unden, J; Romner, B				Unden, Johan; Romner, Bertil			A new objective method for CT triage after minor head injury - serum S100B	SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION			English	Article; Proceedings Paper	Symposium on Diagnosis of Neurological Disorders	NOV, 2007	Karolinska Univ Hosp, Stockholm, SWEDEN		Karolinska Univ Hosp	Biomarker; CT; guidelines; head injury; management; minor; S100B; S100; S-100; serum; TBI	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; S-100 PROTEIN MEASUREMENTS; FIBRILLARY ACIDIC PROTEIN; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; MILD; MANAGEMENT; DAMAGE; RULE	The risk of acute intracranial complication after minor head injury (MHI) is low. Despite this, a computed tomography (CT) scan is generally recommended for all patients following MHI. Admission for clinical observation is a secondary management option when a CT scan is unavailable or is judged inappropriate. Both alternatives are associated with disadvantages and several attempts at refining existing guidelines for MHI management have been proposed as a means of reducing CT and/or admission. However, they are based on potentially unreliable patient history and clinical examination and, furthermore, may be compromised by patient factors such as intoxication. Clinical studies from several research groups have shown the potential of brain biomarker S100B in this patient category. The specificity of S100B is poor, but a high sensitivity for brain damage effectively rules out relevant complications after MHI. Used in conjunction with existing guidelines, serum levels of S100B can accurately identify patients who do not need a CT scan after MHI. Based on 6 prospective studies comprising almost 2,000 patients with MHI, the sensitivity and negative predictive value of S100B for CT findings were 98.2 % and 99.5 %, respectively, and for clinically relevant intracranial complications 100 % and 100 %, respectively. Integration of S100B within existing management routines can reduce the need for CT scans by 30 %, resulting in improved and more efficient patient care.	[Romner, Bertil] Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark; [Unden, Johan] Halmstad Cty Hosp, Dept Anesthesia & Intens Care, Halmstad, Sweden		Romner, B (corresponding author), Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark.	Bertil.Romner@med.lu.se					af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; af Geijerstam JL, 2000, EUR J SURG, V166, P526; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Astrand R, 2006, ACTA NEUROL SCAND, V113, P262, DOI 10.1111/j.1600-0404.2005.00573.x; Bellner J, 1999, ACTA NEUROL SCAND, V100, P355; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Bottiger BW, 2001, CIRCULATION, V103, P2694; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Enochsson L, 2005, EUR J NEUROL, V12, P445, DOI 10.1111/j.1468-1331.2005.00996.x; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Nylen K, 2007, STROKE, V38, P1489, DOI 10.1161/STROKEAHA.106.478362; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; Unden Johan, 2008, Lakartidningen, V105, P1846; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117	45	29	30	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0036-5513	1502-7686		SCAND J CLIN LAB INV	Scand. J. Clin. Lab. Invest.		2009	69	1					13	17	PII 908528277	10.1080/00365510802651833			5	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Research & Experimental Medicine	404IR	WOS:000263145500004	19199125				2022-02-06	
J	Wehman, P; Gentry, T; West, M; Arango-Lasprilla, JC				Wehman, Paul; Gentry, Tony; West, Michael; Arango-Lasprilla, Juan Carlos			Community integration: Current issues in cognitive and vocational rehabilitation for individuals with ABI	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						acquired brain injury; alternative work arrangements; cognitive rehabilitation; community integration; employer supports; posttraumatic stress disorder; race/ethnicity; return-to-work; veterans; vocational rehabilitation	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SPINAL-CORD-INJURY; FUNCTIONAL OUTCOMES; MINORITY STATUS; WORK; RETURN; ENVIRONMENT; PREVALENCE; EMPLOYMENT	In this article, we examine cognitive and vocational rehabilitation and the issues related to minority veterans with acquired brain injury (ABI). As more servicemembers are returning from conflict, ways to help them repair their lives, not only physically but also socially and economically, are increasingly needed. The challenges of ABI are multifactorial; that is, the problems are not just cognitive or emotional but spill over into community living and vocational issues. Individuals from racial/ethnic minority backgrounds often face even more difficulties. Therefore, we review the nature of cognitive and vocational rehabilitation and suggest areas for additional research.	[West, Michael] Virginia Commonwealth Univ, Rehabil Res & Training Ctr, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Occupat Therapy, Richmond, VA 23284 USA		West, M (corresponding author), Virginia Commonwealth Univ, Rehabil Res & Training Ctr, Dept Phys Med & Rehabil, POB 842011, Richmond, VA 23284 USA.	mdwest@vcu.edu			Virginia Commonwealth University Rehabilitation Research and Training Center [H133B040011]	This material was based on work partially supported by the Virginia Commonwealth University Rehabilitation Research and Training Center (grant H133B040011).	[Anonymous], 1998, NIH CONSENS STATEMEN, V16, P1; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; BERGMAN M, 2004, US CENSUS BUREA 0318; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 2007, BRAIN INJURY MED PRI, P765; *GENT HLTH CAR, REH WALLS; GIANUTSOS R, 1980, J REHABIL, V46, P36; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; HOOFT IH, 2005, THESIS KAROLINSKA U; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Kulka RA, 1990, TRAUMA VIETNAM WAR G; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Luria AR, 1963, RESTORATION FUNCTION; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; Ponsford J, 2006, NEUROPSYCHOL REHABIL, V16, P315, DOI 10.1080/09602010500176534; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; SBORDONNE RJ, 1998, ECOLOGICAL VALIDITY; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Targett P, 2004, NEUROREHABILITATION, V19, P131; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; *US DEP DEF, 2005, 2005 DEM REP; *US DEP LAB, 2007, 071678 USDL DEP LAB; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; Wehman P, 1994, Int J Rehabil Res, V17, P268, DOI 10.1097/00004356-199409000-00008; Wehman P., 1989, J HEAD TRAUMA REHAB, V4, P66, DOI [10.1097/00001199-198909000-00010, DOI 10.1097/00001199-198909000-00010]; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Ylvisaker M., 1998, COLLABORATIVE BRAIN; 2007, NY TIMES        1025	53	29	29	1	25	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					909	918		10.1682/JRRD.2008.08.0105			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	531BQ	WOS:000272638100019	20104411	Bronze			2022-02-06	
J	Ahmad, M; Rose, ME; Vagni, V; Griffith, RP; Dixon, CE; Kochanek, PM; Hickey, RW; Graham, SH				Ahmad, Muzamil; Rose, Marie E.; Vagni, Vincent; Griffith, Raymond P.; Dixon, C. Edward; Kochanek, Patrick M.; Hickey, Robert W.; Graham, Steven H.			Genetic Disruption of Cyclooxygenase-2 Does Not Improve Histological or Behavioral Outcome After Traumatic Brain Injury in Mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						cyclooxygenase; prostaglandin E-2; TUNEL staining; behavior; Morris water maze	CELL-DEATH; INHIBITOR ROFECOXIB; COX-2 INHIBITORS; IN-SITU; RATS; EXPRESSION; CELECOXIB; INFLAMMATION; NEURONS; EDEMA	Increasing evidence suggests a role for cyclooxygenase-2 (COX-2) in traumatic brain injury (TBI). In the present study, the role of COX-2 in TBI was investigated using COX-2 gene-disrupted (COX-2 null) mice and wild-type (WT) controls that were subjected to the controlled cortical impact (CCI) model of TBI. There was increased expression of COX-2 in ipsilateral hippocampus in WT mice subjected to CCI. CCI resulted in a significant increase in prostaglandin E-2 concentrations in WT compared with COX-2 null hippocampi. There was a significant increase in TUNEL staining of CA1 neurons 24 hr after CCI in WT, but not in COX-2 null mice, compared with sham-operated controls, which is consistent with a protective role for COX-2 in the early phase of injury after TBI. However, there was no difference in lesion volume 21 days after CCI in COX-2 null and WT mice. COX-2 gene disruption did not alter Morris water maze performance. Taken together, these results suggest only a minor role for COX-2 activity in determining outcome after TBI in mouse. (c) 2008 Wiley-Liss, Inc.	[Ahmad, Muzamil; Rose, Marie E.; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA; [Ahmad, Muzamil; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Vagni, Vincent; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Griffith, Raymond P.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.; Hickey, Robert W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA		Graham, SH (corresponding author), VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, 151-UH,7108 Highland Dr, Pittsburgh, PA 15206 USA.	sgra@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	Department of Veterans Affairs/Department of DefenseUS Department of Veterans AffairsUnited States Department of Defense; Traumatic Brain Injury Initiative Merit Review Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS37459]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS037459] Funding Source: NIH RePORTER	Contract grant sponsor: Department of Veterans Affairs/Department of Defense, Traumatic Brain Injury Initiative Merit Review Program (to S.H.G.); Contract grant sponsor: NIH; Contract grant number: R01 NS37459 (to S.H.G.).	Alkayed NJ, 1996, AM J PHYSIOL-HEART C, V271, pH1541, DOI 10.1152/ajpheart.1996.271.4.H1541; Alloza I, 2006, MOL PHARMACOL, V69, P1579, DOI 10.1124/mol.105.020669; Belton Orina, 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403005842; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chang JW, 1996, NEUROBIOL AGING, V17, P801; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Drachman DB, 2000, ANN NEUROL, V48, P792, DOI 10.1002/1531-8249(200011)48:5<792::AID-ANA14>3.3.CO;2-X; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Han SW, 2006, LUNG CANCER, V51, P283, DOI 10.1016/j.lungcan.2005.10.015; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Kaloustian S, 2007, APOPTOSIS, V12, P1945, DOI 10.1007/s10495-007-0122-4; Kardosh A, 2004, CANCER BIOL THER, V3, P55, DOI 10.4161/cbt.3.1.571; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larsen BT, 2006, EUR J CLIN INVEST, V36, P293, DOI 10.1111/j.1365-2362.2006.01634.x; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; Miyamoto K, 2006, BRAIN, V129, P1984, DOI 10.1093/brain/awl170; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; SASAKI T, 1988, STROKE, V19, P1399, DOI 10.1161/01.STR.19.11.1399; Schwab JM, 2006, CURR OPIN PHARMACOL, V6, P414, DOI 10.1016/j.coph.2006.02.006; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Toscano CD, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r14; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Zhang WR, 2007, J CEREBR BLOOD F MET, V27, P1931, DOI 10.1038/sj.jcbfm.9600494; Zhong H, 2004, INT J CANCER, V112, P585, DOI 10.1002/ijc.20438	48	29	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC	2008	86	16					3605	3612		10.1002/jnr.21809			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	383CO	WOS:000261651900012	18711748	Green Accepted			2022-02-06	
J	Folkersma, H; Breve, JJP; Tilders, FJH; Cherian, L; Robertson, CS; Vandertop, WP				Folkersma, Hedy; Breve, John J. P.; Tilders, Fred J. H.; Cherian, Leela; Robertson, Claudia S.; Vandertop, W. Peter			Cerebral microdialysis of interleukin (IL)-1ss and IL-6: extraction efficiency and production in the acute phase after severe traumatic brain injury in rats	ACTA NEUROCHIRURGICA			English	Article						Brain injury; Cytokines; ELISA; Interleukins; IL-1 beta; IL-6; Microdialysis	TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; CEREBROSPINAL-FLUID; IN-VIVO; HIPPOCAMPAL-NEURONS; TEMPORAL PROFILE; MESSENGER-RNA; HEAD-INJURY; TNF-ALPHA; EXPRESSION	Background As a research tool, cerebral microdialysis might be a useful technique in monitoring the release of cytokines into the extracellular fluid (ECF) following traumatic brain injury (TBI). We established extraction efficiency of Interleukin(IL)-1ss and Interleukin(IL)-6 by an in vitro microdialysis-perfusion system, followed by in vivo determination of the temporal profile of extracellular fluid cytokines after severe TBI in rats. Materials and methods In vitro experiments using a polyether sulfon (PES) microdialysis probe especially developed for recovery of macromolecules such as cytokines, were carried out to establish the extraction efficiency of IL-1ss and IL-6 from artificial cerebrospinal fluid (CSF) with defined IL-1ss and IL-6 concentrations. In vivo experiments in which rats were subjected to TBI or sham and microdialysis samples were collected from the parietal lobe for measurement of cytokines. Findings The extraction efficiency was maximal 6.05% (range, 5.97-6.13%) at 0.5 mu l/min(-1) and decreased at higher flow rates. Both cytokines were detectable in the dialysates. Highest IL-1ss levels were found within 200 min, highest IL-6 concentrations were detected at later intervals (200-400 min). No differences were found between the TBI and control groups. Conclusions Cerebral microdialysis allows measurement of cytokine secretion in the ECF of brain tissue in rats.	[Folkersma, Hedy; Vandertop, W. Peter] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, NL-1008 MB Amsterdam, Netherlands; [Folkersma, Hedy; Vandertop, W. Peter] Vrije Univ Amsterdam, Med Ctr, Neurosurg Ctr Amsterdam, NL-1008 MB Amsterdam, Netherlands; [Breve, John J. P.; Tilders, Fred J. H.] Vrije Univ Amsterdam, Med Ctr, Dept Med Pharmacol, NL-1008 MB Amsterdam, Netherlands; [Cherian, Leela; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Vandertop, WP (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, POB 7057, NL-1008 MB Amsterdam, Netherlands.	hedy.folkersma@vumc.nl; jjp.breve@vumc.nl; fjh.tilders@vumc.nl; claudiar@bcm.tmc.edu; wp.vandertop@vumc.nl	Vandertop, William P./K-9288-2018		Neurosurgery Foundation AZVU	The Neurosurgery Foundation AZVU supported this study. Recombinant rat IL-1ss and IL-6 and reagents for measurements of rat IL-1ss and IL-6 were kindly provided by Dr. Stephan Poole (National Institute for Biological Standards and Control, Potters Bar, UK).	Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; Berger C, 2005, STROKE, V36, pE4, DOI 10.1161/01.STR.0000151328.70519.e9; Cano-Cebrian MJ, 2005, CURR DRUG METAB, V6, P83, DOI 10.2174/1389200053586109; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Friedman WJ, 2001, EXP NEUROL, V168, P23, DOI 10.1006/exnr.2000.7595; Godbout JP, 2004, J NEUROIMMUNOL, V147, P141, DOI 10.1016/j.jneuroim.2003.10.031; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; Jensen SM, 2007, J PHARMACEUT BIOMED, V43, P1751, DOI 10.1016/j.jpba.2006.12.014; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Lenczowski MJP, 1997, AM J PHYSIOL-REG I, V273, pR1870, DOI 10.1152/ajpregu.1997.273.6.R1870; LONNROTH P, 1987, AM J PHYSIOL, V253, pE228, DOI 10.1152/ajpendo.1987.253.2.E228; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; Miyachi T, 2001, NEUROSCI RES, V40, P53, DOI 10.1016/S0168-0102(01)00208-5; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Oprica M, 2003, J CELL MOL MED, V7, P127, DOI 10.1111/j.1582-4934.2003.tb00211.x; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; Peerdeman SM, 2002, J NEUROL, V249, P676, DOI 10.1007/s00415-002-0689-1; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Rees GS, 1999, CYTOKINE, V11, P95, DOI 10.1006/cyto.1998.0408; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; SANTHANAM U, 1989, ARCH BIOCHEM BIOPHYS, V274, P161, DOI 10.1016/0003-9861(89)90427-X; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	52	29	35	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	DEC	2008	150	12					1277	1284		10.1007/s00701-008-0151-y			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	382FF	WOS:000261590000009	19031041	hybrid			2022-02-06	
J	Rapoport, M; Wolf, U; Herrmann, N; Kiss, A; Shammi, P; Reis, M; Phillips, A; Feinstein, A				Rapoport, Mark; Wolf, Uri; Herrmann, Nathan; Kiss, Alex; Shammi, Prathiba; Reis, Marciano; Phillips, Andrea; Feinstein, Anthony			Traumatic brain injury, apolipoprotein E-epsilon 4, and cognition in older adults: A two-year longitudinal study	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	159th Annual Meeting of the American-Psychiatric-Association	MAY 20-25, 2006	Toronto, CANADA	Amer Psychiat Assoc			CLOSED-HEAD INJURY; NEUROBEHAVIORAL CONSEQUENCES; APOE GENOTYPE; FOLLOW-UP; MILD; RECOVERY; PERSPECTIVE; EPSILON-4	Patients with mild-to-moderate traumatic brain injury (TBI) (N= 69) were compared with age-, gender-, and education-matched healthy control group subjects (N=79) on performance of neuropsychological tests at one and 2 years following injury, and informant-rated functional abilities. All subjects were assessed for the presence of the Apolipoprotein E-epsilon 4 (APOE-epsilon 4) allele and rated for "mild cognitive impairment" (MCI) or dementia. Traumatic brain injury patients were no different from the comparison group on measures of cognition or functional impairment. Traumatic brain injury was not associated with higher rates of amnestic mild cognitive impairment or dementia, and APOE-epsilon 4 was not associated with cognition.	[Rapoport, Mark; Wolf, Uri; Herrmann, Nathan; Kiss, Alex; Shammi, Prathiba; Reis, Marciano; Phillips, Andrea; Feinstein, Anthony] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada		Rapoport, M (corresponding author), FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	mark.rapoport@sunnybrook.ca	Rapoport, Mark/AAD-8581-2020				AharonPeretz J, 1997, BRAIN INJURY, V11, P871; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DELIS DC, 1987, CALIFORNIA VERBALL L; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; First M.B., 1996, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Heaton PDRK., 1993, WISCONSIN CARD SORTI; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Mattis S., 1976, GERIATRIC PSYCHIAT H, P77; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; *PSYCH CORP, 1997, WECHSL AD INT SCAL T; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Ritchie K, 1999, INT J GERIATR PSYCH, V14, P695, DOI 10.1002/(SICI)1099-1166(199909)14:9<695::AID-GPS19>3.0.CO;2-R; Rubin D.B., 1987, MULTIPLE IMPUTATION; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	35	29	30	0	11	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2008	20	1					68	73		10.1176/appi.neuropsych.20.1.68			6	Clinical Neurology; Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	264SP	WOS:000253311000007	18305286				2022-02-06	
J	Lu, HX; Li, MJ; Song, TS; Qian, YH; Xiao, XL; Chen, XL; Zhang, PB; Feng, XS; Terence, P; Liu, Y				Lu Haixia; Li Minjie; Song Tusheng; Qian Yihua; Xiao Xinli; Chen Xinlin; Zhang Pengbo; Feng Xinshun; Terence, Parker; Liu Yong			Retrovirus delivered neurotrophin-3 promotes survival, proliferation and neuronal differentiation of human fetal neural stem cells in vitro	BRAIN RESEARCH BULLETIN			English	Article						Neural stem cells; Neurotrophin-3; Retrovirus; Survival; Proliferation; Differentiation	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; PROGENITOR CELLS; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; PRECURSOR CELLS; RETINOIC ACID; AXONAL GROWTH; SCHWANN-CELLS	Poor survival and insufficient neuronal differentiation are the main obstacles to neural stem cell (NSC) transplantation therapy. Genetic modification of NSCs with neurotrophins is considered a promising approach to overcome these difficulties. In this study, the effects on survival, proliferation and neuronal differentiation of human fetal NSCs (hfNSCs) were observed after infection by a neurotrophin-3 (NT-3) recombinant retrovirus. The hfNSCs, from 12-week human fetal brains formed neurospheres, expressed the stem cell marker nestin and differentiated into the three main cell types of the nervous system. NT-3 recombinant retrovirus (Retro-NT-3) infected hfNSCs efficiently expressed NT-3 gene for at least 8 weeks, presented an accelerated proliferation, and therefore produced an increased number of neurospheres and after differentiation in vitro, contained a higher percentage of neuronal cells. Eight weeks after infection, 37.9 +/- 4.2% of hfNSCs in the Retro-NT-3 infection group expressed the neuronal marker, this was significantly higher than the control and mock infection groups. NT-3 transduced hfNSCs also displayed longer protruding neurites compared with other groups. Combined these results demonstrate that NT-3 modification promote the survival/proliferation, neuronal differentiation and growth of neurites of hfNSCs in vitro. This study proposes recombinant retrovirus mediated NT-3 modification may provide a promising means to resolve the poor survival and insufficient neuronal differentiation of NSCs. (c) 2008 Published by Elsevier Inc.	[Lu Haixia; Li Minjie; Xiao Xinli; Chen Xinlin; Zhang Pengbo; Liu Yong] Xian Jiaotong Univ, Sch Med, Inst Neurobiol, Xian 710061, Peoples R China; [Lu Haixia] Xian Jiaotong Univ, Sch Med, Affiliated Hosp 2, Dept Obstet & Gynecol, Xian 710004, Peoples R China; [Song Tusheng] Xian Jiaotong Univ, Sch Med, Dept Genet & Mol Biol, Xian 710061, Peoples R China; [Qian Yihua] Xian Jiaotong Univ, Sch Med, Dept Anat & Histoembryol, Xian 710061, Peoples R China; [Feng Xinshun] Xian Jiaotong Univ, Sch Med, Affiliated Hosp 1, Kidney Transplantat Ctr, Xian 710061, Peoples R China; [Terence, Parker] Univ Nottingham, Sch Biomed Sci, QMC, Dept Human Anat & Cell Biol,Inst Neurosci, Nottingham NG7 2UH, England		Liu, Y (corresponding author), Xian Jiaotong Univ, Sch Med, Inst Neurobiol, Xian 710061, Peoples R China.	lhaixia71@hotmail.com; limin_71@163.com; tusheng@mail.xjtu.edu.cn; qianyh38@mail.xjtu.edu.cn; xxli-2001@163.com; chenxl@mail.xjtu.edu.cn; zhpbo@163.com; xinshunf@163.com; terry.parker@nottingham.ac.uk; liuy5599@mail.xjtu.edu.cn			Natural Science Foundation of Shaanxi ProvinceNatural Science Foundation of Shaanxi Province [2001SM63]; Xi'an Jiaotong University for Stem Cell ResearchXi'an Jiaotong University	This work was supported partly by grants from Natural Science Foundation of Shaanxi Province (2001SM63) and Xi'an Jiaotong University for Stem Cell Research. The authors would like to thank Prof. Guangxiao Yang and Prof. Quanying Wang at Huaguang Biothechnol Co. Ltd., Xi'an for their excellent technical assistance. The authors are also grateful to Dr H. Levis and Dr J. Rimmer from University of Nottingham for their expert help in the English editing.	Bithell A, 2005, CLIN SCI, V108, P13, DOI 10.1042/CS20040276; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Bodmer D, 2002, LARYNGOSCOPE, V112, P2057, DOI 10.1097/00005537-200211000-00028; Caldwell MA, 2001, NAT BIOTECHNOL, V19, P475, DOI 10.1038/88158; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Dutton R, 1999, J NEUROSCI, V19, P2601; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Grider MH, 2005, J NEUROSCI RES, V82, P404, DOI 10.1002/jnr.20635; Grill R, 1997, J NEUROSCI, V17, P5560; Grondin R, 2002, BRAIN, V125, P2191, DOI 10.1093/brain/awf234; Guo JS, 2007, SPINAL CORD, V45, P15, DOI 10.1038/sj.sc.3101943; Hapner SJ, 2006, DEV BIOL, V297, P182, DOI 10.1016/j.ydbio.2006.05.007; Himes BT, 2001, J NEUROSCI RES, V65, P549, DOI 10.1002/jnr.1185; Ito H, 2003, J NEUROSCI RES, V71, P648, DOI 10.1002/jnr.10532; Kamei N, 2007, SPINE, V32, P1272, DOI 10.1097/BRS.0b013e318059afab; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kim S, 2004, CELL MOL NEUROBIOL, V24, P343, DOI 10.1023/B:CEMN.0000022767.74774.38; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lepore AC, 2006, NEUROSCIENCE, V139, P513, DOI 10.1016/j.neuroscience.2005.12.043; Lepore AC, 2004, NEURON GLIA BIOL, V1, P113, DOI 10.1017/S1740925X04000213; Lim MS, 2007, BIOCHEM BIOPH RES CO, V357, P903, DOI 10.1016/j.bbrc.2007.04.045; Liu Y, 1999, EXP NEUROL, V158, P9, DOI 10.1006/exnr.1999.7079; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Park KI, 2006, EXP NEUROL, V199, P179, DOI 10.1016/j.expneurol.2006.03.016; Pyle AD, 2006, NAT BIOTECHNOL, V24, P344, DOI 10.1038/nbt1189; Rothstein JD, 2004, NAT BIOTECHNOL, V22, P283, DOI 10.1038/nbt0304-283; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Sgubin D, 2007, J NEUROSCI RES, V85, P1647, DOI 10.1002/jnr.21303; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Ubiali F, 2007, INT IMMUNOL, V19, P1063, DOI 10.1093/intimm/dxm079; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wada K, 2003, STROKE, V34, P2722, DOI 10.1161/01.STR.0000094421.61917.71; Wang JM, 2007, EXP NEUROL, V203, P123, DOI 10.1016/j.expneurol.2006.07.028; Wang Y, 2007, J NEUROIMMUNE PHARM, V2, P243, DOI 10.1007/s11481-007-9074-2; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Yan J, 2004, J COMP NEUROL, V480, P101, DOI 10.1002/cne.20344; Zhang LY, 2007, CELL TRANSPLANT, V16, P475, DOI 10.3727/000000007783464902; Zhang XB, 2007, J NEUROTRAUM, V24, P1863, DOI 10.1089/neu.2007.0334; Zhao LX, 2004, EXP NEUROL, V190, P396, DOI 10.1016/j.expneurol.2004.06.025; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	53	29	34	0	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	OCT 22	2008	77	4					158	164		10.1016/j.brainresbull.2008.02.037			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	368LW	WOS:000260623600002	19875351				2022-02-06	
J	Zetterberg, H; Jacobsson, J; Rosengren, L; Blennow, K; Andersen, PM				Zetterberg, Henrik; Jacobsson, Johan; Rosengren, Lars; Blennow, Kaj; Andersen, Peter M.			Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						amyotrophic lateral sclerosis; SOD1; apolipoprotein E; age at onset	CUZN-SUPEROXIDE-DISMUTASE; TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; EPSILON-4 ALLELE; GENOTYPE; MUTATIONS; DEMENTIA; FAMILIES; GENE	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative syndrome with familial and sporadic forms. We conducted a study including 60 sporadic and 19 familial ALS patients, 206 reference patients with other neurological disorders and 1265 neurologically healthy controls to assess the Alzheimer-associated apolipoprotein E (APOE) epsilon 4 gene variant as a possible risk factor for ALS. While no major influence of APOE FA on disease risk was detected, a gene dose-dependent effect with lower age at onset of sporadic ALS in epsilon 4 carriers was found (p=0.027). These data support APOE M as a subordinate contributing factor in ALS. (c) 2008 Elsevier B.V. All rights reserved.	[Zetterberg, Henrik] Univ Gothenburg, Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Psychiat & Neurochem, SE-43180 Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, SE-43180 Molndal, Sweden; [Jacobsson, Johan; Andersen, Peter M.] Umea Univ Hosp, Dept Neurol, S-90185 Umea, Sweden; [Rosengren, Lars] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Neurol, SE-43180 Molndal, Sweden		Zetterberg, H (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Psychiat & Neurochem, SE-43180 Molndal, Sweden.	henrik.zetterberg@clinchem.gu.se		Rosengren, Lars/0000-0003-0505-8896	Kempe Foundation; Swedish Brain Research Foundation; Hallstens Research Foundation; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Council for Working Life and Social researchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); Swedish Medical Society; Bjorklund Foundation for ALS Research; Alzheimer Foundation; Swedish Association for the Neurologically Disabled	We are indebted to the patients for their participation in this project. We thank Mona Seibt Palmer for the excellent technical assistance. This study was funded by grants from the Kempe Foundation, the Swedish Brain Research Foundation, the Hallstens Research Foundation, the Swedish Research Council, the Swedish Council for Working Life and Social research, the Swedish Medical Society and the Bjorklund Foundation for ALS Research, the Alzheimer Foundation, and the Swedish Association for the Neurologically Disabled.	Altman D.G., 1990, PRACTICAL STAT MED R; Andersen PM, 2006, CURR NEUROL NEUROSCI, V6, P37, DOI 10.1007/s11910-996-0008-9; Andersen PM, 2005, EUR J NEUROL, V12, P921, DOI 10.1111/j.1468-1331.2005.01351.x; ANDERSEN PM, 1995, NAT GENET, V10, P61, DOI 10.1038/ng0595-61; Bedlack RS, 2000, ARCH NEUROL-CHICAGO, V57, P1561, DOI 10.1001/archneur.57.11.1561; Blennow K, 2000, J NEURAL TRANSM, V107, P1065, DOI 10.1007/s007020070052; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; FARRER LA, 1995, EXP NEUROL, V136, P162, DOI 10.1006/exnr.1995.1093; Greenway MJ, 2006, NAT GENET, V38, P411, DOI 10.1038/ng1742; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Li YJ, 2004, NEUROGENETICS, V5, P209, DOI 10.1007/s10048-004-0193-0; Moulard B, 1996, J NEUROL SCI, V139, P34, DOI 10.1016/0022-510X(96)00085-8; MUI S, 1995, ANN NEUROL, V38, P460, DOI 10.1002/ana.410380318; PERICAKVANCE MA, 1993, GENET EPIDEMIOL, V10, P361, DOI 10.1002/gepi.1370100605; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Prince JA, 2004, NEUROLOGY, V62, P2116, DOI 10.1212/01.WNL.0000128088.08695.05; Siddique T, 1998, NEUROGENETICS, V1, P213, DOI 10.1007/s100480050031; VAN BROECKHOVEN C, 1994, NEUROSCI LETT, V169, P179, DOI 10.1016/0304-3940(94)90385-9; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; Zareparsi S, 2002, AM J MED GENET, V107, P156, DOI 10.1002/ajmg.10111; Zetterberg H, 2007, EUR J NEUROL, V14, P1329, DOI 10.1111/j.1468-1331.2007.01972.x; ZETTERBERG M, 2007, AM J MED GENE B 1228	25	29	29	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	OCT 15	2008	273	1-2					67	69		10.1016/j.jns.2008.06.025			3	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	356CL	WOS:000259756200013	18656208				2022-02-06	
J	Vavilala, MS; Tontisirin, N; Udomphorn, Y; Armstead, W; Zimmerman, JJ; Chesnut, R; Lam, AM				Vavilala, Monica S.; Tontisirin, Nuj; Udomphorn, Yuthana; Armstead, William; Zimmerman, Jerry J.; Chesnut, Randall; Lam, Arthur M.			Hemispheric differences in cerebral autoregulation in children with moderate and severe traumatic brain injury	NEUROCRITICAL CARE			English	Article						pediatric traumatic brain injury; cerebral autoregulation	BLOOD-FLOW; ASYMMETRY; HEMODYNAMICS	Introduction To examine hemispheric differences in cerebral autoregulation in children with traumatic brain injury (TBI). After IRB approval and consent, subjects underwent static cerebral autoregulation testing during the first 9 days after PICU admission. Cerebral autoregulation was quantified using the autoregulatory index (ARI). Results Forty-two (27 M:15 F) children (10 +/- 5 years) with TBI and admission Glasgow coma scale score (5 +/- 2) were enrolled. Seven (54%) of the 13 children with focal TBI and 8 (28%) of 29 children with diffuse TBI had impairment or absence of cerebral autoregulation of atleast one hemisphere. In patients with isolated focal TBI, ARI was lower (0.40 +/- 0.40 vs. 0.67 +/- 0.40; P = 0.03) in the side of TBI than in the unaffected hemisphere, but cerebral autoregulation was often impaired on the side without TBI or shift (5/13) on head CT. There was no difference in ARI between hemispheres in children with diffuse TBI, with or without superimposed focal lesions (P = 0.17). Patients with bilateral intact cerebral autoregulation tended to have higher 6 month Glasgow Outcome Score (GOS) than patients with either unilateral or bilateral cerebral autoregulation impairment (GOS 4.0 +/- 0.60 vs. 3.6 +/- 0.80; P = 0.08). Conclusions Hemispheric differences in cerebral autoregulation were common in children with isolated focal TBI. Absence of TBI on CT was not always associated with intact cerebral autoregulation. Patients with bilaterally intact cerebral autoregulation tended to have better outcomes.	[Vavilala, Monica S.; Tontisirin, Nuj; Udomphorn, Yuthana] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Vavilala, Monica S.; Zimmerman, Jerry J.] Univ Washington, Harborview Med Ctr, Dept Pediat, Seattle, WA 98104 USA; [Vavilala, Monica S.; Chesnut, Randall; Lam, Arthur M.] Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Seattle, WA 98104 USA; [Armstead, William] Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA		Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu		Chesnut, Randall/0000-0001-6377-3666	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632-04]	Thanks to Ms. Domonique Calhoun. This research was supported by National Institute of Child Health and Human Development Award K23HD044632-04.	ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Bakker SLM, 2004, NEUROEPIDEMIOLOGY, V23, P178, DOI 10.1159/000078503; Blaha M, 2003, J CLIN NEUROSCI, V10, P195, DOI 10.1016/S0967-5868(02)00126-1; Bode H., 1988, PEDIAT APPL TRANSCRA; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Cremer OL, 2004, ANESTHESIOLOGY, V100, P1101, DOI 10.1097/00000542-200405000-00011; HANBRICH C, 2004, STROKE, V35, P848; Hilz MJ, 2002, J NEUROL NEUROSUR PS, V72, P657, DOI 10.1136/jnnp.72.5.657; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Kumar A, 2005, J NEUROL NEUROSUR PS, V76, P1570, DOI 10.1136/jnnp.2004.059493; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; Lang EW, 2003, J CLIN NEUROSCI, V10, P670, DOI 10.1016/S0967-5868(03)00197-8; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; Novak V, 2003, NEUROLOGY, V60, P1657, DOI 10.1212/01.WNL.0000068023.14587.06; Park CW, 2003, STROKE, V34, P34, DOI 10.1161/01.STR.0000047122.42591.B3; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Rosengarten B, 2002, CEREBROVASC DIS, V13, P21, DOI 10.1159/000047741; Schmidt EA, 2002, ACT NEUR S, V81, P133; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TOMURA N, 1993, COMPUT MED IMAG GRAP, V17, P443, DOI 10.1016/0895-6111(93)90060-Z; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; VAVILALA MS, 2004, PEDIATR CRIT CARE ME, V5, P298; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X	27	29	29	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2008	9	1					45	54		10.1007/s12028-007-9036-9			10	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	340PM	WOS:000258657500009	18084727				2022-02-06	
J	Fujiki, M; Kubo, T; Kamida, T; Sugita, K; Hikawa, T; Abe, T; Ishii, K; Kobayashi, H				Fujiki, Minoru; Kubo, Takeshi; Kamida, Tohru; Sugita, Kenji; Hikawa, Takamitsu; Abe, Tatsuya; Ishii, Keisuke; Kobayashi, Hidenori			Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						donepezil; mild traumatic brain injury; concussion; neuronal death; memory impairment; neuroprotection	HYDROCHLORIDE E2020; GENE-TRANSCRIPTION; NEUROTOXICITY; EXPRESSION; INHIBITORS	In this study we evaluated the effect of donepezil on the neurodegeneration and behavioral impairments induced by mild traumatic brain injury (MTBI). Donepezil is an acetylcholinesterase inhibitor that is used to treat Alzheimer's disease. Donepezil was given orally to rats subjected to MTBI. Treatment with a single oral dose of donepezil (12 mg/kg) immediately after injury significantly attenuated MTBI-induced neuronal death and cognitive impairment as measured by preservation of neurons in the CA1 region of the hippocampus and a water maze test respectively. However, these neuroprotective effects were prevented by concomitant injection of mecamylamine, a nicotinic acetylcholine-receptor (nAChR) antagonist, indicating that protection is mediated by nAChR activation. (C) 2007 Elsevier Ltd. All rights reserved.	[Fujiki, Minoru; Kubo, Takeshi; Kamida, Tohru; Sugita, Kenji; Hikawa, Takamitsu; Abe, Tatsuya; Ishii, Keisuke; Kobayashi, Hidenori] Oita Univ, Sch Med, Dept Neurosurg, Oita 87011, Japan		Fujiki, M (corresponding author), Oita Univ, Sch Med, Dept Neurosurg, 1-1 Idaigaoka, Hasama, Oita 8795593, Japan.	fujiki@med.oita-u.ac.jp					Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; Fujiki M, 2005, BRAIN RES, V1043, P236, DOI 10.1016/j.brainres.2005.02.063; Fujiki M, 2003, BRAIN RES, V991, P254, DOI 10.1016/S0006-8993(03)03540-6; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kosasa T, 1999, EUR J PHARMACOL, V380, P101, DOI 10.1016/S0014-2999(99)00545-2; Kosasa T, 2000, EUR J PHARMACOL, V389, P173, DOI 10.1016/S0014-2999(99)00876-6; Meunier J, 2006, J PHARMACOL EXP THER, V317, P1307, DOI 10.1124/jpet.106.101527; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; Ogura H, 2000, METHOD FIND EXP CLIN, V22, P609, DOI 10.1358/mf.2000.22.8.701373; STEWARD O, 1991, P NATL ACAD SCI USA, V88, P6819, DOI 10.1073/pnas.88.15.6819; Takada Y, 2003, J PHARMACOL EXP THER, V306, P772, DOI 10.1124/jpet.103.050104	16	29	30	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	JUL	2008	15	7					791	796		10.1016/j.jocn.2007.07.002			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	315DD	WOS:000256857200011	18407501				2022-02-06	
J	Schick, DM; Molloy, MG; Wiley, JP				Schick, D. M.; Molloy, M. G.; Wiley, J. P.			Injuries during the 2006 Women's Rugby World Cup	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PERFORMANCE PROJECT; UNION FOOTBALL; CLUB RUGBY; PLAYERS; EPIDEMIOLOGY; SURVEILLANCE; HEADGEAR; COHORT; FEMALE; SEASON	Background: Although there have been reports of injury rates in men's World Cup rugby, there has been no research into injury rates in women's international rugby. Objective: To determine the rate of injury at the 2006 Women's Rugby World Cup (WRWC). Methods: All participating teams in the 2006 WRWC were enrolled prospectively in this study. Healthcare workers for each team collected data on training and game exposure and information on injuries. Results: 55 players (16%) sustained at least one injury (10.0/1000 player hours); 4 players (1%) sustained two injuries. 45 injuries occurred during games (37.5/1000 player hours) and 14 injuries occurred during practice (12.5/1000 player hours), a statistically significant difference (RR = 12.5, 95% CI 6.9 to 22.8). The injury rate was 39.3/1000 player hours for the forwards and 42.2/1000 player hours for the backs (RR = 1.3, 95% CI 0.7 to 2.3). The front row had the highest injury rate (62.5/1000 player hours). 63.6% of injuries occurred during the tackle. Most injuries occurred to the neck, knee and head/face. The majority of injuries were sprains, muscle injuries and contusions. There were five fractures during the event and four reported concussions. Conclusion: Female players sustained a considerable rate of injury during the 2006 WRWC. Backs had a slightly higher rate of injury than forwards, but the players most often injured were in the front row. The neck/cervical spine and knee were the most commonly injured regions, followed by the head and face. This is the first study to examine injury rates in female rugby players at a World Cup and reports valuable data in this population.	[Wiley, J. P.] Univ Calgary, Sport Med Ctr, Calgary, AB T2N 1N4, Canada; [Schick, D. M.] Trinity Western Univ, Langley, BC, Canada; [Molloy, M. G.] Int Rugby Board, Dublin, Ireland		Wiley, JP (corresponding author), Univ Calgary, Sport Med Ctr, 2500 Univ Dr, Calgary, AB T2N 1N4, Canada.	wiley@ucalgary.ca					Alsop J C, 2000, J Sci Med Sport, V3, P97, DOI 10.1016/S1440-2440(00)80072-9; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Carson JD, 1999, CLIN J SPORT MED, V9, P75, DOI 10.1097/00042752-199904000-00006; CLARK DR, 1990, S AFR MED J, V77, P559; Comstock R, 2002, PATTERNS INJURY FEMA; Comstock RD, 2005, J SCI MED SPORT, V8, P101, DOI 10.1016/S1440-2440(05)80030-1; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; GERRARD DF, 1994, BRIT J SPORT MED, V28, P229, DOI 10.1136/bjsm.28.4.229; HAVKINS SB, 1986, PHYSICIAN SPORTSMED, V14, P111, DOI 10.1080/00913847.1986.11709127; *INT RUGB BOARD, 2006, WOM RUGB WORLD CUP 2; Jakoet I, 1998, S AFR MED J, V88, P45; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Lee AJ, 2000, J SPORT SCI, V18, P91, DOI 10.1080/026404100365153; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; LEWIS ER, 1996, SPORTS EXERC INJURY, V2, P186; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; NATHAN M, 1983, S AFR MED J, V64, P132; Rotem T, 2001, INT SPORTMED J, V2, P1; ROUX CE, 1987, S AFR MED J, V71, P307; Stewart DR, 2004, BRIT J SPORT MED, V38, P457, DOI 10.1136/bjsm.2003.004861; Upton PAH, 1996, S AFR MED J, V86, P531; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Wekesa M, 1996, BRIT J SPORT MED, V30, P61, DOI 10.1136/bjsm.30.1.61; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9	31	29	29	2	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	JUN	2008	42	6					447	451		10.1136/bjsm.2008.046672			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	310HD	WOS:000256518600010	18424486				2022-02-06	
J	Zhang, Z; Fauser, U; Schluesener, HJ				Zhang, Z.; Fauser, U.; Schluesener, H. J.			Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						dexamethasone; FTY720; interleukin-16; microglia; macrophages; traumatic brain injury	SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HEAD-INJURY; ACTIVATED MICROGLIA/MACROPHAGES; INFLAMMATORY CYTOKINES; TIRILAZAD MESYLATE; CEREBRAL-ISCHEMIA; MICROGLIAL CELLS; HUMAN MONOCYTES; NERVOUS-SYSTEM	Aims: Interleukin-16 (IL16) is an immunomodulatory cytokine, which induces lymphocyte migration, expression of proinflammatory IL1 beta, IL6 and tumour necrosis factor-alpha, and modulates apoptosis. IL16 expression has been observed in several central nervous system diseases and may play a role in promoting inflammatory responses. Inflammation contributes considerably to secondary injury following traumatic brain injury (TBI). The aim of this study was to investigate early IL16 expression following experimental TBI and the effects of dexamethasone and FTY720 on early expression of IL16 in TBI rats. Methods: Rat TBI was induced using an open-skull weight-drop model. IL16 expression was studied by immunohistochemistry. TBI rats received an intraperitoneal injection of dexamethasone (1 mg/kg in 1 ml saline), FTY720 (1 mg/kg in 1 ml saline) or saline (1 ml) on Day 0 and Day 2 immediately after surgery. Results: Significant up-regulation of IL16 was seen as early as 24 h post TBI. Double-staining experiments, together with morphological classification, revealed a multicellular origin of IL16, including activated microglia/macrophages (about 85%), astrocytes (about 8%), neurones (about 5%) and granulocytes. Following peripheral administration of dexamethasone and FTY720, attenuated numbers of IL16(+) cells were observed on Days 1 and 2 but not on Day 4 post TBI for dexamethasone and on Day 4 but not earlier for FTY720 respectively. Conclusions: Our observations reveal that dexamethasone and FTY720 have different but complementary effects on reduction of early IL16 expression following TBI.	[Zhang, Z.; Fauser, U.; Schluesener, H. J.] Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany		Zhang, Z (corresponding author), Univ Tubingen, Inst Brain Res, Calwer St 3, D-72076 Tubingen, Germany.	zhangzhiren@yahoo.com	Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835			ADACHI K, 1995, BIOORG MED CHEM LETT, V5, P853, DOI 10.1016/0960-894X(95)00127-F; Arima M, 1999, AM J RESP CELL MOL, V21, P684, DOI 10.1165/ajrcmb.21.6.3671; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Chiba K, 2006, CELL MOL IMMUNOL, V3, P11; Cruikshank WW, 2000, J LEUKOCYTE BIOL, V67, P757, DOI 10.1002/jlb.67.6.757; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Deng JM, 2006, CHINESE MED J-PEKING, V119, P1017, DOI 10.1097/00029330-200606020-00009; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gahm C, 2005, ACTA NEUROCHIR, V147, P1071, DOI 10.1007/s00701-005-0590-7; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Guo LH, 2004, J NEUROIMMUNOL, V146, P39, DOI 10.1016/j.jneuroim.2003.09.017; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; Holmin, 1996, ACTA NEUROCHIR, V138, P418, DOI 10.1007/BF01420304; Kaneider NC, 2004, FASEB J, V18, P1309, DOI 10.1096/fj.03-1050fje; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Klimiuk PA, 1999, J IMMUNOL, V162, P4293; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569, DOI 10.1016/S0091-6749(97)70152-0; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liebrich M, 2007, ARCH IMMUNOL THER EX, V55, P41, DOI 10.1007/s00005-007-0003-0; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mathy NL, 2000, IMMUNOLOGY, V100, P63, DOI 10.1046/j.1365-2567.2000.00997.x; MEINIG G, 1990, ACT NEUR S, V51, P100; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mueller CA, 2006, J NEUROSURG-SPINE, V4, P233, DOI 10.3171/spi.2006.4.3.233; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Rausch M, 2004, J MAGN RESON IMAGING, V20, P16, DOI 10.1002/jmri.20057; Sauerland S, 2004, LANCET, V364, P1291, DOI 10.1016/S0140-6736(04)17202-4; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schwab JM, 2001, J NEUROIMMUNOL, V114, P232, DOI 10.1016/S0165-5728(00)00433-1; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; Skundric DS, 2005, J NEUROSCI RES, V79, P680, DOI 10.1002/jnr.20377; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Webb M, 2004, J NEUROIMMUNOL, V153, P108, DOI 10.1016/j.jneuroim.2004.04.015; Yopp AC, 2006, CLIN TRANSPLANT, V20, P788, DOI 10.1111/j.1399-0012.2006.00570.x; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027; ZHANG Z, J CELL MOL MED, V11, P307; Zhang ZY, 2007, ACTA NEUROPATHOL, V113, P675, DOI 10.1007/s00401-007-0195-8	46	29	30	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	JUN	2008	34	3					330	339		10.1111/j.1365-2990.2007.00893.x			10	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	292SU	WOS:000255287200007	17983426				2022-02-06	
J	Moseley, AM; Hassett, LM; Leung, J; Clare, JS; Herbert, RD; Harvey, LA				Moseley, Anne M.; Hassett, Leanne M.; Leung, Joan; Clare, Jennifer S.; Herbert, Robert D.; Harvey, Lisa A.			Serial casting versus positioning for the treatment of elbow contractures in adults with traumatic brain injury: a randomized controlled trial	CLINICAL REHABILITATION			English	Article							SPINAL-CORD INJURIES; PASSIVE ANKLE DORSIFLEXION; SOLEUS MUSCLE; STRESS-RELAXATION; CONNECTIVE-TISSUE; PROLONGED STRETCH; LOW-LOAD; IMMOBILIZATION; MOBILITY; RABBIT	Objective: To compare the effects of serial casting with positioning for 1 hour per day for the treatment of elbow flexion contracture in adults with traumatic brain injury. Design: Pragmatic randomized controlled trial with concealed allocation and assessor blinding. Setting: Four brain injury rehabilitation units. Subjects: Twenty-six adults with elbow flexion contracture after traumatic brain injury participating in multidisciplinary inpatient rehabilitation. Interventions: Subjects were randomized to receive either serial casting or positioning for two weeks. In the subsequent four weeks subjects could be positioned for up to 1 hour/day. Main measures: Torque-controlled passive elbow extension was measured at baseline, post-intervention (two weeks), post-intervention plus one day, and at follow-up (four weeks post-intervention). Results: All 26 subjects completed the study. Post-intervention, serial casting reduced contracture by an average of 22 degrees (95% confidence interval (0) 13 to 31; P < 0.001) compared with the positioning group. One day later this effect had decreased to 11 degrees (95% CI 0 to 21 degrees; P = 0.052). The effect had almost completely disappeared at the four-week follow-up (mean 2 degrees, 95% CI - 13 to 17; P = 0.782). Conclusions: Serial casting induces transient increases in range of motion. These effects are not maintained.	[Moseley, Anne M.] Univ Sydney, Ctr Evidence Based Physiotherapy, Lidcombe, NSW 1825, Australia; [Hassett, Leanne M.] Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Leung, Joan] Royal Rehabil Ctr, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Clare, Jennifer S.] Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Herbert, Robert D.] Univ Sydney, Ctr Evidence Based Physiotherapy, Sydney, NSW 2006, Australia; [Harvey, Lisa A.] Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Moseley, AM (corresponding author), Univ Sydney, Ctr Evidence Based Physiotherapy, POB 170, Lidcombe, NSW 1825, Australia.	a.moseley@usyd.edu.au	Herbert, Rob/E-9442-2012; Leung, Joan/AAC-8623-2019	Herbert, Rob/0000-0003-4188-9195; Leung, Joan/0000-0003-0888-558X; Harvey, Lisa A/0000-0002-4365-0236; Hassett, Leanne/0000-0002-3546-1822			AKESON WH, 1974, CONNECT TISSUE RES, V2, P315, DOI 10.3109/03008207409152261; Ben M, 2005, AUST J PHYSIOTHER, V51, P251, DOI 10.1016/S0004-9514(05)70006-4; Beurskens AJHM, 1996, PAIN, V65, P71, DOI 10.1016/0304-3959(95)00149-2; BOHANNON RW, 1985, PHYS THER, V65, P1676, DOI 10.1093/ptj/65.11.1676; Boyd RN, 2001, UPPER MOTOR NEURONE SYNDROME AND SPASTICITY, P96; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; Desrosiers J, 1993, CAN J OCCUP THER, V60, P9, DOI DOI 10.1177/000841749306000104; Duong B, 2001, CLIN BIOMECH, V16, P601, DOI 10.1016/S0268-0033(01)00043-2; Folpp H, 2006, AUST J PHYSIOTHER, V52, P45, DOI 10.1016/S0004-9514(06)70061-7; Glanz M, 1996, ARCH PHYS MED REHAB, V77, P549, DOI 10.1016/S0003-9993(96)90293-2; Glasgow Celeste, 2003, J Hand Ther, V16, P207, DOI 10.1016/S0894-1130(03)00036-X; Harvey LA, 2000, ARCH PHYS MED REHAB, V81, P1340, DOI 10.1053/apmr.2000.9168; Harvey LA, 2003, AUST J PHYSIOTHER, V49, P176, DOI 10.1016/S0004-9514(14)60237-3; Harvey Lisa, 2002, Physiother Res Int, V7, P1, DOI 10.1002/pri.236; HERBERT RD, 1993, J ORTHOPAED RES, V11, P358, DOI 10.1002/jor.1100110307; Herbert RD, 1997, EUR J APPL PHYSIOL, V76, P472, DOI 10.1007/s004210050277; HERBERT RD, 2005, SCI BASED REHABILITA, P107; HILL J, 1994, AM J OCCUP THER, V48, P219, DOI 10.5014/ajot.48.3.219; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; HOWELL DC, RESAMPLING PROCEDURE; Hyde SA, 2000, NEUROMUSCULAR DISORD, V10, P257, DOI 10.1016/S0960-8966(99)00135-2; LIGHT KE, 1984, PHYS THER, V64, P330, DOI 10.1093/ptj/64.3.330; Magnusson SP, 1996, SCAND J MED SCI SPOR, V6, P323; Mortenson PA, 2003, PHYS THER, V83, P648, DOI 10.1093/ptj/83.7.648; Moseley A, 1991, Aust J Physiother, V37, P175, DOI 10.1016/S0004-9514(14)60540-7; Moseley AM, 1997, PHYS THER, V77, P240, DOI 10.1093/ptj/77.3.240; Moseley AM, 2005, ARCH PHYS MED REHAB, V86, P1118, DOI 10.1016/j.apmr.2004.11.017; Moseley AM, 2003, J HEAD TRAUMA REHAB, V18, P526, DOI 10.1097/00001199-200311000-00006; STEFFEN TM, 1995, PHYS THER, V75, P886, DOI 10.1093/ptj/75.10.886; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; WILLIAMS PE, 1984, J ANAT, V138, P343; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93	33	29	29	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	MAY	2008	22	5					406	417		10.1177/0269215507083795			12	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	304TN	WOS:000256132100003	18441037				2022-02-06	
J	Loder, RT				Loder, Randall T.			The demographics of playground equipment injuries in children	JOURNAL OF PEDIATRIC SURGERY			English	Article						playground equipment; injuries; children	SEVERITY; SURFACES; SAFETY	Background/Purpose: There have been many different studies of injuries owing to playground equipment but none that have looked in detail using large nationwide databases. It was the purpose of this Study to investigate injuries owing to playground equipment using the National Electronic Injury Surveillance System (NEISS) database and further understand their demographics. Methods: Detailed NEISS injury data from 2002 through 2004 for slides, monkey bars, and swings were analyzed. Appropriate statistical analyses were performed; because of the many analyses on this large data set, P < .01 was considered statistically significant. Results: There were 22728 emergency department visits owing to playground equipment injuries recorded by NEISS between 2002 and 2004; 83.9% were owing to monkey bars, swings, and slides, and the 5 most common diagnoses were fractures (39.3%), contusions/abrasions (20.6%), lacerations (16.6%), strains/sprains (9.9%), and traumatic brain injuries (TBI) (8.5%). There were 9487 boys (54.3%) and 7995 girls (45.7%). The average age was 6.5 +/- 3.0 years. The injuries occurred at school in 38.9%; at a recreation/sporting facility, in 35.5%; and at home, in 25.6%. Most were treated and released (94.4%). Amerindian children were 2 times more likely than blacks to be admitted; compared to contusions, fractures were 9.8 times, and TBIs, 4.7 times more likely to be admitted. Injuries on monkey bars were 1.2 times more likely to be admitted than those on swings or slides. Fractures were 1.9 times more likely to occur on a monkey bar compared with swings or slides. Traumatic brain injuries were 1.4 times more likely to occur on a swing compared to slides or monkey bars. Conclusion: Swings at school are the most common mechanism of injury for TBIs, and the seasonal data would suggest that increased supervision of children using swings during school hours might reduce the occurrence of TBIs. Monkey bars are the most common cause of fracture, and fracture is the most common cause of admission. Prevention strategies to reduce the number of fractures should be directed at monkey bar equipment and landing surfaces. The trend in playground equipment injury also indicates that monkey bars are problematic because the number of injuries per year per capita owing to monkey bars is stable, whereas those from swings and slides is decreasing. (c) 2008 Elsevier Inc. All rights reserved.	[Loder, Randall T.] James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA; [Loder, Randall T.] Indiana Univ, Dept Orthopaed Surg, Indiana Sch Med, Indianapolis, IN 46202 USA		Loder, RT (corresponding author), James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA.	rloder@iupui.edu					BINGHAM C, 1982, CHRONOBIOLOGIA, V9, P397; BOND MT, 1993, AM J PUBLIC HEALTH, V83, P731, DOI 10.2105/AJPH.83.5.731; Eveleth PB, 1990, WORLDWIDE VARIATION; Fiissel D, 2005, INJURY PREV, V11, P337, DOI 10.1136/ip.2005.009167; Gunatilaka AH, 2004, INJURY PREV, V10, P174, DOI 10.1136/ip.2003.004010; Howard AW, 2005, CAN MED ASSOC J, V24, P11; ILLINGWORTH C, 1975, BRIT MED J, V4, P332, DOI 10.1136/bmj.4.5992.332; Laforest S, 2001, Inj Prev, V7, P35, DOI 10.1136/ip.7.1.35; Laforest S, 2000, J EPIDEMIOL COMMUN H, V54, P475, DOI 10.1136/jech.54.6.475; LEWIS LM, 1993, J TRAUMA, V35, P932, DOI 10.1097/00005373-199312000-00020; Mace SE, 2001, ANN EMERG MED, V38, P405, DOI 10.1067/mem.2001.115882; Mack M G, 1997, Inj Prev, V3, P100, DOI 10.1136/ip.3.2.100; Mack M G, 2000, Inj Prev, V6, P141, DOI 10.1136/ip.6.2.141; MAYR J, 1995, ACTA PAEDIATR, V84, P573, DOI 10.1111/j.1651-2227.1995.tb13698.x; Mott A, 1997, LANCET, V349, P1874, DOI 10.1016/S0140-6736(96)10343-3; Norton C, 2004, ARCH DIS CHILD, V89, P103, DOI 10.1136/adc.2002.013045; Petridou E, 2002, ACTA PAEDIATR, V91, P691, DOI 10.1080/080352502760069133; Phelan KJ, 2001, AMBUL PEDIATR, V1, P227, DOI 10.1367/1539-4409(2001)001<0227:TAPOPI>2.0.CO;2; Rivara F P, 1998, Adv Pediatr, V45, P37; Roseveare C A, 1999, Inj Prev, V5, P124; SACKS JJ, 1992, AM J PUBLIC HEALTH, V82, P429, DOI 10.2105/AJPH.82.3.429; Sherker Shauna, 2005, Int J Inj Contr Saf Promot, V12, P63, DOI 10.1080/17457300512331339184; SOSIN DM, 1993, AM J PUBLIC HEALTH, V83, P733, DOI 10.2105/AJPH.83.5.733; Waltzman ML, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.5.e58; Witheaneachi D, 1997, AUST NZ J PUBL HEAL, V21, P577, DOI 10.1111/j.1467-842X.1997.tb01758.x	25	29	29	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	APR	2008	43	4					691	699		10.1016/j.jpedsurg.2007.12.061			9	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics; Surgery	291FY	WOS:000255180500017	18405717				2022-02-06	
J	Hahnel, S; Stippich, C; Weber, I; Darm, H; Schill, T; Jost, J; Friedmann, B; Heiland, S; Blatow, M; Meyding-Lamade, U				Hahnel, S.; Stippich, C.; Weber, I.; Darm, H.; Schill, T.; Jost, J.; Friedmann, B.; Heiland, S.; Blatow, M.; Meyding-Lamade, U.			Prevalence of cerebral microhemorrhages in amateur boxers as detected by 3T MR imaging	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PROFESSIONAL BOXERS; DIFFUSION; DAMAGE	BACKGROUND AND PURPOSE: The evidence for traumatic brain injury in amateur boxers is controversial. Hypothetically, sudden acceleration of the head due to the impact of the blow during the boxing fight might result in diffuse axonal injury or contusion. We wanted to determine whether cerebral microhemorrhages occur more often in amateur boxers than in nonboxers. MATERIALS AND METHODS: In 42 male, classical amateur boxers and in 37 healthy, nonboxing male volunteers we performed cranial MR imaging at 3T. The study protocol included a transverse dual spin-echo MR imaging sequence, a 3D sagittal magnetization-prepared rapid acquisition of gradient echo sequence, a coronal T2*-weighted sequence, and an axial time-of-flight MR angiography sequence. MR imaging data were made anonymous before 2 neuroradiologists independently evaluated the images. In addition, the following risk factors were assessed: total numbers of fights and knockouts, weight division, and duration of boxing. We compared the group proportions of microhemorrhages with Fisher test of exact probability. RESULTS: There was a statistically higher prevalence of cerebral microhemorrhages in the group of boxers (3 of 42; 7.1 %) than in nonboxing persons (0 of 37; 0%). This difference was not statistically significant, however (P = .2479; Fisher exact test). CONCLUSION: Although we detected more microhemorrhages in amateur boxers than in nonboxing persons, this difference did not prove to be significant.	[Hahnel, S.; Stippich, C.; Weber, I.; Schill, T.; Heiland, S.; Blatow, M.] Univ Heidelberg, Med Ctr, Dept Neurol, Div Neuroradiol, D-69120 Heidelberg, Germany; [Friedmann, B.] Univ Heidelberg, Med Ctr, Med Clin & Policlin, Dept Sports Med, Heidelberg, Germany; [Darm, H.; Meyding-Lamade, U.] Univ Heidelberg, Med Ctr, Dept Neurol, Div Neurol, Heidelberg, Germany; [Jost, J.] Natl Training Ctr Boxing, Heidelberg, Germany		Hahnel, S (corresponding author), Univ Heidelberg, Med Ctr, Dept Neurol, Div Neuroradiol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Stefan-Haehnel@med.uni-heidelberg.de		Blatow, Maria/0000-0003-3371-5697			Blennow K., 2005, LAKARTIDINGEN, V102, P2472; Blennow Kaj, 2005, Lakartidningen, V102, P2468; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; Livingston EH, 2005, J SURG RES, V126, P149, DOI 10.1016/j.jss.2004.12.013; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Tokuda T, 1993, No To Shinkei, V45, P1109; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Unterharnscheidt F, 1995, Rev Neurol, V23, P1027; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	12	29	30	0	4	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2008	29	2					388	391		10.3174/ajnr.A0799			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	265FT	WOS:000253345200041	17974608	Green Published, hybrid			2022-02-06	
J	Walz, NC; Cecil, KM; Wade, SL; Michaud, LJ				Walz, Nicolay Chertkoff; Cecil, Kim M.; Wade, Shari L.; Michaud, Linda J.			Late proton magnetic resonance spectroscopy following traumatic brain injury during early childhood: Relationship with neurobehavioral outcomes	JOURNAL OF NEUROTRAUMA			English	Article						early childhood; neurobehavioral outcomes; proton MR spectroscopy; traumatic brain injury	MR SPECTROSCOPY; N-ACETYLASPARTATE; LOCALIZED PROTON; CHILDREN	We sought to extend previous research that demonstrates reduced neurometabolite concentrations during the chronic phase of pediatric traumatic brain injury (TBI) in children injured during early childhood. We hypothesized that young children with TBI in the chronic phase post-injury would have lower N-acetyl aspartate (NAA) metabolite concentrations in gray and white matter in comparison to controls. We also hypothesized that metabolite levels would be correlated with acute TBI severity and neurobehavioral skills. Ten children with a history of TBI between the ages of 3 and 6 years were compared to an age, gender, and race-matched group of 10 children with a history of an orthopedic injury (OI). Children completed neurobehavioral testing at 12 months post-injury. Proton magnetic resonance (MR) spectroscopy was completed at least 12 months post-injury when the children were 6-9 years old. Groups were compared on metabolite concentrations in the medial frontal gray matter and left frontal white matter. Metabolite levels were correlated with Glasgow Coma Scale (GCS) scores and neurobehavioral functioning. There was a trend for lower NAA concentrations in the medial frontal gray matter for the TBI group. Late NAA and Cr levels in the medial frontal gray matter and NAA levels in the left frontal white matter were strongly positively correlated with initial GCS score. Metabolite levels were correlated with some neurobehavioral measures differentially for children with TBI or OI. Some neurometabolite levels differed between the TBI and OI groups more than 1 year post-injury and were related to injury severity, as well as some neurobehavioral outcomes following TBI during early childhood.	[Walz, Nicolay Chertkoff; Cecil, Kim M.; Wade, Shari L.; Michaud, Linda J.] Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, Cincinnati, OH 45229 USA; [Michaud, Linda J.] Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Cecil, Kim M.] Childrens Hosp, Med Ctr, Dept Radiol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA		Walz, NC (corresponding author), Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, MLC 3015,3333 Burnet Ave, Cincinnati, OH 45229 USA.	nicolay.walz@cchmc.org		Cecil, Kim/0000-0001-8233-5485	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01 CA112181, CA112181] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD046690, R01 HD042729, R01 HD044279, R43 HD044279] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R21 ES012524, P01 ES011261] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD044279, K23HD046690] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA112181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P01ES011261] Funding Source: NIH RePORTER		Achenbach TM, 1991, MANUAL CHILD BEHAV C; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bracken B.A., 1998, BRACKEN BASIC CONCEP; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; CARROWWOODFOLK E, 2000, COMPREHENSIVE ASSESS; *CDC, 2003, TRAU BRAIN INJ US AS; Cecil K M, 2001, Top Magn Reson Imaging, V12, P435, DOI 10.1097/00002142-200112000-00005; Elliott C. D., 1990, DIFFERENTIAL ABILITY; Gioia GA IP, 2000, BEHAV RATING INVENTO; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; Jung RE, 2005, NEUROIMAGE, V26, P965, DOI 10.1016/j.neuroimage.2005.02.039; Mather N., 2001, WOODCOCK JOHNSON 3 T; Merrell KM., 2002, HOME COMMUNITY SOCIA; MOFFET JR, 2006, N ACETYLASPARTATE UN; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Parry L, 2004, CHILD NEUROPSYCHOL, V10, P248, DOI 10.1080/09297040490909279; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Traber F, 2004, J MAGN RESON IMAGING, V19, P537, DOI 10.1002/jmri.20053; TZIKA AA, 1993, JMRI-J MAGN RESON IM, V3, P719, DOI 10.1002/jmri.1880030506; VANDERKNAAP MS, 1990, RADIOLOGY, V176, P509, DOI 10.1148/radiology.176.2.2164237; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427	30	29	30	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					94	103		10.1089/neu.2007.0362			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000002	18260792	Green Accepted			2022-02-06	
J	Zhao, X; Rizzo, A; Malek, B; Fakhry, S; Watson, J				Zhao, Xueren; Rizzo, Anne; Malek, Bobby; Fakhry, Samir; Watson, Joseph			Basilar skull fracture: A risk factor for transverse/sigmoid venous sinus obstruction	JOURNAL OF NEUROTRAUMA			English	Article						basilar skull fracture; cerebral venous infarction; cerebral venous sinus thrombosis; CT angiogram; intracranial pressure; traumatic brain injury	SIGMOID SINUS; THROMBOSIS; DIAGNOSIS; ANGIOGRAPHY; INJURY	In trauma practice, basilar skull fracture is an extremely common finding while transverse/sigmoid venous sinus thrombosis is generally considered quite a rare complication. During evaluation of cervical computed tomography (CT) angiography after trauma, we identified five patients in just three months with unexpected transverse/sigmoid venous sinus obstruction ipsilateral to a basilar skull fracture. This number represented a surprisingly high percentage of our neurosurgical trauma consults for the study period (31%). Three of the five patients were found to have sinus thrombosis: two with right transverse/sigmoid sinus thrombosis experienced significant neurological deficits and prolonged hospital courses even with anti-coagulation therapy; one patient with a left transverse/sigmoid sinus thrombosis had a good outcome with anti-coagulation therapy. The other two of the five patients had outflow obstruction, likely from focal epidural bleeding and extrinsic compression: one patient with partial obstruction in the right transverse-siginoid junction, due to epidural bleeding, experienced a difficult recovery; one patient with a right sigmoid sinus obstruction presented and remained asymptomatic and experienced a benign hospital course. Two of the five patients had a posterior temporal hemorrhagic area ipsilateral to the affected sinus, suggesting that this finding may have represented hemorrhagic venous infarction rather than traumatic contusion. We propose that a basilar skull fracture in the region of temporal or occipital bone should be considered as a significant risk factor for the development of transverse/sigmoid venous sinus obstruction and may be an under-recognized and treatable cause of increased intracranial pressure. Failure to detect this complication may explain, in part, unexpected clinical outcomes.	[Zhao, Xueren; Malek, Bobby; Watson, Joseph] Inova Fairfax Hosp, Dept Neurosci, Reg Neurosurg Serv, Falls Church, VA USA; [Rizzo, Anne; Fakhry, Samir] Inova Fairfax Hosp, Dept Gen Surg, Trauma Serv, Falls Church, VA USA		Watson, J (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Reg Neurosurg Serv, Inova Fairfax Campus,3300 Gallows Rd,IHVI 3rd Flo, Falls Church, VA 22042 USA.	joseph.watson@inova.com	Watson, Joe/AAP-2155-2020				Berne JD, 2004, J TRAUMA, V57, P11, DOI 10.1097/01.TA.0000135499.70048.C7; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; BJORNEBRINK J, 1976, ANGIOLOGY, V27, P688, DOI 10.1177/000331977602701203; Cothren CC, 2003, J TRAUMA, V55, P811, DOI 10.1097/01.TA.0000092700.92587.32; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Fink JN, 2002, STROKE, V33, P290, DOI 10.1161/hs0102.101016; Frey JL, 1999, STROKE, V30, P489, DOI 10.1161/01.STR.30.3.489; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HADEISHI H, 1995, NEUROSURGERY, V36, P1220, DOI 10.1227/00006123-199506000-00028; HASSO AN, 1979, RADIOLOGY, V132, P375, DOI 10.1148/132.2.375; HERMAN JM, 1995, J NEUROSURG, V83, P539, DOI 10.3171/jns.1995.83.3.0539; Kim SY, 1997, AM J NEURORADIOL, V18, P639; Kuether TA, 1998, NEUROSURGERY, V42, P1163, DOI 10.1097/00006123-199805000-00129; MARQUARDT G, 2003, ACTA NEUROL SCAND, V10, P1046; MATSUDA M, 1982, SURG NEUROL, V18, P206, DOI 10.1016/0090-3019(82)90394-9; Quinones-Hinojosa A, 2004, J TRAUMA, V56, P201, DOI 10.1097/01.TA.0000032310.26731.C2; Stiefel D, 2000, EUR J PEDIATR SURG, V10, P41, DOI 10.1055/s-2008-1072321; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; Takamura Yukio, 1996, Neurologia Medico-Chirurgica, V36, P650, DOI 10.2176/nmc.36.650; VOGL TJ, 1994, AM J ROENTGENOL, V162, P1191, DOI 10.2214/ajr.162.5.8166009; Yuen HW, 2005, ANN ACAD MED SINGAP, V34, P639	21	29	31	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					104	111		10.1089/neu.2007.0351			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000003	18260793				2022-02-06	
J	Coetzer, R				Coetzer, Rudi			Holistic neuro-rehabilitation in the community: Is identity a key issue?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Identity; Brain injury; Psychotherapy; Holistic neuro-rehabilitation	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; COGNITIVE REHABILITATION; SUBJECTIVE EXPERIENCE; CLOSE RELATIVES; MODEL	Many people experience identity change after brain injury. Impaired self-awareness after acquired brain injury is also common and can, along with other factors, affect the identity change a person may experience. Holistic rehabilitation programmes attempt to address both cognitive and emotional difficulties and specifically problems of self-awareness after brain injury. Does identity change require longer-term rehabilitation interventions? This paper describes a community-based neuro-rehabilitation service that has incorporated some principles from more traditional holistic programmes with a view to providing long-term, low-intensity brain injury rehabilitation. Specific reference is made to problems of identity and how these may be addressed during long-term psychotherapeutic follow-up. The potential relevance of the total duration of rehabilitation input rather than simply the number of sessions when working with adjustment and identity change after brain injury in community settings is discussed. The service model is compared to more traditional holistic rehabilitation programmes. A case study and early outcome data are presented to illustrate some of these points and to provide more information about the nature of the programme.	[Coetzer, Rudi] Colwyn Bay Hosp, N Wales Brain Injury Serv, Conwy & Denbighshire NHS Trust, Colwyn Bay LL29 8AY, Wales; [Coetzer, Rudi] Bangor Univ, Bangor, Gwynedd, Wales		Coetzer, R (corresponding author), Colwyn Bay Hosp, N Wales Brain Injury Serv, Conwy & Denbighshire NHS Trust, Hesketh Rd, Colwyn Bay LL29 8AY, Wales.	Rudi.Coetzer@cd-tr.wales.nhs.uk		Coetzer, Rudi/0000-0003-4505-7230			Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; BATEMAN A, 2006, OL ZANGW CTR 10 ANN; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; *BRIT PSYCH SOC DI, 2005, CLIN NEUR REH SERV A; CAETANO C, 2000, INT HDB NEUROPSYCHOL, P259; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Coetzer B. R., 2003, J COGNITIVE REHABILI, V21, P4; Coetzer R, 2005, INT J REHABIL RES, V28, P361, DOI 10.1097/00004356-200512000-00010; Coetzer R, 2007, J HEAD TRAUMA REHAB, V22, P39, DOI 10.1097/00001199-200701000-00005; Department of Health, 2005, NAT SERV FRAM LONG T; Diller L, 2005, ARCH PHYS MED REHAB, V86, P1075, DOI 10.1016/j.apmr.2004.11.009; Erikson E. H., 1963, CHILDHOOD SOC; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Gracey F, 2007, NEUROPSYCHOL REHABIL, V17, P106, DOI 10.1080/09602010500505260; Hayes S.C., 2004, ACCEPTANCE COMMITMEN; Judd D. P., 1999, COUNSELLING PSYCHOL, V14, P4; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leon-Carrion J, 1997, NEUROPSYCHOL REHABIL, P301; MILLER L, 1993, PSYCHOTHERAPY BRAIN; MORRIS SD, 2004, J COGN REHABIL, V22, P15; Myles SM, 2004, INT J PSYCHOL PSYCHO, V4, P487; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Pollack IW, 2005, TXB TRAUMATIC BRAIN, P641; Ponsford J, 2006, NEUROPSYCHOL REHABIL, V16, P315, DOI 10.1080/09602010500176534; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Sarajuuri JM, 2006, INT J PSYCHOL, V41, P362, DOI 10.1080/01650250500346103; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Trexler L, 2000, INT HDB NEUROPSYCHOL, P215; TREXLER LE, 2000, INT HDB NEUROPSYCHOL, P137; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; Wilson BA, 2005, J INT NEUROPSYCH SOC, V11, P488, DOI 10.1017/S1355617705050599; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 2000, INT HDB NEUROPSYCHOL, P231; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Yeates G, 2007, NEUROPSYCHOL REHABIL, V17, P151, DOI 10.1080/09602010600696423	44	29	29	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	5-6					766	783		10.1080/09602010701860266			18	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	360PQ	WOS:000260070200003	18654932				2022-02-06	
J	Cullen, NK; Park, YG; Bayley, MT				Cullen, Nora K.; Park, Yoon-Ghil; Bayley, Mark T.			Functional recovery following traumatic vs non-traumatic brain injury: A case-controlled study	BRAIN INJURY			English	Article						Outcome assessment; rehabilitation; traumatic brain injury; non-traumatic brain injury	DISABILITY RATING-SCALE; EARLY INTENSIVE NEUROREHABILITATION; PROSPECTIVE MULTICENTER TRIAL; PROLONGED UNCONSCIOUS STATE; SEVERE HEAD-INJURY; INPATIENT REHABILITATION; YOUNG-ADULTS; CHILDREN; OUTCOMES; COMA	Primary objective: To explore differences in rate of recovery and functional outcome in case-matched patients with traumatic (TBI) vs non-traumatic brain injury (non-TBI) during inpatient rehabilitation and 1 year post-insult. Research design: Retrospective comparison study and case-controlled design. Methods and procedures: Demographic data, severity of injury, functional outcome measures and outcomes at 1 year follow-up were collected on 573 patients (404 TBI; 169 non-TBI) admitted to a multidisciplinary neurorehabilitation programme. After general cohort comparisons, 86 TBI and 86 non-TBI patients were matched on age, severity of injury and functional outcome scores. Main outcomes and results: In the general cohort analyses, TBI patients demonstrated better outcomes at discharge as indicated by lower Disability Rating Scale (DRS) scores and higher gain and efficiency scores on both motor and cognitive sub-scales of the Functional Independence Measure (FIM). After matching patients, TBI patients showed greater functional improvement throughout their rehabilitation stay. Outcomes at 1 year follow-up were mixed; TBI patients showed better outcomes compared to non-TBI patients on DRS scores; however, FIM scores were not significantly different. Conclusions: Results from the present study support the hypothesis that TBI patients achieve greater functional improvements compared to non-TBI patients when matched according to injury and demographic characteristics.	[Cullen, Nora K.; Bayley, Mark T.] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Cullen, Nora K.; Bayley, Mark T.] Univ Toronto, Toronto, ON, Canada; [Park, Yoon-Ghil] Yonsei Univ, Coll Med, Seoul, South Korea; [Park, Yoon-Ghil] Yongdong Severance Hosp, Seoul, South Korea		Cullen, NK (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	cullen.nora@torontorehab.on.ca		Bayley, Mark/0000-0001-7860-9463; Park, Yoon Ghil/0000-0001-9054-5300; Cullen, Nora/0000-0001-6359-9418	Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Province of Ontario	We would like to thank the Physicians' Services Foundation Inc. for their generous support of this project and the staff of the Toronto Rehabilitation Institute, ABI service, for their assistance in data collection. The research assistance of Charmagne Crescini is also gratefully acknowledged. Equipment and space have been funded with grants from the Canada Foundation for Innovation and the Province of Ontario. The views expressed here do not necessarily reflect those of the Ontario Ministry of Health and Long-Term Care.	Boake C, 2000, PHYS MED REHABILITAT, P1073; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; CUMMINS RA, 1992, AUST PSYCHOL, V27, P71, DOI 10.1080/00050069208257582; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Eilander HJ, 2007, BRAIN INJURY, V21, P53, DOI 10.1080/02699050601151795; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Haley SM, 2001, PHYS THER, V81, P1425, DOI 10.1093/ptj/81.8.1425; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; LIPPERTGRUNER M, 2002, BRAIN INJURY, V21, P1001; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schmidt JG, 1997, J NEUROL REHABIL, V11, P189; Shah MK, 2004, BRAIN INJURY, V18, P111, DOI 10.1080/0269905031000149551; Shah MK, 2007, J NEUROL SCI, V260, P95, DOI 10.1016/j.jns.2007.04.012; TEASDALE G, 1974, LANCET, V2, P81; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	36	29	29	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	13-14					1013	1020	PII 907306637	10.1080/02699050802530581			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	389ZM	WOS:000262134100005	19117180				2022-02-06	
J	Geurtsen, GJ; Martina, JD; Van Heugten, CM; Geurts, ACH				Geurtsen, G. J.; Martina, J. D.; Van Heugten, C. M.; Geurts, A. C. H.			A prospective study to evaluate a new residential community reintegration programme for severe chronic brain injury: The Brain Integration Programme	BRAIN INJURY			English	Article						community integration; employment; living skills; residential community reintegration programme; neurobehavioural; outcome	COGNITIVE REHABILITATION; SELF-AWARENESS; ADJUSTMENT; PEOPLE	Purpose: To assess the effectiveness of a residential community reintegration programme for participants with chronic sequelae of severe acquired brain injury that hamper community functioning. Design: Prospective cohort study. Subjects: Twenty-four participants with acquired brain injury (traumatic n = 18; stroke n = 3, tumour n = 2, encephalitis n = 1). Participants had impaired illness awareness, alcohol and drug problems and/or behavioural problems. Intervention: A skills-oriented programme with modules related to independent living, work, social and emotional well-being. Methods: The Community Integration Questionnaire, CES-Depression, EuroQOL, Employability Rating Scale, living situation and work status were scored at the start (T0), end of treatment (T1) and 1-year follow-up (T2). Results: Significant effects on the majority of outcome measures were present at T1. Employability significantly improved at T2 and living independently rose from 42% to over 70%. Participants working increased from 38% to 58% and the hours of work per week increased from 8 to 15. Conclusion: The Brain Integration Programme led to a sustained reduction in experienced problems and improved community integration. It is concluded that even participants with complex problems due to severe brain injury who got stuck in life could improve their social participation and emotional well-being through a residential community reintegration programme.	[Geurtsen, G. J.] Rehabil Ctr Groot Klimmendaal, Dept Acquired Brain Injury, NL-6800 GG Arnhem, Netherlands; [Van Heugten, C. M.] Univ Maastricht, Utrecht, Netherlands; [Van Heugten, C. M.] Univ Utrecht, Rudolf Magnus Inst, Rehabil Ctr Hoogstr, Utrecht, Netherlands; [Geurts, A. C. H.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Rehabil, Nijmegen, Netherlands		Geurtsen, GJ (corresponding author), Rehabil Ctr Groot Klimmendaal, Dept Acquired Brain Injury, POB 9044, NL-6800 GG Arnhem, Netherlands.	g.geurtsen@grootklimmendaal.nl	Geurts, Alexander/H-8032-2014	Geurts, Alexander/0000-0001-7478-1119; Geurtsen, G.J./0000-0002-2508-340X			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Arciniegas DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Bouma J, 1995, MEASUREMENT DEPRESSI; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cope DN, 2005, J HEAD TRAUMA REHAB, V20, P128, DOI 10.1097/00001199-200503000-00002; Corrigan J.D., 2005, REHABILITATION TRAUM, P133; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Evans R W, 1991, J Insur Med, V23, P192; GAINOTTI G, 1999, HDB CLIN EXPT NEUROP, P613; Geurtsen GJ, 2004, INT J REHABIL RES, V27, P52; GEURTSEN GJ, 2004, NEUROPRAXIS, V8, P82; HEATON RK, 1993, WISCONSIM CARD SORTI; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Kirk RE, 1968, EXPT DESIGN PROCEDUR; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McCluskey AE, 2000, BRAIN INJURY, V14, P943, DOI 10.1080/02699050050191896; Oddy M, 2003, NEUROPSYCHOL REHABIL, V13, P259, DOI 10.1080/09602010244000345; PETERS M D, 1992, Brain Injury, V6, P299, DOI 10.3109/02699059209034944; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Reitan R, 1985, HALSTEAD REITAN NEUR; Reitan RM, 1992, TRAIL MAKING TEST MA; Rey A., 1964, CLIN PSYCHOL EXAMINA; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Rothwell NA, 1999, BRAIN INJURY, V13, P521; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; TEASDALE G, 1974, LANCET, V2, P81; VANBALEN HGG, 2002, COGNITIVE REHABILITA, P71; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; [No title captured]; [No title captured]	47	29	29	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					545	554		10.1080/02699050802132479			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300005	18568707				2022-02-06	
J	Jakobsson, L; Isaksson-Hellman, I; Lindman, M				Jakobsson, Lotta; Isaksson-Hellman, Irene; Lindman, Magdalena			WHIPS (Volvo Cars' Whiplash Protection System)-The Development and Real-World Performance	TRAFFIC INJURY PREVENTION			English	Article						Rear-End Impact; Whiplash; Protection; Prevention; City Safety	INJURY	Objectives: Present the performance of WHIPS and identify possible next steps of soft tissue neck injury reduction potentials, based on rear-end real-world crash data. Methods: Front-seat occupants (above 14 years of age) have been analyzed regarding influencing factors on reported incidences of soft tissue neck injuries. The outcome of 1858 occupants in cars equipped with WHIPS and 663 occupants in Volvo cars of model year 1999 without WHIPS are studied with respect to WHIPS injury-reducing effect for different impact severities and injury durations. The occupants in WHIPS are further studied with respect to seating position and sitting posture, such as turned head and head-to-head restraint distance. Results: Soft tissue neck injury risk reductions are seen for occupants in WHIPS as compared to prior Volvo cars; mean values ranging from 21 to 47% depending on impact severity and symptom duration. Sitting posture (turned head and increased backset) increases soft tissue neck injury risks. Based on the self-reported injury data, a significantly lower risk was found for occupants facing straight forward with the head in close proximity to the head restraint as compared to the risk for occupants with rotated head and a larger backset. Even though the highest risk of soft tissue neck injuries is found in higher impact severity, the large amount of soft tissue neck injuries sustained at low impact severity emphasizes the need of focusing measures for crash avoidance. Conclusions: This study presents the development and real-world performance of WHIPS as well as identifies situations for further focus and challenges for the next generation of soft tissue neck injury protection and prevention, including areas such as occupant posture and crash avoidance.	[Jakobsson, Lotta] Volvo Cars Safety Ctr, Dept 91410, S-40531 Gothenburg, Sweden		Jakobsson, L (corresponding author), Volvo Cars Safety Ctr, Dept 91410, PV21, S-40531 Gothenburg, Sweden.	ljakobss@volvocars.com					ASBERG A, 1973, P 4 INT TECH C EXP S, P359; CARLSSON G, 1985, P 1985 INT IRCOBI C, P277; COELINGH E, 2007, P 20 ESV C LY FRANC; DAVIES J. M., 1998, P IRCOBI C BIOM IMP, P377; Farmer Charles M, 2003, Traffic Inj Prev, V4, P83, DOI 10.1080/15389580309867; HAGG A, 1999, FOLKSAM CAR MODEL SA; Jakobsson L, 2000, ACCIDENT ANAL PREV, V32, P307, DOI 10.1016/S0001-4575(99)00107-4; Jakobsson L, 2004, P IRCOBI C BIOM IMP, P297; Jakobsson L., 1994, P 1994 INT IRCOBI C, P109; JAKOBSSON L, 2004, J WHIPLASH RELAT DIS, V3, P37; Jonsson Bertil, 2007, Traffic Inj Prev, V8, P87, DOI 10.1080/15389580600911010; KULLGREN A, 2007, P 20 ESV C LY FRANC; LUNDELL B, 1998, P 16 ESV C WINDS CAN, P1586; LUNDELL B, 1998, SAE WORLD C DETR MI; Olsson I, 1990, P INT IRCOBI C BIOM, P269; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; SILVERBAGECARLS.G, 2003, P 47 AAAM C, P598; STURZENEGGER M, 1995, J NEUROL, V242, P443, DOI 10.1007/BF00873547; STURZENEGGER M, 1994, J NEUROL, V544, P688; Temming J., 2000, FRONTIERS WHIPLASH T, P118; Viano DC, 2001, J TRAUMA, V51, P959, DOI 10.1097/00005373-200111000-00022	21	29	29	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.		2008	9	6					600	605		10.1080/15389580802435636			6	Public, Environmental & Occupational Health; Transportation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Transportation	387DN	WOS:000261932000014	19058108				2022-02-06	
J	Nott, MT; Chapparo, C; Heard, R				Nott, Melissa T.; Chapparo, Christine; Heard, Robert			Effective occupational therapy intervention with adults demonstrating agitation during post-traumatic amnesia	BRAIN INJURY			English	Article						agitation information processing; occupational therapy; post-traumatic amnesia	SINGLE-SUBJECT RESEARCH; BRAIN-INJURY; REHABILITATION; DESIGNS; MEMORY; RELIABILITY; PATIENT; STAGE	Objective: To investigate the effectiveness of occupational therapy (OT) with adults demonstrating agitation and post-traumatic amnesia (PTA) following brain injury. Design: Single-system experimental design (ABAB) across subjects. Methods: Eight subjects were recruited during acute rehabilitation. Current OT intervention was alternated with the experimental Perceive, Recall, Plan and Perform (PRPP) System approach over 4-weeks. Therapy was conducted daily. Information processing capacity during occupational tasks was measured using the PRPP System of Task Analysis. PTA status was monitored with the Westmead PTA Scale. Experimental intervention: The PRPP System is a dynamic assessment and intervention approach that directly links results of cognitive task analysis with strategies for intervention. PRPP Intervention adopts an information processing approach that simultaneously focuses on task training, strategy training and strategy application within occupational performance. Results: Seven subjects significantly improved in their application of processing strategies during the PRPP Intervention in comparison to current OT Intervention phases. Large treatment effects favoured the PRPP Intervention. Subjects demonstrated improved information processing strategy use both prior to and following emergence from PTA. Conclusions: Occupational therapy intervention based upon the PRPP System of Task Analysis and Intervention improved subjects' ability to apply information processing strategies during occupational performance when compared to current intervention approaches.	[Nott, Melissa T.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia; [Nott, Melissa T.; Chapparo, Christine; Heard, Robert] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia		Nott, MT (corresponding author), Westmead Hosp, Brain Injury Rehabil Unit, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2415, Australia.	melissan@biru.wsahs.nsw.gov.au	Nott, Melissa T/M-6778-2018	Nott, Melissa T/0000-0001-7088-5826			ADAMOVICH BB, 1985, COGNITIVE REHABILITA; Backman CL, 1997, ARCH PHYS MED REHAB, V78, P1145, DOI 10.1016/S0003-9993(97)90142-8; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; BARLOW DH, 1984, SINGLE CASE EXPT DES; BECK J, 1992, STUDENT BEHAV PROBLE; CHAPPARO C, 1997, MONOGRAPH OCCUPATION, V1, P189; Chapparo C., 2007, PRPP SYSTEM INTERVEN; CHAPPARO C, 1997, MONOGRAPH TOTAL PRIN, V1; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fry K, 2002, AUSTR OCCUPATIONAL T, V49, P182, DOI 10.1046/j.1440-1630.2002.00337.x; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; GILES GM, 1999, REHABILITATION SEVER, P97; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; HAGEN C, 2001, RELEARNING TIMES, V8, P1; Kazdin A.E., 2003, RES DESIGN CLIN PSYC; Kielhofner G, 2004, CONCEPTUAL FDN OCCUP; Kinney A, 2001, J CONTEMP PSYCHOTHER, V31, P89; Lee S S, 2001, Can J Occup Ther, V68, P41; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; MURPHY DP, 1999, COMMUNITY PRACTITION, V72, P322; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; NOTT MT, 2007, AUSTR OCCUPATIONAL T, V54; Olive ML., 2005, ED PSYCHOL, V25, P313, DOI [10.1080/0144341042000301238, DOI 10.1080/0144341042000301238]; Ottenbacher K. J., 1986, EVALUATING CLIN CHAN; Ottenbacher KJ, 2001, AM J PHYS MED REHAB, V80, P786, DOI 10.1097/00002060-200110000-00014; Parker RI, 2003, BEHAV THER, V34, P189, DOI 10.1016/S0005-7894(03)80013-8; Polatajko Helene J., 2001, Physical and Occupational Therapy in Pediatrics, V20, P83, DOI 10.1300/J006v20n02_06; RADOMSKI MV, 2008, OCCUPATIONAL THERAPY, P748; Rankin G, 1998, CLIN REHABIL, V12, P187, DOI 10.1191/026921598672178340; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Thompson CK, 2006, J COMMUN DISORD, V39, P266, DOI 10.1016/j.jcomdis.2006.02.003; van den Broek MD, 2005, J HEAD TRAUMA REHAB, V20, P464, DOI 10.1097/00001199-200509000-00007; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Zhan S, 2001, DISABIL REHABIL, V23, P1, DOI 10.1080/09638280150211202; [No title captured]	41	29	30	0	11	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	9					669	683		10.1080/02699050802227170			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600004	18698517				2022-02-06	
J	Petersen, C; Scherwath, A; Fink, J; Koch, U				Petersen, Corinna; Scherwath, Angela; Fink, Juliane; Koch, Uwe			Health-related quality of life and psychosocial consequences after mild traumatic brain injury in children and adolescents	BRAIN INJURY			English	Article						quality of life; cognitive screening; mild traumatic brain injury; children; adolescents; follow-up	HEAD-INJURY; QUESTIONNAIRE; STRENGTHS; BEHAVIOR	Background: Little is known about the course of health-related quality of life (HRQOL) and functional outcome parameters in children and adolescents with TBI. In addition, a neuropsychological screening instrument would be useful for routine clinical care. Objective: To describe health-related quality of life and psychosocial consequences following mild traumatic brain injury (TBI). Methods: One chose a prospective, longitudinal design (two measurement time points). Methods included a telephone interview and a questionnaire, which was mailed to the parents whose children (older than 4 years of age) were admitted (with TBI) to a collaborating hospital. In addition, a feasibility study for screening children for cognitive side effects, attention and memory tasks was conducted. A group of 59 parents filled out questionnaires assessing health-related quality of life (KINDL), behavioural problems (SDQ) and health status (FS-II-R). Ten families participated in the feasibility study. Results: Results indicated that HRQOL, behavioural problems and health status remained stable over time. Compared to the reference groups, no significant differences in HRQOL were noted. Thirty per cent of the children screened were classified as being cognitively impaired. Conclusion: Mild TBI resulted in no decline in the children's health outcome after injury. The cognitive screening approach proved itself to be a useful instrument for routine clinical care.	[Petersen, Corinna; Scherwath, Angela; Fink, Juliane; Koch, Uwe] Univ Hamburg, Med Ctr, Inst & Policlin Med Psychol, Ctr Psychosocial Med, D-20246 Hamburg, Germany		Petersen, C (corresponding author), Univ Hamburg, Med Ctr, Inst & Policlin Med Psychol, Ctr Psychosocial Med, Martinistr 52, D-20246 Hamburg, Germany.	copeters@uke.unihamburg.de	Scherwath, Angela/Q-4197-2016; Koch, Uwe/A-5825-2009	Scherwath, Angela/0000-0002-7338-5218			Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; Drotar D, 1998, MEASURING HLTH RELAT; Eiser C, 2001, J DEV BEHAV PEDIATR, V22, P248, DOI 10.1097/00004703-200108000-00007; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Helmstaedter C., 2001, VLMT VERBALER LERN M; KENNARD M, 1942, ARCH NEUROL PSYCHIAT, V48, P377; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LAZAR MF, 1995, J HEAD TRAUMA REHAB, V10, P55, DOI 10.1097/00001199-199510000-00007; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; Parmelee D X, 1989, Psychiatr Med, V7, P11; Petersen C, 2006, BRAIN INJURY, V20, P321, DOI 10.1080/02699050500488108; Ravens-Sieberer U, 2000, GESUNDHEITSWESEN, V62, P148, DOI 10.1055/s-2000-10487; Ravens-Sieberer U, 1998, QUAL LIFE RES, V7, P399, DOI 10.1023/A:1008853819715; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEWES U, 2001, HAWIE R HAMBURG WECH; TEWES U, 2001, HAWIK 3 HAMBURG WECH; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; Woerner W, 2004, EUR CHILD ADOLES PSY, V13, P47, DOI 10.1007/s00787-004-2008-0; World Health Organization, 1992, ICD 10 CLASSIFICATIO	26	29	29	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					215	221		10.1080/02699050801935245			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500002	18297593				2022-02-06	
J	Yorkston, KM; Kuehn, CM; Johnson, KL; Ehde, DM; Jensen, MP; Amtmann, D				Yorkston, Kathryn M.; Kuehn, Carrie M.; Johnson, Kurt L.; Ehde, Dawn M.; Jensen, Mark P.; Amtmann, Dagmar			Measuring participation in people living with multiple sclerosis: A comparison of self-reported frequency, importance and self-efficacy	DISABILITY AND REHABILITATION			English	Article						multiple sclerosis; participation; treatment outcomes; healthcare survey	TRAUMATIC BRAIN-INJURY; COMMUNITY INTEGRATION QUESTIONNAIRE; SPINAL-CORD-INJURY; QUALITY-OF-LIFE; REHABILITATION; SATISFACTION; HANDICAP; INDIVIDUALS; DISABILITY; HEALTH	Purpose.To compare three dimensions related to participation in everyday situations in community-dwelling adults with multiple sclerosis (MS). Methods.Mail survey was obtained from 112 respondents. Data were analyzed using Kendall's tau-b correlation coefficients between responses to participation items relative to three question dimensions (importance, frequency, and self-efficacy) and criterion variables (mobility, depression, general health, fatigue and pain). Results.No significant associations were found between item responses in the importance dimension and the criterion variables. Weak associations were found for items in the frequency dimension, and stronger associations were found for items in the self-efficacy dimension. Conclusions.Different dimensions of participation in specific life situations yielded different responses and associations of those responses with key criterion measures. Subjective importance of participating in everyday situations is relatively independent of measures of mobility, general health, depression, fatigue and pain. Subjective judgments of self-efficacy for participation are more closely linked to these criterion measures. Caution is warranted when interpreting scales of participation because participation is a complex construct, potentially composed of several dimensions.	[Yorkston, Kathryn M.; Kuehn, Carrie M.; Johnson, Kurt L.; Ehde, Dawn M.; Jensen, Mark P.; Amtmann, Dagmar] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA		Yorkston, KM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	yorkston@u.washington.edu	Ehde, Dawn/K-1883-2016	Ehde, Dawn/0000-0002-9555-2347	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD033988-09, P01 HD33988, P01 HD033988] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD033988] Funding Source: NIH RePORTER		BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bowen J, 2001, MULT SCLER, V7, P201, DOI 10.1191/135245801678438447; BOWEN J, 2005, PHYS MED REHABIL CLI, V19, P359; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 2002, TOPICS SPINAL CORD I, V7, P83, DOI DOI 10.1310/7U35-GDQ4-FDV3-GVYV; Cardol M, 1999, DISABIL REHABIL, V21, P97, DOI 10.1080/096382899297819; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Chwastiak L, 2002, AM J PSYCHIAT, V159, P1862, DOI 10.1176/appi.ajp.159.11.1862; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Desrosiers J, 2002, DISABIL REHABIL, V24, P774, DOI 10.1080/09638280210125814; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Ehde DM, 2003, MULT SCLER J, V9, P605, DOI 10.1191/1352458503ms939oa; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; HATCHER L, 2004, STEP STEP APPROACH U; Jensen MP, 2001, HDB PAIN ASSESSMENT, P15; JENSEN MP, IN PRESS EVIDENCE OU; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; Kendall Maurice, 1990, RANK CORRELATION MET; King G, 2004, CHILDRENS ASSESSMENT; Kroencke DC, 2001, MULT SCLER, V7, P237, DOI 10.1191/135245801680209349; Lowe B, 2004, J AFFECT DISORDERS, V81, P61, DOI 10.1016/S0165-0327(03)00198-8; Noreau L, 2004, DISABIL REHABIL, V26, P346, DOI 10.1080/09638280410001658649; Ostir GV, 2006, ARCH PHYS MED REHAB, V87, P1043, DOI 10.1016/j.apmr.2006.04.024; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; Salter K, 2005, DISABIL REHABIL, V27, P507, DOI 10.1080/0963828040008552; *SAS I INC, 2003, SAS 9 1 COMP PROGR V; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; *STATA, 2005, STATA 9 1 COMP PROGR; Van Brakel WH, 2006, DISABIL REHABIL, V28, P193, DOI 10.1080/09638280500192785; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, P1793, DOI 10.1016/j.apmr.2004.04.024; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 2007, INT CLASS FUNCT DIS; Yorkston KM, 2003, J MED SPEECH-LANG PA, V11, P73	39	29	29	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2008	30	2					88	97		10.1080/09638280701191891			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	251EB	WOS:000252353000002	17852211	Green Accepted			2022-02-06	
J	Colantonio, A; Stamenova, V; Abramowitz, C; Clarke, D; Christensen, B				Colantonio, A.; Stamenova, V.; Abramowitz, C.; Clarke, D.; Christensen, B.			Brain injury in a forensic psychiatry population	BRAIN INJURY			English	Article						traumatic brain injury; forensic psychiatry	VIOLENT CRIMINAL BEHAVIOR; HEAD-INJURY; PRISON POPULATION; UNITED-STATES; PREVALENCE; OUTCOMES; INMATES; NEUROPSYCHOLOGY; PERSONALITY; DISORDERS	Objectives: The prevalence and profile of adults with a history of traumatic brain injury (TBI) has not been studied in large North American forensic mental health populations. This study investigated how adults with a documented history of TBI differed with the non-TBI forensic population with respect to demographics, psychiatric diagnoses and history of offences. Method: A retrospective chart review of all consecutive admissions to a forensic psychiatry programme in Toronto, Canada was conducted. Information on history of TBI, psychiatric diagnoses, living environments and types of criminal offences were obtained from medical records. Results: History of TBI was ascertained in 23% of 394 eligible patient records. Compared to those without a documented history of TBI, persons with this history were less likely to be diagnosed with schizophrenia but more likely to have alcohol/substance abuse disorder. There were also differences observed with respect to offence profiles. Conclusions: This study provides evidence to support routine screening for a history of TBI in forensic psychiatry.	[Colantonio, A.] Toronto Rehabil Inst, Saunderson Family Chair Acquired Brain Injury Res, Toronto, ON M5G 1V7, Canada; [Colantonio, A.; Stamenova, V.; Clarke, D.] Univ Toronto, Toronto, ON, Canada; [Abramowitz, C.; Christensen, B.] Ctr Addict & Mental Hlth, Toronto, ON, Canada		Colantonio, A (corresponding author), Toronto Rehabil Inst, Saunderson Family Chair Acquired Brain Injury Res, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Stamenova, Vessela/H-1712-2013	Stamenova, Vessela/0000-0003-3252-7766; Colantonio, Angela/0000-0003-2094-4765			BACHYRITA G, 1974, AM J PSYCHIAT, V131, P1015; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Blanchard R, 2002, ARCH SEX BEHAV, V31, P511, DOI 10.1023/A:1020659331965; Brewer-Smyth K, 2004, BIOL PSYCHIAT, V55, P21, DOI 10.1016/S0006-3223(03)00705-4; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Souza Carlos Alberto Crespo de, 2003, Rev. Bras. Psiquiatr., V25, P206, DOI 10.1590/S1516-44462003000400005; Diaz F G, 1995, Med Law, V14, P131; Hawley CA, 2003, BRAIN INJURY, V17, P743, DOI 10.1080/0269905031000089341; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; HWANG S, 2007, AM PUBL HLTH ASS ANN; Jensen J, 1999, J INT NEUROPSYCH SOC, V5, P452, DOI 10.1017/S1355617799555070; KIM H, 2008, INT TRAUMATIC BRAIN; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Merbitz C., 1995, J OFFENDER REHABILIT, V22, P11, DOI DOI 10.1300/J076V22N03_02; Miller E, 1999, J FORENSIC PSYCHIATR, V10, P157, DOI 10.1080/09585189908402146; Miller E, 1999, PSYCHOL CRIME LAW, V5, P297, DOI 10.1080/10683169908401774; Morrell R.F., 1998, J OFFENDER REHABIL, V27, P1, DOI [DOI 10.1300/J076V27N03_01, https://doi.org/10.1300/J076v27n03_01]; NESTOR PG, 1992, J NERV MENT DIS, V180, P418, DOI 10.1097/00005053-199207000-00003; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Pickett William, 2004, Chronic Dis Can, V25, P32; Rasmussen K, 2001, J AM ACAD PSYCHIATRY, V29, P186; Rucklidge JJ, 2006, BIOL PSYCHIAT, V60, P921, DOI 10.1016/j.biopsych.2006.03.067; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Seto Michael, 2001, DEMANDS FORENSIC SER; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Waldmann CA, 2004, HLTH HOMELESS PERSON, P237	30	29	29	0	19	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1353	1360		10.1080/02699050701785054			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200003	18066937				2022-02-06	
J	Gilliland, MGF; Levin, AV; Enzenauer, RW; Smith, C; Parsons, A; Rorke-Adams, LB; Lauridson, JR; La Roche, GR; Christmann, LM; Mian, M; Jentzen, J; Simons, KB; Morad, Y; Alexander, R; Jenny, C; Wygnanski-Jaffe, T				Gilliland, M. G. F.; Levin, Alex V.; Enzenauer, Robert W.; Smith, Charles; Parsons, Andrew; Rorke-Adams, Lucy B.; Lauridson, James R.; La Roche, G. Robert; Christmann, Linda M.; Mian, Marcellina; Jentzen, Jeffrey; Simons, Kenneth B.; Morad, Yair; Alexander, Randell; Jenny, Carole; Wygnanski-Jaffe, Tamara			Guidelines for postmortem protocol for ocular investigation of sudden unexplained infant death and suspected physical child abuse	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						postmortem; autopsy; child abuse; shaken baby syndrome; retinal hemorrhage; orbit	PERIMACULAR RETINAL FOLDS; PERMANENT BRAIN-DAMAGE; HEMORRHAGES; AUTOPSY; INJURY; EYES; MANIFESTATIONS; VICTIMS; SHAKING	Postmortem examination is a cornerstone in identifying the cause of unexplained sudden death in children. Even in cases of suspected or known abuse, an autopsy may help characterize the nature of the abuse, which is particularly important in the forensic autopsy of children in the first 3 to 4 years of life when inflicted neurotrauma is most common. Forensic examinations are vital in cases that might otherwise be diagnosed as sudden infant death syndrome. The ocular autopsy in particular may demonstrate findings that were not appreciated on antemortem clinical examination. This protocol for postmortem examination of the eyes and orbits was developed to promote more consistent documentation of findings, improved clinical and forensic decision making, and more replicable and coherent research outcomes.	E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC USA; Univ Toronto, Hosp Sick Children, Dept Pathol & Vis Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Paediat, Suspected Child Abuse & Neglect Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA; Univ Sheffield, Ophthalm Sci Unit, Sheffield, S Yorkshire, England; Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; Graphics, Montgomery, AL USA; Dalhousie Univ, Dept Ophthalmol, Halifax, NS B3H 3J5, Canada; IWK Hlth Ctr, Halifax, NS, Canada; Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; McGill Univ, Ctr Hlth, Montreal, PQ, Canada; Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; Tel Aviv Univ, Assaf Harofeh Med Ctr, Zerifin, Israel; Univ Florida, Gainesville, FL USA; Morehouse Sch Med, Atlanta, GA 30310 USA; Brown Med Sch, Providence, RI USA; Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel		Levin, AV (corresponding author), Hosp Sick Children, Dept Ophthalmol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	alex.levin@sickids.ca					Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; GAYNON MW, 1988, AM J OPHTHALMOL, V106, P423, DOI 10.1016/0002-9394(88)90877-X; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; GIANGIACOMO J, 1985, Journal of Pediatric Ophthalmology and Strabismus, V22, P234; GILKES MJ, 1967, LANCET, V2, P468; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GILLILAND MGF, 1992, FORENSIC SCI INT, V56, P77, DOI 10.1016/0379-0738(92)90149-Q; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; KIFFNEY GT, 1964, ARCH OPHTHALMOL-CHIC, V72, P231; Kivlin JD, 2001, CURR OPIN OPHTHALMOL, V12, P158, DOI 10.1097/00055735-200106000-00002; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; LEVIN A, 1998, AM ACAD OPHTHALMOL F, V16, P13; LEVIN AV, 2000, RECENT ADV PAEDIAT, V18, P151; Levitt CJ, 1994, CHILD ABUSE MED DIAG, P1; Lin KC, 1999, AM J OPHTHALMOL, V127, P473, DOI 10.1016/S0002-9394(98)00392-4; Marshall DH, 2001, CAN J OPHTHALMOL, V36, P377, DOI 10.1016/S0008-4182(01)80081-8; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; MUSHIN AS, 1971, BRIT MED J, V3, P402, DOI 10.1136/bmj.3.5771.402; Parsons MA, 2001, J CLIN PATHOL, V54, P417, DOI 10.1136/jcp.54.6.417; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; REECE RM, 2003, INFLICTED CHILDHOOD; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; Royal College of Pathologists, 2002, GUID AUT PRACT REP W; Taylor D, 1999, EYE, V13, P3; TOMASI L, 1986, AM J DIS CHILD, V93, P1335; TSENG SS, 1976, ARCH OPHTHALMOL-CHIC, V94, P839; WEIDENTHAL DT, 1976, AM J OPHTHALMOL, V81, P725, DOI 10.1016/0002-9394(76)90353-6; WILLSHAW HE, 2004, EYE, V18, P795; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	44	29	31	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2007	28	4					323	329		10.1097/PAF.0b013e31815b4c00			7	Medicine, Legal; Pathology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Legal Medicine; Pathology	237EH	WOS:000251355900010	18043020				2022-02-06	
J	Peterson, RS; Fernando, G; Day, L; Allen, TA; Chapleau, JD; Menjivar, J; Schlinger, BA; Lee, DW				Peterson, R. Scott; Fernando, Gowry; Day, Lainy; Allen, Timothy A.; Chapleau, Jeanette D.; Menjivar, Jenny; Schlinger, Barney A.; Lee, Diane W.			Aromatase expression and cell proliferation following injury of the adult zebra finch hippocampus	DEVELOPMENTAL NEUROBIOLOGY			English	Article						estrogen; aromatase; astrocytes; proliferation; repair	TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; FEMALE CANARY BRAIN; SUBVENTRICULAR ZONE; TAENIOPYGIA-GUTTATA; CEREBRAL-ISCHEMIA; AVIAN BRAIN; HEME OXYGENASE-1	Estrogens can be neuroprotective following traumatic brain injury. Immediately after trauma to the zebra finch hippocampus, the estrogen-synthetic enzyme aromatase is rapidly upregulated in astrocytes and radial glia around the lesion site. Brain injury also induces high levels of cell proliferation. Estrogens promote neuronal differentiation, migration, and survival naturally in the avian brain. We suspect that glia are a source of estrogens promoting cell proliferation after neural injury. To explore this hypothesis, we examined the spatial and temporal relationship between glial aromatase expression and cell proliferation after neural injury in adult female zebra finches. Birds were ovariectomized and given a blank implant or one filled with estradiol; some birds were also administered an aromatase inhibitor or vehicle. All birds received penetrating injuries to the right hippocampus. Twenty-four hours after lesioning, birds were injected once with BrdU to label mitotically active cells and euthanized 2 h, 24 h, or 7 days later. The brains were processed for double-label BrdU and aromatase immunocytochemistry. Injury-induced glial aromatase expression was unaffected by survival time and aromatase inhibition. BrdU labeling was significantly reduced at 24 h by ovariectomy and by aromatase inhibition; effects were partially reversed by E2 replacement. Irrespective of ovariectomy, the densities of aromatase immunoreactive astrocytes and BrdU-Iabeled cells at known distances from the lesion site were highly correlated. These data suggest that injury-induced glial aromatization may influence the reorganization of injured tissue by providing a rich estrogenic environment available to influence cellular incorporation. (c) 2007 Wiley Periodicals, Inc.	Calif State Univ Long Beach, Dept Psychol, Long Beach, CA 90840 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Neuroendocrinol Lab, Los Angeles, CA 90095 USA		Lee, DW (corresponding author), Calif State Univ Long Beach, Dept Psychol, Long Beach, CA 90840 USA.	dlee6@csulb.edu	Allen, Timothy Alexander/AAD-6903-2020	Allen, Timothy Alexander/0000-0002-3512-9475; Day, Lainy/0000-0002-9122-3044	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07228-18] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06 GM063119] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH59730-03, MH61994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06GM063119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R03MH059730, R01MH061994] Funding Source: NIH RePORTER		ADKINSREGAN E, 1990, GEN COMP ENDOCR, V78, P93, DOI 10.1016/0016-6480(90)90051-M; ADKINSREGAN E, 1990, HORM BEHAV, V24, P114, DOI 10.1016/0018-506X(90)90031-R; Alvarez-Buylla A, 1998, J NEUROSCI, V18, P1020; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; AlvarezBuylla A, 1997, J NEUROBIOL, V33, P585, DOI 10.1002/(SICI)1097-4695(19971105)33:5<585::AID-NEU7>3.0.CO;2-0; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; BARNEA A, 1994, P NATL ACAD SCI USA, V91, P11217, DOI 10.1073/pnas.91.23.11217; Barnett V, 1994, OUTLIERS STAT DATA, V3rd; BROWN SD, 1993, J NEUROSCI, V13, P2024; Cao J, 2002, BRAIN RES, V943, P80, DOI 10.1016/S0006-8993(02)02537-4; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; CHOI DW, 1989, ANN NY ACAD SCI, V568, P219; Cooper-Kuhn CM, 2002, DEV BRAIN RES, V134, P13, DOI 10.1016/S0165-3806(01)00243-7; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DeWulf V, 2002, J NEUROSCI, V22, P4080, DOI 10.1523/JNEUROSCI.22-10-04080.2002; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; FOIDART A, 1994, BRAIN RES, V657, P105, DOI 10.1016/0006-8993(94)90958-X; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Garcia-Segura LM, 2003, PROG NEUROBIOL, V71, P31, DOI 10.1016/j.pneurobio.2003.09.005; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HIDALGO A, 1995, J NEUROBIOL, V27, P470, DOI 10.1002/neu.480270404; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; LEE DW, 2007, J NEUROBIOL, V67, P1107; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; London SE, 2006, ENDOCRINOLOGY, V147, P5975, DOI 10.1210/en.2006-0154; London SE, 2003, J COMP NEUROL, V467, P496, DOI 10.1002/cne.10936; McIntosh TK, 1996, LAB INVEST, V74, P315; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Peterson RS, 2004, J COMP NEUROL, V475, P261, DOI 10.1002/cne.20157; Peterson RS, 2001, J NEUROENDOCRINOL, V13, P317, DOI 10.1046/j.1365-2826.2001.00647.x; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Reiner A, 2004, J COMP NEUROL, V473, P377, DOI 10.1002/cne.20118; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Saldanha CJ, 1998, HORM BEHAV, V34, P85, DOI 10.1006/hbeh.1998.1447; Saldanha CJ, 2000, J COMP NEUROL, V423, P619, DOI 10.1002/1096-9861(20000807)423:4<619::AID-CNE7>3.0.CO;2-U; Saldanha CJ, 2005, J NEUROBIOL, V64, P192, DOI 10.1002/neu.20147; SALDANHA CJ, 2004, HORM BEHAV, V45, P250; Scharff C, 2000, NEURON, V25, P481, DOI 10.1016/S0896-6273(00)80910-1; Soma KK, 2004, ENDOCRINOLOGY, V145, P1668, DOI 10.1210/en.2003-0883; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; STOKES TM, 1974, J COMP NEUROL, V156, P337, DOI 10.1002/cne.901560305; Takeda A, 1996, NEUROSCI LETT, V205, P169, DOI 10.1016/0304-3940(96)12405-8; Tzeng SF, 1999, NEUROREPORT, V10, P2287, DOI 10.1097/00001756-199908020-00012; Williams S, 1999, MOL CELL NEUROSCI, V13, P41, DOI 10.1006/mcne.1998.0729; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wynne RD, 2004, J NEUROENDOCRINOL, V16, P676, DOI 10.1111/j.1365-2826.2004.01217.x; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	63	29	29	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-8451	1932-846X		DEV NEUROBIOL	Dev. Neurobiol.	DEC	2007	67	14					1867	1878		10.1002/dneu.20548			12	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	239TG	WOS:000251540000004	17823932				2022-02-06	
J	Terrte, R; Mearin, F				Terrte, Rosa; Mearin, Fermin			Prospective evaluation of oro-pharyngeal dysphagia after severe traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; dysphagia; aspiration; silent aspiration; outcome; videofluoroscopy	SWALLOWING DISORDERS; HEAD TRAUMA; ASPIRATION; THERAPY; PROGRESSION; STROKE; ADULTS	Primary objective: To evaluate clinical, videofluoroscopic findings and clinical evolution of neurogenic dysphagia and to establish the prognostic factors. Research design: Prospective cohort study. Methods and procedures: Forty-eight patients with severe traumatic brain injury (TBI) and clinically-suspected oropharyngeal dysphagia were studied. Clinical evaluation of oro-pharyngeal dysphagia and videofluoroscopic examination were performed. Clinical evolution was based on feeding mode at discharge, the presence of respiratory complications and body mass index (BMI) at admission and at discharge. Main outcomes and results: Sixty-five per cent of patients had impaired gag reflex and 44% cough during oral feeding. Videofluoroscopy revealed some type of disorder in 90% of cases: 65% in the oral phase and 73% in the pharyngeal phase (aspiration in 62.5%, being silent in 41%). At discharge, 45% were on normal diet, 27% on a modified oral diet 14% combined oral intake and gastrostomy feeding and 14% were fed exclusively by gastrostomy. Feeding mode at discharge substantially correlated with RLCF score at admission (p = 0.04) and with RLCF (p = 0.009) and DRS (p = 0.02) scores at discharge. Conclusions: Aspiration is very frequent in patients with severe TBI, being silent in almost half. Cognitive function evaluated with the RLCF is the best prognostic factor. At discharge, 72% of the patients were on oral food intake despite having severe TBI.	[Terrte, Rosa; Mearin, Fermin] Univ Autonoma Barcelona, Inst Guttmann, Unit Funct Digest Rehabil, Barcelona 08916, Spain		Terrte, R (corresponding author), Univ Autonoma Barcelona, Inst Guttmann, Unit Funct Digest Rehabil, Cami Can Ruti S-N, Barcelona 08916, Spain.	rterre@guttmann.com					Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; Daniels SK., 1997, AM J SPEECH-LANG PAT, V6, P17, DOI [DOI 10.1044/1058-0360.0604.17, 10.1044/1058-0360.0604.17]; DAVIES AE, 1995, LANCET, V345, P487, DOI 10.1016/S0140-6736(95)90584-7; DEPIPPO KL, 1994, NEUROLOGY, V44, P1655, DOI 10.1212/WNL.44.9.1655; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; Hagen C, 1999, REHABILITATION HEAD; Kaye GM, 1997, ANN OTO RHINOL LARYN, V106, P705, DOI 10.1177/000348949710600817; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Lazarus CL, 1989, J HEAD TRAUMA REHAB, V4, P34; Linden P., 1993, Dysphagia, V8, P170, DOI 10.1007/BF01354535; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Logemann JA, 1998, EVALUATION TREATMENT, P307; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Morgan A, 2004, J HEAD TRAUMA REHAB, V19, P226, DOI 10.1097/00001199-200405000-00004; Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Morgan A, 2002, J HEAD TRAUMA REHAB, V17, P220, DOI 10.1097/00001199-200206000-00004; NEUMANN S, 1995, DYSPHAGIA, V10, P1, DOI 10.1007/BF00261272; POUDEROUX P, 1995, GASTROENTEROLOGY, V108, P1418, DOI 10.1016/0016-5085(95)90690-8; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; Spechler SJ, 1999, GASTROENTEROLOGY, V117, P233, DOI 10.1016/S0016-5085(99)70573-1; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; STANNDERS JA, 1993, CLIN PREDICTORS ASPI, P2; Terre R, 2006, NEUROGASTROENT MOTIL, V18, P200, DOI 10.1111/j.1365-2982.2005.00729.x; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992	27	29	33	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1411	1417		10.1080/02699050701785096			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200009	18066943				2022-02-06	
J	Marshall, P; Happe, M				Marshall, Paul; Happe, Maggie			The performance of individuals with mental retardation on cognitive tests assessing effort and motivation	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; VERBAL-LEARNING TEST; CARD SORTING TEST; WORD MEMORY TEST; SUSPECT EFFORT; RECOGNITION TRIAL; CLINICAL-SAMPLES; PATIENT SAMPLES; HEAD-INJURY	The purpose of this study was to determine which tests of effort and motivation would be appropriate for use with patients with mental retardation when feigning of cognitive deficits is suspected. The seven measures evaluated included the WMS-III Rarely Missed Index Test, forced-choice recognition portion of the California Verbal Learning Test-II, Reliable Digit Span test, Rey 15-Item Test, Rey Dot Counting Test, the Rey 15-Item Test with Recognition Trial, and the Vocabulary (V)-Digit Span (DS) difference score. Results indicated that the forced-choice portion of the CVIT-II, the V-DS difference score, and the Rarely Missed Index Test from the WMS-III might be appropriate for use with this population with passing rates of 89%, 98%, and 91% respectivety.	Hennepin Cty Med Ctr, Dept Psychiat, Minneapolis, MN 55415 USA		Marshall, P (corresponding author), Hennepin Cty Med Ctr, Dept Psychiat, Minneapolis, MN 55415 USA.	paul.marshall@co.hennepin.mn.us					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; BOLTER J, 1985, ITEM ERROR FREQUECIE; Boone K., 2002, DOT COUNTING TEST; Boone K. B., 2002, B TEST; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dunn LM., 1981, PEABODY PICTURE VOCA; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Frederick R. I., 1997, VALIDITY INDICATOR P; GOLDBERG JO, 1986, J CLIN PSYCHOL; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; GREEN P, 2003, GREEN WORD MEMORY TE; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2002, J CLIN EXP NEUROPSYC, V24, P48, DOI 10.1076/jcen.24.1.48.968; Griffin GAE, 1996, PSYCHOL ASSESSMENT, V8, P383; Hayes J S, 1998, Appl Neuropsychol, V5, P33, DOI 10.1207/s15324826an0501_4; Hurley KE, 2006, MENT RETARD, V44, P112, DOI 10.1352/0047-6765(2006)44[112:AIMMUW]2.0.CO;2; KENNEDY C, 2005, TEST MEMORY MALINGER; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Larrabee GJ, 2005, FORENSIC NEUROPSYCHO, P3; Lewis R, 1979, MANUAL REPEATABLE CO; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MAJ M, 1993, ARCH CLIN NEUROPSYCH, V8, P123, DOI 10.1016/0887-6177(93)90030-5; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Millis S. R., 2002, J FORENSIC NEUROPSYC, V2, P147; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; MORGAN S, 1997, QUALITATIVE ERROR FR; PAUL DS, 1992, INT J CLIN NEUROPSYC, V14, P1; Pulsifer M B, 1996, J Int Neuropsychol Soc, V2, P159; REY A, 1958, PSYCHOL EXAMINATION; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rogers R., 1992, STRUCTURED INTERVIEW; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O, 1991, COMPENDIUM NEUROPSYC; STEARNS RA, 2003, NEUROPSYCHOLOGICAL A; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; VICTOR TL, 2005, USE EFFORT TESTS MEN; WARRINGTON EK, 1984, RECOGNITION MEMORY; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	55	29	29	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2007	21	5					826	840		10.1080/13854040600801001			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	210KO	WOS:000249455300008	17676547				2022-02-06	
J	Thickpenny-Davis, KL; Barker-Collo, SL				Thickpenny-Davis, Kirsten L.; Barker-Collo, Suzanne L.			Evaluation of a structured group format memory rehabilitation program for adults following brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						group; memory rehabilitation; traumatic brain injury	CLOSED-HEAD-INJURY; PEOPLE; RELATIVES; DEFICIT; IMAGERY; TRAUMA; STROKE; TRIAL; AIDS	Objective: To evaluate the impact of an 8-session structured group format memory rehabilitation program on impaired memory functioning. Participants: Adults with traumatic brain injury (N = 10) or cerebral vascular accidents (N = 2). Design: A waitlist control study with pregroup, postgroup, and 1-month follow-up assessments. Wechsler Memory Scale-Revised: Neuropsychological assessments of memory (California Verbal Learning Test, Wechsler Memory Scale-Revised logical memory, visual-paired associates, and Rey Complex Figure) and both self-report and significant other report of behaviors indicative of memory difficulties and the use of memory strategies. Results: Participation in the memory group increased participants' knowledge of memory and memory strategies as well as use of memory aids and strategies; reduced behaviors indicative of memory impairment; and had a positive effect on neuropsychological assessments of memory (eg, delayed recall for words and figures). All significant improvements exceeded change experienced by waiting-list controls and were maintained at 1-month follow-up assessment. Conclusions: While extension of the findings is needed, the memory group has a positive impact on both neuropsychological measures of memory and everyday memory functioning.	Univ Auckland, Dept Psychol, Auckland 1142, New Zealand		Barker-Collo, SL (corresponding author), Univ Auckland, Dept Psychol, Private Bag 92019, Auckland 1142, New Zealand.	s.barker-collo@auckland.ac.nz					ASHCRAFT HM, 1989, HUMAN MEMORY COGNITI; BADDELEY AD, 1992, CLIN MANAGEMENT MEMO, P1; Barker-Collo S, 2000, J COGN REHABIL, V18, P16; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CARMIEN S, 2003, 2 INT WORKSH WU COMP; *COMM REH SERV, 1990, CRS MEM GROUP PROGR; DELIS D, 1987, CALIFORNIA VERBAL LE; DEPOMPEI R, 2006, 2 FED TBI INT C MARC; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; FRANZEN M D, 1991, Neuropsychology Review, V2, P29, DOI 10.1007/BF01108846; FRIEDMAN M, 2005, MAKING INFORM TECHNO; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Goldfield GS, 2001, INT J OBESITY, V25, P1843, DOI 10.1038/sj.ijo.0801838; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; Harris J E, 1981, Int Rehabil Med, V3, P206; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Jennett S M, 1991, Int Disabil Stud, V13, P83; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P436; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mittenberg W., 1992, PSYCHOL ASSESSMENT, V4, P363; ODDEY M, 1985, J NEUROL NEUROSUR PS, V48, P564; REEVES DW, 1994, CLIN ASSESSMENT MEMO; RICHARDSON JTE, 1985, COGNITIVE NEUROPSYCH, V2, P149, DOI 10.1080/02643298508252864; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SECKLER P, 1995, CHADD C OCT; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Spreen O, COMPENDIUM NEUROPSYC; Stewart FM, 1996, BRIT J CLIN PSYCHOL, V35, P369, DOI 10.1111/j.2044-8260.1996.tb01191.x; Sunderland A, 1996, BRIT J CLIN PSYCHOL, V35, P463, DOI 10.1111/j.2044-8260.1996.tb01200.x; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Turner A., 2000, INTEGRATED VISUAL AU; VANDERLINDEN M, 1989, COGNITIVE APPROACHES, P105; Wechsler D, 1987, MEMORY SCALE REVISED; WHYTE J, 1999, REPORT NIH CONSENSUS; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wilson BA, 1996, ACTA NEUROL BELG, V96, P51; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; WILSON BA, 1995, HDB MEMORY DISORDERS, P683; WILSON BA, 1992, CLIN MANAGEMENT MEMO, P240; WILSON BA, 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI DOI 10.1080/09602019108401386; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161	52	29	29	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2007	22	5					303	313		10.1097/01.HTR.0000290975.09496.93			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	216RA	WOS:000249895500006	17878772				2022-02-06	
J	Ling, X; Liu, DX				Ling, Xiang; Liu, Danxia			Temporal and spatial profiles of cell loss after spinal cord injury: Reduction by a metalloporphyrin	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						secondary cell death; apoptosis; antioxidant therapy; scavenger of reactive species; Mn(III) tetrakis (4-benzoic acid) porphyrin	4-BENZOIC ACID PORPHYRIN; TRAUMATIC BRAIN-INJURY; LIPID-PEROXIDATION; NEURON DEATH; SUPEROXIDE-PRODUCTION; COMPRESSION TRAUMA; HYDROGEN-PEROXIDE; HYDROXYL RADICALS; CONTROLLED TRIAL; POTENTIAL ROLE	This study presents quantitative temporal and spatial profiles of neuronal loss and apoptosis following a contusion spinal cord injury (50 g center dot cm). The profiles were evaluated by counting the cresol violet-stained surviving cells and the total number of TUNEL-positive cells and of TUNEL-positive neurons in sections 0- 4 mm from the epicenter and 1, 6, 12, 24, 48, and 72 hr and 1 week postinjury. We demonstrated that neurons continue to disappear over 1 week postinjury and that neuronal loss shifts to areas longer distances from the epicenter over time. TUNEL-positive cells in both gray and white matter appeared after 6 hr, gradually increased to a peak level after 48 hr, and declined by 72 hr postinjury. TUNEL-positive neurons peaked earlier and were present for 1 week, although the total number of neurons was reduced significantly by the end of the week. The neuronal loss and apoptosis were partially prevented by a metalloporphyrin [Mn(III) tetrakis (4-benzoic acid) porphyrin (MnTBAP)]. We demonstrated that MnTBAP (10 and 50 mg/kg, given intraperitoneally) significantly reduced neuronal death in the sections 1-2.5 mm rostral and 1 mm caudal from the epicenter compared with that in the vehicle-treated group, suggesting MnTBAP is more effective in the sections rostral than in those caudal to the epicenter. MnTBAP (10 mg/kg) significantly reduced the number of TUNEL-positive neurons in the sections 1 mm caudal from the epicenter. Our profiles provide a database for pharmacological intervention, and our results on MnTBAP treatment support an important role for antioxidant therapy in spinal cord injury. (c) 2007 Wiley-Liss, Inc.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA		Liu, DX (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd,Rte 0881, Galveston, TX 77555 USA.	dliu@utmb.edu		liu, danxia/0000-0001-8172-2344			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; BALENTINE JD, 1985, CENTRAL NERVOUS SYST, P455; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Bao F, 2004, NEUROSCIENCE, V126, P285, DOI 10.1016/j.neuroscience.2004.03.054; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; GOODKIN R, 1969, Surgical Forum (Chicago), V20, P430; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hachmeister JE, 2006, J NEUROTRAUM, V23, P1766, DOI 10.1089/neu.2006.23.1766; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Katoh K, 1996, NEUROSCI LETT, V216, P9; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2004, J NEUROTRAUM, V21, P805, DOI 10.1089/0897715041269650; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 2003, FREE RADICAL BIO MED, V34, P64, DOI 10.1016/S0891-5849(02)01184-X; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Liu DX, 2001, J NEUROCHEM, V77, P1036, DOI 10.1046/j.1471-4159.2001.00306.x; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Qian H, 1997, NEUROCHEM RES, V22, P1231, DOI 10.1023/A:1021980929422; Sheng HX, 2004, NEUROSCI LETT, V366, P220, DOI 10.1016/j.neulet.2004.05.050; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Springer JE, 1997, J NEUROCHEM, V68, P2469; Tatton WG, 1997, J NEURAL TRANSM-SUPP, P245; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vaziri ND, 2004, BRAIN RES, V995, P76, DOI 10.1016/j.brainres.2003.09.056; WHITE RJ, 1975, CLIN ORTHOP RELAT R, V112, P16; WU L, 2004, 34 ANN M SOC NEUR SA; Xu W, 2005, SPINAL CORD, V43, P204, DOI 10.1038/sj.sc.3101674; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	61	29	34	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2007	85	10					2175	2185		10.1002/jnr.21362			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	196XO	WOS:000248516700012	17551979				2022-02-06	
J	Yan, B; Bi, XY; He, J; Zhang, YB; Thakur, S; Xu, HY; Gendron, A; Kong, JM; Li, XM				Yan, Bin; Bi, Xiaoying; He, Jue; Zhang, Yanbo; Thakur, Sonia; Xu, Haiyun; Gendron, Alain; Kong, Jiming; Li, Xin-Min			Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice	LIFE SCIENCES			English	Article						quetiapine; common carotid artery occlusion (CCAO); memory; neurodegeneration; hippocampus	TRAUMATIC BRAIN-INJURY; ATYPICAL ANTIPSYCHOTIC-DRUGS; NEUROTROPHIC FACTOR EXPRESSION; TRANSIENT GLOBAL-ISCHEMIA; CEREBRAL-ISCHEMIA; NEURONAL DEGENERATION; SEROQUEL QUETIAPINE; FLUORO-JADE; PC12 CELLS; WATER MAZE	Quetiapine, a new atypical antipsychotic drug, has beneficial effects on cognitive impairment and neuropathological changes in treating chronic neurodegenerative diseases. Our previous studies have demonstrated that quetiapine may have neuroprotective properties. In the present study, we investigated the effects of a 2-week pre-administration of quetiapine (10 mg/kg/day, i.p.) on spatial memory impairment and hippocampal neurodegeneration induced by 60-minute bilateral common carotid artery occlusion (CCAO). Following a 7-day recovery phase from CCAO, the spatial memory of the mice was tested using a modified water maze test. After the behavioural test, the mice were sacrificed and brain sections were stained with NeuN (a neuron-specific soluble nuclear antigen), cresyl violet (Nissl), and Fluoro-Jade B. CCAO significantly induced spatial memory impairment and caused neurodegeneration in the hilus of hippocampus, while quetiapine significantly attenuated these changes. This is the first study showing that quetiapine significantly attenuates CCAO-induced spatial memory impairment and this improvement parallels the alleviative effects of quetiapine on CCAO-induced neurodegeneration in the hilus of hippocampus. The results suggest that quetiapine may have defending effects on the impairments induced by cerebral ischemia, which enhances our understanding about the mechanisms of quetiapine. (c) 2007 Elsevier Inc. All rights reserved.	Univ Saskatchewan, Dept Psychiat, Coll Med, Neuropsychiat Res Unit, Saskatoon, SK S7N 5E4, Canada; So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA; AstraZeneca, Mississauga, ON L4Y 1M4, Canada; Univ Manitoba, Fac Med, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Psychiat, Winnipeg, MB R3E 3N4, Canada		Li, XM (corresponding author), Univ Saskatchewan, Dept Psychiat, Coll Med, Neuropsychiat Res Unit, A114 Med Res Bldg,103 Wiggins Rd, Saskatoon, SK S7N 5E4, Canada.	xin-min.li@usask.ca		Kong, Jiming/0000-0002-2859-9831; Zhang, Yanbo/0000-0002-2421-157X			Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Arvanitis LA, 1997, BIOL PSYCHIAT, V42, P233, DOI 10.1016/S0006-3223(97)00190-X; Bai O, 2002, J NEUROSCI RES, V69, P278, DOI 10.1002/jnr.10290; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Belcher AM, 2005, NEUROPSYCHOPHARMACOL, V30, P2026, DOI 10.1038/sj.npp.1300771; Bendel O, 2005, BRAIN RES, V1033, P135, DOI 10.1016/j.brainres.2004.11.033; Bokura H, 1997, STROKE, V28, P970, DOI 10.1161/01.STR.28.5.970; BRADVIK B, 1989, ACTA NEUROL SCAND, V80, P411, DOI 10.1111/j.1600-0404.1989.tb03902.x; Caccamo D, 2004, AMINO ACIDS, V27, P373, DOI 10.1007/s00726-004-0117-1; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; Cizkova D, 2000, CELL MOL NEUROBIOL, V20, P367, DOI 10.1023/A:1007018327133; DU L, 2000, CHINESE PHARMACOL B, V35, P93; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fumagalli F, 2004, NEUROREPORT, V15, P2109, DOI 10.1097/00001756-200409150-00022; GONGMING Y, 1997, BRAIN RES, V752, P209; Green AR, 2000, NEUROPHARMACOLOGY, V39, P1483, DOI 10.1016/S0028-3908(99)00233-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; He J, 2006, BEHAV BRAIN RES, V168, P236, DOI 10.1016/j.bbr.2005.11.014; He J, 2005, BEHAV BRAIN RES, V160, P178, DOI 10.1016/j.bbr.2004.11.028; Horacek J, 2006, CNS DRUGS, V20, P389, DOI 10.2165/00023210-200620050-00004; JASPERS RMA, 1990, NEUROSCI LETT, V117, P149, DOI 10.1016/0304-3940(90)90135-V; JOHANSEN FF, 1987, ACTA NEUROPATHOL, V73, P110, DOI 10.1007/BF00693775; Kasper S, 2003, PSYCHONEUROENDOCRINO, V28, P27, DOI 10.1016/S0306-4530(02)00115-4; Kim DH, 2006, PHARMACOL BIOCHEM BE, V85, P658, DOI 10.1016/j.pbb.2006.10.025; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kurz AF, 2005, INT PSYCHOGERIATR, V17, pS35, DOI 10.1017/S1041610205001936; Martin LJ, 2001, INT J MOL MED, V7, P455; Nasrallah HA, 2002, J CLIN PSYCHIAT, V63, P12; NUNN JA, 1994, BEHAV BRAIN RES, V62, P41, DOI 10.1016/0166-4328(94)90036-1; Ogren SO, 1996, NEUROSCIENCE, V75, P1127, DOI 10.1016/0306-4522(96)00215-1; Park SW, 2006, NEUROSCI LETT, V402, P25, DOI 10.1016/j.neulet.2006.03.028; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Perez-Neri I, 2006, NEUROCHEM RES, V31, P1279, DOI 10.1007/s11064-006-9162-3; Purdon SE, 2001, J PSYCHIATR NEUROSCI, V26, P137; Qing H, 2003, EUR J NEUROSCI, V17, P1563, DOI 10.1046/j.1460-9568.2003.02590.x; Raggi MA, 2004, CURR MED CHEM, V11, P279, DOI 10.2174/0929867043456089; Riva MA, 1997, MOL BRAIN RES, V50, P136, DOI 10.1016/S0169-328X(97)00175-7; Rodrigo J, 2005, FREE RADICAL BIO MED, V39, P26, DOI 10.1016/j.freeradbiomed.2005.02.010; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Tanaka R, 2004, STROKE, V35, P1454, DOI 10.1161/01.STR.0000126480.40967.b3; Tarazi FI, 2003, J PHARMACOL EXP THER, V306, P1145, DOI 10.1124/jpet.103.052597; Tascedda F, 1999, NEUROPSYCHOPHARMACOL, V21, P211, DOI 10.1016/S0893-133X(99)00034-2; Velligan DI, 2002, SCHIZOPHR RES, V53, P239, DOI 10.1016/S0920-9964(01)00268-7; Wei ZL, 2003, J NEUROSCI RES, V74, P942, DOI 10.1002/jnr.10832; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P; Xu HY, 2002, NEUROSCI LETT, V321, P65, DOI 10.1016/S0304-3940(02)00034-4; Yu L, 1997, CHINESE PHARMACOL B, V13, P223	50	29	31	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	JUL 12	2007	81	5					353	361		10.1016/j.lfs.2007.05.020			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	201NN	WOS:000248839000002	17631910				2022-02-06	
J	Pagulayan, KF; Temkin, NR; Machamer, JE; Dikmen, SS				Farrell Pagulayan, Kathleen; Temkin, Nancy R.; Machamer, Joan E.; Dikmen, Sureyya S.			The measurement and magnitude of awareness difficulties after traumatic brain injury: A longitudinal study	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						impaired self-awareness; sickness impact profile; psychosocial symptoms; measurement; head injury; concordance	QUALITY-OF-LIFE; SELF-AWARENESS; IMPAIRED AWARENESS; HEAD-INJURY; RANDOMIZED-TRIAL; DEFICITS; REHABILITATION; LIMITATIONS; RATINGS; SCALE	Previous research suggests that reduced self-awareness is common following traumatic brain injury (TBI). However. few studies have examined the magnitude of this problem in a sample representative of hospitalized individuals. In this longitudinal study, individuals with complicated mild to severe TBIs and their significant others (SO) were evaluated at 1 and 12 months postinjury on the Sickness Impact Profile. Awareness was measured by comparing the level of injury-related problems reported by a person with TBI and their SO. Overall, individuals with TBI did not report fewer difficulties than their SO. In contrast, they frequently reported more injury-related difficulties than their SO. AS there is no commonly or universally accepted definition for differential awareness, the magnitude of underreporting and overreporting problems is presented using four different cutoff scores. A minimum discrepancy is proposed for defining awareness difficulties that is based on the standard error of measurement of the test-retest difference of the measure. Reduced self-awareness was inconsistent across both time and functional domains. These results suggest that reduced self-awareness is not the norm at 1 or 12 months postinjury and highlight the need for a more standardized approach to the measurement and classification of self-awareness.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Pagulayan, KF (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	farkat@u.washington.edu	Pagulayan, Kati/AAR-9225-2020		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD048030] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS019643, R01 NS19643] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD048030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER		ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; AMADOR XF, 1994, ARCH GEN PSYCHIAT, V51, P826; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Clare L, 2004, BRIT J CLIN PSYCHOL, V43, P177, DOI 10.1348/014466504323088042; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; McCrae RR, 1998, J PERS, V66, P285, DOI 10.1111/1467-6494.00013; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sneeuw KCA, 1997, STROKE, V28, P1541, DOI 10.1161/01.STR.28.8.1541; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Wallace CA, 2000, BRAIN INJURY, V14, P549; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON BA, 1996, BEHAV ASS DYSEXECUTI; Wyrwich KW, 2005, QUAL LIFE RES, V14, P285, DOI 10.1007/s11136-004-0705-2	47	29	29	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2007	13	4					561	570		10.1017/S1355617707070713			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	186GJ	WOS:000247766800002	17521477				2022-02-06	
J	Selvanathan, S; Goldschlager, T; McMillen, J; Campbell, S				Selvanathan, S.; Goldschlager, T.; McMillen, J.; Campbell, S.			Penetrating craniocerebral injuries from nail-gun use	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						foreign bodies; penetrating head injuries; nails; nail-gun; false aneurysms; penetrating eye injuries	OF-THE-LITERATURE; ARTERY ANEURYSM; INTRACRANIAL NAIL; CAROTID-ARTERY; SECONDARY; SINUS; HEAD	Three patients with penetrating craniocerebral nail-gun injuries are described. In the first patient the nail was impinging on the internal carotid artery (ICA) in the carotid canal. On removal of the nail, the patient developed a false aneurysm at the site. To our knowledge, this is the first reported case of nail-gun injury affecting the ICA and also the first case of penetrating head injury affecting the ICA in the carotid canal. The second patient had seven intracranial nails in the frontal area. Three nails penetrated the left orbit, one of which perforated the globe. One nail damaged the optic nerve resulting in optic neuropathy. In the third patient the nail extended through the squamous temporal bone into the temporal lobe. All three were managed successfully via closed gentle traction without craniotomy and/ or endovascular intervention. The literature is reviewed and management options for penetrating head injuries are discussed. (c) 2006 Elsevier Ltd. All rights reserved.	Royal Brisbane Hosp, Kenneth G Jamieson Dept Neurosurg, Herston, Qld 4029, Australia		Goldschlager, T (corresponding author), Royal Brisbane Hosp, Kenneth G Jamieson Dept Neurosurg, Level 7,Ned Hanlon Bldg, Herston, Qld 4029, Australia.	tonygoldschlager@hotmail.com					Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; [Anonymous], 2001, J TRAUMA S, V51, pS34; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; BRAUN J, 1987, J COMPUT ASSIST TOMO, V11, P525, DOI 10.1097/00004728-198705000-00030; Cunningham EJ, 2004, NEUROSURGERY, V55, P1225, DOI 10.1227/01.NEU.0000140991.82075.01; Depauw P, 2003, MINIM INVAS NEUROSUR, V46, P250; Falcioni M, 1999, Acta Otorhinolaryngol Ital, V19, P36; Guyot LL, 2001, NEUROL RES, V23, P291, DOI 10.1179/016164101101198442; Jithoo R, 2001, S AFR MED J, V91, P316; Larson PS, 2000, NEUROSURG FOCUS, V8; Liu James K, 2004, Neurosurg Focus, V17, pE13; Moonis G, 2005, AM J NEURORADIOL, V26, P1324; Musa BS, 1997, BRIT J NEUROSURG, V11, P564; Ravelli V, 1987, J Neurosurg Sci, V31, P153; REZAI AR, 1994, SURG NEUROL, V42, P312, DOI 10.1016/0090-3019(94)90399-9; Sani S, 2005, J NEUROSURG, V103, P567, DOI 10.3171/jns.2005.103.3.0567; Shenoy SN, 2003, NEUROL INDIA, V51, P411; Spennato P, 2005, SURG NEUROL, V64, P368, DOI 10.1016/j.surneu.2004.12.003; Tancioni F, 1994, J Neurosurg Sci, V38, P239; THOMAS MD, 1987, MED J AUSTRALIA, V147, P602, DOI 10.5694/j.1326-5377.1987.tb133698.x	20	29	30	0	2	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	JUL	2007	14	7					678	683		10.1016/j.jocn.2006.02.017			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184QL	WOS:000247656700015	17452105				2022-02-06	
J	Benvenisti-Zarom, L; Regan, RF				Benvenisti-Zarom, Luna; Regan, Raymond F.			Astrocyte-specific heme oxygenase-1 hyperexpression attenuates heme-mediated oxidative injury	NEUROBIOLOGY OF DISEASE			English	Article						cell culture; free radical; gene therapy; iron; hemoglobin toxicity; intracerebral hemorrhage; oxidative stress; stroke	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TRAUMATIC BRAIN-INJURY; SMOOTH-MUSCLE CELLS; GENE-TRANSFER; TRANSGENE EXPRESSION; PROTECTS ASTROCYTES; HEMOGLOBIN TOXICITY; CORTICAL ASTROCYTES; CARBON-MONOXIDE; GFAP PROMOTER	In prior studies, we have observed that HO activity protects astrocytes from heme-mediated injury, but paradoxically increases neuronal injury. In this study, we tested the hypothesis that an adenovirus encoding the human HO-1 gene driven by an enhanced glial fibrillary acidic protein promoter (Ad-GFAP-HO-1) would increase HO-1 expression selectively in astrocytes, and provide cytoprotection. Treatment with 100 MOI Ad-GFAP-HO-1 for 24 h resulted in HO-1 expression that was 6.4-fold higher in cultured primary astrocytes than in neurons. Astrocyte HO activity was increased by approximately fourfold over baseline, which was sufficient to reduce cell death after 24-h hemin exposure by 60%, as assessed by both MTT and LDH release assays. A similar reduction in cell protein oxidation, quantified by carbonyl assay, was also observed. These results suggest that HO-1 transgene expression regulated by an enhanced GFAP promoter selectively increases HO-1 expression in astrocytes, and is cytoprotective. Further investigation of this strategy in vivo is warranted. (c) 2007 Elsevier Inc. All rights reserved.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA		Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,Thompson Bldg Rm 239, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS050662-02, NS50662, R01 NS050662-01A1, R01 NS050662] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050662] Funding Source: NIH RePORTER		Abraham NG, 2002, AM J PHYSIOL-LUNG C, V283, pL1117, DOI 10.1152/ajplung.00365.2001; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Benvenisti-Zarom L, 2006, NEUROSCI LETT, V398, P230, DOI 10.1016/j.neulet.2006.01.003; Botros FT, 2005, KIDNEY INT, V68, P2745, DOI 10.1111/j.1523-1755.2005.00745.x; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; BUNN HF, 1968, J BIOL CHEM, V243, P465; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen J, 2005, CURR NEUROVASC RES, V2, P189, DOI 10.2174/1567202054368344; Chen J, 2004, BIOCHEM BIOPH RES CO, V318, P88, DOI 10.1016/j.bbrc.2004.03.187; Chen-Roetling J, 2006, BIOCHEM BIOPH RES CO, V350, P233, DOI 10.1016/j.bbrc.2006.09.036; de Leeuw B, 2006, J NEUROSCI RES, V83, P744, DOI 10.1002/jnr.20776; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Gennuso F, 2004, P NATL ACAD SCI USA, V101, P2470, DOI 10.1073/pnas.0308452100; Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633; Gong Y, 2006, ACTA NEUROCHIR SUPPL, V96, P232; Hansen TWR, 1997, BIOCHEM MOL MED, V60, P155, DOI 10.1006/bmme.1996.2565; HEBBEL RP, 1989, SEMIN HEMATOL, V26, P136; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; Liu XM, 2002, CIRCULATION, V105, P79, DOI 10.1161/hc0102.101369; Masada T, 2001, J NEUROSURG, V95, P680, DOI 10.3171/jns.2001.95.4.0680; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; McKie EA, 1998, GENE THER, V5, P440, DOI 10.1038/sj.gt.3300621; Morelli AE, 1999, J GEN VIROL, V80, P571, DOI 10.1099/0022-1317-80-3-571; Morimoto S, 2002, J BIOL CHEM, V277, P33235, DOI 10.1074/jbc.M204309200; MUCKE L, 1991, NEW BIOL, V3, P465; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Ono S, 2002, J NEUROSURG, V96, P1094, DOI 10.3171/jns.2002.96.6.1094; Quan S, 2004, KIDNEY INT, V65, P1628, DOI 10.1111/j.1523-1755.2004.00562.x; Quan S, 2002, J CELL BIOCHEM, V85, P410, DOI 10.1002/jcb.10147; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2002, NEUROSCIENCE, V113, P985, DOI 10.1016/S0306-4522(02)00243-9; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; SHAFITZAGARDO B, 1988, GLIA, V1, P346, DOI 10.1002/glia.440010507; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Su M, 2004, NEUROCHEM RES, V29, P2075, DOI 10.1007/s11064-004-6881-1; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Taketani S, 2005, TOHOKU J EXP MED, V205, P297, DOI 10.1620/tjem.205.297; Teng ZP, 2004, NEUROBIOL DIS, V17, P179, DOI 10.1016/j.nbd.2004.07.009; TENG ZP, 2003, ACAD EMERG MED, V10, P480; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163	58	29	29	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2007	26	3					688	695		10.1016/j.nbd.2007.03.006			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	177II	WOS:000247146400019	17467999	Green Accepted			2022-02-06	
J	Cui, Q; Hodgetts, SI; Hu, Y; Luo, JM; Harvey, AR				Cui, Q.; Hodgetts, S. I.; Hu, Y.; Luo, J.-M.; Harvey, A. R.			Strain-specific differences in the effects of cyclosporin A and FK506 on the survival and regeneration of axotomized retinal ganglion cells in adult rats	NEUROSCIENCE			English	Article						retina; axonal regeneration; neuronal survival; autoimmune disease; peripheral nerve grafts; visual system	SPINAL-CORD-INJURY; PERIPHERAL-NERVE REGENERATION; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL PERMEABILITY TRANSITION; IMPROVES FUNCTIONAL RECOVERY; IMMUNOPHILIN-LIGANDS FK506; OPTIC-NERVE; T-CELLS; PROTECTIVE AUTOIMMUNITY	The immune response can influence neuronal viability and plasticity after injury, effects differing in strains of rats with different susceptibility to autoimmune disease. We assessed the effects of i.p. injections of cyclosporin A (CsA) or FK506 on adult retinal ganglion cell (RGC) survival and axonal regeneration into peripheral nerve (PN) autografted onto the cut optic nerve of rats resistant (Fischer F344) or vulnerable (Lewis) to autoimmune disease. Circulating and tissue CsA and FK506 levels were similar in both strains. Three weeks after autologous PN transplantation the number of viable beta-III tubulin-positive RGCs was significantly greater in CsA- and FK506-treated F344 rats compared with saline-injected controls. RGC survival in Lewis rats was not significantly altered. In F344 rats, retrograde labeling of RGCs revealed that CsA or FK506 treatment significantly increased the number of RGCs that regenerated an axon into a PN autograft; however these agents had no beneficial effect on axonal regeneration in Lewis rats. PN grafts in F344 rats also contained comparatively more pan-neurofilament immunoreactive axons. In both strains, 3 weeks after transplantation CsA or FK506 treatment resulted in increased retinal macrophage numbers, but only in F344 rats was this increase significant. At this time-point PN grafts in both strains contained many macrophages and some T cells. T cell numbers in Lewis rats were significantly greater than in F344 animals. The increased RGC axonal regeneration seen in CsA- or FK506-treated F344 but not Lewis rats shows that modulation of immune responses after neurotrauma has complex and not always predictable outcomes. (c) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.	Chinese Univ Hong Kong, Fac Med, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China; Univ Western Australia, Sect Anat & Human Biol, Perth, WA 6009, Australia; Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China; Shantou Univ, Coll Med, Chinese Univ Hong Kong, Shantou, Peoples R China		Cui, Q (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.	qcui@cuhk.edu.hk; arharvey@anhb.uwa.edu.au	Harvey, Alan R/A-4911-2008; Ying, Hu/F-3581-2010	Hodgetts, Stuart/0000-0002-3318-0410; , Alan/0000-0002-2590-831X			Arumugam TV, 2005, NEUROMOL MED, V7, P229, DOI 10.1385/NMM:7:3:229; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Bahr M, 2000, TRENDS NEUROSCI, V23, P483, DOI 10.1016/S0166-2236(00)01637-4; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BRAY GM, 1987, J EXP BIOL, V132, P5; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Carrigan KA, 2004, INT IMMUNOPHARMACOL, V4, P419, DOI 10.1016/j.intimp.2004.01.011; Chierzi S, 2001, RESTOR NEUROL NEUROS, V19, P109; Cizza G, 1994, Immunomethods, V5, P73, DOI 10.1006/immu.1994.1039; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Dhabhar FS, 1998, ANN NY ACAD SCI, V840, P359, DOI 10.1111/j.1749-6632.1998.tb09575.x; DHABHAR FS, 1995, J NEUROIMMUNOL, V56, P77, DOI 10.1016/0165-5728(94)00135-B; Diaz-Ruiz A, 2005, NEUROCHEM RES, V30, P245, DOI 10.1007/s11064-005-2447-0; Dimou L, 2006, J NEUROSCI, V26, P5591, DOI 10.1523/JNEUROSCI.1103-06.2006; Elena G, 1997, INT J IMMUNOPHARMACO, V19, P699; Elenkov IJ, 2004, ANN NY ACAD SCI, V1024, P138, DOI 10.1196/annals.1321.010; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Freeman EE, 2000, INVEST OPHTH VIS SCI, V41, P1111; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Frost P, 2001, J NEUROIMMUNOL, V121, P32, DOI 10.1016/S0165-5728(01)00440-4; Gillon RS, 2003, J NEUROSCI RES, V74, P524, DOI 10.1002/jnr.10788; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Gold BG, 1998, NEUROSCI LETT, V241, P25, DOI 10.1016/S0304-3940(97)00960-9; Gong D, 1998, ANESTH ANALG, V87, P963, DOI 10.1097/00000539-199810000-00040; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Gonzalez-Rey E, 2007, NAT REV IMMUNOL, V7, P52, DOI 10.1038/nri1984; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Hayashi Y, 2005, J NEUROTRAUM, V22, P1267, DOI 10.1089/neu.2005.22.1267; Heiduschka P, 2000, PROG RETIN EYE RES, V19, P577, DOI 10.1016/S1350-9462(00)00011-2; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; Hodgetts SI, 2003, TRANSPLANTATION, V75, P863, DOI 10.1097/01.TP.0000053754.33317.4B; HOLLANDER GA, 1994, TRANSFUS SCI, V15, P207, DOI 10.1016/0955-3886(94)90133-3; Hortelano S, 1999, BRIT J PHARMACOL, V126, P1139, DOI 10.1038/sj.bjp.0702422; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; Ibarra A, 1996, J NEUROTRAUM, V13, P267, DOI 10.1089/neu.1996.13.267; Isenmann S, 2003, PROG RETIN EYE RES, V22, P483, DOI 10.1016/S1350-9462(03)00027-2; Jensen JN, 2005, ANN PLAS SURG, V54, P420, DOI 10.1097/01.sap.0000151461.60911.c0; Jiang HS, 2002, TRANSPLANTATION, V73, P1808, DOI 10.1097/00007890-200206150-00019; Jones TB, 2005, CURR PHARM DESIGN, V11, P1223, DOI 10.2174/1381612053507468; Jones TB, 2004, J NEUROSCI, V24, P3752, DOI 10.1523/JNEUROSCI.0406-04.2004; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Jost SC, 2000, RESTOR NEUROL NEUROS, V17, P39; Kawai R, 1998, J PHARMACOL EXP THER, V287, P457; KAY JE, 1989, IMMUNOLOGY, V67, P473; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kipnis J, 2002, P NATL ACAD SCI USA, V99, P15620, DOI 10.1073/pnas.232565399; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Klettner A, 2003, BRIT J PHARMACOL, V138, P1004, DOI 10.1038/sj.bjp.0705132; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koeberle PD, 2004, NEUROSCIENCE, V125, P903, DOI 10.1016/S0306-4522(03)00398-1; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Ling CY, 2006, J NEUROSCI, V26, P731, DOI 10.1523/JNEUROSCI.3502-05.2006; LYONS WE, 1995, J NEUROSCI, V15, P2985; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marsen TA, 2000, FUNDAM CLIN PHARM, V14, P401, DOI 10.1111/j.1472-8206.2000.tb00422.x; Martucci C, 2004, PAIN, V110, P385, DOI 10.1016/j.pain.2004.04.020; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nevo U, 2003, TRENDS MOL MED, V9, P88, DOI 10.1016/S1471-4914(03)00024-8; NG TF, 1995, J NEUROCYTOL, V24, P487, DOI 10.1007/BF01179974; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Pan YA, 2003, J NEUROSCI, V23, P11479; Pompeo A, 1999, LIFE SCI, V64, P837, DOI 10.1016/S0024-3205(99)00005-3; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Rosenstiel P, 2003, J NEUROTRAUM, V20, P297, DOI 10.1089/089771503321532888; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; Sauve Y, 2001, J NEUROSCI, V21, P951, DOI 10.1523/JNEUROSCI.21-03-00951.2001; Schwartz M, 2005, J NEUROL SCI, V233, P163, DOI 10.1016/j.jns.2005.03.014; Schwartz M, 2002, TRENDS IMMUNOL, V23, P530, DOI 10.1016/S1471-4906(02)02322-0; Sheehan Jason, 2006, Neurosurg Focus, V20, pE9; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Steiniger B, 2001, IMMUNOL REV, V184, P38, DOI 10.1034/j.1600-065x.2001.1840104.x; Sternberg EM, 2001, J ENDOCRINOL, V169, P429, DOI 10.1677/joe.0.1690429; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Stevens DB, 2002, J NEUROIMMUNOL, V126, P25, DOI 10.1016/S0165-5728(02)00045-0; Strestikova P, 2001, IMMUNOPHARM IMMUNOT, V23, P67, DOI 10.1081/IPH-100102568; SUZUKI N, 1990, CLIN EXP IMMUNOL, V79, P240; Tanaka C, 2000, DRUG METAB DISPOS, V28, P582; Taskinen HS, 2000, J NEUROTRAUM, V17, P431, DOI 10.1089/neu.2000.17.431; THANOS S, 1993, J NEUROSCI, V13, P455; TOCCI MJ, 1989, J IMMUNOL, V143, P718; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vidal-Sanz M, 2002, PROG BRAIN RES, V137, P443; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang M S, 1999, J Spinal Cord Med, V22, P287; Warrington AE, 2001, J ALLERGY CLIN IMMUN, V108, pS121, DOI 10.1067/mai.2001.118301; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; WIRT DP, 1993, CLIN IMMUNOL IMMUNOP, V67, P224; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001	99	29	29	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	MAY 25	2007	146	3					986	999		10.1016/j.neuroscience.2007.02.034			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	169HY	WOS:000246584500010	17408862				2022-02-06	
J	Beaudin, M; Saint-Vil, D; Ouimet, A; Mercier, C; Crevier, L				Beaudin, Marianne; Saint-Vil, Dickens; Ouimet, Alain; Mercier, Claude; Crevier, Louis			Clinical algorithm and resource use in the management of children with minor head trauma	JOURNAL OF PEDIATRIC SURGERY			English	Article						minor head trauma; skull x-ray; head computed tomography; infant	INTRACRANIAL INJURY; REQUIRE HOSPITALIZATION; SKULL FRACTURE; ADMISSION; RULE; INFANTS	Purpose: There are no clear guidelines for the management of minor head injury, including the use of skull x-rays and computed tomography (CT) scans of the head. This is reflected in clinical practice by a wide variability in imaging study use and by the fact that some patients are discharged home from the emergency room (ER), whereas others are admitted to the hospital with or without a period of observation before admission. To address this issue, we proposed and applied a new protocol for minor head injury at our institution. Methods: Between January 2004 and December 2005, 417 patients presented to the emergency department at our institution with minor head injury. All of them had fallen from less than I in. Every chart was retrospectively evaluated, and pertinent data were extracted. Results: The mean age of the patients was 9.8 months (2 weeks to 32 months). One hundred fifty-three had a skull x-ray, and 13 had a CT scan of the head. Of the 153 patients who had a skull x-ray, only 15 had a skull fracture. Of these 15 patients, 3 also had a CT scan of the head that confirmed the diagnosis of skull fracture. Of the 13 CT scans that were done, only these 3 were positive. Eleven patients were kept in the ER for 6 hours for close observation, and 5 of these were eventually admitted. Overall, 8 patients were admitted to the hospital for observation. Of these 8 patients, 7 had a skull x-ray, from which 5 were positive. Only 2 of the admitted patients had a CT scan, and they Were both positive for a skull fracture. One of the CT also demonstrated a subdural hematoma along with subarachnoid hemorrhage. These 2 patients also had a positive skull x-ray. None of the patients that were admitted had headaches or neurologic impairments. The mean age of the patients admitted was 3.8 months (2 weeks to 12 months). The mean hospital stay was 1.2 days (1-3 days). Conclusion: Only 10% of the skull x-rays and CT scans were positive for a skull fracture, which led to an admission in half of these patients. The other half was mainly discharged from ER after being observed. Several patients underwent a skull x-ray that we feel was not necessary in the management of their minor head injury. For those who had a head CT scan, only one revealed additional information and none of them had an impact on the final management. Observation in the ER could have been reasonable for most cases. (C) 2007 Elsevier Inc. All rights reserved.	CHU St Justine, Div Pediat Gen Surg, Montreal, PQ H3T 1C5, Canada; CHU St Justine, Div Neurosurg, Montreal, PQ H3T 1C5, Canada		Saint-Vil, D (corresponding author), CHU St Justine, Div Pediat Gen Surg, Montreal, PQ H3T 1C5, Canada.	dickens_saint_vil@ssss.gouv.qc.ca					Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P453; KADISH HA, 1995, ANN EMERG MED, V26, P37, DOI 10.1016/S0196-0644(95)70235-0; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; QUAYLE KS, 1997, PEDIATRICS, V99, P11; Reed MJ, 2005, ARCH DIS CHILD, V90, P859, DOI 10.1136/adc.2004.053603; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Spencer MT, 2003, AM J EMERG MED, V21, P111, DOI 10.1053/ajem.2003.50031; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X	17	29	29	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	MAY	2007	42	5					849	852		10.1016/j.jpedsurg.2006.12.038			4	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	175JS	WOS:000247010500021	17502197				2022-02-06	
J	Thombs, BD; Bresnick, MG; Magyar-Russell, G; Lawrence, JW; McCann, UD; Fauerbach, JA				Thombs, Brett D.; Bresnick, Melissa G.; Magyar-Russell, Gina; Lawrence, John W.; McCann, Una D.; Fauerbach, James A.			Symptoms of depression predict change in physical health after burn injury	BURNS			English	Article						depression; burn; physical function	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; MAJOR DEPRESSION; MYOCARDIAL-INFARCTION; CLINICAL-SIGNIFICANCE; CONTROLLED-TRIAL; MEDICALLY ILL; PREVALENCE	This study investigated the prevalence of symptoms of depression in patients hospitalized with severe burns and the association of symptoms of depression in the hospital with physical health 2 months after discharge, controlling for pre-burn physical health as measured by the SF-36 physical composite score. Survivors of acute burns were evaluated during the hospitalization (N = 262) and at 1 week (N = 165) and 2 months (N = 100) after discharge. The prevalence of at least mild to moderate symptoms of depression (Beck Depression Inventory >= 10) ranged from 23% to 26%. In-hospital symptoms of depression predicted change in physical health from pre-burn to 2 months post-discharge (p =.02), controlling for patient demographics, burn severity, and symptoms of PTSD. These results suggest that patients should be screened for depression, both in-hospital and during rehabilitation after discharge. (c) 2006 Elsevier Ltd and ISBI. All rights reserved.	Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; CUNY Coll Staten Isl, New York, NY 10021 USA		Thombs, BD (corresponding author), Sir Mortimer B Davis Jewish Hosp, Inst Community & Family Psychiat, 4333 Cote Ste Catherine Rd, Montreal, PQ H3T 1E4, Canada.	brett.thombs@mcgill.ca		Thombs, Brett/0000-0002-5644-8432			*AM BURN ASS, 1984, B AM COLL SURG, V69, P24; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Beck AT, 1987, MANUAL REVISED BECK; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Breslau N, 2000, BIOL PSYCHIAT, V48, P902, DOI 10.1016/S0006-3223(00)00933-1; Brown KW, 2003, PSYCHOSOM MED, V65, P636, DOI 10.1097/01.PSY.0000077503.96903.A6; Carrougher GF, 2003, J BURN CARE REHABIL, V24, P1, DOI 10.1097/00004630-200301000-00003; CHOINIERE M, 1989, J TRAUMA, V29, P1531, DOI 10.1097/00005373-198911000-00013; Darnall BD, 2005, ARCH PHYS MED REHAB, V86, P650, DOI 10.1016/j.apmr.2004.10.028; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; de Groot M, 2001, PSYCHOSOM MED, V63, P619, DOI 10.1097/00006842-200107000-00015; Dowson CA, 2004, J PSYCHOSOM RES, V56, P333, DOI 10.1016/S0022-3999(03)00040-0; Dryden DM, 2005, NEUROEPIDEMIOLOGY, V25, P55, DOI 10.1159/000086284; Esselman PC, 2006, AM J PHYS MED REHAB, V85, P383, DOI 10.1097/01.phm.0000202095.51037.a3; Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fauerbach JA, 1997, PSYCHOSOMATICS, V38, P374, DOI 10.1016/S0033-3182(97)71445-2; Garratt AN, 2002, BMJ-BRIT MED J, V324, P1417, DOI 10.1136/bmj.324.7351.1417; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; Holland JC, 1998, PSYCHO-ONCOL, V7, P291, DOI 10.1002/(SICI)1099-1611(199807/08)7:4<291::AID-PON361>3.0.CO;2-U; House A, 2001, STROKE, V32, P696, DOI 10.1161/01.STR.32.3.696; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Kauhanen ML, 2000, ARCH PHYS MED REHAB, V81, P1541, DOI 10.1053/apmr.2000.9391; Kemp BJ, 2004, J SPINAL CORD MED, V27, P22, DOI 10.1080/10790268.2004.11753726; Kilbourne AM, 2005, AM J GERIAT PSYCHIAT, V13, P202; Koenig HG, 1997, AM J PSYCHIAT, V154, P1376; Krause JS, 2004, ARCH PHYS MED REHAB, V85, P1503, DOI 10.1016/j.apmr.2004.01.017; Lenze EJ, 2004, INT J GERIATR PSYCH, V19, P472, DOI 10.1002/gps.1116; Lustman PJ, 2000, DIABETES CARE, V23, P618, DOI 10.2337/diacare.23.5.618; Lyketsos CG, 1997, J NEUROPSYCH CLIN N, V9, P556; Madianos MG, 2001, PSYCHOTHER PSYCHOSOM, V70, P30, DOI 10.1159/000056222; MAGYARRUSSELL GM, 2006, J BURN CARE RES, V27, pS103; McQuaid D, 2003, J BURN CARE REHABIL, V24, P203, DOI 10.1097/01.BCR.0000075849.08794.36; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MORENO JK, 1993, J PERS ASSESS, V61, P511, DOI 10.1207/s15327752jpa6103_7; Pallua N, 2003, BURNS, V29, P143, DOI 10.1016/S0305-4179(02)00238-3; Phillips P, 1999, JAMA-J AM MED ASSOC, V282, P1118, DOI 10.1001/jama.282.12.1118; Raison CL, 2003, BIOL PSYCHIAT, V54, P283, DOI 10.1016/S0006-3223(03)00413-X; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Robinson RG, 2003, BIOL PSYCHIAT, V54, P376, DOI 10.1016/S0006-3223(03)00423-2; Robinson RG, 2000, AM J PSYCHIAT, V157, P351, DOI 10.1176/appi.ajp.157.3.351; Rudisch B, 2003, BIOL PSYCHIAT, V54, P227, DOI 10.1016/S0006-3223(03)00587-0; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; Thombs BD, 2006, J GEN INTERN MED, V21, P30, DOI 10.1111/j.1525-1497.2005.00269.x; Thombs BD, 2006, GEN HOSP PSYCHIAT, V28, P494, DOI 10.1016/j.genhosppsych.2006.08.010; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; van Melle JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.psy.0000146294.82810.9c; Ward H W, 1987, J Burn Care Rehabil, V8, P294, DOI 10.1097/00004630-198707000-00011; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Wiechman SA, 2001, J BURN CARE REHABIL, V22, P417, DOI 10.1097/00004630-200111000-00012; Ziegelstein RC, 2000, ARCH INTERN MED, V160, P1818, DOI 10.1001/archinte.160.12.1818; 2005, NIDRR MODEL SYSTEMS	54	29	29	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179	1879-1409		BURNS	Burns	MAY	2007	33	3					292	298		10.1016/j.burns.2006.10.399			7	Critical Care Medicine; Dermatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Dermatology; Surgery	160WJ	WOS:000245972800002	17382189				2022-02-06	
J	Hinz, J; Rosmus, M; Popov, A; Moerer, O; Frerichs, I; Quintel, M				Hinz, Jose; Rosmus, Martin; Popov, Aron; Moerer, Onnen; Frerichs, Inez; Quintel, Michael			Effectiveness of an intravascular cooling method compared with a conventional cooling technique in neurologic patients	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						temperature control; intravascular cooling catheter	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; RECTAL TEMPERATURES; BODY-TEMPERATURE; FEVER; HYPERTHERMIA; STROKE; SYSTEM	Fever is common among neurologic patients and is usually treated by antipyretic drugs and external cooling. An alternative method for temperature management may be an intravascular approach. The aim of the study was to compare the effectiveness and the therapeutic costs of this new method with conventional treatment in neurologic patients. Twenty-six patients who suffered from subarachnoid hemorrhage or traumatic brain injury with febrile episodes were included the study and were randomized into 2 different groups. In the "Conventional" group, fever was treated with antipyretic drugs and/or surface cooling techniques to achieve a body core temperature of 36.5 degrees C. In the "CoolGard" group, patients were treated with an intravascular cooling catheter (Coolgard, Alsius, CA). We compared the effectiveness of these 2 approaches by calculating the mean deviation from 36.5 degrees C during a 48-hour period (fever burden). We found a significant difference in the fever burden [CoolGard: -0.49 to 1.22 (median -0.06)degrees C vs. Conventional: 1.05-2.34 (median 1.41)degrees C, P < 0.05]. Costs varied significantly between the CoolGard and the Conventional groups, with markedly higher daily costs in the CoolGard group [CoolGard: 15 to 140 US dollars (USD) (median 39 USD) vs. Conventional: 1 to 9 USD (median 5 USD), P < 0.05]. The effectiveness of the intravascular cooling catheter is excellent compared with conventional cooling therapies.	Univ Gottingen, Dept Anaesthestiol Emergency & Intens Care Med, D-3400 Gottingen, Germany; Univ Gottingen, Dept Cardiovasc Thorac Surg, D-3400 Gottingen, Germany; Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, Kiel, Germany		Hinz, J (corresponding author), Robert Koch Str 40D, D-37075 Gottingen, Germany.	mail@josehinz.de	Moerer, Onnen/K-6349-2019; Popov, Aron-Frederik/AAA-9933-2020; Frerichs, I./AAT-3685-2021	Popov, Aron-Frederik/0000-0003-4226-3004; Frerichs, I./0000-0002-7712-6539			Aiyagari V, 2004, NEUROCRIT CARE, V1, P209, DOI 10.1385/NCC:1:2:209; Al-Senani FM, 2004, RESUSCITATION, V62, P143, DOI 10.1016/j.resuscitation.2004.02.016; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Broessner G, 2005, CRIT CARE, V9, pR498, DOI 10.1186/cc3771; CASTELLA X, 1995, CRIT CARE MED, V23, P1327, DOI 10.1097/00003246-199508000-00005; Childs C, 2005, ANAESTHESIA, V60, P759, DOI 10.1111/j.1365-2044.2005.04193.x; Correia M, 2000, COCHRANE DB SYST REV; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; JENNETT B, 1976, LANCET, V1, P1031; Jorgensen HS, 1996, LANCET, V348, P193, DOI 10.1016/S0140-6736(05)66135-1; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lenhardt R, 1999, AM J MED, V106, P550, DOI 10.1016/S0002-9343(99)00068-6; MEMEZAWA H, 1995, BRAIN RES, V670, P48, DOI 10.1016/0006-8993(94)01251-C; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Otawara Y, 2003, SURG NEUROL, V60, P159, DOI 10.1016/S0090-3019(03)00083-1; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ramsay MAE, 2000, JAMA-J AM MED ASSOC, V284, P441, DOI 10.1001/jama.284.4.441; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023	21	29	34	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2007	19	2					130	135		10.1097/ANA.0b013e318032a208			6	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	153IP	WOS:000245426100008	17414000				2022-02-06	
J	Maccotta, L; Buckner, RL; Gilliam, FG; Ojemann, JG				Maccotta, Luigi; Buckner, Randy L.; Gilliam, Frank G.; Ojemann, Jeffrey G.			Changing frontal contributions to memory before and after medial temporal lobectomy	CEREBRAL CORTEX			English	Article						encoding; epilepsy; lateralization; postoperative; prefrontal cortex	POSITRON-EMISSION-TOMOGRAPHY; OBJECT RECOGNITION MEMORY; TRAUMATIC BRAIN-INJURY; FUNCTIONAL MRI; EPISODIC MEMORY; LOBE EPILEPSY; PREFRONTAL CORTEX; RHESUS-MONKEY; ALZHEIMERS-DISEASE; HEMISPHERIC-ASYMMETRY	Frontal recruitment was characterized using functional magnetic resonance imaging (fMRI) during memory encoding in temporal lobe epilepsy (TLE) patients before and after unilateral medial temporal lobectomy. Twenty-four TLE patients and 12 healthy controls underwent a preoperative fMRI session consisting of verbal and nonverbal incidental memory-encoding tasks that typically lead to robust, lateralized frontal activity in controls. A similar postoperative fMRI session was performed in a subset of patients. Preoperatively, the verbal task resulted in significant additional recruitment of right frontal cortex in left TLE patients, compared with controls. Right TLE patients instead showed typically lateralized frontal activation. Bilateral frontal recruitment has been observed in older adults and in young adults in situations of difficult task demands. Typical right-lateralized patterns of frontal recruitment were found in both patient groups during the nonverbal task, indicating that the bilateral frontal recruitment pattern was engaged dynamically depending on the task. After surgery, left TLE patients regained more lateralized frontal activity. These results demonstrated differences in frontal recruitment in left and right TLE patients. Such differences emerged in specific task settings and were influenced by surgery, suggesting a dynamic mechanism of frontal recruitment that can be obtained in TLE patients, possibly as a response to presurgical dysfunction.	Washington Univ, Div Biol & Biomed Sci, Dept Psychol, St Louis, MO USA; Washington Univ, Dept Anat & Neurobiol, St Louis, MO USA; Washington Univ, Dept Radiol, St Louis, MO USA; Washington Univ, Howard Hughes Med Inst, St Louis, MO USA; Washington Univ, Dept Neurol, St Louis, MO USA; Washington Univ, Dept Neurol Surg, St Louis, MO USA		Maccotta, L (corresponding author), Univ Calif San Francisco, Dept Neurol, 505 Parnassus Ave,Box 0114, San Francisco, CA 94143 USA.	luigi.maccotta@ucsf.edu		Ojemann, Jeffrey/0000-0001-7580-8934; Maccotta, Luigi/0000-0003-3702-0331	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24NS047551] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K24 NS047551] Funding Source: Medline		BACHEVALIER J, 1986, BEHAV BRAIN RES, V20, P249, DOI 10.1016/0166-4328(86)90225-1; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BARBAS H, 1993, NEUROSCIENCE, V56, P841, DOI 10.1016/0306-4522(93)90132-Y; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; Barbas H, 2000, BRAIN RES BULL, V52, P319, DOI 10.1016/S0361-9230(99)00245-2; BAUER RH, 1976, J COMP PHYSIOL PSYCH, V90, P293, DOI 10.1037/h0087996; Baxendale SA, 1998, NEUROPSY NEUROPSY BE, V11, P12; Becker JT, 1996, NEUROLOGY, V46, P692, DOI 10.1212/WNL.46.3.692; Bellgowan PSF, 1998, NEUROLOGY, V51, P479, DOI 10.1212/WNL.51.2.479; Benson D.F., 1986, FRONTAL LOBES; Billingsley RL, 2001, BRAIN, V124, P1218, DOI 10.1093/brain/124.6.1218; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Buckner RL, 2001, NAT REV NEUROSCI, V2, P624, DOI 10.1038/35090048; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Cabeza R, 1997, J NEUROSCI, V17, P391; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; DELLAROCCHETTA AI, 1993, NEUROPSYCHOLOGIA, V31, P503; DEMB JB, 1995, J NEUROSCI, V15, P5870; Detre JA, 1998, NEUROLOGY, V50, P926, DOI 10.1212/WNL.50.4.926; Dolan RJ, 1997, NATURE, V388, P582, DOI 10.1038/41561; Dolcos F, 2002, NEUROSCI BIOBEHAV R, V26, P819, DOI 10.1016/S0149-7634(02)00068-4; Dupont S, 2000, BRAIN, V123, P1722, DOI 10.1093/brain/123.8.1722; Easton A, 2001, BEHAV BRAIN RES, V121, P1, DOI 10.1016/S0166-4328(00)00384-3; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Frankland PW, 2005, NAT REV NEUROSCI, V6, P119, DOI 10.1038/nrn1607; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; Gaffan D, 2002, J NEUROSCI, V22, P7288; Golby AJ, 2002, EPILEPSIA, V43, P855, DOI 10.1046/j.1528-1157.2002.20501.x; GRADY CL, 1994, J NEUROSCI, V14, P1450, DOI 10.1523/JNEUROSCI.14-03-01450.1994; Grady CL, 2003, J NEUROSCI, V23, P986, DOI 10.1523/jneurosci.23-03-00986.2003; Grady CL, 2000, CURR OPIN NEUROBIOL, V10, P224, DOI 10.1016/S0959-4388(00)00073-8; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; Janszky T, 2005, EPILEPSIA, V46, P244, DOI 10.1111/j.0013-9580.2005.10804.x; Jokeit H, 1997, BRAIN, V120, P2283, DOI 10.1093/brain/120.12.2283; Jokeit H, 2001, NEUROLOGY, V57, P1786, DOI 10.1212/WNL.57.10.1786; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; Konishi S, 2001, NEUROIMAGE, V13, P364, DOI 10.1006/nimg.2000.0691; Kuera H., 1967, COMPUTATIONAL ANAL P; KUYPERS HGJ, 1965, EXP NEUROL, V11, P245, DOI 10.1016/0014-4886(65)90016-6; Lavenex P, 2002, J COMP NEUROL, V447, P394, DOI 10.1002/cne.10243; Lee TMC, 2002, EPILEPSIA, V43, P283, DOI 10.1046/j.1528-1157.2002.09901.x; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Logan JM, 2002, NEURON, V33, P827, DOI 10.1016/S0896-6273(02)00612-8; Lustig C, 2003, P NATL ACAD SCI USA, V100, P14504, DOI 10.1073/pnas.2235925100; Martin RC, 2001, NEUROLOGY, V57, P597, DOI 10.1212/WNL.57.4.597; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDermott KB, 1999, J COGNITIVE NEUROSCI, V11, P631, DOI 10.1162/089892999563698; Miller BT, 2005, NEURON, V48, P535, DOI 10.1016/j.neuron.2005.11.002; Milner B., 1964, FRONTAL GRANULAR COR, P313; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; Ojemann GA, 1997, ANNU REV MED, V48, P317; Ojemann JG, 2002, EPILEPSY BEHAV, V3, P309, DOI 10.1016/S1525-5050(02)00039-2; Parker A, 1998, EUR J NEUROSCI, V10, P3044, DOI 10.1046/j.1460-9568.1998.00306.x; PENFIELD W, 1958, ARCH NEURO PSYCHIATR, V79, P475, DOI 10.1001/archneurpsyc.1958.02340050003001; PERSSON J, 2005, IN PRESS CEREB CORTE; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Rausch R, 2002, CURR OPIN NEUROL, V15, P185, DOI 10.1097/00019052-200204000-00010; Reuter-Lorenz PA, 2002, TRENDS COGN SCI, V6, P394, DOI 10.1016/S1364-6613(02)01957-5; Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814; Rijntjes M, 2002, PROG NEUROBIOL, V66, P109, DOI 10.1016/S0301-0082(01)00027-2; ROSENE DL, 1977, SCIENCE, V198, P315, DOI 10.1126/science.410102; SCHACTER DL, 1987, PSYCHOBIOLOGY, V15, P21; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Snyder A. Z., 1996, QUANTIFICATION BRAIN, P131, DOI DOI 10.1016/B978-012389760-2/50028-1; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Talairach J., 1988, COPLANAR STEREOTAXIC; Thompson-Schill SL, 2005, CURR OPIN NEUROBIOL, V15, P219, DOI 10.1016/j.conb.2005.03.006; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; UNGERLEIDER LG, 1989, EXP BRAIN RES, V76, P473, DOI 10.1007/BF00248903; VANHOESEN GW, 1982, TRENDS NEUROSCI, V5, P345, DOI 10.1016/0166-2236(82)90201-6; VOYTKO ML, 1986, BEHAV BRAIN RES, V22, P25, DOI 10.1016/0166-4328(86)90078-1; Wagner AD, 1998, NEUROREPORT, V9, P3711, DOI 10.1097/00001756-199811160-00026; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; Wiebe S, 2003, LANCET, V362, pS48, DOI 10.1016/S0140-6736(03)15075-1	81	29	29	2	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	FEB	2007	17	2					443	456		10.1093/cercor/bhj161			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	124JQ	WOS:000243364500019	16547345	Bronze			2022-02-06	
J	Bartnik, BL; Hovda, DA; Lee, PWN				Bartnik, Brenda L.; Hovda, David A.; Lee, Paul W. N.			Glucose metabolism after traumatic brain injury: Estimation of pyruvate carboxylase and pyruvate dehydrogenase flux by mass isotopomer analysis	JOURNAL OF NEUROTRAUMA			English	Article						gas chromatography-mass spectrometry; [1, 2 C-13(2)] glucose; glutamate; pyruvate carboxylase; pyruvate dehydrogenase; rat	CORTICAL CONTUSION INJURY; C-13 NMR; IN-VIVO; RAT-BRAIN; AMINO-ACIDS; NEUROTRANSMITTER GLUTAMATE; CEREBRAL METABOLISM; KREBS CYCLE; TCA CYCLE; COMPARTMENTATION	The metabolism of [1, 2 C-13(2)] glucose via the tricarboxylic acid (TCA) cycle yields a number of key glutamate mass isotoporners whose formation is a function of pyruvate carboxylase (PC) and pyruvate dehydrogenase (PDH). Analysis of the isotopomer distribution patterns was used to determine the relative flux of glucose entry into the TCA cycle through anaplerotic and oxidative pathways in the cerebral cortex of both uninjured and traumatically injured adult male rats. In the cerebral cortex of uninjured animals the PC/PDH ratio showed greater metabolism of glucose via pyruvate carboxylase, which is consistent with the notion that the majority of glucose taken up at rest is used as a substrate for anaplerotic processes and not as an energy source. While traumatic brain injury did not change the overall C-13 enrichment of glutamate indicating a continued oxidation of glucose, the PC/PDH ratio was reduced in the injured cortex at 3.5 h after injury. This suggests that glucose metabolism is primarily directed through pathways associated with energy production in the early post-injury period. By 24 h, the anaplerotic flux decreased and the PC/PDH ratio increased in both the injured and non-injured cortex indicating a switch away from energy production to pathways associated with anabolic and/or regenerative processes.	Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Surg, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Dept Pediat, Torrance, CA 90509 USA		Bartnik, BL (corresponding author), Loma Linda Univ, Dept Radiol, 11234 Anderson St,Room B623, Loma Linda, CA 92354 USA.	bbartnik@llu.edu		Bartnik-Olson, Brenda/0000-0002-1137-9437	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000425] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01 CA 42710] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00425] Funding Source: Medline; ONDIEH CDC HHS [ND 36373, ND 27544] Funding Source: Medline		Aureli T, 1997, BRAIN RES, V765, P218, DOI 10.1016/S0006-8993(97)00514-3; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Behar KL, 2001, J NUTR, V131, p2498S, DOI 10.1093/jn/131.9.2498S; BRAND A, 1992, BIOCHIMIE, V74, P941, DOI 10.1016/0300-9084(92)90078-S; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cruz F, 1998, J NEUROCHEM, V70, P2613; Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.3.CO;2-5; Daikhin Y, 2000, J NUTR, V130, p1026S, DOI 10.1093/jn/130.4.1026S; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; GARFINKEL D, 1966, J BIOL CHEM, V241, P3918; Gruetter R, 2002, NEUROCHEM INT, V41, P143, DOI 10.1016/S0197-0186(02)00034-7; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HASSEL B, 1995, J NEUROCHEM, V64, P2773; Hassel B, 2000, MOL NEUROBIOL, V22, P21, DOI 10.1385/MN:22:1-3:021; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.0.CO;2-N; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Kanamatsu T, 1999, BRAIN RES, V841, P11, DOI 10.1016/S0006-8993(99)01772-2; Kanamori K, 2002, J NEUROCHEM, V83, P682, DOI 10.1046/j.1471-4159.2002.01161.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATZ J, 1993, J BIOL CHEM, V268, P25509; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kondrat RW, 2002, J NEUROSCI METH, V120, P179, DOI 10.1016/S0165-0270(02)00201-7; KUNNECKE B, 1993, NMR BIOMED, V6, P264, DOI 10.1002/nbm.1940060406; LAPIDOT A, 1994, J BIOL CHEM, V269, P27198; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lee WNP, 1996, DEV NEUROSCI-BASEL, V18, P469, DOI 10.1159/000111442; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; LEE WNP, 1993, J BIOL CHEM, V268, P25522; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; LIFSHITZ J, 1993, J CEREB BLOOD FLOW M, V23, P219; McKenna MC, 1996, J NEUROCHEM, V66, P386; Merle M, 2002, J NEUROCHEM, V82, P47, DOI 10.1046/j.1471-4159.2002.00924.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OPIL WO, 2004, 68616 SOC NEUR; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patel AB, 2005, J NEUROSCI RES, V79, P128, DOI 10.1002/jnr.20311; Patel AB, 2004, J CEREBR BLOOD F MET, V24, P972, DOI 10.1097/01.WCB.0000126234.16188.71; Preece NE, 1996, J NEUROCHEM, V67, P1718; Qu H, 2001, J NEUROSCI RES, V66, P1127, DOI 10.1002/jnr.10032; Ramonet D, 2004, HIPPOCAMPUS, V14, P586, DOI 10.1002/hipo.10188; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; SHANK RP, 1985, BRAIN RES, V329, P364, DOI 10.1016/0006-8993(85)90552-9; SHANK RP, 1993, J NEUROCHEM, V61, P315, DOI 10.1111/j.1471-4159.1993.tb03570.x; Sibson NR, 2001, J NEUROCHEM, V76, P975, DOI 10.1046/j.1471-4159.2001.00074.x; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu Y, 2004, J NEUROCHEM, V90, P1104, DOI 10.1111/j.1471-4159.2004.02576.x; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU ACH, 1983, J NEUROCHEM, V41, P1484, DOI 10.1111/j.1471-4159.1983.tb00849.x	61	29	29	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					181	194		10.1089/neu.2006.0038			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100018	17263682				2022-02-06	
J	Cantin, JF; Mcfadyen, BJ; Doyon, J; Swaine, B; Dumas, D; Vallee, M				Cantin, Jean-Francois; Mcfadyen, Bradford J.; Doyon, Julien; Swaine, Bonnie; Dumas, Denyse; Vallee, Marie			Can measures of cognitive function predict locomotor behaviour in complex environments following a traumatic brain injury?	BRAIN INJURY			English	Article						cognition; attention; executive functioning; gait; locomotion	EXECUTIVE FUNCTION; INATTENTIVE BEHAVIOR; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; DIVIDED ATTENTION; GAIT VARIABILITY; HEAD-INJURY; WALKING; TASK; PERFORMANCE	Primary objective: To determine the relationships between clinical measures of executive function and attention, and laboratory measures of anticipatory locomotor adaptations with dual tasks following a TBI. Methods and procedures: Ten people with moderate or severe TBI were compared to 10 healthy subjects for neuropsychological measures in the clinic, as well as locomotor patterns and reading time in the laboratory for adapted Stroop tasks ( Bar and Word) during unobstructed and obstructed walking. Main outcomes and results: As previously found [ 1] ( Vallee M, McFadyen BJ, Swaine B, Doyon J, Cantin JF, Dumas D. Effects of environmental demands on locomotion after traumatic brain injury. Archives of Physical Medicine Rehabilitation 2006; 87: 806 - 813) during the locomotor activities, subjects with TBI walked slower, had higher clearance margins and took longer to read during the Stroop tasks than healthy subjects. In general, subjects with TBI also showed deficits in executive functions and attention. Significant relationships were specifically observed between scores on Trail Making B and clearance margins for subjects with TBI, but not for healthy subjects. Alternatively, significant relationships between clinical scores on Stroop and dual task Stroop reading times were obtained for healthy subjects but not for subjects with TBI. Conclusions: These results suggest that measures of executive functioning and attention may be associated to locomotor behaviour in complex environments following a moderate to severe TBI.	Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ G1M 2S8, Canada; Univ Laval, Sch Psychol, Quebec City, PQ, Canada; Quebec Rehabil Inst, Quebec City, PQ, Canada; Univ Laval, Dept Rehabil, Quebec City, PQ, Canada; Univ Montreal, Dept Psychol, Montreal, PQ, Canada; Univ Montreal, Sch Rehabil, Fac Med, Montreal, PQ, Canada; CHUQ, St Francois Assise Hosp, Quebec City, PQ, Canada		Mcfadyen, BJ (corresponding author), Ctr Interdisciplinary Res Rehabil & Social Integr, 525 Harnel, Quebec City, PQ G1M 2S8, Canada.	brad.mcfadyen@rea.ulaval.ca		McFadyen, Bradford/0000-0003-1992-4927			ALEXANDER NB, 1995, NEUROLOGY, V45, P908, DOI 10.1212/WNL.45.5.908; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Ble A, 2005, J AM GERIATR SOC, V53, P410, DOI 10.1111/j.1532-5415.2005.53157.x; Bowen A, 2001, AGE AGEING, V30, P319, DOI 10.1093/ageing/30.4.319; BRICKENKAMP R, 1981, D2 TEST ATTENTION; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Golden CJ., 1978, STROOP COLOUR WORD T; Hausdorff JM, 2005, EXP BRAIN RES, V164, P541, DOI 10.1007/s00221-005-2280-3; Hausdorff JM, 2003, J GERIATR PSYCH NEUR, V16, P53, DOI 10.1177/0891988702250580; Kantor B, 2004, J AM GERIATR SOC, V52, P1326, DOI 10.1111/j.1532-5415.2004.52363.x; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Meher I, 2004, J AM GERIATR SOC, V52, P1255, DOI 10.1111/j.1532-5415.2004.52353.x; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Regnaux JP, 2005, NEUROREHAB NEURAL RE, V19, P125, DOI 10.1177/1545968305275612; Reitan RM, 1985, HALSTEADREITAN NEURO; Schrodt LA, 2004, GAIT POSTURE, V19, P279, DOI 10.1016/S0966-6362(03)00067-5; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Sheridan PL, 2003, J AM GERIATR SOC, V51, P1633, DOI 10.1046/j.1532-5415.2003.51516.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Weschler D., 1997, WESCHLER MEMORY SCAL; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Yogev G, 2005, EUR J NEUROSCI, V22, P1248, DOI 10.1111/j.1460-9568.2005.04298.x	36	29	29	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	3					327	334		10.1080/02699050701209972			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400008	17453761				2022-02-06	
J	Hang, CH; Shi, JX; Sun, BW; Li, JS				Hang, Chun-Hua; Shi, Ji-Xin; Sun, Bing-Wei; Li, Jie-Shou			Apoptosis and functional changes of dipeptide transporter (PepT1) in the rat small intestine after traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; intestine; mucosal damage; apoptosis; dipeptide transporter	NF-KAPPA-B; EPITHELIAL TRANSPORT; HORMONAL-REGULATION; EXPRESSION CLONING; HPEPT1 EXPRESSION; MOLECULAR-CLONING; CELL-DEATH; PEPTIDES; ISCHEMIA; MUCOSA	Background. Traumatic brain injury (TBI) can induce significant alterations of intestinal mucosal structure c and barrier function. However, it has not been investigated whether, and to what degree, apoptosis and alterations of absorptive function in the intestinal mucosal epithelium occur after TBI. Material and methods. Male Wistar rats were randomly divided into seven groups (five rats each group) including normal group, control group with sham operation, and TBI groups at hours 3, 12, 24, and 72, and on day 7. Parietal brain contusion was adopted using weight-dropping method. Intestinal mucosal structure was examined using histomorphmetric study and electron microscopy, and apoptosis was detected by TUNEL method. An everted sleeve of intestine was securely incubated in Kreb's solution with radioactive dipeptide (H-3-Gly-Sar, 10 mu Ci/mL) to measure the uptake and transport of PepT1 of small intestinal epithelial cells. Results. The villous height, crypt depth and surface area were significantly decreased at 24 h after TBI, and further declined to the degree of mucosal atrophy on day 7 after TBI. Apoptotic changes of condensed nuclei in epithelial cells and fractured, distorted, and sparse microvilli were found by electron microscopy. The number of apoptotic cells in the mucosal epithelium was significantly increased since 3 h after TBI, peaked at 72 h post-injury, then declined at 7 days, but was still higher than that of control. There was a highly negative relation between the apoptotic index and the villous height, the crypt depth, and villous surface area. Compared with that of normal and control rats, the transport and uptake of dipeptide was significantly increased at 3 h post-injury (P < 0.01), peaked at 12 h and declined a bit at 24 h post-injury, and returned to the level of normal and control rats at 72 h and 7 days. Conclusions. It is highly suggested that intestinal mucosa apoptosis plays an important role in the pathogenesis of acute gut damage after TBI. Intestinal PepT1 expression could be up-regulated after traumatic brain injury, and maintained the normal level under the condition of serious intestinal damage. Upregulation of PepT1 may adaptively improve absorption of di- and tripeptides, independent of changes in the mucosal surface area. (c) 2007 Elsevier Inc. All rights reserved.	Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Clin Med, Nanjing 210002, Peoples R China; Nanjing Univ, Jinling Hosp, Res Inst Gen Surg, Sch Clin Med, Nanjing 210002, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, Sch Clin Med, 305 Zhongshan Rd, Nanjing 210002, Peoples R China.	hang1965@public1.ptt.js.cn					Adibi SA, 1997, GASTROENTEROLOGY, V113, P332, DOI 10.1016/S0016-5085(97)70112-4; ADIBI SA, 1971, J CLIN INVEST, V50, P2266, DOI 10.1172/JCI106724; Barbot L, 2003, PARASITOL RES, V89, P364, DOI 10.1007/s00436-002-0776-3; Bolger MB, 1998, J PHARM SCI-US, V87, P1286, DOI 10.1021/js980090u; BOLL M, 1994, PFLUG ARCH EUR J PHY, V429, P146, DOI 10.1007/BF02584043; Brodin B, 2002, PHARMACOL TOXICOL, V90, P285, DOI 10.1034/j.1600-0773.2002.900601.x; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI13219; CALBAN C, 2000, CRIT CARE MED, V28, P643; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hotchkiss RS, 2000, CRIT CARE MED, V28, P3207, DOI 10.1097/00003246-200009000-00016; Hsu CP, 1999, AAPS PHARMSCI, V1; Ihara T, 2000, DIGESTION, V61, P59, DOI 10.1159/000007736; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Merlin D, 1998, J CLIN INVEST, V102, P2011, DOI 10.1172/JCI4179; Merlin D, 2001, GASTROENTEROLOGY, V120, P1666, DOI 10.1053/gast.2001.24845; Nielsen CU, 2001, AM J PHYSIOL-GASTR L, V281, pG191, DOI 10.1152/ajpgi.2001.281.1.G191; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; POTTEN CS, 1994, INT J RADIAT BIOL, V18, P77; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; Shiraga T, 1999, GASTROENTEROLOGY, V116, P354, DOI 10.1016/S0016-5085(99)70132-0; Sun BW, 2003, WORLD J GASTROENTERO, V9, P2782; Tanaka H, 1998, GASTROENTEROLOGY, V114, P714, DOI 10.1016/S0016-5085(98)70585-2; Thamotharan M, 1999, METABOLISM, V48, P681, DOI 10.1016/S0026-0495(99)90164-6; Thamotharan M, 1999, AM J PHYSIOL-CELL PH, V276, pC821, DOI 10.1152/ajpcell.1999.276.4.C821; Zhang C, 2002, BURNS, V28, P731, DOI 10.1016/S0305-4179(02)00210-3; Ziegler TR, 2002, AM J CLIN NUTR, V75, P922, DOI 10.1093/ajcn/75.5.922	34	29	35	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JAN	2007	137	1					53	60		10.1016/j.jss.2006.06.026			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	125NS	WOS:000243449400008	17081567				2022-02-06	
J	Lippert-Gruner, M; Maegele, M; Pokorny, J; Angelov, DN; Svestkova, O; Wittner, M; Trojan, S				Lippert-Gruener, M.; Maegele, M.; Pokorny, J.; Angelov, D. N.; Svestkova, O.; Wittner, M.; Trojan, S.			Early rehabilitation model shows positive effects on neural degeneration and recovery from neuromotor deficits following traumatic brain injury	PHYSIOLOGICAL RESEARCH			English	Article						traumatic brain injury; rehabilitation; motor dysfunction; neural loss	USE-DEPENDENT EXAGGERATION; NERVE GROWTH-FACTOR; ENRICHED ENVIRONMENT; NEUROTROPHIC FACTOR; CEREBRAL INFARCTION; PHYSICAL-ACTIVITY; AFFECTED FORELIMB; AEROBIC EXERCISE; FOCAL ISCHEMIA; RAT	This study used an experimental early rehabilitation model combining an enriched environment, multisensory (visual, acoustic and olfactory) stimulation and motor training after traumatic brain injury (via fluid-percussion model) to simulate early multisensory rehabilitation. This therapy will be used by brain injured patients to improve neural plasticity and to restore brain integration functions. Motor dysfunction was evaluated using a composite neuroscore test. Direct structural effects of traumatic brain injury were examined using Fluoro-Jade staining, which allows identification of degenerating neural cell bodies and processes. Animals in the rehabilitation model group performed significantly better when tested for neuromotor function than the animals in standard housing in the 7-day and 15-day interval after injury (7d: p=0.005; 15d: p < 0.05). Statistical analysis revealed significantly lower numbers of Fluoro-Jade positive cells (degenerating neurons) in the rehabilitation model group (n=5: mean 13.4) compared to the standard housing group (n=6: mean 123.8) (p < 0.005). It appears that the housing of animals in the rehabilitation model led to a clear functional increase in neuromotor functions and to reduced neural loss compared with the animal group in standard housing.	Cologne Univ Hosp, Dept Neurosurg, Cologne, Germany; Charles Univ Prague, Inst Physiol, Prague, Czech Republic; Univ Cologne, Inst Anat, D-5000 Cologne 41, Germany; Univ Hosp, Dept Rehabil, Prague, Czech Republic		Lippert-Gruner, M (corresponding author), Univ Cologne, Klin Allgemeine Neurochirurg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	physres@biomed.cas.cz	Wittner, Michal/A-5892-2008; Jaroslav, Pokorny/I-3838-2017; Svetkova, Olga/O-1062-2017	Jaroslav, Pokorny/0000-0002-9716-3409; Svetkova, Olga/0000-0002-4271-4795			Artola A, 2006, EUR J NEUROSCI, V23, P261, DOI 10.1111/j.1460-9568.2005.04552.x; Benefiel AC, 2005, ILAR J, V46, P95, DOI 10.1093/ilar.46.2.95; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Bland ST, 2001, BEHAV BRAIN RES, V126, P33, DOI 10.1016/S0166-4328(01)00243-1; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; DUA J, 1992, PERCEPT MOTOR SKILL, V75, P355, DOI 10.2466/pms.1992.75.2.355; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; GRABOWSKI M, 1995, EXP NEUROL, V133, P96, DOI 10.1006/exnr.1995.1011; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; GREENOUGH WT, 1988, DEV BRAIN RES, V43, P148, DOI 10.1016/0165-3806(88)90160-5; Gruner ML, 2000, BRAIN INJURY, V14, P585; Humm JL, 1999, EXP NEUROL, V157, P349, DOI 10.1006/exnr.1999.7061; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; INGLIS FM, 1995, NEUROSCIENCE, V66, P81, DOI 10.1016/0306-4522(94)00578-S; Irvine GI, 2006, HIPPOCAMPUS, V16, P149, DOI 10.1002/hipo.20142; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; KELLER A, 1992, J NEUROPHYSIOL, V68, P295, DOI 10.1152/jn.1992.68.1.295; Kolb B., 1995, BRAIN PLASTICITY BEH; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Lippert-Gruner M, 2002, ACT NEUR S, V79, P21; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; Nygren J, 2005, J CEREBR BLOOD F MET, V25, P1625, DOI 10.1038/sj.jcbfm.9600157; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Oliff HS, 1998, MOL BRAIN RES, V61, P147, DOI 10.1016/S0169-328X(98)00222-8; OSTENDORF CG, 1981, PHYS THER, V61, P1022, DOI 10.1093/ptj/61.7.1022; REJESKI WJ, 1992, HEALTH PSYCHOL, V11, P355, DOI 10.1037/0278-6133.11.6.355; Risedal A, 1999, J CEREBR BLOOD F MET, V19, P997, DOI 10.1097/00004647-199909000-00007; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; Saenz JCB, 2006, BEHAV BRAIN RES, V169, P57, DOI 10.1016/j.bbr.2005.12.001; SINSON G, 1995, J NEUROCHEM, V65, P2209; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Zeng JS, 2000, EXP NEUROL, V164, P176, DOI 10.1006/exnr.2000.7423; Zhao LR, 2001, NEUROSCI LETT, V305, P169, DOI 10.1016/S0304-3940(01)01837-7; Zhu SW, 2006, BEHAV BRAIN RES, V169, P10, DOI 10.1016/j.bbr.2005.11.024	45	29	34	0	10	ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY	PRAGUE 4	VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC	0862-8408	1802-9973		PHYSIOL RES	Physiol. Res.		2007	56	3					359	368		10.33549/physiolres.930971			10	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	183VP	WOS:000247600800013	16792466	gold			2022-02-06	
J	Zanier, ER; Ortolano, F; Ghisoni, L; Colombo, A; Losappio, S; Stocchetti, N				Zanier, Elisa Roncati; Ortolano, Fabrizio; Ghisoni, Laura; Colombo, Angelo; Losappio, Sabina; Stocchetti, Nino			Intracranial pressure monitoring in intensive care: clinical advantages of a computerized system over manual recording	CRITICAL CARE			English	Article							CEREBRAL PERFUSION-PRESSURE; ASSESSING AGREEMENT; HEAD-INJURY; DEXANABINOL; TRIAL	Introduction The presence of intracranial hypertension ( HICP) after traumatic brain injury ( TBI) affects patient outcome. Intracranial pressure ( ICP) data from electronic monitoring equipment are usually calculated and recorded hourly in the clinical chart by trained nurses. Little is known, however, about how precisely this method reflects the real patterns of ICP after severe TBI. In this study, we compared hourly manual recording with a validated and continuous computerized reference standard. Methods Thirty randomly selected patients with severe TBI and HICP admitted to the neuroscience intensive care unit ( Policlinico University Hospital, Milan, Italy) were retrospectively studied. A 24-hour interval with ICP monitoring was randomly selected for each patient. The manually recorded data available for analysis covered 672 hours corresponding to 36,492 digital data points. The two methods were evaluated using the correlation coefficient and the Bland and Altman method. We used the proportion test to analyze differences in the number of episodes of HICP ( ICP > 20 mm Hg) detected with the two methods and the paired t test to analyze differences in the percentage of time of HICP. Results There was good agreement between the digitally collected ICP and the manual recordings of the end-hour values. Bland and Altman analysis confirmed a mean difference between the two methods of 0.05 mm Hg ( standard deviation 3.66); 96% of data were within the limits of agreement (+7.37 and -7.28). The average percentages of time of ICP greater than 20 mm Hg were 39% calculated from the digital measurements and 34% from the manual observations. From the continuous digital recording, we identified 351 episodes of ICP greater than 20 mm Hg lasting at least five minutes and 287 similar episodes lasting at least ten minutes. Conversely, end-hour ICP of greater than 20 mm Hg was observed in only 204 cases using manual recording methods. Conclusion Although manually recorded end-hour ICP accurately reflected the computerized end-hour and mean hour values, the important omission of a number of episodes of high ICP, some of long duration, results in a clinical picture that is not accurate or informative of the true pattern of unstable ICP in patients with TBI.	Univ Milan, Osped Maggiore & Policlin Mangiagalli & Regina El, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit,Fdn IRCCS, I-20122 Milan, Italy		Zanier, ER (corresponding author), Univ Milan, Osped Maggiore & Policlin Mangiagalli & Regina El, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit,Fdn IRCCS, Via Sforza 35, I-20122 Milan, Italy.	ezanier@policlinico.mi.it	Zanier, Elisa/AAA-8095-2020; Stocchetti, Nino/O-7444-2017	Zanier, Elisa/0000-0002-3011-8718; Stocchetti, Nino/0000-0003-3250-6834; Ortolano, Fabrizio/0000-0003-1996-948X			BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Cunningham S, 1996, INT J CLIN MONIT COM, V13, P235, DOI 10.1023/A:1016967407632; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGraw C P, 1976, Surg Neurol, P149; SZEWCZYKOWSKI J, 1975, EUR J INTEN CARE MED, V1, P189, DOI 10.1007/BF00624437; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; Tindall G T, 1975, Clin Neurosurg, V22, P332; Turner H B, 1988, J Neurosci Nurs, V20, P236; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7	15	29	30	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2007	11	1							R7	10.1186/cc5155			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185OT	WOS:000247721000007	17233895	Green Published, gold			2022-02-06	
J	Bayir, A; Kalkan, E; Kocak, S; Ak, A; Cander, B; Bodur, S				Bayir, Aysegul; Kalkan, Erdal; Kocak, Sedat; Ak, Ahmet; Cander, Basar; Bodur, Said			Fibrinolytic markers and neurologic outcome in traumatic brain injury	NEUROLOGY INDIA			English	Article						disseminated intravascular coagulopathy; fibrinogen; Glasgow Coma score; prognosis; traumatic brain injury	DISSEMINATED INTRAVASCULAR COAGULATION; HEAD-INJURY; POSTTRAUMA COAGULATION; COAGULOPATHY; CHILDREN	Aims: To determine the usefulness of fibrinolytic markers as early prognostic indicators in patients with isolated head trauma. Materials and Methods: Sixty-two consecutive patients (26 women and 36 men; mean age 61 years, range 2-76 years) with isolated head trauma seen within the first three hours of the trauma were included in the study. The Glasgow Coma score (GCS), platelet counts (Plt), prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, fibrin degradation products (FDP) and D-dimer levels were measured. Head computerized tomography (CT) findings were categorized as brain edema, linear fracture, depressed fracture, contusion and bleeding. Plt counts, PT, PTT, fibrinogen, FDP, D-dimer levels and CT findings were compared with both GCS and mortality in the first week. Statistical significance was accepted at P <= 0.05. Results: A marked negative relationship was found between GCS and PT, PTT, FDP and D-climer levels (P < 0.001). Plt levels did not correlate with GCS. Mortality was most strongly related to GCS, PT, FDP and D-dimer levels (P < 0.001, P < 0.001, P < 0.001 and P < 0.001, respectively). We found no relationship between mortality and CT findings, nor was there any significant relationship between Plt, PTT and fibrinogen levels. Conclusion: GCS and fibrinolytic markers measured within the first three hours were useful in determining the prognosis of patients with isolated head trauma.	Selcuk Univ, Meram Fac Med, Emergency Dept, TR-42060 Konya, Turkey; Selcuk Univ, Meram Fac Med, Emergency Med Dept, TR-42060 Konya, Turkey; Selcuk Univ, Meram Fac Med, Neurosurg Dept, TR-42060 Konya, Turkey; Selcuk Univ, Meram Fac Med, Dept Med Stat, TR-42060 Konya, Turkey		Bayir, A (corresponding author), Selcuk Univ, Meram Fac Med, Emergency Dept, TR-42060 Konya, Turkey.	a_bayir@hotmail.com	Kocak, Sedat/AAB-7479-2020	Kocak, Sedat/0000-0001-8265-9615			AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; BJORKLID E, 1977, THROMB HAEMOSTASIS, V37, P91, DOI 10.1055/s-0038-1649206; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; CLARK JA, 1980, J NEUROSURG, V52, P266, DOI 10.3171/jns.1980.52.2.0266; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; Heesen M, 1997, SURG NEUROL, V47, P32, DOI 10.1016/S0090-3019(96)00373-4; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kirsh TD, 2004, EMERGENCY MED COMPRE, P1557; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Pathak A, 2005, Neurol India, V53, P178; SAWAYA R, 1987, SURG NEUROL, V28, P163, DOI 10.1016/0090-3019(87)90093-0; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; Valadka A, 2000, TRAUMA, P377; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	22	29	36	2	4	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	DEC	2006	54	4					363	365		10.4103/0028-3886.28106			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	110WW	WOS:000242413000013	17114843	Green Submitted			2022-02-06	
J	Geddes, JF; Talbert, DG				Geddes, J. F.; Talbert, D. G.			Paroxysmal coughing, subdural and retinal bleeding: a computer modelling approach	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						paroxysmal coughing; retinal haemorrhage; subdural haemorrhage	SHAKEN BABY SYNDROME; BLOOD-BRAIN-BARRIER; VELOCITY WAVE-FORM; FLOW VELOCITY; TRANSFUSION SYNDROME; HYPOTHETICAL MODEL; DYNAMIC PLACENTA; INJURY; INFANTS; HEMORRHAGE	Unexplained subdural and retinal haemorrhages in an infant are commonly attributed to 'shaking', the mechanism of which is believed to be traumatic venous rupture. However, the haemorrhagic retinopathy reported as a result of Valsalva manoeuvres and the subdural bleeding that is a rare complication of pertussis together demonstrate that if a sustained rise in intrathoracic pressure is transmitted to cerebral and retinal vessels, it may result in bleeding, similar to that reported in inflicted injury. Such haemorrhages would be expected to occur whenever severe paroxysmal coughing were induced, whatever the cause. This study used a computer modelling approach to investigate feeding accidents as the trigger for bleeding. A dynamic circulatory model of a 3-month-old infant was induced to 'cough', and the response to changes in physiological variables monitored. It showed that coughing causes intracranial pressures to build up exponentially to approach a maximum, proportional to the amount of pressure the musculature of the thorax can produce, as venous return is impeded. They do not have time to become dangerous during individual coughs, as blood quickly returns after the cough is over, reestablishing normal pressures. Paroxysmal coughing, however, does not allow blood to return between coughs, with the result that very high luminal pressures may be generated, sufficient to damage veins. A history of coughing, vomiting or choking is not uncommon in otherwise normal infants with retinal and subdural bleeding. Our findings suggest that paroxysmal coughing could account for such bleeding in some cases.	Univ London Imperial Coll Sci & Technol, Sch Med, Inst Reprod & Dev Biol, London, England			jfgeddes@doctors.org.uk					Alaraj AM, 2005, ACTA NEUROCHIR, V147, P85, DOI 10.1007/s00701-004-0415-0; ALSAYED LE, 1994, J APPL PHYSIOL, V77, P78, DOI 10.1152/jappl.1994.77.1.78; Anteby II, 2001, J AAPOS, V5, P90, DOI 10.1067/mpa.2001.113841; ARDRAN GM, 1958, BRIT J RADIOL, V31, P11, DOI 10.1259/0007-1285-31-361-11; ASHBY H, 1905, DIS CHILDREN, P337; Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; BISGARD K, 2000, GUIDELINES CONTROL P, pCH1; Deane JS, 1997, EYE, V11, P137, DOI 10.1038/eye.1997.33; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Georgiou T, 1999, EYE, V13, P686, DOI 10.1038/eye.1999.193; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; HAINES DE, 1991, ANAT RECORD, V230, P3, DOI 10.1002/ar.1092300103; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HOLT LE, 1926, DIS INFANCY CHILDHOO, P840; Jones W L, 1995, J Am Optom Assoc, V66, P301; Kemp AM, 2002, ARCH DIS CHILD, V86, P98, DOI 10.1136/adc.86.2.98; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511, DOI 10.1152/ajpheart.1981.240.4.H511; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; Lumb AB, 2000, NUNNS APPL RESP PHYS, P82; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; Man WDC, 2003, AM J RESP CRIT CARE, V168, P714, DOI 10.1164/rccm.200303-334BC; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Marshall J N, 1885, Glasgow Med J, V23, P24; MAYHAN WG, 1985, AM J PHYSIOL, V248, pH712, DOI 10.1152/ajpheart.1985.248.5.H712; MAYHAN WG, 1986, CIRC RES, V59, P216, DOI 10.1161/01.RES.59.2.216; NOBECOURT P, 1934, TRAITE MED INFANTS, V2, P288; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PERLMAN JM, 1985, NEW ENGL J MED, V312, P1353, DOI 10.1056/NEJM198505233122104; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; Prange M. T., 2003, INFLICTED CHILDHOOD, P237; ROTCH TM, 1901, PEDIAT HYGIENIC MED, P508; Sebire NJ, 2004, MED HYPOTHESES, V62, P520, DOI 10.1016/j.mehy.2003.10.019; Sebire NJ, 2001, PLACENTA, V22, P383, DOI 10.1053/plac.2001.0631; SOUTHALL DP, 1987, CURRENT TOPICS PULMO, V8, P210; Talbert D, 2004, MED HYPOTHESES, V62, P511, DOI 10.1016/j.mehy.2003.10.025; Talbert DG, 2005, MED HYPOTHESES, V64, P8, DOI 10.1016/j.mehy.2004.07.017; Talbert DG, 1996, AM J OBSTET GYNECOL, V174, P598, DOI 10.1016/S0002-9378(96)70434-9; Talbert DG, 2000, ULTRASOUND OBST GYN, V16, P457, DOI 10.1046/j.1469-0705.2000.00224.x; TALBERT DG, 1995, ULTRASOUND OBST GYN, V6, P261, DOI 10.1046/j.1469-0705.1995.06040261.x; VINALL PE, 1981, STROKE, V12, P640, DOI 10.1161/01.STR.12.5.640; Weller R. O., 2005, Morphologie, V89, P22, DOI 10.1016/S1286-0115(05)83235-7; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Yoshimoto Y, 1997, J NEUROSURG, V86, P694, DOI 10.3171/jns.1997.86.4.0694; 2005, GEN PERTUSSIS INFORM, P3; 2003, AM ACAD PEDIAT RED B, P472	49	29	30	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	DEC	2006	32	6					625	634		10.1111/j.1365-2990.2006.00771.x			10	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	101XM	WOS:000241774600007	17083477				2022-02-06	
J	Taylor, AN; Rahman, SU; Tio, DL; Sanders, MJ; Bando, JK; Truong, AH; Prolo, P				Taylor, Anna N.; Rahman, Shayan U.; Tio, Delia L.; Sanders, Matthew J.; Bando, Jennifer K.; Truong, Amy H.; Prolo, Paolo			Lasting neuroendocrine-immune effects of traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						activity; body temperature; corticosterone; lipopolysaccharide; stress	CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENAL AXIS; CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; ALCOHOL-CONSUMPTION; TIME-SERIES; ETHANOL; RESPONSES; STRESS; FEVER	Traumatic brain injury (TBI) is a principal cause of long-term physical, cognitive, behavioral, and social deficits in young adults, which frequently coexist with a high incidence of substance abuse disorders. However, few studies have examined the long-term effects of TBI on the neuroendocrine-immune system. TBI was induced in adult male rats under isoflurane anesthesia by cortical contusion injury with a pneumatic piston positioned stereotaxically over the left parietal cortex. Controls underwent sham surgery without injury. At 4 weeks post-injury, the plasma corticosterone response to 30-min restraint stress was significantly blunted in TBI rats compared to the sham controls. One week later, transmitters were implanted for continuous biotelemetric recording of body temperature and spontaneous locomotor activity. At 6 weeks post-injury, the febrile response to i.p. injection of the bacterial endotoxin, lipopolysaccharide (LPS; 50 mu g/kg), was significantly lower in TBI than in sham rats. At 8 weeks, swimming in the forced swim test was significantly less in TBI than sham rats. At 9 weeks, rats were rendered ethanol (EtOH) dependent by feeding an EtOH-containing liquid diet for 14 days. Cosine rhythmometry analysis of circadian body temperature Midline Estimating Statistic of Rhythm (MESOR), amplitudes, and acrophases indicated differential effects of EtOH and withdrawal in the two groups. Light- and dark-phase activity analysis indicated that TBI rats were significantly more active than the sham group, and that EtOH and withdrawal differentially affected their activity. Given the extensive interactions of the neuroendocrine-immune systems, these results demonstrate that TBI produces lasting dysregulation amidst the central substrates for allostasis and circadian rhythmicity.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Inst Brain Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; W Los Angeles Healthcare Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; NIAID, LCMI, NIH, Bethesda, MD 20892 USA; Univ Calif Los Angeles, Sch Dent, Div Oral Biol, Los Angeles, CA 90095 USA		Taylor, AN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Inst Brain Res, 10833 Le Conte Ave,Box 951763, Los Angeles, CA 90095 USA.	ataylor@mednet.ucla.edu		Bando, Jennifer/0000-0002-1331-7424			Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Blatteis CM, 1998, ANN NY ACAD SCI, V840, P608, DOI 10.1111/j.1749-6632.1998.tb09600.x; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHILDERS MK, 1998, BRAIN INJURY, V12, P547; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; Fernandez JR, 1998, CHRONOBIOL INT, V15, P191, DOI 10.3109/07420529808998683; Frieboes RM, 1999, J NEUROPSYCH CLIN N, V11, P354, DOI 10.1176/jnp.11.3.354; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KLUGER MJ, 1991, PHYSIOL REV, V71, P93, DOI 10.1152/physrev.1991.71.1.93; Kropyvnytskyy I, 2001, BRAIN INJURY, V15, P511, DOI 10.1080/02699050010007515; Lahmame A, 1997, BRAIN RES, V750, P285, DOI 10.1016/S0006-8993(96)01368-6; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; McEwen BS, 2003, HORM BEHAV, V43, P2, DOI 10.1016/S0018-506X(02)00024-7; MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORROW LE, 1993, AM J PHYSIOL, V264, pR1010, DOI 10.1152/ajpregu.1993.264.5.R1010; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Opp MR, 1997, PHYSIOL BEHAV, V63, P67, DOI 10.1016/S0031-9384(97)00390-9; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Rasmussen DD, 2000, ALCOHOL CLIN EXP RES, V24, P1836, DOI 10.1111/j.1530-0277.2000.tb01988.x; REDEI E, 1986, J PHARMACOL EXP THER, V237, P59; REDEI E, 1988, ENDOCRINOLOGY, V123, P2736, DOI 10.1210/endo-123-6-2736; Rivier C, 1996, BRAIN RES, V726, P1, DOI 10.1016/0006-8993(96)00301-0; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; RUDY TA, 1980, THERMOREGULATORY MEC, P75; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Schallert T, 2005, BEHAV LAB RAT, P129; SELYE H, 1946, J ALLERGY, V17, P358, DOI 10.1210/jcem-6-2-117; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Sholkina Margarita N, 2002, Russ J Immunol, V7, P365; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; TABAKOFF B, 1978, J PHARM PHARMACOL, V30, P371, DOI 10.1111/j.2042-7158.1978.tb13259.x; Taylor AN, 1999, J NEUROIMMUNOL, V99, P44, DOI 10.1016/S0165-5728(99)00102-2; Taylor AN, 2005, J NEUROTRAUM, V22, P1253; Taylor AN, 2002, ALCOHOL CLIN EXP RES, V26, P44; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TAYLOR AN, 2005, SOC NEUR ABST; Weinberg J, 1996, ALCOHOL CLIN EXP RES, V20, P122, DOI 10.1111/j.1530-0277.1996.tb01054.x; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	65	29	29	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2006	23	12					1802	1813		10.1089/neu.2006.23.1802			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	120AP	WOS:000243056100008	17184190				2022-02-06	
J	Greenspan, AI; Coronado, VG; MacKenzie, EJ; Schulman, J; Pierce, B; Provenzano, G				Greenspan, Arlene I.; Coronado, Victor G.; MacKenzie, Ellen J.; Schulman, Jane; Pierce, Ben; Provenzano, George			Injury hospitalizations: Using the nationwide inpatient sample	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						hospital discharge; injury; falls; motor vehicle crashes	TRAUMATIC BRAIN-INJURY; TRENDS; SURVEILLANCE; FRACTURE	Background. The aims of this study are to develop estimates of discharge rates and frequencies for all injury-related hospitalizations in the United States for the year 2000 and to characterize patterns of hospitalized injury and anatomic region using a modified Barell Matrix. The utility of the Nationwide Inpatient Sample (NIS) for providing national estimates of hospitalized injuries will be discussed. Methods: This study is a retrospective analysis of hospital discharge data using the Nationwide Inpatient Sample. All hospital discharges with a primary diagnosis of injury were selected. Total number of hospitalizations, annual discharge rates, and 95% confidence intervals were calculated by body region, nature of injury, and injury mechanism. Number of injuries by age, sex, body region, and nature of injury were also calculated for falls and motor vehicle crashes. Results. In 2000, there were an estimated 1,690,780 hospital discharges with a primary injury diagnosis. Discharge rates were highest for the oldest age groups. Falls and motor vehicle crashes were the leading causes of hospitalization. Fracture was the most common diagnosis and lower extremity injury was the most common anatomic region. Conclusions. Hospital discharge data adds another dimension to our understanding of the total injury burden. The Nationwide Inpatient Sample may be useful in providing national estimates of hospital discharges.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Battelle Mem Inst, Atlanta, GA USA; Ctr Publ Hlth Res & Evaluat, Atlanta, GA USA		Greenspan, AI (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop K-63, Atlanta, GA USA.	aig0@cdc.gov					*AG HEALTHC RES QU, 2004, HCUP DAT HEALTHC COS; *AG HEALTHC RES QU, 2004, HCUP NIS DAT DOC HEA; *AM MED ASS, 1999, INT CLASS DIS, V1; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; *CDCP, 10 LEAD CAUS DEATH 2; *CTR DIS CONTR PRE, 2004, WEB BAS INJ STAT QUE; DAVIES M, 2001, STATE INJURY INDICAT; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HALL MJ, 2003, ADV DATA VITAL HLTH, V332; Horan JM, 2003, EPIDEMIOL REV, V25, P24, DOI 10.1093/epirev/mxg010; Injury Surveillance Workgroup, 2003, CONS REC US HOSP DIS; Irwin ZN, 2004, SPINE, V29, P796, DOI 10.1097/01.BRS.0000119400.92204.B5; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006; Mukamel DB, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-10; Quinlan KP, 1999, ANN EMERG MED, V34, P637, DOI 10.1016/S0196-0644(99)70166-6; Shinoda-Tagawa T, 2003, INJURY PREV, V9, P214, DOI 10.1136/ip.9.3.214; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; *US DEP HHS, 2005, DHHS PUBL; Wadman MC, 2003, ANN EMERG MED, V42, P468, DOI 10.1067/S0196-0644(03)00489-X; 2001, MMWR MORB MORTAL WKL, V50, P340	25	29	30	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2006	61	5					1234	1243		10.1097/01.ta.0000231558.71696.1a			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	105TB	WOS:000242054100036	17099535				2022-02-06	
J	Lin, L; Chen, LX; Wei, XL; Fu, X; Zhang, JY; Ma, KT; Zhou, CY; Yu, CL				Lin, Lin; Chen, Lianxu; Wei, Xuelei; Fu, Xin; Zhang, Jiying; Ma, Kangtao; Zhou, Chunyan; Yu, Changlong			Adenovirus-mediated transfer of siRNA against Runx2/Cbfa1 inhibits the formation of heterotopic ossification in animal model	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						siRNA; Runx2/Cbfa1; osteoblast; gene therapy; heterotopic ossification; adenovirus	TOTAL HIP-ARTHROPLASTY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; ECTOPIC BONE-FORMATION; OSTEOBLAST DIFFERENTIATION; RNA INTERFERENCE; IN-VITRO; CLEIDOCRANIAL DYSPLASIA; ENHANCED OSTEOGENESIS	The heterotopic ossification of muscles, tendons, and ligaments is a common problem faced by orthopaedic surgeons. Runx2/Cbfa1 plays an essential role during the osteoblast differentiation and is considered as a molecular switch in osteoblast biology. RNA interference technology is a powerful tool for silencing endogenous or exogenous genes in mammalian cells. In this study, we investigated the effect of Runx2/Cbfa1-specific siRNA on osteoblast differentiation and mineralization in osteoblastic cells, and then constructed adenovirus containing siRNA against Runx2/Cbfa1 (Ad-Runx2-siRNA) to inhibit the formation of heterotopic ossification induced by BMP4, dernineralized bone matrix, and trauma in animal model. Our results showed that the Runx2/Cbfa1-specific siRNA could inhibit the expression of Runx2/Cbfa1 at the level of mRNA and protein. Analysis of the expression of osteoblast maturation genes including type I collagen, osteopontin, bone sialoprotein, and osteocalcin, alkaline phosphatase activity, and matrix mineralization (von kossa) revealed that osteoblast differentiation was inhibited in cultured primary mouse osteoblasts transduced with Ad-Runx2-siRNA. Furthermore, adenovirus-mediated transfer of siRNA against Runx2/Cbfa1 could inhibit the formation of heterotopic ossification induced by BMP4, dernineralized bone matrix, and trauma in animal model. It is likely that the inhibition of Runx2/Cbfa1 by RNAi could be developed as a powerful approach to prevent or treat heterotopic ossification. (c) 2006 Elsevier Inc. All rights reserved.	Peking Univ Third Hosp, Inst Sports Med, Beijing 100083, Peoples R China; Peking Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China		Zhou, CY (corresponding author), Peking Univ Third Hosp, Inst Sports Med, 49 N Garden Rd, Beijing 100083, Peoples R China.	chunyanzhou@bjmu.edu.cn; YCL123@vip.sina.com					AHRENGART L, 1991, CLIN ORTHOP RELAT R, V263, P49; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131-199505000-00006; BANERJEE U, 1997, LOOP TR RESTRUCT COM, V3, P1; BONARIGO BC, 1967, RADIOLOGY, V88, P889, DOI 10.1148/88.5.889; BRADY LW, 1979, SKELETAL RADIOL, V4, P72, DOI 10.1007/BF00349330; BRUMBACK RJ, 1990, J BONE JOINT SURG AM, V72A, P1067, DOI 10.2106/00004623-199072070-00017; BUCK RC, 1953, J PATHOL BACTERIOL, V66, P1, DOI 10.1002/path.1700660103; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36, DOI 10.1302/0301-620X.57B1.36; CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76, DOI 10.1302/0301-620X.64B1.7068725; Crawford C M, 1986, J Burn Care Rehabil, V7, P323, DOI 10.1097/00004630-198607000-00005; DELEE J, 1976, CLIN ORTHOP RELAT R, V121, P53; Dimar JR, 1996, SPINE, V21, P1870, DOI 10.1097/00007632-199608150-00006; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Enomoto H, 2004, J CELL SCI, V117, P417, DOI 10.1242/jcs.00866; FAHRER H, 1988, BRIT J RHEUMATOL, V27, P187; GREEN DP, 1979, J BONE JOINT SURG AM, V61, P1092, DOI 10.2106/00004623-197961070-00021; Hannallah D, 2004, J BONE JOINT SURG AM, V86A, P80, DOI 10.2106/00004623-200401000-00013; Haque S, 1996, ARCH PATHOL LAB MED, V120, P666; HU HP, 1991, CLIN ORTHOP RELAT R, P259; Igarashi M, 2004, J MOL HISTOL, V35, P3, DOI 10.1023/B:HIJO.0000020883.33256.fe; Johns JS, 1999, J HEAD TRAUMA REHAB, V14, P269, DOI 10.1097/00001199-199906000-00007; Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LAL S, 1989, ARCH PHYS MED REHAB, V70, P387; LEE J, 1997, CARBOHYDR LETT, V2, P307; Lianxu C, 2006, OSTEOARTHR CARTILAGE, V14, P367, DOI 10.1016/j.joca.2005.10.009; LIN L, IN PRESS ACTA PHARM; LOVELOCK JE, 1990, SKELETAL RADIOL, V19, P31; MAHY PR, 1988, CLIN ORTHOP RELAT R, P236; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; MCCLURE J, 1983, J PATHOL, V139, P419, DOI 10.1002/path.1711390403; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Musgrave DS, 2000, CLIN ORTHOP RELAT R, P290; Naraghi FF, 1996, ORTHOPEDICS, V19, P145; O'Connor JP, 1998, CLIN ORTHOP RELAT R, P71; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PETERSON SL, 1989, J TRAUMA, V29, P365, DOI 10.1097/00005373-198903000-00015; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PUZAS JE, 1989, CLIN ORTHOP RELAT R, V245, P269; QUINLAN JG, 1995, MUSCLE NERVE, V18, P201, DOI 10.1002/mus.880180209; REDDI AH, 1995, CLIN ORTHOP RELAT R, P115; Richards AM, 1997, BURNS, V23, P64, DOI 10.1016/S0305-4179(96)00074-5; Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804; SHAFRITZ AB, 1998, CLIN ORTHOP RELAT R, V346, P46; SHAMBERGER R, 1985, RECENT RESULTS CANC, V98, P17; SOBALLE K, 1988, CLIN ORTHOP RELAT R, V228, P57; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VIOLA RW, 2000, CLIN ORTHOP RELAT R, V370, P65; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Williams JT, 1999, AM SURGEON, V65, P22; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	55	29	43	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	OCT 20	2006	349	2					564	572		10.1016/j.bbrc.2006.08.089			9	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	088DN	WOS:000240791800016	16949041				2022-02-06	
J	Cuzzocrea, S; Genovese, T; Mazzon, E; Crisafulli, C; Min, W; Di Paola, R; Muia, C; Li, JH; Esposito, E; Bramanti, P; Xu, WZ; Massuda, E; Zhang, J; Wang, ZQ				Cuzzocrea, Salvatore; Genovese, Tiziana; Mazzon, Emanuela; Crisafulli, Concetta; Min, Wookee; Di Paola, Rosanna; Muia, Carmelo; Li, Jia-He; Esposito, Emanuela; Bramanti, Placido; Xu, Weizheng; Massuda, Edmond; Zhang, Jie; Wang, Zhao-Qi			Poly(ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory reaction after experimental spinal cord trauma	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							NITRIC-OXIDE SYNTHASE; CELL-DEATH; DNA FRAGMENTATION; INJURY; INHIBITION; POLYMERASE; SYNTHETASE; EXPRESSION; APOPTOSIS; ISCHEMIA	The aim of the present study was to examine the role of poly( ADP-ribose) glycohydrolase (PARG) on the modulation of the inflammatory response and tissue injury associated with neurotrauma. Spinal cord trauma was induced in wild-type (WT) mice by the application of vascular clips (force of 24 g) to the dura via a two-level T-6 to T-7 laminectomy. Spinal cord injury in WT mice resulted in severe trauma characterized by edema, neutrophil infiltration, and cytokine production followed by recruitment of other inflammatory cells, production of a range of inflammation mediators, tissue damage, apoptosis, and disease. The genetic disruption of the PARG gene in mice or the pharmacological inhibition of PARG with GPI 16552 [N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide] (40 mg/kg i.p. bolus), a novel and potent PARG inhibitor, significantly reduced the degree of spinal cord inflammation and tissue injury (histological score), neutrophil infiltration, cytokine production (tumor necrosis factor-alpha and interleukin-1 beta), and apoptosis. In a separate experiment, we have clearly demonstrated that PARG inhibition significantly ameliorated the recovery of limb function. Taken together, our results indicate that PARG activity modulates the inflammatory response and tissue injury events associated with spinal cord trauma and participate in target organ damage under these conditions.	Univ Messina, Sch Med, Inst Pharmacol, Policlin Univ,Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy; Carattere Sci Ctr Neurolesi Bonino Pulejo, Ist Ric & Cura, Messina, Italy; Int Agcy Res Canc, F-69372 Lyon, France; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; Guilford Pharmaceut Inc, Baltimore, MD USA; Lilium Pharmaceut, Cockeysville, MD USA		Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Inst Pharmacol, Policlin Univ,Dept Clin & Expt Med & Pharmacol, Torre Biol,Via C Valeria, I-98100 Messina, Italy.	salvator@unime.it	di paola, rosanna/U-4356-2019; Mazzon, Emanuela/AAL-4334-2020; Bramanti, Placido/K-5117-2016	di paola, rosanna/0000-0001-6725-8581; mazzon, emanuela/0000-0002-5073-717X; GENOVESE, Tiziana/0000-0002-3335-7327			Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2002, PROG BRAIN RES, V137, P37; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Cortes U, 2004, MOL CELL BIOL, V24, P7163, DOI 10.1128/MCB.24.16.7163-7178.2004; Cozzi A, 2006, J CEREBR BLOOD F MET, V26, P684, DOI 10.1038/sj.jcbfm.9600222; Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96; Cuzzocrea S, 2005, FASEB J, V19, P558, DOI 10.1096/fj.04-3117com; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; Genovese T, 2005, J PHARMACOL EXP THER, V312, P449, DOI 10.1124/jpet.104.076711; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LI J, 2003, Patent No. 6635756; LI J, 2004, Patent No. 6635786; Liu SF, 1997, J IMMUNOL, V159, P3976; Lu XCM, 2003, BRAIN RES, V978, P99, DOI 10.1016/S0006-8993(03)02774-4; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Patel NSA, 2005, J AM SOC NEPHROL, V16, P712, DOI 10.1681/ASN.2004080677; PIELASMITH TH, 1992, J IMMUNOL, V148, P41; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; Schutte B, 1998, J NEUROSCI METH, V86, P63, DOI 10.1016/S0165-0270(98)00147-2; SLAMA JT, 1995, J MED CHEM, V38, P389, DOI 10.1021/jm00002a021; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; West JD, 2005, J BIOL CHEM, V280, P15141, DOI 10.1074/jbc.M413147200; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Zhang ZY, 1998, EXP NEUROL, V149, P221, DOI 10.1006/exnr.1997.6717	40	29	30	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	2006	319	1					127	138		10.1124/jpet.106.108076			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	087UK	WOS:000240767800013	16825529				2022-02-06	
J	Schneider, HJ; Rovere, S; Corneli, G; Croce, CG; Gasco, V; Ruda, R; Grottoli, S; Stalla, GK; Soffietti, R; Ghigo, E; Aimaretti, G				Schneider, H. J.; Rovere, S.; Corneli, G.; Croce, C. G.; Gasco, V.; Ruda, R.; Grottoli, S.; Stalla, G. K.; Soffietti, R.; Ghigo, E.; Aimaretti, G.			Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HORMONE (GH)-RELEASING HORMONE; BODY-MASS INDEX; GH DEFICIENCY; PITUITARY-FUNCTION; SUBARACHNOID HEMORRHAGE; DIAGNOSIS; ADULTS; HYPOPITUITARISM; ARGININE	Objective: Hypopituitarism frequently follows pituitary neurosurgery (NS) and/or irradiation. However, the frequency of hypothalamic-pituitary dysfunction after NS of non-pituitary intracranial tumors is unclear. The aim of this study was to assess the presence of endocrine alterations in patients operated on for intracranial tumors. Design: This is a retrospective study. Methods: We studied 68 consecutive adult patients (28 female, 40 male, age 4 5.0 +/- 1.8 years; body mass index (BMI): 26.5 +/- 0.6) with intracranial tumors who underwent NS only (n=17) or in combination with radiotherapy IRT) and/or chemotherapy (CT) (n=51). In all subjects, basal endocrine parameters and the GH response to GHRH+arginine test (using BMI-dcpendent cut offs) were evaluated. Results: In 20.6% of the patients, peripheral endocrinopathy related to CT and/or RT was present. Hypopituitarism was found in 38.2% of the patients. Total pituitary hormone. multiple pituitary hormone, and isolated pituitary hormone deficits were present in 16.2, 5.8, and 16.2%, respectively. The most common pituitary deficits were, in decreasing order: LH/FSH 29.49%, GH 27.9%, ACTH 19.1%, TSH 17.7%, and diabetes insipidus 4.4%. Hyperprolactinemia was present in 13.2%. The prevalence of hypopituitarism was higher in patients who underwent NS only and with tumors located closely to the sella turcica, but a substantial proportion of patients with tumors not directly neighboring the sella also showed hypopituitarism. Conclusions: Hypopituitarism frequently occurs after NS for intracranial tumors. Also, exposure of these patients to CT and/or RT is frequently associated with peripheral endocrinopathies. Thus, endocrine evaluation and follow-up of patients treated for intracranial tumors should be performed on a regular basis.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab, I-10126 Turin, Italy; Univ Turin, Div Neurol, I-10126 Turin, Italy; Max Planck Inst Psychiat, D-80804 Munich, Germany		Aimaretti, G (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Cso Dogliotti 14, I-10126 Turin, Italy.	gianluca.aimaretti@unito.it	Soffietti, Riccardo/AAA-7965-2022	Soffietti, Riccardo/0000-0002-9204-7038; RUDA', Roberta/0000-0001-9134-1537			Agha A, 2005, J CLIN ENDOCR METAB, V90, P6355, DOI 10.1210/jc.2005-1525; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Bonert VS, 2004, J CLIN ENDOCR METAB, V89, P3397, DOI 10.1210/jc.2003-032213; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Cornelia G, 2003, GROWTH HORM IGF RES, V13, P104, DOI 10.1016/S1096-6374(03)00010-8; Darzy K H, 2005, J Endocrinol Invest, V28, P78; Darzy KH, 2003, J CLIN ENDOCR METAB, V88, P95, DOI 10.1210/jc.2002-021094; Dorin RI, 2003, ANN INTERN MED, V139, P194, DOI 10.7326/0003-4819-139-3-200308050-00009; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; Honegger J, 1999, J NEUROSURG, V90, P251, DOI 10.3171/jns.1999.90.2.0251; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; LAM KSL, 1991, Q J MED, V78, P165; LITTLEY MD, 1989, Q J MED, V70, P145; LIVESEY EA, 1990, BRIT J CANCER, V61, P622, DOI 10.1038/bjc.1990.138; Nieschlag E, 2004, HUM REPROD UPDATE, V10, P409, DOI 10.1093/humupd/dmh035; Nomikos P, 2004, ACTA NEUROCHIR, V146, P27, DOI 10.1007/s00701-003-0174-3; Schneider HJ, 2006, ACTA NEUROCHIR, V148, P449, DOI 10.1007/s00701-005-0724-y; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937	23	29	33	0	3	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643			EUR J ENDOCRINOL	Eur. J. Endocrinol.	OCT	2006	155	4					559	566		10.1530/eje.1.02272			8	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	098CG	WOS:000241498000007	16990655	Bronze			2022-02-06	
J	Nacajauskaite, O; Endziniene, M; Jureniene, K; Schrader, H				Nacajauskaite, Olga; Endziniene, Milda; Jureniene, Kristina; Schrader, Harald			The validity of post-concussion syndrome in children: A controlled historical cohort study	BRAIN & DEVELOPMENT			English	Article						mild brain injury; post-concussion syndrome; post-traumatic stress syndrome	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POSTCONCUSSION SYNDROME; SYMPTOM EXPECTATION; BEHAVIOR PROBLEMS; ADOLESCENTS; OUTCOMES; FAMILY; TERM; ETIOLOGY	The aim of this controlled historical cohort study was to assess the validity of post-concussion syndrome in children. We identified 301 children aged 4-15 years who had sustained an isolated brain concussion, and another group of 301 children who sustained any other mild body injury excluding the head. Parents from both groups filled in standardized questionnaires containing questions about the health condition of the children: headache, neck pain, dizziness, malaise, fatigability, exercise or noise intolerance, irritability, weepiness, sadness, anxiety, nocturnal enuresis, tics, sleep disorders, memory or learning difficulties, hyperactivity, seizures, attention disorder, buzzing in the ears, subjective parental concerns about the child's health condition, and parental concerns about their child having a brain disorder. The severity of the complaints was rated on the Visual Analogue Scale. After the final exclusion, 102 pairs strictly matched by sex, age, and the date of trauma were analyzed. The differences of parental complaints about the health condition of their children between case and control groups were statistically insignificant for all symptoms, except parental concerns about their child having brain damage which were significantly higher in the case group. The likelihood of parental concerns about the possibility of their child having brain damage was 2.7 times higher in the case group. Headache, learning difficulties, and sleep disorders were significant variables predicting the concerns. These results question the validity of the post-concussion syndrome in children. (c) 2006 Elsevier B.V. All rights reserved.	Kaunas Univ Med, Dept Neurol, Kaunas, Lithuania; Vilnius State Univ, Childrens Hosp, Ctr Pediat Surg, Vilnius, Lithuania; Kaunas Univ Med, Dept Phys Math & Biol, Kaunas, Lithuania; Univ Trondheim Hosp, Dept Neurol & Clin Neurophysiol, Trondheim, Norway		Endziniene, M (corresponding author), Kaunas Univ Med, Dept Neurol, Mickeviciaus 9, Kaunas, Lithuania.	olgutene@takas.lt; endziniene@centras.lt; harald.schrader@medisin.ntnu.no		Schrader, Harald/0000-0001-9975-1960			Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; BIJUR PE, 1990, PEDIATRICS, V86, P337; Callaghan M, 2001, DEV MED CHILD NEUROL, V43, P819, DOI 10.1017/S0012162201001487; CASEY R, 1986, PEDIATRICS, V78, P497; DAILIDIENE N, 2001, VISUOMENES SVEIKATA, V14, P13; EMANUELSON I, 1999, THESIS U HELSINKI; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P254, DOI 10.1016/S0303-8467(01)00161-5; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Leathem JM, 2000, J HEAD TRAUMA REHAB, V15, P1246, DOI 10.1097/00001199-200012000-00005; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Overweg-Plandsoen WCG, 1999, EUR J PEDIATR, V158, P249, DOI 10.1007/s004310051061; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; World Health Organization, 2004, ICD 10 INT STAT CLAS; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	45	29	29	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	SEP	2006	28	8					507	514		10.1016/j.braindev.2006.02.010			8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	074UO	WOS:000239837500006	16682158				2022-02-06	
J	Knox, CL; Comstock, RD; McGeehan, J; Smith, GA				Knox, Christy L.; Comstock, R. Dawn; McGeehan, Jennifer; Smith, Gary A.			Differences in the risk associated with head injury for pediatric ice skaters, roller skaters, and in-line skaters	PEDIATRICS			English	Article						skating; recreation; pediatric; head injury; helmet	SKATING INJURIES; WRIST SPLINTS; CHILDREN	OBJECTIVE. The goals were to describe the epidemiologic features of pediatric skating-related injuries sustained from 1993 to 2003 and to compare ice skating - related injuries with roller skating - and in-line skating - related injuries. METHODS. An analysis of pediatric skating-related injury data from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission was performed. RESULTS. An estimated 1 235 467 pediatric skating participants presented to hospital emergency departments with injuries between 1993 and 2003. These children had a mean age of 10.9 years (SD: 3.2 years; range: 1 - 18 years), and 50.0% were male. The most common mechanism of injury was a fall (83.1%). Ice skaters sustained a greater proportion of head injuries (13.3%), compared with roller skaters (4.4%) and in-line skaters (5.0%). Ice skaters also experienced a greater proportion of concussions (4.3%), compared with roller skaters (0.6%) and in-line skaters (0.8%). The proportion of facial injuries among ice skaters was greater than the proportions among roller skaters and in-line skaters. The majority of roller skating - and in-line skating - related injuries were upper-extremity fractures (53.9% and 59.7%, respectively). Children <= 6 years of age experienced a greater proportion of head and facial injuries than did older children in each skating activity. CONCLUSIONS. The epidemiologic features of pediatric ice skating - related injuries differ from those of roller skating - and in-line skating - related injuries. Children should wear helmets during all recreational skating activities, especially ice skating, because of the risk of serious head injuries. Wrist guards should be worn to protect against the common upper-extremity fractures sustained during skating.	Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Pediat, Columbus, OH 43210 USA		Knox, CL (corresponding author), Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	knoxc@pediatrics.ohio-state.edu					Boyce SH, 2001, SCOT MED J, V46, P102, DOI 10.1177/003693300104600403; Cheng SL, 1995, J TRAUMA, V39, P1194, DOI 10.1097/00005373-199512000-00036; de Nooijer J, 2004, EUR J PUBLIC HEALTH, V14, P178, DOI 10.1093/eurpub/14.2.178; FREELAND P, 1998, BRIT MED J, V296, P96; Hassan I, 1999, J ACCID EMERG MED, V16, P348; Katcher ML, 1998, PEDIATRICS, V101, P720, DOI 10.1542/peds.101.4.720; Knox CL, 2006, BRIT J SPORT MED, V40, P268, DOI 10.1136/bjsm.2005.022855; Lam C. K., 1997, Hong Kong Medical Journal, V3, P131; McGeehan J, 2004, PEDIATRICS, V114, P124, DOI 10.1542/peds.114.1.124; McGrath D, 1996, J ACCID EMERG MED, V13, P354; *NAT SAF KIDS CAMP, 2004, RECR INJ FACT SHEET; Nguyen D, 2001, J PEDIATR ORTHOPED, V21, P613, DOI 10.1097/00004694-200109000-00012; O'Farrell DA, 1997, INJURY, V28, P377, DOI 10.1016/S0020-1383(97)00030-2; Osberg JS, 1998, ARCH PEDIAT ADOL MED, V152, P985; Powell EC, 1996, PEDIATR EMERG CARE, V12, P259, DOI 10.1097/00006565-199608000-00006; Pudpud AA, 1997, PEDIATR EMERG CARE, V13, P376, DOI 10.1097/00006565-199712000-00004; Schieber RA, 1996, NEW ENGL J MED, V335, P1630, DOI 10.1056/NEJM199611283352202; SCHIEBER RA, 1995, SPORTS MED, V19, P427, DOI 10.2165/00007256-199519060-00006; *US CONS PROD SAF, NEISS SAMPL DES IMPL	19	29	31	0	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	AUG	2006	118	2					549	554		10.1542/peds.2005-2913			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	069IW	WOS:000239440600014	16882806				2022-02-06	
J	Van Heugten, CM; Hendriksen, J; Rasquin, S; Dijcks, B; Jaeken, D; Vles, JHS				Van Heugten, C. M.; Hendriksen, J.; Rasquin, S.; Dijcks, B.; Jaeken, D.; Vles, J. H. S.			Long-term neuropsychological performance in a cohort of children and adolescents after severe paediatric traumatic brain injury	BRAIN INJURY			English	Article						brain injury; children; cognitive disorders; long-term functioning	REHABILITATION PROGRAM; FOLLOW-UP; RECOVERY; OUTCOMES; PREDICTORS; CHILDHOOD; TBI	Objective: The purpose of the present study was to evaluate progress in neuropsychological performance in children and adolescents with severe paediatric traumatic brain injury (TBI), from admission to the rehabilitation centre up to 3-12 years after the trauma. Methods: Children and adolescents (n = 3 1, mean age at injury 11.8 years, SD = 3.8; at follow-up 18.8 years; SD = 4.5) who all had suffered a TBI participated. A comprehensive neuropsychological test battery was administered at the start of rehabilitation (T 1), around discharge (T2) and in the long-term (at least 3 years after rehabilitation; T3). T I and T2 were clinical assessments; T3 was executed as a follow-up measurement for this study. Results: At T1 and T2, most problems were in the domains of attention, memory and executive functioning. At the start of rehabilitation most deficits were with performal intelligence (61%); at discharge (mean length of stay 411 days) considerably less children had severe deficits on the intelligence domain (23%). At long-term follow-up, most problems were in the domains attention, mental speed and memory. From admission to discharge 42% of the children improved on two or more cognitive tests; from discharge to follow-up this percentage was 13%. Conclusions: In this unique study a clinical cohort of children with severe TBI was followed for many years after injury. Most cognitive deficits were found in the early phase of rehabilitation. Most children did improve on cognitive functioning (40%) during the first year after their injury, whereas at follow-up most children had not changed. At follow-up, more than half of the children (54%) attended a regular school or had a regular job, corresponding to their age and pre-morbid functioning.	Inst Rehabil Res, iRv, NL-6430 AD Hoensbroek, Netherlands; SRL, Rehabil Fdn, Limburgerhof, Germany; Univ Maastricht, Inst Brain & Behav, Maastricht, Netherlands; Univ Hosp Maastricht, Maastricht, Netherlands		Van Heugten, CM (corresponding author), Inst Rehabil Res, iRv, POB 192, NL-6430 AD Hoensbroek, Netherlands.	c.vanheugten@irv.nl					Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Beaulieu CL, 2002, SURG CLIN N AM, V82, P393, DOI 10.1016/S0039-6109(02)00009-9; Beery K, 1989, VMI DEV TEST VISUAL; Brickenkamp R, 2000, TESTKATALOG 2000 200, P60; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fleming J, 1999, BRAIN INJURY, V13, P417; Garth J, 1997, Pediatr Rehabil, V1, P99; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Hoofien D, 2001, BRAIN INJURY, V15, P189; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jennett B., 1997, HEAD INJURY, P439; JOHNSON CA, 2001, BRAIN INJURY, V18, P921; Kaufman A. S, 1983, KAUFMAN ASSESSMENT B; Kieslich M, 2001, DISABIL REHABIL, V23, P665; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kline P, 2000, HDB PSYCHOL TESTING, V2nd; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; RUIJS MBM, 1995, NEUROLOGICAL ASPECTS; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; VANHAASSEN PP, 1986, WISC R DUTCH VERSION; Vos P.G., 1988, BOURDON VOS TEST; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; [No title captured]	46	29	29	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2006	20	9					895	903		10.1080/02699050600832015			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	094ZN	WOS:000241278100002	17062421				2022-02-06	
J	Hotz, GA; Castelblanco, A; Lara, IM; Weiss, AD; Duncan, R; Kuluz, JW				Hotz, Gillian A.; Castelblanco, Andrea; Lara, Isabel M.; Weiss, Alyssa D.; Duncan, Robert; Kuluz, John W.			Snoezelen: A controlled multi-sensory stimulation therapy for children recovering from severe brain injury	BRAIN INJURY			English	Article						behavioural; children; multi-sensory; Snoezelen; therapy	MENTAL-RETARDATION; HEAD TRAUMA; PLASTICITY; DISABILITIES; MANAGEMENT; PEOPLE; SCALE; BEHAVIOR; CARE; AGE	Objective: To investigate the effects of Snoezelen therapy on physiological, cognitive and behavioural changes in children recovering from severe traumatic brain injury (TBI). Methods: An observational study was conducted to assess the physiological, cognitive and behavioural changes of children recovering from severe TBI while receiving Snoezelen therapy. Fifteen subjects completed the pre- and post-Snoezelen treatment measurements computed over 10 consecutive sessions. Physiological, cognitive and behavioural measures were administered. Data was collected prospectively on each session in the Snoezelen room and were analysed by calculating the difference between pre- and post-treatment measurements for each Snoezelen session. Results: Results revealed significant changes on physiological measures. Heart rates decreased for each subject in each treatment session and were found to be significant (p = 0.032). Muscle tone was decreased in all the affected extremities (right upper extremity p=0.009, left upper extremity p=0.020, right lower extremity p=0.036 and left lower extremity p=0.018). Agitation levels decreased over time and the overall cognitive outcome measures showed significant improvement when comparing the beginning of treatment with the end. Conclusion: This study revealed a beneficial use of Snoezelen therapy with children recovering from severe brain injury. However, there continues to be a critical need for evidenced-based research for this patient population and others in this multi-sensory environment.	Ryder Trauma Ctr, DeWitt Daughtry Family Dept Surg, Div Trauma & Surg Crit Care, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33152 USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL 33152 USA		Hotz, GA (corresponding author), Ryder Trauma Ctr, DeWitt Daughtry Family Dept Surg, Div Trauma & Surg Crit Care, 405,1800 NW 10th Ave, Miami, FL 33136 USA.	ghotz@med.miami.edu					ANSELL BJ, 1991, J SPEECH HEAR RES, V34, P1017, DOI 10.1044/jshr.3405.1017; Ayres A. J., 1979, SENSORY INTEGRATION; AYRES AJ, 1980, AM J OCCUP THER, V34, P375, DOI 10.5014/ajot.34.6.375; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; CLELAND CC, 1966, AM J MENT DEF, V71, P213; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; Cuvo AJ, 2001, RES DEV DISABIL, V22, P183, DOI 10.1016/S0891-4222(01)00067-1; deBunsen A., 1994, SENSATIONS DISABILIT, P138; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Fagny M, 2000, REV FRANCOPHONE DEFI, V11, P105; Fields RD, 2005, NEUROSCIENTIST, V11, P528, DOI 10.1177/1073858405282304; Finger S., 1982, BRAIN DAMAGE RECOVER; *FLOR DEP HIGHW SA, 2002, TRAFF CRASH FACTS 20; Gerber CS, 2005, CRIT CARE NURS Q, V28, P94, DOI 10.1097/00002727-200504000-00002; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HAGGAR L, 1991, BIMU PUBLICATIONS, V37, P69; Hogg J, 2001, RES DEV DISABIL, V22, P353, DOI 10.1016/S0891-4222(01)00077-4; Houghton S, 1998, J INTELLECT DEV DIS, V23, P267, DOI 10.1080/13668259800033761; HULSEGGE J, 1987, WORLD; Johnston M V, 2001, Adv Pediatr, V48, P1; Johnston MV, 2004, BRAIN DEV-JPN, V26, P73, DOI 10.1016/S0387-7604(03)00102-5; Johnston MV, 2003, PEDIATR RES, V53, P369, DOI 10.1203/01.PDR.0000049517.47493.E9; KAPLAN H, 2005, RES DEV DISABILITY; Kater K M, 1989, West J Nurs Res, V11, P20, DOI 10.1177/019394598901100103; KENYON J, 1998, BRIT J THERAPY REHAB, V5, P619; Kwok H. W. M., 2003, Hong Kong Medical Journal, V9, P122; Lancioni GE, 2005, DISABIL REHABIL, V27, P83, DOI 10.1080/09638280400007406; Lindsay WR, 1997, J INTELL DISABIL RES, V41, P201, DOI 10.1111/j.1365-2788.1997.tb00698.x; Long A., 1992, BRIT J OCCUPATIONAL, V55, P103; Lotan M, 2005, BRAIN DEV-JPN, V27, pS88, DOI 10.1016/j.braindev.2005.03.021; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MALKMUS D, 1980, REHABILITATION HEAD; Mayr JM, 2003, EUR J PEDIATR, V162, P184, DOI 10.1007/s00431-002-1099-1; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MESSBAUER L, 2004, SNOEZELEN STATE ART; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; Schofield P, 2000, DISABIL REHABIL, V22, P675, DOI 10.1080/096382800445470; Shapiro M, 1997, BRIT J DEV DISABIL, V43, P140, DOI 10.1179/bjdd.1997.014; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; TEUBER HL, 1967, MED CHILD NEUROLOGY, V4, P3; THOMPSON SBN, 1994, BRIT J OCCUPATIONAL, V57, P341; Tolle Patrizia, 2003, Axone, V25, P20; WEGMAN WE, 1981, PEDIATRICS, V75, P835; [No title captured]	50	29	33	1	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					879	888		10.1080/02699050600832635			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300011	17046800				2022-02-06	
J	Svetlov, SI; Xiang, Y; Oli, MW; Foley, DP; Huang, G; Hayes, RL; Ottens, AK; Wang, KKW				Svetlov, S. I.; Xiang, Y.; Oli, M. W.; Foley, D. P.; Huang, G.; Hayes, R. L.; Ottens, A. K.; Wang, K. K. W.			Identification and preliminary validation of novel biomarkers of acute hepatic ischaemia/reperfusion injury using dual-platform proteomic/degradomic approaches	BIOMARKERS			English	Article						biomarkers; rat; liver; ischaemia/ reperfusion; injury; argininosuccinate synthase; estrogen sulfotransferase	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; ISCHEMIA-REPERFUSION; LIVER-INJURY; PRESERVATION; ENDOTOXEMIA; MECHANISMS; DISCOVERY; APOPTOSIS	Hepatic ischaemia/reperfusion (I/R), a major cause of liver damage associated with multiple trauma, haemorrhagic and septic shock, and liver transplantation, contributes significantly to multiple organ failure. Development of novel sensitive biomarkers that detect early stages of liver damage is vital for effective management and treatment of ischaemic liver injury. By using high-throughput immunoblotting and cation-anion exchange chromatography/reversed-phase liquid chromatography-tandem mass-spectrometry, we identified several hepatic proteins, including argininosuccinate synthase ( ASS) and estrogen sulfotransferase (EST-1), which were degraded in the liver and rapidly released into circulation during I/R injury. ASS accumulated in serum within 10 min, reached a steady state at 30 min, and persisted up until 3 h after reperfusion following 30 min of total hepatic ischaemia. EST-1 appeared rapidly in blood and attained maximum within 1 hour followed by a decline at 3 h of reperfusion. No ASS or EST-1 protein was detected in serum of control or sham operated rats. ASS and EST-1 exhibited greater sensitivity and specificity toward I/R liver injury as compared with alanine aminotransferase (ALT), an established marker of hepatocellular necrosis. In contrast, serum ASS and EST-1 were undetectable in rats with chronic alcoholic liver disease, while the levels of ALT protein were significantly increased. In addition, ASS, but not EST-1 or ALT-accumulated in blood only 6 h after treatment with hepatotoxic combination of lipopolysaccharide and D-galactosamine. These data demonstrate the utility of ASS and EST-1 as novel sensitive and specific biomarkers of acute liver ischaemic injury for prospective clinical studies.	Univ Florida, Coll Med, Dept Neurosci, Ctr Prot & Biomarkers Res,Lab Mol & Cellular Mch, Gainesville, FL 32610 USA		Svetlov, SI (corresponding author), Univ Florida, Coll Med, Dept Neurosci, Ctr Prot & Biomarkers Res,Lab Mol & Cellular Mch, Gainesville, FL 32610 USA.	svetlov@mbi.ufl.edu	Ottens, Andrew/K-3352-2012	Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R43AI094877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R21DK061649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R43 AI094877] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK061649] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049175-01] Funding Source: Medline		Aldemir D, 2003, TRANSPL P, V35, P2811, DOI 10.1016/j.transproceed.2003.08.048; Dokladny K, 2001, AM J PHYSIOL-REG I, V280, pR338, DOI 10.1152/ajpregu.2001.280.2.R338; Haskins WE, 2004, ANAL CHEM, V76, P5523, DOI 10.1021/ac049363y; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Ikemoto M, 2001, CLIN CHEM, V47, P946; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5; Jaeschke H, 2003, AM J PHYSIOL-GASTR L, V284, pG15, DOI 10.1152/ajpgi.00342.2002; Jaeschke H, 1996, J HEPATOL, V25, P774, DOI 10.1016/S0168-8278(96)80253-4; Jaeschke H, 1996, TOXICOL APPL PHARM, V139, P213, DOI 10.1006/taap.1996.0160; Jones JJ, 1999, HEPATOLOGY, V30, P714, DOI 10.1002/hep.510300324; Kim JS, 2003, GASTROENTEROLOGY, V124, P494, DOI 10.1053/gast.2003.50059; Lemasters JJ, 1997, ANNU REV PHARMACOL, V37, P327, DOI 10.1146/annurev.pharmtox.37.1.327; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; LIM SP, 1992, DIGEST DIS SCI, V37, P1275, DOI 10.1007/BF01296572; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Namisaki T, 2006, J HEPATOL, V44, P568, DOI 10.1016/j.jhep.2005.08.018; Ottens AK, 2005, ANAL CHEM, V77, P4836, DOI 10.1021/ac050478r; Ozaki M, 1995, ENZYME PROTEIN, V48, P213, DOI 10.1159/000474991; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Sakon M, 2002, SURG TODAY, V32, P1, DOI 10.1007/s595-002-8105-8; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; YANG JC, 2004, DI YI JUN YI DA XUE, V198, P203; Yoo GH, 2002, CLIN CANCER RES, V8, P3910	29	29	30	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1354-750X	1366-5804		BIOMARKERS	Biomarkers	JUL-AUG	2006	11	4					355	369		10.1080/13547500600775110			15	Biotechnology & Applied Microbiology; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Toxicology	083YD	WOS:000240494300006	16908442				2022-02-06	
J	Hart, T; Whyte, J; Millis, S; Bode, R; Malec, J; Richardson, RN; Hammond, F				Hart, T; Whyte, J; Millis, S; Bode, R; Malec, J; Richardson, RN; Hammond, F			Dimensions of disordered attention in traumatic brain injury: Further validation of the Moss Attention Rating Scale	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						attention; brain injuries; cognition disorders; rehabilitation	HEAD-INJURY; DEFICITS; TASK	Objectives: To investigate the factor structure of disordered attention in moderate to severe, acute traumatic brain injury (TBI) and to use factor analysis and item response theory to further validate and refine an observational rating scale of attention for clinical and research purposes. Design: Multicenter inception cohort. Setting: Inpatient rehabilitation units. Participants: Patients with TBI (N=372) consecutively admitted to 8 Traumatic Brain Injury Model System centers within 2 weeks prior to observation, who consistently followed commands and who were on stable doses of all psychotropic medications for a 3-day rating period. Interventions: Not applicable. Main Outcome Measure: Participants were rated independently by treating occupational and physical therapists at an average of 1 month postinjury on the Moss Attention Rating Scale (MARS), a 45-item. Likert-type scale of attention-related behavior. Results: Exploratory and confirmatory factor analyses revealed 3 correlated factors of disordered attention, interpreted as restlessness/distractibility, initiation, and sustained/consistent attention. Item response (Rasch) analysis was used to eliminate redundant items and to fill gaps in item difficulty. The resulting MARS consists of 22 items that can produce 3 factor scores and a total score that covers the broad construct of disordered attention. Conclusions: The factor-scored MARS has potential utility as a quantitative observational method with which to assess and study different dimensions of disordered attention in acute TBI, and to monitor change over time and treatment response within these dimensions.	Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA; Wayne State Univ, Sch Med, Detroit, MI USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Mayo Clin, Rochester, MN USA; Mississippi Methodist Rehabil Ctr, Jackson, MS USA; Charlotte Inst Rehabil, Charlotte, NC USA		Hart, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu		Whyte, John/0000-0002-4381-1474			Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bond T, 2001, APPL RASCH MODEL FUN; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; DELIS D, 2003, J INT NEUROPSYCH SOC, V9, P947; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hinshaw SP, 1999, DIAGNOSTIC ASSESSMENT IN CHILD AND ADOLESCENT PSYCHOPATHOLOGY, P91; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Joreskog K. G., 2000, LISREL 8 NEW STAT FE; Kennedy MA, 2003, CURR ANTHROPOL, V44, P4; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A.F., 1996, ATTENTION MEMORY EXE, P71; POGGE DL, 1994, J CLIN EXP NEUROPSYC, V16, P344, DOI 10.1080/01688639408402645; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Raftery AE., 1993, TESTING STRUCTURAL E, P163; Raz Amir, 2004, Anatomical Record Part B:The New Anatomist, V281, P21, DOI 10.1002/ar.b.20035; Riccio CA, 2004, CLIN NEUROPSYCHOL, V18, P528, DOI 10.1080/138540490516662; Smith E V Jr, 2001, J Appl Meas, V2, P281; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2003, ARCH PHYS MED REHAB, V84, P268, DOI 10.1053/apmr.2003.50108; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; WHYTE J, 1998, INT PERSPECTIVES TRA, P154; Wright B, 1982, RATING SCALE ANAL RA	32	29	30	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2006	87	5					647	655		10.1016/j.apmr.2006.01.016			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	039UW	WOS:000237333900007	16635627				2022-02-06	
J	Kelso, ML; Wehner, JM; Collins, AC; Scheff, SW; Pauly, JR				Kelso, ML; Wehner, JM; Collins, AC; Scheff, SW; Pauly, JR			The pathophysiology of traumatic brain injury in alpha 7 nicotinic cholinergic receptor knockout mice	BRAIN RESEARCH			English	Article						nicotinic cholinergic receptor; alpha 7; neuroprotection; neurotrauma; null mutant mouse	PERIPHERAL BENZODIAZEPINE-RECEPTORS; ACETYLCHOLINE-RECEPTORS; ALZHEIMERS-DISEASE; TEMPORAL CORTEX; BINDING-SITES; TIME-COURSE; RAT-BRAIN; EXPRESSION; ACTIVATION; PROTEIN	The alpha 7 nicotinic cholinergic receptor is a ligand-gated ion channel with calcium permeability similar to that of ionotrophic glutamate receptors. Previous studies from our laboratory have implicated changes in expression alpha 7 nicotinic cholinergic receptors in the pathophysiology of traumatic brain injury (TBI). In rats, TBI causes a time-dependent and significant decrease in cortical and hippocampal alpha-[I-125]-bungarotoxin (BTX) binding. We have postulated that deficits in a7 expression may contribute to TBI-induced cognitive impairment and that nicotinic receptor agonists can reverse alpha 7 binding deficits and result in significant cognitive improvement compared to saline-treated controls. Thus, alpha 7 nAChRs could be involved in a form of cholinergically mediated excitotoxicity following brain injury. In the current study, wild-type, heterozygous and null mutant mice were employed to test the hypothesis that genotypic depletion of the a7 receptor would render animals less sensitive to tissue loss and brain inflammation following experimental brain injury. Mice were anesthetized and subjected to a 0.5-mm cortical contusion injury of the somatosensory cortex. Brain inflammation, changes in nicotinic receptor expression and cortical tissue sparing were evaluated in wild-type, heterozygous and homozygous mice 1 week following TBI. in wild-type mice, brain injury caused a significant decrease in BTX binding in several hippocampal regions, consistent with what we have measured in rat brain following TBI. However, there were no genotypic differences in cortical tissue sparing or brain inflammation in this experiment. Although the results of this study were largely negative, it is still plausible that changes in the activity/expression of native alpha 7 receptors contribute to pathophysiology following TBI. However, when null mutant mice develop in the absence of central alpha 7 expression, it is possible that compensatory changes occur that confound the results obtained. (c) 2006 Elsevier B.V. All rights reserved.	Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, SCOBRIC, Lexington, KY 40536 USA		Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.	jpauly@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042196, R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P30DA015663] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [5P30DA015663-03] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS42196] Funding Source: Medline		Banerjee C, 2000, NEUROBIOL DIS, V7, P666, DOI 10.1006/nbdi.2000.0317; Burghaus L, 2003, PARKINSONISM RELAT D, V9, P243, DOI 10.1016/S1353-8020(03)00028-2; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; CASTRO NG, 1995, BIOPHYS J, V68, P516, DOI 10.1016/S0006-3495(95)80213-4; De Simone R, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-4; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Ferchmin PA, 2003, J PHARMACOL EXP THER, V305, P1071, DOI 10.1124/jpet.102.048173; Fucile S, 2004, CELL CALCIUM, V35, P1, DOI 10.1016/j.ceca.2003.08.006; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hazell AS, 1999, NEUROSCI LETT, V271, P5, DOI 10.1016/S0304-3940(99)00489-9; Hellstrom-Lindahl E, 1999, MOL BRAIN RES, V66, P94, DOI 10.1016/S0169-328X(99)00030-3; Herber DL, 2004, J HISTOCHEM CYTOCHEM, V52, P1367, DOI 10.1369/jhc.4A6319.2004; Keller JJ, 2005, BEHAV BRAIN RES, V162, P143, DOI 10.1016/j.bbr.2005.03.004; Kuhlmann AC, 1999, TOXICOL SCI, V48, P107, DOI 10.1093/toxsci/48.1.107; Lacor P, 1999, BRAIN RES, V815, P70, DOI 10.1016/S0006-8993(98)01105-6; Laudenbach V, 2002, FASEB J, V16, P423, DOI 10.1096/fj.01-0532fje; Lee DHS, 2003, J NEUROBIOL, V55, P25, DOI 10.1002/neu.10203; Martin SE, 2004, BRAIN RES, V1022, P254, DOI 10.1016/j.brainres.2004.07.016; Mike A, 2000, BRAIN RES, V882, P155, DOI 10.1016/S0006-8993(00)02863-8; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; Oddo S, 2005, P NATL ACAD SCI USA, V102, P3046, DOI 10.1073/pnas.0408500102; OrrUrtreger A, 1997, J NEUROSCI, V17, P9165; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Quick MW, 2002, J NEUROBIOL, V53, P457, DOI 10.1002/neu.10109; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rupalla K, 1998, ACTA NEUROPATHOL, V96, P172, DOI 10.1007/s004010050878; Salminen O, 2004, MOL PHARMACOL, V65, P1526, DOI 10.1124/mol.65.6.1526; SEGUELA P, 1993, J NEUROSCI, V13, P596; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wang W.B., 2000, P SPIE, V3917, P75; Wehner JM, 2004, NEUROSCIENCE, V129, P11, DOI 10.1016/j.neuroscience.2004.07.016	40	29	30	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 14	2006	1083						204	210		10.1016/j.brainres.2006.01.127			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	040JG	WOS:000237374200022	16545784				2022-02-06	
J	Hirose, H; Gill, IS; Malangoni, MA				Hirose, H; Gill, IS; Malangoni, MA			Nonoperative management of traumatic aortic injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						aortic injury; blunt trauma; management	THORACIC AORTA; BLUNT TRAUMA; RUPTURE; EXPERIENCE; ISTHMUS; REPAIR	Background: The standard management for patients with blunt aortic injury is surgery; however, a small number of patients have been medically managed. The outcome of these nonoperatively managed patients is unknown. Methods: Seven patients diagnosed as blunt aortic injury were managed without aortic surgery between January 1993 and April 2002, and their outcomes were retrospectively investigated. Results: There were three men and four women, with a mean age of 48.7 +/- 22.7 years and Injury Severity Score of 37.7 +/- 16.9. The reason for nonoperative management was refusal of surgery (2), do-not-resuscitate order (1), diffuse brain injury (2), small intimal tear (1), and technical difficulty (1). Two patients died resulting from associated injuries. Five patients are alive, and in three patients complete resolution of aortic injury was observed. Conclusion: In selected patients with multiple associated injuries or severe comorbidity, nonoperative management after blunt aortic injury can be a treatment of choice.	Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44109 USA; MetroHlth Med Ctr, Dept Surg, Cleveland, OH USA		Gill, IS (corresponding author), Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, ME90 3rd Floor,Hamann Bldg,2500 Metro Hlth Dr, Cleveland, OH 44109 USA.	gillis@ccf.org	Hirose, Hitoshi/B-2281-2008	Hirose, Hitoshi/0000-0001-5210-810X			AKINS CW, 1981, ANN THORAC SURG, V31, P305, DOI 10.1016/S0003-4975(10)60955-1; Camp PC, 1997, J TRAUMA, V43, P413, DOI 10.1097/00005373-199709000-00004; Fabian TC, 1998, ANN SURG, V227, P666, DOI 10.1097/00000658-199805000-00007; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; FISHER RG, 1990, J TRAUMA, V30, P1562, DOI 10.1097/00005373-199012000-00022; Holmes JH, 2002, ANN THORAC SURG, V73, P1149, DOI 10.1016/S0003-4975(01)03585-8; Kasirajan K, 2003, ANN VASC SURG, V17, P589, DOI 10.1007/s10016-003-0066-2; Katsumata T, 1998, ANN THORAC SURG, V66, P774, DOI 10.1016/S0003-4975(98)00519-0; Kepros J, 2002, J TRAUMA, V52, P475, DOI 10.1097/00005373-200203000-00010; Kwon CC, 2002, ANN THORAC SURG, V74, pS1888, DOI 10.1016/S0003-4975(02)04148-6; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Mattox K L, 2000, Chest Surg Clin N Am, V10, P167; Orford VP, 2003, ANN THORAC SURG, V75, P106, DOI 10.1016/S0003-4975(02)04331-X; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Pate JW, 1999, WORLD J SURG, V23, P59, DOI 10.1007/s002689900565; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; Symbas PN, 2002, ANN SURG, V235, P796, DOI 10.1097/00000658-200206000-00006	17	29	29	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2006	60	3					597	601		10.1097/01.ta.0000205044.99771.44			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	026WX	WOS:000236374900030	16531860				2022-02-06	
J	Capilouto, GJ; Wright, HH; Wagovich, SA				Capilouto, Gilson J.; Wright, Heather Harris; Wagovich, Stacy A.			Reliability of main event measurement in the discourse of individuals with aphasia	APHASIOLOGY			English	Article; Proceedings Paper	35th Annual Clinical Aphasiology Conference	MAY 31-JUN 04, 2005	Sanibel Isl, FL				CLOSED-HEAD-INJURY; TRAUMATIC BRAIN-INJURY; NARRATIVE DISCOURSE; CONNECTED SPEECH; ADULTS; COMPREHENSION; STORY	Background: Quantitative measures of discourse skills of adults with aphasia can be valuable in documenting evidenced-based practice. Comprehensive assessment of narrative discourse should include a measure of the ability to relay main events (Nicholas & Brookshire, 1995; Wright, Capilouto, Wagovich, Cranfill, & Davis, 2005). Wright et al. (2005) compared the ability of younger and older healthy adults to relate main events in response to pictured stimuli. Results indicated that the younger group produced a significantly higher proportion of main events as compared to the older group and that the main events measure was stable for individual participants over time. However, performance data and data supporting the stability of the main events measure for individuals with aphasia are needed to extend the clinical usefulness of the main events measure as an assessment tool. Aims: The purpose of this study was (a) to compare the performance of healthy adults and adults with aphasia on their ability to convey main events in pictured stimuli and (b) to establish session-to-session reliability of the authors' main events measure. Methods & Procedures: Eight adults with aphasia (APH) and eight neurologically intact adults (NI) participated in the study. Participants attended two sessions, 7-21 days apart. Each time, participants gave an account of the events from two pictures and two picture sequences (Nicholas & Brookshire, 1993). The resulting language samples were analysed for the proportion of main events conveyed, and test-retest reliability of the measure was assessed. Outcomes & Results: NI adults told a significantly higher proportion of main events than adults with aphasia. The main effect for picture stimulus was also significant; participants told significantly more main events in response to sequential versus single picture stimuli, regardless of group. Test-retest results yielded strong, positive correlations between sessions for both groups. Conclusions: Results indicate that adults with and without aphasia differ in their ability to express the relations and causal links among units of information. Results also indicate that Wright and colleagues' (2005) main events measure demonstrates sufficient stability to provide the foundation for its potential use as a pre- and post-treatment measure. Finally, the finding that the proportion of main events provided in response to stimuli varied according to the nature of the stimuli is consistent with the findings of Wright et al. (2005) and suggests that even for individuals with aphasia, relationships between elements depicted in pictures may be more easily identified and conveyed when sequential pictures are provided as stimuli.	Univ Kentucky, Div Commun Disorders, Lexington, KY 40536 USA; Arizona State Univ, Tempe, AZ USA; Univ Missouri, Columbia, MO USA		Capilouto, GJ (corresponding author), Univ Kentucky, Div Commun Disorders, 900 S Limestone,CTW Bldg, Lexington, KY 40536 USA.	gjcapi2@uky.edu	Wagovich, Stacy/O-8179-2019	Wagovich, Stacy/0000-0001-7800-9310; wright, heather/0000-0001-6922-6364			Armstrong E, 2000, APHASIOLOGY, V14, P875, DOI 10.1080/02687030050127685; BOND S, 1983, CLIN APHASIOLOGY C; BROWNELL HH, 1988, APHASIOLOGY, V2, P247, DOI 10.1080/02687038808248918; Capilouto G, 2005, J COMMUN DISORD, V38, P431, DOI 10.1016/j.jcomdis.2005.03.005; CAPLAN D, 1990, BRAIN LANG, V39, P206, DOI 10.1016/0093-934X(90)90012-6; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); COOPER PV, 1990, J GERONTOL, V45, pP210, DOI 10.1093/geronj/45.5.P210; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Doyle PJ, 1998, APHASIOLOGY, V12, P561, DOI 10.1080/02687039808249558; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; HEATH SB, 1986, TOP LANG DISORD, V7, P84, DOI 10.1097/00011363-198612000-00010; KERTESZ A, 1982, WK APHASIA BATTERY; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; NICHOLAS LE, 1995, J SPEECH HEAR RES, V38, P146, DOI 10.1044/jshr.3801.145; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; OLNESS G, 2005, CLIN APH C SAN FLOR; Olness G. S., 2002, APHASIOLOGY, V16, P623, DOI [DOI 10.1080/02687030244000095, 10.1080/02687030244000095]; Potechin G. G., 1987, APHASIOLOGY, V17, P216; PRINS RS, 1978, BRAIN LANG, V6, P192, DOI 10.1016/0093-934X(78)90058-5; SKA B, 2004, MIT ENCY COMMUNICAT; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; ULATOWSKA H, 1990, DISCOURSE ABILITY BR, P191; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; Ulatowska HK, 2003, APHASIOLOGY, V17, P511, DOI 10.1080/0268703034400102; Ulatowska HK, 2000, BRAIN LANG, V71, P249, DOI 10.1006/brln.1999.2261; Wallach G. P., 1988, Language intervention and academic success; Wertz, 1989, APHASIA CLIN APPROAC; Wright HH, 2005, APHASIOLOGY, V19, P263, DOI 10.1080/02687030444000732; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	34	29	29	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	FEB-APR	2006	20	2-4					205	216		10.1080/02687030500473122			12	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	047PA	WOS:000237890000010		Green Submitted			2022-02-06	
J	Greve, KW; Bianchini, KJ				Greve, KW; Bianchini, KJ			Should the retention trial of the test of memory malingering be optional?	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; TOMM; symptom validity test; traumatic brain injury; chronic pain		The present study examined the false negative error rate associated with the optional use of the Retention trial the Test of Memory Malingering (TOMM). TOMM scores from 150 traumatic brain injury and 150 chronic pain patients were examined. Results indicated that early termination of the TOMM resulted in 3% of patients going undetected by the TOMM. The practical cost of this error was minimized by the inclusion of at least one other SVT. Clinical implications are discussed. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, 2000 Lakefront, New Orleans, LA 70148 USA.	kgreve@uno.edu					Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; DOANE BM, CLIN NEUROPSYCHOLOGI; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260	9	29	29	1	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2006	21	1					117	119		10.1016/j.acn.2005.06.009			3	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	006EA	WOS:000234877100012	16111856	Bronze			2022-02-06	
J	Hutchison, J; Ward, R; Lacroix, J; Hebert, P; Skippen, R; Barnes, M; Meyer, P; Morris, K; Kirpalani, H; Singh, R; Dirks, P; Bohn, D; Moher, D				Hutchison, J.; Ward, R.; Lacroix, J.; Hebert, P.; Skippen, P.; Barnes, M.; Meyer, P.; Morris, K.; Kirpalani, H.; Singh, R.; Dirks, P.; Bohn, D.; Moher, D.		HyP HIT Investigators; Canadian Critical Care Trials Grp	Hypothermia pediatric head injury trial: The value of a pretrial clinical evaluation phase	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric severe traumatic brain injury; hypothermia therapy; multicenter trial	TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; INTENSIVE-CARE; CARDIAC-ARREST; CHILDREN	Background: The utility of a pretrial clinical evaluation or run-in phase prior to conducting trials of complex interventions such as hypothermia therapy following severe traumatic brain injury in children and adolescents has not been established. Methods: The primary objective of this study was to prospectively evaluate the ability of investigators to adhere to the clinical protocols of care including the cooling and rewarming procedures as well as management guidelines in patients with severe traumatic brain injury (Glasgow Coma Scale <= 8) treated with 24 h of hypothermia therapy. A secondary objective was to evaluate the ability of study research assistants to complete the study case report form using a procedures manual. The study was conducted at 18 sites in Canada, the United Kingdom and France prior to proceeding to a randomized controlled trial (RCT). After 2 patients were enrolled at each center, an independent clinical evaluation committee examined the process of care and the completeness of data collection. Centers were permitted to enroll patients in the RCT once they met pre-established adherence criteria. Results: Seventeen of the 18 centers completed the pretrial clinical evaluation phase demonstrating compliance with study procedures and proceeded to an RCT of hypothermia therapy. One center enrolled only 1 patient in the pretrial clinical evaluation phase due to small numbers of patients with traumatic brain injury, and therefore, did not proceed to the RCT. Three centers were required to enroll more than 2 patients in the pretrial clinical evaluation phase prior to proceeding to the RCT because of problems with adherence to the clinical protocols at two centers and the training of new study personnel at another center. Of the 39 patients enrolled during the pretrial clinical evaluation phase, 8 (20.5%) died and 22 (62.9%) had a good outcome defined as normal, mild or moderate disability assessed using the Pediatric Cerebral Performance Category score at 6 months following injury. Discussion: The pretrial clinical evaluation phase was useful to ensure compliance with complex hypothermia therapy and consensus-based clinical management guidelines of care successfully implemented across 17 of 18 centers. This study maneuver allowed us to complete a subsequent RCT in 225 children following severe traumatic brain injury. Copyright (c) 2006 S. Karger AG, Basel.	Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Neurosurg, Dept Surg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Interdepartmental Div Crit Care, Toronto, ON, Canada; Hosp Sick Children, Res Inst, Integrat Biol Program, Toronto, ON M5G 1X8, Canada; Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, Ottawa, ON, Canada; Ottawa Hosp, Dept Crit Care Med, Ottawa Hlth Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; Univ Ottawa, Fac Med, Dept Pediat, Ottawa, ON, Canada; Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada; St Justine Hosp, Dept Pediat, Div Intens Care, Montreal, PQ, Canada; British Columbia Childrens Hosp, Dept Pediat, Div Intens Care, Vancouver, BC, Canada; Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada; Childrens Hosp Hamilton, Dept Pediat, Hamilton, ON, Canada; Childrens Hosp Western Ontario, Dept Pediat, London, ON, Canada; Grp Hosp Necker Enfants Malades, Neurointens Care Unit, Paris, France; Birmingham Childrens Hosp, Intens Care Unit, Birmingham, W Midlands, England		Hutchison, J (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	Jamie.Hutchison@sickkids.ca	Meyer, Philippe/ABE-4242-2020	Meyer, Philippe/0000-0002-3829-6631; Moher, David/0000-0003-2434-4206; skippen, peter/0000-0001-6716-0381			Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; [Anonymous], 2000, J Neurotrauma, V17, P537; Bernard S, 1996, ANAESTH INTENS CARE, V24, P382, DOI 10.1177/0310057X9602400315; Biagas Katherine V., 1998, Current Opinion in Pediatrics, V10, P271, DOI 10.1097/00008480-199806000-00009; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Campbell CGN, 2004, CAN J NEUROL SCI, V31, P213, DOI 10.1017/S0317167100053853; Chambers S, 1999, Nurs Crit Care, V4, P112; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Cullen M L, 2001, Respir Care Clin N Am, V7, P59, DOI 10.1016/S1078-5337(05)70023-X; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Gilliland MGF, 2001, AM J FOREN MED PATH, V22, P200, DOI 10.1097/00000433-200106000-00019; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Linstone H.A., 1975, DELPHI METHOD TECHNI; Marion DW, 1996, CRIT CARE MED, V24, pS81; MCINTYRE L, 2003, JAMA-J AM MED ASSOC, V89, P2992; Sambasivan M, 1999, NEUROL INDIA, V47, P255; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Wechsler D., 1996, WECHSLER INTELLIGENC, V3rd	30	29	31	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					291	301		10.1159/000094155			11	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600006	16943652				2022-02-06	
J	Jacoby, SF; Ackerson, TH; Richmond, TS				Jacoby, Sara F.; Ackerson, Theimann H.; Richmond, Therese S.			Outcome from serious injury in older adults	JOURNAL OF NURSING SCHOLARSHIP			English	Article						injury; trauma; outcome; older adult; geriatric	ELDERLY TRAUMA PATIENTS; INTENSIVE-CARE-UNIT; LONG-TERM SURVIVAL; GERIATRIC TRAUMA; MAJOR TRAUMA; PENETRATING TRAUMA; RIB FRACTURES; MORTALITY; DEPRESSION; SEVERITY	Purpose: To analyze the research published in peer-reviewed journals between 1996 and 2005 about factors affecting the physical outcomes of older adults after serious traumatic injury. Organizing Construct: Twenty-seven primary research studies published in the last 10 years pertained to in-hospital and long-term outcomes of serious injury among older adults. Research specific to isolated hip injury, traumatic brain injury, and burn trauma was excluded. Methods: An integrative review of research published between January 1996 and January 2005 was carried out to examine the relationship between older age and outcome from severe injury. MEDLINE, BIOSIS previews, CINAHL, and PsycINFO databases were searched using the MeSH terms: injury, serious injury, trauma and multiple trauma, and crossed with type, severity, medical/surgical management, complication, outcome, mortality, morbidity, survival, disability, quality of life, functional status, functional recovery, function, and placement. Findings: Older adults in these studies had higher short- and long-term mortality than did younger adults. The relationship between older age and poorer outcome persisted when adjusting for injury severity, number of injuries, comorbidities, and complications. At the same time, injury severity, number of injuries, complications, and gender each independently correlated with increased mortality among older adults. The body of research is limited by overreliance on retrospective data and heterogeneity in definitional criteria for the older adult population. Conclusions: Additional research is needed to clarify the contributory effect of variables such as psychosocial sequelae and physiologic resilience on injury outcome. The field of geriatric trauma would benefit from further population-based prospective investigation of the determinants of injury outcome in older adults in order to guide interventions and acute care treatment.	Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA		Richmond, TS (corresponding author), Univ Penn, Sch Nursing, 420 Guardian Dr, Philadelphia, PA 19104 USA.	terryr@nursing.upenn.edu	Jacoby, Sara F./X-7412-2019	Jacoby, Sara F./0000-0001-6206-5078			Albaugh G, 2000, AM SURGEON, V66, P978; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Battistella FD, 1998, J TRAUMA, V44, P618, DOI 10.1097/00005373-199804000-00010; Bergeron E, 2003, J TRAUMA, V54, P478, DOI 10.1097/01.TA.0000037095.83469.4C; Bulger EM, 2000, J TRAUMA, V48, P1040, DOI 10.1097/00005373-200006000-00007; *BUR CENS, 2001, AG 2000 CENS 2000 BR; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Copes W. S., 1990, P 33 ANN M ASS ADV A, P205; CUNNINGHAM C, 2001, IRISH MED J, V94, P168; Demetriades D, 2002, BRIT J SURG, V89, P1319, DOI 10.1046/j.1365-2168.2002.02210.x; Ferrera PC, 1999, AM J EMERG MED, V17, P629, DOI 10.1016/S0735-6757(99)90146-8; Ferrera PC, 2000, AM J EMERG MED, V18, P575, DOI 10.1053/ajem.2000.9266; Gallagher SF, 2003, AM J SURG, V185, P131, DOI 10.1016/S0002-9610(02)01208-4; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Hannan EL, 2004, J TRAUMA, V56, P1297, DOI 10.1097/01.TA.0000075350.66739.53; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holcomb JB, 2003, J AM COLL SURGEONS, V196, P549, DOI 10.1016/S1072-7515(02)01894-X; Hui T, 2002, AM SURGEON, V68, P1111; Inaba K, 2003, J TRAUMA, V54, P486, DOI 10.1097/01.TA.0000051588.05542.D6; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kempen GIJM, 2003, INT J GERIATR PSYCH, V18, P14, DOI 10.1002/gps.768; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; Mast BT, 1999, J GERONTOL A-BIOL, V54, pM607, DOI 10.1093/gerona/54.12.M607; McGwin G, 2000, J TRAUMA, V49, P470, DOI 10.1097/00005373-200009000-00014; McMahon DJ, 1996, WORLD J SURG, V20, P1113, DOI 10.1007/s002689900170; McMahon DJ, 2000, SURG CLIN N AM, V80, P1005, DOI 10.1016/S0039-6109(05)70110-9; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; Nagy KK, 2000, J TRAUMA, V49, P190, DOI 10.1097/00005373-200008000-00003; O'Brien DP, 2002, SURGERY, V132, P710, DOI 10.1067/msy.2002.127690; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Pickering SAW, 1999, INJURY, V30, P703, DOI 10.1016/S0020-1383(99)00188-6; Ponzetto M, 2003, ARCH GERONTOL GERIAT, V36, P83, DOI 10.1016/S0167-4943(02)00061-4; Pudelek Barbara, 2002, AACN Clin Issues, V13, P61; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Roth BJ, 2001, INJURY, V32, P551, DOI 10.1016/S0020-1383(01)00079-1; Scaf-Klomp W, 2003, AGE AGEING, V32, P88, DOI 10.1093/ageing/32.1.88; Taheri PA, 1997, J TRAUMA, V43, P565, DOI 10.1097/00005373-199710000-00001; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TEASDALE G, 1974, LANCET, V2, P81; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; van der Sluis CK, 1997, INJURY, V28, P588, DOI 10.1016/S0020-1383(97)00094-6; vanderSluis CK, 1996, J TRAUMA, V40, P78, DOI 10.1097/00005373-199601000-00015	43	29	31	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1527-6546	1547-5069		J NURS SCHOLARSHIP	J. Nurs. Scholarsh.		2006	38	2					133	140		10.1111/j.1547-5069.2006.00090.x			8	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	040QQ	WOS:000237395900016	16773916	Green Submitted			2022-02-06	
J	Park, SH; Cho, KH; Shin, YS; Kim, SH; Ahn, YH; Cho, KG; Yoon, SH				Park, Se-Hyuck; Cho, Ki Hong; Shin, Yong Sam; Kim, Se Hyuck; Ahn, Young Hwan; Cho, Kyung Gi; Yoon, Soo Han			Penetrating craniofacial injuries in children with wooden and metal chopsticks	PEDIATRIC NEUROSURGERY			English	Article						penetrating craniofacial injury; chopstick; traumatic brain injury	FOREIGN-BODY; ABSCESS; WOUNDS	Penetrating craniofacial injuries with chopsticks in children are peculiar accidents in the Oriental culture. All 10 cases previously reported were caused by wooden chopsticks that required surgical operations. However, there are no reported injuries with metal chopsticks in the past literature which should have been as common as that of wooden chopstick injuries in Asia. We evaluated the difference of injury patterns and clinical observations between wooden and metal chopstick injuries. We reviewed 6 treated children with penetrating craniofacial injuries from chopsticks: one wooden and five metal chopsticks. One child who had penetration through the nasal cavity presented with temporary rhinorrhea, another with mild hemiparesis, and one child with temporary upward gaze limitation of the left eye. Radiological examination revealed 1 patient with epidural hemorrhage, 1 patient with minimal subdural hemorrhage, and 4 with intracerebral hemorrhage that were fortunately too small to receive surgery. We performed surgical procedure only for a child who had a wooden chopstick that had impacted into the temporal cortex. We followed up all 6 children for more than 1 year, and found that all had fully recovered to near-normal neurological status. We observed that penetrating craniofacial injuries with metal chopsticks rarely require surgical intervention and usually results in good outcome because the resultant wound is usually small without broken fragments compared to injuries with wooden chopsticks. Copyright (c) 2006 S. Karger AG, Basel.	Ajou Univ, Sch Med, Dept Neurosurg, Suwon 443721, South Korea; Hallym Univ, Kandong Sacred Heart Hosp, Dept Neurosurg, Seoul, South Korea		Yoon, SH (corresponding author), Ajou Univ, Sch Med, Dept Neurosurg, Suwon 443721, South Korea.	ee80@ajou.ac.kr					Di Roio C, 2000, CHILD NERV SYST, V16, P503, DOI 10.1007/s003810000291; HANSEN JE, 1988, J NEUROSURG, V68, P752, DOI 10.3171/jns.1988.68.5.0752; ILDAN F, 1994, J TRAUMA, V36, P116, DOI 10.1097/00005373-199401000-00020; Ishikawa E, 2000, NEUROL MED-CHIR, V40, P458, DOI 10.2176/nmc.40.458; Kawamura Shingo, 1997, Neurologia Medico-Chirurgica, V37, P332, DOI 10.2176/nmc.37.332; KUROIWA T, 1995, SURG NEUROL, V43, P68, DOI 10.1016/0090-3019(95)80042-F; Leung C. M., 1995, Singapore Medical Journal, V36, P90; Matsumoto S, 1998, AM J NEURORADIOL, V19, P1163; Matsuyama T, 2001, NEUROL MED-CHIR, V41, P345, DOI 10.2176/nmc.41.345; Nishio Y, 2004, ACTA NEUROCHIR, V146, P847, DOI 10.1007/s00701-004-0283-7; Ochiai H, 1999, NEUROL MED-CHIR, V39, P744, DOI 10.2176/nmc.39.744; Shih TY, 2002, PEDIATR NEUROSURG, V37, P35, DOI 10.1159/000065100; Suzuki H, 2002, PAEDIATR ANAESTH, V12, P88, DOI 10.1046/j.1460-9592.2002.0787g.x; Taniura S, 2004, AM J NEURORADIOL, V25, P871; WOOLFSON JM, 1990, OPHTHALMIC PLAST REC, V6, P237, DOI 10.1097/00002341-199012000-00002; YAMAMOTO I, 1985, SURG NEUROL, V23, P396, DOI 10.1016/0090-3019(85)90215-0	16	29	31	1	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.		2006	42	3					138	146		10.1159/000091855			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	120CC	WOS:000243060200002	16636613				2022-02-06	
J	Thompson, HJ; LeBold, DG; Marklund, N; Morales, DM; Hagner, AP; McIntosh, TK				Thompson, Hilaire J.; LeBold, David G.; Marklund, Niklas; Morales, Diego M.; Hagner, Andrew P.; McIntosh, Tracy K.			Cognitive evaluation of traumatically brain-injured rats using serial testing in the Morris water maze	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	39th Annual Communicating Nursing Research Conference/20th Annual WIN Assembly	APR 06-08, 2006	Albuquerque, NM			head injury; water maze; shift learning; reversal learning; multiple time points	BEHAVIORAL PLASTICITY; TASK; MOTOR; PERFORMANCE; IMPAIRMENT; STRATEGIES; MAGNESIUM	Purpose: As deficits in memory and cognition are commonly observed in survivors of traumatic brain injury (TBI), causing reduced quality of life for the patient, a major goal in experimental TBI research is to identify and evaluate cognitive dysfunction. The present study assessed the applicability of the serial Morris water maze (MWM) test to determine cognitive function following experimental TBI in the same group of rats which is particularly important for long-term studies and increasingly valuable for the evaluation of novel treatment strategies. Methods: Male Sprague-Dawley rats (n = 27) were anesthetized and subjected to either sham injury (n = 9) or lateral fluid percussion (FP) brain injury of moderate severity (n = 18). At 4 weeks post-injury, animals were trained in a water maze over 3 days (acquisition/learning phase) to find a submerged platform. At 8 weeks post-injury the hidden platform was then moved to the opposite quadrant, and animals were trained to find the new position of the platform over 3 days. Forty-eight hours later, animals were tested for memory retention in a probe trial in which the platform was not present. Results: Brain-injured animals had significant learning impairment (p < 0.0001), shifted-learning impairment (p < 0.001) and memory retention deficits (p < 0.01) in comparison to their sham-injured counterparts over the 8 week testing period. Swim speed and distance were not significantly altered by brain injury at any time point. Conclusion: The validation of this testing paradigm using a clinically relevant experimental brain injury model is an important addition to behavioral outcome testing.	Univ Washington, Seattle, WA 98195 USA; Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Uppsala Hosp, Dept Neurosurg, Uppsala, Sweden		Thompson, HJ (corresponding author), Univ Washington, Box 357266, Seattle, WA 98195 USA.	hilairet@u.washington.edu		Morales, Diego/0000-0001-6672-9046; Marklund, Niklas/0000-0002-9797-5626	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [L30 DC008284-01, L30 DC008284] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040978-04, P50 NS008803-320013, R01 NS040978, T32 NS043126, T32 NS043126-01A1, R01-NS40978, P50-NS08803, P50 NS008803, T32-NS043126] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32 NR007106, T32 NR007106-07, T32-NR007106] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126, R01NS040978, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007106] Funding Source: NIH RePORTER		Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Blokland A, 1999, EUR J NEUROSCI, V11, P223, DOI 10.1046/j.1460-9568.1999.00431.x; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Cheney JA, 2001, J CEREBR BLOOD F MET, V21, P396, DOI 10.1097/00004647-200104000-00008; Cirulli F, 2004, HIPPOCAMPUS, V14, P802, DOI 10.1002/hipo.10220; Cirulli F, 2000, NEUROSCI LETT, V287, P207, DOI 10.1016/S0304-3940(00)01173-3; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Graziano A, 2003, J NEUROSCI METH, V130, P33, DOI 10.1016/S0165-0270(03)00187-0; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; National Institute of Neurological Disorders and Stroke, TRAUM BRAIN INJ HOP; Pettenuzzo LF, 2003, BRAIN RES PROTOC, V12, P109, DOI 10.1016/j.brainresprot.2003.09.002; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42	24	29	30	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2006	24	2					109	114					6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	058OH	WOS:000238673800005	16720946				2022-02-06	
J	Engel, DC; Slemmer, JE; Vlug, AS; Maas, AIR; Weber, JT				Engel, DC; Slemmer, JE; Vlug, AS; Maas, AIR; Weber, JT			Combined effects of mechanical and ischemic injury to cortical cells: Secondary ischemia increases damage and decreases effects of neuroprotective agents	NEUROPHARMACOLOGY			English	Article						cell culture; free radicals; neuronal injury; nitric oxide; superoxide; trauma	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; STRETCH-INDUCED INJURY; CEREBRAL-ISCHEMIA; IN-VITRO; SIGNAL-TRANSDUCTION; NEURONAL INJURY; HEAD-INJURY; LUBELUZOLE; DEATH	Traumatic brain injury (TBI) involves direct mechanical damage, which may be aggravated by secondary insults such as ischemia. We utilized an in vitro model of stretch-induced injury to investigate the effects of mechanical and combined mechanical/ ischemic insults to cultured mouse cortical cells. Stretch injury alone caused significant neuronal loss and increased uptake of the dye, propidium iodide, suggesting cellular membrane damage to both glia and neurons. Exposure of cultures to ischemic conditions for 24 h, or a combination of stretch and 24 h of ischemia, caused greater neuronal loss compared to stretch injury alone. Next, we tested the neuroprotective effects of superoxide dismutase (SOD), and the nitric oxide (NO) synthase inhibitors 7-nitroindazole (7-NINA) and lubeluzole. In general, these agents decreased neuronal loss following stretch injury alone, but were relatively ineffective against the combined injury paradigm. A combination of SOD with 7-NINA or lubeluzole offered no additional protection than single drug treatment against stretch alone or combined injury. These results suggest that the effects of primary mechanical damage and secondary ischemia to cortical neurons are cumulative, and drugs that scavenge superoxide or reduce NO production may not be effective for treating the secondary ischemia that often accompanies TBI. (c) 2005 Elsevier Ltd. All rights reserved.	Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Neurosurg, NL-3000 DR Rotterdam, Netherlands		Weber, JT (corresponding author), Erasmus MC, Dept Neurosci, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.weber@erasmusmc.nl	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264			Cho S, 2005, J CEREBR BLOOD F MET, V25, P493, DOI 10.1038/sj.jcbfm.9600058; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Culmsee C, 1998, EUR J PHARMACOL, V342, P193, DOI 10.1016/S0014-2999(97)01499-4; Dawson VL, 1996, P SOC EXP BIOL MED, V211, P33; Dawson VL, 1999, P NATL ACAD SCI USA, V96, P10557, DOI 10.1073/pnas.96.19.10557; Diener HC, 2000, STROKE, V31, P2543, DOI 10.1161/01.STR.31.11.2543; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Glass TF, 2002, NEUROSCI LETT, V328, P133, DOI 10.1016/S0304-3940(02)00510-4; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hoffman WE, 1996, NEUROL RES, V18, P54, DOI 10.1080/01616412.1996.11740378; Huang HM, 2002, J CELL BIOCHEM, V84, P367, DOI 10.1002/jcb.10022; IKEDA J, 1994, ACTA NEUROCHIR, P94; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kamii H, 1996, J CEREBR BLOOD F MET, V16, P1153, DOI 10.1097/00004647-199611000-00009; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Maas Andrew I.R., 2000, Curr Opin Crit Care, V6, P281, DOI 10.1097/00075198-200008000-00008; Maiese K, 1997, J NEUROCHEM, V68, P710; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Mueller RN, 2003, EXP BRAIN RES, V152, P329, DOI 10.1007/s00221-003-1539-9; O'Dell DM, 2000, RESTOR NEUROL NEUROS, V16, P127; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Saito K, 1997, BRAIN RES, V763, P232, DOI 10.1016/S0006-8993(97)00414-9; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SCHREIBER D, 1995, INT RES COMMITTEE BI, P233; Shanker G, 2003, MOL BRAIN RES, V110, P85, DOI 10.1016/S0169-328X(02)00642-3; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Toescu EC, 1998, CELL CALCIUM, V24, P387, DOI 10.1016/S0143-4160(98)90062-8; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	42	29	30	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	DEC	2005	49	7					985	995		10.1016/j.neuropharm.2005.05.021			11	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	984ZZ	WOS:000233347200004	16046227				2022-02-06	
J	Stokic, DS; Yablon, SA; Hayes, A				Stokic, DS; Yablon, SA; Hayes, A			Comparison of clinical and neurophysiologic responses to intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	7th Annual Meeting of the American-Society-of-Neurorehabilitation	APR 27-29, 2000	SAN DIEGO, CA	Amer Soc Neurorehabilitat		baclofen; brain injuries; H-reflex; muscle spasticity; rehabilitation	MODIFIED ASHWORTH SCALE; H-REFLEX TESTS; CEREBRAL ORIGIN; SUPRASPINAL SPASTICITY; ADMINISTERED BACLOFEN; MUSCLE SPASTICITY; TIME-COURSE; F-WAVE; MANAGEMENT; HYPERTONIA	Objectives: To compare clinical and neurophysiologic responses to intrathecal baclofen (ITB) bolus injection in subjects with spasticity after acquired brain injury. Design: Prospective case series. Setting: Tertiary care rehabilitation center. Participants: Thirty consecutive ITB pump candidates with dysfunctional spasticity caused by traumatic brain injury, hypoxic encephalopathy, or stroke. Intervention: A single 50-mu g ITB bolus. Main Outcome Measures: Lower-extremity Ashworth Scale score at 2, 4, and 6 hours after ITB bolus; soleus Hoffmann reflex (H-reflex)/M-wave amplitude (H/M) ratio and abductor hallucis F-wave persistence and F/M ratio at 5 hours. Nonparametric repeated-measures analysis of variance and paired t test were used for statistical analyses. Results: The Ashworth score on the more involved side significantly decreased from 2.4 +/- 0.7 at baseline to 1.5 +/- 0.6 and 1.4 +/- 0.6 at 4- and 6-hour evaluations, respectively (P <.001). H/M ratio significantly decreased bilaterally (more involved side, 62% +/- 28% to 14% +/- 19%; less involved side, 59% +/- 26% to 11% +/- 20%; P < .001). F-wave persistence significantly decreased on the more involved side (86% +/- 17% to 75% +/- 13%, P < .05) with no change in F/M ratio. There was no significant correlation among these outcome measures before or after the ITB bolus injection. Conclusions: H/M ratio is more sensitive than the Ashworth score or F-wave persistence in detecting a physiologic response to ITB bolus. H-reflex is useful for verification of ITB bolus administration, as an adjunct to clinical evaluation, particularly among patients with moderate spasticity at rest or with small changes in Ashworth score. However, potential application of the marked sensitivity of the H-reflex to other clinically challenging situations, such as early detection of possible ITB system malfunction, awaits further investigation.	Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, Jackson, MS 39216 USA; Methodist Rehabil Ctr, Brain Injury Program, Jackson, MS 39216 USA		Stokic, DS (corresponding author), Methodist Rehabil Ctr, Ctr Neurosci & Neurol Recovery, 1350 W Eoodrow Wilson Dr, Jackson, MS 39216 USA.	dstokic@mmrcrehab.org		Stokic, Dobrivoje/0000-0002-1891-5730			Albright AL, 2003, J NEUROSURG, V98, P291, DOI 10.3171/jns.2003.98.2.0291; Albright AL, 1996, J CHILD NEUROL, V11, pS29, DOI 10.1177/0883073896011001S05; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ALBRIGHT AL, 1997, INTRATHECAL BACLOFEN, P1; Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; ANGEL RW, 1963, ARCH NEUROL-CHICAGO, V8, P591, DOI 10.1001/archneur.1963.00460060021002; ASHWORTH B, 1964, PRACTITIONER, V192, P540; AZOUVI P, 1993, J NEUROL NEUROSUR PS, V56, P515, DOI 10.1136/jnnp.56.5.515; Bakheit AMO, 2003, J NEUROL NEUROSUR PS, V74, P646, DOI 10.1136/jnnp.74.5.646; Becher JG, 1999, J NEUROL, V246, P1080, DOI 10.1007/s004150050516; CAMPBELL SK, 1995, PHYS THER, V75, P352, DOI 10.1093/ptj/75.5.352; Dachy B, 2002, CLIN NEUROPHYSIOL, V113, P336, DOI 10.1016/S1388-2457(02)00010-X; Dario A, 2002, ACTA NEUROL SCAND, V105, P83, DOI 10.1034/j.1600-0404.2002.1o042.x; Detrembleur C, 2000, ARCH PHYS MED REHAB, V81, P279; DRESSNANDT J, 1995, MUSCLE NERVE, V18, P103, DOI 10.1002/mus.880180114; EISEN A, 1979, NEUROLOGY, V29, P1306, DOI 10.1212/WNL.29.9_Part_1.1306; FISHER MA, 1983, J NEUROL SCI, V62, P13, DOI 10.1016/0022-510X(83)90186-7; Gelber DA, 1999, NEUROREHAB NEURAL RE, V13, P5, DOI 10.1177/154596839901300103; Gilmartin R, 2000, J CHILD NEUROL, V15, P71, DOI 10.1177/088307380001500201; HARBURN KL, 1992, CAN J PUBLIC HEALTH, V83, pS41; Ivanhoe C B, 2001, Phys Med Rehabil Clin N Am, V12, P923; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; KOELMAN JHTM, 1993, J NEUROL NEUROSUR PS, V56, P776, DOI 10.1136/jnnp.56.7.776; KOELMAN JHTM, 1995, MOVEMENT DISORD, V10, P44, DOI 10.1002/mds.870100109; LATASH ML, 1989, EXP NEUROL, V103, P165, DOI 10.1016/0014-4886(89)90078-2; LEVIN MF, 1993, J NEUROL, V240, P63, DOI 10.1007/BF00858718; MACDONELL RAL, 1989, J NEUROL NEUROSUR PS, V52, P1110, DOI 10.1136/jnnp.52.9.1110; Meythaler JM, 1999, AM J PHYS MED REHAB, V78, P247, DOI 10.1097/00002060-199905000-00012; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; MILANOV I G, 1992, Electromyography and Clinical Neurophysiology, V32, P11; MILANOV IG, 1992, ACTA NEUROL SCAND, V85, P305; Morris, 2002, PHYS THER REV, V7, P53, DOI [10.1179/108331902125001770, DOI 10.1179/108331902125001770]; Murphy NA, 2002, ARCH PHYS MED REHAB, V83, P1721, DOI 10.1053/apmr.2002.36068; Nielsen J F, 1996, Mult Scler, V1, P296; Pandyan AD, 1999, CLIN REHABIL, V13, P373, DOI 10.1191/026921599677595404; Pandyan AD, 2003, CLIN REHABIL, V17, P290, DOI 10.1191/0269215503cr610oa; Parise M, 1997, ELECTROMYOGR MOTOR C, V105, P141, DOI 10.1016/S0924-980X(96)96555-8; Pisano F, 2000, CLIN NEUROPHYSIOL, V111, P1015, DOI 10.1016/S1388-2457(00)00289-3; Pohl M, 2003, J NEUROL, V250, P1195, DOI 10.1007/s00415-003-0178-1; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; Rifici C, 1994, Funct Neurol, V9, P29; Sabbahi M, 2003, CLIN NEUROPHYSIOL, V114, P288, DOI 10.1016/S1388-2457(02)00375-9; SCHILLER HH, 1978, J NEUROL NEUROSUR PS, V41, P45, DOI 10.1136/jnnp.41.1.45; SINKJAER T, 1994, BRAIN, V117, P355, DOI 10.1093/brain/117.2.355; STOKIC DS, 2000, NEUROREHAB NEURAL RE, V14, P77; STOKIC DS, 2001, NEUROREHAB NEURAL RE, V15, P327; THILMANN AF, 1991, BRAIN, V114, P233; Yablon SA, 2004, AM J PHYS MED REHAB, V83, pS10, DOI 10.1097/01.PHM.0000141126.11008.7D; YOUNG RR, 1989, NEW ENGL J MED, V320, P1553, DOI 10.1056/NEJM198906083202310	49	29	30	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1801	1806		10.1016/j.apmr.2005.03.027			6	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	962QM	WOS:000231747300015	16181946				2022-02-06	
J	Kim, DY; Park, CI; Chon, JS; Ohn, SH; Park, TH; Bang, IK				Kim, DY; Park, CI; Chon, JS; Ohn, SH; Park, TH; Bang, IK			Biomechanical assessment with electromyography of post-stroke ankle plantar flexor spasticity	YONSEI MEDICAL JOURNAL			English	Article						spasticity; electromyographic activity; peak torque; threshold angle; stretch reflex	MODIFIED ASHWORTH SCALE; TRAUMATIC BRAIN INJURY; SPINAL-CORD-INJURY; CEREBRAL-PALSY; MUSCLE SPASTICITY; PENDULUM TEST; HYPERTONIA; RELIABILITY; CHILDREN; STROKE	Spasticity has been defined as a motor disorder characterized by a velocity-dependent increase in tonic stretch reflex (muscle tone). Muscle tone consists of mechanical-elastic characteristics, reflex muscle contraction and other elements. The aims of this study were to determine whether to assess,pasticity quantitatively, and to characterize biomechanical and electromyographic spasticity assessment parameters. These assessment parameters were described by investigating the correlation between clinical measures and;he response to passive sinusoidal movement with consecutive velocity increments. Twenty post-stroke hemiplegic patients and twenty normal healthy volunteers were included in the study. Five consecutive sinusoidal passive movements of the ankle were performed at specific velocities (60, 120, 180, and 240 degrees/sec). We recorded the peak torque, work, and threshold angle using a computerized isokinetic dynamometer, and simultaneously measured the rectified integrated electromyographic activity. We compared these parameters both between groups and between different velocities. The peak torque, threshold angle, work, and rectified integrated electromyographic activity were significantly higher in the post-stroke spastic group at all angular velocities than in the normal control group. The threshold angle and integrated electromyographic activity increased significantly and linearly as angular velocity increased, but the peak torque and work were not increased in the post-stroke spastic group. Peak torque, work, and threshold angle were significantly correlated to the Modified Ashworth scale, but the integrated electromyographic activity was not. The biomechanical and electromyographic approach may be useful to quantitatively assess spasticity. However, it may also be very important to consider the different characteristics of each biomechanical parameter.	Inje Univ, Coll Med, Dept Rehabil Med, Pusan, South Korea; Yonsei Univ, Coll Med, Dept Rehabil Med, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Res Inst Rehabil Med, Seoul 120749, South Korea; Hansarang Asan Gen Hosp, Dept Rehabil Med, Asan, South Korea		Bang, IK (corresponding author), Inje Univ, Coll Med, Dept Rehabil Med, Pusan, South Korea.	bangik@sanggyepaik.ac.kr		kim, deog young/0000-0001-7622-6311			Akman MN, 1999, SPINAL CORD, V37, P638, DOI 10.1038/sj.sc.3100892; Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; ALLISON SC, 1995, J NEUROL, V242, P699, DOI 10.1007/BF00866923; BAJD T, 1984, J BIOMED ENG, V6, P9, DOI 10.1016/0141-5425(84)90003-7; Benecke R, 1983, Adv Neurol, V39, P1035; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOITEAU M, 1995, PHYS THER, V75, P796, DOI 10.1093/ptj/75.9.796; Booth CM, 2001, DEV MED CHILD NEUROL, V43, P314, DOI 10.1017/S0012162201000597; BROWN RA, 1988, J NEUROL NEUROSUR PS, V51, P1171, DOI 10.1136/jnnp.51.9.1171; CORCOS DM, 1986, BRAIN, V109, P1043, DOI 10.1093/brain/109.5.1043; Damiano DL, 2002, DEV MED CHILD NEUROL, V44, P112, DOI 10.1017/S0012162201001761; Engsberg JR, 1996, ARCH PHYS MED REHAB, V77, P594, DOI 10.1016/S0003-9993(96)90301-9; FIROOZBAKHSH KK, 1993, AM J PHYS MED REHAB, V72, P379; GIVEN JD, 1995, J NEUROL NEUROSUR PS, V59, P271, DOI 10.1136/jnnp.59.3.271; GOTTLIEB GL, 1978, J NEUROL NEUROSUR PS, V41, P32, DOI 10.1136/jnnp.41.1.32; Johnson GR, 2002, EUR J NEUROL, V9, P10, DOI 10.1046/j.1468-1331.2002.0090s1010.x; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; KATZ RT, 1994, MECH SPASTIC HYPERTO, P441; Lance J.W., 1980, SPASTICITY DISORDERE, P485; LEHMANN JF, 1989, ARCH PHYS MED REHAB, V70, P6; LIN JP, 1994, DEV MED CHILD NEUROL, V36, P290; Nuyens GE, 2002, ARCH PHYS MED REHAB, V83, P930, DOI 10.1053/apmr.2002.33233; ODwyer NJ, 1996, BRAIN, V119, P1737, DOI 10.1093/brain/119.5.1737; Pandyan AD, 2003, CLIN REHABIL, V17, P290, DOI 10.1191/0269215503cr610oa; PINELLI P, 1985, CLIN NEUROPHYSIOL, P141; Singer BJ, 2003, CLIN BIOMECH, V18, P157, DOI 10.1016/S0268-0033(02)00173-0; Skold C, 2002, J REHABIL MED, V34, P86, DOI 10.1080/165019702753557881; Skold C, 2000, ARCH PHYS MED REHAB, V81, P144, DOI 10.1016/S0003-9993(00)90132-1; Skold C, 1998, ARCH PHYS MED REHAB, V79, P959, DOI 10.1016/S0003-9993(98)90095-8; Sloan R L, 1992, Int J Rehabil Res, V15, P158, DOI 10.1097/00004356-199206000-00009; STILLMAN B, 1995, ARCH PHYS MED REHAB, V76, P166, DOI 10.1016/S0003-9993(95)80026-3; Wyke B, 1976, Physiotherapy, V62, P316	33	29	36	0	3	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	AUG 31	2005	46	4					546	554		10.3349/ymj.2005.46.4.546			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	961CR	WOS:000231640000015	16127781	Green Published, Green Submitted, gold			2022-02-06	
J	Meshorer, E; Biton, IE; Ben-Shaul, Y; Ben-Ari, S; Assaf, Y; Soreq, H; Cohen, Y				Meshorer, E; Biton, IE; Ben-Shaul, Y; Ben-Ari, S; Assaf, Y; Soreq, H; Cohen, Y			Chronic cholinergic imbalances promote brain diffusion and transport abnormalities	FASEB JOURNAL			English	Article						cholinergic neurotransmission; acetylcholinesterase; blood-brain barrier; aquaporin 4	ACETYLCHOLINESTERASE-TRANSGENIC MICE; POSTTRAUMATIC-STRESS-DISORDER; AQUAPORIN-4 WATER CHANNEL; CEREBRAL-ISCHEMIA; HEAD-INJURY; READTHROUGH ACETYLCHOLINESTERASE; BARRIER PERMEABILITY; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; UP-REGULATION	Cholinergic imbalances occur after traumatic effects and in the initial stages of neurodegenerative diseases, but their long-lasting effects remained largely unexplained. To address this, we used TgS transgenic mice constitutively overexpressing synaptic acetylcholinesterase (AChE-S) and presenting a complex phenotype of progressive neuro-deterioration. T-1- and T-2- weighted magnetic resonance (MR) brain images appeared similar. However, diffusion-weighted MRI showed decreased baseline water apparent diffusion coefficient in the brains of TgS animals. Furthermore, contrast-enhanced MRI after gadolinium diethylenetriaminepentaacetic acid (Gd- DTPA) injection demonstrated slower recovery of normal signals in the TgS brains than with controls. Perfusion MR imaging and difference T-1 maps calculated from pre- postcontrast T1- weighted MR images indicated accumulation of more Gd- DTPA molecules in the TgS brains than in the parent strain, reflecting impaired blood-brain barrier (BBB) functioning in these transgenic mice. To explore the molecular mechanism(s) underlying these global phenotypes, we performed microarray analysis in the stress-controlling prefrontal cortex of TgS vs. strain-matched wild-type animals. Profound overexpression of numerous ion channels, transporters, and adhesion genes was confirmed by real time RT-PCR tests. Immunohistochemical and immuno-blot analyses revealed corresponding increases in the level and cellular distributions of the chloride channel CLCN3 and the water channel AQP4, both of which contribute to BBB maintenance. Our study attributes to balanced cholinergic neurotransmission, a central role in the brain's maintenance of water diffusion and ion transport, and indicates that chronic impairments in this maintenance facilitate neurodeterioration through interference with BBB function.	Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Israel Ctr Neuronal Computat, IL-91904 Jerusalem, Israel; Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, Ramat Aviv, Israel; Wohl Inst Adv Imaging, Tel Aviv Sourasky Med Ctr, Human Brain Imaging Unit, Tel Aviv, Israel		Soreq, H (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il		assaf, yaniv/0000-0001-6828-7595; Soreq, Hermona/0000-0002-0955-526X; Meshorer, Eran/0000-0003-4777-986X			Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; Arreola J, 2002, J PHYSIOL-LONDON, V545, P207, DOI 10.1113/jphysiol.2002.021980; BADAUT J, 2002, J CEREB BLOOD FLOW M, V22, P367, DOI DOI 10.1097/00004647-200204000-00001; Beeri R, 1997, J NEUROCHEM, V69, P2441; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Benveniste H, 2002, PROG NEUROBIOL, V67, P393, DOI 10.1016/S0301-0082(02)00020-5; Birikh KR, 2003, P NATL ACAD SCI USA, V100, P283, DOI 10.1073/pnas.0135647100; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cao H, 1996, BIOCHEM BIOPH RES CO, V227, P266, DOI 10.1006/bbrc.1996.1499; CHEN Y, 2003, P NATL ACAD SCI US; Cho H, 1998, EXP BRAIN RES, V122, P227, DOI 10.1007/s002210050510; Cohen O, 2002, MOL PSYCHIATR, V7, P874, DOI 10.1038/sj.mp.4001103; Darboux I, 1996, EMBO J, V15, P4835, DOI 10.1002/j.1460-2075.1996.tb00864.x; DELAESCALERA S, 1990, EMBO J, V9, P3593, DOI 10.1002/j.1460-2075.1990.tb07570.x; Erb C, 2001, J NEUROCHEM, V77, P638, DOI 10.1046/j.1471-4159.2001.00287.x; Esposito P, 2001, BRAIN RES, V888, P117, DOI 10.1016/S0006-8993(00)03026-2; Farchi N, 2003, J PHYSIOL-LONDON, V546, P165, DOI 10.1113/jphysiol.2002.030841; Forch P, 2001, APOPTOSIS, V6, P463, DOI 10.1023/A:1012441824719; Franklin KBJ, 2001, MOUSE BRAIN STEROTAX; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Grauer E, 2001, LIFE SCI, V68, P985, DOI 10.1016/S0024-3205(00)01000-6; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HOSSMANN KA, 1995, CEREBROVAS BRAIN MET, V7, P187; Johnson MD, 2002, J BIOL CHEM, V277, P23000, DOI 10.1074/jbc.M201907200; Le Bihan D, 2002, NMR BIOMED, V15, P431, DOI 10.1002/nbm.798; Lu H, 2003, CHINESE MED J-PEKING, V116, P1063; Lupien SJ, 2001, BEHAV BRAIN RES, V127, P137, DOI 10.1016/S0166-4328(01)00361-8; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; McDaniel B, 2001, NEUROIMAGE, V14, P1244, DOI 10.1006/nimg.2001.0934; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Moghaddam B, 2002, BIOL PSYCHIAT, V51, P775, DOI 10.1016/S0006-3223(01)01362-2; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nico B, 2001, J CELL SCI, V114, P1297; Omori N, 2002, BRAIN RES, V954, P317, DOI 10.1016/S0006-8993(02)03366-8; Ovadia H, 2001, BRAIN RES, V905, P21, DOI 10.1016/S0006-8993(01)02361-7; Park SE, 2004, CANCER RES, V64, P2652, DOI 10.1158/0008-5472.CAN-04-0649; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SCHAEFFER E, 1994, P NATL ACAD SCI USA, V91, P3882, DOI 10.1073/pnas.91.9.3882; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SHARMA HS, 1988, NEUROSCI RES, V5, P224, DOI 10.1016/0168-0102(88)90051-X; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Stark D, 1999, MAGNETIC RESONANCE I, V1; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Tomkins O, 2001, CELL MOL NEUROBIOL, V21, P675, DOI 10.1023/A:1015147920283; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; van Eden CG, 2000, PROG BRAIN RES, V126, P49; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang GX, 2003, AM J PHYSIOL-HEART C, V285, pH1453, DOI 10.1152/ajpheart.00244.2003; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Wilson JTL, 2003, J NEUROL NEUROSUR PS, V74, P841, DOI 10.1136/jnnp.74.7.841; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Yongbi MN, 1997, NMR BIOMED, V10, P79, DOI 10.1002/(SICI)1099-1492(199704)10:2<79::AID-NBM449>3.0.CO;2-K; Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008	62	29	29	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2005	19	8					910	922		10.1096/fj.04-2957com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	941IF	WOS:000230207800038	15923401				2022-02-06	
J	Hellmich, HL; Garcia, JM; Shimamura, M; Shah, SA; Avila, MA; Uchida, T; Parsley, MA; Capra, BA; Eidson, KA; Kennedy, DR; Winston, JH; DeWitt, DS; Prough, DS				Hellmich, HL; Garcia, JM; Shimamura, M; Shah, SA; Avila, MA; Uchida, T; Parsley, MA; Capra, BA; Eidson, KA; Kennedy, DR; Winston, JH; DeWitt, DS; Prough, DS			Traumatic brain injury and hemorrhagic hypotension suppress neuroprotective gene expression in injured hippocampal neurons	ANESTHESIOLOGY			English	Article							NF-KAPPA-B; MICROARRAY ANALYSIS; NEUROTROPHIC FACTOR; CONSEQUENCES; ANTIOXIDANTS; ACTIVATION; MECHANISMS; RESPONSES; SHOCK	Background: After traumatic brain injury, memory dysfunction is due in part to damage to the hippocampus. To study the molecular mechanisms of this selective vulnerability, the authors used laser capture microdissection of neurons stained with Fluoro-Jade to directly compare gene expression in injured (Fluoro-jade-positive) and adjacent uninjured (FluoroJade-negative) rat hippocampal neurons after traumatic brain injury and traumatic brain injury plus hemorrhagic hypotension. Methods: Twelve isoflurane-anesthetized Sprague-Dawley rats underwent moderate (2.0 atm) fluid percussion traumatic brain injury followed by either normotension or hemorrhagic hypotension. Animals were killed 24 h after injury. Frozen brain sections were double stained with 1% cresyl violet and 0.001% Fluoro-Jade. RNA from 10 Fluoro-jade-positive neurons and 10 Fluoro-Jade-negative neurons, obtained from the hippocampal CA1, CA3, and dentate gyrus subfields using laser capture microdissection, was linearly amplified and analyzed by quantitative ribonuclease protection assay for nine neuroprotective and apoptosis-related genes. Results: In injured CA3 neurons, expression of the neuroprotective genes glutathione peroxidase 1, heme oxygenase 1, and brain-derived neurotrophic factor was significantly decreased compared with that of adjacent uninjured neurons. Superimposition of hemorrhagic hypotension was associated with downregulation of neuroprotective genes in both injured and uninjured neurons of all subregions. Expression of apoptosis-related genes did not vary between injured and uninjured neurons, with or without superimposed hemorrhage. Conclusions: The authors show, in the first direct comparison of messenger RNA levels in injured and uninjured hippocampal neurons, that injured neurons express lower levels of neuroprotective genes than adjacent uninjured neurons.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Off Biostat, Galveston, TX USA; Univ Texas, Med Branch, Div Gastroenterol, Dept Internal Med, Galveston, TX USA; Yokohama City Univ, Sch Med, Dept Neurol, Yokohama, Kanagawa, Japan		Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS 42849-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER		Ahlemeyer B, 2001, BRAIN RES, V890, P338, DOI 10.1016/S0006-8993(00)03202-9; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Bota M, 2003, NAT NEUROSCI, V6, P795, DOI 10.1038/nn1096; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Egan TD, 1999, ANESTHESIOLOGY, V91, P156, DOI 10.1097/00000542-199907000-00024; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Furling D, 2000, P NATL ACAD SCI USA, V97, P4351, DOI 10.1073/pnas.060574597; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Ho YS, 1998, ENVIRON HEALTH PERSP, V106, P1219, DOI 10.2307/3433989; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Humphrey MF, 1997, EXP EYE RES, V64, P361, DOI 10.1006/exer.1996.0219; Kamme F, 2003, J NEUROSCI, V23, P3607; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Longo VD, 2002, CELL MOL LIFE SCI, V59, P903, DOI 10.1007/s00018-002-8477-8; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Maines MD, 2002, METHOD ENZYMOL, V353, P374; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Martin-Villalba A, 1998, MOL BRAIN RES, V62, P158, DOI 10.1016/S0169-328X(98)00239-3; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Pennypacker KR, 2001, EXP NEUROL, V172, P307, DOI 10.1006/exnr.2001.7817; Rossler OG, 2004, J NEUROCHEM, V88, P1240, DOI 10.1046/j.1471-4159.2003.02255.x; *SAS I, 1999, SAS STAT US GUID VER; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sheng HX, 2002, DRUG NEWS PERSPECT, V15, P654, DOI 10.1358/dnp.2002.15.10.740236; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Szabo A, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r59; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; ZENG YC, 1995, MECH AGEING DEV, V79, P169, DOI 10.1016/0047-6374(94)01559-5	50	29	29	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2005	102	4					806	814		10.1097/00000542-200504000-00017			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	910IG	WOS:000227923900016	15791111				2022-02-06	
J	Kurz, JE; Parsons, JT; Rana, A; Gibson, CJ; Hamm, RJ; Churn, SB				Kurz, JE; Parsons, JT; Rana, A; Gibson, CJ; Hamm, RJ; Churn, SB			A significant increase in both basal and maximal calcineurin activity following fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						calcium; calmodulin; hippocampus; phosphatase; post-translational modification	TRAUMATIC BRAIN-INJURY; APOPTOTIC CELL-DEATH; GABA(A) RECEPTOR; NITRIC-OXIDE; KINASE-II; CALCIUM; PHOSPHORYLATION; NEURONS; PHOSPHATASE; MODEL	Calcineurin, a neuronally enriched, calcium-stimulated phosphatase, is an important modulator of many neuronal processes, including several that are physiologically related to the pathology of traumatic brain injury. This study examined the effects of moderate, central fluid percussion injury on the activity of this important neuronal enzyme. Animals were sacrificed at several time-points post-injury and cortical, hippocampal, and cerebellar homogenates were assayed for calcineurin activity by dephosphorylation of p-nitrophenol phosphate. A significant brain injury-dependent increase was observed in both hippocampal and cortical homogenates under both basal and maximally-stimulated reaction conditions. This increase persisted 2-3 weeks post-injury. Brain injury did not alter substrate affinity, but did induce a significant increase in the apparent maximal dephosphorylation rate. Unlike the other brain regions, no change in calcineurin activity was observed in the cerebellum following brain injury. No brain region tested displayed a significant change in calcineurin enzyme levels as determined by Western blot, demonstrating that increased enzyme synthesis was not responsible for the observed increase in activity. The data support the conclusion that fluid percussion injury results in increased calcineurin activity in the rat forebrain. This increased activity has broad physiological implications, possibly resulting in altered cellular excitability or a greater likelihood of neuronal cell death.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA		Churn, SB (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurol, Box 980599, Richmond, VA 23298 USA.	sbchurn@vcu.edu		Kurz, Jonathan/0000-0002-2259-4263	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS025630] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 399700, P01 NS 25630, NS 07288] Funding Source: Medline		Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Amico C, 1998, NEUROSCIENCE, V84, P529, DOI 10.1016/S0306-4522(97)00555-1; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; BAUGGRASS R, 2001, J BIOL CHEM, V276, P47914; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CHEN QX, 1995, J PHYSIOL-LONDON, V482, P353, DOI 10.1113/jphysiol.1995.sp020522; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; CHURN SB, 1992, J CEREBR BLOOD F MET, V12, P784, DOI 10.1038/jcbfm.1992.109; CHURN SB, 1995, J NEUROSCI, V15, P3200; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EASTER SS, 1993, J NEUROSCI, V13, P285; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; Huang RQ, 1998, J PHARMACOL EXP THER, V286, P243; Jayaraman T, 2000, J BIOL CHEM, V275, P6417, DOI 10.1074/jbc.275.9.6417; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kurz JE, 2003, NEUROBIOL DIS, V14, P483, DOI 10.1016/j.nbd.2003.08.018; Kurz JE, 2001, J NEUROCHEM, V78, P304, DOI 10.1046/j.1471-4159.2001.00426.x; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; Lu YM, 2000, NEURON, V26, P197, DOI 10.1016/S0896-6273(00)81150-2; Luo Chun, 2002, Chin J Traumatol, V5, P24; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; Matsuda T, 1998, J NEUROCHEM, V70, P2004; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; MONCADA S, 1991, PHARMACOL REV, V43, P109; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; PALLEN CJ, 1985, ARCH BIOCHEM BIOPHYS, V237, P281, DOI 10.1016/0003-9861(85)90279-6; Pyrzynska B, 2001, NEUROCHEM INT, V38, P409, DOI 10.1016/S0197-0186(00)00105-4; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Riedel G, 1999, CELL MOL LIFE SCI, V55, P549, DOI 10.1007/s000180050313; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; RINK A, 1995, AM J PATHOL, V147, P1575; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Springer JE, 2000, J NEUROSCI, V20, P7246; SZABO I, 1991, J BIOL CHEM, V266, P3376; TALLANT EA, 1988, BIOCHEMISTRY-US, V27, P2205, DOI 10.1021/bi00406a059; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Tymianski M, 1996, NEUROSURGERY, V38, P1176; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	62	29	30	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2005	22	4					476	490		10.1089/neu.2005.22.476			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	920YM	WOS:000228731400005	15853464				2022-02-06	
J	McNally, HA; Rajwa, B; Sturgis, J; Robinson, JP				McNally, HA; Rajwa, B; Sturgis, J; Robinson, JP			Comparative three-dimensional imaging of living neurons with confocal and atomic force microscopy	JOURNAL OF NEUROSCIENCE METHODS			English	Article						atomic force microscopy; confocal laser scanning microscopy; neurogenesis; neurotrauma; neurobiology	GLIAL-CELLS	Atomic force microscopy applications extend across a number of fields; however, limitations have reduced its effectiveness in live cell analysis. This report discusses the use of AFM to evaluate the three-dimensional (3-D) architecture of living chick dorsal root ganglia and sympathetic ganglia. These data sets were compared to similar images acquired with confocal laser scanning microscopy of identical cells. For this comparison we made use of visualization techniques which were applicable to both sets of data and identified several issues when coupling these technologies. These direct comparisons offer quantitative validation and confirmation of the character of novel images acquired by AFM. This paper is one in a series emphasizing various new applications of AFM in neurobiology. (C) 2004 Elsevier B.V. All rights reserved.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47906 USA; Purdue Univ, Sch Vet Med, Cytometry Labs, W Lafayette, IN 47907 USA; Purdue Univ, Sch Engn, Dept Biomed Engn, W Lafayette, IN 47907 USA		McNally, HA (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47906 USA.	menallyh@purdue.edu	Rajwa, Bartek/B-3169-2009; Robinson, Joseph P/K-8492-2012; Robinson, Joseph/AAA-1001-2020	Rajwa, Bartek/0000-0001-7540-8236; Robinson, Joseph/0000-0001-8383-3240			Abramoff MD, 2002, IEEE T MED IMAGING, V21, P296, DOI 10.1109/TMI.2002.1000254; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Gallant PE, 1997, J NEUROTRAUM, V14, P811, DOI 10.1089/neu.1997.14.811; HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795; Henderson E, 1993, Neuroimage, V1, P145, DOI 10.1006/nimg.1993.1007; Hennig AK, 1998, J NEUROSCI, V18, P3282; HIGGINS D, 1998, CULTURING NERVE CELL; Jena BP, 1997, CELL BIOL INT, V21, P683, DOI 10.1006/cbir.1997.0212; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275, DOI 10.1152/ajpcell.1995.269.1.C275; MAHANTHAPPA NK, 1998, CUTURING NERVE CELLS; Matsumoto B, 2002, CELL BIOL APPL CONFO CELL BIOL APPL CONFO; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Melling M, 2001, NEUROIMAGE, V14, P1348, DOI 10.1006/nimg.2001.0924; MORRIS VJ, 2001, ATOMIC FORCE MICROSC; Niell CM, 2004, ANNU REV PHYSIOL, V66, P771, DOI 10.1146/annurev.physiol.66.082602.095217; PARPURA V, 1993, J CELL SCI, V104, P427; Pawley J. B., 1995, HDB BIOL CONFOCAL MI; Peters A., 1991, FINE STRUCTURES NERV; Piston DW, 1998, BIOL BULL-US, V195, P1, DOI 10.2307/1542768; RICCI D, 2004, ATOMIC FORCE MICROSC; Ryan TA, 2001, CURR OPIN NEUROBIOL, V11, P544, DOI 10.1016/S0959-4388(00)00247-6; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; Sah R, 1999, J NEUROSCI, V19, P9209; SCHABERT F, 1994, ULTRAMICROSCOPY, V53, P147, DOI 10.1016/0304-3991(94)90005-1; Tojima T, 2000, NEUROSCIENCE, V101, P471, DOI 10.1016/S0306-4522(00)00320-1; VESENKA J, 1995, BIOTECHNIQUES, V19, P240; Weissmuller G, 2000, NEUROSCI RES, V38, P217, DOI 10.1016/S0168-0102(00)00159-0; Young IT, 1996, IEEE ENG MED BIOL, V15, P59, DOI 10.1109/51.482844; [No title captured]	29	29	31	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 30	2005	142	2					177	184		10.1016/j.jneumeth.2004.08.018			8	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	901FT	WOS:000227269100002	15698657	Green Published			2022-02-06	
J	McAdoo, DJ; Hughes, MG; Nie, LH; Shah, B; Clifton, C; Fullwood, S; Hulsebosch, CE				McAdoo, DJ; Hughes, MG; Nie, LH; Shah, B; Clifton, C; Fullwood, S; Hulsebosch, CE			The effect of glutamate receptor blockers on glutamate release following spinal cord injury. Lack of evidence for an ongoing feedback cascade of damage -> glutamate release -> damage -> glutamate release -> etc.	BRAIN RESEARCH			English	Article						glutamate receptor blockers; glutamate release; spinal cord injury; damage cascades; secondary damage	EXCITATORY AMINO-ACID; RAT CEREBRAL-CORTEX; METHYL-D-ASPARTATE; TRAUMATIC BRAIN INJURY; FUNCTIONAL DEFICITS; NMDA ANTAGONISTS; CHANNEL BLOCKER; WHITE-MATTER; SODIUM-CHANNELS; IMPACT INJURY	It is widely hypothesized that excitotoxicity of released glutamate following a CNS insult is propagated by the cyclic cascade: glutamate release -> damage -> glutamate release -> further damage -> etc. We tested this hypothesis by determining the effects of attempting to interrupt the loop by administering glutamate receptor antagonists and Na+-channel blockers on glutamate release following spinal cord injury (SCI). The effects of administering the NMDA receptor blockers MK-801 and memantine, the AMPA/kainate receptor blockers NBQX and GYKI 52466, the AMPA receptor desensitization blocker cyclothiazide and the sodium channel blockers riluzole, mexiletine and QX-314 on post-SCI were determined. Agents were administered into the site of injury by direct injection, by microdialysis or systemically. None of these agents had an appreciable effect on glutamate release following SCI. Thus, it is unlikely that the above cascade produces significant secondary glutamate release and ongoing damage following SCI, although such cascades may worsen other CNS insults. We attribute our results to overwhelming effects of much greater release by direct mechanical damage and reversal of transport following SCI. (c) 2005 Elsevier B.V. All rights reserved.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA		McAdoo, DJ (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	djmcadoo@utmb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS039161, P01NS011255] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39161, NS11255] Funding Source: Medline		Agrawal SK, 1997, J NEUROTRAUM, V14, P81, DOI 10.1089/neu.1997.14.81; Azbill RD, 2000, BRAIN RES, V871, P175, DOI 10.1016/S0006-8993(00)02430-6; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Danysz W, 2000, AMINO ACIDS, V19, P167, DOI 10.1007/s007260070045; DEMONTIGNY P, 1987, ANAL CHEM, V59, P1098; DOBLE A, 1995, THERAPIE, V50, P319; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; ELLISON G, 1994, NEUROREPORT, V5, P2688, DOI 10.1097/00001756-199412000-00070; ERDO SL, 1991, EUR J PHARMACOL, V198, P215, DOI 10.1016/0014-2999(91)90625-Z; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; GARTHWAITE G, 1992, EUR J NEUROSCI, V4, P353, DOI 10.1111/j.1460-9568.1992.tb00882.x; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; GOODMAN RM, 1985, NEUROSURGERY, V17, P757, DOI 10.1227/00006123-198511000-00005; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hesselink MB, 1999, PHARMACEUT RES, V16, P637, DOI 10.1023/A:1018856020583; Kanellopoulos GK, 2000, STROKE, V31, P1945, DOI 10.1161/01.STR.31.8.1945; Kwon JY, 1998, ANESTH ANALG, V86, P128, DOI 10.1097/00000539-199801000-00026; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; McAdoo DJ, 1999, EXP NEUROL, V159, P538, DOI 10.1006/exnr.1999.7166; McAdoo DJ, 2000, BRAIN RES, V865, P283, DOI 10.1016/S0006-8993(00)02296-4; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; Mills CD, 2000, NEUROREPORT, V11, P3067, DOI 10.1097/00001756-200009280-00007; Mills CD, 2001, J NEUROCHEM, V79, P835, DOI 10.1046/j.1471-4159.2001.00630.x; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; OLNEY JW, 1995, NEUROPSYCHOPHARMACOL, V13, P335, DOI 10.1016/0893-133X(95)00079-S; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Phillis JW, 2000, BRAIN RES, V868, P105, DOI 10.1016/S0006-8993(00)02303-9; PHILLIS JW, 1994, BRAIN RES BULL, V34, P457, DOI 10.1016/0361-9230(94)90019-1; PHILLIS JW, 1993, NEUROREPORT, V4, P109, DOI 10.1097/00001756-199301000-00029; ROKKAS CK, 1994, ANN THORAC SURG, V58, P312, DOI 10.1016/0003-4975(94)92200-4; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; Stys PK, 1996, NEUROSCIENCE, V71, P27, DOI 10.1016/0306-4522(95)00430-0; Teng YD, 1997, J NEUROSCI, V17, P4359; URENJAK J, 1997, REV CONTEMP PHARMACO, V8, P237; Vera-Portocarrero LP, 2002, BRAIN RES, V927, P104, DOI 10.1016/S0006-8993(01)03329-7; vonEuler M, 1997, J NEUROTRAUM, V14, P53, DOI 10.1089/neu.1997.14.53; WAHL F, 1994, J NEUROCHEM, V63, P1003; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029; Xu GY, 1998, NEUROSCIENCE, V86, P1011, DOI 10.1016/S0306-4522(98)00063-3; YAMADA KA, 1993, J NEUROSCI, V13, P3904; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445	58	29	30	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 15	2005	1038	1					92	99		10.1016/j.brainres.2005.01.024			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	914TP	WOS:000228251000011	15748877				2022-02-06	
J	Melton, AK; Bourgeois, MS				Melton, AK; Bourgeois, MS			Training compensatory memory strategies via the telephone for persons with TBI	APHASIOLOGY			English	Article; Proceedings Paper	34th Annual Clinical Aphasiology Conference	2004	Park City, UT				BRAIN INJURY; DEMENTIA; EFFICACY; ADULTS	Background: Spaced retrieval training has been used to teach individuals with dementia to use compensatory memory strategies. This training has been delivered over the telephone to some persons with dementia. Spaced retrieval applications for individuals with traumatic brain injury have not been reported to date. Aims: The purpose of this study was to investigate the efficacy of spaced retrieval for teaching individuals with traumatic brain injury strategies and facts via the telephone, with an emphasis on generalisation. Methods & Procedures: Seven participants with chronic everyday memory problems due to traumatic brain injury were trained to use memory aids for prospective and episodic memory tasks. Participants demonstrated borderline normal to mild global severity ratings. Functional memory problems were identified and external memory aids were provided if appropriate. Participants were trained using spaced retrieval via the telephone 30 minutes per day; each participant was trained on three memory goals. Participants and some caregivers reported strategy use and generalisation for most trained goals. Outcomes & Results: Results indicated that goal attainment and generalisation were achieved in an average of five 30-minute training sessions, resulting in 94.4% spaced-retrieval goal maintenance at 1 month. Strategy execution at 1 month was reported on 77.7% of goals trained. Conclusions: Spaced retrieval is a viable approach for training individuals with traumatic brain injury to use external memory aids and learn prospective memory tasks. Telephone intervention should be considered as an accessible service delivery alternative to promote generalisation with this population.	Florida State Univ, Reg Rehabil Ctr 302, Tallahassee, FL 32306 USA		Bourgeois, MS (corresponding author), Florida State Univ, Reg Rehabil Ctr 302, Tallahassee, FL 32306 USA.	mbourgeo@garnet.acns.fsu.edu	Bourgeois, Michelle/F-9397-2015	Bourgeois, Michelle/0000-0003-1458-6842			Abrahams Joel P., 1993, Clinical Gerontologist, V12, P57, DOI 10.1300/J018v12n03_06; BIRD M, 1995, INT J GERIATR PSYCH, V10, P305, DOI 10.1002/gps.930100407; Bourgeois MS, 2003, J COMMUN DISORD, V36, P361, DOI 10.1016/S0021-9924(03)00051-0; Brush JA, 1998, THERAPY TECHNIQUE IM; BRUSH JA, 1997, ANN CONV OH SPEECH H; Camp C. J., 1996, PROSPECTIVE MEMORY T, P351; Camp CJ, 1996, APPL COGNITIVE PSYCH, V10, P193, DOI 10.1002/(SICI)1099-0720(199606)10:3<193::AID-ACP374>3.0.CO;2-4; CAMP CJ, 1989, EDUC GERONTOL, V15, P641, DOI 10.1080/0380127890150608; CAMP CJ, 1990, CLIN GERONTOLOGIST, V10, P658; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOSS JW, 1993, COGNITIVE INTERVENTI; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; GOLDSTEIN FC, 1991, MEMORY DISORDERS RES; Hayden Claudia M., 1995, Clinical Gerontologist, V16, P80; Helm-Estabrooks N, 1991, BRIEF TEST HEAD INJU; HONSINGER MJ, 1991, COMMUNICATION DISORD, P103; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; MCKITRICK LA, 1992, J GERONTOL, V47, P337, DOI DOI 10.1093/GERONJ/47.5.P337; McMahon C.M., 2003, CLIN PSYCHOL, V7, P50, DOI [https://doi.org/10.1080/13284200410001707483, DOI 10.1080/13284200410001707483]; Moffat N. J., 1989, EVERYDAY COGNITION A; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1985, PROSPECTIVE MEMORY T; Stevens Alan, 1993, Clinical Gerontologist, V13, P106; WEBB DM, 1991, COGNITIVE REHABILITA, P28; WHYTE J, 1988, REHABILITATION MED P, P565; [No title captured]	31	29	30	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	MAR-MAY	2005	19	3-5					353	364		10.1080/02687030444000804			12	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	931IL	WOS:000229478900013					2022-02-06	
J	David, M; Karmrodt, J; Weiler, N; Scholz, A; Markstaller, K; Eberle, B				David, M; Karmrodt, J; Weiler, N; Scholz, A; Markstaller, K; Eberle, B			High-frequency oscillatory ventilation in adults with traumatic brain injury and acute respiratory distress syndrome	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						acute respiratory distress syndrome; high-frequency oscillatory ventilation; intracranial pressure; traumatic brain injury	END-EXPIRATORY PRESSURE; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; MANAGEMENT	Background: This study observed adverse events of rescue treatment with high-frequency oscillatory ventilation (HFOV) in head-injured patients with acute respiratory distress syndrome (ARDS). Methods: Data of five male patients with ARDS and traumatic brain injury, median age 28 years, who failed to respond to conventional pressure-controlled ventilation (PCV) were analyzed retrospectively during HFOV. Adjusted mean airway pressure at initiation of HFOV was set to 5 cm H2O above the last measured mean airway pressure during PCV. Frequency of pulmonary air leak, mucus obstruction, tracheal injury, and need of HFOV termination due to increased intracranial pressure, decreased cerebral perfusion pressure, or deterioration in PaCO2 were analyzed. Results: During HFOV we found no complications. We recorded 390 datasets of intracranial pressure, cerebral perfusion pressure and PaCO2 simultaneously. Intracranial pressure increased (>25 mmHg) in 11 of 390 datasets, cerebral perfusion pressure was reduced (<70 mmHg) in 66 of 390 datasets, and PaCO2 variations (<4.7 kPa; >6.0 kPa) were observed in eight of 390 datasets after initiation of HFOV. All these alterations were responsive to treatment. PaO2/FIO2-ratio improved in four patients during HFOV. Conclusion: High-frequency oscillatory ventilation appears to be a promising alternative rescue treatment in head-injured patients with ARDS if continuous monitoring of intracranial pressure, cerebral perfusion pressure and PaCO2 are provided, in particular during initiation of HFOV.	Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, D-55131 Mainz, Germany; Univ Kiel, Dept Anaesthesiol, Kiel, Germany; Univ Bern, Inselspital, Dept Anaesthesiol, CH-3010 Bern, Switzerland		David, M (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	Matthias_David@gmx.de	Weiler, Norbert/E-5356-2010				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Andersen FA, 2002, ACTA ANAESTH SCAND, V46, P1082, DOI 10.1034/j.1399-6576.2002.460905.x; Bein T, 2002, INTENS CARE MED, V28, P554, DOI 10.1007/s00134-002-1273-y; Bratton SL, 1997, NEUROSURGERY, V41, P1215, DOI 10.1097/00006123-199711000-00053; CHESNUT RM, 1997, J TRAUMA S, V42, P4; David M, 2003, INTENS CARE MED, V29, P1656, DOI 10.1007/s00134-003-1897-6; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; Fort P, 1997, CRIT CARE MED, V25, P937, DOI 10.1097/00003246-199706000-00008; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; LUCE JM, 1982, J APPL PHYSIOL, V52, P231, DOI 10.1152/jappl.1982.52.1.231; Marini JJ, 1996, CLIN CHEST MED, V17, P555, DOI 10.1016/S0272-5231(05)70331-2; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McGuire G, 1997, CRIT CARE MED, V25, P1059, DOI 10.1097/00003246-199706000-00025; Mehta S, 2001, CRIT CARE MED, V29, P1360, DOI 10.1097/00003246-200107000-00011; NISHIMURA M, 1992, CHEST, V101, P1681, DOI 10.1378/chest.101.6.1681; PINSKY M, 1991, AM REV RESPIR DIS, V143, P25, DOI 10.1164/ajrccm/143.1.25; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; Videtta W, 2002, ACT NEUR S, V81, P93	21	29	32	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2005	49	2					209	214		10.1111/j.1399-6576.2004.00570.x			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	898FQ	WOS:000227062200014	15715623				2022-02-06	
J	Bailes, JE				Bailes, JE			Experience with cervical stenosis and temporary paralysis in athletes	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal stenosis; cervical spine; transient spinal cord injury; athlete	SPINAL-CORD CONCUSSION; TRANSIENT QUADRIPLEGIA; FOOTBALL PLAYERS; INJURIES; MYELOPATHY; PARTICIPATION; NEURAPRAXIA; TOMOGRAPHY; MANAGEMENT; HEAD	Object. Transient spinal cord injury (TSCI) in athletes presents one of the most challenging clinical scenarios. Management difficulties in and subsequent return-to-play decisions are especially important in those with cervical canal stenosis. Methods. Ten athletes (nine male and one female patients) were evaluated for TSCI. The diagnostic survey included physical and neurological examinations, plain radiographs with flexion-extension dynamic studies, computerized tomography, and magnetic resonance (MR) imaging. Clinical courses were followed and, in those who returned to contact sports activities, subsequent experience was noted. Symptoms consisted of paralysis, weakness, or numbness in all four extremities, their duration ranging from 15 minutes to 48 hours. Radiography revealed no evidence of fracture/dislocation or ligamentous instability. Spinal stenosis of 8 to 13 mm in length at three or more levels was evident in all cases. Four patients returned to competition without recurrent TSCI (mean follow-up duration 40 months); six individuals retired. The occurrence of TSCI is not uncommon in athletes involved in contact sports. The diagnostic workup focuses on excluding fracture/dislocation, cord contusion, ligamentous infolding or instability, herniated nucleus pulposus, syrinx, or other surgically correctable lesions. There appear to be two groups of athletes who sustain TSCI: those who experience TSCI yet in whom radiographic studies are normal, and those with cervical stenosis, the most difficult management group. Conclusions. It does not appear that a single episode of TSCI in an athlete with spinal stenosis will substantially increase the risk of subsequent catastrophic spinal cord injury in those in whom MR imaging demonstrates preservation of cerebrospinal fluid signal.	W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA		Bailes, JE (corresponding author), POB 9183, Morgantown, WV 26506 USA.						ALLEY RH, 1964, JAMA-J AM MED ASSOC, V188, P418; Bailes JE, 1999, SPORTS-RELATED CONCUSSION, P140; BAILES JE, 1991, NEUROSURGERY, V29, P491, DOI 10.1227/00006123-199110000-00001; BAILES JE, 1990, SURG NEUROL, V34, P155, DOI 10.1016/0090-3019(90)90064-V; BAILES JE, 1996, PRACTICE NEUROSURGER, V2, P1649; Boden BP, 2002, AM J SPORT MED, V30, P791, DOI 10.1177/03635465020300060601; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; CANTU RC, 1993, MED SCI SPORT EXER, V25, P316; Cantu RC, 2000, SEMIN NEUROL, V20, P173, DOI 10.1055/s-2000-9825; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; EISMONT FJ, 1984, SPINE, V9, P663, DOI 10.1097/00007632-198410000-00001; EPSTEIN JA, 1979, J NEUROSURG, V51, P362, DOI 10.3171/jns.1979.51.3.0362; FIROOZNIA H, 1985, SURG NEUROL, V23, P165, DOI 10.1016/0090-3019(85)90337-4; FUNK FJ, 1975, CLIN ORTHOP RELAT R, P50, DOI 10.1097/00003086-197506000-00007; GORE DR, 1986, SPINE, V11, P521, DOI 10.1097/00007632-198607000-00003; GROAT RA, 1945, SURG GYNECOL OBSTET, V81, P63; HAMILTON MG, 1992, J NEUROSURG, V77, P700, DOI 10.3171/jns.1992.77.5.0700; HASHIMOTO I, 1977, J NEUROSURG, V47, P912, DOI 10.3171/jns.1977.47.6.0912; HERZOG RJ, 1991, SPINE, V16, pS178, DOI 10.1097/00007632-199106001-00001; HOLMES G, 1915, BMJ-BRIT MED J, V27, P769; Kobrine A I, 1975, Surg Neurol, V3, P261; LADD AL, 1986, J BONE JOINT SURG AM, V68A, P1371, DOI 10.2106/00004623-198668090-00009; Maroon JC, 1996, SPINE, V21, P2294, DOI 10.1097/00007632-199610010-00025; MAROON JC, 1977, JAMA-J AM MED ASSOC, V238, P2049; MATSUURA P, 1989, J BONE JOINT SURG AM, V71A, P183, DOI 10.2106/00004623-198971020-00003; MEYER SA, 1994, AM J SPORT MED, V22, P158, DOI 10.1177/036354659402200202; MURONE I, 1974, J BONE JOINT SURG BR, VB 56, P30; OBERSTEINER H, 1879, WEIN MED JB, V34, P531; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; PARKINSON D, 1981, SURG NEUROL, V16, P347, DOI 10.1016/0090-3019(81)90272-X; PAVLOV H, 1987, RADIOLOGY, V164, P771, DOI 10.1148/radiology.164.3.3615879; PENNING L, 1962, NEUROLOGY, V12, P513; SCHER AT, 1981, S AFR MED J, V59, P227; SCHNEIDER R, 1961, JAMA-J AM MED ASSOC, V177, P362, DOI 10.1001/jama.1961.03040320006002; STANLEY JH, 1986, NEURORADIOLOGY, V28, P139, DOI 10.1007/BF00327886; TATOR CH, 1984, CAN J NEUROL SCI, V11, P34, DOI 10.1017/S0317167100045297; TORG JS, 1986, J BONE JOINT SURG AM, V68A, P1354, DOI 10.2106/00004623-198668090-00008; Torg JS, 1996, J BONE JOINT SURG AM, V78A, P1308, DOI 10.2106/00004623-199609000-00003; Torg JS, 1997, J NEUROSURG, V87, P843, DOI 10.3171/jns.1997.87.6.0843; TORG JS, 1993, AM J SPORT MED, V21, P640, DOI 10.1177/036354659302100502; VEIDLINGER OF, 1981, SPINE, V6, P550, DOI 10.1097/00007632-198111000-00004; WATKINS RG, 1996, SPINE SPORTS, P126; ZWIMPFER TJ, 1990, J NEUROSURG, V72, P894, DOI 10.3171/jns.1990.72.6.0894	43	29	30	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	JAN	2005	2	1					11	16		10.3171/spi.2005.2.1.0011			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	895OZ	WOS:000226874100004	15658120				2022-02-06	
J	Demorest, RA; Bernhardt, DT; Best, TM; Landry, GL				Demorest, RA; Bernhardt, DT; Best, TM; Landry, GL			Pediatric residency education: Is sports medicine getting its fair share?	PEDIATRICS			English	Article						pediatric residency education; sports medicine; graduate medical education; musculoskeletal; orthopedics	VISITS	Introduction. Sports are the leading injury-related cause for pediatric primary care visits. Pediatric residency education guidelines suggest incorporating sports medicine (SM) education into curricula; however, research is lacking regarding effective teaching methods. Objective. To assess reported US pediatric residency SM curricula, teaching methods, and resident evaluation of SM education. Design/Methods. Chief residents (CRs) and third-year residents (PL3s) from 100 randomly selected US Accreditation Council for Graduate Medical Education-accredited residency programs, stratified by size and geographic location, received surveys regarding programs' SM curriculum and teaching methods and individuals' methods for learning SM. Results. Response rates were 63% and 39% for CRs and PL3s, respectively. According to CRs, 34% of programs had no one in charge of their SM curriculum. Lecture (77%) was the primary method used for teaching SM. Hands-on teaching (37%) was used less frequently. CRs stated that 29% of programs did not include musculoskeletal examination teaching in their curriculums; 24% did not include formal teaching of concussion management, and 29% did not include reasons for medical disqualification. PL3s rated teaching of joint examinations and the preparticipation physical as the most poorly taught components of the physical examination. PL3s rated hands-on teaching and patient experience as the best methods for improving SM education. CRs reported that only 36% of programs have discussed incorporating more SM into their curriculum. Conclusions. SM education is deficient in US pediatric residency programs. Standardized curricula should be developed with a focus on hands-on training as a means for teaching SM to pediatric residents.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Orthoped & Rehabil & Family Med, Madison, WI USA		Demorest, RA (corresponding author), Childrens Natl Med Ctr, Dept Orthopaed & Sports Med, 111 Michigan Ave NW, Washington, DC 20010 USA.	rdemores@cnmc.org					*ACCR COUNC GRAD M, PROGR REQ RES ED; *AM BOARD PED, 2003 2004 WORKF DAT; *AMB PED ASS, PROP 2004 ED GUID RE; *AMB PED ASS, UPD APA ED GUID REV; BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; Burt CW, 2001, ANN EMERG MED, V37, P301, DOI 10.1067/mem.2001.111707; Camp BW, 1998, ARCH PEDIAT ADOL MED, V152, P210; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; Cherry Donald K, 2003, Adv Data, P1; ECKLER SJ, 2003, CLIN J SPORT MED, V13, P381; Emans SJ, 1998, PEDIATRICS, V102, P588, DOI 10.1542/peds.102.3.588; Freedman KB, 1998, J BONE JOINT SURG AM, V80A, P1421, DOI 10.2106/00004623-199810000-00003; GORDON MJ, 1991, ACAD MED, V66, P762, DOI 10.1097/00001888-199112000-00012; Hambidge SJ, 2002, PEDIATRICS, V109, P559, DOI 10.1542/peds.109.4.559; HERGENROEDER AC, 2001, PEDIATRICS, V107; Jenkins RR, 2003, PEDIATRICS, V112, P752; *NIH, 1992, NIH PUBL; Perron AD, 2000, AM J EMERG MED, V18, P356, DOI 10.1016/S0735-6757(00)90147-5; Roberts KB, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.4.e2; Stirling J, 1997, Acad Med, V72, P452, DOI 10.1097/00001888-199705000-00092; Stirling JM, 1996, ARCH PEDIAT ADOL MED, V150, P211, DOI 10.1001/archpedi.1996.02170270093014; Sweeney CL, 2003, BRIT J SPORT MED, V37, P219, DOI 10.1136/bjsm.37.3.219; TARAS HL, 1990, AM J DIS CHILD, V144, P1102, DOI 10.1001/archpedi.1990.02150340046021; Young MA, 1996, AM J PHYS MED REHAB, V75, P257, DOI 10.1097/00002060-199607000-00003; Ziv A, 1999, PEDIATRICS, V104, P35, DOI 10.1542/peds.104.1.35; Zonia SC, 2000, ACAD MED, V75, P742, DOI 10.1097/00001888-200007000-00020	26	29	30	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2005	115	1					28	33		10.1542/peds.2004-0266			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	884KN	WOS:000226083700025	15629978				2022-02-06	
J	Shimamura, M; Garcia, JM; Prough, DS; Dewitt, DS; Uchida, T; Shah, SA; Avila, MAA; Hellmich, HL				Shimamura, M; Garcia, JM; Prough, DS; Dewitt, DS; Uchida, T; Shah, SA; Avila, MAA; Hellmich, HL			Analysis of long-term gene expression in neurons of the hippocampal subfields following traumatic brain injury in rats	NEUROSCIENCE			English	Article						antioxidant gene expression; apoptotic gene expression; laser capture microdissection; linear mRNA amplification; neurodegeneration; neuroprotective gene expression	CORTICAL IMPACT INJURY; NERVE GROWTH-FACTOR; MESSENGER-RNA; UP-REGULATION; HEAD-INJURY; TRANSCRIPTION FACTORS; REACTIVE ASTROCYTES; NEUROTROPHIC FACTOR; COGNITIVE DEFICITS; NEURITE OUTGROWTH	After experimental traumatic brain injury (TBI), widespread neuronal loss is progressive and continues in selectively vulnerable brain regions, such as the hippocampus, for months to years after the initial insult. To clarify the molecular mechanisms underlying secondary or delayed cell death in hippocampal neurons after TBI, we compared longterm changes in gene expression in the CA1, CA3 and dentate gyrus (DG) subfields of the rat hippocampus at 24 h and 3, 6, and 12 months after TBI with changes in gene expression in sham-operated rats. We used laser capture microdissection to collect several hundred hippocampal neurons from the CA1, CA3, and DG subfields and linearly amplified the nanogram samples of neuronal RNA with T7 RNA polymerase. Subsequent quantitative analysis of gene expression using ribonuclease protection assay revealed that mRNA expression of the anti-apoptotic gene, Bcl-2, and the chaperone heat shock protein 70 was significantly downregulated at 3, 6 (Bcl-2 only), and 12 months after TBI. Interestingly, the expression of the pro-apoptotic genes caspase-3 and caspase-9 was also significantly decreased at 3, 6 (caspase-9 only), and 12 months after TBI, suggesting that long-term neuronal loss after TBI is not mediated by increased expression of pro-apoptotic genes. The expression of two aging-related genes, p21 and integrin beta3 (ITbeta3), transiently increased 24 h after TBI, returned to baseline levels at 3 months and significantly decreased below sham levels at 12 months (ITbeta3 only). Expression of the gene for the antioxidant glutathione peroxidase-1 also significantly increased 6 months after TBI. These results suggest that decreased levels of neuroprotective genes may contribute to long-term neurodegeneration in animals and human patients after TBI. Conversely, long-term increases in antioxidant gene expression after TBI may be an endogenous neuroprotective response that compensates for the decrease in expression of other neuroprotective genes. (C) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Yokohama City Univ, Sch Med, Dept Neurol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Univ Texas, Med Branch, Off Biostat, Galveston, TX 77555 USA		Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhelimic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Asai S, 1996, NEUROREPORT, V7, P1092, DOI 10.1097/00001756-199604100-00028; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; CORKIN S, 1989, J NEUROSCI, V9, P3876; Currie RW, 2000, BRAIN RES, V863, P169, DOI 10.1016/S0006-8993(00)02133-8; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dutcher SA, 2001, NEUROL RES, V23, P203, DOI 10.1179/016164101101198343; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Furling D, 2000, P NATL ACAD SCI USA, V97, P4351, DOI 10.1073/pnas.060574597; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; Geisert EE, 2002, J COMP NEUROL, V453, P22, DOI 10.1002/cne.10364; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GRONWALL D, 1974, LANCET, V2, P605; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Kamme F, 2003, J NEUROSCI, V23, P3607; Katano H, 2000, NEUROREPORT, V11, P2073, DOI 10.1097/00001756-200007140-00003; Katano H, 1998, BRAIN RES, V800, P69, DOI 10.1016/S0006-8993(98)00493-4; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kelley MS, 1997, REV NEUROSCIENCE, V8, P147; Kramer DL, 2001, CANCER RES, V61, P7754; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; PLANAS AM, 1994, MOL BRAIN RES, V27, P127, DOI 10.1016/0169-328X(94)90193-7; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; *SAS I INC, 1999, SAS I I SAS STAT US; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Xu DG, 1999, J NEUROSCI, V19, P5026; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; ZENG YC, 1995, MECH AGEING DEV, V79, P169, DOI 10.1016/0047-6374(94)01559-5; Zhao XY, 2001, J COMP NEUROL, V441, P187, DOI 10.1002/cne.1406	85	29	31	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2005	131	1					87	97		10.1016/j.neuroscience.2004.10.041			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	896RM	WOS:000226951200008	15680694				2022-02-06	
J	Faden, AI; Knoblach, SM; Movsesyan, VA; Cernak, I				Faden, AI; Knoblach, SM; Movsesyan, VA; Cernak, I			Novel small peptides with neuroprotective and nootropic properties	JOURNAL OF ALZHEIMERS DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; COGNITIVE RECOVERY; HORMONE TRH; ANALOG; METHYLPREDNISOLONE; NALOXONE; MOTOR; RATS	The tripeptide thyrotropin-releasing hormone (TRH) and/or related analogues have shown neuroprotective activity across multiple animal trauma models as well as in a small clinical trial of spinal cord injury. The metabolic product of TRH (cyclo-his-pro) retains physiological activity. We have developed a number of novel cyclic dipeptides that are structurally similar to cyclo-his-pro, and have examined their neuroprotective activity across multiple ire vitro models of neuronal injury and after traumatic brain injury (TB() in rodents. Four such compounds were found to reduce cell death after trophic withdrawal or traumatic injury in primary neuronal cultures; two also protected against glutamate or beta-amyloid neurotoxicity. All compounds significantly improved motor and cognitive recovery after controlled cortical impact injury in mice, and markedly reduced lesion volumes as shown by high field magnetic resonance imaging. Further, compound 35b, which is being developed for clinical trials, also showed considerable neuroprotection after fluid percussion induced TBI in rats, and improved cognitive function after daily administration in chronically brain injured rats. At a mechanistic level, the drugs attenuate both apoptotic and necrotic cell death in primary neuronal cultures, markedly reduce intracellular calcium accumulation after injury, and limit changes in mitochondrial membrane potential and associated cytochrome c release. In addition, microarray studies show that 356 reduces transcriptional changes after injury for a number of genes (and proteins) that may be associated with secondary injury, including cell cycle genes, aquaporins and cathepsins. It also upregulates brain-derived neurotrophic factor (BDNF), heat shock proteins (HSP) and hypoxia inducible factor (HIF). Thus, these novel dipeptides have multipotential actions that make them candidates for the treatment of both acute and chronic neurodegeneration.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA.	faden@gices.georgetown.edu	Cernak, Ibolja/A-6399-2008	Ibolja, Cernak/0000-0003-3214-698X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41119] Funding Source: Medline		Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; FADEN AI, 1983, NEUROLOGY, V33, P673, DOI 10.1212/WNL.33.6.673; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1996, NEUROTRAUMA, P1479; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; KOSKINEN LOD, 1986, BRIT J PHARMACOL, V87, P509, DOI 10.1111/j.1476-5381.1986.tb10193.x; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785, DOI 10.1152/ajpregu.1988.254.5.R785; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; PRASAD C, 1995, PEPTIDES, V16, P151, DOI 10.1016/0196-9781(94)00017-Z; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8	18	29	30	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877			J ALZHEIMERS DIS	J. Alzheimers Dis.	DEC	2004	6	6		S			S93	S97					5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	900JT	WOS:000227211900014	15665420				2022-02-06	
J	Yune, TY; Lee, SM; Kim, SJ; Park, HK; Oh, YJ; Kim, YC; Markelonis, GJ; Oh, TH				Yune, TY; Lee, SM; Kim, SJ; Park, HK; Oh, YJ; Kim, YC; Markelonis, GJ; Oh, TH			Manganese superoxide dismutase induced by TNF-alpha is regulated transcriptionally by NF-kappa B after spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						Cu/ZnSOD; MnSOD; NF-kappa B; spinal cord injury; TNF-alpha; TNF-alpha neutralizing antibody	TUMOR-NECROSIS-FACTOR; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL CYTOCHROME-C; ENDOMETRIAL STROMAL CELLS; OXIDATIVE STRESS; TRANSGENIC MICE; MESSENGER-RNA; NEURODEGENERATIVE DISEASES; FUNCTIONAL RECOVERY	Antioxidant enzymes including superoxide dismutase (SOD) may play a role in the mechanism by which cells counteract the deleterious effects of reactive oxygen species (ROS) after spinal cord injury (SCI). Cu/Zn and MnSOD are especially potent scavengers of superoxide anion and likely serve important cytoprotective roles against cellular damage. We investigated expression of SOD after SCI to address its role during the early stages of injury. MnSOD activity was increased 4 h after SCI and persisted at elevated levels up to 24-48 h; by contrast, Cu/ZnSOD activity was not changed. `RT-PCR and Western blot analyses showed increased levels of MnSOD mRNA and protein, respectively, by 4 h and reached maximum levels by 24-48 h. Double immunostaining revealed that MnSOD protein was localized within neurons and oligodendrocytes. Tumor necrosis factor-alpha (TNFalpha) was administered locally into uninjured spinal cords to examine potential mechanisms for MnSOD induction after injury. TNF-alpha administered exogenously increased MnSOD expression in uninjured spinal cords. Western blot and immunostaining also revealed that a transcription factor, NF-kappaB, was activated and translocated into the nuclei of neurons and oligodendrocytes. By contrast, administration of neutralizing antibody against TNF-alpha into injured spinal cords attenuated the increase in MnSOD expression and activation of NF-kappaB. Double immunostaining revealed that MnSOD was co-localized with NF-kappaB in neurons and oligodendrocytes after SCI. These results suggest that TNF-alpha may be an inducer of NF-kappaB activation and MnSOD expression after SCI and that MnSOD expression induced by TNF-alpha is likely mediated through activation of NF-kappaB.	Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Seoul Natl Univ, Coll Pharm, Seoul, South Korea; Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA		Yune, TY (corresponding author), Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea.	rila@kist.re.kr					Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bethea JR, 1998, J NEUROSCI, V18, P3251; BEUTLER B, 1994, ANN NY ACAD SCI, V730, P118, DOI 10.1111/j.1749-6632.1994.tb44244.x; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; DOUGALL WC, 1991, ENDOCRINOLOGY, V129, P2376, DOI 10.1210/endo-129-5-2376; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; EEARMJARDT JN, 2003, J NEUROTRAUM, V19, P1065; Fujimura M, 1999, J NEUROSCI, V19, P3414; Ghadge GD, 1997, J NEUROSCI, V17, P8756; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Guo Z, 2003, J BIOL CHEM, V278, P23570, DOI 10.1074/jbc.M303431200; HARRIS CA, 1991, J IMMUNOL, V147, P149; HASS MA, 1989, J CLIN INVEST, V83, P1241, DOI 10.1172/JCI114007; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Karube-Harada A, 2001, MOL HUM REPROD, V7, P1065, DOI 10.1093/molehr/7.11.1065; Keller JN, 1998, J NEUROSCI, V18, P687; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KINOUCHI K, 1991, BIOCHEM BIOPH RES CO, V181, P1532, DOI 10.1016/0006-291X(91)92113-X; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Kondo T, 1997, J NEUROSCI, V17, P4180; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li YQ, 1996, J CLIN INVEST, V97, P1605, DOI 10.1172/JCI118585; LIN PS, 1993, LYMPHOKINE CYTOK RES, V12, P303; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu XZ, 1997, J NEUROSCI, V17, P5395; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo J, 2002, SPINAL CORD, V40, P656, DOI 10.1038/sj.sc.3101363; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Mu XJ, 2002, J NEUROTRAUM, V19, P917, DOI 10.1089/089771502320317078; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKATA T, 1993, INT J CANCER, V55, P646, DOI 10.1002/ijc.2910550422; NELSON SK, 1995, J MOL CELL CARDIOL, V27, P223, DOI 10.1016/S0022-2828(08)80021-1; NOGAE C, 1995, J MOL CELL CARDIOL, V27, P2091, DOI 10.1016/S0022-2828(95)91155-3; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pan JZ, 2002, J NEUROSCI RES, V68, P315, DOI 10.1002/jnr.10215; Poynter ME, 2003, J IMMUNOL, V170, P6257, DOI 10.4049/jimmunol.170.12.6257; Rogers RJ, 2001, J BIOL CHEM, V276, P20419, DOI 10.1074/jbc.M008915200; Rosenfeld J, 1997, EXP NEUROL, V147, P37, DOI 10.1006/exnr.1997.6604; Saito A, 2003, J NEUROSCI, V23, P1710; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; Siemankowski LM, 1999, FREE RADICAL BIO MED, V26, P919, DOI 10.1016/S0891-5849(98)00273-1; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Skaleric U, 2000, EUR J ORAL SCI, V108, P130, DOI 10.1034/j.1600-0722.2000.90771.x; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Sugino N, 2002, J CLIN ENDOCR METAB, V87, P3845, DOI 10.1210/jc.87.8.3845; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; SYMONYAN MA, 1972, FEBS LETT, V28, P22, DOI 10.1016/0014-5793(72)80667-7; TAOKA Y, 1995, PARAPLEGIA, V33, P450, DOI 10.1038/sc.1995.98; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; VAN AD, 1996, SCIENCE, V274, P787; VISNER GA, 1990, J BIOL CHEM, V265, P2856; Wang CX, 2002, NEUROREPORT, V13, P1391, DOI 10.1097/00001756-200208070-00008; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WARNER GA, 1991, AM J PHYSIOL, V260, P296; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116	96	29	30	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1778	1794		10.1089/neu.2004.21.1778			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400009	15684769				2022-02-06	
J	Duong, TT; Englander, J; Wright, J; Cifu, DX; Greenwald, BD; Brown, AW				Duong, TT; Englander, J; Wright, J; Cifu, DX; Greenwald, BD; Brown, AW			Relationship between strength, balance, and swallowing deficits and outcome after traumatic brain injury: A multicenter analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Association-for-the-Study-of-Brain-Injury	MAY, 2001	Turin, ITALY	Int Assoc Study Brain Injury		balance; brain injuries; multicenter studies; rehabilitation; swallowing; treatment outcome	FUNCTIONAL INDEPENDENCE MEASURE; NIH STROKE SCALE; SYSTEMATIC BIAS; DYNAMIC BALANCE; SITTING BALANCE; FOLLOW-UP; RELIABILITY; REHABILITATION; INDIVIDUALS; ADMISSION	Objective: To examine the relation among strength, balance, and swallowing deficits, as measured on rehabilitation admission, and functional outcome at discharge and 1 year after traumatic brain injury (TBI). Design: Multicenter analysis of consecutive admissions to designated Traumatic Brain Injury Model Systems (TBIMS) facilities. Setting: Seventeen TBIMS centers. Participants: Adults and children older than 16 years of age with TBI (N = 2363) enrolled in the national database from January 1989 to November 2000. Interventions: Not applicable. Main Outcome Measures: Transfers, locomotion, stairs, lower-body dressing, grooming, bathing, upper-body dressing, toileting, and eating as measured by the FIM instrument at acute rehabilitation discharge and at 1 year after TBI. Results: Lower-extremity strength less than 3/5 on admission to acute rehabilitation was associated with increased need for assistance in locomotion, transfers, and lower-body dressing and less than 3/5 upper-extremity strength was associated with the need for assistance in self-care at rehabilitation discharge and at 1 year postinjury. Similar relations were found between impaired swallowing and assistance with eating, grossly impaired dynamic sitting, or standing balance and assistance with locomotion, transfers, eating, and self-care at rehabilitation discharge and at 1 year after TBI. Conclusions: Assessments of physical strength, swallowing ability, and dynamic balance on acute rehabilitation admission are helpful as screening tests in predicting the need for assistance of another person for mobility and self-care at rehabilitation discharge. This association remains strong at 1 year after TBI. By using this information, clinicians should initiate therapeutic interventions that optimize rehabilitation of the identified impairments and should make necessary arrangement for the patient's anticipated postdischarge needs. Further studies are necessary to delineate the amount of unique variance that these early physical examination findings contribute to outcome prediction. (C) 2004 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Virginia Commonwealth Univ, Coll Med, Dept PM&R, Richmond, VA USA; CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA		Duong, TT (corresponding author), Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, 751 S Bascom Ave, San Jose, CA 95128 USA.	thao.duong@hhs.co.santa-clara.ca.us		Cifu, David/0000-0003-1600-9387; Brown, Allen W./0000-0001-7228-3351			ALBANESE MA, 1994, STROKE, V25, P1746, DOI 10.1161/01.STR.25.9.1746; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; CIFU D, 2003, ARCH PHYS MED REHAB, V84, P1433; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Clark S, 2001, ARCH PHYS MED REHAB, V82, P468, DOI 10.1053/apmr.2001.21859; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Desrosiers J, 2003, CLIN REHABIL, V17, P666, DOI 10.1191/0269215503cr662oa; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; Juneja G, 1998, AM J PHYS MED REHAB, V77, P388, DOI 10.1097/00002060-199809000-00005; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; *KESS I REH, 1999, TRAUM BRAIN INJ MOD; Kinzey SJ, 1998, J ORTHOP SPORT PHYS, V27, P356, DOI 10.2519/jospt.1998.27.5.356; Marx RG, 1999, J HAND SURG-AM, V24A, P185; Nichols DS, 1996, ARCH PHYS MED REHAB, V77, P865, DOI 10.1016/S0003-9993(96)90271-3; Ramsey DJC, 2003, STROKE, V34, P1252, DOI 10.1161/01.STR.0000066309.06490.B8; *STAT U NEW YORK, 1997, GUID UN DAT SET MED; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	28	29	30	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2004	85	8					1291	1297		10.1016/j.apmr.2003.11.032			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	846CK	WOS:000223292200013	15295755				2022-02-06	
J	Body, R; Perkins, MR				Body, R; Perkins, MR			Validation of linguistic analyses in narrative discourse after traumatic brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; LANGUAGE DISORDER; STORY STRUCTURE; CHILDREN; COMPREHENSION; ADOLESCENTS; ABILITY; COHESION; ADULTS	Narrative discourse tasks are a common feature of assessment and research after traumatic brain injury (TBI) and other types of brain damage. Although stimulus materials and analysis methods have been developed from a variety of theoretical perspectives, many do not challenge cognitive-linguistic skills sufficiently to highlight individual difficulties in assessment after TBI. This study employed a complex story recall task and it aimed to develop analysis methods that were sensitive to differences in recalled narratives and which could be validated against the perceptions of external raters. Twenty TBI adults and 20 matched control subjects were tested and their narratives analysed in terms of six measures ( T-units , Noun : Pronoun Ratio , Scenes , Errors , Comments and Tentative Statements ). Two groups of raters (one professionally trained, the other not) judged the transcribed narratives on ratings of Content and Clarity. Multiple regression analyses established that two of the linguistic measures in combination predicted ratings of Content, while a further three in combination predicted ratings of Clarity. Cut-off scores were established in order to categorize the TBI and control subjects' performance. The validated measures provide the foundation for analyses of complex narrative as a means of assessment after TBI.	Univ Sheffield, Dept Human Commun Sci, Sheffield S10 2TA, S Yorkshire, England		Body, R (corresponding author), Univ Sheffield, Dept Human Commun Sci, 31 Claremont Crescent, Sheffield S10 2TA, S Yorkshire, England.	r.body@sheffield.ac.uk	Body, Richard/C-2736-2010	Body, Richard/0000-0001-9089-8130			Arnott WL, 1997, APHASIOLOGY, V11, P969, DOI 10.1080/02687039708249422; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Berndt R., 2000, QUANTITATIVE PRODUCT; Body R, 1998, BRAIN INJURY, V12, P963, DOI 10.1080/026990598122016; Boudreau DM, 2000, J SPEECH LANG HEAR R, V43, P1146, DOI 10.1044/jslhr.4305.1146; Brown Gillian., 1983, DISCOURSE ANAL; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHENERY HJ, 1994, APHASIOLOGY, V8, P159, DOI 10.1080/02687039408248648; Cherney LR, 1997, APHASIOLOGY, V11, P351, DOI 10.1080/02687039708248476; CHERNEY LR, 1990, ANN CONV AM SPEECH L; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Davis GA, 1997, BRAIN LANG, V56, P183; Docking K, 1999, BRAIN INJURY, V13, P953; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Duchan J., 1994, DISCOURSE ANAL APPL, P1; Duchan J.F., 1995, DEIXIS NARRATIVE COG, P227; ERNESTBARON CR, 1987, J SPEECH HEAR RES, V30, P44, DOI 10.1044/jshr.3001.44; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hewitt Lynne E., 1995, DEIXIS NARRATIVE COG, P61; Hunt K. W., 1965, GRAMMATICAL STRUCTUR; Joanette Y., 1990, DISCOURSE ABILITY BR, DOI [10.1007/978-1-4612-3262-9_6, DOI 10.1007/978-1-4612-3262-9_6]; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Kintsch W., 1974, REPRESENTATION MEANI; Kuno Susumu, 1987, FUNCTIONAL SYNTAX AN; Li N., 1995, DEIXIS NARRATIVE COG, P287; LILES BZ, 1987, J SPEECH HEAR RES, V30, P185, DOI 10.1044/jshr.3002.185; MANDLER JM, 1977, COGNITIVE PSYCHOL, V9, P111, DOI 10.1016/0010-0285(77)90006-8; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENN L, 1994, APHASIOLOGY, V8, P343, DOI 10.1080/02687039408248664; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; NICHOLAS LE, 1995, J SPEECH HEAR RES, V38, P146, DOI 10.1044/jshr.3801.145; Paivio A., 1986, MENTAL REPRESENTATIO; Perkins M. R., 1995, CASE STUDIES CLIN LI, P293; PURCELL SL, 1992, J SPEECH HEAR RES, V35, P354, DOI 10.1044/jshr.3502.354; ROTH FP, 1986, J SPEECH HEAR DISORD, V51, P8, DOI 10.1044/jshd.5101.08; Schiffrin D., 1994, APPROACHES DISCOURSE; Stein N. L., 1979, NEW DIRECTIONS DISCO, P53; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Ulatowska Hanna K., 1990, DISCOURSE ABILITY BR, P180, DOI 10.1007/978-1-4612-3262-9_8; Van Dijk TA., 1983, STRATEGIES DISCOURSE; Zubin D.A., 1995, DEIXIS NARRATIVE COG, P129	44	29	31	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					707	724		10.1080/02699050310001596914			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700007	15204331				2022-02-06	
J	Goins, MR; Pitovski, DZ				Goins, MR; Pitovski, DZ			Posttonsillectomy taste distortion: A significant complication	LARYNGOSCOPE			English	Article							CHORDA TYMPANI NERVE; GLOSSOPHARYNGEAL; HUMANS; ANESTHESIA; BEHAVIOR; RAT	Objective/Hypothesis. Tonsillectomy is among the most commonly performed procedures. As with any surgery, head and neck surgeons must be aware of possible complications and their potential affects. At our smell and taste center, we have been referred several patients in a 6-month period with the complaint of taste distortion after tonsillectomy. We report in this article a patient that complains of taste distortion after a right tonsillectomy for unilateral tonsillar hypertrophy. Study Design: A prospective study documenting taste distortion after tonsillectomy using clinical, subjective, and objective evaluation. Methods: The clinical course of a patient with taste distortion after a tonsillectomy is described. The gustatory function was investigated by conducting electrogustometry and spatial taste testing. Threshold measurements were determined at three left- and three iright-side tongue regions: 1) the tongue tip region (innervated by the chorda tympani branch of the facial nerve), 2) the lateral margin of the tongue (anterior to the foliate papillae), and 3) the posterior tongue region (innervated by the lingual branch of the glossopharyngeal nerve). Results: After a complete clinical evaluation and taste testing, it was found that the patient suffered an injury to the right lingual branch of the glossopharyngeal nerve. The close anatomic relationship between the palatine tonsil and lingual branch of the glossopharyngeal nerve makes the nerve vulnerable during tonsillectomy. This injury has caused the patient to suffer ageusia to the right posterior one third of the tongue, compensated by a contralateral phantogeusia (phantom taste) with clinical dysgeusia. The phantogeusia was abolished by application of anesthetic to the area where the phantom was perceived. We propose that the phantogeusia is the result of release-of-inhibition in the contralateral glossopharyngeal nerve. Conclusion. Taste distortion (including, phantogeusia and dysgeusia) after tonsillectomy is rarely reported as a complication but has a significant impact on quality of life. This article examines the taste distortion presence as a complication after tonsillectomy to make head and neck surgeons aware of this serious complication and the pathophysiology of taste distortion.	Wake Forest Univ, Bowman Gray Sch Med, Dept Otolaryngol, Ctr Smell & Taste, Winston Salem, NC 27157 USA		Pitovski, DZ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Otolaryngol, Ctr Smell & Taste, Winston Salem, NC 27157 USA.	dzpito@wfubmc.edu					Bartoshuk L. M., 1994, Chemical Senses, V19, P440; COLCLASURE J B, 1990, Ear Nose and Throat Journal, V69, P155; DERKAY CS, 1993, INT J PEDIATR OTORHI, V25, P1, DOI 10.1016/0165-5876(93)90004-M; Dinkins ME, 1999, J NEUROPHYSIOL, V82, P2565, DOI 10.1152/jn.1999.82.5.2565; Duffy VB, 1998, ANN NY ACAD SCI, V855, P805, DOI 10.1111/j.1749-6632.1998.tb10663.x; GIDUCK SA, 1987, J NUTR, V117, P1191, DOI 10.1093/jn/117.7.1191; GRILL HJ, 1992, BRAIN RES, V573, P95, DOI 10.1016/0006-8993(92)90117-R; Heald AE, 1998, AIDS, V12, P1667, DOI 10.1097/00002030-199813000-00015; John SJS, 1997, BEHAV NEUROSCI, V111, P188; KROEZE JHA, 1985, PHYSIOL BEHAV, V35, P779, DOI 10.1016/0031-9384(85)90412-3; KVETON JF, 1994, LARYNGOSCOPE, V104, P25; LEHMAN C, 1991, EFFECT ANESTHESIA CH; LEHMAN CD, 1995, PHYSIOL BEHAV, V57, P943, DOI 10.1016/0031-9384(95)91121-R; MACCARTHYLEVENTHAL EM, 1959, LANCET, V2, P1138; Mathey MFAM, 2001, J GERONTOL A-BIOL, V56, pM200, DOI 10.1093/gerona/56.4.M200; Matsuyama H, 1986, Auris Nasus Larynx, V13 Suppl 1, pS43; MCLAUGHLIN S, 1994, AM SCI, V82, P538; MILLER IJ, 1991, SMELL TASTE HLTH DIS, P205; Ohtsuka K, 2002, ACTA OTO-LARYNGOL, V122, P99, DOI 10.1080/00016480260046472; OSTROM KM, 1985, CHEM SENSES, V10, P459; SCHIFFMAN SS, 1993, PHYSIOL BEHAV, V53, P395, DOI 10.1016/0031-9384(93)90224-4; Schiffman SS, 1997, JAMA-J AM MED ASSOC, V278, P1357, DOI 10.1001/jama.278.16.1357; STJOHN SJ, 1994, BEHAV NEUROSCI, V108, P131, DOI 10.1037/0735-7044.108.1.131; TONOSAKI K, 1993, PHYSIOL BEHAV, V53, P667, DOI 10.1016/0031-9384(93)90171-B; TRAVERS JB, 1987, BEHAV BRAIN RES, V25, P233, DOI 10.1016/0166-4328(87)90071-4; Vories AA, 1999, OTOLARYNG HEAD NECK, V121, P303, DOI 10.1016/S0194-5998(99)70200-7; WARWICK ZS, 1993, PHYSIOL BEHAV, V53, P553, DOI 10.1016/0031-9384(93)90153-7; Yanagisawa K, 1998, PHYSIOL BEHAV, V63, P329, DOI 10.1016/S0031-9384(97)00423-X	28	29	31	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0023-852X	1531-4995		LARYNGOSCOPE	Laryngoscope	JUL	2004	114	7					1206	1213		10.1097/00005537-200407000-00015			8	Medicine, Research & Experimental; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Otorhinolaryngology	837QT	WOS:000222651100015	15235350				2022-02-06	
J	Watson, NF; Barber, JK; Doherty, MJ; Miller, JW; Temkin, NR				Watson, NF; Barber, JK; Doherty, MJ; Miller, JW; Temkin, NR			Does glucocorticoid administration prevent late seizures after head injury?	EPILEPSIA			English	Article						traumatic brain injury; seizures; glucocorticoids; prevention	TRAUMATIC BRAIN-INJURY; CORTICOSTERONE TREATMENT; CONTROLLED TRIALS; EPILEPSY; EPILEPTOGENESIS; STEROIDS	Purpose: preventing posttraumatic epilepsy has been a difficult challenge. In this study we evaluated the association between glucocorticoid administration after traumatic brain injury (TBI) and posttraumatic seizures. Methods: We examined a seizure-prevention trial database of 404 patients with severe TBI for exposure to glucocorticoids in the early (<1 week) posttraumatic period. After controlling for seizure risk, we compared the odds of developing first and second late posttraumatic seizures between those that received glucocorticoids and those that did not. Results: Patients dosed with glucocorticoids within 1 day of their TBI were more likely to develop first late seizures than were those without [p = 0.04; hazard ratio = 1.74; 95% confidence interval (CI), 1.01-2.98]; whereas those receiving glucocorticoids &GE;2 days after their injury had no similar association (p = 0.66 hazard ratio = 0.77; 95% CI, 0.23-2.56; p = 0.10 among the three groups). Receiving glucocorticoids within I day, or &GE;2 days after TBI was not associated with second late seizure development. Conclusions: Glucocorticoid treatment after TBI is not associated with decreased late posttraumatic seizures, and early treatment is associated with increased seizure activity.	Univ Washington, Neurol & Sleep Disorders Ctr, Seattle, WA 98104 USA; Univ Washington, Dept Biostat, Seattle, WA 98104 USA; Swedish Neurosci Inst, Epilepsy Ctr, Seattle, WA USA		Watson, NF (corresponding author), Univ Washington, Sleep Disorders Ctr, Box 359803,325 9th Ave, Seattle, WA 98104 USA.	nwatson@u.washington.edu					Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Frantseva MV, 2000, NEUROSCIENCE, V97, P431, DOI 10.1016/S0306-4522(00)00041-5; Goodman YD, 1996, J NEUROCHEM, V66, P1836; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; Hellsten J, 2002, EUR J NEUROSCI, V16, P283, DOI 10.1046/j.1460-9568.2002.02093.x; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; HOEPPNER TJ, 1986, EXP NEUROL, V94, P519, DOI 10.1016/0014-4886(86)90235-9; Karst H, 1999, EUR J NEUROSCI, V11, P889, DOI 10.1046/j.1460-9568.1999.00495.x; Mackay M, 2002, INT REV NEUROBIOL, V49, P157; Miller JD, 1996, SURG NEUROL, V45, P296; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P531; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	15	29	30	0	0	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0013-9580			EPILEPSIA	Epilepsia	JUN	2004	45	6					690	694		10.1111/j.0013-9580.2004.59403.x			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	828SI	WOS:000221992900018	15144437	Bronze			2022-02-06	
J	Li, J; Goldberg, G; Munin, MC; Wagner, A; Zafonte, R				Li, J; Goldberg, G; Munin, MC; Wagner, A; Zafonte, R			Post-traumatic bilateral facial palsy: a case report and literature review	BRAIN INJURY			English	Article; Proceedings Paper	38th Annual Meeting of the Association-of-Academic-Physiatrists	FEB 28, 2002	LAS VEGAS, NV	Assoc Acad Physiatrists			BELL PALSY; NERVE; PARALYSIS; MANAGEMENT; PREDNISONE; FRACTURES; INJURY	Bilateral facial paralysis due to basilar skull fracture involving the temporal bone is rare and, unlike unilateral facial palsy, it can be difficult to recognize because of a lack of facial asymmetry. Thorough clinical history and physical exam, high-resolution CT scan and electrodiagnostic tests can help to make the diagnosis of bilateral facial nerve palsy and early detection, evaluation and intervention may be important for optimal functional recovery. A 16-year-old male sustained closed head injury after motor vehicle collision. The initial head CT scan showed bilateral temporal bone fractures. On admission to the neurotrauma intensive care unit, his Glasgow Coma Score was 9T. On post-injury day 4, the patient was noted to have incomplete closure of both eyes and 3 days later he had difficulty with bilateral facial muscle movement during a feeding trial. Electrodiagnostic testing confirmed the diagnosis of bilateral facial nerve injury without evidence of significant distal axonal degeneration. A high-resolution CT scan showed bilateral temporal bone fractures without involvement of the fallopian canals. There was no surgical intervention based on the high-resolution CT scan and the delayed onset of facial palsy. A short course of prednisone was administered. By 10 months, the patient showed nearly complete recovery of his bilateral facial nerve function. Early detection, evaluation and intervention are important for optimal functional recovery after facial nerve injury. When the temporal bone is fractured, high suspicion for facial nerve injury, either unilateral or bilateral, is warranted.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA		Zafonte, R (corresponding author), 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	zafonerd@msx.upmc.edu					AUSTIN JR, 1993, LARYNGOSCOPE, V103, P1326; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.1984.03340250025015; Darrouzet V, 2001, OTOLARYNG HEAD NECK, V125, P77, DOI 10.1067/mhn.2001.116182; DIAMOND C, FACIAL NERVE, P162; DUMITRU D, 1988, AM J PHYS MED REHAB, V67, P137, DOI 10.1097/00002060-198808000-00002; FUJITA H, 1983, FACIAL NERVE RES JAP, V3, P124; GEORGE M K, 1991, Ear Nose and Throat Journal, V70, P492; GLASSCOCK ME, 1979, LARYNGOSCOPE, V89, P1389, DOI 10.1002/lary.5540890904; GOIN W, 1980, LARYNGOSCOPE, V90, P1777; GROVE E, 1933, LARYNGOSCOPE ST LOUI, V49, P678; GROVE E, 1933, LARYNGOSCOPE ST LOUI, V49, P833; Harker L A, 1991, OTOLARYNGOLOGIC CLIN, V24, P425; KETTEL K, 1959, P ROY SOC MED, V52, P1069; MAY M, 1976, LARYNGOSCOPE, V86, P1111, DOI 10.1288/00005537-197608000-00003; MCHUGH E, 1963, ARCH OTOLARYNGOL, V78, P433; Miehlke A., 1973, SURG FACIAL NERVE, V2nd; SHERWEN PJ, 1987, J OTOLARYNGOL, V16, P28; STEENERSON RL, 1986, AM J OTOL, V7, P99; TAVERNER D, 1954, LANCET, V2, P1052; TOS M, 1973, ACTA OTO-LARYNGOL, V75, P353, DOI 10.3109/00016487309139745; WOLF SM, 1978, NEUROLOGY, V28, P158, DOI 10.1212/WNL.28.2.158	21	29	33	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2004	18	3					315	320		10.1080/0269905031000149489			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900007	14726289				2022-02-06	
J	Incoccia, C; Formisano, R; Muscato, P; Reali, G; Zoccolotti, P				Incoccia, C; Formisano, R; Muscato, P; Reali, G; Zoccolotti, P			Reaction and movement times in individuals with chronic traumatic brain injury with good motor recovery	CORTEX			English	Article						traumatic brain injury; attention; movement time	CLOSED-HEAD INJURY; ATTENTIONAL PROCESSES; DEFICITS; PATTERNS; SCALE	Reaction times and movement times were studied in 18 individuals with severe traumatic brain injury (TBI) and 36 matched normal controls. Reaction times depended on the type of task: in the case of simple visual stimuli (Alertness condition) they were similar in individuals with TBI and normal controls. In contrast, individuals with FBI were slower in a Go-no-go test. Regardless of task, movement times depended on movement length and were slower in individuals with TBI. These findings indicate the presence of a residual motor programming deficit in individuals with TBI even in the chronic stage and in the presence of good motor recovery, as assessed clinically.	IRCCS, Fdn Santa Lucia, Ctr Ric Neuropsicol, I-00179 Rome, Italy; Univ Roma La Sapienza, Dept Psychol, Rome, Italy		Incoccia, C (corresponding author), IRCCS, Fdn Santa Lucia, Ctr Ric Neuropsicol, Via Ardcatina 306, I-00179 Rome, Italy.	c.incoccia@hsantalucia.it	Zoccolotti, Pierluigi/H-4437-2019	Zoccolotti, Pierluigi/0000-0002-6351-2455; Incoccia, Chiara/0000-0003-4068-6548			ADAMS RJ, 1987, STROKE, V18, P665, DOI 10.1161/01.STR.18.3.665; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1974, J NEUROL NEUROSUR PS, V13, P81; JENNETT B, 1974, LANCET, V13, P81; KEELE SW, 1968, PSYCHOL BULL, V70, P387, DOI 10.1037/h0026739; KLAPP ST, 1975, J EXP PSYCHOL HUMAN, V104, P147; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; VANZOMEREN AH, 1994, CLIN NEUROPSCHOLOGY; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	13	29	29	0	4	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	FEB	2004	40	1					111	115		10.1016/S0010-9452(08)70924-9			5	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	807DU	WOS:000220483000010	15070006				2022-02-06	
J	Malec, JF; Brown, AW; Moessner, AM				Malec, JF; Brown, AW; Moessner, AM			Personality factors and injury severity in the prediction of early and late traumatic brain injury outcomes	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; RECOVERY; TRAITS	Objective: To identify personality features predicting early and late outcome after traumatic brain injury (TBI). Design: Multiple regression analyses of data from an inception cohort. Participants: Sixty-nine persons with moderate to severe TBI and significant others (SOs). Outcome Measures: Rasch measure of supervision, independent living, and work (Participation and Independence Measure) at hospital discharge and at 1-year follow-up. Predictor Variables: Duration of posttraumatic amnesia (PTA) and NEO Personality Inventory-Revised completed by participants and SOs to describe participant's preinjury personality. Results: Overall personality variables were within normal limits. Only self-reported Neuroticism, specifically Depression, added significantly to PTA in predicting early outcome. Conclusions: Although self-reported depression negatively affects TBI outcome, other personality features reported by people with TBI and SOs during early recovery are normal and do not affect outcome.	Mayo Clin, Generose ME TBI, Coll Med, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin, Generose ME TBI, Coll Med, Dept Phys Med & Rehabil, Rochester, MN 55905 USA		Malec, JF (corresponding author), Mayo Clin, Generose ME TBI, Coll Med, Dept Psychiat & Psychol, Rochester, MN 55905 USA.	malec.james@mayo.edu		Brown, Allen W./0000-0001-7228-3351			BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COSTA JPT, 1992, PROFESSIONAL MANUAL; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; HALLINAN MT, 1996, SOC PSYCHOL EDUC, V1, P1, DOI DOI 10.1007/BF02333403; JOHNSON O, 1991, POLYCYCL AROMAT COMP, V2, P155; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wright BD., 1982, RATING SCALE ANAL	17	29	29	0	5	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2004	49	1					55	61		10.1037/0090-5550.49.1.55			7	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	771RQ	WOS:000188800200008					2022-02-06	
J	Chesnut, RM				Chesnut, RM			Management of brain and spine injuries	CRITICAL CARE CLINICS			English	Article							SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; 7.5-PERCENT SODIUM-CHLORIDE; RANDOMIZED CONTROLLED-TRIAL; VENA-CAVAL FILTERS; CORD-INJURY; CERVICAL-SPINE; TRAUMA PATIENTS; VENOUS THROMBOEMBOLISM	Over the past 30 years, remarkable progress has been made in improving outcome from traumatic brain injury (TBI). Overall mortalities from severe TBI have dropped from in the range of 36% in the late 1980s into the low-to-middle teens at specialized TBI centers [1,2]. Although many etiologies for such improvement have been suggested, it is unclear what changes actually affected the improvement in outcome. Despite the fervor for laboratory investigations of TBI models, it is sobering to recognize that no treatments have come from bench to bedside. As such, there are no magic bullets in the treatment of central nervous system (CNS) trauma in general, and TBI in particular. Instead, it appears to be a combination of many improvements in brain injury care, trauma systems, and critical care that has produced the decrease in mortality.	Oregon Hlth & Sci Univ, Dept Neurotrauma & Neurosurg Crit Care, Portland, OR 97201 USA		Chesnut, RM (corresponding author), Oregon Hlth & Sci Univ, Dept Neurotrauma & Neurosurg Crit Care, L-472,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	chesnutr@ohsu.edu					ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BIVINS HG, 1988, ANN EMERG MED, V17, P25, DOI 10.1016/S0196-0644(88)80498-0; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut R M, 1995, New Horiz, V3, P581; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1998, CRIT CARE MED, V26, P210, DOI 10.1097/00003246-199802000-00009; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHESTNUT RM, 2000, HEAD INJURY, P229; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Cooper P R, 1976, Surg Neurol, V5, P25; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; DUH MS, 1994, NEUROSURGERY, V35, P240, DOI 10.1227/00006123-199408000-00009; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fehlings MG, 2001, SPINE, V26, pS101, DOI 10.1097/00007632-200112151-00017; FULTON RL, 1993, SURG GYNECOL OBSTET, V176, P327; GAAB MR, 1990, ACT NEUR S, V51, P326; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Ghajar J, 1995, New Horiz, V3, P395; GHAJAR JB, 1995, NEUROTRAUMA, P1007; Ghanta MK, 2002, AM SURGEON, V68, P563; GREEN D, 1991, SEMIN THROMB HEMOST, V17, P347, DOI 10.1055/s-2007-1002633; GREEN D, 1982, PARAPLEGIA, V20, P227, DOI 10.1038/sc.1982.41; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; Harris S, 1996, AM J PHYS MED REHAB, V75, P326, DOI 10.1097/00002060-199609000-00002; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Holzschuh M, 1998, ACT NEUR S, V71, P170; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Hurlbert RJ, 2001, SPINE, V26, pS39, DOI 10.1097/00007632-200112151-00009; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; LEVI L, 1991, NEUROSURGERY, V29, P216, DOI 10.1227/00006123-199108000-00008; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1987, J NEUROSURG, V66, P400, DOI 10.3171/jns.1987.66.3.0400; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Maxwell RA, 2002, J TRAUMA, V52, P902, DOI 10.1097/00005373-200205000-00013; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Meguro K, 1988, Neurol Med Chir (Tokyo), V28, P34, DOI 10.2176/nmc.28.34; Mirza SK, 1999, CLIN ORTHOP RELAT R, P104, DOI 10.1097/00003086-199902000-00011; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Oertel M, 2002, ACT NEUR S, V81, P69; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rogers FB, 2002, J TRAUMA, V53, P1032, DOI 10.1097/00005373-200211000-00045; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Schenarts PJ, 2001, J TRAUMA, V51, P663, DOI 10.1097/00005373-200110000-00007; Schneider GH, 2002, ACT NEUR S, V81, P77; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; Vaccaro AR, 1997, SPINE, V22, P2609, DOI 10.1097/00007632-199711150-00006; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; WAGNER FC, 1982, J NEUROSURG, V56, P699, DOI 10.3171/jns.1982.56.5.0699; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Winslow C, 2002, CHEST, V121, P1548, DOI 10.1378/chest.121.5.1548; 2001, J TRAUMA INJURY INFE, V51, pS3	85	29	30	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	JAN	2004	20	1					25	+		10.1016/S0749-0704(03)00090-3			32	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	848ID	WOS:000223460000004	14979328				2022-02-06	
J	Walker, WC				Walker, WC			Pain pathoetiology after TBI - Neural and nonneural mechanisms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute pain; brain injury; chronic pain; pain assessment; trauma	TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE CRASHES; HEAD-INJURY; POSTTRAUMATIC HEADACHES; EPIDEMIOLOGY; PATHOGENESIS; DISABILITY; DISORDER	Individuals recovering from traumatic brain injury (YBI) frequently experience acute and chronic pain. Their pain experience is the net effect of many interacting and very complex physiologic, biochemical, and psychological mechanisms involving both the peripheral and central nervous system. This article reviews the basics of neural mechanisms and pathways of pain after TBI, and discusses clinical implications. Numerous intracranial and extracranial tissues must be considered in the evaluation of pain after TBI, with the specific mechanism of trauma influencing the anatomic distribution of injuries. The differential diagnosis usually falls into one of the following pathoetiologic classifications: primary or secondary musculoskeletal, vascular, visceral, and neural pain syndromes.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; McGuire VAMC, Def & Vet Brain Injury Ctr, Richmond, VA USA		Walker, WC (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, MCV Stn,Box 677, Richmond, VA 23298 USA.	wcwalker@mail2.vcu.edu	Walker, William C/N-3162-2014				Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Annoni J M, 1992, Disabil Rehabil, V14, P23; Ashina S, 2003, CEPHALALGIA, V23, P456, DOI 10.1046/j.1468-2982.2003.00559.x; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BENEDITTIS G, 1983, J NEUROSURG SCI, V27, P177; BIGLER ED, 2001, PHYS MED REHABIL STA, V15, P349; BONICA JJ, 2001, BONICAS MANAGEMENT P; Byers MR, 2001, BONICAS MANAGEMENT P, V3rd; CELENTANO DD, 1992, HEADACHE, V32, P223, DOI 10.1111/j.1526-4610.1992.hed3205223.x; Chapman CR, 1996, PROG BRAIN RES, V110, P63; CHUDLER EH, 2001, BONICAS MANAGEMENT P; Coda B, 2001, BONICAS MANAGEMENT P; Coderre TJ, 1997, BEHAV BRAIN SCI, V20, P404, DOI 10.1017/S0140525X97251484; Curatolo M, 2001, CLIN J PAIN, V17, P306, DOI 10.1097/00002508-200112000-00004; DISCHINGER PC, 1993, J TRAUMA, V35, P454, DOI 10.1097/00005373-199309000-00020; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gabriel, 1993, NEUROBIOLOGY CINGULA, P313; Gabriel M, 1995, FRONTIER PAIN RES, P197; GALER BS, 2001, BONICAS MANAGEMENT P; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; GOLDBERG G, 2001, PHYS MED REHABIL STA, V15, P363; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; HAM LP, 1994, CEPHALALGIA, V14, P118, DOI 10.1046/j.1468-2982.1994.1402118.x; HAMM RJ, 2000, NEUROPLASTICITY REOR, P46; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; JACOBSON L, 2001, BONICAS MANAGEMENT; JAY GW, 2001, CURRENT TREND DIAGNO; Jensen TS, 2001, ACTA ANAESTH SCAND, V45, P1128, DOI 10.1034/j.1399-6576.2001.450913.x; Kleppel JB, 2002, AM J PHYS MED REHAB, V81, P114, DOI 10.1097/00002060-200202000-00007; Kwan Oliver, 2002, Med Sci Monit, V8, pRA191; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Melzack R, 2001, J Dent Educ, V65, P1378; Miller L, 2000, NEUROREHABILITATION, V14, P25; MOSKOWITZ MA, 1993, NEUROLOGY, V43, P16; Nicholson K, 2000, NEUROREHABILITATION, V14, P3; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; RAJ PP, 1994, CURRENT REV PAIN, P21; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SIEGEL JH, 1993, J TRAUMA, V34, P736, DOI 10.1097/00005373-199305000-00017; Siegmund GP, 2001, SPINE, V26, P2095, DOI 10.1097/00007632-200110010-00010; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TASKER RR, 2001, BONICAS MANAGEMENT P; Terman G., 2001, BONICAS MANAGEMENT P; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VIJAYAN N, 1977, HEADACHE, V17, P19, DOI 10.1111/j.1526-4610.1977.hed1701019.x; VIJAYAN N, 1989, HEADACHE, V29, P502, DOI 10.1111/j.1526-4610.1989.hed2908502.x; WALKER WC, 2002, ARCH PHYS MED REHAB, V83, P1643; WATANABE TK, 2001, PHYS MED REHABILITAT, V15, P283; ZHOU M, 2001, SCI WORLD J, V1, P204	54	29	30	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					72	81		10.1097/00001199-200401000-00007			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000007	14732832				2022-02-06	
J	Dixon, CE; Ma, XC; Kline, AE; Yan, HQ; Ferimer, H; Kochanek, PM; Wisniewski, SR; Jenkins, LW; Marion, DW				Dixon, CE; Ma, XC; Kline, AE; Yan, HQ; Ferimer, H; Kochanek, PM; Wisniewski, SR; Jenkins, LW; Marion, DW			Acute etomidate treatment reduces cognitive deficits and histopathology in rats with traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						controlled cortical impact; Morris water maze; recovery; spatial learning	EXCITATORY AMINO-ACIDS; CEREBROSPINAL-FLUID; GABA(A) RECEPTOR; GLUTAMATE; RELEASE; ISOFLURANE; CALCIUM; MODEL; ANESTHETICS; HYPOTHERMIA	Objective: To test the hypothesis that etomidate treatment improves functional, cognitive, and histologic outcome after experimental traumatic brain injury. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male Sprague-Dawley rats. Interventions: Traumatic brain injury was produced by controlled cortical impact injury (4 m/sec, 2.6 mm of tissue deformation). Etomidate (2 mg/kg) was administered intravenously immediately before injury (n = 13) or 5 mins after injury (n = 12). Additional rats received saline treatment 5 mins after injury (n 12) or served as sham controls (n = 10). Measurements and Main Results. Rats were evaluated on beam balance and beam walk tasks on postoperative days 1-5 and then trained in the Morris water maze on postoperative days 14-18. On day 28, the rats were killed, and hippocampal CA(1) and CA(3) neuron counts and cortical lesion volume were measured in histologic brain sections. Preinjury etomidate attenuated beam balance deficits, water maze deficits, hippocampal CA(3) neuronal loss, and cortical tissue loss but did not attenuate beam walk deficits or hippocampal CA, neuronal loss. Postinjury etomidate attenuated water maze deficits, but it did not affect any other outcome measure. Conclusions. Administration of etomidate both before and after injury attenuates secondary injury resulting from traumatic brain injury, but the effect is more pronounced with pretreatment. The ineffectiveness of postinjury etomidate on motor and histologic tasks suggests a brief therapeutic treatment window in rats. However, the treatment window in humans is unknown. Lastly, postinjury etomidate did not exacerbate neurologic or histologic outcome.	Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA		Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurosurg, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	ecdixon@msx.upmc.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40125, NS33150, NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318, R01NS033150, R01NS040125] Funding Source: NIH RePORTER		Adnet F, 1998, Eur J Emerg Med, V5, P415; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Belelli D, 1999, NEUROCHEM INT, V34, P447, DOI 10.1016/S0197-0186(99)00037-6; Bergen Joseph M., 1997, Journal of Emergency Medicine, V15, P221, DOI 10.1016/S0736-4679(96)00350-2; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; Bullock R, 1994, INTRACRANIAL PRESSUR, P264; CESHNUT RM, 1991, NEUROSURG CLIN N AM, V2, P267; CHOI DW, 1987, J NEUROSCI, V7, P357; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kindler CH, 1999, ANESTHESIOLOGY, V90, P1137, DOI 10.1097/00000542-199904000-00029; Kline AE, 2001, HEAD TRAUMA, P65; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Moody EJ, 1998, TOXICOL LETT, V101, P209, DOI 10.1016/S0378-4274(98)00187-8; Murugaiah KD, 1998, ANESTHESIOLOGY, V89, P919, DOI 10.1097/00000542-199810000-00017; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PATEL PM, 1995, ANESTH ANALG, V80, P933, DOI 10.1097/00000539-199505000-00013; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PRIOR JGL, 1983, INTENS CARE MED, V9, P313, DOI 10.1007/BF01692549; PUIL E, 1994, NEUROSCI LETT, V176, P63, DOI 10.1016/0304-3940(94)90872-9; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Robertson SC, 1998, NEUROSURGERY, V43, P317, DOI 10.1097/00006123-199808000-00085; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Smith DC, 2000, J EMERG MED, V18, P13, DOI 10.1016/S0736-4679(99)00154-7; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Swanson E R, 2001, Prehosp Emerg Care, V5, P142, DOI 10.1080/10903120190940001; Tentillier E, 2000, ANN FR ANESTH, V19, P275; WATSON JC, 1992, NEUROSURGERY, V30, P540; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	42	29	32	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2003	31	8					2222	2227		10.1097/01.CCM.0000080493.04978.73			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712KV	WOS:000184797600021	12973183				2022-02-06	
J	Santhakumar, V; Voipio, J; Kaila, K; Soltesz, I				Santhakumar, V; Voipio, J; Kaila, K; Soltesz, I			Post-traumatic hyperexcitability is not caused by impaired buffering of extracellular potassium	JOURNAL OF NEUROSCIENCE			English	Article						potassium; buffering; head trauma; FPI; dentate gyrus; seizures	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; CENTRAL NERVOUS-SYSTEM; RAT DENTATE GYRUS; GLIAL-CELLS; HIPPOCAMPAL SLICES; IN-VITRO; ELECTROPHYSIOLOGICAL PROPERTIES; SYNAPTIC TRANSMISSION; EPILEPTIFORM ACTIVITY	Impaired extracellular potassium buffering has been proposed as one of the major mechanisms underlying the increased risk for temporal lobe epilepsy after brain injury (D'Ambrosio et al., 1999). The present study systematically tested this hypothesis by measuring the resting [K+](o) and recovery of the stimulation-evoked [K+](o) increases in the dentate gyrus after experimental head trauma, using a combination of whole-cell recordings and ion-selective microelectrode recordings in rat hippocampal slices. Despite the presence of hyperexcitability, the resting [K+](o) was not increased after injury. The faster rate of increase and larger amplitude of the orthodromically evoked [K+](o) elevation after head trauma occurred in association with a greater population spike with shorter response latency. Contrary to the assumption in previous studies that the evoked activity in control and injured neuronal circuits is the same during antidromic activation, stimulation of granule cell axons in glutamate receptor antagonists evoked a greater [K+](o) increase and a larger population spike. Although perforant path stimulation resulted in a larger [K+](o) elevation after injury, the rate of clearance of the [K+](o) transients evoked either by neuronal activity or by external application of potassium was not compromised. The [K+](o) increase evoked by activation of the presynaptic afferents in isolation was not increased. In addition, the postsynaptic neuronal depolarization and firing evoked by exogenous potassium application was decreased after trauma. These results show that the regulation of [K+](o) is not impaired after injury and indicate that the larger [K+](o) increase evoked by neuronal activity is a consequence, rather than the primary mechanism underlying post-traumatic hyperexcitability.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland		Santhakumar, V (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	vsanthak@uci.edu	Santhakumar, Vijayalakshmi/M-4192-2013; Santhakumar, Viji/K-4856-2019; Kaila, Kai K/R-8528-2016	Santhakumar, Viji/0000-0001-6278-4187; Kaila, Kai K/0000-0003-0668-5955; Voipio, Juha/0000-0001-7096-1286	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035915, R37NS035915, R29NS035915] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS035915, R29 NS035915, NS35915, R37 NS035915] Funding Source: Medline		AITKEN PG, 1986, BRAIN RES, V369, P163, DOI 10.1016/0006-8993(86)90524-X; Amzica F, 2002, J NEUROSCI, V22, P1042, DOI 10.1523/JNEUROSCI.22-03-01042.2002; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; BALLANYI K, 1984, NEUROSCIENCE, V12, P917, DOI 10.1016/0306-4522(84)90179-9; Bordey A, 1998, EPILEPSY RES, V32, P286, DOI 10.1016/S0920-1211(98)00059-X; Brickley SG, 2001, NEUROPHARMACOLOGY, V41, P730, DOI 10.1016/S0028-3908(01)00135-6; Bruton C., 1988, NEUROPATHOLOGY TEMPO; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DIETZEL I, 1986, ANN NY ACAD SCI, V481, P72, DOI 10.1111/j.1749-6632.1986.tb27140.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FISHER RS, 1976, ARCH NEUROL-CHICAGO, V33, P76, DOI 10.1001/archneur.1976.00500020004002; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; HEINEMANN U, 1975, BRAIN RES, V93, P63, DOI 10.1016/0006-8993(75)90286-3; HELEKAR SA, 1992, DEV BRAIN RES, V65, P205, DOI 10.1016/0165-3806(92)90180-5; HERTZ L, 1978, BRAIN RES, V145, P202, DOI 10.1016/0006-8993(78)90812-0; Hinterkeuser S, 2000, EUR J NEUROSCI, V12, P2087, DOI 10.1046/j.1460-9568.2000.00104.x; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412, DOI 10.1152/jn.1996.76.4.2412; HUXLEY AF, 1951, J PHYSIOL-LONDON, V112, P496, DOI 10.1113/jphysiol.1951.sp004546; Janigro D, 1997, J NEUROSCI, V17, P2813; JEFFERYS JGR, 1995, PHYSIOL REV, V75, P689, DOI 10.1152/physrev.1995.75.4.689; JENNETT B, 1975, EPILEPSY NONMISSILE; Jones R.W., 1987, ADV PETROLEUM GEOCHE, P1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Khawaled R, 1999, PFLUG ARCH EUR J PHY, V438, P314, DOI 10.1007/s004240050915; Largo C, 1996, J NEUROSCI, V16, P1219; LOTHMAN EW, 1992, EPILEPSY RES, P301; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUX HD, 1973, EXP BRAIN RES, V17, P190; Maccaferri G, 2002, NEUROPHARMACOLOGY, V43, P523, DOI 10.1016/S0028-3908(02)00161-2; MacFarlane SN, 1997, J NEUROSCI, V17, P7316; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Masukawa L M, 1999, Adv Neurol, V79, P781; MCBAIN CJ, 1992, BRAIN RES, V592, P255, DOI 10.1016/0006-8993(92)91683-6; MCBAIN CJ, 1993, EPILEPSY MODELS MECH, P437; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MISGELD U, 1992, J NEUROPHYSIOL, V68, P1548, DOI 10.1152/jn.1992.68.5.1548; MOODY WJ, 1974, EXP NEUROL, V42, P248, DOI 10.1016/0014-4886(74)90023-5; NEWMAN EA, 1984, SCIENCE, V225, P1174, DOI 10.1126/science.6474173; Nicholson C, 2000, PROG BRAIN RES, V125, P129; Nicholson Charles, 1995, P387; NOEBELS JL, 1978, J NEUROPHYSIOL, V41, P1267, DOI 10.1152/jn.1978.41.5.1267; ONOZUKA M, 1987, BRAIN RES, V420, P259, DOI 10.1016/0006-8993(87)91246-7; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788, DOI 10.1152/jn.1966.29.4.788; PEDLEY TA, 1976, FED PROC, V35, P1254; POLLEN D A, 1970, Science (Washington D C), V167, P1252, DOI 10.1126/science.167.3922.1252; POOLOS NP, 1987, J NEUROPHYSIOL, V58, P404, DOI 10.1152/jn.1987.58.2.404; PRINCE DA, 1973, BRAIN RES, V50, P489, DOI 10.1016/0006-8993(73)90758-0; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; Rose CR, 1996, J PHYSIOL-LONDON, V491, P291, DOI 10.1113/jphysiol.1996.sp021216; Ross ST, 2001, P NATL ACAD SCI USA, V98, P8874, DOI 10.1073/pnas.141042398; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schroder W, 1999, GLIA, V28, P166, DOI 10.1002/(SICI)1098-1136(199911)28:2<166::AID-GLIA8>3.0.CO;2-T; Smirnov S, 1999, J NEUROSCI, V19, P9252; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOMJEN GG, 1985, J NEUROPHYSIOL, V53, P1098, DOI 10.1152/jn.1985.53.4.1098; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; SOMJEN GG, 1984, ELECTROPHYSIOLOGY EP, P303; STASHEFF SF, 1993, J NEUROPHYSIOL, V70, P961, DOI 10.1152/jn.1993.70.3.961; Steinhauser C, 2002, EUR J PHARMACOL, V447, P227, DOI 10.1016/S0014-2999(02)01846-0; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Toth Z, 1997, J NEUROSCI, V17, P8106; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; Voipio J., 1994, MICROELECTRODE TECHN, V2nd ed., P275; Walz W, 2000, NEUROCHEM INT, V36, P291, DOI 10.1016/S0197-0186(99)00137-0; Walz W, 1999, J NEUROSCI RES, V56, P595, DOI 10.1002/(SICI)1097-4547(19990615)56:6<595::AID-JNR5>3.3.CO;2-X; Xiong ZQ, 2000, J NEUROPHYSIOL, V83, P1443, DOI 10.1152/jn.2000.83.3.1443; Xiong ZQ, 1999, EUR J NEUROSCI, V11, P1677, DOI 10.1046/j.1460-9568.1999.00587.x; [No title captured]	74	29	29	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 2	2003	23	13					5865	5876					12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	697CF	WOS:000183924100054	12843291				2022-02-06	
J	Lee, ZI; Byun, WM; Jang, SH; Ahn, SH; Moon, HK; Chang, YM				Lee, ZI; Byun, WM; Jang, SH; Ahn, SH; Moon, HK; Chang, YM			Diffusion tensor magnetic resonance imaging of microstructural abnormalities in children with brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						diffusion tensor imaging; microstructural abnormality; pediatric; brain injury; rehabilitation	BLUNT-HEAD TRAUMA; WHITE-MATTER; MOTOR RECOVERY; MRI; ORGANIZATION; ANISOTROPY	We present two pediatric cases demonstrating that diffusion tensor imaging is more efficient at revealing microstructural abnormalities of the brain than conventional magnetic resonance imaging because it enables measurements; of the directionality and integrity of white matter fiber tracts. One patient suffered from left hemiparesis, and the other had right hemiparesis. However, whereas conventional magnetic resonance imaging showed only the findings of traumatic contusional hemorrhages in the left temporal and parietal lobes of the first patient and focal encephalomalacia in the left anterior thalamus of the second patient, diffusion tensor imaging successfully disclosed microstructural abnormalities in the right cerebral peduncle of the midbrain of the first patient and in the posterior limb of the left internal capsule of the second. Theses two cases demonstrate that diffusion tensor imaging is more capable than magnetic resonance imaging at detecting the microstructural pathologic lesions that are responsible for clinical motor weakness, especially when conventional magnetic resonance imaging has failed to detect subtle structural abnormalities.	Yeungnam Univ, Dept Phys Med & Rehabil, Sch Med, Nam Ku, Taegu 705717, South Korea; Yeungnam Univ, Dept Diagnost Radiol, Sch Med, Taegu 705717, South Korea; Yeungnam Univ, Dept Pediat, Sch Med, Taegu 705717, South Korea; Kyungpook Natl Univ, Sch Med, Dept Diagnost Radiol, Taegu 702701, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Dept Phys Med & Rehabil, Sch Med, Nam Ku, 317-1 Daemyungdong, Taegu 705717, South Korea.						Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Ciccarelli O, 2001, NEUROLOGY, V56, P926, DOI 10.1212/WNL.56.7.926; GENTRY LR, 1994, RADIOLOGY, V191, P1; Higano S, 2001, AM J NEURORADIOL, V22, P456; Huppi PS, 1998, PEDIATR RES, V44, P584; Huppi PS, 2001, PEDIATRICS, V107, P455, DOI 10.1542/peds.107.3.455; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Mamata H, 2002, AM J NEURORADIOL, V23, P67; MILLER G, 1998, CEREBRAL PALSIES CAU, P112; O'Sullivan M, 2001, NEUROLOGY, V57, P2307, DOI 10.1212/WNL.57.12.2307; Ono J, 1997, PEDIATR NEUROL, V16, P63, DOI 10.1016/S0887-8994(96)00249-4; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Shimony JS, 1998, RADIOLOGY, V209P, P240; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Wieshmann UC, 2001, J NEUROL NEUROSUR PS, V70, P521, DOI 10.1136/jnnp.70.4.521	22	29	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2003	82	7					556	559		10.1097/01.PHM.0000073830.15643.6A			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	694DC	WOS:000183757700009	12819543				2022-02-06	
J	Morgan, A; Ward, E; Murdoch, B; Kennedy, B; Murisop, R				Morgan, A; Ward, E; Murdoch, B; Kennedy, B; Murisop, R			Incidence, characteristics, and predictive factors for dysphagia after pediatric traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; dysphagia; incidence; outcomes; pediatric	HEAD-INJURY; SWALLOWING DISORDERS; HEALTH-CARE; COMPLICATIONS; CHILDREN; ADULTS; MANAGEMENT; EMERGENCY; OUTCOMES; EBM	Objective: (1) To establish an incidence figure for dysphagia in a population of pediatric traumatic brain injury (TBI) cases; (2) to provide descriptive data on the admitting characteristics, patterns of resolution, and outcomes of children with and without dysphagia after TBI; and (3) to identify any factors present at admission that may predict dysphagia. Participants: A total of 1, 145 children consecutively admitted to an acute care setting for traumatic brain injury between July 1995 and July 2000. Main outcome measure: Medical parameters relating to dysphagia based on medical chart review. Results: (1) Dysphagia incidence figure of 5.3% across all pediatric head injury admissions. Incidence figures of 68% for severe TBI, 15% for moderate TBI, and only 1% for mild brain injury. (2) Statistically significant differences were found between the dysphagic and nondysphagic subgroups on the variables of length of stay, length of ventilation, Glasgow Coma Scale (GCS), computed tomography classification, duration of speech pathology intervention, supplemental feeding duration, duration until initiation of oral intake (DIOF), duration to total oral intake (DTOF), and period of time from the initiation of intake until achievement of total oral intake (DI-TOF). (3) Significant predictive factors for dysphagia included GCS < 8.5 and a ventilation period in excess of 1.5 days. Conclusion: The provision of incidence data and predictive factors for dysphagia will enable clinicians in acute care settings to allocate resources necessary to deal with the predicted number of dysphagia cases in a pediatric population, and assist in predicting patients who are at risk for dysphagia following TBI. Early detection of patients with swallowing dysfunction will be aided by these data, in turn helping to facilitate effective medical and speech pathology intervention via assisting the reduction of medical complications such as aspiration pneumonia.	Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia		Morgan, A (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Brisbane, Qld 4072, Australia.		Ward, Elizabeth/F-9652-2010; Murdoch, Bruce E/C-1397-2012; Morgan, Angela/J-5235-2017	Ward, Elizabeth/0000-0002-2680-8978; Morgan, Angela/0000-0003-1147-7405			AITKEN M, 1990, STAT MODELLING GLIM; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ANDERSON DW, 1980, J NEUROSURG      NOV, pS11; CHAN BSH, 1989, J TRAUMA, V29, P1540, DOI 10.1097/00005373-198911000-00014; Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; Cherney LR, 1989, J HEAD TRAUMA REHAB, V4, P42; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; FORTUNE N, 1999, 15 AIHW DIS; Foster M, 2000, BRAIN INJURY, V14, P1035; Gazarian M, 2001, MED J AUSTRALIA, V174, P586, DOI 10.5694/j.1326-5377.2001.tb143444.x; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hagen C, 1981, TOP LANG DIS, V1, P73; Halper AS, 1999, J HEAD TRAUMA REHAB, V14, P486, DOI 10.1097/00001199-199910000-00009; Hauck KA, 1999, TOP GERIATR REHABIL, V15, P56; Henry P C, 1992, J Neurosci Nurs, V24, P311; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANZA DC, 1990, LARYNGOSCOPE, V100, P958; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; Little JM, 2001, MED J AUSTRALIA, V174, P641, DOI 10.5694/j.1326-5377.2001.tb143473.x; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; MCLEAN DE, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510000-00003; Mooney GH, 1997, MED J AUSTRALIA, V166, P575, DOI 10.5694/j.1326-5377.1997.tb123266.x; Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006; MORGAN AS, 1992, J NATL MED ASSOC, V84, P1019; Morgan AT, 2001, ASIA PACIFIC J SPEEC, V6, P9; Morgan T., 1894, J MORPHOL, V9, P1, DOI DOI 10.1002/JMOR.1050090102; Murgio A, 2001, CHILD NERV SYST, V17, P257, DOI 10.1007/s003810000403; Rowe LA, 1999, J HEAD TRAUMA REHAB, V14, P497, DOI 10.1097/00001199-199910000-00010; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; SHARPLES PM, 1990, BRIT MED J, V300, P89; Stoelwinder JU, 2001, MED J AUSTRALIA, V174, P644, DOI 10.5694/j.1326-5377.2001.tb143477.x; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; Tolep K, 1996, CHEST, V109, P167, DOI 10.1378/chest.109.1.167; VENABLES WN, 2001, MODERN APPL STAT S P; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Woratyla S P, 1995, Conn Med, V59, P643; YLVISAKER M, 1989, J HEAD TRAUMA REHAB, V4, P51; YORKSTON KM, 1989, J HEAD TRAUMA REHAB, V4, P52	47	29	33	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2003	18	3					239	251		10.1097/00001199-200305000-00002			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	682HM	WOS:000183085700002	12802166				2022-02-06	
J	Thatcher, RW; Biver, CJ; North, DM				Thatcher, RW; Biver, CJ; North, DM			Quantitative EEG and the Frye and Daubert standards of admissibility	CLINICAL ELECTROENCEPHALOGRAPHY			English	Article						Daubert; digital EEG; expert testimony; OEEG	TRAUMATIC BRAIN INJURY; TEST-RETEST RELIABILITY; ACADEMY-OF-NEUROLOGY; CLINICAL-NEUROPHYSIOLOGY-SOCIETY; CLOSED-HEAD INJURY; NEUROMETRIC EVALUATION; SPECTRAL PARAMETERS; BIOPHYSICAL LINKAGE; AMPLITUDE; CHILDREN	The 70-year-old Frye standards of "general acceptance" were replaced by the Supreme Court's 1993 Daubert criteria of the scientific method, which established the standards for admissibility of evidence in Federal Court. The four Daubert criteria were: 1- Hypothesis testing, 2- Estimates of error rates, 3- Peer reviewed publication and 4- General acceptance (Daubert v. Merrell Dow Pharmaceuticals, 61 U.S.L.W 4805 (U.S. June 29, 1993)). The present paper starts with the Daubert four factors and then matches them, step by step, to the scientific peer reviewed literature of quantitative EEG (QEEG) in relation to different clinical evaluations. This process shows how the peer reviewed science of the Digital EEG and the Quantitative EEG (QEEG) meet all of the Daubert standards of scientific knowledge. Furthermore, the science and technical aspects of QEEG in measuring the effects of neurological and psychiatric dysfunction also match the recent Supreme Court standards of "technical" and "other specialized" knowledge (General Electric Co v. Joiner, 1997, Kumho Tire Company, Ltd. v. Carmichael, 1999). Finally, it is shown that QEEG scientific knowledge and QEEG "technical" and "other specialized" knowledge meet the trilogy standards of the Supreme Court rulings in support of QEEG's admissibility as a clinically valid method in the evaluation of the nature and extent of neurological and psychiatric disorders.	Bay Pines VA Med Ctr, NeurolImaging Lab, Bay Pines, FL 33744 USA; Univ S Florida, Coll Med, Dept Neurol, Tampa, FL USA		Thatcher, RW (corresponding author), Bay Pines VA Med Ctr, NeurolImaging Lab, Bldg 23,Room 117, Bay Pines, FL 33744 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arruda JE, 1996, INT J PSYCHOPHYSIOL, V23, P63, DOI 10.1016/0167-8760(96)00032-3; BURGESS A, 1993, ELECTROEN CLIN NEURO, V86, P219, DOI 10.1016/0013-4694(93)90101-Z; Carmines E.G., 1979, RELIABILITY VALIDITY; CHABOT R, 1996, CLIN ELECTROENCEPHAL, V27, P36; CorsiCabrera M, 1997, ELECTROEN CLIN NEURO, V102, P248, DOI 10.1016/S0013-4694(96)95179-6; Duffy F. H., 1994, CLIN ELECTROENCEPHAL, V25, P6; ELUL R, 1969, SCIENCE, V164, P328, DOI 10.1126/science.164.3877.328; FOX SS, 1967, SCIENCE, V147, P888; FROST JD, 1966, EXP NEUROL, V14, P506, DOI 10.1016/0014-4886(66)90134-8; GASSER T, 1985, ELECTROEN CLIN NEURO, V60, P312, DOI 10.1016/0013-4694(85)90005-7; Hamilton-Bruce M A, 1991, Clin Exp Neurol, V28, P219; Harmony T, 1993, Int J Neurosci, V68, P263, DOI 10.3109/00207459308994281; HAYES WL, 1973, STAT SOC SCI; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; John E.R., 1987, HDB ELECTROENCEPHALO, P449; JOHN ER, 1972, SCIENCE, V177, P850, DOI 10.1126/science.177.4052.850; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; JOHN ER, 1980, SCIENCE, V210, P1255, DOI 10.1126/science.7434026; JOHN ER, 1983, PROG NEUROBIOL, V21, P239, DOI 10.1016/0301-0082(83)90014-X; KAISER G, 1999, FRIENDLY GUIDE WAVEL; KAYE H, 1981, INT J NEUROSCI, V13, P15, DOI 10.3109/00207458108991792; LUND TR, 1995, PSYCHOPHYSIOLOGY, V32, P66, DOI 10.1111/j.1469-8986.1995.tb03407.x; MAHLE S, 2001, DAUBERT LAW SCI EXPE; MAS F, 1993, CLIN ELECTROENCEPHAL, V24, P118, DOI 10.1177/155005949302400309; NIEDERMEYER E, 1994, ELCTROENCEPHALOGRAPH; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; POLLOCK VE, 1991, ELECTROEN CLIN NEURO, V79, P20, DOI 10.1016/0013-4694(91)90152-T; ROBINET RW, 1997, QUANTUM MECH; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; SALINSKY MC, 1991, ELECTROEN CLIN NEURO, V79, P382, DOI 10.1016/0013-4694(91)90203-G; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; THATCHER RW, 1987, SCIENCE, V236, P1110, DOI 10.1126/science.3576224; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; THATCHER RW, 1988, J NEUROTHERAPY, V2, P8; Thorndike, 1971, ED MEASUREMENT, P443, DOI DOI 10.1037/14353-009; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; von Bierbrauer A., 1993, EEG EMG Z ELEKTROENZ, V23, P151; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6; [No title captured]	48	29	30	0	6	EEG & CLINICAL NEUROSCIENCE SOC (E C N S)	WHEATON	805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA	0009-9155			CLIN ELECTROENCEPHAL	Clin. Electroencephalogr.	APR	2003	34	2					39	53		10.1177/155005940303400203			15	Engineering, Biomedical; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology	681BD	WOS:000183016000001	12784902				2022-02-06	
J	Blaha, M; Aaslid, R; Douville, CM; Correra, R; Newell, DW				Blaha, M; Aaslid, R; Douville, CM; Correra, R; Newell, DW			Cerebral blood flow and dynamic cerebral autoregulation during ethanol intoxication and hypercapnia	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						alcohol; autoregulation; cerebral blood flow; head injury; hypercapnia; transcranial Doppler ultrasonography	TRAUMATIC BRAIN INJURY; HEAD-INJURY; ALCOHOL; HUMANS; VELOCITY; DOPPLER; ABUSE	More than one-third of patients diagnosed with head injury are intoxicated with ethanol. Most clinical and animal studies have shown alcohol to have a deleterious impact in the setting of cerebrovascular trauma; however, there are also data showing neuroprotective effects in low ethanol doses. Human studies using imaging modalities suggest that small doses of alcohol produce cerebral vasodilatation and higher doses cerebral vasoconstriction. The aim of this study was to investigate the effect of ethanol intake on dynamic cerebral autoregulation and velocities in the middle cerebral arteries, and compare these changes with the effects of hypercapnia. Dynamic cerebral autoregulation and cerebral blood flow velocities were analysed before and after alcohol intake (1.1 g/kg of body weight) in six adult volunteers. Cerebral blood flow velocities in both middle cerebral arteries were monitored continuously by transcranial Doppler. A value for dynamic cerebral autoregulation was calculated from the rate of increase in middle cerebral artery velocities after a rapid-step decrease in arterial blood pressure. A sudden decrease in blood pressure was achieved by the release of previously inflated large blood pressure cuffs around the subject's thighs. Three volunteers were also tested before alcohol intake with CO2 challenge (breathing 6% CO2) during the autoregulation procedure. Blood alcohol level reached 90 mg/dl approximately 60 min after ethanol ingestion. Cerebral blood velocities increased by 8% from baseline for uncorrected end-tidal (et) CO2 and by 24% for correction to et CO2 = 40. Dynamic cerebral autoregulation measured as an autoregulation index decreased from 4.3 +/- 1.3 to 2.9 +/- 1.1 (p = 0.089), which did not reach statistical significance. During hypercapnic conditions, dynamic cerebral autoregulation dropped from 4 +/- 0.8 to 0.9 +/- 0.9. In conclusion, mild alcohol intoxication caused cerebral vasodilatation with a subsequent increase in cerebral blood flow of 8-24%. Dynamic cerebral autoregulation was not found to be significantly impaired by ethanol. Hypercapnia. almost completely destroys the physiological autoregulatory mechanism. A mild hyper-ventilation to etCO(2) = 34-36 may be a compensatory contrameasure for ethanol-induced vasodilatation in the setting of head trauma (C) 2003 Elsevier Science Ltd. All rights reserved.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA		Blaha, M (corresponding author), Royal Perth Hosp, Dept Neurosurg, Box X2213 GPO, Perth, WA 6847, Australia.			Blaha, Martin/0000-0002-9611-498X			AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BERGLUND M, 1987, ACTA PSYCHIAT SCAND, V75, P202, DOI 10.1111/j.1600-0447.1987.tb02775.x; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V7, P93; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MATHEW RJ, 1991, AM J PSYCHIAT, V148, P292; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; SANO M, 1993, J STUD ALCOHOL, V54, P369, DOI 10.15288/jsa.1993.54.369; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; TIIHONEN J, 1994, AM J PSYCHIAT, V151, P1505; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	20	29	30	0	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2003	10	2					195	198		10.1016/S0967-5868(02)00126-1			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	661EQ	WOS:000181878600011	12637048				2022-02-06	
J	Donders, J; Woodward, HR				Donders, J; Woodward, HR			Gender as a moderator of memory after traumatic brain injury in children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; gender; memory; traumatic brain injury	HEAD-INJURY; WISC-III; ADOLESCENTS; MILD; RECOVERY; SEX	Objective: To explore the possibility that gender has a moderating effect on memory after pediatric traumatic brain injury (TBI). Design: Controlled group study. Gender effects between and within groups were evaluated by means of effect size comparisons and hierarchical regression analysis. Setting: Regional rehabilitation center. Participants: Seventy children with TBI, selected from a 4-year series of consecutive referrals, and 70 demographically matched controls. Main outcome measures: Screening version of the Wide Range Assessment of Memory and Learning (WRAML-S) and the Wechsler Intelligence Scale for Children-Third Edition (WISC-III). Results: Boys with TBI performed worse than girls with TBI, and worse than their counterparts in the control group, on the WRAML-S. There was no gender effect in the control group. Gender explained an additional 9% of the variance in WRAML-S performance over and above injury severity and age variables. However, gender differences were largely attenuated when speed of information processing, as assessed by the WISC-III, was used as a covariate. Conclusion: The effect of TBI on children's memory appears to be moderated by gender and may be mediated by speed of information processing.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; Pitt Cty Mem Hosp, Greenville, NC USA		Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson VA, 2000, BRAIN INJURY, V14, P679; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; DELIS D, 1994, CALIFORNIA VERBAL LE; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; MADIGAN KA, 1997, STUDENTS ACQUIRED BR, P123; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; MURPHY KR, 1998, STAT POWER ANAL; RAZ S, 1995, DEV PSYCHOL, V31, P958, DOI 10.1037/0012-1649.31.6.958; RAZ S, 1994, PSYCHOBIOLOGY, V22, P244; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Sheslow D., 1990, WIDE RANGE ASSESSMEN; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; WABER DP, 1992, J CLIN ONCOL, V10, P810, DOI 10.1200/JCO.1992.10.5.810; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS J, 1995, DEV NEUROPSYCHOL, V11, P201, DOI 10.1080/87565649509540613; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Woodward H, 1998, APPL NEUROPSYCHOL, V5, P113, DOI 10.1207/s15324826an0503_1; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P121	39	29	30	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					106	115		10.1097/00001199-200303000-00002			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600002	12802220				2022-02-06	
J	Magnoni, S; Stocchetti, N; Colombo, G; Carlin, A; Colombo, A; Lipton, JM; Catania, A				Magnoni, S; Stocchetti, N; Colombo, G; Carlin, A; Colombo, A; Lipton, JM; Catania, A			alpha-Melanocyte-stimulating hormone is decreased in plasma of patients with acute brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; alpha-melanocyte-stimulating hormone (alpha-MSH); subarachnoid hemorrhage (SAH); traumatic brain injury (TBI); tumor necrosis factor-alpha (TNF-alpha)	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; CEREBROSPINAL-FLUID; HEAD-INJURY; RAT-BRAIN; TNF-ALPHA; CYTOKINES; ACTIVATION; PITUITARY; MSH	The neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) is a proopiomelanocortin derivative that has potent anti-inflammatory influences within the brain. The aim of the present research was to determine if there are changes in blood concentrations of this peptide in patients with acute traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Concomitantly, we recorded clinical parameters and measured blood concentrations of the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). Twenty-three patients were enrolled in this study-18 had TBI and five SAH. Blood samples for determination of alpha-MSH and TNF- a were collected daily from day 1 to day 4 after injury. Baseline concentration of plasma alpha-MSH in patients with acute brain injury of either traumatic or vascular origin was significantly lower than in controls. Patients with TBI or SAH had similar a-MSH concentrations and the peptide remained consistently low over four post-injury days. Circulating TNF-alpha on day one was measurable in all patients and there was a negative correlation between plasma TNF-alpha and alpha-MSH. alpha-MSH was measured again after the acute phase in eight patients. The peptide was substantially increased in all subjects except for two who had an unfavorable outcome. From the well-known protective anti-inflammatory influences of alpha-MSH in the host, reduction in this circulating peptide may have detrimental consequences in brain injury. The data raise the possibility that restoration of normal circulating alpha-MSH through administration of the peptide could be beneficial in patients with brain injury.	IRCCS, Osped Maggiore Milano, Dept Anesthesia & Intens Care, I-20122 Milan, Italy; IRCCS, Osped Maggiore Milano, Div Internal Med, I-20122 Milan, Italy; Zengen Inc, Woodland Hills, CA USA		Catania, A (corresponding author), IRCCS, Osped Maggiore Milano, Div Med Interna 1, Pad Granelli,Via F Sforza 35, I-20122 Milan, Italy.	anna.catania@unimi.it	Colombo, Gualtiero I./B-4737-2010; Magnoni, Sandra/AAC-7479-2022; Stocchetti, Nino/O-7444-2017	Colombo, Gualtiero I./0000-0002-7348-1939; Magnoni, Sandra/0000-0002-1723-0844; Stocchetti, Nino/0000-0003-3250-6834; Catania, Anna/0000-0002-8261-7973			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERKENBOSCH F, 1984, ENDOCRINOLOGY, V115, P1051, DOI 10.1210/endo-115-3-1051; BERTOLINI A, 1986, EUR J PHARMACOL, V130, P19, DOI 10.1016/0014-2999(86)90179-2; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; CARR JA, 1991, NEUROENDOCRINOLOGY, V54, P616, DOI 10.1159/000125968; Carrol JE, 2000, NEUROREPORT, V11, pR1; Catania A, 2000, CRIT CARE MED, V28, P1403, DOI 10.1097/00003246-200005000-00024; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; CHEN CLC, 1983, P NATL ACAD SCI-BIOL, V80, P2211, DOI 10.1073/pnas.80.8.2211; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; DELGADO HR, 1999, NEUROIMMUNOMODULAT, V6, P187; Delgado R, 1998, J LEUKOCYTE BIOL, V63, P740, DOI 10.1002/jlb.63.6.740; Dunbar JC, 2000, PEPTIDES, V21, P211, DOI 10.1016/S0196-9781(99)00192-8; Eberle A.N., 1988, MELANOTROPINS; Fassbender K, 2000, STROKE, V31, P2971, DOI 10.1161/01.STR.31.12.2971; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOLDMAN H, 1993, ANN EMERG MED, V22, P1035, DOI 10.1016/S0196-0644(05)82747-7; GOLDMAN H, 1993, J NEUROTRAUM, V10, P385, DOI 10.1089/neu.1993.10.385; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hirashima Y, 1997, NEUROCHEM RES, V22, P1249, DOI 10.1023/A:1021985030331; Huh SK, 1997, NEUROSURGERY, V40, P132, DOI 10.1097/00006123-199701000-00030; Ichiyama T, 1999, EXP NEUROL, V157, P359, DOI 10.1006/exnr.1999.7064; Ichiyama T, 1999, BRAIN RES, V836, P31, DOI 10.1016/S0006-8993(99)01584-X; JENNETT B, 1975, LANCET, V1, P480; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; KNIGGE U, 1991, ACTA ENDOCRINOL-COP, V124, P609, DOI 10.1530/acta.0.1240609; LAMACZ M, 1991, ARCH INT PHYSIOL BIO, V99, P205, DOI 10.3109/13813459109146925; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MABLEY J, 1991, EUR J PHARMACOL, V209, P127, DOI 10.1016/0014-2999(91)90023-J; MANZANARES J, 1990, NEUROENDOCRINOLOGY, V52, P200, DOI 10.1159/000125582; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mathiesen T, 1997, J NEUROSURG, V87, P215, DOI 10.3171/jns.1997.87.2.0215; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Ono S, 1998, HUM GENE THER, V9, P1003, DOI 10.1089/hum.1998.9.7-1003; Rajora N, 1997, J NEUROSCI, V17, P2181; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SAMSON WK, 1981, PEPTIDES, V2, P419, DOI 10.1016/S0196-9781(81)80098-8; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TILIGADA E, 1989, EXP BRAIN RES, V74, P645	50	29	33	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					251	260		10.1089/089771503321532833			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500003	12820679				2022-02-06	
J	Mueller, CA; Schluesener, HJ; Conrad, S; Meyermann, R; Schwab, JM				Mueller, CA; Schluesener, HJ; Conrad, S; Meyermann, R; Schwab, JM			Lesional expression of a proinflammatory and antiangiogenic cytokine EMAP II confined to endothelium and microglia/macrophages during secondary damage following experimental traumatic brain injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						EMAP II; secondary brain damage; traumatic brain injury; inflammation; antiangiogenic	ACTIVATING POLYPEPTIDE-II; TUMOR-NECROSIS-FACTOR; SPINAL-CORD; INFLAMMATORY RESPONSE; VASCULAR ARCHITECTURE; MICROGLIAL CELLS; CORTICAL IMPACT; MACROPHAGES; RAT; ENCEPHALOMYELITIS	We analyzed expression of Endothelial Monocyte-Activating Polypeptide II (EMAP II), a proinflammatory, antiangiogenic cytokine in rat brains after stab wound injury and observed a highly significant (p<0.0001) lesional accumulation confined to microglia/macrophages. Maximum numbers were seen at day 5 declining until 21 days after injury. Further, EMAP II+ microglia/macrophages formed clusters in perivascular Virchow-Robin spaces. Prolonged accumulation of EMAP II+, EDI+ microglia/macrophages and increased lesional numbers of EMAP II+ endothelial/smooth muscle cells during the acute postinjury period might indicate that EMAP II enrich the proinflammatory and antiangiogenic repertoire of effector molecules expressed by activated microglia/macrophages during secondary damage. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Tubingen, Sch Med, Inst Brain Res, D-72076 Tubingen, Germany		Mueller, CA (corresponding author), Univ Tubingen, Sch Med, Inst Brain Res, Calwerstr 2, D-72076 Tubingen, Germany.	Christian-Andreas.Mueller@med.uni-tuebingen.de		Schwab, Jan/0000-0001-6784-4919			Adelson PD, 1998, ACT NEUR S, V71, P104; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Berger AC, 2000, MICROVASC RES, V60, P70, DOI 10.1006/mvre.2000.2249; CARLOS TM, 1994, BLOOD, V84, P2068; Chang SY, 2002, J BIOL CHEM, V277, P8388, DOI 10.1074/jbc.M108792200; CHAO CC, 1992, J IMMUNOL, V149, P2736; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ESIRI MM, 1990, J NEUROL SCI, V100, P3, DOI 10.1016/0022-510X(90)90004-7; Fujita T, 1998, ACTA NEUROCHIR, V140, P275, DOI 10.1007/s007010050095; Gerlach C, 1997, LAB INVEST, V77, P697; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hsu CY, 1996, NEUROTRAUMA, P1433; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; ImperatoKalmar EL, 1997, EXP NEUROL, V145, P322, DOI 10.1006/exnr.1997.6449; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; LU X, 1991, J NEUROSCI, V11, P972; MALLAT M, 1994, J LEUKOCYTE BIOL, V56, P416, DOI 10.1002/jlb.56.3.416; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McIntosh TK, 1996, LAB INVEST, V74, P315; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; MULLIN JM, 1990, CANCER RES, V50, P2172; Murray JC, 2000, AM J PATHOL, V157, P2045, DOI 10.1016/S0002-9440(10)64843-2; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; RINK A, 1995, AM J PATHOL, V147, P1575; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; STREIT WJ, 1993, J CHEM NEUROANAT, V6, P261, DOI 10.1016/0891-0618(93)90047-8; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; TERADA LS, 1992, INFLAMMATION, V16, P13, DOI 10.1007/BF00917511; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Zheng M, 2001, AM J PATHOL, V159, P1021, DOI 10.1016/S0002-9440(10)61777-4	67	29	30	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	FEB	2003	135	1-2					1	9		10.1016/S0165-5728(02)00427-7			9	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	651XW	WOS:000181349500001	12576219				2022-02-06	
J	Skaper, SD				Skaper, S. D.			Poly(ADP-Ribosyl)ation Enzyme-1 as a Target for Neuroprotection in Acute Central Nervous System Injury	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Poly(ADP-ribose) polymerase; DNA repair; neurotoxicity; brain ischemia; neurodegeneration; neuroinflammation; neuroprotection; gene transcription		Poly(ADP-ribose) polymerase 1 (PARP-1) protects the genome by functioning in the DNA damage surveillance network. In response to stresses that are toxic to the genome, PARP-1 activity increases substantially, an event that appears crucial for maintaining genomic integrity. Massive PARP-1 activation, however, can deplete the cell of NAD+ and ATP, ultimately leading to energy failure and cell death. The discovery that cell death may be suppressed by PARP inhibitors or by deletion of the parp-1 gene has prompted a great deal of interest in the process of poly(ADP-ribosyl)ation. Suppression of PARP-1 is capable of protecting against cerebral and cardiac ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism, traumatic spinal cord injury, and streptozotocin-induced diabetes. The secondary damage of initially surviving neurons in brain stroke accounts for most of the volume of the infarcted area and the subsequent loss of brain function. Microglial migration is strongly controlled in living brain tissue by expression of the integrin CD11a, which is regulated in turn by PARP-1, proposing that PARP-1 downregulation may therefore be a promising strategy in protecting neurons from this secondary damage, as well. As PARP-1 is now recognised as playing a role also in the regulation of gene transcription, this further increases the intricacy of poly(ADP-ribosyl)ation in the control of cell homeostasis and challenges the notion that energy collapse is the sole mechanism by which poly(ADP-ribose) formation contributes to cell death. PARP(s) might regulate cell fate as essential modulators of death and survival transcriptional programs with relation to NF-kappa B and p53, proposing that inhibitors of poly(ADP-ribosyl)ation could therefore prevent the deleterious consequences of neuroinflammation by reducing NF-kappa B activity.	[Skaper, S. D.] GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, New Frontiers Sci Pk,Third Ave, Harlow CM19 5AW, Essex, England		Skaper, SD (corresponding author), GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, New Frontiers Sci Pk,Third Ave, Harlow CM19 5AW, Essex, England.	Stephen_Skaper-1@gsk.com					Abdelkarim GE, 2001, INT J MOL MED, V7, P255; ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALVAREZGONZALEZ R, 1994, MOL CELL BIOCHEM, V138, P33, DOI 10.1007/BF00928440; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; AOKI K, 1993, BIOCHIM BIOPHYS ACTA, V1158, P251, DOI 10.1016/0304-4165(93)90022-Z; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Benchoua A, 2002, J BIOL CHEM, V277, P34217, DOI 10.1074/jbc.M203941200; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; BURKART V, 1993, CLIN EXP IMMUNOL, V93, P273; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Chung KT, 1998, FOOD CHEM TOXICOL, V36, P1053, DOI 10.1016/S0278-6915(98)00086-6; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/0006-8993(96)00571-9; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dawson Ted M., 1997, P319; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Ding YC, 2001, BRAIN RES, V915, P210, DOI 10.1016/S0006-8993(01)02852-9; Drazen DL, 2001, MOL MED, V7, P761, DOI 10.1007/BF03401966; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Eguchi Y, 1997, CANCER RES, V57, P1835; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faro R, 2002, ANN THORAC SURG, V73, P575, DOI 10.1016/S0003-4975(01)03329-X; FERRO AM, 1982, J BIOL CHEM, V257, P7808; FRECHETTE A, 1985, CAN J BIOCHEM CELL B, V63, P764, DOI 10.1139/o85-096; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; Goldfarb RD, 2002, CRIT CARE MED, V30, P974, DOI 10.1097/00003246-200205000-00004; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Gross SS, 1996, TRENDS MICROBIOL, V4, P47, DOI 10.1016/0966-842X(96)81507-1; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; JOHNSON GS, 1981, BIOCHEM INT, V2, P611; Jones B, 2002, SOC NEUR ABSTR, V28; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawamura T, 1998, BIOCHEM BIOPH RES CO, V251, P35, DOI 10.1006/bbrc.1998.9403; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Komjati K, 2002, SOC NEUR ABSTR, V28; KOPIN IJ, 1988, ANNU REV NEUROSCI, V11, P81, DOI 10.1146/annurev.ne.11.030188.000501; Kroger H, 1996, INFLAMMATION, V20, P203, DOI 10.1007/BF01487406; KRUPITZA G, 1989, BIOCHEMISTRY-US, V28, P4054, DOI 10.1021/bi00435a063; KRUPITZA G, 1989, BIOCHEMISTRY-US, V28, P2034, DOI 10.1021/bi00431a011; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; Langston JW, 1996, NEUROLOGY, V47, pS153, DOI 10.1212/WNL.47.6_Suppl_3.153S; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Love S, 1998, NEUROREPORT, V9, P955, DOI 10.1097/00001756-199804200-00001; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Lu X., 2001, Society for Neuroscience Abstracts, V27, P2025; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Mabley JG, 2001, INFLAMM RES, V50, P561, DOI 10.1007/PL00000234; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Mahajan PB, 1998, PLANT PHYSIOL, V118, P895, DOI 10.1104/pp.118.3.895; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mandir AS, 2002, J NEUROCHEM, V83, P186, DOI 10.1046/j.1471-4159.2002.01144.x; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; MIWA M, 1971, J BIOL CHEM, V246, P6362; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OLEINICK NL, 1985, RADIAT RES, V101, P29, DOI 10.2307/3576301; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Parratt JR, 1997, J PHYSIOL PHARMACOL, V48, P493; Perkins E, 2001, CANCER RES, V61, P4175; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schierle GSK, 1999, NEUROREPORT, V10, P3347, DOI 10.1097/00001756-199911080-00017; Schmidt N, 2001, J NEURAL TRANSM, V108, P1263, DOI 10.1007/s007020100004; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shall S, 2001, MUTAT RES, V460, P1; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo G, 2002, CIRC RES, V90, P100, DOI 10.1161/hh0102.102657; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; TSAI YJ, 1992, J BIOL CHEM, V267, P14436; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weise J, 2001, CELL DEATH DIFFER, V8, P801, DOI 10.1038/sj.cdd.4400872; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Williams L., 1999, Society for Neuroscience Abstracts, V25, P1061; Williams L.R, 2002, SOC NEUR ABSTR, V28; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; Yang ZQ, 2000, SHOCK, V13, P60, DOI 10.1097/00024382-200013010-00011; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2000, NEUROREPORT, V11, P1385, DOI 10.1097/00001756-200005150-00007; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; Youdim MBH, 1997, SCI AM, V276, P52, DOI 10.1038/scientificamerican0197-52; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang J, 2000, BIOCHEM BIOPH RES CO, V278, P590, DOI 10.1006/bbrc.2000.3816; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	180	29	29	0	1	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2003	2	5					279	291		10.2174/1568007033482733			13	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5WW	WOS:000497810300001	14529360				2022-02-06	
J	Armstead, WM				Armstead, WM			Age dependent NMDA contribution to impaired hypotensive cerebral hemodynamics following brain injury	DEVELOPMENTAL BRAIN RESEARCH			English	Article						newborn; cerebral circulation; excitatory amino acid	SUPEROXIDE GENERATION CONTRIBUTES; CHANNEL FUNCTION IMPAIRMENT; NOC/OFQ-INDUCED IMPAIRMENT; HEAD-INJURY; BLOOD-FLOW; CEREBROVASODILATION; RAT; VASOPRESSIN; ENDOTHELIN; RESPONSES	Previous studies have observed that fluid percussion brain injury (FPI) impaired NMDA induced pial artery dilation (PAD) in an age dependent manner. Unrelated studies observed a similar age dependent impairment of hypotensive cerebral autoregulation after FPI. This study was designed to test the hypothesis that NMDA receptor activation contributes to impairment of cerebral autoregulation during hypotension after FPI in an age dependent manner. Therefore, the role of NMDA in impaired hypotensive cerebrovascular regulation after FPI was compared in newborn and juvenile pigs equipped with a closed cranial window. Ten minutes of hypotension (10-15 ml blood/kg) decreased mean arterial blood pressure uniformly in both groups (approximate to44%). In the newborn, hypotensive PAD was blunted within 1 h of FPI but partially protected by pretreatment with the NMDA antagonist MK801 (1 mg/kg i.v.) (34+/-1 vs. 8+/-1 vs. 25+/-2% for sham control, FPI, and FPI-MK801, respectively). Cerebral blood flow (CBF) was reduced during normotension by FPI, further reduced by hypotension, but both were partially protected by MK801 in the newborn (56+/-5, 35+/-2, and 16+/-1 vs. 62+/-6, 45+/-3, and 30+/-2 ml/min 100 g for normotension, nonnotension-FPI, and hypotension-FPI in the absence and presence of MK801, respectively). In contrast, blunted hypotensive PAD was protected significantly less by MK801 in the juvenile (32+/-2 vs. 7+/-2 vs. 16+/-2% for sham control, FPI, and FPI-MK801, respectively). Similarly, MK801 had less protective effect on normotensive and hypotensive CBF values post FPI in the juvenile. These data indicate that NMDA receptor activation contributes to impaired hypotensive cerebral hemodynamics following brain injury in an age dependent manner. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA		Armstead, WM (corresponding author), Univ Penn, Dept Anesthesia, 3400 Spruce St, Philadelphia, PA 19104 USA.						Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Armstead WM, 2000, AM J PHYSIOL-HEART C, V279, pH2188, DOI 10.1152/ajpheart.2000.279.5.H2188; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Armstead WM, 2001, PEPTIDES, V22, P39, DOI 10.1016/S0196-9781(00)00354-5; Armstead WM, 2001, J NEUROTRAUM, V18, P615, DOI 10.1089/089771501750291855; Armstead WM, 2001, BRAIN RES, V910, P19, DOI 10.1016/S0006-8993(01)02716-0; Armstead WM, 2001, STROKE, V32, P1408, DOI 10.1161/01.STR.32.6.1408; Armstead WM, 2001, J NEUROTRAUM, V18, P1039, DOI 10.1089/08977150152693737; ARMSTEAD WM, 1999, AM J PHYSIOL, V274, pH1888; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Dobbing J., 1981, SCI F PAEDIATRICS, P744; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kulkarni M, 2000, STROKE, V31, P1990, DOI 10.1161/01.STR.31.8.1990; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MERCHANT RE, 1999, ANN NY ACAD SCI, V890, P41; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; Smith SL, 1998, J NEUROTRAUM, V15, P693, DOI 10.1089/neu.1998.15.693; Tepas J J 3rd, 1995, Semin Pediatr Surg, V4, P120; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	31	29	29	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-3806			DEV BRAIN RES	Dev. Brain Res.	NOV 15	2002	139	1					19	28	PII S0165-3806(02)00511-4	10.1016/S0165-3806(02)00511-4			10	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	618LV	WOS:000179420300003	12414090				2022-02-06	
J	Akasu, T; Muraoka, N; Hasuo, H				Akasu, T; Muraoka, N; Hasuo, H			Hyperexcitability of hippocampal CA1 neurons after fluid percussion injury of the rat cerebral cortex	NEUROSCIENCE LETTERS			English	Article						rat brain; fluid percussion injury; hippocampal CA1; optical recording; field potential; memory dysfunction; post-traumatic seizure	TRAUMATIC BRAIN INJURY; PATHWAY; MODEL	Effects of fluid percussion injury (FPI) of the parietal cerebral cortex on the neuronal activity in the temporal region of the rat hippocampal CA1 area were investigated by using optical and extracellular recording techniques. Application of moderate impact (1.5-2.0 atm) to the parietal cerebral cortex enhanced the optical signal of the neuronal activity in the ipsilateral hippocampal CA1 area. The field potential evoked by the Schaffer collaterals had multiple population spikes in the ipsilateral hippocampal CA1 pyramidal cell layer. Bicuculline (15 muM) increased the amplitude and the number of population spikes of the field potential even after the brain injury. These results suggest that FPI produces hyperexcitability of hippocampal CA1 neurons, probably by increasing the activity of the Schaffer collaterals of hippocampal CA3 neurons. (C) 2002 Published by Elsevier Science Ireland Ltd.	Kurume Univ, Sch Med, Dept Physiol, Kurume, Fukuoka 8300011, Japan; Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan		Akasu, T (corresponding author), Kurume Univ, Sch Med, Dept Physiol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.						Amaral D. G., 1987, HDB PHYSL NERVOUS SY, VV, P211; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bruton C., 1988, NEUROPATHOLOGY TEMPO; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Hasuo H, 2001, NEUROSCI RES, V40, P265, DOI 10.1016/S0168-0102(01)00235-8; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nakagami Y, 1997, NEUROSCIENCE, V81, P1, DOI 10.1016/S0306-4522(97)00161-9; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; Takeya M, 2002, NEUROSCI RES, V42, P175, DOI 10.1016/S0168-0102(01)00317-0; Toth Z, 1997, J NEUROSCI, V17, P8106	16	29	31	0	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	SEP 6	2002	329	3					305	308	PII S0304-3940(02)00707-3	10.1016/S0304-3940(02)00707-3			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	595JA	WOS:000178104400014	12183037				2022-02-06	
J	Glenn, MB; Burke, DT; O'Neil-Pirozzi, T; Goldstein, R; Jacob, L; Kettell, J				Glenn, MB; Burke, DT; O'Neil-Pirozzi, T; Goldstein, R; Jacob, L; Kettell, J			Cutoff score on the apathy evaluation scale in subjects with traumatic brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; DISABILITY RATING-SCALE; RELIABILITY; DEPRESSION; VALIDITY; RECOVERY	This cross-sectional study was designed to determine a cutoff score on the Apathy Evaluation Scale (AES) that predicts a clinician's designation of a subject with TBI as apathetic or not. Forty-five outpatients with TBI completed the AES-S, and 37 family members, friends, or significant others filled out the AES-I. Three clinicians prospectively gave their impressions of the presence or absence of apathy and retrospectively chose the degree of apathy on a 7-point subjective rating scale. The data was analysed by logistic regression and Receiver Operating Characteristic (ROC) curve. Sensitivity and specificity were calculated. No cutoff score on the AES-S or AES-I was found to have reasonable sensitivity and specificity with respect to the ability to predict the clinician's designation of a subject as apathetic. The AES requires further study if it is to be used to measure apathy following TBI.	Spaulding Rehabil Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; Northeastern Univ, Sect Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA; Hebrew Rehabil Ctr Aged, Boston, MA 02131 USA		Glenn, MB (corresponding author), Spaulding Rehabil Hosp, 125 Nashua St, Boston, MA 02114 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980034-00] Funding Source: Medline		Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; COREY MR, 1987, COGNITIVE REHABILITA, V5, P28; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; LAVECCHIO FA, 1996, FINAL REPORT MASSACH; Marin, 1996, Semin Clin Neuropsychiatry, V1, P304; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Murphy KJ., 2000, NEUROPSYCHOLOGY EMOT, P340; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Okada K, 1997, STROKE, V28, P2437, DOI 10.1161/01.STR.28.12.2437; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21	17	29	31	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2002	16	6					509	516		10.1080/02699050110119132			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	569RK	WOS:000176615800005	12119086				2022-02-06	
J	Rose, ME; Huerbin, MB; Melick, J; Marion, DW; Palmer, AM; Schiding, JK; Kochanek, PM; Graham, SH				Rose, ME; Huerbin, MB; Melick, J; Marion, DW; Palmer, AM; Schiding, JK; Kochanek, PM; Graham, SH			Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury	BRAIN RESEARCH			English	Article						brain microdialysis; glucose; glutamate; traumatic brain injury	TRAUMATIC BRAIN INJURY; HUMAN HEAD-INJURY; GLUTAMATE RELEASE; RAT; BW619C89; DAMAGE; ANTAGONISTS; LAMOTRIGINE; ASPARTATE; MECHANISM	Increases in brain interstitial excitatory amino acid (EAA(1)) concentrations after ischemia are ameliorated by use-dependent Na+ channel antagonists and by supplementing interstitial glucose, but the regulation of EAA, after traumatic brain injury (TBI) is unknown. We studied the regulation of EAA, after TBI using the controlled cortical impact model in rats. To monitor changes in EAA,. microdialysis probes were placed in the cortex adjacent to the contusion and in the ipsilateral hippocampus. Significant increases in dialysate EAA, after TBI were found compared to levels measured in sham controls. Treatment with the use-dependent Na+ channel antagonist 619C89 (30 mg/kg i.v.) did not significantly decrease dialysate glutamate compared to vehicle controls in hippocampus (10.4 +/- 2.4 vs. 11.9 +/- 1.6 muM), but there was significant decrease in dialysate glutamate in cortex after 619C89 treatment (19.3 +/- 3 vs. 12.6 +/- 1.1 muM P < 0.05). Addition of 30 mM glucose to the dialysate, a treatment that decreases EAA, after ischemia, had no significant effect upon dialysate glutamate after TBI in cortex (20.0 +/- 4.9 vs. 11.7 +/- 3.4 muM) or in hippocampus ( 10.9 +/- 2.0 vs. 8.9 +/- 2.4 muM). These results suggest that neither increased release of EAAs due to Na+ channel-mediated depolarization nor failure of glutamate reuptake due to glucose deprivation can explain the majority of the increase in EAA, following TBI. (C) 2002 Published by Elsevier Science B.V.	VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15240 USA; Cerebus Ltd, Wokingham, England; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA		Graham, SH (corresponding author), VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15240 USA.	sgra@pitt.edu	Palmer, Alan/AAP-8650-2020; Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS 30318] Funding Source: Medline		Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHOI DW, 1987, J NEUROSCI, V7, P357; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; EDWARDS MD, 1994, ANESTHESIOLOGY, V81, pA857; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; Hayes C., 1989, ARBOVIRUSES EPIDEMIO, VV, P59; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; RATAUD J, 1994, NEUROSCI LETT, V172, P19, DOI 10.1016/0304-3940(94)90652-1; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH SE, 1993, NEUROREPORT, V4, P1339, DOI 10.1097/00001756-199309150-00013; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SWANSON RA, 1992, NEUROSCI LETT, V147, P143, DOI 10.1016/0304-3940(92)90580-Z; SWANSON RA, 1994, J CEREBR BLOOD F MET, V14, P1; SWANSON RA, 1994, BRAIN RES, V664, P94, DOI 10.1016/0006-8993(94)91958-5; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; Zauner A, 1996, ACT NEUR S, V67, P40	27	29	32	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 10	2002	935	1-2					40	46	PII S0006-8993(02)02445-9	10.1016/S0006-8993(02)02445-9			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	555PN	WOS:000175802600006	12062471	Green Submitted			2022-02-06	
J	Martin, RCG; Spain, DA; Richardson, JD				Martin, RCG; Spain, DA; Richardson, JD			Do facial fractures protect the brain or are they a marker for severe head injury?	AMERICAN SURGEON			English	Article							REHABILITATION	Facial fractures (FF) have been suggested to protect the brain from severe injury. However, others have stated that facial fractures are a marker for increased risk of brain injury. The aim of this study is to evaluate the association between facial fractures, brain injury, and functional outcome. A retrospective review of our prospective trauma database was performed for blunt trauma patients during a 7-year period (January 1993 through December 1999) at the University of Louisville Hospital. We identified 7324 blunt trauma patients at a Level 1 trauma center. Severity of head injury in patients with and without FF was compared. The severity of brain injury was evaluated by admission Glasgow Coma Score (GCS) as well as specific head, neck, cervical spine, and face Acute Injury Score (AIS). Length of intensive care unit (ICU) stay, hospital stay, and Functional Independence Measures (FIM) score were also identified. A total of 1068 (14.6%) patients were diagnosed with FF; of these 848 (79.4%) patients suffered some form of brain injury by CT abnormality, clinical examination, or both. A total of 2192 patients were treated for head injury without FF; 220 patients were treated for FF without head injury. FF with traumatic brain injury (TBI) were found to occur significantly greater than FFs without TBI (P < 0.001). The mean GCS on admission for FF with head injury was 12, which was similar to that of patients with head injury alone with a GCS of 10 but was significantly less than that of patients with FF alone with a GCS of 15 (P < 0.05). Injury Severity Score for patients with FF and head injury was significantly worse compared with patients with head injury alone and those with FF alone (P < 0.0001). Mean ICU stay and hospital stay were similar for all three groups (ranges 3-6 and 6-12 days); and were not significant (P < 0.06). FIM score was significantly lower for patients with FF and head injury compared with FF alone (P = 0.0003) and similar to that of patients with head injury. FF were found to have a significantly greater incidence of TBI. FF with TBI had a similar severity of head injury when compared with patients with head injury alone by demonstrating similar GCS, AIS of the head and neck, and early functional recovery. This analysis does not support the hypothesis that the face provides a protective effect for the brain and therefore leading to a more favorable short-term outcome. Thus patients with facial fractures should be treated with the same caution as patients with significant blunt head trauma.	Univ Louisville, Dept Surg, Louisville, KY 40292 USA; Univ Louisville Hosp, Trauma Inst, Louisville, KY USA		Martin, RCG (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.						ADEKEYE EO, 1980, ORAL SURG ORAL MED O, V49, P491, DOI 10.1016/0030-4220(80)90068-7; CHESNUT R, 1999, EVIDENCE REPORT REHA, P1; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; HAUG RH, 1992, J ORAL MAXILLOFAC SU, V530, P218; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MORGAN B D G, 1972, British Journal of Plastic Surgery, V25, P147, DOI 10.1016/S0007-1226(72)80037-7; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; Plaisier BR, 2000, J ORAL MAXIL SURG, V58, P708, DOI 10.1053/joms.2000.7250; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SINCLAIR D, 1988, Journal of Emergency Medicine, V6, P109, DOI 10.1016/0736-4679(88)90148-5; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0	17	29	31	0	0	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	MAY	2002	68	5					477	481					5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	549ER	WOS:000175432000017	12017150				2022-02-06	
J	Lambert, G; Naredi, S; Eden, E; Rydenhag, B; Friberg, P				Lambert, G; Naredi, S; Eden, E; Rydenhag, B; Friberg, P			Sympathetic nervous activation following subarachnoid hemorrhage: Influence of intravenous clonidine	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						alpha-adrenoreceptors; human; norepinephrine; spillover	INJURY; NORADRENALINE; PLASMA; EDEMA; CATECHOLAMINES; THERAPY; HUMANS	Background: Subarachnoid hemorrhage is often accompanied by systemic complications and cerebral vasospasm. Elevated levels of circulating catecholamines may be involved in the pathophysiology behind these events. The alpha-2-agonist clonidine inhibits sympathetic outflow by a central mechanism. Unrestricted sympathoexcitation may be detrimental and administration of clonidine may be beneficial in these patients. Methods: Using isotope dilution methodology, norepinephrine kinetic determinations, comprising determination of arterial norepinephrine concentration and rates of norepinephrine spillover to and removal, or clearance, from plasma, were performed on three occasions during the first week after subarachnoid hemorrhage in 25 patients. Eleven of these patients received clonidine (continuous iv. infusion 5.8 +/- 0.7 mug.k(-1).24h(-1)) and the remainder, standard therapy. Initial results were compared with 17 healthy age-matched subjects and eight patients suffering from severe traumatic brain injury without traumatic subarachnoid hemorrhage. Results; Subarachnoid hemorrhage patients exhibited markedly elevated arterial plasma norepinephrine concentrations [3.74+/-0.48, P<0.001 vs. healthy subjects (1.59+/-0.11nmol/L) and P<0.05 vs. head trauma patients (1.94+/-0.29umol/L)]. The rate of clearance of norepinephrine from plasma in the subarachnoid patients was also significantly greater than that observed in the healthy subjects (2.66+/-0.15 vs. 2.14+/-0.15L/ min, P < 0.05) and the head trauma patients (2.00+/-0.12L/min, P<0.05). Compared with both control groups, on admission the rate of spillover of norepinephrine to plasma following subarachnoid hemorrhage was markedly elevated (9.11+/-1.12, P<0.001). Clonidine treatment (continuous ix. infusion 5.8 0.7mug.kg(-1)-24h(-1)) did not reduce the increased rate of spillover of norepinephrine to plasma following subarachnoid hemorrhage. Conclusion: Sympathetic nervous activity is markedly elevated following subarachnoid bleeding. Clonidine had no effect on the rate of norepinephrine spillover to, or clearance from, plasma in these patients. Clearly, further studies are required to elucidate the mechanisms responsible for generating sympathetic nervous activation following subarachnoid hemorrhage.	Sahlgrenska Univ Hosp, Dept Clin Physiol, Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Neurosci, Dept Neurosurg, Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Surg Sci, Dept Anesthesia & Intens Care, Gothenburg, Sweden; Univ Umea Hosp, Inst Surg & Perioperat Sci, Dept Anesthesia & Intens Care, Umea, Sweden		Lambert, G (corresponding author), Baker Med Res Inst, POB 6492 St Kilda Rd Central, Melbourne, Vic 8008, Australia.		Lambert, Gavin/Q-4869-2017; Lambert, Gavin W/E-7384-2010	Lambert, Gavin/0000-0003-0315-645X; Lambert, Gavin W/0000-0003-0315-645X; Naredi, Silvana/0000-0002-4409-6089			ANDREOLI A, 1987, STROKE, V18, P558, DOI 10.1161/01.STR.18.3.558; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; CRUICKSHANK JM, 1974, BRIT HEART J, V36, P697; ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0; ESLER M, 1990, PHYSIOL REV, V70, P963, DOI 10.1152/physrev.1990.70.4.963; FAULER J, 1993, EUR J CLIN PHARMACOL, V45, P165, DOI 10.1007/BF00315500; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; Horowitz MB, 1998, ACTA NEUROCHIR, V140, P87, DOI 10.1007/s007010050063; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; KIRNO K, 1993, ANESTHESIOLOGY, V78, P1021, DOI 10.1097/00000542-199306000-00003; KULKA PJ, 1995, ANESTH ANALG, V80, P263, DOI 10.1097/00000539-199502000-00011; Lambert E, 2000, CARDIOVASC RES, V45, P1046, DOI 10.1016/S0008-6363(99)00416-2; Lambert GW, 1998, ACTA PHYSIOL SCAND, V163, P155; LOBATO RD, 1980, J NEUROSURG, V53, P480, DOI 10.3171/jns.1980.53.4.0480; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; MAYER SA, 1994, NEUROLOGY, V44, P815, DOI 10.1212/WNL.44.5.815; MEDVEDEV OS, 1990, N-S ARCH PHARMACOL, V341, P192; MEYER JS, 1973, BRAIN, V96, P277, DOI 10.1093/brain/96.2.277; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; Reid J L, 1995, Ann N Y Acad Sci, V763, P673, DOI 10.1111/j.1749-6632.1995.tb32461.x; REID JL, 1981, BRIT J CLIN PHARMACO, V12, P295, DOI 10.1111/j.1365-2125.1981.tb01217.x	25	29	30	0	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	2002	46	2					160	165		10.1034/j.1399-6576.2002.460206.x			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	533VA	WOS:000174549900006	11942863				2022-02-06	
J	Nandoe, RDS; Scheltens, P; Eikelenboom, P				Nandoe, Rishi D. S.; Scheltens, Philip; Eikelenboom, Piet			Head trauma and Alzheimer's disease A case report and review of the literature	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; head trauma; inflammation; atrophy; cholinesterase inhibitors; ApoE; amyloid		The authors describe a case of a 55 year old woman who was diagnosed with Alzheimer's disease 1.5 years after a car accident in which she experienced a mild concussion. Extensive history taking disclosed no cognitive changes prior to the car accident. The case is discussed in view of the inflammation hypothesis regarding Alzheimer's disease and the role of the apolipoprotein E4 genotype of the patient.	[Nandoe, Rishi D. S.; Scheltens, Philip] Vrije Univ, Dept Neurol, Med Ctr, POB 7057, NL-1007 MB Amsterdam, Netherlands; [Eikelenboom, Piet] Vrije Univ, Dept Psychiat, Med Ctr, Amsterdam, Netherlands		Scheltens, P (corresponding author), Vrije Univ, Dept Neurol, Med Ctr, POB 7057, NL-1007 MB Amsterdam, Netherlands.	p.scheltens@vumc.nl	Eikelenboom, Piet/AAF-6359-2020; Scheltens, Philip/AAL-9631-2020	Scheltens, Philip/0000-0002-1046-6408			ABRAHAM CR, 1989, BIO-TECHNOL, V7, P147, DOI 10.1038/nbt0289-147; ABRAHAM CR, 1992, RES IMMUNOL, V143, P631, DOI 10.1016/0923-2494(92)80047-O; ALLSOP D, 1986, NEUROSCI LETT, V68, P252, DOI 10.1016/0304-3940(86)90152-7; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; Blain H., 1998, PRESSE MED, V15, P725; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GENTLEMAN SM, 1989, HISTOCHEMISTRY, V92, P355, DOI 10.1007/BF00500553; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Graham D.I., ACTA NEUROCHIR S, V73, P89; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Jorm A.F., MED J AUST, V167, P443; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MENDEZ MF, 1992, NEUROLOGY, V42, P770, DOI 10.1212/WNL.42.4.770; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Pasquier F, 1997, J NEUROL, V244, P135, DOI 10.1007/s004150050064; Perez M, 2002, EUR J BIOCHEM, V269, P1484, DOI 10.1046/j.1432-1033.2002.02794.x; PERRY G, 1998, PROGR HPLC, V7, P93; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; TARDIFF B, 1994, CIRCULATION, V90, P201; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tokuda T, 1993, No To Shinkei, V45, P1109; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478; vanMuiswinkel FL, 1996, J NEUROCHEM, V66, P2468	37	29	30	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2002	4	4					303	308		10.3233/JAD-2002-4405			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VI5JU	WOS:000493366100005	12446932				2022-02-06	
J	Gorgulu, AK; Palaoglu, S; Ismailoglu, O; Tuncel, M; Surucu, MT; Erbil, M; Kilinc, K				Gorgulu, AK; Palaoglu, S; Ismailoglu, O; Tuncel, M; Surucu, MT; Erbil, M; Kilinc, K			Effect of melatonin on cerebral edema in rats	NEUROSURGERY			English	Article						cold injury; edema; melatonin	TRAUMATIC BRAIN-INJURY; OXYGEN-FREE-RADICALS; NITRIC-OXIDE; NEUROHORMONE MELATONIN; SCAVENGING ACTIVITY; ANTIOXIDANT; SUPEROXIDE; DAMAGE; CELL; PEROXYNITRITE	OBJECTIVE: Melatonin (5-methoxy-N-acetyltrypamine), a chemical naturally produced in the pineal gland, has been suggested to be a free radical scavenger and an antioxidant. In the present study, the effect of melatonin on cold-induced brain edema was evaluated by determination of cerebral water content, blood-brain barrier permeability, and areas of infarct; the effects were also studied histopathologically. METHODS: Brain edema was produced in rats by creating a lesion via cortical freezing. Animals were separated into four groups: sham-operated (craniectomy only); control (cold injury); sham-vehicle (cold injury plus saline); and melatonin treatment (cold injury plus melatonin). Melatonin was administered (50 mg/kg intraperitoneally) 15 minutes after the cold injury was induced. Twenty-four hours later, tissue samples from the core, from the periphery of the cold-injured hemisphere, and from the contralateral hemisphere symmetrical to the cold injury were obtained. RESULTS: Melatonin treatment reduced edema (mean +/- standard deviation; 86.22 +/- 1.54% in the control group versus 80.78 +/- 2.76% in the melatonin treatment group, P < 0.001) and blood-brain barrier permeability (45.34 +/- 2.75% in the control group versus 38.26 +/- 3.40% in the melatonin treatment group, P < 0.001) at the periphery of cold injury. Area of infarct reduced from 5.84 +/- 0.58% in the control group to 3.30 +/- 0.89% in the melatonin treatment group (P < 0.001). The effect of melatonin was also confirmed histopathologically. CONCLUSION: Melatonin was found to be neuroprotective in instances of cold-induced brain edema. Thus, melatonin may be a valuable therapeutic agent in the treatment of cerebral edema.	Trakya Univ, Tip Fak, Sch Med, Dept Neurosurg, TR-22030 Edirne, Turkey; Hacettepe Univ, Sch Med, Dept Neurosurg, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Anat, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Physiol, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biochem, TR-06100 Ankara, Turkey		Gorgulu, AK (corresponding author), Trakya Univ, Tip Fak, Sch Med, Dept Neurosurg, TR-22030 Edirne, Turkey.	askingorgulu@hotmail.com	Tuncer, Meltem/E-9982-2013; Gorgulu, Ahmet Orhan/W-1964-2018; Hayran, Murvet/H-5747-2013	Tuncer, Meltem/0000-0003-0341-7277; Hayran, Murvet/0000-0001-6058-6304			Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; CHAN PH, 1984, FED PROC, V43, P210; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; DEMURA N, 1995, NEUROSCI LETT, V192, P109, DOI 10.1016/0304-3940(95)11629-B; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; Houkin Kiyohiro, 1996, Neurologia Medico-Chirurgica, V36, P72, DOI 10.2176/nmc.36.72; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1994, ACTA NEUROCHIR, P136; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; KIRKALI Z, 1995, J UROLOGY, V154, P1939, DOI 10.1016/S0022-5347(01)66830-7; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KUWASHIMA J, 1976, BRAIN RES, V110, P547, DOI 10.1016/0006-8993(76)90865-9; LEHOUX S, 1992, BRIT J PHARMACOL, V107, P996, DOI 10.1111/j.1476-5381.1992.tb13397.x; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; PALAOGLU S, 1994, ACTA NEUROCHIR, V128, P1, DOI 10.1007/BF01400645; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PIERREFICHE G, 1995, EXP GERONTOL, V30, P213, DOI 10.1016/0531-5565(94)00036-3; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x; Reiter RJ, 1997, ANN NY ACAD SCI, V825, P70, DOI 10.1111/j.1749-6632.1997.tb48415.x; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; Reiter RJ, 1996, EUR J ENDOCRINOL, V134, P412, DOI 10.1530/eje.0.1340412; SELTZER A, 1992, ENDOCRINOLOGY, V130, P1896, DOI 10.1210/en.130.4.1896; TASDEMIR O, 1993, ANN THORAC SURG, V56, P305; TOMINAGA T, 1995, CENTRAL NERVOUS SYST, P85; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807	40	29	30	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2001	49	6					1434	1441					8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	497UU	WOS:000172474500036	11846944				2022-02-06	
J	Moritz, CH; Rowley, HA; Haughton, VM; Swartz, KR; Jones, J; Badie, B				Moritz, CH; Rowley, HA; Haughton, VM; Swartz, KR; Jones, J; Badie, B			Functional MR imaging assessment of a non-responsive brain injured patient	MAGNETIC RESONANCE IMAGING			English	Article						electroencephalogram; evoked potential; magnetic resonance imaging; traumatic brain injury; fMRI	DEATH	Functional magnetic resonance imaging (fMRI) was requested to assist in the evaluation of a comatose 38-year-old woman who had sustained multiple cerebral contusions from a motor vehicle accident. Previous electrophysiologic studies suggested absence of thalamocortical processing in response to median nerve stimulation. Whole-brain fMRI was performed utilizing visual, somatosensory, and auditory stimulation paradigms. Results demonstrated intact task-correlated sensory and cognitive blood oxygen level dependent (BOLD) hemodynamic response to stimuli. Electrodiagnostic studies were repeated and evoked potentials indicated supratentorial recovery in the cerebrum. At 3-months post trauma the patient had recovered many cognitive & sensorimotor functions, accurately reflecting the prognostic fMRI evaluation. These results indicate that fMRI examinations may provide a useful evaluation for brain function in non-responsive brain trauma patients. (C) 2001 Elsevier Science Inc. All rights reserved.	Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol Surg, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA		Moritz, CH (corresponding author), Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA.		Moritz, Chad/A-9298-2009	Moritz, Chad/0000-0002-9985-1176			BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Ishii K, 1996, AM J NEURORADIOL, V17, P731; JONES KM, 1992, AM J NEURORADIOL, V13, P65; Lovblad KO, 2000, STROKE, V31, P539, DOI 10.1161/01.STR.31.2.539; Lowe MJ, 1999, J COMPUT ASSIST TOMO, V23, P463, DOI 10.1097/00004728-199905000-00025; OGAWA S, 1990, P NATL ACAD SCI USA, V97, P9860; ORRISON WW, 1994, AM J NEURORADIOL, V15, P913; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1003, DOI 10.1212/WNL.45.5.1003	9	29	31	0	2	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0730-725X			MAGN RESON IMAGING	Magn. Reson. Imaging	OCT	2001	19	8					1129	1132		10.1016/S0730-725X(01)00432-5			4	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	494XW	WOS:000172312000011	11711238				2022-02-06	
J	Petrov, T; Underwood, BD; Braun, B; Alousi, SS; Rafols, JA				Petrov, T; Underwood, BD; Braun, B; Alousi, SS; Rafols, JA			Upregulation of iNOS expression and phosphorylation of eIF-2 alpha are paralleled by suppression of protein synthesis in rat hypothalamus in a closed head trauma model	JOURNAL OF NEUROTRAUMA			English	Article						eIF-2 alpha(P) protein; iNOS mRNA; phosphorylation; PVN; SON	NITRIC-OXIDE SYNTHASE; BRAIN INJURY; MESSENGER-RNA; PARAVENTRICULAR NUCLEUS; TRANSLATIONAL CONTROL; SUPRAOPTIC NUCLEUS; NADPH-DIAPHORASE; SPINAL-CORD; NEURONS; INITIATION	When the inducible form of nitric oxide synthase (iNOS) is expressed after challenge to the nervous system, it results in abnormally high concentrations of nitric oxide (NO). Under such conditions, NO could phosphorylate the eukaryotic translation initiation factor (eIF)-2(alpha), thus suppressing protein synthesis in neurons that play a role in endocrine and autonomic functions. Using the Marmarou model of traumatic brain injury (TBI), we observed a rapid increase (at 4 h after TBI) of iNOS mRNA in magno- and parvocellular supraoptic and paraventricular neurons, declining gradually by similar to 30% at 24 h and by similar to 80% at 48 h. Western analysis indicated a trend towards increased iNOS protein synthesis at 4 h, which peaked at 8 h, and tended to decrease at the later time points. At the same time points, we detected immunocytochemically the phosphorylated form of eIF-2 alpha (eIF-2 alpha [P]) as cytoplasmic and more often as nuclear labeling. The incidence of double-labeled [iNOS and eIF-2 alpha (P)] neuronal profiles, particularly at 24 h and 48 h after TBI, was high. De novo protein synthesis assessed quantitatively after infusion of S-35 methionine/cysteine was reduced by similar to 20% at 4 h, remained depressed at 24 h, and did not return to control levels up to 48 h following the trauma. The results suggest that MOS may trigger phosphorylation of eIF-2 alpha, which in turn interferes with protein synthesis at the translational (ribosomal complex) and transcriptional (chromatin) levels. The depression in protein synthesis may include downregulation of iNOS itself, which could be an autoregulatory inhibitory feedback mechanism for NO synthesis. Excessive amounts of NO may also participate in dysfunction of hypothalamic circuits that underlie endocrine and autonomic alterations following TBI.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Emergency Med Neurol Surg, Detroit, MI 48202 USA		Petrov, T (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48202 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline		ASSUREY J, 1992, BRIT J PHARMACOL, V108, P833; Atkins CM, 1999, J NEUROSCI, V19, P7241, DOI 10.1523/JNEUROSCI.19-17-07241.1999; BENARROCH EE, 1993, MAYO CLIN PROC, V68, P988, DOI 10.1016/S0025-6196(12)62272-1; Bethea JR, 1998, J NEUROSCI, V18, P3251; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CAVERNER D, 2000, TRANSLATION CONTROL, P66; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Della Corte F, 1998, CRIT CARE MED, V26, P1419; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Goldstein EN, 1999, ACTA NEUROPATHOL, V98, P493, DOI 10.1007/s004010051115; Harada S, 1999, BRAIN RES, V821, P322, DOI 10.1016/S0006-8993(99)01124-5; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Ikonomov OC, 2000, DEV BRAIN RES, V123, P13, DOI 10.1016/S0165-3806(00)00074-2; Jacobs RA, 1997, MOL BRAIN RES, V49, P238, DOI 10.1016/S0169-328X(97)00150-2; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jhamandas JH, 1996, NEUROREPORT, V7, P2843, DOI 10.1097/00001756-199611250-00006; JHAMANDAS JH, 1989, J COMP NEUROL, V282, P15, DOI 10.1002/cne.902820103; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Kishimoto J, 1996, BRAIN RES, V720, P159, DOI 10.1016/0006-8993(96)00101-1; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; Lumme A, 1997, EXP NEUROL, V144, P248, DOI 10.1006/exnr.1996.6369; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCKEOWN TR, 1999, J CEREB BLOOD FLO S1, V19, pS510; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; MOOS F, 1989, J PHYSIOL-LONDON, V408, P1, DOI 10.1113/jphysiol.1989.sp017442; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; Okamoto H, 2000, ANESTH ANALG, V91, P896, DOI 10.1097/00000539-200010000-00023; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PETROV T, 1995, NEUROPHARMACOLOGY, V34, P509, DOI 10.1016/0028-3908(95)00002-N; Petrov T, 1995, J NEUROSCI RES, V42, P835, DOI 10.1002/jnr.490420612; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; Rivier C, 1998, NEUROIMMUNOMODULAT, V5, P203, DOI 10.1159/000026338; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SANCHEZ F, 1994, CELL TISSUE RES, V276, P31, DOI 10.1007/BF00354781; SANDI C, 1995, EUR J PHARMACOL, V274, P17, DOI 10.1016/0014-2999(94)00700-H; Satta MA, 1998, NEUROENDOCRINOLOGY, V67, P109, DOI 10.1159/000054305; SAWCHENKO PE, 1982, J COMP NEUROL, V205, P260, DOI 10.1002/cne.902050306; Schoning B, 1999, BRAIN RES PROTOC, V4, P217, DOI 10.1016/S1385-299X(99)00022-7; Silverman RH, 1999, NATURE, V397, P208, DOI 10.1038/16586; Sood R, 2000, GENETICS, V154, P787; Sporbert A, 1999, MOL BRAIN RES, V67, P258, DOI 10.1016/S0169-328X(99)00067-4; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454; THEODOSIS DT, 1985, NATURE, V313, P682, DOI 10.1038/313682a0; Tschaikowsky K, 2000, ANESTHESIOLOGY, V92, P1093, DOI 10.1097/00000542-200004000-00028; Vanhatalo S, 1998, EXP NEUROL, V150, P107, DOI 10.1006/exnr.1997.6733; Vernet D, 1998, ENDOCRINOLOGY, V139, P3254, DOI 10.1210/en.139.7.3254; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WILLIAMS LM, 1994, AM J PHYSIOL-ENDOC M, V267, pE915, DOI 10.1152/ajpendo.1994.267.6.E915; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219	63	29	30	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					799	812		10.1089/089771501316919166			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600006	11526986				2022-02-06	
J	Keren, O; Reznik, J; Groswasser, Z				Keren, O; Reznik, J; Groswasser, Z			Combined motor disturbances following severe traumatic brain injury: an integrative long-term treatment approach	BRAIN INJURY			English	Article							COMATOSE UNAWARENESS PATIENTS; BOTULINUM TOXIN-A; NEUTROPHIL FUNCTIONS; HEAD-INJURY; RECOVERY; STROKE	Patients surviving severe traumatic brain injury (TBI) often suffer from residual impairments in motor control, communication skills, cognition and social behaviour. These distinctly hamper their capability to return to their 'pre-trauma' activity. Comprehensive and integrated rehabilitation programmes initiate, during the acute phase, a prolonged treatment process which starts at the most sophisticated medical systems. There is no clear end point for the treatment of these patients, since the recovery process and the rehabilitation activity may continue for years, even after patients return home to live with their families. The inherent inability to make a firm early prediction regarding outcome of patients and the late appearance of additional symptoms stress the need for a comprehensive close long-term follow-up. The following presentation concerns the description of the treatment strategy and long-term improvement of a 22-year-old male who suffered from very severe TBI. On admission to the emergency room, he was in the decerebrated position and his Glasgow Coma Scale (GCS) was at the lowest (3). The focus of this presentation is on the recovery of motor function. The initial motor disabilities included weakness in all four limbs, in particular left hemiplegia, and right hemiparesis with severe bilateral ataxic elements and a marked tremor of the right arm. Range of motion was limited in hips, and he suffered from stiff trunk and neck. Goals of physiotherapy were directed towards improving range of motion (ROM) and active movement. Casting, use of orthoses, biofeedback, hydrotherapy, hippotherapy, medication and nerve blocks for reducing spasticity were timely applied during the process. The motor improvement in this very severe TBI patient who is now over 3 years postinjury still continues and has a functional meaning. He has succeeded in being able to stand up by himself from a chair and is able to walk unaided and without orthoses for very short distances-up to five steps. He is able to drink soup without assistance and play a few notes on the piano. Marked cognitive improvement occurred as well. It is concluded that motor improvement may be evident over long periods of time and various timely interventions may assist in the process.	Loewenstein Rehabil Hosp, Dept Brain Injury Rehabil, IL-43100 Raanana, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel		Groswasser, Z (corresponding author), Loewenstein Rehabil Hosp, Dept Brain Injury Rehabil, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.			Reznik, Jacqueline/0000-0002-7324-9531			BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; DOLLY JO, 1984, NATURE, V307, P457, DOI 10.1038/307457a0; DOMOVY ML, 1988, ADV NEUROL, V47, P265; HALLETT M, 1995, ANN NEUROL, V38, P139, DOI 10.1002/ana.410380203; Hesse S, 1998, CLIN REHABIL, V12, P381, DOI 10.1191/026921598668275996; IWADATE Y, 1989, Neurosurgical Review, V12, P500, DOI 10.1007/BF01790695; JANCOVIC J, 1996, MOVEMENT DISORD, V11, P250; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Pantano P, 1996, BRAIN, V119, P1849, DOI 10.1093/brain/119.6.1849; Pullman SL, 1996, ARCH NEUROL-CHICAGO, V53, P617, DOI 10.1001/archneur.1996.00550070055012; RONDOT MD, 1998, ARCH NEUROL-CHICAGO, V19, P421; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; TROSCH RM, 1994, MOVEMENT DISORD, V9, P601, DOI 10.1002/mds.870090604; TWITCHELL TE, 1951, BRAIN, V74, P443, DOI 10.1093/brain/74.4.443; WALSHE FM, 1961, ARCH NEUROL-CHICAGO, V5, P119, DOI 10.1001/archneur.1961.00450140001001; WOLACH B, 1993, BRAIN INJURY, V7, P401, DOI 10.3109/02699059309029683; ZASLER ND, 1993, BRAIN INJURY, V7, P379, DOI 10.3109/02699059309029681	19	29	29	2	28	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2001	15	7					633	638		10.1080/02699050010009568			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	444PD	WOS:000169407900007	11429091				2022-02-06	
J	Yu, CG; Jagid, J; Ruenes, G; Dietrich, WD; Marcillo, AE; Yezierski, RP				Yu, CG; Jagid, J; Ruenes, G; Dietrich, WD; Marcillo, AE; Yezierski, RP			Detrimental effects of systemic hyperthermia on locomotor function and histopathological outcome after traumatic spinal cord injury in the rat	NEUROSURGERY			English	Article						hyperthermia; locomotor function; neuroprotection; secondary injury	CEREBRAL-ARTERY OCCLUSION; PERCUSSION BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; FREE-RADICAL ACTIVITY; ACUTE STROKE; PROGNOSTIC-SIGNIFICANCE; ISCHEMIA-REPERFUSION; MODERATE HYPOTHERMIA; MILD HYPERTHERMIA; GLUTAMATE RELEASE	OBJECTIVE: Posttraumatic hyperthermia has been demonstrated to worsen neurological outcome in models of brain injury. The purpose of this study was to examine the effects of systemic hyperthermia on locomotor and morphological outcome measures after traumatic spinal cord injury (SCI) in the rat. METHODS: After a T10 laminectomy, spinal cord contusions were produced from a height of 12.5 mm onto exposed cords (NYU Impactor; New York University Neurosurgery Laboratory, New York, NY) in adult rats that were divided into three groups. Group 1 (n = 9) underwent whole body hyperthermia (rectal temperature, 39.5 degreesC) 30 minutes postinjury for 4 hours, Group 2 (n = 8) underwent normothermia (rectal temperature, 37 degreesC) 30 minutes postinjury for 4 hours, and Group 3 (n = 10) underwent traumatic SCI with no postinjury thermal treatment. Twice-weekly assessments of locomotor function were made during a 6-week survival period using the Basso-Beattie-Breshnahan locomotor rating scale. Forty-four days after injury, animals were perfused, and their spinal cords serially sectioned. Sections were stained with hematoxylin, eosin, and Luxol fast blue for histopathological analysis. The percentage of tissue damage was quantitatively determined by using computer-aided image analysis. RESULTS: The results showed that 4 hours of postinjury hyperthermia significantly worsened locomotor outcome (final Basso-Beattie-Breshnahan scores were 9.7 +/- 0.3 [Group 1] versus 10.8 +/- 0.4 [Group 2] versus 11.3 +/- 0.3 [Group 3]) and led to an increase in the percentage of tissue damage (32.9 +/- 3.2% [Group 1] versus 22.3 +/- 2.8% [Croup 3]). CONCLUSION: These data suggest that complications of SCI (e.g., fever, infection) leading to an elevation of systemic temperature may add to the severity of secondary injury associated with traumatic SCI and significantly affect neurological outcome.	Univ Miami, Sch Med, Miami Project, Miami, FL USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL USA; Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL USA		Yezierski, RP (corresponding author), Univ Florida, Coll Dent, Dept Orthodont, POB 100444,1600 SW Archer Rd,Room D10-19, Gainesville, FL 32610 USA.	ryezierski@dental.ufl.edu	Yu, Chen Guang/C-6176-2011				Agrawal SK, 1997, J NEUROSCI, V17, P1055; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Alm P, 1998, AMINO ACIDS, V14, P95, DOI 10.1007/BF01345249; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BERALDO PSS, 1993, PARAPLEGIA, V31, P186, DOI 10.1038/sc.1993.35; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1999, CEREBROVASC DIS, V9, P22, DOI 10.1159/000015891; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1999, CURRENT REV CEREBROV, P43; DIETRICH WD, 1997, PRIMER CEREBROVASCUL, P163; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; GLOBUS MYT, 1994, STROKE, V25, P254; Grau AJ, 1999, J NEUROL SCI, V171, P115, DOI 10.1016/S0022-510X(99)00261-0; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; HAMMER B, 1993, NEUROREPORT, V5, P72, DOI 10.1097/00001756-199310000-00018; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lancelot E, 1998, NEUROSCI LETT, V242, P131, DOI 10.1016/S0304-3940(98)00095-0; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; McAdoo DJ, 1997, J NEUROTRAUM, V14, P507, DOI 10.1089/neu.1997.14.507; MCDONALD JW, 1991, NEUROSCI LETT, V126, P83, DOI 10.1016/0304-3940(91)90377-6; Metz GAS, 2000, J NEUROTRAUM, V17, P1, DOI 10.1089/neu.2000.17.1; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Montgomerie JZ, 1997, CLIN INFECT DIS, V25, P1285, DOI 10.1086/516144; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; PRZELOMSKI MM, 1986, NEUROLOGY, V36, P427, DOI 10.1212/WNL.36.3.427; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; STERNAU IL, 1992, ROLE NEUROTRANSMITTE, P33; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; SUGARMAN B, 1982, JAMA-J AM MED ASSOC, V248, P66, DOI 10.1001/jama.248.1.66; TAKAGI K, 1994, AM J PHYSIOL-HEART C, V267, pH1770, DOI 10.1152/ajpheart.1994.267.5.H1770; Tatagiba M, 1997, NEUROSURGERY, V40, P541, DOI 10.1097/00006123-199703000-00023; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Tuzgen S, 1998, SPINAL CORD, V36, P654, DOI 10.1038/sj.sc.3100660; Wakamatsu H, 1999, ANESTH ANALG, V88, P56, DOI 10.1097/00000539-199901000-00011; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yamamoto K, 1998, NEUROREPORT, V9, P1655, DOI 10.1097/00001756-199805110-00072; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085	60	29	30	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2001	49	1					152	158		10.1097/00006123-200107000-00023			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	443MV	WOS:000169345700089	11440437				2022-02-06	
J	Allen, JW; Vicini, S; Faden, AI				Allen, JW; Vicini, S; Faden, AI			Exacerbation of neuronal cell death by activation of group 1 metabotropic glutamate receptors: Role of NMDA receptors and arachidonic acid release	EXPERIMENTAL NEUROLOGY			English	Article						CNS injury; ischemia; trauma; calcium; neuronal-glial culture; signal transduction	CEREBELLAR GRANULE CELLS; TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; RAT HIPPOCAMPAL SLICES; D-ASPARTATE RECEPTORS; DORSAL HORN NEURONS; PROTEIN-KINASE-C; IN-VITRO; GLUCOSE DEPRIVATION; NEOCORTICAL NEURONS	Both ionotropic and metabotropic glutamate receptors have been implicated in the pathogenesis of neuronal injury, Activation of group I metabotropic glutamate receptors (mGluR) exacerbates neuronal cell death, whereas inhibition is neuroprotective. However, the mechanisms involved remain unknown. Activation of group I mGluR modulates multiple signal transduction pathways including stimulation of phosphoinositide hydrolysis, potentiation of NMDA receptor activity, and release of arachidonic acid. Here we demonstrate that whereas activation of group I mGluR by (S)-3,5-dihydroxyphenylglycine (DHPG) potentiates NMDA-induced currents and intracellular calcium increases in rat cortical neuronal cultures, partial effects of group I mGluR activation or inhibition on neuronal injury induced by oxygen-glucose deprivation remain despite NMDA receptor blockade. DHPG stimulation also increases basal arachidonic acid release from rat neuronal-glial cultures and potentiates injury-induced arachidonic acid release in these cultures. Thus, activation of group I mGluR may exacerbate neuronal injury through multiple mechanisms, which include positive modulation of NMDA receptors and enhanced release of arachidonic acid. (C) 2001 Academic Press.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Dept Phys & Biophys, Washington, DC 20007 USA; Georgetown Univ, Interdisciplinary Program Neurosci, Washington, DC 20007 USA; Georgetown Univ, Inst Cognit & Computat Sci, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Dept Neurosci, EP-12B Res Bldg,3970 Reservoir Rd, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu		Vicini, Stefano/0000-0001-8671-5194	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS37313] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER		Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BLEAKMAN D, 1992, MOL PHARMACOL, V42, P192; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CERNE R, 1992, NEUROSCI LETT, V144, P180, DOI 10.1016/0304-3940(92)90745-S; CHAVIS P, 1995, J NEUROSCI, V15, P135; COLWELL CS, 1994, NEUROSCIENCE, V61, P497, DOI 10.1016/0306-4522(94)90429-4; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Contractor A, 1998, P NATL ACAD SCI USA, V95, P8969, DOI 10.1073/pnas.95.15.8969; DEMEDIUK P, 1988, J NEUROSCI RES, V20, P115, DOI 10.1002/jnr.490200116; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARVEY J, 1993, BRIT J PHARMACOL, V109, P1085, DOI 10.1111/j.1476-5381.1993.tb13733.x; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; Hirashima N, 1996, NEUROBIOL AGING, V17, P549; Holohean AM, 1999, BRIT J PHARMACOL, V126, P333, DOI 10.1038/sj.bjp.0702263; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; IKEDA M, 1986, J NEUROCHEM, V44, P465; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pisani A, 1997, BRIT J PHARMACOL, V120, P1007, DOI 10.1038/sj.bjp.0700999; QLLEN JW, 2000, CELL DEATH DIFFER, V7, P470; Rahman S, 1996, BRIT J PHARMACOL, V117, P675, DOI 10.1111/j.1476-5381.1996.tb15243.x; Riedel G, 1996, PROG NEURO-PSYCHOPH, V20, P1253, DOI 10.1016/S0278-5846(96)00110-8; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; Sayer RJ, 1998, J NEUROPHYSIOL, V80, P1981, DOI 10.1152/jn.1998.80.4.1981; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; Ugolini A, 1999, NEUROPHARMACOLOGY, V38, P1569, DOI 10.1016/S0028-3908(99)00095-7; Ugolini A, 1997, NEUROPHARMACOLOGY, V36, P1047, DOI 10.1016/S0028-3908(97)00103-2; VERITY MA, 1993, ANN NY ACAD SCI, V679, P110; Viu E, 1998, J PHARMACOL EXP THER, V285, P527; YOSHIDA S, 1980, J NEUROSURG, V53, P323, DOI 10.3171/jns.1980.53.3.0323; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	63	29	30	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2001	169	2					449	460		10.1006/exnr.2001.7672			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	440TF	WOS:000169189800022	11358458				2022-02-06	
J	Levine, DA; Platt, SL; Foltin, GL				Levine, DA; Platt, SL; Foltin, GL			Scooter injuries in children	PEDIATRICS			English	Article						scooter; children; injury prevention; protective gear	LINE	Objective. To describe a series of non-motorized scooter-related injuries to children to increase public awareness and encourage prevention of such injuries. Design. A descriptive study of a consecutive series of patients. Setting. The pediatric emergency service of a municipal hospital. Participants. All children <18 years old who presented to the Pediatric Emergency Service (PES) with a scooter-related injury from July through September 2000. Methods. Patients were identified by review of the PES medical records. Charts were reviewed for patient data including age, place of injury, use of protective gear, adult supervision, injury sustained, medical management, and disposition. Results. There were 15 children treated in the PES for scooter-related injuries. The mean age was 7.8 years, 73% were male. Approximately 90% of injuries occurred as a result of falling off a scooter. Irregular pavement caused 3 falls and tandem riding caused 2 falls. Inability to use the foot brake caused 1 collision, and 1 child was hit by a motor vehicle while crossing the street. Injuries occurred in a park (33%), on a sidewalk (47%), in a home (13%), and on the street (7%). Adult supervision was present in half of the cases. Only 2 children were wearing helmets at the time of injury; none wore protective padding. Five children (33%) suffered head trauma; 1 lost consciousness, and 2 suffered amnesia. Three children required a head computed tomography scan, and 1 required cervical spine radiographs. All radiographs were negative. None of these 5 children were wearing helmets. Seven children (47%) sustained facial injuries, and 4 of these children required laceration repair. Seven children (47%) sustained extremity trauma, including 1 laceration and 6 fractures (1 supracondylar, 1 distal radius, 2 radius/ulnar, 1 tibia/fibula, and 1 patella). Four fractures involved the upper extremity. Four fractures were managed by closed reduction; 2 required operative repair. One child required splinting of an avulsed tooth. Three of the children (20%) were admitted. The 5 children with head trauma were observed and released. Conclusion. The use of nonmotorized scooters by children may result in serious injury, particularly in the young child. Although not life-threatening, these injuries require significant medical intervention and may result in permanent functional and cosmetic deformity. These injuries are potentially preventable with the proper use of protective gear and supervision. Public and parental awareness and education are essential to prevent additional injuries.	NYU, Sch Med, Bellevue Hosp Ctr, Dept Pediat,Pediat Emergency Serv, New York, NY 10016 USA; NYU, Sch Med, Bellevue Hosp Ctr, Dept Emergency Med Surg, New York, NY 10016 USA		Levine, DA (corresponding author), NYU, Sch Med, Bellevue Hosp Ctr, Dept Pediat,Pediat Emergency Serv, 27th St & 1st Ave,Room 1 S 6, New York, NY 10016 USA.	mlevine336@aol.com					CASS DT, 1990, MED J AUSTRALIA, V153, P140, DOI 10.5694/j.1326-5377.1990.tb136832.x; Osberg JS, 1998, ARCH PEDIAT ADOL MED, V152, P985; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; Schieber RA, 1996, NEW ENGL J MED, V335, P1630, DOI 10.1056/NEJM199611283352202; THOMPSON DC, 2000, COCHRANE DATABASE SY, V2; U. S. Consumer Product Safety Commission, 2000, NAT EL INJ SURV SYST; Wesson D, 2000, J PEDIATR SURG, V35, P688, DOI 10.1053/jpsu.2000.5944	7	29	29	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAY	2001	107	5							e64	10.1542/peds.107.5.e64			3	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	427NA	WOS:000168411100001	11331714				2022-02-06	
J	La Vaque, TJ; Rossiter, T				La Vaque, TJ; Rossiter, T			The ethical use of placebo controls in clinical research: The declaration of Helsinki	APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK			English	Article						ethics of clinical research; EEG biofeedback; sham treatment controls; placebo treatment controls; active treatment controls; ADHD; TBI; depression; Declaration of Helsink	ATTENTION-DEFICIT DISORDER; DOUBLE-BLIND; CONTROLLED-TRIALS; COGNITIVE THERAPY; MEDICAL-RESEARCH; HUMAN-RIGHTS; METHYLPHENIDATE; CHILDREN; TRANSMISSION; DEPRESSION	Medical ethicists have questioned the use of no-treatment (placebo and sham procedure) controlled studies of new therapies when safe and effective standard therapies are available for use as an active or "equivalence" control. Current ethical principles of conduct for biomedical research specifically prohibit designs that withhold or deny "the best proven diagnostic and therapeutic" treatment to any participant in a clinical study, including those individuals who consent to randomization into a control group. Studies of psychophysiological therapies are often criticized on the grounds they lack a placebo or sham treatment control group. This paper briefly reviews the history of the problem and discusses the ethical standards that govern human research as derived from the Nuremberg Code and the Declaration of Helsinki. An examination of the problem with regard to research involving EEG biofeedback therapy for Attention-Deficit/Hyperactivity Disorder Traumatic Brain Injury, and depression serves to highlight the issues. It is concluded that the active treatment control (treatment equivalence) design is most appropriate for those clinical studies examining disorders for which there is a known, effective treatment. Sham- or placebo-controlled studies are ethically acceptable for those disorders for which no effective treatment is available.	Stress Clin, Green Bay, WI 54301 USA; Rogers Mem Hosp, Clin Psychophysiol Ctr, Milwaukee, WI 53704 USA; Biofeedback Ctr, Green Bay, WI 54301 USA		La Vaque, TJ (corresponding author), Stress Clin, 125 S Jefferson,Ste 306, Green Bay, WI 54301 USA.	tlavaque@gbonline.com					ADDINGTON D, 1997, CAN J PSYCHIAT, V42, P6; Alderson P, 1996, J MED ETHICS, V22, P135, DOI 10.1136/jme.22.3.135; Alves WA, 1996, STROKE, V27, P1903, DOI 10.1161/01.STR.27.10.1903; Annas GJ, 1998, AM J PUBLIC HEALTH, V88, P560, DOI 10.2105/AJPH.88.4.560; Antonuccio DO, 1999, PSYCHOTHER PSYCHOSOM, V68, P3, DOI 10.1159/000012304; ANTONUCCIO DO, 1995, PROF PSYCHOL-RES PR, V26, P574, DOI 10.1037/0735-7028.26.6.574; Appelbaum PS, 1997, ARCH GEN PSYCHIAT, V54, P117; ARNOLD LE, 1998, NIH CONS DEV C DIAGN; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; Barkley R. A., 1990, ATTENTION DEFICIT HY; BEARDSLEY T, 1998, SCI AM           JUL, P106; BENEDEK TG, 1978, J CHRON DIS, V31, P35, DOI 10.1016/0021-9681(78)90079-6; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; Brawley OW, 1998, INT J RADIAT ONCOL, V40, P5, DOI 10.1016/S0360-3016(97)00835-3; Brennan TA, 1999, NEW ENGL J MED, V341, P527, DOI 10.1056/NEJM199908123410712; BROWN RT, 1986, J DEV BEHAV PEDIATR, V7, P163; BYMAN B, 1989, MINN MED, V72, P580; CALDWELL JG, 1973, J CHRON DIS, V26, P187, DOI 10.1016/0021-9681(73)90089-1; CAPLAN AL, 1992, HASTINGS CENT REP, V22, P29, DOI 10.2307/3562946; Capron AM, 1999, NEW ENGL J MED, V340, P1430, DOI 10.1056/NEJM199905063401812; Cobb W M, 1973, J Natl Med Assoc, V65, P345; COLLIER J, 1998, BRIT MED J, V311, P821; DeDeyn PP, 1996, J MED ETHICS, V22, P140, DOI 10.1136/jme.22.3.140; Dove A, 1999, NAT MED, V5, P598, DOI 10.1038/9431; EDGAR H, 1992, HASTINGS CENT REP, V22, P32, DOI 10.2307/3562947; EDWARDS SJL, 1998, HLTH TECHNOLOGY ASSE, V2, P1; Fisher RL, 1996, J NERV MENT DIS, V184, P99, DOI 10.1097/00005053-199602000-00006; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; Freeman TB, 1999, NEW ENGL J MED, V341, P988, DOI 10.1056/NEJM199909233411311; FUCHS T, 1999, AUFNERKSAMKEIT NEURO; Glantz LH, 1996, J AM ACAD CHILD PSY, V35, P1283, DOI 10.1097/00004583-199610000-00015; *HLTH HUM SERV, 1999, 01702401653S HLTH HU; Jacobson NS, 1996, J CONSULT CLIN PSYCH, V64, P74, DOI 10.1037/0022-006X.64.1.74; Jarrett RB, 1999, ARCH GEN PSYCHIAT, V56, P431, DOI 10.1001/archpsyc.56.5.431; LEHMANN HE, 1979, PROG NEURO-PSYCHOPHA, V3, P271, DOI 10.1016/0364-7722(79)90090-0; Lehrman NS, 1997, J MENT HEALTH ADMIN, V24, P227, DOI 10.1007/BF02898516; Levine RJ, 1998, J CLIN ETHIC, V9, P167; Levine RJ, 1999, NEW ENGL J MED, V341, P531, DOI 10.1056/NEJM199908123410713; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; LURIE P, 1999, COMMITTEE ADV SCI ED; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; Malone RP, 1998, PSYCHIATR SERV, V49, P1413, DOI 10.1176/ps.49.11.1413; Malt UF, 1999, BRIT MED J, V318, P1180; Marquis D, 1999, NEW ENGL J MED, V341, P691, DOI 10.1056/NEJM199908263410912; Michels R, 1999, NEW ENGL J MED, V340, P1427, DOI 10.1056/NEJM199905063401811; *NEJM BOARD ETH AR, 1997, SCIENCE, V278, P211; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; Piot P, 1998, SCIENCE, V280, P1844, DOI 10.1126/science.280.5371.1844; Quitkin FM, 1999, AM J PSYCHIAT, V156, P829, DOI 10.1176/ajp.156.6.829; Ramsay S, 1999, LANCET, V354, P928, DOI 10.1016/S0140-6736(05)75680-4; RAPOPORT JL, 1978, SCIENCE, V199, P560, DOI 10.1126/science.341313; RAPOPORT JL, 1980, ARCH GEN PSYCHIAT, V37, P933; Rogers MF, 1999, NEW ENGL J MED, V341, P441, DOI 10.1056/NEJM199908053410609; Rossiter T. R., 1995, J NEUROTHERAPY, V1, P48, DOI [DOI 10.1300/J184V01N01_, DOI 10.1300/J184V01N0107]; Rossiter T. R., 1998, J NEUROTHERAPY, V2, P54, DOI [10.1300/J184v02n04_04, DOI 10.1300/J184V02N04_04]; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SPENCER T, 1995, ARCH GEN PSYCHIAT, V52, P434; Stein CM, 1999, LANCET, V353, P400, DOI 10.1016/S0140-6736(98)01373-7; Striefel S., 1998, BIOFEEDBACK, V26, P12; Striefel S., 1998, BIOFEEDBACK, V26, P4; Studdert DM, 1998, MED J AUSTRALIA, V169, P545, DOI 10.5694/j.1326-5377.1998.tb123406.x; Swartwood MO, 1998, PEDIATR NEUROL, V18, P244, DOI 10.1016/S0887-8994(97)00205-1; Task Force on Promotion and Dissemination of Psychological Procedures, 1995, CLIN PSYCHOL, V48, P3; TAUBES G, 1995, SCIENCE, V267, P25, DOI 10.1126/science.7809605; TEMPLE R, 1999, COMMITTEE ADV SCI ED; Temple RJ, 1997, CONTROL CLIN TRIALS, V18, P613, DOI 10.1016/S0197-2456(97)00058-5; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Weijer C, 1999, SCHIZOPHR RES, V35, P211, DOI 10.1016/S0920-9964(98)00127-3; WENDER PH, 1985, AM J PSYCHIAT, V142, P547; Woodman R, 1999, BRIT MED J, V319, P660, DOI 10.1136/bmj.319.7211.660a; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; Zeiner P, 1999, ACTA PAEDIATR, V88, P298, DOI 10.1080/08035259950170060; [No title captured]	76	29	29	0	11	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1090-0586	1573-3270		APPL PSYCHOPHYS BIOF	Appl. Psychophysiol. Biofeedback	MAR	2001	26	1					23	37		10.1023/A:1009563504319			15	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	433LQ	WOS:000168761200004	11387859				2022-02-06	
J	Runnerstam, M; Bao, F; Huang, YL; Shi, JS; Gutierrez, E; Hamberger, A; Hansson, HA; Viano, D; Haglid, K				Runnerstam, M; Bao, F; Huang, YL; Shi, JS; Gutierrez, E; Hamberger, A; Hansson, HA; Viano, D; Haglid, K			A new model for diffuse brain injury by rotational acceleration: II. Effects on extracellular glutamate, intracranial pressure, and neuronal apoptosis	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; glutamate; intracranial pressure; microdialysis; taurine; traumatic brain injury	EXCITATORY AMINO-ACIDS; SPINAL-CORD INJURY; HUMAN HEAD-INJURY; C-JUN EXPRESSION; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; METHYL-D-ASPARTATE; NERVE-CELL DEATH; AXONAL INJURY; RAT-BRAIN	The aim of this study is to monitor excitatory amino acids (EAAs) in the extracellular fluids of the brain and to characterize regional neuronal damage in a new experimental model for brain injury, in which rabbits were exposed to 180-260 krad/s(2) rotational head acceleration, This loading causes extensive subarachnoid hemorrhage, focal tissue bleeding, reactive astrocytosis, and axonal damage. Animals were monitored for intracranial pressure (ICP) and for amino acids in the extracellular fluids, Immunohistochemistry was used to study expression of the gene c-Jun and apoptosis with the terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) technique. Extracellular glutamate, glycine, and taurine increased significantly in the hippocampus within a few hours and remained high after 24 h. Neuronal nuclei in the granule layers of the hippocampus and cerebellum were positive for c-Jun after 24 h. Little immunoreactivity was detected in the cerebral cortex. c-Jun-positive neuronal perikarya and processes were found in granule and pyramidal CA4 layers of the hippocampus and among the Purkinje cells of the cerebellum. Also some microglial cells stained positively for c-Jun. TUNEL reactivity was most intense at 10 days after trauma and was extensive in neurons of the cerebral cortex, hippocampus, and cerebellum. The initial response of the brain after rotational head injury involves brain edema after 24 h and an excitotoxic neuronal microenvironment in the first hour, which leads to extensive delayed neuronal cell death by apoptosis necrosis in the cerebral cortex, hippocampus and cerebellum.	Univ Gothenburg, Dept Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Chalmers Univ Technol, Crash Safety Div, S-41296 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Neurosurg, S-41345 Gothenburg, Sweden; China Med Univ, Brain Res Inst, Shenyang, Peoples R China; Zhunyi Med Coll, Dept Pharmacol, Zhunyi, Peoples R China		Hamberger, A (corresponding author), Univ Gothenburg, Dept Anat & Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	anders.hamberger@anatcell.gu.se	Farewik, Elena M. Gutierrez/AAU-9832-2020; Farewik, Elena M Gutierrez/I-6842-2018; Gutierrez-Farewik, Elena/G-6945-2012	Farewik, Elena M. Gutierrez/0000-0001-5417-5939; Farewik, Elena M Gutierrez/0000-0001-5417-5939; Gutierrez-Farewik, Elena/0000-0001-5417-5939			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Buratta S, 1998, J NEUROCHEM, V71, P2145; Cheung NS, 1998, J NEUROSCI RES, V52, P69, DOI 10.1002/(SICI)1097-4547(19980401)52:1<69::AID-JNR7>3.3.CO;2-L; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEFELIPE C, 1994, J NEUROSCI, V14, P2911; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Ferrer I, 1996, EUR J NEUROSCI, V8, P1286, DOI 10.1111/j.1460-9568.1996.tb01297.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRANDE PO, 1997, ACTA ANAESTH SCAND, V1100, P36; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HENNEBERRY RC, 1989, NEUROBIOL AGING, V10, P611, DOI 10.1016/0197-4580(89)90149-8; HERDEGEN T, 1991, NEUROSCIENCE, V45, P413, DOI 10.1016/0306-4522(91)90237-I; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; HUANG R, 1994, NEUROCHEM RES, V19, P257, DOI 10.1007/BF00971573; Humm JL, 1999, EXP NEUROL, V157, P349, DOI 10.1006/exnr.1999.7061; JENKINS R, 1993, NEUROSCIENCE, V53, P447, DOI 10.1016/0306-4522(93)90208-W; JENKINS R, 1991, NEUROSCI LETT, V129, P107, DOI 10.1016/0304-3940(91)90731-8; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Katoh H, 1998, ACT NEUR S, V71, P247; Koura SS, 1998, ACT NEUR S, V71, P244; KRESPAN B, 1982, J NEUROCHEM, V38, P509, DOI 10.1111/j.1471-4159.1982.tb08657.x; LEHMANN A, 1991, J NEUROCHEM, V56, P690, DOI 10.1111/j.1471-4159.1991.tb08204.x; LEHMANN A, 1983, J NEUROCHEM, V40, P1314, DOI 10.1111/j.1471-4159.1983.tb13572.x; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; Lieth E, 1998, DIABETES, V47, P815, DOI 10.2337/diabetes.47.5.815; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liu XZ, 1997, J NEUROSCI, V17, P5395; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCCABE RT, 1993, J PHARMACOL EXP THER, V264, P1248; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McKenna MC, 1996, DEV NEUROSCI-BASEL, V18, P380, DOI 10.1159/000111431; MOZZI R, 1990, NEUROSCI RES COMMUN, V7, P147; Nedelcu J, 1999, PEDIATR RES, V46, P297, DOI 10.1203/00006450-199909000-00008; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; OMMAYA AK, 1984, BIOMECHANICS IMPACT, P117; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; OTTERSEN OP, 1992, NEUROSCIENCE, V46, P519, DOI 10.1016/0306-4522(92)90141-N; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAPPIUS HM, 1989, IMPLICATIONS BLOOD B, P293; Pittman S, 1997, LEUKEMIA RES, V21, P491, DOI 10.1016/S0145-2126(97)00038-6; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; RINK A, 1995, AM J PATHOL, V147, P1575; Robert F, 1998, J CHROMATOGR A, V817, P195, DOI 10.1016/S0021-9673(98)00321-5; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Viano D., 1997, INT J CRASHWORTHINES, V2, P191; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WESTERGAARD N, 1995, NEUROSCI LETT, V185, P24, DOI 10.1016/0304-3940(94)11216-6; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; Zauner A, 1996, ACT NEUR S, V67, P40; Zielke HR, 1998, J NEUROCHEM, V71, P1315	75	29	35	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					259	273		10.1089/08977150151070892			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000004	11284547				2022-02-06	
J	Shibata, Y; Matsumura, A; Meguro, K; Narushima, K				Shibata, Y; Matsumura, A; Meguro, K; Narushima, K			Differentiation of mechanism and prognosis of traumatic brain stem lesions detected by magnetic resonance imaging in the acute stage	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						brain stem; diffuse axonal injury; head injury; MRI	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; MR; CT; DAMAGE; COMA	We retrospectively evaluated the MRI from 17 patients with primary brain stem injury obtained in the acute stage. Clinical and radiological findings were analyzed in these 17 patients. T2-weighted imaging proved to be most sensitive and specific for the diagnosis of primary brain stem injury. We found two patterns of brain stem injury. The good prognosis group showed ventral brain stem lesions or dorsal superficial brain stem lesions. On the other hand the poor prognosis group showed deep dorsal brain stem lesions. These acute stage findings are seen only temporally in many cases so that it is most important to examine MRI findings in the acute stage to evaluate the prognosis of the patient. MRI was valuable in predicting the outcome. The possible mechanism of brain stem injury in patients with head injury is briefly discussed. (C) 2000 Elsevier Science B.V. All rights reserved.	Tsukuba Med Ctr, Dept Neurosurg, Tsukuba, Ibaraki 305, Japan		Shibata, Y (corresponding author), Tsukuba Med Ctr, Dept Neurosurg, Tsukuba, Ibaraki 305, Japan.	y-shibata@amy.hi-ho.ne.jp					ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; MATSUMURA A, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P192; MATSUMURA A, 1989, JPN J MAGN RESON MED, V8, P268; MITCHELL DE, 1973, LANCET, V2, P215; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; SAEKI N, 1990, NEUROTRAUMATOLOGY, V13, P101; TEASDALE G, 1974, LANCET, V2, P81	15	29	31	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	SEP	2000	102	3					124	128		10.1016/S0303-8467(00)00095-0			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	357LN	WOS:000089503300002	10996708	Green Submitted			2022-02-06	
J	Durham, SR; Raghupathi, R; Helfaer, MA; Marwaha, S; Duhaime, AC				Durham, SR; Raghupathi, R; Helfaer, MA; Marwaha, S; Duhaime, AC			Age-related differences in acute physiologic response to focal traumatic brain injury in piglets	PEDIATRIC NEUROSURGERY			English	Article						trauma; age-dependent response to TBI; physiology; head injury; pediatric	CEREBRAL BLOOD-FLOW; COLORED MICROSPHERE TECHNIQUE; HEAD-INJURY; CHILDREN; METABOLISM; HYPEREMIA; PRESSURE; IMMATURE; NEWBORN; MATURE	Introduction: The goal of the present study was to determine whether age-related differences in the acute physiologic response to scaled cortical impact injury contribute to differences in vulnerability to traumatic brain injury (TBI), Methods: Heart rate (HR), mean arterial pressure (MAP), brain temperature (BrT) and cerebral blood flow (CBF) were measured in 22 piglets (7 of age 5 days, 8 of age 1 month, 7 of age 4 months) at baseline and for 3 h following scaled cortical impact injury. Results: There were no age-dependent variations from baseline in HR, MAP or BrT following injury, CBF increased in the 5-day-old animals following injury while CBF in the 1- and 4-month-old animals decreased following injury (p = 0.0049), Conclusion: CBF was shown to have a significant age-dependent response to TBI with the youngest animals exhibiting increased CBF following injury. Copyright (C) 2000 S. Karger AG, Basel.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Anesthesia Crit Care Med, Philadelphia, PA 19104 USA		Durham, SR (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.	durhamsr@mail.med.upenn.edu					Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bauer R, 1999, PEDIATR NEUROSURG, V30, P62, DOI 10.1159/000028765; Bauer R, 1996, EXP TOXICOL PATHOL, V48, P415; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; CHIRON C, 1992, J NUCL MED, V33, P696; DUHAIME A, IN PRESS J NEUROSURG; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HORIUCHI I, 1993, PEDIATR RES, V34, P385, DOI 10.1203/00006450-199309000-00028; ICHORD RN, 1991, STROKE, V22, P626, DOI 10.1161/01.STR.22.5.626; KETY S S, 1956, J Chronic Dis, V3, P478, DOI 10.1016/0021-9681(56)90146-1; KIRSCH JR, 1990, AM J PHYSIOL, V259, pH1551; MOLLER WD, 1978, EUR NEUROL, V17, P276, DOI 10.1159/000114958; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Nagayama M, 1999, J CEREBR BLOOD F MET, V19, P661, DOI 10.1097/00004647-199906000-00009; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Takahashi T, 1999, AM J NEURORADIOL, V20, P917; Walter B, 1997, BASIC RES CARDIOL, V92, P191, DOI 10.1007/s003950050037; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	23	29	29	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	AUG	2000	33	2					76	82		10.1159/000028980			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	373NL	WOS:000165295500005	11070433				2022-02-06	
J	McColl, MA; Bickenbach, J; Johnston, J; Nishihama, S; Schumaker, M; Smith, K; Smith, M; Yealland, B				McColl, MA; Bickenbach, J; Johnston, J; Nishihama, S; Schumaker, M; Smith, K; Smith, M; Yealland, B			Spiritual issues associated with traumatic-onset disability	DISABILITY AND REHABILITATION			English	Article							HEALTH; ILLNESS; DEFINITION; PEOPLE; SELF	Purpose : The present study used a qualitative approach to discover the concepts used by people with a sudden-onset disability to express issues of spirituality. Using a cross-sectional time frame, the study sought to understand how spiritual issues were experienced at the onset of a disability from the perspective of the disabled person him or herself. The study also compared the perceptions of brain injury respondents to spinal cord injury respondents. Method: The qualitative approach was chosen to capture a detailed understanding of perceptions about spirituality, and the relationship of the disability to the disabled person's spiritual beliefs. The sample consisted of 16 individuals, all of whom had experienced a spinal cord injury or a brain injury. Results : The main findings of the study were as follows: (1) Participants recovering from a disability described spiritual issues relating to five themes which arose directly from the data (awareness, closeness, trust, purpose, vulnerability) and relating to three relationships found throughout the literature on spirituality (intrapersonal, interpersonal and transpersonal). These eight dimensions can be combined to form a matrix, which serves as a framework for considering spiritual issues associated with disability; and (2) There were differences in the spiritual concepts described by the participants with brain injury compared to those with spinal cord injury. In particular, those with brain injuries seemed to place greater emphasis on the importance of their families, and to be more aware of the need for trust in view of their memory deficits. Conclusions : These results represent one of the earliest attempts to take an empirical approach to the development of theory in the area of spirituality and disability. Building on theory developed in other populations (palliative care and ageing), the study offers a theoretical model for clinicians, educators and researchers to better understand spirituality in the context of disability.	Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada; Queens Univ, Dept Philosophy, Kingston, ON, Canada; Reg Community Brain Injury Serv, Kingston, ON, Canada; Queens Univ, Dept Theol, Kingston, ON, Canada; Queens Univ, Dept Rehabil Med, Kingston, ON, Canada		McColl, MA (corresponding author), Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada.						*BARB WIR COLL, 1997, NOT ALL VIOL; Bowers C C, 1987, Rehabil Nurs, V12, P90; CARSON V, 1988, J PSYCHOL THEOL, V16, P159, DOI 10.1177/009164718801600205; COUSINS N, 1976, NEW ENGL J MED, V295, P1458, DOI 10.1056/NEJM197612232952605; Deegan PE., 1988, PSYCHOSOC REHABIL J, V11, P11, DOI DOI 10.1037/H0099565; ELKINS DN, 1988, J HUMANIST PSYCHOL, V28, P5, DOI 10.1177/0022167888284002; ELLISON CW, 1983, J PSYCHOL THEOL, V11, P330, DOI 10.1177/009164718301100406; Emblen J D, 1992, J Prof Nurs, V8, P41, DOI 10.1016/8755-7223(92)90116-G; FINE SB, 1991, AM J OCCUP THER, V45, P493, DOI 10.5014/ajot.45.6.493; Fitzgerald J, 1997, DISABIL REHABIL, V19, P407, DOI 10.3109/09638289709166565; Frankl V., 1984, MANS SEARCH MEANING; HAWKS SR, 1995, AM J HEALTH PROMOT, V9, P371, DOI 10.4278/0890-1171-9.5.371; Horsburgh M, 1997, DISABIL REHABIL, V19, P398, DOI 10.3109/09638289709166564; HUNGELMANN J, 1985, J RELIG HEALTH, V24, P147, DOI 10.1007/BF01532258; JONES C, 1982, STUDY SPIRITUALITY; Lindsey E, 1996, J ADV NURS, V24, P465, DOI 10.1046/j.1365-2648.1996.02135.x; LOWREY BJ, 1985, NURS RES, V34, P82; MILLER J, 1983, COPING CHRONIC ILLNE, P287; Miller J F, 1985, J Prof Nurs, V1, P79; Narayanasamy A, 1996, Br J Nurs, V5, P411; Nekolaichuk CL, 1999, SOC SCI MED, V48, P591, DOI 10.1016/S0277-9536(98)00348-7; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; OBRIEN ME, 1982, J RELIG HEALTH, V21, P68, DOI 10.1007/BF02273896; PALOUTZIAN RF, 1982, LONELINESS SOURCEBOO, P00224; *QSR, 1994, NUD IST APPL SOFTW P; REED PG, 1992, RES NURS HEALTH, V15, P349, DOI 10.1002/nur.4770150505; ROSS L, 1995, INT J NURS STUD, V32, P457, DOI 10.1016/0020-7489(95)00007-K; SCHMIDT ND, 1998, QUALITY, V1, P1; Selway D, 1998, DISABIL SOC, V13, P429, DOI 10.1080/09687599826722; SMITH DW, 1995, NURS SCI QUART, V8, P133, DOI 10.1177/089431849500800309; SOEKEN KL, 1987, NURS CLIN N AM, V22, P603; WESTBROOK MT, 1982, SOC SCI MED, V16, P899, DOI 10.1016/0277-9536(82)90209-X; Young E W, 1984, J Am Coll Health, V32, P273	33	29	29	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	AUG	2000	22	12					555	564		10.1080/096382800416805			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	352QC	WOS:000089228500004	11005745				2022-02-06	
J	Schootman, M; Fuortes, LJ				Schootman, M; Fuortes, LJ			Ambulatory care for traumatic brain injuries in the US, 1995-1997	BRAIN INJURY			English	Article							HEAD-INJURY; MILD; MANAGEMENT; PHYSICIANS; RISK	The burden of mild traumatic brain injury (TBI) is not well understood at the national level, but hospitalization rates show a decline over time. This paper describes ambulatory care for TBI patients at physician offices, hospital outpatient departments, and emergency departments (EDs) in comparison with non-TBI visits for the US during 1995-1997. An estimated 1.4 million visits for TBI were made each year for an average annual rate of 5.4/1000 population. A decline in annual visit rate was noted during 1995-1997. Visit rates were higher for those aged 0-14 and 75 and older. Falls (44%) and motor vehicles (28%) were the primary injury causes. Rural-urban differences were found, also in comparison with non-TBI. In 23% of visits to EDs, a CT scan was ordered or performed and in 33% a mental status exam was conducted. Further investigations are warranted to describe ambulatory care for TBI in more detail, particularly in light of a decline in hospitalization rates.	Iowa Dept Publ Hlth, Des Moines, IA 50319 USA; Univ Iowa, Dept Epidemiol, Iowa City, IA USA		Schootman, M (corresponding author), Washington Univ, Div Hlth Behav Res, Dept Pediat, 4444 Forest Pk Pkwy, St Louis, MO 63108 USA.	mschootm@im.wustl.edu	Schootman, Mario/AAF-3941-2019	Schootman, Mario/0000-0003-1162-8824	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCU703369-11, MCJ-19TB 24-01] Funding Source: Medline		Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Ashwal S, 1997, J HEAD TRAUMA REHAB, V12, P13, DOI 10.1097/00001199-199708000-00004; BASS JL, 1993, PEDIATRICS, V92, P544; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Clements AD, 1997, J REHABIL, V63, P3; Diamond PT, 1998, BRAIN INJURY, V12, P817, DOI 10.1080/026990598122052; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; POTTHOFF RF, 1992, J AM STAT ASSOC, V87, P383, DOI 10.2307/2290269; Quinlan KP, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e55; SCHAPPERT SM, 1997, NATL CTR HLTH STAT V, V13, P129; SCHAPPERT SM, 1998, NATL CTR HLTH STAT V, V13, P134; Schootman M, 1998, BIOM HLTH R, V21, P73; SCHOOTMAN M, 1999, IN PRESS BRAIN INJUR; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Torner James C., 1996, P19; WOODWELL D, 1997, NATL CTR HLTH STAT A, V305, P1999	23	29	29	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2000	14	4					373	381					9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	302UE	WOS:000086383400007	10815845				2022-02-06	
J	Currens, JAB; Coats, TJ				Currens, JAB; Coats, TJ			The timing of disability measurements following injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; MULTIPLE INJURIES; OUTCOME MEASURES; REHABILITATION; CARE; RELIABILITY; IMPAIRMENT; AGREEMENT	Disability following trauma has profound personal, social and economic costs. Currently, measurement of disability is not standardised and no agreed time interval between injury and disability measurement exists. This study was designed to define the best time at which to measure disability following trauma. The functional independence measurement (FIM) and Glasgow outcome scale (GOS) were assessed at 3, 6, 12 and more than 24 months after injury for 201 trauma patients. The best time to measure was defined as the point at which a steady state was reached, i.e. when further functional improvement ceased. Motor FIM showed significant change between 3 and 6 month assessments (p < 0.002) and 6 and 12 months (p < 0.002). No statistically significant change occurred beyond 12 months (p > 0.2). For Cognitive FIM, there was significant change between 3 and 6 months (p = 0.02), but not beyond 6 months (p > 0.2). For GOS there was significant change between 3 and 6 months (p < 0.002) and 6 and 12 months (p < 0.002) but not beyond 12 months (p > 0.2). Disability measurements should be performed 12 months after injury, when patients have reached a steady state. This time of measurement should be adopted as the standard for trauma databases and outcome studies. (C) 2000 Elsevier Science Ltd. All rights reserved.	St Bartholomews & Royal London Sch Med & Dent, Acad Unit Accident & Emergency, London, England		Currens, JAB (corresponding author), Univ E London, Dept Hlth Sci, Stratford Campus,Romford Rd, London E15 4LZ, England.		Coats, Timothy/AAW-1254-2021	Coats, Timothy/0000-0003-2736-2784			ARMITAGE P, 1994, STAT METHODS MED RES, P125; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLAND M, 1995, INTRO MED STAT, P146; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; CURRENS JAB, UNPUB EVALUATION DIS; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; DITUNNO JF, 1992, J NEUROTRAUM, V9, pS301; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; EARLAM R, 1989, ANN R COLL SURG ENG, V71, pS60; EMHOFF TA, 1991, J TRAUMA, V31, P1227, DOI 10.1097/00005373-199109000-00005; FRUTIGER A, 1991, J TRAUMA, V31, P1216, DOI 10.1097/00005373-199109000-00004; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HETHERINGTON H, 1995, INJURY, V26, P97, DOI 10.1016/0020-1383(95)92185-D; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MARSHALL IF, 1992, J NEUROSURG, V75, pS28; MENTER RR, 1991, PARAPLEGIA, V29, P613, DOI 10.1038/sc.1991.90; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pollak N, 1996, ARCH PHYS MED REHAB, V77, P1056, DOI 10.1016/S0003-9993(96)90068-4; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; Seekamp A, 1996, INJURY, V27, P133, DOI 10.1016/0020-1383(95)00178-6; TATE DG, 1994, AM J PHYS MED REHAB, V73, P89, DOI 10.1097/00002060-199404000-00004; TurnerStokes L, 1997, CLIN REHABIL, V11, P306, DOI 10.1177/026921559701100407; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; World Health Organization, 1980, INT CLASS IMP DIS HA; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090	35	29	29	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAR	2000	31	2					93	98		10.1016/S0020-1383(99)00244-2			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	287DW	WOS:000085490700006	10748811				2022-02-06	
J	Klodell, CT; Carroll, M; Carrillo, EH; Spain, DA				Klodell, CT; Carroll, M; Carrillo, EH; Spain, DA			Routine intragastric feeding following traumatic brain injury is safe and well tolerated	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	28th Educational and Scientific Symposium of the Society-of-Critical-Care-Medicine	JAN 23-27, 1999	SAN FRANCISCO, CALIFORNIA	Soc Crit Care Med			PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; NUTRITIONAL SUPPORT; PATIENT; INTOLERANCE; COMPLICATIONS; TRACHEOSTOMY; MANAGEMENT; PASSAGE; TUBES	BACKGROUND: Delayed gastric emptying following traumatic brain injury (TBI) has led some to advocate jejunal feeding. Our purpose was to review our experience with percutaneous endoscopic gastrostomy (PEG) and intragastric feeding in TBI patients to assess safety and effectiveness. METHODS: Ail patients on a TBI clinical pathway at our institution were targeted for early PEG. After PEG, standard enteral nutrition was initiated. Abdominal examination and gastric residual volumes were used to assess tolerance. RESULTS: There were 118 patients with moderate to severe TBI. The average age was 36 years. Mean Injury Severity Score (ISS) was 25. Enteral access was obtained and intragastric feeding was initiated on day 3.6. Intragastric feeding was tolerated without complication in 111 of 114 (97%) patients. Five patients aspirated, but had no evidence of intolerance prior to the event. CONCLUSIONS: PEG provided reliable enteral access in moderate to severe TBI patients. Intragastric feeding was well tolerated with a low complication rate (4%). (C) 2000 by Excerpta Medica, Inc.	Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA; Univ Louisville Hosp, Trauma Program Surg, Louisville, KY USA; Vet Affairs Med Ctr, Louisville, KY USA		Spain, DA (corresponding author), Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA.						ALVERDY J, 1985, ANN SURG, V202, P681, DOI 10.1097/00000658-198512000-00003; BORZOTTA AP, 1993, SURG FORUM, V42, P29; Carrillo EH, 1997, SURG ENDOSC, V11, P1068, DOI 10.1007/s004649900531; Chendrasekhar A, 1996, AM SURGEON, V62, P887; DALY JM, 1995, ANN SURG, V221, P327, DOI 10.1097/00000658-199504000-00002; DAMELIO LF, 1994, AM SURGEON, V60, P180; FOX KA, 1995, AM J SURG, V170, P564, DOI 10.1016/S0002-9610(99)80016-6; Gianotti L, 1997, ARCH SURG-CHICAGO, V132, P1222, DOI 10.1001/archsurg.1997.01430350072012; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; Heyland DK, 1999, NUTR CLIN PRACT, V14, P23; LAZARUS BA, 1990, ARCH PHYS MED REHAB, V71, P46; MARIAN M, 1993, SURG GYNECOL OBSTET, V176, P475; MCCLAVE SA, 1992, JPEN-PARENTER ENTER, V16, P99, DOI 10.1177/014860719201600299; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; SHAILESH LTC, 1992, AM J SURG, V164, P114, DOI 10.1016/S0002-9610(05)80367-8; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; Twyman D, 1997, CRIT CARE CLIN, V13, P39, DOI 10.1016/S0749-0704(05)70295-5; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131	27	29	35	0	5	CAHNERS PUBL CO	NEW YORK	249 WEST 17 STREET, NEW YORK, NY 10011 USA	0002-9610			AM J SURG	Am. J. Surg.	MAR	2000	179	3					168	171		10.1016/S0002-9610(00)00297-X			4	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	318LN	WOS:000087285700002	10827311				2022-02-06	
J	Minton, R; Murray, P; Stephenson, W; Galasko, CSB				Minton, R; Murray, P; Stephenson, W; Galasko, CSB			Whiplash injury - are current head restraints doing their job?	ACCIDENT ANALYSIS AND PREVENTION			English	Article; Proceedings Paper	World Congress on Whiplash Associated Disorders	1999	VANCOUVER, CANADA			whiplash; Whiplash Associated Disorder (WAD); head restraints		It is generally accepted that the incidence of whiplash associated disorders is increasing in all industrialised countries, despite the almost universal fitment of head restraints in at least the front seats of cars. This is usually attributed to the fact that few people can be observed to follow the standard recommendations as regards head restraint positioning, that is, level with the head vertically and as close to the head as possible horizontally. This study set out to determine whether any other factors, in addition to head restraint adjustment, could be found which would influence the severity of whiplash injury. This was done by linking medical assessment of real-world accident victims with engineering assessment of the accident vehicles. A random sample of road accident victims suffering from whiplash associated disorder was studied. The vehicles they had been travelling in were examined to assess impact severity and, where possible, measurements were made of seat and head restraint adjustment with the subject sitting in the vehicle. All subjects were interviewed to assess the disability resulting from their injuries, and their progress was followed for 12 months. The results were subjected to statistical analysis to try to determine relationships between severity of injury (as measured by resultant disability) and a number of occupant- and vehicle-related factors. A significant proportion of the sample had suffered lumbar strain injury in addition to whiplash, and these were excluded from the present analysis. Frontal impact victims suffered symptoms indistinguishable from those of rear impact victims. The beneficial effects of good head restraint adjustment could not be clearly demonstrated, and some trends, especially in rear impacts, where the benefits of a well-adjusted restraint should have been very clear, indicated that larger distances from head to restraint were associated with lower disability. The paper discusses these counter-intuitive results and their implications. (C) 2000 The Transport Research Laboratory. Published by Elsevier Science Ltd. All rights reserved.	Transport Res Lab, Crowthorne RG45 6AU, Berks, England; Univ Manchester, Hope Hosp, Dept Orthopaed Surg, Manchester, Lancs, England		Minton, R (corresponding author), Transport Res Lab, Crowthorne RG45 6AU, Berks, England.						BIGI D, 1998, P 16 ESV C WINDS CAN; BOGDUK N, 1986, CLIN BIOMECH, V1, P92, DOI 10.1016/0268-0033(86)90084-7; CULLEN E, 1996, P 1996 IRCOBI C DUBL; DIPPEL C, 1997, P 1997 IRCOBI C HANN; EICHBERGER A, 1996, P 1996 IRCOBI C DUBL; FORETBRUNO JY, 1991, P 13 ESV C PAR; HOPKIN JM, 1993, 379 TRL DEP TRANSP 1; LOVSUND P, 1988, P 1988 IRCOBI C BERG; LUNDELL B, 1998, P 16 ESV C WINDS CAN; LUNDELL B, 1988, SAE INT C EXP DETR; MAAG U, 1990, P 1990 IRCOBI C BRON; MINTON R, 1998, P 16 ESV C WINDS CAN; MINTON R, 1997, P 1997 IRCOBI C DUBL; MORRIS A, 1996, P 15 ESV C MELB; MURRAY PA, 1994, 106 TRL DEP TRANSP; MURRAY PA, 1993, 45 TRL DEP TRANSP; NYGREN A, 1985, P 10 ESV C OXF UK; NYGREN A, 1984, ACTA OTOLARYNGOLOG S, V395; OLSSON I, 1990, P 1990 IRCOBI C BRON; PARKIN S, 1994, P 14 ESV C MUN; RYAN GA, 1994, P 1994 IRCOBI C LYON; SEKIZUKA M, 1998, P 16 ESV C WINDS CAN; Spitzer W.O., 1995, SPINE S, V20, P8; Svensson MY, 1993, SAESP93963; VONKOCH M, 1995, P 1995 IRCOBI C BRUN	25	29	29	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAR	2000	32	2					177	185		10.1016/S0001-4575(99)00092-5			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	282GG	WOS:000085209300006	10688474				2022-02-06	
J	Vilke, GM; Chan, TC; Guss, DA				Vilke, GM; Chan, TC; Guss, DA			Use of a complete neurological examination to screen for significant intracranial abnormalities in minor head injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						head; trauma; Glasgow Coma Scale; injury; minor; intracranial	CRANIAL COMPUTED-TOMOGRAPHY; SELECTION CRITERIA; TRAUMA; PREDICTORS; HEMATOMA; ALWAYS; SCANS	Indications for head computed tomography (CT) scans are unclear in patients with nonpenetrating head injury and Glasgow Coma Scale (GCS) scores of 15, We performed a prospective study to determine if significant intracranial injury could be excluded in patients with GCS-15 and a normal complete neurological examination. A prospective trial of clinically sober adult patients with GCS = 15 on emergency department (EO) presentation after closed head injury with loss of consciousness or amnesia was conducted from May 1996 through April 1997, All subjects underwent a standardized neurological examination including mental status evaluation, and assessment of motor, sensory, cerebellar and reflex function before CT scan. During the study period, 58 patients met inclusion criteria, Fifty five patients (95%) had normal CT scans and 23 (42%) had focal neurological abnormalities. Three patients (5%) had CT scan findings of acute intracranial injury, two of whom had normal neurological examinations, One patient had an acute subdural hematoma requiring emergent surgical decompression; the other had both an epidural hematoma and pneumocephalus that did not require surgery. Significant brain injury and need for CT scanning cannot be excluded in patients with minor head injury despite a GCS = 15 and normal complete neurological examination on presentation, (Am J Emerg Med 2000;18:159-163, Copyright (C) 2000 by W.B. Saunders Company).	Univ Calif San Diego, Med Ctr, Dept Emergency Med, San Diego, CA 92103 USA		Vilke, GM (corresponding author), Univ Calif San Diego, Med Ctr, Dept Emergency Med, 200 W Arbor Dr Mailcode 8676, San Diego, CA 92103 USA.						BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; FEURMAN T, 1988, NEUROSURGERY, V22, P449; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; MADDEN C, 1995, ACAD EMERG MED, V2, P248, DOI 10.1111/j.1553-2712.1995.tb03217.x; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Price D J, 1986, Acta Neurochir Suppl (Wien), V36, P106; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	18	29	33	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAR	2000	18	2					159	163		10.1016/S0735-6757(00)90009-3			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	295YW	WOS:000085997100010	10750921				2022-02-06	
J	Black, K; Zafonte, R; Millis, S; Desantis, N; Harrison-Felix, C; Wood, D; Mann, N				Black, K; Zafonte, R; Millis, S; Desantis, N; Harrison-Felix, C; Wood, D; Mann, N			Sitting balance following brain injury: does it predict outcome?	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; ACUTE STROKE; REHABILITATION; INDIVIDUALS; RECOVERY	Balance dysfunction is commonly observed following traumatic brain injury. There are many proposed predictors of functional outcome in the traumatic brain injury population. It was hypothesized that the degree of balance dysfunction on admission to rehabilitation would be a significant predictor of the need for assistance at discharge, as measured by the Functional Independence Measure (FIM). This study involved 237 cases of traumatic brain injury patients admitted to a rehabilitation unit between November 1989 and September 1996. Using a multiple regression model, controlling for age, initial Glasgow Coma Score (GCS), rehabilitation admission strength, sitting balance and standing balance, it was found that the degree of impairment in sitting balance at admission to rehabilitation was a significant predictor of Discharge FIM-Total (FIM-T) score (p < 0.0001) and also of selected elements from the Discharge FIM-Motor (FIM-M) score (p < 0.0005). The combination of age, initial admission GCS, rehabilitation admission strength, standing balance and sitting balance accounted for 29% of the variance in the Discharge Total FIM score. Among these, sitting balance was the second most powerful predictor of both selected elements of the Discharge FIM motor score and discharge FIM-T. Sitting balance predictive capacity was exceeded in power only by age. Impairments in sitting balance appear to have a significant impact on functional outcome. Emphasis on unique rehabilitation techniques to treat balance dysfunction in the adult TBI population is warranted.	Wayne State Univ, Dept Phys Med & Rehabil, Inst Rehabil, Detroit, MI 48201 USA		Black, K (corresponding author), Wayne State Univ, Dept Phys Med & Rehabil, Inst Rehabil, 261 Mack Blvd, Detroit, MI 48201 USA.	KBLACK@DMK.org					ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Brosseau L, 1996, AM J PHYS MED REHAB, V75, P422, DOI 10.1097/00002060-199611000-00005; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; Franchignoni FP, 1997, STROKE, V28, P1382, DOI 10.1161/01.STR.28.7.1382; FREGLY AR, 1968, AEROSPACE MED, V39, P277; GILCHRIST E, ARCH NEUROLOGY, V179, P355; GUERTS ACH, 1996, ARCH PHYSICAL MED RE, V77, P639; HAIN TC, 1994, VESTIBULAR REHABILIT, P15; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; Hillier SL, 1997, BRAIN INJURY, V11, P661; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MILLETT D, 1987, PHYS THER, V65, P1697; Miyai I, 1997, NEUROLOGY, V48, P95, DOI 10.1212/WNL.48.1.95; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; Nichols DS, 1996, ARCH PHYS MED REHAB, V77, P865, DOI 10.1016/S0003-9993(96)90271-3; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SANDIN KJ, 1990, STROKE, V21, P82, DOI 10.1161/01.STR.21.1.82; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; *UB FDN ACT, 1993, GUID UN DAT SET MED; WADE DT, 1983, ARCH PHYS MED REHAB, V64, P24; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZAFONTE RD, 1995, AM J PHYS MED REHABI, V74, P176	39	29	30	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2000	14	2					141	152		10.1080/026990500120808			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000004	10695570				2022-02-06	
J	Al-Samsam, RH; Alessandri, B; Bullock, R				Al-Samsam, RH; Alessandri, B; Bullock, R			Extracellular N-acetyl-aspartate as a biochemical marker of the severity of neuronal damage following experimental acute traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						N-acetyl-aspartate; high-performance liquid chromatography; microdialysis; traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; CLOSED-HEAD INJURY; RAT-BRAIN; CEREBRAL-ISCHEMIA; AXONAL INJURY; ACETYLASPARTATE; MICRODIALYSIS; DYSFUNCTION; HYPOXIA	We evaluated the acute changes in interstitial and whole brain N-acetyl-aspartate (NAA) measured by high-performance liquid chromatography in animal models of isolated traumatic brain injury (TBI) and TBI combined with secondary insult (hypotension-hypoxia [HH]). The Marmarou impact-acceleration model was used. Four groups were studied: (1) sham-operated control, (2) TBI alone (TBI 500 gm, 2 m), (3) TBI plus 30 min of hypoxia (PaO2, similar to 40 mm Hg) and hypotension (mean arterial blood pressure, similar to 40 mm Hg) (THH), and (4) HH alone. The baseline value for dialysate NAA (NAA(d)) in the rats was 8.17 +/- 1 mu M. No significant difference between groups was found for this baseline value. The TBI group had a modest (100%) transient increase in NAA(d) after isolated TBI. The HH group had a transient (500%) increase in NAA(d) at 1 h, sustained for 2 h. In the THH group, there was a persistent increase in NAA(d) (800%) that peaked at 2.5 h. The whole brain NAA (NAA(w)) concentration in controls was 8.5 +/- 0.5 mmol/kg wet weight. There was no significant difference between TBI and controls; however, there was a significant decrease in NAA(w) in the THH and HH group compared to controls. Thus, in this animal model of TBI and TBI with secondary insult, we found that persistent, marked elevation in NAA is associated with TBI and secondary ischemic/hypoxic insult, but not with isolated TBI alone.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, MCV Stn, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Pediat Crit Care Med, Richmond, VA 23298 USA		Bullock, R (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, MCV Stn, Box 980631, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478; Al-Samsam R, 1999, CRIT CARE MED, V27, pA104, DOI 10.1097/00003246-199901001-00265; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BERLINGUET L, 1996, CAN J BIOCHEM, V44, P783; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CENDES F, 1994, ANN NEUROL, V35, P211, DOI 10.1002/ana.410350213; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; DADAMO AF, 1966, J NEUROCHEM, V13, P961, DOI 10.1111/j.1471-4159.1966.tb10292.x; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GIDEON P, 1992, STROKE, V23, P1566, DOI 10.1161/01.STR.23.11.1566; Gotoh M, 1997, J NEUROCHEM, V69, P655; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; KOLLER KJ, 1984, J NEUROCHEM, V43, P1136, DOI 10.1111/j.1471-4159.1984.tb12854.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOATS RA, 1994, MAGNET RESON MED, V32, P110, DOI 10.1002/mrm.1910320115; NADLER JV, 1972, J NEUROCHEM, V19, P2091, DOI 10.1111/j.1471-4159.1972.tb05119.x; Nakai A, 1997, NEUROBIOL DIS, V4, P288, DOI 10.1006/nbdi.1997.0146; PEDEN CJ, 1993, DEV MED CHILD NEUROL, V35, P502; Penrice J, 1996, PEDIATR RES, V40, P6, DOI 10.1203/00006450-199607000-00002; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; Sager TN, 1997, J NEUROCHEM, V68, P675; SCHELLER D, 1991, J NEUROSCI METH, V40, P31, DOI 10.1016/0165-0270(91)90114-F; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; TAYLOR DL, 1994, J NEUROCHEM, V62, P2349; TAYLOR DL, 1995, J NEUROCHEM, V65, P275; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	38	29	32	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2000	17	1					31	39		10.1089/neu.2000.17.31			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	278WR	WOS:000085012400003	10674756				2022-02-06	
J	Eijkenboom, M; Blokland, A; Van der Staay, FJ				Eijkenboom, M; Blokland, A; Van der Staay, FJ			Modelling cognitive dysfunctions with bilateral injections of ibotenic acid into the rat entorhinal cortex	NEUROSCIENCE			English	Article						electrolytic; excitotoxic; Morris water maze; parahippocampal area; replicability	WATER MAZE TASK; DENTATE GYRUS; KAINIC ACID; SPATIAL MEMORY; HIPPOCAMPAL DAMAGE; SUBDURAL-HEMATOMA; SELECTIVE LESIONS; RECOVERY; BEHAVIOR; PERFORMANCE	Neurodegenerative diseases, traumatic brain injury and stroke are likely to result in cognitive dysfunctioning. Animal models are needed in which these deficits and recovery of the affected functions can be investigated. In the present study, the entorhinal area was chosen as the target for lesioning and for assessing the lesion-induced deficits in the Morris water maze. The entorhinal cortex is regarded as an interface between the hippocampus and neocortex. Deafferentiating the hippocampus through entorhinal lesions impairs spatial learning. The effects of lesions, induced by either electrocoagulation (experiment 1) or ibotenate excitotoxicity (experiment 2), on spatial orientation behaviour were investigated. Water maze performance after unilateral or bilateral ibotenate injections into the entorhinal cortex was studied in the third experiment. In an additional study, the replicability of the spatial learning deficit after lesions induced by bilateral injections of ibotenic acid into the entorhinal cortex was assessed by comparing the results of nine experiments. We found that spatial learning was impaired after bilateral lesions aimed at the entorhinal cortex. The electrolytic lesion technique produced a relatively large sham effect, whereas the excitotoxic lesioning method did not. Unilateral injections of ibotenic acid into the entorhinal cortex did not affect spatial navigation. The ibotenate induced lesions replicably produced deficits in the Morris tasks. The degree of the induced spatial learning impairments and the effects on the rate of acquisition during training, however, differed between experiments. This result suggests that the fundamental biological diversity between shipments of rats can account for variation in the effects of parahippocampal damage on spatial learning even in highly standardized experimental set-ups. Rats lesioned by bilateral injections of ibotenic acid into the entorhinal cortex provide an interesting and reliable model for investigating cognitive dysfunctions in neurodegenerative diseases, stroke or traumatic brain injury. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Bayer AG, CNS Res, D-5600 Wuppertal, Germany; Maastricht Univ, Fac Psychol, Maastricht, Netherlands		Eijkenboom, M (corresponding author), Bayer AG, CNS Res, D-5600 Wuppertal, Germany.			van der Staay, F. Josef/0000-0002-8704-3366			AUBERT I, 1994, J NEUROSCI, V14, P2476; BARNES CA, 1990, PROGR BRAIN RES; Bobinski M, 1998, BRAIN RES, V805, P267, DOI 10.1016/S0006-8993(98)00759-8; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cain DP, 1998, NEUROSCI BIOBEHAV R, V22, P181, DOI 10.1016/S0149-7634(97)00005-5; CHOI DW, 1988, J NEUROSCI, V8, P185; Cotman CW, 1998, MENT RETARD DEV D R, V4, P223, DOI 10.1002/(SICI)1098-2779(1998)4:3<223::AID-MRDD10>3.0.CO;2-X; COTTON J. W., 1998, ANAL WITHIN SUBJECTS; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; Eijkenboom M, 1999, NEUROSCIENCE, V94, P373, DOI 10.1016/S0306-4522(99)00332-2; EIJKENBOOM M, 1998, P MEAS BEH 98 2 INT, P137; FREUND RJ, 1985, SAS LINEAR MODELS; Frotscher M, 1996, ANN ANAT, V178, P311, DOI 10.1016/S0940-9602(96)80080-X; Galani R, 1998, BEHAV BRAIN RES, V96, P1, DOI 10.1016/S0166-4328(97)00197-6; GLASIER MM, 1995, NEUROBIOL LEARN MEM, V64, P203, DOI 10.1006/nlme.1995.0003; Good M, 1997, BEHAV NEUROSCI, V111, P487, DOI 10.1037/0735-7044.111.3.487; GULDIN WO, 1982, J NEUROSCI METH, V5, P83, DOI 10.1016/0165-0270(82)90055-3; GULDIN WO, 1981, BRAIN RES, V225, P446, DOI 10.1016/0006-8993(81)90852-0; HAGAN JJ, 1992, PHYSIOL BEHAV, V51, P255, DOI 10.1016/0031-9384(92)90139-S; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; HUNT ME, 1994, PSYCHOBIOLOGY, V22, P186; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; JARRARD LE, 1983, BEHAV NEUROSCI, V97, P873, DOI 10.1037/0735-7044.97.6.873; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P121, DOI 10.1016/S0149-7634(96)00001-2; KAHLE JS, 1993, BRAIN RES, V609, P201, DOI 10.1016/0006-8993(93)90874-M; KESSLAK JP, 1991, BRAIN RES, V557, P57, DOI 10.1016/0006-8993(91)90115-C; KIMBLE DP, 1965, J COMP PHYSIOL PSYCH, V60, P474, DOI 10.1037/h0022550; KOHLER C, 1979, NEUROSCI LETT, V15, P223, DOI 10.1016/0304-3940(79)96117-2; LEONARD BW, 1995, J NEUROSCI, V15, P5637; Miettinen R, 1998, BRAIN RES, V813, P9, DOI 10.1016/S0006-8993(98)00915-9; Miwa C, 1996, PSYCHIAT CLIN NEUROS, V50, P223, DOI 10.1111/j.1440-1819.1996.tb02746.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NYAKAS C, 1988, BRAIN RES BULL, V21, P285, DOI 10.1016/0361-9230(88)90243-2; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; PARENT A, 1994, NEUROSCIENCE, V61, P565, DOI 10.1016/0306-4522(94)90434-0; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PETERSON DA, 1994, J NEUROSCI, V14, P6872; RAMIREZ JJ, 1991, BEHAV BRAIN RES, V43, P99, DOI 10.1016/S0166-4328(05)80057-9; RAMIREZ JJ, 1984, BEHAV BRAIN RES, V13, P53, DOI 10.1016/0166-4328(84)90029-9; Ramirez JJ, 1998, RESTOR NEUROL NEUROS, V12, P203; Ramirez JJ, 1996, P NATL ACAD SCI USA, V93, P15512, DOI 10.1073/pnas.93.26.15512; RAMIREZ JJ, 1988, BRAIN RES, V459, P153, DOI 10.1016/0006-8993(88)90296-X; RASMUSSEN M, 1989, PSYCHOBIOLOGY, V17, P335; REEVES TM, 1987, BEHAV NEUROSCI, V101, P179; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; SCHENK F, 1985, EXP BRAIN RES, V58, P11; STEWARD O, 1983, J COMP NEUROL, V214, P370, DOI 10.1002/cne.902140403; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TERRY P, 1990, PSYCHOBIOLOGY, V18, P404; THINUSBLANC C, 1991, BRAIN SPACE; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; Zajaczkowski W, 1997, PHARMACOL BIOCHEM BE, V56, P21, DOI 10.1016/S0091-3057(96)00133-5; Zajaczkowski W, 1996, EUR J PHARMACOL, V296, P239, DOI 10.1016/0014-2999(95)00716-4	53	29	29	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	101	1					27	39		10.1016/S0306-4522(00)00342-0			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	373AA	WOS:000165265200005	11068134				2022-02-06	
J	Kerr, ME; Weber, BB; Sereika, SM; Darby, J; Marion, DW; Orndoff, PA				Kerr, ME; Weber, BB; Sereika, SM; Darby, J; Marion, DW; Orndoff, PA			Effect of endotracheal suctioning on cerebral oxygenation in traumatic brain-injured patients	CRITICAL CARE MEDICINE			English	Article						endotracheal suctioning; cerebral oxygenation; head injury; transcranial Doppler ultrasound; jugular oxygen tension; intracranial pressure; arteriovenous oxygen difference	INTRACRANIAL-PRESSURE; HEAD-INJURY; FLOW VELOCITY; HYPERVENTILATION; ULTRASOUND; TRANSIENT; ADULTS	Objective: In patients with severe head injuries, brain damage occurs not only from the primary trauma but also secondarily from a reduction in cerebral oxygenation as a result of brain swelling, ischemia, and elevated intracranial pressure (ICP), However, routine interventions designed to maintain oxygenation, such as endotracheal suctioning (ETS), also may negatively affect the cerebrovascular status by increasing the ICP, The purpose of this study was to determine whether ETS influences cerebral oxygenation in patients with traumatic brain injury. Design: Descriptive, prospective, with repeated assessments within each patient. Setting: Ten-bed trauma intensive care unit in a university Level I trauma center. Subjects: Nineteen patients who were 16 yrs or older, had acute head injury, a Glasgow Coma Scale score less than or equal to 8, external ventricular drain and arterial pressure devices in place, and were intubated and mechanically ventilated. Interventions: ETS protocol consisting of administration of four ventilator-delivered breaths at 135% of the patients' actual tidal volume, 100% F-IO2, before and after suctioning with a standardized catheter at a 16-L flow rate. Measurements and Main Results: This study examined cerebrovascular responses as measured by the traditional measures of ICP and cerebral perfusion pressure, as well as middle cerebral artery velocity and jugular venous oxygen tension that occurred during ETS in head-injured adults. The results of this study show that both ICP and cerebral perfusion pressure are increased during ETS, In the majority of patients (84%), the ICP returned to baseline values within 2 mins, Conclusions: The increase in jugular venous oxygen tension associated with increases in middle cerebral artery velocity and mean arterial pressure suggests that cerebral oxygen delivery was maintained during ETS. Cerebral changes associated with ETS using the described protocol are consistent with the preservation of cerebral oxygenation.	Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA		Kerr, ME (corresponding author), Univ Pittsburgh, Sch Nursing, 360 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [1R03 NR03391-01] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R03NR003391] Funding Source: NIH RePORTER		AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Akaike H, 1973, 2 INT S INF THEOR BU, P267; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; BUSIJA DW, 1988, AM J PHYSIOL, V255, pH343, DOI 10.1152/ajpheart.1988.255.2.H343; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Diggle PJ, 1995, ANAL LONGITUDINAL DA; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; Graham D.I., 1996, NEUROTRAUMA, P43; GRAHAM DI, 1971, LANCET, V1, P265; Kelly DF, 1996, NEUROTRAUMA, P71; Kerr M E, 1998, Am J Crit Care, V7, P205; Kerr ME, 1997, NURS RES, V46, P195, DOI 10.1097/00006199-199707000-00003; LASSEN NA, 1974, CIRC RES, V34, P749, DOI 10.1161/01.RES.34.6.749; March K, 1990, J Neurosci Nurs, V22, P375; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MITCHELL PH, 1978, NURS RES, V27, P4; PARSONS LC, 1984, HEART LUNG, V13, P372; Ropper Allan H., 1993, P11; RUDY EB, 1991, HEART LUNG, V20, P667; SANTBRINK H, 1996, NEUROSURGERY, V38, P21; SKELLEY BFH, 1980, HEART LUNG, V9, P316; URBAN BJ, 1969, ANESTHESIOLOGY, V31, P473, DOI 10.1097/00000542-196911000-00024; WINSOR T, 1945, P SOC EXP BIOL MED, V58, P165; Wisinger D, 1990, J Neurosci Nurs, V22, P365	29	29	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	DEC	1999	27	12					2776	2781		10.1097/00003246-199912000-00028			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	270EZ	WOS:000084523600028	10628625				2022-02-06	
J	Maxwell, WL; Donnelly, S; Sun, X; Fenton, T; Puri, N; Graham, DI				Maxwell, WL; Donnelly, S; Sun, X; Fenton, T; Puri, N; Graham, DI			Axonal cytoskeletal responses to nondisruptive axonal injury and the short-term effects of posttraumatic hypothermia	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; microtubules; neurofilaments; traumatic axonal injury	TRAUMATIC BRAIN INJURY; AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; PIG OPTIC-NERVE; MODERATE HYPOTHERMIA; BEHAVIORAL DEFICITS; CORTICAL IMPACT; STRETCH-INJURY; PROTECTION; RAT	In human diffuse axonal injury (DAI), axons are exposed to transient tensile strain. Over thee ensuing several hours, injured axons enter a "pathological cascade" of events that lead to secondary axotomy. Use of animal models of traumatic axonal injury (TAI) has allowed description of a number of pathological changes before axotomy occurs, including structural and functional changes in the axolemma, disorientation, and/or loss of microtubules, either compaction and/or dispersion of neurofilaments together with focal compaction at sites where continuity of the axolemma is lost. Recent literature suggests that use of hypothermia may improve behavioral outcomes or reduce the number/density of injured axons in which axonal transport is altered after TAI. But there is presently no ultrastructural, pathological explanation as to how hypothermia may act at the level of the axon to reduce posttraumatic loss of axoplasmic transport. In this study, we tested the hypothesis that posttraumatic hypothermia may ameliorate (a) alteration of axonal transport and (b) early pathological changes in the axonal cytoskeleton prior to secondary axotomy. We have undertaken a pilot study within 4 h of stretch injury to adult guinea pig optic nerve axons as a model of TAI and applied stereological techniques to assess differences in pathology in animals either maintained at 37.5 degrees C or cooled to 32-32.5 degrees C for 2 or 4 h after injury. We provide quantitative evidence that posttraumatic hypothermia significantly reduces the number of axons labelled for beta-APP, a marker for disruption of fast axonal transport, and reduces the loss of microtubules and compaction of neurofilaments, which occurs in normothermic animals over the first 4 h after injury.	Univ Glasgow, Lab Human Anat, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Neuropathol, So Gen Hosp NHS Trust, Glasgow, Lanark, Scotland		Maxwell, WL (corresponding author), Univ Glasgow, Lab Human Anat, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		BAUR PS, 1977, J MICROSC-OXFORD, V109, P315, DOI 10.1111/j.1365-2818.1977.tb01145.x; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Eguchi Y, 1997, J NEUROTRAUM, V14, P109, DOI 10.1089/neu.1997.14.109; GENNARELLI TA, 1989, J NEUROSURG, V71, P315; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GUY J, 1989, J COMP NEUROL, V287, P446, DOI 10.1002/cne.902870404; Hyman BT, 1998, J NEUROPATH EXP NEUR, V57, P305, DOI 10.1097/00005072-199804000-00001; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6	29	29	30	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1225	1234		10.1089/neu.1999.16.1225			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400009	10619200				2022-02-06	
J	Ponsford, J; Olver, J				Ponsford, J; Olver, J			Outcome measurement in an inpatient and outpatient traumatic brain injury rehabilitation programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; PROFILE	This paper outlines approaches taken to the measurement of outcome from a rehabilitation programme for individuals with traumatic brain injury (TBI). It describes methods used to evaluate progress made by individuals towards the attainment of goals within the programme, including the use of a Role Checklist and Goal Attainment Scaling. Maintenance of gains and long-term outcome in a range of life domains over 5 years after injury has been documented using a structured questionnaire, on which we obtained good inter-rater reliability. By 5 years after injury, the majority of individuals with TBI were in reasonable agreement with their close others regarding the presence of cognitive and behavioural changes. Standardised measures used in addition to the structured questionnaire have included the Sickness Impact Profile: the Craig Handicap Assessment and Reporting Technique (CHART), and the Leeds Scales for the Self-assessment of Anxiety and Depression. Findings and inter-correlations of all these measures are discussed. Emotional adjustment appears to have a significant influence upon self-reporting of problems and changes on measures such as the Sickness Impact Profile. It is therefore important to use more objective measures of handicap in a range of domains, such as the CHART, in addition to self-report measures.	Epworth Hosp, Bethesda Rehabil Ctr, Dept Psychol, Richmond, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia; Epworth Hosp, Bethesda Rehabil Unit, Melbourne, Vic, Australia					Olver, John/0000-0001-7069-1191			BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOAKE C, 1996, J PHYSICAL MED REHAB, V75, P1; Daniel A., 1983, POWER PRIVILEGE PRES; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Granger CV, 1987, UNIFORM DATA SET MED; JENNETT B, 1975, LANCET, V1, P480; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Snaith RP, 1976, LEEDS SCALES SELF AS; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; World Health Organization, 1980, INT CLASS IMP DIS HA	20	29	29	0	2	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-OCT	1999	9	3-4					517	534		10.1080/096020199389563			18	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	242GV	WOS:000082932900024					2022-02-06	
J	Gurka, JA; Felmingham, KL; Baguley, IJ; Schotte, DE; Crooks, J; Marosszeky, JE				Gurka, JA; Felmingham, KL; Baguley, IJ; Schotte, DE; Crooks, J; Marosszeky, JE			Utility of the functional assessment measure after discharge from inpatient rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; INDEPENDENCE MEASURE; PERFORMANCE; VALIDATION	Objective: To assess the relationship between the Functional Independence Measure (FIM) and the Functional Assessment Measure (FAM), and community integration and return to work in patients with severe traumatic brain injuries (TBI). Design: A cross-sectional, prospective design was used to collect data at 6 and 24 months postdischarge. The Return to Work Scale (RTW) and Community Integration Questionnaire (CIQ) were selected to assess return to work and community functioning. Predictor variables included the motor and cognitive subscales of the FIM and the FAM. Setting: Follow-up database of an inpatient and community TBI Rehabilitation Unit. Participants: All consenting patients with TBI admitted to the unit, aged 16 or above. There were 88 patients at 6 and 79 patients at 24 month follow-up. Results: At 6 months follow-up, the FAM and the FIM were roughly equivalent in their ability to predict RTW and CIQ scores. At 24 months, FAM motor was the only significant predictor of CIQ, and FAM cognitive scores displayed an advantage over the FIM in predicting employment status. Conclusions: The FAM subscales produced only modest gains in prediction of employment status and community integration at 24 months postdischarge. This may reflect ceiling effects on the functional measures, a limited range on the RTW measure, poor ecologic validity of functional disability measures in assessing handicap, or a combination of these factors.	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia; Westmead Hosp, Dept Rehabil Med, Westmead, NSW 2145, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.		Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALL K, 1993, J HEAD TRAUMA REHAB, V8, P30; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, P10; KAPLAN CP, 1994, ARCH PHYS MED REHAB, V75, P643, DOI 10.1016/0003-9993(94)90186-4; Keith R., 1987, ADV CLIN REHABILITAT, V1, P10; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MAROSSZEKY JE, 1992, 12 ASM ACRM, P43; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; *STAT U NEW YORK, UN DAT SYST MED REH; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	18	29	29	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1999	14	3					247	256		10.1097/00001199-199906000-00005			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	203XY	WOS:000080734500005	10381977				2022-02-06	
J	Doder, M; Jahanshahi, M; Turjanski, N; Moseley, IF; Lees, AJ				Doder, M; Jahanshahi, M; Turjanski, N; Moseley, IF; Lees, AJ			Parkinson's syndrome after closed head injury: a single case report	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						parkinsonism; closed head injury; case report	ORDERED WORKING-MEMORY; FRONTAL-CORTEX; FOCAL LESIONS; BASAL GANGLIA; DISEASE; IMPAIRMENTS; MOVEMENTS; TASKS	A 36 year old man, who sustained a skull fracture in 1984, was unconscious for 24 hours, and developed signs of Parkinson's syndrome 6 weeks after the injury. When assessed in 1995, neuroimaging disclosed a cerebral infarction due to trauma involving the left caudate and lenticular nucleus. Parkinson's syndrome was predominantly right sided, slowly progressive, and unresponsive to levodopa therapy. Reaction time tests showed slowness of movement initiation and execution with both hands, particularly the right. Recording of movement related cortical potentials suggested bilateral deficits in movement preparation. Neuropsychological assessment disclosed no evidence of major deficits on tests assessing executive function or working memory, with the exception of selective impairments on the Stroop and on a test of self ordered random number sequences. There was evidence of abulia. The results are discussed in relation to previous literature on basal ganglia lesions and the effects of damage to different points of the frontostriatal circuits.	UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Inst Neurol, MRC, Human Movement & Balance Unit, Dept Clin Neurol, London WC1N 3BG, England; Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England		Lees, AJ (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.		Lees, Andrew J/A-6605-2009	Lees, Andrew J/0000-0002-2476-4385	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ALTAR A, 1983, BRAIN RES, V279, P1, DOI 10.1016/0006-8993(83)90157-9; BATTIG K, 1991, J COMP PHYSIOL PSYCH, V13, P909; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benton A., 1978, MULTILINGUAL APHASIA; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; BROWN RG, 1993, J NEUROL NEUROSUR PS, V56, P295, DOI 10.1136/jnnp.56.3.295; CHAND RP, 1985, MED J MALAYSIA, V40, P335; CHANDULA.JA, 1970, EXP NEUROL, V29, P101, DOI 10.1016/0014-4886(70)90041-5; CHERAMY A, 1981, NEUROSCIENCE, V6, P2657, DOI 10.1016/0306-4522(81)90110-X; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; CROUZON O, 1929, PRESSE MED, V37, P1325; DE MORSIER G., 1960, PSYCHIAT ET NEUROL, V139, P60; DELLASALA S, 1990, ITAL J NEUROL SCI, V11, P65, DOI 10.1007/BF02334908; DIVAC I, 1967, J COMP PHYSIOL PSYCH, V63, P184, DOI 10.1037/h0024348; Dubois B, 1995, Adv Neurol, V65, P29; FACTOR SA, 1988, MOVEMENT DISORD, V3, P30, DOI 10.1002/mds.870030105; FACTOR SA, 1989, MOVEMENT DISORD, V4, P283; Fenelon G, 1997, MOVEMENT DISORD, V12, P1086, DOI 10.1002/mds.870120642; FOSTER JB, 1976, LANCET, V1, P981; Grimberg L, 1934, J NERV MENT DIS, V79, P14, DOI 10.1097/00005053-193401000-00002; JAHANSHAHI M, 1992, BRAIN, V115, P539, DOI 10.1093/brain/115.2.539; JENTZER A, 1947, SCHWEIZ ARCH NEUROL, V60, P388; LAWLER CP, 1995, SYNAPSE, V21, P299, DOI 10.1002/syn.890210404; LINDENBERG R, 1964, Dtsch Z Nervenheilkd, V185, P637; MILNER B, 1964, FRONTAL AGRANULAR CO; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; Parkinson J, 1817, ESSAY SHAKING PALSY; PETRIDES M, 1995, J NEUROSCI, V15, P359; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A., 1964, EXAMEN CLIN PSYCHOL; Robbins TW, 1995, NEUROCASE, V1, P217; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; Schonell F., 1942, BACKWARDNESS BASIC S; SOURKES TL, 1965, NATURE, V207, P202, DOI 10.1038/207202a0; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Takeda M, 1991, Rinsho Shinkeigaku, V31, P842; TOUGE T, 1995, ANN NEUROL, V37, P791, DOI 10.1002/ana.410370613; Turjanski N, 1997, MOVEMENT DISORD, V12, P1035, DOI 10.1002/mds.870120630; Wechsler DW, ADULT INTELLIGENCE S; Weigl E, 1941, J ABNORM SOC PSYCH, V36, P3, DOI 10.1037/h0055544; WYKE M, 1967, NEUROLOGY, V17, P1113, DOI 10.1212/WNL.17.11.1113	44	29	32	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	1999	66	3					380	385		10.1136/jnnp.66.3.380			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	172MB	WOS:000078927200019	10084539	Green Published, Bronze			2022-02-06	
J	Catroppa, C; Anderson, V				Catroppa, C; Anderson, V			Attentional skills in the acute phase following pediatric traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; SUSTAINED ATTENTION; CHILDREN; CHILDHOOD; DEFICITS; SPEED; AGE	Only a limited number of studies have investigated attention following pediatric head-injury. The present study examined sustained attention and processing speed in a group of children who had sustained a mild (n = 27), moderate (n = 33) or severe (n = 16) traumatic brain injury (TBI). No significant differences were evident between the TBI groups on reaction time measures. Results did show that the severe TBI group exhibited greater deficits in the area of sustained attention, in comparison to children with mild and moderate injuries, in the acute stage following traumatic brain injury. This difficulty may impact on the future development of skills dependent on intact attentional capacity.	Royal Childrens Hosp, Melbourne, Vic, Australia; Univ Melbourne, Parkville, Vic 3052, Australia		Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.		Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			ANDERSON RP, 1973, EXCEPT CHILDREN, P534; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, IN PRESS DEV NEUROPS; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; DANIELS A, 1983, POWER PRIVILEGE PRES; Dennis M, 1995, TRAUMATIC HEAD INJUR; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FENWICK T, IN PRESS CHILD NEURO; HALE S, 1990, CHILD DEV, V61, P653, DOI 10.1111/j.1467-8624.1990.tb02809.x; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; KAIL R, 1986, CHILD DEV, V57, P969, DOI 10.1111/j.1467-8624.1986.tb00259.x; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MILTON SB, 1991, J HEAD TRAUMA REHAB, V6, P35; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Wechsler D., 1992, MANUAL WECHSLER INTE; WILLMOTT C, IN PRESS DEV NEUROPS	28	29	29	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.		1999	5	4					251	264		10.1076/0929-7049(199912)05:04;1-R;FT251			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	324XA	WOS:000087645600005	10925709				2022-02-06	
J	Miyakita, Y; Taguchi, Y; Sakakibara, Y; Matsuzawa, M; Kitagawa, H				Miyakita, Y; Taguchi, Y; Sakakibara, Y; Matsuzawa, M; Kitagawa, H			Transient mutism resolving into cerebellar speech after brain stem infarction following a traumatic injury of the vertebral artery in a child	ACTA NEUROCHIRURGICA			English	Article						mutism; child; trauma; midbrain; infarction	SUPPLEMENTARY MOTOR AREA; DYSARTHRIA; APHASIA; DISEASE	A 3.7-year-old girl presented with an anterior neck injury followed by progressive subcutaneous emphysema and loss of consciousness. After resuscitation, a laceration on the first tracheal cartilage was closed surgically. As she was extubated one week later, she was found to have right hemiplegia and muteness. MRI showed a T2-bright lesion on the tegmentum of the left midbrain down to the upper pens. Right vertebral angiography disclosed an intimal flap with stenosis at the C3 vertebral level presumably caused by a fracture of the right C3 transverse process later confirmed in a cervical 3D-CT scan. Her muteness lasted for 10 days, after which she began to utter some comprehensible words in a dysarthric fashion. Her neurological deficits showed improvement within 3 months of her admission. Transient mutism after brain stem infarction has not been reported previously. We discuss the anatomical bases for this unusual reversible disorder in the light of previous observations and conclude that bilateral damage to the dentatothalamocortical fibers at the decussation of the superior cerebellar peduncle may have been responsible for her transient mutism.	St Marianna Univ, Yokohama City Seibu Hosp, Div Neurosurg, Yokohama, Kanagawa, Japan; St Marianna Univ, Yokohama City Seibu Hosp, Div Paediat Surg, Yokohama, Kanagawa, Japan		Taguchi, Y (corresponding author), St Marianna Univ, Yokohama City Seibu Hosp, Div Neurosurg, Asahi Ku, 1197-1 Yasashi Cho, Kanagawa 2410811, Japan.						CRUTCHFIELD JS, 1994, J NEUROSURG, V81, P115, DOI 10.3171/jns.1994.81.1.0115; Ersahin Y, 1996, NEUROSURGERY, V38, P60; FRAIOLI B, 1975, APPL NEUROPHYSIOL, V38, P81; FRASER RAR, 1975, STROKE, V6, P153, DOI 10.1161/01.STR.6.2.153; FRIM DM, 1995, NEUROSURGERY, V36, P854, DOI 10.1227/00006123-199504000-00031; GESCHWIND N, 1971, NEW ENGL J MED, V284, P654, DOI 10.1056/NEJM197103252841206; HILTONJONES D, 1985, LANCET, V1, P1435; LECHTENBERG R, 1978, ANN NEUROL, V3, P285, DOI 10.1002/ana.410030402; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; MASDEU JC, 1978, NEUROLOGY, V28, P1220, DOI 10.1212/WNL.28.12.1220; MICKLE JP, 1995, NEUROSURGERY, V36, P854; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; REA GL, 1996, PRINCIPLES SPINAL SU, P885; ROSS MK, 1984, ANN NEUROL, V16, P114; ROSTOMILY RC, 1991, J NEUROSURG, V75, P62, DOI 10.3171/jns.1991.75.1.0062; RYDING E, 1993, COGNITIVE BRAIN RES, V1, P94, DOI 10.1016/0926-6410(93)90015-W; SEGARRA JM, 1970, ARCH NEUROL-CHICAGO, V22, P408, DOI 10.1001/archneur.1970.00480230026003; TONKONOGY J, 1981, ARCH NEUROL-CHICAGO, V38, P486, DOI 10.1001/archneur.1981.00510080048005; VANDONGEN HR, 1994, NEUROLOGY, V44, P2040, DOI 10.1212/WNL.44.11.2040	19	29	29	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1999	141	2					209	213		10.1007/s007010050288			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	174MV	WOS:000079039700039	10189505				2022-02-06	
J	Zink, BJ; Sheinberg, MA; Wang, X; Mertz, M; Stern, SA; Betz, AL				Zink, BJ; Sheinberg, MA; Wang, X; Mertz, M; Stern, SA; Betz, AL			Acute ethanol intoxication in a model of traumatic brain injury with hemorrhagic shock: effects on early physiological response	JOURNAL OF NEUROSURGERY			English	Article						ethanol; traumatic brain injury; hemorrhagic shock; cerebral blood flow; ventilation; pig	CEREBRAL BLOOD-FLOW; FREE-RADICAL MECHANISMS; NERVOUS-SYSTEM TRAUMA; SEVERE HEAD-INJURIES; NITRIC-OXIDE; ALCOHOL-INTOXICATION; OXYGEN DELIVERY; INTRACRANIAL-PRESSURE; ARTERIOLES; REDUCTION	Object. Traumatic brain injury (TBI) is exacerbated by hypotension and hypoventilation. Because previous studies have shown a potentiating effect of ethanol (EtOH) on TBI and hemorrhagic shock (HS), the authors investigated the effects of EtOH on the early physiological response to TBI with and without HS. Methods. Anesthetized swine, weighing approximately 20 kg each, underwent fluid-percussion TBI of 3 atm with or without 30 ml/kg hemorrhage for a period of 30 minutes. The mean arterial blood pressure, intracranial pressure, cerebral perfusion pressure (CPP), cardiac output, cerebral venous oxygen saturation, and metabolic parameters were monitored for 3 hours postinjury. Ventilation and the response to hypercapnia were also measured. Regional cerebral blood flow and renal blood flow were measured using dye labeled microspheres. Five groups were studied: control, TBI, TBI/EtOH, TBI/HS, and TBI/HS/EtOH. The EtOH (3.5 g) was given intragastrically 100 minutes preinjury. The TBI/HS/EtOH group demonstrated a 3-hour mortality rate of 56% and postinjury apnea requiring Ventilation in 44% of animals compared with 0% in all other groups. Minute Ventilation and the hypercapnic Ventilatory response were significantly reduced in the postinjury period in the TBI/HS/EtOH group. The animals in this group had significantly lower CPP and cardiac output in the first 60 minutes postinjury, as well as lower renal and cerebral blood flow. Postinjury cerebral venous lactate levels were higher, and cerebral venous pH was lower in the TBI/HS/EtOH group. Conclusions. In this model of TBI, acute EtOH intoxication in the presence of HS potentiates the physiological and metabolic alterations that may contribute to secondary brain injury.	Univ Michigan, Sect Emergency Med, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Neurosurg Sect, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA		Zink, BJ (corresponding author), Univ Michigan, Sect Emergency Med, Dept Surg, 1500 E Med Ctr Dr,TC B1 354, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K08AA000184] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [PHS-G-1-K08AA00184] Funding Source: Medline		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BEARD JD, 1973, Q J STUD ALCOHOL, V34, P1303; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CREWS FT, 1993, NIAAA RES MONOGRAPH, V22, P355; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Deitrich R., 1996, PHARM EFFECTS ETHANO; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DILUZIO NR, 1969, EXP MOL PATHOL, V11, P38, DOI 10.1016/0014-4800(69)90069-0; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; DURCAN MJ, 1989, PHARMACOL BIOCHEM BE, V32, P667, DOI 10.1016/0091-3057(89)90015-4; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; ELMER O, 1985, ACTA CHIR SCAND, V151, P305; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; GORDON EL, 1995, J CEREBR BLOOD F MET, V15, P532, DOI 10.1038/jcbfm.1995.66; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HORTON JW, 1986, SURGERY, V100, P520; ISRAEL RS, 1988, ANN EMERG MED, V17, P560; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; LANCASTER FE, 1992, ALCOHOL CLIN EXP RES, V16, P539, DOI 10.1111/j.1530-0277.1992.tb01413.x; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609000-00010; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MARX J, 1990, Emergency Medicine Clinics of North America, V8, P929; Mayhan WG, 1996, ALCOHOL CLIN EXP RES, V20, P538, DOI 10.1111/j.1530-0277.1996.tb01089.x; MAYHAN WG, 1995, STROKE, V26, P2097, DOI 10.1161/01.STR.26.11.2097; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; Mihic S. J., 1996, PHARM TOXIC, P51; Mill John Stuart, 1996, NEUROTRAUMA, P43; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; NORDMANN R, 1996, PHARM TOXIC, P329; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PITTS LH, 1990, HDB CLIN NEUROLOGY, V57, P65; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RAPPAPORT WD, 1990, J TRAUMA, V30, P1518, DOI 10.1097/00005373-199012000-00014; REVES JG, 1972, Q J STUD ALCOHOL, V33, P464; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCALEA TM, 1994, CRIT CARE MED, V22, P1610; Schmoker JD, 1996, J NEUROTRAUM, V13, P67, DOI 10.1089/neu.1996.13.67; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; SELIGMAN ML, 1977, LIPIDS, V12, P945, DOI 10.1007/BF02533316; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SIGGINS GR, 1996, PHARM TOXIC, P175; Smith DH, 1996, NEUROTRAUMA, P1445; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YUAN XQ, 1991, CIRC SHOCK, V35, P231; ZHANG A, 1993, EUR J PHARM-ENVIRON, V248, P229, DOI 10.1016/0926-6917(93)90049-V; ZINK BJ, 1988, ANN EMERG MED, V17, P15, DOI 10.1016/S0196-0644(88)80496-7; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; ZINK BJ, 1988, CIRC SHOCK, V24, P19; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	75	29	31	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	1998	89	6					983	990		10.3171/jns.1998.89.6.0983			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	168TF	WOS:000078708200012	9833825				2022-02-06	
J	Posmantur, RM; Zhao, X; Kampfl, A; Clifton, GL; Hayes, RL				Posmantur, RM; Zhao, X; Kampfl, A; Clifton, GL; Hayes, RL			Immunoblot analyses of the relative contributions of cysteine and aspartic proteases to neurofilament breakdown products following experimental brain injury in rats	NEUROCHEMICAL RESEARCH			English	Article						neurofilaments; calpain; traumatic brain injury; two-dimensional gel electrophoresis; cortex	CALCIUM-ACTIVATED PROTEOLYSIS; AMYOTROPHIC-LATERAL-SCLEROSIS; CONTROLLED CORTICAL IMPACT; PROTEIN-KINASE-II; ALZHEIMERS-DISEASE; CALPAIN INHIBITOR; SPINAL-CORD; NF-H; ICE/CED-3 PROTEASE; HIPPOCAMPAL DAMAGE	Analyses using either one or two-dimensional gel electrophoresis were performed to identify the contribution of several proteases to lower molecular weight (MW) neurofilament 68 (NF68) break down products (BDPs) detected in cortical homogenates following unilateral cortical impact injury in rats. One dimensional immunoblot of BDPs obtained from in vitro cleavage of enriched neurofilaments (NF) by purified mu-calpain, m-calpain, cathepsin, B, cathepsin D, and CPP32 (caspase-3) were compared to in vivo samples from rats following traumatic brain injury (TBI). Comparison of these blots provided information on the relative contribution of different cysteine or aspartic proteases to NF loss following brain injury. As early as 3 hrs post-injury, cortical impact resulted in the presence of several lower MW NF68 immunopositive bands having patterns similar to those previously reported to be produced by calpain mediated proteolysis of neurofilaments. Only mu-calpain and m-calpain in vitro digestion of enriched neurofilaments contributed to the presence of the low MW 57 kD NF68 break down product (BDP) detected in post-TBI samples. Cathepsin B, cathepsin D, and caspase-3 failed to produce either the 53 kD or 57 kD NF BDPs. Further, 1 and 2 dimensional peptide maps containing a 1:1 ratio of in vivo and in vitro tissue samples showed complete comigration of lower MW immunopositive spots produced by TBI or in vitro incubation with m-calpain, thus providing additional evidence for the potential role of calpain activation to the production of NF68 BDPs following TBI. More importantly, 2-dimensional gel electrophoresis detected that immunopositive NF68 spots shifted to the basic pole (+) suggesting that dephosphorylation of the NF68 subunit pool may be associated with NF protein loss following TBI, an observation not previously noted in any model of experimental brain injury.	Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX 77030 USA; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Immunopathol, Dept Neurosci, Ann Arbor, MI 48105 USA; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria		Hayes, RL (corresponding author), Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, 6431 Fannin,Suite 7-154, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458, P01 NS31998] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; CHIN TK, 1983, BIOCHEM J, V215, P239, DOI 10.1042/bj2150239; CRUMRINE RC, 1990, J NEUROCHEM, V55, P2001, DOI 10.1111/j.1471-4159.1990.tb05788.x; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DAUTIGNY A, 1988, BIOCHEM BIOPH RES CO, V154, P1099, DOI 10.1016/0006-291X(88)90254-9; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GOTO K, 1994, MOL BRAIN RES, V23, P40, DOI 10.1016/0169-328X(94)90209-7; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HANSON SK, 1994, STROKE, V25, P466, DOI 10.1161/01.STR.25.2.466; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1988, J BIOL CHEM, V263, P17401; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Hill IE, 1997, BRAIN RES, V751, P206, DOI 10.1016/S0006-8993(96)01403-5; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWASHIMA S, 1988, BIOCHIM BIOPHYS ACTA, V965, P130, DOI 10.1016/0304-4165(88)90048-7; Kohda Y, 1996, BIOCHEM BIOPH RES CO, V228, P616, DOI 10.1006/bbrc.1996.1706; KUBOTA S, 1986, BIOCHEMISTRY-US, V25, P8396, DOI 10.1021/bi00374a011; LEE VMY, 1987, J NEUROSCI, V7, P3474; Li JH, 1996, J NEUROBIOL, V30, P177, DOI 10.1002/(SICI)1097-4695(199606)30:2<177::AID-NEU1>3.0.CO;2-2; LITERSKY JM, 1995, J NEUROCHEM, V65, P903; LITERSKY JM, 1993, BRAIN RES, V604, P32, DOI 10.1016/0006-8993(93)90349-R; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MIGHELI A, 1994, NEUROPATH APPL NEURO, V20, P282, DOI 10.1111/j.1365-2990.1994.tb00970.x; MORIOKA M, 1992, J NEUROCHEM, V58, P1798, DOI 10.1111/j.1471-4159.1992.tb10056.x; NAGARAJA TN, 1994, ACTA NEUROPATHOL, V88, P349; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NITATORI T, 1996, J NEUROTRAUM, V6, P369; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur R, 1997, J NEUROCHEM, V68, P2328; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SAATMAN KE, 1995, J NEUROPATH EXP NEUR, V55, P852; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SCHLAEPFER W, 1990, CRCS INTRACELLULAR C, P241; SCHLAEPFER WW, 1984, J NEUROCHEM, V43, P857, DOI 10.1111/j.1471-4159.1984.tb12809.x; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; SEUBERT P, 1987, SYNAPSE, V1, P20, DOI 10.1002/syn.890010105; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SMITH MA, 1995, J NEUROCHEM, V64, P2660; SOUSSAN L, 1994, MOL NEUROBIOL, V9, P83, DOI 10.1007/BF02816107; Stabach PR, 1997, BIOCHEMISTRY-US, V36, P57, DOI 10.1021/bi962034i; SUSUKI H, 1984, NEUROSCI LETT, V89, P240; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WEILOCH T, 1991, J NEUROCHEM, V56, P1227; YAMASAKI Y, 1992, NEUROSCIENCE, V49, P545, DOI 10.1016/0306-4522(92)90225-Q; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523; ZHAO X, 1997, IN PRESS J CEREBRAL; ZHAO X, 1997, UNPUB NEUROSCI LETT	86	29	29	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	OCT	1998	23	10					1265	1276		10.1023/A:1020792132629			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	131BY	WOS:000076556900007	9804282				2022-02-06	
J	Armstead, WM				Armstead, WM			Brain injury impairs prostaglandin cerebrovasodilation	JOURNAL OF NEUROTRAUMA			English	Article						cerebral circulation; cyclic nucleotides; newborn; K(+) channel	K+ CHANNEL FUNCTION; PIAL ARTERY DILATION; POTASSIUM CHANNELS; NEWBORN PIGS; VASCULAR-RESPONSES; CEREBRAL-ARTERIES; HEAD-INJURY; RAT-BRAIN; ISCHEMIA; PIGLETS	Previous studies have observed that ATP- and calcium-sensitive K(+) (K(ATP) and K(ca)) channel function is impaired after fluid percussion brain injury (FPI). The present study was designed to characterize the effect of FPI on prostaglandin (PG)E(2) and I(2) pial artery dilation and the role of activation of these K(+) channels in that dilation in newborn pigs equipped with a closed cranial window, FPI of moderate severity (1.9-2.1 atm) was produced by using a pendulum to strike a piston on a saline-filled cylinder that was fluid coupled to the brain via a hollow screw inserted through the cranium. PGE(2) vasodilation was blunted by FPI (9 +/- 1%, 13 +/- 1%, and 19 +/- 1% vs. 2 +/- 1%, 5 +/- 1%, and 9 +/- 1%, for 1, 10, and 100 ng/ml PGE(2) before and after FPI, respectively). PGE(2) dilation was associated with increased CSF cGMP and cAMP concentration and such changes in cyclic nucleotides were blunted by FPI (448 +/- 10 and 793 +/- 38 vs, 316 +/- 11 and 403 +/- 27 fmol/ml for control and PGE(2) induced change in cGMP before and after FPI, respectively), PGI(2)-induced dilation and associated changes in CSF cyclic nucleotide concentration were similarly blunted by FPI. PGE(2) dilation was attenuated by either glibenclamide or iberiotoxin, K(ATP) and K(ca) channel antagonists, and coadministration of both K+ channel antagonists further decremented the dilator response (9 +/- 1%, 14 +/- 1%, and 21 +/- 1%; vs, 4 +/- 1%, 7 +/- 1%, and 12 +/- 1%; vs. 2 +/- 1%, 4 +/- 1%, and 7 +/- 1%, for 1, 10, and 100 ng/ml PGE(2) during control, after glibenclamide, and after combined glibenclamide and iberiotoxin, respectively). Glibenclamide and iberiotoxin had similar effects on PGI(2) dilation. These data show that prostaglandin dilation is attenuated after FPI. These data also show that prostaglandin dilation is dependent on activation of both K(ATP) and K(ca) channels. Further, these data suggest that attenuated prostaglandin dilation following FPI results from diminished prostaglandin-associated elevation in cyclic nucleotide concentration and impaired K(ATP) and K(ca) channel function.	Childrens Hosp Philadelphia, Dept Anesthesia, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA		Armstead, WM (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesia, 34th & Civic Ctr Blvd, Philadelphia, PA 19104 USA.						Al-Turki A, 1998, CRIT CARE MED, V26, P917, DOI 10.1097/00003246-199805000-00029; ARMSTEAD WM, 1995, AM J PHYSIOL-HEART C, V268, pH1436, DOI 10.1152/ajpheart.1995.268.4.H1436; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1996, AM J PHYSIOL-HEART C, V271, pH166, DOI 10.1152/ajpheart.1996.271.1.H166; Armstead WM, 1997, BRAIN RES, V747, P252, DOI 10.1016/S0006-8993(96)01284-X; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423, DOI 10.1152/ajpheart.1996.270.2.H423; ARMSTEAD WM, 1992, P SOC EXP BIOL MED, V199, P149; ARMSTEAD WM, 1988, AM J PHYSIOL, V255, P401; AVELDANO MI, 1975, J NEUROCHEM, V25, P919, DOI 10.1111/j.1471-4159.1975.tb04432.x; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; Bari F, 1996, J CEREBR BLOOD F MET, V16, P1158, DOI 10.1097/00004647-199611000-00010; BAZAN NG, 1971, J NEUROCHEM, V18, P1387, DOI 10.1111/j.1471-4159.1971.tb00003.x; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1989, J NEUROTRAUM, V6, P331; FREDRICKS KT, 1994, AM J PHYSIOL, V267, pH580, DOI 10.1152/ajpheart.1994.267.2.H580; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498, DOI 10.1152/ajpheart.1996.271.4.H1498; Leffler CW, 1997, AM J PHYSIOL-HEART C, V272, pH1323; LEFFLER CW, 1987, AM J PHYSIOL, V252, pH687, DOI 10.1152/ajpheart.1987.252.4.H687; LEFFLER CW, 1989, STROKE, V20, P541, DOI 10.1161/01.STR.20.4.541; LEFFLER CW, 1989, PEDIATR RES, V25, P180; LEFFLER CW, 1990, PROSTAGLANDINS, V40, P241, DOI 10.1016/0090-6980(90)90012-K; LEFFLER CW, 1985, PROSTAGLANDINS, V30, P811, DOI 10.1016/0090-6980(85)90009-7; LEFFLER CW, 1992, AM J PHYSIOL, V263, pH746, DOI 10.1152/ajpheart.1992.263.3.H746; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NELSON MT, 1993, TRENDS CARDIOVAS MED, V3, P54, DOI 10.1016/1050-1738(93)90037-7; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SPINEDI A, 1990, J NEUROCHEM, V54, P778, DOI 10.1111/j.1471-4159.1990.tb02318.x; TEPAS JJ, 1995, PEDIAT SURG, V4, P120; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; ZALESKA MM, 1989, J NEUROCHEM, V52, P255, DOI 10.1111/j.1471-4159.1989.tb10925.x	45	29	29	0	0	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1998	15	9					721	729		10.1089/neu.1998.15.721			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	118ZT	WOS:000075871400007	9753219				2022-02-06	
J	Childers, MK; Rupright, J; Jones, PS; Merveille, O				Childers, MK; Rupright, J; Jones, PS; Merveille, O			Assessment of neuroendocrine dysfunction following traumatic brain injury	BRAIN INJURY			English	Article							DIABETES-INSIPIDUS; INAPPROPRIATE SECRETION; ANTIDIURETIC-HORMONE; HYPONATREMIA; HYPOPITUITARISM; AMANTADINE; POLYDIPSIA	Posttraumatic neuroendocrine pathology may be a clinically significant complication following traumatic blain injury (TBI). Metabolic abnormalities are described after TBI in two cases. A 21 year old male injured in a motor Vehicle accident admitted in a minimally responsive condition presented with fluctuating high sodium levels, undetectable serum testosterone, and depressed cortisol and thyroid function. Imaging revealed near complete avulsion of the pituitary stalk leading to panhypopituitarism. A 38 year old male admitted for occipital skull fractures and brain contusions presented with hyponatremia and low serum testosterone. Both patients required hormonal replacement and correction of electrolyte abnormalities. A screening protocol adapted for selected patients at risk for endocrine problems is described. While neuroendocrine screening is not advocated in all TBI patients, physicians should be aware of the importance of neuroendocrine dysfunction following TBI.	Univ Missouri, Dept PM&R, Howard A Rusk Rehabil Ctr, Columbia, MO 65212 USA; Missouri Rehabil Ctr, Mt Vernon, MO USA		Childers, MK (corresponding author), Univ Missouri, Dept PM&R, Howard A Rusk Rehabil Ctr, DC046-00,1 Hosp Dr, Columbia, MO 65212 USA.			Childers, Martin/0000-0003-4754-0883			BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; BARZILAY Z, 1988, J MED, V19, P47; COWELL LC, 1995, J HEAD TRAUMA REHAB, V10, P91, DOI 10.1097/00001199-199512000-00018; DIXON BS, 1988, AM REV RESPIR DIS, V138, P512, DOI 10.1164/ajrccm/138.3.512; EDWARDS OM, 1986, MEDICINE, V65, P281; Elovic E, 1996, NEUROREHABILITATION, V6, P57, DOI 10.3233/NRE-1996-6107; FARR RW, 1988, SOUTHERN MED J, V81, P677, DOI 10.1097/00007611-198805000-00037; GANDELMAN MS, 1994, PROG NEURO-PSYCHOPH, V18, P211, DOI 10.1016/0278-5846(94)90055-8; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; HAYCOCK GB, 1995, PEDIATR NEPHROL, V9, P375, DOI 10.1007/BF02254219; KAHN A, 1981, EUR J PEDIATR, V135, P293, DOI 10.1007/BF00442106; KLACHKO DM, 1968, J CLIN ENDOCR METAB, V28, P1768, DOI 10.1210/jcem-28-12-1768; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; LABIB M, 1987, POSTGRAD MED J, V63, P33, DOI 10.1136/pgmj.63.735.33; LERAMO OB, 1987, CAN J SURG, V30, P53; Liu BA, 1996, CAN MED ASSOC J, V155, P519; Liu BA, 1996, CAN MED ASSOC J, V155, P1043; Miller M, 1997, Curr Ther Endocrinol Metab, V6, P206; NOTMAN DD, 1980, J TRAUMA, V20, P599, DOI 10.1097/00005373-198007000-00009; RALSTON C, 1990, ARCH DIS CHILD, V65, P896, DOI 10.1136/adc.65.8.896; Saito T, 1996, Nihon Jinzo Gakkai Shi, V38, P429; SHAH PJ, 1992, HOSP COMMUNITY PSYCH, V43, P509; Sihvonen T, 1997, ARCH PHYS MED REHAB, V78, P486, DOI 10.1016/S0003-9993(97)90161-1; Sterns Richard H., 1993, P225; WILCOX JA, 1990, NEUROPSYCHOBIOLOGY, V23, P144	26	29	34	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	1998	12	6					517	523		10.1080/026990598122476			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	ZU400	WOS:000074193300007	9638328				2022-02-06	
J	Chen, MZ; Clark, RSB; Kochanek, PM; Chen, J; Schiding, JK; Stetler, RA; Simon, RP; Graham, SH				Chen, MZ; Clark, RSB; Kochanek, PM; Chen, J; Schiding, JK; Stetler, RA; Simon, RP; Graham, SH			72-kDa heat shock protein and mRNA expression after controlled cortical impact injury with hypoxemia in rats	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	26th Annual Meeting of the Society-for-Neuroscience	NOV 16-21, 1996	WASHINGTON, D.C.	Soc Neurosci		heat shock protein; hippocampus; hsp72; neuron; stress response; traumatic brain injury	TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; OXIDE SYNTHASE EXPRESSION; PROGRAMMED CELL-DEATH; HSP70 MESSENGER-RNA; HYPERTHERMIA PROTECTS; TRANSIENT ISCHEMIA; GERBIL HIPPOCAMPUS; CULTURED NEURONS; THERMAL-STRESS	As part of the stress response, the 72 kDa heat shack protein (hsp72) is induced in neurons after ischemic and traumatic brain injury (TBI). To examine the stress response after TBI with secondary insult, we examined the regional and cellular expression of hsp72 mRNA and protein after controlled cortical impact (CCI) injury with secondary hypoxemia and mild hypotension in rats. Rats were killed at 6, 8, 24, 72, or 168 h after trauma. Naive and sham-operated rats were used as controls. Brains were removed, and in situ hybridization (n = 2/group), immunocytochemistry (n = 4/group), and Western blot analysis (n = 3 to 5/group) for hsp72 was performed. Hsp72 mRNA was expressed in neurons in the ipsilateral cortex, CA3 region of the hippocampus, hilus, and dentate gyrus at 6 h. Hsp72 mRNA was expressed primarily in the ipsilateral cortex, at 24 h, and by 72 h hsp72 mRNA expression returned to near basal levels. Hsp72 protein was seen in ipsilateral cortical neurons, hilar neurons, and neurons in the medial aspect of the CA3 region of the hippocampus (CA3-c) at 24 h. At 72 h, hsp72 immunoreactivity was reduced versus 24 h in these same regions, but it was increased versus baseline. Western blot analysis confirmed an increase in hsp72 protein in the ipsilateral cortex. The regional pattern of hsp72 mRNA induction in neurons was similar to the pattern of protein expression after CCI, with the exceptions that hsp72 mRNA, but not protein, was expressed in the dentate gyrus and the lateral aspect of the CA3 region of the hippocampus (CA3-a). The stress response, as detected by hsp72 expression, is induced in some neurons in some regions that are selectively vulnerable to delayed neuronal death in this model of TBI. The failure to translate some proteins including hsp72 may be associated with delayed neuronal death in certain hippocampal regions after TBI.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA		Clark, RSB (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, K08NS001946] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5P30 HD28836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1KO8 NS01946-01, 2P50 NS 30318-04A1] Funding Source: Medline		ABE K, 1991, NEUROSCI LETT, V125, P166, DOI 10.1016/0304-3940(91)90018-O; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BURDON RH, 1993, MOL ASPECTS MED, V14, P83, DOI 10.1016/0098-2997(93)90020-E; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CURRIE RW, 1981, SCIENCE, V214, P72, DOI 10.1126/science.7280681; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; GRAHAM SH, 1996, J NEUROTRAUM, V13, P620; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KATO H, 1993, BRAIN RES, V615, P240, DOI 10.1016/0006-8993(93)90033-J; KINOUCHI H, 1993, J CEREBR BLOOD F MET, V13, P105, DOI 10.1038/jcbfm.1993.13; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; KRAUSE GS, 1993, STROKE, V24, P747, DOI 10.1161/01.STR.24.5.747; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LI Y, 1992, ACTA NEUROPATHOL, V84, P94, DOI 10.1007/BF00427221; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Matz P, 1996, STROKE, V27, P504, DOI 10.1161/01.STR.27.3.504; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; NOWAK TS, 1994, BRAIN PATHOL, V4, P67; NOWAK TS, 1991, J CEREBR BLOOD F MET, V11, P432, DOI 10.1038/jcbfm.1991.84; NOWAK TS, 1994, HEAT SHOCK PROTEINS, P55; Papadopoulos MC, 1996, NEUROREPORT, V7, P429, DOI 10.1097/00001756-199601310-00013; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; SHARP FR, 1991, J CEREBR BLOOD F MET, V11, P621, DOI 10.1038/jcbfm.1991.113; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; SIMON RP, 1991, J NEUROSCI, V11, P881; SINZ EH, 1997, J NEUROTRAUM, V14, P769; Soares HD, 1995, J NEUROSCI, V15, P8223; States BA, 1996, J CEREBR BLOOD F MET, V16, P1165, DOI 10.1097/00004647-199611000-00011; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; UNEY JB, 1993, FEBS LETT, V334, P313, DOI 10.1016/0014-5793(93)80701-U; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; VASS K, 1989, NEUROSCI LETT, V100, P259, DOI 10.1016/0304-3940(89)90695-2; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	63	29	33	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					171	181		10.1089/neu.1998.15.171			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500002	9528917				2022-02-06	
J	Kadotani, H; Namura, S; Katsuura, G; Terashima, T; Kikuchi, H				Kadotani, H; Namura, S; Katsuura, G; Terashima, T; Kikuchi, H			Attenuation of focal cerebral infarct in mice lacking NMDA receptor subunit NR2C	NEUROREPORT			English	Article						binding assay; cerebral infarction; gene knockout; ischemic brain injury; MCA occlusion; mutant mice; NMDA receptor; stroke	D-ASPARTATE RECEPTOR; MOLECULAR DIVERSITY; GLUTAMATE RECEPTORS; BRAIN; RAT; ANTAGONIST; CHANNEL; BLOCKADE; PROTECT; DAMAGE	NEURONAL death following cerebral vascular occlusion may be caused in part by the action of glutamate acting through the NMDA receptor. Here we demonstrate that gene disruption of the NR2C subunit of the NMDA receptor attenuates focal cerebral ischemic injury after permanent MCA occlusion, and that a low level of NR2C is expressed and active in the cerebral cortex. NR2C-deficient mice do not show impairment of motor coordination or motor learning. Therefore the development of drugs selectively inhibiting NR2C may prove beneficial in the treatment of stroke and traumatic brain injuries. (C) 1998 Rapid Science Ltd.	Kyoto Univ, Fac Med, Dept Biol Sci, Kyoto 606, Japan; Shionogi & Co Ltd, Shionogi Res Labs, Shiga 52034, Japan; Kyoto Univ, Fac Med, Dept Neurosurg, Kyoto 606, Japan		Namura, S (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 149 13th St Room 6403, Charlestown, MA 02129 USA.		Kadotani, Hiroshi/A-7908-2015	Kadotani, Hiroshi/0000-0001-7474-3315			CHEN G, 1959, J PHARMACOL EXP THER, V127, P241; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; EDVINSSON L, 1993, CEREBRAL BLOOD FLOW, P410; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; HONORE T, 1985, NEUROSCI LETT, V54, P27, DOI 10.1016/S0304-3940(85)80113-0; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kadotani H, 1996, J NEUROSCI, V16, P7859; Kishimoto Y, 1997, NEUROREPORT, V8, P3717, DOI 10.1097/00001756-199712010-00012; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LUBY ED, 1962, AM J PSYCHIAT, V119, P61, DOI 10.1176/ajp.119.1.61; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIKAWA E, 1997, J CEREB BLOOD FLOW M, V17, pS450; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Small DL, 1997, NEUROSCI LETT, V232, P87, DOI 10.1016/S0304-3940(97)00592-2; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WARD R, 1990, J ANAT, V173, P87	23	29	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0959-4965			NEUROREPORT	Neuroreport	FEB 16	1998	9	3					471	475		10.1097/00001756-199802160-00021			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ263	WOS:000072236600022	9512392				2022-02-06	
J	Tscherne, H; Regel, G; Pape, HC; Pohlemann, T; Krettek, C				Tscherne, H; Regel, G; Pape, HC; Pohlemann, T; Krettek, C			Internal fixation of multiple fractures in patients with polytrauma	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							EXTREMITY SEVERITY SCORE; PELVIC FRACTURES; TRAUMA; CLASSIFICATION; OSTEOSYNTHESIS; HEMORRHAGE; INJURIES; SALVAGE; STATE	Within the last decade understanding of the pathogenetic consequences of trauma has been improved significantly An additional reduction of lethality has been achieved that in part is related to increasing discrimination of complex injury patterns, Accordingly, additional staging in fracture management of these injuries has been developed, An overview of the current status of fracture management in polytrauma is given and certain regimens that are still controversially are discussed, The principles determined are based on the treatment experience of 4003 multiply injured patients within the past 23 years, The most important principles within the first hours after trauma represent adequate hemorrhage control, In fracture treatment the primary goal remains to perform primary stable osteosynthesis, In severe polytrauma with severe injuries to the extremities, the first decision is whether limb salvage can be achieved without risk of deterioration of the patient's condition, If this is the case, open fractures Grades III b and c usually can be stabilized primarily by unreamed intramedullary nailing or percutaneous plating, The priority pattern in multiple closed fractures is as follows: (1) tibia; (2) femur; (3) pelvis; (4) spine; and (5) upper extremity, Exceptions may ensue if severe head or thoracic trauma is present, Delayed treatment is performed for complex joint reconstruction, definitive treatment of maxillofacial injuries, and soft tissue reconstruction.	Hannover Med Sch, Dept Trauma Surg, D-30623 Hannover, Germany		Pape, HC (corresponding author), Hannover Med Sch, Dept Trauma Surg, D-30623 Hannover, Germany.			Pape, Hans-Christoph/0000-0002-2059-4980; Krettek, Christian/0000-0001-9807-0020			AEBI M, 1986, CLIN ORTHOP RELAT R, P244; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEHRMAN SW, 1990, J TRAUMA, V30, P792, DOI 10.1097/00005373-199007000-00005; BONE L, 1986, J BONE JOINT SURG AM, V68A, P945, DOI 10.2106/00004623-198668060-00023; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BROWN JJ, 1984, AM SURGEON, V50, P150; BROWNER BD, 1987, J TRAUMA, V27, P998, DOI 10.1097/00005373-198709000-00008; BURGESS AR, 1990, J TRAUMA, V30, P848, DOI 10.1097/00005373-199007000-00015; Cotler H B, 1988, J Orthop Trauma, V2, P222, DOI 10.1097/00005131-198802030-00008; CRYER HM, 1988, J TRAUMA, V28, P973, DOI 10.1097/00005373-198807000-00011; FAKHRY SM, 1994, J TRAUMA, V37, P255, DOI 10.1097/00005373-199408000-00018; GANZ R, 1991, CLIN ORTHOP RELAT R, P71; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HANSEN ST, 1987, J BONE JOINT SURG AM, V69A, P799, DOI 10.2106/00004623-198769060-00001; HELFET DL, 1990, CLIN ORTHOP RELAT R, P80; HOWE HR, 1987, AM SURGEON, V53, P205; HOYT DB, 1993, J TRAUMA, V35, P524, DOI 10.1097/00005373-199310000-00005; KRETTEK C, 1995, CLIN ORTHOP RELAT R, P34; Krettek C, 1996, INJURY, V27, P233, DOI 10.1016/0020-1383(96)00008-3; KRETTEK C, 1994, UNFALLCHIRURG, V97, P575; KROPFL A, 1995, J TRAUMA, V38, P717; MCNAMARA MG, 1994, J ORTHOP TRAUMA, V8, P81, DOI 10.1097/00005131-199404000-00001; MODRALL JG, 1993, ORTHOP CLIN N AM, V24, P557; MORENO C, 1986, J TRAUMA, V26, P987, DOI 10.1097/00005373-198611000-00005; PANETTA T, 1985, J TRAUMA, V25, P1021; PAPE HC, 1993, J TRAUMA, V35, P709, DOI 10.1097/00005373-199311000-00010; PAPE HC, 1993, J TRAUMA, V34, P72; Pape HC, 1996, TECH ORTHOP, V11, P2; PAPE HC, 1996, SCI PRACTICE INTRAME, P77; PELIAS ME, 1992, SURGERY, V111, P576; POHLEMANN T, 1994, CLIN ORTHOP RELAT R, P69; Pohlemann T, 1994, TECH ORTHOP, V9, P267, DOI DOI 10.1097/00013611-199400940-00004; QUABA AA, 1996, MANAGEMEN OPEN FRACT, P263; REGEL G, 1993, UNFALLCHIRURG, V96, P341; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020; REGEL G, 1997, IN PRESS J ORTHOP TR; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; Trentz O, 1993, Ther Umsch, V50, P491; TRUNKEY D, 1991, NEW ENGL J MED, V324, P1259; TSCHERNE H, 1987, CHIRURG, V58, P631; TSCHERNE H, 1982, UNFALLHEILKUNDE, V85, P111; TSCHERNE H, 1983, WORLD J SURG, V7, P80, DOI 10.1007/BF01655915; VANOS JP, 1994, J TRAUMA, V36, P495, DOI 10.1097/00005373-199404000-00006; Whitesides, 1996, J Am Acad Orthop Surg, V4, P209	45	29	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	FEB	1998		347					62	78					17	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	ZA795	WOS:000072402600010	9520876				2022-02-06	
J	Baguley, IJ; Felmingham, KL; Lahz, S; Gordon, E; Lazzaro, I; Schotte, DE				Baguley, IJ; Felmingham, KL; Lahz, S; Gordon, E; Lazzaro, I; Schotte, DE			Alcohol abuse and traumatic brain injury: Effect on event-related potentials	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							AUDITORY ODDBALL TASK; CLOSED HEAD-INJURY; REACTION-TIME; P300; PERFORMANCE; VALIDATION; SEQUELAE; STIMULI; AMNESIA; MEMORY	Objective: To examine the individual and combined impact that traumatic brain injury (TBI) and heavy social use of alcohol have on electrophysiologic correlates of working memory and evaluation of task-relevant information. Design: Case-control study. Setting: University hospital brain injury rehabilitation unit. Participants: Forty male volunteers divided into four groups on the basis of their history of TBI and alcohol intake. Subjects with TBI had experienced a severe closed head injury at least 1 year before testing. Main Outcome Measure: Event-related potentials (ERPs) and neuropsychometric tests. Results: Groups showed no significant differences in average age or neuropsychological tests. TBI groups did not differ in time postinjury or on severity measures. Alcohol use measures were significantly greater in the two alcohol groups. N200 latency and P300 amplitude were impaired in heavy social drinkers and in nondrinking subjects with TBI relative to controls, but were significantly impaired in subjects with TBI who were also heavy social drinkers. Conclusion: The results indicate that although alcohol use and TBI independently produce mild alterations in some aspects of late ERP components, the ERP changes an significantly greater when alcohol use and TBI are combined. This study provides evidence that heavy social drinking after TBI has a measurable impact on electrophysiologic correlates of cognition. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	WESTMEAD HOSP,DEPT PSYCHOL MED,COGNIT NEUROSCI UNIT,WESTMEAD,NSW 2145,AUSTRALIA; UNIV SYDNEY,SYDNEY,NSW 2006,AUSTRALIA		Baguley, IJ (corresponding author), WESTMEAD HOSP,BRAIN INJURY REHABIL SERV,WESTMEAD,NSW 2145,AUSTRALIA.		Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			Babor T., 1989, ALCOHOL USE DISORDER; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; CIESIELSKI KT, 1985, ALCOHOL ALCOHOLISM, V20, P403; COHEN HL, 1995, ALCOHOL CLIN EXP RES, V19, P469, DOI 10.1111/j.1530-0277.1995.tb01533.x; CONIGRAVE KM, 1995, ADDICTION, V90, P1349, DOI 10.1111/j.1360-0443.1995.tb03552.x; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; FITZGERALD PG, 1983, BIOL PSYCHOL, V17, P241, DOI 10.1016/0301-0511(83)90003-0; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; HAIG AR, 1995, ELECTROEN CLIN NEURO, V94, P288, DOI 10.1016/0013-4694(95)98480-V; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; KASEDA Y, 1994, JPN J PSYCHIAT NEUR, V48, P23; KEUTZER JS, 1990, COGNITIVE REHABIL, V8, P14; KRULL KR, 1994, PROG NEURO-PSYCHOPH, V18, P1247, DOI 10.1016/0278-5846(94)90091-4; MEARNS J, 1993, J CLIN PSYCHOL, V49, P714, DOI 10.1002/1097-4679(199309)49:5<714::AID-JCLP2270490515>3.0.CO;2-H; NATAANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; NATAANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375; Nichols JM, 1996, J STUD ALCOHOL, V57, P125, DOI 10.15288/jsa.1996.57.125; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; OSCARBERMAN M, 1987, ALCOHOL, V4, P289, DOI 10.1016/0741-8329(87)90025-5; PARSONS OA, 1993, NEUROL CLIN, V11, P205, DOI 10.1016/S0733-8619(18)30178-6; PARSONS OA, 1990, ALCOHOL CLIN EXP RES, V14, P746, DOI 10.1111/j.1530-0277.1990.tb01239.x; POLICH J, 1991, American Journal of EEG Technology, V31, P201; PORJESZ B, 1987, ALCOHOL, V4, P283, DOI 10.1016/0741-8329(87)90024-3; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; REGAN D, 1988, HUMAN BRAIN ELECTROP; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; SEGALOWITZ SJ, 1993, PSYCHOPHYSIOLOGY, V30, P451, DOI 10.1111/j.1469-8986.1993.tb02068.x; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; STEVENS J, 1991, APPL MULTIVARIATE ST; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6	35	29	30	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1997	78	11					1248	1253		10.1016/S0003-9993(97)90339-7			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	YE945	WOS:A1997YE94500014	9365356				2022-02-06	
J	Snow, P; Douglas, J; Ponsford, J				Snow, P; Douglas, J; Ponsford, J			Procedural discourse following traumatic brain injury	APHASIOLOGY			English	Article							CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; AMNESIA; ABILITY; ADULTS	Procedural discourse is a monologue discourse task concerned with explaining to a listener how a particular activity is carried out. The study reported here is part of a series of investigations into discourse abilities following severe traumatic brain injury (TBI). The aim of this study was to compare the procedural discourse skills of a group of 26 TBI speakers, with those of two demographically distinct control groups. The first control group comprised 26 non-TBI orthopaedic patients, and the second control group comprised 26 university students. These control groups were selected because of the hypothesis that premorbid demographic factors could influence sociolinguistic skills, and hence performance on a procedural discourse task. The TBI group was systematically compared with the control groups on content, productivity, and pragmatic measures. They were not significantly different from orthopaedic patients on measures relating to content and productivity; however, they did differ significantly from the university students on these measures. The TBI group differed significantly from both control groups with respect to the production of pragmatic errors, and these were predominantly concerned with information transfer. The results are discussed in relation to issues in selecting control groups for discourse research following TBI, together with the clinical implications of the findings.	LA TROBE UNIV,MELBOURNE,VIC,AUSTRALIA; BETHESDA HOSP,MELBOURNE,VIC,AUSTRALIA				Douglas, Jacinta M/C-2380-2009	Snow, Pamela/0000-0002-2426-8349; Douglas, Jacinta/0000-0003-0940-6624			ANDERSON DW, 1980, J NEUROSURGERY S, V53; BAYLES C, 1994, LANGUAGE INTERVENTIO, P535; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CANNITO M P, 1988, Seminars in Speech and Language, V9, P117, DOI 10.1055/s-0028-1082459; COEHLO CA, 1994, DISCOURSE ANAL APPL, P95; COEHLO CA, 1991, ARCH PHYSICAL MED RE, V72, P465; COEHLO CA, 1991, BRAIN INJURY, V5, P381; COEHLO CA, 1996, J SPEECH HEARING S 1, V39, pS5; COEHLO CA, 1995, APHASIOLOGY, V9, P409; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Damico J. S., 1985, COMMUNICATION SKILLS, P165; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Grice H. P., 1975, SYNTAX SEMANTICS, P41; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HAGEN C, 1981, TOPICS LANGUAGE  SEP, P73; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L, 1995, COGNITIVE COMMUNICAT; HUDSON RA, 1980, SOCIOLINGUISTICS; JORDAN F, 1990, AUSTR J HUMAN COMMUN, V18, P69; KEPPELL G, 1991, DESIGN ANAL RES HDB; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LINSCOTT RJ, 1996, BRAIN INJURY, V10, P3987; Loban W., 1963, 1 NCTE; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; Patry R., 1990, DISCOURSE ABILITY BR, P3, DOI 10.1007/978-1-4612-3262-9_1; Rimel RW, 1990, REHABILITATION ADULT, P8; Ruff R, 1991, COGNITIVE REHABILITA, P23; Shadden B.B., 1991, CLIN APHASIOLOGY, V20, P327; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; SNOW P, 1995, TRAUMATIC BRAIN INJU, P137; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; ULATOWSKA H, 1981, CLIN APHASIOLOGY C P, V17, P75; Ulatowska Hanna K., 1990, DISCOURSE ABILITY BR, P180, DOI 10.1007/978-1-4612-3262-9_8; ULATOWSKA HK, 1983, BRAIN LANG, V18, P315, DOI 10.1016/0093-934X(83)90023-8; ULATOWSKA HK, 1988, NEUROPSYCHOLOGICAL S, P108; [No title captured]	45	29	29	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	OCT	1997	11	10					947	967		10.1080/02687039708249421			21	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	XY420	WOS:A1997XY42000002					2022-02-06	
J	Craig, SC; Morgan, J				Craig, SC; Morgan, J			Parachuting injury surveillance, Fort Bragg, North Carolina, May 1993 to December 1994	MILITARY MEDICINE			English	Article								Surveillance for parachute-related injuries was conducted at Fort Bragg, North Carolina, between May 1993 and December 1994, During this 20-month period, lower-extremity injuries (27% of all injuries), axial skeletal (back and neck) strains and sprains (19.3%), and closed head injuries (18.4%) were the leading causes of injury, The incidence of injuries requiring emergency care was 8/1,000 jumps, This rate is well within the jump injury planning estimate, suggesting that airborne training and operations are conducted in a safe and effective manner at Fort Bragg.			Craig, SC (corresponding author), USA,EPIDEMIOL PROGRAM BRANCH,CTR HLTH PROMOT WELLNESS & PREVENT MED,ABERDEEN PROVING GROUND,MD 21045, USA.						*USA, 1994, T951 US ARM RES I EN	1	29	33	0	1	ASSN MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814	0026-4075			MIL MED	Milit. Med.	MAR	1997	162	3					162	164		10.1093/milmed/162.3.162			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WP113	WOS:A1997WP11300006	9121659	Bronze			2022-02-06	
J	Farooque, M; Hillered, L; Holtz, A; Olsson, Y				Farooque, M; Hillered, L; Holtz, A; Olsson, Y			Effects of moderate hypothermia on extracellular lactic acid and amino acids after severe compression injury of rat spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						excitatory amino acids; glutamate; hypothermia; lactate; microdialysis; rat; spinal cord; trauma	TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; BLOOD-FLOW; TEMPERATURE; RELEASE; LACTATE; PROTECTION; GLUTAMATE	We evaluated in rats, the effect of moderate hypothermia (30-31 degrees C) on extracellular levels of amino acids, with special emphasis on the excitatory amino acids (EAAs) glutamate and aspartate, lactate and pyruvate, after severe spinal cord compression. A laminectomy of Th-7 and Th-8 was made. A probe was inserted in a dorsal horn and microdialysis was performed for 1.5 h before and 4 h after applying se vere compression for 5 min. Dialysate samples were collected at intervals of 10 min and analyzed by high-performance liquid chromatography. In normothermic (37.5 degrees C) animals there was a several-fold rise of glutamate that peaked in the first 10 min fraction after trauma. Hypothermic animals showed a similar increase after trauma, which was statistically significant until 20 min after injury. The level of glutamate was significantly higher in hypothermic animals from 20 to 70 min after injury, compared with normothermic animals. Aspartate also showed a marked increase following injury. The peak concentration was similar for both groups, whereas recovery was delayed in hypothermic animals. There was no significant difference between the normothermic and hypothermic animals for arginine, taurine, alanine, glutamine, histadine, glycine, threonine, tyrosine, and asparagine. No significant effect of hypothermia on lactate or lactate/pyruvate was noted. However, the mean level of lactate tended to be lower and recovery was quicker in hypothermic animals. The results of the present study suggest that moderate hypothermia does not attenuate extracellular accumulation of EAAs or markedly improve energy metabolism in our model. Instead, our findings raise the possibility that moderate hypothermia prolongs the duration of glutamate receptor overactivation. Since hypothermia effectively attenuates glutamate release in CNS and spinal cord ischemia models our results suggest different mechanisms of extracellular accumulation of EAAs in ischemia and trauma.	UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN		Farooque, M (corresponding author), UNIV UPPSALA HOSP,NEUROPATHOL LAB,S-75185 UPPSALA,SWEDEN.						ALLEN BT, 1994, J VASC SURG, V19, P332, DOI 10.1016/S0741-5214(94)70108-3; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BUISSON A, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P417; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FAROOQUE M, 1992, ACTA NEUROPATHOL, V84, P613; FAROOQUE M, 1994, ACTA NEUROL SCAND, V89, P36; Farooque M, 1996, J NEUROCHEM, V66, P1125; FAROOQUE M, 1995, J NEUROTRAUM, V12, P41, DOI 10.1089/neu.1995.12.41; FAROOQUE M, 1996, J NEUROTRAUMA, V13, P535; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1993, RES P ARNMD, V71, P81; HALLSTROM A, 1989, J PHARMACOL METHOD, V22, P113; Hansebout R R, 1975, Surg Neurol, V4, P531; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kuchner E F, 1976, Surg Neurol, V6, P371; Li GL, 1996, ACTA NEUROPATHOL, V91, P155, DOI 10.1007/s004010050407; Li GL, 1996, ACTA NEUROPATHOL, V92, P19, DOI 10.1007/s004010050484; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LI GL, 1995, RESTOR NEUROL NEUROS, V8, P189, DOI 10.3233/RNN-1995-8404; LIN BW, 1995, STROKE, V26, P1634, DOI 10.1161/01.STR.26.9.1634; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LO EH, 1993, NEUROL RES, V15, P281; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MELLERGARD P, 1990, British Journal of Neurosurgery, V4, P31, DOI 10.3109/02688699009000679; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; NATALE JE, 1989, STROKE, V20, P770, DOI 10.1161/01.STR.20.6.770; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P467, DOI 10.1111/j.1600-0404.1988.tb03689.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; SCHOUSBOE A, 1992, CAN J PHYSL PHARM, V70, P356; SHUAIB A, 1993, NEUROCHEM RES, V18, P663, DOI 10.1007/BF00966779; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x	42	29	29	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1997	14	1					63	69		10.1089/neu.1997.14.63			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WK032	WOS:A1997WK03200007	9048312				2022-02-06	
J	Geldmacher, DS; Hills, EC				Geldmacher, DS; Hills, EC			Effect of stimulus number, target-to-distractor ratio, and motor speed on visual spatial search quality following traumatic brain injury	BRAIN INJURY			English	Article							NEGLECT; PERFORMANCE; ATTENTION; DISEASE	The object of this study was to investigate stimulus effects and motor limitations on visuospatial performance after traumatic blain injury (TBI). Previous findings have not fully explained the basis of attentional impairments after TBI. There has been little study of the spatial aspects of attention and information processing in this group. We studied 20 patients after severe TBI and 21 healthy controls. Four random-array letter cancellation tasks, varying in number of stimuli (50 and 100) and target-to-distracter ratio (1:4 and 1:9) were employed. Performance was calculated from the number and proportion of cancelled targets, as well as time to completion. TBI subjects were slower on finger tapping and achieved lower cancellation perfomance scores. Both TBI subjects and controls performed better on tasks with target-to-distractor (T/D) ratios of 1:4 than on those with 1:9. There was no effect of stimulus number. We conclude that there are both quantitative (speed) and qualitative contributors to impaired visuospatial ability following TBI. Motor impairments may slow the overall cancellation performance, but the differential effect of T/D ratio in the two populations suggests that TBI impairs quality of research. Accounting for both speed and accuracy suggests increased utility for the cancellation paradigm in clinical and research assessment of visuospatial attention.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT NEUROL, NEW BRUNSWICK, NJ 08903 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT REHABIL MED, NEW BRUNSWICK, NJ 08903 USA; JOHN F KENNEDY MED CTR, JFK JOHNSON REHABIL INST, CTR HEAD INJURIES, EDISON, NJ USA; JOHN F KENNEDY MED CTR, JFK JOHNSON REHABIL INST, DEPT REHABIL MED, EDISON, NJ USA								ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; FOLDI NS, 1992, J GERONTOL, V47, pP146, DOI 10.1093/geronj/47.3.P146; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; GELDMACHER DS, 1995, NEUROPSY NEUROPSY BE, V8, P259; GELDMACHER DS, 1994, NEUROPSY NEUROPSY BE, V7, P275; Hagen C., 1972, LEVELS COGNITIVE FUN; Heilman KM, 1993, CLIN NEUROPSYCHOLOGY, P279; LEVIN HS, 1988, SCAND J REHABIL MED, P33; LEZAK M, 1983, NEUROPSYCHOLOGICAL A, P554; MCNENY R, 1990, NEUROREHABILITATION, V1, P72; Mesulam M., 1985, PRINCIPLES BEHAV NEU; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1987, NEUROBEHAVIORAL RECO, P390; Shum DHK, 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; STONE SP, 1991, J NEUROL NEUROSUR PS, V54, P345, DOI 10.1136/jnnp.54.4.345; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VILLARDITA C, 1983, ARCH NEUROL-CHICAGO, V40, P737, DOI 10.1001/archneur.1983.04050110055008; WEINTRAUB S, 1987, ARCH NEUROL-CHICAGO, V44, P621, DOI 10.1001/archneur.1987.00520180043014	20	29	29	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1997	11	1					59	66		10.1080/026990597123818			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	WB723	WOS:A1997WB72300006	9012552				2022-02-06	
J	Brucia, J; Rudy, E				Brucia, J; Rudy, E			The effect of suction catheter insertion and tracheal stimulation in adults with severe brain injury	HEART & LUNG			English	Article							HEAD-INJURY; INTRACRANIAL HYPERTENSION; ENDOTRACHEAL; LIDOCAINE; PRESSURE	OBJECTIVE: To determine the effect of suction catheter insertion and tracheal stimulation on cerebrovascular and systemic vascular status in adults with severe traumatic brain injury. DESIGN: Quasi-experimental, within-subject design. SETTING: Two university-affiliated critical care units. SUBJECTS: Thirty intubated and mechanically ventilated adults with severe brain injury. The participants' average age was 31 +/- 15 years. OUTCOME MEASURES: Mean intracranial pressure (MICP), mean arterial pressure (MAP), cerebral perfusion pressure (CPP), and heart rate (HR) were measured. INTERVENTION: Endotracheal suction catheter insertion with tracheal stimulation was performed. RESULTS: Suction catheter insertion and tracheal stimulation, isolated from other components of the suctioning procedure, significantly increased MICP, MAP, and CPP. KR was not significantly increased. During the application of negative pressure for actual suctioning, MICP and HR significantly increased, whereas MAP and CPP did not significantly change compared with catheter insertion. CONCLUSION: Tracheal stimulation during suction catheter insertion initiates both cerebrovascular and systemic vascular responses during the suctioning procedure. Study findings suggest that a potentially productive direction for intervention research is to identify ways to minimize airway stimulation during the suctioning procedure.			Brucia, J (corresponding author), UNIV VIRGINIA,SCH NURSING,MCLEOD HALL,CHARLOTTESVILLE,VA 22903, USA.						BAUN M, 1977, American Review of Respiratory Disease, V115, P186; Baun M M, 1984, West J Nurs Res, V6, P213, DOI 10.1177/019394598400600206; Brucia J J, 1992, J Neurosci Nurs, V24, P205; CAMPBELL V, 1989, THESIS CASE W RES U; CHULAY M, 1988, HEART LUNG, V17, P654; Crosby L J, 1992, J Neurosci Nurs, V24, P40; DONEGAN MF, 1980, ANESTHESIOLOGY, V52, P516, DOI 10.1097/00000542-198006000-00014; ERSSON U, 1990, ACTA ANAESTH SCAND, V34, P99, DOI 10.1111/j.1399-6576.1990.tb03051.x; FELDMAN Z, 1993, HEAD INJURY, P247; FISHER DM, 1982, ANESTHESIOLOGY, V57, P416, DOI 10.1097/00000542-198211000-00013; HAMILL JF, 1981, ANESTHESIOLOGY, V55, P578, DOI 10.1097/00000542-198111000-00016; KONTOS HA, 1978, AM J PHYSIOL, V234, pH582, DOI 10.1152/ajpheart.1978.234.5.H582; KONTOS J, 1977, AM J PHYSIOL, V234, pH371; MARSHALL L, 1986, CLIN NEUR P C NEUR S; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PARSONS LC, 1984, HEART LUNG, V13, P372; PIERCE JB, 1987, HEART LUNG, V16, P34; RIGEL DF, 1989, CIRC RES, V64, P276, DOI 10.1161/01.RES.64.2.276; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; RUDY EB, 1991, HEART LUNG, V20, P667; SAUL T, 1986, CLIN NEUR P C NEUR S; SHAM JSK, 1993, J APPL PHYSIOL, V75, P772, DOI 10.1152/jappl.1993.75.2.772; SHAPIRO HM, 1975, ANESTHESIOLOGY, V43, P445, DOI 10.1097/00000542-197510000-00010; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; SKELLEY BFH, 1980, HEART LUNG, V9, P316; STONE K, 1991, NURS RES, V76, P76; WHITE PF, 1982, ANESTHESIOLOGY, V57, P242, DOI 10.1097/00000542-198209000-00019; YANO M, 1986, ANESTHESIOLOGY, V64, P651, DOI 10.1097/00000542-198605000-00019; [No title captured]	30	29	31	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0147-9563			HEART LUNG	Heart Lung	JUL-AUG	1996	25	4					295	303		10.1016/S0147-9563(96)80065-3			9	Cardiac & Cardiovascular Systems; Nursing; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Nursing; Respiratory System	VA247	WOS:A1996VA24700005	8836745				2022-02-06	
J	Scremin, OU; Jenden, DJ				Scremin, OU; Jenden, DJ			Cholinergic control of cerebral blood flow in stroke, trauma and aging	LIFE SCIENCES			English	Article; Proceedings Paper	Scientific Festschrift on Cholinergic and Related Mechanisms in Aging and Disease - A Tribute to Donald J Jenden, MD	NOV 17-18, 1995	UNIV CALIF LOS ANGELES, LOS ANGELES, CA	Loyola Univ Chicago Stritch Sch Med, Neurosci & Aging Inst	UNIV CALIF LOS ANGELES	cerebrovascular circulation; acetylcholine; choline; brain injuries; aging	ALZHEIMERS-DISEASE; RAT-BRAIN; PLASMA CHOLINE; ACETYLCHOLINE; METABOLISM; DEMENTIA; VASODILATATION; AUTOREGULATION; STIMULATION; TURNOVER	Enhancing the availability of endogenous acetylcholine by inhibition of cholinesterase with physostigmine, eptastigmine or soman at sub-toxic doses increases cerebral blood flow (CBF) and the response of this variable to changes in PaCO2. These effects are not correlated with metabolic activation, suggesting that the function of the cholinergic vasodilatation is not merely to supply metabolic substrates. Since choline (Ch) can exchange between blood and the brain extracellular milieu the stage is set for possible feedback interactions between ACh synthesis and CBF. A negative feedback of CBF on ACh synthesis under conditions of a negative arteriovenous (A-V) difference for Ch across cerebral capillaries may contribute to stabilize CBF in ischemia. Eptastigmine and physostigmine significantly improve perfusion in experimental models of focal cerebral ischemia and traumatic brain injury respectively. During the short periods of time in which the A-V difference for Ch across the brain is positive, a positive feedback between cerebral free Ch and CBF may enhance the ability of the brain to recover Ch from the circulation for synthesis of membrane phospholipids. A loss of cholinergic cerebrovascular control may thus impair the survival of all cells within the CNS and contribute to the pathophysiology of dementia. Perhaps the view that the loss of cholinergic cells is the end point of Alzheimer's dementia could be modified to state that a cholinergic deficit may be the starting point of a decline in cerebral phospholipid turnover and cell membrane renewal that could lead to a generalized deterioration of cerebral function.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,DEPT MOLEC & MED PHARMACOL,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOMATH,LOS ANGELES,CA 90073		Scremin, OU (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,GERIATR RES & EDUC CLIN CTR,11301 WILSHIRE BLVD,LOS ANGELES,CA 90073, USA.						AOYAGI M, 1975, J NEUROSURG, V43, P689, DOI 10.3171/jns.1975.43.6.0689; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRODIE C, 1991, DEV BRAIN RES, V61, P183, DOI 10.1016/0165-3806(91)90130-B; CHOI RL, 1975, J NEUROCHEM, V24, P735, DOI 10.1111/j.1471-4159.1975.tb11672.x; DROSS K, 1972, N-S ARCH PHARMACOL, V274, P91, DOI 10.1007/BF00501010; FALGOUT JC, 1987, J CEREB BLOOD FLO S1, V7, pS405; FREEMAN JJ, 1975, J NEUROCHEM, V24, P729, DOI 10.1111/j.1471-4159.1975.tb11671.x; FREEMAN JJ, 1976, LIFE SCI, V19, P949, DOI 10.1016/0024-3205(76)90285-X; FUMEYA H, 1990, ACT NEUR S, V51, P283; GEANEY DP, 1990, LANCET, V335, P1484, DOI 10.1016/0140-6736(90)93028-N; GUSTAFSON L, 1987, J CEREB BLOOD FLO S1, V7, pS404; HUNTER R, 1990, LANCET, V336, P450, DOI 10.1016/0140-6736(90)92007-5; JAGUST WJ, 1990, ARCH NEUROL-CHICAGO, V47, P628, DOI 10.1001/archneur.1990.00530060036013; JENDEN DJ, 1991, B CLIN NEUROSCI, V55, P99; KAWAMURA Y, 1975, J NEUROSURG, V43, P676, DOI 10.3171/jns.1975.43.6.0676; KETY S S, 1956, J Chronic Dis, V3, P478, DOI 10.1016/0021-9681(56)90146-1; KLEIN J, 1992, J NEUROCHEM, V58, P870, DOI 10.1111/j.1471-4159.1992.tb09337.x; KLEIN J, 1990, J NEUROCHEM, V28, P897; KOMATANI A, 1988, J NUCL MED, V29, P1621; LAKHER M, 1987, BRAIN RES, V419, P131, DOI 10.1016/0006-8993(87)90576-2; LAVY S, 1978, ANN NEUROL, V4, P445, DOI 10.1002/ana.410040510; MONTALDI D, 1990, J NEUROL NEUROSUR PS, V53, P33, DOI 10.1136/jnnp.53.1.33; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; PROHOVNIK I, 1988, NEUROLOGY, V38, P931, DOI 10.1212/WNL.38.6.931; REED BR, 1989, NEUROLOGY, V39, P1537, DOI 10.1212/WNL.39.11.1537; ROGERS RL, 1986, NEUROLOGY, V36, P1; ROVERE AA, 1973, STROKE, V4, P969, DOI 10.1161/01.STR.4.6.969; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; Scremin A M, 1992, J Stroke Cerebrovasc Dis, V2, P87, DOI 10.1016/S1052-3057(10)80212-5; Scremin O. U., 1995, Society for Neuroscience Abstracts, V21, P762; Scremin OU, 1973, STROKE, V4, P232, DOI 10.1161/01.STR.4.2.232; SCREMIN OU, 1983, J CEREBR BLOOD F MET, V3, P362, DOI 10.1038/jcbfm.1983.52; SCREMIN OU, 1989, STROKE, V20, P1524, DOI 10.1161/01.STR.20.11.1524; SCREMIN OU, 1982, J CEREBR BLOOD F MET, V2, P241, DOI 10.1038/jcbfm.1982.24; SCREMIN OU, 1988, NEUROPSYCHOPHARMACOL, V1, P297; SCREMIN OU, 1995, FASEB J, V9, pA381; SCREMIN OU, 1994, FASEB J, V8, pA828; SCREMIN OU, 1992, J NEUROCHEM, V59, P906, DOI 10.1111/j.1471-4159.1992.tb08329.x; SCREMIN OU, 1993, J CEREB BLOOD FLOW M, V130, P702; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SZERB JC, 1967, J PHYSIOL-LONDON, V192, P329, DOI 10.1113/jphysiol.1967.sp008303; TACHIBANA H, 1984, J AM GERIATR SOC, V32, P114, DOI 10.1111/j.1532-5415.1984.tb05850.x; WILSON K, 1991, BRIT J PSYCHIAT, V158, P558, DOI 10.1192/bjp.158.4.558; ZEISEL SH, 1981, ANNU REV NUTR, V1, P95, DOI 10.1146/annurev.nu.01.070181.000523	44	29	29	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0024-3205			LIFE SCI	Life Sci.	APR 26	1996	58	22					2011	2018		10.1016/0024-3205(96)00192-0			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	UH285	WOS:A1996UH28500015	8637431				2022-02-06	
J	Holmin; Mathiesen, T				Holmin; Mathiesen, T			Dexamethasone and colchicine reduce inflammation and delayed oedema following experimental brain contusion	ACTA NEUROCHIRURGICA			English	Article						CNS trauma; experimental contusion; inflammation; brain oedema	CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HIGH-DOSE DEXAMETHASONE; MONONUCLEAR PHAGOCYTES; CEREBRAL EDEMA; TRAUMATIC INJURY; RAT; MACROPHAGES; ANTIGENS	The effect of anti-inflammatory treatment on monocyte/macrophage infiltration, major histocompatibility complex molecules (MHC) class II expression and delayed oedema following experimental brain contusion was studied by immunohistochemistry and tissue-specific gravity measurement in 44 rats. Colchicine, chloroquine and dexamethasone administered once daily for five days after the trauma reduced inflammation and oedema. The difference was statistically significant with colchicine and dexamethasone. The findings comprise further evidence of a pathogenetically important inflammation after experimental contusion. It is probable that anti-inflammatory agents may prevent secondary neurological damage due to elevated intracranial pressure and cell to cell- or cytokine-mediated neuronal degeneration and demyelination.	KAROLINSKA HOSP, DEPT CLIN NEUROSCI, NEUROSURG SECT, S-17176 STOCKHOLM, SWEDEN				mathiesen, tiit/ABC-3627-2021	Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; BARCLAY AN, 1981, IMMUNOLOGY, V42, P593; BAUER J, 1993, J NEUROIMMUNOL, V48, P13, DOI 10.1016/0165-5728(93)90053-2; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1989, P 7 INT S INTR PRESS; DAMOISEAUX JGMC, 1989, J LEUKOCYTE BIOL, V46, P246, DOI 10.1002/jlb.46.3.246; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; DUPLESSIS JJ, 1992, BRIT J NEUROSURG, V6, P145, DOI 10.3109/02688699209002917; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Gobiet W, 1976, INTRACRANIAL PRESSUR, P231; GORDON CR, 1990, ACT NEUR S, V51, P268; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Kobrine A I, 1973, Surg Neurol, V1, P38; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; MCLAURIN RL, 1965, J NEUROSURG, V296; MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; POLMAN CH, 1986, J NEUROIMMUNOL, V11, P215, DOI 10.1016/0165-5728(86)90005-6; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SMINIA T, 1987, IMMUNOBIOLOGY, V174, P43, DOI 10.1016/S0171-2985(87)80083-9; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STEIN SC, 1993, NEUROSURGERY, V32, P30; TODD NV, 1990, ACT NEUR S, V51, P296; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; UNTERBERG A, 1993, NEUROSURGERY, V32, P23; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WOODROOFE MN, 1993, CYTOKINE, V5, P583, DOI 10.1016/S1043-4666(05)80008-0	44	29	29	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1996	138	4					418	424		10.1007/BF01420304			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	UG867	WOS:A1996UG86700018	8738392				2022-02-06	
J	LEWIS, SB; MYBURGH, JA; REILLY, PL				LEWIS, SB; MYBURGH, JA; REILLY, PL			DETECTION OF CEREBRAL VENOUS DESATURATION BY CONTINUOUS JUGULAR BULB OXIMETRY FOLLOWING ACUTE NEUROTRAUMA	ANAESTHESIA AND INTENSIVE CARE			English	Article						MEASUREMENT TECHNIQUES; CONTINUOUS JUGULAR BULB OXIMETRY; INTRACRANIAL PRESSURE; CEREBRAL PERFUSION PRESSURE; CAPNOGRAPHY; BRAIN; VENOUS DESATURATION; TRAUMA	ACUTE BRAIN INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; OXYGENATION; HYPERVENTILATION; HYPOXIA; DAMAGE	A prospective observational study was performed to assess the reliability of fibreoptic oximetric catheters and to identify the incidence and causes of jugular bulb oxygen desaturation in patients with acute closed head injury. There were twenty-five patients (30+/-16 years) with GCS less than or equal to 8 in this study. Jugular bulb oximetry, mean arterial pressure, intracranial pressure, end-tidal CO2 and pulse oximetry were monitored continuously. Catheter calibration against a laboratory oximeter was performed post insertion and thereafter eight-hourly Cerebral venous desaturation was defined as a jugular bulb oxygen saturation < 55% of > 10 minutes duration. There was a poor correlation for the first in vivo calibration (r(2)=0.602, P < 0.001, n=25). Thereafter a close correlation between jugular bulb catheter and oximetry values was demonstrated (r(2)=0.868, P<0.001, n=205). forty-two episodes of jugular bulb oxygen desaturation of 88 minutes mean duration (range 10 to 555) were observed. 83% occurred within 48 hours following injury. Hypocapnia was associated in 45% of episodes; hypoperfusion in 22%; raised ICP in 9% and a combination of the above in 24%. Validation with a laboratory oximeter is essential prior to continuous jugular bulb oximetry. Sustained episodes of cerebral venous desaturation are frequent within the first 48 hours following acute head injury. Factors such as hypocapnia and cerebral hypoperfusion that primarily reduce cerebral blood flow are predominant.	ROYAL ADELAIDE HOSP,DEPT INTENS CARE,ADELAIDE,SA,AUSTRALIA		LEWIS, SB (corresponding author), ROYAL ADELAIDE HOSP,DEPT NEUROSURG,N TERRACE,ADELAIDE,SA 5000,AUSTRALIA.			Reilly, Peter/0000-0003-3173-0666			ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1993, CRIT CARE MED, V21, P1242, DOI 10.1097/00003246-199308000-00027; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; JONES RR, 1993, WORLD WATCH, V6, P4; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38	20	29	30	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	JUN	1995	23	3					307	314		10.1177/0310057X9502300307			8	Anesthesiology; Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; General & Internal Medicine	RB451	WOS:A1995RB45100007	7573917	Green Submitted, Bronze			2022-02-06	
J	LEVIN, BE; BROWN, KL; PAWAR, G; DUNNMEYNELL, A				LEVIN, BE; BROWN, KL; PAWAR, G; DUNNMEYNELL, A			WIDESPREAD AND LATERALIZED EFFECTS OF ACUTE TRAUMATIC BRAIN INJURY ON NOREPINEPHRINE TURNOVER IN THE RAT-BRAIN	BRAIN RESEARCH			English	Article						HEAD TRAUMA; CATECHOLAMINE; 3-METHOXY-4-HYDROXYPHENYLGLYCOL; MHPG; CONTUSION; SENSORIMOTOR CORTEX; SOMATOSENSORY CORTEX	SENSORIMOTOR CORTEX INJURY; LOCUS COERULEUS SYSTEM; TRANSIENT ISCHEMIA; NORADRENALINE METABOLISM; BEAM-WALKING; LESION SIZE; RECOVERY; DAMAGE; HIPPOCAMPUS; AMPHETAMINE	Norepinephrine (NE) has been implicated in recovery of function following traumatic brain injury (TBI). While bilateral decreases in brain NE turnover occur at 6-24 h after TBI, it is unknown what effects unilateral TBI might have on brain NE turnover over the first few minutes after injury. Here male Sprague-Dawley rats had unilateral contusions of either the right or left somatosensory cortex produced by an air driven piston. At 30min after TBI, brain NE turnover was assessed by measuring the ratio of 3-methoxy-4-hydroxyphenylglycol (MHPG) to NE levels in various brain regions. Both right and left TBI produced 32-103% increases in NE turnover at the injury site and in the ipsilateral cerebral cortex surrounding, rostral and caudal to the injury as compared to the contralateral, uninjured site or to the homologous sites in uninjured controls. NE turnover was also altered selectively in some brain areas not affected by right TBI. Left TBI decreased NE turnover by 29% in the frontal cortex contralateral to the injury and by 24% bilaterally in the hypothalamus while increasing locus coeruleus NE turnover by 72% compared to uninjured controls. Thus, unilateral cortical TBI produced predominantly ipsilateral increases in cortical NE turnover but variable, bilateral changes in NE turnover in subcortical areas which were dependent upon the side of injury. These subcortical differences may explain some of the lateralized effects of cortical injury on post-injury behavior.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103		LEVIN, BE (corresponding author), DEPT VET AFFAIRS MED CTR,NEUROL SERV 127,E ORANGE,NJ 07018, USA.						ARVIN B, 1992, BRAIN RES, V579, P279, DOI 10.1016/0006-8993(92)90061-D; BLOMQVIST P, 1985, NEUROSCI LETT, V58, P353, DOI 10.1016/0304-3940(85)90080-1; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BRODIE BB, 1966, J PHARMACOL EXP THER, V154, P493; BUSTO R, 1985, ANN NEUROL, V18, P329, DOI 10.1002/ana.410180310; CALDERINI G, 1978, BRAIN RES, V157, P303, DOI 10.1016/0006-8993(78)90032-X; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; DUNNMEYNELL AA, 1992, 19TH ANN NEUR S; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GUSTAFSON I, 1991, EXP BRAIN RES, V86, P555; GUSTAFSON I, 1989, J CEREBR BLOOD F MET, V9, P171, DOI 10.1038/jcbfm.1989.25; HARIK SI, 1984, ANN NEUROL, V15, P568, DOI 10.1002/ana.410150609; HEILIG M, 1990, J NEURAL TRANSM-GEN, V79, P193, DOI 10.1007/BF01245130; HIAKALA H, 1987, J NEUROCHEM, V49, P1033; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; IDA Y, 1982, NEUROBIOL AGING, V3, P233, DOI 10.1016/0197-4580(82)90044-6; KAMISAKI Y, 1992, EUR J PHARMACOL, V217, P57, DOI 10.1016/0014-2999(92)90511-2; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; LAWTHO D, 1993, EUR J NEUROSCI, V5, P1494, DOI 10.1111/j.1460-9568.1993.tb00217.x; LEVIN BE, 1983, BRAIN RES, V289, P205, DOI 10.1016/0006-8993(83)90021-5; LEVIN BE, 1994, RESTOR NEUROL NEUROS, V7, P5, DOI 10.3233/RNN-1994-7102; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P221, DOI 10.1113/jphysiol.1986.sp016006; MIYAUCHI Y, 1989, J NEUROCHEM, V53, P408, DOI 10.1111/j.1471-4159.1989.tb07349.x; MORAN TH, 1984, LIFE SCI, V35, P1337, DOI 10.1016/0024-3205(84)90389-8; MOURADIAN RD, 1991, BRAIN RES, V546, P83, DOI 10.1016/0006-8993(91)91162-T; NEVANDER G, 1986, EXP BRAIN RES, V63, P439; NISHINO K, 1989, J CEREBR BLOOD F MET, V9, P358, DOI 10.1038/jcbfm.1989.54; NISHINO K, 1991, NEUROSCIENCE, V43, P361, DOI 10.1016/0306-4522(91)90300-D; PACAK K, 1993, HYPERTENSION, V22, P467, DOI 10.1161/01.HYP.22.4.467; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; ROBERT B, 1992, AGENTS ACTIONS, V37, P268, DOI 10.1007/BF02028119; SARMENTO A, 1991, N-S ARCH PHARMACOL, V343, P633; SCHANBERG SM, 1968, BIOCHEM PHARMACOL, V17, P247, DOI 10.1016/0006-2952(68)90330-4; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1993, J NEUROTRAUM, V10, pS181; WESTERINK BHC, 1984, J NEUROCHEM, V42, P934, DOI 10.1111/j.1471-4159.1984.tb12694.x; WIELOCH T, 1986, PHARM CEREBRAL ISCHE, P191	49	29	30	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 20	1995	674	2					307	313		10.1016/0006-8993(95)00032-L			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QN223	WOS:A1995QN22300017	7796111				2022-02-06	
J	WORLEY, G; HOFFMAN, JM; PAINE, SS; KALMAN, SL; CLAERHOUT, SJ; BOYKO, OB; KANDT, RS; SANTOS, CC; HANSON, MW; OAKES, WJ; COLEMAN, RE				WORLEY, G; HOFFMAN, JM; PAINE, SS; KALMAN, SL; CLAERHOUT, SJ; BOYKO, OB; KANDT, RS; SANTOS, CC; HANSON, MW; OAKES, WJ; COLEMAN, RE			18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN CHILDREN AND ADOLESCENTS WITH TRAUMATIC BRAIN INJURY	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							GLUCOSE-UTILIZATION; METABOLIC-RATE; HEAD-INJURIES; COMA	Twenty-two previously normal children and adolescents who suffered a severe, non-penetrating traumatic brain injury had PET during rehabilitation at a median of 1.5 months after the injury. Outcome was assessed at a median of 25 months after brain injury. 16 subjects had CT or MRI within 24 days of PET and 11 subjects had a second PET at the point of outcome (median 28 months after first PET). The PET score (obtained by adding the score of 15 brain regions: normal metabolism=1; reduced=0) was significantly associated with the clinical outcome measure. PET earlier than 12 weeks after head trauma correlated with outcome, but later PET did not. PET scores improved significantly between rehabilitation and outcome for the 11 subjects who had two PETs, but improvement was not associated with improvement in clinical condition. PET score did not add to the amount of variance explained in the last regression model for prediction of outcome when the results of contemporaneous CT/MRI and clinical condition were taken into account. The data suggest that routine PET during rehabilitation is no more useful than contemporaneous CT or MRI for prediction of outcome.	EMORY UNIV,SCH MED,ATLANTA,GA; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROL,WINSTON SALEM,NC 27103; CHILDRENS HOSP ALABAMA,DEPT NEUROSURG,BIRMINGHAM,AL		WORLEY, G (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710, USA.						ALAVI A, 1989, J NEUROPSYCHIAT, V1, P545; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BROWN JC, 1975, PSYCHOL MED, V5, P239, DOI 10.1017/S0033291700056592; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; CHUGANI HT, 1986, SCIENCE, V31, P840; Hagen C, 1979, REHABILITATION HEAD, P87; HUANG SC, 1979, J COMPUT ASSIST TOMO, V3, P804; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; JENNETT B, 1975, LANCET, V1, P480; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x	18	29	29	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	MAR	1995	37	3					213	220					8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	QM941	WOS:A1995QM94100004	7890126				2022-02-06	
J	KRAUS, MF				KRAUS, MF			NEUROPSYCHIATRIC SEQUELAE OF STROKE AND TRAUMATIC BRAIN INJURY - THE ROLE OF PSYCHOSTIMULANTS	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article; Proceedings Paper	1993 Annual Meeting of American-Psychiatric-Association, Issue Workshop 33	1993	SAN FRANCISCO, CA	Amer Psychiat Assoc		TRAUMATIC BRAIN INJURY; STROKE; METHYLPHENIDATE; DEXTROAMPHETAMINE; PSYCHOSTIMULANTS; NEUROPSYCHIATRIC SEQUELAE; COGNITION; MOOD; CORTICAL RECOVERY	CLOSED-HEAD-INJURY; POSTSTROKE DEPRESSION; ANTIDEPRESSANT THERAPY; LOCOMOTOR FUNCTION; MAJOR DEPRESSION; MEDICAL ILLNESS; CORTEX INJURY; D-AMPHETAMINE; METHYLPHENIDATE; DISORDERS	Objective: The primary purpose of this article is to review certain neuropsychiatric sequelae of stroke and traumatic brain injury (TBI), and the role of the psychostimulants methylphenidate (MPD) and dextroamphetamine (DAMP) in their treatment. Method: A general review of the topic is presented. Controlled and uncontrolled studies involving the use of the psychostimulants are discussed. These consist of 11 studies listed with Medline 2000 that deal specifically with stroke or head injury, with the oldest study reviewed dating back to 1984. Studies concerning the use of psychostimulants in the medically or neurologically ill are reviewed to the extent that they are pertinent. Results: The current literature consists primarily of uncontrolled case studies. However, these are reviewed and found to suggest a role for the use of the psychostimulants, which is discussed. Conclusions: In general, these drugs appear to be a reasonable treatment choice for certain types of mood, behavior, and cognitive symptoms following brain injury. However, it is noted that larger scale controlled studies are needed to adequately assess the clinical usefulness of these drugs.			KRAUS, MF (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT PSYCHIAT & BEHAV SCI,OSLER 320,BALTIMORE,MD 21287, USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000149] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32-AG00149] Funding Source: Medline		ALTMAN HJ, 1983, BEHAV BRAIN RES, V7, P51, DOI 10.1016/0166-4328(83)90004-9; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; ANGELERI F, 1993, STROKE, V24, P1478, DOI 10.1161/01.STR.24.10.1478; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; Auerbach S., 1989, PHYSICAL MED REHAB S, P1; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; CHIEUH CC, 1975, J PHARM EXPT THERAPE, V193, P559; CLARK ANG, 1979, J AM GERIATR SOC, V27, P174, DOI 10.1111/j.1532-5415.1979.tb06442.x; COLE JO, 1992, J CLIN PSYCHIAT, V53, P333; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DARVILL FT, 1959, JAMA-J AM MED ASSOC, V169, P1739, DOI 10.1001/jama.1959.03000320041011; DIETRICH WD, 1990, STROKE, V21, P147; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; EVANS RW, 1986, PSYCHOPHARMACOLOGY, V90, P211; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1993, CRIT REV NEURBIOL, V3, P135; FERGUSON JT, 1956, JAMA-J AM MED ASSOC, V160, P259, DOI 10.1001/jama.1956.02960390009003; FERNANDEZ F, 1987, PSYCHOSOMATICS, V28, P455, DOI 10.1016/S0033-3182(87)72476-1; FINKLESTEIN S, 1983, BRAIN RES, V271, P279, DOI 10.1016/0006-8993(83)90290-1; FISCH RZ, 1985, INT J PSYCHIAT MED, V15, P75, DOI 10.2190/FNLD-HTDM-9LP1-X3Y3; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; Gennarelli T. A., 1987, HEAD INJURY, P108; GOLD PE, 1984, BRAIN RES, V305, P103, DOI 10.1016/0006-8993(84)91124-7; GOLDSTEIN LB, 1990, STROKE, V21, P132; GOLDSTEIN LB, 1988, CEREBROVASC DIS, P303; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1985, PSYCHIAT CLIN N AM, V8, P875; HOUSE A, 1987, BMJ-BRIT MED J, V294, P76, DOI 10.1136/bmj.294.6564.76; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; JANE JA, 1982, OUTCOME PATHOLOGY HE, P229; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; KAPLITZ SE, 1975, J AM GERIATR SOC, V23, P271, DOI 10.1111/j.1532-5415.1975.tb00317.x; KATON W, 1980, AM J PSYCHIAT, V137, P963; KAUFMANN MW, 1984, J CLIN PSYCHIAT, V45, P82; KAUFMANN MW, 1984, CAN J PSYCHIAT, V29, P46, DOI 10.1177/070674378402900112; KAUFMANN MW, 1982, PSYCHOSOMATICS, V23, P817; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS MF, 1992, SOUTHERN MED J, V85, P985, DOI 10.1097/00007611-199210000-00012; Kuczenski R., 1983, STIMULANTS NEUROCHEM, P31; LAZARUS LW, 1992, J CLIN PSYCHIAT, V53, P447; LEMBERGER L, 1985, J CLIN PSYCHIAT, V46, P14; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LINGAM VR, 1988, J CLIN PSYCHIAT, V49, P151; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LIPSEY JR, 1984, LANCET, V1, P297; LITTLE KY, 1993, J CLIN PSYCHIAT, V54, P349; MASAND P, 1991, PSYCHOSOMATICS, V32, P203, DOI 10.1016/S0033-3182(91)72093-8; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; MURRAY GB, 1986, J CLIN PSYCHIAT, V47, P258; NATENSHON AL, 1956, DIS NERV SYST, V17, P392; ORLOSKY MJ, 1982, PSYCHOSOMATICS, V23, P609; PARIKH RM, 1987, STROKE, V13, P579; Parmelee D X, 1987, Brain Inj, V1, P41, DOI 10.3109/02699058709034443; PEARLSON GD, 1981, BRAIN RES, V218, P233, DOI 10.1016/0006-8993(81)91303-2; Pickett P, 1990, J Geriatr Psychiatry Neurol, V3, P146, DOI 10.1177/089198879000300304; RANDRUP A, 1970, AMPHETAMINES RELATED, P695; REDING MJ, 1986, ARCH NEUROL-CHICAGO, V43, P763, DOI 10.1001/archneur.1986.00520080011011; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1986, BRIT J PSYCHIAT, V148, P541, DOI 10.1192/bjp.148.5.541; ROBINSON RG, 1982, STROKE, V113, P635; SINYOR D, 1986, STROKE, V17, P1102, DOI 10.1161/01.STR.17.6.1102; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; WADE DT, 1987, BRIT J PSYCHIAT, V151, P200, DOI 10.1192/bjp.151.2.200; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WOODRUFF MI, 1981, LIFE SCI, V29, P2603, DOI 10.1016/0024-3205(81)90633-0; WOODS SW, 1986, J CLIN PSYCHIAT, V47, P12; WROBLEWSKI B, 1990, J CLIN PSYCHOPHARM, V10, P1214; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86	75	29	29	0	8	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1995	25	1					39	51		10.2190/BXRM-3M58-WBC5-A7EL			13	Psychiatry	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	RA699	WOS:A1995RA69900003	7649717				2022-02-06	
J	MCCLELLAND, RJ; FENTON, GW; RUTHERFORD, W				MCCLELLAND, RJ; FENTON, GW; RUTHERFORD, W			THE POSTCONCUSSIONAL-SYNDROME REVISITED	JOURNAL OF THE ROYAL SOCIETY OF MEDICINE			English	Article						POSTCONCUSSION SYNDROME; EEG; BRAIN-STEM EVOKED POTENTIALS; LIFE EVENTS AND SOCIAL DIFFICULTIES	MINOR HEAD-INJURY; CONCUSSION		UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT PSYCHIAT,DUNDEE DD1 9SY,SCOTLAND; ROYAL VICTORIA HOSP,DEPT ACCID & EMERGENCY,BELFAST,NORTH IRELAND		MCCLELLAND, RJ (corresponding author), QUEENS UNIV BELFAST,DEPT MENTAL HLTH,BELFAST,NORTH IRELAND.						Barth JT, 1989, MILD HEAD INJURY; Brown G. W., 1978, SOCIAL ORIGINS DEPRE; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; FENTON GW, 1992, BRIT J PSYCHIAT, V16, P416; GRONWALL D, 1975, LANCET, V2, P995; JENKINS A, 1986, LANCET, V2, P445; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MCKINLEY WW, 1993, J NEUROSURG PSYCHIAT, V46, P1084; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1978, INJURY, V10, P225; RUTHERFORD WH, 1988, ARCH EMERG MED, V5, P12; TAYLOR AR, 1966, LANCET, V2, P178; WATSON MR, 1994, IN PRESS BR J PSYCHI; Wing J. K., 1978, PSE ID CATEGO SYSTEM; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	25	29	30	0	1	ROYAL SOC MEDICINE SERVICES LTD	LONDON	1 WIMPOLE STREET, LONDON, ENGLAND W1M 8AE	0141-0768			J ROY SOC MED	J. R. Soc. Med.	SEP	1994	87	9					508	510					3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PF125	WOS:A1994PF12500006	7932452				2022-02-06	
J	ANDERSON, CV; BIGLER, ED				ANDERSON, CV; BIGLER, ED			THE ROLE OF CAUDATE-NUCLEUS AND CORPUS-CALLOSUM ATROPHY IN TRAUMA-INDUCED ANTERIOR HORN DILATION	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; DEGENERATIVE CHANGES; BRAIN INJURY; RESONANCE; MORPHOLOGY	Day-of-injury computerized tomography (CT) scans were compared to post-injury (at least 6 weeks) magnetic resonance (MR) imaging of 30 traumatic brain-injured (TBI) patients. Scans were matched as closely as possible at the head of the caudate nucleus (CN), a grey matter structure, and the anterior horns (AH) of the lateral ventricle. The CN and AH surface areas and width of the corpus callosum (CC), a white-matter structure, were measured. Results demonstrated a non-significant change in CN surface area, while AH showed a significant increase. CC showed a significant decrease in width. Lack of significant change in the CN, combined with a significant decrease in CC width, suggests that AH dilation is probably due to surrounding white as opposed to grey-matter atrophy.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,1086 SWKT,PROVO,UT 84602								BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1993, IN PRESS BRAIN INJUR; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; DALPAN GJ, 1992, NEUROLOGY, V42, P2125, DOI 10.1212/WNL.42.11.2125; Hall S, 1989, Arch Clin Neuropsychol, V4, P79; JOHNSON SC, IN PRESS NEUROPSYCHO; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SANDOR T, 1992, ARCH NEUROL-CHICAGO, V49, P381, DOI 10.1001/archneur.1992.00530280069024; YEO RA, 1991, J CLIN EXP NEUROPSYC, V13, P63	12	29	29	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					565	569		10.3109/02699059409151008			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200008	7987292				2022-02-06	
J	LEE, SC; ZASLER, ND; KREUTZER, JS				LEE, SC; ZASLER, ND; KREUTZER, JS			MALE PITUITARY-GONADAL DYSFUNCTION FOLLOWING SEVERE TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							TRANSIENT HYPOGONADOTROPIC HYPOGONADISM; HEAD TRAUMA; TESTICULAR FUNCTION; COMA; MEN	A prospective study was conducted to evaluate pituitary-gonadal function and correlated parameters in 21 adult males with severe traumatic brain injury during acute inpatient rehabilitation. Serum concentrations of testosterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were measured within 1 week after the patient was transferred to the rehabilitation unit. Fourteen of 21 patients (67%) had abnormally low testosterone levels. One of 21 patients had a subnormal FSH level and one had a supranormal level. Three of 21 patients had subnormal LH levels and two had supranormal levels. There was no correlation between the severity of brain injury and the levels of testosterone, FSH or LH. The presence of increased intracranial pressure, hypoxia, skull fracture or abnormal CT findings had no significant influence on the levels of testosterone, FSH or LH. The high incidence of hypotestosteronaemia in survivors of severe traumatic brain injury is seemingly more related to accompanying physiological stressors rather than structural or neurochemical disruption of the hypothalamic-pituitary-gonadal axis. Early identification is important relative to the potential neuromedical and rehabilitative consequences of prolonged hypotestosteronaemia in this patient population.	NATL NEUROREHABIL CONSORTIUM INC,11653 RUTGERS DR,SUITE 100,RICHMOND,VA 23233; MACKAY MEM HOSP,DEPT REHABIL MED,TAIPEI,TAIWAN; VIRGINIA COMMONWEALTH UNIV,VIRGINIA HOSP,COLL MED,DEPT PHYS MED & REHABIL,RICHMOND,VA 23284								CAPPA SF, 1988, BEHAV BRAIN RES, V31, P177, DOI 10.1016/0166-4328(88)90021-6; Ceballos R, 1966, Ala J Med Sci, V3, P185; CLARK JDA, 1988, CLIN ENDOCRINOL, V28, P153; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1983, MOD TRENDS ENDOCR, P55; EDWARDS OM, 1986, MEDICINE, V65, P281; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; GORDON HW, 1986, NEUROPSYCHOLOGIA, V24, P563, DOI 10.1016/0028-3932(86)90100-4; HAGEN C, 1971, REHABILITATION HEAD, P10; HARPER CG, 1986, J CLIN PATHOL, V39, P768; HIER DB, 1982, NEW ENGL J MED, V306, P1202, DOI 10.1056/NEJM198205203062003; Kenyon AT, 1938, ENDOCRINOLOGY, V23, P135, DOI 10.1210/endo-23-2-135; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; MEIER DE, 1985, CLIN RES, V33, pA384; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; MORLEY JE, 1993, J AM GERIATR SOC, V41, P149, DOI 10.1111/j.1532-5415.1993.tb02049.x; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SEMPLE PDA, 1980, CLIN SCI, V58, P105, DOI 10.1042/cs0580105; TENOVER JS, 1992, J CLIN ENDOCR METAB, V75, P1092, DOI 10.1210/jc.75.4.1092; Treip CS, 1970, J CLIN PATHOL, V23, P178, DOI DOI 10.1136/JCP.S3-4.1.178; VOGEL AV, 1985, J CLIN ENDOCR METAB, V60, P658, DOI 10.1210/jcem-60-4-658; WANG C, 1978, CLIN ENDOCRINOL, V9, P249, DOI 10.1111/j.1365-2265.1978.tb02207.x; WANG C, 1978, CLIN ENDOCRINOL, V9, P255, DOI 10.1111/j.1365-2265.1978.tb02208.x; WOLMAN L, 1956, J PATHOL BACTERIOL, V72, P575, DOI 10.1002/path.1700720225; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; ZASLER ND, 1993, PSYCHIATRIC ASPECTS	30	29	30	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					571	577					7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200009	7987293				2022-02-06	
J	MORGAN, WE; COKER, NJ; JENKINS, HA				MORGAN, WE; COKER, NJ; JENKINS, HA			HISTOPATHOLOGY OF TEMPORAL BONE-FRACTURES - IMPLICATIONS FOR COCHLEAR IMPLANTATION	LARYNGOSCOPE			English	Article							PROSTHESIS	Temporal bone fractures often cause loss of audiovestibular function. Those patients with bilateral profound sensorineural hearing losses secondary to temporal bone fractures become candidates for cochlear implantation. The authors present the histopathology of five temporal bone fractures in three patients, evaluating specifically the traumatic effects on the neural elements of the inner ear. Transverse fractures of the temporal bone result in severe loss of hair cells, ganglion cells, and other supporting cells in the inner ear. Occasionally labyrinthitis ossificans may occur as a consequence of trauma or infection. While longitudinal fractures do not violate the otic capsule, these same neural elements may be damaged by concussion.	BAYLOR COLL MED,DEPT OTOLARYNGOL & COMMUN SCI,HOUSTON,TX 77030								Benitez J T, 1980, Am J Otol, V1, P163; Clark G M, 1988, Acta Otolaryngol Suppl, V448, P1; CLOPTON BM, 1980, ANN OTO RHINOL LARYN, V89, P5, DOI 10.1177/00034894800890S202; FREDRICKSON JM, 1963, ARCHIV OTOLARYNGOL, V78, P770; GANTZ BJ, 1988, OTOLARYNG HEAD NECK, V98, P72, DOI 10.1177/019459988809800113; GREEN JD, 1991, OTOLARYNG HEAD NECK, V104, P320, DOI 10.1177/019459989110400306; HOGH JVD, 1968, LARYNGOSCOPE, V78, P899; JENKINS H, 1989, LARYNGOSCOPE, V99, P245; Kerr A, 1968, Acta Otolaryngol, V65, P586, DOI 10.3109/00016486809121002; KHAN AA, 1985, OTOLARYNG HEAD NECK, V93, P177, DOI 10.1177/019459988509300210; Konigsmark B.W., 1970, CONT RES METHODS NEU, P315, DOI DOI 10.1007/978-3-642-85986-1_14; LINDSAY JR, 1970, ANN OTO RHINOL LARYN, V79, P699, DOI 10.1177/000348947007900403; LINTHICUM FH, 1991, AM J OTOL, V12, P245; MARSH MA, 1992, ARCH OTOLARYNGOL, V118, P1257; NADOL JB, 1989, ANN OTO RHINOL LARYN, V98, P411, DOI 10.1177/000348948909800602; OTTE J, 1978, LARYNGOSCOPE, V88, P1231; SCHUKNECHT HF, 1951, ANN OTO RHINOL LARYN, V60, P273, DOI 10.1177/000348945106000201; SCHUKNECHT HF, 1950, ANN OTO RHINOL LARYN, V59, P331, DOI 10.1177/000348945005900203; SCHULNECHT H, 1968, Archives of Otolaryngology, V87, P129; STEENERSON RL, 1990, AM J OTOL, V11, P360; WARD PH, 1969, ANN OTO RHINOL LARYN, V78, P227, DOI 10.1177/000348946907800203	21	29	30	0	0	LARYNGOSCOPE CO	ST LOUIS	10 S BROADWAY 14TH FLOOR, ST LOUIS, MO 63102-1741	0023-852X			LARYNGOSCOPE	Laryngoscope	APR	1994	104	4					426	432					7	Medicine, Research & Experimental; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Otorhinolaryngology	NF733	WOS:A1994NF73300006	8164481				2022-02-06	
J	WANG, JY; CHEN, JL				WANG, JY; CHEN, JL			GLYCEROL DEHYDRATES EDEMATOUS AS WELL AS NORMAL BRAIN IN DOGS	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article						CEREBRAL WATER CONTENT; CRYOGENIC EDEMA; DOG; GLYCEROL; NORMAL BRAIN; TRAUMATIC EDEMA	INTRA-CRANICAL HYPERTENSION; INTRAVENOUS GLYCEROL; CEREBRAL EDEMA; DOUBLE-BLIND; ACUTE STROKE; RANDOMIZED TRIAL; ORAL GLYCEROL; WATER-CONTENT; INFUSION; PRESSURE	1. Although the effect of glycerol on reducing intracranial pressure has been widely investigated, only a few studies have reported its dehydrating effect on brain oedema caused by infarction, ischaemia, microembolism and cold injury, but none on traumatic oedema. In this study the effects of glycerol (1 g/kg, i.v. bolus infusion at a rate of 0.04 g/kg per min) on traumatic and cryogenic cerebral oedema and on normal brain were compared in the anaesthetized dog. The tissue water content was measured with the gravimetric method. 2. Oedema resulting from mechanical trauma was initiated 4 h prior to treatment with glycerol (8 dogs) or vehicle (5 dogs) by closed head contusion with fixed force under general anaesthesia. Tissue samples underneath the region of contusion were taken, before and 1 h after infusion of glycerol or vehicle, for the measurement of water content. 3. Glycerol infusion decreased the water content in white matter of the traumatic brain model from 76.54 +/- 1.70% to 70.73 +/- 1.54% (P<0.001). In normal brain the reduction was from 68.42 +/- 0.48% to 65.36 +/- 0.39% (P<0.001). Neither vehicle nor glycerol infusion resulted in significant changes in specific gravity of the gray matter. 4. Cryogenic oedema was initiated 3 h prior to the infusion of glycerol or vehicle by applying unilaterally a brass conical cup (bottom diameter 1 cm) filled with dry ice-acetone (-65 degrees C) to the exposed dura for 1 min. The contralateral hemisphere, which was not subjected to cold injury, was used for determination of water content of normal gray and white matter. 5. Glycerol infusion decreased the water content in the white matter of the cold-injured region from 75.38 +/- 0.69% to 72.57 +/- 0.58% (P<0.001). In the normal white matter the reduction was from 68.63 +/- 0.34% to 65.48 +/- 0.49% (P<0.001). 6. Our data indicate that glycerol decreases water content of the white matter in traumatic and cold-injured oedematous brain as well as in normal brain.	TRISERV GEN HOSP, DEPT SURG, DIV NEUROSURG, TAIPEI, TAIWAN		WANG, JY (corresponding author), NATL DEF MED CTR, DEPT PHYSIOL, POB 90048-503, 10713 TAIPEI, TAIWAN.						ABSOLON MJ, 1966, BRIT J OPHTHALMOL, V50, P683, DOI 10.1136/bjo.50.12.683; ARAKAWA M, 1977, FOLIA PHARMACOL JPN, V73, P541, DOI 10.1254/fpj.73.541; BAETHMAN A, 1978, NEUROSURG REV, V1, P85; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BAYER AJ, 1987, LANCET, V1, P405; BRALET J, 1983, STROKE, V14, P597, DOI 10.1161/01.STR.14.4.597; CASSEN B, 1960, AM J PHYSIOL, V198, P1296, DOI 10.1152/ajplegacy.1960.198.6.1296; CHEN JL, 1989, CLIN SCI, V77, P535, DOI 10.1042/cs0770535; DODSON RF, 1975, J NEUROL SCI, V26, P235, DOI 10.1016/0022-510X(75)90035-0; FRANK MSB, 1981, PHARMACOTHERAPY, V1, P147; FREI A, 1987, STROKE, V18, P373, DOI 10.1161/01.STR.18.2.373; GUISADO R, 1974, AM J PHYSIOL, V227, P865, DOI 10.1152/ajplegacy.1974.227.4.865; GUISADO R, 1976, NEUROLOGY, V26, P69, DOI 10.1212/WNL.26.1.69; Kashiwagi F, 1990, Adv Neurol, V52, P541; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KUMANA CR, 1991, STROKE, V22, P1608, DOI 10.1161/str.22.12.1608a; KUMANA CR, 1990, BRIT J CLIN PHARMACO, V29, P347, DOI 10.1111/j.1365-2125.1990.tb03646.x; MACDONALD JT, 1982, NEUROLOGY, V32, P437, DOI 10.1212/WNL.32.4.437; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MEYER JS, 1975, CIRCULATION, V51, P701, DOI 10.1161/01.CIR.51.4.701; MEYER JS, 1971, LANCET, V2, P993; NAU R, 1992, EUR J CLIN PHARMACOL, V42, P181, DOI 10.1007/BF00278481; NELSON SR, 1971, J APPL PHYSIOL, V30, P268, DOI 10.1152/jappl.1971.30.2.268; Node Y, 1990, Adv Neurol, V52, P359; Ohta K, 1990, Adv Neurol, V52, P275; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAKES PS, 1985, NIH PUBLICATION, V8523; PITLICK WH, 1982, CLIN PHARMACOL THER, V31, P466, DOI 10.1038/clpt.1982.61; QUADBECK G, 1955, Z NATURFORSCH PT B, V10, P168, DOI 10.1515/znb-1955-0310; REINGLASS JL, 1974, NEUROLOGY, V24, P743, DOI 10.1212/WNL.24.8.743; RINDER L, 1968, ACTA NEUROPATHOL, V11, P201; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; ROTTENBERG DA, 1977, NEUROLOGY, V27, P600, DOI 10.1212/WNL.27.7.600; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; Suga S, 1990, Adv Neurol, V52, P185; Tornheim P A, 1976, Surg Neurol, V5, P171; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; TSUBOKAWA T, 1989, Neurological Research, V11, P249; WALD SL, 1982, J NEUROSURG, V56, P323, DOI 10.3171/jns.1982.56.3.0323; WATERHOUSE JM, 1970, J NEUROL SCI, V10, P305, DOI 10.1016/0022-510X(70)90157-7; WOSTER PS, 1990, CLIN PHARMACY, V9, P762; YU YL, 1992, STROKE, V23, P967, DOI 10.1161/01.STR.23.7.967	43	29	30	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1440-1681			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	APR	1994	21	4					263	270		10.1111/j.1440-1681.1994.tb02511.x			8	Pharmacology & Pharmacy; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Physiology	NU288	WOS:A1994NU28800001	7508346				2022-02-06	
J	BERNARD, LC; MCGRATH, MJ; HOUSTON, W				BERNARD, LC; MCGRATH, MJ; HOUSTON, W			DISCRIMINATING BETWEEN SIMULATED MALINGERING AND CLOSED-HEAD INJURY ON THE WECHSLER-MEMORY-SCALE-REVISED	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							DEFICITS; PROSPECTS	We tested the hypothesis that malingering is distinguished by poorer performance on recognition relative to recall tasks by evaluating the ability of discriminant functions to distinguish between 89 subjects simulating malingering and 44 subjects with a history of closed head injury (CHI) on the Wechsler Memory Scale Revised (WMS-R). Functions with good accuracy in discriminating between simulated malingerers and controls in prior studies did not have adequate specificity when applied to the CHI group. A newly derived discriminant function achieved overall classification accuracy of 79% for the malingering versus CHI groups on cross-validation, with 79% sensitivity (true positives for malingering) and 80% specificity (true negatives for closed head injured). A complex performance pattern on seven WMS-R subtests distinguished malingering subjects from those with CHI, but did not support the recognition versus recall hypothesis. The malingering pattern involved. (a) poorer performance on two relatively (but inconspicuously) easy tasks dependent on immediate recall (Visual Reproduction I and Visual Memory Span); (b) better performance on two relatively (but inconspicuously) easy tasks dependent on immediate recall (Visual Paired Associates I and Digit Span); (c) poorer performance an two relatively difficult delayed tasks (Logical Memory II and Visual Paired Associates II); and (d) better performance on another difficult task involving delayed recall (Visual Reproduction II).	ROYAL C JOHNSON VET MEM HOSP,SIOUX FALLS,SD		BERNARD, LC (corresponding author), LOYOLA MARYMOUNT UNIV,DEPT PSYCHOL,7101 W 80TH ST,LOS ANGELES,CA 90045, USA.						BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; Haughton P M, 1979, Br J Audiol, V13, P135, DOI 10.3109/03005367909078888; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Klecka G.R., 1980, DISCRIMINANT ANAL; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LORING DW, 1989, CLIN NEUROPSYCHOL, V3, P59, DOI DOI 10.1080/13854048908404077; OBERG RGE, 1985, ENV HLTH SERIES; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; PANKRATZ L, 1987, ARCH NEUROL-CHICAGO, V44, P798, DOI 10.1001/archneur.1987.00520200006007; PANKRATZ L, 1990, CLIN NEUROPSYCHOL, V4, DOI DOI 10.1080/13854049008401832; Piotrowski C., 1989, HEALTH PSYCHOL, V11, P1; Reitan R., 1985, NEUROANATOMY NEUROPA; ROGERS R, 1988, CLIN ASSESSMENT MALI, P293; Russell E. W., 1970, ASSESSMENT BRAIN DAM; Tabachnick B. G., 1989, USING MULTIVARIATE S; Wechsler D, 1987, MEMORY SCALE REVISED; Wolfson, 1993, HALSTEAD REITAN NEUR; Wolfson, 1988, TRAUMATIC BRAIN INJU, VII	21	29	29	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV-DEC	1993	8	6					539	551		10.1016/0887-6177(93)90054-5			13	Psychology, Clinical; Psychology	Social Science Citation Index (SSCI)	Psychology	MN089	WOS:A1993MN08900008	14591993				2022-02-06	
J	SHIBATA, M; EINHAUS, S; SCHWEITZER, JB; ZUCKERMAN, S; LEFFLER, CW				SHIBATA, M; EINHAUS, S; SCHWEITZER, JB; ZUCKERMAN, S; LEFFLER, CW			CEREBRAL BLOOD-FLOW DECREASED BY ADRENERGIC-STIMULATION OF CEREBRAL VESSELS IN ANESTHETIZED NEWBORN PIGS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						FLUID-PERCUSSION BRAIN INJURY; CEREBRAL BLOOD FLOW; SYMPATHETIC NERVOUS SYSTEM; NEWBORN PIG	SHAKEN BABY SYNDROME; HEAD-INJURY; PIAL-ARTERIES; METABOLISM; RELEASE; DAMAGE; NOREPINEPHRINE; NORADRENALINE; RECOVERY; CORTEX	Changes in cerebral blood flow (CBF), pial arteriolar diameter, and arterial blood pressure, gases, and pH were examined before and for 3 hours after fluid-percussion brain injury in a-chloralose-anesthetized piglets. The brain injury was induced by a percussion of 2.28 +/- 0.06 atm applied for 23.7 +/- 0.5 msec to the right parietal cortex. Regional CBF was measured with radiolabeled microspheres, and changes in pial arteriolar diameter were monitored in the left parietal cortex using closed cranial windows. Immediately following brain injury, mean blood pressure transiently (for approximately 10 minutes) either increased or decreased and then exhibited a prolonged decrease in all of the animals. The brains showed changes consistent with traumatic brain injury such as subarachnoid hemorrhage, contusions, or reactive axonal swelling; none showed histological evidence of a global alternative pathogenetic mechanism such as hypoxic ischemic damage. While CBF of uninjured control animals did not change over a 3-hour observation period, after brain injury blood flow decreased 30% +/- 1% below the baseline level within 10 minutes and remained there for 2 to 3 hours posttrauma. After adrenergic blockade, CBF did not decrease at any time during the 3-hour period in either the uninjured control or the injured animals. Concomitant with the decreased blood flow after brain injury, pial arteriolar diameter decreased 14% below the preinjury level. However, in piglets treated with adrenoceptor antagonists, uninjured control and brain-injured animals did not show a decrease in pial arteriolar diameter. The present results support the hypothesis that increased sympathetic outflow to the cephalic vasculature following the fluid-percussion brain injury causes cerebral vasoconstriction decreasing pial arteriolar diameter and regional CBF.	UNIV TENNESSEE CTR HLTH SCI, DEPT NEUROSURG, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, DIV CRIT CARE MED, MEMPHIS, TN USA		SHIBATA, M (corresponding author), UNIV TENNESSEE CTR HLTH SCI, BRAIN INJURY RES CTR, DEPT PHYSIOL & BIOPHYS, MEMPHIS, TN 38163 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL042875, R01HL042851, R01HL034059, R37HL042851, R29HL042875] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL34059, HL42875, HL42851] Funding Source: Medline		ARAKI T, 1989, ACTA NEUROL SCAND, V80, P451, DOI 10.1111/j.1600-0404.1989.tb03908.x; BIAGAS K V, 1992, Pediatric Research, V31, p27A; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BUSIJA DW, 1985, PEDIATR RES, V19, P1210, DOI 10.1203/00006450-198511000-00020; BUSIJA DW, 1987, DEV PHARMACOL THERAP, V10, P36, DOI 10.1159/000457726; CROCKARD HA, 1977, SURG NEUROL, V7, P281; CROWDER JM, 1987, EUR J PHARMACOL, V143, P343, DOI 10.1016/0014-2999(87)90458-4; DELANGEN CDJ, 1980, BRAIN RES, V185, P399; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FLETCHER AM, 1989, AM J VET RES, V50, P754; FRIEDMAN AH, 1980, BRAIN RES, V183, P89, DOI 10.1016/0006-8993(80)90121-3; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HARIK SI, 1981, J CEREBR BLOOD F MET, V1, P329, DOI 10.1038/jcbfm.1981.36; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; LAPTOOK AR, 1983, BRAIN RES, V276, P51, DOI 10.1016/0006-8993(83)90547-4; LEFFLER CW, 1985, PEDIATR RES, V19, P1160, DOI 10.1203/00006450-198511000-00009; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; LYNCH MA, 1986, NEUROPHARMACOLOGY, V25, P493, DOI 10.1016/0028-3908(86)90173-5; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MEYER JS, 1973, BRAIN, V96, P277, DOI 10.1093/brain/96.2.277; MILLEN JE, 1980, J APPL PHYSIOL, V49, P856, DOI 10.1152/jappl.1980.49.5.856; MILLEN JE, 1983, J APPL PHYSIOL, V54, P666, DOI 10.1152/jappl.1983.54.3.666; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; WAGERLE LC, 1985, FED PROC, V44, P1008; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YONAS H, 1989, NEUROSURGERY, V24, P368, DOI 10.1227/00006123-198903000-00010	46	29	29	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	1993	79	5					696	704		10.3171/jns.1993.79.5.0696			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MD733	WOS:A1993MD73300008	8105043				2022-02-06	
J	CITTAPIETROLUNGO, TJ; ALEXANDER, MA; COOK, SP; PADMAN, R				CITTAPIETROLUNGO, TJ; ALEXANDER, MA; COOK, SP; PADMAN, R			COMPLICATIONS OF TRACHEOSTOMY AND DECANNULATION IN PEDIATRIC AND YOUNG-PATIENTS WITH TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							AIRWAY COMPLICATIONS; TRACHEOTOMY; MANAGEMENT		ALFRED I DUPONT INST,WILMINGTON,DE 19899								BETTS JM, 1989, SINGLE STAGE RECONST; CHEW JY, 1972, ARCHIV OTOLARYNGOL, V96, P538; COTTON RT, 1984, J PEDIATR SURG, V19, P699, DOI 10.1016/S0022-3468(84)80355-3; CRYSDALE WS, 1988, ANN OTO RHINOL LARYN, V97, P439, DOI 10.1177/000348948809700501; DEMPSTER J H, 1986, Journal of the Royal College of Surgeons of Edinburgh, V31, P359; DOWNES JJ, 1985, INT ANESTHESIOL CLIN, V23, P37, DOI 10.1097/00004311-198523040-00005; FISHBURN MJ, 1990, ARCH PHYS MED REHAB, V71, P197; KLINGBEIL GEG, 1988, ARCH PHYS MED REHAB, V69, P493; MALLORY GB, 1991, ARCH PHYS MED REHAB, V72, P43; NOWAK P, 1987, AM J OTOLARYNG, V8, P91, DOI 10.1016/S0196-0709(87)80030-3; OLIVER P, 1962, NEW ENGL J MED, V267, P631, DOI 10.1056/NEJM196209272671301; SABISTON DC, 1986, TXB SURGERY BIOL BAS, P2059; SCOTT JR, 1978, AM J ROENTGENOL, V130, P893; SCOTT JR, 1978, AM J ROENTGENOL, V130, P887; SPLAINGARD ML, 1989, ARCH PHYS MED REHAB, V70, P318; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; TUCKER JA, 1972, ANN OTO RHINOL LARYN, V81, P818, DOI 10.1177/000348947208100611; WETMORE RF, 1982, ANN OTO RHINOL LARYN, V91, P628, DOI 10.1177/000348948209100623; WOO P, 1989, LARYNGOSCOPE, V99, P725	19	29	30	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1993	74	9					905	909					5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	LX551	WOS:A1993LX55100003	8379834				2022-02-06	
J	GUTLING, E; GONSER, A; REGARD, M; GLINZ, W; LANDIS, T				GUTLING, E; GONSER, A; REGARD, M; GLINZ, W; LANDIS, T			DISSOCIATION OF FRONTAL AND PARIETAL COMPONENTS OF SOMATOSENSORY-EVOKED POTENTIALS IN SEVERE HEAD-INJURY	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						SOMATOSENSORY EVOKED POTENTIALS; SEVERE HEAD INJURY; GLASGOW OUTCOME SCALE; FRONTAL SEP COMPONENTS	OUTCOME PREDICTION; BRAIN-FUNCTION; FINGER STIMULATION; COMATOSE PATIENTS; CONDUCTION TIME; TRAUMA; N20; P22; RESPONSES; LESIONS	Reports on the topography of SEPs in non-comatose patients have drawn attention to a second thalamo-cortical loop connecting the thalamus with the frontal cortex, which has a close anatomical relation to the fronto-limbic structures frequently damaged in severe head injury (SHI). We studied whether the frontal component (P20/22) of the somatosensory evoked response (SEP), known to be due to a generator different from that of the traditionally analysed parietal SEP component (N20), would be differently affected by SHI. Moreover, we examined whether its analysis would improve the prognostic evaluation in the Glasgow outcome scale (GOS) after 3-6 months. In 50 patients examined within 72 h after the injury we found a dissociated impairment of frontal and parietal components in 24% of the recorded SEPs. When both frontal and parietal components were used as predictors, discriminant analysis correctly classified 94% of the patients into good (GOS good recovery and moderate disability) or poor (GOS severe disability, persistent vegetative state or death) outcome groups. Classification was less accurate and misclassifications grosser when considering parietal or frontal parameters alone. Our results show that (i) the evaluation of frontal components provides information different from that of the parietal SEPs, confirming the presence of different generators, and (ii) a combined analysis of the two components improves the prognostic evaluation with regard to the global outcome.	UNIV HOSP ZURICH,DEPT NEUROL,CH-8091 ZURICH,SWITZERLAND; UNIV HOSP ZURICH,DEPT SURG,CH-8091 ZURICH,SWITZERLAND								AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; ALLISON T, 1982, ANN NY ACAD SCI, V338, P671; BROUGHTON RJ, 1969, NASA SP191, P79; CHERON G, 1987, ELECTROEN CLIN NEURO, V67, P537, DOI 10.1016/0013-4694(87)90056-3; COHEN LG, 1985, NEUROLOGY, V35, P691, DOI 10.1212/WNL.35.5.691; DEIBER MP, 1986, ELECTROEN CLIN NEURO, V65, P321, DOI 10.1016/0168-5597(86)90012-2; DESMEDT JE, 1981, ELECTROEN CLIN NEURO, V52, P553, DOI 10.1016/0013-4694(81)91430-9; DESMEDT JE, 1987, ELECTROEN CLIN NEURO, V68, P1, DOI 10.1016/0168-5597(87)90065-7; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1982, ANN NY ACAD SCI, V388, P683, DOI 10.1111/j.1749-6632.1982.tb50835.x; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HUME AL, 1979, ANN NEUROL, V5, P379, DOI 10.1002/ana.410050412; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1984, CLOSED HEAD INJURY P, P37; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; MAUGUIERE F, 1983, BRAIN, V106, P271, DOI 10.1093/brain/106.2.271; MAUGUIERE F, 1991, ANN NEUROL, V30, P71, DOI 10.1002/ana.410300113; MAUGUIERE F, 1989, ANN NEUROL, V26, P724, DOI 10.1002/ana.410260607; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NOGUEIRA MC, 1989, NEUROLOGY, V39, P1210, DOI 10.1212/WNL.39.9.1210; PAPAKOSTOPOULOS D, 1980, PROGR CLIN NEUROPHYS, V7, P15; RIFFEL B, 1987, EEG-EMG-Z ELEK ELEKT, V18, P192; ROSSINI PM, 1989, ELECTROEN CLIN NEURO, V74, P277, DOI 10.1016/0168-5597(89)90058-0; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; Urasaki E, 1986, No To Shinkei, V38, P973; VANDESTEEN A, 1991, NEUROLOGY, V41, P913, DOI 10.1212/WNL.41.6.913; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989; [No title captured]	30	29	29	0	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	SEP-OCT	1993	88	5					369	376		10.1016/0168-5597(93)90013-F			8	Engineering, Biomedical; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology	MC725	WOS:A1993MC72500003	7691561				2022-02-06	
J	ZIEGLER, W; HARTMANN, E; HOOLE, P				ZIEGLER, W; HARTMANN, E; HOOLE, P			SYLLABIC TIMING IN DYSARTHRIA	JOURNAL OF SPEECH AND HEARING RESEARCH			English	Article						DYSARTHRIA; SPEECH; TIMING; ACOUSTICS; SYLLABLE	ACQUIRED BRAIN INJURY; SPEECH; COMPATIBILITY; VARIABILITY; UTTERANCES; DURATION; DISEASE; RHYTHM	A new, intensity-based method of measuring syllable duration was used to assess syllabic timing in 75 patients with dysarthria of predominantly traumatic and cerebro-vascular origin and in 30 normal subjects. The applied speech tasks included repetitions of sentences containing chains of plosive-vowel-syllables. The logarithm of the duration of the syllable carrying sentence accent proved to be particularly highly correlated with perceived speech rate. Among the potential sources of temporal variability, segmental influences and the influence of sentence stress were examined. Further, the between-sentence variation of syllable duration was assessed. The resulting measures of variability were correlated with the severity of dysarthric impairment. A strengthening of normal effects was found in the consonant-related variation, whereas intrinsic vowel effects and the influence of sentence stress were largely reduced. These results are discussed from the viewpoint of timing theories in speech and limb motor control. They are considered to provide a valuable background against which the speech impairments of specific neurologic groups can be tested.			ZIEGLER, W (corresponding author), STADT KRANKENHAUS BOGENHAUSEN,NEUROPSYCHOL KLIN,EKN ENTWICKLUNGSGRP,DACHAUER STR 164,W-8000 MUNICH 50,GERMANY.						ACKERMANN H, 1991, J NEUROL NEUROSUR PS, V54, P1093, DOI 10.1136/jnnp.54.12.1093; ADAMS JA, 1987, PSYCHOL BULL, V101, P41, DOI 10.1037/0033-2909.101.1.41; ANTONIADIS Z, 1984, PHONETICA, V41, P72, DOI 10.1159/000261713; Brown J.R., 1975, MOTOR SPEECH DISORDE; CARUSO AJ, 1987, J SPEECH HEAR RES, V30, P80, DOI 10.1044/jshr.3001.80; CAZALETS JR, 1990, BEHAV BRAIN RES, V40, P215, DOI 10.1016/0166-4328(90)90078-S; CHERRY C, 1967, NATURE, V214, P1164, DOI 10.1038/2141164a0; EDWARDS J, 1988, PHONETICA, V45, P156, DOI 10.1159/000261824; FARMER A, 1980, FOLIA PHONIATR, V32, P267, DOI 10.1159/000264347; Fischer-Jorgensen Eli, 1964, Z PHONETIK ALLGEMEIN, V17, P175, DOI [10.1524/stuf.1964.17.16.175, DOI 10.1524/STUF.1964.17.16.175]; FORREST K, 1989, J ACOUST SOC AM, V85, P2608, DOI 10.1121/1.397755; Fowler C. A., 1981, ATTENTION PERFORMANC, VIX, P521; FOWLER CA, 1978, INFORMATION PROCESSI; FUJIMURA O, 1987, HONOR ILSE LEHISTE; GENTIL M, 1990, BRAIN LANG, V38, P438, DOI 10.1016/0093-934X(90)90126-2; Handel S., 1989, LISTENING INTRO PERC; HUBER W, 1989, J COGNITIVE NEUROSCI, V1, P136; KENT RD, 1979, J SPEECH HEAR RES, V22, P627, DOI 10.1044/jshr.2203.627; KENT RD, 1991, DEV TIMING CONTROL T; KLAPP ST, 1979, MEM COGNITION, V7, P375, DOI 10.3758/BF03196942; LEHISTE I, 1972, J ACOUST SOC AM, V51, P2018, DOI 10.1121/1.1913062; LINDBLOM B, 1983, PRODUCTION SPEECH, P217, DOI DOI 10.1007/978-1-4613-8202-7_10; MARSDEN CD, 1989, MOVEMENT DISORD, V4, pS26, DOI 10.1002/mds.870040505; MERMELSTEIN P, 1975, J ACOUST SOC AM, V58, P880, DOI 10.1121/1.380738; MORRIS RJ, 1989, J COMMUN DISORD, V22, P23, DOI 10.1016/0021-9924(89)90004-X; NAGASAKI H, 1990, HUM MOVEMENT SCI, V9, P177, DOI 10.1016/0167-9457(90)90026-A; NEWEKLOWSKY G, 1975, PHONETICA, V32, P38, DOI 10.1159/000259685; NOOTEBOOM SG, 1985, TIME MIND BEHAVIOR, P242; OSTRY DJ, 1985, J ACOUST SOC AM, V77, P640, DOI 10.1121/1.391882; PITT MA, 1990, J EXP PSYCHOL HUMAN, V16, P564, DOI 10.1037/0096-1523.16.3.564; ROSEN S, 1992, PHILOS T ROY SOC B, V336, P367, DOI 10.1098/rstb.1992.0070; ROSENBAUM DA, 1987, MEM COGNITION, V15, P217, DOI 10.3758/BF03197719; Rosenbek, 1984, DYSARTHRIAS PHYSL AC, P101; SAMAR VJ, 1988, J SPEECH HEAR RES, V31, P307, DOI 10.1044/jshr.3103.307; TATSUMI IF, 1979, ANN B RILP, V13, P99; TEASDALE N, 1990, J NEUROL NEUROSUR PS, V52, P862; VIVIANI P, 1991, DEV TIMING CONTROL T, P1; VOGEL M, 1983, FOLIA PHONIATR, V35, P294, DOI 10.1159/000265705; WEISMER G, 1985, J ACOUST SOC AM, V78, P49, DOI 10.1121/1.392453; WING AM, 1973, PERCEPT PSYCHOPHYS, V14, P5, DOI 10.3758/BF03198607; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZIEGLER W, 1988, BRIT J DISORD COMMUN, V23, P215; ZIEGLER W, 1990, AKUSTISCHE DIMENSION; ZIEGLER W, 1ST P C ICPLA AMST; [No title captured]; [No title captured]	46	29	29	0	3	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	10801 ROCKVILLE PIKE RD, ROCKVILLE, MD 20852-3279	0022-4685			J SPEECH HEAR RES	J. Speech Hear. Res.	AUG	1993	36	4					683	693		10.1044/jshr.3604.683			11	Language & Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Linguistics; Rehabilitation	LR907	WOS:A1993LR90700004	8377481				2022-02-06	
J	JAFFE, KM; MASSAGLI, TL; MARTIN, KM; RIVARA, JMB; FAY, GC; POLISSAR, NL				JAFFE, KM; MASSAGLI, TL; MARTIN, KM; RIVARA, JMB; FAY, GC; POLISSAR, NL			PEDIATRIC TRAUMATIC BRAIN INJURY - ACUTE AND REHABILITATION COSTS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						ECONOMIC COSTS; PEDIATRIC TRAUMATIC BRAIN INJURY	HEAD		SEATTLE UNIV,SCH NURSING,SEATTLE,WA; UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH SOCIAL WORK,SEATTLE,WA 98195		JAFFE, KM (corresponding author), CHILDRENS HOSP & MED CTR,POB 5371,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR002299] Funding Source: Medline		ANDERSON DW, 1980, J NEUROSURG, V53, pS11; BENNETT BR, 1989, J TRAUMA, V29, P556, DOI 10.1097/00005373-198905000-00003; Conover W.J., 1998, PRACTICAL NONPARAMET; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KRAUS JF, 1987, PEDIATRICS, V79, P501; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Rice D P, 1985, Health Care Financ Rev, V7, P61; RIVARA FP, 1988, JAMA-J AM MED ASSOC, V260, P221; Rivara Frederick P., 1986, J HEAD TRAUMA REHAB, V1, P7; SAYWELL RM, 1989, J AM GERIATR SOC, V37, P625, DOI 10.1111/j.1532-5415.1989.tb01253.x; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; 1990, REPORT TASK FORCE ME; 1985, ABBREVIATED INJURY S	18	29	29	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1993	74	7					681	686		10.1016/0003-9993(93)90024-5			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	LM079	WOS:A1993LM07900001	8328886				2022-02-06	
J	SHARMA, HS; NYBERG, F; THORNWALL, M; OLSSON, Y				SHARMA, HS; NYBERG, F; THORNWALL, M; OLSSON, Y			MET-ENKEPHALIN-ARG(6)-PHE(7) IN SPINAL-CORD AND BRAIN FOLLOWING TRAUMATIC INJURY TO THE SPINAL-CORD - INFLUENCE OF P-CHLOROPHENYLALANINE - AN EXPERIMENTAL-STUDY IN THE RAT USING RADIOIMMUNOASSAY TECHNIQUE	NEUROPHARMACOLOGY			English	Article						MET-ENKEPHALIN-ARG(6)-PHE(7); OPIOID PEPTIDES; SEROTONIN; SPINAL CORD TRAUMA; P-CHLOROPHENYL-ALANINE (P-CPA); BRAIN	HUMAN CEREBROSPINAL-FLUID; MET-ENKEPHALIN-LIKE; OPIOID-PEPTIDES; SUBSTANCE-P; EDEMA; IMMUNOREACTIVITY; PROENKEPHALIN; SEROTONIN; NEURONS; TISSUES	The possibility that trauma to the dorsal horn may affect the release and distribution of enkephalin was examined using the opioid peptide Met-Enk-Arg6-Phe7 (MEAP) as a marker in a rat model. The peptide content of samples of spinal cord and whole brain was measured using a radioimmunoassay (RIA) technique. In addition, the possible functional relation between this peptide and serotonin was evaluated using a pharmacological approach that included depletion of endogenous serotonin. A focal trauma to the fight dorsal horn in the T10-11 segments (2 mm deep and 5 mm long) markedly modified the content of MEAP of the adjacent rostral and caudal segments of the cord, as well as the content of MEAP of the brain. Depletion of serotonin with p-CPA (an inhibitor of the synthesis of serotonin) significantly elevated the content of MEAP in the whole brain without affecting the regions of the spinal cord (except T9 level which showed a 25% decrease from an intact control group). Trauma to the spinal cord in the serotonin-depleted animals did not alter the content of MEAP further, as compared to a p-CPA-treated but untraumatized group. These results indicate that enkephalin (i) participates in the pathophysiology of spinal cord trauma and (ii) suggest that the peptide is somehow functionally related with serotonin.	UNIV UPPSALA, CTR BIOMED, DEPT PHARMACOL, S-75123 UPPSALA, SWEDEN		SHARMA, HS (corresponding author), UNIV HOSP UPPSALA, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN.		Sharma, Aruna/D-4430-2011				BASBAUM AI, 1988, SOMATOSENS MOT RES, V5, P177, DOI 10.3109/07367228809144625; BOARDER MR, 1982, J NEUROCHEM, V38, P299, DOI 10.1111/j.1471-4159.1982.tb08629.x; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Gibson S. J., 1986, IMMUNOCYTOCHEMISTRY, P360; GIRAUD P, 1983, J NEUROCHEM, V41, P154, DOI 10.1111/j.1471-4159.1983.tb11827.x; GUBLER U, 1982, NATURE, V295, P206, DOI 10.1038/295206a0; HOGAN EL, 1985, HDB NEUROCHEMISTRY, V10, P285; HOKFELT T, 1979, NEUROSCI LETT, V14, P55, DOI 10.1016/0304-3940(79)95343-6; HOKFELT T, 1987, PSYCHOPHARMACOLOGY 3, P401; HOKFELT T, 1978, PSYCHOPHARMACOLOGY G, P39; Hunt S. P., 1983, CHEM NEUROANATOMY, P53; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; Johansson O, 1978, Adv Biochem Psychopharmacol, V18, P51; KOJIMA K, 1982, ARCH BIOCHEM BIOPHYS, V215, P638, DOI 10.1016/0003-9861(82)90125-4; Lee S, 1990, J Neural Transm Suppl, V30, P45; MORLEY JE, 1985, HDB NEUROCHEM, V8, P43; NYBERG F, 1986, J CHROMATOGR, V359, P541, DOI 10.1016/0021-9673(86)80105-4; NYBERG F, 1990, PROG CLIN BIOL RES, V328, P261; Nyberg F, 1988, BASIC MECHANISMS HEA, P241; OLSON GA, 1991, PEPTIDES, V12, P1407, DOI 10.1016/0196-9781(91)90227-G; OLSSON Y, 1990, ACTA NEUROPATHOL, V79, P595, DOI 10.1007/BF00294236; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; Petrusz P., 1985, Handbook of Chemical Neuroanatomy, V4, P273; RUZICKA BB, 1990, BRAIN RES, V536, P227, DOI 10.1016/0006-8993(90)90029-B; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1990, ACTA NEUROPATHOL, V80, P12, DOI 10.1007/BF00294216; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; SHARMA HS, 1992, NEUROSCI RES, V14, P195; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; TANG J, 1982, NEUROPHARMACOLOGY, V21, P595, DOI 10.1016/0028-3908(82)90054-5; TASHIRO T, 1989, BRAIN RES, V491, P360, DOI 10.1016/0006-8993(89)90071-1; TERENIUS L, 1988, INT REV NEUROBIOL, V30, P101; WILLIAMS RG, 1982, BRAIN RES, V240, P167, DOI 10.1016/0006-8993(82)90657-6	35	29	29	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JUL	1993	32	7					711	717		10.1016/0028-3908(93)90085-H			7	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	LK305	WOS:A1993LK30500012	8361583				2022-02-06	
J	MOORE, A; STAMBROOK, M; PETERS, L				MOORE, A; STAMBROOK, M; PETERS, L			CENTRIPETAL AND CENTRIFUGAL FAMILY-LIFE CYCLE FACTORS IN LONG-TERM OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; QUALITY; PREDICTORS; ADJUSTMENT; SCALE	The family life cycle model categorizes stresses on family systems in terms of their source and their effects on family members. Centripetal forces bring members together while centrifugal forces lead to loosened intrafamilial ties. This study examined the association of normative, developmental and centripetal illness-related family forces with patient outcome. Hypothesized centripetal and centrifugal forces acting on 65 families of married male TBI patients were used as independent variables in stepwise multiple regressions with criterion measures of quality of life outcome used as dependent measures. Centripetal variables included measures of family coping, marital adjustment, and number of years married. Centrifugal variables included number of children, age of oldest child, and amount of perceived financial strain. Regression equations obtained had multiple R's ranging from 0.623 to 0.407 (p values <0.017). Results suggest that families normatively dealing with the developmental stage of the family with young children may face unique challenges when a husband sustains a TBI, particularly when financial strain exists. Stages in family development involving conflict between centripetal and centrifugal forces may be most problematic for families to resolve, and potentially the most effective periods for intervention.	UNIV MANITOBA,DEPT PSYCHOL,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,HLTH SCI CLIN RES CTR,DEPT PSYCHIAT,NEUROPSYCHOL RES UNIT,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,SOC MANITOBANS DISABILITIES,DEPT PSYCHIAT,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,SOC MANITOBANS DISABILITIES,DEPT MED,WINNIPEG R3A 1R9,MB,CANADA; UNIV MANITOBA,SOC MANITOBANS DISABILITIES,DEPT PSYCHOL,WINNIPEG R3A 1R9,MB,CANADA								BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BERROL S, 1989, MILD MODERATE HEAD I, P135; Carter B., 1989, CHANGING FAMILY LIFE; Carter E. A., 1980, FAMILY LIFE CYCLE FR; COMBRINCKGRAHAM L, 1985, FAM PROCESS, V24, P139, DOI 10.1111/j.1545-5300.1985.00139.x; FRANK R G, 1990, Brain Injury, V4, P289, DOI 10.3109/02699059009026179; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; KASSUM DA, 1984, CAN J SURG, V27, P64; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MCCUBBIN HE, 1985, FAMILY CRISIS ORIENT; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McNair DM, 1971, EITS MANUAL PROFILE; Miller WG, 1986, NEUROPSYCHOLOGY HDB, P347; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; Rolland J. S., 1989, CHANGING FAMILY LIFE, P433; Spanbock P., 1987, COGNITIVE REHABILITA, V5, P12; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; STAMBROOK M, 1990, CAN J SURG, V33, P115; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; STAMBROOK M, 1989, CANADIAN J REHABILIT, V3, P87; STAMBROOK M, UNPUB BRAIN INJURY R; TEASDALE G, 1974, LANCET, V2, P81	26	29	29	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1993	7	3					247	255		10.3109/02699059309029677			9	Neurosciences; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	MA170	WOS:A1993MA17000006	8508181				2022-02-06	
J	VINK, R				VINK, R			NUCLEAR-MAGNETIC-RESONANCE CHARACTERIZATION OF SECONDARY MECHANISMS FOLLOWING TRAUMATIC BRAIN INJURY	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						MAGNESIUM; EXCITATORY AMINO ACIDS; GLUTAMATE; BIOENERGETICS	INTRACELLULAR FREE MAGNESIUM; ENERGY PHOSPHATE-METABOLISM; PHOSPHOLIPASE-C ACTIVITY; FLUID-PERCUSSION MODEL; P-31 NMR-SPECTROSCOPY; AMINO-ACID RECEPTORS; FREE MG-2+; CENTRAL NEURONS; SPINAL-CORD; RATS	Much of the injury that occurs following a traumatic insult to the central nervous system is the result of physiological and biochemical processes initiated by the primary traumatic event. These processes occur over a period of hours to days following the insult, and although a number of factors have been identified as being associated with this secondary injury process, their role and interrelationship with one another is unclear. Nuclear magnetic resonance spectroscopy has been utilized to characterize many of these secondary factors and their relationship to eventual neurological outcome. In particular, the role of high energy phosphates, pH, lactic acid, excitatory amino acids, and magnesium has been investigated, along with pharmacotherapies directed toward altering the status of these factors following traumatic injury. This review critically examines the role that each of these factors may play in the secondary injury process, and proposes a scheme which theoretically accounts for the interrelationships among the various factors.			VINK, R (corresponding author), JAMES COOK UNIV N QUEENSLAND, DEPT CHEM & BIOCHEM, TOWNSVILLE, QLD 4811, AUSTRALIA.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ALTURA B M, 1985, Magnesium, V4, P245; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; ALVAREZLEEFMANS FJ, 1987, CAN J PHYSIOL PHARM, V65, P915, DOI 10.1139/y87-147; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Bara M., 1984, MAGNESIUM, V3, P212; BYGRAVE FL, 1978, BIOL REV, V53, P43, DOI 10.1111/j.1469-185X.1978.tb00992.x; Cavaliere F, 1985, Recenti Prog Med, V76, P563; CHAUDRY IH, 1986, MAGNESIUM, V5, P211; CHAUDRY IH, 1983, AM J PHYSIOL, V245, pR117, DOI 10.1152/ajpregu.1983.245.2.R117; CHOI DW, 1987, J NEUROSCI, V7, P369; COHEN Y, 1991, MAGNET RESON MED, V17, P225, DOI 10.1002/mrm.1910170125; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DIDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536; DIXON CE, 1987, J NEUROSURG, V65, P615; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; EDGAR AD, 1982, J NEUROCHEM, V39, P1111, DOI 10.1111/j.1471-4159.1982.tb11503.x; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLINK EB, 1986, ALCOHOL CLIN EXP RES, V10, P590, DOI 10.1111/j.1530-0277.1986.tb05150.x; GARFINKEL L, 1984, BIOCHEMISTRY-US, V23, P3547, DOI 10.1021/bi00310a025; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Henneberry R C, 1989, Prog Clin Biol Res, V317, P143; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P173; KIRKELS JH, 1989, J MOL CELL CARDIOL, V21, P1209, DOI 10.1016/0022-2828(89)90697-4; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LEMKE M, 1990, MOL CHEM NEUROPATHOL, V12, P147, DOI 10.1007/BF03159941; LEVY DI, 1990, NEUROSCI LETT, V110, P291, DOI 10.1016/0304-3940(90)90862-4; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P251; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; McGuigan J.A.S., 1991, MG2 PLUS EXCITABLE M, P1; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NIGAM S, 1986, PROSTAG LEUKOTR ESS, V23, P1, DOI 10.1016/0262-1746(86)90070-3; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORDSTROM CH, 1990, PROTECTION BRAIN ISC, P49; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PECASENS M, 1991, CURR ASP NEUROSCI, V3, P104; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SELECKI BR, 1981, INJURIES HEAD SPINE; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1991, AM J PHYSIOL, V261, pR1527, DOI 10.1152/ajpregu.1991.261.6.R1527; VINK R, 1989, BIOCHEM BIOPH RES CO, V165, P913, DOI 10.1016/S0006-291X(89)80053-1; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1993, IN PRESS METABOLISM; VINK R, 1991, MG2PLUS EXCITABLE ME, P125; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; YOUNG W, 1992, CENTRAL NERVOUS SYST, P9	76	29	29	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	APR	1993	18	3					279	297		10.1007/BF03160120			19	Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	KZ118	WOS:A1993KZ11800007	8507306				2022-02-06	
J	DYWAN, J; SEGALOWITZ, SJ; HENDERSON, D; JACOBY, L				DYWAN, J; SEGALOWITZ, SJ; HENDERSON, D; JACOBY, L			MEMORY FOR SOURCE AFTER TRAUMATIC BRAIN INJURY	BRAIN AND COGNITION			English	Article									BROCK UNIV, FAC EDUC, ST CATHARINES L2S 3A1, ONTARIO, CANADA; MCMASTER UNIV, DEPT PSYCHOL, HAMILTON L8S 4L8, ONTARIO, CANADA		DYWAN, J (corresponding author), BROCK UNIV, DEPT PSYCHOL, ST CATHARINES L2S 3A1, ONTARIO, CANADA.						Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Benson D.F., 1986, FRONTAL LOBES; BENTON A, 1985, CLIN NEUROPSYCHOLOGY, P151; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENTON AL, 1980, AM PSYCHOL, V35, P176, DOI 10.1037/0003-066X.35.2.176; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BURKE DM, 1981, PSYCHOL BULL, V90, P513, DOI 10.1037/0033-2909.90.3.513; COHEN G, 1989, PSYCHOL AGING, V4, P10, DOI 10.1037/0882-7974.4.1.10; Cohen J., 1983, APPL MULTIPLE REGRES, V2nd ed.; CRAIK FIM, 1990, PSYCHOL AGING, V5, P148, DOI 10.1037/0882-7974.5.1.148; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis DC, 1988, CLIN NEUROPSYCHOL, V2, P188, DOI DOI 10.1080/13854048808520100; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; DIAMOND A, 1985, CHILD DEV, V56, P868, DOI 10.2307/1130099; DREWE E A, 1974, Cortex, V10, P159; DYWAN J, 1990, PSYCHOL AGING, V5, P379, DOI 10.1037/0882-7974.5.3.379; DYWAN J, 1992, FEB INT NEUR SOC M S; EVANS FJ, 1966, INT J CLIN EXP HYP, V14, P162, DOI 10.1080/00207146608412959; FANTIE BD, 1991, NEUROPSYCHOLOGY LAW, P186; Fuster J. M., 1987, FRONTAL LOBES REVISI, P109; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; GARDINER JM, 1977, J VERB LEARN VERB BE, V16, P45, DOI 10.1016/S0022-5371(77)80006-6; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; HASHTROUDI S, 1989, PSYCHOL AGING, V4, P106, DOI 10.1037/0882-7974.4.1.106; Heaton R.K., 1981, WISCONSIN CARD SORTI; HYVARINEN J, 1982, PARIETAL CORTEX MONK; Jacoby L., 1989, VARIETIES MEMORY CON, P391, DOI DOI 10.1002/ACP.2350050509; JACOBY LL, 1989, J PERS SOC PSYCHOL, V56, P326, DOI 10.1037/0022-3514.56.3.326; JACOBY LL, 1989, J EXP PSYCHOL GEN, V118, P115, DOI 10.1037/0096-3445.118.2.115; JANOWSKY JS, 1989, NEUROPSYCHOLOGIA, V27, P1043, DOI 10.1016/0028-3932(89)90184-X; Jennett B, 1975, Ciba Found Symp, P309; Jennett B, 1981, MANAGEMENT HEAD INJU; JETTER W, 1986, CORTEX, V22, P229, DOI 10.1016/S0010-9452(86)80047-8; JOHNSTON WA, 1985, J EXP PSYCHOL LEARN, V11, P3, DOI 10.1037/0278-7393.11.1.3; KELLEY CM, 1989, J EXP PSYCHOL LEARN, V15, P1101, DOI 10.1037/0278-7393.15.6.1101; KOLB B, 1983, CAN J PSYCHOL, V37, P8, DOI 10.1037/h0080697; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MACMILLAN MB, 1986, BRAIN COGNITION, V5, P67, DOI 10.1016/0278-2626(86)90062-X; MCINTYRE JS, 1987, CAN J PSYCHOL, V41, P175, DOI 10.1037/h0084154; MESULAM MM, 1985, PRINCIPLES BEHAVIOUR; MILNER B, 1984, TRENDS NEUROSCI, V7, P403, DOI 10.1016/S0166-2236(84)80143-5; Milner B, 1963, ARCH NEUROL-CHICAGO, V9, P100, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; Moscovitch M., 1989, VARIETIES MEMORY CON, P133; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PANDYA DN, 1985, CEREBRAL CORTEX ASS, V4; Pedhazur E. J., 1982, MULTIPLE REGRESSION; PETRIDES M, 1989, HDB NEUROPSYCHOLOGY, V3, P75; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RICHARDSONKLAVEHN A, 1988, ANNU REV PSYCHOL, V39, P475, DOI 10.1146/annurev.ps.39.020188.002355; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SCHACTER DL, 1984, J VERB LEARN VERB BE, V23, P593, DOI 10.1016/S0022-5371(84)90373-6; SCHACTER DL, 1987, PSYCHOBIOLOGY, V15, P21; SEGALOWITZ SJ, 1992, DEV NEUROPSYCHOL, V8, P279, DOI 10.1080/87565649209540528; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SHIMAMURA AP, 1987, J EXP PSYCHOL LEARN, V13, P464, DOI 10.1037/0278-7393.13.3.464; TEASDALE G, 1974, LANCET, V2, P81; TREXLER LE, 1988, BRAIN COGNITION, V8, P291, DOI 10.1016/0278-2626(88)90056-5; VARNEY NR, 1991, NEUROPSYCHOLOGY LAW, P24; Wechsler D, 1987, MEMORY SCALE REVISED; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114	65	29	29	0	5	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	JAN	1993	21	1					20	43		10.1006/brcg.1993.1002			24	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	KJ358	WOS:A1993KJ35800002	8424861				2022-02-06	
J	ZENTNER, J; ROHDE, V; FRIEDMAN, WA; DAUBE, JR				ZENTNER, J; ROHDE, V; FRIEDMAN, WA; DAUBE, JR			THE PROGNOSTIC VALUE OF SOMATOSENSORY AND MOTOR EVOKED-POTENTIALS IN COMATOSE PATIENTS	NEUROSURGERY			English	Article						COMA; MOTOR EVOKED POTENTIAL; SOMATOSENSORY EVOKED POTENTIAL	SEVERE HEAD-INJURY; MAGNETIC STIMULATION; CONDUCTION TIME; BRAIN; CORTEX	SOMATOSENSORY AND MOTOR evoked potentials (SEP and MEP) were examined in a total of 213 patients in traumatic (n = 140) and nontraumatic (n = 73) coma. It was the aim of this study to compare the prognostic value of MEP elicited by both electrical and magnetoelectric transcranial stimulation with the use of SEP alone. According to the presence or absence of responses and the duration of central conduction time, SEP and MEP obtained during Days 1 through 3 after the onset of coma were divided into four categories and correlated with the outcome of the patients, as assessed by the Glasgow Outcome Scale. Our results clearly show that in terms of prognostic value, SEP are superior to MEP, with normal findings indicating a favorable outcome and absent responses an unfavorable outcome. On the other hand, patients with normal electromyographic responses after both electrical and magnetoelectric stimulation had favorable and unfavorable outcomes about equally. Thus, unlike SEP, normal MEP do not allow any prognostic conclusions. Only the bilateral absence of MEP in response to electrical stimulation was a definitely unfavorable prognostic sign because all of these patients died. In contrast, with magnetoelectric stimulation, neither normal nor absent responses allowed any prognostic conclusions. Therefore, the prognostic value of electrically evoked motor responses is limited, and magnetoelectric stimulation cannot be recommended in this context.	UNIV TUBINGEN,SCH MED,DEPT MINERAL & PETROL,W-7400 TUBINGEN 1,GERMANY								BARKER AT, 1985, LANCET, V1, P1106; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; DAY BL, 1987, NEUROSCI LETT, V75, P101, DOI 10.1016/0304-3940(87)90083-8; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HUME AL, 1979, ANN NEUROL, V5, P379, DOI 10.1002/ana.410050412; JENNETT B, 1975, LANCET, V1, P480; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; MERTON PA, 1980, NATURE, V285, P227, DOI 10.1038/285227a0; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OBESO J A, 1980, Electromyography and Clinical Neurophysiology, V20, P343; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; TEASDALE G, 1974, LANCET, V2, P81; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; ZENTNER J, 1989, ADV NEUROSURG, V17, P287	15	29	30	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1992	31	3					429	434		10.1227/00006123-199209000-00007			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	JN834	WOS:A1992JN83400007	1407425				2022-02-06	
J	KRAUSS, GL; NIEDERMEYER, E				KRAUSS, GL; NIEDERMEYER, E			ELECTROENCEPHALOGRAM AND SEIZURES IN CHRONIC-ALCOHOLISM	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						ALCOHOLISM; EEG; LOW VOLTAGE RECORDS; WITHDRAWAL (FROM ALCOHOL); EPILEPTIC SEIZURES; MAGNESIUM; CNS COMPLICATIONS (OF ALCOHOLISM)	EEG; ABUSE	CNS complications of chronic alcoholism are frequently difficult to assess due to the variety of direct and secondary conditions which can result from alcoholic drinking and lifestyles. The influence of alcoholism and alcohol-related factors on the EEG of patients with chronic alcoholism was studied in 213 patients (15.4% of all adults who had EEGs) using visual analysis. The influence of a variety of alcohol-related factors - drinking history, clinical complications, traumatic head injuries, head CT findings and laboratory results - on the EEG and alcohol-related seizures was studied. The effect of EEG results on the decision to treat alcohol-related seizures was also assessed. 152 of the patients had seizures, mostly (90% of those with defined seizure types) generalized tonic-clonic seizures. 53% of all seizures occurred in the early withdrawal period (8 h to 7 days abstinence). A history of partial seizures was significantly associated with findings of focal EEG abnormalities, a history of head injuries and structural lesions on CT. The clinical significance of these findings was unclear, however, as the majority of patients who had focal EEG abnormalities or structural brain lesions still appeared to have generalized withdrawal seizures. The EEG and CT appeared to be complementary tests: for most patients, focal abnormalities were demonstrated on only one of the two tests. The majority of patients (56%) with normal EEGs had predominantly low voltage recordings (< 25-mu-V), compared with 13.9% of 1167 patients without a history of alcoholism (P < 0.001). Other alcoholism-related factors, such as head injuries and structural abnormalities on CT and age, did not influence the occurrence of low voltage recordings. A slight increase in frequency of low voltage records occurred in patients with cortical atrophy identified on CT. These findings were verified in a smaller controlled, prospective study of 24 patients. Several other clinical findings in patients with alcohol-related seizures included hypoglycemia in two patients, and the finding of lower serum magnesium levels in patients with seizures (mean 1.36 +/- 0.04 mEq/l) compared with those who had delirium or other diagnosis (mean 1.6 +/- 0.10 mEq/l, P < 0.05). Hypomagnesemia did not appear to be a precipitating factor in the development of alcohol-related seizures, as patients in various stages of abstinence had similar magnesium levels. One-half of patients were treated chronically with anticonvulsants and only one maintained therapeutic drug levels and two had overdosages. A history of recurring seizures (and particularly of partial seizures) was a more important factor in the decision to treat with chronic anticonvulsant therapy than was the results of EEG. The finding of low voltage EEG is useful in detecting alcoholism, although this finding is not specific for alcoholism. The role of EEG in chronic alcoholism is more contributory to the clinical evaluation than it is widely assumed.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205		KRAUSS, GL (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT NEUROL,600 N WOLFE ST,BALTIMORE,MD 21205, USA.						ARENTSEN K, 1963, ACTA PSYCHIAT SCAND, V39, P370; AVOLI M, 1987, BRAIN RES, V417, P199, DOI 10.1016/0006-8993(87)90201-0; BEGLEITER H, 1972, BIOL ALCOHOL, V2, P293; BICKFORD RG, 1952, ELECTROEN CLIN NEURO, V4, P275, DOI 10.1016/0013-4694(52)90052-7; CHAN AWK, 1985, EPILEPSIA, V26, P323, DOI 10.1111/j.1528-1157.1985.tb05658.x; CHARNESS ME, 1989, NEW ENGL J MED, V321, P442, DOI 10.1056/NEJM198908173210706; COGER RW, 1978, BIOL PSYCHIAT, V13, P729; Davis PA, 1941, Q J STUD ALCOHOL, V1, P626; DEISENHAMMER E, 1984, EPILEPSIA, V25, P526, DOI 10.1111/j.1528-1157.1984.tb03455.x; DREYFUS PM, 1961, AM J CLIN NUTR, V9, P414, DOI 10.1093/ajcn/9.4.414; EARNEST MP, 1988, NEUROLOGY, V38, P1561, DOI 10.1212/WNL.38.10.1561; EHLERS CL, 1989, NEUROPHYSIOL, V73, P179; ENGEL GL, 1945, ARCH NEURO PSYCHIATR, V53, P44, DOI 10.1001/archneurpsyc.1945.02300010054004; FEUSSNER JR, 1981, ANN INTERN MED, V494, P519; FISCH B, 1986, NEUROPHYSIOL, V64, P76; FOURNET A, 1956, Rev Neurol (Paris), V94, P644; FRANTZEN E, 1966, ACTA NEUROL SCAND, V42, P426; GERSON IM, 1979, CLIN ELECTROENCEPHAL, V10, P40, DOI 10.1177/155005947901000105; Giove G, 1965, Rev Neurol (Paris), V113, P347; Greenblatt M, 1944, ARCH NEURO PSYCHIATR, V52, P290, DOI 10.1001/archneurpsyc.1944.02290340037003; HAUSER WA, 1988, EPILEPSIA, V29, pS66, DOI 10.1111/j.1528-1157.1988.tb05800.x; HILLBOM ME, 1980, EPILEPSIA, V21, P459, DOI 10.1111/j.1528-1157.1980.tb04296.x; HUDOLIN V, 1967, BRIT J ADDICT, V62, P55; JOHANNESSON G, 1982, ACTA PSYCHIAT SCAND, V65, P148, DOI 10.1111/j.1600-0447.1982.tb00834.x; KELLEY JT, 1983, EEG EVOKED POTENTIAL; KOUFEN H, 1980, NERVENARZT, V51, P100; LITTLE SC, 1952, ELECTROEN CLIN NEURO, V4, P245; MAGNES J, 1961, NATURE SLEEP, P57; Mattson R.H., 1983, EPILEPSY DIAGNOSIS M, P325; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; NEWMAN SE, 1978, ANN NEUROL, V3, P299, DOI 10.1002/ana.410030404; NIEDERMEYER E, 1981, CLIN ELECTROENCEPHAL, V12, P113, DOI 10.1177/155005948101200304; NIEDERMEYER E, 1963, NEUROLOGY, V13, P412, DOI 10.1212/WNL.13.5.412; NIEDERMEYER E, 1987, Epilepsia, V28, P605; NIEDERMEYER E, 1987, ELECTROENCEPHALOGRAP, P275; REILLY EL, 1979, CLIN ELECTROENCEPHAL, V10, P69, DOI 10.1177/155005947901000204; SAINIO K, 1976, NEUROPHYSIOL, V40, P535; SCHEAR HE, 1985, CLIN ELECTROENCEPHAL, V16, P30, DOI 10.1177/155005948501600105; SOKYA M, 1989, J EPILEPSY, V2, P109; VANSWEDEN B, 1983, CLIN NEUROL NEUROSUR, V85, P12, DOI 10.1016/0303-8467(83)90019-7; VANSWEDEN B, 1983, CLIN NEUROL NEUROSUR, V85, P3, DOI 10.1016/0303-8467(83)90018-5; Verceletto P, 1965, Rev Neurol (Paris), V113, P344; VICTOR M., 1967, EPILEPSIA, V8, P1; VOSSLER DG, 1988, EPILEPSIA, V29, P494; WESSELY P, 1974, WIEN KLIN WOCHENSCHR, V86, P618; WIKLER A, 1956, AM J PSYCHIAT, V113, P106, DOI 10.1176/ajp.113.2.106; Zanchetti, 1959, ARCH ITAL BIOL, V97, P33; ZILM DH, 1980, CLIN TOXICOL, V16, P345, DOI 10.3109/15563658008989958; [No title captured]	50	29	29	0	6	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	FEB	1991	78	2					97	104		10.1016/0013-4694(91)90108-G			8	Engineering, Biomedical; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering; Neurosciences & Neurology	EY029	WOS:A1991EY02900002	1704841				2022-02-06	
J	SARAN, A				SARAN, A			ANTIDEPRESSANTS NOT EFFECTIVE IN HEADACHE ASSOCIATED WITH MINOR CLOSED HEAD-INJURY	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article									HIGHLAND VIEW HOSP,CLEVELAND,OH		SARAN, A (corresponding author), CLEVELAND METROPOLITAN GEN HOSP,3395 SCRANTON RD,CLEVELAND,OH 44109, USA.						ALCOFF J, 1982, J FAM PRACTICE, V14, P841; BAKAL DA, 1976, HEADACHE, V11, P123; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; CARASSO RL, 1979, INT J NEUROSCI, V9, P191, DOI 10.3109/00207457909147672; CASSIDY WL, 1957, JAMA-J AM MED ASSOC, V164, P1535, DOI 10.1001/jama.1957.02980140011003; COUCH MR, 1978, ARCH NEUROLOGY, V36, P695; DIAMOND S, 1971, HEADACHE, V11, P110, DOI 10.1111/j.1526-4610.1971.hed1103110.x; DIAMOND S, 1964, Headache, V4, P255, DOI 10.1111/j.1526-4610.1964.hed0403255.x; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; GARVEY MJ, 1983, BRIT J PSYCHIAT, V143, P544, DOI 10.1192/bjp.143.6.544; GERSHON S, 1981, J CLIN PSYCHOPHARM S, V1, P39; JACOBSON SA, 1969, LATE EFFECTS HEAD IN; KOZOL HL, 1946, ARCH NEURO PSYCHIATR, V56, P245, DOI 10.1001/archneurpsyc.1946.02300200002001; LANCE JW, 1964, LANCET, V1, P1236; LIEBOWITZ MR, 1984, J CLIN PSYCHIAT, V45, P22; LISHMAN WA, 1978, PSYCHOL CONSEQUENCES, P191; MARTIN MJ, 1978, MED CLIN N AM, V62, P559, DOI 10.1016/S0025-7125(16)31793-X; MATHEW NT, 1981, HEADACHE, V21, P105, DOI 10.1111/j.1526-4610.1981.hed2103105.x; RUTHERFORD WH, 1977, LANCET, V1, P1; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SCOTT WA, 1969, PRACTITIONER     JUN, P802; SHERWIN D, 1979, AM J PSYCHIAT, V136, P1181; TAUB A, 1973, J NEUROSURG, V39, P235, DOI 10.3171/jns.1973.39.2.0235; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; WARD N, 1984, J CLIN PSYCHIAT, V45, P54; WARD NG, 1982, J CLIN PSYCHIAT, V43, P32; WARD NG, 1979, PAIN, V7, P331, DOI 10.1016/0304-3959(79)90089-7	27	29	29	0	2	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1988	18	1					75	83		10.2190/15AH-JB7Q-U94T-JEAF			9	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	N5275	WOS:A1988N527500007	3294202				2022-02-06	
J	SOCKALOSKY, JJ; KRIEL, RL; KRACH, LE; SHEEHAN, M				SOCKALOSKY, JJ; KRIEL, RL; KRACH, LE; SHEEHAN, M			PRECOCIOUS PUBERTY AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF PEDIATRICS			English	Article									GILLETTE CHILDRENS HOSP, PEDIAT HEAD INJURY SERV, ST PAUL, MN 55101 USA		SOCKALOSKY, JJ (corresponding author), ST PAUL RAMSEY MED CTR, DEPT PEDIAT, 640 JACKSON ST, ST PAUL, MN 55101 USA.			Krach, Linda/0000-0002-0993-8199			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BACON G, 1982, PRACTICAL APPROACH P, P189; BALAGURA S, 1979, SURG NEUROL, V11, P315; BIERICH JR, 1975, CLIN ENDOCRINOL META, V4, P107, DOI 10.1016/S0300-595X(75)80036-3; BRUCE DA, 1983, PEDIATRIC HEAD TRAUM, P213; COMITE F, 1986, JAMA-J AM MED ASSOC, V255, P2613; CONTE FA, 1980, J CLIN ENDOCR METAB, V50, P163, DOI 10.1210/jcem-50-1-163; Grumbach MM, 1980, NEUROENDOCRINOLOGY, P249; KAPLAN SL, 1985, CONTROL ONSET PUBERT; LEVIN HS, 1983, PEDIATRIC HEAD TRAUM, P22; MCKIERNAN J, 1978, BMJ-BRIT MED J, V14, P1059; RAYNER PHW, 1976, BRIT MED J, V1, P1385, DOI 10.1136/bmj.1.6022.1385; REITER EO, 1975, PEDIATR RES, V9, P111, DOI 10.1203/00006450-197509020-00011; ROOT AW, 1978, J PEDIATR, V83, P187; ROSS GT, 1981, TXB ENDOCRINOLOGY, P339; ROTH JC, 1972, J CLIN ENDOCR METAB, V35, P926, DOI 10.1210/jcem-35-6-926; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; SIGURJONSDOTTIR TJ, 1968, AM J DIS CHILD, V115, P309, DOI 10.1001/archpedi.1968.02100010311003; WILKINS L, 1965, DIAGNOSIS TREATMENT, P225	19	29	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAR	1987	110	3					373	377		10.1016/S0022-3476(87)80497-3			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	G3208	WOS:A1987G320800008	3819938				2022-02-06	
J	MEYERS, CA; LEVIN, HS; EISENBERG, HM; GUINTO, FC				MEYERS, CA; LEVIN, HS; EISENBERG, HM; GUINTO, FC			EARLY VERSUS LATE LATERAL VENTRICULAR ENLARGEMENT FOLLOWING CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DIV NEURORADIOL,GALVESTON,TX 77550						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 07377-11, NS 9-2314] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS092314] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; DELEON MJ, 1980, NEUROBIOL AGING, V1, P69, DOI 10.1016/0197-4580(80)90027-5; GRONWALL D, 1974, LANCET, V2, P1452; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Levin HS., 1982, NEUROBEHAVIORAL CONS; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYNEK V, 1976, BRIT J RADIOL, V49, P233, DOI 10.1259/0007-1285-49-579-233; TEASDALE G, 1974, LANCET, V2, P81; [No title captured]	15	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1983	46	12					1092	1097		10.1136/jnnp.46.12.1092			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	RW430	WOS:A1983RW43000005	6607318	Green Published, Bronze			2022-02-06	
J	Bolte, AC; Dutta, AB; Hurt, ME; Smirnov, I; Kovacs, MA; McKee, CA; Ennerfelt, HE; Shapiro, D; Nguyen, BH; Frost, EL; Lammert, CR; Kipnis, J; Lukens, JR				Bolte, Ashley C.; Dutta, Arun B.; Hurt, Mariah E.; Smirnov, Igor; Kovacs, Michael A.; McKee, Celia A.; Ennerfelt, Hannah E.; Shapiro, Daniel; Nguyen, Bao H.; Frost, Elizabeth L.; Lammert, Catherine R.; Kipnis, Jonathan; Lukens, John R.			Meningeal lymphatic dysfunction exacerbates traumatic brain injury pathogenesis	NATURE COMMUNICATIONS			English	Article							HEAD-INJURY; INTERSTITIAL FLUID; SYSTEM; MODEL; RISK; CNS; NEURODEGENERATION; INFLAMMATION; MORTALITY; ALIGNMENT	Traumatic brain injury (TBI) is a leading global cause of death and disability. Here we demonstrate in an experimental mouse model of TBI that mild forms of brain trauma cause severe deficits in meningeal lymphatic drainage that begin within hours and last out to at least one month post-injury. To investigate a mechanism underlying impaired lymphatic function in TBI, we examined how increased intracranial pressure (ICP) influences the meningeal lymphatics. We demonstrate that increased ICP can contribute to meningeal lymphatic dysfunction. Moreover, we show that pre-existing lymphatic dysfunction before TBI leads to increased neuroinflammation and negative cognitive outcomes. Finally, we report that rejuvenation of meningeal lymphatic drainage function in aged mice can ameliorate TBI-induced gliosis. These findings provide insights into both the causes and consequences of meningeal lymphatic dysfunction in TBI and suggest that therapeutics targeting the meningeal lymphatic system may offer strategies to treat TBI.	[Bolte, Ashley C.; Hurt, Mariah E.; Smirnov, Igor; Kovacs, Michael A.; McKee, Celia A.; Ennerfelt, Hannah E.; Shapiro, Daniel; Frost, Elizabeth L.; Lammert, Catherine R.; Kipnis, Jonathan; Lukens, John R.] Univ Virginia, Ctr Brain Immunol & Glia BIG, Dept Neurosci, Charlottesville, VA 22908 USA; [Bolte, Ashley C.; Kovacs, Michael A.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA; [Bolte, Ashley C.; Dutta, Arun B.; Kovacs, Michael A.; Lukens, John R.] Univ Virginia, Med Scientist Training Program, Charlottesville, VA 22908 USA; [Bolte, Ashley C.; Kovacs, Michael A.; Lukens, John R.] Univ Virginia, Immunol Training Program, Charlottesville, VA 22908 USA; [Dutta, Arun B.; Nguyen, Bao H.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Ennerfelt, Hannah E.; Lammert, Catherine R.; Kipnis, Jonathan; Lukens, John R.] Univ Virginia, Neurosci Grad Program, Charlottesville, VA 22908 USA		Lukens, JR (corresponding author), Univ Virginia, Ctr Brain Immunol & Glia BIG, Dept Neurosci, Charlottesville, VA 22908 USA.; Lukens, JR (corresponding author), Univ Virginia, Med Scientist Training Program, Charlottesville, VA 22908 USA.; Lukens, JR (corresponding author), Univ Virginia, Immunol Training Program, Charlottesville, VA 22908 USA.; Lukens, JR (corresponding author), Univ Virginia, Neurosci Grad Program, Charlottesville, VA 22908 USA.	Jrl7n@virginia.edu		Bolte, Ashley/0000-0003-4013-3759; Nguyen, Bao/0000-0003-2198-9578; Dutta, Arun/0000-0003-0114-0921	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS106383]; Alzheimer's AssociationAlzheimer's Association [AARG-18-566113]; Owens Family Foundation; University of Virginia Research and Development Award; Wagner Fellowship; Biomedical Data Sciences Training Grant [T32LM012416]; Cell and Molecular Biology Training Grant [T32GM008136]; R35 grant [5R35GM128635-02]; NIH National Institute of General Medical Sciences predoctoral training grant [3T32GM008328]; National Multiple Sclerosis Foundation Postdoctoral Fellowship [FG-1707-28590]; Medical Scientist Training Program Grant [5T32GM007267-38]; Immunology Training Grant [5T32AI007496-25]	We thank members of the Lukens lab and the Center for Brain Immunology and Glia (BIG) for valuable discussions. Graphical illustrations in Figs. 1a, e, 6h, and Supplementary Fig. 5a were made using BioRender (https://biorender.com/). This work was supported by The National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01NS106383; awarded to J.R.L.), The Alzheimer's Association (AARG-18-566113; awarded to J.R.L.), The Owens Family Foundation (Awarded to J.R.L.), and The University of Virginia Research and Development Award (Awarded to J.R.L.). A.C.B., A.B.D., and M.A.K. were supported by a Medical Scientist Training Program Grant (5T32GM007267-38). A.C.B. and M.A.K. were supported by an Immunology Training Grant (5T32AI007496-25). A.C.B. was supported by a Wagner Fellowship. A.B.D. was supported by a Biomedical Data Sciences Training Grant (T32LM012416). H.E.E. was supported by a Cell and Molecular Biology Training Grant (T32GM008136). B.H.N. was supported by an R35 grant (5R35GM128635-02). C.R.L. was supported by a NIH National Institute of General Medical Sciences predoctoral training grant (3T32GM008328) and a Wagner Fellowship. E.L.F. was supported by a National Multiple Sclerosis Foundation Postdoctoral Fellowship (FG-1707-28590).	Absinta M, 2017, ELIFE, V6, DOI 10.7554/eLife.29738; Ahn JH, 2019, NATURE, V572, P62, DOI 10.1038/s41586-019-1419-5; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; [Anonymous], 2012, LANCET NEUROL, V11, P651, DOI 10.1016/S1474-4422(12)70166-7; Antila S, 2017, J EXP MED, V214, P3645, DOI 10.1084/jem.20170391; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chou A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061616; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Da Mesquita S, 2018, NATURE, V560, P185, DOI 10.1038/s41586-018-0368-8; de Lima KA, 2020, ANNU REV IMMUNOL, V38, P597, DOI 10.1146/annurev-immunol-102319-103410; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Ensari S, 2008, TURK NEUROSURG, V18, P56; Esposito E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13324-w; Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gabory A, 2010, BIOESSAYS, V32, P473, DOI 10.1002/bies.200900170; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Goodman JR, 2020, J CEREBR BLOOD F MET, V40, P1724, DOI 10.1177/0271678X19874134; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Henry RJ, 2020, J NEUROSCI, V40, P2960, DOI 10.1523/JNEUROSCI.2402-19.2020; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hsu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08163-0; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kevin L, 1993, HEAD NECK-J SCI SPEC, V15, P546; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Krukowski K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123753; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kuo PH, 2018, TOMOGRAPHY, V4, P99, DOI 10.18383/j.tom.2018.00013; Labzin LI, 2018, ANNU REV MED, V69, P437, DOI 10.1146/annurev-med-050715-104343; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Louveau A, 2018, NAT NEUROSCI, V21, P1380, DOI 10.1038/s41593-018-0227-9; Louveau A, 2017, J CLIN INVEST, V127, P3210, DOI 10.1172/JCI90603; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma QL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01484-6; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nishimura D., 2001, BIOTECHNOL SOFTW INT, V2, P117, DOI 10.1089/152791601750294344; Nolan A, 2018, J NEUROTRAUM, V35, P2425, DOI 10.1089/neu.2018.5731; Patel TK, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0312-x; Plath N, 2006, NEURON, V52, P437, DOI 10.1016/j.neuron.2006.08.024; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Shepherd JD, 2011, NAT NEUROSCI, V14, P279, DOI 10.1038/nn.2708; Song E, 2020, NATURE, V577, P689, DOI 10.1038/s41586-019-1912-x; Stephan AH, 2013, J NEUROSCI, V33, P13460, DOI 10.1523/JNEUROSCI.1333-13.2013; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Susaki EA, 2015, NAT PROTOC, V10, P1709, DOI 10.1038/nprot.2015.085; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tammela T, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001699; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Willis EF, 2020, CELL, V180, P833, DOI 10.1016/j.cell.2020.02.013; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zou WY, 2019, TRANSL NEURODEGENER, V8, DOI 10.1186/s40035-019-0147-y; 2006, MMWR MORB MORTAL WKL, V55, P201	78	28	29	5	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	2041-1723			NAT COMMUN	Nat. Commun.	SEP 10	2020	11	1							4524	10.1038/s41467-020-18113-4			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR2YW	WOS:000607107700001	32913280	Green Submitted, Green Published, gold			2022-02-06	
J	Provencio, JJ; Hemphill, JC; Claassen, J; Edlow, BL; Helbok, R; Vespa, PM; Diringer, MN; Polizzotto, L; Shutter, L; Suarez, JI; Stevens, RD; Hanley, DF; Akbari, Y; Bleck, TP; Boly, M; Foreman, B; Giacino, JT; Hartings, JA; Human, T; Kondziella, D; Ling, GSF; Mayer, SA; McNett, M; Menon, DK; Meyfroidt, G; Monti, MM; Park, S; Pouratian, N; Puybasset, L; Rohaut, B; Rosenthal, ES; Schiff, ND; Sharshar, T; Wagner, A; Whyte, J; Olson, DM				Provencio, J. Javier; Hemphill, J. Claude; Claassen, Jan; Edlow, Brian L.; Helbok, Raimund; Vespa, Paul M.; Diringer, Michael N.; Polizzotto, Len; Shutter, Lori; Suarez, Jose, I; Stevens, Robert D.; Hanley, Daniel F.; Akbari, Yama; Bleck, Thomas P.; Boly, Melanie; Foreman, Brandon; Giacino, Joseph T.; Hartings, Jed A.; Human, Theresa; Kondziella, Daniel; Ling, Geoffrey S. F.; Mayer, Stephan A.; McNett, Molly; Menon, David K.; Meyfroidt, Geert; Monti, Martin M.; Park, Soojin; Pouratian, Nader; Puybasset, Louis; Rohaut, Benjamin; Rosenthal, Eric S.; Schiff, Nicholas D.; Sharshar, Tarek; Wagner, Amy; Whyte, John; Olson, DaiWai M.		Neurocritical Care Soc Curing Coma	The Curing Coma Campaign: Framing Initial Scientific Challenges-Proceedings of the First Curing Coma Campaign Scientific Advisory Council Meeting	NEUROCRITICAL CARE			English	Article						Coma; Endotype; Biomarker; Consciousness; Recovery	TRAUMATIC BRAIN-INJURY; WITHDRAWAL; DISORDERS	Coma and disordered consciousness are common manifestations of acute neurological conditions and are among the most pervasive and challenging aspects of treatment in neurocritical care. Gaps exist in patient assessment, outcome prognostication, and treatment directed specifically at improving consciousness and cognitive recovery. In 2019, the Neurocritical Care Society (NCS) launched the Curing Coma Campaign in order to address the "grand challenge" of improving the management of patients with coma and decreased consciousness. One of the first steps was to bring together a Scientific Advisory Council including coma scientists, neurointensivists, neurorehabilitationists, and implementation experts in order to address the current scientific landscape and begin to develop a framework on how to move forward. This manuscript describes the proceedings of the first Curing Coma Campaign Scientific Advisory Council meeting which occurred in conjunction with the NCS Annual Meeting in October 2019 in Vancouver. Specifically, three major pillars were identified which should be considered: endotyping of coma and disorders of consciousness, biomarkers, and proof-of-concept clinical trials. Each is summarized with regard to current approach, benefits to the patient, family, and clinicians, and next steps. Integration of these three pillars will be essential to the success of the Curing Coma Campaign as will expanding the "curing coma community" to ensure broad participation of clinicians, scientists, and patient advocates with the goal of identifying and implementing treatments to fundamentally improve the outcome of patients.	[Provencio, J. Javier] Univ Virginia, Dept Neurol & Neurosci, Charlottesville, VA USA; [Hemphill, J. Claude] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Neurol, Bldg 1,Room 101,1001 Potrero Ave, San Francisco, CA 94110 USA; [Claassen, Jan; Park, Soojin] Columbia Univ, New York Presbyterian Hosp, Irving Med Ctr, Dept Neurol, New York, NY USA; [Edlow, Brian L.; Rosenthal, Eric S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA; [Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Neurocrit Care, Innsbruck, Austria; [Vespa, Paul M.] UCLA, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Vespa, Paul M.; Pouratian, Nader] UCLA, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Diringer, Michael N.; Human, Theresa] Washington Univ, Barnes Jewish Hosp, Dept Neurol, St Louis, MO USA; [Polizzotto, Len] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA; [Shutter, Lori] Univ Pittsburgh, Dept Crit Care Med, UPMC Hlth Syst, Pittsburgh, PA USA; [Shutter, Lori] Univ Pittsburgh, Dept Neurol, UPMC Hlth Syst, Pittsburgh, PA 15260 USA; [Shutter, Lori] Univ Pittsburgh, Dept Neurosurg, UPMC Hlth Syst, Pittsburgh, PA USA; [Suarez, Jose, I; Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Suarez, Jose, I; Stevens, Robert D.; Ling, Geoffrey S. F.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Suarez, Jose, I; Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Hanley, Daniel F.] Johns Hopkins Univ, Div Brain Injury Outcomes, Baltimore, MD USA; [Akbari, Yama] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA; [Akbari, Yama] Univ Calif Irvine, Dept Neurosurg, Irvine, CA USA; [Akbari, Yama] Univ Calif Irvine, Beckman Laser Inst, Irvine, CA USA; [Bleck, Thomas P.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Boly, Melanie] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; [Foreman, Brandon] Univ Cincinnati, Coll Med, Gardner Neurosci Inst, Dept Neurol & Rehabil Med, Cincinnati, OH USA; [Giacino, Joseph T.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Hartings, Jed A.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; [Human, Theresa] Washington Univ, Barnes Jewish Hosp, Dept Neurosurg, St Louis, MO 63110 USA; [Kondziella, Daniel] Copenhagen Univ Hosp, Rigshosp, Dept Neurol, Copenhagen, Denmark; [Mayer, Stephan A.] New York Med Coll, Dept Neurol, Valhalla, NY 10595 USA; [Mayer, Stephan A.] New York Med Coll, Dept Neurosurg, Valhalla, NY 10595 USA; [McNett, Molly] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Meyfroidt, Geert] Univ Hosp Leuven, Dept & Lab Intens Care Med, Leuven, Belgium; [Meyfroidt, Geert] Katholieke Univ Leuven, Leuven, Belgium; [Monti, Martin M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA; [Puybasset, Louis] Sorbonne Univ, Piti Salpetriere Hosp, AP HP, DMU DREAM,GRC 29,Dept Anesthesiol & Crit Care, F-75013 Paris, France; [Rohaut, Benjamin] Sorbonne Univ, Pitie Salpetriere Hosp, Dept Neurol, NeuroICU, Paris, France; [Schiff, Nicholas D.] Weill Cornell Med, Dept Neurol, New York, NY USA; [Schiff, Nicholas D.] Weill Cornell Med, Dept Neurosci, New York, NY USA; [Schiff, Nicholas D.] Weill Cornell Med, Dept Med Eth, New York, NY USA; [Sharshar, Tarek] Paris Descartes Univ, St Anne Hosp, Neuroanesthesiol & Intens Care Med, Paris, France; [Sharshar, Tarek] Inst Pasteur, Expt Neuropathol, Infect & Epidemiol Dept, Paris, France; [Wagner, Amy] Univ Pittsburgh, Clin & Translat Sci Inst, Dept Phys Med & Rehabil, Dept Neurosci, Pittsburgh, PA USA; [Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Olson, DaiWai M.] Univ Texas Southwestern, Dept Neurol & Neurotherapeut, Dallas, TX USA		Hemphill, JC (corresponding author), Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Neurol, Bldg 1,Room 101,1001 Potrero Ave, San Francisco, CA 94110 USA.	claude.hemphill@ucsf.edu	Provencio, Jose Javier/AAG-5114-2021; Helbok, Raimund/AAA-8361-2021; Giacino, Joseph/AAF-1952-2021; Sharshar, Tarek/ABF-4117-2021; Shutter, Lori A/G-2957-2013; Hemphill, Claude/AAY-5630-2021; Rohaut, Benjamin/O-9250-2017; Rosenthal, Eric/A-2085-2017	Provencio, Jose Javier/0000-0003-1298-1806; Giacino, Joseph/0000-0002-7916-9698; Hemphill, Claude/0000-0003-4019-7525; Rohaut, Benjamin/0000-0001-6752-8756; Rosenthal, Eric/0000-0003-3900-356X; Hanley, Daniel/0000-0002-9536-4258; Shutter, Lori/0000-0002-1390-0628; Kondziella, Daniel/0000-0001-5562-9808	NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001416] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS105950] Funding Source: Medline		Brogan ME, 2014, J CRIT CARE, V29, P679, DOI 10.1016/j.jcrc.2014.04.014; Giacino Joseph T, 2008, Handb Clin Neurol, V90, P99, DOI 10.1016/S0072-9752(07)01706-X; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; Rubin M, 2017, CURR OPIN CRIT CARE, V23, P134, DOI 10.1097/MCC.0000000000000396; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786	6	28	28	1	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2020	33	1					1	12		10.1007/s12028-020-01028-9		JUN 2020	12	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	MT1KH	WOS:000542494500001	32578124	Green Published, Green Accepted, hybrid			2022-02-06	
J	Hsieh, TH; Kuo, CW; Hsieh, KH; Shieh, MJ; Peng, CW; Chen, YC; Chang, YL; Huang, YZ; Chen, CC; Chang, PK; Chen, KY; Chen, HY				Hsieh, Tsung-Hsun; Kuo, Chi-Wei; Hsieh, Kai-Hsuan; Shieh, Meng-Jyh; Peng, Chih-Wei; Chen, Yen-Chien; Chang, Ying-Ling; Huang, Ying-Zu; Chen, Chih-Chung; Chang, Pi-Kai; Chen, Kai-Yun; Chen, Hsin-Yung			Probiotics Alleviate the Progressive Deterioration of Motor Functions in a Mouse Model of Parkinson's Disease	BRAIN SCIENCES			English	Article						probiotics; Parkinson's disease; neuroprotection; motor function; MitoPark; mice	TRAUMATIC BRAIN-INJURY; CERULEIN-INDUCED PANCREATITIS; GUT-MICROBIOTA; GASTROINTESTINAL SYMPTOMS; SENSORY NEURONS; NITRIC-OXIDE; IN-VITRO; SEROTONIN; AXIS; MODULATION	Parkinson's disease (PD) is one of the common long-term degenerative disorders that primarily affect motor systems. Gastrointestinal (GI) symptoms are common in individuals with PD and often present before motor symptoms. It has been found that gut dysbiosis to PD pathology is related to the severity of motor and non-motor symptoms in PD. Probiotics have been reported to have the ability to improve the symptoms related to constipation in PD patients. However, the evidence from preclinical or clinical research to verify the beneficial effects of probiotics for the motor functions in PD is still limited. An experimental PD animal model could be helpful in exploring the potential therapeutic strategy using probiotics. In the current study, we examined whether daily and long-term administration of probiotics has neuroprotective effects on nigrostriatal dopamine neurons and whether it can further alleviate the motor dysfunctions in PD mice. Transgenic MitoPark PD mice were chosen for this study and the effects of daily probiotic treatment on gait, beam balance, motor coordination, and the degeneration levels of dopaminergic neurons were identified. From the results, compared with the sham treatment group, we found that the daily administration of probiotics significantly reduced the motor impairments in gait pattern, balance function, and motor coordination. Immunohistochemically, a tyrosine hydroxylase (TH)-positive cell in the substantia nigra was significantly preserved in the probiotic-treated PD mice. These results showed that long-term administration of probiotics has neuroprotective effects on dopamine neurons and further attenuates the deterioration of motor dysfunctions in MitoPark PD mice. Our data further highlighted the promising possibility of the potential use of probiotics, which could be the relevant approach for further application on human PD subjects.	[Hsieh, Tsung-Hsun; Kuo, Chi-Wei; Hsieh, Kai-Hsuan; Chen, Chih-Chung] Chang Gung Univ, Sch Phys Therapy, Taoyuan 33302, Taiwan; [Hsieh, Tsung-Hsun; Kuo, Chi-Wei; Hsieh, Kai-Hsuan; Chen, Chih-Chung] Chang Gung Univ, Grad Inst Rehabil Sci, Taoyuan 33302, Taiwan; [Hsieh, Tsung-Hsun; Huang, Ying-Zu] Chang Gung Mem Hosp, Neurosci Res Ctr, Taoyuan 33305, Taiwan; [Hsieh, Tsung-Hsun; Huang, Ying-Zu; Chen, Chih-Chung] Chang Gung Univ, Hlth Aging Res Ctr, Taoyuan 33302, Taiwan; [Kuo, Chi-Wei] Natl Taiwan Univ, Dept Life Sci, Taipei 10617, Taiwan; [Shieh, Meng-Jyh] Tajen Inst Technol, Dept Biotechnol, Pingtung 90741, Taiwan; [Peng, Chih-Wei] Taipei Med Univ, Sch Biomed Engn, Coll Biomed Engn, Taipei 11031, Taiwan; [Chen, Yen-Chien] Taichung Gen Veteran Hosp, Dept Food & Nutr, Taichung 40705, Taiwan; [Chang, Ying-Ling] Chang Gung Univ, Sch & Grad Inst Tradit Chinese Med, Coll Med, Taoyuan 33302, Taiwan; [Chang, Ying-Ling] Chang Gung Mem Hosp, Div Chinese Internal Med, Ctr Tradit Chinese Med, Taoyuan 33305, Taiwan; [Huang, Ying-Zu; Chang, Pi-Kai] Gung Mem Hosp, Dept Neurol, Taoyuan 33305, Taiwan; [Huang, Ying-Zu; Chang, Pi-Kai] Chang Gung Univ, Coll Med, Taoyuan 33305, Taiwan; [Chen, Kai-Yun] Taipei Med Univ, Grad Inst Neural Regenerat Med, Coll Med Sci & Technol, Taipei 11031, Taiwan; [Chen, Hsin-Yung] Chang Gung Univ, Coll Med, Dept Occupat Therapy, Taoyuan 33302, Taiwan; [Chen, Hsin-Yung] Chang Gung Univ, Coll Med, Grad Inst Behav Sci, Taoyuan 33302, Taiwan; [Chen, Hsin-Yung] Chang Gung Mem Hosp, Dept Neurol, Taoyuan 33378, Taiwan; [Chen, Hsin-Yung] Chang Gung Mem Hosp, Dementia Ctr, Taoyuan 33378, Taiwan		Chen, HY (corresponding author), Chang Gung Univ, Coll Med, Dept Occupat Therapy, Taoyuan 33302, Taiwan.; Chen, HY (corresponding author), Chang Gung Univ, Coll Med, Grad Inst Behav Sci, Taoyuan 33302, Taiwan.; Chen, HY (corresponding author), Chang Gung Mem Hosp, Dept Neurol, Taoyuan 33378, Taiwan.; Chen, HY (corresponding author), Chang Gung Mem Hosp, Dementia Ctr, Taoyuan 33378, Taiwan.	hsiehth@mail.cgu.edu.tw; kiwi725@gmail.com; katie911734@yahoo.com.tw; shieh@tajen.eduu.tw; cwpeng@tmu.edu.tw; cychien@vghtc.gov.tw; c1220@mail.cgu.edu.tw; yzhuang@cgmh.org.tw; jackccchen@mail.cgu.edu.tw; tyrant001dx@gmail.com; kychen08@tmu.edu.tw; hychen@mail.cgu.edu.tw	Hsieh, Tung-Hsun/AAZ-5010-2020	Hsieh, Tung-Hsun/0000-0002-1794-7941; Chen, Hsin-Yung/0000-0002-5165-3840; Peng, Chih-Wei/0000-0001-9744-4094	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [106-2410-H-182-008-MY2, 108-2314-B-182-011, 106-2221-E-182-001, 108-2314-B-182-015-MY3, MOST 107-2314-B-038-063]; Chang Gung Memorial Hospital, TaiwanChang Gung Memorial Hospital [CMRPD1H0461 CMRPD1H0462, BMRPE30, CMRPD1H0671, CMRPD3H0021, BMRPA70]	This study was supported by grants from the Ministry of Science and Technology, Taiwan (106-2410-H-182-008-MY2 and 108-2314-B-182-011 to T.H. Hsieh, 106-2221-E-182-001 to K.Y. Chen and 108-2314-B-182-015-MY3 to Y.Z. Huang and MOST 107-2314-B-038-063) and Chang Gung Memorial Hospital, Taiwan (CMRPD1H0461 CMRPD1H0462 and BMRPE30 to T.H. Hsieh and CMRPD1H0671, CMRPD3H0021, and BMRPA70 to H.Y. Chen).	Banks WA, 2010, NEUROBIOL DIS, V37, P26, DOI 10.1016/j.nbd.2009.07.031; Barichella M, 2016, NEUROLOGY, V87, P1274, DOI 10.1212/WNL.0000000000003127; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Borre YE, 2014, TRENDS MOL MED, V20, P509, DOI 10.1016/j.molmed.2014.05.002; Caputi V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061689; Cassani E, 2011, Minerva Gastroenterol Dietol, V57, P117; Cersosimo MG, 2012, J NEUROL SCI, V313, P57, DOI 10.1016/j.jns.2011.09.030; Chapelet G, 2019, PARKINSONISM RELAT D, V59, P26, DOI 10.1016/j.parkreldis.2018.11.014; DEMBINSKI A, 1995, J PHYSIOL PHARMACOL, V46, P351; Dembinski A, 2004, J PHYSIOL PHARMACOL, V55, P223; Dembinski A, 1996, INT J PANCREATOL, V19, P179; Dembinski Artur, 2003, Med Sci Monit, V9, pBR418; Dembinski A, 2016, GASTROENT RES PRACT, V2016, DOI 10.1155/2016/3126280; Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103; Ekstrand MI, 2009, PARKINSONISM RELAT D, V15, pS185, DOI 10.1016/S1353-8020(09)70811-9; Erickson JT, 2001, J NEUROSCI, V21, P581, DOI 10.1523/JNEUROSCI.21-02-00581.2001; Fang X, 2019, NEUROL SCI, V40, P51, DOI 10.1007/s10072-018-3641-6; Forsyth CB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028032; Fukumoto S, 2003, AM J PHYSIOL-REG I, V284, pR1269, DOI 10.1152/ajpregu.00442.2002; Gazerani P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174121; Georgescu D, 2016, CLIN INTERV AGING, V11, P1601, DOI 10.2147/CIA.S106284; Ghaisas S, 2019, NEUROTOXICOLOGY, V75, P186, DOI 10.1016/j.neuro.2019.09.004; Gonzalez-Arancibia C, 2019, PSYCHOPHARMACOLOGY, V236, P1611, DOI 10.1007/s00213-019-05265-5; Hameed MQ, 2014, NEUROREPORT, V25, P532, DOI 10.1097/WNR.0000000000000132; Hill-Burns EM, 2017, MOVEMENT DISORD, V32, P739, DOI 10.1002/mds.26942; Hsieh TH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178186; Hsieh TH, 2011, BEHAV BRAIN RES, V222, P1, DOI 10.1016/j.bbr.2011.03.031; Jaworek J, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/6915059; Jiang PZ, 2018, ACTA NEUROPATHOL, V135, P13, DOI 10.1007/s00401-017-1788-5; Jones JD, 2020, PARKINSONISM RELAT D, V72, P7, DOI 10.1016/j.parkreldis.2020.01.009; KELLER F, 1988, CLIN CHEM, V34, P2486; Kim DY, 2000, AM J GASTROENTEROL, V95, P2698, DOI 10.1016/S0002-9270(00)01970-5; Kim N, 2018, J MICROBIOL, V56, P172, DOI 10.1007/s12275-018-8032-4; Konturek SJ, 2003, J PHYSIOL PHARMACOL, V54, P293; Lai JH, 2019, BRAIN RES, V1720, DOI 10.1016/j.brainres.2019.146301; Lee HY, 2012, MED BIOL ENG COMPUT, V50, P937, DOI 10.1007/s11517-012-0933-5; Leopold NA, 1996, DYSPHAGIA, V11, P14, DOI 10.1007/BF00385794; Li HW, 2019, NEUROGASTROENT MOTIL, V31, DOI 10.1111/nmo.13677; Li XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071341; Liang JI, 2014, J MATER SCI-MATER M, V25, P217, DOI 10.1007/s10856-013-5036-9; Liang S, 2018, FRONT INTEGR NEUROSC, V12, DOI 10.3389/fnint.2018.00033; Liu NK, 2014, BRAIN RES, V1576, P18, DOI 10.1016/j.brainres.2014.05.042; Magistrelli L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00969; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Minato T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187307; Mulak A, 2015, WORLD J GASTROENTERO, V21, P10609, DOI 10.3748/wjg.v21.i37.10609; Musa NH, 2017, J DAIRY RES, V84, P488, DOI [10.1017/S0022029917000620, 10.1017/s0022029917000620]; Nagpal R, 2017, ANN NUTR METAB, V71, P11, DOI 10.1159/000479918; Nirmalkar K, 2018, NUTRIENTS, V10, DOI 10.3390/nu10122009; O'Brien R, 2020, NEUROGASTROENT MOTIL, V32, DOI 10.1111/nmo.13738; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Parashar A, 2017, PARKINSONISM RELAT D, V38, P1, DOI 10.1016/j.parkreldis.2017.02.002; Pendharkar SA, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2016.63; Pietrucci D, 2019, PARKINSONISM RELAT D, V65, P124, DOI 10.1016/j.parkreldis.2019.06.003; Poirier AA, 2016, PARKINSONS DIS-US, V2016, DOI 10.1155/2016/6762528; Polotis M, 2015, BEHAV BRAIN RES, V277, P136, DOI 10.1016/j.bbr.2014.07.037; Rial D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114216; Rodes L, 2013, J MICROBIOL BIOTECHN, V23, P518, DOI 10.4014/jmb.1205.05018; Salari M, 2016, J RES MED SCI, V21, DOI 10.4103/1735-1995.196608; Santos SF, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00574; Scheperjans F, 2015, MOVEMENT DISORD, V30, P350, DOI 10.1002/mds.26069; Spohn SN, 2017, NAT REV GASTRO HEPAT, V14, P412, DOI 10.1038/nrgastro.2017.51; Srivastav S, 2019, J NUTR BIOCHEM, V69, P73, DOI 10.1016/j.jnutbio.2019.03.021; Strandwitz P, 2018, BRAIN RES, V1693, P128, DOI 10.1016/j.brainres.2018.03.015; Sun MF, 2018, BRAIN BEHAV IMMUN, V70, P48, DOI 10.1016/j.bbi.2018.02.005; Tamtaji OR, 2019, CLIN NUTR, V38, P1031, DOI 10.1016/j.clnu.2018.05.018; Tsai WL, 2019, BEHAV NEUROL, V2019, DOI 10.1155/2019/4829572; Tsai YL, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-018-0493-6; Uyar GO, 2019, BIOSCI MICROB FOOD H, V38, P115, DOI [10.12938/bmfh.19-002, https://doi.org/10.12938/bmfh.19-002]; Warzecha Z, 2001, J PHYSIOL PHARMACOL, V52, P679; Warzecha Z, 1997, J PHYSIOL PHARMACOL, V48, P43; Woitalla D, 2015, PARKINSONISM RELAT D, V21, P199, DOI 10.1016/j.parkreldis.2014.11.024	72	28	28	1	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-3425		BRAIN SCI	Brain Sci.	APR	2020	10	4							206	10.3390/brainsci10040206			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LP4EO	WOS:000534271500044	32244769	gold, Green Published			2022-02-06	
J	Cordes, T; Lucas, A; Divakaruni, AS; Murphy, AN; Cabrales, P; Metallo, CM				Cordes, Thekla; Lucas, Alfredo; Divakaruni, Ajit S.; Murphy, Anne N.; Cabrales, Pedro; Metallo, Christian M.			Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury	MOLECULAR METABOLISM			English	Article						Itaconate; Succinate dehydrogenase (SDH); Cerebral ischemia/reperfusion (IR); Redox stress; Mitochondrial metabolism; Brain injury	ISCHEMIA-REPERFUSION; SUCCINATE-DEHYDROGENASE; TCA CYCLE; NRF2; MITOCHONDRIA; MECHANISMS; INHIBITION; PATHOPHYSIOLOGY; DYSFUNCTION; PATHWAYS	Objectives: Cerebral ischemia/reperfusion (IR) drives oxidative stress and injurious metabolic processes that lead to redox imbalance, inflammation, and tissue damage. However, the key mediators of reperfusion injury remain unclear, and therefore, there is considerable interest in therapeutically targeting metabolism and the cellular response to oxidative stress. Methods: The objective of this study was to investigate the molecular, metabolic, and physiological impact of itaconate treatment to mitigate reperfusion injuries in in vitro and in vivo model systems. We conducted metabolic flux and bioenergetic studies in response to exogenous itaconate treatment in cultures of primary rat cortical neurons and astrocytes. In addition, we administered itaconate to mouse models of cerebral reperfusion injury with ischemia or traumatic brain injury followed by hemorrhagic shock resuscitation. We quantitatively characterized the metabolite levels, neurological behavior, markers of redox stress, leukocyte adhesion, arterial blood flow, and arteriolar diameter in the brains of the treated/untreated mice. Results: We demonstrate that the "immunometabolite" itaconate slowed tricarboxylic acid (TCA) cycle metabolism and buffered redox imbalance via succinate dehydrogenase (SDH) inhibition and induction of anti-oxidative stress response in primary cultures of astrocytes and neurons. The addition of itaconate to reperfusion fluids after mouse cerebral IR injury increased glutathione levels and reduced reactive oxygen/ nitrogen species (ROS/RNS) to improve neurological function. Plasma organic acids increased post-reperfusion injury, while administration of itaconate normalized these metabolites. In mouse cranial window models, itaconate significantly improved hemodynamics while reducing leukocyte adhesion. Further, itaconate supplementation increased survival in mice experiencing traumatic brain injury (TBI) and hemorrhagic shock. Conclusions: We hypothesize that itaconate transiently inhibits SDH to gradually "awaken" mitochondria! function upon reperfusion that minimizes ROS and tissue damage. Collectively, our data indicate that itaconate acts as a mitochondrial regulator that controls redox metabolism to improve physiological outcomes associated with IR injury. (C) 2019 The Authors. Published by Elsevier GmbH.	[Cordes, Thekla; Lucas, Alfredo; Cabrales, Pedro; Metallo, Christian M.] Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Divakaruni, Ajit S.; Murphy, Anne N.] Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Divakaruni, Ajit S.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA		Metallo, CM (corresponding author), Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA.	cmetallo@ucsd.edu	Cordes, Thekla/AAQ-4465-2020	Cordes, Thekla/0000-0002-8097-191X; Lucas, Alfredo/0000-0001-9439-735X	NIH Common Fund Metabolite Standards Synthesis Core (NHLBI) [HHSN268201300022C]; US National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01CA188652, R01CA234245]; NSF CAREER AwardNational Science Foundation (NSF)NSF - Office of the Director (OD) [1454425]; Camille and Henry Dreyfus Teacher-Scholar Award; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL126945 NHLBI, R01 HL138116 NHLBI, R01NS087611 NINDS, R21NS104513 NINDS]; Deutsche Forschungsgesellschaft, Germany (German Research Foundation)German Research Foundation (DFG) [CO1488/1-1]	We thank all of the members of the Metallo and Cabrales Laboratories, United States for support and helpful discussions. We thank the NIH Common Fund Metabolite Standards Synthesis Core (NHLBI contract no. HHSN268201300022C) for providing isotopic labeled itaconate ([U-<SUP>13</SUP>C<INF>5</INF>]itaconate). This study was supported, in part, by US National Institutes of Health (NIH) grants R01CA188652 and R01CA234245 (C.M.M.), NSF CAREER Award #1454425 (C.M.M.), a Camille and Henry Dreyfus Teacher-Scholar Award (C.M.M.), NIH grants R01 HL126945 NHLBI (P.C.), R01 HL138116 NHLBI (P.C.), R01NS087611 NINDS (A.N.M.), R21NS104513 NINDS (A.N.M.), and Deutsche Forschungsgesellschaft, Germany (German Research Foundation) (CO1488/1-1 to T.C).	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; Acosta S, 2012, J THROMB THROMBOLYS, V33, P355, DOI 10.1007/s11239-011-0660-z; ADLER J, 1957, J BIOL CHEM, V229, P865; Andreyev A, 2018, NEUROCHEM INT, V117, P15, DOI 10.1016/j.neuint.2017.10.003; Ashrafian H, 2012, CELL METAB, V15, P361, DOI 10.1016/j.cmet.2012.01.017; Balan IS, 2013, J NEUROTRAUM, V30, P367, DOI 10.1089/neu.2012.2339; Bambouskova M, 2018, NATURE, V556, P501, DOI 10.1038/s41586-018-0052-z; BOOTH AN, 1952, J BIOL CHEM, V195, P697; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Burwell LS, 2008, ANTIOXID REDOX SIGN, V10, P579, DOI 10.1089/ars.2007.1845; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Chen FF, 2019, P NATL ACAD SCI USA, V116, P20644, DOI 10.1073/pnas.1908770116; Chouchani ET, 2016, CELL METAB, V23, P254, DOI 10.1016/j.cmet.2015.12.009; Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909; Cordes T, 2019, METHODS MOL BIOL, V1978, P219, DOI 10.1007/978-1-4939-9236-2_14; Cordes T, 2016, J BIOL CHEM, V291, P14274, DOI 10.1074/jbc.M115.685792; Cordes T, 2015, ANNU REV NUTR, V35, P451, DOI 10.1146/annurev-nutr-071714-034243; Dekker SE, 2018, J NEUROSCI RES, V96, P711, DOI 10.1002/jnr.24125; Divakaruni AS, 2017, J CELL BIOL, V216, P1091, DOI 10.1083/jcb.201612067; Divakaruni Ajit S, 2014, Curr Protoc Toxicol, V60, DOI 10.1002/0471140856.tx2502s60; Dorsch Nicholas W C, 2002, Curr Opin Crit Care, V8, P128; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Emmrich R, 1939, HOPPE SEYLERS Z PHYS; Griffin GK, 2012, J IMMUNOL, V188, P6287, DOI 10.4049/jimmunol.1200385; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Kim HJ, 2011, METHODS MOL BIOL, V793, P63, DOI 10.1007/978-1-61779-328-8_4; Kohlhauer M, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0727-0; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Kushnareva YE, 2005, J BIOL CHEM, V280, P28894, DOI 10.1074/jbc.M503090200; Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004; Lussey-Lepoutre C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9784; Martinez-Reyes I, 2016, MOL CELL, V61, P199, DOI 10.1016/j.molcel.2015.12.002; McCord J.M, 1987, FEDERATION P; Meiser Johannes, 2018, Oncotarget, V9, P32098, DOI 10.18632/oncotarget.25956; Michelucci A, 2013, P NATL ACAD SCI USA, V110, P7820, DOI 10.1073/pnas.1218599110; Mills EL, 2018, NATURE, V556, P113, DOI 10.1038/nature25986; Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064; Mindea Stefan A, 2006, Neurosurg Focus, V21, pE13; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Muir A, 2017, ELIFE, V6, DOI 10.7554/eLife.27713; Murakami S, 2015, FREE RADICAL BIO MED, V88, P168, DOI 10.1016/j.freeradbiomed.2015.06.030; Murphy E, 2008, PHYSIOL REV, V88, P581, DOI 10.1152/physrev.00024.2007; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nemeth B, 2016, FASEB J, V30, P286, DOI 10.1096/fj.15-279398; Prakash A, 2015, SHOCK, V44, P272, DOI 10.1097/SHK.0000000000000415; Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Sayin VI, 2017, ELIFE, V6, DOI 10.7554/eLife.28083; Seim GL, 2019, NAT METAB, V1, P731, DOI 10.1038/s42255-019-0083-2; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shen HY, 2017, CELL, V171, P771, DOI 10.1016/j.cell.2017.09.051; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246-200108000-00003; Strelko CL, 2011, J AM CHEM SOC, V133, P16386, DOI 10.1021/ja2070889; Sun XW, 2019, FASEB J, V33, P12929, DOI 10.1096/fj.201900887RR; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Thompson JW, 2015, J BIOENERG BIOMEMBR, V47, P101, DOI 10.1007/s10863-014-9574-8; Toledo-Pereyra Luis H, 2004, Exp Clin Transplant, V2, P174; Valls-Lacalle L, 2016, CARDIOVASC RES, V109, P374, DOI 10.1093/cvr/cvv279; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; Wilhelmsen K, 2014, J BIOL CHEM, V289, P13079, DOI 10.1074/jbc.M113.536953; Wojtovich AP, 2009, BASIC RES CARDIOL, V104, P121, DOI 10.1007/s00395-009-0001-y; Young JD, 2014, BIOINFORMATICS, V30, P1333, DOI 10.1093/bioinformatics/btu015; Zhao DX, 2018, MOL CELL, V69, P699, DOI 10.1016/j.molcel.2018.01.017; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	67	28	28	2	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	2212-8778			MOL METAB	Mol. Metab.	FEB	2020	32						122	135		10.1016/j.molmet.2019.11.019			14	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	KH7QA	WOS:000510843500010	32029222	gold, Green Published			2022-02-06	
J	Khellaf, A; Khan, DZ; Helmy, A				Khellaf, Abdelhakim; Khan, Danyal Zaman; Helmy, Adel			Recent advances in traumatic brain injury	JOURNAL OF NEUROLOGY			English	Article						Traumatic brain injury; TBI; Therapy; Monitoring; Critical care; Neuroprotection; Neurosurgery	CEREBRAL PERFUSION-PRESSURE; INTERLEUKIN-1 RECEPTOR ANTAGONIST; RECOMBINANT-HUMAN-ERYTHROPOIETIN; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; TRANEXAMIC ACID; CLINICAL-TRIAL; PHASE-II; MICRODIALYSIS; PROGESTERONE	Traumatic brain injury (TBI) is the most common cause of death and disability in those aged under 40 years in the UK. Higher rates of morbidity and mortality are seen in low-income and middle-income countries making it a global health challenge. There has been a secular trend towards reduced incidence of severe TBI in the first world, driven by public health interventions such as seatbelt legislation, helmet use, and workplace health and safety regulations. This has paralleled improved outcomes following TBI delivered in a large part by the widespread establishment of specialised neurointensive care. This update will focus on three key areas of advances in TBI management and research in moderate and severe TBI: refining neurointensive care protocolized therapies, the recent evidence base for decompressive craniectomy and novel pharmacological therapies. In each section, we review the developing evidence base as well as exploring future trajectories of TBI research.	[Khellaf, Abdelhakim; Khan, Danyal Zaman; Helmy, Adel] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Box 167,Hills Rd, Cambridge CB2 0QQ, England; [Khellaf, Abdelhakim] McGill Univ, Fac Med, Montreal, PQ, Canada		Helmy, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	adelhelmy@cantab.net; dzk20@cam.ac.uk; aeh33@cam.ac.uk	Helmy, Adel/AAS-3084-2020; Khan, Danyal/AAW-1824-2021	Helmy, Adel/0000-0002-0531-0556; Khan, Danyal Zaman/0000-0001-9213-2550			Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Aloizos S, 2015, TURK NEUROSURG, V25, P552, DOI 10.5137/1019-5149.JTN.9685-14.4; Anandic Medical Systems, 2019, BEDMASTEREX 2019; Andrews PJD, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22450; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Bhullar IS, 2014, J TRAUMA ACUTE CARE, V76, P54, DOI 10.1097/TA.0b013e3182aafd15; Brain Trauma Foundation, 2016, GUID MAN SEV TRAUM B; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Cooper DJ, 2018, JAMA-J AM MED ASSOC, V320, P2211, DOI 10.1001/jama.2018.17075; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dizdarevic K, 2012, CLIN NEUROL NEUROSUR, V114, P142, DOI 10.1016/j.clineuro.2011.10.005; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Dunn CJ, 1999, DRUGS, V57, P1005, DOI 10.2165/00003495-199957060-00017; Excellence NIfHCaC, 2017, HEAD INJ ASS EARL MA; Faul M, 2010, TRAUMATIC BRAIN INJU; Gebel JM, 2002, STROKE, V33, P2636, DOI 10.1161/01.STR.0000035283.34109.EA; Ghalaenovi H, 2018, BRAIN INJURY, V32, P1050, DOI 10.1080/02699052.2018.1476733; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Hammond FM, 2018, J NEUROTRAUM, V35, P2298, DOI 10.1089/neu.2018.5767; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Helmy A, 2017, RANDOMISED DOUBLE BL; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; HUBER A, 1993, INT J LEGAL MED, V106, P152, DOI 10.1007/BF01225238; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Hutchinson P, 2010, LANCET; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kolias AG, 2018, CURR TRAUMA REP, V4, P326, DOI 10.1007/s40719-018-0147-x; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; Kramer AH, 2016, NEUROCRIT CARE, V25, P10, DOI 10.1007/s12028-015-0232-8; Lee J, 2018, AM J EMERG MED, V37, P1101; Lewis SR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub5; Li ZM, 2016, CLIN NEUROL NEUROSUR, V150, P80, DOI 10.1016/j.clineuro.2016.09.001; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; MDialysis, 2018, ISCUSFLEX MICR AN 20; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MIZOGUCHI K, 1994, BRAIN RES, V662, P255, DOI 10.1016/0006-8993(94)90821-4; Moberg, 2019, CNS MON 2019; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; NIH SIREN Emergencies Trials Network, 2018, BRAIN OX OPT SEV TBI; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Okonkwo DO, 2017, CRIT CARE MED, V45, P1907, DOI 10.1097/CCM.0000000000002619; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Pradillo JM, 2012, J CEREBR BLOOD F MET, V32, P1810, DOI 10.1038/jcbfm.2012.101; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Tan HB, 2014, COCHRANE DB SYST REV, V8, pCD011217; TEASDALE G, 1974, LANCET, V2, P81; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00300; Timofeev I, 1800, Adv Tech Stand Neurosurg, V38, P115, DOI 10.1007/978-3-7091-0676-1_6; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Unden L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0533-y; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Williams-Johnson JA, 2010, W INDIAN MED J, V59, P612; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zeiler FA, 2017, ACTA NEUROCHIR, V159, P2245, DOI 10.1007/s00701-017-3338-2	77	28	31	3	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	NOV	2019	266	11					2878	2889		10.1007/s00415-019-09541-4			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JF5NF	WOS:000491432100034	31563989	Green Published, hybrid			2022-02-06	
J	Roberts, AL; Pascual-Leone, A; Speizer, FE; Zafonte, RD; Baggish, AL; Taylor, H; Nadler, LM; Connor, A; Grashow, R; Stillman, AM; Marengi, DA; Weisskopf, MG; Courtney, TK				Roberts, Andrea L.; Pascual-Leone, Alvaro; Speizer, Frank E.; Zafonte, Ross D.; Baggish, Aaron L.; Taylor, Herman, Jr.; Nadler, Lee M.; Connor, Ann; Grashow, Rachel; Stillman, Alexandra M.; Marengi, Dean A.; Weisskopf, Marc G.; Courtney, Theodore K.			Exposure to American Football and Neuropsychiatric Health in Former National Football League Players: Findings From the Football Players Health Study	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports injuries; postconcussion syndrome; cognitive function; depression; anxiety; football	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; LIFE COGNITIVE IMPAIRMENT; POST-CONCUSSION SYMPTOMS; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; 1ST EXPOSURE; HIGH-SCHOOL; DEPRESSION; PREVALENCE	Background: Former American football players have a higher prevalence of cognitive impairment than that of the US general population. It remains unknown what aspects of playing football are associated with neuropsychiatric outcomes. Hypothesis: It was hypothesized that seasons of professional football, playing position, and experience of concussions were associated with cognition-related quality of life (QOL) and indicators of depression and anxiety. Study Design: Descriptive epidemiology study. Methods: The authors examined whether seasons of professional football, playing position, and experience of concussions, as measured by self-report of 10 symptoms, were associated with cognition-related QOL and indicators of depression and anxiety in a cross-sectional survey conducted 2015 to 2017. Cognition-related QOL was measured by the short form of the Quality of Life in Neurological Disorders: Applied Cognition-General Concerns. The Patient Health Questionnaire-4 measured depression and anxiety symptoms. Of 13,720 eligible men with apparently valid contact information, 3506 players returned a questionnaire at the time of this analysis (response rate = 25.6%). Results: Seasons of professional play (risk ratio [RR] per 5 seasons = 1.19, 95% CI = 1.06-1.34) and playing position were associated with cognition-related QOL. Each 5 seasons of play was associated with 9% increased risk of indicators of depression at borderline statistical significance (P = .05). When compared with former kickers, punters, and quarterbacks, men who played any other position had a higher risk of poor cognition-related QOL, depression, and anxiety. Concussion symptoms were strongly associated with poor cognition-related QOL (highest concussion quartile, RR = 22.3, P < .001), depression (highest quartile, RR = 6.0, P < .0001), and anxiety (highest quartile, RR = 6.4, P < .0001), even 20 years after last professional play. Conclusion: The data suggest that seasons of play and playing position in the NFL are associated with lasting neuropsychiatric health deficits. Additionally, poor cognition-related QOL, depression, and anxiety appear to be associated with concussion in the long term.	[Zafonte, Ross D.; Marengi, Dean A.] Harvard Med Sch, Boston, MA 02115 USA; Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Roberts, Andrea L.; Speizer, Frank E.; Grashow, Rachel; Weisskopf, Marc G.; Courtney, Theodore K.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA; [Pascual-Leone, Alvaro; Connor, Ann; Stillman, Alexandra M.] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Cognit Neurol, Boston, MA 02115 USA; [Speizer, Frank E.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Zafonte, Ross D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Baggish, Aaron L.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA; [Taylor, Herman, Jr.; Weisskopf, Marc G.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Taylor, Herman, Jr.] Morehouse Univ, Sch Med, Cardiovasc Res Inst, Atlanta, GA USA; [Nadler, Lee M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Nadler, Lee M.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA		Roberts, AL (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA.	aroberts@hsph.harvard.edu	Courtney, Theodore K./P-4829-2019; Pascual-Leone, Alvaro/AAC-5101-2019	Courtney, Theodore K./0000-0001-8139-1565; Pascual-Leone, Alvaro/0000-0001-8975-0382	Sidney R. Baer Jr Foundation; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA); Football Players Health Study (FPHS) at Harvard University; Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources/National Institutes of Health) [UL1 RR025758]; Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences/National Institutes of Health) [UL1 RR025758]; National Football League Players Association (NFLPA); American Heart AssociationAmerican Heart Association; American Society of Echocardiography; NFLPA; FPHS at Harvard University - NFLPA	One or more of the authors has declared the following potential conflict of interest or source of funding: A. P.-L. was partly supported by the Sidney R. Baer Jr Foundation, Defense Advanced Research Projects Agency, the Football Players Health Study (FPHS) at Harvard University, and Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences/National Institutes of Health, UL1 RR025758); serves on the scientific advisory boards for Neosync, Neuronix, Starlab Neuroscience, Neuroelectrics, Magstim Inc, Constant Therapy, and Cognito; and is listed as an inventor on several issued and pending patents on the real-time integration of transcranial magnetic stimulation with electroencephalography and magnetic resonance imaging. A.L.B. has received funding from the National Football League Players Association (NFLPA), the American Heart Association, and the American Society of Echocardiography and receives compensation for his role as team cardiologist from US Soccer, US Rowing, the New England Patriots, the Boston Bruins, the New England Revolution, and Harvard University. R.D.Z. received royalties from Oakstone for authorship of an educational CD and from Demos Publishing for serving as coeditor of Brain Injury Medicine; serves on the scientific advisory boards of Myomo, Oxeia Biopharma, ElMindA, and Biodirection; and evaluates patients in Massachusetts General Hospital's Brain and Body-Trust Program, which is funded by the NFLPA. All other authors are either partially or fully supported by the FPHS at Harvard University, which is in turn sponsored by the NFLPA. Note that the NFLPA had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.	Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Arola HM, 2010, EUR J PAIN, V14, P966, DOI 10.1016/j.ejpain.2010.02.012; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Caplan B, 2016, J HEAD TRAUMA REHAB, V31, P1, DOI 10.1097/HTR.0000000000000211; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Cella D, 2012, NEUROLOGY, V78, P1860, DOI 10.1212/WNL.0b013e318258f744; CHOI BCK, 1992, J OCCUP ENVIRON MED, V34, P979; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hall EC, 2014, J TRAUMA ACUTE CARE, V76, P859, DOI 10.1097/TA.0000000000000148; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; HealthMeasures, TRANSF HLTH IS MEAS; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kelly JP, 1997, NEUROLOGY, V48, P581; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Plummer F, 2016, GEN HOSP PSYCHIAT, V39, P24, DOI 10.1016/j.genhosppsych.2015.11.005; Pryor James, 2016, J Lifestyle Med, V6, P7, DOI 10.15280/jlm.2016.6.1.7; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Sports Reference LLC, FOOTB REF COM PROF S; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Weir DR., 2009, NATL FOOTBALL LEAGUE; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	52	28	28	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2019	47	12					2871	2880	0363546519868989	10.1177/0363546519868989		AUG 2019	10	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	JE3YH	WOS:000484623200001	31468987	Green Published, hybrid			2022-02-06	
J	Chen, YH; Meng, J; Bi, FF; Li, H; Chang, CC; Ji, C; Liu, W				Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Li, Hua; Chang, Cuicui; Ji, Chen; Liu, Wei			EK7 Regulates NLRP3 Inflammasome Activation and Neuroinflammation Post-traumatic Brain Injury	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						traumatic brain injury; NLRP3 inflammasome; NEK7; caspase-1 activation; pyroptosis; potassium efflux; neuroinflammation	INTERLEUKIN-1 RECEPTOR ANTAGONIST; NEK7; INHIBITOR; CASPASES; DEATH; MODEL	As one of the most common causes of mortality and disability, traumatic brain injury (TBI) is a huge psychological and economic burden to patients, families, and societies worldwide. Neuroinflammation reduction may be a favorable option to alleviate secondary brain injuries and ameliorate the outcome of TBI. The nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome, has been shown to be involved in TBI. NIMA-related kinase 7 (NEK7)has been verified as an essential mediator of NLRP3 inflammasome activation that is recruited upstream of the formation of inflammasomes in response to NLRP3 activators. However, the underlying mechanism by which NEK7 operates post-TBI remains undefined. In this study, we performed both in vivo and in vitro experiments. Using an in vivo mouse TBI model, mice were administered an intracerebroventricular injection of NEK7-shRNA virus. For the in vitro analysis, primary cortical neurons with NEK7-shRNA were stimulated with lipopolysaccharide (LPS)/ATP or potassium (K+). We evaluated the effects of NEK7 knock-down on neurological deficits, NLRP3 inflammasomes, caspase-1 activation, and neuronal injury. During the 0-168 h post-TBI period in vivo, NEK7 and NLRP3 inflammasome activation increased in what appeared to be a time-dependent manner. As well as pyroptosis-related markers, caspase-1 activation (p20) and interleukin-1 beta (IL-1 beta) activation (p17) were up-regulated. NEK7 down-regulation attenuated neurological deficits, NLRP3 inflammasomes, caspase-1 activation, and neuronal injury. The same phenomena were observed during the in vitro experiments. Furthermore, NEK7 knock-down suppressed NLRP3 inflammasome activation and pyroptosis, which were triggered by K+ efflux, and the LPS + ATP-triggered NEK7-NLRP3 complex was reversed in primary cortical neurons placed in 50 mM K+ medium. Collectively, the data demonstrated that NEK7, as a modulator, regulates NLRP3 inflammasomes and downstream neuroinflammation in response to K+ efflux, through NEK7-NLRP3 assembly, pro-caspase-1 recruitment, caspase-1 activation, and pyroptosis in nerve injuries, post-TBI. NEK7 may be a potential therapeutic target for attenuating neuroinflammation and nerve injury post-TBI.	[Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Chang, Cuicui; Ji, Chen] Xian Peihua Univ, Dept Cent Lab, Xian, Shaanxi, Peoples R China; [Chen, Yuhua; Liu, Wei] Xian Med Univ, Dept Neurosurg, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China; [Meng, Jiao; Bi, Fangfang; Li, Hua] Shaanxi Fourth Peoples Hosp, Dept Basic Med Sci, Res Ctr, Xian, Shaanxi, Peoples R China		Liu, W (corresponding author), Xian Med Univ, Dept Neurosurg, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.	vincelau@sina.com			Natural Science Foundation of Shaanxi ProvinceNatural Science Foundation of Shaanxi Province [2018JM7141]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81901270]	This study is supported by the Natural Science Foundation of Shaanxi Province (2018JM7141) and the National Natural Science Foundation of China (No. 81901270).	Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Barlow KM, 2019, J NEUROTRAUM, V36, P523, DOI 10.1089/neu.2018.5752; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen YH, 2019, BRAIN RES, V1710, P163, DOI 10.1016/j.brainres.2019.01.005; Eder C, 2009, IMMUNOBIOLOGY, V214, P543, DOI 10.1016/j.imbio.2008.11.007; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Freixo F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04706-7; Ge XT, 2018, BRAIN RES, V1697, P10, DOI 10.1016/j.brainres.2018.06.008; Green JP, 2018, P NATL ACAD SCI USA, V115, pE9371, DOI 10.1073/pnas.1812744115; Groslambert M, 2018, J INFLAMM RES, V11, P359, DOI 10.2147/JIR.S141220; Guo QL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01197; He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959; Helmy A, 2016, J CEREBR BLOOD F MET, V36, P1434, DOI 10.1177/0271678X15620204; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Hinojosa AJ, 2018, CELL REP, V24, P1231, DOI 10.1016/j.celrep.2018.06.115; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Johann S, 2015, GLIA, V63, P2260, DOI 10.1002/glia.22891; Kerr N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210128; Kuriakose T, 2017, MOL IMMUNOL, V86, P56, DOI 10.1016/j.molimm.2017.01.023; Lazaridis C, 2019, NEUROPHARMACOLOGY, V145, P145, DOI 10.1016/j.neuropharm.2018.06.005; Liu W, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1083-y; Ma ZZ, 2018, J INFLAMM-LOND, V15, DOI 10.1186/s12950-018-0192-9; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Mamik MK, 2017, BRAIN, V140, P2273, DOI 10.1093/brain/awx133; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Man SM, 2015, CELL RES, V25, P1183, DOI 10.1038/cr.2015.124; Martinez BI, 2019, J BIOL ENG, V13, DOI 10.1186/s13036-019-0145-8; McKenzie BA, 2018, P NATL ACAD SCI USA, V115, pE6065, DOI 10.1073/pnas.1722041115; Minoguchi S, 2003, BIOCHEM BIOPH RES CO, V301, P899, DOI 10.1016/S0006-291X(03)00049-4; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; Ross J, 2007, NEUROPHARMACOLOGY, V53, P638, DOI 10.1016/j.neuropharm.2007.07.015; Ruhl S, 2015, EUR J IMMUNOL, V45, P2927, DOI 10.1002/eji.201545772; Saresella M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0088-1; Schmid-Burgk JL, 2016, J BIOL CHEM, V291, P103, DOI 10.1074/jbc.C115.700492; Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z; Shi HX, 2016, NAT IMMUNOL, V17, P250, DOI 10.1038/ni.3333; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Thelin EP, 2017, AAPS J, V19, P367, DOI 10.1208/s12248-016-0027-7; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Xu J, 2016, ACTA BIOCH BIOPH SIN, V48, P966, DOI 10.1093/abbs/gmw080; Xu KY, 2018, BIOCHEM BIOPH RES CO, V503, P3031, DOI 10.1016/j.bbrc.2018.08.089; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Yuan JY, 2016, CELL, V167, P1693, DOI 10.1016/j.cell.2016.11.047; Zeiler FA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00331; Zhou WY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5702103	52	28	29	4	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	AUG 29	2019	12								202	10.3389/fnmol.2019.00202			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IT7EY	WOS:000483039700001	31555089	Green Published, gold			2022-02-06	
J	Kramer, TJ; Hack, N; Bruhl, TJ; Menzel, L; Hummel, R; Griemert, EV; Klein, M; Thal, SC; Bopp, T; Schafer, MKE				Kraemer, Tobias J.; Hack, Nathalia; Bruehl, Till J.; Menzel, Lutz; Hummel, Regina; Griemert, Eva-Verena; Klein, Matthias; Thal, Serge C.; Bopp, Tobias; Schaefer, Michael K. E.			Depletion of regulatory T cells increases T cell brain infiltration, reactive astrogliosis, and interferon-gamma gene expression in acute experimental traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Inflammation; Cytokines; Immune response; T cells; Astrocytes; Microglia	ISCHEMIC-STROKE; INFLAMMATION; SYSTEM; NEUROPROTECTION; ASTROCYTES; MOTOR; MICE; NEUROINFLAMMATION; PATHOPHYSIOLOGY; PROGRANULIN	Background Traumatic brain injury (TBI) is a major cause of death and disability. T cells were shown to infiltrate the brain during the first days after injury and to exacerbate tissue damage. The objective of this study was to investigate the hitherto unresolved role of immunosuppressive, regulatory T cells (Tregs) in experimental TBI. Methods "Depletion of regulatory T cell" (DEREG) and wild type (WT) C57Bl/6 mice, treated with diphtheria toxin (DTx) to deplete Tregs or to serve as control, were subjected to the controlled cortical impact (CCI) model of TBI. Neurological and motor deficits were examined until 5 days post-injury (dpi). At the 5 dpi endpoint, (immuno-) histological, protein, and gene expression analyses were carried out to evaluate the consequences of Tregs depletion. Comparison of parametric or non-parametric data between two groups was done using Student's t test or the Mann-Whitney U test. For multiple comparisons, p values were calculated by one-way or two-way ANOVA followed by specific post hoc tests. Results The overall neurological outcome at 5 dpi was not different between DEREG and WT mice but more severe motor deficits occurred transiently at 1 dpi in DEREG mice. DEREG and WT mice did not differ in the extent of brain damage, blood-brain barrier (BBB) disruption, or neuronal excitotoxicity, as examined by lesion volumetry, immunoglobulin G (IgG) extravasation, or calpain-generated alpha II-spectrin breakdown products (SBDPs), respectively. In contrast, increased protein levels of glial fibrillary acidic protein (GFAP) and GFAP+ astrocytes in the ipsilesional brain tissue indicated exaggerated reactive astrogliosis in DEREG mice. T cell counts following anti-CD3 immunohistochemistry and gene expression analyses of Cd247 (CD3 subunit zeta) and Cd8a (CD8a) further indicated an increased number of T cells infiltrating the brain injury sites of DEREG mice compared to WT. These changes coincided with increased gene expression of pro-inflammatory interferon-gamma (Ifng) in DEREG mice compared to WT in the injured brain. Conclusions The results show that the depletion of Tregs attenuates T cell brain infiltration, reactive astrogliosis, interferon-gamma gene expression, and transiently motor deficits in murine acute traumatic brain injury.	[Kraemer, Tobias J.; Hack, Nathalia; Menzel, Lutz; Hummel, Regina; Griemert, Eva-Verena; Thal, Serge C.; Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Langenbeckstr 1,Bld 505, D-55131 Mainz, Germany; [Bruehl, Till J.; Klein, Matthias; Bopp, Tobias] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Immunol, Langenbeckstr 1, D-55131 Mainz, Germany; [Klein, Matthias; Bopp, Tobias; Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Res Ctr Immunotherapy FZI, Mainz, Germany; [Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Focus Program Translat Neurosci FTN, Mainz, Germany		Schafer, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Langenbeckstr 1,Bld 505, D-55131 Mainz, Germany.; Schafer, MKE (corresponding author), Johannes Gutenberg Univ Mainz, Res Ctr Immunotherapy FZI, Mainz, Germany.	michael.schaefer@unimedizin-mainz.de	Thal, Serge/D-6593-2011; Schaefer, Michael K.E./S-1715-2019	Thal, Serge/0000-0002-1222-8729; Schaefer, Michael K.E./0000-0001-6055-6244; Kramer, Tobias/0000-0001-6900-3486	University Medical Center Mainz; Research Center for Immunotherapy (FZI) Mainz, Germany; Focus Program Translational Neurosciences (FTN) Mainz, Germany	This work was supported by the institutional funding from the University Medical Center Mainz to TB and MS; the Research Center for Immunotherapy (FZI) Mainz, Germany, to TB; and the Focus Program Translational Neurosciences (FTN) Mainz, Germany, to MS.	Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Barcia C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00058; Battaglia M, 2005, BLOOD, V105, P4743, DOI 10.1182/blood-2004-10-3932; Bopp T, 2007, ANN MED, V39, P322, DOI 10.1080/07853890701379700; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Cauli O, 2009, J NEUROSCI RES, V87, P1369, DOI 10.1002/jnr.21947; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Clarkson BDS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09182-5; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dong TT, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0663-y; Duffy SS, 2018, J NEUROSCI RES, V96, P951, DOI 10.1002/jnr.24073; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; FIERZ W, 1985, J IMMUNOL, V134, P3785; Gill D, 2016, CURR OPIN PHARMACOL, V26, P26, DOI 10.1016/j.coph.2015.09.009; Golz C, 2019, J NEUROCHEM, V150, P173, DOI 10.1111/jnc.14678; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Huang CS, 2016, GLIA, V64, P507, DOI 10.1002/glia.22944; Ito M, 2019, NATURE, V565, P246, DOI 10.1038/s41586-018-0824-5; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kelso ML, 2014, CURR PHARM DESIGN, V20, P4284; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kleinschnitz C, 2013, BLOOD, V121, P679, DOI 10.1182/blood-2012-04-426734; Kramer T, 2017, J NEUROCHEM, V143, P523, DOI 10.1111/jnc.14220; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lahl K, 2011, METHODS MOL BIOL, V707, P157, DOI 10.1007/978-1-61737-979-6_10; Li M, 2015, CHINESE MED J-PEKING, V128, P1072, DOI 10.4103/0366-6999.155094; Licastro F, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00189; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liesz A, 2016, TRANSL STROKE RES, V7, P313, DOI 10.1007/s12975-016-0465-7; Liesz A, 2015, STROKE, V46, P1422, DOI 10.1161/STROKEAHA.114.008608; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Mao LL, 2017, CELL MOL NEUROBIOL, V37, P919, DOI 10.1007/s10571-016-0429-1; Mao LL, 2017, BRAIN, V140, P1914, DOI 10.1093/brain/awx111; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; McGill BE, 2018, J NEUROSCI, V38, P200, DOI 10.1523/JNEUROSCI.0936-17.2017; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Menzel L, 2017, GLIA, V65, P278, DOI 10.1002/glia.23091; Menzel L, 2016, ACTA NEUROPATHOL, V132, P703, DOI 10.1007/s00401-016-1607-4; Na SY, 2015, STROKE, V46, P212, DOI 10.1161/STROKEAHA.114.007756; Ndode-Ekane XE, 2018, RESTOR NEUROL NEUROS, V36, P485, DOI 10.3233/RNN-170811; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Prajeeth CK, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0978-3; Qu YY, 2007, TRANSPL IMMUNOL, V17, P153, DOI 10.1016/j.trim.2007.01.002; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; Ren XF, 2011, METAB BRAIN DIS, V26, P87, DOI 10.1007/s11011-010-9226-6; Schafer MKE, 2018, MATRIX BIOL, V68-69, P571, DOI 10.1016/j.matbio.2017.10.002; Schafer M, 2014, CELL TISSUE RES, V357, P395, DOI 10.1007/s00441-014-1807-y; Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Schwarzmaier SM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-32; Sebastiani A, 2015, J NEUROTRAUM, V32, P1599, DOI 10.1089/neu.2014.3751; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Soares HD, 1995, J NEUROSCI, V15, P8223; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Tabares P, 2018, EUR J IMMUNOL, V48, P366, DOI 10.1002/eji.201747244; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Timaru-Kast R, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00063; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Toklu HZ, 2015, OXIDATIVE STRESS BRA; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Ulges A, 2016, ADV IMMUNOL, V132, P1, DOI 10.1016/bs.ai.2016.08.002; Walsh JT, 2014, J IMMUNOL, V193, P5013, DOI 10.4049/jimmunol.1302401; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xie LK, 2015, BRAIN RES, V1623, P63, DOI 10.1016/j.brainres.2015.03.026; Xie LK, 2014, J IMMUNOL, V192, P6009, DOI 10.4049/jimmunol.1303492; Xu XM, 2013, SCI WORLD J, DOI 10.1155/2013/174373	77	28	28	2	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	AUG 5	2019	16	1							163	10.1186/s12974-019-1550-0			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	IO3JI	WOS:000479276100002	31383034	Green Published, gold			2022-02-06	
J	Campos-Pires, R; Hirnet, T; Valeo, F; Ong, BE; Radyushkin, K; Aldhoun, J; Saville, J; Edge, CJ; Franks, NP; Thal, SC; Dickinson, R				Campos-Pires, Rita; Hirnet, Tobias; Valeo, Flavia; Ong, Bee Eng; Radyushkin, Konstantin; Aldhoun, Jitka; Saville, Joanna; Edge, Christopher J.; Franks, Nicholas P.; Thal, Serge C.; Dickinson, Robert			Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury in mice	BRITISH JOURNAL OF ANAESTHESIA			English	Article						hippocampus; general anaesthesia; memory disorders; nerve degeneration; neuroinflammation; neuroprotection; traumatic brain injury	D-ASPARTATE RECEPTOR; WHITE-MATTER DAMAGE; COMPETITIVE-INHIBITION; INHALED XENON; BUPRENORPHINE; HYPOPITUITARISM; EPIDEMIOLOGY; HYPOTHERMIA; ANALGESIA; PATHOLOGY	Background: Xenon is a noble gas with neuroprotective properties that can improve short and long-term outcomes in young adult mice after controlled cortical impact. This follow-up study investigates the effects of xenon on very long-term outcomes and survival. Methods: C57BL/6N young adult male mice (n=72) received single controlled cortical impact or sham surgery and were treated with either xenon (75% Xe:25% O-2) or control gas (75% N-2 :25% O-2). Outcomes measured were: (i) 24 h lesion volume and neurological outcome score; (ii) contextual fear conditioning at 2 weeks and 20 months; (iii) corpus callosum white matter quantification; (iv) immunohistological assessment of neuroinflammation and neuronal loss; and (v) long-term survival. Results: Xenon treatment significantly reduced secondary injury (P<0.05), improved short-term vestibulomotor function (P<0.01), and prevented development of very late-onset traumatic brain injury (TBI)-related memory deficits. Xenon treatment reduced white matter loss in the contralateral corpus callosum and neuronal loss in the contralateral hippocampal CA1 and dentate gyrus areas at 20 months. Xenon's long-term neuroprotective effects were associated with a significant (P<0.05) reduction in neuroinflammation in multiple brain areas involved in associative memory, including reduction in reactive astrogliosis and microglial cell proliferation. Survival was improved significantly (P<0.05) in xenon-treated animals compared with untreated animals up to 12 months after injury. Conclusions: Xenon treatment after TBI results in very long-term improvements in clinically relevant outcomes and survival. Our findings support the idea that xenon treatment shortly after TBI may have long-term benefits in the treatment of brain trauma patients.	[Campos-Pires, Rita; Valeo, Flavia; Ong, Bee Eng; Aldhoun, Jitka; Saville, Joanna; Dickinson, Robert] Dept Surg & Canc, Anaesthet Pain Med & Intens Care Sect, London, England; [Campos-Pires, Rita; Dickinson, Robert] Imperial Coll London, Royal British Leg Ctr Blast Injury Studies, Dept Bioengn, London, England; [Campos-Pires, Rita] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Intens Care Unit, Crit Care Directorate, London, England; [Hirnet, Tobias; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Med Ctr, Mainz, Germany; [Radyushkin, Konstantin] Johannes Gutenberg Univ Mainz, Mouse Behav Outcome Unit, Focus Program Translat Neurosci, Mainz, Germany; [Edge, Christopher J.; Franks, Nicholas P.] Imperial Coll London, Dept Life Sci, London, England; [Edge, Christopher J.] Royal Berkshire Hosp NHS Fdn Trust, Dept Anaesthet, Reading, Berks, England		Dickinson, R (corresponding author), Dept Surg & Canc, Anaesthet Pain Med & Intens Care Sect, London, England.; Dickinson, R (corresponding author), Imperial Coll London, Royal British Leg Ctr Blast Injury Studies, Dept Bioengn, London, England.; Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Med Ctr, Mainz, Germany.	thal@uni-mainz.de; r.dickinson@imperial.ac.uk	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Franks, Nicholas/0000-0003-4874-4212	Medical Research Council, London, UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/N0277361/1, MC_PC_13064]; European Society for Anaesthesiology, Brussels, Belgium; Gas Safety Trust, London, UK; Royal British Legion Centre for Blast Injury Studies, Imperial College London, UK; Royal Centre for Defence Medicine, Birmingham, UK; Association of Anaesthetists of Great Britain and Ireland, London, UK; National Institute of Academic Anaesthesia, London, UK; Royal British Legion; Fundacao para a Ciencia e a Tecnologia, Lisbon, PortugalPortuguese Foundation for Science and Technology [SFRH/BD/78886/2011]; Deutscher Akademischer Austauschdienst (DAAD), German Academic Exchange Service, Bonn, Germany [A/13/72143]; German Federal Ministry of Education and Research, Berlin, GermanyFederal Ministry of Education & Research (BMBF) [BMBF 01EO1003]; Imperial College London President's PhD scholarship, London, UK; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/N027736/1, MC_PC_13064] Funding Source: UKRI	The Medical Research Council, London, UK (MR/N0277361/1; MC_PC_13064); European Society for Anaesthesiology, Brussels, Belgium; The Gas Safety Trust, London, UK; Royal British Legion Centre for Blast Injury Studies, Imperial College London, UK; Royal Centre for Defence Medicine, Birmingham, UK; The Association of Anaesthetists of Great Britain and Ireland, London, UK; National Institute of Academic Anaesthesia, London, UK. We acknowledge the financial support of the Royal British Legion. Rita Campos-Pires was the recipient of a doctoral training award from the Fundacao para a Ciencia e a Tecnologia, Lisbon, Portugal (SFRH/BD/78886/2011), and a scholarship from the Deutscher Akademischer Austauschdienst (DAAD), German Academic Exchange Service, Bonn, Germany (A/13/72143). Tobias Hirnet is funded by the German Federal Ministry of Education and Research, Berlin, Germany (grant BMBF 01EO1003). Flavia Valeo is the recipient of an Imperial College London President's PhD scholarship, London, UK.	Armstrong SP, 2012, ANESTHESIOLOGY, V117, P38, DOI 10.1097/ALN.0b013e31825ada2e; Azzopardi D, 2016, LANCET NEUROL, V15, P145, DOI 10.1016/S1474-4422(15)00347-6; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; Campos-Pires R, 2018, J NEUROTRAUM, V35, P1037, DOI 10.1089/neu.2017.5360; Campos-Pires R, 2015, CRIT CARE MED, V43, P149, DOI 10.1097/CCM.0000000000000624; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; Dingley J, 2014, PEDIATRICS, V133, P809, DOI 10.1542/peds.2013-0787; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dong, 2008, ALLEN REFERENCE ATLA; Donnelly J, 2019, NEUROSURGERY, V85, pE75, DOI 10.1093/neuros/nyy468; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Guarnieri M, 2012, LAB ANIMAL, V41, P337, DOI 10.1038/laban.152; Harris K, 2013, ANESTHESIOLOGY, V119, P1137, DOI 10.1097/ALN.0b013e3182a2a265; Jacobsen KR, 2013, COMPARATIVE MED, V63, P105; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Kalliokoski O, 2010, IN VIVO, V24, P641; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Keene CS, 2008, BEHAV NEUROSCI, V122, P1070, DOI 10.1037/a0012895; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; KUNSTYR I, 1975, J GERONTOL, V30, P157, DOI 10.1093/geronj/30.2.157; Laitio R, 2016, JAMA-J AM MED ASSOC, V315, P1120, DOI 10.1001/jama.2016.1933; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Martin D, 2004, HOSP MED, V65, P674, DOI 10.12968/hosp.2004.65.11.17047; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Osterstock G, 2014, ENDOCRINOLOGY, V155, P1887, DOI 10.1210/en.2013-1336; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pischiutta F, 2018, EXP NEUROL, V300, P167, DOI 10.1016/j.expneurol.2017.11.003; Pottker B, 2017, BRAIN STRUCT FUNCT, V222, P4005, DOI 10.1007/s00429-017-1452-9; Rudy JW, 2004, NEUROSCI BIOBEHAV R, V28, P675, DOI 10.1016/j.neubiorev.2004.09.004; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Siebold L, 2018, EXP NEUROL, V310, P48, DOI 10.1016/j.expneurol.2018.07.004; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; STORER JB, 1966, J GERONTOL, V21, P404, DOI 10.1093/geronj/21.3.404; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tan HJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04008-w; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Trogrlic L, 2011, LEARN MEMORY, V18, P678, DOI 10.1101/lm.2314311; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Warner DS, 2004, ANESTH ANALG, V99, P1208, DOI 10.1213/01.ANE.0000139930.04010.0D; Weib P., 2005, Mathematica Journal, V9, P803; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zoerle T, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00354; Zohar O, 2006, NEUROSCI LETT, V394, P239, DOI 10.1016/j.neulet.2005.10.099	59	28	30	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	JUL	2019	123	1					60	73		10.1016/j.bja.2019.02.032			14	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	IB4WE	WOS:000470272000035	31122738	Green Published, hybrid			2022-02-06	
J	Hammond, FM; Corrigan, JD; Ketchum, JM; Malec, JF; Dams-O'Connor, K; Hart, T; Novack, TA; Bogner, J; Dahdah, MN; Whiteneck, GG				Hammond, Flora M.; Corrigan, John D.; Ketchum, Jessica M.; Malec, James F.; Dams-O'Connor, Kristen; Hart, Tessa; Novack, Thomas A.; Bogner, Jennifer; Dahdah, Marie N.; Whiteneck, Gale G.			Prevalence of Medical and Psychiatric Comorbidities Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						comorbidities; medical conditions; outcomes; prevalence; rehabilitation; traumatic brain injury	HEART-RATE-VARIABILITY; OLDER-ADULTS; INPATIENT REHABILITATION; PITUITARY DYSFUNCTION; RISK; OUTCOMES; HEALTH; REHOSPITALIZATION; DYSAUTONOMIA; ASSOCIATION	Objective: To examine the prevalence of selected medical and psychiatric comorbidities that existed prior to or up to 10 years following traumatic brain injury (TBI) requiring acute rehabilitation. Design: Retrospective cohort. Setting: Six TBI Model Systems (TBIMS) centers. Participants: In total, 404 participants in the TBIMS National Database who experienced TBI 10 years prior. Interventions: Not applicable. Main Outcome Measure: Self-reported medical and psychiatric comorbidities and the onset time of each endorsed comorbidity. Results: At 10 years postinjury, the most common comorbidities developing postinjury, in order, were back pain, depression, hypertension, anxiety, fractures, high blood cholesterol, sleep disorders, panic attacks, osteoarthritis, and diabetes. Comparing those 50 years and older to those younger than 50 years, diabetes (odds ratio [OR] = 3.54; P = .0016), high blood cholesterol (OR = 2.04; P = .0092), osteoarthritis (OR = 2.02; P = .0454), and hypertension (OR = 1.84; P = .0175) were significantly more prevalent in the older cohort while panic attacks (OR = 0.33; P = .0022) were significantly more prevalent in the younger cohort. No significant differences in prevalence rates between the older and younger cohorts were found for back pain, depression, anxiety, fractures, or sleep disorders. Conclusions: People with moderate-severe TBI experience other medical and mental health comorbidities during the long-term course of recovery and life after injury. The findings can inform further investigation into comorbidities associated with TBI and the role of medical care, surveillance, prevention, lifestyle, and healthy behaviors in potentially modifying their presence and/or prevalence over the life span.	[Hammond, Flora M.; Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Hammond, Flora M.; Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Ketchum, Jessica M.; Whiteneck, Gale G.] Craig Hosp, Res Dept, Traumat Brain Injury Model Syst Natl Data & Stat, Englewood, CO USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Dahdah, Marie N.] Baylor Scott & White Inst Rehabil, North Texas TBI Model Syst, Dallas, TX USA; [Dahdah, Marie N.] Baylor Scott White Med Ctr Plano, Plano, TX USA		Hammond, FM (corresponding author), Indiana Univ Sch Med, Phys Med & Rehabil, 4141 Shore Dr, Indianapolis, IN 46254 USA.	flora.hammond@rhin.com	Ketchum, Jessica/AAE-8200-2020		National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR): Indiana University School of Medicine/Rehabilitation Hospital of Indiana [90DP0036]; Icahn School of Medicine at Mount Sinai [90DP0038]; Rocky Mountain Regional Brain Injury System [90DP0034]; Ohio State UniversityOhio State University [90DP0040]; University of Alabama at Birmingham [90DP0044]; Traumatic Brain Injury Model Systems National Data and Statistical Center [90DP0013, 90DP0084]; Moss TBI Model System [90DP0037]; North Texas TBI Model System [90DP0045]; National Institutes of Health National Center for Medical Rehabilitation Research (NICHD) [K01HD074651]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	The contents of this publication were developed under grants from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR): Indiana University School of Medicine/Rehabilitation Hospital of Indiana (grant 90DP0036), Icahn School of Medicine at Mount Sinai (grant 90DP0038), Rocky Mountain Regional Brain Injury System (grant 90DP0034), Ohio State University (grant 90DP0040), University of Alabama at Birmingham (grant 90DP0044), Traumatic Brain Injury Model Systems National Data and Statistical Center (grant 90DP0013 and 90DP0084), Moss TBI Model System (grant 90DP0037), North Texas TBI Model System (grant 90DP0045) and from the National Institutes of Health National Center for Medical Rehabilitation Research (NICHD; K01HD074651). NIDILRR is a center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS).	Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 2009, AM J PHYS MED REHAB, V88, P615, DOI 10.1097/PHM.0b013e3181aeab96; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Bogner JA, 2017, J HEAD TRAUMA REHAB, V32, pE1, DOI 10.1097/HTR.0000000000000291; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Centers for Disease Control and Prevention, 2017, NAT DIAB STAT REP 20; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Dams-O'Connor K, 2017, J HEAD TRAUMA REHAB, V32, P147, DOI 10.1097/HTR.0000000000000263; Dams-O'Connor K, 2016, J AM GERIATR SOC, V64, P844, DOI 10.1111/jgs.14014; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Federal Interagency Forum on Aging-Related Statistics, 2016, OLD AM 2016 KEY IND; Finley EP, 2015, AM J PUBLIC HEALTH, V105, P380, DOI 10.2105/AJPH.2014.301957; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Goldstein FC, 1996, NEUROPSYCHOLOGY, V10, P147; Goldstein FC., 1998, RECOVERY, V9, P28; Goleburn G, 2001, J CLIN GEROPSYCHOL, V7, P161, DOI DOI 10.1023/A:1011335027445; Hammond FM, 2015, ARCH PHYS MED REHAB, V96, pS330, DOI 10.1016/j.apmr.2014.09.041; Harrison-Felix C, 2015, J NEUROTRAUM, V32, P1893, DOI 10.1089/neu.2014.3353; Hart T, 2016, ARCH PHYS MED REHAB, V97, P701, DOI 10.1016/j.apmr.2015.08.436; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Holzman JB, 2017, NEUROSCI BIOBEHAV R, V74, P233, DOI 10.1016/j.neubiorev.2016.12.032; Institute of Medicine, 2009, GULF WAR HLTH, V7; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Jain A, 2014, ASIAN J PSYCHIATR, V8, P99, DOI 10.1016/j.ajp.2013.12.017; Jarczok MN, 2014, J INTERN MED, V276, P667, DOI 10.1111/joim.12295; Jarczok MN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160743; Jarczok MN, 2013, INT J CARDIOL, V167, P855, DOI 10.1016/j.ijcard.2012.02.002; Keller JJ, 2013, NEUROUROL URODYNAM, V32, P354, DOI 10.1002/nau.22309; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kolakowsky-Hayner SA, 2000, NEUROREHABILITATION, V14, P151; Kumar RG, 2018, J HEAD TRAUMA REHAB, V33, P15, DOI 10.1097/HTR.0000000000000273; Liao CC, 2014, MAYO CLIN PROC, V89, P163, DOI 10.1016/j.mayocp.2013.09.019; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; MADDOX GL, 1973, J HEALTH SOC BEHAV, V14, P87, DOI 10.2307/2136940; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; Masel BE, 2015, J NEUROTRAUM, V32, P1833, DOI 10.1089/neu.2015.29004.bm; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Moiyadi AV, 2007, NEUROREHABILITATION, V22, P93; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1884, DOI 10.1016/j.apmr.2012.11.054; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Pasquale MD, 2005, CRIT CARE MED, V33, pA40, DOI 10.1097/00003246-200512002-00148; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Pugh MJV, 2015, J HEAD TRAUMA REHAB, V30, P29, DOI 10.1097/HTR.0000000000000045; Ramirez E, 2015, INT J PSYCHOPHYSIOL, V98, P490, DOI 10.1016/j.ijpsycho.2015.10.007; Schuster AK, 2016, INT J CARDIOL, V203, P728, DOI 10.1016/j.ijcard.2015.11.027; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Stacey A, 2017, J NEUROTRAUM, V34, P1558, DOI 10.1089/neu.2016.4721; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2012, RES GERONTOL NURS, V5, P17, DOI 10.3928/19404921-20111206-02; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547	65	28	28	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2019	34	4					E1	E10		10.1097/HTR.0000000000000465			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	IQ4XH	WOS:000480754400001	30608311	Green Accepted, Green Published			2022-02-06	
J	Gu, JJ; Huang, HP; Huang, YJ; Sun, HT; Xu, HW				Gu, Jiajie; Huang, Haoping; Huang, Yuejun; Sun, Haitao; Xu, Hongwu			Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta-analysis of randomized controlled trials	NEUROSURGICAL REVIEW			English	Article						Intracranial hypertension; Intracranial pressure; Hypertonic saline; Mannitol; Traumatic brain injury; Meta-analysis	SODIUM SOLUTIONS; HETEROGENEITY; HYPERTENSION; EQUIOSMOLAR; CHLORIDE; THERAPY	Hyperosmolar therapy is regarded as the mainstay for treatment of elevated intracranial pressure (ICP) in traumatic brain injury (TBI). This still has been disputed as application of hypertonic saline (HS) or mannitol for treating patients with severe TBI. Thus, this meta-analysis was performed to further compare the advantages and disadvantages of mannitol with HS for treating elevated ICP after TBI. We conducted a systematic search on PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Wan Fang Data, VIP Data, SinoMed, and China National Knowledge Infrastructure (CNKI) databases. Studies were included or not based on the quality assessment by the Jadad scale and selection criteria. Twelve RCTs with 438 patients were enrolled for the meta-analysis. The comparison of HS and mannitol indicated that they were close in field of improving function outcome (RR=1.17, 95% CI 0.89 to 1.54, p=0.258) and reducing intracranial pressure (MD=-0.16, 95% CI: -0.59 to 0.27, p=0.473) and mortality (RR=0.78, 95% CI 0.53 to 1.16, p=0.216). The pooled relative risk of successful ICP control was 1.06 (95% CI: 1.00 to 1.13, p=0.044), demonstrating that HS was more effective than mannitol in ICP management. Both serum sodium (WMD=5.30, 95% CI: 4.37 to 6.22, p<0.001) and osmolality (WMD=3.03, 95% CI: 0.18 to 5.88, p=0.037) were increased after injection of hypertonic saline. The results do not lend a specific recommendation to select hypertonic saline or mannitol as a first-line for the patients with elevated ICP caused by TBI. However, for the refractory intracranial hypertension, hypertonic saline seems to be preferred.	[Gu, Jiajie; Huang, Haoping] Shantou Univ, Coll Med, Shantou, Guangdong, Peoples R China; [Huang, Yuejun] Shantou Univ, Coll Med, Affiliated Hosp 2, Transforming Med Ctr, North Dongxia Rd, Shantou 515041, Guangdong, Peoples R China; [Sun, Haitao] Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China; [Xu, Hongwu] Shantou Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Changping Rd, Shantou 515041, Guangdong, Peoples R China		Xu, HW (corresponding author), Shantou Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Changping Rd, Shantou 515041, Guangdong, Peoples R China.	hwxu@qq.com		/0000-0001-7925-9506	National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [31300927]; Medical Scientific Research Foundation of Guangdong Province [A2016496]; Key, the Pearl River S&T Nova Program of Guangzhou [201710010047]	This work was supported by the National Natural Science Foundation of China (NSFC, 31300927), the Medical Scientific Research Foundation of Guangdong Province (grant number: A2016496), and Key, the Pearl River S&T Nova Program of Guangzhou (201710010047).	Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Berger-Pelleiter E, 2016, CAN J EMERG MED, V18, P112, DOI 10.1017/cem.2016.12; Boone Myles Dustin, 2015, Surg Neurol Int, V6, P177, DOI 10.4103/2152-7806.170248; Burgess S, 2016, ANN PHARMACOTHER, V50, P291, DOI 10.1177/1060028016628893; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Diringer MN, 2016, ACTA NEUROCHIR SUPPL, V121, P3, DOI 10.1007/978-3-319-18497-5_1; Du DY, 2017, NEURAL INJURY FUNCTI, V12, P215; EICHNER E, 1972, AM J OBSTET GYNECOL, V113, P855, DOI 10.1016/0002-9378(72)90582-0; Erdman MJ, 2017, NEUROHOSPITALIST, V7, P9, DOI 10.1177/1941874416665744; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Huang Xuecai, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P723; Infanti JL, 2008, J NEUROSCI NURS, V40, P362, DOI 10.1097/01376517-200812000-00009; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jagannatha AT, 2016, J CLIN NEUROSCI, V27, P68, DOI 10.1016/j.jocn.2015.08.035; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Kjaergard LL, 2008, ANN INTERN MED, V149, P219, DOI 10.7326/0003-4819-149-3-200808050-00023; Lazaridis C, 2013, CRIT CARE MED, V41, P1353, DOI 10.1097/CCM.0b013e31827ca4b3; Li M, 2015, MEDICINE, V94; Mao X, 2007, JIANGSU MED J; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065; Pietrini V, 2010, NEUROL SCI, V31, P227, DOI 10.1007/s10072-009-0173-0; [秦德广 Qin Deguang], 2016, [中华神经医学杂志, Chinese Journal of Neuromedicine], V15, P1267; Reza A, 2018, BRAIN INJURY, V32, P487, DOI 10.1080/02699052.2018.1429658; Rickard AC, 2014, EMERG MED J, V31, P679, DOI 10.1136/emermed-2013-202679; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wakai A, 2007, MANNITOL ACUTE TRAUM; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Yan YF, 2013, J TRAUMA SURG	38	28	28	1	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JUN	2019	42	2					499	509		10.1007/s10143-018-0991-8			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HX1GD	WOS:000467137500030	29905883				2022-02-06	
J	Fadiman, J; Korb, S				Fadiman, James; Korb, Sophia			Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration	JOURNAL OF PSYCHOACTIVE DRUGS			English	Article						Psychedelics; microdosing; LSD; psilocybin		Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration of the effects of "microdoses," comprising hundreds of lengthy descriptive reports, was undertaken. Based on these reports, using a psychedelic in the microdose range (10 micrograms) every three days was determined to be safe across a wide variety of individuals and conditions. Over 18 months, more than a thousand individuals from 59 countries did a daily evaluation of negative and positive emotional state using the PANAS checklist plus written reports for between one week and four months. Participant reports suggested that spaced but repeated microdoses were followed by improvements in negative moods, especially depression, and increases in positive moods. Increased energy, improved work effectiveness, and improved health habits were observed in clinical and non-clinical populations. Smaller samples described alleviation of symptoms in migraine headaches, pre-menstrual syndromes, traumatic brain injury, shingles, and other conditions not previously associated with psychedelic use.	[Fadiman, James] Sofia Univ, Dept Psychol, Palo Alto, CA USA; [Korb, Sophia] Coll St Womens Ctr Hlth Educ & Counselling, Toronto, ON, Canada		Fadiman, J (corresponding author), Sofia Univ, Palo Alto, CA 94303 USA.	jfadiman@gmail.com					Cerletti A., 2005, LSD MY PROBLEM CHILD, P85; Fadiman J., 2016, PSYCHEDELIC PRESS J, V15, P1; Fadiman J, 2019, ADV PSYCHEDELIC MED, P318; Gasser P, 2015, J PSYCHOPHARMACOL, V29, P57, DOI 10.1177/0269881114555249; Grob C., 2002, HALLUCINOGENS READER, P17; Hofmann Albert, 2005, LSD MY PROBLEM CHILD; Knowles R., 2018, 38 ANN C SOC ANTHR C; Madsen M., 2018, 1 C PSYCH PSYCH STOC; Passie T., 2018, SCI MICRODOSING PSYC; Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216	10	28	28	6	33	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0279-1072	2159-9777		J PSYCHOACTIVE DRUGS	J. Psychoact. Drugs		2019	51	2			SI		118	122		10.1080/02791072.2019.1593561		MAR 2019	5	Psychology, Clinical; Substance Abuse	Social Science Citation Index (SSCI)	Psychology; Substance Abuse	IC5EA	WOS:000467762200001	30925850				2022-02-06	
J	Chao, HL; Lin, C; Zuo, Q; Liu, YL; Xiao, MQ; Xu, XP; Li, Z; Bao, ZY; Chen, HM; You, YP; Kochanek, PM; Yin, HY; Liu, N; Kagan, VE; Bayir, H; Ji, J				Chao, Honglu; Lin, Chao; Zuo, Qiang; Liu, Yinlong; Xiao, Mengqing; Xu, Xiupeng; Li, Zheng; Bao, Zhongyuan; Chen, Huimei; You, Yongping; Kochanek, Patrick M.; Yin, Huiyong; Liu, Ning; Kagan, Valerian E.; Bayir, Hulya; Ji, Jing			Cardiolipin-Dependent Mitophagy Guides Outcome after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; autophagy; cardiolipin; mitophagy; neuroprotection; phospholipid	DYNAMIN-RELATED PROTEIN-1; AUTOPHAGIC CELL-DEATH; PHOSPHOLIPID SCRAMBLASE-3; MITOCHONDRIAL FISSION; PATHWAY; ELIMINATION; PARKIN; SIGNAL; MICE; DRP1	Mitochondrial energy production is essential for normal brain function. Traumatic brain injury (TBI) increases brain energy demands, results in the activation of mitochondrial respiration, associated with enhanced generation of reactive oxygen species. This chain of events triggers neuronal apoptosis via oxidation of a mitochondria-specific phospholipid, cardiolipin (CL). One pathway through which cells can avoid apoptosis is via elimination of damaged mitochondria by mitophagy. Previously, we showed that externalization of CL to the mitochondrial surface acts as an elimination signal in cells. Whether CL-mediated mitophagy occurs in vivo or its significance in the disease processes are not known. In this study, we showed that TBI leads to increased mitophagy in the human brain, which was also detected using TBI models in male rats. Knockdown of CL synthase, responsible for de novo synthesis of CL, or phospholipid scramblase-3, responsible for CL translocat ion to the outer mitochondrial membrane, significantly decreased TBI-induced mitophagy. Inhibition of mitochondrial clearance by 3-methyladenine, mdivi-1, or phospholipid scramblase-3 knockdown after TBI led to a worse outcome, suggesting that mitophagy is beneficial. Together, our findings indicate that TBI-induced mitophagy is an endogenous neuroprotective process that is directed by CL, which marks damaged mitochondria for elimination, thereby limiting neuronal death and behavioral deficits.	[Chao, Honglu; Lin, Chao; Liu, Yinlong; Xu, Xiupeng; Li, Zheng; Bao, Zhongyuan; You, Yongping; Liu, Ning; Ji, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China; [Zuo, Qiang] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing 210029, Jiangsu, Peoples R China; [Chao, Honglu; Kagan, Valerian E.; Bayir, Hulya; Ji, Jing] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA; [Chao, Honglu; Kochanek, Patrick M.; Bayir, Hulya; Ji, Jing] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15219 USA; [Xiao, Mengqing; Yin, Huiyong] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Food Safety Res, Shanghai 200031, Peoples R China; [Xiao, Mengqing; Yin, Huiyong] Univ Chinese Acad Sci, CAS, Beijing 100049, Peoples R China; [Xiao, Mengqing; Yin, Huiyong] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China; [Chen, Huimei] Nanjing Univ, Sch Med, Dept Med Genet, Nanjing 210093, Jiangsu, Peoples R China; [Chen, Huimei] Jiangsu Key Lab Mol Med, Nanjing 210029, Jiangsu, Peoples R China; [Yin, Huiyong] Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China; [Kagan, Valerian E.] IM Sechenov Moscow State Med Univ, Lab Nav Redox Lipid, Moscow 119991, Russia; [Kagan, Valerian E.] IM Sechenov Moscow State Med Univ, Dept Human Pathol, Moscow 119991, Russia; [Bayir, Hulya] Childrens Hosp Pittsburgh, Childrens Neurosci Inst, Pittsburgh, PA 15224 USA		Ji, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China.; Bayir, H; Ji, J (corresponding author), Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA.; Bayir, H (corresponding author), Childrens Hosp Pittsburgh, Childrens Neurosci Inst, Pittsburgh, PA 15224 USA.	bayihx@ccm.upmc.edu; jijing@njmu.edu.cn	Zuo, Qiang/AAW-6399-2021	Kagan, Valerian E./0000-0002-7245-1885; yin, hui yong/0000-0001-7049-1560	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061817, NS076511]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81300998, 81471269]; Jiangsu Province's Natural Science FoundationNatural Science Foundation of Jiangsu Province [BK20160047, BK20160044]; Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817, R01NS076511] Funding Source: NIH RePORTER	This work was supported by NIH Grants (NS061817, NS076511) to H.B., National Natural Science Foundation of China (81300998, 81471269) to J.J., Jiangsu Province's Natural Science Foundation (BK20160047, BK20160044) to J.J., and Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Burman JL, 2017, J CELL BIOL, V216, P3231, DOI 10.1083/jcb.201612106; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chu CT, 2014, AUTOPHAGY, V10, P376, DOI 10.4161/auto.27191; Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Feng Y, 2017, NEUROCHEM RES, V42, P3296, DOI 10.1007/s11064-017-2372-z; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; Galluzzi L, 2016, NAT REV NEUROSCI, V17, P467, DOI 10.1038/nrn.2016.51; Gao YY, 2017, AM J TRANSL RES, V9, P887; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; He Y, 2007, J CELL BIOCHEM, V101, P1210, DOI 10.1002/jcb.21243; Huang CY, 2017, J NEUROIMMUNOL, V313, P61, DOI 10.1016/j.jneuroim.2017.10.011; Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Ji J, 2012, J NEUROTRAUM, V29, P776, DOI 10.1089/neu.2010.1602; Jin YC, 2016, WORLD NEUROSURG, V88, P433, DOI 10.1016/j.wneu.2015.10.055; Kagan VE, 2016, CELL DEATH DIFFER, V23, P1140, DOI 10.1038/cdd.2015.160; Kagan VE, 2009, FREE RADICAL BIO MED, V46, P1439, DOI 10.1016/j.freeradbiomed.2009.03.004; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kilbaugh TJ, 2015, EXP NEUROL, V271, P136, DOI 10.1016/j.expneurol.2015.05.009; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kowalczyk JE, 2009, NEUROCHEM INT, V55, P157, DOI 10.1016/j.neuint.2009.01.009; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; Liu JH, 2003, MOL CANCER RES, V1, P892; Liu JH, 2003, CANCER RES, V63, P1153; Liu JH, 2008, BIOCHEMISTRY-US, V47, P4518, DOI 10.1021/bi701962c; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Liu YL, 2017, J NEUROTRAUM, V34, P2119, DOI 10.1089/neu.2016.4764; Liu Y, 2017, BEHAV BRAIN RES, V331, P135, DOI 10.1016/j.bbr.2017.04.024; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mukhida K, 2005, MED HYPOTHESES, V64, P1120, DOI 10.1016/j.mehy.2004.12.020; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007; Preau S, 2016, ANTIOXID REDOX SIGN, V24, P529, DOI 10.1089/ars.2015.6421; Qian W, 2013, EXPERT OPIN THER TAR, V17, P997, DOI 10.1517/14728222.2013.823160; Rosdah AA, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.235; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Smith G, 2017, DEV NEUROBIOL, V77, P1260, DOI 10.1002/dneu.22519; Sun Y, 2012, J BIOL CHEM, V287, P40652, DOI 10.1074/jbc.M112.419721; Tang YC, 2016, PROTEIN CELL, V7, P699, DOI 10.1007/s13238-016-0307-0; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wang CX, 2017, CELL BIOL INT, V41, P1039, DOI 10.1002/cbin.10820; Wang Z, 2012, J MOL NEUROSCI, V46, P192, DOI 10.1007/s12031-011-9575-6; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu Q, 2017, HISTOL HISTOPATHOL, V32, P551, DOI 10.14670/HH-11-841; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Yamashita S, 2016, J CELL BIOL, V215, P649, DOI 10.1083/jcb.201605093; Zhang XN, 2013, AUTOPHAGY, V9, P1321, DOI 10.4161/auto.25132; Zuo W, 2014, NEUROPHARMACOLOGY, V86, P103, DOI 10.1016/j.neuropharm.2014.07.002	59	28	29	1	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 6	2019	39	10					1930	1943		10.1523/JNEUROSCI.3415-17.2018			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HN7WJ	WOS:000460403400014	30626699	Green Published, Bronze			2022-02-06	
J	Tsushima, WT; Siu, AM; Ahn, HJ; Chang, BL; Murata, NM				Tsushima, William T.; Siu, Andrea M.; Ahn, Hyeong Jun; Chang, Bolin L.; Murata, Nathan M.			Incidence and Risk of Concussions in Youth Athletes: Comparisons of Age, Sex, Concussion History, Sport, and Football Position	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; Risks; Sports; Youth	TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; UNITED-STATES; RELATIVE RISK; EPIDEMIOLOGY; COLLEGIATE; SYMPTOMS; CHILDREN; IMPACT; RATES	Objective This study was designed to determine concussion incidence, risk, and relative risk among middle and high school athletes participating in various sports. Method Data were retrospectively obtained from 10,334 athletes of 12 different sports in Hawaii. In addition to determining the overall concussion incidence, comparisons of incidence, risk, and relative risk were made according to age, sex, concussion history, sport, and football position. Results The overall incidence of concussion among youth athletes was 1,250 (12.1%). The relative risk for a concussion was almost two times greater in 18-year olds than in 13-year-old athletes. In comparable sports, girls had a 1.5 times higher concussion risk than boys. Athletes with a prior concussion had 3-5 times greater risk to sustain a concussion than those with no history of a concussion. Among varied sports, wrestling and martial arts had the highest relative risk of a concussion, followed by cheerleading, football, and track and field. No differences in concussion risks were found among the football players in different positions. Conclusions Older youths, females, those with a history of concussion, and those participating in high contact sports were found to have higher risks of sustaining a concussion. The findings increase awareness of concussion patterns in young athletes and raise concerns regarding protective strategies and concussion management in youth sports.	[Tsushima, William T.] Straub Med Ctr, Psychiat & Psychol Dept, Honolulu, HI 96813 USA; [Siu, Andrea M.] Hawaii Pacific Hlth, Res Inst, Honolulu, HI 96813 USA; [Ahn, Hyeong Jun] Univ Hawaii, John A Burns Sch Med, Dept Complementary & Integrat Med, Honolulu, HI 96813 USA; [Chang, Bolin L.] Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18015 USA; [Murata, Nathan M.] Univ Hawaii, Dept Kinesiol & Rehabil Sci, Honolulu, HI 96822 USA		Tsushima, WT (corresponding author), Straub Med Ctr, 888 South King St, Honolulu, HI 96813 USA.	tzking@gsu.edu			National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [U54MD007584]; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [U54MD007601] Funding Source: NIH RePORTER	HJA was partially supported by grant U54MD007584 from the National Institute on Minority Health and Health Disparities. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Comstock R. D. C. D., 2017, NATL HIGH SCH SPORTS; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2011, HDB SPORT NEUROPSYCH, P58; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Houck Z, 2016, AM J SPORT MED, V44, P2269, DOI 10.1177/0363546516645070; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kontos AP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1633; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; O'Connor KL, 2017, J ATHL TRAINING, V52, P175, DOI 10.4085/1062-6050-52.1.15; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Spicer M.A.C.M., 2014, SPORTS RELATED CONCU; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Strand S, 2015, APPL NEUROPSYCH-CHIL, V4, P58, DOI 10.1080/21622965.2013.802650; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	45	28	28	1	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2019	34	1					60	69		10.1093/arclin/acy019			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	HO0SQ	WOS:000460614800007	29554189	Green Published, Bronze			2022-02-06	
J	Liu, L; Urch, B; Szyszkowicz, M; Evans, G; Speck, M; Van Huang, A; Leingartner, K; Shutt, RH; Pelletier, G; Gold, DR; Brook, JR; Pollitt, KG; Silverman, FS				Liu, Ling; Urch, Bruce; Szyszkowicz, Mieczyslaw; Evans, Greg; Speck, Mary; Van Huang, Angela; Leingartner, Karen; Shutt, Robin H.; Pelletier, Guillaume; Gold, Diane R.; Brook, Jeffrey R.; Pollitt, Krystal Godri; Silverman, Frances S.			Metals and oxidative potential in urban particulate matter influence systemic inflammatory and neural biomarkers: A controlled exposure study	ENVIRONMENT INTERNATIONAL			English	Article							CONCENTRATED AMBIENT PARTICLES; EMERGENCY-ROOM VISITS; AIR-POLLUTION; BIOLOGICAL CONSTITUENTS; LIPID-PEROXIDATION; BLOOD-PRESSURE; FINE; STRESS; COARSE; RISK	Background: Oxidative stress and inflammation are considered to be important pathways leading to particulate matter (PM)-associated disease. In this exploratory study, we examined the effects of metals and oxidative potential (OP) in urban PM on biomarkers of systemic inflammation, oxidative stress and neural function. Methods: Fifty-three healthy non-smoking volunteers (mean age 28 years, twenty-eight females) were exposed to coarse (2.5-10 mu m, mean 213 mu g/m(3)), fine (0.15-2.5 mu m, 238 mu g/m(3)), and/or ultrafine concentrated ambient PM (< 0.3 mu m, 136 mu g/m(3)). Exposures lasted 130 min, separated by >= 2 weeks. Metal concentrations and OP (measured by ascorbate and glutathione depletion in synthetic airway fluid) in PM were analyzed. Blood and urine samples were collected pre-exposure, and 1-h and 21-h post exposure for assessment of biomarkers. We used mixed-regression models to analyze associations adjusting for PM size and mass concentration. Results: Results for metals were expressed as change (%) from daily pre-exposure biomarker levels after exposure to a metal at a level equivalent to the mean concentration. Exposure to various metals (silver, aluminum, barium, copper, iron, potassium, lithium, nickel, tin, and/or vanadium) was significantly associated with increased levels of various blood or urinary biomarkers. For example, the blood inflammatory marker vascular endothelia growth factor (VEGF) increased 5.3% (95% confidence interval: 0.3%, 10.2%) 1-h post exposure to nickel; the traumatic brain injury marker ubiquitin C-terminal hydrolase L1 (UCHL1) increased 11% (1.2%, 21%) and 14% (0.3%, 29%) 1-h and 21-h post exposure to barium, respectively; and the systemic stress marker cortisol increased 1.5% (0%, 2.9%) and 1.5% (0.5%, 2.8%) 1-h and 21-h post exposure to silver, respectively. Urinary DNA oxidation marker 8-hydroxy-deoxy-guanosine increased 14% (6.4%, 21%) 1-h post exposure to copper; urinary neural marker vanillylmandelic acid increased 29% (3%, 54%) 1-h post exposure to aluminum; and urinary cortisol increased 88% (0.9%, 176%) 1-h post exposure to vanadium. Results for OP were expressed as change (%) from daily pre-exposure biomarker levels after exposure to ascorbate-related OP at a level equivalent to the mean concentration, or for exposure to glutathione-related OP at a level above the limit of detection. Exposure to ascorbate-or glutathione-related OP was significantly associated with increased inflammatory and neural biomarkers including interleukin-6, VEGF, UCHL1, and S100 calcium-binding protein B in blood, and malondialdehyde and 8-hydroxy-deoxy-guanosine in urine. For example, UCHL1 increased 9.4% (1.8%, 17%) in blood 21-h post exposure to ascorbate-related OP, while urinary malondialdehyde increased 19% (3.6%, 35%) and 8-hydroxydeoxy- guanosine increased 24% (2.9%, 48%) 21-h post exposure to ascorbate-and glutathione-related OP, respectively. Conclusion: Our results from this exploratory study suggest that metal constituents and OP in ambient PM may influence biomarker levels associated with systemic inflammation, oxidative stress, perturbations of neural function, and systemic physiological stress.	[Liu, Ling; Szyszkowicz, Mieczyslaw; Leingartner, Karen; Shutt, Robin H.; Pelletier, Guillaume] Hlth Canada, Hlth Environm & Consumer Safety Branch, PL 0201A,101 Tunneys Pasture Driveway, Ottawa, ON K1A 0K9, Canada; [Urch, Bruce; Evans, Greg; Speck, Mary; Brook, Jeffrey R.; Silverman, Frances S.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Occupat & Environm Hlth, Toronto, ON, Canada; [Urch, Bruce; Evans, Greg; Van Huang, Angela; Brook, Jeffrey R.; Silverman, Frances S.] SOCAAR, Toronto, ON, Canada; [Gold, Diane R.] Harvard Med Sch, Channing Lab, Brigham & Womens Hosp, Boston, MA USA; [Brook, Jeffrey R.] Environm & Climate Change Canada, Toronto, ON, Canada; [Silverman, Frances S.] Univ Toronto, Dept Med, Div Occupat Med, Toronto, ON, Canada; [Silverman, Frances S.] Univ Toronto, Dept Med, Div Respirol, Toronto, ON, Canada; [Pollitt, Krystal Godri] Yale Univ, Environm Hlth Sci, New Haven, CT USA; [Silverman, Frances S.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada		Liu, L (corresponding author), Hlth Canada, Hlth Environm & Consumer Safety Branch, PL 0201A,101 Tunneys Pasture Driveway, Ottawa, ON K1A 0K9, Canada.	ling.liu@canada.ca	Szyszkowicz, Mieczyslaw/N-2490-2019	Pelletier, Guillaume/0000-0002-4200-4515; Godri Pollitt, Krystal/0000-0001-7332-2228; Szyszkowicz, Mieczyslaw/0000-0001-7022-3267	Health Canada's Clean Air Regulatory Agenda; U.S. EPAUnited States Environmental Protection Agency [RD-83241601]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 ES005605]; Environment and Climate Change Canada; AllerGen Networks of Centres of Excellence; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES005605] Funding Source: NIH RePORTER	This work was supported by Health Canada's Clean Air Regulatory Agenda, U.S. EPA RD-83241601, NIH Grant P30 ES005605, Environment and Climate Change Canada, and AllerGen Networks of Centres of Excellence. Infrastructure for concentrated ambient particle exposure facility was provided by SOCAAR through funding from the Canada Foundation for Innovation. The contents of this publication are solely the responsibility of the grantee and do not necessarily represent the official views of the funding agencies. The funding agencies do not endorse the purchase of any commercial products or services mentioned in the publication.	Anderson JL, 1998, J AM COLL CARDIOL, V32, P35, DOI 10.1016/S0735-1097(98)00203-4; Ayres JG, 2008, INHAL TOXICOL, V20, P75, DOI [10.1080/08958370701665517, 10.1080/08958370701665517 ]; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Bates JT, 2015, ENVIRON SCI TECHNOL, V49, P13605, DOI 10.1021/acs.est.5b02967; Behbod B, 2013, OCCUP ENVIRON MED, V70, P761, DOI 10.1136/oemed-2013-101498; Bell Michelle L, 2012, Res Rep Health Eff Inst, P5; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Borm PJA, 2007, OCCUP ENVIRON MED, V64, P73, DOI 10.1136/oem.2006.029090; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Cakmak S, 2014, ENVIRON POLLUT, V189, P208, DOI 10.1016/j.envpol.2014.03.004; Chen LC, 2009, INHAL TOXICOL, V21, P1, DOI 10.1080/08958370802105405 ; Clarke RW, 2000, ENVIRON HEALTH PERSP, V108, P1179, DOI 10.2307/3434831; Crobeddu B, 2017, ENVIRON POLLUT, V230, P125, DOI 10.1016/j.envpol.2017.06.051; Daher N, 2014, SCI TOTAL ENVIRON, V470, P417, DOI 10.1016/j.scitotenv.2013.09.104; FRANKENHAEUSER M, 1986, PHARMACOL BIOCHEM BE, V24, P1521, DOI 10.1016/0091-3057(86)90478-8; Fukuda M, 1996, PSYCHIAT RES, V63, P7, DOI 10.1016/0165-1781(96)02527-9; Gurgueira SA, 2002, ENVIRON HEALTH PERSP, V110, P749, DOI 10.1289/ehp.02110749; Haberzettl P, 2012, ENVIRON HEALTH PERSP, V120, P848, DOI 10.1289/ehp.1104206; Haynes WG, 1996, CIRCULATION, V93, P1860, DOI 10.1161/01.CIR.93.10.1860; Huang YCT, 2003, INHAL TOXICOL, V15, P327, DOI 10.1080/08958370304460; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; Kelly Frank, 2011, Res Rep Health Eff Inst, P73; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Lippmann Morton, 2013, Res Rep Health Eff Inst, P5; Liu L, 2017, ENVIRON INT, V101, P89, DOI 10.1016/j.envint.2017.01.010; Liu L, 2015, ENVIRON HEALTH PERSP, V123, P534, DOI 10.1289/ehp.1408387; Maikawa CL, 2016, ENVIRON HEALTH PERSP, V124, P1616, DOI 10.1289/EHP175; Moylan S, 2013, NEUROSCI BIOBEHAV R, V37, P573, DOI 10.1016/j.neubiorev.2013.02.003; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nishimoto N, 2006, NAT CLIN PRACT RHEUM, V2, P619, DOI 10.1038/ncprheum0338; PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S; Pollitt KJG, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0173-5; Rastogi N, 2012, AEROSOL SCI TECH, V46, P1015, DOI 10.1080/02786826.2012.686674; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schaumann F, 2004, AM J RESP CRIT CARE, V170, P898, DOI 10.1164/rccm.200403-423OC; Strak M, 2012, ENVIRON HEALTH PERSP, V120, P1183, DOI 10.1289/ehp.1104389; Subramanian M, 2016, NATURE, V534, P166, DOI 10.1038/534166a; Tonne C, 2012, EPIDEMIOLOGY, V23, P486, DOI 10.1097/EDE.0b013e31824e613e; Weichenthal S, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0129-9; Weichenthal S, 2016, ENVIRON RES, V146, P92, DOI 10.1016/j.envres.2015.12.013; Weichenthal SA, 2016, AM J RESP CRIT CARE, V194, P577, DOI 10.1164/rccm.201512-2434OC; Weichenthal SA, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-40; Wu S, 1996, J ANAL ATOM SPECTROM, V11, P287, DOI 10.1039/ja9961100287; Yang A, 2016, OCCUP ENVIRON MED, V73, P154, DOI 10.1136/oemed-2015-103175; Yang A, 2015, ENVIRON HEALTH PERSP, V123, P1187, DOI 10.1289/ehp.1408916; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhong J, 2015, HYPERTENSION, V66, P509, DOI 10.1161/HYPERTENSIONAHA.115.05342; Zhou JA, 2011, ENVIRON HEALTH PERSP, V119, P461, DOI 10.1289/ehp.1002613	48	28	28	4	35	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0160-4120	1873-6750		ENVIRON INT	Environ. Int.	DEC	2018	121		2				1331	1340		10.1016/j.envint.2018.10.055			10	Environmental Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology	HE2CS	WOS:000453083000033	30420132	Green Accepted, hybrid			2022-02-06	
J	Brickler, TR; Hazy, A; Correa, FG; Dai, RJ; Kowalski, EJA; Dickerson, R; Chen, J; Wang, X; Morton, PD; Whittington, A; Ahmed, A; Theus, MH				Brickler, Thomas R.; Hazy, Amanda; Correa, Fernanda Guilhaume; Dai, Rujuan; Kowalski, Elizabeth J. A.; Dickerson, Ross; Chen, Jiang; Wang, Xia; Morton, Paul D.; Whittington, Abby; Ahmed, Ansar; Theus, Michelle H.			Angiopoietin/Tie2 Axis Regulates the Age-at-Injury Cerebrovascular Response to Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						angiopoietin; blood-brain barrier; cerebral blood flow; juvenile; miRNA; Tie2 receptor	GLUT1 GLUCOSE-TRANSPORTER; DIFFUSE AXONAL INJURY; IN-VITRO; CEREBRAL MICROBLEEDS; SUBVENTRICULAR ZONE; MICRORNA EXPRESSION; ENDOTHELIAL-CELLS; KETOGENIC DIET; PIGLET BRAIN; BLOOD-FLOW	Although age-at-injury influences chronic recovery from traumatic brain injury (TBI), the differential effects of age on early outcome remain understudied. Using a male murine model of moderate contusion injury, we investigated the underlying mechanism(s) regulating the distinct response between juvenile and adult TBI. We demonstrate similar biomechanical and physical properties of naive juvenile and adult brains. However, following controlled cortical impact (CCI), juvenile mice displayed reduced cortical lesion formation, cell death, and behavioral deficits at 4 and 14 d. Analysis of high-resolution laser Doppler imaging showed a similar loss of cerebral blood flow (CBF) in the ipsilateral cortex at 3 and 24 h post-CCI, whereas juvenile mice showed enhanced subsequent restoration at 2-4 d compared with adults. These findings correlated with reduced blood-brain barrier (BBB) disruption and increased perilesional vessel density. To address whether an age-dependent endothelial cell (EC) response affects vessel stability and tissue outcome, we magnetically isolated CD31(+) ECs from sham and injured cortices and evaluated mRNA expression. Interestingly, we found increased transcripts for BBB stability-related genes and reduced expression of BBB-disrupting genes in juveniles compared with adults. These differences were concomitant with significant changes in miRNA-21-5p and miR-148a levels. Accompanying these findings was robust GFAP immunoreactivity, which was not resolved by day 35. Importantly, pharmacological inhibition of EC-specific Tie2 signaling abolished the juvenile protective effects. These findings shed new mechanistic light on the divergent effects that age plays on acute TBI outcome that are both spatial and temporal dependent.	[Brickler, Thomas R.; Hazy, Amanda; Dai, Rujuan; Kowalski, Elizabeth J. A.; Chen, Jiang; Wang, Xia; Morton, Paul D.; Ahmed, Ansar; Theus, Michelle H.] Virginia Polytech Inst & State Univ, Dept Biomed Sci & Pathobiol, Coll Vet Med, Roanoke, VA 24061 USA; [Correa, Fernanda Guilhaume] Virginia Polytech Inst & State Univ, Translat Biol Med & Hlth Grad Program, Sch Med, Roanoke, VA 24061 USA; [Dickerson, Ross; Whittington, Abby] Virginia Polytech Inst & State Univ, Dept Chem Engn, Sch Biomed Engn & Sci, Roanoke, VA 24061 USA		Theus, MH (corresponding author), Virginia Tech, Dept Biomed Sci & Pathobiol, Coll Vet Med, 970 Washington St SW,MC0910, Blacksburg, VA 24061 USA.	mtheus@vt.edu		Guilhaume Correa, Fernanda/0000-0002-3878-5283	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS096281]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS096281] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (Grant R01NS096281 to M.H.T.). We thank the Regenerative Medicine-Interdisciplinary Graduate Education Program at Virginia Tech and Institute of Critical Technology and Applied Sciences Programs for student support T.R.B., A.H.), the Virginia-Maryland Regional College of Veterinary Medicine, and Dr. William Huckle for the generous gift of qRT-PCR primers.	Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Abdul-Muneer PM, 2016, CNS NEUROSCI THER, V22, P543, DOI 10.1111/cns.12579; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adlakha YK, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-33; Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; Assis-Nascimento P, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0016-5; Baumann G, 2013, EXP BIOL MED, V238, P830, DOI 10.1177/1535370213494558; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; BOADO RJ, 1994, MOL BRAIN RES, V22, P259, DOI 10.1016/0169-328X(94)90054-X; Bouet V, 2007, EXP NEUROL, V203, P555, DOI 10.1016/j.expneurol.2006.09.006; Brickler T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6373506; Brindle NPJ, 2006, CIRC RES, V98, P1014, DOI 10.1161/01.RES.0000218275.54089.12; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Chamorro-Jorganes A, 2013, PHARMACOL RES, V75, P15, DOI 10.1016/j.phrs.2013.04.002; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chittiboina Prashant, 2013, Pathophysiology, V20, P15, DOI 10.1016/j.pathophys.2012.02.004; Clark RE, 2000, J NEUROSCI, V20, P8853; Claus CP, 2010, DEV NEUROSCI-BASEL, V32, P454, DOI 10.1159/000316805; Curvello V, 2017, PEDIATR RES, V82, P108, DOI 10.1038/pr.2017.83; Dai RJ, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-19; Dai RJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014302; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Devraj K, 2011, J NEUROSCI RES, V89, P1913, DOI 10.1002/jnr.22738; Dixon KJ, 2015, J NEUROTRAUM, V32, P753, DOI 10.1089/neu.2014.3390; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Engelhardt B, 2014, CELL TISSUE RES, V355, P687, DOI 10.1007/s00441-014-1811-2; ESTRADA C, 1990, J NEUROPATH EXP NEUR, V49, P539, DOI 10.1097/00005072-199011000-00001; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Fiedler U, 2006, TRENDS IMMUNOL, V27, P552, DOI 10.1016/j.it.2006.10.004; FitzGerald A, 2010, BRAIN INJURY, V24, P1311, DOI 10.3109/02699052.2010.506864; Fukuhara S, 2009, EXP MOL MED, V41, P133, DOI 10.3858/emm.2009.41.3.016; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2019, J NEUROTRAUM, V36, P1291, DOI 10.1089/neu.2018.5728; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Goldstein G W, 1987, Mead Johnson Symp Perinat Dev Med, P15; Gu H, 2016, INT NEUROUROL J, V20, P288, DOI 10.5213/inj.1632692.346; Gurnik S, 2016, ACTA NEUROPATHOL, V131, P753, DOI 10.1007/s00401-016-1551-3; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hashimoto T, 2004, ENDOTHELIUM-J ENDOTH, V11, P207, DOI 10.1080/10623320490512417; Huang Y, 2012, P NATL ACAD SCI USA, V109, P17478, DOI 10.1073/pnas.1209281109; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu YL, 2017, ACTA PHARMACOL SIN, V38, P1445, DOI 10.1038/aps.2017.103; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Lu TP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042390; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Mi HY, 2001, J NEUROSCI, V21, P1538, DOI 10.1523/JNEUROSCI.21-05-01538.2001; Milam KE, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688362.2014.957508; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; Morales Sara, 2017, BioMolecular Concepts, V8, P203, DOI 10.1515/bmc-2017-0024; Moretti R, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00040; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Okyere B, 2018, J NEUROSCI METH, V293, P86, DOI 10.1016/j.jneumeth.2017.09.010; Okyere B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159930; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924, DOI 10.1152/ajpheart.2000.279.3.H924; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Price L., 2016, TRANSLATIONAL RES TR; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Reis C, 2015, INT J MOL SCI, V16, P11903, DOI 10.3390/ijms160611903; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Spoerri PE, 1997, DEV BRAIN RES, V104, P205, DOI 10.1016/S0165-3806(97)00173-9; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Theus MH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.165; Theus MH, 2010, STEM CELLS, V28, P1231, DOI 10.1002/stem.449; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; van der Horn HJ, 2018, BRAIN IMAGING BEHAV, V12, P912, DOI 10.1007/s11682-017-9743-6; Walchli T, 2015, NAT PROTOC, V10, P53, DOI 10.1038/nprot.2015.002; Wagner S, 2000, NEUROSCI LETT, V284, P105, DOI 10.1016/S0304-3940(00)00987-3; Wang JD, 2016, MOL PHARMACEUT, V13, P895, DOI 10.1021/acs.molpharmaceut.5b00805; Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37098; Zeller K, 1996, DEV BRAIN RES, V91, P200, DOI 10.1016/0165-3806(95)00177-8; Zhang J, 2014, BRAIN RES, V1583, P193, DOI 10.1016/j.brainres.2014.06.014; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	102	28	29	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	NOV 7	2018	38	45					9618	9634		10.1523/JNEUROSCI.0914-18.2018			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GZ4HM	WOS:000449355600002	30242049	Green Published, Bronze			2022-02-06	
J	Zeeshan, M; Jehan, F; O'Keeffe, T; Khan, M; Zakaria, E; Hamidi, M; Gries, L; Kulvatunyou, N; Joseph, B				Zeeshan, Muhammad; Jehan, Faisal; O'Keeffe, Terence; Khan, Muhammad; Zakaria, El Rasheid; Hamidi, Mohammad; Gries, Lynn; Kulvatunyou, Narong; Joseph, Bellal			The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	48th Annual Meeting of the Western-Trauma-Association (WTA)	FEB 15-MAR 03, 2018	Whistler, CANADA	Western Trauma Assoc		TBI; warfarin; novel oral anticoagulants; intracranial hemorrhage; NOACs	TRAUMATIC BRAIN-INJURY; LOWER MORTALITY; REVERSAL	INTRODUCTION Novel oral anticoagulant (NOAC) use is increasing in trauma patients. The reversal of these agents after hemorrhage is still evolving. The aim of our study was to evaluate outcomes after traumatic brain injury in patients on NOACs. METHODS 3-year (2014-2016) analysis of our prospectively maintained traumatic brain injury (TBI) database. We included all TBI patients with intracranial hemorrhage (ICH) on anticoagulants. Patients were stratified into two groups, those on NOACs and on warfarin, and were matched in a 1:2 ratio using propensity score matching for demographics, injury and vital parameters, type, and size of ICH. Outcome measures were progression of ICH, mortality, skilled nursing facility (SNF) disposition, and hospital and intensive care unit (ICU) length of stay (LOS). RESULTS We analyzed 1,459 TBI patients, of which 210 patients were matched (NAOCs, 70; warfarin, 140). Matched groups were similar in age (p = 0.21), mechanism of injury (p = 0.61), Glasgow Coma Scale (GCS) score (p = 0.54), Injury Severity Score (p = 0.62), and type and size of ICH (p = 0.09). Patients on preinjury NOACs had higher rate of progression (p = 0.03), neurosurgical intervention (p = 0.04), mortality (p = 0.04), and longer ICU LOS (p = 0.04) compared with patients on warfarin. However, there was no difference in hospital LOS (p = 0.22) and SNF disposition (p = 0.14). On sub-analysis of severe TBI patients (GCS 8), rate of progression (p = 0.59), neurosurgical intervention (p = 0.62), or mortality (p = 0.81) was similar in both groups. CONCLUSIONS The use of NOACs generally carries a high risk of bleeding and can be detrimental in head injuries with ICH. NOAC use is associated with increased risk of progression of ICH, neurosurgical intervention, and mortality after a mild and moderate TBI. Primary care physicians and cardiologists need to reconsider the data on the need for anticoagulation and the type of agent used and weigh it against the risk of bleeding. In addition, development of reversal agents for the NOACs and implementation of a strict protocol for the reversal of these agents may lead to improved outcomes. LEVEL OF EVIDENCE Therapeutic studies, level III.	[Zeeshan, Muhammad; Jehan, Faisal; O'Keeffe, Terence; Khan, Muhammad; Zakaria, El Rasheid; Hamidi, Mohammad; Gries, Lynn; Kulvatunyou, Narong; Joseph, Bellal] Univ Arizona, Coll Med, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ USA		Joseph, B (corresponding author), Univ Arizona, Div Trauma Crit Care & Emergency Surg, Dept Surg, 1501 N Campbell Ave,Room 5411, Tucson, AZ 85727 USA.	bjoseph@surgery.arizona.edu		Zeeshan, Muhammad/0000-0001-5597-8530			[Anonymous], FDA APPR NEW ANT DRU; [Anonymous], FDA BRIEF DOC KENGR; Awad AJ, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS1323; Batchelor JS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000588; Beynon C, 2015, CLIN NEUROL NEUROSUR, V136, P73, DOI 10.1016/j.clineuro.2015.05.035; Cotton BA, 2011, NEW ENGL J MED, V365, P2039, DOI 10.1056/NEJMc1111095; Dossett LA, 2011, ARCH SURG-CHICAGO, V146, P565, DOI 10.1001/archsurg.2010.313; Feeney JM, 2016, J TRAUMA ACUTE CARE, V81, P843, DOI 10.1097/TA.0000000000001245; Garber ST, 2012, J NEUROSURG, V116, P1093, DOI 10.3171/2012.2.JNS112132; Greinacher A, 2015, THROMB HAEMOSTASIS, V113, P931, DOI 10.1160/TH14-11-0982; Kim AK, 2011, RADIOLOGY SECRETS PL, P327; Kobayashi L, 2017, J TRAUMA ACUTE CARE, V82, P827, DOI 10.1097/TA.0000000000001414; Maung AA, 2016, J TRAUMA ACUTE CARE, V81, P652, DOI 10.1097/TA.0000000000001189; Pakraftar S, 2014, WORLD J CLIN CASES, V2, P362, DOI 10.12998/wjcc.v2.i8.362; Parra MW, 2013, J NEUROSURG, V119, P760, DOI 10.3171/2013.3.JNS12503; Pozzessere A, 2015, AM SURGEON, V81, P1039; Prevention CfDCa, 2016, INJ PREV CONTR TRAUM; Riccardi A, 2017, AM J EMERG MED; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Siegal DM, 2015, NEW ENGL J MED, V373, P2413, DOI 10.1056/NEJMoa1510991; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Smith AT, 2017, AM J EMERG MED, V35; Suzuki Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097328; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Wassef SN, 2013, NEUROSURGERY, V73, pE368, DOI 10.1227/01.neu.0000430763.95349.5f	25	28	28	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2018	85	5					915	920		10.1097/TA.0000000000001995			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	GZ0NG	WOS:000449060100013	29851905				2022-02-06	
J	Zuccato, BG; Tyson, BT; Erdodi, LA				Zuccato, Brandon G.; Tyson, Bradley T.; Erdodi, Laszlo A.			Early Bird Fails the PVT? The Effects of Timing Artifacts on Performance Validity Tests	PSYCHOLOGICAL ASSESSMENT			English	Article						Recognition Memory Test; Word Choice Test; performance validity assessment; order effect	TRAUMATIC BRAIN-INJURY; RECOGNITION MEMORY TEST; COMPLEX FIGURE TEST; CARD SORTING TEST; WORD CHOICE TEST; DIGIT SPAN; CLASSIFICATION ACCURACY; RESPONSE BIAS; SUSPECT EFFORT; NEUROPSYCHOLOGICAL ASSESSMENT	This study was designed to investigate the effects of timing on the likelihood of failing the Recognition Memory Test-Words (RMT) and Word Choice Test (WCT). The RMT and WCT were administered in counterbalanced order either at the beginning (Time 1) or at the end (Time 2) of a test battery to a mixed clinical sample of 196 patients (M-age = 44.5 years. 55.1% female) medically referred for neuropsychological evaluation. The risk of failing the accuracy score was higher at Time 1 on both the RMT (relative risk [RR]: 1.44-1.64) and the WCT (RR: 1.21-1.50) across a range of cutoffs. Likewise, the risk of failing the time-to-completion score was higher at Time 1 on both the RMT (RR: 1.30-1.94) and the WCT (RR: 1.58-3.75). Established cutoffs failed to reach specificity standards at Time 1; more liberal cutoffs cleared specificity thresholds at Time 2. According to our findings, the RMT and WCT may be prone to false-positive errors at Time 1. Conversely, when administered at Time 2, existing cutoffs may have lower sensitivity, but they are highly specific to invalid performance. Timing should be considered during both test selection and the interpretation of RMT and WCT scores. Using conservative cutoffs for morning administrations and liberal cutoffs for afternoon administrations may be necessary to neutralize timing artifacts.	[Zuccato, Brandon G.] Univ Windsor, Dept Psychol, Neuropsychol Track, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Tyson, Bradley T.; Erdodi, Laszlo A.] Dartmouth Coll, Dept Psychiat, Hanover, NH 03755 USA		Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, Neuropsychol Track, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Barrash J, 2004, J CLIN EXP NEUROPSYC, V26, P125, DOI 10.1076/jcen.26.1.125.23928; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Erdodi L. A., 2017, ARCH CLIN NEUROPSYCH, DOI [10. 1093/arclin/acx110, DOI 10.1093/ARCLIN/ACX110]; Erdodi LA, 2019, APPL NEUROPSYCH-ADUL, V26, P155, DOI 10.1080/23279095.2017.1384925; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P327, DOI 10.1080/23279095.2017.1298600; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P1, DOI 10.1007/s12207-017-9309-3; Erdodi LA, 2017, BRAIN INJURY, V31, P1362, DOI 10.1080/02699052.2017.1332386; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; HERMANN BP, 1995, J EPILEPSY, V8, P139, DOI 10.1016/0896-6974(95)00022-6; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lloyd KP, 2012, APPL NEUROPSYCH-ADUL, V19, P299, DOI 10.1080/09084282.2012.670153; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Ryan JJ, 2010, APPL NEUROPSYCHOL, V17, P246, DOI 10.1080/09084282.2010.499802; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2009, ADV CLIN SOLUTIONS W; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	54	28	28	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	NOV	2018	30	11					1491	1498		10.1037/pas0000596			8	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	GY8QB	WOS:000448896400008	29952597				2022-02-06	
J	Jang, C; Yadav, DK; Subedi, L; Venkatesan, R; Venkanna, A; Afzal, S; Lee, E; Yoo, J; Ji, E; Kim, SY; Kim, MH				Jang, Cheongyun; Yadav, Dharmendra K.; Subedi, Lalita; Venkatesan, Ramu; Venkanna, Arramshetti; Afzal, Sualiha; Lee, Eunhee; Yoo, Jaewook; Ji, Eunhee; Kim, Sun Yeou; Kim, Mi-hyun			Identification of novel acetylcholinesterase inhibitors designed by pharmacophore-based virtual screening, molecular docking and bioassay	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN INJURY; AMYLOID-BETA-PEPTIDES; IN-VITRO EVALUATION; ALZHEIMERS-DISEASE; ACID-DERIVATIVES; HUMAN BUTYRYLCHOLINESTERASE; IMMUNOMODULATORY ACTIVITY; ANTICANCER ACTIVITY; PERIPHERAL SITE; GAMMA-SECRETASE	In this study, pharmacophore based 3D QSAR models for human acetylcholinesterase (AChE) inhibitors were generated, with good significance, statistical values (r(training)(2) = 0.73) and predictability (q(training)(2) = 0.67). It was further validated by three methods (Fischer's test, decoy set and Guner-Henry scoring method) to show that the models can be used to predict the biological activities of compounds without costly and time-consuming synthesis. The criteria for virtual screening were also validated by testing the selective AChE inhibitors. Virtual screening experiments and subsequent in vitro evaluation of promising hits revealed a novel and selective AChE inhibitor. Thus, the findings reported herein may provide a new strategy for the discovery of selective AChE inhibitors. The IC50 value of compounds 5c and 6a presented selective inhibition of AChE without inhibiting butyrylcholinesterase (BChE) at uM level. Molecular docking studies were performed to explain the potent AChE inhibition of the target compounds studies to explain high affinity.	[Kim, Mi-hyun] Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, Incheon, South Korea; Gachon Univ, Coll Pharm, Dept Pharm, Incheon, South Korea		Kim, MH (corresponding author), Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, Incheon, South Korea.	kmh0515@gachon.ac.kr	Kim, Mi-hyun/L-7805-2014; Yadav, Dharmendra Kumar/L-1846-2015; Subedi, Lalita/I-5943-2019	Kim, Mi-hyun/0000-0002-2718-5637; Yadav, Dharmendra Kumar/0000-0003-1102-1993; Subedi, Lalita/0000-0003-4851-7650	Basic Science Research Program of the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2017R1E1A1A01076642, 2017R1C1B2003380]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry for Health and Welfare, Korea [HI14C1135]	This study was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science and Technology (No.: 2017R1E1A1A01076642 and 2017R1C1B2003380). In addition, a grant was also provided by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry for Health and Welfare, Korea (HI14C1135).	Agrawal RA, 2011, INT J DRUG DES DIS, V2, P511, DOI DOI 10.1016/J.FEBSLET.2005.06.031; Ahmed M, 2006, CHEM-BIOL INTERACT, V162, P165, DOI 10.1016/j.cbi.2006.06.002; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; ARIENS EJ, 1967, ANN NY ACAD SCI, V139, P606, DOI 10.1111/j.1749-6632.1967.tb41232.x; Babic T, 1999, J NEUROL NEUROSUR PS, V67, P558, DOI 10.1136/jnnp.67.4.558; BRISMAR K, 1987, ACTA MED SCAND, V221, P155; Cereto-Massague A, 2012, BIOINFORMATICS, V28, P1661, DOI 10.1093/bioinformatics/bts249; Cheung J, 2013, ACS MED CHEM LETT, V4, P1091, DOI 10.1021/ml400304w; Cheung J, 2012, J MED CHEM, V55, P10282, DOI 10.1021/jm300871x; Dinamarca MC, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-4; Dixon SL, 2006, J COMPUT AID MOL DES, V20, P647, DOI 10.1007/s10822-006-9087-6; DRAYER DE, 1987, PHARMACOTHERAPY, V7, P87; Dziedzic T, 2007, J NEUROL SCI, V252, P53, DOI 10.1016/j.jns.2006.10.007; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Gadhe CG, 2015, ARCH PHARM RES, V38, P2008, DOI 10.1007/s12272-015-0607-6; Gadhe CG, 2015, MOL BIOSYST, V11, P618, DOI 10.1039/c4mb00568f; Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777; Gaur R, 2015, CURR TOP MED CHEM, V15, P1003, DOI 10.2174/1568026615666150317222059; Golbraikh A, 2002, J COMPUT AID MOL DES, V16, P357, DOI 10.1023/A:1020869118689; Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1; Hamblin JN, 2008, BIOORG MED CHEM LETT, V18, P4237, DOI 10.1016/j.bmcl.2008.05.052; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830; Huang YJ, 2007, P NATL ACAD SCI USA, V104, P13603, DOI 10.1073/pnas.0702756104; Igbavboa U, 2006, NEUROSCIENCE, V142, P655, DOI 10.1016/j.neuroscience.2006.06.056; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; Fernandez-Bachiller MI, 2010, J MED CHEM, V53, P4927, DOI 10.1021/jm100329q; Kihara T, 2004, ACTA NEUROBIOL EXP, V64, P99; Kim MH, 2015, CHEM-ASIAN J, V10, P1318, DOI 10.1002/asia.201403417; Kim MH, 2013, BIOORGAN MED CHEM, V21, P2271, DOI 10.1016/j.bmc.2013.02.021; Kim MH, 2013, BIOORG MED CHEM LETT, V23, P1639, DOI 10.1016/j.bmcl.2013.01.082; Kim MH, 2011, BIOORGAN MED CHEM, V19, P1915, DOI 10.1016/j.bmc.2011.01.067; Kirchmair J, 2008, J COMPUT AID MOL DES, V22, P213, DOI 10.1007/s10822-007-9163-6; Kryger G, 2000, ACTA CRYSTALLOGR D, V56, P1385, DOI 10.1107/S0907444900010659; Laowattana S, 2007, NEUROLOGY, V68, P509, DOI 10.1212/01.wnl.0000253186.23949.fd; Martinez A, 2006, EXPERT OPIN INV DRUG, V15, P1, DOI 10.1517/13543784.15.1.1; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Mautes AEM, 2001, ACTA NEUROCHIR, V143, P51, DOI 10.1007/s007010170138; MCAINSH J, 1990, PHARMACOL THERAPEUT, V46, P163, DOI 10.1016/0163-7258(90)90092-G; MCGAHAN DJ, 1984, DRUG INTEL CLIN PHAR, V18, P601, DOI 10.1177/106002808401800709; MIDDLEMISS DN, 1977, NATURE, V267, P289, DOI 10.1038/267289a0; Minati L, 2009, AM J ALZHEIMERS DIS, V24, P95, DOI 10.1177/1533317508328602; Nachon F, 2013, BIOCHEM J, V453, P393, DOI 10.1042/BJ20130013; Nepovimova E, 2014, J MED CHEM, V57, P8576, DOI 10.1021/jm5010804; Ni YX, 2006, NAT MED, V12, P1390, DOI 10.1038/nm1485; Ochiai K, 2012, BIOORG MED CHEM LETT, V22, P5833, DOI 10.1016/j.bmcl.2012.07.088; Orhan I, 2004, J ETHNOPHARMACOL, V91, P57, DOI 10.1016/j.jep.2003.11.016; Ota T, 2010, CLIN NEUROPHARMACOL, V33, P74, DOI 10.1097/WNF.0b013e3181c71be9; PAYKEL ES, 1982, J CLIN PSYCHOPHARM, V2, P14, DOI 10.1097/00004714-198202000-00004; Prati F, 2013, BIOORG MED CHEM LETT, V23, P6254, DOI 10.1016/j.bmcl.2013.09.091; Rafii MS, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0297-4; Roberts BC, 2008, J CHEM INF MODEL, V48, P397, DOI 10.1021/ci700285e; RUFFOLO RR, 1995, J MED CHEM, V38, P3681, DOI 10.1021/jm00019a001; Savitz SI, 2000, J CEREBR BLOOD F MET, V20, P1197, DOI 10.1097/00004647-200008000-00005; Saxena A, 1997, BIOCHEMISTRY-US, V36, P14642, DOI 10.1021/bi971425+; SCHLEIFER SJ, 1991, AM HEART J, V121, P1397, DOI 10.1016/0002-8703(91)90144-7; Schrodinger L., 2013, SMALL MOL DRUG DISCO; Sheridan RP, 2001, J CHEM INF COMP SCI, V41, P1395, DOI 10.1021/ci0100144; Shivakumar D, 2010, J CHEM THEORY COMPUT, V6, P1509, DOI 10.1021/ct900587b; STEINER TJ, 1988, HEADACHE, V28, P15, DOI 10.1111/j.1365-2524.1988.hed2801015.x; Sugimoto H, 2002, JPN J PHARMACOL, V89, P7, DOI 10.1254/jjp.89.7; Tripos S., 2007, MOL MODELING QSAR SO; Tumiatti V, 2010, CURR MED CHEM, V17, P1825, DOI 10.2174/092986710791111206; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Yadav DK, 2013, CURR COMPUT-AID DRUG, V9, P360, DOI 10.2174/1573409911309030012; Yadav DK, 2013, J CHEMOMETR, V27, P21, DOI 10.1002/cem.2488; Yadav DK, 2010, DRUG DES DEV THER, V4, P173; Yadav DK, 2014, CURR DRUG TARGETS, V15, P753, DOI 10.2174/1389450115666140630102711; Yadav DK, 2014, J CHEMOMETR, V28, P499, DOI 10.1002/cem.2606; Yadav DK, 2014, CURR MED CHEM, V21, P1160, DOI 10.2174/09298673113206660330; Yadav DK, 2013, MED CHEM, V9, P1073; Yadav DK, 2012, J MOL MODEL, V18, P2513, DOI 10.1007/s00894-011-1265-3; Yu NN, 2010, BRAIN RES, V1317, P305, DOI 10.1016/j.brainres.2009.12.087	79	28	29	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 8	2018	8								14921	10.1038/s41598-018-33354-6			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW0RP	WOS:000446577100023	30297729	gold, Green Published			2022-02-06	
J	Stephenson, EL; Yong, VW				Stephenson, Erin L.; Yong, V. Wee			Pro-inflammatory roles of chondroitin sulfate proteoglycans in disorders of the central nervous system	MATRIX BIOLOGY			English	Article						Extracellular matrix; Inflammation; Metalloproteinases; Multiple sclerosis; Spinal cord injury	SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NF-KAPPA-B; EXTRACELLULAR-MATRIX; MULTIPLE-SCLEROSIS; PERINEURONAL NETS; CELL-ACTIVATION; P-SELECTIN; PTP-SIGMA; HEPARAN-SULFATE	The extracellular matrix of the central nervous system is an interconnected network of proteins and sugars. It is crucial for homeostasis, but its remodeling in neurological diseases impacts both injury and repair. Here we introduce an extracellular matrix family member that participates in immune-matrix interactions, the chondroitin sulfate proteoglycans. Chondroitin sulfate proteoglycans integrate signals from the microenvironment to activate immune cells, and they boost inflammatory responses by binding immunological receptors including toll-like receptors, selectins, CD44, and beta 1 integrin. Chondroitin sulfate proteoglycans also bind signaling molecules for immune cells such as cytokines and chemokines, and they activate matrix-degrading enzymes. Chondroitin sulfate proteoglycans accumulate in the damaged CNS, including during traumatic brain/spinal cord injury and multiple sclerosis, and they help drive pathogenesis. This Review aims to give new insights into the remodeling of chondroitin sulfate proteoglycans during inflammation, and how these matrix glycoproteins are able to drive neuroinflammation. (C) 2018 Elsevier B.V. All rights reserved.	Hotchkiss Brain Inst, Calgary, AB, Canada; [Yong, V. Wee] Univ Calgary, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canada		Yong, VW (corresponding author), Univ Calgary, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canada.	vyong@ucalgary.ca		Yong, V. Wee/0000-0002-2600-3563	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [363459]; Multiple Sclerosis Society of Canada [2697]; Alberta Innovates Health Solutions, CRIO Team program [201300669]; CIHR Vanier program; Alberta Innovates Health Solutions; Canada Research Chair programCanada Research Chairs	The authors' research has been supported by operating grants from the Canadian Institutes of Health Research (CIHR) (363459), the Multiple Sclerosis Society of Canada (2697), and the Alberta Innovates Health Solutions (201300669) CRIO Team program. ES acknowledges studentship support from the CIHR Vanier program and Alberta Innovates Health Solutions. VWY has salary support from the Canada Research Chair (Tier 1) program.	Adair-Kirk TL, 2008, INT J BIOCHEM CELL B, V40, P1101, DOI 10.1016/j.biocel.2007.12.005; Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Akiyama H, 2004, BIOCHEM J, V382, P269, DOI 10.1042/BJ20031851; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bartus K, 2014, J NEUROSCI, V34, P4822, DOI 10.1523/JNEUROSCI.4369-13.2014; Beggah AT, 2005, NEUROSCIENCE, V133, P749, DOI 10.1016/j.neuroscience.2005.03.005; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Burnside ER, 2014, NEUROPATH APPL NEURO, V40, P26, DOI 10.1111/nan.12114; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Carulli D, 2006, J COMP NEUROL, V494, P559, DOI 10.1002/cne.20822; Chang AS, 2012, ANN NEUROL, V72, P918, DOI 10.1002/ana.23693; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Dickendesher TL, 2012, NAT NEUROSCI, V15, P703, DOI 10.1038/nn.3070; Didangelos A, 2014, J NEUROSCI, V34, P16424, DOI 10.1523/JNEUROSCI.2927-14.2014; Dyck S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1128-2; Dyck SM, 2015, EXP NEUROL, V269, P169, DOI 10.1016/j.expneurol.2015.04.006; Ebert S, 2008, J LEUKOCYTE BIOL, V84, P736, DOI 10.1189/jlb.0208138; Ellyard JI, 2007, J BIOL CHEM, V282, P15238, DOI 10.1074/jbc.M608046200; Engelhardt B, 2005, TRENDS IMMUNOL, V26, P485, DOI 10.1016/j.it.2005.07.004; Feliu A, 2017, J NEUROSCI, V37, P8385, DOI 10.1523/JNEUROSCI.2900-16.2017; Fisher D, 2011, J NEUROSCI, V31, P14051, DOI 10.1523/JNEUROSCI.1737-11.2011; Frevert CW, 2003, AM J RESP CELL MOL, V28, P464, DOI 10.1165/rcmb.2002-0084OC; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; Fry EJ, 2010, GLIA, V58, P423, DOI 10.1002/glia.20934; Furst CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061407; Galtrey CM, 2008, EUR J NEUROSCI, V27, P1373, DOI 10.1111/j.1460-9568.2008.06108.x; Gamier P., 2003, IMMUNOL LETT, V85, P53; Garcia-Alias G, 2012, EXP NEUROL, V235, P26, DOI 10.1016/j.expneurol.2011.09.009; Gerwien H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8020; Gill S, 2010, ANAT REC, V293, P968, DOI 10.1002/ar.21094; Gogolla N, 2009, SCIENCE, V325, P1258, DOI 10.1126/science.1174146; Grimpe B, 2004, J NEUROSCI, V24, P1393, DOI 10.1523/JNEUROSCI.4986-03.2004; Heindryckx F., 2018, MATRIX BIOL; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Hurt-Camejo E, 1999, J BIOL CHEM, V274, P18957, DOI 10.1074/jbc.274.27.18957; Iida J, 2007, BIOCHEM J, V403, P553, DOI 10.1042/BJ20061176; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; Ishikawa H, 1999, SPINE, V24, P1071, DOI 10.1097/00007632-199906010-00005; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kang I, 2017, J BIOL CHEM, V292, P51, DOI 10.1074/jbc.M116.753186; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Keough MB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11312; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Korin B, 2017, NAT NEUROSCI, V20, P1300, DOI 10.1038/nn.4610; Kuipers HF, 2016, P NATL ACAD SCI USA, V113, P1339, DOI 10.1073/pnas.1525086113; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lang BT, 2015, NATURE, V518, P404, DOI 10.1038/nature13974; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Lau LW, 2012, ANN NEUROL, V72, P419, DOI 10.1002/ana.23599; Malla N, 2013, FEBS J, V280, P2870, DOI 10.1111/febs.12291; Miller RT, 2017, MATRIX BIOL, V57-58, P366, DOI 10.1016/j.matbio.2016.07.001; Miyamoto K, 2014, GLYCOBIOLOGY, V24, P469, DOI 10.1093/glycob/cwu014; Mohan H, 2010, BRAIN PATHOL, V20, P966, DOI 10.1111/j.1750-3639.2010.00399.x; Morawski M, 2004, EXP NEUROL, V188, P309, DOI 10.1016/j.expneurol.2004.04.017; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Petersen F, 1998, J IMMUNOL, V161, P4347; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Potter-Perigo S, 2010, AM J RESP CELL MOL, V43, P109, DOI 10.1165/rcmb.2009-0081OC; Pozzi A, 2017, MATRIX BIOL, V57-58, P1, DOI 10.1016/j.matbio.2016.12.009; Ra HJ, 2009, J BIOL CHEM, V284, P27924, DOI 10.1074/jbc.M109.035147; Rachmilewitz J, 1998, BLOOD, V92, P223, DOI 10.1182/blood.V92.1.223.413k15_223_229; Rauch U, 2007, BIOCHEM SOC T, V35, P656, DOI 10.1042/BST0350656; Ringer P, 2017, MATRIX BIOL, V64, P6, DOI 10.1016/j.matbio.2017.03.004; Rolls A, 2006, FASEB J, V20, P547, DOI 10.1096/fj.05-4540fje; Rolls A, 2008, PLOS MED, V5, P1262, DOI 10.1371/journal.pmed.0050171; ROSAMOND S, 1987, J IMMUNOL, V139, P1946; Saigoh K, 2016, NEUROSCI RES, V108, P55, DOI 10.1016/j.neures.2016.01.002; Sajad M, 2011, J MOL NEUROSCI, V43, P531, DOI 10.1007/s12031-010-9476-0; Sashinami H, 2012, LIFE SCI, V91, P1263, DOI 10.1016/j.lfs.2012.09.022; Satoh JI, 2005, J NEUROPATH EXP NEUR, V64, P129, DOI 10.1093/jnen/64.2.129; Schuksz M, 2008, P NATL ACAD SCI USA, V105, P13075, DOI 10.1073/pnas.0805862105; Shen YJ, 2009, SCIENCE, V326, P592, DOI 10.1126/science.1178310; Shijo T, 2018, J NEUROSCI RES, V96, P222, DOI 10.1002/jnr.24127; Singh V., 2015, NEUROINFLAMMATION, V2; Sobel RA, 2001, J NEUROPATH EXP NEUR, V60, P1198, DOI 10.1093/jnen/60.12.1198; Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852; Stephenson EL, 2018, BRAIN, V141, DOI 10.1093/brain/awy033; Tan GK, 2014, ACTA BIOMATER, V10, P2684, DOI 10.1016/j.actbio.2014.02.025; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Troeberg L, 2014, CHEM BIOL, V21, P1300, DOI 10.1016/j.chembiol.2014.07.014; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Wang JY, 2002, P NATL ACAD SCI USA, V99, P14362, DOI 10.1073/pnas.222536599; Warford J, 2014, BIOCHEM BIOPH RES CO, V443, P524, DOI 10.1016/j.bbrc.2013.11.119; Warford JR, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-017-0506-9; Wight TN, 2017, MATRIX BIOL, V60-61, P38, DOI 10.1016/j.matbio.2016.12.001; Winberg JO, 2003, EUR J BIOCHEM, V270, P3996, DOI 10.1046/j.1432-1033.2003.03788.x; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; Yang R, 2002, SCAND J IMMUNOL, V55, P2, DOI 10.1046/j.0300-9475.2001.01033.x; Yong V. W., 2001, METALLOPROTEINASES B; Zhang WX, 2015, CARBOHYD POLYM, V123, P331, DOI 10.1016/j.carbpol.2015.01.059; Zheng PS, 2004, J CELL SCI, V117, P5887, DOI 10.1242/jcs.01516; Zhou JH, 2010, J NEUROIMMUNOL, V223, P55, DOI 10.1016/j.jneuroim.2010.04.002; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	97	28	29	5	38	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0945-053X	1569-1802		MATRIX BIOL	Matrix Biol.	OCT	2018	71-72				SI		432	442		10.1016/j.matbio.2018.04.010			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GW6ZH	WOS:000447113100030	29702175				2022-02-06	
J	Mallah, K; Quanico, J; Trede, D; Kobeissy, F; Zibara, K; Salzet, M; Fournier, I				Mallah, Khalil; Quanico, Jusal; Trede, Dennis; Kobeissy, Firas; Zibara, Kazem; Salzet, Michel; Fournier, Isabelle			Lipid Changes Associated with Traumatic Brain Injury Revealed by 3D MALDI-MSI	ANALYTICAL CHEMISTRY			English	Article							SPHINGOSINE; TISSUES; CANCER; SERUM	Traumatic brain injury (TBI) is a major cause of death and disability in children and young adults worldwide according to the World Health Organization (WHO). The emergence of mass-spectrometry-based techniques, such as MALDI-MSI, has allowed the monitoring and visualization of changes post injury, providing a global picture of the impact of TBI on different classes of molecules in a single study. In this work, we show the ability to track lipid changes post-TBI by three-dimensional matrix-assisted laser desorption/ionization-mass-spectrometry imaging (MALDI-MSI). Controlled cortical impact (CCI) was induced on adult male rats resulting in direct mechanical injury to the cortical tissue on the right ipsilateral hemisphere of the brain. Images of lipid distribution in coronally sectioned injured brains were acquired using a high-resolution mass spectrometer (MALDI-LTQ-Orbitrap-XL). Results reveal unique lipid signatures for the injured cortical tissue, which further segregate into two subgroups of injury (lesion interior and lesion exterior). Although both subgroups show different profiles from that of the noninjured cortical tissue, the lesion interior is more similar to the ventricular system than the lesion exterior. For example, m/z 725.56 showed expression in both injured tissue and the ventricular system, whereas m/z 856.59 (phosphatidylcholine 42:9) is uniquely expressed in injured tissue. On the other hand, m/z 797.59 (also a phosphatidylcholine) showed unique expression to the ventricular system and not to the injured cortical tissue. Our results can help in further monitoring and identifying lesion-specific lipids in a 3D manner to obtain a better understanding and visualization of molecular and cellular events occurring post-TBI.	[Mallah, Khalil; Quanico, Jusal; Salzet, Michel; Fournier, Isabelle] Univ Lille, Lab Prote Reponse Inflammatoire & Spectrometrie M, INSERM, U1192, F-59000 Lille, France; [Mallah, Khalil; Zibara, Kazem] Lebanese Univ, Fac Sci 1, Dept Biol, Lab Stem Cells,PRASE,ER045, Beirut 657314, Lebanon; [Trede, Dennis] SCiLS, D-28359 Bremen, Germany; [Kobeissy, Firas] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut 11072020, Lebanon		Salzet, M; Fournier, I (corresponding author), Univ Lille, Lab Prote Reponse Inflammatoire & Spectrometrie M, INSERM, U1192, F-59000 Lille, France.	michel.salzet@univ-lille.fr; isabelle.fournier@univ-lille.fr	Quanico, Jusal/AAE-3366-2020; Salzet, Michel/A-7675-2011; FOURNIER, Isabelle/H-9195-2015; Kobeissy, Firas/E-7042-2017	Salzet, Michel/0000-0003-4318-0817; FOURNIER, Isabelle/0000-0003-1096-5044; Kobeissy, Firas/0000-0002-5008-6944; Zibara, Kazem/0000-0002-9887-072X; Mallah, Khalil/0000-0001-7622-8106	Ministere de l'Enseignement Superieur, de la Recherche et de l'Innovation (MESRI); Institut National de la Sante et de la Recherche Medicale (Inserm)Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille; Association of Scientific Orientation and Specialization (ASOS)	This research was supported by grants from Ministere de l'Enseignement Superieur, de la Recherche et de l'Innovation (MESRI), Institut National de la Sante et de la Recherche Medicale (Inserm), and Universite de Lille. K.M. received a scholarship from the Association of Scientific Orientation and Specialization (ASOS).	Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Adibhatla RM, 2006, AAPS J, V8, pE314; Aichler M, 2015, LAB INVEST, V95, P422, DOI 10.1038/labinvest.2014.156; Alexandrov T, 2011, BIOINFORMATICS, V27, pI230, DOI 10.1093/bioinformatics/btr246; Barbacci DC, 2017, ACS CHEM NEUROSCI, V8, P2266, DOI 10.1021/acschemneuro.7b00189; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berry KAZ, 2011, CHEM REV, V111, P6491, DOI 10.1021/cr200280p; Blanc L, 2018, ANAL CHEM, V90, P6275, DOI 10.1021/acs.analchem.8b00985; Crecelius AC, 2005, J AM SOC MASS SPECTR, V16, P1093, DOI 10.1016/j.jasms.2005.02.026; Franck J, 2013, ANAL CHEM, V85, P8127, DOI 10.1021/ac4009397; Guo S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05446-2; Harrison JL, 2016, NEURAL REGEN RES, V11, P77, DOI 10.4103/1673-5374.175046; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Kidwell CS, 2004, JAMA-J AM MED ASSOC, V292, P1823, DOI 10.1001/jama.292.15.1823; Le Rhun E, 2017, BBA-PROTEINS PROTEOM, V1865, P875, DOI 10.1016/j.bbapap.2016.11.012; Li M, 2016, OPEN ACCESS, V1, P1; Lotz JM, 2017, BBA-PROTEINS PROTEOM, V1865, P946, DOI 10.1016/j.bbapap.2016.08.018; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McDonnell LA, 2008, J PROTEOME RES, V7, P3619, DOI 10.1021/pr800214d; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Meriaux C, 2014, HIPPOCAMPUS, V24, P628, DOI 10.1002/hipo.22246; Moreno-Gordaliza E, 2017, TALANTA, V164, P16, DOI 10.1016/j.talanta.2016.11.026; Novgorodov SA, 2014, J BIOL CHEM, V289, P13142, DOI 10.1074/jbc.M113.530311; Opara J A, 2014, J Med Life, V7, P124; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Quanico J, 2017, METHODS MOL BIOL, V1598, P21, DOI 10.1007/978-1-4939-6952-4_2; Rauser S, 2010, J PROTEOME RES, V9, P1854, DOI 10.1021/pr901008d; Roux A, 2016, J NEUROSCI METH, V272, P19, DOI 10.1016/j.jneumeth.2016.02.004; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sheth SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129735; Stratchko L, 2016, SEMIN ULTRASOUND CT, V37, P72, DOI 10.1053/j.sult.2016.01.004; Thiele H, 2014, BBA-PROTEINS PROTEOM, V1844, P117, DOI 10.1016/j.bbapap.2013.01.040; Wang X, 2015, GLIA, V63, P635, DOI 10.1002/glia.22774; Weder N, 2014, J AM ACAD CHILD PSY, V53, P417, DOI 10.1016/j.jaac.2013.12.025; Woodcock J, 2006, IUBMB LIFE, V58, P462, DOI 10.1080/15216540600871118	38	28	28	3	29	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	SEP 4	2018	90	17					10568	10576		10.1021/acs.analchem.8b02682			9	Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry	GS9RC	WOS:000444060600065	30070841				2022-02-06	
J	DiStefano, LJ; Dann, CL; Chang, CJ; Putukian, M; Pierpoint, LA; Currie, DW; Knowles, SB; Wasserman, EB; Dompier, TP; Comstock, RD; Marshall, SW; Kerr, ZY				DiStefano, Lindsay J.; Dann, Catie L.; Chang, Cindy J.; Putukian, Margot; Pierpoint, Lauren A.; Currie, Dustin W.; Knowles, Sarah B.; Wasserman, Erin B.; Dompier, Thomas P.; Comstock, R. Dawn; Marshall, Stephen W.; Kerr, Zachary Y.			The First Decade of Web-Based Sports Injury Surveillance: Descriptive Epidemiology of Injuries in US High School Girls' Soccer (2005-2006 Through 2013-2014) and National Collegiate Athletic Association Women's Soccer (2004-2005 Through 2013-2014)	JOURNAL OF ATHLETIC TRAINING			English	Article						female athletes; lower extremity injuries; concussions	CRUCIATE LIGAMENT INJURY; RANDOMIZED-CONTROLLED-TRIAL; FEMALE SOCCER; PREVENTION PROGRAMS; TRAINING-PROGRAM; RISK REDUCTION; WARM-UP; PLAYERS; RECONSTRUCTION; METAANALYSIS	Context: The advent of Web-based sports injury surveillance via programs such as the High School Reporting Information Online system and the National Collegiate Athletic Association Injury Surveillance Program has aided the acquisition of girls' and women's soccer injury data. Objective: To describe the epidemiology of injuries sustained in high school girls' soccer in the 2005-2006 through 2013-2014 academic years and collegiate women's soccer in the 2004-2005 through 2013-2014 academic years using Web-based sports injury surveillance. Design: Descriptive epidemiology study. Setting: Online injury surveillance from soccer teams in high school girls (annual average = 100) and collegiate women (annual average = 52). Patients or Other Participants: Female high school and collegiate soccer players who participated in practices or competitions during the 2004-2005 through 2013-2014 academic years. Main Outcome Measure(s): Athletic trainers collected timeloss (>= 24 hours) injury and exposure data. Injury rates per 1000 athlete-exposures (AEs), injury rate ratios (IRRs) with 95% confidence intervals (CIs), injury proportions by body site, and diagnoses were calculated. Results: The High School Reporting Information Online system documented 3242 time-loss injuries during 1 393 753 AEs; the National Collegiate Athletic Association Injury Surveillance Program documented 5092 time-loss injuries during 772 048 AEs. Injury rates were higher in college than in high school (6.60 versus 2.33/1000 AEs; IRR = 2.84; 95% CI = 2.71, 2.96), and during competitions than during practices in high school (IRR = 4.88; 95% CI = 4.54, 5.26) and college (IRR = 2.93; 95% CI = 2.77, 3.10). Most injuries at both levels affected the lower extremity and were ligament sprains or muscle/tendon strains. Concussions accounted for 24.5% of competition injuries in high school but 14.6% of competition injuries in college. More than one-third of competition injuries to high school goalkeepers were concussions. Conclusions: Injury rates were higher in college versus high school and during competitions versus practices. These differences may be attributable to differences in reporting, activity intensity, and game-play skill level. The high incidence of lower extremity injuries and concussions in girls' and women's soccer, particularly concussions in high school goalkeepers, merits further exploration and identification of prevention strategies.	[DiStefano, Lindsay J.] Univ Connecticut, Dept Kinesiol, Storrs, CT USA; [Dann, Catie L.] Univ Connecticut, Athlet Dept, Storrs, CT USA; [Chang, Cindy J.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA; [Chang, Cindy J.] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Pierpoint, Lauren A.; Currie, Dustin W.; Comstock, R. Dawn] Univ Colorado Anschutz, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA; [Knowles, Sarah B.] Palo Alto Med Fdn Res Inst, Palo Alto, CA USA; [Wasserman, Erin B.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA; [Dompier, Thomas P.] Lebanon Valley Coll, Dept Athlet Training, Annville, PA USA; [Comstock, R. Dawn] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Marshall, Stephen W.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.; Kerr, Zachary Y.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.] Univ North Carolina Chapel Hill, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA		Kerr, ZY (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu		Wasserman, Erin/0000-0001-5957-5878	NCAA; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2 RR025754]; National Federation of State High School Associations (Indianapolis, IN); National Operating Committee on Standards for Athletic Equipment (Overland Park, KS); DonJoy Orthotics (Vista, CA); EyeBlack (Potomac, MD); NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172, R49CE000674] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR025754] Funding Source: NIH RePORTER	The NCAA-ISP data were provided by the Datalys Center for Sports Injury Research and Prevention. The ISP was funded by the NCAA. Funding for HS RIO was funded in part by the Centers for Disease Control and Prevention grants R49/CE000674-01 and R49/CE001172-01 and the National Center for Research Resources award KL2 RR025754. We also acknowledge the research funding contributions of the National Federation of State High School Associations (Indianapolis, IN), National Operating Committee on Standards for Athletic Equipment (Overland Park, KS), DonJoy Orthotics (Vista, CA), and EyeBlack (Potomac, MD). The content of this report is solely our responsibility and does not necessarily represent the official views of the funding organizations. We thank the many ATs who have volunteered their time and efforts to submit data to HS RIO and the NCAA-ISP. Their efforts are greatly appreciated and have had a tremendously positive effect on the safety of high school and collegiate student-athletes.	Al Attar WSA, 2017, SPORTS MED, V47, P907, DOI 10.1007/s40279-016-0638-2; [Anonymous], 2014 15 NCAA SPORTS; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Dick R, 2007, J ATHL TRAINING, V42, P278; Faude O, 2006, BRIT J SPORT MED, V40, P785, DOI 10.1136/bjsm.2006.027540; Gilchrist J, 2008, AM J SPORT MED, V36, P1476, DOI 10.1177/0363546508318188; Goode AP, 2015, BRIT J SPORT MED, V49, P349, DOI 10.1136/bjsports-2014-093466; Grooms DR, 2013, J ATHL TRAINING, V48, P782, DOI 10.4085/1062-6050-48.4.08; Herzog MM, 2017, JAMA PEDIATR, V171, P808, DOI 10.1001/jamapediatrics.2017.0740; Hickey J, 2014, BRIT J SPORT MED, V48, P729, DOI 10.1136/bjsports-2013-092884; Hootman JM, 2002, MED SCI SPORT EXER, V34, P838, DOI 10.1097/00005768-200205000-00017; Joy EA, 2013, J STRENGTH COND RES, V27, P2263, DOI 10.1519/JSC.0b013e31827ef12e; Kerr ZY, 2018, J ATHL TRAINING, V53, P729, DOI 10.4085/1062-6050-143-17; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kreck C, STATES ADDRESS CONCE; Kucera KL, 2011, J ATHL TRAINING, V46, P489; LaBella CR, 2011, ARCH PEDIAT ADOL MED, V165, P1033, DOI 10.1001/archpediatrics.2011.168; Lohmander LS, 2004, ARTHRITIS RHEUM-US, V50, P3145, DOI 10.1002/art.20589; Luc B, 2014, J ATHL TRAINING, V49, P806, DOI 10.4085/1062-6050-49.3.35; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; McGuine TA, 2006, AM J SPORT MED, V34, P1103, DOI 10.1177/0363546505284191; National Collegiate Athletic Association, STUD ATHL PART 1981; Norcross MF, 2016, J SCI MED SPORT, V19, P299, DOI 10.1016/j.jsams.2015.03.009; Participation statistics, 2016, PART STAT; Paterno MV, 2012, CLIN J SPORT MED, V22, P116, DOI 10.1097/JSM.0b013e318246ef9e; Peterson L, 2000, AM J SPORT MED, V28, pS51; Powell JW, 1999, J ATHL TRAINING, V34, P277; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Reeser JC, 2015, SPORTS HEALTH, V7, P504, DOI 10.1177/1941738115600143; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Shelbourne KD, 2009, AM J SPORT MED, V37, P246, DOI 10.1177/0363546508325665; Silvers-Granelli H, 2015, AM J SPORT MED, V43, P2628, DOI 10.1177/0363546515602009; Sugimoto D, 2012, J ATHL TRAINING, V47, P714, DOI 10.4085/1062-6050-47.6.10; Sugimoto D, 2012, BRIT J SPORT MED, V46, P979, DOI 10.1136/bjsports-2011-090895; Tyler TF, 2001, AM J SPORT MED, V29, P124, DOI 10.1177/03635465010290020301; United States Census Bureau, CENS REG US; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Walden M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3042; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	42	28	28	2	15	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP	2018	53	9					880	892		10.4085/1062-6050-156-17			13	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	GY4NU	WOS:000448540500008	30372637	Green Published, gold			2022-02-06	
J	Echemendia, RJ; Bruce, JM; Meeuwisse, W; Hutchison, MG; Comper, P; Aubry, M				Echemendia, Ruben J.; Bruce, Jared M.; Meeuwisse, Willem; Hutchison, Michael G.; Comper, Paul; Aubry, Mark			Can visible signs predict concussion diagnosis in the National Hockey League?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Concussion Signs; Video analyses; Concussion Diagnoses; Ice Hockey	TEMPORAL WINDOW; VULNERABILITY	Background Early identification and evaluation of concussions is critical. We examined the utility of using visible signs (VS) of concussion in predicting subsequent diagnosis of concussion in NHL players. Methods VS of concussion were identified through video review. Coders were trained to detect and record specific visual signs while viewing videos of NHL regular season games. 2460 games were reviewed by at least two independent coders across two seasons. The reliability, sensitivity and specificity of these VS were examined. Results VS were reliably coded with inter-rater agreement rates ranging from 73% to 98.9%. 1215 VS were identified in 861 events that occurred in 735 games. 47% of diagnosed concussions were associated with a VS but 53% of diagnosed concussions had no VS. Of the VS, only loss of consciousness, motor incoordination, and blank/vacant look had positive likelihood ratios greater than 1, indicating a positive association with concussion diagnoses. Slow to get up and clutching of the head were observed frequently but had low positive predictive values. Sensitivity decreased and specificity increased when multiple VS occurred together. Conclusions Non-medical personnel can be trained to reliably identify events in which VS occur and to reliably identify specific VS within each of those events. VS can be useful to detect concussion early but they are not enough since more than half of physician diagnosed concussions occurred without the presence of a visual sign. The results underscore the complexity of this injury and highlight the need for comprehensive approaches to injury detection.	[Echemendia, Ruben J.] Concuss Care Clin, Univ Orthoped Ctr, 101 Regent Court, State Coll, PA 16801 USA; [Echemendia, Ruben J.; Bruce, Jared M.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Comper, Paul] Toronto Rehabil Inst, Toronto, ON, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada		Echemendia, RJ (corresponding author), Concuss Care Clin, Univ Orthoped Ctr, 101 Regent Court, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019				Broglio S, 2014, OXFORD HDB SPORTS RE; Cantu R, 2014, OXFORD HDB SPORTS RE; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; McCrory P, 2014, OXFORD HDB SPORTS RE; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; McCrory Paul, 2009, Scand J Med Sci Sports, V19, P452, DOI 10.1111/j.1600-0838.2009.00978.x; NHL Concussion Working Group, 2011, NHL CONC EV MAN PROT; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8	13	28	28	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2018	52	17					1149	1154		10.1136/bjsports-2016-097090			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	GS4GO	WOS:000443598200014	28377445				2022-02-06	
J	Ponsford, J; Alway, Y; Gould, KR				Ponsford, Jennie; Alway, Yvette; Gould, Kate Rachel			Epidemiology and Natural History of Psychiatric Disorders After TBI	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DSM-IV DISORDERS; COMORBIDITY SURVEY REPLICATION; AXIS-I; MENTAL-HEALTH; PSYCHOTIC DISORDER; MAJOR DEPRESSION; HEAD-INJURY; RISK-FACTOR	This article outlines the epidemiology of psychiatric disorders in individuals with traumatic brain injury (TBI), with a focus on DSM axis I disorders diagnosed on the basis of structured clinical interview. The epidemiology of psychiatric disorders in the general population is described as a basis for understanding the disorders that occur before and after TBI. For each disorder category, including mood disorders, anxiety disorders, acute stress disorder, posttraumatic stress disorder (PTSD), substance use disorders, psychotic disorders, eating disorders, somatoform disorders, and adjustment disorders, the evidence from retrospective, cross-sectional and prospective studies is reviewed, showing the frequency, time course, and predictors of the disorders. Studies show elevated rates of depressive and anxiety disorders after TBI, most commonly major depressive disorder and PTSD, usually emerging in the first year postinjury but with delayed onset in severe injury cases. Although individuals with a preinjury history are more likely to develop these disorders, the nature of the disorders may change after injury, and novel psychiatric disorders are also common. Even though the frequency of anxiety disorders diminishes over the years postinjury, depressive disorders are more persistent during postinjury years. Substance use-while high before injury-declines after injury. The frequency of psychotic, eating, somatoform, and adjustment disorders do not exceed population rates.	[Ponsford, Jennie; Alway, Yvette; Gould, Kate Rachel] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia; [Ponsford, Jennie; Alway, Yvette; Gould, Kate Rachel] Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia; [Ponsford, Jennie; Alway, Yvette; Gould, Kate Rachel] Epworth Healthcare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia.; Ponsford, J (corresponding author), Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia.; Ponsford, J (corresponding author), Epworth Healthcare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia.	jennie.ponsford@monash.edu	Gould, Kate Rachel/AAA-5511-2020	Gould, Kate Rachel/0000-0002-3564-7408			Alway Y, 2016, PSYCHOL MED, V46, P1331, DOI 10.1017/S0033291715002986; Alway Y, 2016, J NEUROTRAUM, V33, P825, DOI 10.1089/neu.2015.3992; Alway Y, 2016, DEPRESS ANXIETY, V33, P19, DOI 10.1002/da.22396; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Australian Bureau of Statistics, 2009, NAT SURV MENT HLTH W; Batty RA, 2013, BRAIN IMPAIR, V14, P21, DOI 10.1017/BrImp.2013.10; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 2013, JAMA PSYCHIAT, V70, P839, DOI 10.1001/jamapsychiatry.2013.1137; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Deb S, 1999, AM J PSYCHIAT, V156, P374; Diaz AP, 2014, REV BRAS PSIQUIATR, V36, P213, DOI 10.1590/1516-4446-2013-1303; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii D, 2012, J NEUROPSYCH CLIN N, V24, P278, DOI 10.1176/appi.neuropsych.11070176; Gibson R, 2015, BRAIN INJURY, V29, P306, DOI 10.3109/02699052.2014.896471; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Harter M, 2007, PSYCHOTHER PSYCHOSOM, V76, P354, DOI 10.1159/000107563; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; Molloy C, 2011, SCHIZOPHRENIA BULL, V37, P1104, DOI 10.1093/schbul/sbr091; Orlovska S, 2014, AM J PSYCHIAT, V171, P463, DOI 10.1176/appi.ajp.2013.13020190; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Silver JM, 1997, NEUROCASE, V3, P151, DOI 10.1080/13554799708404048; Slade T, 2009, AUST NZ J PSYCHIAT, V43, P594, DOI 10.1080/00048670902970882; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wade TD, 2006, AUST NZ J PSYCHIAT, V40, P121, DOI 10.1111/j.1440-1614.2006.01758.x; Wells JE, 2006, AUST NZ J PSYCHIAT, V40, P845, DOI 10.1111/j.1440-1614.2006.01903.x; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa	55	28	29	3	8	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2018	30	4					262	270		10.1176/appi.neuropsych.18040093			9	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	GX8GY	WOS:000448023000002	29939106	Bronze			2022-02-06	
J	Gao, YY; Zhang, ZH; Zhuang, Z; Lu, Y; Wu, LY; Ye, ZN; Zhang, XS; Chen, CL; Li, W; Hang, CH				Gao, Yong-Yue; Zhang, Zi-Huan; Zhuang, Zong; Lu, Yue; Wu, Ling-Yun; Ye, Zhen-nan; Zhang, Xiang-Sheng; Chen, Chun-Lei; Li, Wei; Hang, Chun-Hua			Recombinant milk fat globule-EGF factor-8 reduces apoptosis via integrin beta 3/FAK/PI3K/AKT signaling pathway in rats after traumatic brain injury	CELL DEATH & DISEASE			English	Article							PROVIDES NEUROPROTECTION; SUBARACHNOID HEMORRHAGE; OXIDATIVE STRESS; MFG-E8; INFLAMMATION; MOUSE; CELLS; LACTADHERIN; AUTOPHAGY; PI3K/AKT	Accumulating evidence suggests neuronal apoptosis has the potential to lead to more harmful effects in the pathological processes following traumatic brain injury (TBI). Previous studies have established that milk fat globule-EGF factor-8 (MFG-E8) provides neuroprotection through modulation of inflammation, oxidative stress, and especially apoptosis in cerebral ischemia and neurodegenerative disease. However, the effects of MFG-E8 on neuronal apoptosis in TBI have not yet been investigated. Therefore, we explored the role of MFG-E8 on anti-apoptosis and its potential mechanism following TBI. In the first set of experiments, adult male Sprague-Dawley (SD) rats were randomly divided into Sham and TBI groups that were each further divided into five groups representing different time points (6 h, 24 h, 72 h, and 7 days) (n=9 each). Western blotting, quantitative real-time PCR, and immunofluorescence staining were performed to identify the expression and cellular localization of MFG-E8. In the second set of experiments, four groups were randomly assigned: Sham group, TBI + Vehicle group, and TBI + rhMFG-E8 (1 and 3 mu g) (n=15). Recombinant human MFGE8 (rhMFG-E8) was administrated as two concentrations through intracerebroventricular (i.c.v.) injection at 1 h after TBI induction. Brain water content, neurological severity score, western blotting, and immunofluorescence staining were measured at 24 and 72h following TBI. In the final set of experiments, MFG-E8 siRNA (500 pmol/3 mu l), integrin beta 3 siRNA (500 pmol/3 mu l), and PI3K inhibitor LY294002 (5 and 20 mu M) were injected i.c.v. and thereafter rats exposed to TBI. Western blotting, immunofluorescence staining, brain water content, neurological severity score, and Fluoro-Jade C (FJC) staining were used to investigate the effect of the integrin-beta 3/FAK/PI3K/AKT signaling pathway on MFG-E8-mediated anti-apoptosis after TBI. The expression of MFG-E8 was mainly located in microglial cells and increased to peak at 24 h after TBI. Treatment with rhMFG-E8 (3 mu g) markedly decreased brain water content, improved neurological deficits, and reduced neuronal apoptosis at 24 and 72 h after TBI. rhMFG-E8 significantly enhanced the expression of integrin-beta 3/FAK/PI3K/AKT pathway-related components. Administration of integrin-beta 3 siRNA and LY294002 (5 and 20 mu M) abolished the effect of rhMFG-E8 on antiapoptosis and neuroprotection after TBI. This study demonstrated for the first time that rhMFG-E8 inhibits neuronal apoptosis and offers neuroprotection. This is suggested to occur through the modulation of the integrin-beta 3/FAK/PI3K/AKT signaling pathway, highlighting rhMFG-E8 as a potentially promising therapeutic strategy for TBI patients.	[Gao, Yong-Yue; Zhuang, Zong; Lu, Yue; Wu, Ling-Yun; Zhang, Xiang-Sheng; Li, Wei; Hang, Chun-Hua] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurosurg, Zhongshan Rd 321, Nanjing 210008, Jiangsu, Peoples R China; [Zhang, Zi-Huan] Wannan Med Coll, Dept Neurosurg, Affiliated Hosp 1, Wuhu, Anhui, Peoples R China; [Ye, Zhen-nan] Guangzhou Med Univ, Dept Neurosurg, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China; [Chen, Chun-Lei] Nanjing Med Univ, Affiliated Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China		Li, W; Hang, CH (corresponding author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurosurg, Zhongshan Rd 321, Nanjing 210008, Jiangsu, Peoples R China.	lwxzlw@126.com; hang_neurosurgery@163.com	Li, Wei/ABE-4301-2021	LU, Yue/0000-0001-9111-5943	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371294, 81401029, 81400980]	The authors acknowledge the support for this research by grants from the National Natural Science Foundation of China (No. 81371294 for C.-H.H., No. 81401029 for W.L., and No. 81400980 for Z.Z.).	Aziz MM, 2009, J IMMUNOL, V182, P7222, DOI 10.4049/jimmunol.0803711; Aziz M, 2011, APOPTOSIS, V16, P1077, DOI 10.1007/s10495-011-0630-0; Bassi MS, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00390; Boddaert J, 2007, AM J PATHOL, V170, P921, DOI 10.2353/ajpath.2007.060664; Carrascosa C, 2012, ONCOGENE, V31, P1521, DOI 10.1038/onc.2011.356; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cheyuo C, 2012, NEUROPHARMACOLOGY, V62, P890, DOI 10.1016/j.neuropharm.2011.09.018; Cox-Limpens KEM, 2014, BRAIN RES, V1564, P85, DOI 10.1016/j.brainres.2014.04.001; Deroide N, 2013, J CLIN INVEST, V123, P1176, DOI 10.1172/JCI65167; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Fuller AD, 2008, J NEUROIMMUNE PHARM, V3, P246, DOI 10.1007/s11481-008-9118-2; Gao YY, 2017, AM J TRANSL RES, V9, P887; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Kline AE, 2016, PROG NEUROBIOL, V142, P45, DOI 10.1016/j.pneurobio.2016.05.002; Kranich J, 2010, J EXP MED, V207, P2271, DOI 10.1084/jem.20092401; Li ED, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-148; Liu F, 2014, STROKE, V45, P3691, DOI 10.1161/STROKEAHA.114.006635; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Neuhaus W, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00149; Raymond A, 2009, J CELL BIOCHEM, V106, P957, DOI 10.1002/jcb.22076; Shi XL, 2017, MOL NEUROBIOL, V54, P7777, DOI 10.1007/s12035-016-0255-y; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Silvestre JS, 2005, M S-MED SCI, V21, P683, DOI 10.1051/medsci/2005218-9683; Uchiyama A, 2015, J INVEST DERMATOL, V135, P1157, DOI 10.1038/jid.2014.515; Walker Chandler L, 2013, Front Biol (Beijing), V8, DOI 10.1007/s11515-013-1255-1; Wang JP, 2017, NEUROSCIENCE, V364, P202, DOI 10.1016/j.neuroscience.2017.09.025; Wang JY, 2017, TRANSL STROKE RES, V8, P284, DOI 10.1007/s12975-016-0514-2; Wang Y, 2016, BRAIN RES, V1648, P1, DOI 10.1016/j.brainres.2016.06.043; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Wu LY, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00175; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Zhang Lijuan, 2016, Zhongguo Zhen Jiu, V36, P131; Zhang S, 2015, BRAZ J MED BIOL RES, V48, P1032, DOI 10.1590/1414-431X20154730; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292; Zhao YF, 2015, INT J CLIN EXP PATHO, V8, P2354; Zhou CH, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0415-4	41	28	30	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	AUG 28	2018	9								845	10.1038/s41419-018-0939-5			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	GR9MK	WOS:000443087500002	30154436	Green Published, gold			2022-02-06	
J	Jian, WH; Wang, HC; Kuan, CH; Chen, MH; Wu, HC; Sun, JS; Wang, TW				Jian, Wei-Hong; Wang, Huan-Chih; Kuan, Chen-Hsiang; Chen, Ming-Hong; Wu, Hsi-Chin; Sun, Jui-Sheng; Wang, Tzu-Wei			Glycosaminoglycan-based hybrid hydrogel encapsulated with polyelectrolyte complex nanoparticles for endogenous stem cell regulation in central nervous system regeneration	BIOMATERIALS			English	Article						Glycosaminoglycan; Polyelectrolyte complex nanoparticle; Growth factors; Neural stem cell; Hydrogel; Brain	TRAUMATIC BRAIN-INJURY; NUCLEUS PULPOSUS REGENERATION; NEURAL PROGENITOR CELLS; GROWTH-FACTOR DELIVERY; ISCHEMIC-STROKE; HYALURONIC-ACID; MATRIX METALLOPROTEINASES; TISSUE; BLOOD; MIGRATION	The poor regenerative capability of stem cell transplantation in the central nervous system limits their therapeutic efficacy in brain injuries. The sustained inflammatory response, lack of structural support, and trophic factors deficiency restrain the integration and long-term survival of stem cells. Instead of exogenous stem cell therapy, here we described the synthesis of nanohybrid hydrogel containing sulfated glycosaminoglycan-based polyelectrolyte complex nanoparticles (PCN) to mimic the brain extracellular matrix and control the delivery of stromal-derived factor-1 alpha (SDF-1 alpha) and basic fibroblast factor (bFGF) in response to matrix metalloproteinase (MMP) for recruiting endogenous neural stem cells (NSC) and regulating their cellular fate. Bioactive factors are delivered by electrostatic sequestration on PCN to amplify the signaling of SDF-1 alpha and bFGF to regulate NSC in vitro. In in vivo ischemic stroke model, the factors promoted neurological behavior recovery by enhancing neurogenesis and angiogenesis. These combined strategies may be applied for other tissue regenerations by regulating endogenous progenitors through the delivery of different kinds of glycosaminoglycan-binding molecules. (C) 2018 Elsevier Ltd. All rights reserved.	[Jian, Wei-Hong; Wang, Tzu-Wei] Natl Thing Hua Univ, Dept Mat Sci & Engn, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan; [Wang, Huan-Chih] Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 10002, Taiwan; [Wang, Huan-Chih] Natl Chiao Tung Univ, Coll Biol Sci & Technol, Hsinchu 30010, Taiwan; [Kuan, Chen-Hsiang] Natl Taiwan Univ Hosp, Div Plast Surg, Dept Surg, Taipei 10002, Taiwan; [Kuan, Chen-Hsiang] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei 10002, Taiwan; [Chen, Ming-Hong] Cathay Gen Hosp, Div Neurosurg, Dept Surg, Taipei, Taiwan; [Chen, Ming-Hong] Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei, Taiwan; [Wu, Hsi-Chin] Tatung Univ, Dept Mat Engn, Taipei 10452, Taiwan; [Wu, Hsi-Chin] Tatung Univ, Dept Bioengn, Taipei 10452, Taiwan; [Sun, Jui-Sheng] Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei 10002, Taiwan		Wang, TW (corresponding author), Natl Thing Hua Univ, Dept Mat Sci & Engn, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan.	twwang@mx.nthu.edu.tw		SUN, JUI-SHENG/0000-0001-5142-8777; Wang, Huan-Chih/0000-0001-6192-853X; Kuan, Chen-Hsiang/0000-0001-5599-7125; Chen, Ming-Hong/0000-0001-6306-0818	Taiwan Ministry of Science and Technology [MOST-104-2628-E-007 -002 -MY3, MOST-104-2221-E-007 -140 -MY2, MOST -106-2622-E-007-003 -CC2]	We thank for the technical assistance from Magnetic Resonance Imaging Core Lab of Molecular Imaging Center in National Taiwan University (NTU) and IBEN Service in National Health Research Institutes for MR scanning. We are also grateful to the Technology Commons, College of Life Science, NTU for technical assistance with transmission electron microscopy (TEM), and the help of Instrument Center in National Tsing Hua University (NTHU) with NMR analysis. We also acknowledge Zheng-Wei Lu (Department of Chemical Engineering, NTHU) for assistance with the rheology analysis, and Kun-I Chao (Department of Biomedical Engineering and Environmental Sciences, NTHU) for helpful suggestions in MRI analysis. Funding was provided by the Taiwan Ministry of Science and Technology (MOST-104-2628-E-007 -002 -MY3, MOST-104-2221-E-007 -140 -MY2, MOST -106-2622-E-007-003 -CC2).	Addington CP, 2015, BIOMARK INSIGHTS, V10, P43, DOI [10.4137/BMI.S20062, 10.4137/BMIMI.S20062]; Boddohi S, 2010, ADV MATER, V22, P2998, DOI 10.1002/adma.200903790; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Burdick JA, 2011, ADV MATER, V23, pH41, DOI 10.1002/adma.201003963; Chen YC, 2013, ACTA BIOMATER, V9, P5181, DOI 10.1016/j.actbio.2012.09.039; Dibajnia P, 2013, ACTA PHARMACOL SIN, V34, P78, DOI 10.1038/aps.2012.107; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fiorini F, 2016, SMALL, V12, P4881, DOI 10.1002/smll.201601017; Freudenberg U, 2016, ADV MATER, V28, P8861, DOI 10.1002/adma.201601908; Ge YQ, 2009, NANOSCALE RES LETT, V4, P287, DOI 10.1007/s11671-008-9239-9; Gregoire CA, 2015, GLIA, V63, P1469, DOI 10.1002/glia.22851; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hardy JG, 2015, J BIOMAT SCI-POLYM E, V26, P143, DOI 10.1080/09205063.2014.975393; Huang YC, 2012, ACTA BIOMATER, V8, P1048, DOI 10.1016/j.actbio.2011.12.009; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jin R, 2013, J CARDIOVASC TRANSL, V6, P834, DOI 10.1007/s12265-013-9508-6; Karumbaiah L, 2015, BIOCONJUGATE CHEM, V26, P2336, DOI 10.1021/acs.bioconjchem.5b00397; Khetan S, 2013, NAT MATER, V12, P458, DOI [10.1038/NMAT3586, 10.1038/nmat3586]; Kiprianova I, 2004, EXP NEUROL, V189, P252, DOI 10.1016/j.expneurol.2004.06.004; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Lee SS, 2017, NAT NANOTECHNOL, V12, P821, DOI [10.1038/NNANO.2017.109, 10.1038/nnano.2017.109]; Li HL, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-58; Li YN, 2014, STROKE, V45, P1822, DOI 10.1161/STROKEAHA.114.005078; Lim TC, 2013, FASEB J, V27, P1023, DOI 10.1096/fj.12-221515; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lotz S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056289; Murphy JW, 2007, J BIOL CHEM, V282, P10018, DOI 10.1074/jbc.M608796200; Netelenbos T, 2002, J LEUKOCYTE BIOL, V72, P353; Nih LR, 2016, CURR OPIN BIOTECH, V40, P155, DOI 10.1016/j.copbio.2016.04.021; Oueslati N, 2014, CARBOHYD POLYM, V112, P102, DOI 10.1016/j.carbpol.2014.05.039; Place LW, 2014, BIOMACROMOLECULES, V15, P680, DOI 10.1021/bm401736c; Purcell BP, 2014, NAT MATER, V13, P653, DOI [10.1038/NMAT3922, 10.1038/nmat3922]; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Segovia N, 2015, ADV HEALTHC MATER, V4, P271, DOI 10.1002/adhm.201400235; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Sirko S, 2010, STEM CELLS, V28, P775, DOI 10.1002/stem.309; Sommer CJ, 2017, ACTA NEUROPATHOL, V133, P245, DOI 10.1007/s00401-017-1667-0; Spencer KC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02107-2; Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787; Su WY, 2010, ACTA BIOMATER, V6, P3044, DOI 10.1016/j.actbio.2010.02.037; Sun GJ, 2015, P NATL ACAD SCI USA, V112, P9484, DOI 10.1073/pnas.1508545112; Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237; Tuladhar A, 2015, J CONTROL RELEASE, V215, P1, DOI 10.1016/j.jconrel.2015.07.023; Vulic K, 2012, J AM CHEM SOC, V134, P882, DOI 10.1021/ja210638x; Wang YF, 2013, J CONTROL RELEASE, V172, P1, DOI 10.1016/j.jconrel.2013.07.032; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhong J, 2010, NEUROREHAB NEURAL RE, V24, P636, DOI 10.1177/1545968310361958; Zhu SW, 2015, ADV MATER, V27, P3620, DOI 10.1002/adma.201500417	51	28	29	8	120	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	AUG	2018	174						17	30		10.1016/j.biomaterials.2018.05.009			14	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	GK5OD	WOS:000436223500002	29763775				2022-02-06	
J	Bernick, C; Zetterberg, H; Shan, GG; Banks, S; Blennow, K				Bernick, Charles; Zetterberg, Henrik; Shan, Guogen; Banks, Sarah; Blennow, Kaj			! Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; neurofilament light; tau	INJURY; BIOMARKER; CHAIN; PROTEIN	The aim of this study is to evaluate longitudinal change in plasma neurofilament light (NF-L) and tau levels in relationship to clinical and radiological measures in professional fighters. Participants (active and retired professional fighters and control group) underwent annual blood sampling, 3-Tesla magnetic resonance imaging (MRI) brain imaging, computerized cognitive testing, and assessment of exposure to traumatic brain injury. Plasma tau and NF-L concentrations were measured using Simoa assays. Multiple linear regression models were used to compare the difference across groups in regard to baseline measurements, whereas mixed linear models was used for the longitudinal data with multiple measurements for each participant. Plasma samples were available on 471 participants. Baseline NF-L measures differed across groups (F-3,F-393=6.99; p=0.0001), with the active boxers having the highest levels. Higher NF-L levels at baseline were correlated with lower baseline MRI regional volumes and lower cognitive scores. The number of sparring rounds completed by the active fighters was correlated with NF-L (95% confidence interval, 0.0116-0.4053; p=0.0381), but not tau, levels. Among 126 subjects having multiple yearly samples, there was a significant difference in average yearly percentage change in tau across groups (F-3,F-83=3.87; p=0.0121). We conclude that plasma NF-L and tau behave differently in a group of active and retired fighters; NF-L better reflects acute exposure whereas the role of plasma tau levels in signifying chronic change in brain structure over time requires further study.	[Bernick, Charles; Banks, Sarah] Cleveland Clin, Neurol Inst, 888 West Bonneville Ave, Las Vegas, NV 89106 USA; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Shan, Guogen] Univ Nevada, Environm & Occupat Hlth, Las Vegas, NV 89154 USA		Bernick, C (corresponding author), Cleveland Clin, Neurol Inst, 888 West Bonneville Ave, Las Vegas, NV 89106 USA.	bernicc@ccf.org		Banks, Sarah/0000-0001-7536-2370	UFC; Bellator/Spike TV; Haymon Boxing; Top Rank Promotions; UCLA Dream fund	Charles Bernick receives funding support for the Professional Fighters Brain Health Study from UFC, Bellator/Spike TV, Haymon Boxing, Top Rank Promotions, and UCLA Dream fund; he has been a speaker for Allergan pharmaceuticals. Henrik Zetterberg has served at advisory board meetings for Eli Lilly and Roche Diagnostics; has received travel support from TEVA; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Kaj Blennow has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.	Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; Bishop CA, 2017, NEUROIMAGE-CLIN, V13, P9, DOI 10.1016/j.nicl.2016.11.005; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Lu CH, 2015, NEUROLOGY, V84, P2247, DOI 10.1212/WNL.0000000000001642; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mishra VR, 2017, RADIOLOGY, V285, P555, DOI 10.1148/radiol.2017162403; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Oliver JM, 2017, J NEUROTRAUM, V34, P3295, DOI 10.1089/neu.2017.5064; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Rohrer JD, 2016, NEUROLOGY, V87, P1329, DOI 10.1212/WNL.0000000000003154; Rojas JC, 2016, ANN CLIN TRANSL NEUR, V3, P216, DOI 10.1002/acn3.290; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shan GG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188709; Skillback T, 2014, NEUROLOGY, V83, P1945, DOI 10.1212/WNL.0000000000001015; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163	31	28	29	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2018	35	20					2351	2356		10.1089/neu.2017.5553		JUL 2018	6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GV6DE	WOS:000438238800001	29609512	Green Submitted			2022-02-06	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Detection of Acute and Long-Term Effects of Concussion: Dual-Task Gait Balance Control Versus Computerized Neurocognitive Test	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Attention; Concussion; Locomotion; Postual balance; Rehabilitation	SPORTS-RELATED CONCUSSION; MANAGEMENT PRACTICE PATTERNS; TRAUMATIC BRAIN-INJURY; POSTURAL CONTROL; YOUNG-ADULTS; SINGLE-TASK; HIGH-SCHOOL; RECOVERY; ADOLESCENTS; PERFORMANCE	Objective: To examine the acute (within 72h of injury) and long-term (2mo postinjury) independent associations between objective dual-task gait balance and neurocognitive measurements among adolescents and young adults with a concussion and matched controls. Design: Longitudinal case-control. Setting: Motion analysis laboratory. Participants: A total of 95 participants completed the study: 51 who sustained a concussion (mean age, 17.5 +/- 3.3y; 71% men) and 44 controls (mean age, 17.7 +/- 2.9y; 72% men). Participants who sustained a concussion underwent a dual-task gait analysis and computerized neurocognitive testing within 72 hours of injury and again 2 months later. Uninjured controls also completed the same test protocol in similar time increments. Interventions: Not applicable. Main Outcome Measures: We compared dual-task gait balance control and computerized neurocognitive test performance between groups using independent samples t tests. Multivariable binary logistic regression models were then constructed for each testing time to determine the association between group membership (concussion vs control), dual-task gait balance control, and neurocognitive function. Results: Medial-lateral center-of-mass displacement during dual-task gait was independently associated with group membership at the initial test (adjusted odds ratio [aOR], 2.432; 95% confidence interval [CI], 1.269-4.661) and 2-month follow-up test (aOR, 1.817; 95% CI, 1.014-3.256) tests, Visual memory composite scores were significantly associated with group membership at the initial hour postinjury time point (aOR,.953; 95% CI,.833.998). However, the combination of computerized neurocognitive test variables did not predict dual-task gait balance control for participants with concussion, and no single neurocognitive variable was associated with dual-task gait balance control at either testing time. Conclusions: Dual-task assessments concurrently evaluating gait and cognitive performance may allow for the detection of persistent deficits beyond those detected by computerized neurocognitive deficits alone. (C) 2018 by the American Congress of Rehabilitation Medicine	[Howell, David R.] Childrens Hosp Colorado, Ctr Sports Med, Aurora, CO USA; [Howell, David R.] Univ Colorado, Sch Med, Dept Orthoped, Aurora, CO USA; [Howell, David R.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA		Chou, LS (corresponding author), Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA.	chou@uoregon.edu		Howell, David/0000-0002-2955-0191; Chou, Li-Shan/0000-0002-2777-7034	Department of Defense TATRC Award [W81XWH-11-1-0717]; Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology	Supported by the Department of Defense TATRC Award (award no. W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology.	Baker CS, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12252; Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Beauchet Olivier, 2006, Psychol Neuropsychiatr Vieil, V4, P215; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2011, PM&R, V3, pS445, DOI 10.1016/j.pmrj.2011.08.009; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2018, J SCI MED SPORT, V21, P358, DOI 10.1016/j.jsams.2017.08.004; Howell DR, 2017, J SCI MED SPORT, V20, P622, DOI 10.1016/j.jsams.2016.11.020; Howell DR, 2017, GAIT POSTURE, V54, P284, DOI 10.1016/j.gaitpost.2017.03.034; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2016, GAIT POSTURE, V49, P176, DOI 10.1016/j.gaitpost.2016.07.008; Howell DR, 2016, J HEAD TRAUMA REHAB, V31, P262, DOI 10.1097/HTR.0000000000000176; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Manaseer T. S., 2017, CLIN J SPORT MED; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Oldham JR, 2016, GAIT POSTURE, V49, P437, DOI 10.1016/j.gaitpost.2016.07.327; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Shumway-Cook A, 2000, J GERONTOL A-BIOL, V55, pM10; Stache S, 2016, CLIN J SPORT MED, V26, P381, DOI 10.1097/JSM.0000000000000270; SUTHERLAND DH, 1980, J BONE JOINT SURG AM, V62, P336, DOI 10.2106/00004623-198062030-00004; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2	48	28	28	2	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2018	99	7					1318	1324		10.1016/j.apmr.2018.01.025			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	GL9JZ	WOS:000437552100009	29457997				2022-02-06	
J	Dai, W; Wang, HD; Fang, J; Zhu, YH; Zhou, J; Wang, XL; Zhou, Y; Zhou, ML				Dai, Wei; Wang, Handong; Fang, Jiang; Zhu, Yihao; Zhou, Jian; Wang, Xiaoliang; Zhou, Yuan; Zhou, Mengliang			Curcumin provides neuroprotection in model of traumatic brain injury via the Nrf2-ARE signaling pathway	BRAIN RESEARCH BULLETIN			English	Article						Curcumin; Traumatic brain injury; Nrf2; Neuroprotection	OXIDATIVE STRESS; LIPID-PEROXIDATION; HEAD-INJURY; MICE; ACTIVATION; EXPRESSION; DAMAGE; NANOPARTICLES; INHIBITION; NITRATION	Curcumin has been found to play the protective role in many neurological disorders, however, its roles and the underlying molecular mechanisms in traumatic brain injury (TBI) are not fully understood. The aim of this study was to investigate the potential neuroprotection of curcumin and the possible role of Nrf2-ARE pathway in the weight -drop model of TBI. The administration of curcumin (100 mg/kg, i.p.) significantly ameliorated secondary brain injury induced by TBI, such as brain water content, oxidative stress, neurological severity score, and neuronal apoptosis. Curcumin possessed anti-apoptotic character evidenced by elevating Bcl-2 content and reducing that of cleaved caspase-3. Moreover, curcumin markedly enhanced the translocation of Nrf2 from the cytoplasm to the nucleus, proved by the results of western blot and immunofluorescence, subsequently increased the expression of downstream factors such as heme oxygenase 1 (HO1) and NAD(P)H: quinone oxidoreductase 1 (NQO1) and prevented the decline of antioxidant enzyme activities. In conclusion, curcumin could increase the activities of antioxidant enzymes and attenuate brain injury in the model of TBI, possibly via the activation of the Nrf2-ARE pathway.	[Dai, Wei; Wang, Handong; Zhou, Jian; Zhou, Yuan] Nanjing Med Univ, Jinling Sch Clin Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Fang, Jiang] Southeast Univ, Med Coll, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Zhu, Yihao; Wang, Xiaoliang; Zhou, Mengliang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81401026]; PLA medical science and technology youth training project [16QNP042]	This study was supported by the National Natural Science Fund of China (grant Nos. 81371357 and 81401026) and PLA medical science and technology youth training project (No.16QNP042).	Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Butterfield DA, 2016, PROTEOM CLIN APPL, V10, P1191, DOI 10.1002/prca.201600003; Chen GZ, 2011, J LASERS MED SCI, V2, P89; Chopra D, 2016, BIOMATERIALS, V84, P25, DOI 10.1016/j.biomaterials.2016.01.018; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Alcantara Glaura Fernandes Teixeira, 2017, J Tradit Complement Med, V7, P14, DOI 10.1016/j.jtcme.2015.10.001; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hu YR, 2017, BIOMED PHARMACOTHER, V85, P313, DOI 10.1016/j.biopha.2016.11.031; Jeong YH, 2016, BIOMOL THER, V24, P581, DOI 10.4062/biomolther.2016.141; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Kakkar V, 2011, FOOD CHEM TOXICOL, V49, P2906, DOI 10.1016/j.fct.2011.08.006; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Maiti P, 2016, HISTOCHEM CELL BIOL, V146, P609, DOI 10.1007/s00418-016-1464-1; Miller TW, 2009, CHEM REV, V109, P3099, DOI 10.1021/cr8005125; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Wang BF, 2015, ACTA PHARMACOL SIN, V36, P939, DOI 10.1038/aps.2015.47; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang L, 2017, ONCOTARGET, V8, P65414, DOI 10.18632/oncotarget.18676; Xie YL, 2017, BIOMED PHARMACOTHER, V91, P70, DOI 10.1016/j.biopha.2017.04.070; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xue F, 2016, BEHAV BRAIN RES, V309, P1, DOI 10.1016/j.bbr.2016.04.045; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yin Xiao-Ping, 2015, Drug Des Devel Ther, V9, P5973, DOI 10.2147/DDDT.S79399	34	28	29	4	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JUN	2018	140						65	71		10.1016/j.brainresbull.2018.03.020			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GO0ZR	WOS:000439675700009	29626606				2022-02-06	
J	Tang, R; Lin, YM; Liu, HX; Wang, ES				Tang, Ri; Lin, Yi-Mei; Liu, Hong-Xing; Wang, Er-Song			Neuroprotective effect of docosahexaenoic acid in rat traumatic brain injury model via regulation of TLR4/NF-Kappa B signaling pathway	INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY			English	Article						Traumatic brain injury; TLR-4/NK-Kappa B pathway; Docosahexaenoic acid; Rat model	KAPPA-B; PROMOTES; TLR4; EPIDEMIOLOGY; INFLAMMATION; INHIBITION; ACTIVATION; EXPRESSION; STRESS; IMPACT	Objective: The experiments were conducted to prove that docosahexaenoic acid (DHA) alleviates traumatic brain injury (TBI) through regulating TLR4/NF-Kappa B signaling pathway. Methods: Bioinformatic analysis was performed using published data from Gene Expression Omnibus (GEO) database to investigate differentially expressed genes and signaling pathways. Controlled cortical impact (CCI) injury rat model was built, and DHA (16 mg/kg in DMSO, once each day) was used to treat TBI rats. Neurological severity score (NSS) and beam walking test and rotarod test were used to confirm whether DHA is neuron-protective against TBI. The expression of TLR4, NF-Kappa B p65, (TNF)-alpha and IL-1 beta were examined by qRT-PCR and western blot. The impact of DHA on neurocyte apoptosis was validated by TdT-mediated dUTP Nick-End Labeling (TUNEL) staining. The influence of DHA on CD11b and GFAP expression in the hippocampus was determined through immunohistochemical analysis. Results: TLR4/NF Kappa B pathway was suggested to be closely correlated with TBI by bioinformatic analysis. DHA could improve the neurological function and learning and memory ability of rats after TBI as well as promote neurocytes from apoptosis. TLR4 expression and the expression of inflammatory mediator NF-Kappa B were also repressed by DHA treatment. Conclusions: DHA exerted a neuron-protective influence in a rat model of TBI via repressing TLR4/NF-Kappa B pathway.	[Tang, Ri; Wang, Er-Song] Fudan Univ, Jinshan Hosp, Dept Neurosurg, 1508 Longhang Rd, Shanghai 200540, Peoples R China; [Lin, Yi-Mei] Fuqing City Hosp Fujian Prov, Dept Gastroenterol, Fuqing 350300, Fujian, Peoples R China; [Liu, Hong-Xing] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou 350005, Fujian, Peoples R China		Wang, ES (corresponding author), Fudan Univ, Jinshan Hosp, Dept Neurosurg, 1508 Longhang Rd, Shanghai 200540, Peoples R China.	wersong@aliyun.com					Alfonso-Loeches S, 2016, NEUROCHEM RES, V41, P193, DOI 10.1007/s11064-015-1760-5; Bajo M, 2016, ALCOHOL ALCOHOLISM, V51, P541, DOI 10.1093/alcalc/agw026; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Hwang JK, 2017, ONCOL LETT, V13, P243, DOI 10.3892/ol.2016.5382; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li YJ, 2014, CELL PHYSIOL BIOCHEM, V33, P1527, DOI 10.1159/000358716; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Liu YL, 2013, J NUTR, V143, P1331, DOI 10.3945/jn.113.176255; Liu YL, 2012, J NUTR, V142, P2017, DOI 10.3945/jn.112.164947; Meng XE, 2016, MED SCI MONITOR, V22, P284, DOI 10.12659/MSM.894148; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Sun G. Y., 2017, FATTY ACIDS; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tao XG, 2017, CHINESE MED J-PEKING, V130, P187, DOI 10.4103/0366-6999.198001; Wang Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/124614; Williams-Bey Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097957; Xing Z, 2015, RNA BIOL, V12, P681, DOI 10.1080/15476286.2015.1053687; Yi Y, 2018, MOL NEUROBIOL, V55, P2454, DOI 10.1007/s12035-017-0504-8; Yu WH, 2012, PHYTOTHER RES, V26, P1838, DOI 10.1002/ptr.4662; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu W, 2017, EXP THER MED, V14, P4411, DOI 10.3892/etm.2017.5054	35	28	29	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1357-2725	1878-5875		INT J BIOCHEM CELL B	Int. J. Biochem. Cell Biol.	JUN	2018	99						64	71		10.1016/j.biocel.2018.03.017			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GH7SR	WOS:000433654200008	29597004				2022-02-06	
J	Narad, ME; Kennelly, M; Zhang, NH; Wade, SL; Yeates, KO; Taylor, HG; Epstein, JN; Kurowski, BG				Narad, Megan E.; Kennelly, Megan; Zhang, Nanhua; Wade, Shari L.; Yeates, Keith Owen; Taylor, H. Gerry; Epstein, Jeffery N.; Kurowski, Brad G.			Secondary Attention-Deficit/Hyperactivity Disorder in Children and Adolescents 5 to 10 Years After Traumatic Brain Injury	JAMA PEDIATRICS			English	Article							DEFICIT HYPERACTIVITY DISORDER; TERM BEHAVIOR PROBLEMS; YOUNG-CHILDREN; OUTCOMES; PREDICTORS; CHILDHOOD; PREVALENCE; ADHD; ACHIEVEMENT; ADAPTATION	IMPORTANCE After traumatic brain injury (TBI), children often experience impairment when faced with tasks and situations of increasing complexity. Studies have failed to consider the potential for attention problems to develop many years after TBI or factors that may predict the development of secondary attention-deficit/hyperactivity disorder (SADHD). Understanding these patterns will aid in timely identification of clinically significant problems and appropriate initiation of treatment with the hope of limiting additional functional impairment. OBJECTIVE To examine the development of SADHD during the 5 to 10 years after TBI and individual (sex, age at injury, and injury characteristics) and environmental (socioeconomic status and family functioning) factors that may be associated with SADHD. DESIGN, SETTING, AND PARTICIPANTS Concurrent cohort/prospective study of children aged 3 to 7 years hospitalized overnight for TBI or orthopedic injury (OI; used as control group) who were screened at 3 tertiary care children's hospitals and 1 general hospital in Ohio from January 2003 to June 2008. Parents completed assessments at baseline (0-3 months), 6 months, 12 months, 18 months, 3.4 years, and 6.8 years after injury. A total of 187 children and adolescents were included in the analyses: 81 in the TBI group and 106 in the OI group. MAIN OUTCOMES AND MEASURES Diagnosis of SADHD was the primary outcome. Assessments were all completed by parents. Secondary ADHD was defined as an elevated T score on the DSM-Oriented Attention-Deficit/Hyperactivity Problems Scale of the parent-reported Child Behavior Checklist, report of an ADHD diagnosis, and/or current treatment with stimulant medication not present at the baseline assessment. The Family Assessment Device-Global Functioning measurement was used to assess family functioning; scores ranged from 1 to 4, with greater scores indicating poorer family functioning. RESULTS The analyzed sample included 187 children with no preinjury ADHD. Mean (SD) age was 5.1 (1.1) years; 108 (57.8%) were male, and 50 (26.7%) were of nonwhite race/ethnicity. Of the 187 children, 48 (25.7%) met our definition of SADHD. Severe TBI (hazard ratio [HR], 3.62; 95% CI, 1.59-8.26) was associated with SADHD compared with the OI group. Higher levels of maternal education (HR, 0.33; 95% CI, 0.17-0.62) were associated with a lower risk of SADHD. Family dysfunction was associated with increased risk of SADHD within the TBI group (HR, 4.24; 95% CI, 1.91-9.43), with minimal association within the OI group (HR, 1.32; 95% CI, 0.36-4.91). CONCLUSIONS AND RELEVANCE Early childhood TBI was associated with increased risk for SADHD. This finding supports the need for postinjury monitoring for attention problems. Consideration of factors that may interact with injury characteristics, such as family functioning, will be important in planning clinical follow-up of children with TBI.	[Narad, Megan E.; Kennelly, Megan; Wade, Shari L.; Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Kennelly, Megan] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Kennelly, Megan; Zhang, Nanhua; Wade, Shari L.; Epstein, Jeffery N.; Kurowski, Brad G.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Yeates, Keith Owen] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Taylor, H. Gerry] Nationwide Childrens Hosp, Biobehav Hlth Ctr, Res Inst, Columbus, OH USA; [Taylor, H. Gerry] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Epstein, Jeffery N.] Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH 45229 USA; [Kurowski, Brad G.] Univ Cincinnati, Coll Med, Dept Neurol & Rehabil Med, Cincinnati, OH USA		Narad, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	megan.narad@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Zhang, Nanhua/0000-0001-5796-3404	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; Trauma Research Grant from the State of Ohio Emergency Medical Services; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8 UL1 TR000077]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1F32HD088011-01, K23 HD07468303]; Rehabilitation Research Experience for Medical Students; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD088011] Funding Source: NIH RePORTER	This publication was supported by grant R01 HD42729 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and a Trauma Research Grant from the State of Ohio Emergency Medical Services. Additional support was provided through grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences of the National Institutes of Health. Dr Narad was supported by grant 1F32HD088011-01 from the NICHD. Ms Kennelly was supported by a grant from the Rehabilitation Research Experience for Medical Students. Dr Kurowski was supported by Mentored Patient-Oriented Research Career Development Award K23 HD07468303 from the NICHD.	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Backeljauw B, 2014, PM&R, V6, P814, DOI 10.1016/j.pmrj.2014.04.004; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; Emery CA, 2016, CAN J PSYCHIAT, V61, P259, DOI 10.1177/0706743716643741; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Froehlich TE, 2007, ARCH PEDIAT ADOL MED, V161, P857, DOI 10.1001/archpedi.161.9.857; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 2012, PEDIAT FORENSIC NEUR, P258; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Visser SN, 2014, J AM ACAD CHILD ADOL, V53, pe2; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Yang LY, 2016, PEDIATR RES, V80, P356, DOI 10.1038/pr.2016.85; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	36	28	28	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	MAY	2018	172	5					437	443		10.1001/jamapediatrics.2017.5746			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	GF0RO	WOS:000431638900012	29554197	Green Published, Bronze			2022-02-06	
J	Vedantam, A; Yamal, JM; Hwang, H; Robertson, CS; Gopinath, SP				Vedantam, Aditya; Yamal, Jose-Miguel; Hwang, Hyunsoo; Robertson, Claudia S.; Gopinath, Shankar P.			Factors associated with shunt-dependent hydrocephalus after decompressive craniectomy for traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						posttraumatic hydrocephalus; shunt-dependent hydrocephalus; decompressive craniectomy; severe traumatic brain injury	POSTTRAUMATIC HYDROCEPHALUS; SUBDURAL HYGROMA; RISK-FACTORS; INTRACRANIAL HYPERTENSION; INTERHEMISPHERIC HYGROMA; HEAD-INJURY; COMPLICATIONS; DYNAMICS	OBJECTIVE Posttraumatic hydrocephalus (PTH) affects 11.9%-36% of patients undergoing decompressive craniectomy (DC) and is an important cause of morbidity after traumatic brain injury (TBI). Early diagnosis and treatment of PTH can prevent further neurological compromise in patients who are recovering from TBI. There is limited data on predictors of shunting for PTH after DC for TBI. METHODS Prospectively collected data from the erythropoietin severe TBI randomized controlled trial were studied. Demographic, clinical, and imaging data were analyzed for enrolled patients who underwent a DC. All head CT scans during admission were reviewed and assessed for PTH by the Gudeman criteria or the modified Frontal Horn Index >= 33%. The presence of subdural hygromas was categorized as unilateral/bilateral hemispheric or interhemispheric. Using L1-regularized logistic regression to select variables, a multiple logistic regression model was created with ventriculoperitoneal shunting as the binary outcome. Statistical significance was set at p < 0.05. RESULTS A total of 60 patients who underwent DC were studied. Fifteen patients (25%) underwent placement of a ventriculoperitoneal shunt for PTH. The majority of patients underwent unilateral decompressive hemicraniectomy (n = 46, 77%). Seven patients (12%) underwent bifrontal DC. Unilateral and bilateral hemispheric hygromas were noted in 31 (52%) and 7 (11%) patients, respectively. Interhemispheric hygromas were observed in 19 patients (32%). The mean duration from injury to first CT scan showing hemispheric subdural hygroma and interhemispheric hygroma was 7.9 +/- 6.5 days and 14.9 +/- 11.7 days, respectively. The median duration from injury to shunt placement was 43.7 days. Multivariate analysis showed that the presence of interhemispheric hygroma (OR 63.6, p = 0.001) and younger age (OR 0.78, p = 0.009) were significantly associated with the need for a shunt after DC. CONCLUSIONS The presence of interhemispheric subdural hygromas and younger age were associated with shunt-dependent hydrocephalus after DC in patients with severe TBI.	[Vedantam, Aditya; Robertson, Claudia S.; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA; [Yamal, Jose-Miguel; Hwang, Hyunsoo] Univ Texas Houston, Sch Publ Hlth, Dept Biostat, Houston, TX USA		Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA.	shankarg@bcm.tmc.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660]	This study was supported by grant no. P01-NS38660 from the National Institute of Neurological Disorders and Stroke.	Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P1308, DOI 10.1016/j.clineuro.2012.12.011; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Ki HJ, 2015, J KOREAN NEUROSURG S, V58, P254, DOI 10.3340/jkns.2015.58.3.254; Kiening KL, 2005, ACT NEUR S, V95, P293; Low CYD, 2013, J CLIN NEUROSCI, V20, P867, DOI 10.1016/j.jocn.2012.06.007; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	24	28	32	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2018	128	5					1547	1552		10.3171/2017.1.JNS162721			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	GP2HQ	WOS:000440650000034	28621627	Bronze			2022-02-06	
J	Yoshihara-Hirata, C; Yamashiro, K; Yamamoto, T; Aoyagi, H; Ideguchi, H; Kawamura, M; Suzuki, R; Ono, M; Wake, H; Nishibori, M; Takashiba, S				Yoshihara-Hirata, Chiaki; Yamashiro, Keisuke; Yamamoto, Tadashi; Aoyagi, Hiroaki; Ideguchi, Hidetaka; Kawamura, Mari; Suzuki, Risa; Ono, Mitsuaki; Wake, Hidenori; Nishibori, Masahiro; Takashiba, Shogo			Anti-HMGB1 Neutralizing Antibody Attenuates Periodontal Inflammation and Bone Resorption in a Murine Periodontitis Model	INFECTION AND IMMUNITY			English	Article						periodontal disease; cytokine; infectious disease; molecular imaging; bone resorption	MOBILITY-GROUP BOX-1; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; EPITHELIAL-CELLS; HMGB1; PROTEIN; MICE; LOCALIZATION; PATHOGENESIS	High mobility group box 1 (HMGB1) is a non-histone DNA-binding protein that is secreted into the extracellular milieu in response to inflammatory stimuli. The secreted HMGB1 mediates various inflammatory diseases, including periodontitis; however, the underlying mechanisms of HMGB1-induced periodontal inflammation are not completely understood. Here, we examined whether anti-HMGB1 neutralizing antibody inhibits periodontal progression and investigated the molecular pathology of HMGB1 in vitro and in vivo. In vitro analysis indicated that HMGB1, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-1 beta (IL-1 beta) were secreted in response to tumor necrosis wfactor-alpha (TNF-alpha) stimuli in human gingival epithelial cells (HGECs) and human monocytic leukemia cells (THP-1) treated with phorbol myristate acetate. Increased levels of GM-CSF and IL-1 beta were observed in the conditioned media from TNF-alpha-stimulated HGECs and THP-1 in vitro. Simultaneous stimulation with TNF-alpha and anti-HMGB1 antibody significantly decreased TNF-alpha induced inflammatory cytokine secretion. Experimental periodontitis was induced in mice using Porphyromonas gingivalis-soaked ligatures. The extracellular translocation was confirmed in gingival epithelia in the periodontitis model mice by immunofluorescence analysis. Systemic administration of anti-HMGB1 neutralizing antibody significantly inhibited translocation of HMGB1. The anti-HMGB1 antibody inhibited periodontal inflammation, expression of IL-1 beta and C-X-C motif chemokine ligand 1 (CXCL1), migration of neutrophils, and bone resorption, shown by bioluminescence imaging of myeloperoxidase activity, quantitative reverse transcription-PCR (RT-PCR), and micro-computed tomography analysis. These findings indicate that HMGB1 is secreted in response to inflammatory stimuli caused by periodontal infection, which is crucial for the initiation of periodontitis, and the anti-HMGB1 antibody attenuates the secretion of a series of inflammatory cytokines, consequently suppressing the progression of periodontitis.	[Yoshihara-Hirata, Chiaki; Yamashiro, Keisuke; Yamamoto, Tadashi; Aoyagi, Hiroaki; Ideguchi, Hidetaka; Kawamura, Mari; Suzuki, Risa; Takashiba, Shogo] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathophysiol Periodontal Sci, Okayama, Japan; [Ono, Mitsuaki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama, Japan; [Wake, Hidenori; Nishibori, Masahiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Okayama, Japan		Takashiba, S (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathophysiol Periodontal Sci, Okayama, Japan.	stakashi@okayama-u.ac.jp	Yamashiro, Keisuke/B-2455-2011; YAMAMOTO, Tadashi/B-2213-2011; Takashiba, Shogo/C-9830-2010	Yamashiro, Keisuke/0000-0003-1208-892X; YAMAMOTO, Tadashi/0000-0001-7180-1567; Takashiba, Shogo/0000-0002-4712-6829	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP 24792327]; Kobayashi Magobei Memorial Medical Foundation; Ryobi-Teien Foundation; MEXT, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Japan AMED [H27 seeds B-8-1]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16H06994] Funding Source: KAKEN	This work was supported by research funds from a JSPS KAKENHI Grant-in-Aid for Young Scientists (B) (JP 24792327), the Kobayashi Magobei Memorial Medical Foundation, and the Ryobi-Teien Foundation, by a Grant-in-Aid for the COE projects by MEXT, Japan, entitled "Center of excellence for molecular and gene targeting therapies with micro-dose molecular imaging modalities," and by a Translational Research Network Program (no. H27 seeds B-8-1) from Japan AMED. We declare no potential conflicts of interest with respect to the authorship and/or publication of this article.	Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Andersson U, 2014, J INTERN MED, V276, P420, DOI 10.1111/joim.12309; Andersson U, 2004, J INTERN MED, V255, P344, DOI 10.1111/j.1365-2796.2003.01303.x; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; [Anonymous], 1999, J PERIODONTOL, V70, P457; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Nogueira AVB, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/816320; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002; Ebe N, 2011, J DENT RES, V90, P235, DOI 10.1177/0022034510385688; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; Jonsson D, 2009, INFLAMM RES, V58, P791, DOI 10.1007/s00011-009-0049-z; Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P2320, DOI 10.1161/01.ATV.0000145573.36113.8a; Kanellakis P, 2011, ARTERIOSCL THROM VAS, V31, P313, DOI 10.1161/ATVBAHA.110.218669; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Knorr M, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00295; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Morimoto Y, 2008, J PERIODONTAL RES, V43, P76, DOI 10.1111/j.1600-0765.2007.00996.x; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x; Suda K, 2010, SURG TODAY, V40, P592, DOI 10.1007/s00595-009-4232-1; Tseng JC, 2015, OPTICAL IMAGING IVIS; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Willenbrock S, 2012, CYTOKINE, V57, P210, DOI 10.1016/j.cyto.2011.11.011; Yang H, 2005, J LEUKOCYTE BIOL, V78, P1, DOI 10.1189/jlb.1104648; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zupan J, 2013, BIOCHEM MEDICA, V23, P43, DOI 10.11613/BM.2013.007	34	28	29	1	9	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0019-9567	1098-5522		INFECT IMMUN	Infect. Immun.	MAY	2018	86	5							e00111-18	10.1128/IAI.00111-18			11	Immunology; Infectious Diseases	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases	GD6RY	WOS:000430637300029	29531138	Green Published, Bronze			2022-02-06	
J	Skandsen, T; Einarsen, CE; Normann, I; Bjoralt, S; Karlsen, RH; McDonagh, D; Nilsen, TL; Akslen, AN; Haberg, AK; Vik, A				Skandsen, Toril; Einarsen, Cathrine Elisabeth; Normann, Ingunn; Bjoralt, Stine; Karlsen, Rune Hatlestad; McDonagh, David; Nilsen, Tom Lund; Akslen, Andreas Nylenna; Haberg, Asta Kristine; Vik, Anne			The epidemiology of mild traumatic brain injury: the Trondheim MTBI follow-up study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Cohort studies; Mild traumatic brain injury; CT; Medical care; Epidemiology	ACUTE ALCOHOL-USE; HEAD-INJURY; EMERGENCY-DEPARTMENT; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; POPULATION; TBI; MULTICENTER; HOSPITALS; SEVERITY	Background: Mild traumatic brain injury (MTBI) is a frequent medical condition, and some patients report long-lasting problems after MTBI. In order to prevent MTBI, knowledge of the epidemiology is important and potential bias in studies should be explored. Aims of this study were to describe the epidemiological characteristics of MTBI in a Norwegian area and to evaluate the representativeness of patients successfully enrolled in the Trondheim MTBI follow-up study. Methods: During 81 weeks in 2014 and 2015, all persons aged 16-60 years, presenting with possible MTBI to the emergency department (ED) at St. Olavs Hospital, Trondheim University Hospital or to Trondheim municipal outpatient ED, were evaluated for participation in the follow-up study. Patients were identified by CT referrals and patient lists. Patients who were excluded or missed for enrolment in the follow-up study were recorded. Results: We identified 732 patients with MTBI. Median age was 28 years, and fall was the most common cause of injury. Fifty-three percent of injuries occurred during the weekend. Only 29% of MTBI patients were hospitalised. Study specific exclusion criteria were present in 23%. We enrolled 379 in the Trondheim MTBI follow-up study. In this cohort, Glasgow Coma Scale score was 15 at presentation in 73%; 45% of patients were injured under the influence of alcohol. Patients missed for inclusion were significantly more often outpatients, females, injured during the weekend, and suffering violent injuries, but differences between enrolled and not enrolled patients were small. Conclusion: Two thirds of all patients with MTBI in the 16-60 age group were treated without hospital admission, patients were often young, and half of the patients presented during the weekend. Fall was the most common cause of injury, and patients were commonly injured under the influence of alcohol, which needs to be addressed when considering strategies for prevention. The Trondheim MTBI follow-up study comprised patients who were highly representative for the underlying epidemiology of MTBI.	[Skandsen, Toril; Einarsen, Cathrine Elisabeth; Normann, Ingunn; Bjoralt, Stine; Karlsen, Rune Hatlestad; Akslen, Andreas Nylenna; Haberg, Asta Kristine; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Fac Med & Hlth Sci, Trondheim, Norway; [Skandsen, Toril; Einarsen, Cathrine Elisabeth; Karlsen, Rune Hatlestad] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [McDonagh, David] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Orthopaed, Trondheim, Norway; [McDonagh, David] Trondheim Kommune, Municipal Emergency Dept, Trondheim, Norway; [Haberg, Asta Kristine] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Radiol & Nucl Med, Trondheim, Norway; [Vik, Anne] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Neurosurgery, Trondheim, Norway; [Nilsen, Tom Lund] NTNU, Fac Med & Hlth Sci, Dept Publ Hlth & Nursing, Trondheim, Norway		Skandsen, T (corresponding author), Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Fac Med & Hlth Sci, Trondheim, Norway.; Skandsen, T (corresponding author), Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway.	toril.skandsen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Liaison Committee	The study was funded by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU). Toril Skandsen, Rune H. Karlsen and Cathrine E. Einarsen received separate research grants from the same committee.	Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Borges G, 2006, B WORLD HEALTH ORGAN, V84, P453, DOI 10.2471/BLT.05.027466; Borges G, 2006, ADDICTION, V101, P993, DOI 10.1111/j.1360-0443.2006.01462.x; Bye EK, 2010, DRUG ALCOHOL REV, V29, P131, DOI 10.1111/j.1465-3362.2009.00117.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; de Koning ME, 2017, BRAIN INJURY, V31, P1102, DOI 10.1080/02699052.2017.1296193; Koning ME, 2017, J NEUROTRAUM, V34, P257, DOI 10.1089/neu.2015.4377; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Foks KA, 2017, J NEUROTRAUM, V34, P2529, DOI 10.1089/neu.2016.4919; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Heskestad B, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-6; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Isokuortti H, 2016, J NEUROTRAUM, V33, P232, DOI 10.1089/neu.2015.3888; Kerr Zachary Y, 2014, N C Med J, V75, P8; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Pedersen K, 2015, NEUROEPIDEMIOLOGY, V45, P20, DOI 10.1159/000381780; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Rossow I, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1076; Scheenen ME, 2016, J NEUROTRAUM, V33, P339, DOI 10.1089/neu.2015.3926; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	37	28	28	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	APR 27	2018	26								34	10.1186/s13049-018-0495-0			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	GE6IT	WOS:000431330700002	29703222	gold, Green Published			2022-02-06	
J	Casili, G; Campolo, M; Paterniti, I; Lanza, M; Filippone, A; Cuzzocrea, S; Esposito, E				Casili, Giovanna; Campolo, Michela; Paterniti, Irene; Lanza, Marika; Filippone, Alessia; Cuzzocrea, Salvatore; Esposito, Emanuela			Dimethyl Fumarate Attenuates Neuroinflammation and Neurobehavioral Deficits Induced by Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; NF-kappa B; Nrf-2; oxidative stress; TBI	REMITTING MULTIPLE-SCLEROSIS; NF-KAPPA-B; NITRIC-OXIDE; INFLAMMATION; INHIBITOR; PROTECTS; NEURODEGENERATION; NEUROPROTECTION; EPIDEMIOLOGY; MITOCHONDRIA	Traumatic brain injury (TBI) is a serious neuropathology that causes secondary injury mechanisms, including dynamic interplay between ischemic, inflammatory, and cytotoxic processes. Fumaric acid esters (FAEs) showed beneficial effects in pre-clinical models of neuroinflammation and toxic oxidative stress, so the aim of the present work was to evaluate the potential beneficial effects of dimethyl fumarate (DMF), the most pharmacologically effective molecules among the FAEs, in a mouse model of TBI induced by controlled cortical impact (CCI). Mice were administered DMF orally at the doses of 1, 10, and 30 mg/kg 1 h and 4 h after CCI. We performed histological, molecular, and immunohistochemistry analysis on the traumatic penumbral areas of the brain 24 h after CCI. DMF treatment notably reduced histological damage and behavioral impairments, reducing neurodegeneration as evidenced by assessments of neuronal loss, Fluoro-Jade C, and TUNEL staining; also, treatment with DMF blocked the apoptosis process increasing B-cell lymphoma 2 (Bcl-2) expression in injured cortex. Further, DMF treatment up-regulated antioxidant Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor pathway, inducing activation of manganese superoxide dismutase and heme-oxygenase-1 and reducing 4-hydroxy-2-nonenal staining. Also, regulating the NF-kappa B pathway, DMF treatment decreased the severity of inflammation through a modulation of neuronal nitric oxide synthase, interleukin 1, tumor necrosis factor, cyclooxygenase 2, and myeloperoxidase activity, reducing ionized calcium-binding adapter molecule 1 and glial fibrillary acidic protein expression. Our results support the thesis that DMF may be an effective neuroprotectant after brain trauma and warrants further study.	[Casili, Giovanna; Campolo, Michela; Paterniti, Irene; Lanza, Marika; Filippone, Alessia; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy; [Cuzzocrea, Salvatore] St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO USA		Esposito, E (corresponding author), Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	eesposito@unime.it	Lanza, Marika/AAC-3741-2022; Campolo, Michela/K-6432-2016; Casili, Giovanna/AAC-3740-2022; Filippone, Alessia/AAC-3679-2022	Casili, Giovanna/0000-0002-0552-1396; Cuzzocrea, Salvatore/0000-0001-6131-3690; Filippone, Alessia/0000-0002-9642-6844			Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Arent AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723060; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Bellanti F, 2013, REDOX BIOL, V1, P340, DOI 10.1016/j.redox.2013.05.003; Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bomprezzi R, 2015, THER ADV NEUROL DISO, V8, P20, DOI 10.1177/1756285614564152; Bruschetta Giuseppe, 2017, Front Neurosci, V11, P6, DOI 10.3389/fnins.2017.00006; Campolo M, 2017, ANTIOXID REDOX SIGN, V27, P453, DOI 10.1089/ars.2016.6800; Campolo M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0196-1; Campolo M, 2013, FASEB J, V27, P4489, DOI 10.1096/fj.13-234716; Casili G, 2016, J CROHNS COLITIS, V10, P472, DOI 10.1093/ecco-jcc/jjv231; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00209; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Cheng ZG, 2013, ASIAN PAC J TROP MED, V6, P305, DOI 10.1016/S1995-7645(13)60061-9; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cordaro M, 2017, J NEUROTRAUM, V34, P3027, DOI 10.1089/neu.2016.4678; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; De la Fuente M, 2009, CURR PHARM DESIGN, V15, P3003, DOI 10.2174/138161209789058110; DeLong WG, 2004, CLIN ORTHOP RELAT R, P57, DOI 10.1097/01.blo.0000130840.64528.1e; Esposito E, 2014, PHARMACOL RES, V86, P26, DOI 10.1016/j.phrs.2014.05.009; Esposito E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041880; Garry PS, 2015, EXP NEUROL, V263, P235, DOI 10.1016/j.expneurol.2014.10.017; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Jin W, 2009, J SURG RES, V157, P251, DOI 10.1016/j.jss.2008.08.003; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Kappos L, 2008, LANCET, V372, P1463, DOI 10.1016/S0140-6736(08)61619-0; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Liu YZ, 2015, J NEUROSURG, V123, P915, DOI 10.3171/2014.11.JNS132348; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longbrake EE., 2015, MULT SCLER J EXP TRA, V1; Mendez-David I, 2015, NEUROSCI LETT, V597, P121, DOI 10.1016/j.neulet.2015.04.036; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Ryu S, 2015, EXP NEUROBIOL, V24, P31, DOI 10.5607/en.2015.24.1.31; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Vandermeeren M, 2001, J INVEST DERMATOL, V116, P124, DOI 10.1046/j.1523-1747.2001.00211.x; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang L, 2005, ANN CLIN LAB SCI, V35, P79; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yao Y, 2016, TRANSL STROKE RES, V7, P535, DOI 10.1007/s12975-016-0496-0; Yokoyama H, 2008, NEUROL SCI, V29, P293, DOI 10.1007/s10072-008-0986-2; Yu GL, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0583-x; Zhang XD, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0519-y; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506; Zhao XR, 2015, STROKE, V46, P1923, DOI 10.1161/STROKEAHA.115.009398	71	28	28	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	13					1437	1451		10.1089/neu.2017.5260		APR 2018	15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GJ4CQ	WOS:000430444900001	29361881				2022-02-06	
J	Lv, JF; Zeng, Y; Qian, Y; Dong, JF; Zhang, ZX; Zhang, JN				Lv, Jingfang; Zeng, Yong; Qian, Yu; Dong, Jingfei; Zhang, Zhixiang; Zhang, Jianning			MicroRNA let-7c-5p improves neurological outcomes in a murine model of traumatic brain injury by suppressing neuroinflammation and regulating microglial activation	BRAIN RESEARCH			English	Article						MicroRNA let-7c-5p; Traumatic brain injury; Microglia; Neuroinflammation	MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; KINASE-C-DELTA; NF-KAPPA-B; MACROPHAGE POLARIZATION; CEREBRAL-ISCHEMIA; WHITE-MATTER; INHIBITION; PROMOTES; MICE; PHENOTYPE	MicroRNAs (miRNAs) are a class of non-coding small RNAs that regulate the expression of target genes. They derive from pre-miRNAs that are enzymatically processed by dicer to 22 nucleotide mature miRNAs. Members of the pre-miRNA lethal-7 (let-7) are known to regulate cell proliferation and apoptosis. Here, we showed that the level of let-7c-5p, a key member of the let-7 family, was rapidly reduced in the traumatically injured foci in brains of adult C57BL/6J mice and gradually recovered to the pre-injury level 14 days after traumatic brain injury (TBI) induction. This finding led us to test whether upregulating let-7c-5p in murine cerebral tissue by intracerebroventricular injection (ICV) of let-7c-5p mimic could improve the outcomes of mice subjected to controlled cortical impact (CCI). We found that let-7c-5p overexpression attenuated TBI-induced neurological dysfunction and brain edema. The improvements were attributed to let-7c-5p-mediated inhibiting neuroinflammation and attenuation of microglia/-macrophage activation, both inhibiting M1 polarization and enhancing M2 polarization. In vitro experiments, we observed that let-7c-Sp was decreased in primary microglia activated by LPS treatment or oxygen/glucose deprivation (OGD). Transfection of let-7c-5p mimic suppressed the release of inflammatory mediators in cultured activated primary microglia. In addition, the expressions of caspase-3, a let-7c-5p putative target gene, and the PKC-delta which mediates effect of caspase-3 were inhibited by let-7c-5p in a murine model of TBI. Taken together, these results define the biological activities of cerebral let-7c-5p and delineate its therapeutic potential for improving the neurological outcome of TBI. (C) 2018 Elsevier B.V. All rights reserved.	[Lv, Jingfang; Qian, Yu; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Lv, Jingfang; Zeng, Yong; Qian, Yu; Zhang, Jianning] Tianjin Neurol Inst, Lab Neurotrauma, Tianjin, Peoples R China; [Lv, Jingfang; Zeng, Yong; Qian, Yu; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Lv, Jingfang; Zeng, Yong; Qian, Yu; Zhang, Jianning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin, Peoples R China; [Lv, Jingfang; Zhang, Zhixiang] Tianjin Med Univ, Gen Hosp, Tianjin Gen Surg Inst, Dept Gen Surg, Tianjin, Peoples R China; [Zeng, Yong] Tianjin First Ctr Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Dong, Jingfei] Blood Works Res Inst, Seattle, WA USA; [Dong, Jingfei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA		Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	tjjnzhang@163.com			National Natural Science Foundation of China State Key Program [81330029]; National Natural Science Foundation of China researchNational Natural Science Foundation of China (NSFC) [81271361, 81271359]	This work was supported by National Natural Science Foundation of China State Key Program (grant nos. 81330029) and National Natural Science Foundation of China research (grants nos. 81271361 and 81271359).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Banerjee S, 2013, J IMMUNOL, V190, P6542, DOI 10.4049/jimmunol.1202496; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Cardoso AL, 2016, CURR OPIN PHARMACOL, V26, P1, DOI 10.1016/j.coph.2015.09.001; Chen WW, 2016, MOL MED REP, V13, P3391, DOI 10.3892/mmr.2016.4948; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Dong TT, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0663-y; Essandoh K, 2016, SHOCK, V46, P122, DOI 10.1097/SHK.0000000000000604; Gao HB, 2017, BRAIN RES, V1657, P1, DOI 10.1016/j.brainres.2016.11.028; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jadhav SP, 2014, J NEUROCHEM, V130, P388, DOI 10.1111/jnc.12731; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kozlowski C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031814; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Ma L., 2017, BRAIN RES, V17, P30366; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Ni JS, 2015, BRAIN BEHAV IMMUN, V49, P75, DOI 10.1016/j.bbi.2015.04.014; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Shen XL, 2016, NAT IMMUNOL, V17, P1282, DOI 10.1038/ni.3545; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Tan MS, 2014, J ALZHEIMERS DIS, V38, P633, DOI 10.3233/JAD-131148; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu HT, 2012, BRAIN RES, V1486, P121, DOI 10.1016/j.brainres.2012.09.039; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Yao XL, 2017, J NEUROIMMUNOL, V310, P38, DOI 10.1016/j.jneuroim.2017.06.006; Yuan YM, 2015, BRAIN BEHAV IMMUN, V48, P287, DOI 10.1016/j.bbi.2015.04.008; Zhang JC, 2017, MOL NEUROBIOL, V54, P3652, DOI 10.1007/s12035-016-9924-0; Zhang W, 2015, CELL DEATH DIFFER, V22, P287, DOI 10.1038/cdd.2014.142	37	28	32	0	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	2018	1685						91	104		10.1016/j.brainres.2018.01.032			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GA7AW	WOS:000428488000009	29408500				2022-02-06	
J	Ley, EJ; Leonard, SD; Barmparas, G; Dhillon, NK; Inaba, K; Salim, A; O'Bosky, KR; Tatum, D; Azmi, H; Ball, CG; Engels, PT; Dunn, JA; Carrick, MM; Meizoso, JP; Lombardo, S; Cotton, BA; Schroeppel, TJ; Rizoli, S; Chang, DSJ; de Leon, LA; Rezende-Neto, J; Jacome, T; Xiao, J; Mallory, G; Rao, K; Widdel, L; Godin, S; Coates, A; Benedict, LA; Nirula, R; Kaul, S; Li, T				Ley, Eric J.; Leonard, Samuel D.; Barmparas, Galinos; Dhillon, Navpreet K.; Inaba, Kenji; Salim, Ali; O'Bosky, Karen R.; Tatum, Danielle; Azmi, Hooman; Ball, Chad G.; Engels, Paul T.; Dunn, Julie A.; Carrick, Matthew M.; Meizoso, Jonathan P.; Lombardo, Sarah; Cotton, Bryan A.; Schroeppel, Thomas J.; Rizoli, Sandro; Chang, David S. J.; de Leon, Luis Alejandro; Rezende-Neto, Joao; Jacome, Tomas; Xiao, Jimmy; Mallory, Gina; Rao, Krishnamurti; Widdel, Lars; Godin, Samuel; Coates, Angela; Benedict, Leo Andrew; Nirula, Raminder; Kaul, Sanjeev; Li, Tong			Beta blockers in critically ill patients with traumatic brain injury: Results from a multicenter, prospective, observational American Association for the Surgery of Trauma study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Beta blockade; beta blockers; catecholamines; propranolol; traumatic brain injury	PROGENITOR-CELL MOBILIZATION; EARLY PROPRANOLOL; CEREBRAL PERFUSION; HEAD-INJURY; BLOCKADE; METABOLISM; RECEPTORS; SURVIVAL; HISTORY; DEATH	BACKGROUND Beta blockers, a class of medications that inhibit endogenous catecholamines interaction with beta adrenergic receptors, are often administered to patients hospitalized after traumatic brain injury (TBI). We tested the hypothesis that beta blocker use after TBI is associated with lower mortality, and secondarily compared propranolol to other beta blockers. METHODS The American Association for the Surgery of Trauma Clinical Trial Group conducted a multi-institutional, prospective, observational trial in which adult TBI patients who required intensive care unit admission were compared based on beta blocker administration. RESULTS From January 2015 to January 2017, 2,252 patients were analyzed from 15 trauma centers in the United States and Canada with 49.7% receiving beta blockers. Most patients (56.3%) received the first beta blocker dose by hospital day 1. Those patients who received beta blockers were older (56.7 years vs. 48.6 years, p < 0.001) and had higher head Abbreviated Injury Scale scores (3.6 vs. 3.4, p < 0.001). Similarities were noted when comparing sex, admission hypotension, mean Injury Severity Score, and mean Glasgow Coma Scale. Unadjusted mortality was lower for patients receiving beta blockers (13.8% vs. 17.7%, p = 0.013). Multivariable regression determined that beta blockers were associated with lower mortality (adjusted odds ratio, 0.35; p < 0.001), and propranolol was superior to other beta blockers (adjusted odds ratio, 0.51, p = 0.010). A Cox-regression model using a time-dependent variable demonstrated a survival benefit for patients receiving beta blockers (adjusted hazard ratio, 0.42, p < 0.001) and propranolol was superior to other beta blockers (adjusted hazard ratio, 0.50, p = 0.003). CONCLUSION Administration of beta blockers after TBI was associated with improved survival, before and after adjusting for the more severe injuries observed in the treatment cohort. This study provides a robust evaluation of the effects of beta blockers on TBI outcomes that supports the initiation of a multi-institutional randomized control trial. LEVEL OF EVIDENCE Therapeutic/care management, level III.	[Ley, Eric J.; Barmparas, Galinos; Dhillon, Navpreet K.; Li, Tong] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Leonard, Samuel D.; Cotton, Bryan A.] Univ Texas Houston, Dept Surg, Div Acute Care Surg, Houston, TX USA; [Inaba, Kenji; de Leon, Luis Alejandro] Los Angeles Cty & USC Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA USA; [Salim, Ali; Benedict, Leo Andrew] Brigham & Womens Hosp, Dept Surg, Div Trauma Burns & Surg Crit Care, 75 Francis St, Boston, MA 02115 USA; [O'Bosky, Karen R.; Chang, David S. J.] Loma Linda Univ, Loma Linda, CA 92350 USA; [O'Bosky, Karen R.; Chang, David S. J.] Med Ctr, Dept Surg, Div Acute Care Surg, Loma Linda, CA USA; [Tatum, Danielle; Jacome, Tomas] Our Lady Lake Reg Med Ctr, Trauma Specialist Program, Baton Rouge, LA USA; [Azmi, Hooman; Kaul, Sanjeev] Hackensack Univ, Med Ctr, Dept Neurosurg, Hackensack, NJ USA; [Ball, Chad G.; Xiao, Jimmy] Univ Calgary, Foothills Med Ctr, Dept Surg, Calgary, AB, Canada; [Engels, Paul T.; Coates, Angela] McMaster Univ, Hamilton Gen Hosp, Dept Surg, Hamilton, ON, Canada; [Dunn, Julie A.; Widdel, Lars] Med Ctr Rockies, Dept Trauma & Acute Care Surg, Loveland, CO USA; [Carrick, Matthew M.; Mallory, Gina] Med City Plano, Trauma Serv Dept, Plano, TX USA; [Meizoso, Jonathan P.; Rao, Krishnamurti] Univ Miami, Jackson Mem Med Ctr, DeWitt Daughtry Family Dept Surg, Ryder Trauma Ctr, Miami, FL USA; [Lombardo, Sarah; Nirula, Raminder] Univ Utah, Div Gen Surg, Salt Lake City, UT USA; [Schroeppel, Thomas J.; Godin, Samuel] Mem Hosp, Dept Surg, Colorado Springs, CO USA; [Rizoli, Sandro; Rezende-Neto, Joao] St Michaels Hosp, Dept Trauma & Acute Care Surg, Toronto, ON, Canada		Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, 8700 Beverly Blvd,Suite 8215NT, Los Angeles, CA 90048 USA.	Eric.Ley@cshs.org	Engels, Paul/AAU-3049-2021; Barmparas, Galinos/L-6530-2019; INABA, KENJI/AAC-8532-2020; Meizoso, Jonathan/AAF-5777-2019	Meizoso, Jonathan/0000-0002-6616-6682; Schroeppel, Thomas/0000-0001-9164-5004; De Leon Castro, Luis Alejandro/0000-0001-7623-8603			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Ahl R, 2017, EUR J TRAUMA EMERG S, V43, P783, DOI 10.1007/s00068-017-0779-5; Alali AS, 2017, ANN SURG, V266, P952, DOI 10.1097/SLA.0000000000002286; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; [Anonymous], 2014, PROQUEST; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Baranski GM, 2012, J TRAUMA ACUTE CARE, V73, P343, DOI 10.1097/TA.0b013e31825a785a; Beiermeister KA, 2010, J TRAUMA, V69, P338, DOI 10.1097/TA.0b013e3181e5d35e; Bible LE, 2014, J TRAUMA ACUTE CARE, V77, P54, DOI 10.1097/TA.0000000000000264; Bukur M, 2012, J TRAUMA ACUTE CARE, V72, P1013, DOI 10.1097/TA.0b013e318241bc5b; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Da Luz LT, 2015, CATECHOLAMINES INDEP, V1604258; Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7; Eisenhofer G, 2004, PHARMACOL REV, V56, P331, DOI 10.1124/pr.56.3.1; Faul M, 2010, TRAUMATIC BRAIN INJU; Goldstein DS, 2017, CELL MOL NEUROBIOL; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Han RQ, 2009, ANESTH ANALG, V108, P280, DOI 10.1213/ane.0b013e318187ba6b; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Hendrick LE, 2016, AM SURGEON, V82, P575; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Ko A, 2016, J TRAUMA ACUTE CARE, V80, P637, DOI 10.1097/TA.0000000000000959; Kobilka B, 2013, ANGEW CHEM INT EDIT, V52, P6380, DOI 10.1002/anie.201302116; Lefkowitz RJ, 2013, ANGEW CHEM INT EDIT, V52, P6366, DOI 10.1002/anie.201301924; Ley EJ, 2012, J TRAUMA ACUTE CARE, V73, P33, DOI 10.1097/TA.0b013e31825a769b; Ley EJ, 2010, J SURG RES, V163, P142, DOI 10.1016/j.jss.2010.04.046; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Mohr AM, 2011, J TRAUMA, V70, P1043, DOI 10.1097/TA.0b013e3182169326; Mohseni S, 2014, J TRAUMA ACUTE CARE, V76, P804, DOI 10.1097/TA.0000000000000139; Murry JS, 2016, J SURG RES, V200, P221, DOI 10.1016/j.jss.2015.06.045; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; Pasupuleti LV, 2014, J TRAUMA ACUTE CARE, V76, P970, DOI 10.1097/TA.0000000000000181; Rizoli SB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1620-6; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Shetty T, 2016, SPORTS HEALTH, V8, P26, DOI 10.1177/1941738115588745; Stapleton MP, 1997, TEX HEART I J, V24, P336; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; Wang J, 2010, J NEUROIMMUNOL, V223, P77, DOI 10.1016/j.jneuroim.2010.04.006; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zangbar B, 2016, J SURG RES, V200, P586, DOI 10.1016/j.jss.2015.08.020	50	28	29	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2018	84	2					234	244		10.1097/TA.0000000000001747			11	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	FU7QR	WOS:000424048300002	29251711				2022-02-06	
J	Szarka, N; Pabbidi, MR; Amrein, K; Czeiter, E; Berta, G; Pohoczky, K; Helyes, Z; Ungvari, Z; Koller, A; Buki, A; Toth, P				Szarka, Nikolett; Pabbidi, Mallikarjuna R.; Amrein, Krisztina; Czeiter, Endre; Berta, Gergely; Pohoczky, Krisztina; Helyes, Zsuzsanna; Ungvari, Zoltan; Koller, Akos; Buki, Andras; Toth, Peter			Traumatic Brain Injury Impairs Myogenic Constriction of Cerebral Arteries: Role of Mitochondria-Derived H2O2 and TRPV4-Dependent Activation of BKca Channels	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; intracranial hypertension; oxidative stress; secondary injury	BLOOD-FLOW; HYDROGEN-PEROXIDE; SMOOTH-MUSCLE; NITRIC-OXIDE; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; AUTO-REGULATION; ANGIOTENSIN-II; AUTOREGULATION; DYSFUNCTION	Traumatic brain injury (TBI) impairs autoregulation of cerebral blood flow, which contributes to the development of secondary brain injury, increasing mortality of patients. Impairment of pressure-induced myogenic constriction of cerebral arteries plays a critical role in autoregulatory dysfunction; however, the underlying cellular and molecular mechanisms are not well understood. To determine the role of mitochondria-derived H2O2 and large-conductance calcium-activated potassium channels (BKCa) in myogenic autoregulatory dysfunction, middle cerebral arteries (MCAs) were isolated from rats with severe weight drop-impact acceleration brain injury. We found that 24 h post-TBI MCAs exhibited impaired myogenic constriction, which was restored by treatment with a mitochondria-targeted antioxidant (mitoTEMPO), by scavenging of H2O2 (polyethylene glycol [PEG]-catalase) and by blocking both BKCa channels (paxilline) and transient receptor potential cation channel subfamily V member 4 (TRPV4) channels (HC 067047). Further, exogenous administration of H2O2 elicited significant dilation of MCAs, which was inhibited by blocking either BKCa or TRPV4 channels. Vasodilation induced by the TRPV4 agonist GSK1016790A was inhibited by paxilline. In cultured vascular smooth muscle cells H2O2 activated BKCa currents, which were inhibited by blockade of TRPV4 channels. Collectively, our results suggest that after TBI, excessive mitochondria-derived H2O2 activates BKCa channels via a TRPV4-dependent pathway in the vascular smooth muscle cells, which impairs pressure-induced constriction of cerebral arteries. Future studies should elucidate the therapeutic potential of pharmacological targeting of this pathway in TBI, to restore autoregulatory function in order to prevent secondary brain damage and decrease mortality.	[Szarka, Nikolett; Amrein, Krisztina; Czeiter, Endre; Koller, Akos; Buki, Andras; Toth, Peter] Univ Pecs, Med Sch, Cerebrovasc Lab, Dept Neurosurg, Pecs, Hungary; [Amrein, Krisztina; Czeiter, Endre; Buki, Andras] Univ Pecs, Med Sch, Janos Szentagothai Res Ctr, Neurotrauma Res Grp, Pecs, Hungary; [Szarka, Nikolett; Toth, Peter] Univ Pecs, Med Sch, Dept Translat Med, Pecs, Hungary; [Berta, Gergely] Univ Pecs, Med Sch, Dept Med Biol, Pecs, Hungary; [Pohoczky, Krisztina; Helyes, Zsuzsanna] Univ Pecs, Med Sch, Dept Pharmacol & Pharmacotherapy, Pecs, Hungary; [Pabbidi, Mallikarjuna R.] Univ Mississippi, Med Ctr, Dept Pharmacol & Toxicol, Jackson, MS 39216 USA; [Czeiter, Endre; Toth, Peter] MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary; [Pohoczky, Krisztina; Helyes, Zsuzsanna] MTA PTE NAP B Chron Pain Res Grp, Pecs, Hungary; [Ungvari, Zoltan; Toth, Peter] Univ Oklahoma, Hlth Sci Ctr, Donald W Reynolds Dept Geriatr Med, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK USA; [Koller, Akos] Univ Phys Educ, Inst Nat Sci, Budapest, Hungary; [Koller, Akos] New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA		Toth, P (corresponding author), Univ Pecs, Dept Neurosurg, 2 Ret St, H-7624 Pecs, Hungary.	peter-toth@ouhsc.edu	Czeiter, Endre/B-1404-2009; Akos, Koller/Q-4672-2019	Czeiter, Endre/0000-0002-9578-6944	Marie Curie Actions SMARTER 7th Framework Program of the European Union [606998]; Hungarian Academy of Sciences Bolyai Research Scholarship [BO/00634/15]; PTE AOK-KA [3/2016 04.01/F]; National Research, Development and Innovation OfficeNational Research, Development & Innovation Office (NRDIO) - Hungary [NKFI-FK123798, K108444]; UNKP [UNKP-17-4-I-PTE-7]; Hungarian National Brain Research Program [KTIA_13_NAP-A-II/8]; American Heart AssociationAmerican Heart Association [13SDG14000005]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AT006526, R01-AG047879, R01-AG038747, 3P30AG050911-02S1, R01-NS056218]; Oklahoma Center for the Advancement of Science and Technology;  [GINOP-2.3, 2-15-2016-00048];  [AOK-Post-Doc 3/2012 07.25/C];  [B KTIA_NAP_13-2014-0022];  [888819]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS100782] Funding Source: NIH RePORTER	This work was supported by grants from the Marie Curie Actions SMARTER 7th Framework Program of the European Union 606998 to N.S. and A.K.; the Hungarian Academy of Sciences Bolyai Research Scholarship BO/00634/15 to P.T.; the PTE AOK-KA 3/2016 04.01/F to P.T.; grants from the National Research, Development and Innovation Office to P.T. (NKFI-FK123798) and A.K. (K108444); the UNKP UNKP-17-4-I-PTE-7 Scholarship to P.T.; GINOP-2.3, 2-15-2016-00048 to P.T., E.C., A.B.; AOK-Post-Doc 3/2012 07.25/C to G.B.; the Hungarian National Brain Research Program Grant No. KTIA_13_NAP-A-II/8 to P.T., E.C., and A.B.; Program B KTIA_NAP_13-2014-0022, Research site ID number: 888819 to Z.H.; the American Heart Association to M.R.P. (13SDG14000005), P.T., and Z.U.; the National Institutes of Health R01-AT006526, R01-AG047879, R01-AG038747, 3P30AG050911-02S1, and R01-NS056218 to Z.U.; and the Oklahoma Center for the Advancement of Science and Technology to Z.U. This work is dedicated to the 650th anniversary of the University of Pecs.	Arent AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723060; Armstead WM, 2011, J NEUROTRAUM, V28, P105, DOI 10.1089/neu.2010.1581; Bailey-Downs LC, 2012, J GERONTOL A-BIOL, V67, P553, DOI 10.1093/gerona/glr197; Barlow RS, 2000, AM J PHYSIOL-HEART C, V279, pH475, DOI 10.1152/ajpheart.2000.279.2.H475; Boveris A, 2000, IUBMB LIFE, V50, P245, DOI 10.1080/15216540051080912; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; Bubolz AH, 2012, AM J PHYSIOL-HEART C, V302, pH634, DOI 10.1152/ajpheart.00717.2011; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Budohoski KP, 2012, NEUROCRIT CARE, V17, P211, DOI 10.1007/s12028-011-9572-1; Cao Y, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0251-1; Case AJ, 2013, AM J PHYSIOL-HEART C, V305, pH19, DOI 10.1152/ajpheart.00974.2012; Chaplin NL, 2012, CHANNELS, V6, P385, DOI 10.4161/chan.21708; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Drose S, 2016, BBA-BIOENERGETICS, V1857, P946, DOI 10.1016/j.bbabio.2015.12.013; Earley S, 2005, CIRC RES, V97, P1270, DOI 10.1161/01.RES.0000194321.60300.d6; Earley S, 2009, AM J PHYSIOL-HEART C, V297, pH1096, DOI 10.1152/ajpheart.00241.2009; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; ENEVOLDSEN EM, 1977, ACTA NEUROL SCAND, V56, P514; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Gidday JM, 1999, J NEUROTRAUM, V16, P27, DOI 10.1089/neu.1999.16.27; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Greensmith DJ, 2010, CELL CALCIUM, V48, P341, DOI 10.1016/j.ceca.2010.10.007; Guikema BJ, 2005, FREE RADICAL BIO MED, V38, P597, DOI 10.1016/j.freeradbiomed.2004.11.022; Hayabuchi Y, 1998, HEART VESSELS, V13, P9, DOI 10.1007/BF02750638; Iida Y, 2000, STROKE, V31, P2224, DOI 10.1161/01.STR.31.9.2224; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kim JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163433; Kisler K, 2017, NAT REV NEUROSCI, V18, P419, DOI 10.1038/nrn.2017.48; KNOT HJ, 1995, AM J PHYSIOL-HEART C, V269, pH348, DOI 10.1152/ajpheart.1995.269.1.H348; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Liu YP, 2003, CIRC RES, V93, P573, DOI 10.1161/01.RES.0000091261.19387.AE; Lopez-Fabuel I, 2016, P NATL ACAD SCI USA, V113, P13063, DOI 10.1073/pnas.1613701113; Manucha W, 2017, CLIN INVEST ARTERIOS, V29, P92, DOI 10.1016/j.arteri.2016.04.002; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Matoba T, 2000, J CLIN INVEST, V106, P1521, DOI 10.1172/JCI10506; Modrick ML, 2009, J CEREBR BLOOD F MET, V29, P1130, DOI 10.1038/jcbfm.2009.37; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; OVERGAARD J, 1974, 1 CEREBRAL BLOOD FLO, V41, P531; Paterno R, 2000, AM J PHYSIOL-HEART C, V278, pH2003, DOI 10.1152/ajpheart.2000.278.6.H2003; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Price Raymond S, 2014, Handb Clin Neurol, V119, P161, DOI 10.1016/B978-0-7020-4086-3.00012-6; Randhawa PK, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0512-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Salvucci A, 2000, BRAIN RES, V887, P406, DOI 10.1016/S0006-8993(00)03079-1; Springo Z, 2015, J GERONTOL A-BIOL, V70, P1355, DOI 10.1093/gerona/glu244; Suresh K, 2015, AM J PHYSIOL-LUNG C, V309, pL1467, DOI 10.1152/ajplung.00275.2015; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Toth P, 2017, AM J PHYSIOL-HEART C, V312, pH1, DOI 10.1152/ajpheart.00581.2016; Toth P, 2014, J CEREBR BLOOD F MET, V34, P1887, DOI 10.1038/jcbfm.2014.156; Toth P, 2013, J CEREBR BLOOD F MET, V33, P1732, DOI 10.1038/jcbfm.2013.143; Toth P, 2011, J CEREBR BLOOD F MET, V31, P2096, DOI 10.1038/jcbfm.2011.74; Ungvari Z, 1999, STROKE, V30, P1949, DOI 10.1161/01.STR.30.9.1949; Ungvari Z, 2001, J APPL PHYSIOL, V91, P522, DOI 10.1152/jappl.2001.91.1.522; Villalba N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001474; Wang F, 2014, NEUROTOXICOLOGY, V41, P54, DOI 10.1016/j.neuro.2014.01.002; Wang JN, 2012, FREE RADICAL BIO MED, V52, P173, DOI 10.1016/j.freeradbiomed.2011.10.442; Zhang DX, 2012, CIRC RES, V110, P471, DOI 10.1161/CIRCRESAHA.111.258871; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	71	28	29	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2018	35	7					930	939		10.1089/neu.2017.5056		JAN 2018	10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GC0NF	WOS:000419902500001	29179622	Green Published			2022-02-06	
J	Allan, V; Vierimaa, M; Gainforth, HL; Cote, J				Allan, Veronica; Vierimaa, Matthew; Gainforth, Heather L.; Cote, Jean			The use of behaviour change theories and techniques in research-informed coach development programmes: a systematic review	INTERNATIONAL REVIEW OF SPORT AND EXERCISE PSYCHOLOGY			English	Article						Sport coaching; coach education; implementation science	MOTIVATIONAL CLIMATE INTERVENTION; FOR-DISEASE-CONTROL; PHYSICAL-ACTIVITY; SOCIAL SUPPORT; SPORTS COACHES; SELF-ESTEEM; EDUCATION; PERFORMANCE; EXPERIENCES; CONCUSSION	Coaches are often targeted in interventions to enhance athlete outcomes. While coach development programmes (CDPs) may change coach behaviour, little is known about theories and techniques used to design and implement effective programmes. Examining the use of behaviour change theories and techniques (BCTs) can aid in understanding and improving CDPs. Adhering to PRISMA guidelines, the purpose of this research was to conduct a systematic review examining the use of behaviour change theories and BCTs in CDPs. In total, 29 CDPs met the inclusion criteria. Data were extracted using the Theory Coding Scheme and Behaviour Change Technique Taxonomy (v1). Only six CDPs were explicitly based on behaviour change theory, and no single theory or combination of theories was used more than once. The number of BCTs used per CDP ranged between one and nine. There was no significant difference between theory-based and non-theory-based CDPs concerning the number of BCTs used per CDP. Theoretical frameworks and techniques that have the potential to effectively change coach behaviours are not being used frequently or consistently in the design and implementation of CDPs. To design CDPs that change coach behaviours and facilitate positive outcomes, further research examining theoretical influences on coach behaviours is needed.	[Allan, Veronica; Cote, Jean] Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada; [Vierimaa, Matthew] Utah State Univ, Dept Kinesiol & Hlth Sci, Logan, UT 84322 USA; [Gainforth, Heather L.] Univ British Columbia, Sch Hlth & Exercise Sci, Kelowna, BC, Canada		Allan, V (corresponding author), Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada.	7vra@queensu.ca	Cote, Jean/D-6344-2014	Gainforth, Heather/0000-0002-3281-1110			Banack HR, 2012, INT J SPORTS SCI COA, V7, P301, DOI 10.1260/1747-9541.7.2.301; Barnett N.P., 1992, SPORT PSYCHOL, V6, P111, DOI [DOI 10.1123/TSP.6.2.111, https://doi.org/10.1123/tsp.6.2.111]; Blom L. C., 2010, ATHLETIC INSIGHT, V12, P187; Bowes I, 2006, SPORT PSYCHOL, V20, P235, DOI 10.1123/tsp.20.2.235; Bruner M.W., 2009, INT REV SPORT EXER P, V2, P23, DOI [https://doi.org/10.1080/17509840802687631, DOI 10.1080/17509840802687631]; Bruner MW, 2010, PSYCHOL SPORT EXERC, V11, P133, DOI 10.1016/j.psychsport.2009.05.008; BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V; Callary B, 2014, INT SPORT COACH J, V1, P152, DOI 10.1123/iscj.2014-0094; Callow N, 2010, SPORT PSYCHOL, V24, P277, DOI 10.1123/tsp.24.3.277; Cassidy T., 2009, UNDERSTANDING SPORTS, V2nd; Chambers KL, 2006, SPORT PSYCHOL, V20, P184, DOI 10.1123/tsp.20.2.184; Cheon SH, 2015, PSYCHOL SPORT EXERC, V19, P59, DOI 10.1016/j.psychsport.2015.02.007; Coatsworth JD, 2006, PSYCHOL SPORT EXERC, V7, P173, DOI 10.1016/j.psychsport.2005.08.005; Conroy DE, 2006, SPORT PSYCHOL, V20, P128, DOI 10.1123/tsp.20.2.128; Cushion C., 2010, COACH LEARNING DEV R; Cushion C. J., 2006, INT J SPORTS SCI COA, V1, P247, DOI DOI 10.1260/174795406778604627; Davies P, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-14; Duda JL, 2013, INT J SPORT EXERC PS, V11, P319, DOI 10.1080/1612197X.2013.839413; Duda JL, 2013, INT J SPORT EXERC PS, V11, P311, DOI 10.1080/1612197X.2013.839414; Duncan EM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-86; Edwards J, 2012, INT J SPORTS SCI COA, V7, P317, DOI 10.1260/1747-9541.7.2.317; Evans MB, 2015, BRIT J SPORT MED, V49, P871, DOI 10.1136/bjsports-2015-094634; Franks IM, 1991, J SPORT SCI, V9, P285, DOI 10.1080/02640419108729890; Fraser-Thomas J. L., 2005, Physical Education and Sport Pedagogy, V10, P19, DOI 10.1080/1740898042000334890; Fraser-Thomas J, 2009, SPORT PSYCHOL, V23, P3, DOI 10.1123/tsp.23.1.3; Gainforth HL, 2015, ANN BEHAV MED, V49, P754, DOI 10.1007/s12160-015-9710-7; Gianotti S, 2010, J SCI MED SPORT, V13, P32, DOI 10.1016/j.jsams.2008.07.010; Gilbert WD, 2004, RES Q EXERCISE SPORT, V75, P388, DOI 10.1080/02701367.2004.10609172; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Guagliano JM, 2015, J SCI MED SPORT, V18, P678, DOI 10.1016/j.jsams.2015.05.005; Guagliano JM, 2015, J SCI MED SPORT, V18, P412, DOI 10.1016/j.jsams.2015.01.014; Guagliano JM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-383; Hall C.R., 1989, SPORT PSYCHOL, V3, P142, DOI DOI 10.1123/TSP.3.2.142; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hilland TA, 2015, INT J HEALTH PROMOT, V53, P2, DOI 10.1080/14635240.2014.915758; Jones R. L., 2006, Physical Education and Sport Pedagogy, V11, P181, DOI 10.1080/17408980600708429; Jones RL, 2005, SPORT EDUC SOC, V10, P119, DOI 10.1080/1357332052000308792; Knowles Z., 2001, REFLECTIVE PRACTICE, V2, P185, DOI DOI 10.1080/14623940123820; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langdon J, 2015, J HUM SPORT EXERC, V10, P1, DOI 10.14198/jhse.2015.101.01; Larsen T, 2015, HEALTH EDUC, V115, P570, DOI 10.1108/HE-04-2014-0054; Longshore K, 2015, J CLIN SPORT PSYCHOL, V9, P116, DOI 10.1123/jcsp.2014-0038; Malete L, 2000, SPORT PSYCHOL, V14, P410, DOI 10.1123/tsp.14.4.410; McCullick B. A., 2005, Physical Education and Sport Pedagogy, V10, P121, DOI 10.1080/17408980500105015; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McLaren CD, 2015, SPORT EXERC PERFORM, V4, P113, DOI 10.1037/spy0000026; McSherry LA, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-73; Medical Research Council (UK), 2008, DEV EV COMPL INT NEW; Michie S., 2014, ABC BEHAV CHANGE THE, V1st; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10; Michie S, 2010, HEALTH PSYCHOL, V29, P1, DOI 10.1037/a0016939; Nagel E., 1979, STRUCTURE SCI; Nelson L, 2013, PHYS EDUC SPORT PEDA, V18, P204, DOI 10.1080/17408989.2011.649725; Overton W. F., 2006, HDB CHILD PSYCHOL, V1; Painter JE, 2008, ANN BEHAV MED, V35, P358, DOI 10.1007/s12160-008-9042-y; Meeus MSP, 2010, J CLIN SPORT PSYCHOL, V4, P323, DOI 10.1123/jcsp.4.4.323; Pensgaard AM, 2000, J SPORT SCI, V18, P191, DOI 10.1080/026404100365090; Pensgaard AM, 2002, SCAND J MED SCI SPOR, V12, P54, DOI 10.1034/j.1600-0838.2002.120110.x; Prestwich A, 2014, HEALTH PSYCHOL, V33, P465, DOI 10.1037/a0032853; Rangeon S, 2012, INT SPORT COACH J, V5, P83, DOI 10.1123/jce.5.1.83; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sawyer RJ, 2010, HEALTH PROMOT PRACT, V11, P34, DOI 10.1177/1524839907309377; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]; SMITH RE, 1995, J APPL DEV PSYCHOL, V16, P125, DOI 10.1016/0193-3973(95)90020-9; Smith RE, 2007, J SPORT EXERCISE PSY, V29, P39, DOI 10.1123/jsep.29.1.39; SMOLL FL, 1993, J APPL PSYCHOL, V78, P602, DOI 10.1037/0021-9010.78.4.602; Smoll FL, 2007, J CLIN SPORT PSYCHOL, V1, P23, DOI 10.1123/jcsp.1.1.23; Sousa C, 2008, J CLIN SPORT PSYCHOL, V2, P258, DOI 10.1123/jcsp.2.3.258; Stebbings J, 2012, J SPORT EXERCISE PSY, V34, P481, DOI 10.1123/jsep.34.4.481; Stebbings J, 2011, J SPORT EXERCISE PSY, V33, P255, DOI 10.1123/jsep.33.2.255; Tavender EJ, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-8; THOMPSON N, 2003, THEORY PRACTICE HUMA; Vella SA, 2013, INT J SPORTS SCI COA, V8, P513, DOI 10.1260/1747-9541.8.3.513; Vella SA, 2013, INT J SPORTS SCI COA, V8, P417, DOI 10.1260/1747-9541.8.2.417; Werthner P, 2006, SPORT PSYCHOL, V20, P198, DOI 10.1123/tsp.20.2.198; Zakrajsek RA, 2008, INT SPORT COACH J, V1, P66, DOI 10.1123/ice.1.1.66	77	28	28	1	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1750-984X	1750-9858		INT REV SPORT EXER P	Int. Rev. Sport Exerc. Psychol.		2018	11	1					47	69		10.1080/1750984X.2017.1286514			23	Hospitality, Leisure, Sport & Tourism; Psychology, Applied	Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Psychology	GL1BH	WOS:000436829700003					2022-02-06	
J	Houck, Z; Asken, B; Clugston, J; Perlstein, W; Bauer, R				Houck, Zac; Asken, Breton; Clugston, James; Perlstein, William; Bauer, Russell			Socioeconomic Status and Race Outperform Concussion History and Sport Participation in Predicting Collegiate Athlete Baseline Neurocognitive Scores	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neurocognitive; Baseline; Concussion; Socioeconomic Status; Neurobiopsychosocial; Collegiate student-athletes	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; DEFICIT HYPERACTIVITY DISORDER; AFRICAN-AMERICAN; HEALTH RESEARCH; READING LEVEL; UNITED-STATES; EDUCATION; FOOTBALL; AGE; IQ	Objectives: The purpose of this study was to assess the contribution of socioeconomic status (SES) and other multivariate predictors to baseline neurocognitive functioning in collegiate athletes. Methods: Data were obtained from the Concussion Assessment, Research and Education (CARE) Consortium. Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) baseline assessments for 403 University of Florida student-athletes (202 males; age range: 18-23) from the 2014-2015 and 2015-2016 seasons were analyzed. ImPACT composite scores were consolidated into one memory and one speed composite score. Hierarchical linear regressions were used for analyses. Results: In the overall sample, history of learning disability (beta = -0.164; p = .001) and attention deficit-hyperactivity disorder (beta = -0.102; p = .038) significantly predicted worse memory and speed performance, respectively. Older age predicted better speed performance (beta = .176; p < .001). Black/African American race predicted worse memory (beta = -0.113; p = .026) and speed performance (beta = -.242; p < .001). In football players, higher maternal SES predicted better memory performance (beta = 0.308; p = .007); older age predicted better speed performance (beta = 0.346; p = .001); while Black/African American race predicted worse speed performance (beta = -0.397; p < .001). Conclusions: Baseline memory and speed scores are significantly influenced by history of neurodevelopmental disorder, age, and race. In football players, specifically, maternal SES independently predicted baseline memory scores, but concussion history and years exposed to sport were not predictive. SES, race, and medical history beyond exposure to brain injury or subclinical brain trauma are important factors when interpreting variability in cognitive scores among collegiate athletes. Additionally, sport-specific differences in the proportional representation of various demographic variables (e.g., SES and race) may also be an important consideration within the broader biopsychosocial attributional model.	[Houck, Zac; Asken, Breton; Perlstein, William; Bauer, Russell] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; [Clugston, James] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL 32610 USA		Houck, Z (corresponding author), Univ Florida, 1225 Ctr Dr,Room 3151, Gainesville, FL 32610 USA.	zhouck@phhp.ufl.edu		Asken, Breton/0000-0001-8419-142X; Clugston, James/0000-0002-2103-1039	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of DefenseUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, in part by the National Collegiate Athletic Association (NCAA) and the Department of Defense. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Ford Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense (DHP funds). No conflict of interest exists among authors.	Alosco ML, 2014, BRAIN INJURY, V28, P472, DOI 10.3109/02699052.2014.887145; Andersson HW, 1996, PSYCHOL REP, V79, P3, DOI 10.2466/pr0.1996.79.1.3; [Anonymous], 2015, COLL SPORT RAC GEND; Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Blom G, 1958, STAT ESTIMATES TRANS; Bradley RH, 2001, CHILD DEV, V72, P1868, DOI 10.1111/1467-8624.t01-1-00383; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cook N.E., 2017, CLIN NEUROPSYCHOL, P1; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Darling-Hammond Linda., 2004, WEB DUBOIS REV SOCIA, V1, P213, DOI DOI 10.1017/S1742058X0404202X; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; Dotson VM, 2008, CLIN NEUROPSYCHOL, V22, P989, DOI 10.1080/13854040701679017; Dotson VM, 2009, J INT NEUROPSYCH SOC, V15, P580, DOI 10.1017/S1355617709090821; Duncan G.J., 2003, CHILD CARE HLTH DEV, V27, P97; DUNCAN GJ, 1994, CHILD DEV, V65, P296, DOI 10.2307/1131385; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gerrard PB, 2017, ARCH CLIN NEUROPSYCH, V32, P117, DOI 10.1093/arclin/acw097; GOTTFRIED AW, 1985, MERRILL PALMER QUART, V31, P85; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Jones NS, 2014, CLIN J SPORT MED, V24, P284, DOI 10.1097/JSM.0000000000000031; Kaplan GA, 2001, INT J EPIDEMIOL, V30, P256, DOI 10.1093/ije/30.2.256; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; KORENMAN S, 1995, CHILD YOUTH SERV REV, V17, P127, DOI 10.1016/0190-7409(95)00006-X; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Littleton AC, 2015, ARCH CLIN NEUROPSYCH, V30, P683, DOI 10.1093/arclin/acv043; Lovell M, 2000, IMPACT IMMEDIATE POS; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Manly JJ, 2004, APPL NEUROPSYCHOL, V11, P37, DOI 10.1207/s15324826an1101_5; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCrory P., 2017, BRIT J SPORTS MED; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Pastor P.N., 2009, DIAGNOSED ATTENTION; Shuttleworth-Edwards AB, 2004, J CLIN EXP NEUROPSYC, V26, P903, DOI 10.1080/13803390490510824; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Williams DR, 1997, ANN EPIDEMIOL, V7, P322, DOI 10.1016/S1047-2797(97)00051-3	41	28	28	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2018	24	1					1	10		10.1017/S1355617717000716			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	FR6BL	WOS:000419150300001	28791942				2022-02-06	
S	Lucas, A; Yaron, JR; Zhang, LQ; Ambadapadi, S		Lucas, A		Lucas, Alexandra; Yaron, Jordan R.; Zhang, Liqiang; Ambadapadi, Sriram			Overview of Serpins and Their Roles in Biological Systems	SERPINS: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Serpin; Serpinopathy; Peptides; Bacteria; Malaria; Virus; Phage; Kinetics; Crystallography; Thrombosis; Trypsin; Inflammation; Neurotrauma; Microbiome	PLASMINOGEN-ACTIVATOR; POLYMERIZATION; INHIBITION; PROTEINASE; MECHANISM; SURVIVAL	Serine protease inhibitors are ubiquitous regulators for a multitude of pathways in humans. The serpins represent an ancient pathway now known to be present in all kingdoms and often regulating central pathways for clotting, immunity, and even cancer in man. Serpins have been present from the time of the dinosaurs and can represent a large proportion of circulating blood proteins. With this introductory chapter, we present an overview of serpins as well as an introduction and overview of the chapters describing the methodology used in the new approaches to understanding their molecular mechanisms of action and their roles in health and disease.	[Lucas, Alexandra] Arizona State Univ, Biodesign Ctr Personalized Diagnost, Tempe, AZ 85281 USA; [Lucas, Alexandra; Yaron, Jordan R.; Zhang, Liqiang; Ambadapadi, Sriram] Arizona State Univ, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst, Tempe, AZ 85281 USA; [Lucas, Alexandra; Yaron, Jordan R.; Zhang, Liqiang; Ambadapadi, Sriram] Arizona State Univ, Ctr Personalized Diagnost, Biodesign Inst, Tempe, AZ 85281 USA; [Lucas, Alexandra] St Josephs Hosp, Div Cardiol, Dign Hlth, Phoenix, AZ 85013 USA; [Lucas, Alexandra; Ambadapadi, Sriram] Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL 32611 USA; [Lucas, Alexandra; Ambadapadi, Sriram] Univ Florida, Dept Med, Div Rheumatol, Gainesville, FL 32611 USA; [Ambadapadi, Sriram] Pharmacyclics LLC, Sunnyvale, CA USA		Lucas, A (corresponding author), Arizona State Univ, Biodesign Ctr Personalized Diagnost, Tempe, AZ 85281 USA.; Lucas, A (corresponding author), Arizona State Univ, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst, Tempe, AZ 85281 USA.; Lucas, A (corresponding author), Arizona State Univ, Ctr Personalized Diagnost, Biodesign Inst, Tempe, AZ 85281 USA.; Lucas, A (corresponding author), St Josephs Hosp, Div Cardiol, Dign Hlth, Phoenix, AZ 85013 USA.; Lucas, A (corresponding author), Univ Florida, Dept Med, Div Cardiovasc Med, Gainesville, FL 32611 USA.; Lucas, A (corresponding author), Univ Florida, Dept Med, Div Rheumatol, Gainesville, FL 32611 USA.		Yaron, Jordan R/S-1136-2019; Zhang, Liqiang/D-4987-2015	Yaron, Jordan R/0000-0002-4133-474X; 			Bauman S.J, 2002, CURR PROTOC PROTEIN, V21, P7; Carrell RW, 2017, SEMIN CELL DEV BIOL, V62, P133, DOI 10.1016/j.semcdb.2016.12.007; Chan WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113402; Chen H, 2013, ANTIMICROB AGENTS CH, V57, P4114, DOI 10.1128/AAC.02594-12; Csuka D, 2017, MOL IMMUNOL, V89, P59, DOI 10.1016/j.molimm.2017.05.020; Dai EB, 2006, J BIOL CHEM, V281, P8041, DOI 10.1074/jbc.M509454200; Eappen AG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062937; Foernvik K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183086; Gettins PGW, 2016, BIOCHEM J, V473, P2273, DOI 10.1042/BCJ20160014; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gooptu B, 2014, TRENDS MOL MED, V20, P116, DOI 10.1016/j.molmed.2013.10.007; Gupta KK, 2016, BIOCHEM BIOPH RES CO, V477, P503, DOI 10.1016/j.bbrc.2016.06.065; Hughes VA, 2017, PLOS ONE, V9; Huntington JA, 2011, J THROMB HAEMOST, V9, P26, DOI 10.1111/j.1538-7836.2011.04360.x; Irving JA, 2011, METHOD ENZYMOL, V501, P421, DOI 10.1016/B978-0-12-385950-1.00018-3; Ishikawa M, 2017, J SURG RES, V208, P140, DOI 10.1016/j.jss.2016.09.041; Kawabata S, 2010, J BIOCHEM, V147, P611, DOI 10.1093/jb/mvq026; Leisegang R, 2005, J I BREWING, V111, P112, DOI 10.1002/j.2050-0416.2005.tb00656.x; LOMAS DA, 1993, J BIOL CHEM, V268, P516; Mazzoccoli G, 2012, J CANCER RES CLIN, V138, P501, DOI 10.1007/s00432-011-1126-6; Mejia P, 2016, PLOS ONE, V11; Mejia P, 2016, J INFECT DIS, V213, P80, DOI 10.1093/infdis/jiv439; Mulder R, 2017, BRIT J HAEMATOL, V178, P279, DOI 10.1111/bjh.14658; Rau JC, 2007, J THROMB HAEMOST, V5, P102, DOI 10.1111/j.1538-7836.2007.02516.x; Roussel BD, 2016, EPILEPTIC DISORD, V18, pS103, DOI 10.1684/epd.2016.0847; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Simone TM, 2015, CELL SIGNAL, V27, P923, DOI 10.1016/j.cellsig.2015.01.009; Viswanathan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044694; Williams AR, 2013, INT J PARASITOL, V43, P869, DOI 10.1016/j.ijpara.2013.06.004	29	28	29	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-4939-8645-3; 978-1-4939-8644-6	METHODS MOL BIOL	Methods Mol. Biol.		2018	1826						1	7		10.1007/978-1-4939-8645-3_1	10.1007/978-1-4939-8645-3		7	Biochemical Research Methods; Biochemistry & Molecular Biology	Book Citation Index – Science (BKCI-S)	Biochemistry & Molecular Biology	BM1XI	WOS:000460670300002	30194590				2022-02-06	
J	Perez-Garcia, G; de Gasperi, R; Sosa, MAG; Perez, GM; Otero-Pagan, A; Tschiffely, A; McCarron, RM; Ahlers, ST; Elder, GA; Gandy, S				Perez-Garcia, Georgina; de Gasperi, Rita; Sosa, Miguel A. Gama; Perez, Gissel M.; Otero-Pagan, Alena; Tschiffely, Anna; McCarron, Richard M.; Ahlers, Stephen T.; Elder, Gregory A.; Gandy, Sam			PTSD-Related Behavioral Traits in a Rat Model of Blast-Induced mTBI Are Reversed by the mGluR2/3 Receptor Antagonist BCI-838	ENEURO			English	Article						BCI-838; blast; metabotropic glutamate receptor; mGluR2/3; posttraumatic stress disorder; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HIPPOCAMPAL NEUROGENESIS; NADPH OXIDASE; WAR VETERANS; EXPOSURE; MGS0039; DOUBLECORTIN; ACTIVATION; ANXIETY	Battlefield blast exposure related to improvised explosive devices (IEDs) has become the most common cause of traumatic brain injury (TBI) in the recent conflicts in Iraq and Afghanistan. Mental health problems are common after TBI. A striking feature in the most recent veterans has been the frequency with which mild TBI (mTBI) and posttraumatic stress disorder (PTSD) have appeared together, in contrast to the classical situations in which the presence of mTBI has excluded the diagnosis of PTSD. However, treatment of PTSD-related symptoms that follow blast injury has become a significant problem. BCI-838 (MGS0210) is a Group II metabotropic glutamate receptor (mGluR2/3) antagonist prodrug, and its active metabolite BCI-632 (MGS0039) has proneurogenic, procognitive, and antidepressant activities in animal models. In humans, BCI-838 is currently in clinical trials for refractory depression and suicidality. The aim of the current study was to determine whether BCI-838 could modify the anxiety response and reverse PTSD-related behaviors in rats exposed to a series of low-level blast exposures designed to mimic a human mTBI or subclinical blast exposure. BCI-838 treatment reversed PTSD-related behavioral traits improving anxiety and fear-related behaviors as well as long-term recognition memory. Treatment with BCI-838 also increased neurogenesis in the dentate gyrus (DG) of blast-exposed rats. The safety profile of BCI-838 together with the therapeutic activities reported here, make BCI-838 a promising drug for the treatment of former battlefield Warfighters suffering from PTSD-related symptoms following blast-induced mTBI.	[Perez-Garcia, Georgina; de Gasperi, Rita; Sosa, Miguel A. Gama; Perez, Gissel M.; Otero-Pagan, Alena; Elder, Gregory A.; Gandy, Sam] James J Peters Vet Affairs Med Ctr, Res & Dev, Bronx, NY 10468 USA; [Perez-Garcia, Georgina; Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Perez-Garcia, Georgina; Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA; [de Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [de Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.; Gandy, Sam] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Tschiffely, Anna; McCarron, Richard M.; Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Dept Neurotrauma, Silver Spring, MD 20910 USA; [McCarron, Richard M.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA		Elder, GA; Gandy, S (corresponding author), James J Peters Vet Affairs Med Ctr, Res & Dev, Bronx, NY 10468 USA.; Elder, GA; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Elder, GA; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA.; Elder, GA; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Elder, GA; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.	gregory.elder@mssm.edu; samuel.gandy@mssm.edu		Elder, Gregory/0000-0001-7035-8380	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [1I01RX000684, 1I01RX000996]; DoDUnited States Department of Defense [0000B999.0000.000.A1503]; Veterans AffairsUS Department of Veterans Affairs [I01RX002333, I01RX000996] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000684 (to S.G.) 1I01RX000996 (to G.A.E) and by DoD Work Unit Number 0000B999.0000.000.A1503.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Jorge MSB, 2014, REV ESC ENFERM USP, V48, P1059, DOI 10.1590/S0080-623420140000700014; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Campo B, 2011, J NEUROGENET, V25, P152, DOI 10.3109/01677063.2011.627485; Celanire S, 2015, EXPERT OPIN THER PAT, V25, P69, DOI 10.1517/13543776.2014.983899; Chaki S, 2017, TRENDS PHARMACOL SCI, V38, P569, DOI 10.1016/j.tips.2017.03.008; Chase Alex, 2015, Nat Rev Neurol, V11, P309, DOI 10.1038/nrneurol.2015.83; Cryan JF, 2011, BRIT J PHARMACOL, V164, P1129, DOI 10.1111/j.1476-5381.2011.01362.x; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Gubata ME, 2014, J HEAD TRAUMA REHAB, V29, P65, DOI 10.1097/HTR.0b013e318295f590; Higgins GA, 2004, NEUROPHARMACOLOGY, V46, P907, DOI 10.1016/j.neuropharm.2004.01.018; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kempermann G, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a018812; Kim SH, 2014, MOL PSYCHIATR, V19, P1235, DOI 10.1038/mp.2014.87; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Li NX, 2011, BIOL PSYCHIAT, V69, P754, DOI 10.1016/j.biopsych.2010.12.015; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Lu Y, 2014, NEUROSCIENCE, V274, P429, DOI 10.1016/j.neuroscience.2014.05.057; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Morgan CA, 1996, AM J PSYCHIAT, V153, P64; ORR SP, 1995, J ABNORM PSYCHOL, V104, P75, DOI 10.1037/0021-843X.104.1.75; Perez-Garcia G, 2018, BEHAV BRAIN RES, V340, P117, DOI 10.1016/j.bbr.2016.09.061; Perez-Garcia G, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00176; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Shapiro LA, 2017, CELL TRANSPLANT, V26, P1314, DOI 10.1177/0963689717714099; Sherin Jonathan E, 2011, Dialogues Clin Neurosci, V13, P263; Shetty AK, 2014, EPILEPSY BEHAV, V38, P117, DOI 10.1016/j.yebeh.2013.12.001; Shimazaki T, 2004, EUR J PHARMACOL, V501, P121, DOI 10.1016/j.ejphar.2004.08.016; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Tanielian T, 2008, INVISIBLE WOUNDS WAR, P593; Turner PV, 2012, J AM ASSOC LAB ANIM, V51, P25; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wang XT, 2016, J NEUROTRAUM, V33, P721, DOI 10.1089/neu.2015.4097; Winer JA, 2002, HEARING RES, V168, P181, DOI 10.1016/S0378-5955(02)00489-6; Yoshimizu T, 2004, BIOCHEM BIOPH RES CO, V315, P493, DOI 10.1016/j.bbrc.2004.01.073; Yoshimizu T, 2006, PSYCHOPHARMACOLOGY, V186, P587, DOI 10.1007/s00213-006-0390-7; Yudofsky S.C., 2005, TXB TRAUMATIC BRAIN, P27	48	28	28	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA		2373-2822		ENEURO	eNeuro	JAN-FEB	2018	5	1							UNSP e0357-17.2018	10.1523/ENEURO.0357-17.2018			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GB9QW	WOS:000429409900042	29387781	Green Published, gold			2022-02-06	
J	Salman, MM; Kitchen, P; Woodroofe, MN; Bill, RM; Conner, AC; Heath, PR; Conner, MT				Salman, Mootaz M.; Kitchen, Philip; Woodroofe, M. Nicola; Bill, Roslyn M.; Conner, Alex C.; Heath, Paul R.; Conner, Matthew T.			Transcriptome Analysis of Gene Expression Provides New Insights into the Effect of Mild Therapeutic Hypothermia on Primary Human Cortical Astrocytes Cultured under Hypoxia	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						hypothermia; astrocyte; Wnt signaling pathway; p53 signaling; apoptosis; hypoxia; MAPK	ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; STRESS-INDUCED ACTIVATION; WNT SIGNALING PATHWAY; CELL-SURVIVAL; MAP KINASES; INTEGRATIVE ANALYSIS; INDUCIBLE FACTOR-1; CEREBRAL-ISCHEMIA; INDUCED APOPTOSIS	Hypothermia is increasingly used as a therapeutic measure to treat brain injury. However, the cellular mechanisms underpinning its actions are complex and are not yet fully elucidated. Astrocytes are the most abundant cell type in the brain and are likely to play a critical role. In this study, transcriptional changes and the protein expression profile of human primary cortical astrocytes cultured under hypoxic conditions for 6 h were investigated. Cells were treated either with or without a mild hypothermic intervention 2 h post-insult to mimic the treatment of patients following traumatic brain injury (TBI) and/or stroke. Using human gene expression microarrays, 411 differentially expressed genes were identified following hypothermic treatment of astrocytes following a 2 h hypoxic insult. KEGG pathway analysis indicated that these genes were mainly enriched in the Wnt and p53 signaling pathways, which were inhibited following hypothermic intervention. The expression levels of 168 genes involved in Wnt signaling were validated by quantitative real-time-PCR (qPCR). Among these genes, 10 were up-regulated and 32 were down-regulated with the remainder unchanged. Two of the differentially expressed genes (DEGs), p38 and JNK, were selected for validation at the protein level using cell based ELISA. Hypothermic intervention significantly down-regulated total protein levels for the gene products of p38 and JNK. Moreover, hypothermia significantly up-regulated the phosphorylated (activated) forms of JNK protein, while downregulating phosphorylation of p38 protein. Within the p53 signaling pathway, 35 human apoptosis-related proteins closely associated with Wnt signaling were investigated using a Proteome Profiling Array. Hypothermic intervention significantly down-regulated 18 proteins, while upregulating one protein, survivin. Hypothermia is a complex intervention; this study provides the first detailed longitudinal investigation at the transcript and protein expression levels of the molecular effects of therapeutic hypothermic intervention on hypoxic human primary cortical astrocytes. The identified genes and proteins are targets for detailed functional studies, which may help to develop new treatments for brain injury based on an in-depth mechanistic understanding of the astrocytic response to hypoxia and/or hypothermia.	[Salman, Mootaz M.; Woodroofe, M. Nicola] Sheffield Hallam Univ, Biomol Sci Res Ctr, Sheffield, S Yorkshire, England; [Kitchen, Philip; Conner, Alex C.] Univ Birmingham, Inst Clin Sci, Birmingham, W Midlands, England; [Bill, Roslyn M.] Aston Univ, Sch Life & Hlth Sci, Birmingham, W Midlands, England; [Heath, Paul R.] Univ Sheffield, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England; [Conner, Matthew T.] Univ Wolverhampton, Res Inst Hlth Sci, Wolverhampton Sch Sci, Wolverhampton, W Midlands, England		Conner, MT (corresponding author), Univ Wolverhampton, Res Inst Hlth Sci, Wolverhampton Sch Sci, Wolverhampton, W Midlands, England.	m.conner@wlv.ac.uk	Kitchen, Philip/J-6936-2019; Salman, Mootaz M./J-3111-2019; Bill, Roslyn M/D-4554-2012	Kitchen, Philip/0000-0002-1558-4673; Salman, Mootaz M./0000-0002-5683-1706; Bill, Roslyn M/0000-0003-1331-0852	HCED [GD-13-3]; BMRC Sheffield Hallam University; University of Sheffield; RIHS School of Sciences University of Wolverhampton	This work was supported by HCED grant number GD-13-3 (M Salman), BMRC Sheffield Hallam University, University of Sheffield and RIHS School of Sciences University of Wolverhampton.	Andresen M, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0121-3; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Ang SF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013064; Ayakannu T, 2015, MOL HUM REPROD, V21, P723, DOI 10.1093/molehr/gav033; Badawi Y, 2012, ASN NEURO, V4, P231, DOI 10.1042/AN20120006; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bikkavilli Rama Kamesh, 2009, Commun Integr Biol, V2, P46; Blagodatski Artem, 2014, Mol Cell Ther, V2, P28, DOI 10.1186/2052-8426-2-28; Boutilier RG, 2001, J EXP BIOL, V204, P3171; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cenik C, 2015, GENOME RES, V25, P1610, DOI 10.1101/gr.193342.115; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Chenn Anjen, 2008, Organogenesis, V4, P76; Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939; Choudhury GR, 2014, BRAIN RES, V1551, P45, DOI 10.1016/j.brainres.2014.01.013; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dienel GA, 2005, GLIA, V50, P362, DOI 10.1002/glia.20157; Diestel A, 2009, VASC PHARMACOL, V51, P246, DOI 10.1016/j.vph.2009.06.006; Ding ZY, 2010, J CANCER RES CLIN, V136, P1697, DOI 10.1007/s00432-010-0828-5; Frink M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/762840; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Goossens J, 2014, CURR NEUROPHARMACOL, V12, P399, DOI 10.2174/1570159X12666140424233036; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Harrison JG, 2004, BBA-MOL CELL RES, V1644, P17, DOI 10.1016/j.bbamcr.2003.10.008; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jakel S, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00024; Jeong Ji Eun, 2017, Korean J Pediatr, V60, P181, DOI 10.3345/kjp.2017.60.6.181; Ju R, 2010, P NATL ACAD SCI USA, V107, P6906, DOI 10.1073/pnas.1001075107; Karnatovskaia LV, 2014, NEUROHOSPITALIST, V4, P153, DOI 10.1177/1941874413519802; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kim J., 2015, BRAIN CIRC, V1, P14, DOI [10.4103/2394-8108.164997, DOI 10.4103/2394-8108.164997]; Kogel D, 2005, CELL DEATH DIFFER, V12, P1, DOI 10.1038/sj.cdd.4401495; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Lazaridis C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0681-2; Lee JH, 2012, RESUSCITATION, V83, P633, DOI 10.1016/j.resuscitation.2011.11.008; Li Y, 2011, NEUROL RES, V33, P583, DOI 10.1179/1743132810Y.0000000013; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Liu AL, 2009, EXP TOXICOL PATHOL, V61, P137, DOI 10.1016/j.etp.2008.06.004; Liu YH, 2010, J NEUROTRAUM, V27, P361, DOI 10.1089/neu.2008.0581; Loor G, 2008, CELL DEATH DIFFER, V15, P686, DOI 10.1038/cdd.2008.13; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Ma H, 2012, CURR MOL MED, V12, P1282, DOI 10.2174/156652412803833517; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Matijasevic Z, 1998, ONCOL RES, V10, P605; Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mimeault M, 2010, PHARMACOL REV, V62, P497, DOI 10.1124/pr.109.002329; Moore EM, 2011, INJURY, V42, P843, DOI 10.1016/j.injury.2011.03.027; Mormile R, 2012, J PEDIATR ENDOCR MET, V25, P1045, DOI 10.1515/jpem-2012-0232; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Munji RN, 2011, J NEUROSCI, V31, P1676, DOI 10.1523/JNEUROSCI.5404-10.2011; Nedergaard M, 2005, GLIA, V50, P281, DOI 10.1002/glia.20205; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Nozari A, 2004, J TRAUMA, V57, P1266, DOI 10.1097/01.TA.0000124268.24159.8B; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Ou LP, 2016, MOL MED REP, V13, P720, DOI 10.3892/mmr.2015.4586; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Podmirseg SR, 2016, ONCOGENE, V35, P4580, DOI 10.1038/onc.2015.524; Previch LE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071146; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenberger J, 2001, J NEUROCHEM, V79, P35, DOI 10.1046/j.1471-4159.2001.00520.x; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Salman MM, 2017, EUR J NEUROSCI, V46, P2121, DOI 10.1111/ejn.13652; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Senchenko VN, 2015, FEBS J, V282, P263; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tan SC, 2017, CANCER INVEST, V35, P163, DOI 10.1080/07357907.2017.1278767; Tanaka T, 2009, BIOCHEM J, V424, P143, DOI 10.1042/BJ20090120; Tollenaere MAX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10075; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vangeison G, 2009, NEUROSCIENTIST, V15, P579, DOI 10.1177/1073858409332405; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Wallace BK, 2012, AM J PHYSIOL-CELL PH, V302, pC505, DOI 10.1152/ajpcell.00261.2011; Walluscheck D, 2013, J CELL MOL MED, V17, P976, DOI 10.1111/jcmm.12071; Yang D, 2010, CARDIOVASC RES, V85, P520, DOI 10.1093/cvr/cvp323; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang H, 2010, NEUROL RES, V32, P384, DOI 10.1179/016164110X12670144526228; ZHANG W, 2004, MICROARRAY QUALITY C; Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51	98	28	29	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	DEC 14	2017	11								386	10.3389/fncel.2017.00386			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FP9EL	WOS:000417950200001	29311824	Green Published, gold, Green Accepted			2022-02-06	
J	Su, WS; Wu, CH; Chen, SF; Yang, FY				Su, Wei-Shen; Wu, Chun-Hu; Chen, Szu-Fu; Yang, Feng-Yi			Transcranial ultrasound stimulation promotes brain-derived neurotrophic factor and reduces apoptosis in a mouse model of traumatic brain injury	BRAIN STIMULATION			English	Article						Ultrasound; Traumatic brain injury; Neurotrophic factor; BDNF; Apoptosis	INTENSITY PULSED ULTRASOUND; BLOOD-BRAIN; HEAD-INJURY; FOCUSED ULTRASOUND; CELL-DEATH; RAT MODEL; BDNF; INCREASES; NEUROPROTECTION; PERMEABILITY	Background: The protein expressions of brain-derived neurotrophic factor (BDNF) can be elevated by transcranial ultrasound stimulation in the rat brain. Objective: The purpose of this study was to investigate the effects and underlying mechanisms of BDNF enhancement by low-intensity pulsed ultrasound (LIPUS) on traumatic brain injury (TBI). Methods: Mice subjected to controlled cortical impact injury were treated with LIPUS in the injured region daily for a period of 4 days. Western blot analysis and immunohistochemistry were performed to assess the effects of LIPUS. Results: The results showed that the LIPUS treatment significantly promoted the neurotrophic factors BDNF and vascular endothelial growth factor (VEGF) at day 4 after TBI. Meanwhile, LIPUS also enhanced the phosphorylation of Tropomyosin-related kinase B (TrkB), Akt, and cAMP-response element binding protein (CREB). Furthermore, treatment with LIPUS significantly decreased the level of cleaved caspase-3. The reduction of apoptotic process was inhibited by the anti-BDNF antibody. Conclusions: In short, post-injury LIPUS treatment increased BDNF protein levels and inhibited the progression of apoptosis following TBI. The neuroprotective effects of LIPUS may be associated with enhancements of the protein levels of neurotrophic factors, at least partially via the TrkB/Akt-CREB signaling pathway. (C) 2017 Elsevier Inc. All rights reserved.	[Su, Wei-Shen; Yang, Feng-Yi] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei, Taiwan; [Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol & Biophys, Taipei, Taiwan; [Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, 45 Cheng Hsin St, Taipei 11221, Taiwan; [Yang, Feng-Yi] Natl Yang Ming Univ, Biophoton & Mol Imaging Res Ctr, Taipei, Taiwan		Chen, SF (corresponding author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, 45 Cheng Hsin St, Taipei 11221, Taiwan.; Yang, FY (corresponding author), Natl Yang Ming Univ, Sch Biomed Sci & Engn, Dept Biomed Imaging & Radiol Sci, 155,Sec 2,Li Nong St, Taipei 11221, Taiwan.	szufuchen@yahoo.com.tw; fyyang@ym.edu.tw	WU, CHUN-HU/P-3958-2018	WU, CHUN-HU/0000-0001-6851-7936	Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST 105-2221-E-010-003, MOST 104-2314-B-010-003-MY3, 101-2314-B-350-001-MY3]; Veterans General Hospitals University System of Taiwan Joint Research Program [VGHUST106-G7-6-1]; Cheng Hsin General Hospital Foundation [CY10622, CY10418, CHGH103-34]; Taiwan Ministry of Education's Aim for the Top University Plan	This study was supported by grants from the Ministry of Science and Technology of Taiwan (no. MOST 105-2221-E-010-003, MOST 104-2314-B-010-003-MY3, and 101-2314-B-350-001-MY3), the Veterans General Hospitals University System of Taiwan Joint Research Program (#VGHUST106-G7-6-1), the Cheng Hsin General Hospital Foundation (no. CY10622, CY10418 and CHGH103-34), and the Taiwan Ministry of Education's Aim for the Top University Plan.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Chen CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115694; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Dalecki D, 2004, ANNU REV BIOMED ENG, V6, P229, DOI 10.1146/annurev.bioeng.6.040803.140126; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FRY WJ, 1968, J ACOUST SOC AM, V44, P919, DOI 10.1121/1.1911230; Fulmer CG, 2014, J NEUROSCI, V34, P8186, DOI 10.1523/JNEUROSCI.4267-13.2014; Gavrilov LR, 1996, ULTRASOUND MED BIOL, V22, P179, DOI 10.1016/0301-5629(96)83782-3; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hanawa K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104863; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang SL, 2017, RADIOLOGY, V282, P113, DOI 10.1148/radiol.2016160095; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Jeon SJ, 2011, NEUROSCI RES, V69, P214, DOI 10.1016/j.neures.2010.11.008; Krasovitski B, 2011, P NATL ACAD SCI USA, V108, P3258, DOI 10.1073/pnas.1015771108; Lin WT, 2015, SCI REP-UK, V5, DOI 10.1038/srep09671; Liu SH, 2017, CEREB CORTEX, V27, P3152, DOI 10.1093/cercor/bhw169; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Pandya CD, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0047-9; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Su WS, 2015, ONCOTARGET, V6, P42290, DOI 10.18632/oncotarget.5978; ter Haar G, 2007, PROG BIOPHYS MOL BIO, V93, P111, DOI 10.1016/j.pbiomolbio.2006.07.005; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Wang ZT, 2013, J MOL NEUROSCI, V49, P409, DOI 10.1007/s12031-012-9908-0; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Xia P, 2015, ULTRASOUND MED BIOL, V41, P1690, DOI 10.1016/j.ultrasmedbio.2015.01.014; Yang FY, 2015, BRAIN STIMUL, V8, P465, DOI 10.1016/j.brs.2014.11.017; Yang FY, 2014, NEUROIMAGE, V90, P93, DOI 10.1016/j.neuroimage.2013.12.033; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje	42	28	35	2	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	NOV-DEC	2017	10	6					1032	1041		10.1016/j.brs.2017.09.003			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FL2UE	WOS:000414074400003	28939348				2022-02-06	
J	Tulsky, DS; Carlozzi, NE; Holdnack, J; Heaton, RK; Wong, A; Goldsmith, A; Heinemann, AW				Tulsky, David S.; Carlozzi, Noelle E.; Holdnack, James; Heaton, Robert K.; Wong, Alex; Goldsmith, Arielle; Heinemann, Allen W.			Using the NIH Toolbox Cognition Battery (NIHTB-CB) in Individuals With Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						TBI; traumatic brain injury; cognitive assessment; neuropsychological assessment; psychometrics	MEASURING EPISODIC MEMORY; PROCESSING SPEED TEST; NEUROPSYCHOLOGICAL ASSESSMENT; BEHAVIORAL FUNCTION; EXECUTIVE FUNCTION; HEAD-INJURY; CRITERION VALIDITY; SCALE-4TH EDITION; COMPOSITE SCORES; COMPLICATED MILD	Purpose/Objective: The NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery (NIHTB-CB) is a common data element for use in individuals with traumatic brain injury (TBI). This study evaluates its sensitivity and specificity in distinguishing individuals with complicated mild, moderate, or severe TBI, and provides support for the construct validity of the NIHTB-CB in individuals with TBI. Research Method: One hundred eighty-two individuals with TBI (n = 83 complicated mild/moderate; n = 99 severe) completed the NIHTB-CB and neuropsychological criterion measures. Complete data were obtained on 158 participants. A control sample of 158 individuals without known neurological impairment was extracted from the NIHTB-CB normative sample. Multivariate analyses of variance determined the sensitivity of the NIHTB-CB measures to TBI and injury severity (complicated mild/ moderate TBI, severe TBI, and controls) on the demographically corrected NIHTB-CB composite scores and seven subtests. A descriptive analysis of the sensitivity of each subtest was conducted. Finally, correlations between NIHTB-CB measures and criterion tests assessed convergent and discriminant validity. Results: Multivariate analyses indicated that there was a main effect for group (complicated mild/ moderate vs. severe vs. controls) for fluid scores in the NIHTB-CB as opposed to only marginally significant results for the verbal scores. Moderate to strong relationships were found between the NIHTB-CB measures and their corresponding neuropsychological measures (convergent validity), whereas much smaller correlations were found between measures of different cognitive domains (discriminant validity). Conclusions: Findings provide evidence of construct validity and the clinical utility of the NIHTB-CB in individuals with TBI.	[Tulsky, David S.; Holdnack, James] Univ Delaware, Ctr Hlth Assessment Res & Translat, Newark, DE 19713 USA; [Tulsky, David S.] Univ Delaware, Dept Phys Therapy, Newark, DE 19713 USA; [Tulsky, David S.] Univ Delaware, Dept Psychol & Brain Sci, Newark, DE 19713 USA; [Carlozzi, Noelle E.] Univ Michigan, Ctr Clin Outcomes Dev & Applicat CODA, Ann Arbor, MI 48109 USA; [Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Holdnack, James] Pearson Assessment, San Antonio, TX USA; [Heaton, Robert K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Wong, Alex] Washington Univ, Program Occupat Therapy, St Louis, MO USA; [Wong, Alex] Washington Univ, Dept Neurol, St Louis, MO USA; [Goldsmith, Arielle; Heinemann, Allen W.] Shirley Ryan AbilityLab, Ctr Rehabil Outcomes Res, Chicago, IL USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Evanston, IL 60208 USA		Tulsky, DS (corresponding author), Univ Delaware, STAR Hlth Sci, 540 South Coll Ave, Newark, DE 19713 USA.	dtulsky@udel.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Tulsky, David/0000-0002-4335-4509; Wong, Alex/0000-0002-4423-2685	National Institute on Disability, Independent Living, and Research Rehabilitation grant [H133B090024]; Office of Behavioral and Social Sciences Research, National Institutes of Health [HHS-N-260-2006-00007-C]; Institutional Development Award (IDeA) from NIH, National Institute of General Medical Sciences [U54-GM104941]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH062512] Funding Source: NIH RePORTER	Support was provided by the National Institute on Disability, Independent Living, and Research Rehabilitation grant H133B090024 (PI: Allen W. Heinemann). The Blueprint for Neuroscience Research. The Office of Behavioral and Social Sciences Research, National Institutes of Health, supported the collection of the adult norming sample under contract HHS-N-260-2006-00007-C (PI: Richard C. Gershon). Salary support for Dr. Holdnack was provided by an Institutional Development Award (IDeA) from the NIH, National Institute of General Medical Sciences, Grant U54-GM104941 (PI: Binder-Macleod). We thank their talented and dedicated research staff: Ana Miskovic, Sara Jerousek, Sue Tucker, Jessica Dashner, Cathy Crawley, Ben Aziz, Julie Grech, Livia Vanden Belt, and Angela Miciura.	Aiken L. S., 2013, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441; Akshoomoff N, 2013, MONOGR SOC RES CHILD, V78, P119, DOI 10.1111/mono.12038; Bauer PJ, 2013, MONOGR SOC RES CHILD, V78, P34, DOI 10.1111/mono.12033; Baughman RW, 2006, J NEUROSCI, V26, P10329, DOI 10.1523/JNEUROSCI.3979-06.2006; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Carlozzi NE, 2015, ARCH CLIN NEUROPSYCH, V30, P359, DOI 10.1093/arclin/acv031; Carlozzi NE, 2015, CLIN NEUROPSYCHOL, V29, P21, DOI 10.1080/13854046.2015.1005677; Carlozzi NE, 2014, J INT NEUROPSYCH SOC, V20, P630, DOI 10.1017/S1355617714000319; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Carlozzi NE, 2013, MONOGR SOC RES CHILD, V78, P88, DOI 10.1111/mono.12036; Casaletto KB, 2015, J INT NEUROPSYCH SOC, V21, P378, DOI 10.1017/S1355617715000351; Corey DM, 1998, J GEN PSYCHOL, V125, P245, DOI 10.1080/00221309809595548; Crowe SF, 2013, J CLIN EXP NEUROPSYC, V35, P298, DOI 10.1080/13803395.2013.771616; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2014, J INT NEUROPSYCH SOC, V20, P611, DOI 10.1017/S1355617714000460; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2016, ARCH CLIN NEUROPSYCH, V31, P29, DOI 10.1093/arclin/acv048; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Donders J, 2012, ARCH CLIN NEUROPSYCH, V27, P440, DOI 10.1093/arclin/acs043; Fisher R. A., 1958, STAT METHODS RES WOR; Gershon RC, 2014, J INT NEUROPSYCH SOC, V20, P642, DOI 10.1017/S1355617714000411; Gershon RC, 2013, MONOGR SOC RES CHILD, V78, P49, DOI 10.1111/mono.12034; Gershon RC, 2013, NEUROLOGY, V80, pS2, DOI 10.1212/WNL.0b013e3182872e5f; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Heaton RK, 2009, NEUROPSYCHOLOGICAL A, P127; Heaton RK, 2014, J INT NEUROPSYCH SOC, V20, P588, DOI 10.1017/S1355617714000241; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Holdnack J., 2006, WISC 4 ADV CLIN INTE, P201; Iverson GL, 2013, PRACT RESOUR MENT, P485, DOI 10.1016/B978-0-12-386934-0.00010-9; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P497, DOI 10.1080/01688638508401281; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Magasi S, 2017, REHABIL PSYCHOL, V62, P455, DOI 10.1037/rep0000191; Merkley TL, 2013, J INT NEUROPSYCH SOC, V19, P899, DOI 10.1017/S135561771300074X; Mungas D, 2014, J INT NEUROPSYCH SOC, V20, P579, DOI 10.1017/S1355617714000307; Mungas D, 2013, MONOGR SOC RES CHILD, V78, P103, DOI 10.1111/mono.12037; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sinclair KL, 2013, J CLIN EXP NEUROPSYC, V35, P210, DOI 10.1080/13803395.2012.762340; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; TEASDALE G, 1974, LANCET, V2, P81; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tulsky DS, 2014, J INT NEUROPSYCH SOC, V20, P599, DOI 10.1017/S135561771400040X; Tulsky DS, 2013, MONOGR SOC RES CHILD, V78, P70, DOI 10.1111/mono.12035; Tulsky DS, 2003, PSYCHOL ASSESSMENT, V15, P149, DOI 10.1037/1040-3590.15.2.149; Weintraub S, 2014, J INT NEUROPSYCH SOC, V20, P567, DOI 10.1017/S1355617714000320; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wright MJ, 2014, J CLIN EXP NEUROPSYC, V36, P268, DOI 10.1080/13803395.2014.884543; Zelazo PD, 2014, J INT NEUROPSYCH SOC, V20, P620, DOI 10.1017/S1355617714000472; Zelazo PD, 2013, MONOGR SOC RES CHILD, V78, P16, DOI 10.1111/mono.12032	60	28	28	0	5	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2017	62	4					413	424		10.1037/rep0000174			12	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	FT1CK	WOS:000422871400002	29265862	Green Accepted, Bronze			2022-02-06	
J	DiMaggio, CJ; Avraham, JB; Lee, DC; Frangos, SG; Wall, SP				DiMaggio, Charles J.; Avraham, Jacob B.; Lee, David C.; Frangos, Spiros G.; Wall, Stephen P.			The Epidemiology of Emergency Department Trauma Discharges in the United States	ACADEMIC EMERGENCY MEDICINE			English	Article							NATIONAL TRAUMA; INJURY; MORTALITY	Objective: Injury-related morbidity and mortality is an important emergency medicine and public health challenge in the United States. Here we describe the epidemiology of traumatic injury presenting to U.S. emergency departments (EDs), define changes in types and causes of injury among the elderly and the young, characterize the role of trauma centers and teaching hospitals in providing emergency trauma care, and estimate the overall economic burden of treating such injuries. Methods: We conducted a secondary retrospective, repeated cross-sectional study of the Nationwide Emergency Department Data Sample (NEDS), the largest all-payer ED survey database in the United States. Main outcomes and measures were survey-adjusted counts, proportions, means, and rates with associated standard errors (SEs) and 95% confidence intervals. We plotted annual age-stratified ED discharge rates for traumatic injury and present tables of proportions of common injuries and external causes. We modeled the association of Level I or II trauma center care with injury fatality using a multivariable survey-adjusted logistic regression analysis that controlled for age, sex, injury severity, comorbid diagnoses, and teaching hospital status. Results: There were 181,194,431 (SE = 4,234) traumatic injury discharges from U.S. EDs between 2006 and 2012. There was a mean year-to-year decrease of 143 (95% CI = -184.3 to -68.5) visits per 100,000 U.S. population during the study period. The all-age, all-cause case-fatality rate for traumatic injuries across U.S. EDs during the study period was 0.17% (SE = 0.001%). The case-fatality rate for the most severely injured averaged 4.8% (SE = 0.001%), and severely injured patients were nearly four times as likely to be seen in Level I or II trauma centers (relative risk = 3.9 [95% CI = 3.7 to 4.1]). The unadjusted risk ratio, based on group counts, for the association of Level I or II trauma centers with mortality was risk ratio = 4.9 (95% CI = 4.5 to 5.3); however, after sex, age, injury severity, and comorbidities were accounted for, Level I or II trauma centers were not associated with an increased risk of fatality (odds ratio = 0.96 [95% CI = 0.79 to 1.18]). There were notable changes at the extremes of age in types and causes of ED discharges for traumatic injury between 2009 and 2012. Age-stratified rates of diagnoses of traumatic brain injury increased 29.5% (SE = 2.6%) for adults older than 85 and increased 44.9% (SE = 1.3%) for children younger than 18. Firearm-related injuries increased 31.7% (SE = 0.2%) in children 5 years and younger. The total inflation-adjusted cost of ED injury care in the United States between 2006 and 2012 was (sic) 99.75 billion (SE = $0.03 billion). Conclusions: Emergency departments are a sensitive barometer of the continuing impact of traumatic injury as an important cause of morbidity and mortality in the United States. Level I or II trauma centers remain a bulwark against the tide of severe trauma in the United States, but the types and causes of traumatic injury in the United States are changing in consequential ways, particularly at the extremes of age, with traumatic brain injuries and firearm-related trauma presenting increased challenges.	[DiMaggio, Charles J.; Avraham, Jacob B.; Frangos, Spiros G.] NYU, Sch Med, Dept Surg, Div Acute Care & Trauma Surg, New York, NY 10003 USA; [Lee, David C.; Wall, Stephen P.] NYU, Sch Med, Ronald O Perelman Dept Emergency Med, New York, NY USA; [DiMaggio, Charles J.; Lee, David C.; Wall, Stephen P.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA		DiMaggio, CJ (corresponding author), NYU, Sch Med, Dept Surg, Div Acute Care & Trauma Surg, New York, NY 10003 USA.; DiMaggio, CJ (corresponding author), NYU, Sch Med, Dept Populat Hlth, New York, NY 10003 USA.	Charles.DiMaggio@nyumc.org		DiMaggio, Charles/0000-0003-2356-6659; Wall, Stephen/0000-0003-3965-5074; Frangos, Spiros/0000-0003-2860-8969	National Institute of Child Health and Human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01-HD087460]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD087460] Funding Source: NIH RePORTER	This study was funded in part by grant R01-HD087460, awarded by the National Institute of Child Health and Human Development at the National Institutes of Health. The study funders had no role in the study design, analysis, drafting of the manuscript, or decision to submit the study for publication.	Agency for Healthcare Research and Quality, 2012, INTR HCUP NAT EM DEP; Agency for Healthcare Research and Quality, 2011, HCUP METH SER SPEC S; Agency for Healthcare Research and Quality, 2015, INTR HEALTHC COST UT; American Medical Association, 2005, CLIN MOD PHYS ICD 9; [Anonymous], 2016, WEB BAS INJ STAT QUE; [Anonymous], US CONS PROD SAF COM; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Auguie B., 2017, MISCELLANEOUS FUNCTI; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bieler GS, 2010, AM J EPIDEMIOL, V171, P618, DOI 10.1093/aje/kwp440; Bonnie R.J., 1999, REDUCING BURDEN INJU; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Calland JF, 2013, J TRAUMA ACUTE CARE, V75, P501, DOI 10.1097/TA.0b013e31829bb75c; Centers for Disease Control and Prevention, 2015, WISQARS LEAD CAUS DE; Centers for Disease Control and Prevention, 2013, LEAD CAUS NONF INJ R; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DiMaggio C, 2016, INJURY, V47, P1393, DOI 10.1016/j.injury.2016.04.002; Feeney JM, 2017, INJURY, V48, P47, DOI 10.1016/j.injury.2016.08.016; Fingerhut LA, 2002, INJ PREV, V8, P259, DOI 10.1136/ip.8.3.259; Fox J, 2010, R COMPANION APPL REG; Gedeborg R., 2009, JOINT M INT COLL EFF; Haider AH, 2004, J AM COLL SURGEONS, V198, P906, DOI 10.1016/j.jamcollsurg.2004.02.013; Harrell F.E, RMS REGRESSION MODEL; Hirshon JM, 2009, ACAD EMERG MED, V16, P1103, DOI 10.1111/j.1553-2712.2009.00554.x; Hu GQ, 2010, INJURY PREV, V16, P26, DOI 10.1136/ip.2009.023481; Institute for Social and Preventative Medicine University of Bern, 2007, STROBE STATEMENTCHEC; Jain NB, 2015, JAMA-J AM MED ASSOC, V313, P2236, DOI 10.1001/jama.2015.6250; Kalesan B, 2016, LANCET, V387, P1847, DOI 10.1016/S0140-6736(15)01026-0; Kalesan B, 2016, ANN EPIDEMIOL, V26, P1, DOI 10.1016/j.annepidem.2015.10.009; Kalesan B, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005628; Kauvar DS, 2011, J VASC SURG, V53, P1598, DOI 10.1016/j.jvs.2011.01.056; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; Lumley T., 2004, J STAT SOFTW, V9, P1, DOI DOI 10.18637/JSS.V009.I08; Lumley Thomas, 2014, SQLSURVEY ANAL VERY; Miller Matthew L, 2008, Ann Adv Automot Med, V52, P101; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Ottochian M, 2009, INJURY, V40, P354, DOI 10.1016/j.injury.2008.10.015; Owens PL, 2010, ANN EMERG MED, V56, P150, DOI 10.1016/j.annemergmed.2009.11.022; Palmer Cameron, 2007, Annu Proc Assoc Adv Automot Med, V51, P13; Ripley B.D, 2002, MODERN APPL STAT S, DOI DOI 10.1007/978-0-387-21706-2; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Segui-Gomez M., 2012, INJURY RES, P291; Sim J, 2015, ANN SURG TREAT RES, V89, P215, DOI 10.4174/astr.2015.89.4.215; Sise RG, 2014, J TRAUMA ACUTE CARE, V76, P913, DOI 10.1097/TA.0000000000000169; Srinivasan S, 2014, ARCH DIS CHILD, V99, P331, DOI 10.1136/archdischild-2013-304642; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Tashiro J, 2016, J TRAUMA ACUTE CARE, V81, pS54, DOI 10.1097/TA.0000000000001177; Venkat A., 2011, EMERG MED NEWS, V33; Wasey J, 2016, ICD9 TOOLS WORKING I; Wood B, 2016, CJEM, V18, pS125; Zafar SN, 2012, BRIT J SURG, V99, P155, DOI 10.1002/bjs.7735; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696	53	28	28	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	OCT	2017	24	10					1244	1256		10.1111/acem.13223			13	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	FK2YM	WOS:000413349800007	28493608	Green Accepted, Bronze			2022-02-06	
J	Liu, DC; Li, Z; Zhang, XX; Zhao, LP; Jia, JP; Sun, F; Wang, YX; Ma, DQ; Wei, WB				Liu, Dachuan; Li, Zhen; Zhang, Xuxiang; Zhao, Liping; Jia, Jianping; Sun, Fei; Wang, Yaxing; Ma, Daqing; Wei, Wenbin			Assessment of intracranial pressure with ultrasonographic retrobulbar optic nerve sheath diameter measurement	BMC NEUROLOGY			English	Article						B-scan ultrasonography; Optic nerve sheath diameter; Intracranial pressure	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; HYPERTENSION; ULTRASOUND	Background: Ultrasonograpic retrobulbar optic nerve sheath diameter (ONSD) measurement is considered to be an alternative noninvasive method to estimate intracranial pressure, but the further validation is urgently needed. The aim of the current study was to investigate the association of the ultrasonographic ONSD and intracranial pressure (ICP) in patients. Methods: One hundred and ten patients whose intracranial pressure measured via lumbar puncture were enrolled in the study. Their retrobulbar ONSD with B-scan ultrasound was determined just before lumber puncture. The correlation between the ICP and the body mass index (BMI), ONSD or age was established respectively with the Pearson correlation coefficient analysis. The discriminant analysis was used to obtain a discriminant formula for predicting ICP with the ONSD. BMI. gender and age. Another 20 patients were recruited for further validation the efficiency of this discriminant equation. Results: The mean ICP was 215.3 +/- 81.2 mmH(2)O. ONSD was 5.70 +/- 0.80 mm in the right eye and 5.80 +/- 0.77 mm in the left eye. A significant correlation was found between ICP and BMI (r = 0.554, p < 0.001), the mean ONSD (r = 0.61, P < 0.001), but not with age (r = -0.131, p = 0.174) and gender (r = 0.03, p = 0.753). Using receiver operating characteristic (ROC) curve analysis, the critical value for the risk mean-ONSD was 5.6 mm from the ROC curve, with the sensitivity of 86.2% and specificity of 73.1%. With 200 mmH(2)O as the cutoff point for a high or low ICP, stepwise discriminant was applied, the sensitivity and specificity of ONSD predicting ICP was 84.5%-85.7% and 86.5%-92.3%. Conclusions: Ophthalmic ultrasound measurement of ONSD may be a good surrogate of invasive ICP measurement. This non-invasive method may be an alternative approach to predict the ICP value of patients whose ICP measurement via lumbar puncture are in high risk. The discriminant formula, which incorporated the factor of BMI, had similar sensitivity and higher specificity than the ROC curve.	[Liu, Dachuan; Wei, Wenbin] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Tongren Hosp,Beijing Ophthalmol & Visual, Beijing 100730, Peoples R China; [Liu, Dachuan; Li, Zhen; Zhang, Xuxiang; Zhao, Liping] Capital Med Univ, Dept Ophthalmol, Xuanwu Hosp, Beijing, Peoples R China; [Jia, Jianping] Capital Med Univ, Dept Neurol, Xuanwu Hosp, Beijing, Peoples R China; [Sun, Fei] Beijing Geriatr Healthcare Ctr, Beijing, Peoples R China; [Wang, Yaxing] Beijing Inst Ophthalmol, Beijing, Peoples R China; [Ma, Daqing] Imperial Coll London, Anaesthet Pain Med & Intens Care, Dept Surg & Canc, Fac Med, London, England; [Ma, Daqing] Chelsea & Westminster Hosp, London, England		Wei, WB (corresponding author), Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Tongren Hosp,Beijing Ophthalmol & Visual, Beijing 100730, Peoples R China.	weiwenbintr@163.com		Ma, Daqing/0000-0003-1235-0537; Jia, Jianping/0000-0003-4624-0336	Beijing Municipal Science & Technology CommissionBeijing Municipal Science & Technology Commission [Z111107067311016, Z151100003915127]	This study was supported by Beijing Municipal Science & Technology Commission No. Z111107067311016 and Z151100003915127. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amini A, 2013, AM J EMERG MED, V31, P236, DOI 10.1016/j.ajem.2012.06.025; Atsumi Hideki, 2014, Tokai J Exp Clin Med, V39, P34; Bauerle J, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-187; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Frumin E, 2014, WEST J EMERG MED, V15, P217, DOI 10.5811/westjem.2013.9.16191; Gjerris F, 2004, CLIN NEUROL NEUROSUR, P179; HANSEN HC, 1994, NEURO-OPHTHALMOLOGY, V14, P345, DOI 10.3109/01658109409024061; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Kalantari H, 2013, AM J EMERG MED, V31, P1595, DOI 10.1016/j.ajem.2013.07.028; Kimberly HH, 2008, CRIT CARE, V12, DOI 10.1186/cc7008; Li Z., 2014, J CLIN ULTRASOUND ME, V14, P160; Li Z, 2014, OPHTHALMOL CHN, V23, P347; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; Maude RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081013; Qayyum H, 2013, EUR J EMERG MED, V20, P91, DOI 10.1097/MEJ.0b013e32835105c8; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rickert K., 2003, OPER TECH GEN SURG, V5, P170; Sekhon MS, 2014, INTENS CARE MED, V40, P1267, DOI 10.1007/s00134-014-3392-7; Shimbles S, 2005, PHYSIOL MEAS, V26, P1085, DOI 10.1088/0967-3334/26/6/017; Speck V, 2011, NEUROCRIT CARE, V14, P208, DOI 10.1007/s12028-010-9459-6; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Tamburrelli C., 1993, OPHTHALMIC ECHOGRAPH, P101; Xie XB, 2013, CRIT CARE, V17, DOI 10.1186/cc12841; Zeng T, 2010, CHIN J TRAUMATOL, V13, P146, DOI 10.3760/cma.j.issn.1008-1275.2010.03.003	29	28	33	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	SEP 29	2017	17								188	10.1186/s12883-017-0964-5			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FI6CU	WOS:000412078700001	28962603	gold, Green Published			2022-02-06	
J	AlAzri, A; Mok, K; Chankowsky, J; Mullah, M; Marcoux, J				AlAzri, Ahmed; Mok, Kelvin; Chankowsky, Jeffrey; Mullah, Mohammad; Marcoux, Judith			Placement accuracy of external ventricular drain when comparing freehand insertion to neuronavigation guidance in severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; External ventricular drain; Neuronavigation	CATHETER PLACEMENT; COMPLICATIONS; GUIDE; HYDROCEPHALUS; NAVIGATION; SAFETY; CT	Background External ventricular drain (EVD) placement is a frequently performed neurosurgical procedure. Inaccuracies in drain positioning and the need for multiple passes using the classic freehand insertion technique is well reported in the literature, especially in the traumatic brain injury (TBI) population. The purpose of this study was to evaluate if electromagnetic neuronavigation guidance for EVD insertion improves placement accuracy and minimizes the number of passes in severe TBI patients. Methods Navigation was applied prospectively for all new severe TBI patients who required ventricular catheter placement over a period of 1 year, and compared with a retrospective cohort of severe TBI patients who had EVD inserted freehand in the preceding year. The placement accuracy was evaluated using the Kakarla grading system; the number of passes was also compared. Results Fifty-four cases were recruited: 35 (64.8%) had their EVD placed using the freehand technique and 19 (35.2%) using navigation guidance. In the navigation group, the placement accuracy was: 94.7% (18/19) grade 1, 5.3% (1/19) grade 2, and none at grade 3. In comparison, freehand placement was associated with misplacement (grades 2 and 3) in 42.9% of the cases (p value = 0.009). The number of passes was significantly lower in the navigation group (mean of 1.16 +/- 0.38), compared with the freehand group (mean of 1.63 +/- 0.88) (p value = 0.018). Conclusions Using the navigation to guide EVD placement was associated with a significantly better accuracy and a lower number of passes in severe TBI patients.	[AlAzri, Ahmed; Marcoux, Judith] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [AlAzri, Ahmed; Marcoux, Judith] McGill Univ, Hlth Ctr, Dept Neurosurg, 1650 Cedar Ave,Room L7-516, Montreal, PQ H3G 1A4, Canada; [Mok, Kelvin] McGill Univ, Montreal Neurol Inst, Dept Biomed Engn, Montreal, PQ, Canada; [Chankowsky, Jeffrey] McGill Univ, Dept Diagnost Radiol, Montreal, PQ, Canada; [Chankowsky, Jeffrey] McGill Univ, Hlth Ctr, Dept Radiol, Montreal, PQ, Canada; [Mullah, Mohammad] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada		Marcoux, J (corresponding author), McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.; Marcoux, J (corresponding author), McGill Univ, Hlth Ctr, Dept Neurosurg, 1650 Cedar Ave,Room L7-516, Montreal, PQ H3G 1A4, Canada.	judith.marcoux@mcgill.ca		Marcoux, Judith/0000-0002-7000-642X	StealthStation AxiEM system	Medtronic of Canada Ltd. provided in-kind funding in the form of the StealthStation AxiEM system plus its disposable kits, each containing a registration probe, patient reference device and a sterile navigation stylet. None of the authors received any financial support or any other form of support to conduct this study. The sponsor had no role in the design or conduct of this research.	Abdoh MG, 2012, ACTA NEUROCHIR, V154, P153, DOI 10.1007/s00701-011-1136-9; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; BOGDAHN U, 1992, NEUROSURGERY, V31, P898, DOI 10.1227/00006123-199211000-00011; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Chai FY, 2013, TURK NEUROSURG, V23, P561, DOI 10.5137/1019-5149.JTN.5724-12.1; Cooke D L, 2011, AJNR Am J Neuroradiol, V32, pE69, DOI 10.3174/ajnr.A2066; Crowley RW, 2014, WORLD NEUROSURG, V81, P397, DOI 10.1016/j.wneu.2013.01.039; Evans WA, 1942, AM J DIS CHILD, V64, P820, DOI 10.1001/archpedi.1942.02010110052006; Fiorella D, 2014, J NEUROINTERV SURG, V6, P457, DOI 10.1136/neurintsurg-2013-010856; Flannery AM, 2014, J NEUROSURG-PEDIATR, V14, P24, DOI 10.3171/2014.7.PEDS14323; Foreman PM, 2015, CLIN NEUROL NEUROSUR, V128, P94, DOI 10.1016/j.clineuro.2014.09.026; Franz AM, 2014, IEEE T MED IMAGING, V33, P1702, DOI 10.1109/TMI.2014.2321777; Gautschi OP, 2014, ACTA NEUROCHIR, V156, P777, DOI 10.1007/s00701-014-2026-8; GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985; Grandhi R, 2015, J NEUROIMAGING, V25, P140, DOI 10.1111/jon.12080; Hayhurst C, 2009, J NEUROSURG, V111, P1179, DOI 10.3171/2008.12.JNS08628; Hsieh CT, 2011, ACTA NEUROL BELG, V111, P22; Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088; Kakarla UK, 2008, NEUROSURGERY, V63, P162, DOI 10.1227/01.NEU.0000312390.83127.7F; Kandasamy J, 2011, WORLD NEUROSURG, V75, P155, DOI 10.1016/j.wneu.2010.10.025; Koivukangas T, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-90; Kosty J, 2013, NEUROSURGERY, V72, P208; Krotz M, 2004, EUR RADIOL, V14, P227, DOI 10.1007/s00330-003-2134-y; Lee Ji Hoon, 2010, Journal of Cerebrovascular and Endovascular Neurosurgery, V12, P82; Lollis SS, 2009, BRIT J NEUROSURG, V23, P516, DOI 10.1080/02688690902948192; Mahan M, 2013, J CLIN NEUROSCI, V20, P1718, DOI 10.1016/j.jocn.2013.03.005; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Muirhead WR, 2012, BRIT J NEUROSURG, V26, P710, DOI 10.3109/02688697.2012.671973; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; O'Leary ST, 2000, J NEUROSURG, V92, P801, DOI 10.3171/jns.2000.92.5.0801; Park YG, 2011, J KOREAN NEUROSURG S, V50, P317, DOI 10.3340/jkns.2011.50.4.317; Phillips SB, 2014, WORLD NEUROSURG, V82, P739, DOI 10.1016/j.wneu.2013.08.030; Phillips SB, 2012, NEUROCRIT CARE, V17, P255, DOI 10.1007/s12028-011-9571-2; Rehman T, 2013, WORLD NEUROSURG, V80, P173, DOI 10.1016/j.wneu.2012.12.012; Rosenbaum BP, 2013, CLIN NEUROL NEUROSUR, V115, P1514, DOI 10.1016/j.clineuro.2012.12.008; Rosenow JM, 2007, STEREOT FUNCT NEUROS, V85, P75, DOI 10.1159/000097922; Ruchholtz S, 1998, J TRAUMA, V45, P505, DOI 10.1097/00005373-199809000-00013; Saladino A, 2009, NEUROCRIT CARE, V10, P248, DOI 10.1007/s12028-008-9154-z; Schuette AJ, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.09.015; Srinivasan VM, 2014, J NEUROSURG, V120, P228, DOI 10.3171/2013.6.JNS121577; Stangl AP, 1998, SURG NEUROL, V50, P77, DOI 10.1016/S0090-3019(97)00301-7; Stieglitz LH, 2010, NEUROSURGERY, V67, P131, DOI 10.1227/01.NEU.0000382964.72262.9A; Stroszczynski C, 2006, MINIMALLY INVASIVE T; Thomale UW, 2013, CHILD NERV SYST, V29, P131, DOI 10.1007/s00381-012-1943-1; Toma AK, 2009, NEUROSURGERY, V65, P1197, DOI 10.1227/01.NEU.0000356973.39913.0B; Wilson TJ, 2013, J NEUROSURG, V119, P66, DOI 10.3171/2012.11.JNS111384; Yamada SM, 2012, CLIN NEUROL NEUROSUR, V114, P622, DOI 10.1016/j.clineuro.2011.12.025	47	28	30	1	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	AUG	2017	159	8					1399	1411		10.1007/s00701-017-3201-5			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FA6CM	WOS:000405530900005	28555269	Green Submitted			2022-02-06	
J	Holdnack, JA; Tulsky, DS; Brooks, BL; Slotkin, J; Gershon, R; Heinemann, AW; Iverson, GL				Holdnack, James A.; Tulsky, David S.; Brooks, Brian L.; Slotkin, Jerry; Gershon, Richard; Heinemann, Allen W.; Iverson, Grant L.			Interpreting Patterns of Low Scores on the NIH Toolbox Cognition Battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Multivariate base rates; Cognition; NIH Toolbox; Traumatic brain injury; Cognitive impairment	TRAUMATIC BRAIN-INJURY; HEALTHY OLDER-ADULTS; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; IQ-ADJUSTED NORMS; BEHAVIORAL FUNCTION; BASE RATES; SCALE-4TH EDITION; MEMORY SCORES; WAIS-IV; WMS-IV	Introduction: The National Institutes of Health Toolbox for Assessment of Neurological and Behavioral Function Cognition Battery is comprised of seven cognitive tests, including two tests measuring crystallized cognitive ability (i.e., vocabulary and reading) and five tests measuring fluid cognitive functioning (i.e., working memory, memory, speed of processing, and executive functioning). This study presents comprehensive base rate tables for the frequency of low scores in adults and older adults from the normative sample. Methods: Participants were 843 adults, ages 20-85, from the NIH Toolbox standardization sample who completed all seven cognition tests. Rates of low scores were derived for standard age-adjusted and fully-demographically-adjusted scores at multiple cut-scores. Base rates were stratified by education, crystallized intellectual ability, and cognitive domain. Results: Using the five demographically-adjusted fluid cognitive test scores, 45.9% of adults obtained one or more scores at or below the 16th percentile, and 16.8% obtained one or more score at or below the 5th percentile, which is consistent with findings from other neurocognitive test batteries. Discussion: Based on the study findings, nearly 50% of adults in the general population would meet psychometric criteria for a diagnosis of the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Mild Neurocognitive Disorder (MND). We developed new psychometric criteria for identifying MND using the NIH Toolbox Cognition Battery that reduce the false positive rate. Knowing these multivariate normative base rates will help researchers and clinicians interpret NIH Toolbox scores in people with neurodevelopmental, psychiatric, medical, neurological, and neurodegenerative disorders that affect cognitive functioning.	[Holdnack, James A.; Tulsky, David S.; Slotkin, Jerry] Univ Delaware, Ctr Assessment Res & Translat, Newark, DE 19716 USA; [Tulsky, David S.] Univ Delaware, Dept Phys Therapy, Newark, DE 19716 USA; [Tulsky, David S.] Univ Delaware, Dept Psychol Sci, Newark, DE 19716 USA; [Tulsky, David S.] Univ Delaware, Dept Brain Sci, Newark, DE 19716 USA; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program Brain Injury & Rehabil, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Paediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Gershon, Richard] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Evanston, IL 60208 USA; [Gershon, Richard] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Div Biomed Informat, Evanston, IL 60208 USA; [Heinemann, Allen W.] Northwestern Univ, Rehabil Inst Chicago, Feinberg Sch Med, Evanston, IL 60208 USA; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp Children, Sports Concuss Program, Cambridge, MA USA; [Iverson, Grant L.] Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA		Holdnack, JA (corresponding author), 5 Rose Hill Dr, Bear, DE 19701 USA.	jhold@udel.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Tulsky, David/0000-0002-4335-4509; Iverson, Grant/0000-0001-7348-9570	Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [U54-GM104941]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133B040032]; Mooney-Reed Charitable Foundation	Support for JAH was provided by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number U54-GM104941 (PI: Binder-Macleod). BLB acknowledges support from the Canadian Institutes of Health Research. AWH received funding for the Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness (H133B040032) from the National Institute on Disability, Independent Living, and Rehabilitation Research. GLI acknowledges support from the Mooney-Reed Charitable Foundation. GLI notes that this work is related in part to the TBI Endpoints Development Initiative and a grant titled Development and Validation of a Cognition Endpoint for Traumatic Brain Injury Clinical Trials.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Beaumont JL, 2013, NEUROLOGY, V80, pS87, DOI 10.1212/WNL.0b013e3182872e70; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brooks BL, 2013, PRACT RESOUR MENT, P75, DOI 10.1016/B978-0-12-386934-0.00002-X; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Brooks BL, 2009, CAN PSYCHOL, V50, P196, DOI 10.1037/a0016066; Brooks BL, 2009, J INT NEUROPSYCH SOC, V15, P613, DOI 10.1017/S1355617709090651; Brooks BL, 2009, DEMENT GERIATR COGN, V27, P439, DOI 10.1159/000215390; Carlozzi NE, 2015, CLIN NEUROPSYCHOL, V29, P21, DOI 10.1080/13854046.2015.1005677; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Casaletto KB, 2015, J INT NEUROPSYCH SOC, V21, P378, DOI 10.1017/S1355617715000351; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Gershon RC, 2014, J INT NEUROPSYCH SOC, V20, P642, DOI 10.1017/S1355617714000411; Gershon RC, 2013, NEUROLOGY, V80, pS2, DOI 10.1212/WNL.0b013e3182872e5f; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Grober E, 1997, PSYCHOL AGING, V12, P183, DOI 10.1037/0882-7974.12.1.183; Heaton R. K., 2004, REVISED COMPREHENSIV; Heaton RK, 1991, COMPREHENSIVE NORMS; Heaton RK, 2014, J INT NEUROPSYCH SOC, V20, P588, DOI 10.1017/S1355617714000241; Holdnack J. A., REHABILITAT IN PRESS; Horton AM, 1999, INT J NEUROSCI, V99, P221, DOI 10.3109/00207459908994326; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson G. L., 2008, NEUROPSYCHOLOGY HDB, P279; Iverson GL, 2008, NEUROPSYCHOLOGY COUR, P243; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mungas D, 2014, J INT NEUROPSYCH SOC, V20, P579, DOI 10.1017/S1355617714000307; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Sinclair KL, 2013, J CLIN EXP NEUROPSYC, V35, P210, DOI 10.1080/13803395.2012.762340; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P464, DOI 10.1080/13854040590945193; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Tremont G, 1998, CLIN NEUROPSYCHOL, V12, P560, DOI 10.1076/clin.12.4.560.7238; Tulsky D. S., REHABILITATION PSYCH; WARNER MH, 1987, J CLIN EXP NEUROPSYC, V9, P545, DOI 10.1080/01688638708410768; Weintraub S, 2014, J INT NEUROPSYCH SOC, V20, P567, DOI 10.1017/S1355617714000320; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded	41	28	28	1	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2017	32	5					574	584		10.1093/arclin/acx032			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	FC8RL	WOS:000407108500006	28419177	Bronze, Green Published			2022-02-06	
J	Tchekalarova, J; Atanasova, D; Nenchovska, Z; Atanasova, M; Kortenska, L; Gesheva, R; Lazarov, N				Tchekalarova, Jana; Atanasova, Dimitrinka; Nenchovska, Zlatina; Atanasova, Milena; Kortenska, Lidia; Gesheva, Rumyana; Lazarov, Nikolai			Agomelatine protects against neuronal damage without preventing epileptogenesis in the kainate model of temporal lobe epilepsy	NEUROBIOLOGY OF DISEASE			English	Article						Agomelatine; Kainate; Epileptogenesis; Behavior; Neuronal loss	INDUCED STATUS-EPILEPTICUS; TRAUMATIC BRAIN-INJURY; LONG-TERM TREATMENT; OXIDATIVE STRESS; BEHAVIORAL ALTERATIONS; HIPPOCAMPAL-FORMATION; SPATIAL MEMORY; MELATONIN; RECEPTORS; ANTIDEPRESSANT	Recent studies about the novel antidepressant agomelatine, which is a mixed MT1 and MT2 melatonin receptor agonist and 5HT(2c) serotonin receptor antagonist possessing an anticonvulsant and neuroprotective action, suggest that it may have potential to contribute against epileptogenesis and epilepsy-induced memory impairment. In order to ascertain whether protection of some brain structures could suppress epileptogenesis, in the present study, we evaluated the effect of chronic post-status treatment with agomelatine on epileptogenesis, behavioral and neuronal damage induced by kainate acid (KA) status epilepticus (SE). Agomelatine/vehicle treatment (40 mg/kg, i.p.) started one hour after SE and continued up to 10 weeks in Wistar rats. Latency for onset of spontaneous motor seizures (SMS) and their frequency was detected by a 24-h video-recording. Locomotor activity, anxiety and hippocampus-dependent spatial memory in open field (OF), elevated plus maze (EPM), light-dark test (LDT) and radial arm maze (RAM) test, respectively, were evaluated during the last two weeks after SE. Agomelatine significantly decreased the latency for onset of SMS and increased the seizure frequency during the 2nd and the 3rd week of treatment. The MT1 and MT2 receptor agonist and serotonin 5HT2c receptor antagonist exacerbated the KA-induced hyperlocomotion and impulsive behavior and it was unable to prevent spatial memory impairment of epileptic rats. However, agomelatine induced a neuroprotection in the dorsal hippocampus, specifically in the CA1, septal CA2 and partially in the CA3c region, the hilus of the dentate gyrus, piriform cortex and septo-temporal and temporal basolateral amygdala. Our findings suggest that the beneficial impact against SE-induced neuronal loss exerted by agomelatine is not crucial for the suppression of epileptogenesis and its deleterious consequences in MA model of temporal lobe epilepsy. (C) 2017 Elsevier Inc. All rights reserved.	[Tchekalarova, Jana; Atanasova, Dimitrinka; Nenchovska, Zlatina; Kortenska, Lidia; Gesheva, Rumyana; Lazarov, Nikolai] Bulgarian Acad Sci, Inst Neurobiol, Acad G Bonchev Str,Bl 23, Sofia 1113, Bulgaria; [Atanasova, Dimitrinka] Trakia Univ, Dept Anat, Fac Med, Stara Zagora 6003, Bulgaria; [Atanasova, Milena] Med Univ Pleven, Dept Biol, Pleven 5800, Bulgaria; [Lazarov, Nikolai] Med Univ Sofia, Dept Anat & Histol, Sofia 1431, Bulgaria		Tchekalarova, J (corresponding author), Bulgarian Acad Sci, Inst Neurobiol, Acad G Bonchev Str,Bl 23, Sofia 1113, Bulgaria.	janetchekalarova@gmail.com	J, Tchekalarova/H-3826-2014; Atanasova, Dimitrinka/AAK-9242-2020	Atanasova, Dimitrinka/0000-0003-1745-7755	Medical University of Pleven [7/2016]; Medical University of Sofia, Bulgaria [4/2015]; National Science Fund of BulgariaNational Science Fund of Bulgaria [HI 03/10]	This work was supported by the Medical University of Pleven (grant No. 7/2016), the Medical University of Sofia, Bulgaria (grant No. 4/2015) and the National Science Fund of Bulgaria (research grant # NoHI 03/10). The authors would like to thank Sabina Mitova, Faculty of Medicine, Medical University of Sofia for her technical assistance. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.	Akaike K, 2001, BRAIN RES, V900, P65, DOI 10.1016/S0006-8993(01)02252-1; Atanasova M, 2013, PHARMACOL BIOCHEM BE, V111, P44, DOI 10.1016/j.pbb.2013.08.006; Banasr M, 2006, BIOL PSYCHIAT, V59, P1087, DOI 10.1016/j.biopsych.2005.11.025; Barbiero VS, 2007, EUR NEUROPSYCHOPHARM, V17, pS365, DOI 10.1016/S0924-977X(07)70535-7; Bazil CW, 2000, NEUROLOGY, V55, P1746, DOI 10.1212/WNL.55.11.1746; Bertaina-Anglade V, 2011, PHARMACOL BIOCHEM BE, V98, P511, DOI 10.1016/j.pbb.2011.02.015; Borowicz KK, 1999, EUR NEUROPSYCHOPHARM, V9, P185, DOI 10.1016/S0924-977X(98)00022-4; Boulle F, 2016, EUR NEUROPSYCHOPHARM, V26, P65, DOI 10.1016/j.euroneuro.2015.11.003; Brandt C, 2006, NEUROPHARMACOLOGY, V51, P789, DOI 10.1016/j.neuropharm.2006.05.021; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; Comai S, 2014, J PSYCHIATR NEUROSCI, V39, P6, DOI 10.1503/jpn.130009; Conboy L, 2009, INT J NEUROPSYCHOPH, V12, P329, DOI 10.1017/S1461145708009255; Costa-Lotufo LV, 2002, COMP BIOCHEM PHYS C, V131, P521, DOI 10.1016/S1532-0456(02)00037-6; Dagyte G, 2011, BEHAV BRAIN RES, V218, P121, DOI 10.1016/j.bbr.2010.11.045; Dastgheib M, 2014, EUR J PHARMACOL, V736, P10, DOI 10.1016/j.ejphar.2014.04.039; de Mello AH, 2016, PSYCHIAT CLIN NEUROS, V70, P159, DOI 10.1111/pcn.12371; Delagrange P, 1997, CLIN NEUROPHARMACOL, V20, P482, DOI 10.1097/00002826-199712000-00002; Demirdas A., 2016, METAB BRAIN DIS; Detour J, 2005, EPILEPSIA, V46, P499, DOI 10.1111/j.0013-9580.2005.38704.x; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; GILBERT M, 1985, BRAIN RES, V361, P389, DOI 10.1016/0006-8993(85)91309-5; Guardiola-Lemaitre B, 2014, BRIT J PHARMACOL, V171, P3604, DOI 10.1111/bph.12720; Gupta M, 2004, EPILEPSIA, V45, P1636, DOI 10.1111/j.0013-9580.2004.17604.x; Isaac M, 2005, CURR TOP MED CHEM, V5, P59, DOI 10.2174/1568026053386980; Isaev D, 2015, NEUROBIOL DIS, V78, P68, DOI 10.1016/j.nbd.2015.03.026; Kennett GA, 1997, NEUROPHARMACOLOGY, V36, P609, DOI 10.1016/S0028-3908(97)00038-5; Kjelstrup KG, 2002, P NATL ACAD SCI USA, V99, P10825, DOI 10.1073/pnas.152112399; Lapin IP, 1998, J PINEAL RES, V24, P215; Lima E, 2011, EPILEPSY BEHAV, V20, P607, DOI 10.1016/j.yebeh.2011.01.018; Mairesse J, 2013, INT J NEUROPSYCHOPH, V16, P323, DOI 10.1017/S1461145711001970; Mallei M, 2009, EUR NEUROPSYCHOPHARM, V19, pS441, DOI 10.1016/S0924-977X(09)70687-X; Markgraf CG, 2014, J PHARMACOL TOX MET, V70, P224, DOI 10.1016/j.vascn.2014.08.005; Mazor A, 2009, WORLD J BIOL PSYCHIA, V10, P856, DOI 10.1080/15622970701561383; Morley-Fletcher S, 2011, PSYCHOPHARMACOLOGY, V217, P301, DOI 10.1007/s00213-011-2280-x; NAGAHARA AH, 1993, HIPPOCAMPUS, V3, P269, DOI 10.1002/hipo.450030304; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Ozkay UD, 2015, BEHAV PHARMACOL, V26, P469, DOI 10.1097/FBP.0000000000000153; Petkova Z, 2014, EPILEPSY BEHAV, V31, P198, DOI 10.1016/j.yebeh.2013.12.013; Pitkanen A, 2000, ANN NY ACAD SCI, V911, P369; RACINE R, 1977, CAN J NEUROL SCI, V4, P273, DOI 10.1017/S0317167100025117; Rainer Q, 2012, INT J NEUROPSYCHOPH, V15, P321, DOI 10.1017/S1461145711000356; RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M; Rufo-Campos M, 2002, REV NEUROL S, V1, P51; Schwarcz R, 2002, EPILEPSY RES, V50, P161, DOI 10.1016/S0920-1211(02)00077-3; Sejourne J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136494; Shin EJ, 2011, NEUROCHEM INT, V59, P122, DOI 10.1016/j.neuint.2011.03.025; Singh SP, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0087-15.2015; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Soumier A, 2008, EUR NEUROPSYCHOPHARM, V18, pS350, DOI 10.1016/S0924-977X(08)70491-7; Srivastava N, 2008, NEUROCHEM RES, V33, P1169, DOI 10.1007/s11064-007-9478-7; STAFSTROM CE, 1993, EPILEPSIA, V34, P420, DOI 10.1111/j.1528-1157.1993.tb02582.x; Stahl SM, 2014, CNS SPECTRUMS, V19, P207, DOI 10.1017/S1092852914000248; Tchekalarova J, 2016, BEHAV BRAIN RES, V302, P11, DOI 10.1016/j.bbr.2015.12.043; Tchekalarova J, 2013, EPILEPSY BEHAV, V27, P174, DOI 10.1016/j.yebeh.2013.01.009; Tchekalarova J, 2011, EPILEPSY BEHAV, V20, P277, DOI 10.1016/j.yebeh.2010.12.021; Tchekalarova J, 2010, EPILEPSY BEHAV, V17, P23, DOI 10.1016/j.yebeh.2009.11.001; Aguiar CCT, 2012, EPILEPSY BEHAV, V24, P324, DOI 10.1016/j.yebeh.2012.04.134; Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5; Wolden-Hanson T, 2000, ENDOCRINOLOGY, V141, P487, DOI 10.1210/en.141.2.487; Wu HJ, 2016, J PINEAL RES, V61, P241, DOI 10.1111/jpi.12344; Yahyavi-Firouz-Abadi N, 2006, EPILEPSY RES, V68, P103, DOI 10.1016/j.eplepsyres.2005.09.057; Yapca OE, 2014, ADV CLIN EXP MED, V23, P715, DOI 10.17219/acem/37227; YEHUDA S, 1993, PEPTIDES, V14, P203, DOI 10.1016/0196-9781(93)90030-K	63	28	31	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	AUG	2017	104						1	14		10.1016/j.nbd.2017.04.017			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX6WY	WOS:000403384000001	28438504				2022-02-06	
J	Harrison, EB; Emanuel, K; Lamberty, BG; Morsey, BM; Li, M; Kelso, ML; Yelamanchili, SV; Fox, HS				Harrison, Emily B.; Emanuel, Katy; Lamberty, Benjamin G.; Morsey, Brenda M.; Li, Min; Kelso, Matthew L.; Yelamanchili, Sowmya V.; Fox, Howard S.			Induction of miR-155 after Brain Injury Promotes Type 1 Interferon and has a Neuroprotective Effect	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						gene expression; injury; neurodegeneration; inflammation	TOLL-LIKE RECEPTORS; INFLAMMATORY RESPONSES; MICRORNA EXPRESSION; SIGNALING PATHWAY; DENDRITIC CELLS; CORTICAL IMPACT; I INTERFERON; NEURONS; NEUROINFLAMMATION; MICROGLIA	Traumatic brain injury (TBI) produces profound and lasting neuroinflammation that has both beneficial and detrimental effects. Recent evidence has implicated microRNAs (miRNAs) in the regulation of inflammation both in the periphery and the CNS. We examined the expression of inflammation associated miRNAs in the context of TBI using a mouse controlled cortical impact (CCI) model and found increased levels of miR-21, miR-223 and miR-155 in the hippocampus after CCI. The expression of miR-155 was elevated 9-fold after CCI, an increase confirmed by in situ hybridization (ISH). Interestingly, expression of miR-155 was largely found in neuronal nuclei as evidenced by co-localization with DAPI in MAP2 positive neurons. In miR-155 knock out (KO) mice expression of type I interferons IFN alpha and IFN beta, as well as IFN regulatory factor 1 and IFN-induced chemokine CXCL10 was decreased after TBI relative to wild type (WT) mice. Unexpectedly, miR-155 KO mice had increased levels of microglial marker Iba1 and increased neuronal degeneration as measured by fluoro-jade C (FJC) staining, suggesting a neuroprotective role for miR-155 in the context of TBI. This work demonstrates a role for miR-155 in regulation of the IFN response and neurodegeneration in the aftermath of TBI. While the presence of neuronal nuclear miRNAs has been described previously, their importance in disease states is relatively unknown. Here, we show evidence of dynamic regulation and pathological function of a nuclear miRNA in TBI.	[Harrison, Emily B.; Emanuel, Katy; Lamberty, Benjamin G.; Morsey, Brenda M.; Li, Min; Yelamanchili, Sowmya V.; Fox, Howard S.] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Kelso, Matthew L.] Univ Nebraska Med Ctr, Coll Med, Dept Pharm Practice, Omaha, NE USA; [Harrison, Emily B.] Univ North Carolina Chapel Hill, Chapel Hill, NC USA; [Li, Min] Creighton Univ, Omaha, NE 68178 USA; [Kelso, Matthew L.] Medpace Reference Labs, Cincinnati, OH USA		Fox, HS (corresponding author), Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.	hfox@unmc.edu	Harrison, Emily B./AAW-1826-2021	Harrison, Emily B./0000-0002-6934-3875	Nebraska Research Initiative Grant; University of Nebraska Medical Center Graduate Studies Research Fellowship; Herbert L. Davis Fellowship in Pharmacology; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA196589] Funding Source: NIH RePORTER	This work was supported by a Nebraska Research Initiative Grant, a University of Nebraska Medical Center Graduate Studies Research Fellowship and a Herbert L. Davis Fellowship in Pharmacology.	Bhela S, 2014, J IMMUNOL, V192, P2734, DOI 10.4049/jimmunol.1302326; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Butovsky O, 2015, INT J DEV NEUROSCI, V47, P5, DOI 10.1016/j.ijdevneu.2015.04.023; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Cardoso AL, 2016, CURR OPIN PHARMACOL, V26, P1, DOI 10.1016/j.coph.2015.09.001; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106; Chaudhuri AD, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00160; Chen RL, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0050957, 10.1371/journal.pone.0051246]; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dagan LN, 2012, BLOOD, V119, P513, DOI 10.1182/blood-2011-08-370536; Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007; Delhaye S, 2006, P NATL ACAD SCI USA, V103, P7835, DOI 10.1073/pnas.0602460103; Di Filippo M, 2013, NEUROBIOL DIS, V52, P229, DOI 10.1016/j.nbd.2012.12.009; Eisenhardt SU, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0490-9; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fitch MT, 1999, J NEUROSCI, V19, P8182; Gabhann JN, 2010, J IMMUNOL, V184, P2314, DOI 10.4049/jimmunol.0902589; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Gesuete R, 2014, J NEUROPATH EXP NEUR, V73, P378, DOI 10.1097/NEN.0000000000000068; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; Guedes JR, 2014, HUM MOL GENET, V23, P6286, DOI 10.1093/hmg/ddu348; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109; Harrison EB, 2016, FEBS OPEN BIO, V6, P835, DOI 10.1002/2211-5463.12092; Hauss-Wegrzyniak B, 2002, EXP NEUROL, V176, P336, DOI 10.1006/exnr.2002.7966; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Khudayberdiev SA, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00043; Kieseier BC, 2011, CNS DRUGS, V25, P491, DOI 10.2165/11591110-000000000-00000; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Koval ED, 2013, HUM MOL GENET, V22, P4127, DOI 10.1093/hmg/ddt261; Ksiazek-Winiarek DJ, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/172351; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lippai D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070945; Liu L, 2014, ADV DIFFER EQU, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0103948; Loeb GB, 2012, MOL CELL, V48, P760, DOI 10.1016/j.molcel.2012.10.002; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Maussion G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039301; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nudo RJ, 2011, J COMMUN DISORD, V44, P515, DOI 10.1016/j.jcomdis.2011.04.004; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Parisi C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.491; Rasko JEJ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0375-x; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Roberts TC, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.40; Rosato PC, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005028; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Serafini G, 2014, CELL MOL NEUROBIOL, V34, P17, DOI 10.1007/s10571-013-9997-5; Singh RP, 2013, AUTOIMMUN REV, V12, P1160, DOI 10.1016/j.autrev.2013.07.003; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stanczyk J, 2008, ARTHRITIS RHEUM, V58, P1001, DOI 10.1002/art.23386; Sun TY, 2014, J HUAZHONG U SCI-MED, V34, P548, DOI 10.1007/s11596-014-1313-1; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Thounaojam MC, 2013, MOL NEUROBIOL, V47, P1034, DOI 10.1007/s12035-013-8400-3; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wang P, 2010, J IMMUNOL, V185, P6226, DOI 10.4049/jimmunol.1000491; Yelamanchili SV, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.56; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404; Zhang XM, 2012, CANCER RES, V72, P4707, DOI 10.1158/0008-5472.CAN-12-0639; Zhou HB, 2010, BLOOD, V116, P5885, DOI 10.1182/blood-2010-04-280156	72	28	28	0	1	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	JUL 28	2017	10								228	10.3389/fnmol.2017.00228			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FC1MO	WOS:000406601700001	28804446	Green Published, gold			2022-02-06	
J	Girard, R; Fam, MD; Zeineddine, HA; Tan, H; Mikati, AG; Shi, CB; Jesselson, M; Shenkar, R; Wu, MJ; Cao, Y; Hobson, N; Larsson, HBW; Christoforidis, GA; Awad, IA				Girard, Romuald; Fam, Maged D.; Zeineddine, Hussein A.; Tan, Huan; Mikati, Abdul Ghani; Shi, Changbin; Jesselson, Michael; Shenkar, Robert; Wu, Meijing; Cao, Ying; Hobson, Nicholas; Larsson, Henrik B. W.; Christoforidis, Gregory A.; Awad, Issam A.			Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations	JOURNAL OF NEUROSURGERY			English	Article						cerebral cavernous malformation; biomarker; dynamic contrast-enhanced quantitative permeability; quantitative susceptibility mapping; iron; vascular disorders	SOMATIC MUTATIONS; CCM PATHOGENESIS; DISEASE; RELIABILITY; HEMORRHAGE; SEVERITY; LESION; MODEL; ECHO; MRI	OBJECTIVE Vascular permeability and iron leakage are central features of cerebral cavernous malformation (CCM) pathogenesis. The authors aimed to correlate prospective clinical behavior of CCM lesions with longitudinal changes in biomarkers of dynamic contrast-enhanced quantitative permeability (DCEQP) and quantitative susceptibility mapping (QSM) assessed by MRI. METHODS Forty-six patients with CCMs underwent 2 or more permeability and/or susceptibility studies in conjunction with baseline and follow-up imaging and clinical surveillance during a mean 12.05 months of follow-up (range 2.4-31.27 months). Based on clinical and imaging features, cases/lesions were classified as stable, unstable, or recovering. Associated and predictive changes in quantitative permeability and susceptibility were investigated. RESULTS Lesional mean permeability and QSM values were not significantly different in stable versus unstable lesions at baseline. Mean lesional permeability in unstable CCMs with lesional bleeding or growth increased significantly (+85.9% change; p = 0.005), while mean permeability in stable and recovering lesions did not significantly change. Mean lesional QSM values significantly increased in unstable lesions (+44.1% change; p = 0.01), decreased slightly with statistical significance in stable lesions (-3.2% change; p = 0.003), and did not significantly change in recovering lesions. Familial cases developing new lesions during the follow-up period showed a higher background brain permeability at baseline (p = 0.001), as well as higher regional permeability (p = 0.003) in the area that would later develop a new lesion as compared with the homologous contralateral brain region. CONCLUSIONS In vivo assessment of vascular permeability and iron deposition on MRI can serve as objective and quantifiable biomarkers of disease activity in CCMs. This may be applied in natural history studies and may help calibrate clinical trials. The 2 techniques are likely applicable in other disorders of vascular integrity and iron leakage such as aging, hemorrhagic microangiopathy, and traumatic brain injury.	[Girard, Romuald; Fam, Maged D.; Zeineddine, Hussein A.; Tan, Huan; Mikati, Abdul Ghani; Shi, Changbin; Jesselson, Michael; Shenkar, Robert; Wu, Meijing; Cao, Ying; Hobson, Nicholas; Awad, Issam A.] Univ Chicago Med, Sect Neurosurg, Neurovasc Surg Program, Chicago, IL USA; [Larsson, Henrik B. W.] Univ Copenhagen, Funct Imaging Unit, Dept Clin Physiol Nucl Med & PET, Rigshosp Glostrup Inst Clin Med,Fac Hlth Sci, Copenhagen, Denmark; [Larsson, Henrik B. W.] Norwegian Univ Technol & Sci, Dept Circulat & Med Imaging, Trondheim, Norway; [Christoforidis, Gregory A.] Univ Chicago Med, Dept Radiol, Chicago, IL USA		Awad, IA (corresponding author), Univ Chicago Med, Sect Neurosurg, 5841 S Maryland Ave,MC3026 Neurosurg J341, Chicago, IL 60637 USA.	iawad@uchicago.edu	Shenkar, Robert/AAC-7065-2020	Girard, Romuald/0000-0002-5893-9315	NIH, William and Judith Davis Fund in Neurovascular Surgery Research [R21NS087328]; Safadi Translational Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087328] Funding Source: NIH RePORTER	This work was partially supported by a grant from the NIH (R21NS087328) to Dr. Awad by the William and Judith Davis Fund in Neurovascular Surgery Research, and by a grant from the Safadi Translational Fellowship to Dr. Girard.	Abdulrauf SI, 1999, NEUROSURGERY, V44, P41, DOI 10.1097/00006123-199901000-00020; Akers AL, 2009, HUM MOL GENET, V18, P919, DOI 10.1093/hmg/ddn430; Awad IA, 2005, SURG NEUROL, V63, P317, DOI 10.1016/j.surneu.2004.12.032; Choquet H, 2014, CEREBROVASC DIS, V38, P440, DOI 10.1159/000369200; de Champfleur NM, 2011, NEUROSURGERY, V68, P641, DOI 10.1227/NEU.0b013e31820773cf; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; de Souza JM, 2008, AM J NEURORADIOL, V29, P154, DOI 10.3174/ajnr.A0748; Flemming KD, 2015, J CLIN NEUROSCI, V22, P969, DOI 10.1016/j.jocn.2015.01.007; Gault J, 2005, STROKE, V36, P872, DOI 10.1161/01.STR.0000157586.20479.fd; Gault J, 2006, NEUROSURGERY, V59, P1278, DOI 10.1227/01.NEU.0000249188.38409.03; Gault J, 2009, NEUROSURGERY, V65, P138, DOI 10.1227/01.NEU.0000348049.81121.C1; Gibson CC, 2015, CIRCULATION, V131, P289, DOI 10.1161/CIRCULATIONAHA.114.010403; Girard R, 2016, BIOMARK MED, V10, P255, DOI 10.2217/bmm.15.118; Gunel M, 1996, NEW ENGL J MED, V334, P946, DOI 10.1056/NEJM199604113341503; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hart BL, 2013, TRANSL STROKE RES, V4, P500, DOI 10.1007/s12975-013-0285-y; Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8; Huberty C., 1994, APPL DISCRIMINANT AN; JOHNSON EW, 1995, GENOME RES, V5, P368, DOI 10.1101/gr.5.4.368; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Larsson HBW, 2009, MAGN RESON MED, V62, P1270, DOI 10.1002/mrm.22136; Lehnhardt FG, 2005, ARCH NEUROL-CHICAGO, V62, P653, DOI 10.1001/archneur.62.4.653; Liu T, 2011, MAGN RESON MED, V66, P777, DOI 10.1002/mrm.22816; Liu T, 2011, NMR BIOMED, V24, P1129, DOI 10.1002/nbm.1670; McDonald DA, 2014, HUM MOL GENET, V23, P4357, DOI 10.1093/hmg/ddu153; McDonald DA, 2012, STROKE, V43, P571, DOI 10.1161/STROKEAHA.111.625467; McDonald DA, 2011, HUM MOL GENET, V20, P211, DOI 10.1093/hmg/ddq433; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Mikati AG, 2015, J CEREBR BLOOD F MET, V35, P1632, DOI 10.1038/jcbfm.2015.98; Mikati AG, 2014, STROKE, V45, P598, DOI 10.1161/STROKEAHA.113.003548; Petersen TA, 2010, AM J NEURORADIOL, V31, P377, DOI 10.3174/ajnr.A1822; Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190; Rencher A.C., 2012, METHODS MULTIVARIATE; Rigby AS, 2000, DISABIL REHABIL, V22, P339, DOI 10.1080/096382800296575; Salman RAS, 2008, STROKE, V39, P3222, DOI 10.1161/STROKEAHA.108.515544; Shenkar R, 2015, GENET MED, V17, P188, DOI 10.1038/gim.2014.97; Sim J, 2005, PHYS THER, V85, P257; STEIGER HJ, 1987, NEUROSURGERY, V21, P879, DOI 10.1227/00006123-198712000-00016; Stockton RA, 2010, J EXP MED, V207, P881, DOI 10.1084/jem.20091258; Tan H, 2016, AJNR AM J NEURORADIO; Tan H, 2014, INVEST RADIOL, V49, P498, DOI 10.1097/RLI.0000000000000043; Whitehead KJ, 2009, NAT MED, V15, P462, DOI 10.1038/nm0409-462c; Yadla S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.5.FOCUS10121; ZWEIG MH, 1993, CLIN CHEM, V39, P561	44	28	28	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2017	127	1					102	110		10.3171/2016.5.JNS16687			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EY6JB	WOS:000404087500016	27494817	Green Accepted			2022-02-06	
J	Lutton, EM; Razmpour, R; Andrews, AM; Cannella, LA; Son, YJ; Shuvaev, VV; Muzykantov, VR; Ramirez, SH				Lutton, Evan M.; Razmpour, Roshanak; Andrews, Allison M.; Cannella, Lee Anne; Son, Young-Jin; Shuvaev, Vladimir V.; Muzykantov, Vladimir R.; Ramirez, Servio H.			Acute administration of catalase targeted to ICAM-1 attenuates neuropathology in experimental traumatic brain injury	SCIENTIFIC REPORTS			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; OXIDATIVE STRESS; BARRIER PERMEABILITY; INFLAMMATORY RESPONSE; ANTIOXIDANT THERAPIES; SODIUM FLUORESCEIN; ENDOTHELIUM; ACTIVATION	Traumatic brain injury (TBI) contributes to one third of injury related deaths in the US. Treatment strategies for TBI are supportive, and the pathophysiology is not fully understood. Secondary mechanisms of injury in TBI, such as oxidative stress and inflammation, are points at which intervention may reduce neuropathology. Evidence suggests that reactive oxygen species (ROS) propagate blood-brain barrier (BBB) hyperpermeability and inflammation following TBI. We hypothesized that targeted detoxification of ROS may improve the pathological outcomes of TBI. Following TBI, endothelial activation results in a time dependent increase in vascular expression of ICAM-1. We conjugated catalase to anti-ICAM-1 antibodies and administered the conjugate to 8 wk old C57BL/6J mice 30 min after moderate controlled cortical impact injury. Results indicate that catalase targeted to ICAM-1 reduces markers of oxidative stress, preserves BBB permeability, and attenuates neuropathological indices more effectively than non-targeted catalase and anti-ICAM-1 antibody alone. Furthermore, the study of microglia by two-photon microscopy revealed that anti-ICAM-1/catalase prevents the transition of microglia to an activated phenotype. These findings demonstrate the use of a targeted antioxidant enzyme to interfere with oxidative stress mechanisms in TBI and provide a proof-of-concept approach to improve acute TBI management that may also be applicable to other neuroinflammatory conditions.	[Lutton, Evan M.; Razmpour, Roshanak; Andrews, Allison M.; Cannella, Lee Anne; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA; [Andrews, Allison M.; Son, Young-Jin; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Shriners Hosp, Pediat Res Ctr, Philadelphia, PA 19140 USA; [Cannella, Lee Anne; Ramirez, Servio H.] Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA; [Shuvaev, Vladimir V.; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA		Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA.; Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Shriners Hosp, Pediat Res Ctr, Philadelphia, PA 19140 USA.; Ramirez, SH (corresponding author), Temple Univ, Lewis Katz Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19140 USA.	servio@temple.edu		ramirez, servio/0000-0002-4609-5653	National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F32 DA041282, P30 DA013429-16]; NIH/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS086570-01]; Shriners Hospitals for Children [85110-PHI-14]; NIH/HLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [1R01 HL126874-01A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL126874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007237, F32DA041282, P30DA013429] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) F32 DA041282 (AMA), P30 DA013429-16 (SHR), NIH/National Institute of Neurological Disorders and Stroke (NINDS) R01 NS086570-01 (SHR), The Shriners Hospitals for Children 85110-PHI-14 (SHR), and NIH/HLBI 1R01 HL126874-01A1 (VRM).	ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; Amenta PS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0191-6; Andrews AM, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00043; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Deng-Bryant Y, 2016, METHODS MOL BIOL, V1462, P89, DOI 10.1007/978-1-4939-3816-2_6; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dietrich JB, 2002, J NEUROIMMUNOL, V128, P58, DOI 10.1016/S0165-5728(02)00114-5; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Frankowski JC, 2015, SCI REP-UK, V5, DOI 10.1038/srep17956; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Grant G., 2016, TRANSLATIONAL RES TR; Hadad N, 2011, J IMMUNOL, V186, P1816, DOI 10.4049/jimmunol.1000193; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hood ED, 2014, BIOMATERIALS, V35, P3708, DOI 10.1016/j.biomaterials.2014.01.023; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kozler P, 2003, PHYSIOL RES, V52, P607; Kozower BD, 2003, NAT BIOTECHNOL, V21, P392, DOI 10.1038/nbt806; Kudinov AE, 2016, P NATL ACAD SCI USA, V113, P6955, DOI 10.1073/pnas.1513616113; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; Lochhead JJ, 2010, J CEREBR BLOOD F MET, V30, P1625, DOI 10.1038/jcbfm.2010.29; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mannix R, 2017, J NEUROTRAUM, V34, P495, DOI 10.1089/neu.2016.4457; Margulies S, 2016, J NEUROTRAUM, V33, P101, DOI 10.1089/neu.2014.3855; McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049; Merkel S. F., 2016, CELL TRANSPLANT, DOI [10.3727/096368916X694175, DOI 10.3727/096368916X694175]; Merkel SF, 2017, NEUROSCI BIOBEHAV R, V77, P209, DOI 10.1016/j.neubiorev.2017.03.015; Merkel SF, 2017, J NEUROTRAUM, V34, P165, DOI 10.1089/neu.2015.4275; Merrill JE, 1997, BRAIN BEHAV IMMUN, V11, P245, DOI 10.1006/brbi.1997.0496; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; OISHI R, 1989, N-S ARCH PHARMACOL, V339, P159; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G; Rochfort KD, 2015, BIOCHEM SOC T, V43, P702, DOI 10.1042/BST20140319; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Scherpereel A, 2001, FASEB J, V15, P416, DOI 10.1096/fj.00-0022com; Shen QH, 2016, WORLDV EVID-BASED NU, V13, P380, DOI 10.1111/wvn.12167; Shuvaev VV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077002; Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789; Shuvaev VV, 2011, J CONTROL RELEASE, V149, P236, DOI 10.1016/j.jconrel.2010.10.026; Shuvaev VV, 2009, J PHARMACOL EXP THER, V331, P404, DOI 10.1124/jpet.109.156877; Simone E, 2009, CELL TISSUE RES, V335, P283, DOI 10.1007/s00441-008-0676-7; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Soni KS, 2016, J CONTROL RELEASE, V240, P109, DOI 10.1016/j.jconrel.2015.11.009; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; TAKEI F, 1985, J IMMUNOL, V134, P1403; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Tsuhako MH, 2010, FREE RADICAL BIO MED, V48, P704, DOI 10.1016/j.freeradbiomed.2009.12.013; Vialou V, 2012, J NEUROSCI, V32, P7577, DOI 10.1523/JNEUROSCI.1381-12.2012; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zanier Elisa R, 2015, Intensive Care Med Exp, V3, P39, DOI 10.1186/s40635-015-0039-0; Zhang M, 2010, NEUROSCIENCE, V171, P852, DOI 10.1016/j.neuroscience.2010.09.029; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	79	28	30	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 19	2017	7								3846	10.1038/s41598-017-03309-4			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY0LT	WOS:000403650300089	28630485	Green Published, gold			2022-02-06	
J	Rachmany, L; Tweedie, D; Rubovitch, V; Li, YZ; Holloway, HW; Kim, DS; Ratliff, WA; Saykally, JN; Citron, BA; Hoffer, BJ; Greig, NH; Pick, CG				Rachmany, Lital; Tweedie, David; Rubovitch, Vardit; Li, Yazhou; Holloway, Harold W.; Kim, Dong Seok; Ratliff, Whitney A.; Saykally, Jessica N.; Citron, Bruce A.; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration	SCIENTIFIC REPORTS			English	Article							GLUCAGON-LIKE PEPTIDE-1; REVERSES BEHAVIORAL IMPAIRMENTS; BRIGADE COMBAT TEAM; OBJECT RECOGNITION; AUTOMATED QUANTIFICATION; RODENT HIPPOCAMPUS; RECEPTOR AGONIST; GENE-EXPRESSION; ANIMAL-MODELS; MICE	Mild blast traumatic brain injury (B-TBI) induced lasting cognitive impairments in novel object recognition and less severe deficits in Y-maze behaviors. B-TBI significantly reduced the levels of synaptophysin (SYP) protein staining in cortical (CTX) and hippocampal (HIPP) tissues. Treatment with exendin-4 (Ex-4) delivered by subcutaneous micro-osmotic pumps 48 hours prior to or 2 hours immediately after B-TBI prevented the induction of both cognitive deficits and B-TBI induced changes in SYP staining. The effects of a series of biaxial stretch injuries (BSI) on a neuronal derived cell line, HT22 cells, were assessed in an in vitro model of TBI. Biaxial stretch damage induced shrunken neurites and cell death. Treatment of HT22 cultures with Ex-4 (25 to 100 nM), prior to injury, attenuated the cytotoxic effects of BSI and preserved neurite length similar to sham treated cells. These data imply that treatment with Ex-4 may represent a viable option for the management of secondary events triggered by blast-induced, mild traumatic brain injury that is commonly observed in militarized zones.	[Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Dr Miriam & Sheldon G Adelson Chair, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Ctr Biol Addict Dis, IL-69978 Tel Aviv, Israel; [Tweedie, David; Li, Yazhou; Holloway, Harold W.; Kim, Dong Seok; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Kim, Dong Seok] Peptron Inc, 37-24,Yuseong Daero 1628 Beon Gil, Daejeon 305811, South Korea; [Ratliff, Whitney A.; Saykally, Jessica N.; Citron, Bruce A.] Bay Pines VA Healthcare Syst, Lab Mol Biol, Res & Dev 151, Bay Pines, FL 33744 USA; [Ratliff, Whitney A.; Saykally, Jessica N.; Citron, Bruce A.] USF Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA		Tweedie, D (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov	Ratliff, Whitney/L-3556-2016	Ratliff, Whitney/0000-0002-5461-7802	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Sackler School of Medicine, Tel-Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; Joseph Sagol fellowships; Ari and Regine Aprijaskis Fund, Tel-Aviv University, Tel-Aviv, Israel; Depts. of Defense and Veterans Affairs; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001520] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, (D.T., Y.L., H.W.H., DS.K., N.H.G.), (ii) the Sackler School of Medicine, Tel-Aviv University (C.G.P., V.R., L.R.), (iii) a grant from the Israel Science Foundation, grant number 108/09 (C.G.P., V.R., L.R.), (iv) and the Joseph Sagol fellowships (C.G.P., V.R., L.R.), (v) the Ari and Regine Aprijaskis Fund, Tel-Aviv University, Tel-Aviv 69978, Israel (C.G.P., V.R., L.R.), (vi) the Depts. of Defense and Veterans Affairs (B.A.C., W.A.R., J.N.S.). This work was performed in partial fulfillment of the requirements for a Ph.D. degree of L.R., Sackler Faculty of Medicine, Tel Aviv University, Israel.	[Anonymous], 2006, J NEUROL SCI, V249, P63; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Beaudet G, 2016, ALCOHOL CLIN EXP RES, V40, P2591, DOI 10.1111/acer.13256; Belmont Philip J, 2010, J Surg Orthop Adv, V19, P2; Belmont PJ, 2010, J TRAUMA, V68, P204, DOI 10.1097/TA.0b013e3181bdcf95; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00117; CHOI DW, 1987, J NEUROSCI, V7, P357; Cohen SJ, 2013, CURR BIOL, V23, P1685, DOI 10.1016/j.cub.2013.07.002; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Courtney E, 2014, DEF TECHNOL, V10, P245, DOI 10.1016/j.dt.2014.04.003; Deacon RMJ, 2002, BEHAV BRAIN RES, V133, P57, DOI 10.1016/S0166-4328(01)00451-X; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Du JF, 2016, AM J PHYSIOL-CELL PH, V310, pC270, DOI 10.1152/ajpcell.00194.2015; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faul M, 2010, TRAUMATIC BRAIN INJU; Fischer H., 2015, RS22452 CRS; Gardner AJ, 2016, HAND CLINIC, V138, P207, DOI 10.1016/B978-0-12-802973-2.00012-4; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gu YL, 2014, NEUROSCI LETT, V570, P86, DOI 10.1016/j.neulet.2014.04.004; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Kane MJ, 2011, BRAIN RES, V1425, P123, DOI 10.1016/j.brainres.2011.09.047; Kastin AJ, 2003, INT J OBESITY, V27, P313, DOI 10.1038/sj.ijo.0802206; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Leea AS, 2008, P NATL ACAD SCI USA, V105, P17163, DOI 10.1073/pnas.0807749105; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Linnebjerg H, 2007, BRIT J CLIN PHARMACO, V64, P317, DOI 10.1111/j.1365-2125.2007.02890.x; Liu J, 2009, PROCEEDINGS OF THE 2009 INTERNATIONAL CONFERENCE ON COMPUTER AND COMMUNICATIONS SECURITY, P84, DOI 10.1109/ICCCS.2009.21; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Ning YL, 2015, CHIN J TRAUMATOL, V18, P187, DOI 10.1016/j.cjtee.2015.04.005; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Pool M, 2008, J NEUROSCI METH, V168, P134, DOI 10.1016/j.jneumeth.2007.08.029; Popivanov G, 2014, J ROY ARMY MED CORPS, V160, P52, DOI 10.1136/jramc-2013-000132; Preston AR, 2013, CURR BIOL, V23, pR764, DOI 10.1016/j.cub.2013.05.041; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Sannino S, 2012, LEARN MEMORY, V19, P211, DOI 10.1101/lm.025213.111; Schatzle P, 2012, J NEUROSCI METH, V204, P144, DOI 10.1016/j.jneumeth.2011.11.010; Shi S, 2012, ARZNEIMITTEL-FORSCH, V62, P75, DOI 10.1055/s-0031-1295484; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Smith M, 2016, EXP NEUROL, V286, P107, DOI 10.1016/j.expneurol.2016.10.002; Sun LD, 2016, BIOCHEM PHARMACOL, V110, P80, DOI 10.1016/j.bcp.2016.04.016; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Vogel EW, 2017, J NEUROTRAUM, V34, P1063, DOI 10.1089/neu.2016.4578; Vogel EW, 2016, J NEUROTRAUM, V33, P652, DOI 10.1089/neu.2015.4045; Wang DM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160159; Wang SL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151397; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang JL, 2016, THERANOSTICS, V6, P2015, DOI 10.7150/thno.15993; Yi JH, 2016, BEHAV BRAIN RES, V297, P141, DOI 10.1016/j.bbr.2015.10.018; Yusta B, 2006, CELL METAB, V4, P391, DOI 10.1016/j.cmet.2006.10.001; Zhang HN, 2016, AAPS J, V18, P385, DOI 10.1208/s12248-015-9854-1; Zhang HN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148827	77	28	29	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 16	2017	7								3735	10.1038/s41598-017-03792-9			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EX7FN	WOS:000403413700097	28623327	Green Published, gold			2022-02-06	
J	Kaminski, L; Cordemans, V; Cernat, E; M'Bra, KI; Mac-Thiong, JM				Kaminski, Ludovic; Cordemans, Virginie; Cernat, Eduard; M'Bra, Kouame Innocent; Mac-Thiong, Jean-Marc			Functional Outcome Prediction after Traumatic Spinal Cord Injury Based on Acute Clinical Factors	JOURNAL OF NEUROTRAUMA			English	Article						ASIA impairment scale; clinical prediction model; functional outcome; spinal cord injury	INDEPENDENCE MEASURE; SURGICAL DECOMPRESSION; MULTICENTER; RELIABILITY; PROGNOSIS; RECOVERY; VALIDITY; SURGERY; SCI	Spinal cord injury (SCI) is a devastating condition that affects patients on both a personal and societal level. The objective of the study is to improve the prediction of long-term functional outcome following SCI based on the acute clinical findings. A total of 76 patients with acute traumatic SCI were prospectively enrolled in a cohort study in a single Level I trauma center. Spinal Cord Independence Measure (SCIM) at 1 year after the trauma was the primary outcome. Potential predictors of functional outcome were recorded during the acute hospitalization: age, sex, level and type of injury, comorbidities, American Spinal Injury Association (ASIA) Impairment Scale (AIS), ASIA Motor Score (AMS), ASIA Light Touch score (LT), ASIA Pin Prick score (PP), Injury Severity Score (ISS), traumatic brain injury, and delay from trauma to surgery. A linear regression model was created with the primary outcome modeled relative to the acute clinical findings. Only four variables were selected in the model, with performance averaging an R-square value of 0.57. In descending order, the best predictors for SCIM at 1 year were: LT, AIS grade, ISS, and AMS. One-year functional outcome (SCIM) can be estimated by a simple equation that takes into account four parameters of the initial physical examination. Estimating the patient long-term outcome early after traumatic SCI is important in order to define the management strategies that might diminish the costs and to give the patient and family a better view of the long-term expectations.	[Kaminski, Ludovic] Clin Univ St Luc, Serv Orthopedie & Traumatol Appareil Locomoteur, Brussels, Belgium; [Cordemans, Virginie] Catholic Univ Louvain, Inst Rech Expt & Clin, Comp Assisted & Robot Surg CARS, Brussels, Belgium; [Cernat, Eduard] Cent Mil Univ Hosp Dr Carol Davila, Bucharest, Romania; [M'Bra, Kouame Innocent] Ctr Hosp Univ CHU, Serv Orthopedie & Traumatol, Bouake, Bouake, Cote Ivoire; [Mac-Thiong, Jean-Marc] Univ Montreal, Dept Surg, Fac Med, Montreal, PQ, Canada; [Mac-Thiong, Jean-Marc] Hop Sacre Coeur Montreal, Dept Surg, Montreal, PQ, Canada		Kaminski, L (corresponding author), UCL St Luc, Ave Hippocrate 10, B-1200 Brussels, Belgium.	kaminski.ludovic@gmail.com			Department of the Army (United States Army Medical Research Acquisition Activity); Rick Hansen Spinal Cord Injury Registry	The authors would like to thank for their financial support the Department of the Army (United States Army Medical Research Acquisition Activity) and the Rick Hansen Spinal Cord Injury Registry.	Anderson KD, 2011, SPINAL CORD, V49, P880, DOI 10.1038/sc.2011.20; Anderson K, 2008, J SPINAL CORD MED, V31, P133, DOI 10.1080/10790268.2008.11760704; Battistuzzo CR, 2016, J NEUROTRAUM, V33, P1161, DOI 10.1089/neu.2015.4207; Bernhard M, 2005, RESUSCITATION, V66, P127, DOI 10.1016/j.resuscitation.2005.03.005; Bourassa-Moreau E, 2016, J NEUROTRAUM, V33, P301, DOI 10.1089/neu.2015.3957; Bourassa-Moreau E, 2013, J TRAUMA ACUTE CARE, V74, P849, DOI 10.1097/TA.0b013e31827e1381; Burke DA, 2001, SPINAL CORD, V39, P274, DOI 10.1038/sj.sc.3101158; CROZIER KS, 1991, ARCH PHYS MED REHAB, V72, P119; DeVivo MJ., 2011, TOP SPINAL CORD INJ, V16, P1, DOI DOI 10.1310/SCI1604-1; Furlan JC, 2011, J NEUROTRAUM, V28, P1413, DOI 10.1089/neu.2009.1148; Furlan JC, 2009, J NEUROTRAUM, V26, P1707, DOI [10.1089/neu.2009.0888, 10.1089/neu.2009-0888]; Grant RA, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-014-0334-1; Grassner L, 2016, J NEUROTRAUM, V33, P1658, DOI 10.1089/neu.2015.4325; Itzkovich M, 2007, DISABIL REHABIL, V29, P1926, DOI 10.1080/09638280601046302; Jazayeri SB, 2015, EUR SPINE J, V24, P905, DOI 10.1007/s00586-014-3424-6; Jug M, 2015, J NEUROTRAUM, V32, P1385, DOI 10.1089/neu.2014.3767; Krueger H, 2013, CHRON DIS INJ CAN, V33, P113; National Spinal Cord Injury Statistical Center, 2013, J Spinal Cord Med, V36, P1, DOI 10.1179/1079026813Z.000000000136; Nott Melissa T, 2014, Top Spinal Cord Inj Rehabil, V20, P225, DOI 10.1310/sci2003-225; Sharma B, 2014, J REHABIL MED, V46, P370, DOI 10.2340/16501977-1261; Simpson LA, 2012, J NEUROTRAUM, V29, P1548, DOI 10.1089/neu.2011.2226; Stephan K, 2015, SPINE J, V15, P1994, DOI 10.1016/j.spinee.2015.04.041; van Middendorp JJ, 2009, SPINAL CORD, V47, P555, DOI 10.1038/sc.2008.162; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Vasquez N, 2013, SPINAL CORD, V51, P375, DOI 10.1038/sc.2012.175; Wilson JR, 2014, SPINE J, V14, P1192, DOI 10.1016/j.spinee.2013.08.005; Wilson JR, 2012, J NEUROTRAUM, V29, P2263, DOI 10.1089/neu.2012.2417	27	28	28	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 15	2017	34	12					2027	2033		10.1089/neu.2016.4955			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EX0AN	WOS:000402880600003	28129730				2022-02-06	
J	Abdelgadir, J; Smith, ER; Punchak, M; Vissoci, JR; Staton, C; Muhindo, A; Kitya, D; Park, LP; Haglund, MM				Abdelgadir, Jihad; Smith, Emily R.; Punchak, Maria; Vissoci, Joao Ricardo; Staton, Catherine; Muhindo, Alex; Kitya, David; Park, Lawrence P.; Haglund, Michael M.			Epidemiology and Characteristics of Neurosurgical Conditions at Mbarara Regional Referral Hospital	WORLD NEUROSURGERY			English	Article						Africa; Epidemiology; Global surgery; Neurosurgery; Uganda	TRAUMATIC BRAIN-INJURY; UGANDA; CARE; CHALLENGES; COUNTRIES; SURGERY	BACKGROUND: The unmet surgical need, specifically neurosurgical need, in Uganda is significant, yet only 2 public hospitals currently perform neurosurgery in the country. This study examines the epidemiology and outcomes of neurosurgical conditions presenting to 1 of 12 regional referral hospitals in Uganda, in an effort to understand the neurosurgical needs of this population. METHODS: The study was conducted at Mbarara Regional Referral Hospital (MRRH), in southwestern Uganda. Demographics, clinical characteristics, and outcomes were retrospectively collected for all patients who presented to MRRH with a neurosurgical condition between January 2012 and September 2015. RESULTS: During the study period, 1854 patients presented to MRRH with a neurosurgical condition. More than half of the patients were between 19 and 40 years old, and the majority were males (76.1%). The overall median length of stay was 5 days (interquartile range: 2.5-10). The majority of admissions were due to trauma (87%), with almost 60% due to road traffic incidents. The overall mortality rate was 12.8%. A multivariable Cox proportional hazards model revealed that age, closed head injury, and admission Glasgow Coma Scale have a strong positive correlation with mortality while getting a diagnostic image and neurosurgical procedure were negatively correlated with mortality. CONCLUSION: Traumatic brain injury represented the majority of neurosurgical admissions at MRRH, disproportionately affecting young males. Age, closed head injury, admission Glasgow Coma Scale, getting a diagnostic image, and neurosurgical procedure were all independent predictors of mortality. Resource appropriate interventions throughout the health system are needed to meet the demand and improve outcomes.	[Abdelgadir, Jihad; Smith, Emily R.; Punchak, Maria; Vissoci, Joao Ricardo; Staton, Catherine; Haglund, Michael M.] Duke Univ, Div Global Neurosurg & Neurol, Durham, NC 27708 USA; [Abdelgadir, Jihad; Smith, Emily R.; Vissoci, Joao Ricardo; Staton, Catherine; Park, Lawrence P.; Haglund, Michael M.] Duke Univ, Global Hlth Inst, Durham, NC USA; [Vissoci, Joao Ricardo; Staton, Catherine] Duke Univ, Dept Emergency Med, Durham, NC USA; [Park, Lawrence P.] Duke Univ, Dept Med, Div Infect Dis, Durham, NC USA; [Haglund, Michael M.] Duke Univ, Dept Neurosurg, Durham, NC USA; [Punchak, Maria] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Muhindo, Alex] Mulago Natl Referral Hosp, Dept Neurosurg, Kampala, Uganda; [Kitya, David] Mbarara Reg Referral Hosp, Dept Neurosurg, Mbarara, Uganda		Smith, ER (corresponding author), Duke Univ, Div Global Neurosurg & Neurol, Durham, NC 27708 USA.	emily.smith1@duke.edu		Staton, Catherine/0000-0002-6468-2894; Smith, Emily/0000-0002-1745-5728	Duke Global Health Institute, Duke University, Department of Neurosurgery, Division of Global Neurosurgery and Neuroscience; Fogarty International Center, National Institute of Health, US [K01 TW010000-01A1]; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [K01TW010000] Funding Source: NIH RePORTER	Role of Funding Sources: Funding was provided by the Duke Global Health Institute, Duke University, Department of Neurosurgery, Division of Global Neurosurgery and Neuroscience. Dr. Staton received salary support funding from the Fogarty International Center, National Institute of Health, US (Staton, K01 TW010000-01A1). Funding sources played no role in study design, data collection, data analysis, or writing of the manuscript. All authors had full access to the data and had final responsibility for the decision to submit for publication.	Aenderl I, 2014, ETHIOP J HEALTH SCI, V24, P27, DOI 10.4314/ejhs.v24i1.4; Basso A, 2001, WORLD J SURG, V25, P1174; Capone-Neto A, 2009, CURR OPIN CRIT CARE, V15, P290, DOI 10.1097/MCC.0b013e32832e383e; Contini Sandro, 2007, Acta Biomed, V78, P4; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; El Khamlichi Abdeslam, 2005, Clin Neurosurg, V52, P214; Fuller A, 2015, NEUROSURGICAL OUTCOM; Fuller Anthony, 2016, eNeurologicalSci, V3, P1, DOI 10.1016/j.ensci.2015.10.003; Balanzar GG, 2010, WORLD NEUROSURG, V74, P41, DOI 10.1016/j.wneu.2010.03.001; Haglund MM, 2011, WORLD J SURG, V35, P1175, DOI 10.1007/s00268-011-1080-0; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jayaraman S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006955; Linden AF, 2012, WORLD J SURG, V36, P1056, DOI 10.1007/s00268-012-1482-7; Meara JG, 2016, INT J OBSTET ANESTH, V25, P75, DOI 10.1016/j.ijoa.2015.09.006; Meara JG, 2014, LANCET, V383, P12, DOI 10.1016/S0140-6736(13)62345-4; Mock C, 2012, WORLD J SURG, V36, P959, DOI 10.1007/s00268-012-1459-6; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Saidi H., 2014, J TRAUMA MANAG OUTCO, V8, P1; StataCorp, 2012, STAT STAT SOFTW REL; Staton CA, 2017, INT J INJ CONTROL SA, V24, P69, DOI 10.1080/17457300.2015.1061562; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tran TM, 2015, WORLD NEUROSURG, V83, P269, DOI 10.1016/j.wneu.2014.12.028; Warf BC, 2013, WORLD NEUROSURG S, V79; Wong JC, 2016, EUR J NEUROL, V23, P382, DOI 10.1111/ene.12877	25	28	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2017	102						526	532		10.1016/j.wneu.2017.03.019			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FA5HA	WOS:000405472500067	28342925				2022-02-06	
J	McHugo, GJ; Krassenbaum, S; Donley, S; Corrigan, JD; Bogner, J; Drake, RE				McHugo, Gregory J.; Krassenbaum, Sarah; Donley, Sachiko; Corrigan, John D.; Bogner, Jennifer; Drake, Robert E.			The Prevalence of Traumatic Brain Injury Among People With Co-Occurring Mental Health and Substance Use Disorders	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community psychiatry; co-occurring disorders; dual diagnosis; traumatic brain injury	TBI IDENTIFICATION METHOD; PSYCHIATRIC-DISORDERS; POPULATION; ABUSE; RELIABILITY; VALIDITY; ADULTS; RISK; METAANALYSIS; ADOLESCENTS	Objective: To estimate the rate and severity of traumatic brain injury (TBI) among people with co-occurring mental health and substance use disorders and to compare demographic, diagnostic, and institutionalization differences between those who screen positive or negative. Setting: Outpatient community mental health center in Washington, District of Columbia. Participants: A total of 295 people with co-occurring mental health and substance use disorders enrolled in a prospective study of integrated treatment of substance abuse. Design: Cross-sectional baseline assessment. Main Measures: The Ohio State University TBI Identification Method. Standardized measures assessed psychiatric diagnoses, symptom severity, current and lifetime substance use, and history of institutionalization. Results: Eighty percent screened positive for TBI, and 25% reported at least 1 moderate or severe TBI. TBI was associated with current alcohol use and psychiatric symptom severity and with lifetime institutionalization and homelessness. It was more common among participants with posttraumatic stress disorder, borderline personality disorder, and antisocial personality disorder. Men (vs women) and participants with psychotic disorders (vs those with mood disorders) had an earlier age of first TBI with loss of consciousness. Conclusion: TBI is common among people with co-occurring mental health and substance use disorders. Repeated and serious TBIs are common in this population. Failure to detect TBI in people with co-occurring disorders who are seeking integrated treatment could lead to misdiagnosis and inappropriately targeted treatment and rehabilitation.	[McHugo, Gregory J.; Drake, Robert E.] Dartmouth Coll, Dartmouth Psychiat Res Ctr, Hanover, NH 03755 USA; [Krassenbaum, Sarah] Community Connect, Washington, DC USA; [Donley, Sachiko] Univ Calif Irvine, Dept Psychol & Social Behav, Irvine, CA USA; [Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		McHugo, GJ (corresponding author), Dartmouth Psychiat Res Ctr, 46 Centerra Pkwy,Suite 300, Lebanon, NH 03766 USA.	gregory.mchugo@dartmouth.edu	Drake, Robert/AAS-3310-2020; Corrigan, John D./E-2921-2011		West Family Foundation	This research was funded by a gift from the West Family Foundation.	Adams RS, 2012, J SOC WORK PRACT ADD, V12, P28, DOI 10.1080/1533256X.2012.647580; Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Batty R, 2015, J CLIN EXP NEUROPSYC, V37, P917, DOI 10.1080/13803395.2015.1068279; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI [10.1089/neu.2008.0849, 10.1089/neu.2008-0849]; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Boothroyd RA, 2008, ADM POLICY MENT HLTH, V35, P370, DOI 10.1007/s10488-008-0179-6; Brady KT, 2009, J ADDICT MED, V3, P179, DOI 10.1097/ADM.0b013e3181aa244f; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Conrad K J, 2001, Ment Health Serv Res, V3, P141, DOI 10.1023/A:1011571531303; Corrigan J, 2016, 11 WORLD C BRAIN INJ; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Corrigan JD, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1315; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; First MB, 1995, STRUCTURED CLIN INTE; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Ilie G, 2015, J NEUROTRAUM, V32, P1130, DOI 10.1089/neu.2014.3619; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Molloy C, 2011, SCHIZOPHRENIA BULL, V37, P1104, DOI 10.1093/schbul/sbr091; Orellana Gricel, 2013, Front Psychiatry, V4, P35, DOI 10.3389/fpsyt.2013.00035; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Sacks JAY, 2003, J NERV MENT DIS, V191, P145, DOI 10.1097/00005053-200303000-00002; Saunders B., 1980, EVAL ALCOHOL DRUG AB, P129, DOI DOI 10.1016/B978-0-08-022997-3.50013-2; Shiroma EJ, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e3182571c14; Shiroma Eric J, 2010, J Correct Health Care, V16, P273, DOI 10.1177/1078345810378253; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE43, DOI 10.1097/HTR.0000000000000141; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005	40	28	28	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2017	32	3					E65	E74		10.1097/HTR.0000000000000249			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EV4GM	WOS:000401716900014	27455436				2022-02-06	
J	Zhao, B; Zheng, ZB				Zhao, Bing; Zheng, Zebao			Insulin Growth Factor 1 Protects Neural Stem Cells Against Apoptosis Induced by Hypoxia Through Akt/Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase (Akt/MAPK/ERK) Pathway in Hypoxia-Ishchemic Encephalopathy	MEDICAL SCIENCE MONITOR			English	Article						Apoptosis; Cell Survival; Insulin-Like Growth Factor Binding Protein 1; MAP Kinases; Neural Stem Cells; Phosphatidylinositol 3-Kinases	FACTOR-I; ISCHEMIC ENCEPHALOPATHY; TREATMENT OPTIONS; RECEPTOR; DIFFERENTIATION; PROLIFERATION; INVOLVEMENT; HYPOTHERMIA; OXYGEN; MODEL	Background: Insulin growth factor 1 (IGF-1) is reported to modulate cell growth and acts as potential therapy for traumatic brain injury. This study was designed to investigate the effect of IGF-1 on hypoxia-induced apoptosis in neural stem cells (NSCs). Material/Methods: A hypoxia model was constructed using NSCs separated from the hippocampus of rat. NSCs were divided into four groups: cells under normoxic conditions that acted as controls (C group), cells under hypoxia (H group), cells under hypoxia with IGF-1 (HI group), and cells under hypoxia with IGF-1 as well as picropodophyllin (PPP), which acts as an inhibitor of the IGF-1 receptor (HIP group). The cell viability and apoptosis were respectively measured by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and flow cytometry. Finally, the phosphorylation levels of apoptosis-associated proteins and key kinases in the phosphatidylinositol3- kinase (PI3K)/AKT and the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways were detected by Western blot analysis. Results: In comparison with the H group, the cell viability was increased while the cell apoptosis was reduced by IGF1 in the HI group. Besides, the expression levels of Bax, cytochrome c, and activated caspase-3 were all improved in the H group, and the remarkable differences were eliminated in the HI group compared with the C group. The expression level of Bcl-2 was the opposite. Additionally, down-regulations of phosphorylated AKT, MAPK, and ERK induced by hypoxia were all improved by IGF-1. All the influences of IGF-1 were weakened by addition of PPP. Conclusions: IGF-1 increased cell viability while decreasing apoptosis in hypoxic NSCs through the PI3K/AKT and MAPK/ERK pathways.	[Zhao, Bing; Zheng, Zebao] Jining 1 Peoples Hosp, Dept Children Rehabil, Jining, Shandong, Peoples R China		Zheng, ZB (corresponding author), Jining 1 Peoples Hosp, Dept Children Rehabil, Jining, Shandong, Peoples R China.	zhengzebao604@126.com					Bath C, 2013, STEM CELL RES, V10, P349, DOI 10.1016/j.scr.2013.01.004; Chalak LF, 2014, J PEDIATR-US, V164, P468, DOI 10.1016/j.jpeds.2013.10.067; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Dai Y, 2014, BRAIN DEV-JPN, V36, P228, DOI 10.1016/j.braindev.2013.04.007; Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Haiyan H, 2016, EVID-BASED COMPL ALT, V2016, P3106980; Higgins RD, 2011, J PEDIATR-US, V159, P851, DOI 10.1016/j.jpeds.2011.08.004; Huat TJ, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-91; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Li Y, 2013, ASIAN PAC J CANCER P, V14, P4599, DOI 10.7314/APJCP.2013.14.8.4599; Llambi F, 2011, MOL CELL, V44, P517, DOI 10.1016/j.molcel.2011.10.001; Loison F, 2014, J CLIN INVEST, V124, P4445, DOI 10.1172/JCI76246; Ma JC, 2010, J SURG RES, V160, P90, DOI 10.1016/j.jss.2008.08.016; Merchant NM, 2015, EXPERT OPIN ORPHAN D, V3, P357, DOI 10.1517/21678707.2015.1021776; Molyneaux BJ, 2007, NAT REV NEUROSCI, V8, P427, DOI 10.1038/nrn2151; Neubauer JA, 2004, J APPL PHYSIOL, V96, P367, DOI 10.1152/japplphysiol.00831.2003; Papademetrio DL, 2015, TARGETED ONCOLOGY, V11, P1; PUCILOWSKA JB, 1993, J CLIN ENDOCR METAB, V77, P1516, DOI 10.1210/jc.77.6.1516; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; Rink C, 2011, ANTIOXID REDOX SIGN, V14, P1889, DOI 10.1089/ars.2010.3474; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; SELL C, 1995, CANCER RES, V55, P303; Shoemaker LD, 2016, MOL CELL PROTEOMICS, V15, P344, DOI 10.1074/mcp.O115.052704; Studer L, 2000, J NEUROSCI, V20, P7377; Supeno NE, 2013, INT J MED SCI, V10, P522, DOI 10.7150/ijms.5325; Valenciano A, 2012, TRANSL ONCOL, V5, P1, DOI 10.1593/tlo.11265; Van LH, 2013, PEDIATRICS, V131, P88; Vasilcanu R, 2008, ONCOGENE, V27, P1629, DOI 10.1038/sj.onc.1210797; Vhaouari P, 2005, ARCH DIS CHILD-FETAL, V90, P257; Xiang L, 2007, MED HYPOTHESES, V69, P629; Yan Y, 2012, HISTOCHEM CELL BIOL, V137, P513; Yu ML, 2015, CELL BIOL INT, V39, P910, DOI 10.1002/cbin.10466; [袁丽丽 Yuan Lili], 2008, [神经解剖学杂志, Chinese Journal of Neuroanatomy], V24, P343; Zhang XL, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/249485; Zhu LL, 2005, MOL NEUROBIOL, V31, P231, DOI 10.1385/MN:31:1-3:231	36	28	30	2	7	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	APR 19	2017	23						1872	1879		10.12659/MSM.901055			8	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	ES3AH	WOS:000399398900001	28420864	Green Published, Green Submitted			2022-02-06	
J	Archbold, HAP; Rankin, AT; Webb, M; Nicholas, R; Eames, NWA; Wilson, RK; Henderson, LA; Heyes, GJ; Bleakley, CM				Archbold, H. A. P.; Rankin, A. T.; Webb, M.; Nicholas, R.; Eames, N. W. A.; Wilson, R. K.; Henderson, L. A.; Heyes, G. J.; Bleakley, C. M.			RISUS study: Rugby Injury Surveillance in Ulster Schools	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							UNION PLAYERS; WORLD-CUP; CONSENSUS STATEMENT; CONCUSSION; TERM; FOOTBALL; OUTCOMES; SPORTS; AGE	Objective To examine injury patterns in adolescent rugby players and determine factors associated with injury risk. Design Prospective injury surveillance study. Setting N=28 Grammar Schools in Ulster, Ireland (2014-2015 playing season). Participants 825 adolescent rugby players, across in 28 school first XV rugby squads; mean age 16.9 years. Main outcome measures Injuries were classified by body part and diagnosis, and injury incidence using injuries per 1000 match hours of exposure. HRs for injury were calculated through Cox proportional hazard regression after correction for influential covariates. Results A total of n=426 injuries were reported across the playing season. Over 50% of injuries occurred in the tackle situation or during collisions (270/426), with few reported during set plays. The 3 most common injury sites were head/face (n=102, 23.9%), clavicle/shoulder (n=65, 15.3%) and the knee (n=56, 13.1%). Sprain (n=133, 31.2%), concussion (n=81, 19%) and muscle injury (n=65, 15.3%) were the most common diagnoses. Injury incidence is calculated at 29.06 injuries per 1000 match hours. There were no catastrophic injuries. A large percentage of injuries (208/424) resulted in absence from play for more than 28 days. Concussion carried the most significant time out from play (n=33; 15.9%), followed by dislocations of the shoulder (n=22; 10.6%), knee sprains (n=19, 9.1%), ankle sprains (n=14, 6.7%), hand/finger/thumb (n=11; 5.3%). 36.8% of participants in the study (304/825) suffered at least one injury during the playing season. Multivariate models found higher risk of injury (adjusted HR (AHR); 95% CI) with: higher age (AHR 1.45; 1.14 to 1.83), heavier weight (AHR 1.32; 1.04 to 1.69), playing representative rugby (AHR 1.42; 1.06 to 1.90) and undertaking regular strength training (AHR 1.65; 1.11 to 2.46). Playing for a lower ranked team (AHR 0.67; 0.49 to 0.90) and wearing a mouthguard (AHR 0.70; 0.54 to 0.92) were associated with lower risk of injury. Conclusions There was a high incidence of severe injuries, with concussion, ankle and knee ligament injuries and upper limb fractures/dislocations causing greatest time loss. Players were compliant with current graduated return-to-play regulations following concussion. Physical stature and levels of competition were important risk factors and there was limited evidence for protective equipment.	[Archbold, H. A. P.; Nicholas, R.; Eames, N. W. A.; Henderson, L. A.; Heyes, G. J.] Royal Victoria Hosp, Belfast, Antrim, North Ireland; [Rankin, A. T.] Bupa Hlth Clin, Belfast, Antrim, North Ireland; [Webb, M.] Kingspan Stadium, Ulster Rugby, Belfast, Antrim, North Ireland; [Wilson, R. K.] Musgrave Pk Hosp, Belfast, Antrim, North Ireland; [Bleakley, C. M.] Univ Ulster, Sport & Exercise Sci Res Inst, Newtownabbey BT37 0QB, North Ireland		Bleakley, CM (corresponding author), Univ Ulster, Sport & Exercise Sci Res Inst, Newtownabbey BT37 0QB, North Ireland.	c.bleakley@ulster.ac.uk		Bleakley, Chris/0000-0001-9032-9691	Irish Rugby Football Union; MITRE Trust; Ulster Rugby	Financial support was received by the following institutions: Irish Rugby Football Union, MITRE Trust and Ulster Rugby.	Alexander DG, 2015, BRAIN INJURY, V29, P1113, DOI 10.3109/02699052.2015.1031699; Bahr R, 2014, BRIT J SPORT MED, V48, P1265, DOI 10.1136/bjsports-2014-093832; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bleakley C, 2011, J ATHL TRAINING, V46, P555; Carman AJ, 2015, NAT REV NEUROL, V11, P230, DOI 10.1038/nrneurol.2015.30; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Delahunt E, 2013, J STRENGTH COND RES, V27, P3252, DOI 10.1519/JSC.0b013e3182915ea6; Delahunty SE, 2015, J SCHOOL HEALTH, V85, P17, DOI 10.1111/josh.12219; Freitag A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1587; Freitag A, 2015, BRIT J SPORT MED, V49, P511, DOI 10.1136/bjsports-2014-093684; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Fuller CW, 2010, J SCI MED SPORT, V13, P36, DOI 10.1016/j.jsams.2008.09.008; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Kirkwood G, 2015, BRIT J SPORT MED, V49, P506, DOI 10.1136/bjsports-2014-093774; Krause LM, 2015, J SCI MED SPORT, V18, P358, DOI 10.1016/j.jsams.2014.05.012; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Quarrie KL, 2005, BRIT J SPORT MED, V39, P650, DOI 10.1136/bjsm.2004.016022; Schwebel DC, 2014, J ATHL TRAINING, V49, P780, DOI 10.4085/1062-6050-49.3.41; Sedeaud A, 2012, BRIT J SPORT MED, V46, P580, DOI 10.1136/bjsports-2011-090506; Smith AR, 2013, HORM BEHAV, V64, P323, DOI 10.1016/j.yhbeh.2013.03.006; Solomon GS, 2011, CLIN SPORT MED, V30, P165, DOI 10.1016/j.csm.2010.09.002; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Watson AWS, 1988, J SPORT SCI, V6, P131, DOI 10.1080/02640418808729803	29	28	29	1	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2017	51	7					600	606		10.1136/bjsports-2015-095491			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EQ1GC	WOS:000397816800012	26701931				2022-02-06	
J	Cebak, JE; Singh, IN; Hill, RL; Wang, JA; Hall, ED				Cebak, John E.; Singh, Indrapal N.; Hill, Rachel L.; Wang, Juan A.; Hall, Edward D.			Phenelzine Protects Brain Mitochondrial Function In Vitro and In Vivo following Traumatic Brain Injury by Scavenging the Reactive Carbonyls 4-Hydroxynonenal and Acrolein Leading to Cortical Histological Neuroprotection	JOURNAL OF NEUROTRAUMA			English	Article						4-hydroxynonenal; acrolein; brain mitochondria; lipid peroxidation; neuroprotection; phenelzine; traumatic brain injury	SPINAL-CORD-INJURY; MEDIATED OXIDATIVE DAMAGE; LIPID-PEROXIDATION; ANTIOXIDANT THERAPIES; UNITED-STATES; FREE-RADICALS; CNS INJURY; PEROXYNITRITE; DYSFUNCTION; STRESS	Lipid peroxidation (LP) is a key contributor to the pathophysiology of traumatic brain injury (TBI). Traditional antioxidant therapies are intended to scavenge the free radicals responsible for either initiation or propagation of LP. A more recently explored approach involves scavenging the terminal LP breakdown products that are highly reactive and neurotoxic carbonyl compounds, 4-hydroxynonenal (4-HNE) and acrolein (ACR), to prevent their covalent modification and rendering of cellular proteins nonfunctional leading to loss of ionic homeostasis, mitochondrial failure, and subsequent neuronal death. Phenelzine (PZ) is a U.S. Food and Drug Administration-approved monoamine oxidase (MAO) inhibitor (MAO-I) used for treatment of refractory depression that possesses a hydrazine functional group recently discovered by other investigators to scavenge reactive carbonyls. We hypothesized that PZ will protect mitochondrial function and reduce markers of oxidative damage by scavenging LP-derived aldehydes. In a first set of in vitro studies, we found that exogenous application of 4-HNE or ACR significantly reduced respiratory function and increased markers of oxidative damage (p < 0.05) in isolated noninjured rat brain cortical mitochondria, whereas PZ pretreatment significantly prevented mitochondrial dysfunction and oxidative modification of mitochondrial proteins in a concentration-related manner (p < 0.05). This effect was not shared by a structurally similar MAO-I, pargyline, which lacks the hydrazine group, confirming that the mitochondrial protective effects of PZ were related to its carbonyl scavenging and not to MAO inhibition. In subsequent in vivo studies, we documented that PZ treatment begun at 15 min after controlled cortical impact TBI significantly attenuated 72-h post-injury mitochondrial respiratory dysfunction. The cortical mitochondrial respiratory protection occurred together with a significant increase in cortical tissue sparing.	[Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, BBSRB Room 477,741 South Limestone St, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, BBSRB Room 477,741 South Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		National Institute of Neurological Disorder and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01 NS083405, 5R01 NS084857, 5P30 NS051220, 2T32 NS077889]; Kentucky Spinal Cord & Head Injury Research Trust (KSCHIRT); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS077889, R01NS084857] Funding Source: NIH RePORTER	This work was supported by National Institute of Neurological Disorder and Stroke 5R01 NS083405, 5R01 NS084857, 5P30 NS051220, and 2T32 NS077889 and funding from the Kentucky Spinal Cord & Head Injury Research Trust (KSCHIRT).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Burcham PC, 2004, MOL PHARMACOL, V65, P655, DOI 10.1124/mol.65.3.655; Burcham PC, 2006, MOL PHARMACOL, V69, P1056, DOI 10.1124/mol.105.018168; Burcham PC, 2002, TOXICOLOGY, V181, P229, DOI 10.1016/S0300-483X(02)00287-1; Burcham PC, 2008, CHEM RES TOXICOL, V21, P779, DOI 10.1021/tx700399q; CDC, 2003, REP C MILD TRAUM BRA; Communications M. O. o. S, 2013, DOD NUMB TRAUM BRAIN; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005; Ferrick DA, 2008, DRUG DISCOV TODAY, V13, P268, DOI 10.1016/j.drudis.2007.12.008; Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026; Gerencser AA, 2009, ANAL CHEM, V81, P6868, DOI 10.1021/ac900881z; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hamann K, 2008, J NEUROCHEM, V107, P712, DOI 10.1111/j.1471-4159.2008.05622.x; Hamann K, 2009, J NEUROCHEM, V111, P1348, DOI 10.1111/j.1471-4159.2009.06395.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lai J C, 1979, Methods Enzymol, V55, P51; LoPachin RM, 2009, CHEM RES TOXICOL, V22, P1499, DOI 10.1021/tx900147g; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Rogers GW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021746; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toninello A, 2004, AMINO ACIDS, V26, P339, DOI 10.1007/s00726-004-0080-x; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Zhu Q, 2009, CHEM RES TOXICOL, V22, P1721, DOI 10.1021/tx900221s	50	28	29	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1302	1317		10.1089/neu.2016.4624			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600002	27750484	Green Published			2022-02-06	
J	Kurt, M; Laksari, K; Kuo, C; Grant, GA; Camarillo, DB				Kurt, Mehmet; Laksari, Kaveh; Kuo, Calvin; Grant, Gerald A.; Camarillo, David B.			Modeling and Optimization of Airbag Helmets for Preventing Head Injuries in Bicycling	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Concussion; Head trauma; Bicycle helmets; Airbag helmets	FINITE-ELEMENT-ANALYSIS; FOOTBALL; CONCUSSION; ACCIDENTS; CYCLISTS; BARRIERS; SYSTEM; RISK; FOAM; MASS	Bicycling is the leading cause of sports-related traumatic brain injury. Most of the current bike helmets are made of expanded polystyrene (EPS) foam and ultimately designed to prevent blunt trauma, e.g., skull fracture. However, these helmets have limited effectiveness in preventing brain injuries. With the availability of high-rate micro-electrical-mechanical systems sensors and high energy density batteries, a new class of helmets, i.e., expandable helmets, can sense an impending collision and expand to protect the head. By allowing softer liner medium and larger helmet sizes, this novel approach in helmet design provides the opportunity to achieve much lower acceleration levels during collision and may reduce the risk of brain injury. In this study, we first develop theoretical frameworks to investigate impact dynamics of current EPS helmets and airbag helmets-as a form of expandable helmet design. We compared our theoretical models with anthropomorphic test dummy drop test experiments. Peak accelerations obtained from these experiments with airbag helmets achieve up to an 8-fold reduction in the risk of concussion compared to standard EPS helmets. Furthermore, we construct an optimization framework for airbag helmets to minimize concussion and severe head injury risks at different impact velocities, while avoiding excessive deformation and bottoming-out. An optimized airbag helmet with 0.12 m thickness at 72 +/- 8 kPa reduces the head injury criterion (HIC) value to 190 +/- 25 at 6.2 m/s head impact velocity compared to a HIC of 1300 with a standard EPS helmet. Based on a correlation with previously reported HIC values in the literature, this airbag helmet design substantially reduces the risks of severe head injury up to 9 m/s.	[Kurt, Mehmet; Laksari, Kaveh; Camarillo, David B.] Stanford Univ, Dept Bioengn, 443 Via Ortega,Shriram Bldg,Room 202, Stanford, CA 94305 USA; [Kuo, Calvin; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Grant, Gerald A.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA		Kurt, M (corresponding author), Stanford Univ, Dept Bioengn, 443 Via Ortega,Shriram Bldg,Room 202, Stanford, CA 94305 USA.	mkurt@stanford.edu	Kurt, Mehmet/AAX-3303-2021; Kuo, Calvin/AAH-1933-2019	Kuo, Calvin/0000-0001-8401-9136; Kurt, Mehmet/0000-0002-5618-0296	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB0176 1101S1]; Thrasher Research Fund; David and Lucile Packard FoundationThe David & Lucile Packard Foundation [38454]; Child Health Research Institute Transdisciplinary Initiatives Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR000093]; Thrasher Research Fund Early Career Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000093] Funding Source: NIH RePORTER	The study was supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB0176 1101S1, Thrasher Research Fund, David and Lucile Packard Foundation 38454, Child Health Research Institute Transdisciplinary Initiatives Program, and NIH UL1 TR000093 for biostatistics consultation. Dr. Kurt is the recipient of the Thrasher Research Fund Early Career Award. A provisional patent application has been filed for a helmet design using the optimization strategy described in this paper and will be assigned to Stanford University. 26 Royalties gained from any intellectual property granted for this work will be shared among the inventors, the department, and the school, according to Stanfords technology licensing policies.	Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Bourdet N, 2012, P I MECH ENG P-J SPO, V226, P282, DOI 10.1177/1754337112442326; Camacho DLA, 2001, J BIOMECH ENG-T ASME, V123, P432, DOI 10.1115/1.1389086; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cheng ZQ, 1999, SHOCK VIB, V6, P299, DOI 10.1155/1999/146458; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; Croop B, 2009, P 7 EUR LS DYNA C DY; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; de Geus B, 2012, ACCIDENT ANAL PREV, V45, P683, DOI 10.1016/j.aap.2011.09.045; de Vries DVWM., 2009, CHARACTERIZATION POL; Do S, 2012, ACTA ASTRONAUT, V81, P239, DOI 10.1016/j.actaastro.2012.06.022; EilertPetersson E, 1997, ACCIDENT ANAL PREV, V29, P363, DOI 10.1016/S0001-4575(97)00002-X; Ellen Hertz, 1993, 37 ANN P ASS ADV AUT, V37, P303; Esgar J.B., 1960, ANAL STUDY SOFT LAND; Faul M, 2010, TRAUMATIC BRAIN INJU; Federal Motor Vehicle Safety Standards (FMVSS), 571202A FMVSS; Finnoff JT, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e4; Folksam, 2015, TECHNICAL REPORT; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Hansen K, 2013, ACCIDENT ANAL PREV, V59, P109, DOI 10.1016/j.aap.2013.05.019; Healy D. G., 2015, ABC SPORTS EXERCISE, P10; Hernandez F., 2014, ANN BIOMED ENG, V43, P1; HOWLAND J, 1989, AM J DIS CHILD, V143, P741, DOI 10.1001/archpedi.1989.02150180123033; Juhra C, 2012, INJURY, V43, P2026, DOI 10.1016/j.injury.2011.10.016; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kurt M., 2015, U.S. Provisional Patent Application, Patent No. [62/141,675, 62141675]; Laksari K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0331; Lamb L, 2009, P I MECH ENG H, V223, P1021, DOI 10.1243/09544119JEIM573; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Marieb E., 2007, HUMAN ANATOMY PHYSL; Mertz H. J., 1997, INJURY RISK CURVES C; Mills NJ, 2008, INT J IMPACT ENG, V35, P1087, DOI 10.1016/j.ijimpeng.2007.05.006; Mills NJ, 2006, P I MECH ENG L-J MAT, V220, P167, DOI 10.1243/14644207JMDA100; Moss W. C., 2011, TECHNICAL REPORT; Moss WC, 2014, COMPUT METHOD BIOMEC, V17, P1173, DOI 10.1080/10255842.2012.739162; Nagurka M, 2004, P AMER CONTR CONF, P499; Newman J. A., 2002, BIOMECHANICS HEAD TR, P303; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; Ozturk UE, 2011, MATER DESIGN, V32, P773, DOI 10.1016/j.matdes.2010.07.025; Paquette S., 2009, TECHNICAL REPORT; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; RAMON O, 1990, J APPL POLYM SCI, V40, P1683, DOI 10.1002/app.1990.070400922; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; United States Consumer Product Safety Commision (CPSC), 1998, TECHNICAL REPORT; United States Consumer Product Safety Commision (CPSC), 2003, TECHNICAL REPORT; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zhang J, 1998, INT J IMPACT ENG, V21, P369, DOI 10.1016/S0734-743X(97)00087-0; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	48	28	30	0	52	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	APR	2017	45	4					1148	1160		10.1007/s10439-016-1732-1			13	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering	ER3YV	WOS:000398737100026	27679447				2022-02-06	
J	Wennberg, AMV; Savica, R; Hagen, CE; Roberts, RO; Knopman, DS; Hollman, JH; Vemuri, P; Jack, CR; Petersen, RC; Mielke, MM				Wennberg, Alexandra M. V.; Savica, Rodolfo; Hagen, Clinton E.; Roberts, Rosebud O.; Knopman, David S.; Hollman, John H.; Vemuri, Prashanthi; Jack, Clifford R., Jr.; Petersen, Ronald C.; Mielke, Michelle M.			Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY			English	Article						amyloid-beta; gait; neuroimaging; epidemiology; cohort	MEDICAL-RECORDS-LINKAGE; ALZHEIMERS-DISEASE; OLDER-ADULTS; COGNITIVE IMPAIRMENT; SLOW GAIT; BRAIN; EPIDEMIOLOGY; AGE; DISORDERS; PATHOLOGY	ObjectivesTo determine the cross-sectional association between cerebral amyloid-beta (A) deposition and gait. DesignCross-sectional. SettingPopulation-based cohort study in Olmsted County, MN. ParticipantsCognitively normal individuals (n = 611), aged 50 to 69 years, enrolled in the Mayo Clinic Study of Aging with concurrent PiB-PET imaging and gait assessment. Participants with a history of stroke, alcoholism, Parkinson's disease, subdural hematoma, traumatic brain injury, or normal pressure hydrocephalus were excluded. MeasurementsPiB-PET SUVR was measured in prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, posterior cingulate, and motor-specific regions of interest (ROIs). Gait parameters (speed, cadence, stride length, double support time, and intra-individual stance time variability) were measured using GAITRite((R)) instrumentation. Linear regression models were adjusted for age, sex, body mass index, education, APOE epsilon 4 allele, Charlson comorbidity index, and depression. In secondary analyses, we additionally adjusted for neurodegeneration (hippocampal volume, FDG PET SUVR, and cortical thickness) in AD-associated regions. ResultsIn fully adjusted models including neuroimaging measures of neurodegeneration, higher PiB-PET SUVR across all ROIs was associated with slower gait speed (P < .05 except for the parietal ROI), lower cadence and longer double support time (P .05 except for the motor ROI), and greater stance time variability (P < .05). In sex-stratified analyses, the association between higher PiB-PET SUVR across all ROIs and measures of gait was only present among women. ConclusionPiB-PET SUVR across ROIs, independent of general measures of AD-associated neurodegeneration, is associated with poorer performance on multiple gait parameters among cognitively normal women, aged 50 to 69 years. Longitudinal studies are needed to determine whether A predicts gait decline in both women and men.	[Wennberg, Alexandra M. V.; Savica, Rodolfo; Hagen, Clinton E.; Roberts, Rosebud O.; Petersen, Ronald C.; Mielke, Michelle M.] Mayo Clin, Dept Hlth Sci Res, 200 First St SW, Rochester, MN 55905 USA; [Savica, Rodolfo; Roberts, Rosebud O.; Knopman, David S.; Petersen, Ronald C.; Mielke, Michelle M.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Hollman, John H.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Vemuri, Prashanthi; Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA		Mielke, MM (corresponding author), Mayo Clin, Dept Hlth Sci Res, 200 First St SW, Rochester, MN 55905 USA.	mielke.michelle@mayo.edu	Hollman, John H./AAG-9301-2019; Jack, Clifford R/F-2508-2010	Jack, Clifford R/0000-0001-7916-622X; Mielke, Michelle/0000-0001-7177-1185; Hollman, John/0000-0003-4690-223X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; TauRX Pharmaceuticals; Lilly Pharmaceuticals; Alzheimer's Disease Cooperative Study; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic; National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Michael J. Fox Foundation; National Institutes of Health/National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG006786, R01 AG011378, R01 AG041851, R01 AG049704]; Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program; Rochester Epidemiology Project [R01 AG034676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS097495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG049704, R01AG034676, R01AG011378, P50AG044170, U01AG006786, R01AG041851] Funding Source: NIH RePORTER	Drs. Wennberg, Savica, and Hollman, and Mr. Hagen report no disclosures. Drs. Roberts and Vemuri receive funding from the National Institutes of Health. Dr. Knopman serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Cooperative Study; and receives research support from the NIH. Dr. Jack has provided consulting services for Eli Lilly. He receives research funding from the National Institutes of Health, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Petersen serves on data monitoring committees for Pfizer, Inc., Janssen Alzheimer Immunotherapy, and is a consultant for Roche, Inc., Merck, Inc., and Genentech, Inc.; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), and receives research support from the National Institutes of Health. Dr. Mielke served as a consultant to Lysosomal Therapeutics, Inc., and receives research support from the National Institute on Aging, National Institutes of Health, and the Michael J. Fox Foundation.; This study was supported by funding from the National Institutes of Health/National Institute on Aging grants U01 AG006786, R01 AG011378, R01 AG041851, and R01 AG049704; the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, and was made possible by the Rochester Epidemiology Project (R01 AG034676).	Aboutorabi A, 2016, AGING CLIN EXP RES, V28, P393, DOI 10.1007/s40520-015-0420-6; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Annweiler C, 2013, J NEURAL TRANSM, V120, P1083, DOI 10.1007/s00702-012-0926-4; Annweiler C, 2012, PANMINERVA MED, V54, P189; Annweiler C, 2014, EXP GERONTOL, V57, P256, DOI 10.1016/j.exger.2014.06.015; Annweiler C, 2013, BRAIN, V136, P859, DOI 10.1093/brain/aws373; Barnes LL, 2005, ARCH GEN PSYCHIAT, V62, P685, DOI 10.1001/archpsyc.62.6.685; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Buchman AS, 2013, NEUROLOGY, V80, P2055, DOI 10.1212/WNL.0b013e318294b462; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Curiati PK, 2011, AM J NEURORADIOL, V32, P560, DOI 10.3174/ajnr.A2321; del Campo N, 2016, NEUROLOGY, V86, P36, DOI 10.1212/WNL.0000000000002235; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Dominguez-del-Toro E, 2004, EUR J NEUROSCI, V20, P1945, DOI 10.1111/j.1460-9568.2004.03643.x; Ewers M, 2006, NEUROBIOL AGING, V27, P1118, DOI 10.1016/j.neurobiolaging.2005.05.019; Fritz S, 2009, J GERIATR PHYS THER, V32, P2, DOI 10.1519/00139143-200932020-00002; Hollman JH, 2011, GAIT POSTURE, V34, P111, DOI 10.1016/j.gaitpost.2011.03.024; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; Jack CR, 2015, JAMA NEUROL, V72, P511, DOI 10.1001/jamaneurol.2014.4821; Jack CR, 2014, NEUROLOGY, V82, P1605, DOI 10.1212/WNL.0000000000000386; Jack CR, 2012, ANN NEUROL, V71, P765, DOI 10.1002/ana.22628; Kaplan E, 1983, BOSTON NAMING TEST; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Landau SM, 2011, NEUROBIOL AGING, V32, P1207, DOI 10.1016/j.neurobiolaging.2009.07.002; Lowe VJ, 2009, J NUCL MED, V50, P878, DOI 10.2967/jnumed.108.058529; Michaud M, 2013, J AM MED DIR ASSOC, V14, P877, DOI 10.1016/j.jamda.2013.05.009; Mielke MM, 2013, J GERONTOL A-BIOL, V68, P929, DOI 10.1093/gerona/gls256; Mucke L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006338; Reinders I, 2015, J AM GERIATR SOC, V63, P1615, DOI 10.1111/jgs.13524; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Roberts RO, 2008, NEUROEPIDEMIOLOGY, V30, P58, DOI 10.1159/000115751; Rocca WA, 2012, MAYO CLIN PROC, V87, P1202, DOI 10.1016/j.mayocp.2012.08.012; Rosano C, 2007, J GERONTOL A-BIOL, V62, P1048, DOI 10.1093/gerona/62.9.1048; Rosso AL, 2013, J GERONTOL A-BIOL, V68, P1379, DOI 10.1093/gerona/glt089; Senjem ML, 2005, NEUROIMAGE, V26, P600, DOI 10.1016/j.neuroimage.2005.02.005; St Sauver JL, 2012, INT J EPIDEMIOL, V41, P1614, DOI 10.1093/ije/dys195; Stark AK, 2007, NEUROSCIENCE, V150, P121, DOI 10.1016/j.neuroscience.2007.06.062; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Su Y, 2015, NEUROIMAGE, V107, P55, DOI 10.1016/j.neuroimage.2014.11.058; van Kan GA, 2009, J NUTR HEALTH AGING, V13, P881; Verghese J, 2006, J AM GERIATR SOC, V54, P255, DOI 10.1111/j.1532-5415.2005.00580.x; Wang HX, 2012, BEHAV BRAIN RES, V233, P237, DOI 10.1016/j.bbr.2012.05.007; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Winkler AM, 2010, NEUROIMAGE, V53, P1135, DOI 10.1016/j.neuroimage.2009.12.028; Zheng JJJ, 2011, STROKE, V42, P2086, DOI 10.1161/STROKEAHA.110.610360	47	28	28	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-8614	1532-5415		J AM GERIATR SOC	J. Am. Geriatr. Soc.	APR	2017	65	4					792	799		10.1111/jgs.14670			8	Geriatrics & Gerontology; Gerontology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology	ES7CL	WOS:000399707100021	27869301	Green Accepted			2022-02-06	
J	Hopp, S; Nolte, MW; Stetter, C; Kleinschnitz, C; Siren, AL; Albert-Weissenberger, C				Hopp, Sarah; Nolte, Marc W.; Stetter, Christian; Kleinschnitz, Christoph; Siren, Anna-Leena; Albert-Weissenberger, Christiane			Alleviation of secondary brain injury, posttraumatic inflammation, and brain edema formation by inhibition of factor XIIa	JOURNAL OF NEUROINFLAMMATION			English	Article						Focal brain lesion; Brain edema; Factor XII	COAGULATION-FACTOR-XII; KALLIKREIN-KININ SYSTEM; RECEPTOR B1 PROTECTS; IN-VIVO; IMMUNE-RESPONSE; HEAD-INJURY; MICE; BRADYKININ; DAMAGE; ACTIVATION	Background: Traumatic brain injury (TBI) is a devastating neurological condition and a frequent cause of permanent disability. Posttraumatic inflammation and brain edema formation, two pathological key events contributing to secondary brain injury, are mediated by the contact-kinin system. Activation of this pathway in the plasma is triggered by activated factor XII. Hence, we set out to study in detail the influence of activated factor XII on the abovementioned pathophysiological features of TBI. Methods: Using a cortical cryogenic lesion model in mice, we investigated the impact of genetic deficiency of factor XII and inhibition of activated factor XII with a single bolus injection of recombinant human albumin-fused Infestin-4 on the release of bradykinin, the brain lesion size, and contact-kinin system-dependent pathological events. We determined protein levels of bradykinin, intracellular adhesion molecule-1, CC-chemokine ligand 2, and interleukin-1 beta by enzyme-linked immunosorbent assays and mRNA levels of genes related to inflammation by quantitative real-time PCR. Brain lesion size was determined by tetrazolium chloride staining. Furthermore, protein levels of the tight junction protein occludin, integrity of the blood-brain barrier, and brain water content were assessed by Western blot analysis, extravasated Evans Blue dye, and the wet weight-dry weight method, respectively. Infiltration of neutrophils and microglia/activated macrophages into the injured brain lesions was quantified by immunohistological stainings. Results: We show that both genetic deficiency of factor XII and inhibition of activated factor XII in mice diminish brain injury-induced bradykinin release by the contact-kinin system and minimize brain lesion size, blood-brain barrier leakage, brain edema formation, and inflammation in our brain injury model. Conclusions: Stimulation of bradykinin release by activated factor XII probably plays a prominent role in expanding secondary brain damage by promoting brain edema formation and inflammation. Pharmacological blocking of activated factor XII could be a useful therapeutic principle in the treatment of TBI-associated pathologic processes by alleviating posttraumatic inflammation and brain edema formation.	[Hopp, Sarah; Kleinschnitz, Christoph] Univ Hosp Wurzburg, Dept Neurol, Wurzburg, Germany; [Hopp, Sarah; Stetter, Christian; Siren, Anna-Leena; Albert-Weissenberger, Christiane] Univ Hosp Wurzburg, Dept Neurosurg, Josef Schneider Str 11, Wurzburg, Germany; [Nolte, Marc W.] CSL Behring GmbH, Marburg, Germany; [Kleinschnitz, Christoph] Univ Duisburg Essen, Dept Neurol, Essen, Germany		Albert-Weissenberger, C (corresponding author), Univ Hosp Wurzburg, Dept Neurosurg, Josef Schneider Str 11, Wurzburg, Germany.	Albert_C2@ukw.de	Siren, Anna-Leena/AAE-1374-2019	Siren, Anna-Leena/0000-0002-2217-0081; Kleinschnitz, Christoph/0000-0002-1650-8875	Else Kroner-Fresenius Foundation, Germany,; CSL Behring GmbH, Germany; German Federal Ministry of Education and Research under the framework of EU-ERA-NET NEURON CnsAFlame [BMBF 01EW1502]; Interdisciplinary Clinical Research Center (IZKF) Wurzburg [A-226, E-313]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB 688, TP A13]; University of Wurzburg	This work was supported by the Else Kroner-Fresenius Foundation, Germany, CSL Behring GmbH, Germany, the German Federal Ministry of Education and Research under the framework of EU-ERA-NET NEURON CnsAFlame (BMBF 01EW1502B), the Interdisciplinary Clinical Research Center (IZKF) Wurzburg (A-226 and E-313), and the Deutsche Forschungsgemeinschaft (SFB 688, TP A13). This publication was supported by the Open Access Publication Fund of the University of Wurzburg.	Albert-Weissenberger C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00345; Albert-Weissenberger C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00269; Albert-Weissenberger C, 2013, PROG NEUROBIOL, V101, P65, DOI 10.1016/j.pneurobio.2012.11.004; Albert-Weissenberger C, 2012, J CEREBR BLOOD F MET, V32, P1747, DOI 10.1038/jcbfm.2012.62; Bjorkqvist J, 2014, THROMB HAEMOSTASIS, V112, P868, DOI 10.1160/TH14-04-0311; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; De Meyer SF, 2016, STROKE, V47, P1165, DOI 10.1161/STROKEAHA.115.011238; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gill P, 2015, J ALLERGY CLIN IMMUN, V135, P1424, DOI 10.1016/j.jaci.2015.04.019; Hopp S, 2016, ANN NEUROL, V79, P970, DOI 10.1002/ana.24655; Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351; Kunz M, 2013, J NEUROTRAUM, V30, P1638, DOI 10.1089/neu.2012.2774; Langer HF, 2009, J CELL MOL MED, V13, P1211, DOI 10.1111/j.1582-4934.2009.00811.x; Langhauser F, 2012, BLOOD, V120, P4082, DOI 10.1182/blood-2012-06-440057; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P381, DOI 10.1007/978-3-211-85578-2_73; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Negraes PD, 2015, CELL TRANSPLANT, V24, P613, DOI 10.3727/096368915X687778; Pauer HU, 2004, THROMB HAEMOSTASIS, V92, P503, DOI 10.1160/TH04-04-0250; Raslan Furat, 2012, Exp Transl Stroke Med, V4, P6, DOI 10.1186/2040-7378-4-6; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Renne T, 2005, J EXP MED, V202, P271, DOI 10.1084/jem.20050664; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	31	28	28	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 20	2017	14								39	10.1186/s12974-017-0815-8			10	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	EP1OQ	WOS:000397154600001	28219400	Green Published, gold			2022-02-06	
J	Burger, N; Lambert, MI; Viljoen, W; Brown, JC; Readhead, C; den Hollander, S; Hendricks, S				Burger, Nicholas; Lambert, Mike Ian; Viljoen, Wayne; Brown, James Craig; Readhead, Clint; den Hollander, Steve; Hendricks, Sharief			Mechanisms and Factors Associated With Tackle-Related Injuries in South African Youth Rugby Union Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						tackle; rugby injuries; youth rugby; etiology	CERVICAL-SPINE INJURIES; HIGH-SCHOOL; CONSENSUS STATEMENT; AMERICAN FOOTBALL; INCIDENT ANALYSIS; VIDEO ANALYSIS; EPIDEMIOLOGY; HEAD; CONCUSSIONS; CONTACT	Background: The majority of injuries in rugby union occur during tackle events. The mechanisms and causes of these injuries are well established in senior rugby union. Purpose: To use information from an injury database and assess video footage of tackle-related injuries in youth rugby union matches to identify environmental factors and mechanisms that are potentially confounding to these injuries. Study Design: Descriptive epidemiological study. Methods: Injury surveillance was conducted at the under-18 Craven Week rugby tournament. Tackle-related injury information was used to identify injury events in match video footage (role-matched noninjury tackle events were identified for the cohort of injured players). Events were coded using match situational variables (precontact, contact, and postcontact). Relative risk ratio (RRR; ratio of probability of an injury or noninjury outcome occurring when a characteristic was observed) was reported by use of logistic regression. Results: In comparison with the first quarter, injury risk was greater in the third (RRR = 9.75 [95% CI, 1.71-55.64]; P = .010) and fourth quarters (RRR = 6.97 [95% CI, 1.09-44.57]; P = .040) for ball carriers and in the fourth quarter (RRR = 9.63 [95% CI, 1.94-47.79]; P = .006) for tacklers. Ball carriers were less likely to be injured when they were aware of impending contact (RRR = 0.14 [95% CI, 0.03-0.66]; P = .012) or when they executed a moderate fend (hand-off) (RRR = 0.22 [95% CI, 0.06-0.84]; P = .026). Tacklers were less likely to be injured when performing shoulder tackles (same side as leading leg) in comparison to an arm-only tackle (RRR = 0.02 [95% CI, 0.001-0.79]; P = .037). Ball carriers (RRR = 0.09 [95% CI, 0.01-0.89]; P = .040) and tacklers (RRR = 0.02 [95% CI, 0.001-0.32]; P =.006) were less likely to be injured when initial contact was made with the tackler's shoulder/arm instead of his head/neck. Conclusion: The relative risk of tackle-related injury was higher toward the end of matches. Incorrect technique may contribute to increased injury risk. Implementing recovery strategies between matches, training safe and effective techniques, and improving levels of conditioning may counter the negative effects of fatigue. These findings may assist stakeholders in youth rugby to formulate injury prevention strategies and may improve the preparation of field-side medical staff for managing tackle-related injuries at these or similar tournaments.	[Burger, Nicholas; Lambert, Mike Ian; Viljoen, Wayne; Brown, James Craig; Readhead, Clint; den Hollander, Steve; Hendricks, Sharief] Univ Cape Town, Div Exercise Sci & Sports Med, Dept Human Biol, Fac Hlth Sci, Boundary Rd, ZA-7725 Cape Town, WP, South Africa; [Viljoen, Wayne; Readhead, Clint] South African Rugby Union SA Rugby, Cape Town, South Africa; [Lambert, Mike Ian; Brown, James Craig] Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Lambert, Mike Ian; Brown, James Craig] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Hendricks, Sharief] Leeds Beckett Univ, Ctr Sport Performance, Inst Sport Phys Act & Leisure, Sch Sport, Fairfax Hall,Headingley Campus, Leeds, W Yorkshire, England		Burger, N (corresponding author), Univ Cape Town, Div Exercise Sci & Sports Med, Dept Human Biol, Fac Hlth Sci, Boundary Rd, ZA-7725 Cape Town, WP, South Africa.	nicholas.burger@uct.ac.za	Hendricks, Sharief/U-3278-2019; Brown, James Craig/H-7637-2019	Hendricks, Sharief/0000-0002-3416-6266; Brown, James Craig/0000-0002-7778-7783; Viljoen, Wayne/0000-0002-9432-6153; den Hollander, Steve/0000-0002-6064-038X	National Research Foundation (Scarce Skills Development Fund Doctoral Scholarship)	One or more of the authors has declared the following potential conflict of interest or source of funding: Funding for N.B. was provided by the National Research Foundation (Scarce Skills Development Fund Doctoral Scholarship). The injury data and video footage used in this study were provided by SA Rugby and the BokSmart National Rugby Safety Programme. C.R. is the senior medical manager and W.V. is the senior rugby safety manager at SA Rugby. No payment was received from SA Rugby for formulating this manuscript.	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Balague N, 2013, J SYST SCI COMPLEX, V26, P4, DOI 10.1007/s11424-013-2285-0; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Brown JC, 2012, S AFR J SPORTS MED, V24, P49; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Burger N, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005556; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; COUNCIL SPORTS MED FITNESS, 2015, PEDIATRICS, V136, pE1419, DOI 10.1542/peds.2015-3282; Emery CA, 2010, BRIT J SPORT MED, V44, P555, DOI 10.1136/bjsm.2010.074377; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gabbett TJ, 2011, J STRENGTH COND RES, V25, P72, DOI 10.1519/JSC.0b013e3181ff506f; Gabbett TJ, 2009, J STRENGTH COND RES, V23, P540, DOI 10.1519/JSC.0b013e31818efe8b; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Haseler CM, 2010, BRIT J SPORT MED, V44, P1093, DOI 10.1136/bjsm.2010.074021; Heck JF, 2004, J ATHL TRAINING, V39, P101; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hendricks S, 2014, J SPORT SCI MED, V13, P715; Hendricks S, 2013, PERCEPT MOTOR SKILL, V117, P65, DOI 10.2466/30.25.PMS.117x17z6; Hendricks S, 2010, INT J SPORTS SCI COA, V5, P117, DOI 10.1260/1747-9541.5.1.117; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Institute for Digital Research and Education University of California Los Angeles, STAT ANN OUTP MULT L; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; King D, 2012, RES SPORTS MED, V20, P86, DOI 10.1080/15438627.2012.660824; Knowles SB, 2009, EPIDEMIOLOGY, V20, P302, DOI 10.1097/EDE.0b013e318193107c; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGuine TA, 2014, AM J SPORT MED, V42, P2470, DOI 10.1177/0363546514541926; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McKay CD, 2014, BRIT J SPORT MED, V48, P57, DOI 10.1136/bjsports-2013-092860; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Nicol A, 2011, J PUBLIC HEALTH-UK, V33, P256, DOI 10.1093/pubmed/fdq047; O'Donoghue P., 2010, RES METHODS PERFORMA; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; Orchard J, 2002, BRIT J SPORT MED, V36, P270, DOI 10.1136/bjsm.36.4.270; Palmer-Green DS, 2013, AM J SPORT MED, V41, P749, DOI 10.1177/0363546512473818; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; Roberts SP, 2015, BRIT J SPORT MED, V49, P536, DOI 10.1136/bjsports-2013-092988; Salces JN, 2014, J SPORT SCI, V32, P1263, DOI 10.1080/02640414.2014.884720; Sparks J P, 1985, Br J Sports Med, V19, P71; Torg JS, 2002, J BONE JOINT SURG AM, V84A, P112, DOI 10.2106/00004623-200201000-00017; Viljoen W, 2012, BRIT J SPORT MED, V46, P692, DOI 10.1136/bjsports-2012-091278; Viljoen W, 2012, SA RUGBY BOKSMART SA; Wheeler K, 2009, INT J SPORTS SCI COA, V4, P535, DOI 10.1260/174795409790291420; Wheeler KW, 2010, J SPORT SCI MED, V9, P445; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; Willigenburg NW, 2016, AM J SPORT MED, V44, P753, DOI 10.1177/0363546515622389; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9; World Rugby Training and Education, RUGB READ COLL RESP	62	28	28	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2017	45	2					278	285		10.1177/0363546516677548			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	EL7BU	WOS:000394776900002	28125898				2022-02-06	
J	Howel, DR; Oldham, JR; DiFabio, M; Vallabhajosula, S; Hall, EE; Ketcham, CJ; Meehan, WP; Buckley, TA				Howel, David R.; Oldham, Jessie R.; DiFabio, Melissa; Vallabhajosula, Srikant; Hall, Eric E.; Ketcham, Caroline J.; Meehan, William P., III; Buckley, Thomas A.			Single-Task and Dual-Task Gait Among Collegiate Athletes of Different Sport Classifications: Implications for Concussion Management	JOURNAL OF APPLIED BIOMECHANICS			English	Article						clinical biomechanics; gait analysis; head injury; sports medicine	ERROR SCORING SYSTEM; BALANCE CONTROL; EXECUTIVE FUNCTION; NORMATIVE DATA; ATTENTION; PERFORMANCE; DEFICITS; ADOLESCENTS; STABILITY; PARADIGM	Gait impairments have been documented following sport-related concussion. Whether preexisting gait pattern differences exist among athletes who participate in different sport classifications, however, remains unclear. Dual-task gait examinations probe the simultaneous performance of everyday tasks (ie, walking and thinking), and can quantify gait performance using inertial sensors. The purpose of this study was to compare the single-task and dual-task gait performance of collision/contact and noncontact athletes. A group of collegiate athletes (n = 265) were tested before their season at 3 institutions (mean age= 19.1 +/- 1.1 years). All participants stood still (single-task standing) and walked while simultaneously completing a cognitive test (dual-task gait), and completed walking trials without the cognitive test (single-task gait). Spatial-temporal gait parameters were compared between collision/contact and noncontact athletes using MANCOVAs; cognitive task performance was compared using ANCOVAs. No significant single-task or dual-task gait differences were found between collision/contact and noncontact athletes. Noncontact athletes demonstrated higher cognitive task accuracy during single-task standing (P = .001) and dual-task gait conditions (P = .02) than collision/contact athletes. These data demonstrate the utility of a dual-task gait assessment outside of a laboratory and suggest that preinjury cognitive task performance during dual-tasks may differ between athletes of different sport classifications.	[Howel, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA; [Howel, David R.; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA 02115 USA; [Howel, David R.; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA; [DiFabio, Melissa; Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [DiFabio, Melissa; Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA; [Vallabhajosula, Srikant] Elon Univ, Dept Phys Therapy Educ, Elon, NC USA; [Hall, Eric E.; Ketcham, Caroline J.] Elon Univ, Dept Exercise Sci, Elon, NC USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA		Howel, DR (corresponding author), Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA.; Howel, DR (corresponding author), Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA 02115 USA.; Howel, DR (corresponding author), Boston Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA.	David.Howel12@childrens.harvard.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Vallabhajosula, Srikant/0000-0002-7984-1106; Oldham, Jessie/0000-0003-2801-2110	National Football League Players Association; National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament; National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense	Dr. Meehan receives royalties from ABC-Clio publishing for the sale of his book, Kids, Sports, and Concussion: A Guide for Coaches and Parents, and royalties from Wolters Kluwer for working as an author for UpToDate. He is under contract with ABC-Clio publishing for a future book titled, Concussions, and with Springer International publishing for a future book titled, Head and Neck Injuries in Young Athletes. His research is funded, in part, by a grant from the National Football League Players Association and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament. Dr. Buckley's research is funded, in part, by a grant from the National Collegiate Athletic Association and the Department of Defense. Dr. Howell, Ms. Oldham, Ms. DiFabio, Dr. Vallabhajosula, Dr. Hall, and Dr. Ketcham have no conflicts of interest to report.	Baker CS, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12252; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P417, DOI 10.1016/j.jshs.2015.03.010; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Evans KM, 2015, INT J PHYS MED REHAB, V3; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Godde B, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00139; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Iverson GL, 2013, BRAIN INJURY, V27, P596, DOI 10.3109/02699052.2013.772237; Kerrigan DC, 1998, AM J PHYS MED REHAB, V77, P2, DOI 10.1097/00002060-199801000-00002; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Leitner Y, 2007, J NEUROL, V254, P1330, DOI 10.1007/s00415-006-0522-3; Lovell M.R.C.M., 2003, IMMEDIATE POSTCONCUS; Mancini M, 2011, J BIOENG BIONZED S1; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; Mancini M, 2012, GAIT POSTURE, V36, P471, DOI 10.1016/j.gaitpost.2012.04.010; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meagher J, 2015, WORLD J PSYCHIATR, V5, P305, DOI 10.5498/wjp.v5.i3.305; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Ponta ML, 2014, OBES SURG, V24, P1915, DOI 10.1007/s11695-014-1254-6; Rahn C, 2015, CLIN J SPORT MED, V25, P248, DOI 10.1097/JSM.0000000000000141; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; SUTHERLAND DH, 1980, J BONE JOINT SURG AM, V62, P336, DOI 10.2106/00004623-198062030-00004; Vallabhajosula S, 2015, J BIOMECH, V48, P921, DOI 10.1016/j.jbiomech.2015.02.024; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wang JJ, 2009, J NEURAL TRANSM, V116, P1087, DOI 10.1007/s00702-009-0269-y; Wright JM, 2014, WILD ENVIRON MED, V25, P319, DOI 10.1016/j.wem.2014.01.004; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	47	28	28	4	17	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483	1543-2688		J APPL BIOMECH	J. Appl. Biomech.	FEB	2017	33	1					24	31		10.1123/jab.2015-0323			8	Engineering, Biomedical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	EL9EH	WOS:000394921800004	27705076				2022-02-06	
J	Krolikowski, MP; Black, AM; Palacios-Derflingher, L; Blake, TA; Schneider, KJ; Emery, CA				Krolikowski, Maciej P.; Black, Amanda M.; Palacios-Derflingher, Luz; Blake, Tracy A.; Schneider, Kathryn J.; Emery, Carolyn A.			The Effect of the "Zero Tolerance for Head Contact" Rule Change on the Risk of Concussions in Youth Ice Hockey Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; child and adolescent; ice hockey; injury prevention	SPORT-RELATED CONCUSSION; BODY-CHECKING; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; RATES; INJURIES; EPIDEMIOLOGY; MANAGEMENT; EMERGENCY; FOOTBALL	Background: Ice hockey is a popular winter sport in Canada. Concussions account for the greatest proportion of all injuries in youth ice hockey. In 2011, a policy change enforcing zero tolerance for head contact was implemented in all leagues in Canada. Purpose: To determine if the risk of game-related concussions and more severe concussions (ie, resulting in >10 days of time loss) and the mechanisms of a concussion differed for Pee Wee class (ages 11-12 years) and Bantam class (ages 13-14 years) players after the 2011 zero tolerance for head contact policy change compared with players in similar divisions before the policy change. Study Design: Cohort study; Level of evidence, 3. Methods: The retrospective cohort included Pee Wee (most elite 70%, 2007-2008; n = 891) and Bantam (most elite 30%, 2008-2009; n = 378) players before the rule change and Pee Wee (2011-2012; n = 588) and Bantam (2011-2012; n = 242) players in the same levels of play after the policy change. Suspected concussions were identified by a team designate and referred to a sport medicine physician for diagnosis. Incidence rate ratios (IRRs) were estimated based on multiple Poisson regression analysis, controlling for clustering by team and other important covariates and offset by game-exposure hours. Incidence rates based on the mechanisms of a concussion were estimated based on univariate Poisson regression analysis. Results: The risk of game-related concussions increased after the head contact rule in Pee Wee (IRR, 1.85; 95% CI, 1.20-2.86) and Bantam (IRR, 2.48; 95% CI, 1.17-5.24) players. The risk of more severe concussions increased after the head contact rule in Pee Wee (IRR, 4.12; 95% CI, 2.00-8.50) and Bantam (IRR, 7.91; 95% CI, 3.13-19.94) players. The rates of concussions due to body checking and direct head contact increased after the rule change. Conclusion: The zero tolerance for head contact policy change did not reduce the risk of game-related concussions in Pee Wee or Bantam class ice hockey players. Increased concussion awareness and education after the policy change may have contributed to the increased risk of concussions found after the policy change.	[Krolikowski, Maciej P.; Black, Amanda M.; Palacios-Derflingher, Luz; Blake, Tracy A.; Schneider, Kathryn J.; Emery, Carolyn A.] Univ Calgary, Calgary, AB, Canada; [Krolikowski, Maciej P.; Black, Amanda M.; Palacios-Derflingher, Luz; Blake, Tracy A.; Schneider, Kathryn J.; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada; [Black, Amanda M.; Schneider, Kathryn J.] Alberta Childrens Prov Gen Hosp, Res Inst, Calgary, AB, Canada; [Black, Amanda M.; Schneider, Kathryn J.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Palacios-Derflingher, Luz; Emery, Carolyn A.] Univ Calgary, Cumming Sch Med, Community Hlth Sci, Calgary, AB, Canada; [Emery, Carolyn A.] Univ Calgary, Dept Paediat, Calgary, AB, Canada		Krolikowski, MP (corresponding author), Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	mkrolikowski9@gmail.com	Black, Amanda/O-7675-2017; Emery, Carolyn/AAI-2761-2020	Black, Amanda/0000-0001-5668-9706; Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute (ACHRI) for Child and Maternal Health; Max Bell Foundation; Undergraduate Student Research Program; Alberta Innovates: Health Solutions Summer Studentship; ACHRI's Scholars Training Program and Talisman Energy Fund in Support of Healthy Living and Injury Prevention; CIHR's Frederick Banting and Charles Best Canada Graduate Scholarship; Hotchkiss Brain Institute's Dr. T. Chen Fong Doctoral Scholarship in Neuroscience; Alberta Children's Hospital Foundation; Canadian Foundation for Innovation's John R. Evans Leaders Fund; Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation; Alberta Innovates [201201160] Funding Source: researchfish	This study was funded by the Canadian Institutes of Health Research (CIHR), the Alberta Children's Hospital Research Institute (ACHRI) for Child and Maternal Health, and the Max Bell Foundation. M.P.K. is supported by the Undergraduate Student Research Program, an Alberta Innovates: Health Solutions Summer Studentship, the ACHRI's Scholars Training Program and Talisman Energy Fund in Support of Healthy Living and Injury Prevention, and a CIHR's Frederick Banting and Charles Best Canada Graduate Scholarship. A.M.B. is supported by a Hotchkiss Brain Institute's Dr. T. Chen Fong Doctoral Scholarship in Neuroscience. K.J.S. is supported by the Alberta Children's Hospital Foundation and the Canadian Foundation for Innovation's John R. Evans Leaders Fund. C.A.E. is supported by an Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bjorneboe J, 2013, BRIT J SPORT MED, V47, P508, DOI 10.1136/bjsports-2012-091522; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cusimano Michael D, 2011, Open Med, V5, pe57; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Fuller CW, 2004, AM J SPORT MED, V32, p17S, DOI 10.1177/0363546503261249; Gordon KE, 2014, BRAIN INJURY, V28, P311, DOI 10.3109/02699052.2013.862740; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hockey Canada, 2013, HOCK CAN ANN REP; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; Malenfant S, 2012, J SCI MED SPORT, V15, P463, DOI 10.1016/j.jsams.2012.03.003; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091	29	28	28	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2017	45	2					468	473		10.1177/0363546516669701			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	EL7BU	WOS:000394776900027	27789471				2022-02-06	
J	Liu, YM; Hu, CY; Shen, JD; Wu, SH; Li, YC; Yi, LT				Liu, Ya-Min; Hu, Chun-Yue; Shen, Ji-Duo; Wu, Su-Hui; Li, Yu-Cheng; Yi, Li-Tao			Elevation of synaptic protein is associated with the antidepressant-like effects of ferulic acid in a chronic model of depression	PHYSIOLOGY & BEHAVIOR			English	Article						Ferulic acid; Brain-derived neurotrophic factor; Synaptic protein; Depression; Chronic unpredictable mild stress	TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; INVOLVEMENT; STRESS; MTOR; MICE; BDNF; EXPRESSION; HIPPOCAMPUS; ANTAGONISTS	Ferulic acid is a hydroxycinnamic acid that widely presents in plant cell wall components. It has been demonstrated that ferulic acid can reverse depressive-like behaviors in both forced swimming test and tail suspension test. However, it is undear whether chronic ferulic acid treatment can ameliorate the depressive-like behaviors in chronic unpredictable mild stress (CUMS). Because of the putative relationship between neurotrophic system and antidepressant-like activity, we also investigated the effects of chronic ferulic acid on the brain-derived neurotrophic factor (BDNF), postsynaptic protein PSD95, presynaptic protein synapsin I in both prefrontal cortex and hippocampus. The results showed that ferulic acid significantly alleviated CUMS-induced depressive-like behaviors in sucrose preference test and forced swimming test. In addition, ferulic acid significantly up-regulated the levels of BDNF, PSD95 and synapsin I in the prefrontal cortex and hippocampus. The present data indicated that ferulic acid exerted the antidepressant-like effects on behaviors by increasing neurotrophin-related synaptic protein levels in CUMS mice. (C) 2016 Elsevier Inc. All rights reserved.	[Liu, Ya-Min; Hu, Chun-Yue; Shen, Ji-Duo; Wu, Su-Hui; Li, Yu-Cheng] Henan Univ Tradit Chinese Med, Coll Pharm, Zhengzhou 450046, Henan Province, Peoples R China; [Yi, Li-Tao] Huaqiao Univ, Dept Chem & Pharmaceut Engn, Coll Chem Engn, Xiamen 361021, Fujian Province, Peoples R China		Li, YC (corresponding author), Henan Univ Tradit Chinese Med, Coll Pharm, Zhengzhou 450046, Henan Province, Peoples R China.	Liyucheng@hactcm.edu.cn; litao.yi@yahoo.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303278, 81673629]; Provincial Scientific Research Special Foundation of Henan University of Traditional Chinese Medicine [2014KYYWF-QN19]; Talent Project of Science and Technology Innovation of Henan University of Traditional Chinese Medicine [2015XCXRC03]	This work was supported by the National Natural Science Foundation of China (No.81303278, 81673629), the Provincial Scientific Research Special Foundation of Henan University of Traditional Chinese Medicine (2014KYYWF-QN19), and the Talent Project of Science and Technology Innovation of Henan University of Traditional Chinese Medicine (2015XCXRC03).	Akinfiresoye L, 2013, PSYCHOPHARMACOLOGY, V230, P291, DOI 10.1007/s00213-013-3153-2; Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130; Bartkowska K, 2010, ACTA NEUROBIOL EXP, V70, P454; Zeni ALB, 2012, PHARMACOL BIOCHEM BE, V103, P181, DOI 10.1016/j.pbb.2012.08.020; Birkenhager TK, 2012, J PSYCHIATR RES, V46, P285, DOI 10.1016/j.jpsychires.2011.12.006; Bumb JM, 2015, EUR ARCH PSY CLIN N, V265, P227, DOI 10.1007/s00406-014-0543-3; Chen JL, 2015, METAB BRAIN DIS, V30, P129, DOI 10.1007/s11011-014-9635-z; Czeh B, 2016, PROG NEURO-PSYCHOPH, V64, P293, DOI 10.1016/j.pnpbp.2015.04.004; Dell'Osso L, 2010, NEUROPSYCHOBIOLOGY, V62, P207, DOI 10.1159/000319946; Duman RS, 2012, PHILOS T R SOC B, V367, P2475, DOI 10.1098/rstb.2011.0357; Ghosh R, 2015, ASIAN J PSYCHIATR, V18, P37, DOI 10.1016/j.ajp.2015.10.006; Giese M, 2014, J PSYCHIATR RES, V59, P1, DOI 10.1016/j.jpsychires.2014.09.005; Kang HJ, 2012, NAT MED, V18, P1413, DOI 10.1038/nm.2886; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kim MJ, 2007, BIOSCI BIOTECH BIOCH, V71, P1063, DOI 10.1271/bbb.60564; Lakshminarasimhan H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030481; Lenzi J, 2015, METAB BRAIN DIS, V30, P1453, DOI 10.1007/s11011-015-9725-6; Lepack A.E., 2014, INT J NEUROPSYCHOPHA, P18; Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Mizuki D, 2014, J ETHNOPHARMACOL, V156, P16, DOI 10.1016/j.jep.2014.08.014; Mu RH, 2016, PSYCHOPHARMACOLOGY, V233, P3211, DOI 10.1007/s00213-016-4357-z; Nase Sarah, 2016, Neurosignals, V24, P1, DOI 10.1159/000442607; Neis VB, 2016, EUR NEUROPSYCHOPHARM, V26, P959, DOI 10.1016/j.euroneuro.2016.03.009; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Razzoli M, 2011, GENES BRAIN BEHAV, V10, P424, DOI 10.1111/j.1601-183X.2011.00681.x; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; Vigers AJ, 2012, NEUROSCIENCE, V212, P1, DOI 10.1016/j.neuroscience.2012.03.031; Wenk GL, 2004, J NEUROCHEM, V89, P484, DOI 10.1111/j.1471-4159.2004.02359.x; Xie Y, 2013, AMINO ACIDS, V44, P413, DOI 10.1007/s00726-012-1347-2; Yang B, 2016, PSYCHOPHARMACOLOGY; Yasuda S, 2014, CELL MOL NEUROBIOL, V34, P1199, DOI 10.1007/s10571-014-0097-y; Yi LT, 2014, J PSYCHIATR NEUROSCI, V39, P348, DOI 10.1503/jpn.130169; Zhang LM, 2015, EXP THER MED, V9, P972, DOI 10.3892/etm.2014.2157; Zhang YJ, 2011, BRAIN RES BULL, V86, P222, DOI 10.1016/j.brainresbull.2011.07.002; Zhuang FZ, 2016, BEHAV BRAIN RES, V313, P158, DOI 10.1016/j.bbr.2016.06.057	37	28	33	3	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	FEB 1	2017	169						184	188		10.1016/j.physbeh.2016.12.003			5	Psychology, Biological; Behavioral Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Behavioral Sciences	EI8RB	WOS:000392774100025	27940143				2022-02-06	
J	Abrahamson, V; Jensen, J; Springett, K; Sakel, M				Abrahamson, Vanessa; Jensen, Jan; Springett, Kate; Sakel, Mohamed			Experiences of patients with traumatic brain injury and their carers during transition from in-patient rehabilitation to the community: a qualitative study	DISABILITY AND REHABILITATION			English	Article						Community rehabilitation; integrated care; traumatic brain injury	SENTINEL EVENTS; LIFE; INDIVIDUALS; HOME; EPIDEMIOLOGY; INTEGRATION; CONTINUITY; CAREGIVERS; PEOPLE	Purpose: To explore the experiences of individuals who have had a severe traumatic brain injury (TBI) and their carers in the first month post-discharge from in-patient rehabilitation into living in the community.Method: Using a qualitative approach underpinned by critical realism, we explored the narratives of 10 patients and nine carers using semi-structured interviews approximately one month post-discharge. Thematic analysis was carried out independently by two researchers.Results: Firstly, perceptions of support were mixed but many patients and carers felt unsupported in the inpatient phase, during transitions between units and when preparing for discharge. Secondly, they struggled to accept a new reality of changed abilities, loss of roles and loss of autonomy. Thirdly, early experiences post-discharge exacerbated fears for the future.Conclusions: Most patients and carers struggled to identify a cohesive plan that supported their transition to living in the community. Access to services required much persistence on the part of carers and tended to be short-term, and therefore did not meet their long-term needs. We propose the need for a case manager to be involved at an early stage of their rehabilitation and act as a key point for information and access to on-going rehabilitation and other support services.Implications for RehabilitationTraumatic Brain Injury (TBI) is a major cause of long-term disability. It can affect all areas of daily life and significantly reduce quality of life for both patient and carer.Professionals appear to underestimate the change in abilities and impact on daily life once patients return home. Community services maintain a short-term focus, whereas patients and carers want to look further ahead - this dissonance adds to anxiety.The study's findings on service fragmentation indicate an urgent need for better integration within health services and across health, social care and voluntary sectors.A link person/case manager who oversees the patient journey from admission onwards would help improve integrated care and ensure the patient, and carer, are at the center of service provision.	[Abrahamson, Vanessa] Canterbury Christ Church Univ, Canterbury, Kent, England; [Jensen, Jan; Springett, Kate] Canterbury Christ Church Univ, Sch Allied Hlth Profess, Canterbury, Kent, England; [Sakel, Mohamed] East Kent Hosp Univ NHS Fdn Trust, Kent & Canterbury Hosp, Canterbury, Kent, England		Abrahamson, V (corresponding author), Univ Kent, George Allen Wing, CHSS, Canterbury CT2 7NZ, Kent, England.	va63@kent.ac.uk		Abrahamson, Vanessa/0000-0002-1169-9457			[Anonymous], 2013, COUNTING COST REHABI; [Anonymous], 2010, MED REHABILITATION 2; [Anonymous], 2014, OPTIMIZINGS COPES PR; [Anonymous], 2014, MANDATE GOVT NHS ENG; [Anonymous], 2012, LIFE BRAIN INJURY WA; [Anonymous], 2015, INVISIBLE PATIENTS R; [Anonymous], 2013, COORDINATED CARE PEO; [Anonymous], 2005, NATL SERVICE FRAMEWO; [Anonymous], 2008, HIGH QUALITY CARE AL; [Anonymous], 2015, TRANSITION INPATIENT; [Anonymous], 2011, WHAT IS INTEGRATED C; [Anonymous], 2015, ACQUIRED BRAIN INJUR; Aspinal F, 2012, J ADV NURS, V68, P2309, DOI 10.1111/j.1365-2648.2011.05928.x; Baker A, 2017, CLIN REHABIL, V31, P45, DOI 10.1177/0269215516639357; Bhaskar R., 1978, REALIST THEORY SCI; Brands I, 2015, CLIN REHABIL, V29, P611, DOI 10.1177/0269215514549484; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Clark Alexander M, 2008, ANS Adv Nurs Sci, V31, pE67, DOI 10.1097/01.ANS.0000341421.34457.2a; Conneeley AL, 2012, BRAIN IMPAIR, V13, P72, DOI 10.1017/BrImp.2012.3; Emerson R.M., 2011, WRITING ETHNOGRAPHIC; Gray J, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0573-6; Haggerty JL, 2013, ANN FAM MED, V11, P262, DOI 10.1370/afm.1499; Hesse-Biber S. N., 2011, PRACTICE QUALITATIVE, V2nd; Kneebone II, 2012, NEUROREHAB NEURAL RE, V26, P834, DOI 10.1177/1545968311431962; Kodner Dennis L, 2009, Healthc Q, V13 Spec No, P6; Laver K, 2014, BMC HEALTH SERV RES, V14, P1; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Maxwell J.A., 2012, REALIST APPROACH QUA; Morse JM, 2015, QUAL HEALTH RES, V25, P1212, DOI 10.1177/1049732315588501; Nalder E, 2016, ARCH PHYS MED REHAB, V97, pS46, DOI 10.1016/j.apmr.2014.07.428; Nalder E, 2013, BRAIN INJURY, V27, P1294, DOI 10.3109/02699052.2013.823560; Nalder E, 2012, J REHABIL MED, V44, P837, DOI 10.2340/16501977-1033; Nalder E, 2012, BRAIN IMPAIR, V13, P108, DOI 10.1017/BrImp.2012.4; Paterson B, 2001, Rehabil Nurs, V26, P48; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Piccenna L, 2016, BRAIN INJURY, V30, P241, DOI 10.3109/02699052.2015.1113569; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sander AM, 2010, J HEAD TRAUMA REHAB, V25, P121, DOI 10.1097/HTR.0b013e3181cd1635; Sayer R, 2000, REALISM SOCIAL SCI; Sayer RA., 1992, METHOD SOCIAL SCI RE, V2nd edn.; Schonberger M, 2014, NEUROPSYCHOL REHABIL, V24, P202, DOI 10.1080/09602011.2013.878252; Sherer M, 2015, REHABIL PSYCHOL, V60, P138, DOI 10.1037/rep0000030; Tennant A., 2005, 0300067 U LEEDS; Turner BJ, 2011, DISABIL REHABIL, V33, P818, DOI 10.3109/09638288.2010.513422; Tverdov AH, 2016, BRAIN INJURY, V30, P324, DOI 10.3109/02699052.2015.1113566; Whiffin CJ, 2015, J ADV NURS, V71, P849, DOI 10.1111/jan.12551; Williams MW, 2014, REHABIL PSYCHOL, V59, P298, DOI 10.1037/a0037164; Yin R., 1994, CASE STUDY RES DESIG, V2	49	28	28	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2017	39	17					1683	1694		10.1080/09638288.2016.1211755			12	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	EV4CM	WOS:000401705900001	27557977	Green Accepted			2022-02-06	
J	Kanser, RJ; Rapport, LJ; Bashem, JR; Billings, NM; Hanks, RA; Axelrod, BN; Miller, JB				Kanser, Robert J.; Rapport, Lisa J.; Bashem, Jesse R.; Billings, Nia M.; Hanks, Robin A.; Axelrod, Bradley N.; Miller, Justin B.			Strategies of successful and unsuccessful simulators coached to feign traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Assessment; performance validity; traumatic brain injury; malingering	SYMPTOM VALIDITY; PERFORMANCE VALIDITY; NEUROPSYCHOLOGICAL ASSESSMENT	Objective: The present study evaluated strategies used by healthy adults coached to simulate traumatic brain injury (TBI) during neuropsychological evaluation. Method: Healthy adults (n=58) were coached to simulate TBI while completing a test battery consisting of multiple performance validity tests (PVTs), neuropsychological tests, a self-report scale of functional independence, and a debriefing survey about strategies used to feign TBI. Results: Successful simulators (n=16) were classified as participants who failed 0 or 1 PVT and also scored as impaired on one or more neuropsychological index. Unsuccessful simulators (n=42) failed2 PVTs or passed PVTs but did not score impaired on any neuropsychological index. Compared to unsuccessful simulators, successful simulators had significantly more years of education, higher estimated IQ, and were more likely to use information provided about TBI to employ a systematic pattern of performance that targeted specific tests rather than performing poorly across the entire test battery. Conclusion: Results contribute to a limited body of research investigating strategies utilized by individuals instructed to feign neurocognitive impairment. Findings signal the importance of developing additional embedded PVTs within standard cognitive tests to assess performance validity throughout a neuropsychological assessment. Future research should consider specifically targeting embedded measures in visual tests sensitive to slowed responding (e.g. response time).	[Kanser, Robert J.; Rapport, Lisa J.; Bashem, Jesse R.; Billings, Nia M.; Miller, Justin B.] Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA; [Hanks, Robin A.] Wayne State Univ, Sch Med, Detroit, MI USA; [Axelrod, Bradley N.] John D Dingell Vet Affairs Med Ctr, Detroit, MI USA; [Miller, Justin B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA		Kanser, RJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	Robert.Kanser@wayne.edu	Billings, Nia/AAG-2001-2021	Miller, Justin B./0000-0002-4439-6604; Rapport, Lisa/0000-0001-8014-9523	Wayne State University; Del Harder Foundation; National Institute on Disability and Rehabilitation Research [H133A080044]	This work was supported by Wayne State University, the Del Harder Foundation, and the National Institute on Disability and Rehabilitation Research [grant number H133A080044].	Bashem JR, 2014, CLIN NEUROPSYCHOL, V28, P851, DOI 10.1080/13854046.2014.927927; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cohen J., 1965, HDB CLIN PSYCHOL, P95; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Davis JJ, 2012, CLIN NEUROPSYCHOL, V26, P850, DOI 10.1080/13854046.2012.686631; Delis D.C., 2000, CALIFORNIA VERBAL LE; Demakis G, 2015, APPL NEUROPSYCH-ADUL, V22, P262, DOI 10.1080/23279095.2014.920842; Green P., 2005, MED SYMPTOM VALIDITY; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Hedges LV., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.2307/1164588]; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; IVERSON GL, 1995, BRAIN INJURY, V9, P35, DOI 10.3109/02699059509004569; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Pearson Education I, 2008, WECHSL MEM SCAL CLIN; Prigatano G., 1986, PATIENT COMPETENCY R; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reitan R, 1985, HALSTEAD REITAN NEUR; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; The Psychological Corporation, 2001, WECHSLER TEST ADULT; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260	25	28	28	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	3					644	653		10.1080/13854046.2016.1278040			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	EM5FX	WOS:000395338500011	28084893				2022-02-06	
J	Manskow, US; Friborg, O; Roe, C; Braine, M; Damsgard, E; Anke, A				Manskow, Unn Sollid; Friborg, Oddgeir; Roe, Cecilie; Braine, Mary; Damsgard, Elin; Anke, Audny			Patterns of change and stability in caregiver burden and life satisfaction from 1 to 2 years after severe traumatic brain injury: A Norwegian longitudinal study	NEUROREHABILITATION			English	Article						Caregiver burden; life satisfaction; traumatic brain injury; social network	QUALITY-OF-LIFE; CLOSED-HEAD-INJURY; FAMILY CAREGIVERS; NATIONAL COHORT; RELATIVES; HEALTH; MULTICENTER; SCALE; CARE; PREDICTORS	OBJECTIVE: To assess burden and life satisfaction in family members of patients with severe traumatic brain injury (sTBI) at 1 and 2 years post-injury, examine if change in burden can be predicted by family member and patient demographics, patient's functional status, family members social network or level of burden at 1 year. METHODS: Prospective national multicenter study. Self-report from family members, patient data collected from a national cohort study on patients with sTBI. 80 family members participated. MAIN OUTCOME MEASURE: The Caregiver Burden Scale (CBS), life satisfaction. RESULTS: Total burden increased between years 1 and 2 post-injury (P = 0.04). Thirty percent of the family members reported an increased burden, 55% were stable, and 15% had a decrease in burden between the two follow-up times. Logistic regression analyses revealed that experiencing loneliness was an independent predictor of increased burden from 1 to 2 years post-injury (OR = 4.35, P < 0.05). Life Satisfaction was lower at the 2 year follow-up than at 1 year (p = 0.03). CONCLUSIONS: The results demonstrate a need for long-term follow-up of patients and family members that focuses on professional support to relieve burden and risk of loneliness or social isolation. This group may benefit from additional follow-up interventions tailored to their needs.	[Manskow, Unn Sollid; Anke, Audny] Univ Hosp North Norway, Dept Rehabil, Sykehusvegen 38, N-9038 Tromso, Norway; [Manskow, Unn Sollid; Damsgard, Elin] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Hlth & Care Sci, Tromso, Norway; [Friborg, Oddgeir] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Psychol, Tromso, Norway; [Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, Oslo, Norway; [Braine, Mary] Univ Salford, Fac Hlth & Social Care, Sch Nursing & Midwifery, Salford, Lancs, England; [Anke, Audny] Arctic Univ Norway, Fac Hlth Sci, Dept Clin Med, Tromso, Norway		Manskow, US (corresponding author), Univ Hosp North Norway, Dept Rehabil, Sykehusvegen 38, N-9038 Tromso, Norway.	unn.manskow@gmail.com		Friborg, Oddgeir/0000-0001-6629-0782; Anke, Audny/0000-0002-2491-2560	North Norwegian Health Authorities [8744/SFP1108-13]	This study was supported by grants from the North Norwegian Health Authorities (grant no. 8744/SFP1108-13).	Adelman RD, 2014, JAMA-J AM MED ASSOC, V311, P1052, DOI 10.1001/jama.2014.304; Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andren S, 2005, SCAND J CARING SCI, V19, P157, DOI 10.1111/j.1471-6712.2005.00328.x; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Anke A, 2015, J HEAD TRAUMA REHAB, V30, pE38, DOI 10.1097/HTR.0000000000000080; Association for the Advancement of Automotive Medicine (AAAM), 2005, ABBR INJ SCAL AIS 20; Bayen E, 2016, J HEAD TRAUMA REHAB, V31, pE59, DOI 10.1097/HTR.0000000000000079; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Becker F, 2014, NEUROREHABILITATION, V34, P87, DOI 10.3233/NRE-131015; Bergstrom AL, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-1; Boycott N, 2013, J HEAD TRAUMA REHAB, V28, P106, DOI 10.1097/HTR.0b013e31823fe07e; Braine ME, 2011, J NEUROSCI NURS, V43, P156, DOI 10.1097/JNN.0b013e3182135bb2; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cacioppo JT, 2014, COGNITION EMOTION, V28, P3, DOI 10.1080/02699931.2013.837379; Copay AG, 2007, SPINE J, V7, P541, DOI 10.1016/j.spinee.2007.01.008; Dahlrup B, 2011, CLIN INTERV AGING, V6, P9, DOI 10.2147/CIA.S14237; Diener E, 2003, ANNU REV PSYCHOL, V54, P403, DOI 10.1146/annurev.psych.54.101601.145056; Doser K, 2016, BRAIN INJURY, V30, P334, DOI 10.3109/02699052.2015.1114143; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Fayers PM, 2007, J CLIN EPIDEMIOL, V60, P1034, DOI 10.1016/j.jclinepi.2007.03.005; Fayers PM, 2002, LANCET, V359, P187, DOI 10.1016/S0140-6736(02)07466-4; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Fujita F, 2005, J PERS SOC PSYCHOL, V88, P158, DOI 10.1037/0022-3514.88.1.158; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Godwin EE, 2013, BRAIN INJURY, V27, P637, DOI 10.3109/02699052.2012.750745; Gottlieb BH, 2010, J PSYCHOSOM RES, V69, P511, DOI 10.1016/j.jpsychores.2009.10.001; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Kasuya RT, 2000, POSTGRAD MED, V108, P119, DOI 10.3810/pgm.2000.12.1324; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Manskow US, 2015, J HEAD TRAUMA REHAB, V30, P411, DOI 10.1097/HTR.0000000000000085; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Nicholson NR, 2012, J PRIM PREV, V33, P137, DOI 10.1007/s10935-012-0271-2; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Norup A, 2015, NEUROREHABILITATION, V36, P203, DOI 10.3233/NRE-151208; Norup A, 2012, BRAIN INJURY, V26, P1192, DOI 10.3109/02699052.2012.672790; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; O'Neill L J, 1998, Br J Nurs, V7, P842; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Ramkumar NA, 2010, NEUROREHABILITATION, V27, P105, DOI 10.3233/NRE-2010-0585; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Simpson G, 2013, CLIN REHABIL, V27, P367, DOI 10.1177/0269215512457961; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	61	28	28	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2017	40	2					211	222		10.3233/NRE-161406			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ER7FW	WOS:000398976700006	27935561	Green Submitted			2022-02-06	
J	Wijenberg, MLM; Stapert, SZ; Verbunt, JA; Ponsford, JL; Van Heugten, CM				Wijenberg, Melloney L. M.; Stapert, Sven Z.; Verbunt, Jeanine A.; Ponsford, Jennie L.; Van Heugten, Caroline M.			Does the fear avoidance model explain persistent symptoms after traumatic brain injury?	BRAIN INJURY			English	Article						Catastrophizing; chronic phase; fear avoidance behaviour; persistent symptoms; post concussional syndrome; Traumatic brain injury	PAIN CATASTROPHIZING SCALE; CONCUSSION SYMPTOMS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; MUSCULOSKELETAL PAIN; MULTIPLE-SCLEROSIS; DEPRESSION SCALE; CROSS-VALIDATION; HOSPITAL ANXIETY; CHRONIC TINNITUS	Background: A minority of patients with mild traumatic brain injury (mTBI) experience a persistent symptom complex also known as post-concussion syndrome. Explanations for this syndrome are still lacking.Objective: To investigate if the fear avoidance model, including catastrophizing thoughts and fear avoidance behaviour, poses a possible biopsychosocial explanation for lingering symptoms and delay in recovery after traumatic brain injury (TBI) with special focus on mTBI.Design: Cross-sectional study.Participants: 48 patients with TBI, of which 31 patients with mTBI, had persistent symptoms (mean time since injury 48.2months); 92% of the entire sample fulfilled the criteria for post-concussion syndrome.Outcome variables: catastrophizing, fear-avoidance, depression and post-concussion symptoms.Results: High levels of catastrophizing were found in 10% and high levels of fear avoidance behaviour were found in 35%. Catastrophizing, fear avoidance behaviour, depressive symptoms and post-concussion symptoms correlated significantly with each other (p<0.05).Conclusion: The fear-avoidance model proposes a possible explanation for persistent symptoms. Validation and normative data are needed for suitable measures of catastrophizing and fear avoidance of post-concussion symptoms after TBI. Longitudinal prospective cohort studies are needed to establish its causal and explanatory nature.	[Wijenberg, Melloney L. M.; Stapert, Sven Z.; Van Heugten, Caroline M.] Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, POB 616, NL-6200 MD Maastricht, Netherlands; [Wijenberg, Melloney L. M.; Van Heugten, Caroline M.] Limburg Brain Injury Ctr, Limburg, Netherlands; [Stapert, Sven Z.] Zuyderland Med Ctr, Dept Med Psychol, Sittard Geleen, Netherlands; [Verbunt, Jeanine A.] Adelante, Ctr Expertise Rehabil & Audiol, Hoensbroek, Netherlands; [Ponsford, Jennie L.] Maastricht Univ, Res Sch CAPHRI, Dept Rehabil Med, Maastricht, Netherlands; [Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia; [Van Heugten, Caroline M.] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Maastricht, Netherlands		Stapert, SZ (corresponding author), Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, POB 616, NL-6200 MD Maastricht, Netherlands.	s.stapert@maastrichtuniversity.nl	Ponsford, Jennie/H-8341-2014	Ponsford, Jennie/0000-0003-0430-125X; Verbunt, Jeanine/0000-0002-9060-9455			Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bol Y, 2010, J BEHAV MED, V33, P355, DOI 10.1007/s10865-010-9266-8; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chaput G, 2016, PAIN RES MANAG, V2016, DOI 10.1155/2016/2825856; Cima RFF, 2011, EAR HEARING, V32, P634, DOI 10.1097/AUD.0b013e31821106dd; Clarke LA, 2012, BRAIN INJURY, V26, P298, DOI 10.3109/02699052.2012.654588; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P429, DOI 10.1348/014466501163904; Crombez G, 1996, PAIN CATASTROP UNPUB; Crombez G, 2012, CLIN J PAIN, V28, P475, DOI 10.1097/AJP.0b013e3182385392; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; GOUBERT L, 2000, GEDRAG GEZONDHEID, V28, P54; Houben RMA, 2005, J BEHAV MED, V28, P415, DOI 10.1007/s10865-005-9011-x; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kamper SJ, 2012, PAIN, V153, P113, DOI 10.1016/j.pain.2011.09.023; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kleinstauber M, 2013, COGN BEHAV THERAPY, V42, P84, DOI 10.1080/16506073.2012.717301; Leeuw M, 2007, J BEHAV MED, V30, P77, DOI 10.1007/s10865-006-9085-0; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Martelli MF, 1999, ARCH CLIN NEUROPSYCH, V14, P804, DOI 10.1016/S0887-6177(99)80356-4; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Miller R, 1991, UNPUB; Miro J, 2008, J PAIN, V9, P397, DOI 10.1016/j.jpain.2007.12.004; Nieto R, 2013, REHABIL PSYCHOL, V58, P361, DOI 10.1037/a0034267; Nieto R, 2009, EUR J PAIN, V13, P518, DOI 10.1016/j.ejpain.2008.06.005; Nijs J, 2013, CLIN RHEUMATOL, V32, P1121, DOI 10.1007/s10067-013-2277-4; Oldenburg C, 2016, BRAIN INJURY, V30, P146, DOI 10.3109/02699052.2015.1089598; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Osman A, 2000, J BEHAV MED, V23, P351, DOI 10.1023/A:1005548801037; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rivest K, 2010, MANUAL THER, V15, P154, DOI 10.1016/j.math.2009.10.001; Roelofs J, 2011, PAIN, V152, P1090, DOI 10.1016/j.pain.2011.01.028; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schmidt AJM, 2003, BEHAV RES THER, V41, P1243, DOI 10.1016/S0005-7967(03)00155-4; Severeijns R, 2002, PAIN, V99, P367, DOI 10.1016/S0304-3959(02)00219-1; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Sterling M, 2008, CLIN J PAIN, V24, P124, DOI 10.1097/AJP.0b013e31815ca293; Suhr J, 2012, CLIN NEUROPSYCHOL, V26, P1128, DOI 10.1080/13854046.2012.713121; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Todd D., 1998, COGNIPHOBIA SCALE C, pdomain; van Damme S., 2000, GEDRAGSTHERAPIE, V33, P209; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; Velthuis MJ, 2012, ARCH PHYS MED REHAB, V93, P332, DOI 10.1016/j.apmr.2011.08.014; Verhage F., 1983, CODEREN OPLEIDINGSNI; Vlaeyen JWS, 2012, PAIN, V153, P1144, DOI 10.1016/j.pain.2011.12.009; Vlaeyen JWS, 1995, J OCCUP REHABIL, V5, P235, DOI 10.1007/BF02109988; Volders S, 2015, BEHAV RES THER, V64, P31, DOI 10.1016/j.brat.2014.11.003; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wijenberg MLM, 2016, J BEHAV MED, V39, P815, DOI 10.1007/s10865-016-9749-3; Wood RL, 2007, J NEUROL NEUROSUR PS, V78, P552, DOI 10.1136/jnnp.2006.113845; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	67	28	28	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	12					1597	1604		10.1080/02699052.2017.1366551			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FN4KB	WOS:000415973200005	28980825	hybrid			2022-02-06	
J	Wilson, L; Marsden-Loftus, I; Koskinen, S; Bakx, W; Bullinger, M; Formisano, R; Maas, A; Neugebauer, E; Powell, J; Sarajuuri, J; Sasse, N; von Steinbuechel, N; von Wild, K; Truelle, JL				Wilson, Lindsay; Marsden-Loftus, Isaac; Koskinen, Sanna; Bakx, Wilbert; Bullinger, Monika; Formisano, Rita; Maas, Andrew; Neugebauer, Edmund; Powell, Jane; Sarajuuri, Jaana; Sasse, Nadine; von Steinbuechel, Nicole; von Wild, Klaus; Truelle, Jean-Luc			Interpreting Quality of Life after Brain Injury Scores: Cross-Walk with the Short Form-36	JOURNAL OF NEUROTRAUMA			English	Article						GOSE; health-related quality of life; outcome measures; QOLIBRI; SF-36; TBI	ITEM SELECTION; HEALTH SURVEY; QOLIBRI; SCALE; VALIDATION; TBI	The Quality of Life after Brain Injury (QOLIBRI) instruments are traumatic brain injury (TBI)-specific assessments of health-related quality of life (HRQoL), with established validity and reliability. The purpose of the study is to help improve the interpretability of the two QOLIBRI summary scores (the QOLIBRI Total score and the QOLBRI Overall Scale [OS] score). An analysis was conducted of 761 patients with TBI who took part in the QOLIBRI validation studies. A cross-walk between QOLIBRI scores and the SF-36 Mental Component Summary norm-based scoring system was performed using geometric mean regression analysis. The exercise supports a previous suggestion that QOLIBRI Total scores <60 indicate low or impaired HRQoL and indicate that the corresponding score on the QOLIBRI-OS is <52. The percentage of cases in the sample that fell into the "impaired HRQoL'' category was 36% for the Mental Component Summary, 38% for the QOLIBRI Total, and 39% for the QOLIBRI-OS. Relationships between the QOLIBRI scales and the Glasgow Outcome Scale-Extended (GOSE), as a measure of global function, are presented in the form of means and standard deviations that allow comparison with other studies, and data on age and sex are presented for the QOLIBRI-OS. While bearing in mind the potential imprecision of the comparison, the findings provide a framework for evaluating QOLIBRI summary scores in relation to generic HRQoL that improves their interpretability.	[Wilson, Lindsay; Marsden-Loftus, Isaac] Univ Stirling, Div Psychol, Stirling FK9 4LA, Scotland; [Koskinen, Sanna] Univ Helsinki, Inst Behav Sci, Helsinki, Finland; [Bakx, Wilbert] Hoensbroek & Maastricht Univ, Dept Brain Injury, Adelante Adult Rehabil, Maastricht, Netherlands; [Bullinger, Monika] Univ Hosp Eppendorf, Dept Med Psychol, Hamburg, Germany; [Formisano, Rita] Santa Lucia Fdn, Rehabil Hosp, IRCCS, Rome, Italy; [Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Maas, Andrew] Univ Antwerp, Antwerp, Belgium; [Neugebauer, Edmund] Witten Herdecke Univ Campus, Cologne, Germany; [Powell, Jane] Goldsmiths Coll, Dept Psychol, London, England; [Sarajuuri, Jaana] Validia Rehabil Helsinki, Dept Clin Neuropsychol & Psychol, Helsinki, Finland; [Sasse, Nadine; von Steinbuechel, Nicole] Georg August Univ, Dept Med Psychol & Med Sociol, Gottingen, Germany; [von Wild, Klaus] Westfalian Wilhelms Univ Munster, Clemens Hosp, Dept Neurosurg & Early Neurotraumatol Rehabil, Munster, Germany; [Truelle, Jean-Luc] CHU Raymond Poincare, Serv Med Phys & Readapt, Garches, France		Wilson, L (corresponding author), Univ Stirling, Div Psychol, Stirling FK9 4LA, Scotland.	J.T.L.Wilson@stir.ac.uk	Wilson, Lindsay/O-8883-2019; Wilson, Lindsay/A-3659-2009; Sarajuuri, Jaana/AAD-8665-2019	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Sarajuuri, Jaana/0000-0002-6432-0295; Koskinen, Sanna/0000-0002-3453-5084; Bullinger, Monika/0000-0001-8876-0159	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602150-2]	The work was performed in the context of CENTER-TBI, supported by the European Commission 7th Framework programme (Grant Number 602150-2).	Brazier JE, 2010, EUR J HEALTH ECON, V11, P215, DOI 10.1007/s10198-009-0168-z; Fayers PM, 2014, VALUE HEALTH, V17, P261, DOI 10.1016/j.jval.2013.12.002; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Giustini M, 2014, FUNCT NEUROL, V29, P167, DOI 10.11138/FNeur/2014.29.3.167; Koskinen S, 2011, DISABIL REHABIL, V33, P2464, DOI 10.3109/09638288.2011.574776; Lin YN, 2014, J HEAD TRAUMA REHAB, V29, pE37, DOI 10.1097/HTR.0b013e3182816363; Losoi H, 2015, J NEUROTRAUM, V32, P942, DOI 10.1089/neu.2014.3799; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Mitchell AJ, 2010, J AFFECT DISORDERS, V126, P335, DOI 10.1016/j.jad.2010.01.067; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Richardson J., 2012, 78 MON CTR HLTH EC; Soberg HL, 2013, J REHABIL MED, V45, P785, DOI 10.2340/16501977-1158; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Turner-Bowker, 2007, USERS MANUAL SF 36V2; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong GKC, 2014, J CLIN NEUROSCI, V21, P954, DOI 10.1016/j.jocn.2013.09.010	21	28	28	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					59	65		10.1089/neu.2015.4287			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100008	27297289	Green Accepted			2022-02-06	
J	Anderson, BJ; Reilly, JP; Shashaty, MGS; Palakshappa, JA; Wysoczanski, A; Dunn, TG; Kazi, A; Tommasini, A; Mikkelsen, ME; Schweickert, WD; Kolson, DL; Christie, JD; Meyer, NJ				Anderson, Brian J.; Reilly, John P.; Shashaty, Michael G. S.; Palakshappa, Jessica A.; Wysoczanski, Alex; Dunn, Thomas G.; Kazi, Altaf; Tommasini, Anna; Mikkelsen, Mark E.; Schweickert, William D.; Kolson, Dennis L.; Christie, Jason D.; Meyer, Nuala J.			Admission plasma levels of the neuronal injury marker neuron-specific enolase are associated with mortality and delirium in sepsis	JOURNAL OF CRITICAL CARE			English	Article						Sepsis; Critical care; Brain injury; Delirium; Neuron-specific enolase	INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; TERM COGNITIVE IMPAIRMENT; CRITICALLY-ILL PATIENTS; BRAIN; SERUM; DYSFUNCTION; PREDICTOR; BLOOD	Purpose: Neuron-specific enolase (NSE) concentrations are prognostic following traumatic and anoxic brain injury and may provide a method to quantify neuronal injury in other populations. We determined the association of admission plasma NSE concentrations with mortality and delirium in critically ill septic patients. Methods: We performed a retrospective analysis of 124 patients from a larger sepsis cohort. Plasma NSE was measured in the earliest blood draw at intensive care unit admission. Primary outcomes were 30-day mortality and intensive care unit delirium determined by chart review. Results: Sixty-one patients (49.2%) died within 30 days, and delirium developed in 34 (31.5%) of the 108 patients who survived at least 24 hours and were not persistently comatose. Each doubling of the NSE concentration was associated with a 7.3% (95% confidence interval [CI] 2.5-12.0, P=.003) increased risk of 30-day mortality and a 5.2% (95% CI 3.2-7.2, P<.001) increased risk of delirium. An NSE concentration N12.5 mu g/L was independently associated with a 23.3% (95% CI 6.7-39.9, P=. 006) increased risk of 30-day mortality and a 29.3% (95% CI 8.8-49.8, P=.005) increased risk of delirium. Conclusions: Higher plasma NSE concentrations were associated with mortality and delirium in critically ill septic patients, suggesting that NSE may have utility as a marker of neuronal injury in sepsis. (C) 2016 Elsevier Inc. All rights reserved.	[Anderson, Brian J.; Reilly, John P.; Shashaty, Michael G. S.; Palakshappa, Jessica A.; Wysoczanski, Alex; Dunn, Thomas G.; Kazi, Altaf; Tommasini, Anna; Mikkelsen, Mark E.; Schweickert, William D.; Christie, Jason D.; Meyer, Nuala J.] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Anderson, Brian J.; Shashaty, Michael G. S.; Palakshappa, Jessica A.; Mikkelsen, Mark E.; Christie, Jason D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kolson, Dennis L.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA		Anderson, BJ (corresponding author), Univ Penn, Pulm Allergy & Crit Care Div, 3600 Spruce St,5048 Gates Bldg, Philadelphia, PA 19104 USA.	brian.anderson@uphs.upenn.edu	Shashaty, Michael/X-3690-2019	Shashaty, Michael/0000-0002-8766-3418; Anderson, Brian/0000-0002-2426-9683; Christie, Jason/0000-0003-0519-218X; Reilly, John/0000-0003-3937-5320; Palakshappa, Jessica/0000-0002-6333-365X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32NS061779, F32GM116637, K23HL125723, K23DK097307, K23HL102254, K24HL115354]; American Thoracic Society Foundation Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K24HL115354, K23HL102254, K23HL125723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K23DK097307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [F32GM116637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS061779] Funding Source: NIH RePORTER	This study was supported in part by National Institutes of Health grants T32NS061779 (BJA), F32GM116637 (BJA), K23HL125723 (JPR), K23DK097307 (MGSS), K23HL102254 (NJM), and K24HL115354 (JDC) and an American Thoracic Society Foundation Award (NJM).	Al-Qadheeb NS, 2014, CRIT CARE MED, V42, P1442, DOI 10.1097/CCM.0000000000000224; Barakat MT, 2004, ENDOCR-RELAT CANCER, V11, P1, DOI 10.1677/erc.0.0110001; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fizazi K, 1998, CANCER, V82, P1049, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1049::AID-CNCR6>3.0.CO;2-9; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Grandi C, 2011, J CRIT CARE, V26, P133, DOI 10.1016/j.jcrc.2010.10.006; Gunther ML, 2012, CRIT CARE MED, V40, P2022, DOI 10.1097/CCM.0b013e318250acc0; Herrmann M, 2000, STROKE, V31, P645, DOI 10.1161/01.STR.31.3.645; KATO K, 1983, CLIN CHIM ACTA, V127, P353, DOI 10.1016/0009-8981(83)90162-6; Kleinman LC, 2009, HEALTH SERV RES, V44, P288, DOI 10.1111/j.1475-6773.2008.00900.x; Kramer L, 2007, CRIT CARE MED, V35, P1099, DOI 10.1097/01.CCM.0000259462.97164.A0; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Magder LS, 1997, AM J EPIDEMIOL, V146, P195; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Matthay MA, 2016, JAMA-J AM MED ASSOC, V315, P747, DOI 10.1001/jama.2016.0661; McNicoll L, 2003, J AM GERIATR SOC, V51, P591, DOI 10.1034/j.1600-0579.2003.00201.x; Mehta NJ, 2004, INT J CARDIOL, V95, P13, DOI 10.1016/j.ijcard.2003.02.005; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Norton EC, 2013, STATA J, V13, P492, DOI 10.1177/1536867X1301300304; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Palakshappa JA, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1244-2; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Pfuntner A., 2013, MOST FREQUENT CONDIT; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rasmussen LS, 2000, BRIT J ANAESTH, V84, P242, DOI 10.1093/oxfordjournals.bja.a013410; Reade MC, 2011, CRIT CARE RESUSC, V13, P217; Reilly JP, 2015, CLIN J AM SOC NEPHRO, V10, P1911, DOI 10.2215/CJN.12201214; Salluh JIF, 2016, LANCET RESP MED, V4, pE17, DOI 10.1016/S2213-2600(16)30020-0; Schwebel C, 2013, CRIT CARE MED, V41, P1919, DOI 10.1097/CCM.0b013e31828a3bbd; Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Sonneville R, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-15; Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538; TAYLOR CB, 1983, ISOZYMES-CURR T BIOL, V11, P95; van Munster BC, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-21; Vasilevskis EE, 2011, J AM GERIATR SOC, V59, pS249, DOI 10.1111/j.1532-5415.2011.03673.x; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Xu JMDM, 2016, NATL VITAL STAT REPO	50	28	31	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	DEC	2016	36						18	23		10.1016/j.jcrc.2016.06.012			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EJ2YS	WOS:000393078100005	27546742	Green Accepted			2022-02-06	
J	Merchant-Borna, K; Asselin, P; Narayan, D; Abar, B; Jones, CMC; Bazarian, JJ				Merchant-Borna, Kian; Asselin, Patrick; Narayan, Darren; Abar, Beau; Jones, Courtney M. C.; Bazarian, Jeffrey J.			Novel Method of Weighting Cumulative Helmet Impacts Improves Correlation with Brain White Matter Changes After One Football Season of Sub-concussive Head Blows	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Mild traumatic brain injury; Subconcussive head trauma; Diffusion tensor imaging; Football; Sensors; Biomechanics	CHRONIC TRAUMATIC ENCEPHALOPATHY; TENSOR IMAGING FINDINGS; AXONAL INJURY; EXPOSURE; ACCELERATION; INTEGRITY; DAMAGE; RISK; VULNERABILITY; DEFORMATION	One football season of sub-concussive head blows has been shown to be associated with subclinical white matter (WM) changes on diffusion tensor imaging (DTI). Prior research analyses of helmet-based impact metrics using mean and peak linear and rotational acceleration showed relatively weak correlations to these WM changes; however, these analyses failed to account for the emerging concept that neuronal vulnerability to successive hits is inversely related to the time between hits (TBH). To develop a novel method for quantifying the cumulative effects of sub-concussive head blows during a single season of collegiate football by weighting helmet-based impact measures for time between helmet impacts. We further aim to compare correlations to changes in DTI after one season of collegiate football using weighted cumulative helmet-based impact measures to correlations using non-weighted cumulative helmet-based impact measures and non-cumulative measures. We performed a secondary analysis of DTI and helmet impact data collected on ten Division III collegiate football players during the 2011 season. All subjects underwent diffusion MR imaging before the start of the football season and within 1 week of the end of the football season. Helmet impacts were recorded at each practice and game using helmet-mounted accelerometers, which computed five helmet-based impact measures for each hit: linear acceleration (LA), rotational acceleration (RA), Gadd Severity Index (GSI), Head Injury Criterion (HIC15), and Head Impact Technology severity profile (HITsp). All helmet-based impact measures were analyzed using five methods of summary: peak and mean (non-cumulative measures), season sum-totals (cumulative unweighted measures), and season sum-totals weighted for time between hits (TBH), the interval of time from hit to post-season DTI assessment (TUA), and both TBH and TUA combined. Summarized helmet-based impact measures were correlated to statistically significant changes in fractional anisotropy (FA) using bivariate and multivariable correlation analyses. The resulting R (2) values were averaged in each of the five summary method groups and compared using one-way ANOVA followed by Tukey post hoc tests for multiple comparisons. Total head hits for the season ranged from 431 to 1850. None of the athletes suffered a clinically evident concussion during the study period. The mean R (2) value for the correlations using cumulative helmet-based impact measures weighted for both TUA and TBH combined (0.51 +/- A 0.03) was significantly greater than the mean R (2) value for correlations using non-cumulative HIMs (vs. 0.19 +/- A 0.04, p < 0.0001), unweighted cumulative helmet-based impact measures (vs. 0.27 + 0.03, p < 0.0001), and cumulative helmet-based impact measures weighted for TBH alone (vs. 0.34 +/- A 0.02, p < 0.001). R (2) values for weighted cumulative helmet-based impact measures ranged from 0.32 to 0.77, with 60% of correlations being statistically significant. Cumulative GSI weighted for TBH and TUA explained 77% of the variance in the percent of white matter voxels with statistically significant (PWMVSS) increase in FA from pre-season to post-season, while both cumulative GSI and cumulative HIC15 weighted for TUA accounted for 75% of the variance in PWMVSS decrease in FA. A novel method for weighting cumulative helmet-based impact measures summed over the course of a football season resulted in a marked improvement in the correlation to brain WM changes observed after a single football season of sub-concussive head blows. Our results lend support to the emerging concept that sub-concussive head blows can result in sub-clinical brain injury, and this may be influenced by the time between hits. If confirmed in an independent data set, our novel method for quantifying the cumulative effects of sub-concussive head blows could be used to develop threshold-based countermeasures to prevent the accumulation of WM changes with multiple seasons of play.	[Merchant-Borna, Kian; Asselin, Patrick; Abar, Beau; Jones, Courtney M. C.; Bazarian, Jeffrey J.] Univ Rochester, Dept Emergency Med, Sch Med & Dent, 265 Crittenden Blvd,Box 655C, Rochester, NY 14642 USA; [Narayan, Darren] Rochester Inst Technol, Sch Math Sci, Rochester, NY 14623 USA		Merchant-Borna, K (corresponding author), Univ Rochester, Dept Emergency Med, Sch Med & Dent, 265 Crittenden Blvd,Box 655C, Rochester, NY 14642 USA.	kian.merchant-borna@rochester.edu		Abar, Beau/0000-0003-1536-220X; Merchant-Borna, Kian/0000-0002-6643-1597	National Football League Charities	This study was supported by funds from the National Football League Charities https://www.nflcharities.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Duma SM, 2014, J BIOMECH, V47, P1557, DOI 10.1016/j.jbiomech.2013.08.022; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Effgen G. W., 2012, P 2012 INT IRCOBI C, P455; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gons RAR, 2013, NEUROLOGY, V81, P971, DOI 10.1212/WNL.0b013e3182a43e33; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Stern RA, 2015, NEUROLOGY, V85, P1008; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Wu L. C., 2015, ENG ANN BIOMED; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhu T, 2008, NEUROIMAGE, V40, P1144, DOI 10.1016/j.neuroimage.2008.01.016	51	28	28	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	DEC	2016	44	12					3679	3692		10.1007/s10439-016-1680-9			14	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	EC4MB	WOS:000388103900020	27350072				2022-02-06	
J	Wang, Y; Fan, XG; Tang, T; Fan, R; Zhang, CH; Huang, ZB; Peng, WJ; Gan, PP; Xiong, XG; Huang, W; Huang, X				Wang, Yang; Fan, Xuegong; Tang, Tao; Fan, Rong; Zhang, Chunhu; Huang, Zebing; Peng, Weijun; Gan, Pingping; Xiong, Xingui; Huang, Wei; Huang, Xi			Rhein and rhubarb similarly protect the blood-brain barrier after experimental traumatic brain injury via gp91(phox) subunit of NADPH oxidase/ROS/ERK/MMP-9 signaling pathway	SCIENTIFIC REPORTS			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; TRADITIONAL CHINESE MEDICINE; OXIDATIVE STRESS; KNOCK-OUT; MATRIX-METALLOPROTEINASE-9; NEUROPROTECTION; ASTROCYTES; INHIBITION; RATS; PHARMACOKINETICS	Oxidative stress chiefly contributes to the disruption of the BBB following traumatic brain injury (TBI). The Chinese herbal medicine rhubarb is a promising antioxidant in treating TBI. Here we performed in vivo and in vitro experiments to determine whether rhubarb and its absorbed bioactive compound protected the BBB after TBI by increasing ZO-1 expression through inhibition of gp91(phox) subunit of NADPH oxidase/ROS/ERK/MMP-9 pathway. Rats were subjected to the controlled cortical impact (CCI) model, and primary rat cortical astrocytes were exposed to scratch-wound model. The liquid chromatography with tandem mass spectrometry method showed that rhein was the compound absorbed in the brains of CCI rats after rhubarb administration. The wet-dry weights and Evans blue measurements revealed that rhubarb and rhein ameliorated BBB damage and brain edema in CCI rats. Western blots showed that rhubarb and rhein downregulated GFAP in vitro. RT-PCR, immunohistochemistry, Western blot and dichlorodihydrofluorescein diacetate analysis indicated that rhubarb prevented activation of gp91(phox) subunit of NADPH oxidase induced ROS production, subsequently inhibited ERK/MMP-9 pathway in vivo and in vitro. Interestingly, rhein and rhubarb similarly protected the BBB by inhibiting this signaling cascade. The results provide a novel herbal medicine to protect BBB following TBI via an antioxidative molecular mechanism.	[Wang, Yang; Tang, Tao; Fan, Rong; Zhang, Chunhu; Xiong, Xingui; Huang, Wei; Huang, Xi] Cent S Univ, Inst Integrated Tradit Chinese & Western Med, Xiangya Hosp, Lab Ethnopharmacol, Changsha 410008, Hunan, Peoples R China; [Wang, Yang; Fan, Xuegong; Huang, Zebing] Cent S Univ, Xiangya Hosp, Dept Infect Dis, Key Lab Viral Hepatitis Hunan, Changsha 410008, Hunan, Peoples R China; [Peng, Weijun] Cent S Univ, Xiangya Hosp 2, Dept Integrated Tradit Chinese & Western Med, Changsha 410011, Hunan, Peoples R China; [Gan, Pingping] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Huang, Xi] Nanjing Univ Chinese Med, Inst TCM Related Depress Comorbid, Nanjing 210046, Jiangsu, Peoples R China		Huang, X (corresponding author), Cent S Univ, Inst Integrated Tradit Chinese & Western Med, Xiangya Hosp, Lab Ethnopharmacol, Changsha 410008, Hunan, Peoples R China.; Huang, X (corresponding author), Nanjing Univ Chinese Med, Inst TCM Related Depress Comorbid, Nanjing 210046, Jiangsu, Peoples R China.	tcmhuangx59@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303074, 81673719, 30572339, 81403259]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine)	This study was supported by the National Natural Science Foundation of China (Grant Nos 81303074, 81673719, 30572339 and 81403259), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine).	Abdul-Muneer PM, 2016, MOL NEUROBIOL, V53, P6106, DOI 10.1007/s12035-015-9520-8; Al Ahmad A, 2012, MICROVASC RES, V84, P222, DOI 10.1016/j.mvr.2012.05.008; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Arai K, 2003, GLIA, V43, P254, DOI 10.1002/glia.10255; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bhattacharyya S, 2015, J NEUROCHEM, V134, P728, DOI 10.1111/jnc.13156; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cotte J, 2014, NEW ENGL J MED, V371, P971, DOI 10.1056/NEJMc1407775; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Donkin J. J., CURR OPIN NEUROL; Elmann A, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/157598; Gau BS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-211; Haring RS, 2015, J SURG RES, V195, P1, DOI 10.1016/j.jss.2015.01.017; He SM, 2010, CURR MED CHEM, V17, P4072, DOI 10.2174/092986710793205336; Hsieh HL, 2010, ANTIOXID REDOX SIGN, V13, P1829, DOI 10.1089/ars.2009.2957; Kim HU, 2015, NAT BIOTECHNOL, V33, P264, DOI 10.1038/nbt.3167; Kim MJ, 2005, BRAIN RES, V1040, P178, DOI 10.1016/j.brainres.2005.01.066; Kochanek PM, 2016, LANCET NEUROL, V15, P13, DOI 10.1016/S1474-4422(15)00339-7; Kou K, 2014, WORLD J EMERG MED, V5, P245, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.001; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu CL, 2014, TURK NEUROSURG, V24, P363, DOI 10.5137/1019-5149.JTN.8551-13.0; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Rehman Hina, 2015, J Complement Integr Med, V12, P61, DOI 10.1515/jcim-2014-0004; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Shen QH, 2016, WORLDV EVID-BASED NU, V13, P380, DOI 10.1111/wvn.12167; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stocchetti N, 2016, MINERVA ANESTESIOL, V82, P499; Sun H, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00247; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tyagi N, 2009, J CELL PHYSIOL, V220, P257, DOI 10.1002/jcp.21757; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wang S, 2016, J NUTR BIOCHEM, V36, P42, DOI 10.1016/j.jnutbio.2016.07.008; Wang WZ, 2016, MOL NEUROBIOL, V53, P4809, DOI 10.1007/s12035-015-9385-x; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wang Y, 2015, J SEP SCI, V38, P1100, DOI 10.1002/jssc.201401197; Wang Y, 2012, CHIN J INTEGR MED, V18, P690, DOI 10.1007/s11655-012-1053-7; Watzlawick R, 2016, JAMA NEUROL, V73, P149, DOI 10.1001/jamaneurol.2015.3627; Wv WY, 2014, CHIN J NAT MEDICINES, V12, P241, DOI [10.3724/SP.J.1009.2014.00241, 10.1016/S1875-5364(14)60050-9]; Xing ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep20040; Xue TH, 2003, SCIENCE, V300, P740, DOI 10.1126/science.300.5620.740; Yousefipour Z, 2013, J HEALTH CARE POOR U, V24, P118, DOI 10.1353/hpu.2014.0002; Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559; Zhou YX, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/578107	57	28	33	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 30	2016	6								37098	10.1038/srep37098			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ED4FR	WOS:000388803700001	27901023	gold, Green Published			2022-02-06	
J	Shikov, AN; Pozharitskaya, ON; Makarov, VG				Shikov, Alexander N.; Pozharitskaya, Olga N.; Makarov, Valery G.			Aralia elata var. mandshurica (Rupr. & Maxim.) J.Wen: An overview of pharmacological studies	PHYTOMEDICINE			English	Article						Aralia; Adaptogen; Clinical data; Pharmacology; Toxicity	NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; ELATOSIDE C PROTECTS; MIQ SEEM TASAES; OLEANOLIC ACID; ROOT BARK; ISCHEMIA-REPERFUSION; TRITERPENE SAPONINS; BIOACTIVE SAPONINS; ETHANOL ABSORPTION	Purpose: Aralia elata var. mandshurica (Rupr. & Maxim.) J.Wen syn. A. mandshurica Rupr. & Maxim is evaluated for its medicinal application. The aim of this study is to analyze pharmacological studies on A. data var. mandshurica published until December 2015. Methods: The information regarding the chemistry, safety, effectiveness, and pharmacological and clinical effects of A. elata was systematically collected from the scientific literature through library catalogs; online services such as E-library.ru, Medline/PubMed, Scopus, Web of Science, and Google Scholar. Results: A. elata is often considered an example of a medicinal plant used in Chinese, Korean, and Japanese traditional medicine. However, the contemporary applications of Aralia in officinal medicine result primarily from a large number of pharmacological and clinical investigations carried out in the former USSR in the mid-20th century. Since the 1950s, medicinal preparations from radices of A. elata and radices of A. mandshurica have secured an established position within Russian/USSR medicine as evidenced by the inclusion of the drug in recent editions of the National Pharmacopoeia of the USSR and in the Register of Medicinal Preparations of Russia. Pharmacological studies on animals have shown that Aralia increases physical working capacity and affords a stress-protective effect against a broad spectrum of harmful factors including cold stress, immobilization, UV irradiation, and low air pressure. The phytoadaptogen exerts an effect on the central nervous, reproductive, immune, respiratory, and gastrointestinal systems; the metabolic syndrome including hypolipidemic and antidiabetic effects; and blood coagulation. Together with general properties of adaptogens, Aralia has its own specificity, which manifests in cardioprotective and antiarrhythmic activities. Studies on isolated organs, cells, and enzymes have revealed that Aralia preparations exhibit antioxidant activities and enhance sarcoplasmic reticulum Ca2+-ATPase activity, inhibit endoplasmic reticulum stress-associated apoptosis markers (GRP78, CHOP, Caspase-12, and JNK), and increase phosphorylation of STAT3 and Bc12/Bax ratio; they also show cytotoxic activities against some tumor cell lines; affect NF-kappa B and PPARs activities; and regulate biosynthesis of pro-inflammatory cytokines and inflammation-related protein expression, tissue respiration, and oxygen consumption. In healthy subjects, Aralia increases mental performance, working capacity, and endurance of movement. Numerous clinical trials have shown the efficiency of Aralia preparations in. patients with traumatic brain injury (accompanied with asthenic syndrome and neurotic reactions, depression, neurasthenia, and psychasthenia), neurological diseases (accompanied with astheno-depressive and astheno-hypochondriasis syndromes), myasthenia syndrome (accompanied with chronic post-influenza arachnoiditis), and arterial hypotension. Aralia tincture and "Saparal" are useful as antiviral remedies. Radioprotective properties of Aralia have been reported in pregnant women. Synergistic antiobesity effect was reported for the combination of A. mandshurica and Engelhardtia chrysolepfs extracts and antidiabetic effect for the combination of Aralia and glipizide. Promising stress-relieving effects of Aralia are reported for professionals whose work requires a high level of attention. Its proposed ability to moderate stress-induced damage and dysfunction in the cardiovascular tissue might make Aralia the adaptogen of choice among patients with higher risk for cardiovascular diseases. Because Aralia extract administration appears to affect plasma glucose level and hepatic lipid accumulation and ameliorate hyperinsulinemia, it might also provide benefits and be the adaptogen of choice for patients with obesity and diabetes. Conclusion: This review describes the considerable diversity of pharmacological effects of A. elata reported in numerous studies carried out in the former USSR and other countries, which have been confirmed over >47 years of use of the plant as an official medicinal remedy. The knowledge discussed in this review can be applied to the expansion of the use of this high-value plant in the pharmacotherapy of European and other countries and for the further discovery of new drugs based on the secondary metabolites of this plant. Modern approaches in mechanisms of action, including a study of gene expression profiling, suggest the most up-to-date challenges for the future research of Aralia. (C) 2016 Elsevier GmbH. All rights reserved.	[Shikov, Alexander N.; Pozharitskaya, Olga N.; Makarov, Valery G.] St Petersburg Inst Pharm, P 245, Vsevolozhsky Dist 188663, Kuzmolovo, Russia		Shikov, AN (corresponding author), St Petersburg Inst Pharm, P 245, Vsevolozhsky Dist 188663, Kuzmolovo, Russia.	spb.pharmacy@gmail.com	Shikov, Alexander/B-1804-2008; Pozharitskaya, Olga N/D-9671-2014	Shikov, Alexander/0000-0003-4351-0695; Pozharitskaya, Olga N/0000-0003-1061-0665			Abidov M, 2003, B EXP BIOL MED+, V136, P585, DOI 10.1023/B:BEBM.0000020211.24779.15; Abidov MT, 2006, B EXP BIOL MED+, V141, P343, DOI 10.1007/s10517-006-0167-3; AHUMADA F, 1991, PHYTOTHER RES, V5, P29, DOI 10.1002/ptr.2650050108; Asea A, 2013, PHYTOMEDICINE, V20, P1323, DOI 10.1016/j.phymed.2013.07.001; BARANOV AI, 1982, J ETHNOPHARMACOL, V6, P339, DOI 10.1016/0378-8741(82)90055-1; Barnaulov OD, 2006, PSYCHOPHARMACOL BIOL, V6, P1232; BREKHMAN II, 1969, ANNU REV PHARMACOLOG, V9, P419, DOI 10.1146/annurev.pa.09.040169.002223; Brekhman II, 1963, PRIMORSKOE KNIZHNOE, V5, P219; Brown R.P., 2002, HERBALGRAM, V56, P40; BURGOS R, 1994, PHYTOTHER RES, V8, P1, DOI 10.1002/ptr.2650080102; Burgos RA, 1997, PHYTOTHER RES, V11, P59, DOI 10.1002/(SICI)1099-1573(199702)11:1<59::AID-PTR944>3.0.CO;2-8; Chernyak D. M., 2014, PACIFIC MED J, V2, P28; Chung YS, 2005, J ETHNOPHARMACOL, V101, P49, DOI 10.1016/j.jep.2005.03.020; Clement JA, 2014, CURR TOP MED CHEM, V14, P2783; Denisenko P. P., 2000, PSYCHONEUROENDOCRINO, V25, pS57; Dorovskikh V. A., 2015, B PHYSL PATHOL RESP, V55, P95; Duke J. A., 1985, MED PLANTS CHINA, P1; Fedorova M. V., 1994, Rossiiskii Vestnik Perinatologii i Pediatrii, V39, P13; Fruentov N. K., 1974, MED PLANTS FAR E; Garkaev L. H., 1998, ANTISTRESS REACTIONS, P656; Gubchenko P.P., 1986, NEW DATA ELEUTHEROCO, P171; Gubina G., 1988, MED PREPARATIONS PLA, P263; GUBINA GP, 1959, ZH NEVROPATOL PSIKH, V59, P1239; HERNANDEZ DE, 1988, J ETHNOPHARMACOL, V23, P109, DOI 10.1016/0378-8741(88)90120-1; Hwang KA, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0871-5; [Ишрефова Л.Р. Ishrefova L.R.], 2011, [Профилактическая и клиническая медицина, Preventive and Clinical Medicine, Profilakticheskaya i klinicheskaya meditsina], P98; ISKENDEROV G B, 1989, Farmatsiya (Moscow), V38, P44; Jung Chun Sik, 1993, Yakhak Hoeji, V37, P581; Kazakevich V. V., 1972, MED SOVIET FAR E; Kazakevich V. V., 1971, BIOL ACTIVE COMPOUND, P119; Kharin S. A., 2011, ADV MODERN SCI, V8, P75; Kochetkov N.K., 1963, B ACAD SCI USSR CH+, V12, P1282; KOCHETKOV NK, 1962, TETRAHEDRON LETT, P713; KOLKHIR V K, 1982, Pharmaceutical Chemistry Journal (English Translation of Khimiko-Farmatsevticheskii Zhurnal), V16, P335, DOI 10.1007/BF00762048; KOMISSARENKO B T, 1962, Sov Med, V25, P115; Kuang HX, 2013, CHEM BIODIVERS, V10, P703, DOI 10.1002/cbdv.201200087; Lee EB, 2005, BIOL PHARM BULL, V28, P523, DOI 10.1248/bpb.28.523; Lee JH, 2009, ARCH PHARM RES, V32, P831, DOI 10.1007/s12272-009-1603-5; Li Feng-jin, 2013, Chinese Pharmacological Bulletin, V29, P1663, DOI 10.3969/j.issn.1001-1978.2013.12.009; Liu XH, 2015, J SCI FOOD AGR, V95, P739, DOI 10.1002/jsfa.6829; Liu Y, 2011, AFR J PHARM PHARMACO, V5, P462; Luo Y, 2015, J ETHNOPHARMACOL, V163, P241, DOI 10.1016/j.jep.2015.01.017; Montiel-Ruiz RM, 2012, DRUG DEVELOP RES, V73, P106, DOI 10.1002/ddr.21001; Markin V.V., 2007, SIBERIAN MED REV, V45, P54; Markina L.D., 2008, PACIFIC MED J, V3, P30; Mashkovsky M. D., 2002, MED DRUGS MANUAL PHA, V1, P135; Maslov LN, 2009, B EXP BIOL MED+, V147, P331, DOI 10.1007/s10517-009-0502-6; Maslov L. N., 2007, Eksperimental'naya i Klinicheskaya Farmakologiya, V70, P48; Miroshnichenko I. V., 1985, PHARM CHEM J, V19, P85; MITSUHASHI H, 1976, ECON BOT, V30, P209, DOI 10.1007/BF02909729; Najhin A. N., 1989, VOPROSY VIRUSOLOGII; Namba T., 1980, ENCY WAKAN YAKU COLO, VII, P180; New Medical College of Jiangsu ed, 1977, DICT CHIN MAT MED, P2583; Nhiem NX, 2011, BIOORG MED CHEM LETT, V21, P6143, DOI 10.1016/j.bmcl.2011.08.024; Panossian A, 1999, PHYTOMEDICINE, V6, P287, DOI 10.1016/S0944-7113(99)80023-3; Panossian A., 2003, ALTERN COMPLEMENT TH, V9, P327, DOI DOI 10.1089/107628003322658610; Panossian A, 2008, J ETHNOPHARMACOL, V118, P183, DOI 10.1016/j.jep.2008.04.020; Panossian A, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00016; Panossian A, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00006; Panossian A, 2010, PHARMACEUTICALS, V3, P188, DOI 10.3390/ph3010188; Panossian A, 2009, CURR CLIN PHARMACOL, V4, P198, DOI 10.2174/157488409789375311; Panossian A, 2009, PHYTOMEDICINE, V16, P617, DOI 10.1016/j.phymed.2008.12.003; Panossian AG, 2013, PSYCHIAT CLIN N AM, V36, P49, DOI 10.1016/j.psc.2012.12.005; PARAMONOVA MS, 1994, VOP VIRUSOL+, V39, P131; Perfumi M, 2007, PHYTOTHER RES, V21, P37, DOI 10.1002/ptr.2013; Perry L. M., 1990, MED PLANTS E SE ASIA, P41; Pivovarova A.S., 2003, RASTIT RESUR, V1, P94; Pospelova ML, 2000, HUMAN PHYSL, V26, P86; Poyarkova A.I., 1950, FLORA SSSR, V16, P1; SAITO S, 1993, CHEM PHARM BULL, V41, P1395, DOI 10.1248/cpb.41.1395; Sergeeva N. V., 1977, PHARM CHEM J, V11, P1393; Shikov AN, 2014, J ETHNOPHARMACOL, V154, P481, DOI 10.1016/j.jep.2014.04.007; Shreter, 1975, MED FLORA SOVIET FAR; Sim JS, 2005, BIOL PHARM BULL, V28, P1043, DOI 10.1248/bpb.28.1043; Smolyakova G. P., 1997, FAR E MED J, V4, P49; Sokolov, 2000, PHYTOTHERAPY PHYTOPH; Sokolov S., 1971, BIOL ACTIVE SUBSTANC, P113; Sokolov S. Ya., 1982, MED PREPARATIONS PLA, P270; SOKOLOV SY, 1968, B EXP BIOL MED-USSR, V66, P1353; SOKOLOV SY, 1966, B EXP BIOL MED-USSR, V61, P295, DOI 10.1007/BF00783689; SOKOLOV SY, 1965, B EXP BIOL MED-USSR, V60, P916, DOI 10.1007/BF00805046; Suh SJ, 2007, ARCH BIOCHEM BIOPHYS, V467, P227, DOI 10.1016/j.abb.2007.08.025; Syrov V. N., 1988, UZBEKSKII BIOL ZH, V3, P61; The State Pharmacopoeia of the USSR, 1990, RAD AR MANDSH RAD 2, P345; Turova AD, 1974, MED PLANTS USSR THEI; Voskanyan V.L., 1983, PHARM CHEM J, V17, P123; Vostrikova G. G., 1973, VOPROSY PHARM DALNEM, V1, P60; Wang M, 2015, INT J CARDIOL, V185, P167, DOI 10.1016/j.ijcard.2015.03.140; Wang M, 2014, APOPTOSIS, V19, P1727, DOI 10.1007/s10495-014-1039-3; Wang M, 2014, J ETHNOPHARMACOL, V155, P240, DOI 10.1016/j.jep.2014.05.024; Wiegant FAC, 2009, BIOGERONTOLOGY, V10, P27, DOI 10.1007/s10522-008-9151-9; WOJCICKI J, 1977, HERBA POL, V23, P285; Xi SG, 2009, EXP MOL MED, V41, P538, DOI 10.3858/emm.2009.41.8.059; Yook C.S., 1981, MED PLANTS KOREA, P272; Yoshikawa M, 1996, CHEM PHARM BULL, V44, P1915, DOI 10.1248/cpb.44.1915; Yoshikawa M, 1996, CHEM PHARM BULL, V44, P1923, DOI 10.1248/cpb.44.1923; YOSHIKAWA M, 1993, CHEM PHARM BULL, V41, P2069, DOI 10.1248/cpb.41.2069; YOSHIKAWA M, 1995, CHEM PHARM BULL, V43, P1878, DOI 10.1248/cpb.43.1878; Zhang Y, 2013, FOOD CHEM, V138, P208, DOI 10.1016/j.foodchem.2012.10.041; Zhuravlev YuN., 1996, ARALIACEAE GINSENG O	100	28	30	2	41	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0944-7113	1618-095X		PHYTOMEDICINE	Phytomedicine	NOV 15	2016	23	12					1409	1421		10.1016/j.phymed.2016.07.011			13	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	EB2KZ	WOS:000387192300016	27765361				2022-02-06	
J	Mutch, CA; Talbott, JF; Gean, A				Mutch, Christopher A.; Talbott, Jason F.; Gean, Alisa			Imaging Evaluation of Acute Traumatic Brain Injury	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; TBI; Imaging; MRI; CT	DIFFUSE AXONAL INJURY; CEREBRAL FAT-EMBOLISM; CRANIAL COMPUTED-TOMOGRAPHY; COMMON DATA ELEMENTS; CLOSED-HEAD INJURY; MAGNETIC-RESONANCE; SUBARACHNOID HEMORRHAGE; CORPUS-CALLOSUM; PROGNOSTIC VALUE; BASAL GANGLIA	Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. Imaging plays an important role in the evaluation, diagnosis, and triage of patients with TBI. Recent studies suggest that it also helps predict patient outcomes. TBI consists of multiple pathoanatomic entities. This article reviews the current state of TBI imaging including its indications, benefits and limitations of the modalities, imaging protocols, and imaging findings for each of these pathoanatomic entities. Also briefly surveyed are advanced imaging techniques, which include several promising areas of TBI research.	[Mutch, Christopher A.] Univ Calif San Francisco, Dept Radiol, 505 Parnassus Ave,M391, San Francisco, CA 94143 USA; [Talbott, Jason F.; Gean, Alisa] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, 1001 Potrero Ave, San Francisco, CA 94110 USA		Talbott, JF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, 1001 Potrero Ave, San Francisco, CA 94110 USA.	jason.talbott@ucsf.edu			NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA094143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS051864] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA094143] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30 NS051864] Funding Source: Medline		Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Al-Nakshabandi NA, 2001, RADIOLOGY, V218, P433, DOI 10.1148/radiology.218.2.r01fe09433; Arbelaez A, 1999, AM J NEURORADIOL, V20, P999; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; BARR HWK, 1971, BRAIN, V94, P607, DOI 10.1093/brain/94.4.607; BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bodanapally UK, 2013, NEURORADIOLOGY, V55, P771, DOI 10.1007/s00234-013-1166-5; BRADLEY WG, 1985, RADIOLOGY, V156, P99, DOI 10.1148/radiology.156.1.4001427; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BRITT RH, 1980, NEUROSURGERY, V6, P623, DOI 10.1227/00006123-198006000-00002; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; CAPLAN LR, 1977, ANN NEUROL, V1, P587, DOI 10.1002/ana.410010613; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHAKERES DW, 1986, AM J NEURORADIOL, V7, P223; Chen PC, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2013.05.003; CITERIO G, 1995, INTENS CARE MED, V21, P679, DOI 10.1007/BF01711549; Cohen AR, 2015, AM J EMERG MED, V33, P887, DOI 10.1016/j.ajem.2015.03.052; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; COLQUHOUN IR, 1989, CLIN RADIOL, V40, P619, DOI 10.1016/S0009-9260(89)80324-1; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; Cooper PR, 1987, HEAD INJURY; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coskun O, 2000, AM J NEURORADIOL, V21, P712; Davalos Deana B, 2002, Appl Neuropsychol, V9, P92, DOI 10.1207/S15324826AN0902_4; DAVIS JM, 1983, NEURORADIOLOGY, V25, P55, DOI 10.1007/BF00333294; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Edwards J D, 1993, Ann Vasc Surg, V7, P368, DOI 10.1007/BF02002892; Faul M, 2010, TRAUMATIC BRAIN INJU; FELDMAN RA, 1980, NEUROSURGERY, V6, P670, DOI 10.1227/00006123-198006000-00013; FRIEDE RL, 1966, NEUROLOGY, V16, P1210, DOI 10.1212/WNL.16.12.1210; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Gean AD, 2010, RADIOLOGY, V257, P212, DOI 10.1148/radiol.10092075; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1989, RADIOL CLIN N AM, V27, P435; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; George EO, 2014, J NEUROTRAUM, V31, P1018, DOI 10.1089/neu.2013.3224; Given CA, 2003, AM J NEURORADIOL, V24, P254; GLAUBITT D, 1983, AM J NEURORADIOL, V4, P560; GOLDBERG HI, 1986, RADIOLOGY, V158, P157, DOI 10.1148/radiology.158.1.3940374; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; HAN BK, 1990, AM J ROENTGENOL, V154, P361, DOI 10.2214/ajr.154.2.2105031; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; JACOBS A, 1994, J NUCL MED, V35, P942; JACOBSON DM, 1986, NEUROLOGY, V36, P847, DOI 10.1212/WNL.36.6.847; JAYAKUMAR PN, 1989, ACTA NEUROCHIR, V97, P114, DOI 10.1007/BF01772820; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JENNETT B, 1976, LANCET, V1, P1031; Johnson PL, 2002, NEUROIMAG CLIN N AM, V12, P217, DOI 10.1016/S1052-5149(02)00008-4; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; Komiyama M, 1989, Neurol Med Chir (Tokyo), V29, P573, DOI 10.2176/nmc.29.573; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; LANG DA, 1991, ACTA NEUROCHIR, V109, P5, DOI 10.1007/BF01405689; Le TT, 2012, AM J NEURORADIOL, V33, P61, DOI 10.3174/ajnr.A2761; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lloyd KM, 2008, RADIOLOGY, V248, P725, DOI 10.1148/radiol.2483070362; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Maeda M, 2003, EUR RADIOL, V13, pL192, DOI 10.1007/s00330-003-1877-9; Mata-Mbemba D, 2015, J NEUROTRAUM, V32, P359, DOI 10.1089/neu.2014.3453; Maura E, ACR APPROPRIATENESS; Menditto VG, 2012, ANN EMERG MED, V59, P451, DOI 10.1016/j.annemergmed.2011.12.003; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MILO R, 1987, ACTA NEUROCHIR, V84, P13, DOI 10.1007/BF01456345; Mitchell P, 2001, J NEUROL NEUROSUR PS, V70, P205, DOI 10.1136/jnnp.70.2.205; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; MOKRI B, 1982, MAYO CLIN PROC, V57, P310; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Park SY, 2010, J KOREAN NEUROSURG S, V48, P399, DOI 10.3340/jkns.2010.48.5.399; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P75; POZZATI E, 1989, SURG NEUROL, V32, P300, DOI 10.1016/0090-3019(89)90234-6; Prabhu SP, 2013, PEDIATR RADIOL, V43, P575, DOI 10.1007/s00247-012-2546-4; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reljic T, 2014, J NEUROTRAUM, V31, P78, DOI 10.1089/neu.2013.2873; Ro YS, 2011, ACAD EMERG MED, V18, P597, DOI 10.1111/j.1553-2712.2011.01094.x; Rodallec MH, 2008, RADIOGRAPHICS, V28, P1711, DOI 10.1148/rg.286085512; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; Ross BD, 1998, NEUROIMAG CLIN N AM, V8, P809; Rostami E, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00114; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; SAEKI N, 1985, Neurologia Medico-Chirurgica, V25, P939, DOI 10.2176/nmc.25.939; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2002, ACT NEUR S, V81, P373; SKLAR EML, 1992, RADIOL CLIN N AM, V30, P353; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stoeger A, 1998, EUR RADIOL, V8, P1590, DOI 10.1007/s003300050592; Stone JA, 1999, AM J NEURORADIOL, V20, P706; Stuckey SL, 2007, AM J ROENTGENOL, V189, P913, DOI 10.2214/AJR.07.2424; Takahashi M, 1999, J TRAUMA, V46, P324, DOI 10.1097/00005373-199902000-00021; Tha KK, 2009, BRIT J RADIOL, V82, P610, DOI 10.1259/bjr/29238647; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Trenchs V, 2009, EUR J EMERG MED, V16, P150, DOI 10.1097/MEJ.0b013e328321b7b5; TSAI FY, 1980, AM J ROENTGENOL, V134, P717, DOI 10.2214/ajr.134.4.717; Turazzi S, 1975, J Neurosurg Sci, V19, P215; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Vassilyadi M, 2009, CAN J NEUROL SCI, V36, P751, DOI 10.1017/S0317167100008386; Venkatasubramanian C, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000090; Verma RK, 2013, EUR J RADIOL, V82, P1539, DOI 10.1016/j.ejrad.2013.03.021; Vilaas S, ACR APPROPRIATENESS; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3; Wang X, 2015, J NEUROTRAUM, V32, P455, DOI 10.1089/neu.2014.3492; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; Wei SC, 2010, AM J NEURORADIOL, V31, P334, DOI 10.3174/ajnr.A1824; WERNICK S, 1989, J COMPUT ASSIST TOMO, V13, P323, DOI 10.1097/00004728-198903000-00027; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wintermark M, 2015, AJNR Am J Neuroradiol, V36, pE1, DOI 10.3174/ajnr.A4181; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark Max, 2015, J Am Coll Radiol, V12, pe1, DOI 10.1016/j.jacr.2014.10.014; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yamaki T, 1996, J NUCL MED, V37, P1166; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Yuh EL, 2010, NEUROIMAG CLIN N AM, V20, P597, DOI 10.1016/j.nic.2010.07.012; Zacharia TT, 2010, EMERG RADIOL, V17, P97, DOI 10.1007/s10140-009-0842-6; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; ZIMMERMAN RA, 1985, NEURORADIOLOGY, V27, P16, DOI 10.1007/BF00342511	177	28	33	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					409	+		10.1016/j.nec.2016.05.011			32	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800005	27637393	Green Accepted			2022-02-06	
J	Potter, SDS; Brown, RG; Fleminger, S				Potter, Sebastian D. S.; Brown, Richard G.; Fleminger, Simon			Randomised, waiting list controlled trial of cognitive-behavioural therapy for persistent postconcussional symptoms after predominantly mild-moderate traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC AMNESIA; RISK-FACTORS; QUESTIONNAIRE; REHABILITATION; RECOVERY; PREVENTION; FATIGUE; SCALE	Background Persistent postconcussional symptoms (PCS) can be a source of distress and disability following traumatic brain injury (TBI). Such symptoms have been viewed as difficult to treat but may be amenable to psychological approaches such as cognitive-behavioural therapy (CBT). Objectives To evaluate the effectiveness of a 12-session individualised, formulation-based CBT programme. Method Two-centre randomised waiting list controlled trial with 46 adults with persistent PCS after predominantly mild-to-moderate TBI (52% with post-traumatic amnesia (PTA)<= 24 hours), but including some with severe TBIs (20% with PTA>7 days). Results Improvements associated with CBT were found on the primary outcome measures relating to quality of life (using the Quality of Life Assessment Schedule and the Brain Injury Community Rehabilitation Outcome Scale). Treatment effects after covarying for treatment duration were also found for PCS and several secondary outcomes, including measures of anxiety and fatigue (but not depression or post-traumatic stress disorder (PTSD)). Improvements were more apparent for those completing CBT sessions over a shorter period of time, but were unrelated to medicolegal status, injury severity or length of time since injury. Conclusions This study suggests that CBT can improve quality of life for adults with persistent PCS and potentially reduce symptoms for some, in the context of outpatient brain injury rehabilitation services.	[Potter, Sebastian D. S.; Brown, Richard G.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, London, England; [Fleminger, Simon] Kings Coll London, Inst Psychiat Psychol & Neurosci, Sect Cognit Neuropsychiat, London, England; [Potter, Sebastian D. S.; Brown, Richard G.; Fleminger, Simon] South London & Maudsley NHS Fdn Trust, Maudsley Hosp, Lishman Unit, London, England		Potter, SDS (corresponding author), Inst Psychiat Psychol & Neurosci PO77, Dept Psychol, De Crespigny Pk, London SE5 8AZ, England.	sebastian.potter@kcl.ac.uk		Brown, Richard/0000-0001-9021-0172; Potter, Sebastian/0000-0002-2173-9870	National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London	RGB acknowledges salary support from the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Andersson EE, 2011, J REHABIL MED, V43, P323, DOI 10.2340/16501977-0666; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beurskens AJHM, 2000, OCCUP ENVIRON MED, V57, P353, DOI 10.1136/oem.57.5.353; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Creamer M, 2003, BEHAV RES THER, V41, P1489, DOI 10.1016/j.brat.2003.07.010; Davies R, 2005, BRAIN INJURY, V19, P941, DOI 10.1080/02699050400000565; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; FETTES PA, 1992, INT J EAT DISORDER, V11, P97, DOI 10.1002/1098-108X(199203)11:2&lt;97::AID-EAT2260110202&gt;3.0.CO;2-H; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frank J. D., 1982, PSYCHOTHERAPY RES BE, P5; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Gurr B, 2005, BRAIN INJURY, V19, P481, DOI 10.1080/02699050400005176; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kraft S, 2006, CLIN PSYCHOL PSYCHOT, V13, P397, DOI 10.1002/cpp.505; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MAHONEY F I, 1965, Md State Med J, V14, P61; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Selai CE, 2001, NEUROPSYCHOL REHABIL, V11, P219, DOI 10.1080/09602010042000033; Selai CE, 2000, EPILEPSY RES, V38, P67; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Spielberger C. D., 1999, STATE TRAIT ANGER EX; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Weiss D, 1997, ASSESSING PSYCHOL TR, P399, DOI DOI 10.1037/T12199-000; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; World Health Organization, 1993, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 CLASSIFICATIO; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	55	28	28	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2016	87	10					1075	1083		10.1136/jnnp-2015-312838			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	DW9OU	WOS:000383991400007	27496149	Green Submitted			2022-02-06	
J	Shultz, EL; Hoskinson, KR; Keim, MC; Dennis, M; Taylor, HG; Bigler, ED; Rubin, KH; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Shultz, Emily L.; Hoskinson, Kristen R.; Keim, Madelaine C.; Dennis, Maureen; Taylor, H. Gerry; Bigler, Erin D.; Rubin, Kenneth H.; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Adaptive Functioning Following Pediatric Traumatic Brain Injury: Relationship to Executive Function and Processing Speed	NEUROPSYCHOLOGY			English	Article						pediatrics; traumatic brain injury; adaptive functioning	QUALITY-OF-LIFE; HEAD-INJURY; CHILDHOOD; CHILDREN; OUTCOMES; PREDICTORS; MEDIATOR; BEHAVIOR; RATINGS; SAMPLE	Objective: Pediatric traumatic brain injury (TBI) may affect children's ability to perform everyday tasks (i.e., adaptive functioning). Guided by the American Association for Intellectual and Developmental Disabilities (AAIDD) model, we explored the association between TBI and adaptive functioning at increasing levels of specificity (global, AAIDD domains, and subscales). We also examined the contributions of executive function and processing speed as mediators of TBI's effects on adaptive functioning. Method: Children (ages 8-13) with severe TBI (STBI; n = 19), mild-moderate TBI (MTBI; n = 50), or orthopedic injury (OI; n = 60) completed measures of executive function (TEA-Ch) and processing speed (WISC-IV) an average of 2.7 years postinjury (SD = 1.2; range: 1-5.3). Parents rated children's adaptive functioning (ABAS-II, BASC-2, CASP). Results: STBI had lower global adaptive functioning (eta(2) = .04-.08) than the MTBI and OI groups, which typically did not differ. Deficits in the STBI group were particularly evident in the social domain, with specific deficits in social participation, leisure, and social adjustment (eta(2) = .06-.09). Jointly, executive function and processing speed were mediators of STBI's effects on global adaptive functioning and in conceptual and social domains. In the STBI group, executive function mediated social functioning, and processing speed mediated social participation. Conclusions: Children with STBI experience deficits in adaptive functioning, particularly in social adjustment, with less pronounced deficits in conceptual and practical skills. Executive function and processing speed may mediate the effects of STBI on adaptive functioning. Targeting adaptive functioning and associated cognitive deficits for intervention may enhance quality of life for pediatric TBI survivors.	[Shultz, Emily L.; Hoskinson, Kristen R.; Keim, Madelaine C.; Vannatta, Kathryn; Gerhardt, Cynthia A.] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA; [Hoskinson, Kristen R.; Vannatta, Kathryn; Gerhardt, Cynthia A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Dennis, Maureen] Hosp Sick Kids, Toronto, ON, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Magnet Resonance Imaging MRI Res Facil, Provo, UT 84602 USA; [Rubin, Kenneth H.] Univ Maryland, Dept Human Dev & Quantitat Methodol, College Pk, MD 20742 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Psychol, Calgary, AB T2N 1N4, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON, Canada		Hoskinson, KR (corresponding author), Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA.; Hoskinson, KR (corresponding author), Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.	Kristen.hoskinson@nationwidechildrens.org	Stancin, Terry/L-7993-2019; Rubin, Kenneth H/M-5276-2018; Hoskinson, Kristen/AAL-9162-2020; Yeates, Keith/AAJ-4223-2020	Rubin, Kenneth H/0000-0002-2608-2484; Hoskinson, Kristen/0000-0003-4044-9753; Yeates, Keith/0000-0001-7680-2892; Moscato, Emily/0000-0002-0207-0251	National Institute of Child HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 R01 HD048946]; Human Development; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Erin D. Bigler co-directs the BYU Neurological Assessment lab, which provides forensic consulation. This research was supported in part by grant 5 R01 HD048946 from the National Institute of Child Health and Human Development to Keith Owen Yeates.	Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chapman S.B, 1995, TRAUMATIC HEAD INJUR, P95; DEEGAN J, 1978, EDUC PSYCHOL MEAS, V38, P873, DOI 10.1177/001316447803800404; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Faul M, 2010, TRAUMATIC BRAIN INJU; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Fritz MS, 2007, PSYCHOL SCI, V18, P233, DOI 10.1111/j.1467-9280.2007.01882.x; Gale SD, 2010, J HEAD TRAUMA REHAB, V25, P15, DOI 10.1097/HTR.0b013e3181c39960; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hayes, 2018, INTRO MEDIATION MODE; Heverly-Fitt S, 2014, J INT NEUROPSYCH SOC, V20, P684, DOI 10.1017/S1355617714000393; Howard I, 2005, ETHNIC DIS, V15, pS51; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T, 1999, TEA CH TEST EVERYDAY; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Reynolds C. R., 2004, BEHAV ASSESSMENT SYS, V2nd; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Schalock R.L., 2010, INTELLECTUAL DISABIL, V11th ed.; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Wechsler D, 2003, WECHSLER INTELLIGENC; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2014, CLIN PSYCHOL SCI, V2, P97, DOI 10.1177/2167702613499734	42	28	29	1	23	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2016	30	7					830	840		10.1037/neu0000288			11	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	DY9FX	WOS:000385440400007	27182708	Bronze, Green Accepted			2022-02-06	
J	Brady, RD; Grills, BL; Church, JE; Walsh, NC; McDonald, AC; Agoston, DV; Sun, MJ; O'Brien, TJ; Shultz, SR; McDonald, SJ				Brady, Rhys D.; Grills, Brian L.; Church, Jarrod E.; Walsh, Nicole C.; McDonald, Aaron C.; Agoston, Denes V.; Sun, Mujun; O'Brien, Terence J.; Shultz, Sandy R.; McDonald, Stuart J.			Closed head experimental traumatic brain injury increases size and bone volume of callus in mice with concomitant tibial fracture	SCIENTIFIC REPORTS			English	Article							ENHANCED OSTEOGENESIS; MINERAL DENSITY; MODEL; NEUROINFLAMMATION; EPIDEMIOLOGY; OUTCOMES; ADULTS; RAT	Concomitant traumatic brain injury (TBI) and long bone fracture are commonly observed in multitrauma and polytrauma. Despite clinical observations of enhanced bone healing in patients with TBI, the relationship between TBI and fracture healing remains poorly understood, with clinical data limited by the presence of several confounding variables. Here we developed a novel trauma model featuring closed-skull weight-drop TBI and concomitant tibial fracture in order to investigate the effect of TBI on fracture healing. Male mice were assigned into Fracture + Sham TBI (FX) or Fracture + TBI (MULTI) groups and sacrificed at 21 and 35 days post-injury for analysis of healing fractures by micro computed tomography (mu CT) and histomorphometry. mu CT analysis revealed calluses from MULTI mice had a greater bone and total tissue volume, and displayed higher mean polar moment of inertia when compared to calluses from FX mice at 21 days post-injury. Histomorphometric results demonstrated an increased amount of trabecular bone in MULTI calluses at 21 days post-injury. These findings indicate that closed head TBI results in calluses that are larger in size and have an increased bone volume, which is consistent with the notion that TBI induces the formation of a more robust callus.	[Brady, Rhys D.; Grills, Brian L.; Church, Jarrod E.; McDonald, Aaron C.; McDonald, Stuart J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic 3086, Australia; [Walsh, Nicole C.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia; [Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Sun, Mujun; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3010, Australia		McDonald, SJ (corresponding author), La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic 3086, Australia.	stuart.mcdonald@latrobe.edu.au	O'Brien, Terence/L-8102-2013; O'Brien, Terence/AAU-5525-2021	McDonald, Stuart/0000-0001-5190-3179; Sun, Mujun/0000-0002-9923-9913; Church, Jarrod/0000-0001-8266-4043; O'Brien, Terence/0000-0002-7198-8621	NHMRCNational Health and Medical Research Council of Australia; CIHRCanadian Institutes of Health Research (CIHR); La Trobe University Understanding Disease RFA; La Trobe University School of Life Science Postgraduate Publication Award	Acknowledgements This work was supported by grants to SS and TO from the NHMRC, a fellowship to SS from CIHR, funding from La Trobe University Understanding Disease RFA to SM and La Trobe University School of Life Science Postgraduate Publication Award to RB. The authors are particularly grateful to Aaron Schindeler, David Little, Lauren Peacock and Kathy Mikulec for their help in implementing the fracture procedure in our laboratory.	Al-Thani H., 2014, J ENV PUBLIC HLTH, V2014; Baldock PA, 2014, J BONE MINER RES, V29, P2238, DOI 10.1002/jbmr.2205; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Baldock PA, 2006, J BONE MINER RES, V21, P1600, DOI 10.1359/JBMR.060705; Beaupre GS, 2006, AM J PHYS MED REHAB, V85, P464, DOI 10.1097/01.phm.0000214275.69286.7a; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Brady RD, 2015, J NEUROTRAUMA; Brady RD, 2014, J ORTHOP RES, V32, P1277, DOI 10.1002/jor.22686; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Genet F, 2015, J PATHOL, V236, P229, DOI 10.1002/path.4519; Hofman M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/204842; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Liu XQ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054077, 10.1371/journal.pone.0077367, 10.1371/journal.pone.0058489]; Locher RJ, 2015, J MUSCULOSKEL NEURON, V15, P309; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; Menetrez Jennifer S, 2002, Phys Med Rehabil Clin N Am, V13, P67, DOI 10.1016/S1047-9651(03)00072-X; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; MUELLER M, 1991, J BONE MINER RES, V6, P401; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Oppl B, 2014, J BONE MINER RES, V29, P1096, DOI 10.1002/jbmr.2122; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; Rosen CJ, 2008, CELL METAB, V7, P7, DOI 10.1016/j.cmet.2007.12.004; Schindeler A, 2008, J ORTHOP RES, V26, P1053, DOI 10.1002/jor.20628; Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Smith E, 2016, IRISH J MED SCI, V185, P473, DOI 10.1007/s11845-016-1399-5; Smith EM, 2009, ARCH PHYS MED REHAB, V90, P1127, DOI 10.1016/j.apmr.2008.09.578; SMITH R, 1987, J BONE JOINT SURG BR, V69, P518, DOI 10.1302/0301-620X.69B4.3611149; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Swift JM, 2013, MED SCI SPORT EXER, V45, P1665, DOI 10.1249/MSS.0b013e31828d39bc; Takeda S, 2005, BIOCHEM BIOPH RES CO, V328, P697, DOI 10.1016/j.bbrc.2004.11.071; Tsitsilonis S, 2015, INJURY, V46, P661, DOI 10.1016/j.injury.2015.01.044; Wang L, 2011, CHIN J TRAUMATOL, V14, P7, DOI 10.3760/cma.j.issn.1008-1275.2011.01.002; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang LC, 2013, MED HYPOTHESES, V81, P713, DOI 10.1016/j.mehy.2013.07.034	42	28	30	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 29	2016	6								34491	10.1038/srep34491			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DX2IM	WOS:000384191800001	27682431	Green Published, gold			2022-02-06	
J	Desai, A; Park, T; Barnes, J; Kevala, K; Chen, HZ; Kim, HY				Desai, Abhishek; Park, Taeyeop; Barnes, Jaquel; Kevala, Karl; Chen, Huazhen; Kim, Hee-Yong			Reduced acute neuroinflammation and improved functional recovery after traumatic brain injury by alpha-linolenic acid supplementation in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Polyunsaturated fatty acids (PUFA); Docosahexaenoic acid (DHA); Alpha-linolenic acid (ALA); Traumatic brain injury (TBI); Inflammation; Diet; Nutrition	SPINAL-CORD-INJURY; FATTY-ACIDS; HEAD-INJURY; RAT-BRAIN; ER STRESS; DHA; ACTIVATION; ASTROCYTES; NEUROPROTECTION; INFLAMMATION	Background: Adequate consumption of polyunsaturated fatty acids (PUFA) is vital for normal development and functioning of the central nervous system. The long-chain n-3 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid are anti-inflammatory and neuroprotective in the models of central nervous system injury including traumatic brain injury (TBI). In the present study, we tested whether a higher brain DHA status in a mouse model on an adequate dietary alpha-linolenic acid (ALA) leads to reduced neuroinflammation and improved spontaneous recovery after TBI in comparison to a moderately lowered brain DHA status that can occur in humans. Methods: Mice reared on diets with differing ALA content were injured by a single cortical contusion impact. Change in the expression of inflammatory cytokines was measured, and cellular changes occurring after injury were analyzed by immunostaining for macrophage/microglia and astrocytes. Behavioral studies included rotarod and beam walk tests and contextual fear conditioning. Results: Marginal supply (0.04 %) of ALA as the sole dietary source of n-3 PUFA from early gestation produced reduction of brain DHA by 35 % in adult offspring mice in comparison to the mice on adequate ALA diet (3.1 %). The DHA-depleted group showed significantly increased TBI-induced expression of pro-inflammatory cytokines TNF-alpha, IL-1 beta, and IL-6 in the brain as well as slower functional recovery from motor deficits compared to the adequate ALA group. Despite the reduction of pro-inflammatory cytokine expression, adequate ALA diet did not significantly alter either microglia/macrophage density around the contusion site or the relative M1/M2 phenotype. However, the glial fibrillary acidic protein immunoreactivity was reduced in the injured cerebral cortex of the mice on adequate ALA diet, indicating that astrocyte activation may have contributed to the observed differences in cellular and behavioral responses to TBI. Conclusions: Increasing the brain DHA level even from a moderately DHA-depleted state can reduce neuroinflammation and improve functional recovery after TBI, suggesting possible improvement of functional outcome by increasing dietary n-3 PUFA in human TBI.	[Desai, Abhishek; Park, Taeyeop; Barnes, Jaquel; Kevala, Karl; Chen, Huazhen; Kim, Hee-Yong] NIAAA, Lab Mol Signaling, NIH, 5625 Fishers Lane,Rm 3N-07, Bethesda, MD 20892 USA		Kim, HY (corresponding author), NIAAA, Lab Mol Signaling, NIH, 5625 Fishers Lane,Rm 3N-07, Bethesda, MD 20892 USA.	hykim@nih.gov			Henry M. Jackson Foundation; Intramural Research Program of the National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000501] Funding Source: NIH RePORTER	This study was funded by the Henry M. Jackson Foundation and the Intramural Research Program of the National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health. The funding agencies did not participate in planning the experiments, data analysis, or preparing the manuscript.	Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Berman JW, 1996, J IMMUNOL, V156, P3017; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Fernandes A, 2014, CELL MOL LIFE SCI, V71, P3969, DOI 10.1007/s00018-014-1670-8; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gorina R, 2011, GLIA, V59, P242, DOI 10.1002/glia.21094; Hamazaki K, 2010, J PSYCHIATR RES, V44, P688, DOI 10.1016/j.jpsychires.2009.11.017; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Jamieson EC, 1999, LIPIDS, V34, P1065, DOI 10.1007/s11745-999-0458-5; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Liu HQ, 2013, NUTR RES, V33, P849, DOI 10.1016/j.nutres.2013.07.004; MAKRIDES M, 1994, AM J CLIN NUTR, V60, P189, DOI 10.1093/ajcn/60.2.189; Mishra A, 2004, ARTERIOSCL THROM VAS, V24, P1621, DOI 10.1161/01.ATV.0000137191.02577.86; Moriguchi T, 2001, J LIPID RES, V42, P419; Mullen A, 2010, J NUTR BIOCHEM, V21, P444, DOI 10.1016/j.jnutbio.2009.02.008; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Sidhu VK, 2016, NEUROBIOL AGING, V41, P73, DOI 10.1016/j.neurobiolaging.2016.02.007; Simopoulos AP, 2006, BIOMED PHARMACOTHER, V60, P502, DOI 10.1016/j.biopha.2006.07.080; Swanson D, 2012, ADV NUTR, V3, P1, DOI 10.3945/an.111.000893; Wen ZM, 2004, J NEUROCHEM, V89, P1368, DOI 10.1111/j.1471-4159.2004.02433.x; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Zhang WT, 2010, STROKE, V41, P2341, DOI 10.1161/STROKEAHA.110.586081; Zhao GX, 2007, AM J CLIN NUTR, V85, P385, DOI 10.1093/ajcn/85.2.385; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	36	28	28	0	18	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	SEP 23	2016	13								253	10.1186/s12974-016-0714-4			10	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	DX8ED	WOS:000384620000003	27663791	Green Published, gold			2022-02-06	
J	Kuriakose, M; Skotak, M; Misistia, A; Kahali, S; Sundaramurthy, A; Chandra, N				Kuriakose, Matthew; Skotak, Maciej; Misistia, Anthony; Kahali, Sudeepto; Sundaramurthy, Aravind; Chandra, Namas			Tailoring the Blast Exposure Conditions in the Shock Tube for Generating Pure, Primary Shock Waves: The End Plate Facilitates Elimination of Secondary Loading of the Specimen	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; INDUCED NEUROTRAUMA; NERVOUS-SYSTEM; PRESSURE; IMPACT; MODEL; RAT	The end plate mounted at the mouth of the shock tube is a versatile and effective implement to control and mitigate the end effects. We have performed a series of measurements of incident shock wave velocities and overpressures followed by quantification of impulse values (integral of pressure in time domain) for four different end plate configurations (0.625, 2, 4 inches, and an open end). Shock wave characteristics were monitored by high response rate pressure sensors allocated in six positions along the length of 6 meters long 229 mm square cross section shock tube. Tests were performed at three shock wave intensities, which was controlled by varying the Mylar membrane thickness (0.02, 0.04 and 0.06 inch). The end reflector plate installed at the exit of the shock tube allows precise control over the intensity of reflected waves penetrating into the shock tube. At the optimized distance of the tube to end plate gap the secondary waves were entirely eliminated from the test section, which was confirmed by pressure sensor at T4 location. This is pronounced finding for implementation of pure primary blast wave animal model. These data also suggest only deep in the shock tube experimental conditions allow exposure to a single shock wave free of artifacts. Our results provide detailed insight into spatiotemporal dynamics of shock waves with Friedlander waveform generated using helium as a driver gas and propagating in the air inside medium sized tube. Diffusion of driver gas (helium) inside the shock tube was responsible for velocity increase of reflected shock waves. Numerical simulations combined with experimental data suggest the shock wave attenuation mechanism is simply the expansion of the internal pressure. In the absence of any other postulated shock wave decay mechanisms, which were not implemented in the model the agreement between theory and experimental data is excellent.	[Kuriakose, Matthew; Skotak, Maciej; Misistia, Anthony; Kahali, Sudeepto; Sundaramurthy, Aravind; Chandra, Namas] New Jersey Inst Technol, Ctr Injury Biomech Mat & Med CIBM3, Dept Biomed Engn, Newark, NJ 07102 USA		Chandra, N (corresponding author), New Jersey Inst Technol, Ctr Injury Biomech Mat & Med CIBM3, Dept Biomed Engn, Newark, NJ 07102 USA.	namas.chandra@njit.edu	Kahali, Sudeepto/G-9413-2018; Skotak, Maciej/H-4769-2019; Sundaramurthy, Aravind/O-2047-2019	Kahali, Sudeepto/0000-0001-8675-7466; Skotak, Maciej/0000-0003-2584-7294; Sundaramurthy, Aravind/0000-0002-0359-8680	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [14059001]	This work was supported by grant no. 14059001 entitled "Primary Blast Injury Criteria for Animal/Human TBI Models using Field Validated Shock Tubes" received from the U.S. Army Medical Research and Materiel Command.	BECKER H, 1965, J APPL POLYM SCI, V9, P911, DOI 10.1002/app.1965.070090309; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Burnside R, 1965, J AUSTRALIAN MATH SO, V5, P258; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I., 2015, FRONTIERS NEUROENGIN; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cullis I G, 2001, J R Army Med Corps, V147, P16; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DRYER M, 1967, J GEOPHYS RES, V72, P2955, DOI 10.1029/JZ072i011p02955; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; EMRICH RJ, 1953, J APPL PHYS, V24, P360, DOI 10.1063/1.1721279; GLASS II, 1955, J AERONAUT SCI, V22, P73, DOI 10.2514/8.3282; Gould KE, 1981, DTIC DOCUMENT; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOOKER WJ, 1963, J CHEM PHYS, V38, P214, DOI 10.1063/1.1733464; Hyde D., 2004, CONWEP 2 1 0 8; KIEFER JH, 1985, J PHYS CHEM-US, V89, P2013, DOI 10.1021/j100256a043; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; MIURA H, 1990, FLUID DYN RES, V6, P251, DOI 10.1016/0169-5983(90)90015-Q; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Needham C. E., 2010, BLAST WAVE PROPAGATI; Needham CE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00072; Newman AJ, 2010, J FLUID ENG-T ASME, V132, DOI 10.1115/1.4002183; PARK C, 1973, COMBUST FLAME, V20, P369, DOI 10.1016/0010-2180(73)90029-1; Rafaels KA, 2010, BLAST BRAIN INJURY R; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; SLEPICKA F, 1966, PHYS FLUIDS, V9, P1865, DOI 10.1063/1.1761946; SOMMERFELD M, 1985, EXP FLUIDS, V3, P197; Stuhmiller J.H., 1991, CONVENTIONAL WARFARE, P241; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vieille P., 1899, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, V129, P1228; Yattoo Gh, 2008, J Trauma Manag Outcomes, V2, P5, DOI 10.1186/1752-2897-2-5; Zel'dovlch YB, 1965, PHYS SHOCK WAVES HIG, P1966	44	28	28	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2016	11	9							e0161597	10.1371/journal.pone.0161597			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DV9IX	WOS:000383255200019	27603017	Green Submitted, Green Published, gold			2022-02-06	
J	Kataria, H; Lutz, D; Chaudhary, H; Schachner, M; Loers, G				Kataria, Hardeep; Lutz, David; Chaudhary, Harshita; Schachner, Melitta; Loers, Gabriele			Small Molecule Agonists of Cell Adhesion Molecule L1 Mimic L1 Functions In Vivo	MOLECULAR NEUROBIOLOGY			English	Article						Cell adhesion molecule L1; Spinal cord injury; Femoral nerve injury; Neurite outgrowth; Neuronal survival; Small molecule	TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; MICE DEFICIENT; SPINAL-CORD; ISCHEMIA-REPERFUSION; POLYSIALIC ACID; NERVE INJURY; RECOVERY	Lack of permissive mechanisms and abundance of inhibitory molecules in the lesioned central nervous system of adult mammals contribute to the failure of functional recovery after injury, leading to severe disabilities in motor functions and pain. Peripheral nerve injury impairs motor, sensory, and autonomic functions, particularly in cases where nerve gaps are large and chronic nerve injury ensues. Previous studies have indicated that the neural cell adhesion molecule L1 constitutes a viable target to promote regeneration after acute injury. We screened libraries of known drugs for small molecule agonists of L1 and evaluated the effect of hit compounds in cell-based assays in vitro and in mice after femoral nerve and spinal cord injuries in vivo. We identified eight small molecule L1 agonists and showed in cell-based assays that they stimulate neuronal survival, neuronal migration, and neurite outgrowth and enhance Schwann cell proliferation and migration and myelination of neurons in an L1-dependent manner. In a femoral nerve injury mouse model, enhanced functional regeneration and remyelination after application of the L1 agonists were observed. In a spinal cord injury mouse model, L1 agonists improved recovery of motor functions, being paralleled by enhanced remyelination, neuronal survival, and monoaminergic innervation, reduced astrogliosis, and activation of microglia. Together, these findings suggest that application of small organic compounds that bind to L1 and stimulate the beneficial homophilic L1 functions may prove to be a valuable addition to treatments of nervous system injuries.	[Kataria, Hardeep; Lutz, David; Chaudhary, Harshita; Loers, Gabriele] Univ Klinikum Hamburg Eppendorf, Inst Biosynth Neuraler Strukturen, Zentrum Mol Neurobiol Hamburg, Falkenried 94, D-20251 Hamburg, Germany; [Schachner, Melitta] Rutgers State Univ, Keck Ctr Collaborat Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA; [Schachner, Melitta] Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA; [Schachner, Melitta] Shantou Univ, Ctr Neurosci, Coll Med, 22 Xin Ling Rd, Shantou 515041, Guangdong, Peoples R China		Schachner, M (corresponding author), Rutgers State Univ, Keck Ctr Collaborat Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.; Schachner, M (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.; Schachner, M (corresponding author), Shantou Univ, Ctr Neurosci, Coll Med, 22 Xin Ling Rd, Shantou 515041, Guangdong, Peoples R China.	schachner@stu.edu.cn	Kataria, Hardeep/AAI-8411-2020; Lutz, David/AAX-1607-2021	Kataria, Hardeep/0000-0001-8413-0600	New Jersey Commission for Spinal Cord Research; Li Kashing Foundation at the Shantou University Medical College	We thank Eva Kronberg and Ulrike Wolters for excellent animal caretaking and Ute Bork for genotyping of mice, Dagmar Drexler and Barbara Holstermann for help with electron microscopy, and Torsten Renz and Fritz Kutschera for technical support. Melitta Schachner is supported by the New Jersey Commission for Spinal Cord Research and the Li Kashing Foundation at the Shantou University Medical College.	APPEL F, 1995, J NEUROBIOL, V28, P297, DOI 10.1002/neu.480280304; Ball Susan G, 2013, Drugs Context, V2013, P212245, DOI 10.7573/dic.212245; Barbin G, 2004, NEURON GLIA BIOL, V1, P65, DOI [10.1017/S1740925X04000092, 10.1017/s1740925x04000092]; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BRUSHART TME, 1988, J NEUROSCI, V8, P1026; Buffet M, 2003, FUND CLIN PHARMACOL, V17, P217, DOI 10.1046/j.1472-8206.2003.00173.x; Calabrese F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037916; Casacalenda N, 2002, AM J PSYCHIAT, V159, P1354, DOI 10.1176/appi.ajp.159.8.1354; Chen J, 2005, J NEUROTRAUM, V22, P896, DOI 10.1089/neu.2005.22.896; Chen J, 2007, BRAIN, V130, P954, DOI 10.1093/brain/awm049; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; Chenu F, 2009, INT J NEUROPSYCHOPH, V12, P475, DOI 10.1017/S1461145708009218; CRISMON ML, 1994, ANN PHARMACOTHER, V28, P744, DOI 10.1177/106002809402800612; Cui XZ, 2011, BRAIN BEHAV, V1, P73, DOI 10.1002/brb3.15; Cui YF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017126; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Dityatev A, 2008, NEURON GLIA BIOL, V4, P197, DOI 10.1017/S1740925X09990111; Djogo N, 2013, NEUROBIOL DIS, V56, P104, DOI 10.1016/j.nbd.2013.04.014; Du QH, 2013, PHARM BIOL, V51, P1347, DOI 10.3109/13880209.2013.792849; Ferguson IA, 2001, EUR J NEUROSCI, V13, P1059, DOI 10.1046/j.1460-9568.2001.01482.x; Godenschwege TA, 2006, CURR BIOL, V16, P12, DOI 10.1016/j.cub.2005.11.062; Guan HJ, 2010, CEREB CORTEX, V20, P2684, DOI 10.1093/cercor/bhq016; Guseva D, 2011, EXP NEUROL, V229, P339, DOI 10.1016/j.expneurol.2011.02.018; He XW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046223; Hu ZY, 2013, BRAIN RES, V1491, P204, DOI 10.1016/j.brainres.2012.11.004; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Irintchev A, 2005, EUR J NEUROSCI, V22, P802, DOI 10.1111/j.1460-9568.2005.04274.x; Irintchev A, 2012, NEUROSCIENTIST, V18, P452, DOI 10.1177/1073858411419047; Itoh K, 2005, MOL CELL NEUROSCI, V29, P245, DOI 10.1016/j.mcn.2005.02.014; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; Kamiguchi H, 1997, J NEUROSCI RES, V49, P1, DOI 10.1002/(SICI)1097-4547(19970701)49:1<1::AID-JNR1>3.0.CO;2-H; Lanzilli G, 2012, INFLAMMATION, V35, P240, DOI 10.1007/s10753-011-9310-z; Lavdas AA, 2011, CURR GENE THER, V11, P90; Lavdas AA, 2010, EXP NEUROL, V221, P206, DOI 10.1016/j.expneurol.2009.10.024; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; Li JH, 2013, INT UROL NEPHROL, V45, P679, DOI 10.1007/s11255-013-0410-6; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Loers G, 2005, J NEUROCHEM, V92, P1463, DOI 10.1111/j.1471-4159.2004.02983.x; Loers G, 2014, BIOCHEM J, V460, P437, DOI 10.1042/BJ20131677; Loers G, 2014, J NEUROCHEM, V128, P88, DOI 10.1111/jnc.12408; Loers G, 2012, J NEUROSCI, V32, P3917, DOI 10.1523/JNEUROSCI.6165-11.2012; Lundborg G, 2007, ACTA PHYSIOL, V189, P207, DOI 10.1111/j.1748-1716.2006.01653.x; Lutz D., 2015, MOL NEUROBIOL; Lutz D, 2014, J BIOL CHEM, V289, P13503, DOI 10.1074/jbc.M113.530238; Lutz D, 2014, J NEUROCHEM, V128, P713, DOI 10.1111/jnc.12473; Maness PF, 2007, NAT NEUROSCI, V10, P19, DOI 10.1038/nn1827; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Matsumoto-Miyai K, 2003, J NEUROSCI, V23, P7727; Mehanna A, 2010, MOL THER, V18, P34, DOI 10.1038/mt.2009.235; Mehanna A, 2009, BRAIN, V132, P1449, DOI 10.1093/brain/awp128; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; Montag-Sallaz M, 2002, MOL CELL BIOL, V22, P7967, DOI 10.1128/MCB.22.22.7967-7981.2002; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; NORMAN TR, 1989, J NEURAL TRANSM-GEN, P53; Pasinetti GM, 2015, BBA-MOL BASIS DIS, V1852, P1202, DOI 10.1016/j.bbadis.2014.10.006; Picazo O, 2010, CELL MOL NEUROBIOL, V30, P675, DOI 10.1007/s10571-009-9490-3; Poynard T, 2001, ALIMENT PHARM THER, V15, P355, DOI 10.1046/j.1365-2036.2001.00937.x; RATHJEN FG, 1984, EMBO J, V3, P1; Reidy M, 2006, J BIOMED MATER RES A, V77A, P542, DOI 10.1002/jbm.a.30590; Rocha-Gonzalez HI, 2008, CNS NEUROSCI THER, V14, P234, DOI 10.1111/j.1755-5949.2008.00045.x; Roonprapunt C, 2013, J NEUROTRAUM, V20, P871; Saghatelyan AK, 2004, MOL CELL NEUROSCI, V26, P191, DOI 10.1016/j.mcn.2004.01.008; Sandi C, 2007, NEUROENDOCRINOLOGY, V85, P158, DOI 10.1159/000101535; Schulz F, 2013, NANOSCALE, V5, P10605, DOI 10.1039/c3nr02707d; Shipton OA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0163; Simova O, 2006, ANN NEUROL, V60, P430, DOI 10.1002/ana.20948; Simpson SM, 2012, PHARMACOL BIOCHEM BE, V102, P109, DOI 10.1016/j.pbb.2012.03.027; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Skaper Stephen D, 2012, Methods Mol Biol, V846, P13, DOI 10.1007/978-1-61779-536-7_2; Tsoory MM, 2010, J NEUROSCI RES, V88, P369, DOI 10.1002/jnr.22203; Vega-Rivera NM, 2013, NEUROSCIENCE, V250, P102, DOI 10.1016/j.neuroscience.2013.06.058; Venero C, 2002, NEUROSCIENCE, V115, P1211, DOI 10.1016/S0306-4522(02)00543-2; Wang HQ, 2014, NEUROPHARMACOLOGY, V86, P9, DOI 10.1016/j.neuropharm.2014.06.018; Wei CH, 2012, EXP MOL MED, V44, P413, DOI 10.3858/emm.2012.44.7.050; Welzl H, 2003, NEWS PHYSIOL SCI, V18, P147, DOI 10.1152/nips.01422.2002; Witheford M, 2013, GLIA, V61, P1873, DOI 10.1002/glia.22564; WOOD PM, 1990, J NEUROSCI, V10, P3635; Woodbury A, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00130; Xu G, 2004, NEUROREPORT, V15, P2167, DOI 10.1097/00001756-200410050-00004; Zhang P, 2013, NEUROSCI LETT, V534, P123, DOI 10.1016/j.neulet.2012.11.052; Zhang Y, 2008, RESTOR NEUROL NEUROS, V26, P81; Zhong ZG, 1997, J NEUROCHEM, V68, P2291; Zhou LJ, 2012, J BIOL CHEM, V287, P25927, DOI 10.1074/jbc.M112.377465	83	28	28	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	SEP	2016	53	7					4461	4483		10.1007/s12035-015-9352-6			23	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DS3JI	WOS:000380678600017	26253722				2022-02-06	
J	Lemarchant, S; Dunghana, H; Pomeshchik, Y; Leinonen, H; Kolosowska, N; Korhonen, P; Kanninen, KM; Garcia-Berrocoso, T; Montaner, J; Malm, T; Koistinaho, J				Lemarchant, Sighild; Dunghana, Hiramani; Pomeshchik, Yuriy; Leinonen, Henri; Kolosowska, Natalia; Korhonen, Paula; Kanninen, Katja M.; Garcia-Berrocoso, Teresa; Montaner, Joan; Malm, Tarja; Koistinaho, Jari			Anti-Inflammatory Effects of ADAMTS-4 in a Mouse Model of Ischemic Stroke	GLIA			English	Article						ADAMTS-4; stroke; microglia; astrocyte; neuroinflammation	SPINAL-CORD-INJURY; CHONDROITIN SULFATE PROTEOGLYCAN; PROMOTES FUNCTIONAL RECOVERY; FIBROBLAST-LIKE SYNOVIOCYTES; CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; ABC PROMOTES; KAPPA-B; DIFFERENTIAL REGULATION; MACROPHAGE ACTIVATION	ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs type 4) is a metalloprotease capable to degrade chondroitin sulfate proteoglycans leading to cartilage destruction during arthritis or to neuroplasticity during spinal cord injury (SCI). Although ADAMTS-4 is an inflammatory-regulated enzyme, its role during inflammation has never been investigated. The aim of this study was to investigate the role of ADAMTS-4 in neuroinflammation. First, we evidenced an increase of ADAMTS-4 expression in the ischemic brain hemisphere of mouse and human patients suffering from ischemic stroke. Then, we described that ADAMTS-4 has predominantly an anti-inflammatory effect in the CNS. Treatment of primary microglia or astrocyte cultures with low doses of a human recombinant ADAMTS-4 prior to LPS exposure decreased NO production and the synthesis/release of pro-inflammatory cytokines including NOS2, CCL2, TNF-alpha, IL-1 beta and MMP-9. Accordingly, when cell cultures were transfected with silencing siRNA targeting ADAMTS-4 prior to LPS exposure, the production of NO and the synthesis/release of pro-inflammatory cytokines were increased. Finally, the feasibility of ADAMTS-4 to modulate neuroinflammation was investigated in vivo after permanent middle cerebral artery occlusion in mice. Although ADAMTS-4 treatment did not influence the lesion volume, it decreased astrogliosis and macrophage infiltration, and increased the number of microglia expressing arginase-1, a marker of alternatively activated cells with inflammation inhibiting functions. Additionally, ADAMTS-4 increased the production of IL-10 and IL-6 in the peri-ischemic area. By having anti-inflammatory and neuroregenerative roles, ADAMTS-4 may represent an interesting target to treat acute CNS injuries, such as ischemic stroke, SCI or traumatic brain injury.	[Lemarchant, Sighild; Dunghana, Hiramani; Pomeshchik, Yuriy; Leinonen, Henri; Kolosowska, Natalia; Korhonen, Paula; Kanninen, Katja M.; Malm, Tarja; Koistinaho, Jari] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Bioctr Kuopio, POB 1627, Kuopio, Finland; [Garcia-Berrocoso, Teresa; Montaner, Joan] Univ Autonoma Barcelona, Neurovasc Res Lab, VHIR, Barcelona, Spain		Lemarchant, S (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, POB 1627, Kuopio 70211, Finland.	sighild.lemarchant@uef.fi	Leinonen, Henri/V-2684-2019; Montaner, Joan/D-3063-2015	Leinonen, Henri/0000-0002-0388-832X; Montaner, Joan/0000-0003-4845-2279; Dhungana, Hiramani/0000-0003-3738-5410; GARCIA-BERROCOSO, TERESA/0000-0001-8072-8533; Malm, Tarja/0000-0002-9530-7472; Pomeshchik, Yuriy/0000-0002-1412-7403	Academy of FinlandAcademy of FinlandEuropean Commission; ERANET-Neuron research program "ProteA: Proteases before, during and after stroke"	Grant sponsor: Academy of Finland and the ERANET-Neuron research program "ProteA: Proteases before, during and after stroke," 2012-2015.	Amantea D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00147; Ashlin TG, 2013, CYTOKINE, V64, P234, DOI 10.1016/j.cyto.2013.06.315; Bartus K, 2014, J NEUROSCI, V34, P4822, DOI 10.1523/JNEUROSCI.4369-13.2014; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bradbury EJ, 2011, BRAIN RES BULL, V84, P306, DOI 10.1016/j.brainresbull.2010.06.015; Cai P, 2015, STROKE, V46, P2647, DOI 10.1161/STROKEAHA.115.009526; Casse F, 2012, J NEUROSCI, V32, P5186, DOI 10.1523/JNEUROSCI.5296-11.2012; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Cross AK, 2006, BRAIN RES, V1088, P19, DOI 10.1016/j.brainres.2006.02.136; Demircan K, 2013, NEUROSCI LETT, V544, P25, DOI 10.1016/j.neulet.2013.02.064; Denorme F, 2016, BLOOD, V127, P2337, DOI 10.1182/blood-2015-08-662650; Didangelos A, 2014, J NEUROSCI, V34, P16424, DOI 10.1523/JNEUROSCI.2927-14.2014; Franco R, 2015, PROG NEUROBIOL, V131, P65, DOI 10.1016/j.pneurobio.2015.05.003; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Gherardini L, 2015, CEREB CORTEX, V25, P202, DOI 10.1093/cercor/bht217; Goldring MB, 2011, CURR OPIN RHEUMATOL, V23, P471, DOI 10.1097/BOR.0b013e328349c2b1; Haddock G, 2006, MULT SCLER J, V12, P386, DOI 10.1191/135248506ms1300oa; Hamel MG, 2005, J NEUROCHEM, V93, P1533, DOI 10.1111/j.1471-4159.2005.03144.x; Hamel MG, 2008, EXP NEUROL, V210, P428, DOI 10.1016/j.expneurol.2007.11.014; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hill JJ, 2012, P NATL ACAD SCI USA, V109, P9155, DOI 10.1073/pnas.1205697109; Hobohm C, 2005, J NEUROSCI RES, V80, P539, DOI 10.1002/jnr.20459; Howell MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047226; Hsu YP, 2012, INT J EXP PATHOL, V93, P70, DOI 10.1111/j.1365-2613.2011.00802.x; Huh JE, 2012, J ETHNOPHARMACOL, V143, P779, DOI 10.1016/j.jep.2012.06.041; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Koh TJ, 2013, METHODS MOL BIOL, V1037, P507, DOI 10.1007/978-1-62703-505-7_30; Korhonen P, 2015, BRAIN BEHAV IMMUN, V49, P322, DOI 10.1016/j.bbi.2015.06.013; Krstic D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047793; Lemarchant S, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0078-3; Lemarchant S, 2014, NEUROBIOL DIS, V66, P28, DOI 10.1016/j.nbd.2014.02.005; Lemarchant S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-133; Malm T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0229-9; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marzolo MP, 2000, J NEUROSCI RES, V60, P401, DOI 10.1002/(SICI)1097-4547(20000501)60:3<401::AID-JNR15>3.0.CO;2-L; Mimata Y, 2012, INT J RHEUM DIS, V15, P36, DOI 10.1111/j.1756-185X.2011.01656.x; Murray KN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00018; Novak ML, 2013, AM J PATHOL, V183, P1352, DOI 10.1016/j.ajpath.2013.06.034; Pihlaja R, 2011, GLIA, V59, P1643, DOI 10.1002/glia.21212; Pocivavsek A, 2009, GLIA, V57, P444, DOI 10.1002/glia.20772; Reid MJ, 2009, NEUROSCI LETT, V452, P252, DOI 10.1016/j.neulet.2009.01.058; Ren PP, 2013, ANN THORAC SURG, V95, P570, DOI 10.1016/j.athoracsur.2012.10.084; Rolova T, 2014, NEUROBIOL DIS, V64, P16, DOI 10.1016/j.nbd.2013.12.003; Sasaki M, 2001, MOL BRAIN RES, V89, P158, DOI 10.1016/S0169-328X(01)00046-8; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Seguin CA, 2006, MATRIX BIOL, V25, P409, DOI 10.1016/j.matbio.2006.07.002; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; Skaper SD, 2014, CNS NEUROL DISORD-DR, V13, P1654; Soleman S, 2012, BRAIN, V135, P1210, DOI 10.1093/brain/aws027; Tauchi R, 2012, NEUROSCI LETT, V517, P1, DOI 10.1016/j.neulet.2012.03.002; Tauchi R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-53; Tian Y, 2013, AM J PATHOL, V182, P2310, DOI 10.1016/j.ajpath.2013.02.037; Wagsater D, 2008, ATHEROSCLEROSIS, V196, P514, DOI 10.1016/j.atherosclerosis.2007.05.018; Wang LX, 2013, ANN NEUROL, V73, P189, DOI 10.1002/ana.23762; Yamamoto K, 2014, J BIOL CHEM, V289, P6462, DOI 10.1074/jbc.M113.545376; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang C, 2009, AM J PATHOL, V174, P586, DOI 10.2353/ajpath.2009.080661; Zhao BQ, 2009, BLOOD, V114, P3329, DOI 10.1182/blood-2009-03-213264; Zuo J, 1998, EXP NEUROL, V154, P654, DOI 10.1006/exnr.1998.6951; Zuo J, 2002, EXP NEUROL, V176, P221, DOI 10.1006/exnr.2002.7922	61	28	34	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	SEP	2016	64	9					1492	1507		10.1002/glia.23017			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DY2OG	WOS:000384931300003	27301579				2022-02-06	
J	Levy, D; Edut, S; Baraz-Goldstein, R; Rubovitch, V; Defrin, R; Bree, D; Gariepy, H; Zhao, J; Pick, CG				Levy, Dan; Edut, Shahaf; Baraz-Goldstein, Renana; Rubovitch, Vardit; Defrin, Ruth; Bree, Dara; Gariepy, Helaine; Zhao, Jun; Pick, Chaim G.			Responses of dural mast cells in concussive and blast models of mild traumatic brain injury in mice: Potential implications for post-traumatic headache	CEPHALALGIA			English	Article						Minimal traumatic brain injury; concussion; blast; mouse; mast cell; dura; posttraumatic headache	COGNITIVE DEFICITS; RECEPTOR AGONISTS; PAIN; MIGRAINE; ACTIVATION; DEGRANULATION; SENSITIZATION; DISRUPTION; MECHANISM; PROTEASES	Background Chronic post-traumatic headache (PTH) is one of the most common symptoms of mild traumatic brain injury (mTBI) but its underlying mechanisms remain unknown. Inflammatory degranulation of dural mast cells (MCs) is thought to promote headache, and may play a role in PTH. Whether mTBI is associated with persistent degranulation of dural MCs is yet to be determined. Methods Histochemistry was used to evaluate time course changes in dural MC density and degranulation level in concussive head trauma and blast mouse models of mTBI. The effects of sumatriptan and the MC stabilizer cromolyn sodium on concussion-evoked dural MC degranulation were also investigated. Results Concussive head injury evoked persistent MC degranulation for at least 30 days. Blast trauma gave rise to a delayed MC degranulation response commencing at seven days that also persisted for at least 30 days. Neither sumatriptan nor cromolyn treatment reduced concussion-evoked persistent MC degranulation. Conclusions mTBI evoked by closed head injury or blast exposure is associated with persistent dural MC degranulation. Such a response in mTBI patients may contribute to PTH. Amelioration of PTH by sumatriptan may not involve inhibition of dural MC degranulation. If persistent dural MC degranulation contributes to PTH, then cromolyn treatment may not be effective.	[Levy, Dan; Bree, Dara; Gariepy, Helaine; Zhao, Jun] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA; [Levy, Dan; Bree, Dara; Gariepy, Helaine] Harvard Med Sch, Boston, MA USA; [Edut, Shahaf; Baraz-Goldstein, Renana; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Defrin, Ruth] Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel; [Defrin, Ruth; Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel		Levy, D (corresponding author), Dept Anesthesia Crit Care & Pain Med, 330 Brookline Av DA719, Boston, MA 02215 USA.	dlevy1@bidmc.harvard.edu	Levy, Dan/AAF-1871-2021		NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS077882, NS086830, NS078263]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086830, R01NS078263, R21NS077882] Funding Source: NIH RePORTER	The study was supported by grants from the NIH/NINDS (NS077882, NS086830, NS078263 to DL).	Bankova LG, 2014, J IMMUNOL, V192, P2812, DOI 10.4049/jimmunol.1301794; Benromano T, 2015, EUR J PAIN, V19, P621, DOI 10.1002/ejp.583; BUZZI MG, 1992, BRAIN RES, V583, P137, DOI 10.1016/S0006-8993(10)80017-4; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; DiTommaso C, 2014, HEADACHE, V54, P511, DOI 10.1111/head.12254; Ericsson A, 1997, J NEUROSCI, V17, P7166; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Hendrix S, 2013, FASEB J, V27, P920, DOI 10.1096/fj.12-204800; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Keidel M, 2006, HEADACHES, P863; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; Levy D, 2004, P NATL ACAD SCI USA, V101, P4274, DOI 10.1073/pnas.0306147101; Levy D, 2007, PAIN, V130, P166, DOI 10.1016/j.pain.2007.03.012; Levy D, 2009, HEADACHE, V49, P953, DOI 10.1111/j.1526-4610.2009.01444.x; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Messlinger K, 2009, EXP BRAIN RES, V196, P179, DOI 10.1007/s00221-009-1756-y; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Olesen J, 2009, LANCET NEUROL, V8, P679, DOI 10.1016/S1474-4422(09)70090-0; Pedersen SH, 2015, CEPHALALGIA, V35, P1287, DOI 10.1177/0333102415574846; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Russo AF, 2015, ANNU REV PHARMACOL, V55, P533, DOI 10.1146/annurev-pharmtox-010814-124701; Shimada R, 2012, J CLIN NEUROSCI, V19, P447, DOI 10.1016/j.jocn.2011.06.033; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Walker WC, 2013, CEPHALALGIA, V33, P998, DOI 10.1177/0333102413482197; Zhang T, 2016, EUR J PHARMACOL, V778, P158, DOI 10.1016/j.ejphar.2015.05.071; Zhang XC, 2007, J PHARMACOL EXP THER, V322, P806, DOI 10.1124/jpet.107.123745; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	35	28	28	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	SEP	2016	36	10					915	923		10.1177/0333102415617412			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DV3XR	WOS:000382859300002	26566937	Green Accepted			2022-02-06	
J	Bambakidis, T; Dekker, SE; Sillesen, M; Liu, BL; Johnson, CN; Jin, G; de Vries, HE; Li, YQ; Alam, HB				Bambakidis, Ted; Dekker, Simone E.; Sillesen, Martin; Liu, Baoling; Johnson, Craig N.; Jin, Guang; de Vries, Helga E.; Li, Yongqing; Alam, Hasan B.			Resuscitation with Valproic Acid Alters Inflammatory Genes in a Porcine Model of Combined Traumatic Brain Injury and Hemorrhagic Shock	JOURNAL OF NEUROTRAUMA			English	Article						genomics; inflammation; in vivo studies; therapeutic approaches for the treatment of central nervous system injury; traumatic brain injury	CLOSED-HEAD INJURY; LARGE ANIMAL-MODEL; PHARMACOLOGICAL RESUSCITATION; NORMAL SALINE; TNF-ALPHA; EXPRESSION; STRATEGIES; ACTIVATION; DEFICIENT; PHENOTYPE	Traumatic brain injury and hemorrhagic shock (TBI+HS) elicit a complex inflammatory response that contributes to secondary brain injury. There is currently no proven pharmacologic treatment for TBI+HS, but modulation of the epigenome has been shown to be a promising strategy. The aim of this study was to investigate whether valproic acid (VPA), a histone deacetylase inhibitor, modulates the expression of cerebral inflammatory gene profiles in a large animal model of TBI+HS. Ten Yorkshire swine were subjected to computer-controlled TBI+HS (40% blood volume). After 2 h of shock, animals were resuscitated with Hextend (HEX) or HEX+VPA (300 mg/kg, n = 5/group). Six hours after resuscitation, brains were harvested, RNA was isolated, and gene expression profiles were measured using a porcine microarray. Ingenuity Pathway Analysis (R) (IPA), gene ontology (GO), Parametric Gene Set Enrichment Analysis (PGSEA), and DAVID (Database for Annotation, Visualization, and Integrated Discovery) were used for pathway analysis. Key microarray findings were verified using real-time polymerase chain reaction (PCR). IPA analysis revealed that VPA significantly down-regulated the complement system (p < 0.001), natural killer cell communication (p < 0.001), and dendritic cell maturation (p < 0.001). DAVID analysis indicated that a cluster of inflammatory pathways held the highest rank and gene enrichment score. Real-time PCR data confirmed that VPA significantly down-expressed genes that ultimately regulate nuclear factor-kB (NF-kB)-mediated production of cytokines, such as TYROBP, TREM2, CCR1, and IL-1 beta. This high-throughput analysis of cerebral gene expression shows that addition of VPA to the resuscitation protocol significantly modulates the expression of inflammatory pathways in a clinically realistic model of TBI+HS.	[Bambakidis, Ted; Dekker, Simone E.; Liu, Baoling; Jin, Guang; Li, Yongqing; Alam, Hasan B.] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA; [Dekker, Simone E.] Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Dept Anesthesiol, Amsterdam, Netherlands; [Sillesen, Martin] Copenhagen Univ Hosp, Dept Surg Gastroenterol, Copenhagen, Denmark; [Johnson, Craig N.] Univ Michigan, DNA Sequencing Core, Ann Arbor, MI 48109 USA; [de Vries, Helga E.] Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands		Alam, HB (corresponding author), Univ Michigan Hosp, Dept Gen Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Johnson, Craig/0000-0003-3955-7394; Sillesen, Martin/0000-0001-9494-5475			Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bambakidis T, 2015, J SURG RES, V196, P159, DOI 10.1016/j.jss.2015.02.036; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111; Brown AL, 2006, J LEUKOCYTE BIOL, V80, P433, DOI 10.1189/jlb.0206112; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; Dekker SE, 2014, SURGERY, V156, P556, DOI 10.1016/j.surg.2014.04.016; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fukudome EY, 2012, SURGERY, V152, P254, DOI 10.1016/j.surg.2012.03.013; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204; Han Zhe, 2014, J Pharm Pract, V27, P487; Helming L, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159665; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Ichiyama T, 2000, BRAIN RES, V857, P246, DOI 10.1016/S0006-8993(99)02439-7; Imam A, 2015, J NEUROTRAUM, V32, P307, DOI 10.1089/neu.2014.3535; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kiialainen A, 2005, NEUROBIOL DIS, V18, P314, DOI 10.1016/j.nbd.2004.09.007; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lee MMK, 2009, J LEUKOCYTE BIOL, V86, P1319, DOI 10.1189/jlb.0209052; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li YQ, 2012, ADV EXP MED BIOL, V710, P107, DOI 10.1007/978-1-4419-5638-5_11; Liu ZC, 2014, SHOCK, V41, P104, DOI 10.1097/SHK.0000000000000074; Luer MS, 1996, PHARMACOTHERAPY, V16, P830; Ma J, 2015, MOL NEUROBIOL, V51, P820, DOI 10.1007/s12035-014-8811-9; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Okkenhaug K, 2007, TRENDS IMMUNOL, V28, P80, DOI 10.1016/j.it.2006.12.007; Paradowska-Gorycka A, 2013, HUM IMMUNOL, V74, P730, DOI 10.1016/j.humimm.2013.02.003; Piccio L, 2007, EUR J IMMUNOL, V37, P1290, DOI 10.1002/eji.200636837; Ritchie ME, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-261; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Smyth GK., 2004, STAT APPL GENET MOL, V3, pArticl, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tomasello E, 2005, EUR J IMMUNOL, V35, P1670, DOI 10.1002/eji.200425932; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4	53	28	29	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2016	33	16					1514	1521		10.1089/neu.2015.4163			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DU6ED	WOS:000382305900005	26905959	Green Submitted			2022-02-06	
J	Li, Q; Han, XN; Wang, J				Li, Qian; Han, Xiaoning; Wang, Jian			Organotypic Hippocampal Slices as Models for Stroke and Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Organotypic hippocampal slice cultures; Stoke; Traumatic brain injury	IN-VITRO MODEL; OXYGEN-GLUCOSE DEPRIVATION; NEURONAL CELL-DEATH; KAINIC ACID; CEREBRAL-ISCHEMIA; POLY(ADP-RIBOSE) POLYMERASE; GLUTAMATE RECEPTORS; ELECTRICAL-ACTIVITY; NEURAL PROGENITORS; LIPID-PEROXIDATION	Organotypic hippocampal slice cultures (OHSCs) have been used as a powerful ex vivo model for decades. They have been used successfully in studies of neuronal death, microglial activation, mossy fiber regeneration, neurogenesis, and drug screening. As a pre-animal experimental phase for physiologic and pathologic brain research, OHSCs offer outcomes that are relatively closer to those of whole-animal studies than outcomes obtained from cell culture in vitro. At the same time, mechanisms can be studied more precisely in OHSCs than they can be in vivo. Here, we summarize stroke and traumatic brain injury research that has been carried out in OHSCs and review classic experimental applications of OHSCs and its limitations.	[Li, Qian; Han, Xiaoning; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA		Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA.	jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Li, Qian/0000-0003-0359-5604	AHAAmerican Heart Association [13GRNT15730001]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078026, R01AT007317]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG031926] Funding Source: NIH RePORTER	This work was supported by an AHA Mid-Atlantic Affiliate Grant-in-Aid 13GRNT15730001, NIH grants R01NS078026 and R01AT007317 (JW), and an AHA Mid-Atlantic Affiliate Postdoctoral Fellowship Award (XH).	AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Ahlgren H, 2011, CELL TISSUE RES, V345, P329, DOI 10.1007/s00441-011-1218-2; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Allard J, 2015, HIPPOCAMPUS, V25, P197, DOI 10.1002/hipo.22364; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Avaliani N, 2014, STEM CELLS, V32, P3088, DOI 10.1002/stem.1823; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Bai JZ, 2014, NEUROTOXICOLOGY, V41, P64, DOI 10.1016/j.neuro.2014.01.001; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Barth A, 1996, EXP NEUROL, V141, P330, DOI 10.1006/exnr.1996.0168; Barth A, 1996, NEUROREPORT, V7, P1461, DOI 10.1097/00001756-199606170-00003; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Belmadani A, 2006, J NEUROSCI, V26, P3182, DOI 10.1523/JNEUROSCI.0156-06.2006; Benakis C, 2010, BRAIN BEHAV IMMUN, V24, P800, DOI 10.1016/j.bbi.2009.11.001; Bernard A, 1999, EUR J NEUROSCI, V11, P604, DOI 10.1046/j.1460-9568.1999.00479.x; Bernardi A, 2010, NEUROCHEM INT, V57, P629, DOI 10.1016/j.neuint.2010.07.012; Bickler PE, 2009, ANESTHESIOLOGY, V111, P258, DOI 10.1097/ALN.0b013e3181a8647f; Birgbauer E, 2004, J NEUROSCI RES, V78, P157, DOI 10.1002/jnr.20248; BRUCE AJ, 1995, EXP NEUROL, V132, P209, DOI 10.1016/0014-4886(95)90026-8; Budd SL, 1998, PHARMACOL THERAPEUT, V80, P203, DOI 10.1016/S0163-7258(98)00029-1; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chip S, 2013, J CEREBR BLOOD F MET, V33, P508, DOI 10.1038/jcbfm.2012.190; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Cho SG, 2004, NEUROCHEM INT, V45, P117, DOI 10.1016/j.neuint.2003.11.012; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Cooke Sam F, 1800, Curr Opin Investig Drugs, V6, P25; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cui HS, 2009, BIOL PHARM BULL, V32, P79, DOI 10.1248/bpb.32.79; Daviaud N, 2013, EXP NEUROL, V248, P429, DOI 10.1016/j.expneurol.2013.07.012; De Simoni A, 2003, J PHYSIOL-LONDON, V550, P135, DOI 10.1113/jphysiol.2003.039099; De Simoni A, 2006, NAT PROTOC, V1, P1439, DOI 10.1038/nprot.2006.228; del Zoppo GJ, 2001, ARCH NEUROL-CHICAGO, V58, P669, DOI 10.1001/archneur.58.4.669; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Feiner JR, 2005, ANESTH ANALG, V100, P215, DOI 10.1213/01.ANE.0000142129.17005.73; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Fujimoto S, 2006, NEUROBIOL DIS, V22, P130, DOI 10.1016/j.nbd.2005.10.008; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; Gatherer M, 1998, NEUROSCI LETT, V253, P119, DOI 10.1016/S0304-3940(98)00619-3; Gerace Elisabetta, 2012, Methods Mol Biol, V846, P343, DOI 10.1007/978-1-61779-536-7_29; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gill R, 2013, EUR J NEUROSCI, V38, P3554, DOI 10.1111/ejn.12367; Gogolla N, 2006, NAT PROTOC, V1, P2452, DOI 10.1038/nprot.2006.180; Gong QZ, 1996, INT J DEV NEUROSCI, V14, P841, DOI 10.1016/S0736-5748(96)00056-1; Granziera C, 2007, BRAIN RES, V1148, P217, DOI 10.1016/j.brainres.2007.02.025; Gregersen M, 2013, THER HYPOTHERMIA TEM, V3, P178, DOI 10.1089/ther.2013.0017; Hassen GW, 2004, BRAIN RES PROTOC, V13, P135, DOI 10.1016/j.brainresprot.2004.03.004; Hellwig S, 2011, J NEUROSCI, V31, P2352, DOI 10.1523/JNEUROSCI.3984-10.2011; HOGUE MJ, 1947, J EXP ZOOL, V106, P85, DOI 10.1002/jez.1401060104; Holopainen IE, 2004, NEUROCHEM INT, V45, P1, DOI 10.1016/j.neuint.2004.01.005; Hong J, 2010, J BIOL CHEM, V285, P39447, DOI 10.1074/jbc.M110.132522; Horn AP, 2011, STEM CELLS DEV, V20, P1171, DOI 10.1089/scd.2010.0157; Huang Yunke, 2014, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V39, P195, DOI 10.11817/j.issn.1672-7347.2014.02.015; Hughes RH, 2014, BRAIN RES, V1543, P308, DOI 10.1016/j.brainres.2013.11.020; Ikeda-Matsuo Y, 2010, BRIT J PHARMACOL, V160, P847, DOI 10.1111/j.1476-5381.2010.00711.x; Jakobsen B, 2002, AMINO ACIDS, V23, P37, DOI 10.1007/s00726-001-0107-5; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; Jung YJ, 2012, KOREAN J PHYSIOL PHA, V16, P423, DOI 10.4196/kjpp.2012.16.6.423; Kao C, 2012, J NEUROSURG, V117, P316, DOI 10.3171/2012.4.JNS111170; Kim HA, 2014, INT J MOL SCI, V15, P5940, DOI 10.3390/ijms15045940; KIRINO T, 1984, ACTA NEUROPATHOL, V64, P139, DOI 10.1007/BF00695577; Ko HK, 2001, BRAIN RES, V894, P297, DOI 10.1016/S0006-8993(00)03188-7; Koch H, 2010, J NEUROSCI, V30, P11678, DOI 10.1523/JNEUROSCI.4665-09.2010; Kovacs R, 2009, J NEUROSCI, V29, P8565, DOI 10.1523/JNEUROSCI.5698-08.2009; Krassioukov AV, 2002, BRAIN RES PROTOC, V10, P60, DOI 10.1016/S1385-299X(02)00180-0; Kristensen BW, 2001, BRAIN RES, V896, P1, DOI 10.1016/S0006-8993(00)03304-7; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Kurihara D, 2012, J BIOL CHEM, V287, P13822, DOI 10.1074/jbc.M111.314070; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Lamprecht MR, 2014, BRAIN RES, V1563, P131, DOI 10.1016/j.brainres.2014.03.037; Leonardo CC, 2009, NEUROSCIENCE, V160, P755, DOI 10.1016/j.neuroscience.2009.02.080; Li CT, 2009, J NEUROSCI RES, V87, P991, DOI 10.1002/jnr.21913; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Lossi L, 2009, PROG NEUROBIOL, V88, P221, DOI 10.1016/j.pneurobio.2009.01.002; Maisano X, 2012, J NEUROSCI, V32, P46, DOI 10.1523/JNEUROSCI.2683-11.2012; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McManus T, 2004, J NEUROCHEM, V91, P327, DOI 10.1111/j.1471-4159.2004.02711.x; Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003; Meli E, 2003, TOXICOL LETT, V139, P153, DOI 10.1016/S0378-4274(02)00429-0; Mielke JG, 2013, NEUROSCI LETT, V553, P13, DOI 10.1016/j.neulet.2013.07.050; Mirante O, 2013, INT J MOL SCI, V14, P16719, DOI 10.3390/ijms140816719; Molnar Z, 1999, EXP NEUROL, V156, P363, DOI 10.1006/exnr.1999.7032; Montero M, 2009, BRAIN RES, V1291, P140, DOI 10.1016/j.brainres.2009.06.097; Morin-Brureau M, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-11; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Moroni F, 2009, BRIT J PHARMACOL, V157, P854, DOI 10.1111/j.1476-5381.2009.00232.x; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; NEWELL DW, 1995, J NEUROSCI, V15, P7702; NEWELL DW, 1990, NEUROSCI LETT, V116, P325, DOI 10.1016/0304-3940(90)90095-Q; NITSCH C, 1989, BRAIN RES, V495, P243, DOI 10.1016/0006-8993(89)90218-7; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; Ohashi H, 2002, Z NATURFORSCH C, V57, P348; Pacher P, 2012, J MOL MED, V90, P347, DOI 10.1007/s00109-012-0884-1; Peng Y, 2010, NEUROPATHOLOGY, V30, P565, DOI 10.1111/j.1440-1789.2010.01102.x; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PHILLIS JW, 1994, BRAIN RES BULL, V34, P457, DOI 10.1016/0361-9230(94)90019-1; Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124; Rau TF, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0040881, 10.1371/journal.pone.0047877]; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; RIMVALL K, 1987, ACTA NEUROPATHOL, V74, P183, DOI 10.1007/BF00692850; RIVERA S, 1994, MOL BRAIN RES, V27, P12, DOI 10.1016/0169-328X(94)90179-1; Rosenblad C, 1998, NEUROSCIENCE, V82, P129; Runden E, 1998, J NEUROSCI, V18, P7296; Rytter A, 2003, J CEREBR BLOOD F MET, V23, P23, DOI 10.1097/01.WCB.0000034361.37277.1B; Sarnowska A, 2009, EXP NEUROL, V215, P317, DOI 10.1016/j.expneurol.2008.10.023; Sarntinoranont M, 2012, J NEUROTRAUM, V29, P418, DOI 10.1089/neu.2011.1772; Schoeler M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-20; Shetty AK, 2008, J NEUROSCI RES, V86, P3062, DOI 10.1002/jnr.21764; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Strassburger M, 2008, EUR J PHARMACOL, V592, P55, DOI 10.1016/j.ejphar.2008.06.099; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Suuronen T, 2003, J NEUROCHEM, V87, P407, DOI 10.1046/j.1471-4159.2003.02004.x; Takano T, 2014, GLIA, V62, P78, DOI 10.1002/glia.22588; Tanabe M, 1998, J NEUROPHYSIOL, V80, P2268, DOI 10.1152/jn.1998.80.5.2268; TASKER RC, 1992, J NEUROSCI, V12, P4298; Thevenet J, 2009, J NEUROCHEM, V111, P828, DOI 10.1111/j.1471-4159.2009.06369.x; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; VALLEE L, 1994, EUR J PEDIATR, V153, P598, DOI 10.1007/s004310050198; Van Kanegan MJ, 2014, J NEUROSCI, V34, P963, DOI 10.1523/JNEUROSCI.2700-13.2014; de Almeida LMV, 2008, ARCH BIOCHEM BIOPHYS, V480, P27, DOI 10.1016/j.abb.2008.09.006; VORNOV JJ, 1994, STROKE, V25, P457, DOI 10.1161/01.STR.25.2.457; WAHL P, 1989, J NEUROCHEM, V53, P1316, DOI 10.1111/j.1471-4159.1989.tb07430.x; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; Xiang ZM, 2000, J NEUROSCI METH, V98, P145, DOI 10.1016/S0165-0270(00)00197-7; Yoon JJ, 2010, EPILEPSY RES, V92, P153, DOI 10.1016/j.eplepsyres.2010.08.014; Yoshinaga H, 2003, CAN J PHYSIOL PHARM, V81, P683, DOI 10.1139/Y03-060; Yu Z, 2009, IEEE ENG MED BIO, P4210, DOI 10.1109/IEMBS.2009.5333791; Yu Z, 2009, IEEE ENG MED BIO, P1135; Yu Z, 2009, J NEUROTRAUM, V26, P1135, DOI 10.1089/neu.2008.0810; Zehendner CM, 2014, METHODS MOL BIOL, V1135, P403, DOI 10.1007/978-1-4939-0320-7_33; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038; Ziemka-Nalecz M, 2013, ACTA NEUROBIOL EXP, V73, P130	152	28	28	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2016	53	6					4226	4237		10.1007/s12035-015-9362-4			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DR2AO	WOS:000379707600061	26223803	Green Accepted			2022-02-06	
J	LoBue, C; Wilmoth, K; Cullum, CM; Rossetti, HC; Lacritz, LH; Hynan, LS; Hart, J; Womack, KB				LoBue, Christian; Wilmoth, Kristin; Cullum, C. Munro; Rossetti, Heidi C.; Lacritz, Laura H.; Hynan, Linda S.; Hart, John, Jr.; Womack, Kyle B.			Traumatic brain injury history is associated with earlier age of onset of frontotemporal dementia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ENVIRONMENTAL RISK-FACTORS; HEAD-INJURY; ALZHEIMERS-DISEASE; POPULATION; ENCEPHALOPATHY; DEGENERATION; TDP-43	Objective We retrospectively examined whether a history of traumatic brain injury (TBI) is associated with an earlier age of symptom onset and diagnosis in a large sample of patients with behavioural variant frontotemporal dementia (bvFTD). Methods Data on patients with bvFTD (n=678) were obtained from the National Alzheimer's Coordinating Center Uniform Data Set. TBI was categorised based on reported lifetime history of TBI with loss of consciousness (LOC) but no chronic deficits occurring more than 1 year prior to diagnosis of bvFTD. Analysis of covariance (ANCOVA) was used to determine if clinician-estimated age of symptom onset and age at diagnosis of bvFTD differed between those who reported a history of TBI with LOC (TBI+) and those who did not (TBI-). Results Controlling for sex, the TBI+ bvFTD group had an age of symptom onset and age of diagnosis that was on average 2.8 and 3.2 years earlier (p<0.01) than the TBI-bvFTD group. Conclusions TBI history with LOC occurring more than 1 year prior to diagnosis is associated with an earlier age of symptom onset and diagnosis in patients with bvFTD. TBI may be related to the underlying neurodegenerative processes in bvFTD, but the implications of age at time of injury, severity and repetitive injuries remain unclear.	[LoBue, Christian; Wilmoth, Kristin; Cullum, C. Munro; Rossetti, Heidi C.; Lacritz, Laura H.; Hynan, Linda S.; Hart, John, Jr.; Womack, Kyle B.] Univ Texas Southwestern Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; [Cullum, C. Munro; Lacritz, Laura H.; Hart, John, Jr.; Womack, Kyle B.] Univ Texas Southwestern Med Ctr, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Hynan, Linda S.] Univ Texas Southwestern Med Ctr, Dept Clin Sci, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.] Univ Texas Dallas, Ctr BrainHlth, Sch Behav & Brain Sci, Dallas, TX 75230 USA		Womack, KB (corresponding author), Univ Texas Southwestern Med Ctr, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	kyle.womack@utsouthwestern.edu	Wilmoth, Kristin/ABB-4014-2020; Cullum, C. Munro/AAC-2496-2019; Womack, Kyle/O-5422-2018; Hynan, Linda S/P-6473-2016	Wilmoth, Kristin/0000-0003-4192-8756; Cullum, C. Munro/0000-0001-9706-5465; Womack, Kyle/0000-0002-6060-9075; Hynan, Linda/0000-0002-4642-7769	NIH/NIA Alzheimer's Disease Center grant [P30 AG012300]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017]; National Institute of AgeingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG010161, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501]; (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG012300, P30 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P50 AG005136, P50 AG033514, P50 AG005681, P50 AG000000, U01 AG032984]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG032984, P50AG005134, P30AG008017, P01AG003991, P50AG005131, P50AG016573, P30AG013846, P30AG012300, P30AG010129, P50AG005138, P50AG005681, P50AG005136, P50AG005142, P30AG019610, P30AG028383, U01AG016976, P30AG013854, P30AG035982, P30AG010124, P50AG025688, P30AG010133, P50AG005133, P30AG008051, P50AG016574, P50AG033514, P50AG023501, P50AG008702, P50AG005146, P30AG010161, P50AG016570] Funding Source: NIH RePORTER	This study was provided funding in part by the NIH/NIA P30 AG012300 Alzheimer's Disease Center grant. The NACC database is funded by NIA/NIH grant U01 AG016976. NACC data are contributed by the NIA funded: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD), P50 AG000000 (PI Bruce Wayne and Co-PI Richard Grayson, Gotham City Concussion Study). The Alzheimer's Disease Genetic Consortium (ADGC) is funded by NIA grant U01 AG032984.	Allen MD, 2011, PSYCHOL INJ LAW, V4, P140, DOI 10.1007/s12207-011-9105-4; Barker WW, 2002, ALZ DIS ASSOC DIS, V16, P203, DOI 10.1097/00002093-200210000-00001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Boot BP, 2013, NEUROLOGY, V81, P833, DOI 10.1212/WNL.0b013e3182a2cbd1; Brunnstrom H, 2009, ARCH GERONTOL GERIAT, V49, P146, DOI 10.1016/j.archger.2008.06.005; Chapman J, 2001, NEUROLOGY, V57, P1482, DOI 10.1212/WNL.57.8.1482; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; CORSELLIS JAN, 1959, J MENT SCI, V105, P714, DOI 10.1192/bjp.105.440.714; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Deutsch MB, 2015, DEMENT GERIATR COGN, V39, P143, DOI 10.1159/000369787; Faul M, 2010, TRAUMATIC BRAIN INJU, V2, P1; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kalkonde YV, 2012, ALZHEIMERS DEMENT, V8, P204, DOI 10.1016/j.jalz.2011.03.011; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ng ASL, 2015, ANN NY ACAD SCI, V1338, P71, DOI 10.1111/nyas.12638; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pupillo E, 2012, EUR J NEUROL, V19, P1509, DOI 10.1111/j.1468-1331.2012.03723.x; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Rosso SM, 2003, J NEUROL NEUROSUR PS, V74, P1574, DOI 10.1136/jnnp.74.11.1574; Schoenberg MR, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P357, DOI 10.1007/978-0-387-76978-3_14; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	40	28	28	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2016	87	8					817	820		10.1136/jnnp-2015-311438			4	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	DS1VP	WOS:000380392200004	26359171	Green Accepted			2022-02-06	
J	Emmerich, T; Abdullah, L; Crynen, G; Dretsch, M; Evans, J; Ait-Ghezala, G; Reed, J; Montague, H; Chaytow, H; Mathura, V; Martin, J; Pelot, R; Ferguson, S; Bishop, A; Phillips, J; Mullan, M; Crawford, F				Emmerich, Tanja; Abdullah, Laila; Crynen, Gogce; Dretsch, Michael; Evans, James; Ait-Ghezala, Ghania; Reed, Jon; Montague, Hannah; Chaytow, Helena; Mathura, Venkatarajan; Martin, Justin; Pelot, Robert; Ferguson, Scott; Bishop, Alex; Phillips, John; Mullan, Michael; Crawford, Fiona			Plasma Lipidomic Profiling in a Military Population of Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder with Apolipoprotein E epsilon 4-Dependent Effect	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; human studies; lipidomics; phospholipids; post-traumatic stress disorder; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; N-3 FATTY-ACIDS; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; ANIMAL-MODELS; APOE GENOTYPE; E ISOFORMS; FOLLOW-UP; SERUM	In the military population, there is high comorbidity between mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) due to the inherent risk of psychological trauma associated with combat. These disorders present with long-term neurological dysfunction and remain difficult to diagnose due to their comorbidity and overlapping clinical presentation. Therefore, we performed cross-sectional analysis of blood samples from demographically matched soldiers (total, n = 120) with mTBI, PTSD, and mTBI+PTSD and those who were considered cognitively and psychologically normal. Soldiers were genotyped for apolipoprotein E (APOE) epsilon 4, and phospholipids (PL) were examined using liquid chromatography/mass spectrometry analysis. We observed significantly lower levels of several major PL classes in TBI, PTSD, and TBI+PTSD, compared with controls. PTSD severity analysis revealed that significant PL decreases were primarily restricted to the moderate-to-severe PTSD group. An examination of the degree of unsaturation showed that monounsaturated fatty acid-containing phosphatidylcholine (PC) and phosphatidylinositol (PI) species were lower in the TBI and TBI+PTSD groups. However, these PLs were unaltered among PTSD subjects, compared with controls. Similarly, ether PC (ePC) levels were lower in PTSD and TBI+PTSD subjects, relative to controls. Ratios of arachidonic acid (AA) to docosahexaenoic acid (DHA)-containing species were significantly decreased within PC and phosphatidylethanolamine (PE) classes. APOE epsilon 4 (+) subjects exhibited higher PL levels than their APOE epsilon 4 (-) counterparts within the same diagnostic groups. These findings suggest that PL profiles, together with APOE genotyping, could potentially aid to differentiate diagnosis of mTBI and PTSD and warrant further validation. In conclusion, PL profiling may facilitate clinical diagnosis of mTBI and PTSD currently hindered by comorbid pathology and overlapping symptomology of these two conditions.	[Emmerich, Tanja; Abdullah, Laila; Crynen, Gogce; Evans, James; Ait-Ghezala, Ghania; Reed, Jon; Montague, Hannah; Chaytow, Helena; Mathura, Venkatarajan; Martin, Justin; Pelot, Robert; Ferguson, Scott; Bishop, Alex; Phillips, John; Mullan, Michael; Crawford, Fiona] Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA; [Emmerich, Tanja; Abdullah, Laila; Crynen, Gogce; Ait-Ghezala, Ghania; Mathura, Venkatarajan; Pelot, Robert; Ferguson, Scott; Mullan, Michael; Crawford, Fiona] Open Univ, Milton Keynes, Bucks, England; [Emmerich, Tanja; Abdullah, Laila; Ait-Ghezala, Ghania; Reed, Jon; Mathura, Venkatarajan; Pelot, Robert; Ferguson, Scott; Crawford, Fiona] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Dretsch, Michael] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Dretsch, Michael] US Army, Aeromed Res Lab, Rucker, AL USA		Emmerich, T (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	temmerich@roskampinstitute.net		Emmerich, Tanja/0000-0001-5064-7150; Chaytow, Helena/0000-0003-2257-7620; Ait-Ghezala, Ghania/0000-0002-9836-8617			Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Abdullah L, 2012, NEUROMOL MED, V14, P349, DOI 10.1007/s12017-012-8192-z; Baker DG, 2012, NEUROPHARMACOLOGY, V62, P663, DOI 10.1016/j.neuropharm.2011.02.027; Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820; Beydoun MA, 2007, AM J CLIN NUTR, V85, P1103; Binder EB, 2009, PSYCHONEUROENDOCRINO, V34, P99, DOI [10.1016/j.psyneuen.2008.08.018, 10.1016/j.psyneuen.2009.05.021]; Binder EB, 2004, NAT GENET, V36, P1319, DOI 10.1038/ng1479; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Breslau N, 2002, PSYCHOL MED, V32, P573, DOI 10.1017/S0033291701004998; Conquer JA, 2000, LIPIDS, V35, P1305, DOI 10.1007/s11745-000-0646-3; Copeland WE, 2012, BIOL PSYCHIAT, V71, P15, DOI 10.1016/j.biopsych.2011.09.023; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; Department of Defense, 2014, DOD WORLDW NUMB TBI; EMI M, 1988, GENOMICS, V3, P373, DOI 10.1016/0888-7543(88)90130-9; FADEN AI, 1992, AM J PHYSIOL, V263, pR909, DOI 10.1152/ajpregu.1992.263.4.R909; Fisher H, 2014, GUIDE US MILITARY CA; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fredman G, 2011, BIOCHEM J, V437, P185, DOI 10.1042/BJ20110327; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Glenn TC, 2015, J NEUROTRAUM, V32, P820, DOI 10.1089/neu.2014.3483; Hamilton JA, 2007, J MOL NEUROSCI, V33, P2, DOI 10.1007/s12031-007-0060-1; Heude B, 2003, AM J CLIN NUTR, V77, P803, DOI 10.1093/ajcn/77.4.803; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Huang TL, 2005, NEUROLOGY, V65, P1409, DOI 10.1212/01.wnl.0000183148.34197.2e; Jacobs A, 1996, J NUCL MED, V37, P1605; Kagan BL, 1999, BIOL PSYCHIAT, V45, P374, DOI 10.1016/S0006-3223(98)00059-6; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Karlovic D, 2004, J KOREAN MED SCI, V19, P431, DOI 10.3346/jkms.2004.19.3.431; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kennelly S, 2012, INT J GERIATR PSYCH, V27, P415, DOI 10.1002/gps.2735; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Langeland W, 2008, NEUROSCI BIOBEHAV R, V32, P161, DOI 10.1016/j.neubiorev.2007.07.002; Lehrner A, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.23797; Lekman M, 2008, BIOL PSYCHIAT, V63, P1103, DOI 10.1016/j.biopsych.2007.10.026; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Lyons MJ, 2013, AM J MED GENET B, V162, P762, DOI 10.1002/ajmg.b.32154; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MAHLEY RW, 1983, KLIN WOCHENSCHR, V61, P225, DOI 10.1007/BF01496128; McKeen HD, 2011, BIOCHEM SOC T, V39, P663, DOI 10.1042/BST0390663; Mitchell RW, 2011, PROSTAG LEUKOTR ESS, V85, P293, DOI 10.1016/j.plefa.2011.04.007; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Polozova A, 2007, J MOL NEUROSCI, V33, P56, DOI 10.1007/s12031-007-0039-y; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schaefer EJ, 2006, ARCH NEUROL-CHICAGO, V63, P1545, DOI 10.1001/archneur.63.11.1545; Schwab KA, 2006, NEUROLOGY, V66, pA235; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Shannon R. J., 2015, J NEUROTRAUMA; Solter V, 2002, CROAT MED J, V43, P685; Spector AA, 2001, J MOL NEUROSCI, V16, P159, DOI 10.1385/JMN:16:2-3:159; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; VA National Center for PTSD, 2014, PTSD CHECKL DSM 4; Vandal M, 2014, J NEUROCHEM, V129, P516, DOI 10.1111/jnc.12640; Weathers F. W., 1991, PCL M FOR DSM 4; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; Whalley LJ, 2008, AM J CLIN NUTR, V87, P449, DOI 10.1093/ajcn/87.2.449; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	73	28	28	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2016	33	14					1331	1348		10.1089/neu.2015.4061			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DQ5CX	WOS:000379223100005	26714394				2022-02-06	
J	Root, JM; Zuckerbraun, NS; Wang, L; Winger, DG; Brent, D; Kontos, A; Hickey, RW				Root, Jeremy M.; Zuckerbraun, Noel S.; Wang, Li; Winger, Daniel G.; Brent, David; Kontos, Anthony; Hickey, Robert W.			History of Somatization Is Associated with Prolonged Recovery from Concussion	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; FUNCTIONAL SOMATIC SYMPTOMS; ABDOMINAL-PAIN; HIGH-SCHOOL; CHILDREN; MILD; PREDICTORS; ADOLESCENTS; SLEEP	Objective To determine the association between a history of somatization and prolonged concussion symptoms, including sex differences in recovery. Study design A prospective cohort study of 10- to 18-year-olds with an acute concussion was conducted from July 2014 to April 2015 at a tertiary care pediatric emergency department. One hundred twenty subjects completed the validated Children's Somatization Inventory (CSI) for pre-injury somatization assessment and Postconcussion Symptoms Scale (PCSS) at diagnosis. PCSS was re-assessed by phone at 2 and 4 weeks. CSI was assessed in quartiles with a generalized estimating equation model to determine relationship of CSI to PCSS over time. Results The median age of our study participants was 13.8 years (IQR 11.5, 15.8), 60% male, with separate analyses for each sex. Our model showed a positive interaction between total CSI score, PCSS and time from concussion for females P < .01, and a statistical trend for males, P = .058. Females in the highest quartile of somatization had higher PCSS than the other 3 CSI quartiles at each time point (B - 26.7 to - 41.1, P values < . 015). Conclusions Patients with higher pre-injury somatization had higher concussion symptom scores over time. Females in the highest somatization quartile had prolonged concussion recovery with persistently high symptom scores at 4 weeks. Somatization may contribute to sex differences in recovery, and assessment at the time of concussion may help guide management and target therapy.	[Root, Jeremy M.] Childrens Natl Med Ctr, Emergency Med & Trauma Serv, 111 Michigan Ave NW, Washington, DC 20010 USA; [Zuckerbraun, Noel S.; Hickey, Robert W.] Childrens Hosp Pittsburgh, Dept Pediat, Div Pediat Emergency Med, Pittsburgh, PA 15213 USA; [Wang, Li; Winger, Daniel G.] Univ Pittsburgh, Off Clin Res, Hlth Sci, Pittsburgh, PA USA; [Brent, David] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Kontos, Anthony] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA		Root, JM (corresponding author), Childrens Natl Med Ctr, Emergency Med & Trauma Serv, 111 Michigan Ave NW, Washington, DC 20010 USA.	jroot@childrensnational.org		Kontos, Anthony/0000-0002-3749-4310; Root, Jeremy/0000-0003-2650-6889	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1TR000005]; University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders [1K01DC012332-01A1]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	Supported by the National Institutes of Health (UL1TR000005 [to L.W. and D.W.]). A.K. is supported by the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1). The authors declare no conflicts of interest.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Campo JV, 2012, J CHILD PSYCHOL PSYC, V53, P575, DOI 10.1111/j.1469-7610.2012.02535.x; CAMPO JV, 1994, J AM ACAD CHILD PSY, V33, P1223, DOI 10.1097/00004583-199411000-00003; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; ERNST AR, 1984, J PEDIATR PSYCHOL, V9, P77, DOI 10.1093/jpepsy/9.1.77; Essau C. A., 2013, FRONT PUBLIC HEALTH, V1, P1, DOI DOI 10.3389/FPUBH.2013.00072; Fearon I, 1996, PAIN, V68, P55, DOI 10.1016/S0304-3959(96)03200-9; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Janssens KAM, 2014, J PEDIATR-US, V164, P900, DOI 10.1016/j.jpeds.2013.12.003; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, IMMEDIATE POSTCONCUS; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; Mollayeva T, 2015, SLEEP MED; Postilnik I, 2006, J CAN ACAD CHILD ADO, V15, P64; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Sufrinko A, 2015, AM J SPORT MED, V43, P830, DOI 10.1177/0363546514566193; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857; Taddio A, 2009, PEDIATRICS, V123, pe425, DOI 10.1542/peds.2008-3028; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Walker L. S., 2003, MANUAL CHILDRENS SOM; WALKER LS, 1991, J ABNORM CHILD PSYCH, V19, P379, DOI 10.1007/BF00919084; Walker LS, 2009, J PEDIATR PSYCHOL, V34, P430, DOI 10.1093/jpepsy/jsn093; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Zeman J., 1991, PSYCHOL ASSESSMENT, V3, P588, DOI [10.1037/1040-3590.3.4.588, DOI 10.1037/1040-3590.3.4.588]	41	28	28	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JUL	2016	174						39	+		10.1016/j.jpeds.2016.03.020			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	DP6PX	WOS:000378620800010	27059916	Green Accepted			2022-02-06	
J	Zakharov, S; Pelclova, D; Urban, P; Navratil, T; Nurieva, O; Kotikova, K; Diblik, P; Kurcova, I; Belacek, J; Komarc, M; Eddleston, M; Hovda, KE				Zakharov, Sergey; Pelclova, Daniela; Urban, Pavel; Navratil, Tomas; Nurieva, Olga; Kotikova, Katerina; Diblik, Pavel; Kurcova, Ivana; Belacek, Jaromir; Komarc, Martin; Eddleston, Michael; Hovda, Knut Erik			Use of Out-of-Hospital Ethanol Administration to Improve Outcome in Mass Methanol Outbreaks	ANNALS OF EMERGENCY MEDICINE			English	Article							ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; FORMATE CONCENTRATIONS; ADHESIVE INTERACTIONS; CLINICAL-FEATURES; ALCOHOL; MORTALITY; POISONINGS; TOXICITY; DAMAGE	Study objective: Methanol poisoning outbreaks are a global public health issue, with delayed treatment causing poor outcomes. Out-of-hospital ethanol administration may improve outcome, but the difficulty of conducting research in outbreaks has meant that its effects have never been assessed. We study the effect of out-of-hospital ethanol in patients treated during a methanol outbreak in the Czech Republic between 2012 and 2014. Methods: This was an observational case-series study of 100 hospitalized patients with confirmed methanol poisoning. Out-of-hospital ethanol as a "first aid antidote" was administered by paramedic or medical staff before the confirmation of diagnosis to 30 patients; 70 patients did not receive out-of-hospital ethanol from the staff (12 patients self-administered ethanol shortly before presentation). Results: The state of consciousness at first contact with paramedic or medical staff, delay to admission, and serum methanol concentration were similar among groups. The median serum ethanol level on admission in the patients with out-of-hospital administration by paramedic or medical staff was 84.3 mg/dL (interquartile range 32.7 to 129.5 mg/dL). No patients with positive serum ethanol level on admission died compared with 21 with negative serum ethanol level (0% versus 36.2%). Patients receiving out-of-hospital ethanol survived without visual and central nervous system sequelae more often than those not receiving it (90.5% versus 19.0%). A positive association was present between out of-hospital ethanol administration by paramedic or medical staff, serum ethanol concentration on admission, and both total survival and survival without sequelae of poisoning. Conclusion: We found a positive association between out-of-hospital ethanol administration and improved clinical outcome. During mass methanol outbreaks, conscious adults with suspected poisoning should be considered for administration of out-of-hospital ethanol to reduce morbidity and mortality.	[Zakharov, Sergey; Pelclova, Daniela; Urban, Pavel; Navratil, Tomas; Nurieva, Olga; Kotikova, Katerina] Charles Univ Prague, Fac Med 1, Dept Occupat Med, Toxicol Informat Ctr, Prague, Czech Republic; [Kurcova, Ivana] Charles Univ Prague, Fac Med 1, Dept Toxicol & Forens Med, Prague, Czech Republic; [Belacek, Jaromir; Komarc, Martin] Charles Univ Prague, Fac Med 1, Inst Biophys & Informat, Prague, Czech Republic; [Belacek, Jaromir; Komarc, Martin] Gen Univ Hosp, Prague, Czech Republic; [Navratil, Tomas] AS CR, Dept Biomimet Electrochem, J Heyrovsky Inst Phys Chem, Prague, Czech Republic; [Diblik, Pavel] Gen Univ Hosp, Dept Ophthalmol, Prague, Czech Republic; [Eddleston, Michael] Univ Edinburgh, Univ BHF Ctr Cardiovasc Sci, Pharmacol Toxicol & Therapeut, Edinburgh, Midlothian, Scotland; [Hovda, Knut Erik] Oslo Univ Hosp, Dept Acute Med, Norwegian CBRNe Ctr Med, Oslo, Norway		Zakharov, S (corresponding author), Charles Univ Prague, Fac Med 1, Dept Occupat Med, Toxicol Informat Ctr, Prague, Czech Republic.	sergey.zakharov@vfn.cz	Kotikova, Katerina/D-7852-2017; Urban, Pavel/D-7801-2017; Komarc, Martin/A-7308-2017; Komarc, Martin/O-2575-2019; Zakharov, Sergey/O-2896-2019; Zacharov, Sergej/C-8946-2017; Belacek, Jaromir/AAI-5516-2021; Belacek, Jaromir/AAM-7404-2021; Navratil, Tomas/F-4000-2012; Zakharov, Sergey/L-8511-2014; Diblik, Pavel/I-2515-2017; Nurieva, Olga/D-7844-2017; Pelclova, Daniela/C-8885-2017; Zacharov, Sergej/C-8946-2017	Kotikova, Katerina/0000-0002-6750-6482; Urban, Pavel/0000-0002-0898-5524; Komarc, Martin/0000-0003-4106-5217; Komarc, Martin/0000-0003-4106-5217; Zakharov, Sergey/0000-0001-9864-8304; Zacharov, Sergej/0000-0003-4480-5460; Belacek, Jaromir/0000-0002-5405-9345; Belacek, Jaromir/0000-0002-5405-9345; Navratil, Tomas/0000-0003-4633-2601; Zakharov, Sergey/0000-0001-9864-8304; Diblik, Pavel/0000-0001-9025-8176; Pelclova, Daniela/0000-0002-0240-5146; Urban, Pavel/0000-0002-6869-1341; Hovda, Knut Erik/0000-0001-6341-8699; Zacharov, Sergej/0000-0003-0280-9236; Kotikova, Katerina/0000-0002-6546-3730; Nurieva, Olga/0000-0001-8105-5895	Charles University in Prague [P25/1LF/2, P28/1LF/6]; Ministry of Health of the Czech RepublicMinistry of Health, Czech Republic [9/15/NAP]	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the following details: This study was supported by the Projects of the Charles University in Prague P25/1LF/2 and P28/1LF/6, and the Project of the Ministry of Health of the Czech Republic 9/15/NAP.	Ahmad K, 2000, LANCET, V356, P1911, DOI 10.1016/S0140-6736(05)73469-3; Barceloux DG, 2002, J TOXICOL-CLIN TOXIC, V40, P415; BENNETT IL, 1953, MEDICINE, V32, P431, DOI 10.1097/00005792-195312000-00002; BERGERON R, 1982, NEW ENGL J MED, V307, P1528; Bezdicek O, 2014, CESK SLOV NEUROL N, V77, P320; Blondell RD, 2002, J STUD ALCOHOL, V63, P380, DOI 10.15288/jsa.2002.63.380; Brent J, 2001, NEW ENGL J MED, V344, P424, DOI 10.1056/NEJM200102083440605; Chen CH, 2008, SCIENCE, V321, P1493, DOI 10.1126/science.1158554; Churchill EN, 2009, J MOL CELL CARDIOL, V46, P278, DOI 10.1016/j.yjmcc.2008.09.713; Collins MA, 2009, ALCOHOL CLIN EXP RES, V33, P206, DOI 10.1111/j.1530-0277.2008.00828.x; Eltzschig HK, 2004, BRIT MED BULL, V70, P71, DOI 10.1093/bmb/ldh025; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman LS, 2012, ALCOHOL, V46, P769, DOI 10.1016/j.alcohol.2012.08.006; Hantson P, 2002, Eur J Emerg Med, V9, P278, DOI 10.1097/00063110-200209000-00015; Hovda KE, 2005, J INTERN MED, V258, P181, DOI 10.1111/j.1365-2796.2005.01521.x; Hovda KE, 2004, INTENS CARE MED, V30, P1842, DOI 10.1007/s00134-004-2373-7; JACOBSEN D, 1982, ACTA MED SCAND, V212, P5; JACOBSEN D, 1986, MED TOXICOL ADV DRUG, V1, P309, DOI 10.1007/BF03259846; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kumar S S, 2003, J Assoc Physicians India, V51, P425; LIESIVUORI J, 1991, PHARMACOL TOXICOL, V69, P157, DOI 10.1111/j.1600-0773.1991.tb01290.x; Louboutin JP, 2012, ALCOHOL, V46, P441, DOI 10.1016/j.alcohol.2012.02.001; Megarbane B, 2005, INTENS CARE MED, V31, P189, DOI 10.1007/s00134-004-2521-0; Megarbane B, 2010, OPEN ACCESS EMERG M, V2, P67, DOI 10.2147/OAEM.S5346; Miyamae M, 1998, AM J PHYSIOL-HEART C, V275, pH50, DOI 10.1152/ajpheart.1998.275.1.H50; Miyamae M, 1997, P NATL ACAD SCI USA, V94, P3235, DOI 10.1073/pnas.94.7.3235; Nurieva O, 2016, MONATSH CHEM, V147, P239; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; OSTERLOH JD, 1986, ANN INTERN MED, V104, P200, DOI 10.7326/0003-4819-104-2-200; Paasma R, 2007, CLIN TOXICOL, V45, P152, DOI 10.1080/15563650600956329; Pagel PS, 2002, ANESTH ANALG, V94, P841, DOI 10.1097/00000539-200204000-00012; Roberts DM, 2015, CRIT CARE MED, V43, P461, DOI 10.1097/CCM.0000000000000708; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; SEJERSTED OM, 1983, ACTA MED SCAND, V213, P105; Stehman CR, 2015, J CRIT CARE, V30, P1382, DOI 10.1016/j.jcrc.2015.08.023; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Wang Q, 2007, FREE RADICAL BIO MED, V43, P1048, DOI 10.1016/j.freeradbiomed.2007.06.018; Wang Q, 2010, MICROCIRCULATION, V17, P427, DOI 10.1111/j.1549-8719.2010.00041.x; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Yaghoubian A, 2009, AM SURGEON, V75, P950; Yamaguchi T, 2003, FREE RADICAL BIO MED, V34, P365, DOI 10.1016/S0891-5849(02)01292-3; Yamaguchi T, 2002, AM J PHYSIOL-HEART C, V283, pH1019, DOI 10.1152/ajpheart.00173.2002; Yuan Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025811; Zakharov S, 2016, MONATSH CHEM, V147, P251, DOI 10.1007/s00706-015-1581-x; Zakharov S, 2015, BIOMED PAP, V159, P666, DOI 10.5507/bp.2015.008; Zakharov S, 2015, CLIN TOXICOL, V53, P884, DOI 10.3109/15563650.2015.1086488; Zakharov S, 2015, CLIN TOXICOL, V53, P797, DOI 10.3109/15563650.2015.1059946; Zakharov S, 2015, MONATSH CHEM, V146, P787, DOI 10.1007/s00706-014-1374-7; Zakharov S, 2015, BASIC CLIN PHARMACOL, V116, P445, DOI 10.1111/bcpt.12338; Zakharov S, 2014, BIOMED PAP, V158, P641, DOI 10.5507/bp.2014.056; Zakharov S, 2014, CLIN TOXICOL, V52, P1013, DOI 10.3109/15563650.2014.974106; Zakharov S, 2014, J APPL BIOMED, V12, P309, DOI 10.1016/j.jab.2014.04.001; Zakharov S, 2014, KIDNEY INT, V86, P199, DOI 10.1038/ki.2014.60; Zhang G., 2012, APPL INCLUDE FOMEPIZ	54	28	28	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUL	2016	68	1					52	61		10.1016/j.annemergmed.2016.01.010			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	DQ1SF	WOS:000378980000012	26875060	Green Submitted			2022-02-06	
J	Xu, JL; Ypma, M; Chiarelli, PA; Park, J; Ellenbogen, RG; Stayton, PS; Mourad, PD; Lee, D; Convertine, AJ; Kievit, FM				Xu, Julia; Ypma, Menko; Chiarelli, Peter A.; Park, Joshua; Ellenbogen, Richard G.; Stayton, Patrick S.; Mourad, Pierre D.; Lee, Donghoon; Convertine, Anthony J.; Kievit, Forrest M.			Theranostic Oxygen Reactive Polymers for Treatment of Traumatic Brain Injury	ADVANCED FUNCTIONAL MATERIALS			English	Article							RADICAL POLYMERIZATION; SUPEROXIDE-DISMUTASE; TARGETED DELIVERY; OXIDATIVE STRESS; HUMAN NEURONS; NANOPARTICLES; PROGESTERONE; ACID; NANOTHERANOSTICS; PEROXIDATION	Traumatic brain injury (TBI) is the leading cause of disability and death in children and adults under 45, with approximately ten million new cases per year worldwide. Significant progress has been made in understanding the complex pathophysiological response to TBI; however, reducing the damage associated with the reactive oxygen species (ROS)-dependent secondary phase of the injury remains a substantial challenge. The development of an image-guided, Gd-conjugated, oxygen reactive polymer (ORP) to reduce ROS levels in damaged brain tissue is reported. ORP effectively sequesters ROS while remaining biocompatible even at elevated concentrations. ORP is retained in damaged brains of controlled cortical impact (CCI) mouse models of TBI for over 24 h when injected intravenously immediately and up to 3 h post-CCI. The polymer reduces neurodegeneration tenfold and gliosis twofold in these mouse models. ORP shows initial promise as an effective therapy for TBI and helps provide a better understanding of nanomaterial interaction with damaged brain.	[Xu, Julia] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA; [Ypma, Menko; Stayton, Patrick S.; Convertine, Anthony J.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Chiarelli, Peter A.; Ellenbogen, Richard G.; Mourad, Pierre D.; Kievit, Forrest M.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Park, Joshua; Lee, Donghoon] Univ Washington, Dept Radiol, Seattle, WA 98109 USA; [Stayton, Patrick S.; Convertine, Anthony J.] Univ Washington, Dept Mol Engn, Seattle, WA 98195 USA; [Mourad, Pierre D.] Univ Washington, Div Engn & Math, Bothell, WA 98011 USA		Convertine, AJ (corresponding author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.; Kievit, FM (corresponding author), Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.; Convertine, AJ (corresponding author), Univ Washington, Dept Mol Engn, Seattle, WA 98195 USA.	aconv@uw.edu; fmkemt@neurosurgery.washington.edu	Stayton, Patrick/C-1975-2018	Stayton, Patrick/0000-0001-6939-6371			Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Astete CE, 2011, ACS NANO, V5, P9313, DOI 10.1021/nn102845t; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Berguig GY, 2015, MOL THER, V23, P907, DOI 10.1038/mt.2015.22; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Boyd BJ, 2015, J DRUG TARGET, V23, P847, DOI 10.3109/1061186X.2015.1034280; Boyer C, 2009, CHEM REV, V109, P5402, DOI 10.1021/cr9001403; Chen YC, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00100; Chu DSH, 2012, ACCOUNTS CHEM RES, V45, P1089, DOI 10.1021/ar200242z; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Clond MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061819; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cruz LJ, 2016, J CONTROL RELEASE, V223, P31, DOI 10.1016/j.jconrel.2015.12.029; Driessen MD, 2015, PART FIBRE TOXICOL, V12, DOI 10.1186/s12989-015-0108-2; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kievit FM, 2011, ADV MATER, V23, pH217, DOI 10.1002/adma.201102313; Lane DD, 2015, POLYM CHEM-UK, V6, P1286, DOI 10.1039/c4py01250j; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Miyamoto K, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/379206; Moad G, 2012, AUST J CHEM, V65, P985, DOI 10.1071/CH12295; Muthu MS, 2014, THERANOSTICS, V4, P660, DOI 10.7150/thno.8698; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1; Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Roy D, 2014, POLYM CHEM-UK, V5, P1791, DOI 10.1039/c3py01404e; Singhal A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.362; Spizzirri UG, 2009, BIOMACROMOLECULES, V10, P1923, DOI 10.1021/bm900325t; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Wan AJ, 2013, J AGR FOOD CHEM, V61, P6921, DOI 10.1021/jf402242e; Wei J, 2013, ACTA PHARMACOL SIN, V34, P1485, DOI 10.1038/aps.2013.160; Xie J, 2010, ADV DRUG DELIVER REV, V62, P1064, DOI 10.1016/j.addr.2010.07.009	41	28	28	8	62	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1616-301X	1616-3028		ADV FUNCT MATER	Adv. Funct. Mater.	JUN 20	2016	26	23					4124	4133		10.1002/adfm.201504416			10	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	DR2JT	WOS:000379731500009					2022-02-06	
J	Feng, Y; Cui, Y; Gao, JL; Li, R; Jiang, XH; Tian, YX; Wang, KJ; Li, MH; Zhang, HA; Cui, JZ				Feng, Yan; Cui, Ying; Gao, Jun-Ling; Li, Ran; Jiang, Xiao-Hua; Tian, Yan-Xia; Wang, Kai-Jie; Li, Ming-Hang; Zhang, Hong-Ao; Cui, Jian-Zhong			Neuroprotective effects of resveratrol against traumatic brain injury in rats: Involvement of synaptic proteins and neuronal autophagy	MOLECULAR MEDICINE REPORTS			English	Article						neuroprotective; resveratrol; traumatic brain injury; synaptic proteins; autophagy	CONTROLLED CORTICAL IMPACT; CELL-DEATH; MODEL; MICE; PATHOPHYSIOLOGY; SYNAPTOGENESIS; HEMORRHAGE; EXPRESSION; APOPTOSIS; PROTECTS	Traumatic brain injury (TBI) involves primary and secondary injury cascades that underlie delayed neuronal dysfunction and death, leading to long-term cognitive deficits, and effective therapeutic strategies targeting neuronal death remain elusive. The present study aimed to determine whether the administration of resveratrol (100 mg/kg) was able to significantly enhance functional recovery in a rat model of TBI and whether resveratrol treatment was able to upregulate synaptic protein expression and suppress post-TBI neuronal autophagy. The results demonstrated that daily treatment with resveratrol attenuated TBI-induced brain edema and improved spatial cognitive function and neurological impairment in rats. The expression of synaptic proteins was downregulated following TBI and this phenomenon was partly reversed by treatment with resveratrol. In addition, resveratrol was observed to significantly reduce the levels of the autophagic marker proteins, microtubule-associated protein light chain 3-II and Beclin1, in the hippocampus compared with the TBI group. Therefore, these results suggest that resveratrol may represent a novel therapeutic strategy for TBI, and that this protection may be associated with the upregulation of synaptophysin, postsynaptic density protein 95 and the suppression of neuronal autophagy.	[Feng, Yan] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China; [Cui, Ying; Wang, Kai-Jie; Cui, Jian-Zhong] Tangshan Workers Hosp, Dept Neurosurg, 27 Wen Hua Rd, Tangshan 063000, Hebei, Peoples R China; [Gao, Jun-Ling; Li, Ran; Jiang, Xiao-Hua; Tian, Yan-Xia; Li, Ming-Hang; Zhang, Hong-Ao] North China Univ Sci & Technol, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Gao, Jun-Ling; Li, Ran; Jiang, Xiao-Hua; Tian, Yan-Xia] North China Univ Sci & Technol, Tangshan Key Lab Preclin & Basic Res Chron Dis, Hebei Key Lab Chron Dis, Tangshan 063000, Hebei, Peoples R China		Cui, JZ (corresponding author), Tangshan Workers Hosp, Dept Neurosurg, 27 Wen Hua Rd, Tangshan 063000, Hebei, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (grant no. H2014105079).	Alayev A, 2014, CELL CYCLE, V13, P371, DOI 10.4161/cc.27355; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; BROCK TO, 1987, J NEUROSCI, V7, P931; Bursch W, 2000, J CELL SCI, V113, P1189; Chen P, 2007, MOL PHARMACOL, V72, P40, DOI 10.1124/mol.107.034942; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cordaro M, 2015, J NEUROTRAUMA; Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Delmas D, 2005, MOL NUTR FOOD RES, V49, P377, DOI 10.1002/mnfr.200400098; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Jing CH, 2012, NEUROSCIENCE, V213, P144, DOI 10.1016/j.neuroscience.2012.03.055; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Liu CJ, 2011, BRAIN RES, V1374, P100, DOI 10.1016/j.brainres.2010.11.061; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meng HD, 2006, BRAIN RES, V1124, P197, DOI 10.1016/j.brainres.2006.09.086; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Sakata Y, 2010, EXP NEUROL, V224, P325, DOI 10.1016/j.expneurol.2010.03.032; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Semchenko V V, 2006, Neurosci Behav Physiol, V36, P613, DOI 10.1007/s11055-006-0065-1; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6	37	28	30	0	10	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	JUN	2016	13	6					5248	5254		10.3892/mmr.2016.5201			7	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	DO7UR	WOS:000377989000096	27122047	Bronze			2022-02-06	
J	Giannoudi, M; Harwood, P				Giannoudi, M.; Harwood, P.			Damage control resuscitation: lessons learned	EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY			English	Article						Polytrauma; Damage control surgery; Severe haemorrhage; Resuscitation	ACUTE TRAUMATIC COAGULOPATHY; ENDOVASCULAR BALLOON OCCLUSION; HEMOSTATIC RESUSCITATION; PERMISSIVE HYPOTENSION; MASSIVE TRANSFUSION; FLUID RESUSCITATION; PELVIC TRAUMA; BRAIN-INJURY; HEMORRHAGE; HYPOTHERMIA	Background Damage control resuscitation describes an approach to the early care of very seriously injured patients. The aim is to keep the patient alive whilst avoiding interventions and situations that risk worsening their situation by driving the lethal triad of hypothermia, coagulopathy and acidosis or excessively stimulating the immune-inflammatory system. It is critical that the concepts and practicalities of this approach are understood by all those involved in the early management of trauma patients. This review aims to summarise this and discusses current knowledge on the subject. Interventions Damage control resuscitation forms part of an overall approach to patient care rather than a specific intervention and has evolved from damage control surgery. It is characterised by early blood product administration, haemorrhage arrest and restoration of blood volume aiming to rapidly restore physiologic stability. The infusion of large volumes of crystalloid is no longer appropriate, instead the aim is to replace lost blood and avoid dilution and coagulopathy. In specific situations, permissive hypotension may also be of benefit, particularly in patients with severe haemorrhage from an arterial source. As rapid arrest of haemorrhage is so important, team-based protocols that deliver patients rapidly but safely, via CT scan where appropriate, to operating theatres or interventional radiology suites form a critical part of this process. Conclusions Given that interventions are so time dependent in the severely injured, it is likely that by further improving trauma systems and protocols, improvements in outcome can still be made. Further research work in this area will allow us to target these approaches more accurately to those patients who can benefit most.	[Giannoudi, M.; Harwood, P.] Leeds Gen Infirm, Clarendon Wing,Level A,Great George St, Leeds LS1 3EX, W Yorkshire, England		Harwood, P (corresponding author), Leeds Gen Infirm, Clarendon Wing,Level A,Great George St, Leeds LS1 3EX, W Yorkshire, England.	pauljharwood@me.com	Harwood, Paul/I-2360-2019	Harwood, Paul/0000-0003-4564-4689			Bailey AM, 2014, ADV EMERG NURS J, V36, P123, DOI 10.1097/TME.0000000000000018; Ball CG, 2014, CAN J SURG, V57, P55, DOI 10.1503/cjs.020312; Beekley AC, 2008, CRIT CARE MED, V36, pS267, DOI 10.1097/CCM.0b013e31817da7dc; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Brenner ML, 2013, J TRAUMA ACUTE CARE, V75, P506, DOI 10.1097/TA.0b013e31829e5416; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Chesser TJS, 2012, INJURY, V43, P667, DOI 10.1016/j.injury.2012.04.003; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Cohen MJ, 2011, J TRAUMA, V70, pS47, DOI 10.1097/TA.0b013e31821a5c24; Davenport R, 2013, TRANSFUSION, V53, p23S, DOI 10.1111/trf.12032; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Dutton RP, 2012, BRIT J ANAESTH, V109, pI39, DOI 10.1093/bja/aes389; Feinman M, 2014, CURR OPIN CRIT CARE, V20, P366, DOI 10.1097/MCC.0000000000000104; Fox Charles J, 2011, Perspect Vasc Surg Endovasc Ther, V23, P112, DOI 10.1177/1531003511400627; Gantner D, 2014, CURR OPIN CRIT CARE, V20, P385, DOI 10.1097/MCC.0000000000000114; Geeraedts LMG, 2009, INJURY, V40, P11, DOI 10.1016/j.injury.2008.10.007; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Giannoudis PV, 2006, INJURY, V37, pS3, DOI 10.1016/S0020-1383(07)70005-0; Giannoudis PV, 2009, INJURY, V40, pS47, DOI 10.1016/j.injury.2009.10.036; Giannoudis PV, 2003, J BONE JOINT SURG BR, V85B, P478, DOI 10.1302/0301-620X.85B4.14217; Hamilton H, 2014, J CARDIOVASC SURG, V55, P151; Hildebrand F, 2009, UNFALLCHIRURG, V112, P959, DOI 10.1007/s00113-009-1683-1; HIRSHBERG A, 1994, J TRAUMA, V37, P365, DOI 10.1097/00005373-199409000-00005; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Hsu Jeremy M, 2011, Int J Crit Illn Inj Sci, V1, P66, DOI 10.4103/2229-5151.79285; Jansen JO, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1778; Kaafarani HMA, 2014, SCAND J SURG, V103, P81, DOI 10.1177/1457496914524388; Khan S, 2014, J TRAUMA ACUTE CARE, V76, P561, DOI 10.1097/TA.0000000000000146; Kim Y, 2014, J KOREAN MED SCI, V29, P1007, DOI 10.3346/jkms.2014.29.7.1007; Kobbe P, 2009, UNFALLCHIRURG, V112, P1055, DOI 10.1007/s00113-009-1711-1; Kornblith LZ, 2014, J TRAUMA ACUTE CARE, V77, P818, DOI 10.1097/TA.0000000000000354; Kragh JF, 2011, J EMERG MED, V41, P590, DOI 10.1016/j.jemermed.2009.07.022; Lamb CM, 2014, BRIT J ANAESTH, V113, P242, DOI 10.1093/bja/aeu233; Langan NR, 2014, JAMA SURG, V149, P904, DOI 10.1001/jamasurg.2014.940; Lasanianos NG, 2011, INJURY, V42, P617, DOI 10.1016/j.injury.2011.02.011; Lasanianos NG, 2010, CLIN ORTHOP RELAT R, V468, P2514, DOI 10.1007/s11999-009-1191-1; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; McDaniel LM, 2014, TRANSFUSION MED, V24, P138, DOI 10.1111/tme.12125; Mitra B, 2014, SHOCK, V42, P307, DOI 10.1097/SHK.0000000000000219; Mizushima Y, 2000, ARCH SURG-CHICAGO, V135, P175, DOI 10.1001/archsurg.135.2.175; Pape Hans-Christoph, 2005, J Orthop Trauma, V19, P551, DOI 10.1097/01.bot.0000161712.87129.80; Perel P, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001664; Roberts Craig S, 2005, Instr Course Lect, V54, P447; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Scharbert G, 2010, PLATELETS, V21, P44, DOI 10.3109/09537100903420269; Schmidt BM, 2012, WORLD J EMERG SURG, V7, DOI 10.1186/1749-7922-7-S1-S9; Schwartz DA, 2014, J TRAUMA ACUTE CARE, V76, P134, DOI 10.1097/TA.0b013e3182ab0cfc; Shapiro MB, 2000, J TRAUMA, V49, P969, DOI 10.1097/00005373-200011000-00033; Smith A, 2013, CAN J SURG, V56, pE154, DOI 10.1503/cjs.020012; Spahn DR, 2010, BRIT J ANAESTH, V105, P103, DOI 10.1093/bja/aeq166; Spinella PC, 2014, SHOCK, V41, P1, DOI 10.1097/SHK.0000000000000059; Stannard A, 2011, J TRAUMA, V71, P1869, DOI 10.1097/TA.0b013e31823fe90c; Taylor DM, 2013, MIL MED, V178, P1196, DOI 10.7205/MILMED-D-13-00223; Tobin JM, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2013.11.017; Tosounidis TI, 2013, SURG-J R COLL SURG E, V11, P344, DOI 10.1016/j.surge.2013.07.004; Zipfel B, 2014, ANN THORAC SURG, V97, P774, DOI 10.1016/j.athoracsur.2013.09.034	56	28	32	0	5	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-9933	1863-9941		EUR J TRAUMA EMERG S	Eur. J. Trauma Emerg. Surg.	JUN	2016	42	3					273	282		10.1007/s00068-015-0628-3			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	DS3SR	WOS:000380703500002	26847110	hybrid, Green Published			2022-02-06	
J	Nezhadi, A; Sheibani, V; Esmaeilpour, K; Shabani, M; Esmaeili-Mahani, S				Nezhadi, Akram; Sheibani, Vahid; Esmaeilpour, Khadijeh; Shabani, Mohammad; Esmaeili-Mahani, Saeed			Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson's disease	BEHAVIOURAL BRAIN RESEARCH			English	Article						Parkinson's disease; Allopregnanolone; 6-OHDA; Cognitive behaviors; Learning and memory	TRAUMATIC BRAIN-INJURY; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; FUNCTIONAL DEFICITS; GENE-EXPRESSION; DORSAL STRIATUM; MESSENGER-RNA; WATER MAZE; PROGESTERONE; BDNF	Cognitive deficits have an extensive influence on the quality of life of the Parkinson's disease (PD) patients. Previous studies have shown that lack of steroid hormones have an important role in the development of PD. Therefore, in this study the effects of neurosteroid allopregnanolone (Allo) on the PD-induced cognitive disorders were assessed. To simulate PD, 6-hydroxydopamine (6-OHDA) was injected into the rat's substantia nigra. Alio (5 and 20 mg/kg, orally) were administered on the day after the 6-OHDA injection and continued during the entire treatment period (two months). Cognitive behaviors were assessed by Moris water maze (MWM), novel object recognition (NOR) and object location tasks. The data indicated that Allo significantly improved the 6-OHDA-induced cognitive impairment which revealed by the reduction of time spent to find out platform (escape latency) and the increase of retention time in MWM test and also with increase in the exploration index in NOR and object location tasks. Present study strongly supports the pro-cognitive property of allopregnanolone in PD. (c) 2016 Elsevier B.V. All rights reserved.	[Nezhadi, Akram; Sheibani, Vahid; Esmaeilpour, Khadijeh; Shabani, Mohammad; Esmaeili-Mahani, Saeed] Kerman Univ Med Sci, Inst Neuropharmacol, Kerman Neurosci Res Ctr, Lab Mol Neurosci, Kerman, Iran; [Esmaeili-Mahani, Saeed] Shahid Bahonar Univ Kerman, Fac Sci, Dept Biol, POB 76135-133, Kerman, Iran		Esmaeili-Mahani, S (corresponding author), Shahid Bahonar Univ Kerman, Fac Sci, Dept Biol, POB 76135-133, Kerman, Iran.	semahani@yahoo.com	Shabani, Mohammad/AAZ-3682-2020; sheibani, vahid/ABB-5259-2020	Shabani, Mohammad/0000-0002-2082-5849; sheibani, vahid/0000-0003-4321-6103; Esmaeilpour, Khadije/0000-0002-5349-9285; Nezhadi, Akram/0000-0002-3821-9441; Esmaeili Mahani, Saeed/0000-0001-5550-9806	Kerman Neuroscience Research Center, Kerman University of Medical Sciences [93/37]	This work was supported by funds from Kerman Neuroscience Research Center (#93/37), Kerman University of Medical Sciences. The authors would like to thank the editor and two anonymous reviewers for their critical comments on an earlier version of this manuscript.	Adeosun SO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050040; Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; Arancibia S, 2008, NEUROBIOL DIS, V31, P316, DOI 10.1016/j.nbd.2008.05.012; Baulieu E., 2001, NEUROSTEROIDS BRAIN; Calabresi P, 2000, TRENDS NEUROSCI, V23, pS57, DOI 10.1016/S1471-1931(00)00017-3; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Carlini V.P., 2011, OBJECT RECOGNITION, DOI [10.5772/613, DOI 10.5772/613]; Chao OY, 2011, NEUROSCIENCE, V196, P228, DOI 10.1016/j.neuroscience.2011.08.043; Chao Y.-H., 2013, INVESTIGATION ALTERN; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; Cools R, 2002, BRAIN, V125, P584, DOI 10.1093/brain/awf052; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Da Cunha C, 2002, CELL MOL NEUROBIOL, V22, P227, DOI 10.1023/A:1020736131907; Dagher A, 2001, BRAIN, V124, P1020, DOI 10.1093/brain/124.5.1020; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; De Psychophysiologie L., 1988, BRAIN RES, V31, P47; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Duvoisin R.C., 2016, ADV NEUROL, V60, P306; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Findley L, 2003, MOVEMENT DISORD, V18, P1139, DOI 10.1002/mds.10507; Franklin TB, 2006, PSYCHONEUROENDOCRINO, V31, P38, DOI 10.1016/j.psyneuen.2005.05.008; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Frye CA, 2010, PHYSIOL BEHAV, V99, P218, DOI 10.1016/j.physbeh.2009.09.006; Fukui K., 2006, ANN NY ACAD SCI, V959, P275; Gibbs RB, 1999, BRAIN RES, V844, P20, DOI 10.1016/S0006-8993(99)01880-6; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grobin AC, 2006, NEUROSCIENCE, V138, P809, DOI 10.1016/j.neuroscience.2005.12.026; Haik KL, 2008, EXP CLIN PSYCHOPHARM, V16, P178, DOI 10.1037/1064-1297.16.2.178; Hajali V, 2015, NEUROBIOL LEARN MEM, V123, P140, DOI 10.1016/j.nlm.2015.05.008; HANSEN S, 1991, PHARMACOL BIOCHEM BE, V39, P71, DOI 10.1016/0091-3057(91)90399-M; Hritcu L, 2014, PROG NEURO-PSYCHOPH, V51, P126, DOI 10.1016/j.pnpbp.2014.01.016; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Janvin CC, 2007, COGNITIVE IMPAIRMENT; Klein RL, 1999, BRAIN RES, V847, P314, DOI 10.1016/S0006-8993(99)02116-2; LENNARD SN, 1995, MOL REPROD DEV, V42, P131, DOI 10.1002/mrd.1080420202; LENNARD SN, 1995, J REPROD FERTIL, V103, P169, DOI 10.1530/jrf.0.1030169; Lindenbach D, 2015, NEUROSCIENCE, V310, P12, DOI 10.1016/j.neuroscience.2015.09.018; Luchetti S, 2010, BRAIN PATHOL, V20, P945, DOI 10.1111/j.1750-3639.2010.00396.x; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Menza M, 2009, MOVEMENT DISORD, V24, P1325, DOI 10.1002/mds.22586; Nezhadi Akram, 2011, Pathophysiology, V18, P317, DOI 10.1016/j.pathophys.2011.05.004; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Ryan L, 2010, HIPPOCAMPUS, V20, P11, DOI 10.1002/hipo.20607; RYBICKI BA, 1993, MOVEMENT DISORD, V8, P87, DOI 10.1002/mds.870080116; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SHULTS CW, 1995, NEUROREPORT, V6, P1109, DOI 10.1097/00001756-199505300-00009; Singh C, 2012, NEUROBIOL AGING, V33, P1493, DOI 10.1016/j.neurobiolaging.2011.06.008; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Sriraksa N, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/823206; Sun CY, 2012, CURR ALZHEIMER RES, V9, P473, DOI 10.2174/156720512800492567; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; TANDBERG E, 1995, MOVEMENT DISORD, V10, P541, DOI 10.1002/mds.870100503; van den Pol AN, 2004, NAT NEUROSCI, V7, P7, DOI 10.1038/nn0104-7; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Weintraub D, 2004, J AM GERIATR SOC, V52, P784, DOI 10.1111/j.1532-5415.2004.52219.x; Wooten GF, 2004, J NEUROL NEUROSUR PS, V75, P637, DOI 10.1136/jnnp.2003.020982	59	28	28	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAY 15	2016	305						258	264		10.1016/j.bbr.2016.03.019			7	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	DK0OZ	WOS:000374613400032	26970579				2022-02-06	
J	Anderson, BL; Gittelman, MA; Mann, JK; Cyriac, RL; Pomerantz, WJ				Anderson, Brit L.; Gittelman, Michael A.; Mann, Jessica K.; Cyriac, RoseAnn L.; Pomerantz, Wendy J.			High School Football Players' Knowledge and Attitudes About Concussions	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; athletes; knowledge; attitudes	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORT HELD; ZURICH	Objectives: To assess high school (HS) football players' knowledge of concussions and to determine whether increased knowledge is correlated with better attitudes toward reporting concussion symptoms and abstaining from play. Design: Two survey tools were used to assess athletes' knowledge and attitudes about concussions. Surveys collected information about demographics, knowledge about concussions, and attitudes about playing sports after a concussion. All athletes present completed one of the 2 surveys. A knowledge and attitude score for each survey was calculated. Frequencies and mean values were used to characterize the population; regression analysis, analysis of variance, and t tests were used to look for associations. Setting: A football camp for HS athletes in the Cincinnati area. Participants: Male HS football players from competitive football programs in the Cincinnati area. Intervention: None. Main Outcome Measure: Scores on knowledge and attitude sections; responses to individual questions. Results: One hundred twenty (100%) athletes were enrolled although not every athlete responded to every question. Thirty (25%) reported history of a concussion; 82 (70%) reported receiving prior concussion education. More than 75% correctly recognized all concussion symptoms that were asked, except "feeling in a fog" [n = 63 (53%)]. One hundred nine (92%) recognized a risk of serious injury if they return to play too quickly. Sixty-four (54%) athletes would report symptoms of a concussion to their coach; 62 (53%) would continue to play with a headache from an injury. There was no association between knowledge score and attitude score (P = 0.08). Conclusions: Despite having knowledge about the symptoms and danger of concussions, many HS football athletes in our sample did not have a positive attitude toward reporting symptoms or abstaining from play after a concussion. Clinical Relevance: Physicians should be aware that young athletes may not report concussion symptoms.	[Anderson, Brit L.; Gittelman, Michael A.; Cyriac, RoseAnn L.; Pomerantz, Wendy J.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Gittelman, Michael A.; Mann, Jessica K.; Pomerantz, Wendy J.] Cincinnati Childrens Hosp Med Ctr, Comprehens Childrens Injury Ctr, Cincinnati, OH 45229 USA; [Mann, Jessica K.] Univ Cincinnati, Phys Orthopaed & Sports Med, Cincinnati, OH USA		Anderson, BL (corresponding author), Kosair Childrens Hosp, Div Emergency Med, 231 E Chestnut St, Louisville, KY 40202 USA.	brit.anderson@louisville.edu			Ohio Department of Public Safety Division of EMS; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER	Supported by a grant from the Ohio Department of Public Safety Division of EMS.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Centers for Disease Control National Center for Injury Prevention and Control, 2013, HEADS CONC HIGH SCH; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; McCrea HJ, 2013, SPORTS HEALTH, V5, P160, DOI 10.1177/1941738112462203; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	17	28	28	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2016	26	3					206	209		10.1097/JSM.0000000000000214			4	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	DL4KX	WOS:000375605800008	26035681				2022-02-06	
J	Bryant, RA; McFarlane, AC; Silove, D; O'Donnell, ML; Forbes, D; Creamer, M				Bryant, Richard A.; McFarlane, Alexander C.; Silove, Derrick; O'Donnell, Meaghan L.; Forbes, David; Creamer, Mark			The Lingering Impact of Resolved PTSD on Subsequent Functioning	CLINICAL PSYCHOLOGICAL SCIENCE			English	Article						posttraumatic stress disorder; trauma; life satisfaction	POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; TRAUMATIC-BRAIN-INJURY; MALE VIETNAM VETERANS; RISK-FACTORS; SYMPTOMS; METAANALYSIS; MILITARY; HEALTH; ADULTS	This study investigated whether impairment persists after posttraumatic stress disorder (PTSD) has resolved. Traumatically injured patients (N = 1,035) were assessed during hospital admission and at 3 (85%) and 12 months (73%). Quality of life prior to traumatic injury was measured with the World Health Organization Quality of Life-BREF during hospitalization and at each subsequent assessment. PTSD was assessed using the Clinician-Administered PTSD Scale at 3 and 12 months. After controlling for preinjury functioning, current pain, and comorbid depression, patients whose PTSD symptoms had resolved by 12 months were more likely to have poorer quality of life in psychological (OR = 3.51), physical (OR = 10.17), social (OR = 4.54), and environmental (OR = 8.83) domains than those who never developed PTSD. These data provide initial evidence that PTSD can result in lingering effects on functional capacity even after remission of symptoms.	[Bryant, Richard A.] Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Bryant, Richard A.] Westmead Millennium Inst, Brain Dynam Ctr, Westmead, NSW, Australia; [McFarlane, Alexander C.] Univ Adelaide, Ctr Mil & Vet Hlth, Adelaide, SA, Australia; [Silove, Derrick] Univ New South Wales, Sch Psychiat, Sydney, NSW, Australia; [O'Donnell, Meaghan L.; Forbes, David; Creamer, Mark] Univ Melbourne, Dept Psychiat, Ctr Posttraumat Mental Hlth, Phoenix Australia, Melbourne, Vic, Australia		Bryant, RA (corresponding author), Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [568970]; Victorian Trauma Foundation [V-11]; National Health and Medical Research Council Australian Clinical Research FellowshipNational Health and Medical Research Council of Australia [359284]	This research was supported by National Health and Medical Research Council Program Grant 568970, Victorian Trauma Foundation Grant #V-11, and National Health and Medical Research Council Australian Clinical Research Fellowship 359284. The study sponsors had no role in the design or conduct of the study, or in the collection, analysis, or interpretation of the data. R.A.B. had full access to all the data and had final responsibility for the decision to submit for publication.	Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bolton D, 2004, J CHILD PSYCHOL PSYC, V45, P1007, DOI 10.1111/j.1469-7610.2004.t01-1-00292.x; Breslau N, 1998, REV PSYCHIAT SER, V17, P1; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2007, J ABNORM PSYCHOL, V116, P837, DOI 10.1037/0021-843X.116.4.837; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Connell MJO, 2008, PSYCHIAT SERV, V59, P268, DOI 10.1176/appi.ps.59.3.268; Cornelis MC, 2010, CURR PSYCHIAT REP, V12, P313, DOI 10.1007/s11920-010-0126-6; Cotella EM, 2013, STRESS, V16, P477, DOI 10.3109/10253890.2013.775241; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Foa EB, 2009, EFFECTIVE TREATMENTS, V2nd; Gadermann AM, 2012, DEPRESS ANXIETY, V29, P797, DOI 10.1002/da.21924; Gladis MM, 1999, J CONSULT CLIN PSYCH, V67, P320, DOI 10.1037/0022-006X.67.3.320; Guthrie RM, 2006, PSYCHOSOM MED, V68, P307, DOI 10.1097/01.psy.0000208629.67653.cc; Hawthorne G, 2006, SOC INDIC RES, V77, P37, DOI 10.1007/s11205-005-5552-1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; LeardMann CA, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1273; Li B, 2011, AM J EPIDEMIOL, V174, P761, DOI 10.1093/aje/kwr154; Lunney CA, 2007, J TRAUMA STRESS, V20, P955, DOI 10.1002/jts.20269; Mikulincer M., J SOCIAL CLIN PSYCHO; Morina N, 2014, CLIN PSYCHOL REV, V34, P249, DOI 10.1016/j.cpr.2014.03.002; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; Rona RJ, 2009, J PSYCHIATR RES, V43, P649, DOI 10.1016/j.jpsychires.2008.09.006; Samper RE, 2004, J TRAUMA STRESS, V17, P311, DOI 10.1023/B:JOTS.0000038479.30903.ed; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Schnurr PP, 2006, J CONSULT CLIN PSYCH, V74, P707, DOI 10.1037/0022-006X.74.4.707; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Stein MB, 2002, INT J METH PSYCH RES, V11, P143, DOI 10.1002/mpr.132; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; WHOQoL Group, 1996, WHOQOL BREF INTR ADM; Yehuda R, 2003, PSYCHIAT ANN, V33, P30, DOI 10.3928/0048-5713-20030101-06; Yehuda R, 2007, PROG BRAIN RES, V167, P121, DOI 10.1016/S0079-6123(07)67009-5; Zlotnick C, 2002, COMPR PSYCHIAT, V43, P413, DOI 10.1053/comp.2002.35900	36	28	28	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2167-7026	2167-7034		CLIN PSYCHOL SCI	Clin. Psychol. Sci.	MAY	2016	4	3					493	498		10.1177/2167702615598756			6	Psychology, Clinical; Psychiatry; Psychology	Emerging Sources Citation Index (ESCI)	Psychology; Psychiatry	FE9OW	WOS:000408534000010					2022-02-06	
J	Powell, JM; Fraser, R; Brockway, JA; Temkin, N; Bell, KR				Powell, Janet M.; Fraser, Robert; Brockway, Jo Ann; Temkin, Nancy; Bell, Kathleen R.			A Telehealth Approach to Caregiver Self-Management Following Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; caregivers; problem solving; randomized controlled trial; telehealth; telemedicine	PROBLEM-SOLVING ABILITIES; FAMILY-MEMBER ADJUSTMENT; SEVERE HEAD-INJURY; PARTICIPATION ASSESSMENT; STROKE SURVIVORS; INTERVENTION; REHABILITATION; OUTCOMES; CARE; APPRAISAL	Objective: To determine whether a telephone-based, individualized education and mentored problem-solving intervention would improve outcomes for caregivers of persons with traumatic brain injury (TBI). Design: Parallel group, randomized controlled trial with blinded outcome assessment. Setting: General community. Participants: A total of 153 caregivers (mean age = 49.7 years; 82% female; 54% spouses/partners, 35% parents) of persons with moderate to severe TBI who received acute and/or rehabilitation care at a level I trauma center. Eighty-two percent of participants were evaluated at 6-month follow-up. Intervention: Individualized education and mentored problem-solving intervention focused on caregivers' primary concerns delivered via up to 10 telephone calls at 2-week intervals. Main Outcome Measures: Composite of Bakas Caregiving Outcomes Scale (BCOS) and Brief Symptom Inventory (BSI-18) at 6 months post-TBI survivor discharge. Secondary measures included the Brief COPE. Results: Caregivers in the treatment arm scored higher on the BCOS-BSI composite (P = .032), with more active coping (P = .020) and less emotional venting (P = .028) as measured by the Brief COPE. Conclusions: An individualized education and mentored problem-solving approach delivered via telephone in the first few months following community discharge of the TBI survivor resulted in better caregiver outcomes than usual care. Consideration should be given to using this approach to augment the limited support typically offered to caregivers.	[Powell, Janet M.; Fraser, Robert] Univ Washington, Dept Rehabil Med, Div Occupat Therapy, Box 356490, Seattle, WA 98195 USA; [Fraser, Robert] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Fraser, Robert; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Brockway, Jo Ann] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bell, Kathleen R.] Univ Texas Southwestern, Dept Phys Med & Rehabil, Dallas, TX USA		Powell, JM (corresponding author), Univ Washington, Dept Rehabil Med, Div Occupat Therapy, Box 356490, Seattle, WA 98195 USA.	jmpowell@uw.edu		Bell, Kathleen/0000-0002-0928-2046	Department of Education, National Institute on Disability and Rehabilitation Research, TBI Model Systems: University of Washington Traumatic Brain Injury Model System [H133A070032]	This study was funded by the Department of Education, National Institute on Disability and Rehabilitation Research, TBI Model Systems: University of Washington Traumatic Brain Injury Model System (H133A070032). The authors thank Kimberly Glorieux for her contributions as the study coordinator; Jason Barber for his assistance with data analysis; Heather Porter, MSW, for her work as the study interventionist; and Melissa Mayes for assistance with data collection.	Bakas T, 1999, NURS RES, V48, P250, DOI 10.1097/00006199-199909000-00005; Bakas T, 2006, NURS RES, V55, P346, DOI 10.1097/00006199-200609000-00007; Berry JW, 2012, REHABIL PSYCHOL, V57, P98, DOI 10.1037/a0028229; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Broadstock MJ, 1997, PATIENT EDUC COUNS, V32, P141, DOI 10.1016/S0738-3991(97)00036-0; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Campbell C H, 1988, Rehabil Nurs, V13, P320; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; Corbin JM, 1988, UNENDING WORK CARE M; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DZurilla TJ, 2010, HDB COGNITIVE BEHAV, P197, DOI 10.1891/0889-8391.2.4.283a; Elliott TR, 2008, BEHAV RES THER, V46, P1220, DOI 10.1016/j.brat.2008.08.004; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleig L, 2013, REHABIL PSYCHOL, V58, P323, DOI 10.1037/a0033885; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Grant JS, 2001, REHABIL PSYCHOL, V46, P44, DOI 10.1037/0090-5550.46.1.44; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Holman H, 2004, PUBLIC HEALTH REP, V119, P239, DOI 10.1016/j.phr.2004.04.002; Jordan JE, 2007, MED J AUSTRALIA, V186, P84, DOI 10.5694/j.1326-5377.2007.tb00807.x; Karlik B A, 1990, J Cardiovasc Nurs, V4, P70; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Kurylo M, 2004, J CLIN PSYCHOL MED S, V11, P151, DOI 10.1023/B:JOCS.0000037609.23007.24; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LORIG K, 1986, J RHEUMATOL, V13, P763; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Machamer J, 2013, J NEUROTRAUM, V30, P1845, DOI 10.1089/neu.2013.2920; Newton KM, 1998, PROG CARDIOVASC NURS, V3, P62; Nezu CM., 2007, SOLVING LIFES PROBLE; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Paterson B, 2001, Rehabil Nurs, V26, P48; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Schulz R, 2002, GERONTOLOGIST, V42, P589, DOI 10.1093/geront/42.5.589; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; Tremont Geoffrey, 2008, Dementia (London), V7, P503, DOI 10.1177/1471301208096632; vanVeenendaal H, 1996, PATIENT EDUC COUNS, V28, P265, DOI 10.1016/0738-3991(95)00853-5; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002	56	28	29	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2016	31	3					180	190		10.1097/HTR.0000000000000167			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DR3FK	WOS:000379787800010	26394294				2022-02-06	
J	Fishbein, D; Dariotis, JK; Ferguson, PL; Pickelsimer, EE				Fishbein, Diana; Dariotis, Jacinda K.; Ferguson, Pamela L.; Pickelsimer, E. Elisabeth			Relationships Between Traumatic Brain Injury and Illicit Drug Use and Their Association With Aggression in Inmates	INTERNATIONAL JOURNAL OF OFFENDER THERAPY AND COMPARATIVE CRIMINOLOGY			English	Article						traumatic brain injury; drug use; aggression; inmates; dysregulation	HEAD-INJURIES; SUBSTANCE USE; RISK; PREVALENCE; DISORDERS; BEHAVIOR; TBI; CHILDHOOD; OUTCOMES; ABUSE	Extensive interviews of correctional inmates in South Carolina (2009-2010) were conducted under a Center for Disease Control and Prevention (CDC) grant. We evaluated the extent to which early traumatic brain injury (TBI) and subsequent illicit drug abuse may conjointly influence development of aggression, controlling for alcohol use, and whether cognitive or emotional dysregulation mediated this relationship. Early TBI predicted greater severity and earlier onset of drug use, and an earlier age at first use predicted greater aggression regardless of the age of TBI. Emotional dysregulation mediated effects of TBI on aggression. The potential to design more targeted treatments for this susceptible population are discussed.	[Fishbein, Diana] Univ Maryland, Sch Med, 5900 Waterloo Rd,2nd Floor, Ellicott City, MD 21045 USA; [Dariotis, Jacinda K.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Ferguson, Pamela L.; Pickelsimer, E. Elisabeth] Med Univ S Carolina, Charleston, SC USA		Fishbein, D (corresponding author), Univ Maryland, Sch Med, 5900 Waterloo Rd,2nd Floor, Ellicott City, MD 21045 USA.	dfishbei@psych.umaryland.edu		fishbein, diana/0000-0003-1644-2762	Division of Injury Response (DIR), National Center for Injury Prevention and Control (NCIPC); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE001318]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by the Division of Injury Response (DIR), National Center for Injury Prevention and Control (NCIPC), and Centers for Disease Control and Prevention (CDC); Cooperative Agreement No. U49CE001318).	Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI [10.1089/neu.2008.0849, 10.1089/neu.2008-0849]; Blanchard R, 2003, ARCH SEX BEHAV, V32, P573, DOI 10.1023/A:1026093612434; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bradley B, 2011, J CLIN PSYCHIAT, V72, P685, DOI 10.4088/JCP.10m06409blu; Bradshaw CP, 2010, J YOUTH ADOLESCENCE, V39, P953, DOI 10.1007/s10964-009-9442-8; Brewer-Smyth Kathleen, 2004, Health Care Women Int, V25, P835, DOI 10.1080/07399330490517118; Brophy M, 2002, INFANT CHILD DEV, V11, P125, DOI 10.1002/icd.301; Bryant FB, 2001, J RES PERS, V35, P138, DOI 10.1006/jrpe.2000.2302; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Calkins SD, 2002, DEV PSYCHOPATHOL, V14, P477, DOI 10.1017/S095457940200305X; CARLSSON GS, 1983, J NEUROL NEUROSUR PS, V46, P818, DOI 10.1136/jnnp.46.9.818; CASPI Y, 2001, ALCOHOL TREAT Q, V19, P49, DOI DOI 10.1300/J020V19N04_; Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI 10.1001/jama.2008.976; Cicchetti D., 1994, HDB DEPRESSION CHILD, P123, DOI DOI 10.1007/978-1-4899-1510-8_7; Cohen R A, 1999, Violence Vict, V14, P397; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Deckel AW, 1996, ALCOHOL CLIN EXP RES, V20, P1173, DOI 10.1111/j.1530-0277.1996.tb01107.x; Diamond PM, 2005, CRIM JUSTICE BEHAV, V32, P546, DOI 10.1177/0093854805278416; DURKIN MS, 1994, AM J PUBLIC HEALTH, V84, P587, DOI 10.2105/AJPH.84.4.587; Eshel N, 2007, NEUROPSYCHOLOGIA, V45, P1270, DOI 10.1016/j.neuropsychologia.2006.10.004; Farrer TJ, 2013, CHILD NEUROPSYCHOL, V19, P225, DOI 10.1080/09297049.2011.647901; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Fein G, 2010, ALCOHOL CLIN EXP RES, V34, P1045, DOI 10.1111/j.1530-0277.2010.01179.x; Ferguson P. L., 2011, SCORING SCALES STATE; Ferguson P. L., 2012, J HEAD TRAUMA REHAB, V27, pE1; Fishbein D, 2000, CRIM JUSTICE BEHAV, V27, P139, DOI 10.1177/0093854800027002001; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Giancola PR, 1999, PSYCHOL SCI, V10, P203, DOI 10.1111/1467-9280.00135; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Hayatbakhsh MR, 2009, AM J DRUG ALCOHOL AB, V35, P399, DOI 10.3109/00952990903353415; Hayes A. F., 2013, STAT MEDIATION ANAL; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hill J, 2002, J CHILD PSYCHOL PSYC, V43, P133, DOI 10.1111/1469-7610.00007; HINSHAW SP, 1992, PSYCHOL BULL, V111, P127, DOI 10.1037/0033-2909.111.1.127; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Jane-Llopis E, 2006, DRUG ALCOHOL REV, V25, P515, DOI 10.1080/09595230600944461; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Lo CC, 2000, AM J DRUG ALCOHOL AB, V26, P229, DOI 10.1081/ADA-100100602; Lynam DR, 2001, CA CH AD PS, P235; Mezzich AC, 2001, J CHILD ADOLES SUBST, V10, P35, DOI 10.1300/J029v10n04_04; MOELLER FG, 1994, PROG NEURO-PSYCHOPH, V18, P1027, DOI 10.1016/0278-5846(94)90128-7; Moffitt T. E., 1989, NEUROPSYCHOLOGY AGGR, P131; Moffitt TE, 1989, DEV PSYCHOPATHOL, V1, P105; Moss H., 1993, AM J ADDICTION, V2, P149, DOI DOI 10.1111/J.1521-0391.1993.TB00215.X; Pardini DA, 2003, J AM ACAD CHILD PSY, V42, P364, DOI 10.1097/00004583-200303000-00018; Pihet S, 2012, PSYCHIAT PSYCHOL LAW, V19, P427, DOI 10.1080/13218719.2011.598634; Reeves RR, 2011, J PSYCHOSOC NURS MEN, V49, P42, DOI 10.3928/02793695-20110201-03; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SPELLACY F, 1977, J CLIN PSYCHOL, V33, P966, DOI 10.1002/1097-4679(197710)33:4<966::AID-JCLP2270330409>3.0.CO;2-4; Sugden SG, 2006, J NEUROPSYCH CLIN N, V18, P302, DOI 10.1176/appi.neuropsych.18.3.302; Taylor J, 1999, PSYCHOPHYSIOLOGY, V36, P193, DOI 10.1111/1469-8986.3620193; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; WHITE JL, 1994, J ABNORM PSYCHOL, V103, P192, DOI 10.1037/0021-843X.103.2.192	59	28	28	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0306-624X	1552-6933		INT J OFFENDER THER	Int. J. Offender Ther. Comp. Criminol.	APR	2016	60	5					575	597		10.1177/0306624X14554778			23	Criminology & Penology; Psychology, Applied	Social Science Citation Index (SSCI)	Criminology & Penology; Psychology	DI6US	WOS:000373636300005	25326469				2022-02-06	
J	Dixon, CE; Bramlett, HM; Dietrich, WD; Shear, DA; Yan, HQ; Deng-Bryant, Y; Mondello, S; Wang, KKW; Hayes, RL; Empey, PE; Povlishock, JT; Tortella, FC; Kochanek, PM				Dixon, C. Edward; Bramlett, Helen M.; Dietrich, W. Dalton; Shear, Deborah A.; Yan, Hong Q.; Deng-Bryant, Ying; Mondello, Stefania; Wang, Kevin K. W.; Hayes, Ronald L.; Empey, Philip E.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.			Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						therapy; rat; biomarker; fluid percussion; calcineurin; neuroprotection; controlled cortical impact; penetrating ballistic-like brain injury; phosphatase	MITOCHONDRIAL PERMEABILITY TRANSITION; DOSE-RESPONSE; AXONAL INJURY; DAMAGE; MODEL; NIM811; MOTOR	Operation Brain Trauma Therapy (OBTT) is a consortium of investigators using multiple pre-clinical models of traumatic brain injury (TBI) to bring acute therapies to clinical trials. To screen therapies, we used three rat models (parasagittal fluid percussion injury [FPI], controlled cortical impact [CCI], and penetrating ballistic-like brain injury [PBBI]). We report results of the third therapy (cyclosporin-A; cyclosporine; [CsA]) tested by OBTT. At each site, rats were randomized to treatment with an identical regimen (TBI + vehicle, TBI + CsA [10 mg/kg], or TBI + CsA [20 mg/kg] given intravenously at 15 min and 24 h after injury, and sham). We assessed motor and Morris water maze (MWM) tasks over 3 weeks after TBI and lesion volume and hemispheric tissue loss at 21 days. In FPI, CsA (10 mg/kg) produced histological protection, but 20 mg/kg worsened working memory. In CCI, CsA (20 mg/kg) impaired MWM performance; surprisingly, neither dose showed benefit on any outcome. After PBBI, neither dose produced benefit on any outcome, and mortality was increased (20 mg/kg) partly caused by the solvent vehicle. In OBTT, CsA produced complex effects with histological protection at the lowest dose in the least severe model (FPI), but only deleterious effects as model severity increased (CCI and PBBI). Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No positive treatment effects were seen on biomarker levels in any of the models, whereas significant increases in 24 h UCH-L1 levels were seen with CsA (20 mg/kg) after CCI and 24 h GFAP levels in both CsA treated groups in the PBBI model. Lack of behavioral protection in any model, indicators of toxicity, and a narrow therapeutic index reduce enthusiasm for clinical translation.	[Dixon, C. Edward; Yan, Hong Q.] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Shear, Deborah A.; Deng-Bryant, Ying; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Ctr Pharmaceut Sci, Pittsburgh, PA 15260 USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Empey, Philip/L-9604-2019; Mondello, Stefania/A-1813-2012	Empey, Philip/0000-0001-7474-2339; Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Aminmansour Bahram, 2014, Adv Biomed Res, V3, P35, DOI 10.4103/2277-9175.125031; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Lemaire M, 1996, CANCER CHEMOTH PHARM, V38, P481, DOI 10.1007/s002800050515; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Tanaka C, 1999, J PHARMACOKINET BIOP, V27, P597, DOI 10.1023/A:1020978509566; Van den Heuvel C, 2004, J NEUROTRAUM, V21, P1562, DOI 10.1089/0897715042441783; WINDEBANK AJ, 1994, J PHARMACOL EXP THER, V268, P1051; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Zhang ZQ, 2011, TRANSL STROKE RES, V2, P455, DOI 10.1007/s12975-011-0137-6; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	38	28	29	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					553	566		10.1089/neu.2015.4122			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800005	26671075				2022-02-06	
J	Olson, DM; Fishel, M				Olson, DaiWai M.; Fishel, Megan			The Use of Automated Pupillometry in Critical Care	CRITICAL CARE NURSING CLINICS OF NORTH AMERICA			English	Article						Multimodal monitoring; Neurologic assessment; Pupillometer; Cranial nerve assessment	TRAUMATIC BRAIN-INJURY; INFRARED PUPILLOMETRY; HEAD-INJURY; PUPIL SIZE; COMA SCALE; 4 SCORE; DIAMETER; PATIENT; UNIT	The neurologic examination (neuroexamination) is one of the most powerful tools available to nurses and physicians caring for patients with neurologic or neurosurgical illness. Assessing cranial nerve function is one of the most vital components of the neuroexamination. The pupillary light reflex helps to evaluate the status of the second and third cranial nerves and is one of the most well-known elements of the cranial nerve examination. Automated pupillometers have been developed that provide objective measures of size of the pupil and the responsiveness of the pupil to light (neuropupillary index).	[Olson, DaiWai M.; Fishel, Megan] Univ Texas Southwestern, 5323 Harry Hines Blvd, Dallas, TX 75390 USA		Olson, DM (corresponding author), Univ Texas Southwestern, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	DaiWai.Olson@UTSouthwestern.edu	Olson, DaiWai/I-5932-2019	Olson, DaiWai/0000-0002-9280-078X			Bader M, 2010, AANN CORE CURRICULUM; Blumenfeld H., 2002, NEUROANATOMY CLIN CA; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Campbell WW, 2005, DEJONGS NEUROLOGIC E; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chen JW, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-548; Clark A, 2006, EMERG MED J, V23, P440, DOI 10.1136/emj.2005.030247; Du R, 2005, NEUROSURGERY, V57, P198, DOI 10.1227/01.NEU.0000163425.79170.CB; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; GOEBERT HW, 1970, SURG CLIN N AM, V50, P427; Greenberg M, 2006, HDB NEUROSURGERY; Greenberg MS., 2010, HDB NEUROSURGERY, V7th; HESS EH, 1960, SCIENCE, V132, P349, DOI 10.1126/science.132.3423.349; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Litvan I, 2000, NEUROLOGY, V54, P530, DOI 10.1212/WNL.54.2.530; Loewenfeld I. E., 1993, PUPIL ANATOMY PHYSL; Mahdavi Z, 2015, CRIT CARE NURS CLIN, V27, P213, DOI 10.1016/j.cnc.2015.02.002; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; Mazzoni P, 2006, MERRITTS NEUROLOGY H; McMullen W H, 1917, Br J Ophthalmol, V1, P593, DOI 10.1136/bjo.1.10.593; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Olson DM, 2005, AACN ADV CRIT CARE, V16, P441, DOI 10.1097/00044067-200510000-00003; Olson DM, 2015, NEUROCRIT CARE; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; Rebolleda G, 2013, ARCH SOC ESP OFTALMO, V88, P125, DOI [10.1016/j.oftal.2013.02.014, DOI 10.1016/J.0FTAL.2013.02.014]; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Schallenberg M, 2010, J REFRACT SURG, V26, P134, DOI 10.3928/1081597X-20100121-09; Singhal NS, 2014, J CRIT CARE, V29, P627, DOI 10.1016/j.jcrc.2014.02.014; Song Z, 2012, CLIN NEUROL NEUROSUR, V114, P634, DOI 10.1016/j.clineuro.2011.12.029; TEASDALE G, 1974, LANCET, V2, P81; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wilson S F, 1988, J Neurosci Nurs, V20, P189; WILSONPAUWELS L, 1988, CRANIAL NERVES ANATO; Worthley L I, 2000, Crit Care Resusc, V2, P7; Zafar SF, 2014, J CRIT CARE, V29, P599, DOI 10.1016/j.jcrc.2014.01.012	35	28	29	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0899-5885	1558-3481		CRIT CARE NURS CLIN	Crit. Care Nurs. Clin. N. Am.	MAR	2016	28	1					101	+		10.1016/j.cnc.2015.09.003			8	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	DD1TR	WOS:000369705200010	26873763				2022-02-06	
J	Samantaray, S; Das, A; Matzelle, DC; Yu, SP; Wei, L; Varma, A; Ray, SK; Banik, NL				Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Yu, Shan P.; Wei, Ling; Varma, Abhay; Ray, Swapan K.; Banik, Naren L.			Administration of low dose estrogen attenuates gliosis and protects neurons in acute spinal cord injury in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						acute spinal cord injury; calpain; estrogen; estrogen receptors; gliosis; neuroprotection	APOPTOTIC CELL-DEATH; TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-VESSELS; RECEPTOR-ALPHA; UP-REGULATION; NEUROPROTECTIVE AGENT; FUNCTIONAL RECOVERY; SIGNAL-TRANSDUCTION; CALPAIN INHIBITORS; CORTICAL-NEURONS	Spinal cord injury (SCI) is a debilitating condition with neurological deficits and loss of motor function that, depending on the severity, may lead to paralysis. The only treatment currently available is methylprednisolone, which is widely used and renders limited efficacy in SCI. Therefore, other therapeutic agents must be developed. The neuroprotective efficacy of estrogen in SCI was studied with a pre-clinical and pro-translational perspective. Acute SCI was induced in rats that were treated with low doses of estrogen (1, 5, 10, or 100g/kg) and compared with vehicle-treated injured rats or laminectomy control (sham) rats at 48h post-SCI. Changes in gliosis and other pro-inflammatory responses, expression and activity of proteolytic enzymes (e.g., calpain, caspase-3), apoptosis of neurons in SCI, and cell death were monitored via Western blotting and immunohistochemistry. Negligible pro-inflammatory responses or proteolytic events and very low levels of neuronal death were found in sham rats. In contrast, vehicle-treated SCI rats showed profound pro-inflammatory responses with reactive gliosis, elevated expression and activity of calpain and caspase-3, elevated Bax:Bcl-2 ratio, and high levels of neuronal death in lesion and caudal regions of the injured spinal cord. Estrogen treatment at each dose reduced pro-inflammatory and proteolytic activities and protected neurons in the caudal penumbra in acute SCI. Estrogen treatment at 10g was found to be as effective as 100g in ameliorating the above parameters in injured animals. Results from this investigation indicated that estrogen at a low dose could be a promising therapeutic agent for treating acute SCI.	[Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Varma, Abhay; Banik, Naren L.] Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,Suite 309 CSB,MSC 606, Charleston, SC 29425 USA; [Yu, Shan P.; Wei, Ling] Emory Univ, Sch Med, Dept Anesthesia, Atlanta, GA USA; [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA; [Banik, Naren L.] Ralph H Johnson Vet Adm, Med Ctr, Charleston, SC USA		Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,Suite 309 CSB,MSC 606, Charleston, SC 29425 USA.	baniknl@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS31622, R01 NS45967]; Veterans AdministrationUS Department of Veterans Affairs [1IOBX00126 and 1IOBX002349]; South Carolina State Spinal Cord Research Fund [SCIRF-2015-P-01, SCIRF-2015-P-04, SCIRF-2015-I-01]; Department of Neurosurgery, MUSC; MUSC-CTSA program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031622, R01NS045967] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002349, I01BX001262] Funding Source: NIH RePORTER	This work was supported in part by funding from NIH (R01-NS31622 and R01 NS45967); Veterans Administration (1IOBX00126 and 1IOBX002349); South Carolina State Spinal Cord Research Fund (SCIRF-2015-P-01, SCIRF-2015-P-04, and SCIRF-2015-I-01); Department of Neurosurgery, MUSC; and MUSC-CTSA program. We also thank Dr. Kelly Guyton for her valuable contribution to this work. Authors declare no conflict of interests.	Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; BANIK NL, 1983, NEUROCHEM RES, V8, P1389, DOI 10.1007/BF00964996; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Battaglia F, 2003, J MOL NEUROSCI, V20, P357, DOI 10.1385/JMN:20:3:357; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.1984.03340250025015; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Cox A, 2015, J NEUROTRAUM, V32, P1413, DOI 10.1089/neu.2014.3730; Cuzzocrea S, 2008, SHOCK, V29, P362, DOI 10.1097/shk.0b013e31814545dc; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Duckles SP, 2003, NEURONAL AND VASCULAR PLASTICITY: ELUCIDATING BASIC CELLULAR MECHANISMS FOR FUTURE THERAPEUTIC DISCOVERY, P95; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2009, CELL MOL NEUROBIOL, V29, P27, DOI 10.1007/s10571-008-9291-0; Guyton MK, 2005, ANN NY ACAD SCI, V1053, P48, DOI 10.1196/annals.1344.005; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hu R, 2012, CRIT CARE MED, V40, P3230, DOI 10.1097/CCM.0b013e3182657560; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Kachadroka S, 2010, J NEUROTRAUM, V27, P611, DOI 10.1089/neu.2009.1069; Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149; Lee JY, 2012, ENDOCRINOLOGY, V153, P3815, DOI 10.1210/en.2012-1068; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Perot P.L., 1987, J AM PARALYSIS ASS, V4, P149, DOI DOI 10.1089/cns.1987.4.149; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Ritz MF, 2008, BRAIN RES, V1203, P177, DOI 10.1016/j.brainres.2008.01.091; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sakurai M, 2003, J VASC SURG, V37, P446, DOI 10.1067/mva.2003.100; Samantaray S, 2007, NEUROSCIENCE, V146, P741, DOI 10.1016/j.neuroscience.2007.01.056; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Samantaray S, 2013, J NEUROCHEM, V127, P880, DOI 10.1111/jnc.12374; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Shields DC, 1998, EXP EYE RES, V67, P403, DOI 10.1006/exer.1998.0537; Shields DC, 1998, BRAIN RES, V794, P68, DOI 10.1016/S0006-8993(98)00193-0; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Shields DC, 2000, J NEUROSCI RES, V61, P146; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2004, NEUROCHEM RES, V29, P2007, DOI 10.1007/s11064-004-6874-0; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2010, J NEUROSCI RES, V88, P1738, DOI 10.1002/jnr.22337; Sribnick EA, 2009, BRAIN RES, V1276, P159, DOI 10.1016/j.brainres.2009.04.022; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Stirone C, 2003, EUR J PHARMACOL, V478, P35, DOI 10.1016/j.ejphar.2003.08.037; Stirone C, 2003, AM J PHYSIOL-ENDOC M, V284, pE184, DOI 10.1152/ajpendo.00165.2002; Sur P, 2005, GLIA, V50, P160, DOI 10.1002/glia.20168; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tiwari-Woodruff S, 2007, P NATL ACAD SCI USA, V104, P14813, DOI 10.1073/pnas.0703783104; Wei Ling, 2005, Pathophysiology, V12, P47, DOI 10.1016/j.pathophys.2004.11.002; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xie LP, 2002, EUR J IMMUNOL, V32, P2837, DOI 10.1002/1521-4141(2002010)32:10<2837::AID-IMMU2837>3.0.CO;2-V; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086	73	28	29	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2016	136	5					1064	1073		10.1111/jnc.13464			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	DE5BT	WOS:000370646500016	26662641	Green Accepted, Bronze			2022-02-06	
J	Alsalaheen, B; Haines, J; Yorke, A; Diebold, J				Alsalaheen, B.; Haines, J.; Yorke, A.; Diebold, J.			King-Devick Test reference values and associations with balance measures in high school American football players	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						Concussion; head injury; normative values; adolescents; visual; screening; reliability; validity; minimum detectable change	VISUAL SCREENING TOOL; ICE HOCKEY PLAYERS; RUGBY LEAGUE; CONCUSSION; ADOLESCENTS; YOUTH	The King-Devick test appears to be a promising tool in screening for concussions. However, limited evidence exists on the baseline associations between the K-D test and age and baseline screening tools used after concussion. Additionally, there are no published reference values for the K-D test in high school football players. The K-D test, the Balance Error Scoring System, and the Limits of Stability (LOS) test were administered to 157 high school football players. Additionally, a subsample of 62 participants completed the test twice to examine the reliability of K-D test. There was no relationship between the K-D test and the BESS, or the reaction time and directional control of LOS test. Students aged between 16 and 18years demonstrated faster K-D test performance compared to students between 13 and 15years of age. However, there was no association between K-D test and history of concussion. The reliability of the K-D test was (ICC2,1=0.89), and the minimal detectable change was 6.10s. Normative reference values for high school football players are presented in this study.	[Alsalaheen, B.; Haines, J.; Yorke, A.; Diebold, J.] Univ Michigan, Dept Phys Therapy, Flint, MI 48502 USA		Alsalaheen, B (corresponding author), Univ Michigan, Phys Therapy Dept, 2157 William S White Bldg,303 E Kearsley St, Flint, MI 48502 USA.	alsalahe@umich.edu	Yorke, Amy/Q-4091-2019	Yorke, Amy/0000-0003-4998-0313	Dr. Ben F. Bryer Foundation Medical Research Fund; University of Michigan-Flint's Research and Creative Activity (RCA) Award	This project was funded by Dr. Ben F. Bryer Foundation Medical Research Fund, and by the University of Michigan-Flint's Research and Creative Activity (RCA) Award. We thank Mitch Smelis, AT, ATC and Kirk Cabanilla AT, ATC for their assistance in recruitment.	Allum J H J, 2012, Front Neurol, V3, P83, DOI 10.3389/fneur.2012.00083; Alsalaheen B, 2015, ARCH PHYS MED REHAB, V96, P2194, DOI 10.1016/j.apmr.2015.08.418; Alsalaheen BA, 2016, CLIN J SPORT MED, V26, P46, DOI 10.1097/JSM.0000000000000185; Baumgartner T. A., 1999, MEASUREMENT EVALUATI; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Khan S, 2013, NEUROREHABILITATION, V32, P437, DOI 10.3233/NRE-130866; King D, 2015, J NEUROL SCI, V357, P75, DOI 10.1016/j.jns.2015.06.069; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Lovell M.R.C.M., 2003, IMMEDIATE POSTCONCUS; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Vartiainen MV, 2015, SCAND J MED SCI SPOR, V25, pe327, DOI 10.1111/sms.12307	22	28	28	0	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	FEB	2016	26	2					235	239		10.1111/sms.12628			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DB9TU	WOS:000368860600013	26648587				2022-02-06	
J	Osborn, AJ; Mathias, JL; Fairweather-Schmidt, AK				Osborn, A. J.; Mathias, J. L.; Fairweather-Schmidt, A. K.			Prevalence of Anxiety Following Adult Traumatic Brain Injury: A Meta-Analysis Comparing Measures, Samples and Postinjury Intervals	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; anxiety; generalized anxiety disorder; prevalence; meta-analysis	QUALITY-OF-LIFE; II PSYCHIATRIC-DISORDERS; HEAD-INJURY; DSM-IV; DEPRESSION SCALE; HOSPITAL ANXIETY; AXIS-I; PSYCHOSOCIAL ADJUSTMENT; POSTCONCUSSION SYNDROME; DIAGNOSTIC INTERVIEW	Objective: Anxiety following a traumatic brain injury (TBI) is a common problem; however, disparate prevalence estimates limit the clinical utility of research. The purpose of the current study was to examine how differences in methodological variables and sample characteristics impact on the prevalence of anxiety. Method: Data from 41 studies that examined either the prevalence of generalized anxiety disorder (GAD) diagnoses or clinically significant "cases" of self-reported anxiety following adult, nonpenetrating TBI were analyzed, and the impact of diagnostic criteria, measure, postinjury interval and injury severity was evaluated. Results: Overall, 11% of people were diagnosed with GAD and 37% reported clinically significant levels of anxiety following TBI. Prevalence estimates varied for different diagnostic criteria (range: 2%-19%), interview schedules (range: 2%-28%), and self-report measures (range: 36%-50%). GAD and "cases" of anxiety were most prevalent 2 to 5 years postinjury. The rates of GAD increased with injury severity (mild: 11%, severe 15%), but "cases" decreased (mild: 53%, severe: 38%), although neither difference was significant. Conclusions: Anxiety is common after a TBI and ongoing monitoring and treatment should be provided. Methodological and sample characteristics should be clear and well-defined, as differences across studies (e.g., how anxiety is conceptualized, which measure is used, time since injury, injury severity) impact prevalence rates.	[Osborn, A. J.; Mathias, J. L.; Fairweather-Schmidt, A. K.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia; [Fairweather-Schmidt, A. K.] Flinders Univ S Australia, Sch Psychol, Adelaide, SA, Australia		Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au		Mathias, Jane/0000-0001-8957-8594			Al-Adawi S, 2007, BRAIN INJURY, V21, P385, DOI 10.1080/02699050701311059; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; Alway Y, 2012, NEUROPSYCHOL REHABIL, V22, P374, DOI 10.1080/09602011.2011.648757; American Psychiatric Association, 2000, HDB PSYCHIAT MEASURE, V1st; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2001, DIAGN STAT MAN MENT; Andruszkow H, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-26; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; Baxter AJ, 2014, DEPRESS ANXIETY, V31, P506, DOI 10.1002/da.22230; Beaupre M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/924692; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Bertisch HC, 2013, REHABIL PSYCHOL, V58, P429, DOI 10.1037/a0034554; Borenstein M., 2009, INTRO META ANAL; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Boyles AL, 2011, EPIDEMIOLOGY, V22, P746, DOI 10.1097/EDE.0b013e318225ba48; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; Chen HN, 2010, COMMUN STAT-SIMUL C, V39, P860, DOI 10.1080/03610911003650383; Clarke LA, 2012, BRAIN INJURY, V26, P298, DOI 10.3109/02699052.2012.654588; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Downing MG, 2013, J HEAD TRAUMA REHAB, V28, P171, DOI 10.1097/HTR.0b013e31828b4f63; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; Fairweather-Schmidt AK, 2012, SOC PSYCH PSYCH EPID, V47, P515, DOI 10.1007/s00127-011-0369-5; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First M., 1997, STRUCTURED CLIN INTE; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2014, J CLIN EXP NEUROPSYC, V36, P1, DOI 10.1080/13803395.2013.863832; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Gregorio GW, 2014, J HEAD TRAUMA REHAB, V29, pE43, DOI 10.1097/HTR.0b013e318292fb00; Haller H, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-128; HAMMELL KRW, 1994, INT J REHABIL RES, V17, P319; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; HASIN DS, 1987, J PSYCHIAT RES, V21, P7, DOI 10.1016/0022-3956(87)90005-7; Hawthorne G, 2011, J CLIN NEUROSCI, V18, P197, DOI 10.1016/j.jocn.2010.06.015; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hopkins WG., 2002, NEW VIEW STAT SCALE; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kit KA, 2007, REHABIL PSYCHOL, V52, P25, DOI 10.1037/0090-5550.52.1.25; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kurtz JE, 2007, J PERS ASSESS, V88, P66, DOI 10.1207/s15327752jpa8801_09; Landau J., 2008, FAMILIES SYSTEMS HLT, V26, P69, DOI [10.1037/1091-7527.26.1.69, DOI 10.1037/1091-7527.26.1.69]; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; Lipsey M. W., 2001, APPL SOCIAL RES METH, V49; Ma HP, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004205; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mathias JL, 2014, J NEUROTRAUM, V31, P658, DOI 10.1089/neu.2013.3160; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McLean CP, 2011, J PSYCHIATR RES, V45, P1027, DOI 10.1016/j.jpsychires.2011.03.006; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mendlowicz MV, 2000, AM J PSYCHIAT, V157, P669, DOI 10.1176/appi.ajp.157.5.669; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; Orwin R.G., 1983, J EDUC STAT, V8, P157, DOI [10.2307/1164923, DOI 10.2307/1164923]; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Ponsford J., 2003, Z NEUROPSYCHOL, V14, P155, DOI [10.1024/1016-264X.14.3.155, DOI 10.1024/1016-264X.14.3.155]; Ponsford J., 2014, J HEAD TRAUMA REHABI; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Powell T, 2012, DISABIL REHABIL, V34, P1461, DOI 10.3109/09638288.2011.644384; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Richman WL, 1999, J APPL PSYCHOL, V84, P754, DOI 10.1037/0021-9010.84.5.754; Rickels K, 2001, J CLIN PSYCHIAT, V62, P4; Rieger E., 2008, ABNORMAL PSYCHOL LEA; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; Ruddle Jean Jean, 2011, SOCIAL CARE NEURODIS, V2, P200, DOI [10.1108/20420911111188452, DOI 10.1108/20420911111188452]; Schnieders J, 2012, J HEAD TRAUMA REHAB, V27, P404, DOI 10.1097/HTR.0b013e3182306341; Senathi-Raja D, 2010, J HEAD TRAUMA REHAB, V25, P330, DOI 10.1097/HTR.0b013e3181ccc893; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Skilbeck C, 2013, NEUROPSYCHOL REHABIL, V23, P234, DOI 10.1080/09602011.2012.747968; Slade T, 2001, SOC PSYCH PSYCH EPID, V36, P45, DOI 10.1007/s001270050289; Smith H.E., 1992, CLIN REHABIL, V6, P31; SNAITH RP, 1976, BRIT J PSYCHIAT, V128, P156, DOI 10.1192/bjp.128.2.156; Spielberger CD., 1970, STATE TRAIT ANXIETY; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Williams J, 2012, HDB ASSESSMENT CHILD; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589; Wing JK, 1974, DESCRIPTION CLASSIFI; Wise EK, 2012, ARCH PHYS MED REHAB, V93, P1319, DOI 10.1016/j.apmr.2012.05.009; Wittchen HU, 2001, J CLIN PSYCHIAT, V62, P15; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; World Health Organization, 1992, ICD 10 CLASSIFICATIO; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	141	28	28	2	25	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	FEB	2016	30	2					247	261		10.1037/neu0000221			15	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	DD6YM	WOS:000370070600010	26146855				2022-02-06	
J	Meng, XE; Zhang, Y; Li, N; Fan, DF; Yang, C; Li, H; Guo, DZ; Pan, SY				Meng, Xiang-En; Zhang, Yu; Li, Na; Fan, Dan-Feng; Yang, Chen; Li, Hang; Guo, Da-Zhi; Pan, Shu-Yi			Hyperbaric Oxygen Alleviates Secondary Brain Injury After Trauma Through Inhibition of TLR4/NF-kappa B Signaling Pathway	MEDICAL SCIENCE MONITOR			English	Article						Brain Injuries; Hyperbaric Oxygenation; Toll-Like Receptor 4	MICROGLIAL ACTIVATION; INFLAMMATION; TLR4; RAT	Background: The aim of this study was to investigate the efficacy of hyperbaric oxygen in secondary brain injury after trauma and its mechanism in a rat model. Material/Methods: A rat model of TBI was constructed using the modified Feeney's free-fall method, and 60 SD rats were randomly divided into three groups - the sham group, the untreated traumatic brain injury (TBI) group, and the hyperbaric oxygen-treated TBI group. The neurological function of the rats was evaluated 12 and 24 hours after TBI modeling; the expression levels of TLR4, I kappa B, p65, and cleaved caspase-3 in the peri-trauma cortex were determined by Western blot; levels of TNF-alpha, IL-6, and IL-1 beta were determined by ELISA; and apoptosis of the neurons was evaluated by TUNEL assay 24 hours after TBI modeling. Results: Hyperbaric oxygen therapy significantly inhibited the activation of the TLR4/NF-kappa B signaling pathway, reduced the expression of cleaved caspase-3, TNF-alpha, IL-6 and IL-1 beta (P<0.05), reduced apoptosis of the neurons and improved the neurological function of the rats (P<0.05). Conclusions: Hyperbaric oxygen therapy protects the neurons after traumatic injury, possibly through inhibition of the TLR4/NF-kappa B signaling pathway.	[Meng, Xiang-En; Zhang, Yu; Li, Na; Fan, Dan-Feng; Yang, Chen; Li, Hang; Guo, Da-Zhi; Pan, Shu-Yi] Navy Gen Hosp, Dept Hyperbar Oxygen, Beijing, Peoples R China		Pan, SY (corresponding author), Navy Gen Hosp, Dept Hyperbar Oxygen, Beijing, Peoples R China.	shuyipan_oooo@126.com					Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Liu Y, 2014, CLIN REV ALLERG IMMU, V47, P136, DOI 10.1007/s12016-013-8402-y; Mattson MP, J CLIN INVEST, V107, P247; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/124614; Yao LL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-23; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Zhu BF, 2010, CLIN EMERGENCY, V11, P204	13	28	32	0	3	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	JAN 26	2016	22						284	288		10.12659/MSM.894148			5	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	DC0EY	WOS:000368891200002	26812205	Green Published			2022-02-06	
J	Delouche, A; Attye, A; Heck, O; Grand, S; Kastler, A; Lamalle, L; Renard, F; Krainik, A				Delouche, Aurelie; Attye, Arnaud; Heck, Olivier; Grand, Sylvie; Kastler, Adrian; Lamalle, Laurent; Renard, Felix; Krainik, Alexandre			Diffusion MRI: Pitfalls, literature review and future directions of research in mild traumatic brain injury	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Brain injury; Diffusion tractography; Post concussion syndrome; Magnetic resonance imaging	CONSTRAINED SPHERICAL DECONVOLUTION; AXONAL INJURY; MATTER ABNORMALITIES; SPATIAL STATISTICS; ENDURING FREEDOM; CORPUS-CALLOSUM; GRAY-MATTER; KURTOSIS; DTI; TRACTOGRAPHY	Mild traumatic brain injury (mTBI) is a leading cause of disability in adults, many of whom report a distressing combination of physical, emotional and cognitive symptoms, collectively known as post-concussion syndrome, that persist after the injury. Significant developments in magnetic resonance diffusion imaging, involving voxel-based quantitative analysis through the measurement of fractional anisotropy or mean diffusivity, have enhanced our knowledge on the different stages of mTBI pathophysiology. Other diffusion imaging-derived techniques, including diffusion kurtosis imaging with multi-shell diffusion and high-order tractography models, have recently demonstrated their usefulness in mTBI. Our review starts by briefly outlining the physical basis of diffusion tensor imaging including the pitfalls for use in brain trauma, before discussing findings from diagnostic trials testing its usefulness in assessing brain structural changes in patients with mTBI. Use of different post-processing techniques for the diffusion imaging data, identified the corpus callosum as the most frequently injured structure in mTBI, particularly at sub-acute and chronic stages, and a crucial location for evaluating functional outcome. However, structural changes appear too subtle for identification using traditional diffusion biomarkers, thus disallowing expansion of these techniques into clinical practice. In this regard, more advanced diffusion techniques are promising in the assessment of this complex disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Delouche, Aurelie; Attye, Arnaud; Heck, Olivier; Grand, Sylvie; Kastler, Adrian; Renard, Felix; Krainik, Alexandre] Grenoble Univ Hosp, SFR RMN Neurosci, Dept Neuroradiol & MRI, F-38043 Grenoble 9, France; [Attye, Arnaud; Heck, Olivier; Grand, Sylvie; Kastler, Adrian; Lamalle, Laurent; Krainik, Alexandre] Univ Grenoble Alpes, IRMaGe, F-38000 Grenoble, France; [Attye, Arnaud; Heck, Olivier; Grand, Sylvie; Kastler, Adrian; Lamalle, Laurent; Renard, Felix; Krainik, Alexandre] UMS IRMaGe, Grenoble, France		Attye, A (corresponding author), Grenoble Univ Hosp, Neuroradiol & MR Unit, CS 10217, F-38043 Grenoble 9, France.	aattye@chu-grenoble.fr	KRAINIK, Alexandre/L-5874-2014; Attye, Arnaud/AAM-7762-2020	Attye, Arnaud/0000-0002-0233-0367; Lamalle, Laurent/0000-0002-8930-7337			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2005, NEUROIMAGE, V27, P48, DOI 10.1016/j.neuroimage.2005.03.042; Attye A, 2015, EUR RADIOL; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beaulieu C, 1999, ANN NEUROL, V46, P568, DOI 10.1002/1531-8249(199910)46:4<568::AID-ANA4>3.0.CO;2-R; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Calamante F, 2013, HUM BRAIN MAPP, V34, P2538, DOI 10.1002/hbm.22083; Calamante F, 2012, NEUROIMAGE, V59, P286, DOI 10.1016/j.neuroimage.2011.07.014; de Groot M, 2013, NEUROIMAGE, V76, P400, DOI 10.1016/j.neuroimage.2013.03.015; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; Fukunaga I, 2013, RADIOL PHYS TECHNOL, V6, P343, DOI 10.1007/s12194-013-0206-5; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237; Hui ES, 2008, IEEE ENG MED BIO, P3941, DOI 10.1109/IEMBS.2008.4650072; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Kim S, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001900; Kristo G, 2013, MAGN RESON MED, V70, P1544, DOI 10.1002/mrm.24602; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kurki T, 2014, NEURORADIOLOGY, V56, P833, DOI 10.1007/s00234-014-1410-7; Latt J, 2013, J MAGN RESON IMAGING, V37, P610, DOI 10.1002/jmri.23857; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Maier SE, 2008, MAGN RESON IMAGING, V26, P897, DOI 10.1016/j.mri.2008.01.042; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; Paydar A, 2014, NEURAL REGEN RES, V9, P1108, DOI 10.4103/1673-5374.135309; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Szczepankiewicz F, 2013, NEUROIMAGE, V76, P145, DOI 10.1016/j.neuroimage.2013.02.078; Tournier JD, 2008, NEUROIMAGE, V42, P617, DOI 10.1016/j.neuroimage.2008.05.002; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Veraart J, 2011, MAGN RESON MED, V65, P138, DOI 10.1002/mrm.22603; Wang X, 2014, NEUROL SCI, V35, P1533, DOI 10.1007/s10072-014-1788-3; Watts R, 2014, RADIOLOGY, V272, P217, DOI 10.1148/radiol.14131856; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	62	28	28	0	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	JAN	2016	85	1					25	30		10.1016/j.ejrad.2015.11.004			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	CZ8OA	WOS:000367357800004	26724645				2022-02-06	
J	Hong, Y; Sarntinoranont, M; Subhash, G; Canchi, S; King, MA				Hong, Y.; Sarntinoranont, M.; Subhash, G.; Canchi, S.; King, M. A.			Localized Tissue Surrogate Deformation due to Controlled Single Bubble Cavitation	EXPERIMENTAL MECHANICS			English	Article						Cavitation collapse; Traumatic brain injury; Agarose hydrogel; Shockwave; Brain tissue	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; STRAIN-RATE; MECHANICAL STRETCH; BLAST OVERPRESSURE; SOLID BOUNDARY; SLICE CULTURES; RAT-BRAIN; COLLAPSE; MODEL	Cavitation-induced shock wave, as might occur in the head during exposure to blast waves, was investigated as a possible damage mechanism for soft brain tissues. A novel experimental technique was developed to visualize and control single bubble cavitation and its collapse, and the influence of this process on a nearby tissue surrogate was investigated. The experiment utilized a Hopkinson pressure bar system which transmits a simulated blast pressure wave (with over-pressure and under-pressure components) to a fluid-filled test chamber implanted with a seed gas bubble. Growth and collapse of this bubble was recorded during passage of the blast wave with a high speed camera. To investigate the potential for cavitation damage to a tissue surrogate, local changes in strain were measured in hydrogel slices placed in various configurations next to the bubble. The strain measurements were made using digital image correlation (DIC) technique by monitoring the motion of material points on the tissue surrogate. In one configuration, bubble contact dynamics resulted in compression contact (> 60 mu s) followed by inertially-driven tension (> 140 mu s). In another configuration, the influence of local shock waves emanating from collapsed bubbles was captured. Large compressive strains (0.25 to 0.5) that were highly localized (0.18 mm(2)) were measured over a short time period (< 24 mu s) after bubble collapse. High bubble collapse pressures 29 to 125 times that of peak blast overpressure are predicted to be the source of these large strains. Consistent with theoretical predictions, these cavitation-based strains are far larger than the strains imposed by passage of the simulated blast wave alone. Finally, the value of this experimental platform to investigate the single bubble cavitation-induced damage in a biological tissue is illustrated with an example test on rat brain slices.	[Hong, Y.; Sarntinoranont, M.; Subhash, G.; Canchi, S.] Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL 32611 USA; [King, M. A.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32611 USA		Subhash, G (corresponding author), Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL 32611 USA.	subhash@ufl.edu	Subhash, Ghatu/J-4851-2017	Subhash, Ghatu/0000-0002-5996-0909	Army Research Office [W911NF-10-1-0276]	This research was funded by the Army Research Office award number W911NF-10-1-0276.	APFEL RE, 1991, ULTRASOUND MED BIOL, V17, P179, DOI 10.1016/0301-5629(91)90125-G; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BENJAMIN TB, 1966, PHILOS TR R SOC S-A, V260, P221, DOI 10.1098/rsta.1966.0046; Blatteau JE, 2006, ANN FR ANESTH, V25, P874, DOI 10.1016/j.annfar.2006.04.007; Brennen C. E., 1995, CAVITATION BUBBLE DY; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Delius M, 2002, EUR SURG RES, V34, P30, DOI 10.1159/000048884; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Gateau J, 2013, ULTRASOUND MED BIOL, V39, P1812, DOI 10.1016/j.ultrasmedbio.2013.04.011; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Goldsmith W, 2001, CRIT REV BIOMED ENG, V29, P441, DOI 10.1615/CritRevBiomedEng.v29.i56.10; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; HARRISON M, 1952, J ACOUST SOC AM, V24, P454, DOI 10.1121/1.1917513; HARVEY EN, 1945, B NEW YORK ACAD MED, V21, P505; JONES IR, 1960, J FLUID MECH, V7, P596, DOI 10.1017/S0022112060000311; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; KENNER VH, 1973, J BIOMECH, V6, P1, DOI 10.1016/0021-9290(73)90032-8; Kornfeld M, 1944, J APPL PHYS, V15, P495, DOI 10.1063/1.1707461; Kurosawa Y, 2009, IEEE ENG MED BIO, P7224, DOI 10.1109/IEMBS.2009.5335260; Lee SJ, 2011, J BIOMED MATER RES B, V97B, P84, DOI 10.1002/jbm.b.31789; Liu QL, 2006, MECH MATER, V38, P1105, DOI 10.1016/j.mechmat.2006.01.001; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; LUBOCK P, 1980, J BIOMECH, V13, P1041, DOI 10.1016/0021-9290(80)90048-2; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1861, DOI 10.1016/j.apmr.2013.05.027; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Ohl CD, 2006, BIOPHYS J, V91, P4285, DOI 10.1529/biophysj.106.075366; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pan B, 2007, OPT ENG, V46, DOI 10.1117/1.2714926; Pan B, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/6/062001; PLESSET MS, 1971, J FLUID MECH, V47, P283, DOI 10.1017/S0022112071001058; RAVICHANDRAN G, 1994, J AM CERAM SOC, V77, P263, DOI 10.1111/j.1151-2916.1994.tb06987.x; Rayleigh, 1917, PHILOS MAG, V34, P94, DOI 10.1080/14786440808635681; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Sarntinoranont M, 2012, J NEUROTRAUM, V29, P418, DOI 10.1089/neu.2011.1772; SHIMA A, 1981, J FLUID ENG-T ASME, V103, P370; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Subhash G, 2006, INT J IMPACT ENG, V32, P1113, DOI 10.1016/j.ijimpeng.2004.11.006; Subhash G, 2011, EXP MECH, V51, P255, DOI 10.1007/s11340-010-9354-2; Subhash G., 2000, MECH TESTING EVALUAT, V8, P497, DOI DOI 10.1361/ASMHBA0003299; TOMITA Y, 1986, J FLUID MECH, V169, P535, DOI 10.1017/S0022112086000745; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; VOGEL A, 1989, J FLUID MECH, V206, P299, DOI 10.1017/S0022112089002314; Wang YC, 2006, EXP FLUIDS, V41, P365, DOI 10.1007/s00348-006-0135-8	50	28	28	0	21	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4851	1741-2765		EXP MECH	Exp. Mech.	JAN	2016	56	1			SI		97	109		10.1007/s11340-015-0024-2			13	Materials Science, Multidisciplinary; Mechanics; Materials Science, Characterization & Testing	Science Citation Index Expanded (SCI-EXPANDED)	Materials Science; Mechanics	DC6JN	WOS:000369326200008					2022-02-06	
J	Olabarrieta-Landa, L; Caracuel, A; Perez-Garcia, M; Panyavin, I; Morlett-Paredes, A; Arango-Lasprilla, JC				Olabarrieta-Landa, Laiene; Caracuel, Alfonso; Perez-Garcia, Miguel; Panyavin, Ivan; Morlett-Paredes, Alejandra; Carlos Arango-Lasprilla, Juan			The profession of neuropsychology in Spain: results of a national survey	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neuropsychology survey; Spain; professional development	NEURONORMA PROJECT NORMS; BOSTON NAMING TEST; UNITED-STATES; CLINICAL NEUROPSYCHOLOGISTS; NORMATIVE DATA; SALARY SURVEY; SPANISH; BELIEFS; INCOMES; TESTS	Objective: To examine the current status of professional neuropsychology in Spain, with particular focus on the areas of professional training, current work situation, evaluation and diagnostic practice, rehabilitation, teaching, and research. Methods: Three hundred and thirty-nine self-identified professionals in neuropsychology from Spain completed an online survey between July and December of 2013. Respondents had an average age of 35.8years and 77% were women. Results: Ninety-seven percent of the respondents identified as psychologists; 82% of the sample had a master's degree, and 33% a doctoral degree. The majority (91%) received their neuropsychological training at a graduate level; 88% engaged in neuropsychological evaluation, 59% in rehabilitation, 50% in research, and 40% in teaching. Average number of hours per week dedicated to work in neuropsychology was 29.7, with 28% of the respondents reporting working in hospitals, 17% in not-for-profit rehabilitation centers, 15% in universities, and 14% in private clinics. Clinicians primarily work with individuals with stroke, traumatic brain injury, and dementia. The top perceived barriers to development of neuropsychology in Spain included lack of clinical and academic training opportunities, and negative attitude toward professional collaboration. Conclusions: The field of neuropsychology in Spain is young and rapidly growing. There is a need to regulate professional neuropsychology, improve graduate curricula, enhance existing clinical training, develop professional certification programs, validate and create normative data for existing neuropsychological tests, and create new, culturally relevant instruments.	[Olabarrieta-Landa, Laiene; Panyavin, Ivan] Univ Deusto, Dept Psychol, Bilbao, Spain; [Caracuel, Alfonso; Perez-Garcia, Miguel] Univ Granada, CIMCYC, Granada, Spain; [Perez-Garcia, Miguel] Comis Neuropsicol Colegio Oficial Psicol Andaluci, Granada, Spain; [Morlett-Paredes, Alejandra] Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USA; [Carlos Arango-Lasprilla, Juan] Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Carlos Arango-Lasprilla, Juan] Cruces Univ Hosp, BioCruces Hlth Res Inst, Baracaldo, Spain		Arango-Lasprilla, JC (corresponding author), Basque Fdn Sci, Ikerbasque, Bilbao, Spain.; Arango-Lasprilla, JC (corresponding author), Cruces Univ Hosp, BioCruces Hlth Res Inst, Baracaldo, Spain.	jcalasprilla@gmail.com	Caracuel, Alfonso/V-3695-2019; Landa, Laiene Olabarrieta/V-6207-2017; Arango-Lasprilla, Juan Carlos/AAB-5407-2019; Garcia, Miguel Perez/F-9630-2010	Caracuel, Alfonso/0000-0002-9738-8456; Landa, Laiene Olabarrieta/0000-0002-8305-8720; Arango-Lasprilla, Juan Carlos/0000-0002-7184-8311; Garcia, Miguel Perez/0000-0003-4775-7556			Aceituno P., 2014, NOVENO INFORM INNOVA; Alegret M, 2012, J CLIN EXP NEUROPSYC, V34, P209, DOI 10.1080/13803395.2011.630652; [Anonymous], 2014, EF ENGL PROF IND; Carrobles JA, 2014, BEHAV PSYCHOL, V22, P161; Arango-Lasprilla J., 2015, NEUROPSICOLOGIA COLO; Arango-Lasprilla J. C., APPL NEUROP IN PRESS; Arango-Lasprilla J. C. O., 2015, NEUROPSICOLOGIA COLO, P21; Ardila A, 2013, ARCH CLIN NEUROPSYCH, V28, P751, DOI 10.1093/arclin/act036; Bandres J., 1989, REV HIST PSICOLOGIA, V10, P131; Bauermeister J. J., 2010, ADHD REPORT, V18, P12, DOI [10.1521/adhd.2010.18.1.12, DOI 10.1521/ADHD.2010.18.1.12]; Beaumont J. G., 2008, INTRO NEUROPSYCHOLOG, V2nd; Campos-Bueno J. J., 2002, REV HIST PSICOLOGIA, V23, P85; Carpintero H., 2014, L SIMARRO PSICOLOGIA; Elbulok-Charcape MM, 2014, CULT DIVERS ETHN MIN, V20, P353, DOI 10.1037/a0035023; Fonseca-Aguilar Paola, 2015, Psicol. caribe, V32, P344, DOI 10.14482/psdc.32.3.7896; Garcia EG, 2009, REV HIST PSICOL, V30, P107; Hartlage LC, 2011, HANDBOOK OF CLINICAL CHILD NEUROPSYCHOLOGY, THIRD EDITION, P3, DOI 10.1007/978-0-387-78867-8_1; Heilbronner RL, 2004, CLIN NEUROPSYCHOL, V18, P312, DOI 10.1080/13854040490501574; Instituto Nacional de Estadistica, 2015, ENC POBL ACT EPA SER; Instituto Nacional de Estadistica, 2014, PROYECC POBL ESP 201; Instituto Nacional de Estadistica, 2015, EST ACT I D RES DEF; Instituto Nacional de Estadistica, 2015, DEF SEG CAUS MUERT A; Junque Plaja C., 2011, HIST NEUROLOGIA CATA, P211; Kolb B., 2015, FUNDAMENTALS HUMAN N; Martinez Riera Jose Ramon, 2012, Rev Enferm, V35, P6; Pena-Casanova J, 2012, NEUROLOGIA, V27, P253, DOI 10.1016/j.nrl.2011.12.019; Pena-Casanova J., 1991, PROGRAMA INTEGRADO E; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P413, DOI 10.1093/arclin/acp043; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P343, DOI 10.1093/arclin/acp039; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P371, DOI 10.1093/arclin/acp041; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P321, DOI 10.1093/arclin/acp038; Quijano TD, 2004, MED CLIN-BARCELONA, V122, P727, DOI 10.1157/13062190; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rabin LA, 2014, PROF PSYCHOL-RES PR, V45, P368, DOI 10.1037/a0037987; Rami L, 2007, REV NEUROLOGIA, V45, P268, DOI 10.33588/rn.4505.2007112; Rami L, 2008, J CLIN EXP NEUROPSYC, V30, P1, DOI 10.1080/13803390701743954; SCImago Journal and Country Rank, 2015, COUNTR SEARCH W EUR; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P325, DOI 10.1080/13854040600760488; Sweet JJ, 2011, CLIN NEUROPSYCHOL, V25, P12, DOI 10.1080/13854046.2010.544165; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P109, DOI 10.1076/clin.16.2.109.13237; Trincado-Alonso F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/904985; Wilson B. A., 2004, CLIN NEUROPSYCHOLOGY, P345; Wykes T, 2015, LANCET PSYCHIAT, V2, P1036, DOI 10.1016/S2215-0366(15)00332-6	43	28	29	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2016	30	8					1335	1355		10.1080/13854046.2016.1183049			21	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	EA8NR	WOS:000386893100014	27684408	Green Submitted			2022-02-06	
J	Park, JH; Park, YS; Lee, JB; Park, KH; Paik, MK; Jeong, M; Koh, HC				Park, Jae Hyeon; Park, Youn Sun; Lee, Je-Bong; Park, Kyung-Hun; Paik, Min-kyoung; Jeong, Mihye; Koh, Hyun Chul			Meloxicam inhibits fipronil-induced apoptosis via modulation of the oxidative stress and inflammatory response in SH-SY5Y cells	JOURNAL OF APPLIED TOXICOLOGY			English	Article						fipronil; cyclooxygenase-2; p53; meloxicam; anti-inflammatory; antioxidant	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; TRAUMATIC BRAIN-INJURY; DOPAMINERGIC-NEURONS; NUCLEAR TRANSLOCATION; PARKINSONS-DISEASE; BAX TRANSLOCATION; INDUCED ARTHRITIS; COX-2 EXPRESSION; KINASE PATHWAYS	Oxidative stress and inflammatory responses have been identified as key elements of neuronal cell apoptosis. In this study, we investigated the mechanisms by which inflammatory responses contribute to apoptosis in human neuroblastoma SH-SY5Y cells treated with fipronil (FPN). Based on the cytotoxic mechanism of FPN, we examined the neuroprotective effects of meloxicam against FPN-induced neuronal cell death. Treatment of SH-SY5Y cells with FPN induced apoptosis via activation of caspase-9 and -3, leading to nuclear condensation. In addition, FPN induced oxidative stress and increased expression of cyclooxygenase-2 (COX-2) and tumor necrosis factor- (TNF-) via inflammatory stimulation. Pretreatment of cells with meloxicam enhanced the viability of FPN-exposed cells through attenuation of oxidative stress and inflammatory response. FPN activated mitogen activated protein kinase (MAPK) and inhibitors of MAPK abolished FPN-induced COX-2 expression. Meloxicam also attenuated FPN-induced cell death by reducing MAPK-mediated pro-inflammatory factors. Furthermore, we observed both nuclear accumulation of p53 and enhanced levels of cytosolic p53 in a concentration-dependent manner after FPN treatment. Pretreatment of cells with meloxicam blocked the translocation of p53 from the cytosol to the nucleus. Together, these data suggest that meloxicam may exert anti-apoptotic effects against FPN-induced cytotoxicity by both attenuating oxidative stress and inhibiting the inflammatory cascade via inactivation of MAPK and p53 signaling. Copyright (c) 2015 John Wiley & Sons, Ltd. Oxidative stress and inflammatory responses have been identified as key elements of neuronal cell apoptosis. In this study, we investigated the mechanisms by which inflammatory responses contribute to apoptosis in human neuroblastoma SH-SY5Y cells treated with fipronil (FPN). Based on the cytotoxic mechanism of FPN, we examined the neuroprotective effects of meloxicam against FPN-induced neuronal cell death.	[Park, Jae Hyeon; Park, Youn Sun; Koh, Hyun Chul] Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea; [Park, Jae Hyeon; Park, Youn Sun; Koh, Hyun Chul] Hanyang Biomed Res Inst, Seoul, South Korea; [Park, Jae Hyeon; Koh, Hyun Chul] Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul 133791, South Korea; [Lee, Je-Bong; Park, Kyung-Hun; Paik, Min-kyoung; Jeong, Mihye] Natl Acad Agr Sci, Rural Dev Adm, Dept Agrofood Safety, Suwon, South Korea		Koh, HC (corresponding author), Hanyang Univ, Coll Med, Dept Pharmacol, Heandang Dong 17, Seoul 133791, South Korea.	mhjeong@korea.kr; hckoh@hanyang.ac.kr			Agenda Program, Rural Development Administration, Republic of KoreaRural Development Administration (RDA) [PJ008582]	This work was supported by a grant from the Agenda Program (PJ008582), Rural Development Administration, Republic of Korea.	Agha AM, 1999, PHARMACOL RES, V40, P385, DOI 10.1006/phrs.1999.0522; Arafa HMM, 2007, EUR J PHARMACOL, V564, P181, DOI 10.1016/j.ejphar.2007.02.065; Baek BS, 2001, J GERONTOL A-BIOL, V56, pB426, DOI 10.1093/gerona/56.10.B426; Barbieri SS, 2003, CARDIOVASC RES, V60, P187, DOI 10.1016/S0008-6363(03)00365-1; Bedner E, 2000, CYTOMETRY, V41, P83, DOI 10.1002/1097-0320(20001001)41:2<83::AID-CYTO1>3.0.CO;2-R; Chen C, 2010, NAT CHEM BIOL, V6, P401, DOI 10.1038/nchembio.375; Chen ZX, 2009, J HUAZHONG U SCI-MED, V29, P383, DOI 10.1007/s11596-009-0324-9; Choi EM, 2005, BIOCHEM BIOPH RES CO, V328, P1107, DOI 10.1016/j.bbrc.2005.01.072; Cimen MYB, 2003, DRUG CHEM TOXICOL, V26, P169, DOI 10.1081/DCT-120022645; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Das PC, 2006, CHEM-BIOL INTERACT, V164, P200, DOI 10.1016/j.cbi.2006.09.013; Edfawy M, 2012, INT J TOXICOL, V31, P276, DOI 10.1177/1091581812442939; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; Gomez-Santos C, 2002, BRAIN RES, V935, P32, DOI 10.1016/S0006-8993(02)02422-8; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Gurocak S, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.03.040; Hakan T, 2010, NEUROL RES, V32, P629, DOI 10.1179/016164109X12464612122731; Hsuan SL, 2006, J NEUROSCI, V26, P4481, DOI 10.1523/JNEUROSCI.4922-05.2006; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x; Jang JH, 2005, FREE RADICAL BIO MED, V38, P1604, DOI 10.1016/j.freeradbiomed.2005.02.023; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Ki YW, 2013, TOXICOL LETT, V218, P235, DOI 10.1016/j.toxlet.2013.02.003; Ki YW, 2012, TOXICOL LETT, V211, P18, DOI 10.1016/j.toxlet.2012.02.022; Kyaw M, 2001, HYPERTENS RES, V24, P251, DOI 10.1291/hypres.24.251; Leavy O, 2011, NAT REV IMMUNOL, V11, P162, DOI 10.1038/nri2943; Lee JE, 2011, TOXICOL LETT, V202, P133, DOI 10.1016/j.toxlet.2011.01.030; Lei XH, 2013, CNS NEUROSCI THER, V19, P109, DOI 10.1111/cns.12045; Leung WK, 2001, BRIT J CANCER, V84, P335, DOI 10.1054/bjoc.2000.1607; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Narita M, 2008, NEUROSCIENCE, V152, P477, DOI 10.1016/j.neuroscience.2007.10.039; Nieminen R, 2005, MEDIAT INFLAMM, P249, DOI 10.1155/MI.2005.249; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Overmyer JP, 2007, J ENVIRON SCI HEAL B, V42, P471, DOI 10.1080/03601230701391823; Park JH, 2013, TOXICOL LETT, V223, P25, DOI 10.1016/j.toxlet.2013.08.015; Ramesh G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/480739; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tasaki Y, 2010, BRAIN RES, V1344, P25, DOI 10.1016/j.brainres.2010.04.085; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Tingle CCD, 2003, REV ENVIRON CONTAM T, V176, P1; Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128; Vidau C, 2011, NEUROTOXICOLOGY, V32, P935, DOI 10.1016/j.neuro.2011.04.006; Vidau C, 2009, TOXICOL IN VITRO, V23, P589, DOI 10.1016/j.tiv.2009.01.017; Wen ZH, 2013, OSTEOARTHR CARTILAGE, V21, P1976, DOI 10.1016/j.joca.2013.09.005; Won JH, 2006, BRIT J PHARMACOL, V148, P216, DOI 10.1038/sj.bjp.0706718; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Yang W, 2010, TOXICOL LETT, V199, P239, DOI 10.1016/j.toxlet.2010.09.005; Yu CR, 2004, EXP CELL RES, V295, P555, DOI 10.1016/j.yexcr.2004.02.001	56	28	28	3	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0260-437X	1099-1263		J APPL TOXICOL	J. Appl. Toxicol.	JAN	2016	36	1					10	23		10.1002/jat.3136			14	Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Toxicology	CX6FF	WOS:000365795900002	25772694				2022-02-06	
J	Reith, FCM; Brennan, PM; Maas, AIR; Teasdale, GM				Reith, Florence C. M.; Brennan, Paul M.; Maas, Andrew I. R.; Teasdale, Graham M.			Lack of Standardization in the Use of the Glasgow Coma Scale: Results of International Surveys	JOURNAL OF NEUROTRAUMA			English	Article						consciousness; Glasgow Coma Scale; humans; questionnaires; reproducibility of results	INJURY	The Glasgow Coma Scale (GCS) was introduced 40 years ago and has received world-wide acceptance. The GCS rates eye, motor, and verbal responses to assess the level of consciousness. Concerns have been expressed with regard to reliability and consistency of assessments. We considered that lack of standardization in application techniques and reporting of the GCS may have contributed to these concerns, and aimed to assess current procedures in its use. Questionnaire-based assessments were conducted by an online survey and during neurosurgical training courses. Overall, 616 participants were recruited, representing 48 countries and including physicians and nurses from different disciplines. Use of the GCS was reported by nearly all participants for assessment of patients with traumatic brain injury, but not for all patients with a reduced level of consciousness from other causes (78%). Major differences were found regarding the type of stimulus applied when patients do not obey commands: Nail bed pressure, supraorbital pressure, trapezius or pectoralis pinch, and sternal rub were all frequently used, whereas 25% of responders reported to never use a peripheral stimulus. Strategies for reporting the GCS varied greatly, and 35% of participants limited the reporting to a summary score. Moreover, different approaches were used when one of the components could not be assessed. Overall, the surveys have identified a general lack of standardization in assessment and reporting of the GCS. The results illustrate the need for continued education to improve reliability of assessments through guidance to a standard approach.	[Reith, Florence C. M.; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Reith, Florence C. M.; Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Brennan, Paul M.] Western Gen Hosp, Dept Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland; [Teasdale, Graham M.] Univ Glasgow, Neurosurg, Glasgow, Lanark, Scotland		Reith, FCM (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	florence.reith@uza.be					Baker M, 2008, J NEUROSCI NURS, V4, P342; Edwards S L, 2001, Br J Nurs, V10, P92; Fielding K, 1990, Aust J Adv Nurs, V7, P13; Fischer J, 2001, Crit Care Nurs Q, V23, P52; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Heron R, 2001, Aust Crit Care, V14, P100, DOI 10.1016/S1036-7314(01)80026-6; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koch D, 2000, INT MED J, V7, P51; KOZIOL JA, 1990, J NEUROL, V237, P461, DOI 10.1007/BF00314762; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Mattar I, 2013, J NEUROSCI NURS, V45, P272, DOI 10.1097/JNN.0b013e31829db970; Middleton PM, 2012, AUSTRALAS EMERG NURS, V15, P170, DOI 10.1016/j.aenj.2012.06.002; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Shoqirat N, 2006, Nurs Stand, V20, P41; TEASDALE G, 1983, LANCET, V2, P678; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1975, Nurs Times, V71, P914; Teasdale G, 2014, NURS TIMES, V110, P12; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	23	28	29	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					89	94		10.1089/neu.2014.3843			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200011	25951090	Green Accepted			2022-02-06	
J	Tierney, GJ; Lawler, J; Denvir, K; McQuilkin, K; Simms, CK				Tierney, Gregory J.; Lawler, John; Denvir, Karl; McQuilkin, Kurt; Simms, Ciaran K.			Risks associated with significant head impact events in elite rugby union	BRAIN INJURY			English	Article						Sport; video analysis; statistical analysis	WORLD-CUP; INJURY SURVEILLANCE; TACKLE INJURIES; PLAYERS; EPIDEMIOLOGY; CONCUSSION; FOOTBALL; PROJECT; SEASON; SPORT	Primary objectives: To conduct video and statistical analysis on Rugby Union play, focusing mainly on the tackle, to establish the player to player configurations for significant direct head impacts and non-direct head impacts.Research design: Quantitative, observational cohort study.Methods and procedures: Video analysis of 52 significant direct head impacts (31 Tackle, 10 Ruck, 7 Dive and 4 Ground) and 40 non-direct head impact tackles from 2014/15 International Rugby Union matches. Relative risk, 95% CI and p-values were calculated for a range of tackle variables.Main outcome and results: Upper body tackles and lower body tackles accounted for 37% (19) and 23% (12) of cases, respectively, with the tackler as the head impacted player for 97% (30) of cases. The majority (81%) of tackle-related significant direct head impacts occurred in the second half of the game, with 63% of upper body tackle significant direct head impacts occurring in the final quarter. Tackler head placement and high speed tackles had statistical significance for causing tackle related significant direct head impacts as well as foot planting and difference in tackler and ball carrier mass for upper body tackles and ball carrier change in direction for lower body tackles.Conclusion: Tackle variables that statistically increased the risk of significant direct head impact were identified, which can aid player protection strategies.	[Tierney, Gregory J.; Lawler, John; Simms, Ciaran K.] Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin, Ireland; [Denvir, Karl; McQuilkin, Kurt] Leinster Rugby, Dublin, Ireland		Tierney, GJ (corresponding author), Trinity Coll Dublin, Trinity Ctr Bioengn, Dept Mech & Mfg Engn, Dublin 2, Ireland.	gtierne@tcd.ie	Simms, Ciaran/K-3100-2019	Simms, Ciaran/0000-0001-5564-1620; Tierney, Gregory/0000-0002-4666-4473	Irish Research CouncilIrish Research Council for Science, Engineering and Technology	Acknowledgement should be given to the Irish Research Council for funding this study. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Alexander DG, 2015, BRAIN INJURY, V29, P1113, DOI 10.3109/02699052.2015.1031699; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Cross M, 2015, BRIT J SPORT MED; Fraas MR, 2014, PHYS THER SPORT, V15, P136, DOI 10.1016/j.ptsp.2013.08.002; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hendricks S, 2014, BRIT J SPORT MED, V48, P606; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hutchison MG, 2013, BRIT J SPORT MED, V49, P552; Jakoet I, 1998, INJURY, V29, P27; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; MacQueen AE, 2010, CURR SPORT MED REP, V9, P139, DOI 10.1249/JSR.0b013e3181df124c; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2005, BRIT J SPORT MED, V39, P2, DOI 10.1136/bjsm.2004.016188; Pagano M, 2000, PRINCIPLES BIOSTATIS, V2nd; por Chapman y Hall/CRC, 1990, PRACTICAL STAT MED R; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Shuttleworth-Edwards AB, 2008, CLIN J SPORT MED, V18, P403, DOI 10.1097/JSM.0b013e3181895910; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002	30	28	28	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	11					1350	1361		10.1080/02699052.2016.1193630			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DZ8TP	WOS:000386144900008	27715327	Green Accepted			2022-02-06	
J	Soltani, Z; Khaksari, M; Jafari, E; Iranpour, M; Shahrokhi, N				Soltani, Zahra; Khaksari, Mohammad; Jafari, Elham; Iranpour, Maryam; Shahrokhi, Nader			Is genistein neuroprotective in traumatic brain injury?	PHYSIOLOGY & BEHAVIOR			English	Article						Brain injury; Intracranial pressure; Blood-brain barrier; Brain edema	KINASE INHIBITOR GENISTEIN; ESTROGEN-RECEPTOR-ALPHA; SEX STEROID-HORMONES; INTRACRANIAL-PRESSURE; OXIDATIVE STRESS; NEUROLOGIC OUTCOMES; EXPERIMENTAL STROKE; SOY PHYTOESTROGENS; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE	The concerns about negative consequences of estrogen therapy have led to introduce other strategies to obtain estrogen's benefits in the brain. The present study tests the hypothesis that a major isoflavone of soy; genistein with estrogen-like activity can be neuroprotective in traumatic brain injury (TBI). The male Wistar rats were randomly divided to four groups: sham, TB!, vehicle and genistein. The TBI was induced by Marmarou method. The brain edema and the disruption of blood-brain-barrier (BBB) were evaluated 48 h post-TBI. Genistein (15 mg/kg) or dimethyl sulfoxide (DMSO) was injected i.p., twice after TBI. The intracranial pressure (ICP), the motor performance, and the beam-walk task (WB) were determined before trauma, on trauma day (DO), and first (D1) and second (D2) days post-TBI, Genistein inhibited a development of brain edema and a BBB permeability in TB! animals. An increase of ICP and a defect in motor and WB performance were showed following TB!, in all times evaluated. An increase of ICP induced by TBI was suppressed by genistein on D1 and D2 times. Genistein improved a motor disorder induced by TB!, on D1 and D2 times. Also an increase of traversal time in WB task was suppressed by genistein in TBI animals, on D1 and D2 times. The results of this study demonstrated that genistein can be neuroprotective in TB!. Genistein inhibited the disruption of BBB, the brain edema and the increase of ICP, and the disturbance of neurobehavioral performance in TBI. (C) 2015 Elsevier Inc All rights reserved.	[Soltani, Zahra] Kerman Univ Med Sci, Physiol Res Ctr, Inst Neuropharmacol, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Neurosci Res Ctr, Inst Neuropharmacol, Kerman, Iran; [Jafari, Elham; Iranpour, Maryam] Kerman Univ Med Sci, Dept Pathol, Aftalipour Coll Med Sci, Kerman, Iran; [Shahrokhi, Nader] Kerman Univ Med Sci, Endocrinol & Metab Res Ctr, Inst Basic & Clin Physiol Sci, Kerman, Iran		Khaksari, M (corresponding author), Kerman Univ Med Sci, Neurosci Res Ctr, Inst Neuropharmacol, Kerman, Iran.	mkhaksari@kmu.ac.ir	Jafari, Elham/AAC-2580-2019; IRANPOUR, MARYAM/AAH-7467-2019; Shahrokhi, Nader/AAV-3747-2020; Soltani, Zahra/AAC-1350-2019; Haddad, Mohammad Khaksari/AAB-9025-2019; jafari, elham/AAA-1028-2020	IRANPOUR, MARYAM/0000-0001-8749-8080; Shahrokhi, Nader/0000-0002-0149-7819; Soltani, Zahra/0000-0002-8423-6189; Haddad, Mohammad Khaksari/0000-0003-0770-4281; 			AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Aras A.B., 2015, INFLAMMATION; Azcoitia I, 2006, GYNECOL ENDOCRINOL, V22, P63, DOI 10.1080/09513590500519161; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bang OY, 2004, NEUROBIOL DIS, V16, P21, DOI 10.1016/j.nbd.2003.12.017; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Choi EJ, 2004, LIFE SCI, V75, P499, DOI 10.1016/j.lfs.2004.01.010; Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Dixon RA, 2004, ANNU REV PLANT BIOL, V55, P225, DOI 10.1146/annurev.arplant.55.031903.141729; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Duckles S.P., 2007, CLIN EXP PHARM PHYSL, V34, P801; Fazel MR, 2012, ARCH TRAUMA RES, V1, P63, DOI 10.5812/atr.6770; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Felton M, 2001, DISCOURSE PROCESS, V32, P135; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Hart SA, 2001, J COMP NEUROL, V440, P144, DOI 10.1002/cne.1376; HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015; Huang RQ, 1999, MOL BRAIN RES, V67, P177, DOI 10.1016/S0169-328X(99)00061-3; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; Kim H, 1998, AM J CLIN NUTR, V68, p1418S, DOI 10.1093/ajcn/68.6.1418S; KINDY MS, 1993, J CEREBR BLOOD F MET, V13, P372, DOI 10.1038/jcbfm.1993.50; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Lee YW, 2008, J NUTR BIOCHEM, V19, P819, DOI 10.1016/j.jnutbio.2007.10.006; Liang HW, 2008, NEUROSCI LETT, V438, P116, DOI 10.1016/j.neulet.2008.04.058; Linford NJ, 2001, J PHARMACOL EXP THER, V299, P67; Lovekamp-Swan T, 2007, NEUROSCIENCE, V148, P644, DOI 10.1016/j.neuroscience.2007.06.046; Ma YL, 2013, ENDOCRINOLOGY, V154, P1589, DOI 10.1210/en.2012-2120; Ma YL, 2010, AM J PHYSIOL-REG I, V299, pR871, DOI 10.1152/ajpregu.00031.2010; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; MARKOVITS J, 1989, CANCER RES, V49, P5111; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; MILDE LN, 1985, ANESTHESIOLOGY, V63, P371, DOI 10.1097/00000542-198510000-00005; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Patel RP, 2001, FREE RADICAL BIO MED, V31, P1570, DOI 10.1016/S0891-5849(01)00737-7; Patisaul HB, 2002, ENDOCRINOLOGY, V143, P2189, DOI 10.1210/en.143.6.2189; Prongay KD, 2010, LAB ANIM-UK, V44, P238, DOI 10.1258/la.2009.009031; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Schreihofer DA, 2009, NEUROSCIENCE, V158, P602, DOI 10.1016/j.neuroscience.2008.10.003; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shakeril M, 2013, ARCH TRAUMA RES, V2, P76, DOI 10.5812/atr.8549; Shambayati M, 2014, BRAIN RES, V1593, P76, DOI 10.1016/j.brainres.2014.09.042; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sirotkin AV, 2014, EUR J PHARMACOL, V741, P230, DOI 10.1016/j.ejphar.2014.07.057; Soltani Z., 2014, J NEUROL NEUROPHYSIO; Sonee M, 2004, NEUROTOXICOLOGY, V25, P885, DOI 10.1016/j.neuro.2003.11.001; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Trieu VN, 1999, RADIAT RES, V152, P508, DOI 10.2307/3580147; Wang SQ, 2014, INT J BIOL SCI, V10, P457, DOI 10.7150/ijbs.7562; Wei M, 2014, BRAIN RES, V1585, P150, DOI 10.1016/j.brainres.2014.06.018; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1602/neurorx.1.1.5; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Zeng HY, 2004, FREE RADICAL BIO MED, V36, P180, DOI 10.1016/j.freeradbiomed.2003.10.018; Zhao LX, 2002, EXP BIOL MED, V227, P509, DOI 10.1177/153537020222700716	63	28	28	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	DEC 1	2015	152		A				26	31		10.1016/j.physbeh.2015.08.037			6	Psychology, Biological; Behavioral Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Behavioral Sciences	CZ2RZ	WOS:000366953600004	26367454	Green Accepted			2022-02-06	
J	Michael, AP; Stout, J; Roskos, PT; Bolzenius, J; Gfeller, J; Mogul, D; Bucholz, R				Michael, Alex P.; Stout, Jeffrey; Roskos, P. Tyler; Bolzenius, Jacob; Gfeller, Jeffrey; Mogul, David; Bucholz, Richard			Evaluation of Cortical Thickness after Traumatic Brain Injury in Military Veterans	JOURNAL OF NEUROTRAUMA			English	Article						cortical thickness; magnetic resonance imaging; military veterans; traumatic brain injury	WHITE-MATTER INTEGRITY; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; SERVICE MEMBERS; IMAGING APPROACH; MILD; BLAST; SEGMENTATION; MODERATE; DIFFUSE	Military service members frequently sustain traumatic brain injuries (TBI) while on active duty, a majority of which are related to explosive blasts and are mild in severity. Studies evaluating the cortical gray matter in persons with injuries of this nature remain scarce. The purpose of this study was to assess cortical thickness in a sample of military veterans with chronic blast-related TBI. Thirty-eight veterans with mild TBI and 17 veterans with moderate TBI were compared with 58 demographically matched healthy civilians. All veterans with TBI sustained injuries related to a blast and were between 5 and 120 months post-injury (M=62.08). Measures of post-traumatic stress disorder (PTSD) and depression were administered, along with a battery of neuropsychological tests to assess cognition. The Freesurfer software package was used to calculate cortical thickness of the participants. Results demonstrated significant clusters of cortical thinning in the right hemispheric insula and inferior portions of the temporal and frontal lobe in both mild and moderate TBI participants. The TBI sample from this study demonstrated a high incidence of comorbid PTSD and depression symptoms, which is consistent with the previous literature. Cortical thickness values correlated with measures of PTSD, depression, and post-concussive symptoms. This study provides evidence of cortical thinning in the context of chronic blast-related mild and moderate TBI in military veterans who have comorbid psychiatric symptoms. Our findings provide important insight into the natural progression of long-term cortical change in this population and may have implications for future clinical evaluation and treatment.	[Michael, Alex P.] So Illinois Univ, Sch Med, Div Neurosurg, Springfield, IL 62702 USA; [Stout, Jeffrey; Mogul, David] IIT, Dept Biomed Engn, Chicago, IL 60616 USA; [Roskos, P. Tyler] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Dearborn, MI USA; [Bolzenius, Jacob] Univ Missouri, St Louis, MO 63121 USA; [Gfeller, Jeffrey] St Louis Univ, Dept Psychol, Sch Med, St Louis, MO 63103 USA; [Bucholz, Richard] St Louis Univ, Sch Med, Dept Neurosurg, St Louis, MO USA		Michael, AP (corresponding author), So Illinois Univ, Sch Med, Div Neurosurg, 421 N 9th St, Springfield, IL 62702 USA.	amichael@siumed.edu	Stout, Jeffrey R/F-5805-2014; Mogul, David/L-2765-2019	Stout, Jeffrey R/0000-0001-6114-1649; 	Department of Defense: Evidence-Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress DisorderUnited States Department of Defense [W81XWH-08-2-0191]	We would first like to thank the participants for taking part in this study. We would also like to thank D. Whitson, S. Taylor, and L. McDurmont for their work in recruitment and collection of data. This research was supported by the following grant from the Department of Defense: Evidence-Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder. Contract Number W81XWH-08-2-0191, Richard Bucholz, Principal Investigator.	[Anonymous], 1944, MAN DIR SCOR; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Christopoulos GI, 2009, J NEUROSCI, V29, P12574, DOI 10.1523/JNEUROSCI.2614-09.2009; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Corbo V, 2014, PSYCHIAT RES-NEUROIM, V223, P53, DOI 10.1016/j.pscychresns.2014.04.013; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dickerson BC, 2008, NEUROIMAGE, V39, P10, DOI 10.1016/j.neuroimage.2007.08.042; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Liberzon I, 2006, ANN NY ACAD SCI, V1071, P87, DOI 10.1196/annals.1364.009; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Soble JR, 2014, CLIN NEUROPSYCHOL, V28, P614, DOI 10.1080/13854046.2014.894576; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Weathers F.W., 1993, ANN CONV INT SOC TRA, V141; Weschsler D., 1997, WAIS 3 ADM SCORING M; White SF, 2015, NEUROIMAGE-CLIN, V7, P19, DOI 10.1016/j.nicl.2014.11.012; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160	56	28	30	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1751	1758		10.1089/neu.2015.3918			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500005	26131617	Green Submitted			2022-02-06	
J	Zhang, CC; Chen, JQ; Lu, H				Zhang, Chengcheng; Chen, Jianqiang; Lu, Hong			Expression of aquaporin-4 and pathological characteristics of brain injury in a rat model of traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						traumatic brain injury; cerebral edema; histopathology; aquaporin 4; contralateral non-damaged side; vasogenic edema	EDEMA; ASTROCYTES; TISSUE	Aquaporin 4 (AQP4) is a widely distributed membrane protein, which is found in glial cells, ependymocytes and capillary endothelial cells in the brain, and particularly in the choroid plexus. AQP4 is a key regulator of water metabolism, and changes in its expression following brain injury are associated with pathological changes in the damaged side of the brain; however, the effects of brain injury on AQP4 and injury-induced pathological changes in the contralateral non-damaged side of the brain remain to be fully elucidated. In the present study, male Sprague-Dawley rats were subjected to traumatic brain injury (TBI) and changes in brain water content, the expression of AQP4 expression and pathological characteristics in the damaged and contralateral non-damaged sides of the brain were examined. In the damaged side of the brain, vasogenic edema appeared first, followed by cellular edema. The aggravated cellular edema in the damaged side of the brain resulted in two periods of peak edema severity. Pathological changes in the contralateral non-damaged side of the brain occurred later than those in the damaged side; cellular edema appeared first, followed by vasogenic edema, which was alleviated earlier than the cellular edema. AQP4 was downregulated during vasogenic edema, and upregulated during cellular edema. Taken together, these results suggested that the downregulation of AQP4 was a result of vasogenic edema and that the upregulation of AQP4 may have induced cellular edema.	[Zhang, Chengcheng; Chen, Jianqiang; Lu, Hong] Cent S Univ, Affiliated Haikou Hosp, Xiangya Sch Med, Dept Radiol, Haikou 570208, Hainan, Peoples R China		Lu, H (corresponding author), Cent S Univ, Affiliated Haikou Hosp, Xiangya Sch Med, Dept Radiol, 43 Renmin Rd, Haikou 570208, Hainan, Peoples R China.	471739847@qq.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81160181]; Hainan Provincial International Corporation Project of China [2012-GH016]	This study was supported by the National Natural Science Foundation of China (grant. no.81160181) and the Hainan Provincial International Corporation Project of China (grant. no. 2012-GH016).	Badaut J, 2014, BBA-GEN SUBJECTS, V1840, P1554, DOI 10.1016/j.bbagen.2013.10.032; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Ding Z, 2013, CHINESE J DIFFICULT, V12, P950; Easton AS, 2013, ADV EXP MED BIOL, V763, P1; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Hu H, 2012, NEURAL REGEN RES, V7, P1659, DOI 10.3969/j.issn.1673-5374.2012.21.009; Imam AM, 2013, J TRAUMA ACUTE CARE, V75, P976, DOI 10.1097/TA.0b013e31829e2186; Kim JY, 2015, J KOREAN MED SCI, V30, P943, DOI 10.3346/jkms.2015.30.7.943; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; [刘辉 Liu Hui], 2009, [解剖学杂志, Chinese Journal of Anatomy], V32, P68; Lo Pizzo M, 2013, NEUROL SCI, V34, P1309, DOI 10.1007/s10072-012-1233-4; Lu H, 2011, CHINESE J ANATOMY, V34, P47; Lu H, 2013, CHINESE MED J-PEKING, V126, P4316, DOI 10.3760/cma.j.issn.0366-6999.20131139; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Sabre L, 2013, SPINAL CORD, V51, P623, DOI 10.1038/sc.2013.41; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Wei XE, 2012, J NEUROTRAUM, V29, P2413, DOI 10.1089/neu.2010.1510; Yang J, 2013, LIFE SCI, V93, P1033, DOI 10.1016/j.lfs.2013.10.015; Yao XM, 2008, J NEUROSCI, V28, P5460, DOI 10.1523/JNEUROSCI.0257-08.2008; Zhang L, 2008, SHOUDU YIKE DAXUE XU, V29, P732	24	28	29	1	5	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	NOV	2015	12	5	B				7351	7357		10.3892/mmr.2015.4372			7	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	CW3JR	WOS:000364889100020	26459070	hybrid, Green Submitted, Green Published			2022-02-06	
J	Lewis, PM; Czosnyka, M; Carter, BG; Rosenfeld, JV; Paul, E; Singhal, N; Butt, W				Lewis, Philip M.; Czosnyka, Marek; Carter, Bradley G.; Rosenfeld, Jeffrey V.; Paul, Eldho; Singhal, Nitesh; Butt, Warwick			Cerebrovascular Pressure Reactivity in Children With Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						arterial pressure; cerebrovascular circulation; children; Glasgow Outcome Scale; intracranial pressure; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW AUTOREGULATION; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; VASOMOTOR REACTIVITY; CRITICAL THRESHOLDS; MYOGENIC RESPONSES; HYPERTENSION; MORTALITY; CARE	Objective: Traumatic brain injury is a significant cause of morbidity and mortality in children. Cerebral autoregulation disturbance after traumatic brain injury is associated with worse outcome. Pressure reactivity is a fundamental component of cerebral autoregulation that can be estimated using the pressure-reactivity index, a correlation between slow arterial blood pressure, and intracranial pressure fluctuations. Pressure-reactivity index has shown prognostic value in adult traumatic brain injury, with one study confirming this in children. Pressure-reactivity index can identify a cerebral perfusion pressure range within which pressure reactivity is optimal. An increasing difference between optimal cerebral perfusion pressure and cerebral perfusion pressure is associated with worse outcome in adult traumatic brain injury; however, this has not been investigated in children. Our objective was to study pressure-reactivity index and optimal cerebral perfusion pressure in pediatric traumatic brain injury, including associations with outcome, age, and cerebral perfusion pressure. Design: Prospective observational study. Setting: ICU, Royal Children's Hospital, Melbourne, Australia. Patients: Patients with traumatic brain injury who are 6 months to 16 years old, are admitted to the ICU, and require arterial blood pressure and intracranial pressure monitoring. Interventions: None. Measurements and Main Results: Arterial blood pressure, intracranial pressure, and end-tidal Co-2 were recorded electronically until ICU discharge or monitoring cessation. Pressure-reactivity index and optimal cerebral perfusion pressure were computed according to previously published methods. Clinical data were collected from electronic medical records. Outcome was assessed 6 months post discharge using the modified Glasgow Outcome Score. Thirty-six patients were monitored, with 30 available for follow-up. Pressure-reactivity index correlated with modified Glasgow Outcome Score (Spearman rho = 0.42; p = 0.023) and was higher in patients with unfavorable outcome (0.23 vs -0.09; p = 0.0009). A plot of pressure-reactivity index averaged within 5 mm Hg cerebral perfusion pressure bins showed a U-shape, reaffirming the concept of cerebral perfusion pressure optimization in children. Optimal cerebral perfusion pressure increased with age (rho = 0.40; p = 0.02). Both the duration and magnitude of negative deviations in the difference between cerebral perfusion pressure and optimal cerebral perfusion pressure were associated with unfavorable outcome. Conclusions: In pediatric patients with traumatic brain injury, pressure-reactivity index has prognostic value and can identify cerebral perfusion pressure targets that may differ from treatment protocols. Our results suggest but do not confirm that cerebral perfusion pressure targeting using pressure-reactivity index as a guide may positively impact on outcome. This question should be addressed by a prospective clinical study.	[Lewis, Philip M.; Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Lewis, Philip M.; Rosenfeld, Jeffrey V.] Monash Univ, Cent Clin Sch, Dept Surg, Melbourne, Vic 3004, Australia; [Czosnyka, Marek] Univ Cambridge, Dept Clin Neurosci, Neurosurg Unit, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Carter, Bradley G.] Royal Childrens Hosp, Paediat Intens Care Unit, Clin Technol Serv, Parkville, Vic 3052, Australia; [Rosenfeld, Jeffrey V.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Surg, Bethesda, MD 20814 USA; [Paul, Eldho] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia; [Paul, Eldho] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Singhal, Nitesh; Butt, Warwick] Royal Childrens Hosp, Paediat Intens Care Unit, Parkville, Vic 3052, Australia; [Butt, Warwick] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia		Lewis, PM (corresponding author), Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia.	p.lewis@alfred.org.au		czosnyka, marek/0000-0003-2446-8006; Paul, Eldho/0000-0003-1263-7255	Transport Accident Commission; National Institute of Health Research, UK, Biomedical Research Center; National Institute of Health Research, UKNational Institute for Health Research (NIHR); TAC; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390] Funding Source: UKRI	Supported, in part, by the Transport Accident Commission.; Dr. Lewis has a financial interest in a fraction of the licensing fee of ICM+ Tools. Dr. Czosnyka was supported by the National Institute of Health Research, UK, Biomedical Research Center (Neuroscience Theme) and has a financial interest in a fraction of the licensing fee of ICM+. ICM+ (http://www.neurosurg.cam.ac.uk/icmplus) is licensed by Cambridge Enterprise (Cambridge, United Kingdom). ICM+ Tools (http://www.med.monash.edu.au/surgery/alfred/services/icm.html) is licensed by Monash University. Dr. Lewis disclosed royalties (Software only recently licensed, royalties to Dr. Lewis and his institution not received yet. ICM+ Tools is licensed by Monash University. As its developer, Dr. Lewis has a financial interest in a small part of the licensing fee). Dr. Czosnyka received grant support from the National Institute of Health Research, UK; consulted for J&J Codman; is employed by the University of Cambridge; lectured for Integra LifeScience; and received royalties from Cambridge Enterprise Ltd. Dr. Carter's institution received grant support from TAC. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; Bayreuther J, 2009, ARCH DIS CHILDHOOD-E, V94, P37, DOI 10.1136/adc.2007.132787; Bowles AP, 2012, BRAIN INJURY, V26, P1415, DOI 10.3109/02699052.2012.694558; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2012, J APPL PHYSIOL, V113, P1362, DOI 10.1152/japplphysiol.00853.2012; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brady KM, 2009, ANESTH ANALG, V108, P1278, DOI 10.1213/ane.0b013e3181964848; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Cremer OL, 2004, ANESTH ANALG, V99, P1211, DOI 10.1213/01.ANE.0000133917.67728.2A; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DAVIS MJ, 1990, AM J PHYSIOL, V259, pH1890, DOI 10.1152/ajpheart.1990.259.6.H1890; Deasy C, 2012, INJURY, V43, P2006, DOI 10.1016/j.injury.2011.08.032; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias Celeste, 2015, NEUROCRIT CARE; Faul M, 2010, TRAUMATIC BRAIN INJU; Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7; Jaeger M, 2013, NEUROCRIT CARE, V19, P69, DOI 10.1007/s12028-013-9857-7; Johnson U, 2014, NEUROCRIT CARE, V21, P259, DOI 10.1007/s12028-014-9954-2; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150; Miller J D, 1972, Prog Brain Res, V35, P411; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Paulson O. B., 1990, BRAIN METAB REV, V2, P161; Sanchez-Porras R, 2012, ACTA NEUROCHIR, V154, P1575, DOI 10.1007/s00701-012-1423-0; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2002, ANESTH ANALG, V95, P1463, DOI 10.1097/00000539-200211000-00078; Tang SC, 2013, J FORMOS MED ASS; Taylor A, 2003, INTENS CARE MED, V29, P795, DOI 10.1007/s00134-003-1690-6; Thorat JD, 2008, J CLIN NEUROSCI, V15, P143, DOI 10.1016/j.jocn.2006.08.014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Wallis SJ, 1996, STROKE, V27, P2287, DOI 10.1161/01.STR.27.12.2287; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wolff HG, 1928, ARCH NEURO PSYCHIATR, V20, P1035, DOI 10.1001/archneurpsyc.1928.02210170142002; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	45	28	29	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	OCT	2015	16	8					739	749		10.1097/PCC.0000000000000471			11	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	DD1UP	WOS:000369708000015	26132743				2022-02-06	
J	O'Brien, NF; Maa, T; Reuter-Rice, K				O'Brien, Nicole F.; Maa, Tensing; Reuter-Rice, Karin			Noninvasive screening for intracranial hypertension in children with acute, severe traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						intracranial pressure; traumatic brain injury; transcranial Doppler ultrasound; pulsatility index; end diastolic flow velocity; intracranial hypertension; pediatrics; trauma	DOPPLER PULSATILITY INDEX; BLOOD-FLOW-VELOCITY; SEVERE HEAD-INJURY; TRANSCRANIAL DOPPLER; CEREBROVASCULAR RESPONSE; PRESSURE; AUTOREGULATION; METABOLISM; ULTRASOUND; HYPEREMIA	OBJECT The aim of this study was to determine the relationship between transcranial Doppler (TCD) derived pulsatility index (PI), end diastolic flow velocity (Vd), and intracranial pressure (ICP). The subjects in this study were 36 children admitted after severe traumatic brain injury (TBI) (postresuscitation Glasgow Coma Scale <= 8) undergoing invasive ICP monitoring., METHODS Subjects underwent a total of 148 TCD studies. TCD measurements of systolic flow velocity (Vs), Vd, and mean flow velocity (Vm) were performed on the middle cerebral artery (MCA) ipsilateral to the ICP monitor. The PI was calculated by the TCD software (Vs-Vd/Vm). ICP registrations were made in parallel with TCD measurements. RESULTS Using a PI threshold of 1.3, postinjury Day 0-1 PI had 100% sensitivity and 82% specificity at predicting an ICP >= 20 mm Hg (n = 8). During this time frame, a moderately strong relationship was observed between the MCA PI and actual ICP (r = 0.611, p = 0.01). When using a threshold of < 25 cm/sec, postinjury Day 0-1 Vd had a 56% sensitivity to predict an ICP 20 mm Hg. Beyond the initial 24 hours from injury, the sensitivity of an MCA PI of 1.3 to detect an ICP >= 20 mm Hg was 47%, and a weak relationship between actual ICP values and MCA PI (r = 0.376, p = 0.01) and MCA Vd (r = 0.284, p = 0.01) was found. CONCLUSIONS Postinjury Day 0-1 MCA PI > 1.3 has good sensitivity and specificity at predicting an ICP >= 20 mm Hg. In those children with TBI who initially do not meet clear criteria for invasive ICP monitoring but who are at risk for development of intracranial hypertension, TCD may be used as a noninvasive tool to screen for the development of elevated ICP in the first 24 hours following injury.	[O'Brien, Nicole F.; Maa, Tensing] Ohio State Univ, Nationwide Childrens Hosp, Div Crit Care Med, Dept Pediat, Columbus, OH 43205 USA; [Reuter-Rice, Karin] Duke Univ, Dept Pediat, Sch Nursing, Sch Med, Durham, NC 27706 USA		O'Brien, NF (corresponding author), Ohio State Univ, Nationwide Childrens Hosp, Div Crit Care Med, Dept Pediat, 700 Childrens Dr,ED-350, Columbus, OH 43205 USA.	nicole.obrien@nationwidechildrens.org	Maa, Tensing/J-9791-2012	Maa, Tensing/0000-0001-6104-8401; Reuter-Rice, Karin/0000-0003-1501-8994	Intramural Funding Program Nationwide Children's Hospital	This work was supported by the Intramural Funding Program Nationwide Children's Hospital.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Behrens A, 2010, NEUROSURGERY, V66, P1050, DOI 10.1227/01.NEU.0000369519.35932.F2; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; de Riva N, 2012, NEUROCRIT CARE, V17, P58, DOI 10.1007/s12028-012-9672-6; Faul M, 2010, TRAUMATIC BRAIN INJU; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; Goutorbe PV, 2001, ANN FR ANESTH S, V20, pR451; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Moreno J A, 2000, Neurosurg Focus, V8, pe8; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Nagai H, 1997, STROKE, V28, P603, DOI 10.1161/01.STR.28.3.603; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Melo JRT, 2011, CHILD NERV SYST, V27, P979, DOI 10.1007/s00381-010-1367-8; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Zierski J, 1987, Acta Neurochir Suppl (Wien), V40, P95; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	32	28	28	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2015	16	4					420	425		10.3171/2015.3.PEDS14521			6	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CS1XS	WOS:000361862800010	26140576	Bronze			2022-02-06	
J	Park, JM; Josan, S; Mayer, D; Hurd, RE; Chung, YR; Bendahan, D; Spielman, DM; Jue, T				Park, Jae Mo; Josan, Sonal; Mayer, Dirk; Hurd, Ralph E.; Chung, Youngran; Bendahan, David; Spielman, Daniel M.; Jue, Thomas			Hyperpolarized C-13 NMR observation of lactate kinetics in skeletal muscle	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						Muscle metabolism; Lactate bioenergetics; Hyperpolarized C-13; Pyruvate	PYRUVATE-DEHYDROGENASE ACTIVITY; TRAUMATIC BRAIN-INJURY; IN-VIVO; METABOLIC-RESPONSE; GLYCOGEN-SYNTHESIS; INTENSE EXERCISE; ACID CYCLE; TRANSPORT; ONSET; MITOCHONDRIAL	The production of glycolytic end products, such as lactate, usually evokes a cellular shift from aerobic to anaerobic ATP generation and O-2 insufficiency. In the classical view, muscle lactate must be exported to the liver for clearance. However, lactate also forms under well-oxygenated conditions, and this has led investigators to postulate lactate shuttling from non-oxidative to oxidative muscle fiber, where it can serve as a precursor. Indeed, the intracellular lactate shuttle and the glycogen shunt hypotheses expand the vision to include a dynamic mobilization and utilization of lactate during a muscle contraction cycle. Testing the tenability of these provocative ideas during a rapid contraction cycle has posed a technical challenge. The present study reports the use of hyperpolarized [1-C-13] lactate and [2-C-13] pyruvate in dynamic nuclear polarization (DNP) NMR experiments to measure the rapid pyruvate and lactate kinetics in rat muscle. With a 3 s temporal resolution, C-13 DNP NMR detects both [1-C-13] lactate and [2-C-13] pyruvate kinetics in muscle. Infusion of dichloroacetate stimulates pyruvate dehydrogenase activity and shifts the kinetics toward oxidative metabolism. Bicarbonate formation from [1-C-13] lactate increases sharply and acetyl-L-carnitine, acetoacetate and glutamate levels also rise. Such a quick mobilization of pyruvate and lactate toward oxidative metabolism supports the postulated role of lactate in the glycogen shunt and the intracellular lactate shuttle models. The study thus introduces an innovative DNP approach to measure metabolite transients, which will help delineate the cellular and physiological role of lactate and glycolytic end products.	[Park, Jae Mo; Josan, Sonal; Spielman, Daniel M.] Stanford Univ, Radiol, Stanford, CA 94305 USA; [Josan, Sonal; Mayer, Dirk] SRI Int, Program Neurosci, Menlo Pk, CA 94025 USA; [Mayer, Dirk] Univ Maryland, Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Hurd, Ralph E.] GE Healthcare, Appl Sci Lab, Hyderabad, Andhra Pradesh, India; [Chung, Youngran; Jue, Thomas] Univ Calif Davis, Biochem & Mol Med, Davis, CA 95616 USA; [Bendahan, David] Aix Marseille Univ, Ctr Resonance Magnet Biol & Med, F-13385 Marseille, France		Jue, T (corresponding author), Univ Calif Davis, Biochem & Mol Med, Davis, CA 95616 USA.	TJue@ucdavis.edu	Park, Jae Mo/H-6470-2019; Bendahan, David/AAU-1420-2020; Mayer, Dirk/AAJ-5906-2020	Park, Jae Mo/0000-0002-7404-6971; Mayer, Dirk/0000-0001-7557-9019	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41 EB015891, AA05965, AA018681, AA13521-INIA, CA176836, OD012283, EB009070]; Department of DefenseUnited States Department of Defense [PC100427]; Lucas Foundation; France Berkeley Fund; GE HealthcareGeneral ElectricGE Healthcare; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA176836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009070, P41EB015891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA005965, R01AA005965, R01AA018681, U01AA013521] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD012283] Funding Source: NIH RePORTER	The project received funding support from the National Institutes of Health [P41 EB015891, AA05965, AA018681, AA13521-INIA, CA176836, OD012283 and EB009070], The Department of Defense [PC100427], The Lucas Foundation, France Berkeley Fund and GE Healthcare. Deposited in PMC for release after 12 months.	Ardenkjaer-Larsen JH, 2003, P NATL ACAD SCI USA, V100, P10158, DOI 10.1073/pnas.1733835100; Atherton HJ, 2011, NMR BIOMED, V24, P201, DOI 10.1002/nbm.1573; Bangsbo J, 2002, AM J PHYSIOL-REG I, V282, pR273, DOI 10.1152/ajpregu.2002.282.1.R273; Bangsbo J, 2006, PFLUG ARCH EUR J PHY, V452, P737, DOI 10.1007/s00424-006-0075-4; Bastiaansen JAM, 2014, METABOLOMICS, V10, P986, DOI 10.1007/s11306-014-0630-5; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684, DOI 10.1152/jappl.1999.87.5.1684; Bertocci LA, 1999, J APPL PHYSIOL, V86, P2077, DOI 10.1152/jappl.1999.86.6.2077; Bertocci LA, 1997, J APPL PHYSIOL, V83, P32, DOI 10.1152/jappl.1997.83.1.32; BOCK HG, 1975, J BIOL CHEM, V250, P5774; BONEN A, 1990, AM J PHYSIOL, V258, pC693; Boron W. F., 2003, MED PHYSL CELLULAR M; Brooks GA, 1998, AM J PHYSIOL-REG I, V275, pR1192, DOI 10.1152/ajpregu.1998.275.4.R1192; BROOKS GA, 1986, MED SCI SPORT EXER, V18, P360, DOI 10.1249/00005768-198606000-00019; BROOKS GA, 1986, FASEB J, V45, P2924; Brooks GA, 2000, MED SCI SPORT EXER, V32, P790, DOI 10.1097/00005768-200004000-00011; Brooks GA, 2000, EXERCISE PHYSL HUMAN; Brooks GEA, 2007, J PHYSIOL-LONDON, V584, P705, DOI 10.1113/jphysiol.2007.142992; Brooks GA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00408; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; Chung YR, 2005, AM J PHYSIOL-CELL PH, V288, pC730, DOI 10.1152/ajpcell.00138.2004; Chung YR, 1998, AM J PHYSIOL-CELL PH, V274, pC846, DOI 10.1152/ajpcell.1998.274.3.C846; Day SE, 2007, NAT MED, V13, P1382, DOI 10.1038/nm1650; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Glenn TC, 2015, J NEUROTRAUM, V32, P811, DOI 10.1089/neu.2014.3482; GOODMAN MN, 1978, DIABETES, V27, P1065, DOI 10.2337/diab.27.11.1065; Grassi B, 1998, J APPL PHYSIOL, V85, P1394, DOI 10.1152/jappl.1998.85.4.1394; Grieshaber M K, 1994, Rev Physiol Biochem Pharmacol, V125, P43, DOI 10.1007/BFb0030909; Howlett RA, 2003, AM J PHYSIOL-REG I, V284, pR481, DOI 10.1152/ajpregu.00078.2002; Howlett RA, 1999, AM J PHYSIOL-ENDOC M, V277, pE18, DOI 10.1152/ajpendo.1999.277.1.E18; JOHNSON JL, 1988, J APPL PHYSIOL, V64, P1591, DOI 10.1152/jappl.1988.64.4.1591; Juel C, 1999, J PHYSIOL-LONDON, V517, P633, DOI 10.1111/j.1469-7793.1999.0633s.x; JUEL C, 1991, BIOCHIM BIOPHYS ACTA, V1065, P15, DOI 10.1016/0005-2736(91)90004-R; KARK RAP, 1970, NEUROLOGY, V20, P404; Kettunen MI, 2010, MAGN RESON MED, V63, P872, DOI 10.1002/mrm.22276; KREUTZER U, 1995, AM J PHYSIOL-HEART C, V268, pH1675, DOI 10.1152/ajpheart.1995.268.4.H1675; Kreutzer U, 1997, EUR J BIOCHEM, V243, P233, DOI 10.1111/j.1432-1033.1997.0233a.x; LANOUE KF, 1973, J BIOL CHEM, V248, P7171; LEWANDOWSKI ED, 1992, BIOCHEMISTRY-US, V31, P8916, DOI 10.1021/bi00152a031; Li YJ, 2009, AM J PHYSIOL-CELL PH, V296, pC25, DOI 10.1152/ajpcell.00094.2008; Mayer D, 2009, MAGN RESON MED, V62, P557, DOI 10.1002/mrm.22041; MCDERMOTT JC, 1993, MOL CELL BIOCHEM, V122, P113, DOI 10.1007/BF01076095; MCDERMOTT JC, 1992, CAN J PHYSIOL PHARM, V70, P142, DOI 10.1139/y92-021; MCLANE JA, 1979, J BIOL CHEM, V254, P6548; Park JM, 2013, NMR BIOMED, V26, P1197, DOI 10.1002/nbm.2935; Park JM, 2013, NEURO-ONCOLOGY, V15, P433, DOI 10.1093/neuonc/nos319; Passarella S, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00407; PILEGAARD H, 1993, AM J PHYSIOL, V264, pE156, DOI 10.1152/ajpendo.1993.264.2.E156; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P386, DOI 10.1016/0003-9861(90)90506-T; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P377, DOI 10.1016/0003-9861(90)90505-S; Sahlin K, 2002, J PHYSIOL-LONDON, V541, P569, DOI 10.1113/jphysiol.2002.016683; SCHNEIDER SH, 1981, METABOLISM, V30, P590, DOI 10.1016/0026-0495(81)90137-2; Schroeder MA, 2013, P NATL ACAD SCI USA, V110, pE958, DOI 10.1073/pnas.1213471110; Schroeder MA, 2013, EUR J HEART FAIL, V15, P130, DOI 10.1093/eurjhf/hfs192; Shulman RG, 2005, EXERC SPORT SCI REV, V33, P157, DOI 10.1097/00003677-200510000-00002; Shulman RG, 2001, P NATL ACAD SCI USA, V98, P457, DOI 10.1073/pnas.98.2.457; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; STANLEY WC, 1986, J APPL PHYSIOL, V60, P1116, DOI 10.1152/jappl.1986.60.4.1116; STANLEY WC, 1985, AM J PHYSIOL, V249, pE595, DOI 10.1152/ajpendo.1985.249.6.E595; STANLEY WC, 1987, AM J PHYSIOL, V253, pE472, DOI 10.1152/ajpendo.1987.253.4.E472; Tschakovsky ME, 1999, J APPL PHYSIOL, V86, P1101, DOI 10.1152/jappl.1999.86.4.1101; WASSERMAN K, 1987, CIRCULATION, V76, P29; Whipp B. J., 1994, MED SCI SPORTS EXERC, V26, P1297; White AT, 2012, AM J PHYSIOL-ENDOC M, V303, pE308, DOI 10.1152/ajpendo.00054.2012; Yoshida Y, 2007, J PHYSIOL-LONDON, V582, P1317, DOI 10.1113/jphysiol.2007.135095	68	28	28	1	7	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0022-0949	1477-9145		J EXP BIOL	J. Exp. Biol.	OCT	2015	218	20					3308	3318		10.1242/jeb.123141			11	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	CU3UO	WOS:000363451300021	26347554	Green Published, Bronze			2022-02-06	
J	Huang, KB; Gu, Y; Hu, YF; Ji, Z; Wang, SN; Lin, ZZ; Li, X; Xie, ZS; Pan, SY				Huang, Kaibin; Gu, Yong; Hu, Yafang; Ji, Zhong; Wang, Shengnan; Lin, Zhenzhou; Li, Xing; Xie, Zuoshan; Pan, Suyue			Glibenclamide Improves Survival and Neurologic Outcome After Cardiac Arrest in Rats	CRITICAL CARE MEDICINE			English	Article						apoptosis; cardiac arrest; cytokines; glibenclamide; necrosis	EMERGENCY CARDIOVASCULAR CARE; AMERICAN-HEART-ASSOCIATION; TRAUMATIC BRAIN-INJURY; POTENTIAL MELASTATIN 4; NON-SHOCKABLE RHYTHMS; SPINAL-CORD-INJURY; ISCHEMIC-STROKE; CARDIOPULMONARY-RESUSCITATION; THERAPEUTIC HYPOTHERMIA; SUBARACHNOID HEMORRHAGE	Objectives: Glibenclamide confers neuroprotection in animal models as well as in retrospective clinical studies. This study determines whether glibenclamide improves outcome after cardiac arrest in rats. Design: Prospective randomized laboratory study. Setting: University research laboratory. Subjects: Male Sprague-Dawley rats (n = 126). Interventions: Rats successfully resuscitated from 8-minute asphyxial cardiac arrest were randomized to glibenclamide or vehicle group. Rats in the glibenclamide group were intraperitoneally administered glibenclamide with a loading dose of 10 mu g/kg at 10 minutes and a maintenance dose of 1.2 mu g at 6, 12, 18, and 24 hours after return of spontaneous circulation, whereas rats in the vehicle group received equivalent volume of vehicle solution. Measurements and Main Results: Survival was recorded every day, and neurologic deficit scores were assessed at 24, 48, and 72 hours and 7 days after return of spontaneous circulation (n = 22 in each group). Results showed that glibenclamide treatment increased 7-day survival rate, reduced neurologic deficit scores, and prevented neuronal loss in the hippocampal cornu ammonis 1 region. To investigate the neuroprotective effects of glibenclamide in acute phase, we observed neuronal injury at 24 hours after return of spontaneous circulation and found that glibenclamide significantly decreased the rate of neuronal necrosis and apoptosis. In addition, glibenclamide reduced the messenger RNA expression of tumor necrosis factor-a and monocyte chemoattractant protein-1 in the cortex after return of spontaneous circulation. Furthermore, the sulfonylurea receptor 1 and transient receptor potential M4 heteromers, the putative therapeutic targets of glibenclamide, were up-regulated after cardiac arrest and cardiopulmonary resuscitation, indicating that they might be involved in neuroprotective effect of glibenclamide. Conclusions: Glibenclamide treatment substantially improved survival and neurologic outcome throughout a 7-day period after return of spontaneous circulation. The salutary effects of glibenclamide were associated with suppression of neuronal necrosis and apoptosis, as well as inflammation in the brain.	[Huang, Kaibin; Gu, Yong; Hu, Yafang; Ji, Zhong; Wang, Shengnan; Lin, Zhenzhou; Li, Xing; Xie, Zuoshan; Pan, Suyue] Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou, Guangdong, Peoples R China		Pan, SY (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Neurol, Guangzhou, Guangdong, Peoples R China.	pansuyue82@126.com	Huang, Kaibin/AAC-6346-2019	Huang, Kaibin/0000-0002-3360-7031	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271521, 81471339]; Science and Technology Planning Project of Guangdong Province of China [2012A030400011]; Ministry of Education of ChinaMinistry of Education, China [20124433110017]	This work is supported, in part, by the National Natural Science Foundation of China (grant No. 81271521, 81471339), the Science and Technology Planning Project of Guangdong Province of China (grant No. 2012A030400011), and the Doctoral Fund of Ministry of Education of China (grant No. 20124433110017).	Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Callaway CW, 2008, CRIT CARE MED, V36, P2607, DOI 10.1097/CCM.0b013e318184443b; Ebmeyer U, 2014, RESUSCITATION, V85, P276, DOI 10.1016/j.resuscitation.2013.10.009; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Gao CJ, 2010, NEUROSCIENCE, V168, P531, DOI 10.1016/j.neuroscience.2010.02.025; Gao CJ, 2012, NEUROSCIENCE, V202, P352, DOI 10.1016/j.neuroscience.2011.11.060; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Hickey RW, 2000, CRIT CARE MED, V28, P3511, DOI 10.1097/00003246-200010000-00027; Holzer M, 2002, NEW ENGL J MED, V346, P549; Huo TT, 2014, ANESTH ANALG, V119, P368, DOI 10.1213/ANE.0000000000000303; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; Katz LM, 2004, CRIT CARE MED, V32, P806, DOI 10.1097/01.CCM.0000114998.00860.FD; Kunte H, 2012, ANN NEUROL, V72, P799, DOI 10.1002/ana.23680; Lundbye JB, 2012, RESUSCITATION, V83, P202, DOI 10.1016/j.resuscitation.2011.08.005; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Ortega FJ, 2013, J CEREBR BLOOD F MET, V33, P356, DOI 10.1038/jcbfm.2012.166; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Sheth KN, 2014, STROKE, V45, P281, DOI 10.1161/STROKEAHA.113.003352; Simard JM, 2013, SPINAL CORD, V51, P823, DOI 10.1038/sc.2013.99; Simard JM, 2012, PFLUG ARCH EUR J PHY, V464, P573, DOI 10.1007/s00424-012-1166-z; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Testori C, 2011, RESUSCITATION, V82, P1162, DOI 10.1016/j.resuscitation.2011.05.022; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Tosun C, 2013, BRAIN SCI, V3, P215, DOI 10.3390/brainsci3010215; Vennekens R., 2007, V179, P269; Wang JM, 2013, J CEREBR BLOOD F MET, V33, P1574, DOI 10.1038/jcbfm.2013.111; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Xiao F, 2004, RESUSCITATION, V61, P209, DOI 10.1016/j.resuscitation.2003.12.022; Yang L, 2014, RESUSCITATION, V85, P299, DOI 10.1016/j.resuscitation.2013.10.022; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhou YL, 2009, BRAIN RES, V1270, P131, DOI 10.1016/j.brainres.2009.03.010; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	37	28	28	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2015	43	9					E341	E349		10.1097/CCM.0000000000001093			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DC5JH	WOS:000369256800002	26010685				2022-02-06	
J	Kummer, TT; Magnoni, S; MacDonald, CL; Dikranian, K; Milner, E; Sorrell, J; Conte, V; Benetatos, JJ; Zipfel, GJ; Brody, DL				Kummer, Terrance T.; Magnoni, Sandra; MacDonald, Christine L.; Dikranian, Krikor; Milner, Eric; Sorrell, James; Conte, Valeria; Benetatos, Joey J.; Zipfel, Gregory J.; Brody, David L.			Experimental subarachnoid haemorrhage results in multifocal axonal injury	BRAIN			English	Article						subarachnoid haemorrhage; traumatic brain injury; axonal injury; diffusion tensor imaging; brain haemorrhage	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; WHITE-MATTER INJURY; MOUSE MODEL; EPIDEMIOLOGY; VASOSPASM; IMMUNOREACTIVITY; PERMEABILITY; DYSFUNCTION; TRANSPORT	Mechanisms of brain injury after haemorrhagic stroke are poorly understood. Kummer et al. provide experimental evidence in a mouse model that subarachnoid haemorrhage causes widespread axonal injury similar to that seen after traumatic brain injury, suggesting that these disease entities share common underlying mechanisms.Mechanisms of brain injury after haemorrhagic stroke are poorly understood. Kummer et al. provide experimental evidence in a mouse model that subarachnoid haemorrhage causes widespread axonal injury similar to that seen after traumatic brain injury, suggesting that these disease entities share common underlying mechanisms.The great majority of acute brain injury results from trauma or from disorders of the cerebrovasculature, i.e. ischaemic stroke or haemorrhage. These injuries are characterized by an initial insult that triggers a cascade of injurious cellular processes. The nature of these processes in spontaneous intracranial haemorrhage is poorly understood. Subarachnoid haemorrhage, a particularly deadly form of intracranial haemorrhage, shares key pathophysiological features with traumatic brain injury including exposure to a sudden pressure pulse. Here we provide evidence that axonal injury, a signature characteristic of traumatic brain injury, is also a prominent feature of experimental subarachnoid haemorrhage. Using histological markers of membrane disruption and cytoskeletal injury validated in analyses of traumatic brain injury, we show that axonal injury also occurs following subarachnoid haemorrhage in an animal model. Consistent with the higher prevalence of global as opposed to focal deficits after subarachnoid haemorrhage and traumatic brain injury in humans, axonal injury in this model is observed in a multifocal pattern not limited to the immediate vicinity of the ruptured artery. Ultrastructural analysis further reveals characteristic axonal membrane and cytoskeletal changes similar to those associated with traumatic axonal injury. Diffusion tensor imaging, a translational imaging technique previously validated in traumatic axonal injury, from these same specimens demonstrates decrements in anisotropy that correlate with histological axonal injury and functional outcomes. These radiological indicators identify a fibre orientation-dependent gradient of axonal injury consistent with a barotraumatic mechanism. Although traumatic and haemorrhagic acute brain injury are generally considered separately, these data suggest that a signature pathology of traumatic brain injury-axonal injury-is also a functionally significant feature of subarachnoid haemorrhage, raising the prospect of common diagnostic, prognostic, and therapeutic approaches to these conditions.	[Kummer, Terrance T.; MacDonald, Christine L.; Sorrell, James; Benetatos, Joey J.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Magnoni, Sandra; Conte, Valeria] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Anaesthesiol & Intens Care, I-20122 Milan, Italy; [Dikranian, Krikor] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; [Milner, Eric; Zipfel, Gregory J.] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA		Kummer, TT (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave, St Louis, MO 63110 USA.	kummert@neuro.wustl.edu	Magnoni, Sandra/AAC-7479-2022	Magnoni, Sandra/0000-0002-1723-0844	Hope Center for Neurological Diseases; American Heart AssociationAmerican Heart Association; US National Institutes of Health K12 grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ICTS UL1 TR000448]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065069, NS071011]; National Institutes of Health Shared Instrumentation GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10 RR0227552]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000450, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065069, R01NS071011] Funding Source: NIH RePORTER	This study was supported by a grant from the Hope Center for Neurological Diseases (to T.T.K.), an American Heart Association Scientist Development Grant (to T.T.K.), a US National Institutes of Health K12 grant (ICTS UL1 TR000448; to T.T.K.), a National Institutes of Health R01 grant (NS065069; to D.L.B.), a National Institutes of Health R01 grant (NS071011; to G.J.Z.), an American Heart Association Grant-in-Aid (to G.J.Z.), and a National Institutes of Health Shared Instrumentation Grant (S10 RR0227552).	Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendel P, 2009, NEURORADIOLOGY, V51, P711, DOI 10.1007/s00234-009-0552-5; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cai JY, 2013, CLIN CHIM ACTA, V424, P182, DOI 10.1016/j.cca.2013.06.019; CARPENTER DA, 1991, J CEREBR BLOOD F MET, V11, P837, DOI 10.1038/jcbfm.1991.143; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Egashira Y, 2014, STROKE, V45, P2141, DOI 10.1161/STROKEAHA.114.005307; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Frattalone AR, 2013, NEUROSURG CLIN N AM, V24, P309, DOI 10.1016/j.nec.2013.03.006; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Helbok R, 2015, J NEUROL NEUROSUR PS, V86, P79, DOI 10.1136/jnnp-2013-307326; Hu HT, 2012, CLIN BIOCHEM, V45, P1320, DOI 10.1016/j.clinbiochem.2012.06.003; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnston SC, 1998, NEUROLOGY, V50, P1413, DOI 10.1212/WNL.50.5.1413; Kim-Han JS, 2006, STROKE, V37, P2457, DOI 10.1161/01.STR.0000240674.99945.4e; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Milner E, 2014, J CEREBR BLOOD F MET, V34, P1571, DOI 10.1038/jcbfm.2014.108; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; Nylen K, 2006, NEUROSCI LETT, V404, P132, DOI 10.1016/j.neulet.2006.05.029; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; Parra A, 2002, NEUROL RES, V24, P510, DOI 10.1179/016164102101200276; Passier PECA, 2011, J STROKE CEREBROVASC, V20, P324, DOI 10.1016/j.jstrokecerebrovasdis.2010.02.001; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Powers WJ, 2010, STROKE, V41, pS107, DOI 10.1161/STROKEAHA.110.595058; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Rincon F, 2013, NEUROSURGERY, V73, P217, DOI 10.1227/01.neu.0000430290.93304.33; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Venkatasubramanian C, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000090; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wasserman JK, 2008, EXP NEUROL, V214, P266, DOI 10.1016/j.expneurol.2008.08.010; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yu CS, 2009, NEUROIMAGE, V47, P451, DOI 10.1016/j.neuroimage.2009.04.066; Zanier ER, 2013, BRIT J ANAESTH, V111, P424, DOI 10.1093/bja/aet149; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	60	28	31	1	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP 1	2015	138		9				2608	2618		10.1093/brain/awv180			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR5PS	WOS:000361396200022	26115676	Green Published, Bronze			2022-02-06	
J	Mahler, B; Carlsson, S; Andersson, T; Adelow, C; Ahlbom, A; Tomson, T				Mahler, Benno; Carlsson, Sofia; Andersson, Tomas; Adelow, Cecilia; Ahlbom, Anders; Tomson, Torbjorn			Unprovoked seizures after traumatic brain injury: A population-based case-control study	EPILEPSIA			English	Article						Epidemiology; Seizure; Epilepsy; Traumatic brain injury; Case-control; Population-based	LATE POSTTRAUMATIC SEIZURES; RISK-FACTORS; HEAD-INJURY; EPILEPSY; HOSPITALIZATION; EPIDEMIOLOGY; IMPACT	ObjectiveTo quantify the risk of unprovoked seizures after traumatic brain injury (TBI) MethodsWe used the Stockholm Incidence Registry on Epilepsy to carry out a population-based case-control study, including 1,885 cases with incident unprovoked seizures from September 1, 2000 through August 31, 2008, together with 15,080 matched controls. Information of prior hospitalizations for TBI was obtained through record linkage with the Swedish National Inpatient Registry for the period 1980-2008. Relative risks (RRs) for unprovoked seizures were estimated after various TBI diagnoses, and influences of TBI severity and time since trauma were studied in detail. ResultsAfter hospitalization for mild TBI, the RR was 2.0 (95% confidence interval [CI] 1.5-2.7). The RR was higher after brain contusion (5.9, 95% CI 2.4-15.0) or intracranial hemorrhage (ICH) (4.5, 95% CI 2.2-9.0), whereas a combination of both diagnoses led to a further sevenfold increase in RR (42.6, 95% CI 12.2-148.5). The risk was greatest during the first 6months after severe TBI (RR 48.9, 95% CI 10.9-218.9) or mild TBI (RR 8.1, 95% CI 3.1-21.7), but was still elevated >10years after any TBI. SignificanceHerein we present a large population-based case-control study on TBI as a risk factor for unprovoked epileptic seizures, including cases of all ages with individually validated seizure diagnoses. The risk for epileptic seizures was substantially increased after TBI, especially during the first 6months after the injury and in patients with a combination of ICH and brain contusion.	[Mahler, Benno; Adelow, Cecilia; Tomson, Torbjorn] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Carlsson, Sofia; Ahlbom, Anders] Karolinska Inst, Inst Environm Med, Epidemiol Unit, S-10401 Stockholm, Sweden; [Andersson, Tomas] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden		Mahler, B (corresponding author), Karolinska Univ, Sjukhuset Huddinge, S-14186 Huddinge, Sweden.	benno.mahler@karolinska.se		carlsson, sofia/0000-0002-9497-2331	Stockholm County Council (ALF)Stockholm County Council; AFA Insurance	This study was supported by a grant from the Stockholm County Council (ALF) and AFA Insurance.	Adelow C, 2012, NEUROLOGY, V78, P396, DOI 10.1212/WNL.0b013e318245f461; Adelow C, 2009, EPILEPSIA, V50, P1094, DOI 10.1111/j.1528-1167.2008.01726.x; Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1986, KLASS SJUKD 1968 SYS; [Anonymous], 1996, KLASS SJUKD HOLS 199; [Anonymous], 1986, KLASS SJUKD 1987 SYS; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Banerjee PN, 2009, EPILEPSY RES, V85, P31, DOI 10.1016/j.eplepsyres.2009.03.003; Bharucha NE, 1997, EPILEPSIA, V38, P614; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; DASILVA AM, 1990, ACT NEUR S, V50, P48; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Engel J., 2008, EPILEPSY COMPREHENSI, P45; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; JENNETT B, 1973, LANCET, V2, P652; JENNETT B, 1978, SCOT MED J, V23, P102, DOI 10.1177/003693307802300145; Kessing LV, 1998, EUR PSYCHIAT, V13, P392, DOI 10.1016/S0924-9338(99)80685-3; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; Roe C, 2013, J REHABIL MED, V45, P734, DOI 10.2340/16501977-1198; Rothman K.J., 2008, Modern epidemiology, V3rd; Salazar A, 1999, POSTTRAUMATIC EPILEP; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Samokhvalov AV, 2010, EPILEPSIA, V51, P1177, DOI 10.1111/j.1528-1167.2009.02426.x; Smedby BSG., 2006, HLTH CLASSIFICATIONS; Vandenbroucke JP, 2012, INT J EPIDEMIOL, V41, P1480, DOI 10.1093/ije/dys147; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547	42	28	29	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	SEP	2015	56	9					1438	1444		10.1111/epi.13096			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CQ7PF	WOS:000360795400020	26332184	Bronze			2022-02-06	
J	Dang, H; Stayman, JW; Sisniega, A; Xu, J; Zbijewski, W; Wang, X; Foos, DH; Aygun, N; Koliatsos, VE; Siewerdsen, JH				Dang, H.; Stayman, J. W.; Sisniega, A.; Xu, J.; Zbijewski, W.; Wang, X.; Foos, D. H.; Aygun, N.; Koliatsos, V. E.; Siewerdsen, J. H.			Statistical reconstruction for cone-beam CT with a post-artifact-correction noise model: application to high-quality head imaging	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						cone-beam CT; traumatic brain injury; intracranial hemorrhage; model-based iterative reconstruction; artifact correction; measurement noise model; soft-tissue image quality	X-RAY CT; FLAT-PANEL IMAGERS; COMPUTED-TOMOGRAPHY; DIAGNOSTIC-RADIOLOGY; SCATTER CORRECTION; ORDERED SUBSETS; BREAST CT; OPTIMIZATION; PERFORMANCE; DETECTABILITY	Non-contrast CT reliably detects fresh blood in the brain and is the current front-line imaging modality for intracranial hemorrhage such as that occurring in acute traumatic brain injury (contrast similar to 40-80 HU, size > 1 mm). We are developing flat-panel detector (FPD) cone-beam CT (CBCT) to facilitate such diagnosis in a low-cost, mobile platform suitable for point-of-care deployment. Such a system may offer benefits in the ICU, urgent care/concussion clinic, ambulance, and sports and military theatres. However, current FPD-CBCT systems face significant challenges that confound low-contrast, soft-tissue imaging. Artifact correction can overcome major sources of bias in FPD-CBCT but imparts noise amplification in filtered backprojection (FBP). Model-based reconstruction improves soft-tissue image quality compared to FBP by leveraging a high-fidelity forward model and image regularization. In this work, we develop a novel penalized weighted least-squares (PWLS) image reconstruction method with a noise model that includes accurate modeling of the noise characteristics associated with the two dominant artifact corrections (scatter and beam-hardening) in CBCT and utilizes modified weights to compensate for noise amplification imparted by each correction. Experiments included real data acquired on a FPD-CBCT test-bench and an anthropomorphic head phantom emulating intra-parenchymal hemorrhage. The proposed PWLS method demonstrated superior noise-resolution tradeoffs in comparison to FBP and PWLS with conventional weights (viz. at matched 0.50 mm spatial resolution, CNR = 11.9 compared to CNR = 5.6 and CNR = 9.9, respectively) and substantially reduced image noise especially in challenging regions such as skull base. The results support the hypothesis that with high-fidelity artifact correction and statistical reconstruction using an accurate post-artifact-correction noise model, FPD-CBCT can achieve image quality allowing reliable detection of intracranial hemorrhage.	[Dang, H.; Stayman, J. W.; Sisniega, A.; Xu, J.; Zbijewski, W.; Siewerdsen, J. H.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; [Wang, X.; Foos, D. H.] Carestream Hlth, Rochester, NY 14608 USA; [Aygun, N.; Siewerdsen, J. H.] Johns Hopkins Univ, Russell H Morgan Dept Radiol, Baltimore, MD 21205 USA; [Koliatsos, V. E.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA		Dang, H (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA.	jeff.siewerdsen@jhu.edu	Dang, Hao/U-4865-2018	Dang, Hao/0000-0001-5861-6535; Stayman, Joseph/0000-0003-4358-378X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-CA-112163]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA112163] Funding Source: NIH RePORTER	This work was supported by NIH R01-CA-112163 and the academic-industry partnership with Carestream Health (Rochester, NY). The authors also thank Dr Adam Wang and Mr Nicholas Uebele (Johns Hopkins University, Baltimore, MD) for assistance with the head phantom and simulated intracranial hemmorrhage.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barrett H. H., 2004, FDN IMAGE SCI; Benaroya H., 2005, PROBABILITY MODELS E; Boone JM, 2001, RADIOLOGY, V221, P657, DOI 10.1148/radiol.2213010334; BOONE JM, 1988, MED PHYS, V15, P721, DOI 10.1118/1.596186; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US F; Dang H, 2015, PROC SPIE, V9412, DOI 10.1117/12.2082075; Dang H, 2014, PHYS MED BIOL, V59, P4799, DOI 10.1088/0031-9155/59/17/4799; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; Erdogan H, 1999, PHYS MED BIOL, V44, P2835, DOI 10.1088/0031-9155/44/11/311; Fessler JA, 1996, IEEE T IMAGE PROCESS, V5, P1346, DOI 10.1109/83.535846; Gang GJ, 2014, MED PHYS, V41, P260, DOI 10.1118/1.4883816; Greenberg M, 2006, HDB NEUROSURGERY; Hsieh J, 2000, MED PHYS, V27, P23, DOI 10.1118/1.598853; JOSEPH PM, 1978, J COMPUT ASSIST TOMO, V2, P100, DOI 10.1097/00004728-197801000-00017; Kachelriess M, 2001, MED PHYS, V28, P475, DOI 10.1118/1.1358303; Kim D, 2015, IEEE T MED IMAGING, V34, P167, DOI 10.1109/TMI.2014.2350962; Kim D, 2013, IEEE T MED IMAGING, V32, P1965, DOI 10.1109/TMI.2013.2266898; Koskinen SK, 2013, SKELETAL RADIOL, V42, P649, DOI 10.1007/s00256-012-1516-0; Kwan ALC, 2006, MED PHYS, V33, P391, DOI 10.1118/1.2163388; La Riviere PJ, 2006, IEEE T MED IMAGING, V25, P1022, DOI 10.1109/TMI.2006.875429; Li TF, 2004, IEEE T NUCL SCI, V51, P2505, DOI 10.1109/TNS.2004.834824; Long Y, 2010, IEEE T MED IMAGING, V29, P1839, DOI 10.1109/TMI.2010.2050898; Ning R, 2004, MED PHYS, V31, P1195, DOI 10.1118/1.1711475; Parizel PM, 2001, EUR RADIOL, V11, P1770, DOI 10.1007/s003300000800; Penninger RT, 2011, OTOL NEUROTOL, V32, P453, DOI 10.1097/MAO.0b013e31820d962c; PETERS TM, 1981, IEEE T NUCL SCI, V28, P3641, DOI 10.1109/TNS.1981.4331812; SAUER K, 1993, IEEE T SIGNAL PROCES, V41, P534, DOI 10.1109/78.193196; SIDDON RL, 1985, MED PHYS, V12, P252, DOI 10.1118/1.595715; Siewerdsen JH, 2006, MED PHYS, V33, P187, DOI 10.1118/1.2148916; Siewerdsen JH, 1997, MED PHYS, V24, P71, DOI 10.1118/1.597919; Siewerdsen JH, 1998, P SOC PHOTO-OPT INS, V3336, P546, DOI 10.1117/12.317057; Siewerdsen JH, 1999, MED PHYS, V26, P2635, DOI 10.1118/1.598803; Siewerdsen JH, 2001, MED PHYS, V28, P220, DOI 10.1118/1.1339879; Sisniega A, 2015, PHYS MED BIOL, V60, P1415, DOI 10.1088/0031-9155/60/4/1415; Sisniega A, 2013, MED PHYS, V40, DOI 10.1118/1.4801895; Stayman JW, 2014, PROC SPIE, V9033, DOI 10.1117/12.2043067; Stayman JW, 2013, PHYS MED BIOL, V58, P7563, DOI 10.1088/0031-9155/58/21/7563; Thibault JB, 2007, MED PHYS, V34, P4526, DOI 10.1118/1.2789499; Tilley Steven 2nd, 2014, Conf Proc Int Conf Image Form Xray Comput Tomogr, V2014, P363; Tward DJ, 2007, MED PHYS, V34, P4459, DOI 10.1118/1.2790586; Tward DJ, 2008, MED PHYS, V35, P5510, DOI 10.1118/1.3002414; Wang AS, 2015, MED PHYS, V42, P2699, DOI 10.1118/1.4914378; Wang AS, 2014, PHYS MED BIOL, V59, P1005, DOI 10.1088/0031-9155/59/4/1005; Wunderlich A, 2008, PHYS MED BIOL, V53, P2471, DOI 10.1088/0031-9155/53/10/002; Xu J, 2012, MED PHYS, V39, P4932, DOI 10.1118/1.4736805; Yang WT, 2007, AM J ROENTGENOL, V189, P1312, DOI 10.2214/AJR.07.2403; Zbijewski W, 2011, MED PHYS, V38, P4700, DOI 10.1118/1.3611039; Zbijewski W, 2009, P SPIE MED IMAGING, V7258; Zhu L, 2006, IEEE T MED IMAGING, V25, P1573, DOI 10.1109/TMI.2006.884636; Zhu L, 2009, MED PHYS, V36, P741, DOI 10.1118/1.3063001	51	28	28	0	10	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	AUG 21	2015	60	16					6153	6175		10.1088/0031-9155/60/16/6153			23	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Radiology, Nuclear Medicine & Medical Imaging	CR0ZO	WOS:000361052600003	26225912	Green Accepted			2022-02-06	
J	Bellerose, J; Bernier, A; Beaudoin, C; Gravel, J; Beauchamp, MH				Bellerose, Jenny; Bernier, Annie; Beaudoin, Cindy; Gravel, Jocelyn; Beauchamp, Miriam H.			When Injury Clouds Understanding of Others: Theory of Mind after Mild TBI in Preschool Children	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Pediatric; Head injury; Concussion; Social cognition; Perspective taking; Outcome; Social skills	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; SOCIAL COMPETENCE; HEAD-INJURIES; NEUROPSYCHOLOGICAL FUNCTION; NEUROSURGICAL INTERVENTION; NEUROCOGNITIVE OUTCOMES; INTRACRANIAL LESIONS; BEHAVIORAL OUTCOMES; SHORT-TERM	There is evidence to suggest that social skills, such as the ability to understand the perspective of others (theory of mind), may be affected by childhood traumatic brain injuries; however, studies to date have only considered moderate and severe traumatic brain injury (TBI). This study aimed to assess theory of mind after early, mild TBI (mTBI). Fifty-one children who sustained mTBI between 18 and 60 months were evaluated 6 months post-injury on emotion and desires reasoning and false-belief understanding tasks. Their results were compared to that of 50 typically developing children. The two groups did not differ on baseline characteristics, except for pre- and post-injury externalizing behavior. The mTBI group obtained poorer scores relative to controls on both the emotion and desires task and the false-belief understanding task, even after controlling for pre-injury externalizing behavior. No correlations were found between TBI injury characteristics and theory of mind. This is the first evidence that mTBI in preschool children is associated with theory of mind difficulties. Reduced perspective taking abilities could be linked with the social impairments that have been shown to arise following TBI.	[Bellerose, Jenny; Bernier, Annie; Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Bellerose, Jenny; Beaudoin, Cindy; Gravel, Jocelyn; Beauchamp, Miriam H.] Ste Justine Hosp Res Ctr, Montreal, PQ, Canada		Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succursale Ctr Ville, Montreal, PQ, Canada.	miriam.beauchamp@umontreal.ca			Fonds de Recherche du Quebec en SanteFonds de la Recherche en Sante du Quebec; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP11036]	This work was supported by the Fonds de Recherche du Quebec en Sante (J.B.) and the Canadian Institutes of Health Research (MOP11036 to M.H.B.). The authors declare no competing financial interests.	Abidin, 1995, PARENTING STRESS IND; Achenbach T.M., 2000, MANUAL ASEBA PRESCHO; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2012, J NEUROTRAUM, V29, P143, DOI 10.1089/neu.2011.2012; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Astington J. W., 2003, INDIVIDUAL DIFFERENC, P13; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bayley N., 2005, BAYLEY SCALES INFANT; Beauchamp MH, 2013, HAND CLINIC, V112, P913, DOI 10.1016/B978-0-444-52910-7.00013-1; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Blishen B. R., 1987, CANADIAN REV SOCIOLO, V24, P365; Cohen J., 2013, STAT POWER ANAL BEHA; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Faul M, 2010, TRAUMATIC BRAIN INJU; Feinman S., 1992, SOCIAL REFERENCING S; Garcia D, 2015, J PEDIATR PSYCHOL, V40, P391, DOI 10.1093/jpepsy/jsu093; Harrison L. P., 2003, ADAPTIVE BEHAV ASSES; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hughes C, 2011, J EXP CHILD PSYCHOL, V108, P96, DOI 10.1016/j.jecp.2010.07.012; Johnson C., 2000, EARLY CHILD EDUC J, V27, P207, DOI [DOI 10.1023/B:ECEJ.0000003356.30481.7A, 10.1023/b:ecej.0000003356.30481.7a]; Kaldoja ML, 2012, BRAIN INJURY, V26, P1005, DOI 10.3109/02699052.2012.660516; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Ladd GW, 1999, ANNU REV PSYCHOL, V50, P333, DOI 10.1146/annurev.psych.50.1.333; Ladd GW, 1996, CHILD DEV, V67, P1103, DOI 10.2307/1131882; Ladd GW, 2003, ADV CHILD DEV BEHAV, V31, P43; Ladd GW, 2003, CHILD DEV, V74, P1344, DOI 10.1111/1467-8624.00611; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Mathias JL, 2013, BRAIN INJURY, V27, P887, DOI 10.3109/02699052.2013.793398; Max JE, 1998, BRAIN INJURY, V12, P41; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Miller Scott, 2012, THEORY MIND PRESCHOO; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moore C, 1995, JOINT ATTENTION ITS; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; Pears KC, 2003, SOC DEV, V12, P1, DOI 10.1111/1467-9507.00219; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Razza RA, 2009, J APPL DEV PSYCHOL, V30, P332, DOI 10.1016/j.appdev.2008.12.020; Repacholi BM, 1997, DEV PSYCHOL, V33, P12, DOI 10.1037/0012-1649.33.1.12; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shay N, 2014, J NEUROTRAUM, V31, P1305, DOI 10.1089/neu.2013.3275; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; SREBNIK DS, 1993, AM J ORTHOPSYCHIAT, V63, P526, DOI 10.1037/h0079484; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wechsler D., 2002, WECHSLER PRESCHOOL P; Wellman H. M., 1990, CHILDS THEORY MIND; Wellman HM, 2011, CHILD DEV, V82, P780, DOI 10.1111/j.1467-8624.2011.01583.x; WELLMAN HM, 1990, COGNITION, V35, P245, DOI 10.1016/0010-0277(90)90024-E; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	82	28	28	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	AUG	2015	21	7					483	493		10.1017/S1355617715000569			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	CQ9UW	WOS:000360961700002	26243654				2022-02-06	
J	Cole, MA; Muir, JJ; Gans, JJ; Shin, LM; D'Esposito, M; Harel, BT; Schembri, A				Cole, Michael A.; Muir, James J.; Gans, Jennifer J.; Shin, Lisa M.; D'Esposito, Mark; Harel, Brian T.; Schembri, Adrian			Simultaneous Treatment of Neurocognitive and Psychiatric Symptoms in Veterans with Post-Traumatic Stress Disorder and History of Mild Traumatic Brain Injury: A Pilot Study of Mindfulness-Based Stress Reduction	MILITARY MEDICINE			English	Article							PERSISTENT POSTCONCUSSIVE SYMPTOMS; COGNITIVE IMPAIRMENT; CHRONIC PAIN; MEDITATION; MECHANISMS; BATTERY; PROGRAM; PARTICIPATION; SCHIZOPHRENIA; INTERVENTION	Treating patient populations with significant psychiatric and neurocognitive symptomatology can present a unique clinical dilemma: progress in psychotherapy can be significantly fettered by cognitive deficits, whereas neurocognitive rehabilitation efforts can be ineffective because of psychiatric overlay. Application of mindfulness-based interventions to address either cognitive or psychiatric symptoms in isolation appears efficacious in many contexts; however, it remains unclear whether this type of intervention might help address simultaneous neurocognitive and psychiatric symptomatology. In a pre-post mixed methods design pilot study, nine Veterans with post-traumatic stress disorder (PTSD) and a history of mild traumatic brain injury with chronic cognitive complaints participated in Mindfulness-Based Stress Reduction (MBSR). Clinical interview, questionnaires, and attention and PTSD measures were administered immediately before, immediately after, and 3 months after MBSR completion. Qualitative and quantitative findings suggest high levels of safety, feasibility, and acceptability. Measurement of attention revealed significant improvement immediately following MBSR (p < 0.05, d = 0.57) and largely sustained improvement 3 months after completion of MBSR (p < 0.10, d = 0.48). Significant reduction in PTSD symptoms was found immediately after MBSR (p < 0.05, d = -1.56), and was sustained 3 months following MBSR completion (p < 0.05, d = -0.93). These results warrant a randomized controlled trial follow-up. Potential mechanisms for the broad effects observed will be explored.	[Cole, Michael A.; Muir, James J.; Gans, Jennifer J.; D'Esposito, Mark] Vet Affairs Northern Calif Hlth Care Syst, Martinez, CA 94553 USA; [Cole, Michael A.] Univ Calif Davis, Dept Neurol, Davis, CA 95817 USA; [Cole, Michael A.; D'Esposito, Mark] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; [Gans, Jennifer J.] Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94115 USA; [Shin, Lisa M.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA; [Harel, Brian T.; Schembri, Adrian] Cogstate Inc, New Haven, CT 06510 USA; [Harel, Brian T.] Yale Univ, Yale Child Study Ctr, New Haven, CT 06519 USA; [Schembri, Adrian] RMIT Univ, Sch Hlth Sci, Div Psychol, Melbourne, Vic 3000, Australia		Cole, MA (corresponding author), Vet Affairs Northern Calif Hlth Care Syst, 150 Muir Rd, Martinez, CA 94553 USA.				VA Research and Development Career Development Award (Cole); CogStateCogState Limited	Support for this work was provided by a VA Research and Development Career Development Award (Cole). Authors BTH and AS are employed by CogState. CogState provided support in the form of salaries for authors BTH and AS and use of CogState tests, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank Heather G. Cole, MSW, for her helpful feedback on earlier drafts of this manuscript.	Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Barnes V, 2013, MIL MED, V178, P836; Bedard Michel, 2012, Adv Mind Body Med, V26, P14; Bishop SR, 2004, CLIN PSYCHOL-SCI PR, V11, P230, DOI 10.1093/clipsy/bph077; Boden MT, 2012, PSYCHIAT RES, V200, P609, DOI 10.1016/j.psychres.2012.07.011; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bryant R, 2006, COGN BEHAV PRACT, V160, P585; Carlson K, ASSESSMENT TREATMENT; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carmody J, 2009, J CLIN PSYCHOL, V65, P613, DOI 10.1002/jclp.20579; Chambers R, 2009, CLIN PSYCHOL REV, V29, P560, DOI 10.1016/j.cpr.2009.06.005; Chiesa A, 2010, PSYCHOL MED, V40, P1239, DOI 10.1017/S0033291709991747; Chiesa A, 2014, HOLIST NURS PRACT, V28, P124, DOI 10.1097/HNP.0000000000000017; Chiesa A, 2011, CLIN PSYCHOL REV, V31, P449, DOI 10.1016/j.cpr.2010.11.003; Chiesa A, 2010, J ALTERN COMPLEM MED, V16, P37, DOI 10.1089/acm.2009.0362; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 2013, STAT POWER ANAL BEHA; Cole M, 2011, J INT NEUROPSYCH SOC, V17, P118; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Follette V., 2006, J RAT EMO COGNITIVE, V24, P45, DOI [DOI 10.1007/S10942-006-0025-2, 10.1007/s10942-006-0025-2]; Fox KCR, 2014, NEUROSCI BIOBEHAV R, V43, P48, DOI 10.1016/j.neubiorev.2014.03.016; Gabbard GO, 2007, OXFORD TXB PSYCHOTHE; Goldin P, 2013, SOC COGN AFFECT NEUR, V8, P65, DOI 10.1093/scan/nss054; Hammers D, 2011, AM J ALZHEIMERS DIS, V26, P326, DOI 10.1177/1533317511411907; Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kabat-Zinn J., 1990, USING WISDOM YOUR BO; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kearney DJ, 2013, J CLIN PSYCHOL, V69, P14, DOI 10.1002/jclp.21911; Kearney DJ, 2012, J CLIN PSYCHOL, V68, P101, DOI 10.1002/jclp.20853; Kimbrough E, 2010, J CLIN PSYCHOL, V66, P17, DOI 10.1002/jclp.20624; King AP, 2013, DEPRESS ANXIETY, V30, P638, DOI 10.1002/da.22104; Kinney A, 2001, J CONTEMP PSYCHOTHER, V31, P89; Lang AJ, 2012, BEHAV MODIF, V36, P759, DOI 10.1177/0145445512441200; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Marchand WR, 2012, J PSYCHIATR PRACT, V18, P233, DOI 10.1097/01.pra.0000416014.53215.86; Maruff Paul, 2013, BMC Psychol, V1, P30, DOI 10.1186/2050-7283-1-30; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Pietrzak RH, 2009, J CLIN EXP NEUROPSYC, V31, P848, DOI 10.1080/13803390802592458; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Rosenthal JZ, 2011, MIL MED, V176, P626, DOI 10.7205/MILMED-D-10-00254; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schmied EA, 2013, MIL MED, V178, P1051, DOI 10.7205/MILMED-D-13-00135; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shapiro SL, 2006, J CLIN PSYCHOL, V62, P373, DOI 10.1002/jclp.20237; Tang YY, 2012, CHILD DEV PERSPECT, V6, P361, DOI 10.1111/j.1750-8606.2012.00250.x; Tang YY, 2012, P NATL ACAD SCI USA, V109, P10570, DOI 10.1073/pnas.1207817109; Thompson BL, 2010, J ANXIETY DISORD, V24, P409, DOI 10.1016/j.janxdis.2010.02.005; Vago DR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00296; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P82; Vita A, 2013, SCHIZOPHR RES, V150, P51, DOI 10.1016/j.schres.2013.08.011; Vujanovic AA, 2009, J ANXIETY DISORD, V23, P297, DOI 10.1016/j.janxdis.2008.08.005; Weathers F. W., 1993, 9 ANN M INT SOC TRAU	62	28	28	1	39	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	AUG	2015	180	9					956	963		10.7205/MILMED-D-14-00581			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CQ3TL	WOS:000360525600007	26327547	Bronze			2022-02-06	
J	Corrigan, JD; Horn, SD; Barrett, RS; Smout, RJ; Bogner, J; Hammond, FM; Brandstater, ME; Majercik, S				Corrigan, John D.; Horn, Susan D.; Barrett, Ryan S.; Smout, Randall J.; Bogner, Jennifer; Hammond, Flora M.; Brandstater, Murray E.; Majercik, Sarah			Effects of Patient Preinjury and Injury Characteristics on Acute Rehabilitation Outcomes for Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Craniocerebral trauma; Outcome assessment (health care); Rehabilitation	FUNCTIONAL RECOVERY; IMPACT; PREDICTION; DISABILITY; SEVERITY; TIME; AGE	Objective: To examine associations of patient and injury characteristics with outcomes at inpatient rehabilitation discharge and 9 months postdischarge for patients with traumatic brain injury (TBI). Design: Prospective, longitudinal observational study. Setting: Inpatient rehabilitation centers. Participants: Consecutive patients (N=2130) enrolled between 2008 and 2011, admitted for inpatient rehabilitation after index TBI, and divided into 5 subgroups based on rehabilitation admission FIM cognitive score. Interventions: Not applicable. Main Outcome Measures: Rehabilitation length of stay, discharge to home, and FIM at discharge and 9 months postdischarge. Results: Severity indices increased explained variation in outcomes beyond that accounted for by patient characteristics. FIM motor scores were generally the most predictable. Higher functioning subgroups had more predictable outcomes then subgroups with lower cognitive function at admission. Age at injury, time from injury to rehabilitation admission, and functional independence at rehabilitation admission were the most consistent predictors across all outcomes and subgroups. Conclusions: Findings from previous studies of the relations among patient and injury characteristics and rehabilitation outcomes were largely replicated. Discharge outcomes were most strongly associated with injury severity characteristics, whereas predictors of functional independence at 9 months postdischarge included both patient and injury characteristics. (C) 2015 by the American Congress of Rehabilitation Medicine	[Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Horn, Susan D.; Barrett, Ryan S.; Smout, Randall J.] Int Sever Informat Syst, Inst Clin Outcomes Res, Salt Lake City, UT USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Brandstater, Murray E.] Loma Linda Univ, Med Ctr, Loma Linda, CA USA; [Majercik, Sarah] Intermt Med Ctr, Div Trauma & Surg Crit Care, Salt Lake City, UT USA		Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu			National Institutes of Health, National Center for Medical Rehabilitation ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD050439-01]; National Institute on Disability and Rehabilitation Research [H133A080023]; Ontario Neurotrauma Foundation [2007-ABI-ISIS-525]; American Congress of Rehabilitation Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	Supported by the National Institutes of Health, National Center for Medical Rehabilitation Research (grant no. 1R01HD050439-01); National Institute on Disability and Rehabilitation Research (grant no. H133A080023); and Ontario Neurotrauma Foundation (grant no. 2007-ABI-ISIS-525).; Publication of this article was supported by the American Congress of Rehabilitation Medicine.	Avesani R, 2012, EUR J PHYS REHAB MED, V48, P433; Barker MD, 2014, J HEAD TRAUMA REHAB, V29, P400, DOI 10.1097/HTR.0b013e31828a0a45; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coronado V, MORTALITY M IN PRESS; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Corrigan JD, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1315; Eastvold AD, 2013, J HEAD TRAUMA REHAB, V28, P48, DOI 10.1097/HTR.0b013e31823c9317; Gardizi E, 2014, ARCH PHYS MED REHAB, V95, P2396, DOI 10.1016/j.apmr.2014.06.004; Godbolt AK, 2015, J HEAD TRAUMA REHAB, V30, pE41, DOI 10.1097/HTR.0000000000000050; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hart T, 2014, ARCH PHYS MED REHAB, V95, P2103, DOI 10.1016/j.apmr.2014.07.001; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Horn SD, 2015, ARCH PHYS MED REHAB, V96, pS178, DOI 10.1016/j.apmr.2014.09.042; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Leon-Carrion J, 2013, BRAIN INJURY, V27, P1119, DOI 10.3109/02699052.2013.804204; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; Pedersen AR, 2015, NEUROREHAB NEURAL RE, V29, P299, DOI 10.1177/1545968314545171; Perrin PB, 2015, J HEAD TRAUMA REHAB, V30, P136, DOI 10.1097/HTR.0000000000000026; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Sigurdardottir S, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000039; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023	27	28	30	1	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2015	96	8		3			S209	S221		10.1016/j.apmr.2015.03.026			13	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	CO3CV	WOS:000359035100004	26212398	Bronze, Green Accepted			2022-02-06	
J	Goiaei, A; Adhikari, U; Berkowitz, ML				Goiaei, Ardeshir; Adhikari, Upendra; Berkowitz, Max L.			Opening of the Blood-Brain Barrier Tight Junction Due to Shock Wave Induced Bubble Collapse: A Molecular Dynamics Simulation Study	ACS CHEMICAL NEUROSCIENCE			English	Article						Blood-brain barrier; shock wave; cavitation effect; traumatic brain injury; claudin protein; tight junction	DRUG-DELIVERY; FOCUSED ULTRASOUND; FORCE-FIELD; INJURY; INFLAMMATION; DISRUPTION; MELITTIN; MODEL; MICROBUBBLES; DYSFUNCTION	Passage of a shock wave across living organisms may produce bubbles in the blood vessels and capillaries. It was suggested that collapse of these bubbles imposed by an impinging shock wave can be responsible for the damage or even destruction of the blood-brain barrier. To check this possibility, we performed molecular dynamics computer simulations on systems that contained a model of tight junction from the blood-brain barrier. In our model, we represent the tight junction by two pairs of interacting proteins, claudin-15. Some of the simulations were done in the absence of a nanobubble, some in its presence. Our simulations show that when no bubble is present in the system, no damage to tight junction is observed when the shock wave propagates across it. In the presence of a nanobubble, even when the impulse of the shock wave is relatively low, the implosion of the bubble causes serious damage to our model tight junction.	[Goiaei, Ardeshir] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Goiaei, Ardeshir] Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA; [Adhikari, Upendra; Berkowitz, Max L.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA		Berkowitz, ML (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	maxb@unc.edu		Berkowitz, Max/0000-0002-9116-0362	Office of Naval ResearchOffice of Naval Research [N00014-14-1-0241]	The support by Grant N00014-14-1-0241 from the Office of Naval Research is gratefully acknowledged.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Adcock SA, 2006, CHEM REV, V106, P1589, DOI 10.1021/cr040426m; Adhikari U, 2015, J PHYS CHEM B, V119, P6225, DOI 10.1021/acs.jpcb.5b02218; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Choubey A, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3518472; de Jong DH, 2013, J CHEM THEORY COMPUT, V9, P687, DOI 10.1021/ct300646g; Del Razo M. J., 2015, ARXIV150309157; Dodson GG, 2008, EMBO REP, V9, P144, DOI 10.1038/sj.embor.7401160; Goliaei A, 2014, J PHYS CHEM B, V118, P12673, DOI 10.1021/jp507919p; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Husseini GA, 2014, COLLOID SURFACE B, V123, P364, DOI 10.1016/j.colsurfb.2014.07.051; Karplus M, 2005, P NATL ACAD SCI USA, V102, P6679, DOI 10.1073/pnas.0408930102; Kodama T, 2000, BIOPHYS J, V79, P1821, DOI 10.1016/S0006-3495(00)76432-0; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Liu HL, 2014, THERANOSTICS, V4, P432, DOI 10.7150/thno.8074; Liu HL, 2010, RADIOLOGY, V255, P415, DOI 10.1148/radiol.10090699; Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f; Marrink SJ, 2013, CHEM SOC REV, V42, P6801, DOI 10.1039/c3cs60093a; McDannold N, 2012, CANCER RES, V72, P3652, DOI 10.1158/0008-5472.CAN-12-0128; Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x; Nomura KI, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.148303; Ollila OHS, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.078101; Santo KP, 2015, J PHYS CHEM B, V119, P8879, DOI 10.1021/jp505720d; Santo KP, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4862987; Santo KP, 2013, J PHYS CHEM B, V117, P5031, DOI 10.1021/jp312328n; Santo KP, 2012, J PHYS CHEM B, V116, P3021, DOI 10.1021/jp212018f; Sheikov N, 2004, ULTRASOUND MED BIOL, V30, P979, DOI 10.1016/j.ultrasmedbio.2004.04.010; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Suzuki H, 2014, SCIENCE, V344, P304, DOI 10.1126/science.1248571; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tribello GA, 2014, COMPUT PHYS COMMUN, V185, P604, DOI 10.1016/j.cpc.2013.09.018; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; Vedadi M, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.014503; Vykhodtseva N, 2008, ULTRASONICS, V48, P279, DOI 10.1016/j.ultras.2008.04.004; Warshel A, 2002, ACCOUNTS CHEM RES, V35, P385, DOI 10.1021/ar010033z; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yesylevskyy SO, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000810; Zhao YZ, 2013, INT J NANOMED, V8, P1621, DOI 10.2147/IJN.S43589	44	28	28	5	48	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	AUG	2015	6	8					1296	1301		10.1021/acschemneuro.5b00116			6	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	CP6AS	WOS:000359967300005	26075566				2022-02-06	
J	Wee, HY; Lim, SW; Chio, CC; Niu, KC; Wang, CC; Kuo, JR				Wee, Hsiao-Yue; Lim, Sher-Wei; Chio, Chung-Ching; Niu, Ko-Chi; Wang, Che-Chuan; Kuo, Jinn-Rung			Hyperbaric oxygen effects on neuronal apoptosis associations in a traumatic brain injury rat model	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Hyperbaric oxygen therapy; Apoptosis; Tumor necrosis factor-alpha; Transforming growth-interacting factor; Transforming growth factor-beta1	TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; IMPACT INJURY; TNF-ALPHA; THERAPY; MECHANISMS; CONTUSION; PROTEIN; NEURODEGENERATION; INFLAMMATION	Background: The neuroprotective mechanisms of hyperbaric oxygen (HBO) therapy on traumatic brain injury (TBI) remain unclear, especially neuronal apoptosis associations such as the expression of tumor necrosis factor alpha (TNF-alpha), transforming growthinteracting factor (TGIF), and TGF-beta 1 after TBI. The aim of this study was to investigate the neuroprotective effects of HBO therapy in a rat model of TBI. Materials and methods: The experimental rats were randomly divided into three groups as follows: TBI + normobaric air (21% O-2 at one absolute atmosphere), TBI + HBO, and shamoperated normobaric air. The TBI + HBO rats received 100% O-2 at 2.0 absolute atmosphere for 1 h immediately after TBI. Local and systemic TNF-alpha expression, neuropathology, levels of the neuronal apoptosis-associated proteins TGIF and TGF-beta 1, and functional outcome were evaluated 72 h after the onset of TBI. Results: Compared to the TBI control groups, the running speed of rats on the TreadScan after TBI was significantly attenuated by HBO therapy. The TBI-induced local and systemic TNF-alpha expression, neuronal damage score, and neuronal apoptosis were also significantly reduced by HBO therapy. Moreover, HBO treatment attenuated the expression of TGIF but increased TGF-beta 1 expression in neurons. Conclusions: We concluded that treatment of TBI with HBO during the acute phase of injury can decrease local and systemic proinflammatory cytokine TNF-alpha production, resulting in neuroprotective effects. We also suggest that decreased levels of TGIF and increased levels of TGF-beta in the injured cortex leading to decreased neuronal apoptosis is one mechanism by which functional recovery may occur. (C) 2015 Elsevier Inc. All rights reserved.	[Wee, Hsiao-Yue] Dept Neurosurg, Tainan, Taiwan; [Lim, Sher-Wei] Chiali Chi Mei Hosp, Dept Neurosurg, Tainan, Taiwan; [Lim, Sher-Wei] Min Hwei Coll Hlth Care Management, Dept Nursing, Tainan, Taiwan; [Chio, Chung-Ching; Wang, Che-Chuan; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Neurosurg, Tainan 710, Yung Kang, Taiwan; [Niu, Ko-Chi] Chi Mei Med Ctr, Dept Hyperbar Oxygen, Tainan 710, Yung Kang, Taiwan; [Wang, Che-Chuan] Southern Taiwan Univ Sci & Technol, Dept Child Care, Tainan, Taiwan; [Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan		Kuo, JR (corresponding author), Chi Mei Med Ctr, Dept Neurosurg, 901 Chung Hwa Roado, Tainan 710, Yung Kang, Taiwan.	kuojinnrung@gmail.com					Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Beare JE, 2009, J NEUROTRAUM, V26, P2045, DOI 10.1089/neu.2009.0914; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Chuang CH, 2013, ACUPUNCT MED, V31, P395, DOI 10.1136/acupmed-2013-010406; Demange C, 2009, MOL CELL, V36, P1073, DOI 10.1016/j.molcel.2009.12.009; Hickey RW, 2000, CRIT CARE MED, V28, P3511, DOI 10.1097/00003246-200010000-00027; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; Lee YS, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/512978; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Lin HC, 2005, EUR J PHARMACOL, V508, P249, DOI 10.1016/j.ejphar.2004.12.021; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Niu KC, 2007, EUR J PHARMACOL, V570, P229, DOI 10.1016/j.ejphar.2007.05.056; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Villapol S, 2013, EXP NEUROL, V250, P353, DOI 10.1016/j.expneurol.2013.10.008; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yu CH, 2011, J VET SCI, V12, P299, DOI 10.4142/jvs.2011.12.3.299; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	45	28	35	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	AUG	2015	197	2					382	389		10.1016/j.jss.2015.04.052			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	CK3CZ	WOS:000356095100024	25982374				2022-02-06	
J	Wood, JN; French, B; Song, LH; Feudtner, C				Wood, Joanne N.; French, Benjamin; Song, Lihai; Feudtner, Chris			Evaluation for Occult Fractures in Injured Children	PEDIATRICS			English	Article							ABUSIVE HEAD TRAUMA; SKELETAL SURVEYS; SUSPECTED ABUSE; INFANTS; DIAGNOSIS; IDENTIFICATION; OUTCOMES; YOUNGER; YIELD; AGE	OBJECTIVES: To examine variation across US hospitals in evaluation for occult fractures in (1) children <2 years old diagnosed with physical abuse and (2) infants,1 year old with injuries associated with a high likelihood of abuse and to identify factors associated with such variation. METHODS: We performed a retrospective study in children,2 years old with a diagnosis of physical abuse and in infants,1 year old with non-motor vehicle crash-related traumatic brain injury or femur fractures discharged from 366 hospitals in the Premier database from 2009 to 2013. We examined across-hospital variation and identified child-and hospital-level factors associated with evaluation for occult fractures. RESULTS: Evaluations for occult fractures were performed in 48% of the 2502 children with an abuse diagnosis, in 51% of the 1574 infants with traumatic brain injury, and in 53% of the 859 infants with femur fractures. Hospitals varied substantially with regard to their rates of evaluation for occult fractures in all 3 groups. Occult fracture evaluations were more likely to be performed at teaching hospitals than at nonteaching hospitals (all P < .001). The hospital-level annual volume of young, injured children was associated with the probability of occult fracture evaluation, such that hospitals treating more young, injured patients were more likely to evaluate for occult fractures (all P < .001). CONCLUSIONS: Substantial variation in evaluation for occult fractures among young children with a diagnosis of abuse or injuries associated with a high likelihood of abuse highlights opportunities for quality improvement in this vulnerable population.	[Wood, Joanne N.; Feudtner, Chris] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Song, Lihai] Childrens Hosp Philadelphia, PolicyLab, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [French, Benjamin] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA		Wood, JN (corresponding author), Childrens Hosp Philadelphia, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD071967-01]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD071967] Funding Source: NIH RePORTER	Dr Wood received salary funding from the National Institute of Child Health and Human Development grant (1K23HD071967-01). Funded by the National Institutes of Health (NIH).	American College of Radiology, 2011, ACR SPR PRACT GUID S; Belfer RA, 2001, AM J EMERG MED, V19, P122, DOI 10.1053/ajem.2001.21345; Berger RP, 2015, INJURY PREV, V21, pE133, DOI 10.1136/injuryprev-2013-040924; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Brehaut JC, 2010, MED DECIS MAKING, V30, P398, DOI 10.1177/0272989X09344747; Centers for Disease Control and Prevention; National Center for Injury Prevention and Control; Division of Unintentional Injury Prevention, 2014, PERC DISTR TBI REL H; Coffey C, 2005, J PEDIATR SURG, V40, P120, DOI 10.1016/j.jpedsurg.2004.09.003; DALTON HJ, 1990, AM J DIS CHILD, V144, P875, DOI 10.1001/archpedi.1990.02150320039022; Damiani G, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-2; Day Fiona, 2006, J Clin Forensic Med, V13, P55, DOI 10.1016/j.jcfm.2005.08.001; Deye KP, 2013, J TRAUMA ACUTE CARE, V74, P1553, DOI 10.1097/TA.0b013e31828b7fc4; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; Duffy SO, 2011, PEDIATRICS, V127, pE47, DOI 10.1542/peds.2010-0298; Feudtner C, 2013, PHARMACOEPIDEM DR S, V22, P890, DOI 10.1002/pds.3456; Fisher BT, 2012, PHARMACOEPIDEM DR S, P246; French B, 2012, STAT MED, V31, P366, DOI 10.1002/sim.4410; Hicks RA, 2007, PEDIATR EMERG CARE, V23, P308, DOI 10.1097/01.pec.0000270174.39228.30; Hooft A, 2013, J PEDIATR-US, V162, P80, DOI 10.1016/j.jpeds.2012.06.037; Hui C, 2008, J PEDIATR ORTHOPED, V28, P297, DOI 10.1097/BPO.0b013e3181653bf9; Hulson OS, 2014, PEDIATR RADIOL, V44, P1557, DOI 10.1007/s00247-014-3063-4; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C, 2007, PEDIATRICS, V119, P1232, DOI 10.1542/peds.2007-0883; Karmazyn B, 2011, AM J ROENTGENOL, V197, pW159, DOI 10.2214/AJR.10.5733; Kemp, 2013, EVID BASED CHILD HLT, V5, P2044, DOI [10.1002/ebch.1941, DOI 10.1002/ebch.1941]; Kemp AM, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1518; Lane WG, 2007, CLIN ORTHOP RELAT R, P219, DOI 10.1097/BLO.0b013e31805c0849; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Laskey AL, 2013, J PEDIATR-US, V162, P86, DOI 10.1016/j.jpeds.2012.06.038; Laskey AL, 2012, J PEDIATR-US, V160, P1003, DOI 10.1016/j.jpeds.2011.11.042; Leventhal JM, 2008, PEDIATRICS, V122, P599, DOI 10.1542/peds.2007-1959; Leventhal JM, 2010, PEDIATRICS, V126, pE104, DOI 10.1542/peds.2009-1076; Lindberg DM, 2014, J PEDIATR-US, V164, P1268, DOI 10.1016/j.jpeds.2014.01.068; Loder RT, 2006, J PEDIATR ORTHOPED, V26, P561, DOI 10.1097/01.bpo.0000230335.19029.ab; MERTEN DF, 1983, RADIOLOGY, V146, P377, DOI 10.1148/radiology.146.2.6849085; Myhre MC, 2007, ACTA PAEDIATR, V96, P1159, DOI 10.1111/j.1651-2227.2007.00356.x; Normand SLT, 2007, STAT SCI, V22, P206, DOI 10.1214/088342307000000096; Oderda Gary M, 2013, J Pain Palliat Care Pharmacother, V27, P62, DOI 10.3109/15360288.2012.751956; Oral R, 2003, PEDIATR EMERG CARE, V19, P148, DOI 10.1097/01.pec.0000081234.20228.33; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Petska HW, 2013, CLIN PEDIATR, V52, P86, DOI 10.1177/0009922812441675; Prior M, 2008, J EVAL CLIN PRACT, V14, P888, DOI 10.1111/j.1365-2753.2008.01014.x; Rangel EL, 2009, J PEDIATR SURG, V44, P1229, DOI 10.1016/j.jpedsurg.2009.02.044; Ravichandiran N, 2010, PEDIATRICS, V125, P60, DOI 10.1542/peds.2008-3794; Robinson Scott B, 2014, Infect Dis Clin Pract (Baltim Md), V22, P320; Sheets LK, 2013, PEDIATRICS, V131, P701, DOI 10.1542/peds.2012-2780; Thackeray JD, 2007, PEDIATR EMERG CARE, V23, P735, DOI 10.1097/PEC.0b013e3181568039; Thorpe EL, 2014, PEDIATR EMERG CARE, V30, P771, DOI 10.1097/PEC.0000000000000257; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277; Wood JN, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-169; Wood JN, 2012, PEDIATRICS, V130, P853, DOI 10.1542/peds.2012-0244; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467; Ziegler DS, 2005, J PAEDIATR CHILD H, V41, P251, DOI 10.1111/j.1440-1754.2005.00605.x	54	28	28	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	2015	136	2					232	240		10.1542/peds.2014-3977			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CN9SA	WOS:000358788100042	26169425	Green Published			2022-02-06	
J	Dams-O'Connor, K; Pretz, C; Billah, T; Hammond, FM; Harrison-Felix, C				Dams-O'Connor, Kristen; Pretz, Christopher; Billah, Tausif; Hammond, Flora M.; Harrison-Felix, Cynthia			Global Outcome Trajectories After TBI Among Survivors and Nonsurvivors: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							LONGITUDINAL DESCRIPTION; LIFE EXPECTANCY; SCALE; MORTALITY; INDIVIDUALS; AGE; POPULATION; PREDICTORS; PATTERNS; DATABASE	Objective: To compare long-term functional outcome trajectories of individuals with traumatic brain injury (TBI) who survive with those who expire more than 5 years postinjury, using individual growth curve analysis. Design: Secondary analysis of data from a multicenter longitudinal cohort study. Setting: Acute inpatient rehabilitation facilities that are current or former TBI Model Systems. Participants: Individuals 16 years and older with a primary diagnosis of TBI. Main Outcome Measures: Glasgow Outcome Scale-Extended; Disability Rating Scale. Results: Individuals in the TBI Model Systems who expire several years after injury demonstrate worse functional status at baseline and a steeper rate of decline over time as measured by both the Glasgow Outcome Scale-Extended and the Disability Rating Scale. There was significant variability in each growth parameter (P < .05) for both instruments. A reduced model was built for each outcome, including all covariates that related significantly to the growth parameters. An interactive tool was created for each outcome to generate individual-level trajectories based on various combinations of covariate values. Conclusion: Individuals with TBI who die several years after injury demonstrate functional trajectories that differ markedly from those of survivors. Opportunities should be sought for health management interventions to improve health and longevity after TBI.	[Dams-O'Connor, Kristen; Billah, Tausif] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Pretz, Christopher; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA		Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, One Gustave Levy Pl,Box 1240B, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org			Traumatic Brain Injury Model Systems (TBIMS) National Data and Statistical Center (National Institute on Disability and Rehabilitation Research [NIDRR]) [H133A110006]; New York TBIMS (NIDRR) [H133A070033]; Indiana University TBIMS (NIDRR) [H133A120035]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	This work was funded by the Traumatic Brain Injury Model Systems (TBIMS) National Data and Statistical Center (National Institute on Disability and Rehabilitation Research [NIDRR] grant no. H133A110006), the New York TBIMS (NIDRR grant no. H133A070033), and Indiana University TBIMS (NIDRR grant no. H133A120035).	Adler M., 1990, DISABLED THEIR HLTH; Arango-Lasprilla JC, 2010, ARCH PHYS MED REHAB, V91, P1495, DOI 10.1016/j.apmr.2010.07.010; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Chan L, 2002, ARCH PHYS MED REHAB, V83, P1196, DOI 10.1053/apmr.2002.34811; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Faul M, 2010, TRAUMATIC BRAIN INJU; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Hall A, 2007, INTELLECT DEV DISAB, V45, P310, DOI 10.1352/0047-6765(2007)45[310:PIPHCU]2.0.CO;2; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Institute of Medicine Committee on Gulf War Health, 2009, GULF WAR HLTH; JENNETT B, 1975, LANCET, V1, P480; Kolakowsky-Hayner SA, 2012, BRAIN INJURY, V26, P1328, DOI 10.3109/02699052.2012.706353; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P2486, DOI 10.1016/j.apmr.2013.06.021; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P2478, DOI 10.1016/j.apmr.2013.06.019; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Strauss D, 2004, NEUROREHABILITATION, V19, P257; Swaine JG, 2014, J INTELL DISABIL RES, V58, P651, DOI 10.1111/jir.12062; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	38	28	29	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					E1	E10		10.1097/HTR.0000000000000073			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CM8JB	WOS:000357944800001	24922043	Green Accepted			2022-02-06	
J	Gao, Y; Xu, SY; Cui, ZW; Zhang, MK; Lin, YY; Cai, L; Wang, ZG; Luo, XG; Zheng, Y; Wang, Y; Luo, QZ; Jiang, JY; Neale, JH; Zhong, CL				Gao, Yang; Xu, Siyi; Cui, Zhenwen; Zhang, Mingkun; Lin, Yingying; Cai, Lei; Wang, Zhugang; Luo, Xingguang; Zheng, Yan; Wang, Yong; Luo, Qizhong; Jiang, Jiyao; Neale, Joseph H.; Zhong, Chunlong			Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						behavior; gene knockout; Glutamate carboxypep-tidase II; histopathology; N-acetylaspartylglutamate; traumatic brain injury	NAAG PEPTIDASE INHIBITOR; N-ACETYLASPARTYLGLUTAMATE NAAG; MEMBRANE ANTIGEN; NEUROPATHIC PAIN; GCP-II; MODEL; NAALADASE; ENZYME; NEUROTRANSMITTER; ASTROCYTES	Glutamate carboxypeptidase II (GCPII) is a transmembrane zinc metallopeptidase found mainly in the nervous system, prostate and small intestine. In the nervous system, glia-bound GCPII mediates the hydrolysis of the neurotransmitter N-acetylaspartylglutamate (NAAG) into glutamate and N-acetylaspartate. Inhibition of GCPII has been shown to attenuate excitotoxicity associated with enhanced glutamate transmission under pathological conditions. However, different strains of mice lacking the GCPII gene are reported to exhibit striking phenotypic differences. In this study, a GCPII gene knockout (KO) strategy involved removing exons 3-5 of GCPII. This generated a new GCPII KO mice line with no overt differences in standard neurological behavior compared to their wild-type (WT) littermates. However, GCPII KO mice were significantly less susceptible to moderate traumatic brain injury (TBI). GCPII gene KO significantly lessened neuronal degeneration and astrocyte damage in the CA2 and CA3 regions of the hippocampus 24h after moderate TBI. In addition, GCPII gene KO reduced TBI-induced deficits in long-term spatial learning/memory tested in the Morris water maze and motor balance tested via beam walking. Knockout of the GCPII gene is not embryonic lethal and affords histopathological protection with improved long-term behavioral outcomes after TBI, a result that further validates GCPII as a target for drug development consistent with results from studies using GCPII peptidase inhibitors.	[Gao, Yang; Xu, Siyi; Cui, Zhenwen; Zhang, Mingkun; Lin, Yingying; Zheng, Yan; Wang, Yong; Luo, Qizhong; Jiang, Jiyao; Zhong, Chunlong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China; [Cai, Lei; Wang, Zhugang] Shanghai Res Ctr Model Organisms, Shanghai, Peoples R China; [Luo, Xingguang] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [Neale, Joseph H.] Georgetown Univ, Dept Biol, Washington, DC 20057 USA		Zhong, CL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	drchunlongzhong@126.com			basic research program of project 973 by the Ministry of Science and Technology of China [2011CB013304]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070990, 30670719, 30500525]; Shanghai Science and Technology CommissionShanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM) [10QH1401700, 09140901300]; Shanghai Municipal Education CommissionShanghai Municipal Education Commission (SHMEC) [09SG20]	The authors report no conflicts of interest. This research was supported in part by a basic research program of project 973 by the Ministry of Science and Technology of China (2011CB013304), and by grants from the National Natural Science Foundation of China (No. 81070990, 30670719, 30500525), the Shanghai Science and Technology Commission (No. 10QH1401700, 09140901300) and the Shanghai Municipal Education Commission (No. 09SG20). JN supported by an endowment and generous gifts from Nancy and Daniel Paduano.	Bacich DJ, 2005, J NEUROCHEM, V95, P314, DOI 10.1111/j.1471-4159.2005.03361.x; Bacich DJ, 2002, J NEUROCHEM, V83, P20, DOI 10.1046/j.1471-4159.2002.01117.x; Bacich DJ, 2001, MAMM GENOME, V12, P117, DOI 10.1007/s003350010240; Barinka C, 2012, CURR MED CHEM, V19, P856, DOI 10.2174/092986712799034888; Berger UV, 1999, J COMP NEUROL, V415, P52, DOI 10.1002/(SICI)1096-9861(19991206)415:1<52::AID-CNE4>3.0.CO;2-K; Bzdega T, 2004, J NEUROCHEM, V89, P627, DOI 10.1111/j.1471-4159.2004.02361.x; Cao P, 2013, CNS NEUROSCI THER, V19, P337, DOI 10.1111/cns.12082; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CASSIDY M, 1993, NEUROPEPTIDES, V24, P271, DOI 10.1016/0143-4179(93)90015-3; Chang SS, 1999, CLIN CANCER RES, V5, P2674; Chopra M, 2009, J PHARMACOL EXP THER, V330, P212, DOI 10.1124/jpet.109.152553; Crawley JN, 2008, NEURON, V57, P809, DOI 10.1016/j.neuron.2008.03.001; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dvela-Levitt M, 2014, J NEUROTRAUM, V31, P1942, DOI 10.1089/neu.2014.3544; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Feng JF, 2012, BRAIN RES, V1469, P144, DOI 10.1016/j.brainres.2012.06.021; Feng JF, 2011, BRAIN RES, V1395, P62, DOI 10.1016/j.brainres.2011.04.022; Fricker AC, 2009, NEUROPHARMACOLOGY, V56, P1060, DOI 10.1016/j.neuropharm.2009.03.002; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Gurkoff GG, 2013, BRAIN RES, V1515, P98, DOI 10.1016/j.brainres.2013.03.043; Han LQ, 2009, SYNAPSE, V63, P625, DOI 10.1002/syn.20649; Hlouchova K, 2007, J NEUROCHEM, V101, P682, DOI 10.1111/j.1471-4159.2006.04341.x; ISRAELI RS, 1993, CANCER RES, V53, P227; Jackson PF, 1996, J MED CHEM, V39, P619, DOI 10.1021/jm950801q; Janczura KJ, 2013, EUR J PHARMACOL, V701, P27, DOI 10.1016/j.ejphar.2012.11.027; Kozikowski AP, 2004, J MED CHEM, V47, P1729, DOI 10.1021/jm0306226; Kunkler PE, 1997, J CEREBR BLOOD F MET, V17, P26, DOI 10.1097/00004647-199701000-00005; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Marmiroli P, 2012, CURR MED CHEM, V19, P1277, DOI 10.2174/092986712799462568; McKinzie DL, 2000, ADDICT BIOL, V5, P411, DOI 10.1111/j.1369-1600.2000.tb00209.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nagel J, 2006, NEUROPHARMACOLOGY, V51, P1163, DOI 10.1016/j.neuropharm.2006.07.018; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; Neale JH, 2011, J NEUROCHEM, V119, P891, DOI 10.1111/j.1471-4159.2011.07380.x; Neale JH, 2011, J NEUROCHEM, V118, P490, DOI 10.1111/j.1471-4159.2011.07338.x; Olszewski RT, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.68; Olszewski RT, 2008, BIOL PSYCHIAT, V63, P86, DOI 10.1016/j.biopsych.2007.04.016; Olszewski RT, 2012, SCHIZOPHR RES, V136, P160, DOI 10.1016/j.schres.2012.01.007; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; Popik P, 2003, NEUROPSYCHOPHARMACOL, V28, P457, DOI 10.1038/sj.npp.1300048; Rahn KA, 2012, P NATL ACAD SCI USA, V109, P20101, DOI 10.1073/pnas.1209934109; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; Romei C, 2013, NEUROPHARMACOLOGY, V66, P311, DOI 10.1016/j.neuropharm.2012.05.030; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Slusher BS, 2001, SYNAPSE, V41, P22, DOI 10.1002/syn.1056; Thomas AG, 2001, EUR J PHARMACOL, V426, P35, DOI 10.1016/S0014-2999(01)01198-0; Thomas AG, 2001, EUR J PHARMACOL, V430, P33, DOI 10.1016/S0014-2999(01)01239-0; Tsai G, 2003, SYNAPSE, V50, P285, DOI 10.1002/syn.10263; Vornov JJ, 2013, J PHARMACOL EXP THER, V346, P406, DOI 10.1124/jpet.113.205039; Wolfer DP, 1998, NEWS PHYSIOL SCI, V13, P118, DOI 10.1152/physiologyonline.1998.13.3.118; Wozniak KM, 2012, CURR MED CHEM, V19, P1323, DOI 10.2174/092986712799462630; Wozniak KM, 2012, J PHARMACOL EXP THER, V343, P746, DOI 10.1124/jpet.112.197665; Yamada T, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-67; Yamamoto T, 2004, EUR J NEUROSCI, V20, P483, DOI 10.1111/j.1460-9568.2004.03504.x; Yamamoto T, 2001, NEUROSCIENCE, V102, P473, DOI 10.1016/S0306-4522(00)00502-9; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x; Zhong CL, 2014, INT J NEUROSCI, V124, P867, DOI 10.3109/00207454.2014.890935; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zhou J, 2005, NAT REV DRUG DISCOV, V4, P1015, DOI 10.1038/nrd1903; Zuo DY, 2012, J BIOL CHEM, V287, P21773, DOI 10.1074/jbc.M112.363226; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	66	28	28	3	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2015	134	2					340	353		10.1111/jnc.13123			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	CM3QK	WOS:000357598000014	25872793	Bronze			2022-02-06	
J	Pang, CH; Lee, SE; Kim, CH; Kim, JE; Kang, HS; Park, CK; Paek, SH; Kim, CH; Jahng, TA; Kim, JW; Kim, YH; Kim, DG; Chung, CK; Jung, HW; Yoo, H				Pang, Chang Hwan; Lee, Soo Eon; Kim, Chang Hyeun; Kim, Jeong Eun; Kang, Hyun-Seung; Park, Chul-Kee; Paek, Sun Ha; Kim, Chi Heon; Jahng, Tae-Ahn; Kim, Jin Wook; Kim, Yong Hwy; Kim, Dong Gyu; Chung, Chun Kee; Jung, Hee-Won; Yoo, Heon			Acute intracranial bleeding and recurrence after bur hole craniostomy for chronic subdural hematoma	JOURNAL OF NEUROSURGERY			English	Article						acute intracranial bleeding; bur hole craniostomy; chronic subdural hematoma; recurrence; traumatic brain injury	CLOSED-SYSTEM DRAINAGE; RETROSPECTIVE ANALYSIS; SURGICAL-MANAGEMENT; INTERVENTION; ANTIPLATELET; CRANIOTOMY; THERAPY; INJURY; SINGLE; ADULTS	OBJECT There is inconsistency among the perioperative management strategies currently used for chronic subdural hematoma (cSDH). Moreover, postoperative complications such as acute intracranial bleeding and cSDH recurrence affect clinical outcome of cSDH surgery. This study evaluated the risk factors associated with acute intracranial bleeding and cSDH recurrence and identified an effective perioperative strategy for cSDH patients. METHODS A retrospective study of patients who underwent bur hole craniostomy for cSDH between 2008 and 2012 was performed. RESULTS A consecutive series of 303 cSDH patients (234 males and 69 females; mean age 67.17 years) was analyzed. Postoperative acute intracranial bleeding developed in 14 patients (4.57%) within a mean of 3.07 days and recurrence was observed in 37 patients (12.21%) within a mean of 31.69 days (range 10-104 days) after initial bur hole craniostomy. The comorbidities of hematological disease and prior shunt surgery were clinical factors associated with acute bleeding. There was a significant risk of recurrence in patients with diabetes mellitus, but recurrence did not affect the final neurological outcome (p = 0.776). Surgical details, including the number of operative bur holes, saline irrigation of the hematoma cavity, use of a drain, and type of postoperative ambulation, were not significantly associated with outcome. However, a large amount of drainage was associated with postoperative acute bleeding. CONCLUSIONS Bur hole craniostomy is an effective surgical procedure for initial and recurrent cSDH. Patients with hematological disease or a history of prior shunt surgery are at risk for postoperative acute bleeding; therefore, these patients should be carefully monitored to avoid overdrainage. Surgeons should consider informing patients with diabetes mellitus that this comorbidity is associated with an increased likelihood of recurrence.	[Pang, Chang Hwan; Lee, Soo Eon; Kim, Chang Hyeun; Kim, Jeong Eun; Kang, Hyun-Seung; Park, Chul-Kee; Paek, Sun Ha; Kim, Chi Heon; Kim, Yong Hwy; Kim, Dong Gyu; Chung, Chun Kee; Jung, Hee-Won] Seoul Natl Univ Hosp, Dept Neurosurg, Seoul 110744, South Korea; [Jahng, Tae-Ahn; Kim, Jin Wook] Bundang Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea; [Kim, Jeong Eun; Kang, Hyun-Seung; Park, Chul-Kee; Paek, Sun Ha; Kim, Chi Heon; Jahng, Tae-Ahn; Kim, Dong Gyu; Chung, Chun Kee; Jung, Hee-Won] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea; [Yoo, Heon] Natl Canc Ctr, Dept Neurosurg, Seoul, South Korea		Yoo, H (corresponding author), Natl Canc Ctr, Specif Organs Canc Ctr, Dept Neurosurg, 323 Ilsan Ro, Goyang Si 410769, Gyeonggi Do, South Korea.	heonyoo@ncc.re.kr	Park, Chul-Kee/J-5499-2012; Park, Chul-Kee/O-7842-2019; Kim, Yong Hwy/L-8289-2019	Park, Chul-Kee/0000-0002-2350-9876; Pang, Chang hwan/0000-0002-9017-9336	Korean Brain and Spinal Cord Research Foundation	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This work was supported by the Korean Brain and Spinal Cord Research Foundation.	Adeolu AA, 2012, BRIT J NEUROSURG, V26, P743, DOI 10.3109/02688697.2012.690912; Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255; Aspegren OP, 2013, CLIN NEUROL NEUROSUR, V115, P981, DOI 10.1016/j.clineuro.2012.10.008; Bergsneider M, 2005, NEUROSURGERY SUPPL, V57, pii; Carmel P W, 1999, Neurosurg Focus, V7, pe7; Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y; Erol FS, 2005, J CLIN NEUROSCI, V12, P261, DOI 10.1016/j.jocn.2003.09.012; Gokmen M, 2008, ZBL NEUROCHIR, V69, P129, DOI 10.1055/s-2007-1004587; HAMILTON MG, 1993, NEUROSURGERY, V33, P67; Kansal R, 2010, J CLIN NEUROSCI, V17, P428, DOI 10.1016/j.jocn.2009.07.109; Karibe Hiroshi, 2011, No Shinkei Geka, V39, P1149; Lega BC, 2010, J NEUROSURG, V113, P615, DOI 10.3171/2009.9.JNS08825; Lindvall P, 2009, J CLIN NEUROSCI, V16, P1287, DOI 10.1016/j.jocn.2009.01.001; Markwalder TM, 2000, NEUROSURG CLIN N AM, V11, P541, DOI 10.1016/S1042-3680(18)30120-7; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; MCCULLOUGH DC, 1974, J NEUROSURG, V40, P372, DOI 10.3171/jns.1974.40.3.0372; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298; Mizutani K, 2014, CLIN NEUROL NEUROSUR, V117, P100, DOI 10.1016/j.clineuro.2013.11.035; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Pahatouridis D, 2013, NEUROSURG REV, V36, P151, DOI 10.1007/s10143-012-0412-3; Reinges MHT, 2000, J NEUROL NEUROSUR PS, V69, P40, DOI 10.1136/jnnp.69.1.40; Rohde V, 2002, NEUROSURG REV, V25, P89, DOI 10.1007/s101430100182; Sambasivan M, 1997, SURG NEUROL, V47, P418, DOI 10.1016/S0090-3019(97)00188-2; Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6; Van der Veken J, 2014, ACTA NEUROCHIR, V156, P981, DOI 10.1007/s00701-014-2042-8	26	28	31	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2015	123	1					65	74		10.3171/2014.12.JNS141189			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CL5DY	WOS:000356981200009	25679282				2022-02-06	
J	Brizuela, M; Blizzard, CA; Chuckowree, JA; Dawkins, E; Gasperini, RJ; Young, KM; Dickson, TC				Brizuela, Mariana; Blizzard, Catherine A.; Chuckowree, Jyoti A.; Dawkins, Edgar; Gasperini, Robert J.; Young, Kaylene M.; Dickson, Tracey C.			The microtubule-stabilizing drug Epothilone D increases axonal sprouting following transection injury in vitro	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Epothilone D; Microtubule-stabilizing drug; Axotomy; Microtubules; Traumatic brain injury	CORTICAL-NEURONS; BRAIN-PENETRANT; MOUSE MODEL; REGENERATION; PLASTICITY; DYNAMICS; DIFFERENTIATION; THERAPEUTICS; MECHANISMS; TRANSPORT	Neuronal cytoskeletal alterations, in particular the loss and misalignment of microtubules, are considered a hallmark feature of the degeneration that occurs after traumatic brain injury (TBI). Therefore, microtubule-stabilizing drugs are attractive potential therapeutics for use following TBI. The best-known drug in this category is Paclitaxel, a widely used anti-cancer drug that has produced promising outcomes when employed in the treatment of various animal models of nervous system trauma. However, Paclitaxel is not ideal for the treatment of patients with TBI due to its limited blood-brain barrier (BBB) permeability. Herein we have characterized the effect of the brain penetrant microtubule-stabilizing agent Epothilone D (Epo D) on post-injury axonal sprouting in an in vitro model of CNS trauma. Epo D was found to modulate axonal sprout number in a dose dependent manner, increasing the number of axonal sprouts generated post-injury. Elevated sprouting was observed when analyzing the total population of injured neurons, as well as in selective analysis of Thy1-YFP-labeled excitatory neurons. However, we found no effect of Epo D on axonal sprout length or outgrowth speed. These findings indicate that Epo D specifically affects injury-induced axonal sprout generation, but not net growth. Our investigation demonstrates that primary cultures of cortical neurons are tolerant of Epo D exposure, and that Epo D significantly increases their regenerative response following structural injury. Therefore Epo D may be a potent therapeutic for enhancing regeneration following CNS injury. This article is part of a Special Issue entitled 'Traumatic Brain Injury'. (C) 2015 Elsevier Inc. All rights reserved.	[Brizuela, Mariana; Blizzard, Catherine A.; Chuckowree, Jyoti A.; Dawkins, Edgar; Gasperini, Robert J.; Young, Kaylene M.; Dickson, Tracey C.] Univ Tasmania, Menzies Inst Med Res Tasmania, Hobart, Tas 7000, Australia		Dickson, TC (corresponding author), Univ Tasmania, Menzies Inst Med Res Tasmania, Hobart, Tas 7000, Australia.	Tracey.Dickson@utas.edu.au	Dawkins, Edgar/L-1720-2013	Dawkins, Edgar/0000-0003-1737-9435; Chuckowree, Jyoti/0000-0002-1245-1402; Young, Kaylene/0000-0002-1686-3463; Dickson, Tracey/0000-0002-9196-1661; Gasperini, Rob/0000-0001-6859-1247; Blizzard, Catherine/0000-0002-8683-2937	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1042556]; Tasmanian Masonic Centenary Medical Research Foundation; Clive and Vera Ramaciotti Foundation; Marian and E.H. Flack Trust	We would like to thank our colleagues at the University of Tasmania for their helpful feedback and comments on this manuscript. Work in the author's laboratories was supported by the National Health and Medical Research Council of Australia (1042556), the Tasmanian Masonic Centenary Medical Research Foundation, the Clive and Vera Ramaciotti Foundation and the Marian and E.H. Flack Trust.	Andrieux A, 2006, BIOL PSYCHIAT, V60, P1224, DOI 10.1016/j.biopsych.2006.03.048; Baas PW, 2013, BRAIN, V136, P2937, DOI 10.1093/brain/awt153; Bahrey HLP, 2003, J NEUROPHYSIOL, V89, P1761, DOI 10.1152/jn.00972.2002; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barten DM, 2012, J NEUROSCI, V32, P7137, DOI 10.1523/JNEUROSCI.0188-12.2012; Beer TM, 2007, INVEST NEW DRUG, V25, P565, DOI 10.1007/s10637-007-9068-1; Blizzard CA, 2007, EUR J NEUROSCI, V26, P1100, DOI 10.1111/j.1460-9568.2007.05750.x; Blizzard CA, 2013, J NEUROTRAUM, V30, P1908, DOI 10.1089/neu.2013.2850; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Bradke F, 2012, NAT REV NEUROSCI, V13, P183, DOI 10.1038/nrn3176; Brunden KR, 2012, BIOCHEM SOC T, V40, P661, DOI 10.1042/BST20120010; Brunden KR, 2011, PHARMACOL RES, V63, P341, DOI 10.1016/j.phrs.2010.12.002; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Cafferty WBJ, 2008, TRENDS NEUROSCI, V31, P215, DOI 10.1016/j.tins.2008.02.004; Canty AJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3038; Carmichael ST, 2003, NEUROSCIENTIST, V9, P64, DOI 10.1177/1073858402239592; Cartelli D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01837; Cengiz N, 2012, J NEUROTRAUM, V29, P2465, DOI 10.1089/neu.2009.0947; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; Cheng KL, 2008, BIOL-TARGETS THER, V2, P789; Chuckowree JA, 2004, NEUROSCIENTIST, V10, P280, DOI 10.1177/1073858404263511; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2002, EXP NEUROL, V178, P1, DOI 10.1006/exnr.2002.8017; Clarke LE, 2012, J NEUROSCI, V32, P8173, DOI 10.1523/JNEUROSCI.0928-12.2012; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Cortes J, 2007, ONCOLOGIST, V12, P271, DOI 10.1634/theoncologist.12-3-271; DeLima AD, 1997, J COMP NEUROL, V382, P230, DOI 10.1002/(SICI)1096-9861(19970602)382:2<230::AID-CNE7>3.0.CO;2-4; DICHTER MA, 1978, BRAIN RES, V149, P279, DOI 10.1016/0006-8993(78)90476-6; Dickey CA, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-6; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Erturk A, 2007, J NEUROSCI, V27, P9169, DOI 10.1523/JNEUROSCI.0612-07.2007; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fournet V, 2012, J NEUROCHEM, V123, P982, DOI 10.1111/jnc.12027; Gomis-Ruth S, 2008, CURR BIOL, V18, P992, DOI 10.1016/j.cub.2008.06.026; Goodin S, 2004, J CLIN ONCOL, V22, P2015, DOI 10.1200/JCO.2004.12.001; Hanell A., 2014, TRAUMATIC BRAIN INJU; Hellal F, 2011, SCIENCE, V331, P928, DOI 10.1126/science.1201148; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Janke C, 2010, TRENDS NEUROSCI, V33, P362, DOI 10.1016/j.tins.2010.05.001; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kar S, 2003, EMBO J, V22, P70, DOI 10.1093/emboj/cdg001; King AE, 2006, J COMP NEUROL, V498, P277, DOI 10.1002/cne.21053; King CE, 2000, CLIN EXP PHARMACOL P, V27, P548, DOI 10.1046/j.1440-1681.2000.03292.x; Kolman Ada, 2005, Curr Opin Investig Drugs, V6, P616; Loov C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055983; Lou K, 2014, J MED CHEM, V57, P6116, DOI 10.1021/jm5005623; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; Maxwell W. L., 1995, Journal of Neurotrauma, V12, P363; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McKinney RA, 1999, P NATL ACAD SCI USA, V96, P11631, DOI 10.1073/pnas.96.20.11631; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rampersad SN, 2012, SENSORS-BASEL, V12, P12347, DOI 10.3390/s120912347; Rossignol S, 1999, PROG BRAIN RES, V123, P349, DOI 10.1016/S0079-6123(08)62870-8; Sengottuvel Vetrivel, 2011, Commun Integr Biol, V4, P391, DOI 10.4161/cib.4.4.15552; Sengottuvel V, 2011, J NEUROSCI, V31, P2688, DOI 10.1523/JNEUROSCI.4885-10.2011; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; TYTELL M, 1984, P NATL ACAD SCI-BIOL, V81, P1570, DOI 10.1073/pnas.81.5.1570; Wang H, 2005, CANCER CHEMOTH PHARM, V56, P255, DOI 10.1007/s00280-004-0965-0; Wang H., 2005, PRECLINICAL PHARM EP; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011	68	28	29	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		129	140		10.1016/j.mcn.2015.02.006			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK7FT	WOS:000356398900009	25684676				2022-02-06	
J	Liu, MD; Zhang, C; Liu, WB; Luo, P; Zhang, L; Wang, Y; Wang, ZJ; Fei, Z				Liu, Mengdong; Zhang, Chi; Liu, Wenbo; Luo, Peng; Zhang, Lei; Wang, Yuan; Wang, Zhanjiang; Fei, Zhou			A novel rat model of blast-induced traumatic brain injury simulating different damage degree: implications for morphological, neurological, and biomarker changes	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						blast-induced traumatic brain injury; animal model; biomarker; inflammation; metabolic change	COGNITIVE DEFICITS; OXIDATIVE STRESS; MOUSE MODEL; EXPLOSIONS; INFLAMMATION; MANAGEMENT; CASUALTIES; DIAGNOSIS; MICE	In current military conflicts and civilian terrorism, blast-induced traumatic brain injury (bIBI) is the primary cause of neurotrauma. However, the effects and mechanisms of bTBI are poorly understood. Although previous researchers have made significant contributions to establishing animal models for the simulation of bTBI, the precision and controllability of blast-induced injury in animal models must be improved. Therefore, we established a novel rat model to simulate blast-wave injury to the brain. To simulate different extents of bTBI injury, the animals were divided into moderate and severe injury groups. The miniature spherical explosives (pentaerythritol tetranitrate) used in each group were of different sizes (2.5 mm diameter in the moderate injury group and 3.0 mm diameter in the severe injury group). A specially designed apparatus was able to precisely adjust the positions of the miniature explosives and create eight rats with bTBI simultaneously, using a single electric detonator. Neurological functions, gross pathologies, histopathological changes and the expression levels of various biomarkers were examined after the explosion. Compared with the moderate injury group, there were significantly more neurological dysfunctions, cortical contusions, intraparenchymal hemorrhages, cortical expression of S-100 beta, myelin basic protein, neuron-specific enolase, IL-8, IL-10, inducible nitric oxide synthase, and HIF-1 alpha in the severe injury group. These results demonstrate that we have created a reliable and reproducible bTBI model in rats. This model will be helpful for studying the mechanisms of bTBI and developing strategies for clinical bTBI treatment.	[Liu, Mengdong; Zhang, Chi; Liu, Wenbo; Luo, Peng; Zhang, Lei; Wang, Yuan; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China; [Wang, Zhanjiang] Northwest Inst Nucl Technol, Xian 710024, Peoples R China		Wang, ZJ (corresponding author), Northwest Inst Nucl Technol, Hong Qing Bao Rd, Xian 710024, Peoples R China.	wangzhanjiangnint@126.com; zhoufeifmmu@126.com		Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81430043]; National Science and Technology Major Project of China [2013ZX 09J13109-02C]; National Science and Technology Pillar Program of China [2012BAI11B02]; Research Foundation of PLA [2010gxjs078, AWS11J008]	The work was supported by National Natural Science Foundation of China (No. 81430043), National Science and Technology Major Project of China (2013ZX 09J13109-02C), National Science and Technology Pillar Program of China (No. 2012BAI11B02), and Research Foundation of PLA (No. 2010gxjs078 and No. AWS11J008).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bochicchio GV, 2008, AM SURGEON, V74, P267; Bolzenius JD, 2015, APPL NEUROPSYCH-ADUL, V22, P79, DOI 10.1080/23279095.2013.845823; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Jaffee MS, 2009, J REHABIL RES DEV, V46, P655, DOI 10.1682/JRRD.2008.09.0114; Kluger Yoram, 2007, Am J Disaster Med, V2, P21; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Li AH, 2013, J MOL NEUROSCI, V51, P1052, DOI 10.1007/s12031-013-0084-7; Long JB, 2010, IFMBE PROC, V32, P26, DOI 10.1007/978-3-642-14998-6_7; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Neher MD, 2014, SOUTH MED J, V107, P248, DOI 10.1097/SMJ.0000000000000086; Oran ES, 2012, PHILOS T R SOC A, V370, P534, DOI 10.1098/rsta.2011.0385; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Wang ZL, 2003, MIL MED, V168, P330, DOI 10.1093/milmed/168.4.330; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	42	28	30	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	MAY 1	2015	9								138	10.3389/fincel.2015.00168			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CI5LW	WOS:000354799000001	25983677				2022-02-06	
J	Miao, W; Bao, TH; Han, JH; Yin, M; Yan, Y; Wang, WW; Zhu, YH				Miao, W.; Bao, T. H.; Han, J. H.; Yin, M.; Yan, Y.; Wang, W. W.; Zhu, Y. H.			Voluntary exercise prior to traumatic brain injury alters miRNA expression in the injured mouse cerebral cortex	BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH			English	Article						Voluntary exercise; Running wheel; miRNA; Traumatic brain injury	SPINAL-CORD-INJURY; MICRORNAS; RECOVERY; RATS; MODEL	MicroRNAs (miRNAs) may be important mediators of the profound molecular and cellular changes that occur after traumatic brain injury (TBI). However, the changes and possible roles of miRNAs induced by voluntary exercise prior to TBI are still not known. In this report, the microarray method was used to demonstrate alterations in miRNA expression levels in the cerebral cortex of TBI mice that were pretrained on a running wheel (RW). Voluntary RW exercise prior to TBI: i) significantly decreased the mortality rate and improved the recovery of the righting reflex in TBI mice, and ii) differentially changed the levels of several miRNAs, upregulating some and downregulating others. Furthermore, we revealed global upregulation of miR-21, miR-92a, and miR-874 and downregulation of miR-138, let-7c, andmiR-124 expression among the sham-non-runner, TBI-non-runner, and TBI-runner groups. Quantitative reverse transcription polymerase chain reaction data (RT-qPCR) indicated good consistency with the microarray results. Our microarray-based analysis of miRNA expression in mice cerebral cortex after TBI revealed that some miRNAs such as miR-21, miR-92a, miR-874, miR-138, let-7c, and miR-124 could be involved in the prevention and protection afforded by voluntary exercise in a TBI model.	[Miao, W.; Bao, T. H.; Han, J. H.; Yin, M.; Yan, Y.; Zhu, Y. H.] Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming, Peoples R China; [Bao, T. H.] Psychiat Hosp Yunnan Prov, Kunming, Peoples R China; [Wang, W. W.] Kunming Med Univ, Affiliated Hosp 2, Dept Cardiol, Kunming, Peoples R China		Zhu, YH (corresponding author), Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming, Peoples R China.	yuhong_lilin@aliyun.com					Banzet S, 2013, J APPL PHYSIOL, V115, P1237, DOI 10.1152/japplphysiol.00075.2013; Bao TH, 2014, J MOL NEUROSCI, V54, P622, DOI 10.1007/s12031-014-0344-1; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Denham J, 2014, SPORTS MED, V44, P189, DOI 10.1007/s40279-013-0114-1; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Gu X, 2014, J MOL NEUROSCI, V52, P156, DOI 10.1007/s12031-013-0190-6; Hou WH, 2012, BBA-GENE REGUL MECH, V1819, P1113, DOI 10.1016/j.bbagrm.2012.06.001; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Koo HM, 2013, J PHYS THER SCI, V25, P1103, DOI 10.1589/jpts.25.1103; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li J, 2014, NUCLEIC ACIDS RES, V42, P458, DOI 10.1093/nar/gkt839; Ouchi Y, 2013, J NEUROSCI, V33, P9408, DOI 10.1523/JNEUROSCI.2700-12.2013; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pasiakos SM, 2013, ADV NUTR, V4, P412, DOI 10.3945/an.113.003699; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rosi S, 2012, HIPPOCAMPUS, V22, P544, DOI 10.1002/hipo.20920; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057	27	28	30	1	8	ASSOC BRAS DIVULG CIENTIFICA	SAO PAULO	FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL	0100-879X	1678-4510		BRAZ J MED BIOL RES	Brazilian J. Med. Biol. Res.	MAY	2015	48	5					433	439		10.1590/1414-431X20144012			7	Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine	CH6ZU	WOS:000354186100009	25760028	gold, Green Submitted, Green Published			2022-02-06	
J	Wasserman, EB; Abar, B; Shah, MN; Wasserman, D; Bazarian, JJ				Wasserman, Erin B.; Abar, Beau; Shah, Manish N.; Wasserman, Daniel; Bazarian, Jeffrey J.			Concussions Are Associated With Decreased Batting Performance Among Major League Baseball Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussion; baseball; softball; epidemiology; proprioception; balance	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; CLOSED-HEAD INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; CLINICAL MANAGEMENT; REACTION-TIME; RECOVERY; SYMPTOMS; FOOTBALL	Background: Concussions impair balance, visual acuity, and reaction timeall of which are required for high-level batting performancebut the effects of concussion on batting performance have not been reported. The authors examined this relationship between concussion and batting performance among Major League Baseball (MLB) players. Hypothesis: Batting performance among concussed MLB players will be worse upon return to play than batting performance among players missing time for noninjury reasons. Study Design: Cohort study; Level of evidence, 3. Methods: The authors identified MLB players who sustained a concussion between 2007 and 2013 through league disabled-list records and a Baseball Prospectus database. For a comparison group, they identified players who went on paternity or bereavement leave during the same period. Using repeated-measures generalized linear models, the authors compared 7 batting metrics between the 2 groups for the 2 weeks upon return, as well as 4 to 6 weeks after return, controlling for pre-leave batting metrics, number of days missed, and position. Results: The authors identified 66 concussions and 68 episodes of bereavement/paternity leave to include in the analysis. In the 2 weeks after return, batting average (.235 vs .266), on-base percentage (.294 vs .326), slugging percentage (.361 vs .423), and on-base plus slugging (.650 vs .749) were significantly lower among concussed players relative to the bereavement/paternity leave players (time x group interaction, P < .05). In weeks 4 to 6 after leave, these metrics were slightly lower in concussed players but not statistically significantly so. Conclusion: Although concussed players may be asymptomatic upon return to play, the residual effects of concussion on the skills required for batting may still be present. Further work is needed to clarify the mechanism through which batting performance after concussion is adversely affected and to identify better measures to use for return-to-play decisions.	[Wasserman, Erin B.; Abar, Beau; Shah, Manish N.; Wasserman, Daniel; Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA		Wasserman, EB (corresponding author), Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, 265 Crittenden Blvd,Box 644, Rochester, NY 14642 USA.	erin_wasserman@urmc.rochester.edu		Shah, Manish/0000-0001-6331-1074; Wasserman, Erin/0000-0001-5957-5878; Abar, Beau/0000-0003-1536-220X			Ahmad CS, 2014, AM J SPORT MED, V42, P1464, DOI 10.1177/0363546514529083; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Athiviraham A, 2012, AM J SPORT MED, V40, P2808, DOI 10.1177/0363546512461754; Bell S., 2011, ANAL MLBS CONCUSSION; Beyer JA, 2012, ANN BIOMED ENG, V40, P150, DOI 10.1007/s10439-011-0412-4; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Castaneda B, 2007, J SPORT EXERCISE PSY, V29, P60, DOI 10.1123/jsep.29.1.60; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Clark JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029109; Classe J G, 1997, J Am Optom Assoc, V68, P43; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Dawkins C, 2011, CONCUSSION DISCUSSIO; Dutton C, 2008, BATTERS AND BABIP; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fast M, 2011, DOES QUALITY CONTACT; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Fortenbaugh D, 2011, SPORT BIOMECH, V10, P270, DOI 10.1080/14763141.2011.629205; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gray R, 2004, J EXP PSYCHOL-APPL, V10, P42, DOI 10.1037/1076-898X.10.1.42; Green W, 2010, OPTOMETRY, V81, P129, DOI 10.1016/j.optm.2009.07.015; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kida N, 2005, COGNITIVE BRAIN RES, V22, P257, DOI 10.1016/j.cogbrainres.2004.09.003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kumar NS, 2014, AM J SPORT MED, V42, P2050, DOI 10.1177/0363546514539449; Laby DM, 1996, AM J OPHTHALMOL, V122, P476, DOI 10.1016/S0002-9394(14)72106-3; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Major League Baseball, 2011, MAJ LEAG BAS MAJ LEA; Major League Baseball, MLB PLAY T; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; Muraskin J., 2013, 7 ANN MIT SLOAN SPOR; Nakamoto H, 2008, PERCEPT MOTOR SKILL, V106, P163, DOI 10.2466/PMS.106.1.163-170; Nakamoto H, 2013, EXP BRAIN RES, V228, P193, DOI 10.1007/s00221-013-3547-8; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Radlo SJ, 2001, RES Q EXERCISE SPORT, V72, P22, DOI 10.1080/02701367.2001.10608928; Regan D, 1997, J SPORT SCI, V15, P533, DOI 10.1080/026404197366985; Schwarz A, 2011, NY TIMES; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Slowinski S, 2010, BABIP WHAT DO WE KNO; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Taliep MS, 2008, PERCEPTION, V37, P96, DOI 10.1068/p5620; WELCH CM, 1995, J ORTHOP SPORT PHYS, V22, P193, DOI 10.2519/jospt.1995.22.5.193; Yamashiro K, 2013, EXP BRAIN RES, V225, P197, DOI 10.1007/s00221-012-3361-8; Zhang J, 2005, PERCEPT MOTOR SKILL, V100, P1127, DOI 10.2466/PMS.100.4.1127-1136	58	28	28	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2015	43	5					1127	1133		10.1177/0363546515576130			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	CH4CV	WOS:000353980000018	25784627				2022-02-06	
J	Lorente, L; Martin, MM; Almeida, T; Hernandez, M; Ramos, L; Argueso, M; Caceres, JJ; Sole-Violan, J; Jimenez, A				Lorente, Leonardo; Martin, Maria M.; Almeida, Teresa; Hernandez, Mariano; Ramos, Luis; Argueso, Monica; Caceres, Juan J.; Sole-Violan, Jordi; Jimenez, Alejandro			Serum substance P levels are associated with severity and mortality in patients with severe traumatic brain injury	CRITICAL CARE			English	Article							NF-KAPPA-B; HEAD-INJURY; FUNCTIONAL DEFICITS; BLOOD MONOCYTES; NK-1 RECEPTOR; SPINAL-CORD; NEUROPEPTIDE; TACHYKININS; ASTROCYTES; EXPRESSION	Introduction: Substance P (SP) is a member of the tachykinin family of neuropeptides, which are widely distributed throughout the central nervous system (CNS) and actively involved in inflammatory processes. SP is released early following acute injury to the CNS, promoting a neurogenic inflammatory response characterized by an increase in the permeability of the blood-brain barrier and the development of vasogenic edema. High levels of SP could lead to an exacerbated inflammatory response that could be fatal for patients with traumatic brain injury (TBI). Thus, the main goal of the present study was to determine whether serum SP levels are associated with injury severity and mortality in patients with severe TBI. Methods: This multicenter, observational, prospective study was carried out in six Spanish intensive care units and included patients with Glasgow Coma Scale (GCS) scores <= 8. Patients with an Injury Severity Score >= 10 in non-cranial aspects were excluded. Blood samples were collected on day 1 of TBI to measure serum SP levels. The endpoint was 30-day mortality. Results: We found higher serum SP levels (P = 0.002) in non-surviving patients (n = 27) than in surviving patients (n = 73). The area under the curve for serum SP levels with regard to predicting 30-day mortality was 0.70 (95% confidence interval (CI), 0.60 to 0.79; P < 0.001). Survival analysis showed that patients with serum SP levels >299 pg/ml had higher 30-day mortality than patients with lower levels (hazard ratio = 3.7; 95% CI, 1.75 to 7.94; P < 0.001). Multiple binomial logistic regression analysis showed that serum SP levels >299 pg/ml were associated with 30-day mortality when we controlled for APACHE II score and Marshall computed tomography lesion classification (odds ratio (OR) = 5.97; 95% CI, 1.432 to 24.851; P = 0.01) and for GCS score and age (OR = 5.71; 95% CI, 1.461 to 22.280; P = 0.01). We found a negative association between serum SP levels and GCS score (Spearman's rho = -0.22; P = 0.03). Conclusions: We report, for the first time to our knowledge, that serum SP levels were associated with injury severity and mortality in patients with severe TBI. These results open the possibility that SP antagonists may be useful in the treatment of patients with severe TBI.	[Lorente, Leonardo] Hosp Univ Canarias, Intens Care Unit, Tenerife 38320, Spain; [Martin, Maria M.] Hosp Univ Nuestra Senora Candelaria, Intens Care Unit, Santa Cruz de Tenerife 38010, Spain; [Almeida, Teresa; Hernandez, Mariano] Univ La Laguna, Inst Enfermedades Trop & Salud Publ Canarias, Unidad Genet, Tenerife 38071, Spain; [Ramos, Luis] Hosp Gen La Palma, Intens Care Unit, La Palma 38713, Spain; [Argueso, Monica] Hosp Clin Univ Valencia, Intens Care Unit, Valencia 46004, Spain; [Caceres, Juan J.] Hosp Insular, Intens Care Unit, Las Palmas Gran Canaria 35016, Spain; [Sole-Violan, Jordi] Hosp Univ Dr Negrin, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Intens Care Unit, Las Palmas Gran Canaria 35010, Spain; [Jimenez, Alejandro] Hosp Univ Canarias, Res Unit, Santa Cruz De Tenerife 38320, Spain		Lorente, L (corresponding author), Hosp Univ Canarias, Intens Care Unit, S-N La Laguna, Tenerife 38320, Spain.	lorentemartin@msn.com	Hernandez, Mariano/K-6679-2015; Hernandez, Mariano/AAK-3143-2020; Almeida, Teresa A/S-1166-2018	Hernandez, Mariano/0000-0003-1219-0246; Hernandez, Mariano/0000-0003-1219-0246; Almeida, Teresa A/0000-0002-7644-3436; Argueso, Monica/0000-0001-5917-1056	Fundacion Canaria de Investigacion Sanitaria (FUNCANIS) (La Laguna, Tenerife, Spain)	We thank Andreina Leon Carmenatis and Henoc del Rosario Garcia for their technical assistance. This study was supported by the Fundacion Canaria de Investigacion Sanitaria (FUNCANIS) (La Laguna, Tenerife, Spain). The funders had no role in study design, sample collection, data analysis, decision to publish or preparation of the manuscript.	Almeida TA, 2004, CURR MED CHEM, V11, P2045, DOI 10.2174/0929867043364748; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carthew HL, 2012, NEUROSCIENCE, V214, P78, DOI 10.1016/j.neuroscience.2012.04.028; Chavolla-Calderon M, 2003, J CLIN INVEST, V111, P973, DOI 10.1172/JCI200317458; Czeh B, 2006, EXPERT OPIN INV DRUG, V15, P479, DOI 10.1517/13543784.15.5.479; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; De Swert KO, 2006, EUR J PHARMACOL, V533, P171, DOI 10.1016/j.ejphar.2005.12.066; DEFELIPE C, 1995, SCIENCE, V267, P899, DOI 10.1126/science.7531367; Delgado AV, 2005, EXP BIOL MED, V230, P271; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Duffy Ruth A, 2004, Expert Opin Emerg Drugs, V9, P9; EDVINSSON L, 1988, REGUL PEPTIDES, V20, P181, DOI 10.1016/0167-0115(88)90075-4; Fiebich BL, 2000, J IMMUNOL, V165, P5606, DOI 10.4049/jimmunol.165.10.5606; Bernal EF, 2013, MED INTENSIVA, V37, P327, DOI 10.1016/j.medin.2012.05.015; Gabrielian Levon, 2013, Acta Neurochir Suppl, V118, P201, DOI 10.1007/978-3-7091-1434-6_37; Graham DI, 1996, ACT NEUR S, V66, P96; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Ho WZ, 1996, J NEUROIMMUNOL, V71, P73, DOI 10.1016/S0165-5728(96)00132-4; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Kleinbaum D. G., 1998, APPL REGRESSION ANAL, P281; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAURENZI MA, 1990, SCAND J IMMUNOL, V31, P529, DOI 10.1111/j.1365-3083.1990.tb02801.x; Li Y, 2003, J NEUROSCI RES, V71, P559, DOI 10.1002/jnr.10504; Lieb K, 1997, J IMMUNOL, V159, P4952; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; Lu J, 2005, ACT NEUR S, V95, P281; Maeda K, 1997, GERONTOLOGY, V43, P11; MANTYH PW, 1989, P NATL ACAD SCI USA, V86, P5193, DOI 10.1073/pnas.86.13.5193; Marmarou A, 2001, J NEUROSURG, V94, P349; MARRIOTT DR, 1991, J NEUROCHEM, V56, P259, DOI 10.1111/j.1471-4159.1991.tb02590.x; Marriott I, 2004, FRONT BIOSCI, V9, P2153, DOI 10.2741/1377; Marriott I, 2000, J NEUROIMMUNOL, V102, P163, DOI 10.1016/S0165-5728(99)00182-4; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTIN FC, 1993, J NEUROIMMUNOL, V42, P53, DOI 10.1016/0165-5728(93)90212-H; MARTIN FC, 1992, BRAIN RES, V599, P13, DOI 10.1016/0006-8993(92)90846-2; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Munoz M, 2014, AMINO ACIDS, V46, P1727, DOI 10.1007/s00726-014-1736-9; Munoz M, 2011, CURR DRUG TARGETS, V12, P909, DOI 10.2174/138945011795528796; NEWBOLD P, 1995, BRIT J PHARMACOL, V114, P570, DOI 10.1111/j.1476-5381.1995.tb17177.x; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Palma C, 1997, GLIA, V21, P183, DOI 10.1002/(SICI)1098-1136(199710)21:2<183::AID-GLIA2>3.0.CO;2-8; Park SW, 2007, J NEUROSURG, V107, P593, DOI 10.3171/JNS-07/09/0593; Petroni G, 2010, J TRAUMA, V68, P564, DOI 10.1097/TA.0b013e3181ce1eed; Rasley A, 2002, GLIA, V37, P258, DOI 10.1002/glia.10034; Shi HY, 2014, J NEUROSURG, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Yang S, 2014, CRIT CARE MED, V42, P2092, DOI 10.1097/CCM.0000000000000486; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39; Zhang Y, 2006, CURR DRUG TARGETS, V7, P1011, DOI 10.2174/138945006778019363	58	28	30	1	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	APR 27	2015	19								192	10.1186/s13054-015-0911-z			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH7VG	WOS:000354244100001	25928056	gold, Green Published			2022-02-06	
J	Fuller, GW; Kemp, SPT; Decq, P				Fuller, Gordon Ward; Kemp, Simon P. T.; Decq, Philippe			The International Rugby Board (IRB) Pitch Side Concussion Assessment trial: a pilot test accuracy study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Head Injuries; Injury Prevention; Rugby	SENSITIVITY; INJURIES; SPORT; SPECIFICITY; STATEMENT; FRACTURES; RISK	Background On the field and on the run' assessments of head impact events in professional rugby have resulted in a high proportion of players subsequently diagnosed with confirmed concussion not leaving the field of play at the time of injury. The International Rugby Board (IRB) consequently developed a process to support team doctors in the recognition and management of players at risk of concussion, including development of a multimodal assessment instrumentthe Pitch Side Concussion Assessment (PSCA) tool. Methods This was a pilot cohort study designed to determine the feasibility of assessing the accuracy of the IRB PSCA tool in elite male rugby. The study population comprised consecutive players identified with a head impact event with the potential to result in concussion during eight international/national competitions. Players were assessed off field by match-day or team doctors, following a temporary substitution. The accuracy of the PSCA tool was measured against a reference standard of postmatch confirmed concussion, based on clinical judgement aided by an established concussion support instrument. Results A total of 165 head injury events with the potential to cause concussion were included in the study. The PSCA tool demonstrated a sensitivity of 84.6% (95% CI 73.5% to 92.4%) and a specificity of 74% (95% CI 64.3% to 82.3%) to identify players subsequently diagnosed with confirmed concussion. The negative predictive value was 88.1% (95% CI 79.2% to 94.1%); the positive predictive value was 67.9% (95% CI 56.6% to 77.8%). There were no major barriers identified that would prevent the evaluation of the PSCA process or tool in a future large-scale study. Conclusions This pilot study has provided the first preliminary estimates for the performance of the PSCA tool, suggesting a potentially favourable balance between positive and negative predictive values. The study has also offered a strong basis to conduct a further larger trial, providing information for sample size calculations and highlighting areas for methodological development.	[Fuller, Gordon Ward] Univ Sheffield, Sch Hlth & Related Res, Emergency Med Res Sheffield Grp, Sheffield S1 4DA, S Yorkshire, England; [Kemp, Simon P. T.] Rugby Football Union, Twickenham, Middx, England; [Decq, Philippe] Hop Beaujon, Assistance Publ Hop Paris, French Federat Rugby, Dept Neurosurg,Med Sch Rene Diderot Paris 7, Paris, France		Fuller, GW (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Emergency Med Res Sheffield Grp, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England.	g.fuller@sheffield.ac.uk		Fuller, Gordon Ward/0000-0001-8532-3500; Kemp, Simon/0000-0002-3250-2713			Anderson L, 2011, BRIT J SPORT MED, V45, P948, DOI 10.1136/bjsm.2011.083881; Bachmann LM, 2004, ANN INTERN MED, V140, P121, DOI 10.7326/0003-4819-140-5-200403020-00013; Bachmann LM, 2003, BMJ-BRIT MED J, V326, P417, DOI 10.1136/bmj.326.7386.417; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2010, CLIN J SPORT MED, V20, P179, DOI 10.1097/JSM.0b013e3181df1eea; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Genders TSS, 2012, RADIOLOGY, V265, P910, DOI 10.1148/radiol.12120509; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Helmy A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5748; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158; Rutjes AWS, 2005, CLIN CHEM, V51, P1335, DOI 10.1373/clinchem.2005.048595; Spirduso WW, 2005, PHYS DIMENSIONS AGIN, V2nd, P144; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1	25	28	29	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	8					529	535		10.1136/bjsports-2014-093498			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CF4OI	WOS:000352529000009	24997205				2022-02-06	
J	Miao, XY; Wu, XY; Shi, W				Miao, Xingyu; Wu, Xiaoying; Shi, Wei			Umbilical cord mesenchymal stem cells in neurological disorders: A clinical study	INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS			English	Article						Neurological diseases; Umbilical cord mesenchymal stem cells; Stem cell; Intrathecal administration; Lumbar puncture	AMYOTROPHIC-LATERAL-SCLEROSIS; BRAIN-INJURY; TRANSPLANTATION; THERAPY; IMMUNOASSAY; INHIBITION; TISSUE; BLOOD; TRIAL; RATS	We investigated the intrathecally administrated unbilical cord mesenchymal stem cells (UC-MSCs) by lumbar puncture and assessed the technical difficulties and effects in various neurological conditions. One hundred patients underwent subarachnoid placement of UC-MSCs between December 2006 and May 2010 in the Affiliated Hospital of Medicine. Technical difficulties in patients in the form of localization of subarachnoid space, number of attempts, and post-procedural complications were evaluated. Functional evaluation was done using Hauser Ambulation Index (HAT) by the stem cell transplant team on a regular basis. All patients were followed-up for more than 1 yr after the treatment. Clinical symptoms, related biochemical index and photographic examinations were observed regularly. We encountered technical difficulties in 31 patients (31%) in the form of general anesthesia supplementation and difficulty localizing the lumbar space. Side effects (headache, low-grade fever, low back pain and lower limb pain) were observed in 22 (22%) patients, which were treated with symptomatic therapy within 48 h. One year after the treatment, functional indices improved in 47 patients (47%): 12 patients with spinal cord injury, 11 patients with cerebral palsy, 9 patients with post-traumatic brain syndroine, 9 patients with post-brain infarction syndrome, 3 patients with spinocerebellar ataxias, and 3 patients with motor nenton-disease. In conclusion, intrathecal administration of UC-MSCs is a safe and effective way to treat neurological disorders. Our encouraging results of intrathecal administration of UC-MSCs indicate the potential of restoration of lost tissue and improvement of function in patients with profound neurological defects and inefficient conventional cure. These data support expanded double-blind, placebo-controlled studies for this treatment modality.	[Miao, Xingyu] Xi An Jiao Tong Univ, Affiliated Hosp 3, Dept Neurosurg, Xian 710068, Shanxi Province, Peoples R China; [Miao, Xingyu; Shi, Wei] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Neurosurg, Xian 710004, Shanxi Province, Peoples R China; [Wu, Xiaoying] Xi An Jiao Tong Univ, Affiliated Hosp 3, Dept Orthoped, Xian 710068, Shanxi Province, Peoples R China		Shi, W (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Neurosurg, 157 West Fifth Rd, Xian 710004, Shanxi Province, Peoples R China.	sweins@126.com					Carrion FA, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt64; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen YC, 2011, MYCOSES, V54, pE248, DOI 10.1111/j.1439-0507.2009.01847.x; Cui XY, 2015, MOL MED REP, V11, P3269, DOI 10.3892/mmr.2015.3198; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; Dotsikas Y, 2007, TALANTA, V71, P906, DOI 10.1016/j.talanta.2006.05.068; Glass JD, 2012, STEM CELLS, V30, P1144, DOI 10.1002/stem.1079; Gu Z, 2010, LUPUS, V19, P1502, DOI 10.1177/0961203310373782; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; Kang EJ, 2013, J TISSUE ENG REGEN M, V7, P169, DOI 10.1002/term.504; Kawai T, 2015, CYTOTHERAPY, V17, P369, DOI 10.1016/j.jcyt.2014.11.009; Kim DW, 2013, INT J MOL SCI, V14, P11692, DOI 10.3390/ijms140611692; Lepore AC, 2011, JOVE-J VIS EXP, V55, P3069; Li JF, 2014, CELL TRANSPLANT, V23, pS113, DOI 10.3727/096368914X685005; Lim JY, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt79; Liu J, 2013, CYTOTHERAPY, V15, P185, DOI 10.1016/j.jcyt.2012.09.005; Lundberg J, 2012, CELL TRANSPLANT, V21, P333, DOI 10.3727/096368911X576036; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marquez ME, 2015, BRIT J HAEMATOL, V169, P211, DOI 10.1111/bjh.13286; Mehta T, 2008, TRANSPL P, V40, P1145, DOI 10.1016/j.transproceed.2008.03.026; Messerli M, 2013, REPROD SCI, V20, P1455, DOI 10.1177/1933719113488443; Questroy M, 1995, SOINS PEDIAT PUERIC, V166, P28; Riley J, 2012, NEUROSURGERY, V71, P405, DOI 10.1227/NEU.0b013e31825ca05f; Titomanlio L, 2011, ANN NEUROL, V70, P698, DOI 10.1002/ana.22518; Trivanovic D, 2013, SRP ARK CELOK LEK, V141, P178, DOI 10.2298/SARH1304178T; Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013; Wang Liming, 2013, Case Rep Transplant, V2013, P146347, DOI 10.1155/2013/146347; Wang WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066599; Wang ZP, 2011, LUMINESCENCE, V26, P136, DOI 10.1002/bio.1196; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Xinaris C, 2013, CELL TRANSPLANT, V22, P423, DOI 10.3727/096368912X653246; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zhang RY, 2015, MOL MED REP, V11, P1807, DOI 10.3892/mmr.2014.2985	34	28	31	0	17	NATL INST SCIENCE COMMUNICATION-NISCAIR	NEW DELHI	DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA	0301-1208	0975-0959		INDIAN J BIOCHEM BIO	Indian J. Biochem. Biophys.	APR	2015	52	2					140	146					7	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	CO0EF	WOS:000358822200004	26118125				2022-02-06	
J	Hakon, J; Ruscher, K; Romner, B; Tomasevic, G				Hakon, Jakob; Ruscher, Karsten; Romner, Bertil; Tomasevic, Gregor			Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; INTERCELLULAR-ADHESION MOLECULE-1; PEPTIDE-1 RECEPTOR AGONIST; ENDOTHELIAL-CELLS; GENE-EXPRESSION; EDEMA FORMATION; RATS; IMPACT; MICE; HYPERGLYCEMIA	Cerebral edema is a common complication following moderate and severe traumatic brain injury (TBI), and a significant risk factor for development of neuronal death and deterioration of neurological outcome. To this date, medical approaches that effectively alleviate cerebral edema and neuronal death after TBI are not available. Glucagon-like peptide-1 (GLP-1) has anti-inflammatory properties on cerebral endothelium and exerts neuroprotective effects. Here, we investigated the effects of GLP-1 on secondary injury after moderate and severe TBI. Male Sprague Dawley rats were subjected either to TBI by Controlled Cortical Impact (CCI) or sham surgery. After surgery, vehicle or a GLP-1 analogue, Liraglutide, were administered subcutaneously twice daily for two days. Treatment with Liraglutide (200 mu g/kg) significantly reduced cerebral edema in pericontusional regions and improved sensorimotor function 48 hours after CCI. The integrity of the blood-brain barrier was markedly preserved in Liraglutide treated animals, as determined by cerebral extravasation of Evans blue conjugated albumin. Furthermore, Liraglutide reduced cortical tissue loss, but did not affect tissue loss and delayed neuronal death in the thalamus on day 7 post injury. Together, our data suggest that the GLP-1 pathway might be a promising target in the therapy of cerebral edema and cortical neuronal injury after moderate and severe TBI.	[Hakon, Jakob; Ruscher, Karsten; Tomasevic, Gregor] Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, Lund, Sweden; [Hakon, Jakob; Romner, Bertil] Copenhagen Univ Hosp, Risgshosp, Dept Neurosurg, Copenhagen, Denmark; [Romner, Bertil; Tomasevic, Gregor] Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden		Hakon, J (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, Lund, Sweden.	jakobhakon@gmail.com		Hakon, Jakob/0000-0003-1079-0141			Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Astrup A, 2009, LANCET, V374, P1606, DOI 10.1016/S0140-6736(09)61375-1; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Briyal S, 2012, BRAIN RES, V1427, P23, DOI 10.1016/j.brainres.2011.10.026; Ceriello A, 2013, DIABETES CARE, P1; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Collard CD, 2002, J BIOL CHEM, V277, P14801, DOI 10.1074/jbc.M110557200; Conti AC, 1998, J NEUROSCI, V18, P5663; Cummings BP, 2010, DIABETES, V59, P2653, DOI 10.2337/db09-1564; Darsalia V, 2012, CLIN SCI, V122, P473, DOI 10.1042/CS20110374; DeFronzo R, 2014, EFFECTS LIRAGLUTIDE; DellaValle B, 2014, ANN CLIN TRANSL NEUR, V1, P721, DOI 10.1002/acn3.99; DERYCK M, 1992, BRAIN RES, V573, P44; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Eakins James, 2009, J Diabetes Sci Technol, V3, P1373; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Fischer S, 2005, EUR J CELL BIOL, V84, P687, DOI 10.1016/j.ejcb.2005.03.002; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Fukui S, 2003, J CEREBR BLOOD F MET, V23, P1212, DOI 10.1097/01.WCB.0000088762.02615.30; Gejl Michael, 2013, Front Neuroenergetics, V5, P2, DOI 10.3389/fnene.2013.00002; Gejl M, 2012, J CEREBR BLOOD F MET, V32, P2146, DOI 10.1038/jcbfm.2012.118; Godoy DA, 2010, NEUROCRIT CARE, V13, P425, DOI 10.1007/s12028-010-9404-8; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071; Holst JJ, 2007, PHYSIOL REV, V87, P1409, DOI 10.1152/physrev.00034.2006; Holst JJ, 2011, CURR MED RES OPIN, V27, P547, DOI 10.1185/03007995.2010.549466; Hou J, 2012, J INEQUAL APPL, P1, DOI 10.1186/1029-242X-2012-60; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Hunter K, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-33; Iwai T, 2006, NEUROSCI RES, V55, P352, DOI 10.1016/j.neures.2006.04.008; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Krasner NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097554; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Lee CH, 2011, J NEUROSCI RES, V89, P1103, DOI 10.1002/jnr.22596; Li PA, 2000, STROKE, V31, P183, DOI 10.1161/01.STR.31.1.183; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Madinier A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093121; McClean PL, 2014, NEUROPHARMACOLOGY, V76, P57, DOI 10.1016/j.neuropharm.2013.08.005; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nauck MA, 2002, J CLIN ENDOCR METAB, V87, P1239, DOI 10.1210/jc.87.3.1239; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Rachmany L, 2012, AGE; Raun K, 2007, DIABETES, V56, P8, DOI 10.2337/db06-0565; Sato K, 2013, INT J MOL SCI, V14, P21513, DOI 10.3390/ijms141121513; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwarzkopf TM, 2013, EXP BIOL MED, V238, P84, DOI 10.1258/ebm.2012.012261; Secher A, 2014, J CLIN INVEST, V124, P4473, DOI 10.1172/JCI75276; [Services USDoHaH Food and Drug Adminstration CfDEaR], 2005, GUID IND EST MAX SAF; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shiraki A, 2012, ATHEROSCLEROSIS, V221, P375, DOI 10.1016/j.atherosclerosis.2011.12.039; Sturis J, 2003, BRIT J PHARMACOL, V140, P123, DOI 10.1038/sj.bjp.0705397; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; SZTRIHA L, 1986, ACTA NEUROPATHOL, V70, P169, DOI 10.1007/BF00691435; Teramoto S, 2011, J CEREBR BLOOD F MET, V31, P1696, DOI 10.1038/jcbfm.2011.51; Tomlinson DR, 2008, NAT REV NEUROSCI, V9, P36, DOI 10.1038/nrn2294; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yrjanheikki J, 2005, BRAIN RES, V1052, P174, DOI 10.1016/j.brainres.2005.06.004; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	76	28	28	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2015	10	3							e0120074	10.1371/journal.pone.0120074			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE9AD	WOS:000352134700054	25822252	Green Published, gold, Green Submitted			2022-02-06	
J	Xie, CC; Cong, DM; Wang, XJ; Wang, YH; Liang, HS; Zhang, XT; Huang, Q				Xie, Chuncheng; Cong, Damin; Wang, Xiujuan; Wang, Yuehua; Liang, Hongsheng; Zhang, Xiangtong; Huang, Qi			The effect of simvastatin treatment on proliferation and differentiation of neural stem cells after traumatic brain injury	BRAIN RESEARCH			English	Article						Simvastatin; Neural stem cells; Notch signaling; Traumatic brain injury	DENTATE GYRUS; NEURONS; NEUROGENESIS; ACTIVATION; FOREBRAIN; INCREASE; THERAPY; DEATH; RAT	Objective: To study the effect of simvastatin on neurological functional recovery after traumatic brain injuries (TBI) and the possible molecular mechanisms, we evaluated simvastatin-induced proliferation and differentiation of neural stem cells (NSCs) in vitro and in vivo and possible involvement of Notch-1 signaling in this process. Methods: Adult Wistar rats were randomly divided into three groups (n=28 for each): sham group, saline-treated group and simvastatin-treated group. Simvastatin was given orally at a dose of 1 mg/kg/day starting at day 1 after TBI. At 1, 3, 7, 14, 21, 28, and 35 days after simvastatin treatment, functional outcome was measured using modified neurological severity scores (mNSS). Immunofluorescence of nestin was used to identify neurogenesis of NSCs in injured area of TBI rats. Western blot was applied to detect the expression level of Notch-1 protein in TBI rats with simvastatin. Results: Immunostaining showed a significant increase in the number of nestin-positive cells in injured area of the simvastatin-treated group compared to that of the salinetreated group (p < 0.05). In in vitro experiment, simvastatin induced enhanced proliferation and neurogenesis of cultured NSCs and elevated Notch-1 protein expression. Coincubation of y-secretase inhibitor, an inhibitor of Notch-1 pathway, with simvastatin abolished its neurorestoration effect. Most importantly, the simvastatin-treated group had significantly decreased mNSS at day 35 after TBI compared with the saline-treated group (p < 0.05). Conclusion: Simvastatin treatment enhanced neurological functional recovery after TBI possibly via activation of Notch signaling and increasing neurogenesis in the injured area. (C) 2014 Elsevier B.V. All rights reserved.	[Xie, Chuncheng; Wang, Yuehua; Liang, Hongsheng; Zhang, Xiangtong] Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin 150001, Heilongjiang, Peoples R China; [Cong, Damin] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150001, Heilongjiang, Peoples R China; [Wang, Xiujuan] Heilongjiang Prov Hosp, Dept Pediat, Harbin, Heilongjiang, Peoples R China; [Huang, Qi] Harbin Med Univ, Dept Pathol, Harbin 150001, Heilongjiang, Peoples R China		Zhang, XT (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.	zgxgtg@sina.com			Science Foundation of Heilongjiang Province [D200922/C160802]; Director Foundation of Science Department [81041082]	This work was supported by the Science Foundation of Heilongjiang Province (D200922/C160802) and Director Foundation of Science Department(81041082). The founders did not participate in study design, data collection and analysis, and writing the manuscript.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Arumugam TV, 2011, MOL PHARMACOL, V80, P23, DOI 10.1124/mol.111.071076; Baliko F, 2007, AM J PATHOL, V170, P1686, DOI 10.2353/ajpath.2007.060971; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Devaraj S, 2006, J CLIN ENDOCR METAB, V91, P4489, DOI 10.1210/jc.2006-0299; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; Keilani S, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-69; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Shimada IS, 2011, STROKE, V42, P3231, DOI 10.1161/STROKEAHA.111.623280; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; VanDussen KL, 2012, DEVELOPMENT, V139, P488, DOI 10.1242/dev.070763; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2011, NEUROSURGERY, V68, P1363, DOI 10.1227/NEU.0b013e31820c06b9; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; Xu J, 2009, AM J PHYSIOL-CELL PH, V296, pC535, DOI 10.1152/ajpcell.00310.2008; Zacharek A, 2009, STROKE, V40, P254, DOI 10.1161/STROKEAHA.108.524116	25	28	28	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 30	2015	1602						1	8		10.1016/j.brainres.2014.03.021			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG2CK	WOS:000353082300001	25445996				2022-02-06	
J	Barrus, MM; Hosking, JG; Zeeb, FD; Tremblay, M; Winstanley, CA				Barrus, Michael M.; Hosking, Jay G.; Zeeb, Fiona D.; Tremblay, Melanie; Winstanley, Catharine A.			Disadvantageous decision-making on a rodent gambling task is associated with increased motor impulsivity in a population of male rats	JOURNAL OF PSYCHIATRY & NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; REACTION-TIME-TASK; DOPAMINERGIC MODULATION; ORBITOFRONTAL CORTEX; FUNCTIONAL NEUROCHEMISTRY; REFLECTION-IMPULSIVITY; PSYCHIATRIC-DISORDERS; BASOLATERAL AMYGDALA; PREFRONTAL CORTEX; NEGATIVE URGENCY	Background: Impulsivity is understood as a range of behaviours, but the association between these behaviours is not well understood. Although high motor impulsivity is a key symptom of disorders like pathological gambling and addiction, in which decision-making on laboratory tasks is compromised, there have been no clear demonstrations that choice and motor impulsivity are associated in the general population. We examined this association in a large population of rodents. Methods: We performed a meta-analysis on behavioural data from 211 manipulation-naive male animals that performed a rodent gambling task in our laboratory between 2008 and 2012. The task measures an aspect of both impulsive decision-making and impulsive action, making it possible to evaluate whether these 2 forms of maladaptive behaviour are related. Results: Our meta-analysis revealed that motor impulsivity was positively correlated with poor decision-making under risk. Highly motor impulsive rats were slower to adopt an advantageous choice strategy and quicker to make a choice on individual trials. Limitations: The data analyzed were limited to that produced by our laboratory and did not include data of other researchers who have used the task. Conclusion: This work may represent the first demonstration of a clear association between choice and motor impulsivity in a nonclinical population. This lends support to the common practice of studying impulsivity in nonclinical populations to gain insight into impulse control disorders and suggests that differences in impulsive behaviours between clinical and nonclinical populations may be ones of magnitude rather than ones of quality.	[Barrus, Michael M.; Hosking, Jay G.; Zeeb, Fiona D.; Tremblay, Melanie; Winstanley, Catharine A.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada; [Zeeb, Fiona D.] Ctr Addict & Mental Hlth, Toronto, ON, Canada		Barrus, MM (corresponding author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	michaelbarrus@psych.ubc.ca	Winstanley, Catharine/K-5003-2015	Winstanley, Catharine/0000-0001-7032-4471	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); National Sciences and Engineering Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC); Michael Smith Foundation for Health Research (MSFHR)Michael Smith Foundation for Health Research; Parkinson Society Canada; National Council for Responsible Gambling; Canadian Foundation for InnovationCanada Foundation for Innovation; MSFHRMichael Smith Foundation for Health Research; CIHRCanadian Institutes of Health Research (CIHR)	This work was supported by operating grant funding to C.A. Winstanley from the Canadian Institutes of Health Research (CIHR), The National Sciences and Engineering Council of Canada, the Michael Smith Foundation for Health Research (MSFHR), Parkinson Society Canada, the Institute for Research into Pathological Gambling and Related Disorders (now the National Council for Responsible Gambling) and the Canadian Foundation for Innovation. C.A. Winstanley also receives salary support through the MSFHR and CIHR New Investigator Award program.	Adams ZW, 2012, ADDICT BEHAV, V37, P848, DOI 10.1016/j.addbeh.2012.03.016; AINSLIE G, 1975, PSYCHOL BULL, V82, P463, DOI 10.1037/h0076860; Baarendse PJJ, 2013, PSYCHOPHARMACOLOGY, V225, P719, DOI 10.1007/s00213-012-2857-z; Bari A, 2013, PSYCHOPHARMACOLOGY, V230, P89, DOI 10.1007/s00213-013-3141-6; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Clark L, 2006, BIOL PSYCHIAT, V60, P515, DOI 10.1016/j.biopsych.2005.11.007; Crean J, 2002, BEHAV BRAIN RES, V136, P349, DOI 10.1016/S0166-4328(02)00132-8; Crean JP, 2000, EXP CLIN PSYCHOPHARM, V8, P155, DOI 10.1037/1064-1297.8.2.155; Cunningham KA, 2014, NEUROPHARMACOLOGY, V76, P460, DOI 10.1016/j.neuropharm.2013.06.030; Cyders MA, 2008, PSYCHOL BULL, V134, P807, DOI 10.1037/a0013341; Dalley JW, 2008, PHARMACOL BIOCHEM BE, V90, P250, DOI 10.1016/j.pbb.2007.12.021; de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x; Dickman S.J., 1993, IMPULSIVE CLIENT THE, P151, DOI [10.1037/10500-010, DOI 10.1037/10500-010]; Dougherty DM, 2003, J CHILD PSYCHOL PSYC, V44, P1145, DOI 10.1111/1469-7610.00197; Eagle DM, 2010, NEUROSCI BIOBEHAV R, V34, P50, DOI 10.1016/j.neubiorev.2009.07.003; Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481; Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P422, DOI 10.1007/PL00005487; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Flagel SB, 2010, NEUROPSYCHOPHARMACOL, V35, P388, DOI 10.1038/npp.2009.142; Flagel SB, 2009, NEUROPHARMACOLOGY, V56, P139, DOI 10.1016/j.neuropharm.2008.06.027; Fletcher PJ, 2011, NEUROPHARMACOLOGY, V61, P468, DOI 10.1016/j.neuropharm.2011.02.025; Frank MJ, 2006, NEURAL NETWORKS, V19, P1120, DOI 10.1016/j.neunet.2006.03.006; Hajcak G, 2007, PSYCHOPHYSIOLOGY, V44, P91, DOI 10.1111/j.1469-8986.2006.00487.x; Howell DC., 1997, STAT METHODS PSYCHOL, V4th ed; Hulka LM, 2014, PSYCHOL MED, V44, P1015, DOI 10.1017/S0033291713001839; Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; Mendez IA, 2012, PSYCHOPHARMACOLOGY, V224, P489, DOI 10.1007/s00213-012-2777-y; Mendez M F, 2000, Curr Psychiatry Rep, V2, P440, DOI 10.1007/s11920-000-0030-6; Mitchell JM, 2005, ALCOHOL CLIN EXP RES, V29, P2158, DOI 10.1097/01.alc.0000191755.63639.4a; Moeller FG, 2001, AM J PSYCHIAT, V158, P1783, DOI 10.1176/appi.ajp.158.11.1783; Monterosso J, 2001, ADDICTION, V96, P1825, DOI 10.1046/j.1360-0443.2001.9612182512.x; Murphy ER, 2012, PSYCHOPHARMACOLOGY, V219, P401, DOI 10.1007/s00213-011-2572-1; Pattij T, 2008, TRENDS PHARMACOL SCI, V29, P192, DOI 10.1016/j.tips.2008.01.002; Pattij T, 2007, PSYCHOPHARMACOLOGY, V193, P85, DOI 10.1007/s00213-007-0773-4; Pattij T, 2013, CURR OPIN NEUROBIOL, V23, P700, DOI 10.1016/j.conb.2013.01.023; Perales JC, 2009, J CLIN EXP NEUROPSYC, V31, P927, DOI 10.1080/13803390902758793; Reynolds B, 2006, PHARMACOL BIOCHEM BE, V83, P194, DOI 10.1016/j.pbb.2006.01.007; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Robinson ESJ, 2009, BEHAV BRAIN RES, V196, P310, DOI 10.1016/j.bbr.2008.09.021; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Specker S M, 1995, Ann Clin Psychiatry, V7, P175, DOI 10.3109/10401239509149623; STEIN DJ, 1993, J NEUROPSYCH CLIN N, V5, P9; Sun HS, 2012, PSYCHOPHARMACOLOGY, V219, P285, DOI 10.1007/s00213-011-2419-9; Tomie A, 1998, PSYCHOPHARMACOLOGY, V139, P376, DOI 10.1007/s002130050728; Tomie A, 2008, BRAIN RES REV, V58, P121, DOI 10.1016/j.brainresrev.2007.12.003; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777, DOI 10.1016/j.neubiorev.2007.11.003; Voon V, 2014, BIOL PSYCHIAT, V75, P148, DOI 10.1016/j.biopsych.2013.05.013; Winstanley CA, 2004, NEUROPSYCHOPHARMACOL, V29, P1331, DOI 10.1038/sj.npp.1300434; Winstanley CA, 2006, CLIN PSYCHOL REV, V26, P379, DOI 10.1016/j.cpr.2006.01.001; Winstanley CA, 2011, BRIT J PHARMACOL, V164, P1301, DOI 10.1111/j.1476-5381.2011.01323.x; Winstanley CA, 2010, ALCOHOL CLIN EXP RES, V34, P1306, DOI 10.1111/j.1530-0277.2010.01215.x; Winstanley CA, 2010, BEHAV BRAIN RES, V210, P263, DOI 10.1016/j.bbr.2010.02.044; Zeeb FD, 2013, J NEUROSCI, V33, P6434, DOI 10.1523/JNEUROSCI.3971-12.2013; Zeeb FD, 2013, PSYCHOPHARMACOLOGY, V225, P381, DOI 10.1007/s00213-012-2822-x; Zeeb FD, 2011, J NEUROSCI, V31, P2197, DOI 10.1523/JNEUROSCI.5597-10.2011; Zeeb FD, 2009, NEUROPSYCHOPHARMACOL, V34, P2329, DOI 10.1038/npp.2009.62	63	28	28	0	8	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	1180-4882	1488-2434		J PSYCHIATR NEUROSCI	J. Psychiatry Neurosci.	MAR	2015	40	2					108	117		10.1503/jpn.140045			10	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	CD6NU	WOS:000351206800006	25703645	Green Published			2022-02-06	
J	O'Brien, NF; Maa, T; Yeates, KO				O'Brien, Nicole F.; Maa, Tensing; Yeates, Keith O.			The Epidemiology of Vasospasm in Children With Moderate-to-Severe Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						cerebral blood flow; pediatrics; secondary brain injury; transcranial Doppler ultrasound; traumatic brain injury; vasospasm	CEREBRAL-BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; POSTTRAUMATIC VASOSPASM; ANGIOGRAPHIC FINDINGS; COMPUTED-TOMOGRAPHY; GENDER-DIFFERENCES; AGE-DEPENDENCE; VELOCITY	Objective: To gain a description of the prevalence and time course of vasospasm in children suffering moderate-to-severe traumatic brain injury. Design: A prospective, observational study was performed. Children with a diagnosis of traumatic brain injury, a Glasgow Coma Score less than or equal to 12, and abnormal head imaging were enrolled. Transcranial Doppler ultrasound was performed to identify and follow vasospasm. Diagnostic criteria included flow velocity elevation more than or equal to 2 so above age and gender normal values for the middle cerebral and basilar arteries. Additional criteria required for vasospasm diagnosis in the middle cerebral artery was a ratio of flow in the middle cerebral artery to extracranial internal carotid artery more than or equal to 3. Interventions: None. Measurements and Main Results: Sixty-nine children were included. The prevalence of middle cerebral artery vasospasm in children with moderate traumatic brain injury (Glasgow Coma Score, 9-12) was 8.5% and was 33.5% in those with severe traumatic brain injury (Glasgow Coma Score, 5 8). The prevalence of basilar artery vasospasm in children with moderate traumatic brain injury was 3% and with severe traumatic brain injury was 21%. Mean time to onset of vasospasm was 4 days (+/- 2 d) in the middle cerebral arteries and 5 days (+/- 2.5 d) in the basilar artery. Mean duration of vasospasm in the middle cerebral artery was 2 days (+/- 2 d) and 1.5 days (1 d) in the basilar artery. Children in whom vasospasm developed were more likely to have been involved in motor vehicle accidents, had higher Injury Severity Scores, had fever at admission, and had lower Glasgow Coma Score scores. Good neurologic outcome (Glasgow Outcome Score Extended Pediatric version of 4) at 1 month from injury was seen in 76% of those with moderate traumatic brain injury without vasospasm and in 40% of those with vasospasm. In those with severe traumatic brain injury, good neurologic outcome was seen in 29% of those children without vasospasm and in 15% of those with vasospasm. Conclusions: Vasospasm occurs in a sizeable number of children with moderate and severe traumatic brain injury. Children in whom vasospasm developed were more likely to have been involved in a motor vehicle accident, had higher Injury Severity Scores, had fever at admission, and had lower Glasgow Coma scores than in those whom vasospasm did not develop. Based on these findings, we recommend aggressive screening for posttraumatic vasospasm in these patients. Future studies should establish the relationship between vasospasm and long-term functional outcomes and should also evaluate potential preventative or therapeutic options for vasospasm in these children.	[O'Brien, Nicole F.; Maa, Tensing] Ohio State Univ, Nationwide Childrens Hosp, Div Crit Care Med, Columbus, OH 43210 USA; [O'Brien, Nicole F.; Maa, Tensing; Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Sect Pediat Psychol & Neuropsychol, Columbus, OH USA		O'Brien, NF (corresponding author), Ohio State Univ, Nationwide Childrens Hosp, Div Crit Care Med, Columbus, OH 43210 USA.	nicole.obrien@nation-widechildrens.org; tensing.maa@nationwidechildrens.org; kyeates@ucalgary.ca	O'brien, Nicole/E-3776-2011; Maa, Tensing/J-9791-2012; Yeates, Keith/AAJ-4223-2020	Maa, Tensing/0000-0001-6104-8401; Yeates, Keith/0000-0001-7680-2892	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	Dr. Yeates provided expert testimony for various attorneys, lectured for various scientific and professional organizations, and received royalties from Guilford Press. His institution received grant support from the National Institutes of Health and Centers for Disease Control and Prevention. The remaining authors have disclosed that they do not have any potential conflicts of interest.	AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; BODE H, 1988, ARCH DIS CHILD, V63, P606, DOI 10.1136/adc.63.6.606; BODE H, 1989, J CHILD NEUROL, V4, pS68, DOI 10.1177/0883073889004001S11; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; CHAN KH, 1992, NEUROSURGERY, V30, P697; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Katsnelson M, 2012, NEUROSURGERY, V70, P1095, DOI 10.1227/NEU.0b013e318240c1ed; Lee DJ, 2008, NEUROSURGERY, V63, P1004, DOI 10.1227/01.NEU.0000327685.90800.F7; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Merkel S I, 1997, Pediatr Nurs, V23, P293; Nakayama K, 2003, BIORHEOLOGY, V40, P307; Newell D W, 1992, Clin Neurosurg, V39, P348; O'Brien NF, 2010, INTENS CARE MED, V36, P680, DOI 10.1007/s00134-009-1747-2; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Philip S, 2009, CRIT CARE MED, V37, P2973, DOI 10.1097/CCM.0b013e3181a963f6; Pluta RM, 2005, PHARMACOL THERAPEUT, V105, P23, DOI 10.1016/j.pharmthera.2004.10.002; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Sarkar K, 2014, J NEUROSURG-PEDIATR, V13, P307, DOI 10.3171/2013.12.PEDS13223; SCHONING M, 1993, STROKE, V24, P1305, DOI 10.1161/01.STR.24.9.1305; Shahlaie K, 2011, J NEUROSURG, V115, P602, DOI 10.3171/2011.5.JNS101667; Shahlaie K, 2009, NEUROCRIT CARE, V10, P61, DOI 10.1007/s12028-008-9138-z; Society of Critical Care Medicine, 2012, PEDIAT CRIT CARE S1, V13, pS1; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; VARDIMAN AB, 1995, AM J NEURORADIOL, V16, P319; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; Voepel-Lewis T, 2010, AM J CRIT CARE, V19, P55, DOI 10.4037/ajcc2010624; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; Wintermark M, 2004, PEDIATRICS, V113, P1642, DOI 10.1542/peds.113.6.1642; Zubkov ZY, 2000, SURG NEUROL, V53, P126	45	28	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2015	43	3					674	685		10.1097/CCM.0000000000000745			12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CB9PI	WOS:000349963600033	25479116				2022-02-06	
J	Ramski, DE; Hennrikus, WP; Bae, DS; Baldwin, KD; Patel, NM; Waters, PM; Flynn, JM				Ramski, David E.; Hennrikus, William P.; Bae, Donald S.; Baldwin, Keith D.; Patel, Neeraj M.; Waters, Peter M.; Flynn, John M.			Pediatric Monteggia Fractures: A Multicenter Examination of Treatment Strategy and Early Clinical and Radiographic Results	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						Monteggia; internal fixation; outcomes; pediatric	OPEN REDUCTION; ANNULAR LIGAMENT; RADIAL HEAD; CHILDREN; DISLOCATIONS; LESIONS; RECONSTRUCTION; INJURIES	Background: Monteggia fractures remain challenging pediatric injuries because of difficulties in diagnosis, propensity for instability, and complexity of late reconstruction. The objective of this investigation was to assess the efficacy of the following treatment strategy based upon ulnar fracture pattern: closed reduction (CR) for plastic/greenstick fractures, intramedullary (IM) pin fixation for transverse/short oblique fractures, and open reduction and internal fixation for long oblique/comminuted fractures. Methods: A total of 112 acute Monteggia fracture patients were retrospectively analyzed at two level 1 pediatric trauma centers from 2000 to 2011. Mean age was 6.9 +/- 2.9 years (range, 0.6 to 16.7 y); 54% were male. Mean clinical follow-up was 19.8 weeks. Fracture patterns were classified and patients were separated into 3 groups: treatment according to the strategy versus more rigorous versus less rigorous intervention. The Fisher exact test was used to compare the rates of failure between the groups. "Failure" was defined as failure to obtain and maintain an anatomic reduction of the radial head and/or loss of ulnar reduction during follow-up. Results: None of the 57 patients treated according to the strategy experienced failure, nor did any of the 23 patients treated more rigorously. In contrast, 6 of 32 patients (19%) who were treated less rigorously compared with the recommended strategy demonstrated recurrent radiocapitellar instability (n = 3), loss of ulnar fracture reduction requiring revision surgery (n = 2), or both events together (n = 1) (P < 0.001). Specifically, all treatment failures occurred in complete fractures treated nonoperatively-there were 6/18 failures (33% failure rate) of complete fractures treated nonoperatively compared with 0/52 failures of complete fractures treated operatively (P < 0.001). Other complications were similarly distributed between the treatment groups and consisted of 1 ulnar nonunion, 2 compartment syndromes, and 3 transient nerve palsies/neuropraxias. Comminuted fractures required open reduction of the radiocapitellar joint more than other fracture types (P < 0.001). Conclusions: In this pediatric Monteggia series, recurrent instability only occurred in patients who were not treated according to the ulnar-based strategy. Complete ulnar fracture patterns are at risk of failure without initial operative treatment.	[Ramski, David E.; Baldwin, Keith D.; Patel, Neeraj M.; Flynn, John M.] Childrens Hosp Philadelphia, Dept Orthopaed Surg, Philadelphia, PA 19104 USA; [Hennrikus, William P.; Bae, Donald S.; Waters, Peter M.] Boston Childrens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA		Waters, PM (corresponding author), Boston Childrens Hosp, 300 Longwood Ave,Hunnewell 2, Boston, MA 02115 USA.	peter.waters@childrens.harvard.edu		Patel, Neeraj/0000-0002-0255-8783			Bado J L, 1967, Clin Orthop Relat Res, V50, P71; Beutel BG, 2012, ORTHOPEDICS, V35, P138, DOI 10.3928/01477447-20120123-32; David-West KS, 2005, INJURY, V36, P1206, DOI 10.1016/j.injury.2004.12.033; Degreff I, 2004, J ORTHOP TRAUMA, V18, P375, DOI 10.1097/00005131-200407000-00008; DORMANS JP, 1990, ORTHOP CLIN N AM, V21, P251; FOWLES JV, 1983, J BONE JOINT SURG AM, V65, P1276, DOI 10.2106/00004623-198365090-00008; Hui JHP, 2005, J PEDIATR ORTHOPED, V25, P501, DOI 10.1097/01.bpo.0000158812.37225.b3; Kunkel S, 2011, J PEDIATR ORTHOPED, V31, P628, DOI 10.1097/BPO.0b013e3182210988; Leonidou A, 2012, J PEDIATR ORTHOPED, V32, P352, DOI 10.1097/BPO.0b013e31825611fc; LETTS M, 1985, J BONE JOINT SURG BR, V67, P724, DOI 10.1302/0301-620X.67B5.4055869; Monteggia GB, 1914, I CHIRURG, P1813; Nakamura K, 2009, J BONE JOINT SURG AM, V91A, P1394, DOI 10.2106/JBJS.H.00644; Nanno Mitsuhiko, 2007, Am J Orthop (Belle Mead NJ), V36, pE80; OLNEY BW, 1989, J PEDIATR ORTHOPED, V9, P219; Ring D, 1996, J BONE JOINT SURG BR, V78B, P734, DOI 10.1302/0301-620X.78B5.0780734; Rodgers WB, 1996, J BONE JOINT SURG AM, V78A, P1322, DOI 10.2106/00004623-199609000-00005; Tan JW, 2008, INJURY, V39, P451, DOI 10.1016/j.injury.2007.07.010; WILEY JJ, 1985, J BONE JOINT SURG BR, V67, P728, DOI 10.1302/0301-620X.67B5.4055870	18	28	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-6798	1539-2570		J PEDIATR ORTHOPED	J. Pediatr. Orthop.	MAR	2015	35	2					115	120		10.1097/BPO.0000000000000213			6	Orthopedics; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Pediatrics	CB9UM	WOS:000349978700005	24978320				2022-02-06	
J	Sierra, A; Laitinen, T; Grohn, O; Pitkanen, A				Sierra, Alejandra; Laitinen, Teemu; Grohn, Olli; Pitkanen, Asla			Diffusion tensor imaging of hippocampal network plasticity	BRAIN STRUCTURE & FUNCTION			English	Article						Diffusion tensor imaging; Epilepsy; Epileptogenesis; Hippocampus; Magnetic resonance imaging; Mossy fiber sprouting; Myelin; Status epilepticus; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; SYNAPTIC REORGANIZATION; STATUS EPILEPTICUS; WATER DIFFUSION; RAT; MRI; EPILEPSY; TRACTOGRAPHY; ANISOTROPY; SCHEMES	Diffusion tensor imaging (DTI) has become a valuable tool to investigate white matter integrity in the brain. DTI also gives contrast in gray matter, which has been relatively little explored in studies assessing post-injury structural abnormalities. The present study was designed to compare white and gray matter reorganization in the rat hippocampus after two epileptogenic brain injuries, status epilepticus (SE) and traumatic brain injury (TBI), using ex vivo high-resolution DTI. Imaging was performed at 6-12 months post-injury and findings were compared to histological analyses of Nissl, myelin, and Timm-stained preparations from the same animals. In agreement with the severity of histological damage, fractional anisotropy (FA), axial (D (||)) and radial (D (aSyen)) diffusivities, and mean diffusivity (MD) measurements were altered in the order SE > TBI ipsilaterally > TBI contralaterally. After SE, the most severe abnormalities were found in the dentate gyrus and CA3b-c subfields, in which the mean FA was increased to 125 % (p < 0.001) and 143 % (p < 0.001) of that in controls, respectively. In both subfields, the change in FA was associated with an increase in D (||) (p < 0.01). In the stratum radiatum of the CA1, FA was decreased to 81 % of that in controls (p < 0.05) which was associated with an increase in D (aSyen) (p < 0.01). After TBI, DTI did not reveal any major abnormalities in the dentate gyrus. In the ipsilateral CA3b-c, however, FA was increased to 126 % of that in controls (p < 0.01) and associated with a mild decrease in D (aSyen) (p < 0.05). In the stratum radiatum of the ipsilateral CA1, FA was decreased to 88 % of that in controls (p < 0.05). Our data demonstrate that DTI reveals subfield-specific abnormalities in the hippocampus with remarkable qualitative and quantitative differences between the two epileptogenic etiologies, suggesting that DTI could be a valuable tool for follow-up of focal circuitry reorganization during the post-injury aftermath.	[Sierra, Alejandra; Laitinen, Teemu; Grohn, Olli; Pitkanen, Asla] Univ Eastern Finland, Dept Neurobiol, AI Virtanen Inst Mol Sci, Kuopio 70211, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, Kuopio 70211, Finland		Pitkanen, A (corresponding author), Univ Eastern Finland, Dept Neurobiol, AI Virtanen Inst Mol Sci, POB 1627, Kuopio 70211, Finland.	asla.pitkanen@uef.fi		Sierra Lopez, Alejandra/0000-0001-5399-2056	Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; University of Eastern Finland	This study was supported by the Academy of Finland (A.S., O.G., A.P.), Sigrid Juselius Foundation (A.P.), and UEF-Brain strategic funding from the University of Eastern Finland. We thank Ms. Maarit Pulkkinen for assistance in histology, Dr. Jari Nissinen and Dr. Tamuna Bolkvadze for technical assistance, MSc Juha-Pekka Niskanen for drawing the diffusion ellipsoids, and Dr. Nick Hayward for revising the language of the manuscript.	Amaral D.G., 1990, HUMAN NERVOUS SYSTEM, P711, DOI [10.1016/B978-0-12-547625-6.50026-X, DOI 10.1016/B978-0-12-547625-6.50026-X]; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Banerjee PN, 1997, EPILEPSY COMPREHENSI, P47, DOI 10.1007/978-88-470-2903-3_81; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baulac M, 2008, EPILEPSIA; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Buckmaster PS, 2012, JASPERS BASIC MECH E, DOI [10.1093/med/9780199746545.003.0032, DOI 10.1093/MED/9780199746545.003.0032]; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Chan KC, 2012, NEUROIMAGE, V59, P2274, DOI 10.1016/j.neuroimage.2011.09.055; Christidi F, 2011, J NEUROTRAUM, V28, P711, DOI 10.1089/neu.2010.1644; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Cross DJ, 2007, EPILEPSY RES, V73, P156, DOI 10.1016/j.eplepsyres.2006.09.004; Dauguet J, 2007, NEUROIMAGE, V37, P530, DOI 10.1016/j.neuroimage.2007.04.067; deLanerolle N. C., 2012, JASPERS BASIC MECH E; Dityatev A, 2008, NEURON GLIA BIOL, V4, P235, DOI 10.1017/S1740925X09000118; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Heidemann RM, 2012, NEUROIMAGE, V60, P967, DOI 10.1016/j.neuroimage.2011.12.081; Horsfield MA, 2002, NMR BIOMED, V15, P570, DOI 10.1002/nbm.787; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Kaufman JA, 2005, ANAT REC PART A, V287A, P1026, DOI 10.1002/ar.a.20264; Kelley Melinda S, 2009, Epilepsia, V50, P579, DOI 10.1111/j.1528-1167.2008.01813.x; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kuo LW, 2008, NEUROIMAGE, V41, P789, DOI 10.1016/j.neuroimage.2008.03.013; Laitinen T, 2010, NEUROIMAGE, V51, P521, DOI 10.1016/j.neuroimage.2010.02.077; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; Leergaard TB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008595; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Nairismagi J, 2006, NEUROIMAGE, V30, P130, DOI 10.1016/j.neuroimage.2005.09.007; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Ni H, 2006, AM J NEURORADIOL, V27, P1776; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Oechslin MS, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.076.2009; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.3.CO;2-A; Parekh MB, 2010, EXP NEUROL, V224, P258, DOI 10.1016/j.expneurol.2010.03.031; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; Pitkanen A, 2010, EPILEPSIA, V51, P2, DOI 10.1111/j.1528-1167.2010.02602.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rangel CD, 2011, MAGN RESON IMAGING C, V19, P23, DOI 10.1016/j.mric.2010.10.006; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rigau V, 2007, BRAIN, V130, P1942, DOI 10.1093/brain/awm118; Savander V, 1996, J COMP NEUROL, V374, P291, DOI 10.1002/(SICI)1096-9861(19961014)374:2<291::AID-CNE10>3.0.CO;2-Y; Shepherd TM, 2006, NEUROIMAGE, V32, P1499, DOI 10.1016/j.neuroimage.2006.04.210; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sierra A, 2011, BRAIN STRUCT FUNCT, V216, P123, DOI 10.1007/s00429-010-0299-0; Sigal T, 2012, J NEUROIMAGING, V22, P33, DOI 10.1111/j.1552-6569.2010.00556.x; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; Wong M, 2005, EPILEPSY BEHAV, V7, P569, DOI 10.1016/j.yebeh.2005.08.007; Yassa MA, 2010, P NATL ACAD SCI USA, V107, P12687, DOI 10.1073/pnas.1002113107; Zalesky A, 2011, BIOL PSYCHIAT, V69, P80, DOI 10.1016/j.biopsych.2010.08.022; Zhang JY, 2007, MAGN RESON MED, V58, P454, DOI 10.1002/mrm.21371; Zhang JY, 2002, NEUROIMAGE, V15, P892, DOI 10.1006/nimg.2001.1012; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	63	28	29	0	16	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAR	2015	220	2					781	801		10.1007/s00429-013-0683-7			21	Anatomy & Morphology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anatomy & Morphology; Neurosciences & Neurology	CC4UU	WOS:000350350300011	24363120				2022-02-06	
J	Naderi, V; Khaksari, M; Abbasi, R; Maghool, F				Naderi, Vida; Khaksari, Mohammad; Abbasi, Reza; Maghool, Fatemeh			Estrogen provides neuroprotection against brain edema and blood brain barrier disruption through both estrogen receptors alpha and beta following traumatic brain injury	IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES			English	Article						Blood-brain-barrier; Brain edema; ER alpha antagonist; ER beta antagonist; ICI182780; Traumatic brain injury	ER-ALPHA; INTRACRANIAL-PRESSURE; NEUROLOGIC OUTCOMES; FOOD-INTAKE; CELL-DEATH; ACTIVATION; ESTRADIOL; 17-BETA-ESTRADIOL; NEURONS; DAMAGE	Objective(s): Estrogen (E-2) has neuroprotective effects on blood-brain-barrier (BBB) after traumatic brain injury (TBI). In order to investigate the roles of estrogen receptors (ERs) in these effects, ER-alpha antagonist (MPP) and, ER-beta antagonist (PHTPP), or non-selective estrogen receptors antagonist (ICI 182780) were administered. Materials and Methods: Ovariectomized rats were divided into 10 groups, as follows: Sham, TBI, E-2, oil, MPP+E-2, PHTPP+E-2, MPP+PHTPP+E-2, ICI+E-2, MPP, and DMSO.E-2 (33.3 mu g/Kg) or oil were administered 30 min after TBI. 1 dose (150 mu g/Kg) of each of MPP, PHTPP, and (4 mg/kg) ICI182780 was injected two times, 24 hr apart, before TBI and estrogen treatment. BBB disruption (Evans blue content) and brain edema (brain water content) evaluated 5 hr and 24 hr after the TBI were evaluated, respectively. Results: The results showed that E-2 reduced brain edema after TBI compared to vehicle (P<0.01). The brain edema in the MPP+E-2 and PHTPP+E-2 groups decreased compared to the vehicle (P<0.001). There was no significant difference in MPP+PHTPP+E-2 and ICI+E-2 compared to TBI. This parameter in MPP was similar to vehicle. Evans blue content in E-2 group was lower than vehicle (P<0.05). The inhibitory effect of E-2 on Evans blue was not reduced by MPP+E-2 and PHTPP+E-2 groups, but decreased by treatment with MPP+PHTPP or ICI. MPP had no effect on Evans blue content. Conclusion: A combined administration of MPP and PHTPP or ICI inhibited the E-2-induced decrease in brain edema and BBB disruption; this may suggest that these effects were mediated via both receptors.	[Naderi, Vida] Kerman Univ Med Sci, Inst Neuropharmacol, Neurosci Res Ctr, Kerman, Iran; [Khaksari, Mohammad; Maghool, Fatemeh] Kerman Univ Med Sci, Physiol Res Ctr, Inst Neuropharmacol, Kerman, Iran; [Abbasi, Reza] Kerman Univ Med Sci, Dept Physiol, Kerman, Iran		Khaksari, M (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Kerman, Iran.	khaksar38@yahoo.co.uk	Maghool, Fatemeh/ABI-7612-2020; naderi-boldaji, vida/AAZ-4291-2020; Haddad, Mohammad Khaksari/AAB-9025-2019	naderi-boldaji, vida/0000-0001-9909-207X; Haddad, Mohammad Khaksari/0000-0003-0770-4281	Neuroscience Research Center and Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran	The present study was financially supported by the Neuroscience Research Center and Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran. The results reported in this paper were part of a student thesis.	Aguirre C, 2010, J NEUROCHEM, V115, P1277, DOI 10.1111/j.1471-4159.2010.07038.x; Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Bains M, 2007, EXP NEUROL, V204, P767, DOI 10.1016/j.expneurol.2007.01.020; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Bliedtner A, 2010, MOL CELL ENDOCRINOL, V314, P41, DOI 10.1016/j.mce.2009.07.032; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Carswell HV, 2004, J CEREBR BLOOD F MET, V24, P298, DOI 10.1097/01.WCB.0000112322.75217.FD; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cotroneo MS, 2005, FOOD CHEM TOXICOL, V43, P637, DOI 10.1016/j.fct.2004.12.022; Davis AM, 2006, MOL REPROD DEV, V73, P1034, DOI 10.1002/mrd.20520; Davis LK, 2010, J STEROID BIOCHEM, V122, P272, DOI 10.1016/j.jsbmb.2010.05.009; Dhillon SS, 2011, INT J OBESITY, V35, P198, DOI 10.1038/ijo.2010.124; Eckel LA, 2011, PHYSIOL BEHAV, V104, P517, DOI 10.1016/j.physbeh.2011.04.014; Evans MJ, 2002, ENDOCRINOLOGY, V143, P3785, DOI 10.1210/en.2002-220356; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003-0550; Kansra S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010060; Keshavarzi Z, 2011, IRAN J BASIC MED SCI, V14, P231; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; Liu R, 2005, BRAIN RES, V1060, P55, DOI 10.1016/j.brainres.2005.08.048; Mattsson A, 2011, GEN COMP ENDOCR, V172, P251, DOI 10.1016/j.ygcen.2011.03.010; Mazzucco CA, 2006, NEUROSCIENCE, V141, P1793, DOI 10.1016/j.neuroscience.2006.05.032; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Morissette M, 2008, J STEROID BIOCHEM, V108, P327, DOI 10.1016/j.jsbmb.2007.09.011; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Patisaul HB, 2009, HORM BEHAV, V55, P319, DOI 10.1016/j.yhbeh.2008.11.004; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Santollo J, 2010, HORM BEHAV, V58, P872, DOI 10.1016/j.yhbeh.2010.08.012; Santollo J, 2009, PHYSIOL BEHAV, V97, P193, DOI 10.1016/j.physbeh.2009.02.021; Sarvari M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-82; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shimada K, 2011, HYPERTENSION, V57, P1161, DOI 10.1161/HYPERTENSIONAHA.110.167650; Sierens JE, 2004, J MOL ENDOCRINOL, V32, P703, DOI 10.1677/jme.0.0320703; Somjen D, 2011, J CELL BIOCHEM, V112, P625, DOI 10.1002/jcb.22959; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Szymczak S, 2006, HIPPOCAMPUS, V16, P453, DOI 10.1002/hipo.20172; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Venero JL, 2004, CURR PHARM DESIGN, V10, P2153, DOI 10.2174/1381612043384150; Waters EM, 2009, BRAIN RES, V1290, P1, DOI 10.1016/j.brainres.2009.06.090; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wong JK, 2003, J NEUROSCI, V23, P4984; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7	45	28	30	0	5	MASHHAD UNIV MED SCIENCES	MASHHAD	VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN	2008-3866	2008-3874		IRAN J BASIC MED SCI	Iran. J. Basic Med. Sci.	FEB	2015	18	2					138	144					7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	CF3IO	WOS:000352442100005	25810887				2022-02-06	
J	Rincon, F; Patel, U; Schorr, C; Lee, E; Ross, S; Dellinger, RP; Zanotti-Cavazzoni, S				Rincon, Fred; Patel, Utkal; Schorr, Christa; Lee, Elizabeth; Ross, Steven; Dellinger, R. Phillip; Zanotti-Cavazzoni, Sergio			Brain Injury as a Risk Factor for Fever Upon Admission to the Intensive Care Unit and Association With In-Hospital Case Fatality: A Matched Cohort Study	JOURNAL OF INTENSIVE CARE MEDICINE			English	Article						fever; stroke; intracerebral hemorrhage; traumatic brain injury	SPECIAL WRITING GROUP; SUBARACHNOID HEMORRHAGE; EMERGENCY-DEPARTMENT; BODY-TEMPERATURE; STROKE-COUNCIL; INTRACEREBRAL HEMORRHAGE; DELAYED TRANSFER; CARDIAC-ARREST; HYPERTHERMIA; GUIDELINES	Purpose: To test the hypothesis that fever was more frequent in critically ill patients with brain injury when compared to nonneurological patients and to study its effect on in-hospital case fatality. Methods: Retrospective matched cohort study utilizing a single-center prospectively compiled registry. Critically ill neurological patients 18 years and consecutively admitted to the intensive care unit (ICU) with acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), and traumatic brain injury (TBI) were selected. Patients were matched by sex, age, and Acute Physiology and Chronic Health Evaluation II (APACHE-II) to a cohort of nonneurological patients. Fever was defined as any temperature 37.5 degrees C within the first 24 hours upon admission to the ICU. The primary outcome measure was in-hospital case fatality. Results: Mean age among neurological patients was 65.6 15 years, 46% were men, and median APACHE-II was 15 (interquartile range 11-20). There were 18% AIS, 27% ICH, and 6% TBI. More neurological patients experienced fever than nonneurological patients (59% vs 47%, P = .007). The mean hospital length of stay was higher for nonneurological patients (18 +/- 20 vs 14 +/- 15 days, P = .007), and more neurological patients were dead at hospital discharge (29% vs 20%, P < .0001). After risk factor adjustment, diagnosis (neurological vs nonneurological), and the probability of being exposed to fever (propensity score), the following variables were associated with higher in-hospital case fatality: APACHE-II, neurological diagnosis, mean arterial pressure, cardiovascular and respiratory dysfunction in ICU, and fever (odds ratio 1.9, 95% confidence interval 1.04-3.6, P = .04). Conclusion: These data suggest that fever is a frequent occurrence after brain injury, and that it is independently associated with in-hospital case fatality.	[Rincon, Fred; Patel, Utkal; Schorr, Christa; Lee, Elizabeth; Dellinger, R. Phillip; Zanotti-Cavazzoni, Sergio] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Univ Hosp, Div Crit Care & Cardiovasc Med,Dept Med, Camden, NJ 08103 USA; [Ross, Steven] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Univ Hosp, Div Trauma & Crit Care,Dept Surg, Camden, NJ 08103 USA		Rincon, F (corresponding author), Thomas Jefferson Univ, Dept Neurol Surg, Div Crit Care & Neurotrauma, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.	fred.rincon@jefferson.edu		Rincon, Fred/0000-0002-8510-118X; Schorr, Christa/0000-0001-7777-4280	American Heart AssociationAmerican Heart Association [AHA 12CRP12050342]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Rincon has received salary support from the American Heart Association (AHA 12CRP12050342).	Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Badjatia N, 2009, CRIT CARE MED, V37, pS250, DOI 10.1097/CCM.0b013e3181aa5e8d; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Childs Charmaine, 2010, Front Neurol, V1, P146, DOI 10.3389/fneur.2010.00146; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cummings P, 2003, EPIDEMIOL REV, V25, P43, DOI 10.1093/epirev/mxg002; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Fernandez A, 2007, NEUROLOGY, V68, P1013, DOI 10.1212/01.wnl.0000258543.45879.f5; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Haveman J, 2005, INT J HYPERTHER, V21, P473, DOI 10.1080/02656730500159079; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; O'Grady NP, 2008, CRIT CARE MED, V36, P1330, DOI 10.1097/CCM.0b013e318169eda9; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rincon F, 2013, NEUROCRIT CARE, V18, P45, DOI 10.1007/s12028-012-9779-9; Rincon F, 2011, J CRIT CARE, V26, P620, DOI 10.1016/j.jcrc.2011.02.009; Rincon F, 2010, NEUROCRIT CARE, V13, P75, DOI 10.1007/s12028-010-9347-0; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Romanovsky AA, 1998, MED HYPOTHESES, V50, P219, DOI 10.1016/S0306-9877(98)90022-6; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Sacho RH, 2010, J NEUROTRAUM, V27, P2157, DOI 10.1089/neu.2010.1384; Saini M, 2009, STROKE, V40, P3051, DOI 10.1161/STROKEAHA.109.556134; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1371/journal.pmed.0040297, 10.1371/journal.pmed.0040296, 10.1157/13119325, 10.1016/S0140-6736(07)61602-X]; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	42	28	29	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0885-0666	1525-1489		J INTENSIVE CARE MED	J. Intensive Care Med.	FEB	2015	30	2					107	114		10.1177/0885066613508266			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ0RY	WOS:000347953400006	24132129				2022-02-06	
J	Wijdicks, EFM; Kramer, AA; Rohs, T; Hanna, S; Sadaka, F; O'Brien, J; Bible, S; Dickess, SM; Foss, M				Wijdicks, Eelco F. M.; Kramer, Andrew A.; Rohs, Thomas, Jr.; Hanna, Susan; Sadaka, Farid; O'Brien, Jacklyn; Bible, Shonna; Dickess, Stacy M.; Foss, Michelle			Comparison of the Full Outline of UnResponsiveness Score and the Glasgow Coma Scale in Predicting Mortality in Critically III Patients	CRITICAL CARE MEDICINE			English	Article						brainstem reflexes; coma; critical illness; intensive care unit; prognosis; scales	TRAUMATIC BRAIN-INJURY; VALIDATION; VERSION	Objective: Impaired consciousness has been incorporated in prediction models that are used in the ICU. The Glasgow Coma Scale has value but is incomplete and cannot be assessed in intubated patients accurately. The Full Outline of UnResponsiveness score may be a better predictor of mortality in critically ill patients. Setting: Thirteen ICUs at five U.S. hospitals. Subjects: One thousand six hundred ninety-five consecutive unselected ICU admissions during a six-month period in 2012. Design: Glasgow Coma Scale and Full Outline of UnResponsiveness score were recorded within 1 hour of admission. Baseline characteristics and physiologic components of the Acute Physiology and Chronic Health Evaluation system, as well as mortality were linked to Glasgow Coma Scale/Full Outline of UnResponsiveness score information. Interventions: None. Measurements and Results: We recruited 1,695 critically ill patients, of which 1,645 with complete data could be linked to data in the Acute Physiology and Chronic Health Evaluation system. The area under the receiver operating characteristic curve of predicting ICU mortality using the Glasgow Coma Scale was 0.715 (95% Cl, 0.663-0.768) and using the Full Outline of UnResponsiveness score was 0.742 (95% Cl, 0.694-0.790), statistically different (p = 0.001). A similar but nonsignificant difference was found for predicting hospital mortality (p = 0.078). The respiratory and brainstem reflex components of the Full Outline of UnResponsiveness score showed a much wider range of mortality than the verbal component of Glasgow Coma Scale. In multivariable models, the Full Outline of UnResponsiveness score was more useful than the Glasgow Coma Scale for predicting mortality. Conclusions: The Full Outline of UnResponsiveness score might be a better prognostic tool of ICU mortality than the Glasgow Coma Scale in critically ill patients, most likely a result of incorporating brainstem reflexes and respiration into the Full Outline of UnResponsiveness score.	[Wijdicks, Eelco F. M.] Mayo Clin, Div Crit Care Neurol, Dept Neurol, Rochester, MN 55905 USA; [Kramer, Andrew A.] Cerner Corp, Vienna, VA USA; [Rohs, Thomas, Jr.] Borgess Med Ctr, Dept Trauma & Emergency Surg, Kalamazoo, MI USA; [Hanna, Susan] Borgess Med Ctr, Dept Crit Care, Kalamazoo, MI USA; [Sadaka, Farid; O'Brien, Jacklyn] Mercy Hosp, Dept Crit Care Med, St Louis, MO USA; [Bible, Shonna] Spartanburg Reg Med Ctr, Project Management Qual, Spartanburg, SC USA; [Dickess, Stacy M.] St Marys Hosp, Performance Improvement Dept, Huntington, WV USA; [Foss, Michelle] Shawnee Mission Med Ctr, Intens Care Unit, Shawnee Mission, KS USA		Wijdicks, EFM (corresponding author), Mayo Clin, Div Crit Care Neurol, Dept Neurol, Rochester, MN 55905 USA.	wijde@mayo.edu	Kramer, Andrew/AAI-9086-2020	Kramer, Andrew/0000-0002-5681-5781			Akavipat P, 2009, NEUROL MED-CHIR, V49, P565, DOI 10.2176/nmc.49.565; Breslow MJ, 2012, CHEST, V141, P245, DOI 10.1378/chest.11-0330; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Higgins TL, 2007, CRIT CARE MED, V35, P827, DOI 10.1097/01.CCM.0000257337.63529.9F; Idrovo L, 2010, EUR NEUROL, V63, P364, DOI 10.1159/000292498; Kevric J, 2011, EMERG MED J, V28, P486, DOI 10.1136/emj.2009.085845; Knox DB, 2013, C104 CRITICAL ILLNES, pA5073; Kramer AA, 2013, CRIT CARE MED, V41, P24, DOI 10.1097/CCM.0b013e3182657b8a; Kramer AA, 2012, CRIT CARE MED, V40, P2671, DOI 10.1097/CCM.0b013e318258fd88; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marcati E, 2012, INTERN EMERG MED, V7, P145, DOI 10.1007/s11739-011-0583-x; Pepe MS, 2013, STAT MED, V32, P1467, DOI 10.1002/sim.5727; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Prasad V, 2011, ARCH INTERN MED, V171, P1675, DOI 10.1001/archinternmed.2011.295; Riechers RG, 2005, J NEUROTRAUM, V22, P1327, DOI 10.1089/neu.2005.22.1327; Sadaka F, 2012, NEUROCRIT CARE, V16, P95, DOI 10.1007/s12028-011-9617-5; TEASDALE G, 1974, LANCET, V2, P81; Weiss N, 2009, REV NEUROL-FRANCE, V165, P796, DOI 10.1016/j.neurol.2009.01.045; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	23	28	33	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2015	43	2					439	444		10.1097/CCM.0000000000000707			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AZ2YX	WOS:000348096200021	25393699				2022-02-06	
J	Naro, A; Calabro, RS; Russo, M; Leo, A; Pollicino, P; Quartarone, A; Bramanti, P				Naro, Antonino; Calabro, Rocco Salvatore; Russo, Margherita; Leo, Antonino; Pollicino, Patrizia; Quartarone, Angelo; Bramanti, Placido			Can transcranial direct current stimulation be useful in differentiating unresponsive wakefulness syndrome from minimally conscious state patients?	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Disorders of consciousness; minimally conscious state; unresponsive wakefulness syndrome; transcranial direct current stimulation; transcranial magnetic stimulation; cortical excitability; cortical connectivity	CORTICAL EFFECTIVE CONNECTIVITY; HUMAN MOTOR CORTEX; TRAUMATIC BRAIN-INJURY; COMA RECOVERY SCALE; MAGNETIC STIMULATION; VEGETATIVE STATE; FUNCTIONAL CONNECTIVITY; ELECTRICAL-STIMULATION; OSCILLATORY ACTIVITIES; ORBITOFRONTAL CORTEX	Purpose: Disorders of consciousness (DOC) diagnosis relies on the presence or absence of purposeful motor responsiveness, which characterizes the minimally conscious state (MCS) and the unresponsive wakefulness syndrome (UWS), respectively. Functional neuroimaging studies have raised the question of possible residual conscious awareness also in clinically-defined UWS patients. The aim of our study was to identify electrophysiological parameters, by means of a transcranial magnetic stimulation approach, which might potentially express the presence of residual networks sustaining fragmentary behavioral patterns, even when no conscious behavior can be observed. Methods: We enrolled 25 severe DOC patients, following post-anoxic or traumatic brain injury and 20 healthy individuals (HC) as control group. Baseline electrophysiological evaluation evidenced, in comparison to HC, a partial preservation of cortical effective connectivity and excitability in clinically defined MCS, whereas these components were absent in clinically defined UWS. Then, we applied an anodal transcranial direct current stimulation (a-tDCS) protocol over the orbitofrontal cortex. Result: a-tDCS was able to boost cortical connectivity and excitability in all HC, MCS, and to unmask such excitability/connectivity in some UWS patients. Conclusion: a-tDCS could be useful in identifying residual connectivity markers in clinically-defined UWS, who may lack of purposeful behavior as a result of a motor-output failure.	[Naro, Antonino; Calabro, Rocco Salvatore; Russo, Margherita; Leo, Antonino; Pollicino, Patrizia; Bramanti, Placido] IRCCS Ctr Neurolesi Bonino Pulejo Messina, I-98124 Messina, Italy; [Quartarone, Angelo] Univ Messina, Dept Neurosci, I-98100 Messina, Italy		Calabro, RS (corresponding author), IRCCS Ctr Neurolesi Bonino Pulejo Messina, SS 113, I-98124 Messina, Italy.	salbro77@tiscali.it	Leo, Antonino/K-7529-2016; Calabro, Rocco S/K-7520-2016; Leo, Antonino/ABI-7198-2020; Bramanti, Placido/K-5117-2016; calabro, rocco salvatore/L-9570-2019	Leo, Antonino/0000-0003-4163-5830; Leo, Antonino/0000-0003-4163-5830; calabro, rocco salvatore/0000-0002-8566-3166; QUARTARONE, Angelo/0000-0003-1485-6590			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Alon G, 2011, BRAIN RES, V1403, P37, DOI 10.1016/j.brainres.2011.06.013; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Angelakis E, 2014, ARCH PHYS MED REHAB, V95, P283, DOI 10.1016/j.apmr.2013.09.002; [Anonymous], 2003, Clin Med (Lond), V3, P249; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bagnato S, 2013, NEUROSCI BIOBEHAV R, V37, P2721, DOI 10.1016/j.neubiorev.2013.09.007; Bagnato S, 2012, CLIN NEUROPHYSIOL, V123, P1937, DOI 10.1016/j.clinph.2012.03.014; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Baudewig J, 2001, MAGN RESON MED, V45, P196, DOI 10.1002/1522-2594(200102)45:2<196::AID-MRM1026>3.0.CO;2-1; Bekinschtein P, 2008, P NATL ACAD SCI USA, V105, P2711, DOI 10.1073/pnas.0711863105; Bikson M, 2010, CLIN NEUROPHYSIOL, V121, P1976, DOI 10.1016/j.clinph.2010.05.020; BINDMAN LJ, 1964, J PHYSIOL-LONDON, V172, P369, DOI 10.1113/jphysiol.1964.sp007425; Boly M, 2012, BRAIN CONNECT, V2, P1, DOI 10.1089/brain.2011.0049; Boly M, 2011, CURR OPIN NEUROL, V24, P394, DOI 10.1097/WCO.0b013e328347da94; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Boros K, 2008, EUR J NEUROSCI, V27, P1292, DOI 10.1111/j.1460-9568.2008.06090.x; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Busl KM, 2010, NEUROREHABILITATION, V26, P5, DOI 10.3233/NRE-2010-0531; Cavanna AE, 2007, CNS SPECTRUMS, V12, P545, DOI 10.1017/S1092852900021295; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Civardi C, 2001, NEUROIMAGE, V14, P1444, DOI 10.1006/nimg.2001.0918; CREPEL V, 1993, J NEUROPHYSIOL, V70, P2045, DOI 10.1152/jn.1993.70.5.2045; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Demertzi A, 2013, CURR OPIN NEUROBIOL, V23, P239, DOI 10.1016/j.conb.2012.12.003; Di Filippo M, 2008, NEUROPHARMACOLOGY, V55, P353, DOI 10.1016/j.neuropharm.2008.01.012; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; Di Perri C, 2014, EPILEPSY BEHAV, V30, P28, DOI 10.1016/j.yebeh.2013.09.014; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Ferreri F, 2013, REV NEUROSCIENCE, V24, P431, DOI 10.1515/revneuro-2013-0019; Fuggetta G, 2005, NEUROIMAGE, V27, P896, DOI 10.1016/j.neuroimage.2005.05.013; Fuggetta G, 2008, HUM BRAIN MAPP, V29, P1, DOI 10.1002/hbm.20371; Fuggetta G, 2013, EXP NEUROL, V245, P87, DOI 10.1016/j.expneurol.2012.10.010; Fumagalli M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008865; Gerrard P., 2014, ARCH PHYS MED REHABI; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GOLDMANRAKIC PS, 1984, TRENDS NEUROSCI, V7, P419, DOI 10.1016/S0166-2236(84)80146-0; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Gosseries O, 2014, ANN FR ANESTH, V33, P65, DOI 10.1016/j.annfar.2013.11.002; Gosseries O, 2011, NEUROREHABILITATION, V28, P3, DOI 10.3233/NRE-2011-0625; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; John ER, 2005, PROG BRAIN RES, V150, P143, DOI 10.1016/S0079-6123(05)50011-6; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Keeser D, 2011, NEUROIMAGE, V55, P644, DOI 10.1016/j.neuroimage.2010.12.004; Kokaia Z, 1998, EXP NEUROL, V154, P289, DOI 10.1006/exnr.1998.6888; Komssi S, 2004, HUM BRAIN MAPP, V21, P154, DOI 10.1002/hbm.10159; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Lansbergen MM, 2007, BRAIN RES, V1148, P161, DOI 10.1016/j.brainres.2007.02.034; Lapitskaya N, 2013, BRAIN STIMUL, V6, P590, DOI 10.1016/j.brs.2013.01.002; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Luria A. R., 1966, HUMAN BRAIN PSYCHOL; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Manganotti P, 2013, BRAIN STIMUL, V6, P913, DOI 10.1016/j.brs.2013.06.006; Manuel AL, 2014, NEUROSCIENCE, V265, P21, DOI 10.1016/j.neuroscience.2014.01.052; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Massimini M, 2012, ARCH ITAL BIOL, V150, P44, DOI 10.4449/aib.v150i2.1361; Massimini M, 2009, PROG BRAIN RES, V177, P201, DOI 10.1016/S0079-6123(09)17714-2; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Munchau A, 2002, J NEUROSCI, V22, P554, DOI 10.1523/JNEUROSCI.22-02-00554.2002; Muri RM, 1996, J NEUROPHYSIOL, V76, P2102, DOI 10.1152/jn.1996.76.3.2102; NAGEL T, 1974, PHILOS REV, V83, P435, DOI 10.2307/2183914; Nakase-Richardson R, 2009, NEUROLOGY, V73, P1120, DOI 10.1212/WNL.0b013e3181bacf34; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nudo Randolph J, 2013, Handb Clin Neurol, V110, P13, DOI 10.1016/B978-0-444-52901-5.00002-2; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; Piccione F, 2011, NEUROREHAB NEURAL RE, V25, P98, DOI 10.1177/1545968310369802; Polania R, 2011, HUM BRAIN MAPP, V32, P1236, DOI 10.1002/hbm.21104; Pollonini L, 2010, BRAIN TOPOGR, V23, P221, DOI 10.1007/s10548-010-0139-9; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166, DOI 10.1152/jn.1965.28.1.166; Ragazzoni A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057069; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Sarasso S, 2014, CLIN EEG NEUROSCI, V45, P40, DOI 10.1177/1550059413513723; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Sehm B, 2012, J NEUROPHYSIOL, V108, P3253, DOI 10.1152/jn.00606.2012; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Song SB, 2011, RESTOR NEUROL NEUROS, V29, P427, DOI 10.3233/RNN-2011-0614; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Takano Y, 2011, NEUROSCI LETT, V491, P40, DOI 10.1016/j.neulet.2011.01.004; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Torres J, 2013, RESTOR NEUROL NEUROS, V31, P501, DOI 10.3233/RNN-130314; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Varotto G, 2014, CLIN NEUROPHYSIOL, V125, P63, DOI 10.1016/j.clinph.2013.06.016; Veniero D, 2011, PSYCHOPHYSIOLOGY, V48, P1381, DOI 10.1111/j.1469-8986.2011.01218.x; VOLKOW ND, 1992, SYNAPSE, V11, P184, DOI 10.1002/syn.890110303; Vucic S, 2009, BRAIN RES, V1273, P39, DOI 10.1016/j.brainres.2009.03.043; Walton ME, 2010, NEURON, V65, P927, DOI 10.1016/j.neuron.2010.02.027; Zaehle T, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-2; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	116	28	33	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2015	33	2					159	176		10.3233/RNN-140448			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB7UX	WOS:000349835000007	25588461				2022-02-06	
J	Porro, C; Cianciulli, A; Calvello, R; Panaro, MA				Porro, Chiara; Cianciulli, Antonia; Calvello, Rosa; Panaro, Maria Antonietta			Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities	CURRENT PHARMACEUTICAL DESIGN			English	Article						Microglial cells; neuroinflammation; resveratrol	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; GROWTH-FACTOR-BETA; NIGRAL DOPAMINERGIC-NEURONS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE	Resveratrol (3,5,4'-trihydroxy-trans-stilbene), a natural phytoalexin found in grape-skin, exerts multiple biological activities, including anti-inflammatory, antiproliferative and antioxidant effects. In the past few years, mounting evidence has suggested that resveratrol is neuroprotective against a number of neurological diseases. An important contributor to the pathogenesis of neurological disorders is neuroinflammation, of which microglial activation is an important hallmark. It is possible that M1/M2 polarization of microglia may play an important role in controlling the balance between promoting and resolving neuroinflammation in the CNS. Immunomodulatory strategies capable of redirecting the microglial response toward the neuroprotective M2 phenotype could offer attractive options for neurodegenerative diseases with inflammatory components. The neuroprotective actions of resveratrol seem to be attributable to its anti-inflammatory properties, due not only to its direct scavenger effects versus toxic molecules but also to a capacity to upregulate natural anti-inflammatory defences, thus counteracting excessive responses of classically activated M1 microglia. The goal of this review is to summarize recent insights into the therapeutic potential of resveratrol as a natural modulator of microglia-mediated neurotoxicity.	[Porro, Chiara] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy; [Cianciulli, Antonia; Calvello, Rosa; Panaro, Maria Antonietta] Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Via Orabona 4, I-70125 Bari, Italy		Panaro, MA (corresponding author), Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Via Orabona 4, I-70125 Bari, Italy.	mariaantonietta.panaro@uniba.it	Porro, Chiara/G-7849-2018	Porro, Chiara/0000-0002-7526-6968			Akiyama H, 2000, ALZ DIS ASSOC DIS, V14, pS47, DOI 10.1097/00002093-200000001-00008; de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amiot MJ, 2013, BIOCHIMIE, V95, P1233, DOI 10.1016/j.biochi.2013.01.008; Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025; Augustin MA, 2013, ANN NY ACAD SCI, V1290, P107, DOI 10.1111/nyas.12130; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001; Barton BE, 1996, INFECT IMMUN, V64, P714, DOI 10.1128/IAI.64.3.714-718.1996; Bayer C, 2013, J VIROL, V87, P67, DOI 10.1128/JVI.01585-12; Behrens MM, 2008, J NEUROSCI, V28, P13957, DOI 10.1523/JNEUROSCI.4457-08.2008; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bi XL, 2005, INT IMMUNOPHARMACOL, V5, P185, DOI 10.1016/j.intimp.2004.08.008; Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; Bureau G, 2008, J NEUROSCI RES, V86, P403, DOI 10.1002/jnr.21503; Burkon A, 2008, MOL NUTR FOOD RES, V52, P549, DOI 10.1002/mnfr.200700290; Burton MD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-54; Candelario-Jalil E, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-25; Capiralla H, 2012, J NEUROCHEM, V120, P461, DOI 10.1111/j.1471-4159.2011.07594.x; Cardozo LFMF, 2013, BIOCHIMIE, V95, P1525, DOI 10.1016/j.biochi.2013.04.012; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Choi SH, 2003, J NEUROSCI, V23, P5877; Chung YC, 2010, BMB REP, V43, P225, DOI 10.5483/BMBRep.2010.43.4.225; Cianciulli A, 2015, INT IMMUNOPHARMACOL, V24, P369, DOI 10.1016/j.intimp.2014.12.035; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Constant JP, 2012, NEUROSCIENCE, V222, P333, DOI 10.1016/j.neuroscience.2012.06.067; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13; Dawn B, 2007, J MOL CELL CARDIOL, V42, P484, DOI 10.1016/j.yjmcc.2006.11.014; de Bilbao F, 2009, J NEUROCHEM, V110, P12, DOI 10.1111/j.1471-4159.2009.06098.x; De Simone R, 2004, MOL NEUROBIOL, V29, P197, DOI 10.1385/MN:29:2:197; Delmas D, 2011, ANN NY ACAD SCI, V1215, P48, DOI 10.1111/j.1749-6632.2010.05871.x; Doi Y, 2009, AM J PATHOL, V175, P2121, DOI 10.2353/ajpath.2009.090418; Dragone T, 2014, TOXICOL IN VITRO, V28, P1126, DOI 10.1016/j.tiv.2014.05.005; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Estrela JM, 2013, CRIT REV CL LAB SCI, V50, P65, DOI 10.3109/10408363.2013.805182; Farber K, 2006, GLIA, V54, P656, DOI 10.1002/glia.20412; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Gomez-Nicola D, 2010, GLIA, V58, P264, DOI 10.1002/glia.20920; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365-2567.2004.01959.x; Griffiths MR, 2009, J NEUROPATH EXP NEUR, V68, P217, DOI 10.1097/NEN.0b013e3181996688; Guo Y, 2013, NEUROSCIENCE, V238, P1, DOI 10.1016/j.neuroscience.2013.01.047; Gutteridge J M, 1989, Baillieres Clin Haematol, V2, P195, DOI 10.1016/S0950-3536(89)80017-4; Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; Haupt C, 2007, MOL CELL NEUROSCI, V35, P89, DOI 10.1016/j.mcn.2007.02.005; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hoffmann A, 2003, J NEUROSCI, V23, P4410; Hoozemans JJM, 2006, INT J DEV NEUROSCI, V24, P157, DOI 10.1016/j.ijdevneu.2005.11.001; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; Huang TC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029102; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Hwang J, 2010, NEUROPHARMACOLOGY, V58, P1122, DOI 10.1016/j.neuropharm.2010.02.003; Izzi V, 2012, FRONT BIOSCI-LANDMRK, V17, P2396, DOI 10.2741/4061; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Juhasz B, 2010, CURR PHARM BIOTECHNO, V11, P810, DOI 10.2174/138920110793262079; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008; Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248; Kesherwani V, 2013, NEUROSCIENCE, V241, P80, DOI 10.1016/j.neuroscience.2013.03.015; Kim SR, 2010, J NEUROSCI RES, V88, P1537, DOI 10.1002/jnr.22318; Kiyota T, 2012, GENE THER, V19, P724, DOI 10.1038/gt.2011.126; Kiyota T, 2010, FASEB J, V24, P3093, DOI 10.1096/fj.10-155317; Krakauer Teresa, 2004, Current Drug Targets - Inflammation and Allergy, V3, P317; Lacey DC, 2012, J IMMUNOL, V188, P5752, DOI 10.4049/jimmunol.1103426; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lee CH, 2011, J NEUROL SCI, V300, P120, DOI 10.1016/j.jns.2010.09.005; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lim JY, 2010, EUR J PHARMACOL, V642, P10, DOI 10.1016/j.ejphar.2010.05.047; Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531; Lofrumento DD, 2014, INNATE IMMUN-LONDON, V20, P249, DOI 10.1177/1753425913488429; Lu JY, 2013, KIDNEY INT, V84, P745, DOI 10.1038/ki.2013.135; Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212; Lu XF, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-46; Lund S, 2006, J NEUROIMMUNOL, V180, P71, DOI 10.1016/j.jneuroim.2006.07.007; Lyons A, 2007, J NEUROCHEM, V101, P771, DOI 10.1111/j.1471-4159.2006.04370.x; Maher FO, 2005, NEUROBIOL AGING, V26, P717, DOI 10.1016/j.neurobiolaging.2004.07.002; Mandel S, 2003, TRENDS PHARMACOL SCI, V24, P184, DOI 10.1016/S0165-6147(03)00067-1; Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Markus MA, 2008, CLIN INTERV AGING, V3, P331; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; MATTIVI F, 1993, Z LEBENSM UNTERS FOR, V196, P522, DOI 10.1007/BF01201331; McGeer PL, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00077; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Minghetti L, 2005, BRAIN RES REV, V48, P251, DOI 10.1016/j.brainresrev.2004.12.015; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; Neves AR, 2013, INT J NANOMED, V8, P177, DOI 10.2147/IJN.S37840; Nimmagadda VK, 2013, J IMMUNOL, V190, P4595, DOI 10.4049/jimmunol.1202584; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nimmo Alan J, 2009, Recent Pat CNS Drug Discov, V4, P86; Nolan Y, 2005, J BIOL CHEM, V280, P9354, DOI 10.1074/jbc.M412170200; Nomura Y, 2001, LIFE SCI, V68, P1695, DOI 10.1016/S0024-3205(01)00967-5; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Orsu P, 2013, J NEURAL TRANSM, V120, P1217, DOI 10.1007/s00702-013-0982-4; Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682; Panaro MA, 2012, CURR PHARM DESIGN, V18, P200; Park EJ, 2015, BBA-MOL BASIS DIS, V1852, P1071, DOI 10.1016/j.bbadis.2015.01.014; Park KW, 2007, EXP MOL MED, V39, P812, DOI 10.1038/emm.2007.88; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Pervaiz S, 2009, ANTIOXID REDOX SIGN, V11, P2851, DOI [10.1089/ars.2008.2412, 10.1089/ARS.2008.2412]; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pfister HW, 1997, CURR OPIN NEUROL, V10, P254, DOI 10.1097/00019052-199706000-00015; Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200; Piotrowska H, 2012, MUTAT RES-REV MUTAT, V750, P60, DOI 10.1016/j.mrrev.2011.11.001; Pizzolato G, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00002; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Pratico D, 2004, J ALZHEIMERS DIS, V6, P171; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Qin HW, 2006, J IMMUNOL, V177, P7761, DOI 10.4049/jimmunol.177.11.7761; Rahman Arshad, 2011, Proc Am Thorac Soc, V8, P497, DOI 10.1513/pats.201101-009MW; Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Rajendrasozhan S, 2008, AM J RESP CRIT CARE, V177, P861, DOI 10.1164/rccm.200708-1269OC; Ramanan S, 2008, FREE RADICAL BIO MED, V45, P1695, DOI 10.1016/j.freeradbiomed.2008.09.002; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046; Richard KL, 2008, J NEUROSCI, V28, P5784, DOI 10.1523/JNEUROSCI.1146-08.2008; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Robb EL, 2008, BIOCHEM BIOPH RES CO, V372, P254, DOI 10.1016/j.bbrc.2008.05.028; Rubartelli A, 2007, TRENDS IMMUNOL, V28, P429, DOI 10.1016/j.it.2007.08.004; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0; Samavati L, 2008, J BIOL CHEM, V283, P21134, DOI 10.1074/jbc.M801954200; Scholtzova H, 2009, J NEUROSCI, V29, P1846, DOI 10.1523/JNEUROSCI.5715-08.2009; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Shastri A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/342931; Sheu JN, 2013, COMP IMMUNOL MICROB, V36, P137, DOI 10.1016/j.cimid.2012.11.002; Silva SL, 2012, NEUROPHARMACOLOGY, V62, P2398, DOI 10.1016/j.neuropharm.2012.02.002; Song J, 2014, INT J MOL SCI, V15, P15512, DOI 10.3390/ijms150915512; Souto Eliana B, 2013, Methods Mol Biol, V1028, P37, DOI 10.1007/978-1-62703-475-3_3; Spasic MR, 2009, NEUROSCIENTIST, V15, P309, DOI 10.1177/1073858408327805; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Stone DK, 2009, ANTIOXID REDOX SIGN, V11, P2151, DOI [10.1089/ars.2009.2460, 10.1089/ARS.2009.2460]; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; Szczepanik AM, 2001, J NEUROIMMUNOL, V113, P49, DOI 10.1016/S0165-5728(00)00404-5; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tansey MG, 2008, FRONT BIOSCI-LANDMRK, V13, P709, DOI 10.2741/2713; Tilleux S, 2007, J NEUROSCI RES, V85, P2059, DOI 10.1002/jnr.21325; Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004; Tsuda Y, 2011, EUR J PHARMACOL, V666, P189, DOI 10.1016/j.ejphar.2011.05.019; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Vingtdeux V, 2011, FASEB J, V25, P219, DOI 10.1096/fj.10-167361; Vingtdeux V, 2010, J BIOL CHEM, V285, P9100, DOI 10.1074/jbc.M109.060061; Vitrac X, 2003, LIFE SCI, V72, P2219, DOI 10.1016/S0024-3205(03)00096-1; Vivien D, 2006, CYTOKINE GROWTH F R, V17, P121, DOI 10.1016/j.cytogfr.2005.09.011; Vogel DYS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-35; Waddell SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009753; Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749-6632.2010.05842.x; Wang J, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00042; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005; Weisser Shelley B, 2013, Methods Mol Biol, V946, P225, DOI 10.1007/978-1-62703-128-8_14; Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167; Williams LM, 2007, J BIOL CHEM, V282, P6965, DOI 10.1074/jbc.M609101200; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Xu XY, 2000, LIFE SCI, V67, P3221, DOI 10.1016/S0024-3205(00)00902-4; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Yasuda S., 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P45; Ye JM, 2013, NEUROSCI LETT, V553, P72, DOI 10.1016/j.neulet.2013.08.020; Ye YX, 2012, INT IMMUNOPHARMACOL, V12, P384, DOI 10.1016/j.intimp.2011.12.011; Yet SF, 2003, FASEB J, V17, P1759, DOI 10.1096/fj.03-0187fje; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yoshizaki T, 2009, MOL CELL BIOL, V29, P1363, DOI 10.1128/MCB.00705-08; Zhang F, 2013, PHYTOTHER RES, V27, P344, DOI 10.1002/ptr.4734; Zhong LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032195; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	216	28	29	0	10	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2015	21	36					5277	5291		10.2174/1381612821666150928155612			15	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	CV8FW	WOS:000364517500011	26416082				2022-02-06	
J	Pugh, MJV; Orman, JA; Jaramillo, CA; Salinsky, MC; Eapen, BC; Towne, AR; Amuan, ME; Roman, G; McNamee, SD; Kent, TA; McMillan, KK; Hamid, H; Grafman, JH				Pugh, Mary Jo V.; Orman, Jean A.; Jaramillo, Carlos A.; Salinsky, Martin C.; Eapen, Blessen C.; Towne, Alan R.; Amuan, Megan E.; Roman, Gustavo; McNamee, Shane D.; Kent, Thomas A.; McMillan, Katharine K.; Hamid, Hamada; Grafman, Jordan H.			The Prevalence of Epilepsy and Association With Traumatic Brain Injury in Veterans of the Afghanistan and Iraq Wars	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						epidemiology; epilepsy; traumatic brain injury; Veterans	NEW-ONSET EPILEPSY; POSTTRAUMATIC EPILEPSY; BIDIRECTIONAL RELATION; SEIZURE DISORDERS; CHRONIC PAIN; COMORBIDITY; HYPERTENSION; DEPRESSION; MINNESOTA; ROCHESTER	Objective: To examine the association of epilepsy with traumatic brain injury (TBI) in Afghanistan and Iraq (Operation Enduring Freedom [OEF]/Operation Iraqi Freedom [OIF]) Veterans. Design: Cross-sectional observational study. Participants: A total 256 284 OEF/OIF Veterans who received inpatient and outpatient care in the Veterans Health Administration in fiscal years 2009-2010. Main Outcome Measures: We used algorithms developed for use with International Classification of Diseases, Ninth Revision, Clinical Modification, codes to identify epilepsy, TBI (penetrating TBI [pTBI]/other TBI), and other risk factors for epilepsy (eg, stroke). TBI and other risk factors were identified prior to the index date (first date of seizure or October 1, 2009) for primary analyses. Results: Epilepsy prevalence was 10.6 per 1000 (N = 2719) in fiscal year 2010; age-adjusted prevalence was 6.1. Of 37 718 individuals with a diagnosis of TBI, 29 297 Veterans had a diagnosis of TBI prior to the index date. Statistically significant associations were found between epilepsy and prior TBI diagnosis (pTBI: adjusted odds ratio = 18.77 [95% confidence interval, 9.21-38.23]; other TBI: adjusted odds ratio = 1.64 [1.43-1.89]). Conclusions: Among OEF/OIF Veterans, epilepsy was associated with previous TBI diagnosis, with pTBI having the strongest association. Because war-related epilepsy in Vietnam War Veterans with TBI continued 35 years postwar, a detailed, prospective study is needed to understand the relationship between epilepsy and TBI severity in OEF/OIF Veterans.	[Pugh, Mary Jo V.; McMillan, Katharine K.] South Texas Vet Hlth Care Syst VERDICT, San Antonio, TX USA; [Pugh, Mary Jo V.; Orman, Jean A.; McMillan, Katharine K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Pugh, Mary Jo V.] Texas A&M Univ, Dept Med, Sch Med, College Stn, TX 77843 USA; [Orman, Jean A.] US Army Inst Surg Res, Houston, TX USA; [Orman, Jean A.] Univ Texas San Antonio, Sch Publ Hlth, San Antonio, TX USA; [Jaramillo, Carlos A.; Eapen, Blessen C.] UT Hlth Sci Ctr San Antonio, Dept Rehabil Med, Polytrauma Rehabil Ctr South Texas Vet Hlth Care, San Antonio, TX USA; [Salinsky, Martin C.] Portland VA Med Ctr, Portland, OR USA; [Salinsky, Martin C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Towne, Alan R.] Virginia Commonwealth Univ, Richmond, VA 23284 USA; [Towne, Alan R.] McGuire Vet Adm Hosp, Epilepsy Ctr Excellence, Richmond, VA USA; [Amuan, Megan E.] Edith Nourse Rogers Mem Hosp, CHQOER, Bedford, MA USA; [Roman, Gustavo] Methodist Neurol Inst, Nantz Natl Alzheimer Ctr, Houston, TX USA; [McNamee, Shane D.] Hunter Holmes McGuire Vet Adm Hosp, Phys Med & Rehabil Serv, Richmond, VA USA; [Kent, Thomas A.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Kent, Thomas A.] Baylor Coll Med, Houston, TX 77030 USA; [Hamid, Hamada] West Haven VA Med Ctr, West Haven, CT USA; [Grafman, Jordan H.] Rehabil Inst Chicago, Chicago, IL 60611 USA		Pugh, MJV (corresponding author), South Texas Vet Hlth Care Syst ALMD, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA.	pughm@uthscsa.edu	Altalib, Hamada/B-9656-2018; Pugh, Mary Jo/K-5336-2019	Altalib, Hamada/0000-0001-7154-1400; Pugh, Mary Jo/0000-0003-4196-7763; Kent, Thomas/0000-0002-9877-7584	VA Health Services Research and DevelopmentUS Department of Veterans Affairs [DHI 09-237]	The study was funded by VA Health Services Research and Development (DHI 09-237). Administrative, technical, or material support was provided by Kathleen Franklin, South Texas Veterans Healthcare System. Data analysis was conducted by Ms Amuan.	Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P19; Banerjee PN, 2009, EPILEPSY RES, V85, P31, DOI 10.1016/j.eplepsyres.2009.03.003; Borzecki AM, 2004, AM J MED QUAL, V19, P201, DOI 10.1177/106286060401900504; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; Chang YT, 2011, EPILEPSIA, V52, P2036, DOI 10.1111/j.1528-1167.2011.03268.x; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; De Simone R, 2007, NEUROL SCI, V28, pS150, DOI 10.1007/s10072-007-0769-1; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Department of Defense, 2004, DOD INSTR 6130 4 CRI; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Ettinger AB, 2009, EPILEPSY BEHAV, V15, pS60, DOI 10.1016/j.yebeh.2009.03.010; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1992, EPILEPSIA, V33, pS6; Hebert P L, 1999, Am J Med Qual, V14, P270, DOI 10.1177/106286069901400607; Hesdorffer DC, 2012, ANN NEUROL, V72, P184, DOI 10.1002/ana.23601; Hesdorffer DC, 1996, NEUROLOGY, V46, P727, DOI 10.1212/WNL.46.3.727; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hope OA, 2009, EPILEPSIA, V50, P1085, DOI 10.1111/j.1528-1167.2008.01892.x; Kanner AM, 2012, EPILEPSY BEHAV, V24, P156, DOI 10.1016/j.yebeh.2012.01.007; Kanner AM, 2011, EPILEPSIA, V52, P21, DOI 10.1111/j.1528-1167.2010.02907.x; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Li XH, 1997, EPILEPSIA, V38, P1216, DOI 10.1111/j.1528-1157.1997.tb01219.x; Mazza M, 2007, NEUROSCIENTIST, V13, P392, DOI 10.1177/10738584070130041101; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; NG SKC, 1993, NEUROLOGY, V43, P425, DOI 10.1212/WNL.43.2.425; Pugh MJV, 2008, NEUROLOGY, V70, P2171, DOI 10.1212/01.wnl.0000313157.15089.e6; Pugh MJV, 2009, J AM GERIATR SOC, V57, P237, DOI 10.1111/j.1532-5415.2008.02124.x; Pugh MJV, 2005, J AM GERIATR SOC, V53, P1282, DOI 10.1111/j.1532-5415.2005.53402.x; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rieger R, 2012, EPILEPSY CTR EXCELLE; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salinsky M, 2012, EPILEPSY BEHAV, V25, P345, DOI 10.1016/j.yebeh.2012.07.013; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Selim A, 2002, MEASURING MANAGING H, V4, P91; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; Tanielian T. L., 2008, INVISIBLE WOUNDS WAR, V720; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; US Department of Veterans Affairs, COMPR TBI EV VHA SUM; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; [No title captured]	51	28	29	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					29	37		10.1097/HTR.0000000000000045			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400012	24695268				2022-02-06	
J	Sharma, VK; Rango, J; Connaughton, AJ; Lombardo, DJ; Sabesan, VJ				Sharma, Vinay K.; Rango, Juan; Connaughton, Alexander J.; Lombardo, Daniel J.; Sabesan, Vani J.			The Current State of Head and Neck Injuries in Extreme Sports	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						extreme sports; head and neck injuries; concussions; epidemiology	HEALTH; EPIDEMIOLOGY; CHILDREN; RISK	Background: Since their conception during the mid-1970s, international participation in extreme sports has grown rapidly. The recent death of extreme snowmobiler Caleb Moore at the 2013 Winter X Games has demonstrated the serious risks associated with these sports. Purpose: To examine the incidence and prevalence of head and neck injuries (HNIs) in extreme sports. Study Design: Descriptive epidemiological study. Methods: The National Electronic Injury Surveillance System (NEISS) was used to acquire data from 7 sports (2000-2011) that were included in the Winter and Summer X Games. Data from the NEISS database were collected for each individual sport per year and type of HNI. Cumulative data for overall incidence and injuries over the entire 11-year period were calculated. National estimates were determined using NEISS-weighted calculations. Incidence rates were calculated for extreme sports using data from Outdoor Foundation Participation Reports. Results: Over 4 million injuries were reported between 2000 and 2011, of which 11.3% were HNIs. Of all HNIs, 83% were head injuries and 17% neck injuries. The 4 sports with the highest total incidence of HNI were skateboarding (129,600), snowboarding (97,527), skiing (83,313), and motocross (78,236). Severe HNI (cervical or skull fracture) accounted for 2.5% of extreme sports HNIs. Of these, skateboarding had the highest percentage of severe HNIs. Conclusion: The number of serious injuries suffered in extreme sports has increased as participation in the sports continues to grow. A greater awareness of the dangers associated with these sports offers an opportunity for sports medicine and orthopaedic physicians to advocate for safer equipment, improved on-site medical care, and further research regarding extreme sports injuries.	[Sharma, Vinay K.; Rango, Juan; Connaughton, Alexander J.; Lombardo, Daniel J.; Sabesan, Vani J.] Western Michigan Univ, Homer Stryker MD Sch Med, Kalamazoo, MI 49008 USA		Sabesan, VJ (corresponding author), Wayne State Univ, Sch Med, Dept Orthopaed Surg, Suite 305,18100 Oakwood Blvd, Detroit, MI 48124 USA.	vsabesan@med.wayne.edu					Ackery A, 2007, INJURY PREV, V13, P368, DOI 10.1136/ip.2007.017285; Balthrop PM, 2009, J EMERG MED, V36, P121, DOI 10.1016/j.jemermed.2007.05.013; Bergeron MF, 2012, BRIT J SPORT MED, V46, DOI 10.1136/bjsports-2012-091457; Brymer E, 2013, J HEALTH PSYCHOL, V18, P477, DOI 10.1177/1359105312446770; Caine DJ, 2012, MED SPORT SCI, V58, P1, DOI 10.1159/000338558; (CPSC) USCPSC, NEISS NAT EL INJ SUR; de Jong P, 2012, RISK ANAL, V32, P782, DOI 10.1111/j.1539-6924.2011.01785.x; Goulet C, 2010, J SCI MED SPORT, V13, P39, DOI 10.1016/j.jsams.2008.10.002; Graves JM, 2013, INJURY PREV, V19, P399, DOI 10.1136/injuryprev-2012-040727; Jennum P, 2013, SPINE, V38, P449, DOI 10.1097/BRS.0b013e3182819203; Larson AN, 2009, J PEDIATR ORTHOPED, V29, P847, DOI 10.1097/BPO.0b013e3181c1e2fa; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Ogawa H, 2010, AM J SPORT MED, V38, P532, DOI 10.1177/0363546509348763; Osberg JS, 1998, ARCH PEDIAT ADOL MED, V152, P985; Pikora TJ, 2012, MED SPORT SCI, V58, P80, DOI 10.1159/000338583; Rice MR, 2000, PEDIATRICS, V105, P615, DOI 10.1542/peds.105.3.615; Schroeder T., NEISS SAMPLE DESIGN; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; TATOR CH, 1993, PARAPLEGIA, V31, P700, DOI 10.1038/sc.1993.112; The Outdoor Foundation, 2013, 2013 OUTD RECR PART; Wedcliffe T, 2001, S Afr J Commun Disord, V48, P77; Willig C, 2008, J HEALTH PSYCHOL, V13, P690, DOI 10.1177/1359105307082459	22	28	28	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA		2325-9671		ORTHOP J SPORTS MED	Orthop. J. Sports Med.	JAN	2015	3	1							2325967114564358	10.1177/2325967114564358			6	Orthopedics; Sport Sciences	Emerging Sources Citation Index (ESCI)	Orthopedics; Sport Sciences	DA7II	WOS:000367977400006	26535369	Green Published, gold			2022-02-06	
J	Titus, DJ; Furones, C; Atkins, CM; Dietrich, WD				Titus, David J.; Furones, Concepcion; Atkins, Coleen M.; Dietrich, W. Dalton			Emergence of cognitive deficits after mild traumatic brain injury due to hyperthermia	EXPERIMENTAL NEUROLOGY			English	Article						Cognition; Concussion; Hyperthermia; Memory; Temperature; Traumatic brain injury	SPORT-RELATED CONCUSSION; WORKING-MEMORY DYSFUNCTION; FLUID PERCUSSION INJURY; CENTRAL-NERVOUS-SYSTEM; INTENSIVE-CARE-UNIT; SPINAL-CORD-INJURY; POSTTRAUMATIC HYPERTHERMIA; EXERCISE PERFORMANCE; FOOTBALL PLAYERS; COOLING METHODS	Mild elevations in core temperature can occur in individuals involved in strenuous activities that are risky for potentially sustaining a mild traumatic brain injury (mTBI) or concussion. Recently, we have discovered that mild elevations in brain temperature can significantly aggravate the histopathological consequences of mTBI. However, whether this exacerbation of brain pathology translates into behavioral deficits is unknown. Therefore, we investigated the behavioral consequences of elevating brain temperature to mildly hyperthermic levels prior to mTBI. Adult male Sprague Dawley rats underwent mild fluid-percussion brain injury or sham surgery while normothermic (37 degrees C) or hyperthermic (39 degrees C) and were allowed to recover for 7 days. Animals were then assessed for cognition using the water maze and cue and contextual fear conditioning. We found that mTBI alone at normothermia had no effect on long-term cognitive measures whereas mTBI animals that were hyperthermic for 15 min prior to and for 4 h after brain injury were significantly impaired on long-term retention for both the water maze and fear conditioning. In contrast, hyperthermic mTBI animals cooled within 15 min to normothermia demonstrated no significant long-term cognitive deficits. Mild TBI irrespective of temperature manipulations resulted in significant short-term working memory deficits. Cortical atrophy and contusions were detected in all mTBI treatment groups and contusion volume was significantly less in hyperthermic mTBI animals that were cooled as compared to hyperthermic mTBI animals that remained hyperthermic. These results indicate that brain temperature is an important variable for mTBI outcome and that mildly elevated temperatures at the time of injury result in persistent cognitive deficits. Importantly, cooling to normothermia after mTBI prevents the development of long-term cognitive deficits caused by hyperthermia. Reducing temperature to normothermic levels soon after mTBI represents a rational approach to potentially mitigate the long-term consequences of mTBI. (C) 2014 Elsevier Inc. All rights reserved.	[Titus, David J.; Furones, Concepcion; Atkins, Coleen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14 Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu		Atkins, Coleen/0000-0003-4718-7493	National Football League Medical Charities; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [PT110767]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133] Funding Source: NIH RePORTER	This work was supported by the National Football League Medical Charities, US Army Medical Research and Materiel Command PT110767, and The Miami Project to Cure Paralysis. We thank Melissa Carballosa, Jonathan Mendoza, and Rosmery Santos for technical assistance.	Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bao L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090956; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Cadarette BS, 2001, AVIAT SPACE ENVIR MD, V72, P32; Campos F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078429; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; CHOPP M, 1988, STROKE, V19, P1521, DOI 10.1161/01.STR.19.12.1521; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cornelussen RNM, 2001, AM J PHYSIOL-HEART C, V280, pH1736, DOI 10.1152/ajpheart.2001.280.4.H1736; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; DeMartini JK, 2011, J STRENGTH COND RES, V25, P2065, DOI 10.1519/JSC.0b013e3182259b1d; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Goosey-Tolfrey V, 2008, J APPL PHYSIOL, V105, P37, DOI 10.1152/japplphysiol.01084.2007; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hermstad Erik, 2010, J Emerg Trauma Shock, V3, P66, DOI 10.4103/0974-2700.58660; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Langlois J.A., 2004, TRAUMATIC BRAIN INJU, P1; Lin DW, 2011, NEUROPHARMACOLOGY, V61, P1354, DOI 10.1016/j.neuropharm.2011.08.011; Lingsma H., 2014, J NEUROTRAU IN PRESS; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Nybo L, 2008, J APPL PHYSIOL, V104, P871, DOI 10.1152/japplphysiol.00910.2007; Nybo L, 2012, EXP PHYSIOL, V97, P333, DOI 10.1113/expphysiol.2011.062273; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Sakurai A, 2012, J NEUROTRAUM, V29, P313, DOI 10.1089/neu.2011.2152; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Shelef, 2011, CARDIOVASC PSYCHIAT, V2011, DOI [DOI 10.1155/2011/765923, 10.1155/2011/765923]; Siegel R, 2012, SPORTS MED, V42, P89, DOI 10.2165/11596870-000000000-00000; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; TAKAGI K, 1994, AM J PHYSIOL-HEART C, V267, pH1770, DOI 10.1152/ajpheart.1994.267.5.H1770; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tyler C.J., 2013, BR J SPORTS MED; U.S. Army, 2003, DEP ARM AIR FORC TEC, P48; Uchimoto K, 2014, ANESTHESIOLOGY, V121, P302, DOI 10.1097/ALN.0000000000000269; Urdzikova L, 2006, SPINAL CORD, V44, P113, DOI 10.1038/sj.sc.3101792; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang CX, 2009, INT J STROKE, V4, P274, DOI 10.1111/j.1747-4949.2009.00317.x; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	76	28	28	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2015	263						254	262		10.1016/j.expneurol.2014.10.020			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX0EM	WOS:000346626100026	25447938	Green Accepted			2022-02-06	
J	Wells, TS; Seelig, AD; Ryan, MAK; Jones, JM; Hooper, TI; Jacobson, IG; Boyko, EJ				Wells, Timothy S.; Seelig, Amber D.; Ryan, Margaret A. K.; Jones, Jason M.; Hooper, Tomoko I.; Jacobson, Isabel G.; Boyko, Edward J.			Hearing loss associated with US military combat deployment	NOISE & HEALTH			English	Article						Combat disorders; hearing loss; military personnel	TRAUMATIC BRAIN-INJURY; MILLENNIUM COHORT; SERVICE MEMBERS; NATIONAL-HEALTH; IMPULSE NOISE; ADULTS; PERSONNEL; RISK; POPULATION; IMPAIRMENT	The objective of this study was to define the risk of hearing loss among US military members in relation to their deployment experiences. Data were drawn from the Millennium Cohort Study. Self-reported data and objective military service data were used to assess exposures and outcomes. Among all 48,540 participants, 7.5% self-reported new-onset hearing loss. Self-reported hearing loss showed moderate to substantial agreement (k = 0.57-0.69) with objective audiometric measures. New-onset hearing loss was associated with combat deployment (adjusted odds ratio [AOR] = 1.63, 95% confidence interval [CI] = 1.49-1.77), as well as male sex and older age. Among deployers, new-onset hearing loss was also associated with proximity to improvised explosive devices (AOR = 2.10, 95% CI = 1.62-2.73) and with experiencing a combat-related head injury (AOR = 6.88, 95% CI = 3.77-12.54). These findings have implications for health care and disability planning, as well as for prevention programs.	[Wells, Timothy S.] Adv Analyt Optum, Ann Arbor, MI USA; [Wells, Timothy S.] Adv Analyt Optum, San Diego, CA USA; [Seelig, Amber D.; Jacobson, Isabel G.] Naval Hlth Res Ctr, San Diego, CA USA; [Ryan, Margaret A. K.; Jones, Jason M.] Naval Hosp Camp Pendleton, San Diego, CA USA; [Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Seelig, Amber D.; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA; [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA		Wells, TS (corresponding author), 1839 Waverly Rd, Holt, MI USA.	tmlbwells@wowway.com	Boyko, Edward J/G-2484-2017	Boyko, Edward J/0000-0002-3695-192X			Abel SM, 2008, AVIAT SPACE ENVIR MD, V79, P591, DOI 10.3357/ASEM.2262.2008; Agrawal Y, 2009, OTOL NEUROTOL, V30, P139, DOI 10.1097/MAO.0b013e318192483c; Boyko EJ, 2010, DIABETES CARE, V33, P1771, DOI 10.2337/dc10-0296; Casali JG, 2009, NOISE HEALTH, V11, P69, DOI 10.4103/1463-1741.48564; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Durch, 2005, NOISE MILITARY SERVI; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Ferrite S, 2011, REV SAUDE PUBL, V45, P824, DOI 10.1590/S0034-89102011005000050; Geckle L., 2004, FORC HLTH PROT C ALB; Gray GC, 2002, MIL MED, V167, P483, DOI 10.1093/milmed/167.6.483; Groenewold Matthew R., 2011, Morbidity and Mortality Weekly Report, V60, P955; Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); Helfer TM, 2010, AM J PREV MED, V38, pS71, DOI 10.1016/j.amepre.2009.10.025; HENDERSON D, 1986, J ACOUST SOC AM, V80, P569, DOI 10.1121/1.394052; Hong OS, 2011, NURS RES, V60, P326, DOI 10.1097/NNR.0b013e3182281ca0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LeardMann CA, 2007, HUM VACCINES, V3, P245, DOI 10.4161/hv.4589; Lee DJ, 1996, EPIDEMIOLOGY, V7, P443, DOI 10.1097/00001648-199607000-00019; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lin FR, 2012, JARO-J ASSOC RES OTO, V13, P109, DOI 10.1007/s10162-011-0298-8; Littman AJ, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-99; Mac Crawford J, 2008, J OCCUP ENVIRON MED, V50, P817, DOI 10.1097/JOM.0b013e31816a8caf; Mahboubi H, 2013, EUR ARCH OTO-RHINO-L, V270, P461, DOI 10.1007/s00405-012-1979-6; Mcllwain DS, 2008, AM J PUBLIC HEALTH, V98, P2167, DOI 10.2105/AJPH.2007.128504; Muhr P, 2006, INT J AUDIOL, V45, P247, DOI 10.1080/14992020500190052; Murphy WJ, 2012, INT J AUDIOL, V51, pS31, DOI 10.3109/14992027.2011.630330; Niebuhr DW, 2007, MIL MED, V172, P63, DOI 10.7205/MILMED.172.1.63; Nondahl DM, 1998, AUDIOLOGY, V37, P295; Paakkonen R, 2005, Noise Health, V7, P11; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Rovig GW, 2004, MIL MED, V169, P429, DOI 10.7205/MILMED.169.6.429; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; Saunders GH, 2009, NOISE HEALTH, V11, P14, DOI 10.4103/1463-1741.45308; Sindhusake D, 2001, INT J EPIDEMIOL, V30, P1371, DOI 10.1093/ije/30.6.1371; Smith B, 2007, ANN EPIDEMIOL, V17, P976, DOI 10.1016/j.annepidem.2007.07.102; Smith B, 2007, AM J EPIDEMIOL, V166, P1345, DOI 10.1093/aje/kwm212; Smith B, 2007, AM J PREV MED, V32, P347, DOI 10.1016/j.amepre.2006.12.015; Smith TC, 2007, INT J ENVIRON HEAL R, V17, P271, DOI 10.1080/09603120701372243; Smith TC, 2007, ANN EPIDEMIOL, V17, P525, DOI 10.1016/j.annepidem.2006.12.002; Smith TC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-69; Starck J, 2003, Noise Health, V5, P63; Trost RP, 2007, MIL MED, V172, P426, DOI 10.7205/MILMED.172.4.426; US Government Accountability Office, 2011, HEAR LOSS PREV IMPR; VOIGT P, 1980, SCAND AUDIOL, P319; Vyskocil A, 2012, TOXICOL IND HEALTH, V28, P796, DOI 10.1177/0748233711425067; Wells TS, 2008, EUR J EPIDEMIOL, V23, P79, DOI 10.1007/s10654-007-9216-0	48	28	28	0	10	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1463-1741	1998-4030		NOISE HEALTH	Noise Health	JAN-FEB	2015	17	74					34	42		10.4103/1463-1741.149574			9	Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health	AZ7EH	WOS:000348381200005	25599756	Green Published, gold			2022-02-06	
J	Yang, LPH; Deeks, ED				Yang, Lily P. H.; Deeks, Emma D.			Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect	DRUGS			English	Article							AFFECT PBA; QUINIDINE; MANAGEMENT	Fixed-dose dextromethorphan/quinidine capsules (Nuedexta (R)) utilize quinidine to inhibit the metabolism of dextromethorphan, enabling high plasma dextromethorphan concentrations to be reached without using a larger dose of the drug. The drug combination is the first treatment to be approved for pseudobulbar affect (PBA), a condition of contextually inappropriate/exaggerated emotional expression that often occurs in adults with neurological damage conditions, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury, Alzheimer's disease or Parkinson's disease. Dextromethorphan/quinidine at the recommended dosages of 20/10 or 30/10 mg twice daily reduced the rate of PBA episodes and improved PBA severity in a 12-week, double-blind, placebo-controlled trial in adults with ALS or MS (STAR), with further improvements in the severity of the condition observed in a 12-week open-label extension phase. Dextromethorphan/quinidine 20/10 mg twice daily also improved PBA secondary to dementia in a cohort of a 12-week noncomparative trial (PRISM II). The drug combination was generally well tolerated in these studies, with no particular safety or tolerability concerns. Although longer-term efficacy and tolerability data for dextromethorphan/quinidine 20/10 or 30/10 mg twice daily would be beneficial, current evidence indicates that it is a useful option in the treatment of adults with PBA.	[Yang, Lily P. H.; Deeks, Emma D.] Springer, Auckland 0754, New Zealand		Deeks, ED (corresponding author), Springer, Private Bag 65901, Auckland 0754, New Zealand.	demail@springer.com					Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x; Avanir Pharmaceuticals, 2013, SAF EFF AVP 923 PBA; Avanir Pharmaceuticals Inc, 2010, NUED DEXTR HYDR QUIN; Brooks BR, 2012, ANN NEUROL, V72, pS65; Capon DA, 1996, CLIN PHARMACOL THER, V60, P295, DOI 10.1016/S0009-9236(96)90056-9; CODD EE, 1995, J PHARMACOL EXP THER, V274, P1263; Cruz MP, 2013, DRUG FORCAST, V38, P325; Cummings J., 2009, NEUROPSYCHIATRIC INV; Doody RS, 2014, 139 ANN M AM NEUR AS; European Medicines Agency, NUED DEXTR QUIN OR C; European Medicines Agency, 2013, NEUD DEXTR QUIN ASS; Haiman G, 2009, J CLIN PSYCHOPHARM, V29, P444, DOI 10.1097/JCP.0b013e3181b5ae5c; Jillapalli D., 2010, US FDA CTR DRUG EVAL; Marier JF, 2005, LIFE SCI, V77, P2911, DOI 10.1016/j.lfs.2005.04.025; Miller A, 2011, EXPERT REV NEUROTHER, V11, P1077, DOI [10.1586/ERN.11.68, 10.1586/ern.11.68]; Miller RG, 2009, NEUROLOGY, V73, P1227, DOI 10.1212/WNL.0b013e3181bc01a4; Nguyen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089985; Parvizi J, 2006, MAYO CLIN PROC, V81, P1482, DOI 10.4065/81.11.1482; Parvizi J, 2009, J NEUROPSYCH CLIN N, V21, P75, DOI 10.1176/appi.neuropsych.21.1.75; Pattee GL, 2014, CURR MED RES OPIN, V30, P2255, DOI 10.1185/03007995.2014.940040; Pioro E, 2010, 62 ANN M AM AC NEUR; Pioro E, 2010, NEUROLOGY, V75, P380; Pioro EP, 2011, DRUGS, V71, P1193, DOI 10.2165/11591450-000000000-00000; Pioro EP, 2010, ANN NEUROL, V68, P693, DOI 10.1002/ana.22093; Pope LE, 2004, J CLIN PHARMACOL, V44, P1132, DOI 10.1177/0091270004269521; Schoedel KA, 2012, CLIN DRUG INVEST, V32, P157, DOI 10.2165/11633850-000000000-00000; Siffert J, 2013, CONSULT PHARM, V28; Werling LL, 2007, EXP NEUROL, V207, P248, DOI 10.1016/j.expneurol.2007.06.013; Zawertailo LA, 2010, HUM PSYCHOPHARM CLIN, V25, P71, DOI 10.1002/hup.1086	29	28	30	0	10	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs	JAN	2015	75	1					83	90		10.1007/s40265-014-0328-z			8	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	AX8GR	WOS:000347148600006	25420446				2022-02-06	
J	Ansari, MA; Roberts, KN; Scheff, SW				Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.			A time course of NADPH-oxidase up-regulation and endothelial nitric oxide synthase activation in the hippocampus following neurotrauma	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						NADPH-oxidase; Free radicals; Secondary injury cascades; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; MEDIATED OXIDATIVE DAMAGE; PROTEIN-KINASE-C; SUPEROXIDE-DISMUTASE; CELL-DEATH; RAT-BRAIN; POLY(ADP-RIBOSE) POLYMERASE; SYNAPTIC PROTEINS; INOS EXPRESSION; NEURONAL DEATH	Nicotinamide adenine dinucleotide phosphate oxidase (NADPH-oxidase; NOX) is a complex enzyme responsible for increased levels of reactive oxygen species (ROS), superoxide (O-2(center dot-)). NOX-derived O-2(center dot-) is a key player in oxidative stress and inflammation-mediated multiple secondary injury cascades (SIC) following traumatic brain injury (TBI). The O-2(center dot-) reacts with nitric oxide (NO), produces various reactive nitrogen species (RNS), and contributes to apoptotic cell death. Following a unilateral cortical contusion, young adult rats were killed at various times postinjury (1, 3, 6, 12, 24, 48, 72, and 96 h). Fresh tissue from the hippocampus was analyzed for NOX activity, and level of O-2(center dot-). In addition we evaluated the translocation of cytosolic NOX proteins (p67(Phox), p47(Phox), and p40(Phox)) to the membrane, along with total NO and the activation (phosphorylation) of endothelial nitric oxide synthase (p-eNOS). Results show that both enzymes and levels of O-2(center dot-) and NO have time-dependent injury effects in the hippocampus. Translocation of cytosolic NOX proteins into membrane, NOX activity, and O-2(center dot-) were also increased in a time-dependent fashion. Both NOX activity and Or were increased at 6 h. Levels of p-eNOS increased within 1 h, with significant elevation of NO at 12 h post-TBI. Levels of NO failed to show a significant association with p-eNOS, but did associate with O-2(center dot-). NOX up-regulation strongly associated with both the levels of O-2(center dot-) and the total NO. The initial 12 h post-TBI are very important as a possible window of opportunity to interrupt SIC. It may be important to selectively target the translocation of cytosolic subunits for the modulation of NOX function. (C) 2014 Elsevier Inc. All rights reserved.	[Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Spinal Cord Brain Injury Res Ctr, Lexington, KY 40536 USA		Ansari, MA (corresponding author), Univ Kentucky, Ctr Aging, 101 Sanders Brown, Lexington, KY 40536 USA.	mubeen.ansari@uky.edu; knorbe2@email.uky.edu; sscheff@email.uky.edu		Ansari, Mubeen Ahmad/0000-0002-1132-5965	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R21NS66117]; Kentucky Spinal Cord Head Injury Research Trust [12-16A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS066117] Funding Source: NIH RePORTER	This research was supported by NIH 5R21NS66117 and the Kentucky Spinal Cord Head Injury Research Trust No. 12-16A.	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; Abramov AY, 2005, J NEUROSCI, V25, P9176, DOI 10.1523/JNEUROSCI.1632-05.2005; Anantharam V, 2007, NEUROTOXICOLOGY, V28, P988, DOI 10.1016/j.neuro.2007.08.008; Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ansari MA, 2013, J NEUROTRAUM, V30, P1542, DOI 10.1089/neu.2013.2910; Ansari MA, 2011, FREE RADICAL BIO MED, V51, P171, DOI 10.1016/j.freeradbiomed.2011.03.025; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P1510, DOI 10.1016/j.freeradbiomed.2008.08.025; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Campese VM, 2007, BRAIN RES, V1134, P27, DOI 10.1016/j.brainres.2006.11.067; Chang CC, 2011, TOXICOL APPL PHARM, V257, P137, DOI 10.1016/j.taap.2011.08.027; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Chern CM, 2011, PLANTA MED, V77, P1669, DOI 10.1055/s-0030-1271019; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Choi SH, 2005, J NEUROSCI, V25, P4082, DOI 10.1523/JNEUROSCI.4306-04.2005; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; Egea J, 2012, NEUROPHARMACOLOGY, V62, P1082, DOI 10.1016/j.neuropharm.2011.10.022; Fabian RH, 2008, AM J PHYSIOL-HEART C, V295, pH1809, DOI 10.1152/ajpheart.00301.2007; FUKUI T, 1995, BBA-BIOENERGETICS, V1231, P215, DOI 10.1016/0005-2728(95)00098-4; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gilmer LK, 2010, MECH AGEING DEV, V131, P133, DOI 10.1016/j.mad.2009.12.011; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hortobagyi T, 2003, NEUROSCIENCE, V121, P983, DOI 10.1016/S0306-4522(03)00482-2; Hsieh HL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-110; Hsieh HL, 2010, ANTIOXID REDOX SIGN, V13, P1829, DOI 10.1089/ars.2009.2957; Hur J, 2010, BIOCHEM BIOPH RES CO, V391, P1526, DOI 10.1016/j.bbrc.2009.12.114; Hwang JJ, 2002, J NEUROCHEM, V82, P894, DOI 10.1046/j.1471-4159.2002.01040.x; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Jin R, 2011, STROKE, V42, P2033, DOI 10.1161/STROKEAHA.110.601369; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kandasamy R, 2013, INT J NEUROSCI, V123, P385, DOI 10.3109/00207454.2012.761983; Kim JH, 2013, BRAIN RES, V1499, P163, DOI 10.1016/j.brainres.2013.01.007; Kim S, 1998, EXP MOL MED, V30, P221, DOI 10.1038/emm.1998.32; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Lee ST, 2006, J NEUROCHEM, V96, P1728, DOI 10.1111/j.1471-4159.2006.03697.x; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu X. X., 2012, CHIN J INTEGR MED; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Mathis DM, 2011, JOVE-J VIS EXP, DOI 10.3791/2330; McCann SK, 2008, J NEUROSCI RES, V86, P2524, DOI 10.1002/jnr.21700; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568, DOI 10.1152/ajpheart.1994.266.6.H2568; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Reeves EP, 1999, BIOCHEM J, V344, P859, DOI 10.1042/0264-6021:3440859; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Sastry KVH, 2002, ANAL BIOCHEM, V306, P79, DOI 10.1006/abio.2002.5676; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shin HK, 2004, CLIN EXP PHARMACOL P, V31, P1, DOI 10.1111/j.1440-1681.2004.03943.x; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIESJO BK, 1994, ANN NY ACAD SCI, V747, P140; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Stoffel M, 2001, J NEUROTRAUM, V18, P425, DOI 10.1089/089771501750171010; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tammariello SP, 2000, J NEUROSCI, V20; Tejada-Simon MV, 2005, MOL CELL NEUROSCI, V29, P97, DOI 10.1016/j.mcn.2005.01.007; VALLANCE P, 1989, LANCET, V2, P997; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wu DM, 2012, TOXICOL SCI, V128, P209, DOI 10.1093/toxsci/kfs124; Yoshitomi H, 2011, J STROKE CEREBROVASC, V20, P406, DOI 10.1016/j.jstrokecerebrovasdis.2010.01.014; Zhan XH, 2003, J HISTOCHEM CYTOCHEM, V51, P81, DOI 10.1177/002215540305100110; Zhang Q., 2012, PLOS ONE, V7; Zhou H, 2012, FREE RADICAL BIO MED, V52, P303, DOI 10.1016/j.freeradbiomed.2011.10.488; Zhou YF, 2014, BRAIN RES BULL, V100, P14, DOI 10.1016/j.brainresbull.2013.10.013	94	28	28	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC	2014	77						21	29		10.1016/j.freeradbiomed.2014.08.025			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AW6QA	WOS:000346392500003	25224032	Green Accepted			2022-02-06	
J	Brands, I; Kohler, S; Stapert, S; Wade, D; van Heugten, C				Brands, Ingrid; Kohler, Sebastian; Stapert, Sven; Wade, Derick; van Heugten, Caroline			Influence of Self-Efficacy and Coping on Quality of Life and Social Participation After Acquired Brain Injury: A 1-Year Follow-Up Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Coping; Quality of life; Rehabilitation; Self-efficacy; Social participation	FRENCHAY ACTIVITIES INDEX; STROKE PATIENTS; HEALTH-STATUS; SATISFACTION; STRATEGIES; REHABILITATION; INTERVENTION; PREDICTORS; DISABILITY; ADJUSTMENT	Objectives: To investigate the relations linking self-efficacy and coping to quality of life (QOL) and social participation and what effect self-efficacy, changes in self-efficacy, and coping style have on long-term QOL and social participation. Design: Prospective clinical cohort study. Setting: General hospitals, rehabilitation centers. Participants: Patients with newly acquired brain injury (ABI) (N = 148) were assessed at baseline (start outpatient rehabilitation or discharge hospital/inpatient rehabilitation; mean time since injury, 15wk) and 1 year later (mean time since injury, 67wk). Interventions: Not applicable. Main Outcome Measures: QOL was measured with the EuroQuol 5D (the EQ-5D index and the EQ-5D visual analog scale [EQ VAS]) and the 9-item Life Satisfaction Questionnaire (LiSat-9), social participation with the modified Frenchay Activities Index, coping with the Coping Inventory for Stressful Situations, and self-efficacy with the Traumatic Brain Injury Self-efficacy Questionnaire. Results: At baseline, self-efficacy moderated the effect of emotion-oriented coping on the EQ-5D index and of avoidance coping on the EQ VAS. Self-efficacy mediated the relation between emotion-oriented coping and LiSat-9. An increase in self-efficacy over time predicted better scores on the EQ-5D index (beta = .30), the EQ VAS (beta = .49), and LiSat-9 (beta = .44) at follow-up. In addition, higher initial self-efficacy (beta = .40) predicted higher LiSat-9 scores at follow-up; higher initial emotion-oriented coping (beta = -.23) predicted lower EQ VAS scores at follow-up. Higher modified Frenchay Activities Index scores at follow-up were predicted by higher self-efficacy (beta =.19) and higher task-oriented coping (beta = .14) at baseline (combined R-2 = 5.1%). Conclusions: Self-efficacy and coping predict long-term QOL but seem less important in long-term social participation. High self-efficacy protects against the negative effect of emotion-oriented coping. Enhancing self-efficacy in the early stage after ABI may have beneficial long-term effects. (C) 2014 by the American Congress of Rehabilitation Medicine	[Brands, Ingrid] Dept Neurorehabil Libra Rehabil Med & Audiol, Eindhoven, Netherlands; [Kohler, Sebastian; van Heugten, Caroline] Maastricht Univ, Fac Hlth Med & Life Sci, Alzheimer Ctr Limburg, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Stapert, Sven; van Heugten, Caroline] Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands; [Wade, Derick] Maastricht Univ, Sch Publ Hlth & Primary Care, Dept Rehabil Med, Maastricht, Netherlands; [Wade, Derick] Oxford Ctr Enablement, Oxford, England		Brands, I (corresponding author), POB 1355, NL-5602 BJ Eindhoven, Netherlands.	i.brands@libranet.nl		Wade, Derick/0000-0002-1188-8442	CZ Fund [AFVV11-045]	Supported by CZ Fund (grant no AFVV11-045).	Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bandura A., 1997, SELF EFFICACY EXERCI; Belgen B, 2006, ARCH PHYS MED REHAB, V87, P554, DOI 10.1016/j.apmr.2005.12.027; Bonetti D, 2008, BRIT J HEALTH PSYCH, V13, P463, DOI 10.1348/135910707X216648; Brands I, 2014, J REHABIL MED; Brands IM, 2014, PSYCHOL ASSESS; Brands IMH, 2012, CLIN REHABIL, V26, P840, DOI 10.1177/0269215511432018; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; De Bie S. E., 1987, STANDAARDVRAGEN 1987; De Ridder DT, 2004, CISS HANDLEIDING; Deno M, 2012, PSYCHO-ONCOLOGY, V21, P144, DOI 10.1002/pon.1877; Devlin NJ, 2007, EQ 5D VALUE SETS INV; Devonport TJ, 2006, SOC BEHAV PERSONAL, V34, P127, DOI 10.2224/sbp.2006.34.2.127; Dumont C, 2004, J HEAD TRAUMA REHAB, V19, P431, DOI 10.1097/00001199-200411000-00002; Endler NS, 1990, COPING INVENTORY STR; EuroQol Group, MEAS SELF REP POP HL; Finset A, 2000, BRAIN INJURY, V14, P887; Fugl-Meye KS., 1991, CLIN REHABIL, V5, P25, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105]; Gregorio GW, 2014, J HEAD TRAUMA REHAB, V29, pE43, DOI 10.1097/HTR.0b013e318292fb00; Gregorio GW, 2014, J HEAD TRAUMA REHAB, V29, pE30, DOI 10.1097/HTR.0b013e31828f93db; Hellstrom K, 2003, J REHABIL MED, V35, P202, DOI 10.1080/16501970310000836; Herrmann M, 2000, DISABIL REHABIL, V22, P539, DOI 10.1080/096382800416788; Hesselink AE, 2004, QUAL LIFE RES, V13, P509, DOI 10.1023/B:QURE.0000018474.14094.2f; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Jones F, 2009, CLIN REHABIL, V23, P522, DOI 10.1177/0269215508101749; Kristofferzon ML, 2011, SCAND J CARING SCI, V25, P476, DOI 10.1111/j.1471-6712.2010.00851.x; Levin C, 2007, PSYCHOL ADDICT BEHAV, V21, P108, DOI 10.1037/0893-164X.21.1.108; Lowe R, 2008, PSYCHOL HEALTH, V23, P155, DOI 10.1080/14768320601139160; Miller C, 1998, ANXIETY STRESS COPIN, V11, P311, DOI 10.1080/10615809808248317; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; Post MWM, 2003, CLIN REHABIL, V17, P548, DOI 10.1191/0269215503cr648oa; Prati G, 2010, ANXIETY STRESS COPIN, V23, P463, DOI 10.1080/10615800903431699; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Trouillet R, 2009, AGING MENT HEALTH, V13, P357, DOI 10.1080/13607860802626223; Visser-Meily A, 2005, CEREBROVASC DIS, V20, P443, DOI 10.1159/000088983; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; Wolters Gregorio G, 2012, BRAIN IMPAIR, V13, P167; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; [No title captured]	47	28	28	0	40	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2014	95	12					2327	2334		10.1016/j.apmr.2014.06.006			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	AW0AY	WOS:000345954000013	24973499	Green Published			2022-02-06	
J	Dekker, SE; Bambakidis, T; Sillesen, M; Liu, BL; Johnson, CN; Jin, G; Li, YQ; Alam, HB				Dekker, Simone E.; Bambakidis, Ted; Sillesen, Martin; Liu, Baoling; Johnson, Craig N.; Jin, Guang; Li, Yongqing; Alam, Hasan B.			Effect of pharmacologic resuscitation on the brain gene expression profiles in a swine model of traumatic brain injury and hemorrhage	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	44th Annual Meeting of the Western-Trauma-Association	MAR 02-07, 2014	Steamboat Springs, CO	Western Trauma Assoc		Injury; brain; genes; apoptosis; hemorrhage; pigs	VALPROIC ACID; PRO-SURVIVAL; INFLAMMATION; APOPTOSIS; CELLS; IDENTIFICATION; ACETYLATION; ACTIVATION; INHIBITOR; PHENOTYPE	BACKGROUND: We have previously shown that addition of valproic acid (VPA; a histone deacetylase inhibitor) to hetastarch (Hextend [HEX]) resuscitation significantly decreases lesion size in a swine model of traumatic brain injury (TBI) and hemorrhagic shock (HS). However, the precise mechanisms have not been well defined. As VPA is a transcriptional modulator, the aim of this study was to investigate its effect on brain gene expression profiles. METHODS: Swine were subjected to controlled TBI and HS (40% blood volume), kept in shock for 2 hours, and resuscitated with HEX or HEX + VPA (n = 5 per group). Following 6 hours of observation, brain RNA was isolated, and gene expression profiles were measured using a Porcine Gene ST 1.1 microarray (Affymetrix, Santa Clara, CA). Pathway analysis was done using network analysis tools Gene Ontology, Ingenuity Pathway Analysis, and Parametric Gene Set Enrichment Analysis. Real-time polymerase chain reaction was used to verify the key microarray findings. RESULTS: A total of 1,668 probe sets mapping to 370 known genes were differentially expressed between the HEX and HEX + VPA groups. Expression of apoptotic genes differed between groups, and biologic function analysis predicted a significant downregulation of apoptosis (p = 1.29 x 10(-12)), cell death (p = 8.46 x 10(-12)), and necrosis (p = 9.07 x 10(-11)). Pathway analysis indicated a significant modulation of pathways involved in cell signaling, dendritic cell response, and the complement system. CONCLUSION: This is the first high-throughput analysis of cerebral gene profiling following TBI + HS. It shows that treatment with VPA significantly alters early transcription of pathways related to cell survival, which may explain its neuroprotective effects. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Dekker, Simone E.; Bambakidis, Ted; Liu, Baoling; Jin, Guang; Li, Yongqing; Alam, Hasan B.] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA; [Dekker, Simone E.] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, Inst Cardiovasc Res, Amsterdam, Netherlands; [Sillesen, Martin] Harvard Univ, Sch Med, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care,Massac, Boston, MA 02115 USA; [Sillesen, Martin] Copenhagen Univ Hosp, Dept Surg, Hillerod, Denmark; [Johnson, Craig N.] Univ Michigan, Biomed Res Core Facil, DNA Sequencing Core Lab, Ann Arbor, MI 48109 USA		Alam, HB (corresponding author), Univ Michigan Hosp, Dept Surg, 2920 Taubman Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Johnson, Craig/0000-0003-3955-7394; Sillesen, Martin/0000-0001-9494-5475			Affymetrix, 2008, GENECHIP 3 IVT EXPR; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Finkelstein RA, 2010, J SURG RES, V163, P146, DOI 10.1016/j.jss.2010.04.024; Gene Ontology, NEUR LIGHT POL ASS S; Gene Ontology, SIN OC HOM HOM 4 ASS; Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008-5472.CAN-07-2531; Holt SV, 2012, BRIT J CANCER, V106, P858, DOI 10.1038/bjc.2012.8; Ichiba T, 2003, BLOOD, V102, P763, DOI 10.1182/blood-2002-09-2748; Ichiyama T, 2000, BRAIN RES, V857, P246, DOI 10.1016/S0006-8993(99)02439-7; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Klintman D, 2005, ANN SURG, V242, P830, DOI 10.1097/01.sla.0000189132.86878.f7; Kochanek AR, 2012, J SURG RES, V176, P185, DOI 10.1016/j.jss.2011.06.007; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Li P, 2010, SCIENCE, V329, P85, DOI 10.1126/science.1188063; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Li YQ, 2012, SURGERY, V152, P455, DOI 10.1016/j.surg.2012.06.036; Li YQ, 2012, ADV EXP MED BIOL, V710, P107, DOI 10.1007/978-1-4419-5638-5_11; Liu HL, 2014, BIOMED PHARMACOTHER, V68, P267, DOI 10.1016/j.biopha.2013.12.003; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manson J, 2012, BRIT J SURG, V99, P12, DOI 10.1002/bjs.7717; McLachlan JL, 2005, BBA-MOL BASIS DIS, V1741, P271, DOI 10.1016/j.bbadis.2005.03.007; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Ritchie ME, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-261; Rutella S, 2006, BLOOD, V108, P218, DOI 10.1182/blood-2005-08-3141; Smyth GK., 2004, STAT APPL GENET MOL, V3, pArticl, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Suganuma T, 2012, J MOL CELL BIOL, V4, P348, DOI 10.1093/jmcb/mjs043; Wang ZW, 2012, ONCOTARGET, V3, P1294; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4	36	28	29	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2014	77	6					906	912		10.1097/TA.0000000000000345			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	AU8EE	WOS:000345828500027	25051383				2022-02-06	
J	Mannix, R; Berglass, J; Berkner, J; Moleus, P; Qiu, JH; Jantzie, LL; Meehan, WP; Stanley, RM; Robinson, S				Mannix, Rebekah; Berglass, Jacqueline; Berkner, Justin; Moleus, Philippe; Qiu, Jianhua; Jantzie, Lauren L.; Meehan, William P., III; Stanley, Rachel M.; Robinson, Shenandoah			Sex differences in the effect of progesterone after controlled cortical impact in adolescent mice: a preliminary study	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; progesterone; adolescent; sex differences; neuroprotection	TRAUMATIC BRAIN-INJURY; INFLAMMATORY RESPONSE; IMMATURE; EDEMA; EXPRESSION; RAT	Object. While progesterone has been well studied in experimental models of adult traumatic brain injury (TBI), it has not been evaluated in pediatric models. The study of promising interventions in pediatric TBI is important because children have the highest public health burden of such injuries. Therapies that are beneficial in adults may not necessarily be effective in the pediatric population. The purpose of this study was to evaluate whether progesterone treatment improves outcomes in an experimental model of pediatric TBI. Methods. The authors determined whether progesterone administered after controlled cortical impact (CCI) improves functional and histopathological outcomes in 4-week-old mice. Both male and female mice (58 mice total) were included in this study, as the majority of prior studies have used only male and/or reproductively senescent females. Mice were randomized to treatment with progesterone or vehicle and to CCI injury or sham injury. Motor (wire grip test) and memory (Morris water maze) testing were performed to determine the effect of progesterone on TBI. Lesion volume was also assessed. Results. Compared with their vehicle-treated counterparts, the progesterone-treated CCI-injured male mice had improved motor performance (p < 0.001). In contrast, progesterone-treated CCI-injured female mice had a worse performance than their vehicle-treated counterparts (p = 0.001). Progesterone treatment had no effect on spatial memory performance or lesion volume in injured male or female mice. Conclusions. These data suggest a sex-specific effect of progesterone treatment after CCI in adolescent mice and could inform clinical trials in children.	[Mannix, Rebekah; Berglass, Jacqueline; Berkner, Justin; Moleus, Philippe; Qiu, Jianhua; Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA 02115 USA; [Jantzie, Lauren L.; Robinson, Shenandoah] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Mannix, Rebekah; Qiu, Jianhua; Jantzie, Lauren L.; Meehan, William P., III; Robinson, Shenandoah] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Stanley, Rachel M.] Univ Michigan Hlth Syst, Dept Emergency Med, Ann Arbor, MI USA		Mannix, R (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	rebekah.mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		HRSAUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [U03 MC 00003]; Baby Alex Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103400] Funding Source: NIH RePORTER	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Drs. Mannix and Stanley were supported by Grant HRSA U03 MC 00003, and Drs. Mannix and Robinson were supported by The Baby Alex Foundation.	Adelson PD, 1998, ACT NEUR S, V71, P104; Behl C, 1997, EUR J NEUROSCI, V9, P912, DOI 10.1111/j.1460-9568.1997.tb01442.x; Bergeron R, 1996, J NEUROSCI, V16, P1193; CAMPAGNE MV, 1994, J CEREBR BLOOD F MET, V14, P1011, DOI 10.1038/jcbfm.1994.133; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Concas A, 1999, EUR J PHARMACOL, V375, P225, DOI 10.1016/S0014-2999(99)00232-0; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Ma JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub3; Mannix RC, 2011, J NEUROTRAUM, V28, P1855, DOI 10.1089/neu.2011.1759; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Uysal N, 2013, TURK NEUROSURG, V23, P129, DOI 10.5137/1019-5149.JTN.5582-11.1; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	25	28	28	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2014	121	6					1337	1341		10.3171/2014.8.JNS14715			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AU3CP	WOS:000345490700006	25280093	Green Accepted			2022-02-06	
J	Knutsen, AK; Magrath, E; McEntee, JE; Xing, FX; Prince, JL; Bayly, PV; Butman, JA; Pham, DL				Knutsen, Andrew K.; Magrath, Elizabeth; McEntee, Julie E.; Xing, Fangxu; Prince, Jerry L.; Bayly, Philip V.; Butman, John A.; Pham, Dzung L.			Improved measurement of brain deformation during mild head acceleration using a novel tagged MRI sequence	JOURNAL OF BIOMECHANICS			English	Article						Magnetic resonance imaging (MRD); Acceleration; Deformation; Strain; Traumatic brain injury (TBI)	MAGNETIC-RESONANCE ELASTOGRAPHY; SINGLE IMAGE PLANE; MOTION TRACKING; ALZHEIMERS-DISEASE; MYOCARDIAL MOTION; IN-VIVO; INJURY; TISSUE; TRAUMA; IMPACT	In vivo measurements of human brain deformation during mild acceleration are needed to help validate computational models of traumatic brain injury and to understand the factors that govern the mechanical response of the brain. Tagged magnetic resonance imaging is a powerful, noninvasive technique to track tissue motion in vivo which has been used to quantify brain deformation in live human subjects. However, these prior studies required from 72 to 144 head rotations to generate deformation data for a single image slice, precluding its use to investigate the entire brain in a single subject. Here, a novel method is introduced that significantly reduces temporal variability in the acquisition and improves the accuracy of displacement estimates. Optimization of the acquisition parameters in a gelatin phantom and three human subjects leads to a reduction in the number of rotations from 72 to 144 to as few as 8 for a single image slice. The ability to estimate accurate, well-resolved, fields of displacement and strain in far fewer repetitions will enable comprehensive studies of acceleration-induced deformation throughout the human brain in vivo. (C) 2014 Elsevier Ltd. All rights reserved.	[Knutsen, Andrew K.; Magrath, Elizabeth; McEntee, Julie E.; Butman, John A.; Pham, Dzung L.] Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, Bethesda, MD 20892 USA; [Xing, Fangxu; Prince, Jerry L.] Johns Hopkins Univ, Dept Elect & Comp Engn, Baltimore, MD 21218 USA; [Prince, Jerry L.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Bayly, Philip V.] Dept Mech Engn & Mat Sci, St Louis, MO USA; [Bayly, Philip V.] Washington Univ, Dept Biomed Engn, St Louis, MO USA; [Butman, John A.] NIH, Dept Diagnost Radiol, Ctr Clin, Bethesda, MD 20892 USA		Knutsen, AK (corresponding author), Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, 9000 Rockville Pike,Bldg 10-B1N264B, Bethesda, MD 20892 USA.	andrew.knutsen@nih.gov	Pham, Dzung/AAR-8263-2020; Butman, John/J-2780-2013; Butman, John A/A-2694-2008	Butman, John/0000-0002-1547-9195; Bayly, Philip/0000-0003-4303-0704; Xing, Fangxu/0000-0002-0517-0952	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	We would like to thank the seven participants for their time and effort. We would also like to acknowledge Bruce Pritchard, Danny Trang, and George Do Id at the NINDS Machine Shop for their assistance. Support for this work included funding from Department of Defense in the Center for Neuroscience and Regenerative Medicine and from the National Institutes of Health (R01-NS055951).	Abd-Elmoniem KZ, 2007, MAGN RESON MED, V58, P92, DOI 10.1002/mrm.21267; Abd-Elmoniem KZ, 2005, LECT NOTES COMPUT SC, V3565, P639; Augenstein KF, 2005, J BIOMECH ENG-T ASME, V127, P148, DOI 10.1115/1.1835360; AXEL L, 1989, RADIOLOGY, V171, P841, DOI 10.1148/radiology.171.3.2717762; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bayly PV, 2008, J MECH PHYS SOLIDS, V56, P2036, DOI 10.1016/j.jmps.2007.10.012; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Clayton EH, 2012, J R SOC INTERFACE, V9, P2899, DOI 10.1098/rsif.2012.0325; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Feng Y, 2013, J MECH BEHAV BIOMED, V23, P117, DOI 10.1016/j.jmbbm.2013.04.007; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu XF, 2012, IEEE T MED IMAGING, V31, P326, DOI 10.1109/TMI.2011.2168825; Liu XF, 2010, IEEE T MED IMAGING, V29, P1560, DOI 10.1109/TMI.2010.2045509; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; MOULTON MJ, 1995, J BIOMECH, V28, P935, DOI 10.1016/0021-9290(94)00144-S; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Osman NF, 1999, MAGN RESON MED, V42, P1048; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Taber LA, 2004, NONLINEAR THEORY ELA; Van Houten EEW, 1999, MAGNET RESON MED, V42, P779, DOI 10.1002/(SICI)1522-2594(199910)42:4<779::AID-MRM21>3.3.CO;2-Q; Vappou J, 2008, J BIOMECH, V41, P2954, DOI 10.1016/j.jbiomech.2008.07.034; ZERHOUNI EA, 1988, RADIOLOGY, V169, P59, DOI 10.1148/radiology.169.1.3420283; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhong XD, 2010, MAGN RESON MED, V64, P1089, DOI 10.1002/mrm.22503	34	28	28	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	NOV 7	2014	47	14					3475	3481		10.1016/j.jbiomech.2014.09.010			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	AT8KZ	WOS:000345183500007	25287113	Green Accepted			2022-02-06	
J	Gabriel, WM; Rowe, AS				Gabriel, Wendy M.; Rowe, A. Shaun			Long-Term Comparison of GOS-E Scores in Patients Treated With Phenytoin or Levetiracetam for Posttraumatic Seizure Prophylaxis After Traumatic Brain Injury	ANNALS OF PHARMACOTHERAPY			English	Article						phenytoin; levetiracetam; traumatic brain injury; seizure; post-traumatic seizure prophylaxis; Glasgow Outcome Scale-Extended; GOS-E; Keppra; fosphenytoin	PREVENTION; CARE	Background: Much debate exists on the optimal medication for posttraumatic seizure prophylaxis after traumatic brain injury (TBI). There is some evidence that levetiracetam (LEV) could be neuroprotective and provide long-term benefits in this patient population. Objective: The primary objective was to compare the Glasgow Outcome Scale Extended (GOS-E) 6 months or more after severe TBI. Secondary end points were presence of early seizures (0 to 7 days post-TBI) or late seizures (8 days post-TBI to phone interview), use of anticonvulsant medication when interviewed, medication-related hospital complications, and a summary of phenytoin (PHT) and LEV dosing regimens. Methods: This was an IRB-approved, single-center, prospective cohort analysis. Patients were identified by cross-referencing a list of patients receiving LEV or PHT, with a list of patients with ICD-9 code consistent with TBI. After study inclusion, patients were contacted by telephone, and the GOS-E was administered. Data for secondary end points were gathered by retrospective chart review. Results: In all, 19 patients were included in the final analysis. There was no difference in the GOS-E score assessed >= 6 months after injury (5.07 +/- 1.69 vs 5.60 +/- 2.07, P = 0.58). There was no difference in the secondary end points of early seizures (P = 0.53) or late seizures (P = 0.53). However, the PHT group experienced a higher rate of hospital days with recorded fever (0.20 +/- 0.22 vs 0 0; P = 0.014). Conclusions: Long-term functional outcome in patients who experienced a TBI was not affected by treatment with PHT or LEV; however, patients treated with PHT had a higher incidence of fever during hospitalization.	[Gabriel, Wendy M.] Univ Tennessee, Med Ctr, Knoxville, TN USA; [Gabriel, Wendy M.; Rowe, A. Shaun] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Knoxville, TN 37996 USA		Rowe, AS (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Knoxville Campus,1924 Alcoa Highway,Box 117, Knoxville, TN 37996 USA.	arowe@uthsc.edu					Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Cook AM, 2013, NEUROCRIT CARE, V19, P210, DOI 10.1007/s12028-013-9837-y; Fuller KL, 2013, EPILEPSIA, V54, P45, DOI 10.1111/j.1528-1167.2012.03563.x; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Klein P, 2012, EPILEPSY BEHAV, V24, P457, DOI 10.1016/j.yebeh.2012.05.011; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; Rowe AS, 2014, PHARMACOTHERAPY, V34, P396, DOI 10.1002/phar.1374; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Scheinfeld Noah, 2003, Dermatol Online J, V9, P6; Schierhout G, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000173; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Taylor S, 2011, NEUROCRIT CARE, V15, P80, DOI 10.1007/s12028-010-9341-6; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Walia Kulbir S, 2004, Pain Pract, V4, P194, DOI 10.1111/j.1533-2500.2004.04304.x; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30	21	28	30	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	NOV	2014	48	11					1440	1444		10.1177/1060028014549013			5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	AR1PE	WOS:000343356300005	25169249				2022-02-06	
J	Lv, QS; Lan, WY; Sun, WS; Ye, RD; Fan, XB; Ma, MM; Yin, Q; Jiang, YJ; Xu, GL; Dai, JW; Guo, RB; Liu, XF				Lv, Qiushi; Lan, Wenya; Sun, Wenshan; Ye, Ruidong; Fan, Xiaobing; Ma, Minmin; Yin, Qin; Jiang, Yongjun; Xu, Gelin; Dai, Jianwu; Guo, Ruibing; Liu, Xinfeng			Intranasal nerve growth factor attenuates tau phosphorylation in brain after traumatic brain injury in rats	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; Nerve growth factor; Tau; Intranasal; GSK-3 beta; IL-1 beta	NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; A-BETA; MICE; NEURODEGENERATION; PATHOLOGY; ACCUMULATION; DELIVERY; NEURONS; IMPACT	Traumatic brain injury (TBI) is a considerable cause of mild cognitive impairment and dementia. Intranasal administration of nerve growth factor (NGF) has previously been found to improve cognitive function after TBI, but the mechanism remains unclear. This study aimed to investigate the effects of intranasal NGF on the tau hyperphosphorylation following TBI. A modified Feeney's weight-drop model was used to induce TBI. Rats were randomly divided into control group, TBI group, TBI + NGF group, TBI + PDTC group and TBI + IL-1ra group. Rats in TBI + NGF group were administered with NGF (5 mu g/d) for 3 d before surgery. Hyperphosphorylated tau protein was remarkable in the peri-contusional cortex area with TBI. Both western blotting and immunostaining results displayed intranasal pretreatment of NGF significantly reduced tau phosphorylation. To evaluate the underlying mechanism, the levels of glycogen synthase kinase 3 beta (GSK-3 beta), interleukin-1 beta (IL-1 beta), and the DNA binding activity of nuclear factor-kappa B (NF-kappa B) were assayed. NGF markedly inhibited GSK-3 beta. NGF also reduced TBI-induced elevation of IL-1 beta and NF-kappa B DNA binding activity. Furthermore, PDTC and IL-1ra were injected to prove a potential signaling pathway among NF-kappa B, IL-1 beta and GSK-3 beta. Taken together, these findings demonstrated that intranasal NGF could effectively attenuate the hyperphosphorylation of tau after TBI, which might involve an integrated signaling pathway related to NF-kappa B. (C) 2014 Published by Elsevier B.V.	[Lv, Qiushi; Lan, Wenya; Sun, Wenshan; Ye, Ruidong; Fan, Xiaobing; Ma, Minmin; Yin, Qin; Jiang, Yongjun; Xu, Gelin; Guo, Ruibing; Liu, Xinfeng] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurol, Nanjing 210002, Jiangsu, Peoples R China; [Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China		Guo, RB (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurol, Nanjing 210002, Jiangsu, Peoples R China.	grb1995@163.com; xfliu2@viop.163.com		Xu, Gelin/0000-0002-6194-0341	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31171016, 31100784, 31200817]; Jinling Hospital Foundation [2012005]	This work was supported by the grant from National Natural Science Foundation of China (#31171016, 31100784 and 31200817) and Jinling Hospital Foundation (#2012005).	Albeck D, 2003, BRAIN RES, V967, P306, DOI 10.1016/S0006-8993(03)02272-8; Calissano P, 2010, DEV NEUROBIOL, V70, P372, DOI 10.1002/dneu.20759; Capsoni S, 2002, P NATL ACAD SCI USA, V99, P12432, DOI 10.1073/pnas.192442999; Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010; DEGARCINI EM, 1986, BIOCHEM BIOPH RES CO, V141, P790, DOI 10.1016/S0006-291X(86)80242-X; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Fan Xin-ying, 2012, Zhonghua Yi Xue Za Zhi, V92, P2366; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Guo R, 2012, J MED POSTGRAD, V5, P471; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jiang Y, 2011, NEUROSCIENCE, V172, P398, DOI 10.1016/j.neuroscience.2010.10.054; Jiang YJ, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/372423; Jiang YJ, 2011, EXPERT OPIN DRUG DEL, V8, P623, DOI 10.1517/17425247.2011.566267; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Li YK, 2003, J NEUROSCI, V23, P1605; Liu XF, 2001, J NEUROL SCI, V187, P91, DOI 10.1016/S0022-510X(01)00532-9; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Lv QS, 2013, BRAIN RES, V1493, P80, DOI 10.1016/j.brainres.2012.11.028; Mandelkow E, 2007, BRAIN PATHOL, V17, P83, DOI 10.1111/j.1750-3639.2007.00053.x; McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medeiros R, 2011, CNS NEUROSCI THER, V17, P514, DOI 10.1111/j.1755-5949.2010.00177.x; Metcalfe MJ, 2010, MT SINAI J MED, V77, P50, DOI 10.1002/msj.20163; Obulesu M, 2011, NEUROCHEM RES, V36, P1329, DOI 10.1007/s11064-011-0475-5; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Vossel KA, 2010, SCIENCE, V330, P198, DOI 10.1126/science.1194653; Williams BJ, 2006, PROG NEUROBIOL, V80, P114, DOI 10.1016/j.pneurobio.2006.09.001; Yamaguchi H, 1996, ACTA NEUROPATHOL, V92, P232, DOI 10.1007/s004010050513; Ye R, 2011, NEUROSCIENCE, V178, P169, DOI 10.1016/j.neuroscience.2011.01.007; Ye RD, 2012, CRIT CARE MED, V40, P2685, DOI 10.1097/CCM.0b013e318258fb90; Ye X, 2011, NEUROSCIENCE, V190, P339, DOI 10.1016/j.neuroscience.2011.06.004; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Zhu J, 2012, NEUROSCIENCE, V202, P342, DOI 10.1016/j.neuroscience.2011.11.070	44	28	29	1	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2014	345	1-2					48	55		10.1016/j.jns.2014.06.037			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR6JJ	WOS:000343689600007	25128470				2022-02-06	
J	Snyder, AR; Bauer, RM				Snyder, Aliyah R.; Bauer, Russell M.		Hlth IMPACTS Florida Network	A Normative Study of the Sport Concussion Assessment Tool (SCAT2) in Children and Adolescents	CLINICAL NEUROPSYCHOLOGIST			English	Article						SCAT2; Standardized Assessment of Concussion; BESS.; Child; Concussion assessment; Balance Error Scoring System; Adolescent; SAC; Sport-related concussion	TRAUMATIC BRAIN-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; STANDARDIZED ASSESSMENT; CONSENSUS STATEMENT; SYMPTOMS; AGE; MANAGEMENT; ZURICH; SEX	Recent clinical practice parameters encourage systematic use of concussion surveillance/management tools that evaluate participating athletes at baseline and after concussion. Office-based tools (Sports Concussion Assessment Tool; SCAT2) require accurate baseline assessment to maximize utility but no normative data exist for children on the SCAT2, limiting identification of "normal" or "impaired" score ranges. The purpose of this study was to develop child and adolescent baseline norms for the SCAT2 to provide reference values for different age groups. A community-based approach was implemented to compile baseline performance data on the SCAT2 in 761 children aged 9 to 18 to create age- and sex-graded norms. Findings indicate a significant age effect on SCAT2 performance such that older adolescents and teenagers produced higher (better) total scores than younger children (ages 9 to 11) driven by age differences on individual components measuring cognition (SAC), postural stability (BESS), and symptom report. Females endorsed greater numbers of symptoms at baseline than males. Normative data tables are presented. Findings support the SCAT2 as a useful clinical tool for assessing baseline functioning in teenagers, but suggest clinical utility may be limited in children under age 11. Follow-up studies after incident concussion are needed to confirm this assumption.	[Snyder, Aliyah R.; Bauer, Russell M.] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32610 USA; Univ Florida, Clin & Translat Sci Inst, Jacksonville, FL 32209 USA; [Hlth IMPACTS Florida Network] Florida State Univ, Coll Med, Clin Res Network, Tallahassee, FL 32306 USA		Snyder, AR (corresponding author), Univ Florida, POB 100165, Gainesville, FL 32610 USA.	aliyahsnyder@phhp.ufl.edu	Meijer, Anna/K-5118-2016; Snyder, Aliyah/AAT-6250-2020	Snyder, Aliyah/0000-0003-1185-7424	State of Florida [NCATS UL1 RR029890-03S3]; NIH/NCATS Clinical and Translational Science AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000064]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR000066, UL1TR000064] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029890] Funding Source: NIH RePORTER	This work was supported by State of Florida under Grant number NCATS UL1 RR029890-03S3; NIH/NCATS Clinical and Translational Science Award to the University of Florida under Grant number UL1 TR000064.	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faul M, 2010, TRAUMATIC BRAIN INJU; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; Mayfield R. M., 2013, BRIT J SPORT MED, V47, pe1; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Steindl R, 2006, DEV MED CHILD NEUROL, V48, P477, DOI 10.1017/S0012162206001022; Storrow AB, 1997, AM J EMERG MED, V15, P700, DOI 10.1016/S0735-6757(97)90190-X; VanWijk CMTG, 1997, SOC SCI MED, V45, P231, DOI 10.1016/S0277-9536(96)00340-1	33	28	28	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	OCT 3	2014	28	7					1091	1103		10.1080/13854046.2014.952667			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AR2MK	WOS:000343421300002	25244434	Green Accepted			2022-02-06	
J	Donaldson, L; Li, B; Cusimano, MD				Donaldson, Laura; Li, Bing; Cusimano, Michael D.			Economic burden of time lost due to injury in NHL hockey players	INJURY PREVENTION			English	Article							LEAGUE PLAYERS; CONCUSSIONS; VIOLENCE	Objective To determine the economic burden of salary costs lost due to injury in the National Hockey League (NHL). Methods All NHL players who engaged in at least one regular season game during the 2009-2010 to 2011-2012 seasons comprised the study population. We performed a retrospective cross-sectional analysis of publically available media sources to collect injury and salary data. Outcome measurements were games missed during regular season play due to hockey-related injury and lost salary. Results A total of 50.9% of all NHL players missed at least one game within a season of play, and injuries represented a total salary cost of approximately US$ 218 million per year. Concussions alone amounted to a salary loss of US$ 42.8 million a year. Head/neck injuries and leg/foot injuries were the most expensive in terms of overall cost, while head/neck and shoulder injuries had the highest mean cost. Conclusions NHL players commonly miss time due to injury, which creates a substantial burden in lost salary costs.	[Donaldson, Laura; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada; [Donaldson, Laura; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Donaldson, Laura; Cusimano, Michael D.] Canadian Brain Injury & Violence Res Team, Toronto, ON, Canada; [Li, Bing] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5B 1W8, Canada		Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation; University of Toronto Faculty of Medicine CREMS funding	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research no. TIR-103946, the Ontario Neurotrauma Foundation, as well as University of Toronto Faculty of Medicine CREMS funding.	[Anonymous], 2011, THN COM; [Anonymous], 2012, NHL CONCUSSIONS PUT; [Anonymous], 2011, CANADIANS HOCKEY FAN; [Anonymous], 2010, NATIONAL HOCKEY LEAG; [Anonymous], 2011, NATIONAL HOCKEY LEAG; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Daly B, 2012, CONCUSSION CLAIMS WO; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Haisken-DeNew JP, 2008, RUHR ECONOMIC PAPERS, V47, P1; Hutchison MG, 2015, BRIT J SPORT MED, V49, P552, DOI 10.1136/bjsports-2013-092235; Jones JCH, 1996, AM J ECON SOCIOL, V55, P231, DOI 10.1111/j.1536-7150.1996.tb03203.x; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Monette M, 2012, CAN MED ASSOC J, V184, pE641, DOI 10.1503/cmaj.109-4244; Orchard J., 2001, INT SPORT MED J, V2, P1; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Paul RJ, 2003, AM J ECON SOCIOL, V62, P345, DOI 10.1111/1536-7150.t01-2-00003; Schoalts D, 2011, NHL WONT EVEN CONSID; Stuart MJ, 2000, AM SOC TEST MATER, V1341, P19, DOI 10.1520/STP15224S; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X	21	28	28	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	OCT	2014	20	5								10.1136/injuryprev-2013-041016			3	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	AQ0SL	WOS:000342492900012	24446078	Green Accepted			2022-02-06	
J	Khailova, LS; Silachev, DN; Rokitskaya, TI; Avetisyan, AV; Lyamsaev, KG; Severina, II; Il'yasova, TM; Gulyaev, MV; Dedukhova, VI; Trendeleva, TA; Plotnikov, EY; Zvyagilskaya, RA; Chernyak, BV; Zorov, DB; Antonenko, YN; Skulachev, VP				Khailova, Ljudmila S.; Silachev, Denis N.; Rokitskaya, Tatyana I.; Avetisyan, Armine V.; Lyamsaev, Konstantin G.; Severina, Irma I.; Il'yasova, Tatyana M.; Gulyaev, Mikhail V.; Dedukhova, Vera I.; Trendeleva, Tatyana A.; Plotnikov, Egor Y.; Zvyagilskaya, Renata A.; Chernyak, Boris V.; Zorov, Dmitry B.; Antonenko, Yuri N.; Skulachev, Vladimir P.			A short-chain alkyl derivative of Rhodamine 19 acts as a mild uncoupler of mitochondria and a neuroprotector	BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS			English	Article						Mitochondria; Mild uncoupler; Protonophore; Rhodamine; Membrane potential	TRAUMATIC BRAIN-INJURY; NEURONAL DEATH; OXIDATIVE-PHOSPHORYLATION; PENETRATING CATIONS; PROTEIN-2 PROTECTS; PROTON TRANSPORT; FATTY-ACIDS; MECHANISM; OXYGEN; ISCHEMIA	Limited uncoupling of oxidative phosphorylation is known to be-beneficial in various laboratory models of diseases. The search for cationic uncouplers is promising as their protonophorous effect is self-limiting because these uncouplers lower membrane potential which is the driving force for their accumulation in mitochondria. In this work, the penetrating cation Rhodamine 19 butyl ester (C(4)R1) was found to decrease membrane potential and to stimulate respiration of mitochondria, appearing to be a stronger uncoupler than its more hydrophobic analog Rhodamine 19 dodecyl ester (C(12)R1). Surprisingly, C(12)R1 increased H+ conductance of artificial bilayer lipid membranes or induced mitochondria swelling in potassium acetate with valinomycin at concentrations lower than C(4)R1. This paradox might be explained by involvement of mitochondrial proteins in the uncoupling action of C(4)R1. In experiments with HeLa cells, C(4)R1 rapidly and selectively accumulated in mitochondria and stimulated oligomycin-sensitive respiration as a mild uncoupler. C(4)R1 was effective in preventing oxidative stress induced by brain ischemia and reperfusion in rats: it suppressed stroke-induced brain swelling and prevented the decline in neurological status more effectively than C(12)R1. Thus, C(4)R1 seems to be a promising example of a mild uncoupler efficient in treatment of brain pathologies related to oxidative stress. (C) 2014 Elsevier B.V. All rights reserved.	[Khailova, Ljudmila S.; Silachev, Denis N.; Rokitskaya, Tatyana I.; Avetisyan, Armine V.; Lyamsaev, Konstantin G.; Severina, Irma I.; Il'yasova, Tatyana M.; Dedukhova, Vera I.; Plotnikov, Egor Y.; Chernyak, Boris V.; Zorov, Dmitry B.; Antonenko, Yuri N.; Skulachev, Vladimir P.] Moscow MV Lomonosov State Univ, Belozersky Inst Phys Chem Biol, Moscow 119991, Russia; [Khailova, Ljudmila S.; Silachev, Denis N.; Rokitskaya, Tatyana I.; Avetisyan, Armine V.; Lyamsaev, Konstantin G.; Severina, Irma I.; Il'yasova, Tatyana M.; Dedukhova, Vera I.; Plotnikov, Egor Y.; Zvyagilskaya, Renata A.; Chernyak, Boris V.; Zorov, Dmitry B.; Antonenko, Yuri N.; Skulachev, Vladimir P.] Moscow MV Lomonosov State Univ, Inst Mitoengn, Moscow 119991, Russia; [Skulachev, Vladimir P.] Moscow MV Lomonosov State Univ, Fac Bioengn & Bioinformat, Moscow 119991, Russia; [Gulyaev, Mikhail V.] Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow 117192, Russia; [Trendeleva, Tatyana A.; Zvyagilskaya, Renata A.] Russian Acad Sci, AN Bach Inst Biochem, Moscow 119071, Russia		Antonenko, YN (corresponding author), Moscow MV Lomonosov State Univ, Belozersky Inst Phys Chem Biol, Moscow 119991, Russia.	antonen@genebee.msu.ru; skulach@belozersky.msu.ru	Chernyak, Boris V/D-9917-2012; Zorov, Dmitry B./AAB-1738-2019; Plotnikov, Egor Y/F-8592-2019; Antonenko, Yuri N/K-1323-2013; Avetisyan, Armine/O-2426-2014; Rokitskaya, Tatyana/J-3541-2013; Lyamzaev, Konstantin/D-3405-2012; Silachev, Denis/ABE-8515-2020; Gulyaev, Mikhail/A-6163-2014; Silachev, Denis N/C-9464-2012	Chernyak, Boris V/0000-0003-1523-0864; Zorov, Dmitry B./0000-0003-0863-8490; Plotnikov, Egor Y/0000-0003-2838-3704; Lyamzaev, Konstantin/0000-0001-9921-8031; Gulyaev, Mikhail/0000-0003-4684-2484; Silachev, Denis/0000-0003-0581-9755; Rokitskaya, Tatyana/0000-0002-7719-1875; Avetisyan, Armine/0000-0002-3882-2013; Skulachev, Vladimir/0000-0001-5141-7517	Russian Foundation for Basic ResearchRussian Foundation for Basic Research (RFBR) [12-04-00199, 13-04-01530, 12-04-31970, 14-04-00300, 14-94-00542]; Institute of Mitoengineering, Moscow State University; RSFRussian Science Foundation (RSF) [14-15-00107, 14-15-00147, 14-24-00107]; Grant of the President of Russia [MK-2508.2014.4]; Russian Science FoundationRussian Science Foundation (RSF) [14-15-00107, 14-15-00147, 14-24-00107] Funding Source: Russian Science Foundation	The authors thank Dr. Elena Kotova and Dr. Lev Yaguzhinsky for valuable comments and Dr. Elena Omarova for technical assistance. This work was supported in part by the Russian Foundation for Basic Research grants 12-04-00199,13-04-01530, 12-04-31970, 14-04-00300, and 14-94-00542 and the Institute of Mitoengineering, Moscow State University. RSF grants 14-15-00107, 14-15-00147, 14-24-00107 and Grant of the President of Russia MK-2508.2014.4.	ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Antonenko YN, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1273, DOI 10.1134/S0006297908120018; Antonenko YN, 2012, J BIOENERG BIOMEMBR, V44, P453, DOI 10.1007/s10863-012-9449-9; Antonenko YN, 2011, J BIOL CHEM, V286, P17831, DOI 10.1074/jbc.M110.212837; Arnold S, 2012, ADV EXP MED BIOL, V748, P305, DOI 10.1007/978-1-4614-3573-0_13; BARONE FC, 1991, BRAIN RES BULL, V26, P285, DOI 10.1016/0361-9230(91)90240-K; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Conti B, 2005, J NEUROCHEM, V93, P493, DOI 10.1111/j.1471-4159.2005.03052.x; Cunha FM, 2011, CURR DRUG TARGETS, V12, P783; Duchen MR, 2012, PFLUG ARCH EUR J PHY, V464, P111, DOI 10.1007/s00424-012-1112-0; DUGAN LL, 1995, J NEUROSCI, V15, P6377; GARLID KD, 1983, J BIOL CHEM, V258, P7974; GEAR ARL, 1974, J BIOL CHEM, V249, P3628; Grundlingh J, 2011, J MED TOXICOL, V7, P205, DOI 10.1007/s13181-011-0162-6; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Jolkkonen J, 2000, EUR J PHARMACOL, V400, P211, DOI 10.1016/S0014-2999(00)00409-X; Kadenbach B, 2010, BBA-GEN SUBJECTS, V1800, P205, DOI 10.1016/j.bbagen.2009.04.019; Kaim G, 1999, EMBO J, V18, P4118, DOI 10.1093/emboj/18.15.4118; Korde AS, 2005, J NEUROTRAUM, V22, P1142, DOI 10.1089/neu.2005.22.1142; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Lardy H., 1967, METHOD ENZYMOL, V10, P94, DOI [DOI 10.1016/0076-6879(67)10018-9, 10.1016/0076-6879(67)10018-9]; LARIS PC, 1975, BIOCHIM BIOPHYS ACTA, V376, P415, DOI 10.1016/0005-2728(75)90163-2; Lou PH, 2007, BIOCHEM J, V407, P129, DOI 10.1042/BJ20070606; Maragos WF, 2003, BRAIN RES, V966, P312, DOI 10.1016/S0006-8993(02)04225-7; Martel C, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/213403; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Perevoshchikova IV, 2008, BBA-BIOMEMBRANES, V1778, P2182, DOI 10.1016/j.bbamem.2008.04.008; Plotnikov EY, 2012, BIOCHEMISTRY-MOSCOW+, V77, P1029, DOI 10.1134/S0006297912090106; Rokitskaya TI, 2013, EUR BIOPHYS J BIOPHY, V42, P477, DOI 10.1007/s00249-013-0898-9; Rokitskaya TI, 2010, BBA-BIOMEMBRANES, V1798, P1698, DOI 10.1016/j.bbamem.2010.05.018; Rupprecht A, 2010, BIOPHYS J, V98, P1503, DOI 10.1016/j.bpj.2009.12.4301; Schonfeld P, 2000, FEBS LETT, V471, P108, DOI 10.1016/S0014-5793(00)01376-4; Severin FF, 2010, P NATL ACAD SCI USA, V107, P663, DOI 10.1073/pnas.0910216107; Silachev DN, 2009, B EXP BIOL MED+, V147, P269, DOI 10.1007/s10517-009-0489-z; Silachev DN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051553; SKULACHEV V. P., 1968, CURR MOD BIOL, V2, P98; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; STARKOV AA, 1994, FEBS LETT, V355, P305, DOI 10.1016/0014-5793(94)01211-3; Strom JO, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-41; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Wu YN, 2011, BRAIN RES, V1395, P86, DOI 10.1016/j.brainres.2011.04.032; YAGUZHINSKY LS, 1973, J BIOENERG, V5, P163, DOI 10.1007/BF01648987	51	28	34	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0005-2728	1879-2650		BBA-BIOENERGETICS	Biochim. Biophys. Acta-Bioenerg.	OCT	2014	1837	10					1739	1747		10.1016/j.bbabio.2014.07.006			9	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	AP7RA	WOS:000342273200017	25038514	Bronze			2022-02-06	
J	Lu, XP; Chen-Roetling, J; Regan, RF				Lu, Xiangping; Chen-Roetling, Jing; Regan, Raymond F.			Systemic hemin therapy attenuates blood-brain barrier disruption after intracerebral hemorrhage	NEUROBIOLOGY OF DISEASE			English	Article						Heme; Heme oxygenase; Preconditioning; Stroke	OXYGENASE-1 INDUCTION; TRANSCRIPTION FACTORS; PROTECTS; KIDNEY; INJURY; HEME-OXYGENASE-1; HEMOGLOBIN; EDEMA; RAT; TRANSDUCTION	Injury to the blood-brain barrier (BBB) is a key feature of intracerebral hemorrhage (ICH) and may contribute to perihematomal cell injury. Pretreatment with the heme oxygenase (HO)-1 inducer hemin improves barrier function and neurological outcome in experimental models of traumatic and ischemic CNS injury. Since hemin is already in clinical use to treat acute porphyrias, this translational study was designed to test its effect on BBB function when initiated after ICH in two mouse models. At a dose similar to those used in most preconditioning studies (26 mg/kg i.p.), post-hemorrhage treatment with hemin reduced parenchymal extravasation of Evans blue by about three-quarters in both the blood injection and collagenase ICH models. Similar efficacy was observed when treatment was begun at 1 or 3 h. At the lower dose that is currently in clinical use (4 mg/kg beginning at 3 h), hemin also improved barrier function in both models, as assessed by both Evans blue and FITC-dextran leakage; however, it was somewhat less potent, reducing Evans blue leakage by about half. This dose was nevertheless sufficient to attenuate striatal cell loss and accelerate neurological recovery. Consistent with prior observations, striatal HO-1 expression was increased by hemin, and was localized to perivascular cells. These results suggest that hemin may be an effective therapy for ICH with a clinically relevant time window. Further study of the repurposing of this old drug seems warranted. (C) 2014 Elsevier Inc. All rights reserved.	[Lu, Xiangping; Chen-Roetling, Jing; Regan, Raymond F.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA		Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1025 Walnut St,Coll Bldg,Room 813, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS079500]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079500] Funding Source: NIH RePORTER	This study was supported by a grant from the National Institutes of Health (NS079500) to R.F.R.	Abraham NG, 2003, J CELL BIOCHEM, V90, P1098, DOI 10.1002/jcb.10736; Anderson KE, 2005, ANN INTERN MED, V142, P439, DOI 10.7326/0003-4819-142-6-200503150-00010; Attuwaybi BO, 2004, J SURG RES, V118, P53, DOI 10.1016/j.jss.2004.01.010; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Belcher JD, 2006, J CLIN INVEST, V116, P808, DOI 10.1172/JCI26857; BUNN HF, 1968, J BIOL CHEM, V243, P465; Chen LF, 2011, J NEUROSURG, V114, P1159, DOI 10.3171/2010.10.JNS10861; Chen-Roetling J, 2013, J NEUROSCI METH, V216, P128, DOI 10.1016/j.jneumeth.2013.03.025; Chen-Roetling J, 2012, TRANSL STROKE RES, V3, P452, DOI 10.1007/s12975-012-0195-4; Chok Mohammed Koussai, 2009, Inflammation & Allergy Drug Targets, V8, P252; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; Correa-Costa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049569; Demirogullari B, 2006, NEPHRON EXP NEPHROL, V103, P1, DOI 10.1159/000090113; Desbuards N, 2009, NEPHRON EXP NEPHROL, V113, pE35, DOI 10.1159/000228081; DHAR GJ, 1978, ACTA MED SCAND, V203, P437; Habtezion A, 2011, GUT, V60, P671, DOI 10.1136/gut.2010.217208; Hangaishi M, 2000, BIOCHEM BIOPH RES CO, V279, P582, DOI 10.1006/bbrc.2000.3973; Holzen JP, 2008, J SURG RES, V148, P126, DOI 10.1016/j.jss.2007.10.007; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Jadhav A, 2009, AM J PHYSIOL-RENAL, V296, pF521, DOI 10.1152/ajprenal.00510.2007; Kang K, 2013, SHOCK, V40, P136, DOI 10.1097/SHK.0b013e31829d23f5; Keep RF, 2008, ACT NEUR S, V105, P73; Kim JH, 2006, J AM SOC NEPHROL, V17, P1373, DOI 10.1681/ASN.2005091001; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; Li RC, 2009, J CEREBR BLOOD F MET, V29, P953, DOI 10.1038/jcbfm.2009.19; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; LINDEN IB, 1987, J PHARM PHARMACOL, V39, P96, DOI 10.1111/j.2042-7158.1987.tb06952.x; Lindenblatt N, 2004, ARTERIOSCL THROM VAS, V24, P601, DOI 10.1161/01.ATV.0000118279.74056.8a; Liu DZ, 2008, NEUROBIOL DIS, V30, P201, DOI 10.1016/j.nbd.2008.01.006; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; Mense SM, 2006, CELL RES, V16, P681, DOI 10.1038/sj.cr.7310086; Nakamura T, 2004, J CEREBR BLOOD F MET, V24, P487, DOI 10.1097/00004647-200405000-00002; Ogawa T, 2011, J CEREBR BLOOD F MET, V31, P2231, DOI 10.1038/jcbfm.2011.87; Ono S, 2002, J NEUROSURG, V96, P1094, DOI 10.3171/jns.2002.96.6.1094; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Robinson SR, 2009, REDOX REP, V14, P228, DOI 10.1179/135100009X12525712409931; Suzuki H, 1999, J CLIN INVEST, V104, P59, DOI 10.1172/JCI5357; Takizawa S, 1998, J CEREBR BLOOD F MET, V18, P559, DOI 10.1097/00004647-199805000-00011; TENHUNEN R, 1987, J PHARM PHARMACOL, V39, P780, DOI 10.1111/j.2042-7158.1987.tb05119.x; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xue H, 2007, WORLD J GASTROENTERO, V13, P5384, DOI 10.3748/wjg.v13.i40.5384; Yamauchi T, 2004, J NEUROTRAUM, V21, P1017, DOI 10.1089/0897715041651042; Zhang B, 2008, ANESTHESIOLOGY, V109, P260, DOI 10.1097/ALN.0b013e31817f5c2e; Zhong WW, 2010, J PEDIATR GASTR NUTR, V50, P132, DOI 10.1097/MPG.0b013e3181c61591	49	28	29	1	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	OCT	2014	70						245	251		10.1016/j.nbd.2014.06.005			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN6FW	WOS:000340691400023	24952361	Green Accepted			2022-02-06	
J	Rodriguez, CLR; Szu, JI; Eberle, MM; Wang, Y; Hsu, MS; Binder, DK; Park, BH				Rodriguez, Carissa L. R.; Szu, Jenny I.; Eberle, Melissa M.; Wang, Yan; Hsu, Mike S.; Binder, Devin K.; Park, B. Hyle			Decreased light attenuation in cerebral cortex during cerebral edema detected using optical coherence tomography	NEUROPHOTONICS			English	Article						cerebral edema; optical coherence tomography; brain swelling	BLOOD-FLOW; BRAIN EDEMA; REAL-TIME; SPEED	Cerebral edema develops in response to a variety of conditions, including traumatic brain injury and stroke, and contributes to the poor prognosis associated with these injuries. This study examines the use of optical coherence tomography (OCT) for detecting cerebral edema in vivo. Three-dimensional imaging of an in vivo water intoxication model in mice was performed using a spectral-domain OCT system centered at 1300 nm. The change in attenuation coefficient was calculated and cerebral blood flow was analyzed using Doppler OCT techniques. We found that the average attenuation coefficient in the cerebral cortex decreased over time as edema progressed. The initial decrease began within minutes of inducing cerebral edema and a maximum decrease of 8% was observed by the end of the experiment. Additionally, cerebral blood flow slowed during late-stage edema. Analysis of local regions revealed the same trend at various locations in the brain, consistent with the global nature of the cerebral edema model used in this study. These results demonstrate that OCT is capable of detecting in vivo optical changes occurring due to cerebral edema and highlights the potential of OCT for precise spatiotemporal detection of cerebral edema. (C) The Authors.	[Rodriguez, Carissa L. R.; Eberle, Melissa M.; Park, B. Hyle] Univ Calif Riverside, Dept Bioengn, 900 Univ Ave, Riverside, CA 92521 USA; [Szu, Jenny I.; Hsu, Mike S.; Binder, Devin K.] Univ Calif Riverside, Div Biomed Sci, Sch Med, Riverside, CA 92521 USA; [Wang, Yan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Wang, Yan] Harvard Med Sch, Pulm & Crit Care Unit, Boston, MA 02114 USA; [Hsu, Mike S.; Binder, Devin K.] Umbrella Neurotechnol, Irvine, CA 92620 USA		Park, BH (corresponding author), Univ Calif Riverside, Dept Bioengn, 900 Univ Ave, Riverside, CA 92521 USA.	hylepark@engr.ucr.edu		Wang, Yan/0000-0002-6401-7464	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R00EB007241] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R00 EB007241] Funding Source: Medline		Chen ZP, 1997, OPT LETT, V22, P1119, DOI 10.1364/OL.22.001119; Fujimoto JG, 2003, NAT BIOTECHNOL, V21, P1361, DOI 10.1038/nbt892; Gill AS, 2011, J NEUROSURG, V114, P470, DOI 10.3171/2010.2.JNS091017; Harlow G, 2013, I S BIOMED IMAGING, P910; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; OLSON JE, 1990, ANN EMERG MED, V19, P1113, DOI 10.1016/S0196-0644(05)81514-8; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Rabinstein AA, 2006, NEUROLOGIST, V12, P59, DOI 10.1097/01.nrl.0000186810.62736.f0; Szu JI, 2012, JOVE-J VIS EXP, DOI 10.3791/50053; Thiagarajah JR, 2005, J NEUROSCI RES, V80, P293, DOI 10.1002/jnr.20439; Vermeer KA, 2014, BIOMED OPT EXPRESS, V5, P322, DOI 10.1364/BOE.5.000322; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Wang Y, 2012, OPT EXPRESS, V20, P14797, DOI 10.1364/OE.20.014797; Weed L., 1919, AM J PHYSIOL, V73, P194; Westphal V, 2002, OPT LETT, V27, P34, DOI 10.1364/OL.27.000034; White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490; Zhao YH, 2000, OPT LETT, V25, P114, DOI 10.1364/OL.25.000114	19	28	30	0	1	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	2329-423X	2329-4248		NEUROPHOTONICS	Neurophotonics	OCT-DEC	2014	1	2							025004	10.1117/1.NPh.1.2.025004			7	Neurosciences; Optics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Optics	V45SP	WOS:000209836600006	25674578	Green Published, hybrid, Green Accepted			2022-02-06	
J	Ryan, ME; Palasis, S; Saigal, G; Singer, AD; Karmazyn, B; Dempsey, ME; Dillman, JR; Dory, CE; Garber, M; Hayes, LL; Iyer, RS; Mazzola, CA; Raske, ME; Rice, HE; Rigsby, CK; Sierzenski, PR; Strouse, PJ; Westra, SJ; Wootton-Gorges, SL; Coley, BD				Ryan, Maura E.; Palasis, Susan; Saigal, Gaurav; Singer, Adam D.; Karmazyn, Boaz; Dempsey, Molly E.; Dillman, Jonathan R.; Dory, Christopher E.; Garber, Matthew; Hayes, Laura L.; Iyer, Ramesh S.; Mazzola, Catherine A.; Raske, Molly E.; Rice, Henry E.; Rigsby, Cynthia K.; Sierzenski, Paul R.; Strouse, Peter J.; Westra, Sjirk J.; Wootton-Gorges, Sandra L.; Coley, Brian D.			ACR Appropriateness Criteria Head Trauma-Child	JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY			English	Article						Appropriateness criteria; head trauma; nonaccidental injury; pediatric; CT; MRI	MAGNETIC-RESONANCE SPECTROSCOPY; PEDIATRIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; CERVICAL-SPINE; NEUROBEHAVIORAL OUTCOMES; INTRACRANIAL INJURY; RADIATION-EXPOSURE; UNIQUE FEATURES; DECISION RULE; SKULL	Head trauma is a frequent indication for cranial imaging in children. CT is considered the first line of study for suspected intracranial injury because of its wide availability and rapid detection of acute hemorrhage. However, the majority of childhood head injuries occur without neurologic complications, and particular consideration should be given to the greater risks of ionizing radiation in young patients in the decision to use CT for those with mild head trauma. MRI can detect traumatic complications without radiation, but often requires sedation in children, owing to the examination length and motion sensitivity, which limits rapid assessment and exposes the patient to potential anesthesia risks. MRI may be helpful in patients with suspected nonaccidental trauma, with which axonal shear injury and ischemia are more common and documentation is critical, as well as in those whose clinical status is discordant with CT findings. Advanced techniques, such as diffusion tensor imaging, may identify changes occult by standard imaging, but data are currently insufficient to support routine clinical use. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.	[Ryan, Maura E.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Palasis, Susan] Childrens Hosp Atlanta, Atlanta, GA USA; [Saigal, Gaurav] Univ Miami Hlth Syst, Miami, FL USA; [Singer, Adam D.] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA; [Karmazyn, Boaz] Indiana Univ, James Whitcomb Riley Hosp Children, Indianapolis, IN USA; [Dempsey, Molly E.] Texas Scottish Rite Hosp Crippled Children, Dallas, TX USA; [Dillman, Jonathan R.; Strouse, Peter J.] CS Mott Childrens Hosp, Ann Arbor, MI USA; [Dory, Christopher E.] Childrens Hosp, San Diego, CA USA; [Garber, Matthew] Div Gen & Hosp Pediat, Columbia, SC USA; [Garber, Matthew] Amer Acad Pediat, Elk Grove Village, IL USA; [Hayes, Laura L.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Iyer, Ramesh S.] Seattle Childrens Hosp, Seattle, WA USA; [Mazzola, Catherine A.] New Jersey Pediat Neurosci Inst, Morristown, NJ USA; [Mazzola, Catherine A.] Amer Assoc Neurol Surg, Rolling Meadows, IL USA; [Mazzola, Catherine A.] Illinois Congress Neurol Surg, Schaumburg, IL USA; [Raske, Molly E.] St Paul Radiol PA, St Paul, MN USA; [Rice, Henry E.] Duke Univ, Med Ctr, Durham, NC USA; [Rice, Henry E.] Amer Pediat Surg Assoc, Deerfield, IL USA; [Rigsby, Cynthia K.] Childrens Mem Hosp, Chicago, IL 60614 USA; [Sierzenski, Paul R.] Christiana Care Hlth Syst, Newark, DE USA; [Sierzenski, Paul R.] Amer Coll Emergency Phys, Irving, TX USA; [Westra, Sjirk J.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Wootton-Gorges, Sandra L.] Univ Calif Davis, Sacramento, CA 95817 USA; [Coley, Brian D.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA		Ryan, ME (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, 225 E Chicago Ave, Chicago, IL 60611 USA.	mryan@luriechildrens.org	Hayes, Laura L./AAS-5574-2020; Rigsby, Cynthia/AAC-9351-2019; Palasis, Susan/AAD-3550-2019	Coley, Brian/0000-0003-0354-4727; Rigsby, Cynthia/0000-0003-1224-2333	Siemens Medical	Boaz K Karmazyn, MD, receives grant funding for research into CT dose and dose reduction techniques from Siemens Medical, but does not have any ownership in or receive any direct compensation from Siemens Medical.	Amodio J, 2005, PEDIATR RADIOL, V35, P1113, DOI 10.1007/s00247-005-1503-x; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Ashwal S, 2010, DEV NEUROSCI-BASEL, V32, P343, DOI 10.1159/000316801; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bainbridge J, 2012, BRIT J RADIOL, V85, P183, DOI 10.1259/bjr/56169980; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brown RL, 2001, J PEDIATR SURG, V36, P1107, DOI 10.1053/jpsu.2001.25665; Chen CY, 1996, RADIOLOGY, V201, P389, DOI 10.1148/radiology.201.2.8888229; Teruel GC, 2007, J PEDIATR SURG, V42, P1903, DOI 10.1016/j.jpedsurg.2007.07.020; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Datta S, 2005, ARCH DIS CHILD, V90, P947, DOI 10.1136/adc.2002.021154; Davis PC, ACR APPROPRIATENESS; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Faul M, TRAUMATIC BRAIN INJU; Ghatan S, 2002, NEUROSURG CLIN N AM, V13, P227, DOI 10.1016/S1042-3680(01)00002-X; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Goshen E, 1996, NUCL MED COMMUN, V17, P418, DOI 10.1097/00006231-199605000-00011; Halley Michelle K, 2004, Pediatr Crit Care Med, V5, P230, DOI 10.1097/01.PCC.0000123543.40224.73; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P57; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jones TS, 2012, AM J SURG, V204, P7, DOI 10.1016/j.amjsurg.2011.07.015; Kadom N, 2014, PEDIATR RADIOL, V44, P839, DOI 10.1007/s00247-014-2874-7; Keiper MD, 1998, NEURORADIOLOGY, V40, P359, DOI 10.1007/s002340050599; Kemp AM, 2011, ARCH DIS CHILD, V96, P1103, DOI 10.1136/archdischild-2011-300630; Kemp AM, 2009, CLIN RADIOL, V64, P473, DOI 10.1016/j.crad.2008.11.011; Kopelman TR, 2011, J TRAUMA, V71, P559, DOI 10.1097/TA.0b013e318226eadd; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Mogbo KI, 1998, RADIOLOGY, V208, P521, DOI 10.1148/radiology.208.2.9680586; Mortazavi MM, 2011, CHILD NERV SYST, V27, P2045, DOI 10.1007/s00381-011-1409-x; Munson S, 2006, PEDIATRICS, V117, P1372, DOI 10.1542/peds.2005-0826; Nakahara K, 2011, J TRAUMA, V70, P180, DOI 10.1097/TA.0b013e3181d76737; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Pinto PS, 2012, J NEUROIMAGING, V22, pe18, DOI 10.1111/j.1552-6569.2011.00690.x; Pinto PS, 2012, J NEUROIMAGING, V22, pe1, DOI 10.1111/j.1552-6569.2011.00688.x; Prabhu SP, 2013, PEDIATR RADIOL, V43, P575, DOI 10.1007/s00247-012-2546-4; Reed MJ, 2005, ARCH DIS CHILD, V90, P859, DOI 10.1136/adc.2004.053603; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schachar JL, 2011, PEDIATR RADIOL, V41, P971, DOI 10.1007/s00247-011-2032-4; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Sepelyak K, 2010, EUR J PEDIATR, V169, P557, DOI 10.1007/s00431-009-1066-1; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Stence NV, 2011, CURR TREAT OPTION NE, V13, P636, DOI 10.1007/s11940-011-0149-2; Tavarez MM, 2012, CURR OPIN PEDIATR, V24, P307, DOI 10.1097/MOP.0b013e3283531ce6; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Willis AP, 2008, CLIN RADIOL, V63, P165, DOI 10.1016/j.crad.2007.05.027; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213	68	28	28	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1546-1440			J AM COLL RADIOL	J. Am. Coll. Radiol.	OCT	2014	11	10					939	947		10.1016/j.jacr.2014.07.017			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	AQ1FY	WOS:000342528500008	25164794				2022-02-06	
J	Wang, X; Wei, XE; Li, MH; Li, WB; Zhou, YJ; Zhang, B; Li, YH				Wang, Xuan; Wei, Xiao-Er; Li, Ming-Hua; Li, Wen-Bin; Zhou, Ya-Jun; Zhang, Bin; Li, Yue-Hua			Microbleeds on susceptibility-weighted MRI in depressive and non-depressive patients after mild traumatic brain injury	NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; Depression; Magnetic resonance imaging; Susceptibility-weighted imaging; Microbleeds	DIFFUSE AXONAL INJURY; MAJOR DEPRESSION; DISORDERS; LESIONS	The aim of this study was to explore the relationship between abnormality on susceptibility-weighted imaging (SWI) and newly-developed depression after mild traumatic brain injury. The study registered 200 patients with closed TBI and normal finding at CT and conventional MRI. All patients underwent MRI including conventional MR sequences and SWI. The number and volume of microbleed lesions were semi-automatically outlined and manually counted. All patients were followed up with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IV) within 1 year after TBI. The difference in microbleed lesions on SWI was compared between the depressive and non-depressive groups. The depressive group had a higher rate of abnormality on SWI than did the non-depressive group (p < 0.001). Among patients that had exhibited microbleed lesions, the number and volume of lesions were greater in the depressive group than the non-depressive group (both p < 0.001). These differences in numbers and volume of lesions were found only at the frontal, parietal and temporal lobes (all p < 0.001). Among patients that had exhibited microbleed lesions, the number and volume of lesions in other areas were not significantly different between the depressive and non-depressive groups (all p > 0.05). In conclusion, SWI was useful to identify the microbleed lesions after mild TBI. The distribution range and location of microbleed lesions were correlated with depression after TBI.	[Wang, Xuan; Wei, Xiao-Er; Li, Ming-Hua; Li, Wen-Bin; Li, Yue-Hua] Shanghai Jiao Tong Univ, Inst Diagnost & Intervent Radiol, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China; [Zhou, Ya-Jun; Zhang, Bin] Shanghai Jiao Tong Univ, Dept Neurol, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China		Li, YH (corresponding author), Shanghai Jiao Tong Univ, Inst Diagnost & Intervent Radiol, Affiliated Peoples Hosp 6, 600 Yi Shan Rd, Shanghai 200233, Peoples R China.	xvanwang@163.com			National Natural Scientific Fund of ChinaNational Natural Science Foundation of China (NSFC) [81000609, 81271540, 81301213]	This study is supported by the National Natural Scientific Fund of China (No. 81000609, No. 81271540 and No. 81301213).	Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; First M., 2002, BIOMETRICS RES; Freire MAM, 2012, W INDIAN MED J, V61, P751; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Maller JJ, 2014, HUM BRAIN MAPP, V35, P227, DOI 10.1002/hbm.22171; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Ohara Kazuyuki, 2004, Seishin Shinkeigaku Zasshi, V106, P458; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Rao V, 2012, J NEUROPSYCH CLIN N, V24, P309, DOI 10.1176/appi.neuropsych.11080188; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P231, DOI 10.1176/appi.neuropsych.22.2.231; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050706; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	28	28	28	1	12	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	OCT	2014	35	10					1533	1539		10.1007/s10072-014-1788-3			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AP9YP	WOS:000342438400006	24740482				2022-02-06	
J	Salentijn, EG; Peerdeman, SM; Boffano, P; van den Bergh, B; Forouzanfar, T				Salentijn, Erik G.; Peerdeman, Saskia M.; Boffano, Paolo; van den Bergh, Bart; Forouzanfar, Tymour			A ten-year analysis of the traumatic maxillofacial and brain injury patient in Amsterdam: Incidence and aetiology	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article						Maxillofacial trauma; Neurotrauma; Brain injury; Incidence; Aetiology; Treatment	CLOSED-HEAD INJURIES; FACIAL FRACTURES; MANAGEMENT; SEVERITY; IMPACT	In the literature it is questioned if the presence of maxillofacial trauma is associated with the presence of brain injury. The aim of this study is to present a 10-year retrospective study of the incidence and aetiology of maxillofacial trauma associated with brain injury that required both oral and maxillofacial and neurosurgical intervention during the same hospital stay. Forty-seven patients from a population of 579 trauma patients undergoing maxillofacial surgery were identified. The main cause of injury was road traffic collision, followed by falls. Interpersonal violence correlated less well with traumatic brain injury. Most of the patients were males, aged 20-39 years. Frontal sinus fractures were the most common maxillofacial fractures (21.9%) associated with neurosurgical input, followed by mandibular fractures and zygomatic complex fractures. In the general maxillofacial trauma population, frontal sinus fractures were only found in 2.2% of the cases. At presentation to the Emergency Department the majority of the patients were diagnosed with severe traumatic brain injury and a Marshall CT class 2. Intracranial pressure monitoring was the most common neurosurgical intervention, followed by reconstruction of a bone defect and haematoma evacuation. Although it is a small population, our data suggest that maxillofacial trauma does have an association with traumatic brain injury that requires neurosurgical intervention (8.14 In comparison with the overall maxillofacial trauma population, our results demonstrate that frontal sinus fractures are more commonly diagnosed in association with brain injury, most likely owing to the location of the impact of the trauma. In these cases the frontal sinus seems not specifically to act as a barrier to protect the brain. This report provides useful data concerning the joint management of oral and maxillofacial surgeons and neurosurgeons for the treatment of cranio-maxillofacial trauma and brain injury patients in Amsterdam. (C) 2014 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.	[Salentijn, Erik G.; Boffano, Paolo; van den Bergh, Bart; Forouzanfar, Tymour] Vrije Univ Amsterdam, Med Ctr, Dept Oral & Maxillofacial Surg Oral Pathol, Acad Ctr Dent Amsterdam ACTA, NL-1007 MB Amsterdam, Netherlands; [Peerdeman, Saskia M.] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, NL-1007 MB Amsterdam, Netherlands		Salentijn, EG (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Oral & Maxillofacial Surg Oral Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	e.salentijn@vumc.nl	Boffano, Paolo/J-1094-2016	Boffano, Paolo/0000-0002-0782-9933			Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Bogusiak K, 2010, J CRANIOFAC SURG, V21, P1018, DOI 10.1097/SCS.0b013e3181e62e47; BRANDT KE, 1991, J TRAUMA, V31, P15, DOI 10.1097/00005373-199101000-00003; Calderoni DR, 2011, J CRANIO MAXILL SURG, V39, P593, DOI 10.1016/j.jcms.2010.11.018; CHANG CJ, 1994, J TRAUMA, V37, P807, DOI 10.1097/00005373-199411000-00017; Chrcanovic BR, 2010, J TRAUMA, V69, pE73, DOI 10.1097/TA.0b013e3181cc847b; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; Fasola AO, 2003, DENT TRAUMATOL, V19, P2, DOI 10.1034/j.1600-9657.2003.00073.x; Forouzanfar T, 2013, J CRANIO MAXILL SURG, V41, P616, DOI 10.1016/j.jcms.2012.12.004; Gassner R, 2003, J CRANIO MAXILL SURG, V31, P51, DOI 10.1016/S1010-5182(02)00168-3; Giuliani G., 1997, Revue de Stomatologie et de Chirurgie Maxillo-Faciale, V98, P100; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Katzen JT, 2003, J TRAUMA, V54, P1026, DOI 10.1097/01.TA.0000066180.14666.8B; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; Lee KH, 2009, J ORAL MAXIL SURG, V67, P1878, DOI 10.1016/j.joms.2009.04.117; Lee Kai H., 2009, New Zealand Dental Journal, V105, P4; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; Lee TT, 1998, J TRAUMA, V44, P665, DOI 10.1097/00005373-199804000-00018; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Naveen Shankar A, 2011, J CRANIOMAXILLOFAC S, V40, P675; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Salentijn EG, 2013, J CRANIOMAXILLOFAC S; Salentijn EG, 2013, J CRANIO MAXILL SURG, V41, P630, DOI 10.1016/j.jcms.2012.11.043; Servadei F, 2002, ACT NEUR S, V81, P81; Singh Vibha, 2012, Natl J Maxillofac Surg, V3, P166, DOI 10.4103/0975-5950.111372; van Beek GJ, 1999, INT J ORAL MAX SURG, V28, P424, DOI 10.1016/S0901-5027(99)80055-1; van den Bergh B, 2011, J CRANIOMAXILLOFAC S, V40, pe165; Weider L, 1999, AM SURGEON, V65, P790	30	28	29	0	12	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1010-5182	1878-4119		J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	SEP	2014	42	6					705	710		10.1016/j.jcms.2013.12.008			6	Dentistry, Oral Surgery & Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine; Surgery	AO6LG	WOS:000341463000001	24703508				2022-02-06	
J	Williams, RM; Welch, CE; Weber, ML; Parsons, JT; McLeod, TCV				Williams, Richelle M.; Welch, Cailee E.; Weber, Michelle L.; Parsons, John T.; McLeod, Tamara C. Valovich			Athletic Trainers' Management Practices and Referral Patterns for Adolescent Athletes After Sport-Related Concussion	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						sport-related concussion; adolescent athletes; referral patterns; management practices	STATES HIGH-SCHOOL; EPIDEMIOLOGY	Background: Athletic trainers (ATs) play an important role in the evaluation, management, and referral of student-athletes after sport-related concussion. Understanding factors that influence ATs' patient care decisions is important to ensure best practices are followed. Purpose: To identify ATs' current concussion management practices and referral patterns for adolescent student-athletes after sport-related concussion as well as the factors associated with those practices. Study Design: Cross-sectional study. Methods: A total of 851 participants from a convenience sample of 3286 ATs employed in the secondary school setting (25.9% response rate) completed the Athletic Trainers' Beliefs, Attitudes, and Knowledge of Pediatric Athletes with Concussions (BAKPAC-AT) survey. The BAKPAC-AT consists of several questions to assess ATs' concussion management, referral practices, and established relationships with other health care professionals. Results: The majority of ATs had a written concussion policy (82.4%, n = 701) and standing orders approved by their directing physician (67.3%, n = 573); 75.1% (n = 639) of ATs conduct baseline testing, with the majority using computerized neurocognitive tests (71.2%, n = 606). Follow-up concussion testing was employed by 81.8% (n = 696). Years of certification (P = 0.049) and type of secondary school (P = 0.033) predicted ATs' use of baseline testing. Nearly half of the respondents (48.8%, n = 415) refer 100% of concussion cases to a physician. The most influential factors that lead to a referral were state law (40.3%, n = 343), personal preference (34.7%, n = 295), and school district policy (24.8%, n = 211). Conclusion: Of the ATs surveyed, most were engaged in baseline and follow-up testing, primarily with neurocognitive tests. Most ATs refer patients to physicians after concussion. While state regulation and personal preference were primary factors influencing referral decisions, it is unclear at what point of care the referral occurs.	[Williams, Richelle M.] Univ Michigan, Ann Arbor, MI 48109 USA; [Welch, Cailee E.; Weber, Michelle L.; McLeod, Tamara C. Valovich] AT Still Univ, Mesa, AZ USA; [Parsons, John T.] Natl Collegiate Athlet Assoc, Indianapolis, IN USA		Welch, CE (corresponding author), AT Still Univ, Dept Interdisciplinary Hlth Sci, 5850 East Still Circle, Mesa, AZ 85206 USA.	cwelch@atsu.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Williams, Richelle/0000-0003-4728-7443			Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Board of Certification for the Athletic Trainer, 2006, BOC STAND PROF PRACT; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Centers for Disease Control and Prevention, CONC PREV YOUTH; Diaz Anne L, 2013, NASN Sch Nurse, V28, P110; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greiner A. C., 2003, HLTH PROFESSIONS ED; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Lynall RC, 2013, J ATHL TRAINING, V48, P844, DOI 10.4085/1062-6050-48.6.04; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; Pennington N, 2010, J SCH NURS, V26, P26, DOI 10.1177/1059840509341881; Pew Health Professional Commission, CRIT CHALL REV HLTH; Williams RM, 2014, J ATHL TRAI IN PRESS	23	28	29	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	SEP-OCT	2014	6	5					434	439		10.1177/1941738114545612			6	Sport Sciences	Emerging Sources Citation Index (ESCI)	Sport Sciences	V20FU	WOS:000214873300010	25177421	Green Published			2022-02-06	
J	Zhang, DD; Li, H; Li, T; Zhou, ML; Hao, SY; Yan, HY; Yu, Z; Li, W; Li, KY; Hang, CH				Zhang, Dingding; Li, Hua; Li, Tao; Zhou, Mengliang; Hao, Shuangying; Yan, Huiying; Yu, Zhuang; Li, Wei; Li, Kuanyu; Hang, Chunhua			TLR4 inhibitor resatorvid provides neuroprotection in experimental traumatic brain injury: Implication in the treatment of human brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Toll-like receptor 4; Resatorvid; Apoptosis	NEURONAL DEATH; RECEPTOR 4; TAK-242; TAK1; RATS; PATHWAY; ACTIVATION; MICE	Toll-like receptor 4 (TLR4) is considered to play an important role in neuronal death in animal models and could be an important therapeutic target following traumatic brain injury (TBI). Resatorvid is a small molecule, commonly accepted to inhibit TLR4-mediated pathway. The purpose of this study was to investigate the neuroprotective effect of resatorvid after TBI. Our data revealed that inhibition of TLR4 by resatorvid attenuated the development of TBI in mouse model. And we found that resatorvid administration dramatically reduced neuronal apoptosis. To investigate the cellular mechanism, we evaluated the expression of transforming growth factor-beta-activated kinase 1 (TAK1), which plays a crucial role in TLR4 signal transduction pathway and is activated by phosphorylation in response to TBI. In addition, enzyme-linked immunosorbent assay was used to determine the expression of tumor necrosis factor-alpha (TNF-alpha) and interlukin-1 beta (IL-1 beta) at 24 h after injury. Our results showed that resatorvid treatment significantly reduced the protein levels of TAK1, p-TAK1, TNF-alpha, and IL-1 beta compared with vehicle treatment. Importantly, the delayed therapy (4 h post injury) once daily consecutively for 5 days ameliorated brain damage and improved neurological recovery, suggesting that this drug has a wide therapeutic time window. Clinically, we observed that TLR4 and TAK1 expression was significantly increased in human contusion specimens after TBI. These data provide an experimental rationale for the evaluation of TLR4 as a clinical target and therapeutic implication of resatorvid in human traumatic brain injury. (C) 2014 Elsevier Ltd. All rights reserved.	[Zhang, Dingding; Li, Hua; Li, Tao; Zhou, Mengliang; Yan, Huiying; Yu, Zhuang; Li, Wei; Hang, Chunhua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Hao, Shuangying; Li, Kuanyu] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing 210093, Jiangsu, Peoples R China		Li, KY (corresponding author), Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, 22 Hankou Rd, Nanjing 210093, Jiangsu, Peoples R China.	likuanyu@nju.edu.cn; hang_neurosurgery@163.com	Li, Kuanyu/AAL-2051-2020; Li, Wei/ABE-4301-2021	Li, Hua/0000-0001-5893-535X; Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170, 31071085, 31371060]; Nature Science Foundation of the Jiangsu Province, China [BK2010459]	This study was supported by the National Natural Science Foundation, China (Nos. 81171170, 31071085, 31371060) and the Nature Science Foundation of the Jiangsu Province, China (BK2010459).	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Ii M, 2006, MOL PHARMACOL, V69, P1288, DOI 10.1124/mol.105.019695; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kawamoto T, 2008, EUR J PHARMACOL, V584, P40, DOI 10.1016/j.ejphar.2008.01.026; Klatt AR, 2006, BIOMED PHARMACOTHER, V60, P55, DOI 10.1016/j.biopha.2005.08.007; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Li W, 2014, MOL NEUROBIOL, V49, P187, DOI 10.1007/s12035-013-8509-4; Maas AIR, 2004, ACT NEUR S, V89, P113; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Rice TW, 2010, CRIT CARE MED, V38, P1685, DOI 10.1097/CCM.0b013e3181e7c5c9; Sakurai H, 2012, TRENDS PHARMACOL SCI, V33, P522, DOI 10.1016/j.tips.2012.06.007; Sha T, 2007, EUR J PHARMACOL, V571, P231, DOI 10.1016/j.ejphar.2007.06.027; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Suzuki Y, 2012, SCI REP-UK, V2, DOI 10.1038/srep00896; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Vassar M. J., 2013, J NEUROTRAUMA; Wang YC, 2013, STROKE, V44, P2545, DOI 10.1161/STROKEAHA.113.001038; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	30	28	34	3	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	SEP	2014	75						11	18		10.1016/j.neuint.2014.05.003			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AN8JZ	WOS:000340851800002	24858944				2022-02-06	
J	Giacci, MK; Wheeler, L; Lovett, S; Dishington, E; Majda, B; Bartlett, CA; Thornton, E; Harford-Wright, E; Leonard, A; Vink, R; Harvey, AR; Provis, J; Dunlop, SA; Hart, NS; Hodgetts, S; Natoli, R; Van Den Heuvel, C; Fitzgerald, M				Giacci, Marcus K.; Wheeler, Lachlan; Lovett, Sarah; Dishington, Emma; Majda, Bernadette; Bartlett, Carole A.; Thornton, Emma; Harford-Wright, Elizabeth; Leonard, Anna; Vink, Robert; Harvey, Alan R.; Provis, Jan; Dunlop, Sarah A.; Hart, Nathan S.; Hodgetts, Stuart; Natoli, Riccardo; Van Den Heuvel, Corinna; Fitzgerald, Melinda			Differential Effects of 670 and 830 nm Red near Infrared Irradiation Therapy: A Comparative Study of Optic Nerve Injury, Retinal Degeneration, Traumatic Brain and Spinal Cord Injury	PLOS ONE			English	Article							LEVEL LASER THERAPY; CONTROLLED CORTICAL IMPACT; CYTOCHROME-C-OXIDASE; LIGHT THERAPY; SECONDARY DEGENERATION; IN-VIVO; ABSORPTION-MEASUREMENTS; FUNCTIONAL RECOVERY; OXIDATIVE DAMAGE; WHITE-MATTER	Red/near-infrared irradiation therapy (R/NIR-IT) delivered by laser or light-emitting diode (LED) has improved functional outcomes in a range of CNS injuries. However, translation of R/NIR-IT to the clinic for treatment of neurotrauma has been hampered by lack of comparative information regarding the degree of penetration of the delivered irradiation to the injury site and the optimal treatment parameters for different CNS injuries. We compared the treatment efficacy of R/NIR-IT at 670 nm and 830 nm, provided by narrow-band LED arrays adjusted to produce equal irradiance, in four in vivo rat models of CNS injury: partial optic nerve transection, light-induced retinal degeneration, traumatic brain injury (TBI) and spinal cord injury (SCI). The number of photons of 670 nm or 830 nm light reaching the SCI injury site was 6.6% and 11.3% of emitted light respectively. Treatment of rats with 670 nm R/NIR-IT following partial optic nerve transection significantly increased the number of visual responses at 7 days after injury (P <= 0.05); 830 nm R/NIR-IT was partially effective. 670 nm R/NIR-IT also significantly reduced reactive species and both 670 nm and 830 nm R/NIR-IT reduced hydroxynonenal immunoreactivity (P <= 0.05) in this model. Pre-treatment of light-induced retinal degeneration with 670 nm R/NIR-IT significantly reduced the number of Tunel+ cells and 8-hydroxyguanosine immunoreactivity (P <= 0.05); outcomes in 830 nm R/NIR-IT treated animals were not significantly different to controls. Treatment of fluid-percussion TBI with 670 nm or 830 nm R/NIR-IT did not result in improvements in motor or sensory function or lesion size at 7 days (P>0.05). Similarly, treatment of contusive SCI with 670 nm or 830 nm R/NIR-IT did not result in significant improvements in functional recovery or reduced cyst size at 28 days (P>0.05). Outcomes from this comparative study indicate that it will be necessary to optimise delivery devices, wavelength, intensity and duration of R/NIR-IT individually for different CNS injury types.	[Giacci, Marcus K.; Wheeler, Lachlan; Lovett, Sarah; Dishington, Emma; Majda, Bernadette; Bartlett, Carole A.; Harvey, Alan R.; Dunlop, Sarah A.; Hodgetts, Stuart; Fitzgerald, Melinda] Univ Western Australia, Crawley, WA 6009, Australia; [Giacci, Marcus K.; Bartlett, Carole A.; Dunlop, Sarah A.; Hart, Nathan S.; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Giacci, Marcus K.; Wheeler, Lachlan; Lovett, Sarah; Dishington, Emma; Majda, Bernadette; Harvey, Alan R.; Hodgetts, Stuart] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA 6009, Australia; [Thornton, Emma; Harford-Wright, Elizabeth; Leonard, Anna; Vink, Robert; Van Den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Adelaide, SA, Australia; [Provis, Jan; Natoli, Riccardo] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia; [Provis, Jan; Natoli, Riccardo] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; [Hart, Nathan S.] Univ Western Australia, Oceans Inst, Neuroecol Grp, Crawley, WA 6009, Australia		Fitzgerald, M (corresponding author), Univ Western Australia, Crawley, WA 6009, Australia.	lindy.fitzgerald@uwa.edu.au	Hart, Nathan S/B-8564-2011; Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019; Fitzgerald, Melinda/C-4235-2011; Provis, Jan/C-9529-2009	Hart, Nathan S/0000-0002-7289-9399; Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Fitzgerald, Melinda/0000-0002-4823-8179; , Corinna/0000-0003-0664-8935; Dunlop, Sarah/0000-0002-1306-3962; Provis, Jan/0000-0002-6405-2868; , Alan/0000-0002-2590-831X; Giacci, Marcus/0000-0002-8330-678X; Natoli, Riccardo/0000-0002-9350-0439; Hodgetts, Stuart/0000-0002-3318-0410	Neurotrauma Research Program (Western Australia); Road Trauma Trust Account; University of Western Australia; Western Australian State Government as part of a Western Australian Premiers Fellowship	This work was supported by the Neurotrauma Research Program (Western Australia) (http://www.nrp.org.au/). This project is funded through the Road Trauma Trust Account, but does not reflect views or recommendations of the Road Safety Council. NSH was funded by The University of Western Australia and The Western Australian State Government as part of a Western Australian Premiers Fellowship to Prof. Shaun Collin. No individuals employed or contracted by the funders (other than the named authors) played any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abler AS, 1996, RES COMMUN MOL PATH, V92, P177; Albarracin R, 2012, PHOTOCHEM PHOTOBIOL; Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664; Albarracin RS, 2012, ADV EXP MED BIOL, V723, P121, DOI 10.1007/978-1-4614-0631-0_17; Ando T, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.9.098002; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Aonuma H, 1999, JPN J OPHTHALMOL, V43, P171, DOI 10.1016/S0021-5155(99)00011-8; Back SA, 2005, ANN NEUROL, V58, P108, DOI 10.1002/ana.20530; Back SA, 1998, J NEUROSCI, V18, P6241; Ball KA, 2011, J PHOTOCH PHOTOBIO B, V102, P182, DOI 10.1016/j.jphotobiol.2010.12.002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI 10.1089/neu.2008-0870; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; Cummins N, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-98; Demidova-Rice TN, 2007, LASER SURG MED, V39, P706, DOI 10.1002/lsm.20549; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Fitzgerald M, 2013, REV NEUROSCIENCE, V24, P205, DOI 10.1515/revneuro-2012-0086; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023; Godinho MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069987; Gupta A, 2014, LASER MED SCI, V29, P257, DOI 10.1007/s10103-013-1319-0; Hacke W, 2013, TRANSCRANIAL LASER T; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEBEDA KM, 1994, NEUROSURGERY, V35, P720, DOI 10.1227/00006123-199410000-00019; Hodgetts SI, 2013, EXP NEUROL, V248, P343, DOI 10.1016/j.expneurol.2013.06.018; Hodgetts SI, 2013, CELL TRANSPLANT, V22, P393, DOI 10.3727/096368912X656081; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2008, PHOTOMED LASER SURG, V26, P593, DOI 10.1089/pho.2008.2246; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2012, EXPERT REV MED DEVIC, V9, P71, DOI 10.1586/ERD.11.64; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lenz P, 1999, APPL OPTICS, V38, P3662, DOI 10.1364/AO.38.003662; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Lim J, 2010, J PHOTOCH PHOTOBIO B, V99, P105, DOI 10.1016/j.jphotobiol.2010.03.002; Lim J, 2009, J BIOCHEM MOL TOXIC, V23, P1, DOI 10.1002/jbt.20257; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667; Mason MG, 2006, P NATL ACAD SCI USA, V103, P708, DOI 10.1073/pnas.0506562103; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Medalha CC, 2010, PHOTOMED LASER SURG, V28, P669, DOI 10.1089/pho.2009.2691; Metz GA, 2009, J VIS EXP; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; Moody DJ, 2005, SPECIFIC EXTINCTION; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Natoli R, 2010, MOL VIS, V16, P1801; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Peoples Cassandra, 2012, ISRN Neurol, V2012, P850150, DOI 10.5402/2012/850150; Qu C, 2010, ADV EXP MED BIOL, V664, P365, DOI 10.1007/978-1-4419-1399-9_42; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257; Sutherland JC, 2002, PHOTOCHEM PHOTOBIOL, V76, P164, DOI 10.1562/0031-8655(2002)076<0164:BEOPL>2.0.CO;2; Sykova E, 2008, NEUROCHEM INT, V52, P5, DOI 10.1016/j.neuint.2007.04.007; Szymanski CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066448; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	80	28	29	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2014	9	8							e104565	10.1371/journal.pone.0104565			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AR0CG	WOS:000343231900072	25105800	Green Published, gold			2022-02-06	
J	Gawryluk, JR; Mazerolle, EL; Beyea, SD; D'Arcy, RCN				Gawryluk, Jodie R.; Mazerolle, Erin L.; Beyea, Steven D.; D'Arcy, Ryan C. N.			Functional MRI activation in white matter during the Symbol Digit Modalities Test	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						neuroimaging; functional magnetic resonance imaging; white matter; Symbol Digit Modalities Test; neuropsychology	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; INTERHEMISPHERIC-TRANSFER; NEUROPSYCHOLOGICAL ASSESSMENT; CEREBROVASCULAR REACTIVITY; VISUOMOTOR INFORMATION; MOTION CORRECTION; AXONAL INJURY	Background: Recent evidence shows that functional magnetic resonance imaging (fMRI) can detect activation in white matter (WM). Such advances have important implications for understanding WM dysfunction. A key step in linking neuroimaging advances to the evaluation of clinical disorders is to examine whether WM activation can be detected at the individual level during clinical tests associated with WM function. We used an adapted Symbol Digit Modalities Test (SDMT) in a 4T fMRI study of healthy adults. Results: Results from 17 healthy individuals revealed WM activation in 88% of participants (15/17). The activation was in either the corpus callosum (anterior and/or posterior) or internal capsule (left and/or right). Conclusions: The findings link advances in fMRI to an established clinical test of WM function. Future work should focus on evaluating patients with WM dysfunction.	[Gawryluk, Jodie R.] Univ Victoria, Dept Psychol Neurosci, Victoria, BC, Canada; [Mazerolle, Erin L.] Univ Calgary, Fac Med, Dept Radiol, Calgary, AB, Canada; [Beyea, Steven D.] IWK Hlth Ctr, Biomed Translat Imaging Ctr, Halifax, NS, Canada; [D'Arcy, Ryan C. N.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada; [D'Arcy, Ryan C. N.] Surrey Mem Hosp, Fraser Hlth Author, Surrey, BC V3T 0H1, Canada		D'Arcy, RCN (corresponding author), Surrey Mem Hosp, Fraser Hlth Author, Suite 400,Cent City Tower 13450-102nd Ave, Surrey, BC V3T 0H1, Canada.	rdarcy@sfu.ca		Beyea, Steven/0000-0001-7851-0017; Gawryluk, Jodie/0000-0003-4924-7517	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; National Research Council; Nova Scotia Health Research Foundation; Killam Trusts	The authors thank C. Liu, D. McAllindon, and J. Quenneville, who assisted with data collection. This work was funded by the Natural Sciences and Engineering Research Council of Canada, the National Research Council, the Nova Scotia Health Research Foundation, and the Killam Trusts.	Alsop, 1999, P 7 ANN M INT SOC MA; Amato MP, 2010, MULT SCLER, V16, P1474, DOI 10.1177/1352458510380089; Andersson JL, 2007, TR07JA1 FMRIB FMRIB TECH REP TRO7J; Andersson JL, 2007, FMRIB TECH REP TRO7J FMRIB TECHNICAL REPO; ANZOLA GP, 1990, J NEUROL NEUROSUR PS, V53, P142, DOI 10.1136/jnnp.53.2.142; Barbaresi P, 2014, BRAIN BEHAV, V4, P317, DOI 10.1002/brb3.218; Baudewig J., 2008, P 14 ANN M ORG HUM B, P618; Black SE, 2007, BRAIN COGNITION, V63, P192, DOI 10.1016/j.bandc.2006.08.010; Brewer KD, 2009, NMR BIOMED, V22, P654, DOI 10.1002/nbm.1380; Chakravarty MM, 2009, HUM BRAIN MAPP, V30, P3574, DOI 10.1002/hbm.20780; Charil A, 2003, NEUROIMAGE, V19, P532, DOI 10.1016/S1053-8119(03)00117-4; Chiaravalloti ND, 2008, LANCET NEUROL, V7, P1139, DOI 10.1016/S1474-4422(08)70259-X; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V37, P31, DOI 10.1016/S0167-8760(00)00093-3; D'Arcy RCN, 2006, MAGN RESON MED, V55, P952, DOI 10.1002/mrm.20839; Ding ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082107; Driver I, 2010, NEUROIMAGE, V51, P274, DOI 10.1016/j.neuroimage.2009.12.113; Fabri M, 2011, BRAIN RES, V1370, P99, DOI 10.1016/j.brainres.2010.11.039; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Figley CR, 2011, EUR J NEUROSCI, V33, P577, DOI 10.1111/j.1460-9568.2010.07584.x; Forn C, 2009, NEUROSCI LETT, V456, P11, DOI 10.1016/j.neulet.2009.03.081; Fraser LM, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-91; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; Gawryluk JR, 2011, NEUROIMAGE, V54, P10, DOI 10.1016/j.neuroimage.2010.07.028; Gawryluk JR, 2009, NEUROIMAGE, V45, P83, DOI 10.1016/j.neuroimage.2008.11.005; Genova HM, 2009, J INT NEUROPSYCH SOC, V15, P383, DOI 10.1017/S1355617709090535; Helenius J, 2003, ACTA RADIOL, V44, P538, DOI 10.1034/j.1600-0455.2003.00104.x; Hoffmann S, 2007, CURR OPIN NEUROL, V20, P275, DOI 10.1097/WCO.0b013e32810c8e87; Iacoboni M, 2004, NEUROPSYCHOLOGIA, V42, P419, DOI 10.1016/j.neuropsychologia.2003.10.007; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kalsi AS, 2004, J ANAT, V204, P475, DOI 10.1111/j.0021-8782.2004.00288.x; Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Macey PM, 2003, RESP PHYSIOL NEUROBI, V139, P41, DOI 10.1016/j.resp.2003.09.006; Mandell DM, 2008, STROKE, V39, P1993, DOI 10.1161/STROKEAHA.107.501692; Mazerolle EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058130; Mazerolle EL, 2010, NEUROIMAGE, V50, P616, DOI 10.1016/j.neuroimage.2009.12.102; Mazerolle EL, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-84; Miller MB, 2009, NEUROIMAGE, V48, P625, DOI 10.1016/j.neuroimage.2009.06.033; Morrow SA, 2010, CLIN NEUROPSYCHOL, V24, P1131, DOI 10.1080/13854046.2010.511272; Newman AJ, 2010, P NATL ACAD SCI USA, V107, P7539, DOI 10.1073/pnas.1003174107; Nolte J., 2002, HUMAN BRAIN INTRO IT; Oakes TR, 2005, NEUROIMAGE, V28, P529, DOI 10.1016/j.neuroimage.2005.05.058; Omura K, 2004, NEUROREPORT, V15, P2707; Orthmann-Murphy JL, 2008, J MOL NEUROSCI, V35, P101, DOI 10.1007/s12031-007-9027-5; Pelletier J, 2009, Int MS J, V16, P26; Petzold GC, 2011, NEURON, V71, P782, DOI 10.1016/j.neuron.2011.08.009; Preibisch C, 2001, MAGNET RESON MED, V46, P172, DOI 10.1002/mrm.1173; Ranjeva JP, 2006, J NEUROL SCI, V245, P161, DOI 10.1016/j.jns.2005.09.019; Rogers JM, 2007, J CLIN NEUROSCI, V14, P919, DOI 10.1016/j.jocn.2007.02.006; Rostrup E, 2000, NEUROIMAGE, V11, P87, DOI 10.1006/nimg.1999.0526; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith AM, 2012, J NEUROL SCI, V312, P131, DOI 10.1016/j.jns.2011.08.003; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; Stancak A, 2000, NEUROREPORT, V11, P329, DOI 10.1097/00001756-200002070-00021; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Tettamanti M, 2002, J NEUROPHYSIOL, V88, P1051, DOI 10.1152/jn.2002.88.2.1051; Thomas BP, 2014, J CEREBR BLOOD F MET, V34, P242, DOI 10.1038/jcbfm.2013.194; van der Zande FHR, 2005, NEURORADIOLOGY, V47, P114, DOI 10.1007/s00234-004-1274-3; Weber B, 2005, J COGNITIVE NEUROSCI, V17, P113, DOI 10.1162/0898929052880002; Weis S, 2011, INT J NEUROSCI, V121, P384, DOI 10.3109/00207454.2011.565892; Wise RG, 2004, NEUROIMAGE, V21, P1652, DOI 10.1016/j.neuroimage.2003.11.025; Wishart H A, 2001, Curr Psychiatry Rep, V3, P373, DOI 10.1007/s11920-996-0029-8; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Woolrich MW, 2001, NEUROIMAGE, V14, P1370, DOI 10.1006/nimg.2001.0931; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Yarkoni T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004257; Yu HJ, 2012, NEUROIMAGE, V59, P3713, DOI 10.1016/j.neuroimage.2011.10.053; Zarei M, 2006, J ANAT, V209, P311, DOI 10.1111/j.1469-7580.2006.00615.x; ZEFFIRO T, 2007, P 13 ANN M ORG HUM B	75	28	28	0	11	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	AUG 4	2014	8								589	10.3389/fnhum.2014.00589			8	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	AN5HG	WOS:000340620800001	25136311	Green Published, gold			2022-02-06	
J	Kolar, MK; Kingham, PJ; Novikova, LN; Wiberg, M; Novikov, LN				Kolar, Mallappa K.; Kingham, Paul J.; Novikova, Liudmila N.; Wiberg, Mikael; Novikov, Lev N.			The Therapeutic Effects of Human Adipose-Derived Stem Cells in a Rat Cervical Spinal Cord Injury Model	STEM CELLS AND DEVELOPMENT			English	Article							MARROW STROMAL CELLS; HUMAN BONE-MARROW; FIBROBLAST GROWTH-FACTORS; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; GLIAL SCAR; IN-VITRO; MATRIX METALLOPROTEINASES; CORTICOSPINAL NEURONS; REGENERATIVE MEDICINE	Spinal cord injury triggers a cascade of degenerative changes leading to cell death and cavitation. Severed axons fail to regenerate across the scar tissue and are only capable of limited sprouting. In this study, we investigated the effects of adult human adipose-derived stem cells (ASC) on axonal regeneration following transplantation into the injured rat cervical spinal cord. ASC did not induce activation of astrocytes in culture and supported neurite outgrowth from adult rat sensory dorsal root ganglia neurons. After transplantation into the lateral funiculus 1mm rostral and caudal to the cervical C3-C4 hemisection, ASC continued to express brain-derived neurotrophic factor, vascular endothelial growth factor, and fibroblast growth factor-2 for 3 weeks but only in animals treated with cyclosporine A. Transplanted ASC stimulated extensive ingrowth of 5HT-positive raphaespinal axons into the trauma zone with some terminal arborizations reaching the caudal spinal cord. In addition, ASC induced sprouting of raphaespinal terminals in C2 contralateral ventral horn and C6 ventral horn on both sides. Transplanted cells also changed the structure of the lesion scar with numerous astrocytic processes extended into the middle of the trauma zone in a chain-like pattern and in close association with regenerating axons. The density of the astrocytic network was also significantly decreased. Although the transplanted cells had no effect on the density of capillaries around the lesion site, the activity of OX42-positive microglial cells was markedly reduced. However, ASC did not support recovery of forelimb function. The results suggest that transplanted ASC can modify the structure of the glial scar and stimulate axonal sprouting.	[Kolar, Mallappa K.; Kingham, Paul J.; Novikova, Liudmila N.; Wiberg, Mikael; Novikov, Lev N.] Umea Univ, Sect Anat, Dept Integrat Med Biol, S-90187 Umea, Sweden; [Kolar, Mallappa K.; Wiberg, Mikael] Umea Univ, Sect Hand & Plast Surg, Dept Surg & Perioperat Sci, S-90187 Umea, Sweden		Novikov, LN (corresponding author), Umea Univ, Sect Anat, Dept Integrat Med Biol, S-90187 Umea, Sweden.	lev.novikov@anatomy.umu.se		Novikov, Lev/0000-0001-5520-3890; Kingham, Paul/0000-0003-2596-5936	Swedish Research CouncilSwedish Research CouncilEuropean Commission; European UnionEuropean Commission; Umea University; county of Vasterbotten	We would like to thank Mrs. G. Folkesson and Mrs. G. Hellstrom for their excellent technical assistance. This study was supported by the Swedish Research Council, European Union, Umea University, and county of Vasterbotten.	Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Arboleda D, 2011, CELL MOL NEUROBIOL, V31, P1113, DOI 10.1007/s10571-011-9712-3; Attar A, 2011, CYTOTHERAPY, V13, P54, DOI 10.3109/14653249.2010.510506; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; Banas A, 2008, STEM CELLS, V26, P2705, DOI 10.1634/stemcells.2008-0034; Bradbury EJ, 2011, BRAIN RES BULL, V84, P306, DOI 10.1016/j.brainresbull.2010.06.015; Brohlin M, 2009, NEUROSCI RES, V64, P41, DOI 10.1016/j.neures.2009.01.010; Choi JS, 2012, KOREAN J PHYSIOL PHA, V16, P405, DOI 10.4196/kjpp.2012.16.6.405; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Chung CS, 2013, J VET MED SCI, V75, P879, DOI 10.1292/jvms.12-0470; Cizkova D, 2011, J NEUROTRAUM, V28, P1951, DOI 10.1089/neu.2010.1413; Cizkova D, 2006, CELL MOL NEUROBIOL, V26, P1167, DOI 10.1007/s10571-006-9093-1; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deumens R, 2005, PROG NEUROBIOL, V77, P57, DOI 10.1016/j.pneurobio.2005.10.004; Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Forostyak S, 2013, BIOCHIMIE, V95, P2257, DOI 10.1016/j.biochi.2013.08.004; Fric J, 2012, BLOOD, V120, P1380, DOI 10.1182/blood-2012-02-404475; Garcia-Alias G, 2012, EXP NEUROL, V235, P26, DOI 10.1016/j.expneurol.2011.09.009; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Grimpe B, 2005, MOL CELL NEUROSCI, V28, P18, DOI 10.1016/j.mcn.2004.06.010; Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Hawryluk GWJ, 2012, STEM CELLS DEV, V21, P2222, DOI 10.1089/scd.2011.0596; Hawryluk GWJ, 2012, STEM CELLS DEV, V21, P432, DOI 10.1089/scd.2011.0242; Hawthorne AL, 2011, J NEUROSCI, V31, P5605, DOI 10.1523/JNEUROSCI.6663-10.2011; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hollis ER, 2011, NEUROTHERAPEUTICS, V8, P694, DOI 10.1007/s13311-011-0074-9; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kalbermatten DF, 2011, CELL TISSUE RES, V344, P251, DOI 10.1007/s00441-011-1142-5; Karalija A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041086; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kim HJ, 2009, J ORTHOP RES, V27, P612, DOI 10.1002/jor.20766; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Kumar AA, 2009, EXP CLIN TRANSPLANT, V7, P241; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Liu J, 2013, J NEUROL SCI, V325, P127, DOI 10.1016/j.jns.2012.11.022; Lu P, 2007, EXP NEUROL, V203, P8, DOI 10.1016/j.expneurol.2006.07.030; Macaya DJ, 2013, BIOMATERIALS, V34, P3591, DOI 10.1016/j.biomaterials.2012.12.050; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; Moskowitz MAE, 1995, CER DIS 19 PRINC STR; Mothe AJ, 2012, J CLIN INVEST, V122, P3824, DOI 10.1172/JCI64124; Muir GD, 2007, EUR J NEUROSCI, V25, P1501, DOI 10.1111/j.1460-9568.2007.05411.x; Nacev BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024793; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Novikova LN, 2008, BIOMATERIALS, V29, P1198, DOI 10.1016/j.biomaterials.2007.11.033; Novikova LN, 2011, CYTOTHERAPY, V13, P873, DOI 10.3109/14653249.2011.574116; Novikova LN, 2011, EXP NEUROL, V229, P132, DOI 10.1016/j.expneurol.2010.09.021; Novikova LN, 2000, J COMP NEUROL, V428, P671, DOI 10.1002/1096-9861(20001225)428:4<671::AID-CNE7>3.0.CO;2-H; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Oh JS, 2012, NEUROREPORT, V23, P277, DOI 10.1097/WNR.0b013e3283505ae2; Pluchino S, 2013, GLIA, V61, P1379, DOI 10.1002/glia.22500; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Ra JC, 2011, STEM CELLS DEV, V20, P1297, DOI 10.1089/scd.2010.0466; Reilly JF, 1998, GLIA, V22, P202, DOI 10.1002/(SICI)1098-1136(199802)22:2<202::AID-GLIA11>3.0.CO;2-1; Roh DH, 2013, CELL TRANSPLANT, V22, P1577, DOI 10.3727/096368912X659907; Ryu HH, 2012, J VET MED SCI, V74, P1617, DOI 10.1292/jvms.12-0065; Sahni V, 2010, NAT REV NEUROL, V6, P363, DOI 10.1038/nrneurol.2010.73; Salgado AJ, 2010, CURR STEM CELL RES T, V5, P103; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schira J, 2012, BRAIN, V135, P431, DOI 10.1093/brain/awr222; Shi D, 2011, EXP HEMATOL, V39, P214, DOI 10.1016/j.exphem.2010.10.009; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Strem Brian M., 2005, Keio Journal of Medicine, V54, P132, DOI 10.2302/kjm.54.132; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Tetzlaff W, 2011, J NEUROTRAUM, V28, P1611, DOI 10.1089/neu.2009.1177; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Uccelli A, 2011, BEST PRACT RES CL HA, V24, P59, DOI 10.1016/j.beha.2011.01.004; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Vawda R, 2013, CURR STEM CELL RES T, V8, P25, DOI 10.2174/1574888X11308010005; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; WALICKE PA, 1988, J NEUROSCI, V8, P2618; Weishaupt N, 2013, EXP NEUROL, V247, P241, DOI 10.1016/j.expneurol.2013.05.003; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; YOUNG HE, 1995, DEV DYNAM, V202, P137, DOI 10.1002/aja.1002020205; Yuan YM, 2013, NEUROSCI BULL, V29, P421, DOI 10.1007/s12264-013-1358-3; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhou ZL, 2012, BRAIN RES, V1481, P79, DOI 10.1016/j.brainres.2012.08.051; Zhou ZL, 2013, CYTOTHERAPY, V15, P434, DOI 10.1016/j.jcyt.2012.11.015	92	28	30	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	JUL 15	2014	23	14					1659	1674		10.1089/scd.2013.0416			16	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	AL7LJ	WOS:000339315000009	24803143				2022-02-06	
J	Joseph, B; Aziz, H; Pandit, V; Kulvatunyou, N; Hashmi, A; Tang, A; Sadoun, M; O'Keeffe, T; Vercruysse, G; Green, DJ; Friese, RS; Rhee, P				Joseph, Bellal; Aziz, Hassan; Pandit, Viraj; Kulvatunyou, Narong; Hashmi, Ammar; Tang, Andrew; Sadoun, Moutamn; O'Keeffe, Terence; Vercruysse, Gary; Green, Donald J.; Friese, Randall S.; Rhee, Peter			A Three-Year Prospective Study of Repeat Head Computed Tomography in Patients with Traumatic Brain Injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							CT; MILD	BACKGROUND: A definitive consensus on the standardization of practice of a routine repeat head CT (RHCT) scan in patients with traumatic intracranial hemorrhage is lacking. We hypothesized that in examinable patients without neurologic deterioration, RHCT scan does not lead to neurosurgical intervention (craniotomy/craniectomy). STUDY DESIGN: This was a 3-year prospective cohort analysis of patients aged 18 years and older, without antiplatelet or anticoagulation therapy, presenting to our level 1 trauma center with intracranial hemorrhage on initial head CT and a follow-up RHCT. Neurosurgical intervention was defined by craniotomy/craniectomy. Neurologic deterioration was defined as altered mental status, focal neurologic deficits, and/or pupillary changes. RESULTS: A total of 1,129 patients were included. Routine RHCT was performed in 1,099 patients. The progression rate was 19.7% (216 of 1,099), with subsequent neurosurgical intervention in 4 patients. Four patients had an abnormal neurologic examination, with a Glasgow Coma Scale (GCS) of <= 8 requiring intubation. Thirty patients had an RHCT secondary to neurologic deterioration; 53% (16 of 30) had progression on RHCT, of which 75% (12 of 16) required neurosurgical intervention. There was an association between deterioration in neurologic examination and need for neurosurgical intervention (odds ratio 3.98; 95% CI 1.7 to 9.1). The negative predictive value of a deteriorating neurologic examination in predicting the need for neurosurgical intervention was 100% in patients with GCS > 8. CONCLUSIONS: Routine repeat head CT scan is not warranted in patients with normal neurologic examination. Routine repeat head CT scan does not supplement the need for neurologic examination for determining management in patients with traumatic brain injury. (C) 2014 by the American College of Surgeons	[Joseph, Bellal; Aziz, Hassan; Pandit, Viraj; Kulvatunyou, Narong; Hashmi, Ammar; Tang, Andrew; Sadoun, Moutamn; O'Keeffe, Terence; Vercruysse, Gary; Green, Donald J.; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021	Aziz, Hassan/0000-0003-0406-1946			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Aziz H, 2013, J TRAUMA ACUTE CARE, V75, P550, DOI 10.1097/TA.0b013e3182a53a77; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; CDC IPaC, TRAUMATIC BRAIN INJU; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Harbrecht BG, 2010, J TRAUMA, V68, P1367, DOI 10.1097/TA.0b013e3181d990da; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Joseph B, 2014, AM SURGEON, V80, P43; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Laack TA, 2011, J TRAUMA, V70, P1362, DOI 10.1097/TA.0b013e3181e1707f; Roudsari B, 2010, J AM COLL RADIOL, V7, P796, DOI 10.1016/j.jacr.2010.05.006; Salim A, 2013, J TRAUMA ACUTE CARE, V74, P973; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Shackford SR, 2004, J TRAUMA, V56, P480; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Sinson G, 2001, J TRAUMA, V51, P875; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Thorson CM, 2013, J TRAUMA ACUTE CARE, V74, P967, DOI 10.1097/TA.0b013e3182877fed; Valadka A, 2002, TRAUMA, P385; Valadka AB, 2010, J TRAUMA, V68, P1372	26	28	28	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	JUL	2014	219	1					45	51		10.1016/j.jamcollsurg.2013.12.062			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	AL7NI	WOS:000339320300008	24745622				2022-02-06	
J	Ye, YQ; Xu, HY; Zhang, X; Li, Z; Jia, YF; He, XS; Huang, JH				Ye, Yuqin; Xu, Hongyu; Zhang, Xin; Li, Ze; Jia, Yanfeng; He, Xiaosheng; Huang, Jason H.			Association between Toll-Like Receptor 4 Expression and Neural Stem Cell Proliferation in the Hippocampus Following Traumatic Brain Injury in Mice	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						toll-like receptor 4 (TLR4); neural stem cells (NSCs); hippocampus; traumatic brain injury (TBI); mice	NEUROGENESIS; ADULT; INFLAMMATION; DISEASE	Whether or how neural stem cells (NSCs) respond to toll-like receptor 4 (TLR4) in an inflammatory environment caused by traumatic brain injury (TBI) has not been understood. In the present study, association between TLR4 expression and NSCs proliferation in the hippocampus was investigated in a mouse model of TBI using controlled cortical impact (CCI). Hippocampal proliferating cells were labeled with the thymidine analog 5-bromo-2-deoxyuridine (BrdU). In order to identify NSCs, the proliferating cells were further co-labeled with BrdU/sex determination region of Y chromosome related high mobility group box gene 2 (SOX2). Morphological observation on the expression of BrdU, SOX2, and TLR4 in the hippocampus was performed by inmmunofluorescence (IF). Relative quantification of TLR4 expression at the protein and mRNA level was performed using Western blotting and real-time polymerase chain reaction (PCR). It was observed that BrdU(+)/SOX2(+) cells accounted for 95.80% +/- 7.91% among BrdU(+) cells; several BrdU(+) cells and SOX2(+) cells in the hippocampus were also TLR4-positive post injury, and that BrdU(+) cell numbers, together with TLR4 expression at either protein or mRNA level, increased significantly in TBI mice over 1, 3, 7, 14, and 21 days survivals and changed in a similar temporal pattern with a peak at 3 day post-injury. These results indicate that hippocampal proliferating cells (suggestive of NSCs) expressed TLR4, and that there was a potential association between increased expression of TLR4 and the proliferation of NSCs post TBI. It is concluded that hippocampal TLR4 may play a potential role in endogenous neurogenesis after TBI.	[Ye, Yuqin; Xu, Hongyu; Zhang, Xin; Li, Ze; Jia, Yanfeng; He, Xiaosheng] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China; [Ye, Yuqin] Hunan Normal Univ, Affiliated Hosp 2, Dept Neurosurg, Changsha 410000, Hunan, Peoples R China; [Huang, Jason H.] Baylor Scott & White Hlth, Dept Neurosurg, Temple, TX 76508 USA		He, XS (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China.	chinayeyuqin@163.com; xuhy@fmmu.edu.cn; heartychang@163.com; lizewyl@163.com; sjwkjyf@126.com; hexiaos@fmmu.edu.cn; JHUANG@sw.org	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	NSFCNational Natural Science Foundation of China (NSFC) [81171155]	The present study was supported by funds from the 2012 NSFC proposal (Item No. 81171155). We want to thank Glen Cryer, manager of publications at Bayor Scott & White Healthcare (Temple, TX, USA) for editing and proofreading the manuscript.	Acosta C, 2008, J NEUROSCI RES, V86, P1077, DOI 10.1002/jnr.21565; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Amaral DG, 2007, PROG BRAIN RES, V163, P3, DOI 10.1016/S0079-6123(07)63001-5; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Carty M, 2011, BIOCHEM PHARMACOL, V81, P825, DOI 10.1016/j.bcp.2011.01.003; Covacu R, 2009, J IMMUNOL, V182, P6889, DOI 10.4049/jimmunol.0802907; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Kim HJ, 2012, INT NEUROUROL J, V16, P57, DOI 10.5213/inj.2012.16.2.57; Kohman RA, 2013, BRAIN BEHAV IMMUN, V27, P22, DOI 10.1016/j.bbi.2012.09.003; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629; Sauerzweig S, 2009, J NEUROSCI METH, V177, P149, DOI 10.1016/j.jneumeth.2008.10.009; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Stella N, 2012, SCIENCE, V338, P1303, DOI 10.1126/science.1232331; Trudler D, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/497987	22	28	32	1	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	JUL	2014	15	7					12651	12664		10.3390/ijms150712651			14	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	AM7ID	WOS:000340038500089	25036030	gold, Green Published, Green Submitted			2022-02-06	
J	Honzel, N; Justus, T; Swick, D				Honzel, Nikki; Justus, Timothy; Swick, Diane			Posttraumatic stress disorder is associated with limited executive resources in a working memory task	COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE			English	Article						Working memory; PTSD; ERP; Dual task; Executive function; Sternberg memory task	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; SHORT-TERM-MEMORY; RECOGNITION MEMORY; INTERFERENCE RESOLUTION; RESPONSE-INHIBITION; PREFRONTAL CORTEX; PERFORMANCE; ATTENTION; ANXIETY	Patients with posttraumatic stress disorder (PTSD) can show declines in working memory. A dual-task design was used to determine whether these impairments are linked to executive control limitations. Participants performed a Sternberg memory task with either one or four letters. In the dual-task condition, the maintenance period was filled with an arrow flanker task. PTSD patients were less accurate on the working memory task than were controls, especially in the dual-task condition. In the single-task condition, both groups showed similar patterns of brain potentials from 300 to 500 ms when discriminating old and new probes. However, when taxed with an additional task, the event-related potentials (ERPs) of the PTSD group no longer differentiated old and new probes. In contrast, interference resolution processes in both the single- and dual-task conditions of the flanker task were intact. The lack of differentiation in the ERPs reflects impaired working memory performance under more difficult, dual-task conditions. Exacerbated difficulty in performing a working memory task with concurrent task demands suggests a specific limitation in executive control resources in PTSD.	[Honzel, Nikki; Swick, Diane] VA Northern Calif Hlth Care Syst, Med Res Serv, Martinez, CA 94553 USA; [Justus, Timothy] Pitzer Coll, Psychol Field Grp, Claremont, CA 91711 USA; [Swick, Diane] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA		Honzel, N (corresponding author), VA Northern Calif Hlth Care Syst, Med Res Serv, 150 Muir Rd,Ste 151-1, Martinez, CA 94553 USA.	nhonzel@gmail.com			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0086]; VA Merit Review grant from the Clinical Science Research and Development Service; Veterans AffairsUS Department of Veterans Affairs [I01CX000566] Funding Source: NIH RePORTER	We thank Jary Larsen and Victoria Ashley for their assistance in recruiting our veteran population. In addition, we thank Devin Adair and Julien Cayton for their assistance with scheduling and running participants, and Adrian Willoughby for task design. This work was supported by the U.S. Army Medical Research and Materiel Command under Grant No. W81XWH-08-2-0086 and by a VA Merit Review grant from the Clinical Science Research and Development Service. The authors declare that they have no conflicts of interest. The information in this article and the article itself have never been published, either electronically or in print. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andres P, 2002, NEUROPSYCHOLOGIA, V40, P835, DOI 10.1016/S0028-3932(01)00182-8; Aupperle RL, 2012, ARCH GEN PSYCHIAT, V69, P360, DOI 10.1001/archgenpsychiatry.2011.1539; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; BADDELEY A, 1986, Q J EXP PSYCHOL-A, V38, P603, DOI 10.1080/14640748608401616; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bledowski C, 2004, NEUROIMAGE, V22, P530, DOI 10.1016/j.neuroimage.2003.12.034; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Chao LL, 1998, J COGNITIVE NEUROSCI, V10, P167, DOI 10.1162/089892998562636; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Cowey CM, 1996, MEMORY, V4, P19, DOI 10.1080/741940668; Danckwerts A, 2003, NEUROPSYCHOL REV, V13, P221, DOI 10.1023/B:NERV.0000009485.76839.b7; Danker JF, 2008, PSYCHOPHYSIOLOGY, V45, P784, DOI 10.1111/j.1469-8986.2008.00672.x; de Fockert JW, 2001, SCIENCE, V291, P1803, DOI 10.1126/science.1056496; Downing PE, 2000, PSYCHOL SCI, V11, P467, DOI 10.1111/1467-9280.00290; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Dreher JC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003227; Elzinga BM, 2002, J AFFECT DISORDERS, V70, P1, DOI 10.1016/S0165-0327(01)00351-2; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336; EYSENCK MW, 1992, COGNITION EMOTION, V6, P409, DOI 10.1080/02699939208409696; Fales CL, 2008, COGN AFFECT BEHAV NE, V8, P239, DOI 10.3758/CABN.8.3.239; Folstein JR, 2011, PSYCHOPHYSIOLOGY, V48, P825, DOI 10.1111/j.1469-8986.2010.01146.x; FRIEDMAN D, 1990, BIOL PSYCHOL, V30, P61, DOI 10.1016/0301-0511(90)90091-A; Garcia-Larrea L, 1998, EVOKED POTENTIAL, V108, P260, DOI 10.1016/S0168-5597(97)00085-3; Gazzaley A, 2011, NEUROPSYCHOLOGIA, V49, P1410, DOI 10.1016/j.neuropsychologia.2010.12.022; Henry Julie D, 2006, Cogn Neuropsychiatry, V11, P156, DOI 10.1080/13546800444000227; Hopf JM, 2000, CLIN NEUROPHYSIOL, V111, P1241, DOI 10.1016/S1388-2457(00)00313-8; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Johnsen GE, 2009, PSYCHIAT RES, V165, P68, DOI 10.1016/j.psychres.2008.01.001; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Lavie N, 2005, PSYCHON B REV, V12, P669, DOI 10.3758/BF03196756; Lavie N, 2004, J EXP PSYCHOL GEN, V133, P339, DOI 10.1037/0096-3445.133.3.339; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake A, 2012, CURR DIR PSYCHOL SCI, V21, P8, DOI 10.1177/0963721411429458; Nee DE, 2007, COGN AFFECT BEHAV NE, V7, P1, DOI 10.3758/CABN.7.1.1; Nee DE, 2013, CEREB CORTEX, V23, P264, DOI 10.1093/cercor/bhs007; Neylan TC, 2003, BIOL PSYCHIAT, V53, P216, DOI 10.1016/S0006-3223(02)01450-6; Nielsen-Bohlman L, 1999, COGNITIVE BRAIN RES, V8, P299, DOI 10.1016/S0926-6410(99)00035-X; Pantelis C, 2002, J PSYCHOSOM RES, V53, P655, DOI 10.1016/S0022-3999(02)00434-8; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; Pratt N, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00057; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Roussel M, 2012, BRAIN, V135, P2192, DOI 10.1093/brain/aws132; RUGG MD, 1992, J COGNITIVE NEUROSCI, V4, P69, DOI 10.1162/jocn.1992.4.1.69; Rugg MD, 2007, TRENDS COGN SCI, V11, P251, DOI 10.1016/j.tics.2007.04.004; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Sebastian A, 2013, NEUROIMAGE, V64, P601, DOI 10.1016/j.neuroimage.2012.09.020; SMITH ME, 1993, J COGNITIVE NEUROSCI, V5, P1, DOI 10.1162/jocn.1993.5.1.1; Soto D, 2005, J EXP PSYCHOL HUMAN, V31, P248, DOI 10.1037/0096-1523.31.2.248; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Swick D, 1997, J EXP PSYCHOL LEARN, V23, P123, DOI 10.1037/0278-7393.23.1.123; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Swick D, 2011, NEUROIMAGE, V56, P1655, DOI 10.1016/j.neuroimage.2011.02.070; Tays WJ, 2008, J COGNITIVE NEUROSCI, V20, P2250, DOI 10.1162/jocn.2008.20158; Tays WJ, 2011, BRAIN RES, V1393, P62, DOI 10.1016/j.brainres.2011.04.006; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Wager TD, 2005, NEUROIMAGE, V27, P323, DOI 10.1016/j.neuroimage.2005.01.054; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Weathers F.W., 1994, PTSD CHECKLIST MILIT; Weber DL, 2005, PSYCHIAT RES-NEUROIM, V140, P27, DOI 10.1016/j.pscychresns.2005.07.003; Wilding EL, 2006, CLIN EEG NEUROSCI, V37, P315, DOI 10.1177/155005940603700409	73	28	28	3	35	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1530-7026	1531-135X		COGN AFFECT BEHAV NE	Cogn. Affect. Behav. Neurosci.	JUN	2014	14	2					792	804		10.3758/s13415-013-0219-x			13	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	AK6CY	WOS:000338516800024	24165904	Green Accepted			2022-02-06	
J	Qiao, Y; Zhang, PP; Wang, CM; Ma, LY; Su, M				Qiao, Yong; Zhang, Peipei; Wang, Chaoming; Ma, Liyuan; Su, Ming			Reducing X-Ray Induced Oxidative Damages in Fibroblasts with Graphene Oxide	NANOMATERIALS			English	Article						X-ray; graphene oxide; DNA damage; oxidative; reactive oxygen species (ROS)	TRAUMATIC BRAIN-INJURY; RADIATION-THERAPY; CEREBROVASCULAR DYSFUNCTION; IONIZING-RADIATION; IN-VITRO; DNA; RADIOTHERAPY; ASSAY; RADIOSENSITIZERS; NANOCARRIER	A major issue of X-ray radiation therapy is that normal cells can be damaged, limiting the amount of X-rays that can be safely delivered to a tumor. This paper describes a new method based on graphene oxide (GO) to protect normal cells from oxidative damage by removing free radicals generated by X-ray radiation using grapheme oxide (GO). A variety of techniques such as cytotoxicity, genotoxicity, oxidative assay, apoptosis, gamma-H2AX expression, and micro-nucleus assay have been used to assess the protective effect of GO in cultured fibroblast cells. It is found that although GO at higher concentration (100 and 500 mu g/mL) can cause cell death and DNA damage, it can effectively remove oxygen free radicals at a lower concentration of 10 mu g/mL. The level of DNA damage and cell death is reduced by 48%, and 39%, respectively. Thus, low concentration GO can be used as an effective radio-protective agent in occupational and therapeutic settings.	[Qiao, Yong; Zhang, Peipei; Wang, Chaoming; Ma, Liyuan; Su, Ming] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA		Ma, LY (corresponding author), Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA.	qiaoyong83@gmail.com; pzhang2@wpi.edu; cwang4@wpi.edu; lma2@wpi.edu; msu2@wpi.edu	Su, Ming/F-4001-2014		National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1DP2EB016572]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [DP2EB016572] Funding Source: NIH RePORTER	This work is supported with a Director's New Innovator Award (1DP2EB016572) from National Institute of Health.	Ali H, 1999, CHEM REV, V99, P2379, DOI 10.1021/cr980439y; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Borek C, 2004, J NUTR, V134, p3207S, DOI 10.1093/jn/134.11.3207S; Box HC, 1999, RADIAT RES, V152, P575, DOI 10.2307/3580252; Bucci MK, 2005, CA-CANCER J CLIN, V55, P117, DOI 10.3322/canjclin.55.2.117; Cabiscol Elisa, 2000, International Microbiology, V3, P3; Chandra A, 2005, RADIOTHER ONCOL, V77, P247, DOI 10.1016/j.radonc.2005.10.017; Chang YL, 2011, TOXICOL LETT, V200, P201, DOI 10.1016/j.toxlet.2010.11.016; COMPORTI M, 1989, CHEM-BIOL INTERACT, V72, P1, DOI 10.1016/0009-2797(89)90016-1; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Elshaikh M, 2006, ANNU REV MED, V57, P19, DOI 10.1146/annurev.med.57.121304.131431; Fang Y, 2013, SCI REP-UK, V3, DOI [10.1038/srep02811, 10.1038/srep02852]; Fischer TW, 2008, EXP DERMATOL, V17, P713, DOI 10.1111/j.1600-0625.2008.00767.x; Harrison LB, 2002, ONCOLOGIST, V7, P492, DOI 10.1634/theoncologist.7-6-492; He JL, 2000, CHINESE MED J-PEKING, V113, P911; Hosseinimehr SJ, 2007, DRUG DISCOV TODAY, V12, P794, DOI 10.1016/j.drudis.2007.07.017; Huang P, 2011, THERANOSTICS, V1, P240, DOI 10.7150/thno/v01p0240; Lawrence Theodore S, 2003, Oncology (Williston Park), V17, P23; Liu GD, 2013, ACS APPL MATER INTER, V5, P6909, DOI 10.1021/am402128s; Lobo V, 2010, Pharmacogn Rev, V4, P118, DOI 10.4103/0973-7847.70902; Maity AR, 2014, NANOSCALE, V6, P2752, DOI 10.1039/c3nr05431d; Marcano DC, 2013, J NEUROTRAUM, V30, P789, DOI 10.1089/neu.2011.2301; MARK F, 1989, RADIAT ENVIRON BIOPH, V28, P81, DOI 10.1007/BF01210293; MILAS L, 1988, PHARMACOL THERAPEUT, V39, P179, DOI 10.1016/0163-7258(88)90059-9; NAKANO H, 1994, RADIAT RES, V140, P1, DOI 10.2307/3578561; Qiao Y, 2013, ANAL CHEM, V85, P4107, DOI 10.1021/ac400242w; Qiao Y, 2012, ANAL CHEM, V84, P1112, DOI 10.1021/ac202773g; Qin XC, 2013, J PHOTOCH PHOTOBIO B, V120, P156, DOI 10.1016/j.jphotobiol.2012.12.005; Redon CE, 2009, ADV SPACE RES, V43, P1171, DOI 10.1016/j.asr.2008.10.011; Rydberg B, 1996, RADIAT RES, V145, P200, DOI 10.2307/3579175; Salas EC, 2010, ACS NANO, V4, P4852, DOI 10.1021/nn101081t; Teh B S, 1999, Oncologist, V4, P433; Wardman P, 2007, CLIN ONCOL-UK, V19, P397, DOI 10.1016/j.clon.2007.03.010; Wu J, 2013, CLIN CANCER RES, V19, P721, DOI 10.1158/1078-0432.CCR-12-2529; Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680	35	28	28	0	25	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2079-4991			NANOMATERIALS-BASEL	Nanomaterials	JUN	2014	4	2					522	534		10.3390/nano4020522			13	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	AP6QJ	WOS:000342202000019	25530873	gold, Green Published, Green Accepted, Green Submitted			2022-02-06	
J	Sullivan-Singh, SJ; Sawyer, K; Ehde, DM; Bell, KR; Temkin, N; Dikmen, S; Williams, RM; Hoffman, JM				Sullivan-Singh, Sarah J.; Sawyer, Kathryn; Ehde, Dawn M.; Bell, Kathleen R.; Temkin, Nancy; Dikmen, Sureyya; Williams, Rhonda M.; Hoffman, Jeanne M.			Comorbidity of Pain and Depression Among Persons With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Pain; Rehabilitation	CUT-POINTS; SEVERITY; PREVALENCE; DISORDERS; VALIDITY; OUTCOMES	Objective: To assess the prevalence of pain, depression, and comorbid pain and depression among a civilian sample of persons with traumatic brain injury (TBI). Design: Longitudinal survey design with 1-year follow-up. Setting: Inpatient rehabilitation and the community. Participants: Participants (N = 158) admitted to inpatient rehabilitation after moderate to severe TBI. Interventions: Not applicable. Main Outcome Measures: Depression was assessed with the Patient Health Questionnaire-9 (PHQ-9); pain was assessed with a numerical rating scale from 0 (no pain) to 10 (worst pain). Participants who reported average pain >= 4 were classified as having pain, and participants with PHQ-9 scores >= 10 were classified as depressed. Results: Both pain and depression were more prevalent at baseline assessment (pain: 70%; depression: 31%) than at year 1 (pain: 34%; depression: 22%). Comorbid pain and depression declined from 27% at baseline to 18% at year 1. Pain was significantly associated with depression at baseline (relative risk: 2.62, P = .003) and at year 1 (relative risk: 7.98, P<.001). Conclusions: Pain and depression are common and frequently co-occur in persons with TBI. Although their frequency declined over the first year after injury, the strength of their association increased. Assessment and treatment of both conditions simultaneously may lead to improved outcomes, both early after TBI and over time. (C) 2014 by the American Congress of Rehabilitation Medicine	[Sullivan-Singh, Sarah J.; Sawyer, Kathryn; Ehde, Dawn M.; Bell, Kathleen R.; Temkin, Nancy; Dikmen, Sureyya; Williams, Rhonda M.; Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98104 USA; [Temkin, Nancy; Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Sch Med, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Sch Med, Seattle, WA 98104 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Biobehav Sci, Sch Med, Seattle, WA 98104 USA; [Williams, Rhonda M.] Vet Affairs Puget Sound Healthcare Syst, Rehabil Care Serv, Seattle, WA USA		Sullivan-Singh, SJ (corresponding author), Univ Washington, Dept Rehabil Med, Harborview Med Ctr, 325 Ninth Ave,Box 359612, Seattle, WA 98104 USA.	sarahsullivansingh@gmail.com	Ehde, Dawn/K-1883-2016	Ehde, Dawn/0000-0002-9555-2347; Bell, Kathleen/0000-0002-0928-2046	National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems [H133A070032]; Department of Defense Congressionally Directed Medical Research ProgramsUnited States Department of Defense [W81XWH-12-2-0109]	Supported by the National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems (grant no. H133A070032) and Department of Defense Congressionally Directed Medical Research Programs (grant no. W81XWH-12-2-0109).	Alschuler KN, 2013, REHABIL PSYCHOL, V58, P217, DOI 10.1037/a0032008; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Centers for Disease Control and Prevention USA, 2010, HLTH US; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fejer R, 2005, PAIN, V119, P176, DOI 10.1016/j.pain.2005.09.033; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Jensen MP, 2001, HDB PAIN ASSESSMENT, P15; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2008, PAIN, V134, P209, DOI 10.1016/j.pain.2007.09.021; Kroenke K, 2011, J PAIN, V12, P964, DOI 10.1016/j.jpain.2011.03.003; LINDSAY PG, 1981, PSYCHOSOMATICS, V22, P571; Mavandadi S, 2007, J AM GERIATR SOC, V55, P202, DOI 10.1111/j.1532-5415.2007.01042.x; Miller LR, 2009, J PAIN, V10, P619, DOI 10.1016/j.jpain.2008.12.007; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Tan G., 2008, PSYCHOL, V5, P239, DOI [10.1037/1541-1559.5.3.239, DOI 10.1037/1541-1559.5.3.239, DOI 10.1037/1541-1559. 5. 3. 239]; Tsang A, 2008, J PAIN, V9, P883, DOI 10.1016/j.jpain.2008.05.005; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zelman DC, 2005, PAIN, V115, P29, DOI 10.1016/j.pain.2005.01.028	27	28	28	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2014	95	6					1100	1105		10.1016/j.apmr.2014.02.001			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	AI3OY	WOS:000336773000014	24561058				2022-02-06	
J	Neher, MD; Rich, MC; Keene, CN; Weckbach, S; Bolden, AL; Losacco, JT; Patane, J; Flierl, MA; Kulik, L; Holers, M; Stahel, PF				Neher, Miriam D.; Rich, Megan C.; Keene, Chesleigh N.; Weckbach, Sebastian; Bolden, Ashley L.; Losacco, Justin T.; Patane, Jenee; Flierl, Michael A.; Kulik, Liudmila; Holers, Michael; Stahel, Philip F.			Deficiency of complement receptors CR2/CR1 in Cr2(-/-) mice reduces the extent of secondary brain damage after closed head injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Closed head injury; Neuroinflammation; Complement receptor; Cr2(-/-) mice; Secondary brain injury	NATURAL ANTIBODIES; TISSUE-INJURY; ACTIVATION; SYSTEM; IMMUNITY; C3; COMPLEMENT-RECEPTOR-2; NEUROPROTECTION; AUTOANTIBODIES; ACCUMULATION	Complement activation at the C3 convertase level has been associated with acute neuroinflammation and secondary brain injury after severe head trauma. The present study was designed to test the hypothesis that Cr2(-/-) mice, which lack the receptors CR2/CD21 and CR1/CD35 for complement C3-derived activation fragments, are protected from adverse sequelae of experimental closed head injury. Adult wild-type mice and Cr2(-/-) mice on a C57BL/6 genetic background were subjected to focal closed head injury using a standardized weight-drop device. Head-injured Cr2(-/-) mice showed significantly improved neurological outcomes for up to 72 hours after trauma and a significantly decreased post-injury mortality when compared to wild-type mice. In addition, the Cr2(-/-) genotype was associated with a decreased extent of neuronal cell death at seven days post-injury. Western blot analysis revealed that complement C3 levels were reduced in the injured brain hemispheres of Cr2(-/-) mice, whereas plasma C3 levels remained unchanged, compared to wild-type mice. Finally, head-injured Cr2(-/-) had an attenuated extent of post-injury C3 tissue deposition, decreased astrocytosis and microglial activation, and attenuated immunoglobulin M deposition in injured brains compared to wild-type mice. Targeting of these receptors for complement C3 fragments (CR2/CR1) may represent a promising future approach for therapeutic immunomodulation after traumatic brain injury.	[Neher, Miriam D.; Rich, Megan C.; Keene, Chesleigh N.; Weckbach, Sebastian; Bolden, Ashley L.; Losacco, Justin T.; Patane, Jenee; Flierl, Michael A.; Stahel, Philip F.] Univ Colorado, Sch Med, Dept Orthoped Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA; [Kulik, Liudmila; Holers, Michael] Univ Colorado, Barbara Davis Ctr, Dept Med, Aurora, CO 80045 USA; [Kulik, Liudmila; Holers, Michael] Univ Colorado, Barbara Davis Ctr, Dept Immunol, Aurora, CO 80045 USA; [Stahel, Philip F.] Univ Colorado, Sch Med, Dept Neurosurg, Denver Hlth Med Ctr, Denver, CO 80204 USA		Stahel, PF (corresponding author), Univ Colorado, Sch Med, Dept Orthoped Surg, Denver Hlth Med Ctr, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org		Losacco, Justin/0000-0001-7867-1152	Colorado Traumatic Brain Injury Trust Fund/Colorado Brain Injury Program; German Research Foundation (DFG)German Research Foundation (DFG); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR051749]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051749] Funding Source: NIH RePORTER	This study was supported by a project grant from The Colorado Traumatic Brain Injury Trust Fund/Colorado Brain Injury Program to PFS and MAF. SW was supported by a Research Fellowship by the German Research Foundation (DFG). VMH was supported by an R01 grant from the NIH (Number AR051749). We are indebted to our long-time friend, Dr Scott R. Barnum (University of Alabama at Birmingham, Alabama, United States) for critical review of this manuscript, and for his continuing leadership and mentorship in the field of 'neuro-complementology'.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Ankeny DP, 2010, TRENDS IMMUNOL, V31, P332, DOI 10.1016/j.it.2010.06.006; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bellander BM, 2010, EXP BRAIN RES, V205, P103, DOI 10.1007/s00221-010-2342-z; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Carroll MC, 2012, IMMUNITY, V37, P199, DOI 10.1016/j.immuni.2012.08.002; Ehrenstein MR, 2010, NAT REV IMMUNOL, V10, P778, DOI 10.1038/nri2849; Elvington A, 2012, J IMMUNOL, V188, P1460, DOI 10.4049/jimmunol.1102132; Fleming SD, 2004, J IMMUNOL, V173, P7055, DOI 10.4049/jimmunol.173.11.7055; Fleming SD, 2006, AUTOIMMUNITY, V39, P379, DOI 10.1080/08916930600739381; Fleming SD, 2012, ADV EXP MED BIOL, V750, P174, DOI 10.1007/978-1-4614-3461-0_13; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gasque P, 1996, J IMMUNOL, V156, P2247; Glushakov AV, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-132; Griffiths MR, 2009, J NEUROPATH EXP NEUR, V68, P217, DOI 10.1097/NEN.0b013e3181996688; Holers VM, 2007, MOL IMMUNOL, V44, P64, DOI 10.1016/j.molimm.2006.07.003; Holers VM, 2013, ADV EXP MED BIOL, V735, P137, DOI 10.1007/978-1-4614-4118-2_9; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kaveri SV, 2012, J IMMUNOL, V188, P939, DOI 10.4049/jimmunol.1102107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kelso ML, 2013, CURR PHARM DES; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Menet C, 1999, J VIROL, V73, P7722, DOI 10.1128/JVI.73.9.7722-7733.1999; MOLINA H, 1990, J IMMUNOL, V145, P2974; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moriyama M, 2011, J NEUROSCI, V31, P3981, DOI 10.1523/JNEUROSCI.3617-10.2011; Neher MD, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-90; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Xu ZL, 2013, NAT MED, V19, P452, DOI 10.1038/nm.3107	39	28	28	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 24	2014	11								95	10.1186/1742-2094-11-95			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	AI9MU	WOS:000337257500001	24885042	gold, Green Published			2022-02-06	
J	Novgorodov, SA; Riley, CL; Yu, J; Borg, KT; Hannun, YA; Proia, RL; Kindy, MS; Gudz, TI				Novgorodov, Sergei A.; Riley, Christopher L.; Yu, Jin; Borg, Keith T.; Hannun, Yusuf A.; Proia, Richard L.; Kindy, Mark S.; Gudz, Tatyana I.			Essential Roles of Neutral Ceramidase and Sphingosine in Mitochondrial Dysfunction Due to Traumatic Brain Injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Brain; Cell Death; Mitochondria; Respiratory Chain; Sphingolipid	CYTOCHROME-C-OXIDASE; SUBCELLULAR-LOCALIZATION; CHRONIC ACTIVATION; RESPIRATORY-CHAIN; MOLECULAR-CLONING; RAT-BRAIN; IN-VITRO; KINASE; SPHINGOSINE-1-PHOSPHATE; SPHINGOLIPIDS	Background: A cardinal feature of many neurological disorders is mitochondrial dysfunction. Results: Knocking down neutral ceramidase reduces mitochondrial sphingosine, preserves mitochondrial function, and improves brain function recovery after trauma. Conclusion: Activation of the sphingosine-generating pathway plays a significant role in promoting mitochondrial injury. Significance: This is the first direct evidence of endogenous sphingosine involvement in regulation of mitochondrial function. In addition to immediate brain damage, traumatic brain injury (TBI) initiates a cascade of pathophysiological events producing secondary injury. The biochemical and cellular mechanisms that comprise secondary injury are not entirely understood. Herein, we report a substantial deregulation of cerebral sphingolipid metabolism in a mouse model of TBI. Sphingolipid profile analysis demonstrated increases in sphingomyelin species and sphingosine concurrently with up-regulation of intermediates of de novo sphingolipid biosynthesis in the brain. Investigation of intracellular sites of sphingosine accumulation revealed an elevation of sphingosine in mitochondria due to the activation of neutral ceramidase (NCDase) and the reduced activity of sphingosine kinase 2 (SphK2). The lack of change in gene expression suggested that post-translational mechanisms are responsible for the shift in the activities of both enzymes. Immunoprecipitation studies revealed that SphK2 is complexed with NCDase and cytochrome oxidase (COX) subunit 1 in mitochondria and that brain injury hindered SphK2 association with the complex. Functional studies showed that sphingosine accumulation resulted in a decreased activity of COX, a rate-limiting enzyme of the mitochondrial electron transport chain. Knocking down NCDase reduced sphingosine accumulation in mitochondria and preserved COX activity after the brain injury. Also, NCDase knockdown improved brain function recovery and lessened brain contusion volume after trauma. These studies highlight a novel mechanism of secondary TBI involving a disturbance of sphingolipid-metabolizing enzymes in mitochondria and suggest a critical role for mitochondrial sphingosine in promoting brain injury after trauma.	[Riley, Christopher L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA; [Yu, Jin; Kindy, Mark S.; Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Novgorodov, Sergei A.; Kindy, Mark S.; Gudz, Tatyana I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Borg, Keith T.] Med Univ S Carolina, Dept Emergency Med, Charleston, SC 29425 USA; [Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Proia, Richard L.] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA		Gudz, TI (corresponding author), 114 Doughty St, Charleston, SC 29425 USA.	gudz@musc.edu	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 GM103339]; Veterans Affairs Merit AwardsUS Department of Veterans Affairs [I01RX000206, I01BX001104, I01RX000331]; American Diabetes AssociationAmerican Diabetes Association [7-12-IN-28]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA172517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [ZIADK056014, ZIADK056016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R37GM043825, P30GM103339] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001104, I01RX000331, I01RX000206] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grant P30 GM103339 (to S. A. N.). This work was also supported by Veterans Affairs Merit Awards I01RX000206 (to T. I. G.), I01BX001104 (to T. I. G.), and I01RX000331 (to M. S. K.). The Lipidomics Core Facility at Medical University of South Carolina is supported in part by National Institutes of Health Grant P30 GM103339.; Supported in part by American Diabetes Association Innovation Grant 7-12-IN-28.	Arnold S, 2012, ADV EXP MED BIOL, V748, P305, DOI 10.1007/978-1-4614-3573-0_13; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Bionda C, 2004, BIOCHEM J, V382, P527, DOI 10.1042/BJ20031819; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Chan HS, 2013, BBA-MOL CELL BIOL L, V1831, P147, DOI 10.1016/j.bbalip.2012.07.005; Chudakova DA, 2008, J BIOL CHEM, V283, P28806, DOI 10.1074/jbc.M803301200; Clarke CJ, 2011, J BIOL CHEM, V286, P21565, DOI 10.1074/jbc.M110.193375; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Galadari S, 2006, BIOCHEM J, V393, P687, DOI 10.1042/BJ20050682; Geoffroy K, 2004, J BIOL CHEM, V279, P34343, DOI 10.1074/jbc.M403273200; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hwang YH, 2005, BIOCHEM BIOPH RES CO, V331, P37, DOI 10.1016/j.bbrc.2005.03.134; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Kolter T, 2002, J BIOL CHEM, V277, P25859, DOI 10.1074/jbc.R200001200; Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Merrill AH, 2011, CHEM REV, V111, P6387, DOI 10.1021/cr2002917; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Novgorodov AS, 2007, FASEB J, V21, P1503, DOI 10.1096/fj.06-7420com; Novgorodov Sergei A, 2011, Int J Biochem Mol Biol, V2, P347; Novgorodov SA, 2011, J BIOL CHEM, V286, P25352, DOI 10.1074/jbc.M110.214866; Novgorodov SA, 2011, J BIOL CHEM, V286, P4644, DOI 10.1074/jbc.M110.164392; Noygorodov SA, 2009, J CARDIOVASC PHARM, V53, P198, DOI 10.1097/FJC.0b013e31819b52d5; O'Neill SM, 2011, ARCH BIOCHEM BIOPHYS, V511, P31, DOI 10.1016/j.abb.2011.04.009; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rotstein NP, 2010, J LIPID RES, V51, P1247, DOI 10.1194/jlr.R003442; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; Stancevic B, 2010, FEBS LETT, V584, P1728, DOI 10.1016/j.febslet.2010.02.026; Strub GM, 2011, FASEB J, V25, P600, DOI 10.1096/fj.10-167502; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Tani M, 1999, J BIOCHEM-TOKYO, V125, P746; Tani M, 2007, CELL SIGNAL, V19, P229, DOI 10.1016/j.cellsig.2006.07.001; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Veenith Tonny, 2009, World J Emerg Surg, V4, P7, DOI 10.1186/1749-7922-4-7; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wong-Riley MTT, 2012, ADV EXP MED BIOL, V748, P283, DOI 10.1007/978-1-4614-3573-0_12; Woodcock J, 2006, IUBMB LIFE, V58, P462, DOI 10.1080/15216540600871118; Wu BX, 2010, J BIOL CHEM, V285, P17993, DOI 10.1074/jbc.M110.102988; Yu J, 2007, J BIOL CHEM, V282, P25940, DOI 10.1074/jbc.M701812200; Zhu Q, 2008, ACTA PHARMACOL SIN, V29, P593, DOI 10.1111/j.1745-7254.2008.00781.x; Zigdon H, 2013, J BIOL CHEM, V288, P4947, DOI 10.1074/jbc.M112.402719	64	28	30	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2014	289	19					13142	13154		10.1074/jbc.M113.530311			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AG6IR	WOS:000335522800016	24659784	Green Published, hybrid			2022-02-06	
J	Kaba, F; Diamond, P; Haque, A; MacDonald, R; Venters, H				Kaba, Fatos; Diamond, Pamela; Haque, Alpha; MacDonald, Ross; Venters, Homer			Traumatic Brain Injury Among Newly Admitted Adolescents in the New York City Jail System	JOURNAL OF ADOLESCENT HEALTH			English	Article						Jail; Traumatic brain injury; Violence	RISK-FACTORS	Purpose: Relatively little is known about the prevalence of traumatic brain injury (TBI) among adolescents who come into contact with the criminal justice system. Methods: We undertook screening for TBI among newly admitted adolescents in the New York City jail system using a validated TBI screening tool. A convenience sample of 300 male and 84 female screenings was examined. Results: Screening revealed that 50% of male and 49% of female adolescents enter jail with a history of TBI. Incidence of TBI was assessed using patient health records, and revealed an incidence of 3,107 TBI per 100,000 person-years. Conclusions: Elevated prevalence and incidence of TBI among incarcerated adolescents may relate to criminal justice involvement as well as friction in jail. Given the large representation of violence as a cause of TBI among our patients, we have begun focus groups with them to elicit meaningful strategies for living with and avoiding TBI. (C) 2014 Society for Adolescent Health and Medicine. All rights reserved.	[Kaba, Fatos; Haque, Alpha; MacDonald, Ross; Venters, Homer] New York City Dept Hlth & Mental Hyg, New York, NY USA; [Diamond, Pamela] Univ Texas Houston, Div Hlth Promot & Behav Sci, Houston, TX USA		Venters, H (corresponding author), NYC DOHMH, 42-09 28th St, Queens, NY 11101 USA.	Hventer1@health.nyc.gov					Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; Moore E, 2013, J HEAD TRAUMA REHABI; National TBI estimates: Injury prevention & control, NAT TBI EST INJ PREV; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613	9	28	28	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	MAY	2014	54	5					615	617		10.1016/j.jadohealth.2013.12.013			3	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Public, Environmental & Occupational Health; Pediatrics	AF1XG	WOS:000334506600019	24529834				2022-02-06	
J	Eramudugolla, R; Bielak, AAM; Bunce, D; Easteal, S; Cherbuin, N; Anstey, KJ				Eramudugolla, Ranmalee; Bielak, Allison A. M.; Bunce, David; Easteal, Simon; Cherbuin, Nicolas; Anstey, Kaarin J.			Long-Term Cognitive Correlates of Traumatic Brain Injury across Adulthood and Interactions with APOE Genotype, Sex, and Age Cohorts	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive decline; Dementia; Prospective study; Head injury; Epidemiology	APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; GENDER-DIFFERENCES; AMYLOID-BETA; EPSILON-4; ASSOCIATION; POPULATION; METAANALYSIS	There is continuing debate about long-term effects of brain injury. We examined a range of traumatic brain injury (TBI) variables (TBI history, severity, frequency, and age of injury) as predictors of cognitive outcome over 8 years in an adult population, and interactions with apolipoprotein E (APOE) genotype, sex, and age cohorts. Three randomly sampled age cohorts (20-24, 40-44, 60-64 years at baseline; N = 6333) were each evaluated three times over 8 years. TBI variables, based on self-report, were separately modeled as predictors of cognitive performance using linear mixed effects models. TBI predicted longitudinal cognitive decline in all three age groups. APOE epsilon 4 ( + ) genotypes in the young and middle-aged groups predicted lower baseline cognitive performance in the context of TBI. Baseline cognitive performance was better for young females than males but this pattern reversed in middle age and old age. The findings suggest TBI history is associated with long-term cognitive impairment and decline across the adult lifespan. A role for APOE genotype was apparent in the younger cohorts but there was no evidence that it is associated with impairment in early old age. The effect of sex and TBI on cognition varied with age cohort, consistent with a proposed neuroprotective role for estrogen. (JINS, 2014, 20, 444-454)	[Eramudugolla, Ranmalee; Cherbuin, Nicolas; Anstey, Kaarin J.] Australian Natl Univ, Ctr Res Aging Hlth & Wellbeing, Canberra, ACT 0200, Australia; [Bielak, Allison A. M.] Colorado State Univ, Dept Human Dev & Family Studies, Ft Collins, CO 80523 USA; [Bunce, David] Univ Leeds, Inst Psychol Sci, Fac Med & Hlth, Leeds, W Yorkshire, England; [Easteal, Simon] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 0200, Australia		Eramudugolla, R (corresponding author), Australian Natl Univ, Ctr Res Aging Hlth & Wellbeing, GPO Box 4, Canberra, ACT 0200, Australia.	ranmalee.eramudugolla@anu.edu.au	Anstey, Kaarin/A-3852-2008; Eramudugolla, Ranmalee/AAL-7661-2021; Cherbuin, Nicolas/A-8515-2008; Bielak, Allison A. M./H-2388-2012	Anstey, Kaarin/0000-0002-9706-9316; Cherbuin, Nicolas/0000-0001-6481-0748; Bielak, Allison A. M./0000-0003-2925-0372; Easteal, Simon/0000-0002-0462-502X; Eramudugolla, Ranmalee/0000-0001-5097-8267; Bunce, David/0000-0003-3265-2700	National Health and Medical Research Council (NHMRC) of Australia Unit GrantNational Health and Medical Research Council of Australia [973302, 179805]; NHMRC project grantNational Health and Medical Research Council of Australia [157125]; Australian Rotary Health Research Fund; Australian Brewers Foundation; NHMRCNational Health and Medical Research Council of Australia [1002560]; Dr. Cherbuin by ARC FellowshipAustralian Research Council [120100227]; Leverhulme Trust, UKLeverhulme Trust	The authors are grateful to the PATH Chief Investigators, Chantal Meslin, Patricia Jacomb, Karen Maxwell, and the PATH interviewers. Susan Tan and Karen Nunweek provided technical assistance with the APOE genotyping. The study was supported by the National Health and Medical Research Council (NHMRC) of Australia Unit Grant No. 973302, Program Grant No. 179805, NHMRC project grant No. 157125, grants from the Australian Rotary Health Research Fund, and the Australian Brewers Foundation. Prof Anstey was funded by NHMRC Fellowships No. 1002560, and Dr. Cherbuin by ARC Fellowship 120100227. Dr. Bunce was funded by the Leverhulme Trust, UK. The authors declare there are no financial or other relationships that could be interpreted as a conflict of interest affecting this manuscript. The authors have no conflicts of interest to declare.	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Anstey KJ, 2012, INT J EPIDEMIOL, V41, P951, DOI 10.1093/ije/dyr025; Ardelt AA, 2012, BRAIN RES, V1461, P76, DOI 10.1016/j.brainres.2012.04.024; BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Bunce D., 2013, J GERONTOLOGY A; Bunce D, 2011, NEUROPSYCHOLOGIA, V49, P1693, DOI 10.1016/j.neuropsychologia.2011.02.042; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Dardiotis E, 2012, CURR OPIN PSYCHIATR, V25, P231, DOI 10.1097/YCO.0b013e3283523c0e; Delis DC, 1987, CALIFORNIA VERBAL LE; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Han SD, 2008, ALZHEIMERS DEMENT, V4, P251, DOI 10.1016/j.jalz.2008.02.006; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Hartman RE, 2002, J NEUROSCI, V22, P10083; Ihle A, 2012, NEUROPSYCHOLOGY, V26, P267, DOI 10.1037/a0026769; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jorm AF, 2007, NEUROPSYCHOLOGY, V21, P1, DOI 10.1037/0894-4105.21.1.1; Katzman R, 1996, NEUROLOGY, V46, P889; Kokjohn TA, 2012, ALZHEIMERS DEMENT, V8, P574, DOI 10.1016/j.jalz.2011.05.2429; Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Mondadori CRA, 2007, CEREB CORTEX, V17, P1934, DOI 10.1093/cercor/bhl103; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wechsler D., 1955, MANUAL WECHSLER ADUL; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Zhong N, 2008, ALZHEIMERS DEMENT, V4, P179, DOI 10.1016/j.jalz.2008.01.006	49	28	29	0	19	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	APR	2014	20	4					444	454		10.1017/S1355617714000174			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	AD9CI	WOS:000333561900010	24670469	Green Accepted			2022-02-06	
J	Rowe, AS; Goodwin, H; Brophy, GM; Bushwitz, J; Castle, A; Deen, D; Johnson, D; Lesch, C; Liang, N; Potter, E; Roels, C; Samaan, K; Rhoney, DH				Rowe, A. Shaun; Goodwin, Haley; Brophy, Gretchen M.; Bushwitz, Jennifer; Castle, Amber; Deen, David; Johnson, Dachelle; Lesch, Christine; Liang, Norah; Potter, Emily; Roels, Christina; Samaan, Karen; Rhoney, Denise H.		Neurocritical Care Soc Pharm Sect	Seizure Prophylaxis in Neurocritical Care: A Review of Evidence-Based Support	PHARMACOTHERAPY			English	Article						seizure; prophylaxis; phenytoin; levetiracetam; critical care	ANEURYSMAL SUBARACHNOID HEMORRHAGE; QUALITY STANDARDS SUBCOMMITTEE; STEVENS-JOHNSON-SYNDROME; BRAIN-TUMORS; INTRACEREBRAL HEMORRHAGE; ARTERIOVENOUS-MALFORMATIONS; ANTICONVULSANT PROPHYLAXIS; PRACTICE PARAMETER; AMERICAN-ACADEMY; ISCHEMIC-STROKE	Seizures are a well-described complication of acute brain injury and neurosurgery. Antiepileptic drugs (AEDs) are frequently utilized for seizure prophylaxis in neurocritical care patients. In this review, the Neurocritical Care Society Pharmacy Section describes the evidence associated with the use of AEDs for seizure prophylaxis in patients with intracerebral tumors, traumatic brain injury, aneurysmal subarachnoid hemorrhage, craniotomy, ischemic stroke, and intracerebral hemorrhage. Clear evidence indicates that the short-term use of AEDs for seizure prophylaxis in patients with traumatic brain injury and aneurysmal subarachnoid hemorrhage may be beneficial; however, evidence to support the use of AEDs in other disease states is less clear.	[Rowe, A. Shaun] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Dept Clin Pharm, Knoxville, TN USA; [Goodwin, Haley] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA; [Bushwitz, Jennifer] Shands Univ Florida, Dept Pharm, Gainesville, FL USA; [Castle, Amber] Yale New Haven Med Ctr, Dept Pharm, New Haven, CT 06504 USA; [Deen, David] Mem Hlth Univ Med Ctr, Dept Pharm, Savannah, GA 31404 USA; [Johnson, Dachelle] Johns Hopkins Bayview Med Ctr, Dept Pharm, Baltimore, MD USA; [Lesch, Christine] NewYork Presbyterian, Dept Pharm, New York, NY USA; [Liang, Norah] Hartford Hosp, Dept Pharm, Hartford, CT 06115 USA; [Potter, Emily] Dwight D Eisenhower Med Ctr, Dept Vet Affairs, Leavenworth, KS USA; [Roels, Christina] Forsyth Med Ctr, Dept Pharm, Winston Salem, NC USA; [Samaan, Karen] St Vincent Hosp, Dept Pharm, Indianapolis, IN USA; [Rhoney, Denise H.] Univ N Carolina, Eshelman Sch Pharm, Div Practice Adv & Clin Educ, Chapel Hill, NC USA		Goodwin, H (corresponding author), Johns Hopkins Univ Hosp, Dept Pharm, 600 North Wolfe St Carnegie 180, Baltimore, MD 21287 USA.	hgood-wi3@jhmi.edu		Rowe, Anthony/0000-0002-2533-9233; Brophy, Gretchen/0000-0002-4749-2693			Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], CENTR NERV SYST CANC; BAKER CJ, 1995, NEUROSURGERY, V37, P863, DOI 10.1227/00006123-199511000-00003; Beghi E, 2011, NEUROLOGY, V77, P1785, DOI 10.1212/WNL.0b013e3182364878; BERGER AR, 1988, NEUROLOGY, V38, P1363, DOI 10.1212/WNL.38.9.1363; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Burn J, 1997, BRIT MED J, V315, P1582, DOI 10.1136/bmj.315.7122.1582; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chumnanvej S, 2007, NEUROSURGERY, V60, P99, DOI 10.1227/01.NEU.0000249207.66225.D9; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2007, NEUROSURGERY, V61, P60, DOI 10.1227/01.neu.0000279724.05898.e7; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; De Herdt V, 2011, NEUROLOGY, V77, P1794, DOI 10.1212/WNL.0b013e31823648a6; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; Forsyth PA, 2003, CAN J NEUROL SCI, V30, P106, DOI 10.1017/S0317167100053361; Gilmore E, 2010, NEUROLOGIST, V16, P165, DOI 10.1097/NRL.0b013e3181c7cd0b; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; Hanon E, 2001, SEIZURE-EUR J EPILEP, V10, P287, DOI 10.1053/seiz.2000.0511; Hart Y, 2011, J NEUROSURG, V115, P1159, DOI 10.3171/2011.6.JNS101836; Hoh BL, 2011, NEUROSURGERY, V69, P644, DOI 10.1227/NEU.0b013e31821bc46d; HORNER S, 1995, J NEUROL SCI, V132, P57, DOI 10.1016/0022-510X(95)00122-I; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; JENNETT B, 1973, SCOT MED J, V18, P8, DOI 10.1177/003693307301800103; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Josephson CB, 2011, NEUROLOGY, V76, P1548, DOI 10.1212/WNL.0b013e3182190f37; Kandil AO, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-49; Kern K, 2012, J CLIN NEUROSCI, V19, P99, DOI 10.1016/j.jocn.2011.07.021; Khafaga YM, 1999, ACTA ONCOL, V38, P111, DOI 10.1080/028418699431898; KILPATRICK CJ, 1992, ARCH NEUROL-CHICAGO, V49, P509, DOI 10.1001/archneur.1992.00530290097017; Komotar RJ, 2011, J NEUROSURG, V115, P483, DOI 10.3171/2011.4.JNS101585; Kruer RM, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.11.020; Kwan J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005398.pub2; Lamy C, 2003, NEUROLOGY, V60, P400, DOI 10.1212/WNL.60.3.400; LANCMAN ME, 1993, EPILEPSIA, V34, P141, DOI 10.1111/j.1528-1157.1993.tb02386.x; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Meador KJ, 2007, NEUROLOGY, V69, P2076, DOI 10.1212/01.wnl.0000281104.55418.60; Messe S, 2009, NEUROCRIT CARE, V11, P38, DOI 10.1007/s12028-009-9207-y; Mikkelsen T, 2010, J NEURO-ONCOL, V96, P97, DOI 10.1007/s11060-009-0056-5; Milligan TA, 2008, NEUROLOGY, V71, P665, DOI 10.1212/01.wnl.0000324624.52935.46; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Murphy-Human T, 2011, WORLD NEUROSURG, V75, P269, DOI 10.1016/j.wneu.2010.09.002; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458; Olafsson E, 2000, EPILEPSIA, V41, P1201, DOI 10.1111/j.1528-1157.2000.tb00326.x; Passero S, 2002, EPILEPSIA, V43, P1175, DOI 10.1046/j.1528-1157.2002.00302.x; PECHADRE JC, 1991, PRESSE MED, V20, P841; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Schierhout G, 2001, COCHRANE DB SYST REV, V4; Sirven JI, 2004, MAYO CLIN PROC, V79, P1489, DOI 10.4065/79.12.1489; Smith KM, 2006, NEUROSURGERY, V58, P426, DOI 10.1227/01.NEU.000197321.57853.83; Szaflarski JP, 2008, EPILEPSIA, V49, P974, DOI 10.1111/j.1528-1167.2007.01513.x; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TARTARA A, 1991, BRIT J CLIN PHARMACO, V32, P335, DOI 10.1111/j.1365-2125.1991.tb03908.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Tremont-Lukats IW, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004424.pub2; UCBI, 2006, KEPPR LEV PACK INS; van Breemen MSM, 2007, LANCET NEUROL, V6, P421, DOI 10.1016/S1474-4422(07)70103-5; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; Wu AS, 2013, J NEUROSURG, V118, P873, DOI 10.3171/2012.12.JNS111970; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x; Zachenhofer I, 2011, J NEURO-ONCOL, V101, P101, DOI 10.1007/s11060-010-0235-4	75	28	29	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-0008	1875-9114		PHARMACOTHERAPY	Pharmacotherapy	APR	2014	34	4					396	409		10.1002/phar.1374			14	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	AE1RC	WOS:000333746000013	24277723				2022-02-06	
J	Teel, EF; Ray, WJ; Geronimo, AM; Slobounov, SM				Teel, E. F.; Ray, W. J.; Geronimo, A. M.; Slobounov, S. M.			Residual alterations of brain electrical activity in clinically asymptomatic concussed individuals: An EEG study	CLINICAL NEUROPHYSIOLOGY			English	Article						Concussion; EEG; Power; Coherence; ImPACT; Virtual Reality (VR)	SYMPTOMS; QEEG	Objective: To examine the neural substrates underlying performance on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and HeadRehab Virtual Reality (VR) balance and spatial modules in a concussed and control group. Methods: Thirteen controls and seven concussed participants were fitted with a Geodesic 128-channel EEG cap and completed three assessments: EEG baseline, ImPACT testing, and VR balance and spatial modules. Concussed participants completed were tested within 8 (5 +/- 1) days after injury. Results: EEG power was significantly (p <.05) decreased in the concussed group over all testing modalities. EEG coherence was significantly (p <.05) increased in the concussed group during EEG baseline and ImPACT. For VR testing, two conditions showed significant (p <.05) increases in EEG coherence between ROIs, while two different conditions showed significant (p <.05) decreases in coherence levels. Conclusions: Concussed participants passed all clinical concussion testing tools, but showed pathophysiological dysfunction when evaluating EEG variables. Significance: Concussed participants are able to compensate and achieve normal functioning due to recruiting additional brain networks. This allows concussed participants to pass clinical tests while still displaying electrophysiological deficits and clinicians must consider this information when making return-to-play decisions. (C) 2013 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Teel, E. F.; Slobounov, S. M.] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Teel, E. F.; Slobounov, S. M.] Penn State Ctr Sport Concuss Res & Serv, University Pk, PA 16802 USA; [Ray, W. J.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Geronimo, A. M.] Penn State Univ, Dept Engn Sci & Mech, University Pk, PA 16802 USA		Slobounov, SM (corresponding author), 276 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu		Teel, Elizabeth/0000-0002-2846-5884	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2R01 NS056227-06]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	This research was supported by National Institute of Health Grant # 2R01 NS056227-06 "The Effects of Mild Traumatic Brain Injury on Neuropsychological Test Scores, Postural Stability and General Brain Function''. The authors would like to thank Katie Finelli, Jordan Griswold, Chris Ertle, and Phil Derise for their assistance with data collection and signal pre-processing.	Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Cannon RL, 2012, NEUROSCI LETT, V518, P27, DOI 10.1016/j.neulet.2012.04.035; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hillman CH, 2000, BIOL PSYCHOL, V52, P71, DOI 10.1016/S0301-0511(99)00021-6; Knyazev GG, 2007, NEUROSCI BIOBEHAV R, V31, P377, DOI 10.1016/j.neubiorev.2006.10.004; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; R Development Core Team, 2012, R LANG ENV STAT COMP; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006	12	28	28	5	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	APR	2014	125	4					703	707		10.1016/j.clinph.2013.08.027			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AC3FH	WOS:000332400300010	24140103				2022-02-06	
J	Alharfi, IM; Stewart, TC; Al Helali, I; Daoud, H; Fraser, DD				Alharfi, Ibrahim M.; Stewart, Tanya Charyk; Al Helali, Ibrahim; Daoud, Hani; Fraser, Douglas D.			Infection Rates, Fevers, and Associated Factors in Pediatric Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						children; nosocomial infection; severe traumatic brain injury; treatment	POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER; WAR VETERANS; AXONAL INJURY; MULTIPLE-SCLEROSIS; DIFFUSION MRI; STEADY-STATE; HEAD-INJURY; FDG-PET; IMAGES	Infections can increase medical costs and worsen patient outcomes. Our aims in pediatric severe traumatic brain injury (sTBI) patients were to determine the infection and fever rates, and to report on associated clinical, imaging, treatment, and outcome factors. We included 180 sTBI patients (presedation Glasgow Coma Scale <= 8 and Maximum Abbreviated Injury Scale >= 4) admitted to our pediatric intensive care unit. Overall, 17% of sTBI patients (n=30 of 180) developed 36 infections, consisting primarily of urinary tract infections (UTIs; n=13 of 36) and ventilator-associated pneumonias (n=11 of 36). Most infections were nosocomial, occurring >2 days after admission. Fever was found in 36% of sTBI patients during the first few hospital days, but fewer than 7% of patients had infections. Infections occurred more frequently in sTBI patients who were older, heavier, and with a higher injury severity score (ISS; p<0.05). Admission head computed tomography imaging abnormalities (subarachnoid hemorrhage, intraventricular hemorrhage, and diffuse axonal injury), placement of an intracranial pressure (ICP) monitor, and administration of ICP-lowering therapies (hypertonic saline, mannitol, and thiopental) were associated with infections (p<0.05). Those with infections had fewer ventilator-free days, greater hospital lengths of stays, and were less likely to be discharged home. Logistic regression demonstrated that infections were independently associated with use of hypertonic saline (odds ratio [OR], 4.46; p=0.001) and higher ISS (OR, 1.05; p=0.028). In summary, infections were prevalent in sTBI patients and were associated with greater head-imaging abnormalities and use of ICP-lowering therapies. Hypertonic saline administration was strongly associated with infection, but further analyses are required to determine the nature of this relationship. Fever was a poor indicator of infection after sTBI.	[Alharfi, Ibrahim M.; Al Helali, Ibrahim; Daoud, Hani; Fraser, Douglas D.] Univ Western Ontario, Dept Paediat, London, ON, Canada; [Stewart, Tanya Charyk] Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada; [Fraser, Douglas D.] Univ Western Ontario, London, ON, Canada; [Alharfi, Ibrahim M.] King Fahad Med City, Dept Pediat Crit Care, Riyadh, Saudi Arabia; [Stewart, Tanya Charyk] London Hlth Sci Ctr, Trauma Program, London, ON, Canada; [Fraser, Douglas D.] Translat Res Ctr, London, ON, Canada; [Fraser, Douglas D.] Childrens Hlth Res Inst, London, ON, Canada; [Fraser, Douglas D.] Ctr Crit Illness Res, London, ON, Canada		Fraser, DD (corresponding author), Childrens Hosp, London Hlth Sci Ctr, Room C2-C82 800 Commissioners Rd East, London, ON N6A 5W9, Canada.	Douglas.Fraser@lhsc.on.ca					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ayling E, 2012, CURR PSYCHIAT REP, V14, P197, DOI 10.1007/s11920-012-0273-z; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; BOOKSTEIN FL, 1989, IEEE T PATTERN ANAL, V11, P567, DOI 10.1109/34.24792; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clark WEL, 1936, J ANAT, V71, P7; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Edden RA, 2011, J NEUROSCI METH, V201, P213, DOI 10.1016/j.jneumeth.2011.07.025; Eibner C, 2009, NEW ENGL J MED, V361, P537; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hosaka K, 2005, EUR J NUCL MED MOL I, V32, P92, DOI 10.1007/s00259-004-1576-z; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kang XJ, 2012, MAGN RESON IMAGING, V30, P1111, DOI 10.1016/j.mri.2012.04.004; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu ZX, 2009, 2009 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: FROM NANO TO MACRO, VOLS 1 AND 2, P807, DOI 10.1109/ISBI.2009.5193172; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; MARTINEZMARTIN P, 1994, MOVEMENT DISORD, V9, P76, DOI 10.1002/mds.870090112; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1992, J NUCL MED, V33, P1579; MINOSHIMA S, 1993, J NUCL MED, V34, P322; MINOSHIMA S, 1994, J NUCL MED, V35, P949; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Minoshima S, 2002, J GERIATR PSYCH NEUR, V15, P200, DOI 10.1177/089198870201500405; Minoshima S., 2009, PRINCIPLES AND PRACT, P500; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Oishi K., 2011, MRI ATLAS HUMAN WHIT, V2nd Edn.; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Rausch M, 2009, MULT SCLER, V15, P16, DOI 10.1177/1352458508096006; Samsonov A, 2012, NEUROIMAGE, V62, P1390, DOI 10.1016/j.neuroimage.2012.05.077; Schmierer K, 2007, J MAGN RESON IMAGING, V26, P41, DOI 10.1002/jmri.20984; Sigford B, 2009, NEW ENGL J MED, V361, P536, DOI 10.1056/NEJMc096180; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Skinner TE, 1997, MAGN RESON MED, V37, P628, DOI 10.1002/mrm.1910370426; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Talairach J., 1988, COPLANAR STEREOTAXIC; Tustison NJ, 2012, HUM BRAIN MAPP; Underhil HR, 2009, NEUROIMAGE, V47, P1568, DOI 10.1016/j.neuroimage.2009.05.075; Underhill HR, 2011, NEUROIMAGE, V54, P2052, DOI 10.1016/j.neuroimage.2010.10.065; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Yarnykh VL, 2007, MAGN RESON MED, V57, P192, DOI 10.1002/mrm.21120; Yarnykh VL, 2012, MAGN RESON MED, V68, P166, DOI 10.1002/mrm.23224; Yarnykh VL, 2010, MAGN RESON MED, V63, P1610, DOI 10.1002/mrm.22394; Yarnykh VL, 2004, NEUROIMAGE, V23, P409, DOI 10.1016/j.neuroimage.2004.04.029; Yarnykh VL, 2002, MAGNET RESON MED, V47, P929, DOI 10.1002/mrm.10120	71	28	33	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					452	458		10.1089/NEU.2013.2904			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600243	24093309				2022-02-06	
J	Knutson, KM; Dal Monte, O; Raymont, V; Wassermann, EM; Krueger, F; Grafman, J				Knutson, Kristine M.; Dal Monte, Olga; Raymont, Vanessa; Wassermann, Eric M.; Krueger, Frank; Grafman, Jordan			Neural correlates of apathy revealed by lesion mapping in participants with traumatic brain injuries	HUMAN BRAIN MAPPING			English	Article						voxel-based lesion-symptom mapping; apathy; cingulate cortex; fatigue; traumatic brain injury; insula	PENETRATING HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC INVENTORY; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; COGNITIVE FATIGUE; RATING-SCALE; CORTEX; PERFUSION; SYMPTOMS	Apathy, common in neurological disorders, is defined as disinterest and loss of motivation, with a reduction in self-initiated activity. Research in diseased populations has shown that apathy is associated with variations in the volume of brain regions such as the anterior cingulate and the frontal lobes. The goal of this study was to determine the neural signatures of apathy in people with penetrating traumatic brain injuries (pTBIs), as to our knowledge, these have not been studied in this sample. We studied 176 male Vietnam War veterans with pTBIs using voxel-based lesion-symptom mapping (VLSM) and apathy scores from the UCLA Neuropsychiatric Inventory (NPI), a structured inventory of symptoms completed by a caregiver. Our results revealed that increased apathy symptoms were associated with brain damage in limbic and cortical areas of the left hemisphere including the anterior cingulate, inferior, middle, and superior frontal regions, insula, and supplementary motor area. Our results are consistent with the literature, and extend them to people with focal pTBI. Apathy is a significant symptom since it can reduce participation of the patient in family and other social interactions, and diminish affective decision-making. Hum Brain Mapp 35:943-953, 2014. (c) 2013 Wiley Periodicals, Inc.	[Knutson, Kristine M.; Dal Monte, Olga; Wassermann, Eric M.] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Dal Monte, Olga] Univ Turin, Dept Neuropsychol, Turin, Italy; [Dal Monte, Olga] Henry M Jackson Fdn, Rockville, MD USA; [Raymont, Vanessa] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England; [Raymont, Vanessa] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Grafman, Jordan] Rehabil Inst Chicago, Brain Injury Res Program, Chicago, IL 60611 USA		Grafman, J (corresponding author), Rehabil Inst Chicago, Brain Injury Res Program, 345 East Super St, Chicago, IL 60611 USA.	fkrueger@gmu.edu; jgrafman@ric.org	Wassermann, Eric M./AAC-9064-2020; Dal Monte, Olga/P-3759-2018	Wassermann, Eric M./0000-0003-0628-0210; Dal Monte, Olga/0000-0002-7823-4769; Grafman, Jordan H./0000-0001-8645-4457; Knutson, Kristine/0000-0003-4626-4514	U.S. National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]	This work was supported by funding from the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the United States Army Medical Research and Material Command administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study, grant number DAMD17-01-1-0675).	Aalten P, 2008, DEMENT GERIATR COGN, V25, P1, DOI 10.1159/000111082; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Apostolova LG, 2007, DEMENT GERIATR COGN, V24, P91, DOI 10.1159/000103914; Beck, 1978, BECK DEPRESSION INVE; Benoit M, 2004, INT J GERIATR PSYCH, V19, P864, DOI 10.1002/gps.1163; Benoit M, 2002, PSYCHIAT RES-NEUROIM, V114, P103, DOI 10.1016/S0925-4927(02)00003-3; Benoit M, 1999, DEMENT GERIATR COGN, V10, P511, DOI 10.1159/000017198; Bruen PD, 2008, BRAIN, V131, P2455, DOI 10.1093/brain/awn151; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Cook DB, 2007, NEUROIMAGE, V36, P108, DOI 10.1016/j.neuroimage.2007.02.033; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Craig AH, 1996, ARCH NEUROL-CHICAGO, V53, P1116, DOI 10.1001/archneur.1996.00550110056012; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Damasio A., 1994, DESCARTES ERROR EMOT; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; Dujardin K, 2008, MOVEMENT DISORD, V23, P845, DOI 10.1002/mds.21968; First M., 1995, STRUCTURED CLIN INTE, V9, P92; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Glascher J, 2009, NEURON, V61, P681, DOI 10.1016/j.neuron.2009.01.026; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Greene J G, 1982, Age Ageing, V11, P121, DOI 10.1093/ageing/11.2.121; Guimaraes HC, 2008, ARQ NEURO-PSIQUIAT, V66, P436, DOI 10.1590/S0004-282X2008000300035; Hoare J, 2010, J NEUROPSYCH CLIN N, V22, P313, DOI 10.1176/appi.neuropsych.22.3.313; Holthoff VA, 2005, BIOL PSYCHIAT, V57, P412, DOI 10.1016/j.biopsych.2004.11.035; JENNETT B, 1975, LANCET, V1, P480; Jouvent E, 2011, NEUROLOGY, V76, P1472, DOI 10.1212/WNL.0b013e31821810a4; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Kim JW, 2011, AM J GERIAT PSYCHIAT, V19, P644, DOI 10.1097/JGP.0b013e31820dcc73; Kirsch-Darrow L, 2011, J INT NEUROPSYCH SOC, V17, P1058, DOI 10.1017/S1355617711001068; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kumral E, 2002, EUR J NEUROL, V9, P615, DOI 10.1046/j.1468-1331.2002.00452.x; Lanctot KL, 2007, DEMENT GERIATR COGN, V24, P65, DOI 10.1159/000103633; Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x; LAPLANE D, 1981, J NEUROL SCI, V51, P289, DOI 10.1016/0022-510X(81)90107-6; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; LUDLOW CL, 1986, BRAIN, V109, P55, DOI 10.1093/brain/109.1.55; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Manes F, 1999, J NERV MENT DIS, V187, P707, DOI 10.1097/00005053-199912000-00001; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; Marshall GA, 2006, DEMENT GERIATR COGN, V21, P144, DOI 10.1159/000090674; Marshall GA, 2007, ARCH NEUROL-CHICAGO, V64, P1015, DOI 10.1001/archneur.64.7.1015; Massimo L, 2009, DEMENT GERIATR COGN, V27, P96, DOI 10.1159/000194658; Migneco O, 2001, NEUROIMAGE, V13, P896, DOI 10.1006/nimg.2000.0741; Miller B. L., 1999, SCI PRACT NEUROPSYCH; Mori S, 2005, MRI ATLAS HUMAN WHIT; Mortby Moyra Elizabeth, 2012, Aging Clin Exp Res, V24, P305, DOI 10.3275/8105; Nieuwenhuys R, 2012, PROG BRAIN RES, V195, P123, DOI 10.1016/B978-0-444-53860-4.00007-6; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pardini M, 2010, NEUROLOGY, V74, P749, DOI 10.1212/WNL.0b013e3181d25b6b; Plassmann H, 2007, J NEUROSCI, V27, P9984, DOI 10.1523/JNEUROSCI.2131-07.2007; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Reijnders JSAM, 2010, MOVEMENT DISORD, V25, P2318, DOI 10.1002/mds.23268; Robert PH, 2006, EUR J NEUROL, V13, P729, DOI 10.1111/j.1468-1331.2006.01088.x; Robert PH, 2002, INT J GERIATR PSYCH, V17, P1099, DOI 10.1002/gps.755; Rosen HJ, 2005, BRAIN, V128, P2612, DOI 10.1093/brain/awh628; Rudebeck PH, 2006, NAT NEUROSCI, V9, P1161, DOI 10.1038/nn1756; Rushworth MFS, 2007, TRENDS COGN SCI, V11, P168, DOI 10.1016/j.tics.2007.01.004; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Sescousse G, 2010, J NEUROSCI, V30, P13095, DOI 10.1523/JNEUROSCI.3501-10.2010; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.987.872; Starkstein SE, 2009, J NEUROPSYCH CLIN N, V21, P259, DOI 10.1176/appi.neuropsych.21.3.259; Tunnard C, 2011, INT J GERIATR PSYCH, V26, P741, DOI 10.1002/gps.2603; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Woolley SC, 2011, AMYOTROPH LATERAL SC, V12, P52, DOI 10.3109/17482968.2010.521842; Zamboni G, 2008, NEUROLOGY, V71, P736, DOI 10.1212/01.wnl.0000324920.96835.95	75	28	29	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAR	2014	35	3					943	953		10.1002/hbm.22225			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AF0IW	WOS:000334398500016	23404730	Green Published, Green Accepted			2022-02-06	
J	Gu, XJ; Xu, J; Ma, BY; Chen, G; Gu, PY; Wei, D; Hu, WX				Gu Xiangjin; Xu Jin; Ma Banyou; Chen Gong; Gu Peiyuan; Wei Dong; Hu Weixing			Effect of glycyrrhizin on traumatic brain injury in rats and its mechanism	CHINESE JOURNAL OF TRAUMATOLOGY			English	Article						Glycyrrhizic acid; HMGB1 protein; Brain injuries; Neuroprotective agents		Objective: To investigate the neuroprotective effects of glycyrrhizin (Gly) as well as its effect on expression of high-mobility group box 1 (HMGB1) in rats after traumatic brain injury (TBI). Methods: Male Sprague-Dawley rats were randomly divided into three groups: sham group, TBI group, and TBI+Gly group (n=36 per group). Rat TBI model was made by using the modified Feeney's method. In TBI+Gly group, Gly was administered intravenously at a dosage of 10 mg/kg 30 min after TBI. At 24 h after TBI, motor function and brain water content were evaluated. Meanwhile, HMGB1/HMGB1 receptors including toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE)/nuclear factor - kappa B(NF - kappa B) signaling pathway and inflammatory cytokines in the injured brain tissues were detected using quantitative real-time polymerase chain reaction, western blot, electrophoretic mobility shift assay and enzyme-linked immunosorbent assay. Furthermore, HMGB1, RAGE and TLR4 immunohistochemistry and apoptosis were analyzed. Results: Beam walking performance impairment and brain edema were significantly reduced in TBI+Gly group compared with TBI group; meanwhile, the over-expressions of HMGB1/HMGB1 receptors (TLR4 and RAGE)/NF - kappa B DNA-binding activity and inflammatory cytokines were inhibited. The percentages of HMGB1, RAGE and TLR4-positive cells and apoptotic cells were respectively 58.37%+/- 5.06%, 54.15%+/- 4.65%, 65.50%+/- 4.83%, 52.02%+/- 4.63% in TBI group and 39.99%+/- 4.99%, 34.87%+/- 5.02%, 43.33%+/- 4.54%, 37.84%+/- 5.16% in TBI+Gly group (all P<0.01 compared with TBI group). Conclusion: Gly can reduce secondary brain injury and improve outcomes in rat following TBI by down-regulation of HMGB1/HMGB1 receptors (TLR4 and RAGE)/NF - kappa B - mediated inflammatory responses in the injured rat brain.	[Gu Xiangjin] Nanjing Med Univ, Jiangning Hosp, Dept Neurosurg, Nanjing 211100, Jiangsu, Peoples R China; [Xu Jin; Ma Banyou; Chen Gong; Gu Peiyuan; Wei Dong; Hu Weixing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China		Hu, WX (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China.	hwx66@126.com					Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Imtiaz KE, 2011, QJM-INT J MED, V104, P1093, DOI 10.1093/qjmed/hcq233; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Luan ZG, 2010, IMMUNOBIOLOGY, V215, P956, DOI 10.1016/j.imbio.2009.11.001; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Oh YJ, 2009, J IMMUNOL, V182, P5800, DOI 10.4049/jimmunol.0801873; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; van Rossum TGJ, 2001, AM J GASTROENTEROL, V96, P2432, DOI 10.1111/j.1572-0241.2001.04049.x; Wang KY, 2012, CLIN CHIM ACTA, V413, P1737, DOI 10.1016/j.cca.2012.07.002; Zhu Shu, 2010, Inflammation & Allergy Drug Targets, V9, P60	24	28	29	0	5	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	1008-1275			CHIN J TRAUMATOL	Chin. J. Traumatol.	FEB	2014	17	1					1	7		10.3760/cma.j.issn.1008-1275.2014.01.001			7	Orthopedics	Emerging Sources Citation Index (ESCI)	Orthopedics	VF1IX	WOS:000442039700001	24506915				2022-02-06	
J	Vaaramo, K; Puljula, J; Tetri, S; Juvela, S; Hillbom, M				Vaaramo, K.; Puljula, J.; Tetri, S.; Juvela, S.; Hillbom, M.			Head trauma sustained under the influence of alcohol is a predictor for future traumatic brain injury: a long-term follow-up study	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						alcohol; harmful drinking; hazardous drinking; head trauma; traumatic brain injury	DRINKING; INTERVENTIONS; RISK	Background and purposeHazardous drinking may result in recurrent head trauma. It was investigated whether head trauma sustained under the influence of alcohol is a predictor of future traumatic brain injury (TBI). MethodsAll subjects with head trauma (n=827) brought to the emergency room at Oulu University Hospital during 1999 were identified and followed up until death or the end of 2009. The National Hospital Discharge Register and hospital charts were used to identify TBIs during the follow-up and Kaplan-Meier curves and the Cox proportional hazards model were used to characterize predictors of TBI. ResultsDuring the total follow-up of 7386 person-years, 52/827 subjects sustained a new head trauma with TBI and the risk of TBI was significantly (P=0.005) higher amongst subjects who had been under the influence of alcohol at the time of the index trauma in 1999. New TBI occurred under the influence of alcohol in 30/52 cases (57.7%). An alcohol-related index trauma [adjusted hazard ratio (HR) 2.51, 95% confidence interval (CI) 1.38-4.56, P<0.01] and history of TBI (HR 3.39, 95% CI 1.32-8.72, P<0.05) were independent risk factors for subsequent TBI after adjustment for sex and age. A history of harmful drinking was also a significant risk factor (adjusted HR 10.37, 95% CI 5.53-19.43, P<0.001). In the subset of 396 patients having an index head trauma without TBI, this being alcohol related was also a significant risk factor for subsequent TBI after adjustment for sex, age and history of TBI (HR 3.54, 95% CI 1.36-9.18, P=0.009). ConclusionsEven head trauma without TBI under the influence of alcohol implies an elevated risk of subsequent TBI. A brief intervention to reduce hazardous drinking is needed to prevent TBI.	[Vaaramo, K.; Puljula, J.; Hillbom, M.] Univ Oulu, Dept Neurol, Oulu Univ Hosp, Oulu, Finland; [Tetri, S.] Univ Oulu, Dept Neurosurg, Oulu Univ Hosp, Oulu, Finland; [Juvela, S.] Univ Helsinki, Dept Clin Neurosci, Helsinki, Finland		Vaaramo, K (corresponding author), Oulu Univ Hosp, Dept Neurol, Box 25, Oulu 90029, Finland.	kallevaa@mail.student.oulu.fi		Juvela, Seppo/0000-0003-4944-4983	Maire Taponen Foundation	This research was supported in part by a grant to Dr Vaaramo from the Maire Taponen Foundation.	Babor TF, 2005, J TRAUMA, V59, pS80, DOI 10.1097/01.ta.0000174664.88603.21; BABOR TF, 1994, LEXICON ALCOHOL OTHE; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dinh-Zarr T, 1999, ALCOHOL ALCOHOLISM, V34, P609, DOI 10.1093/alcalc/34.4.609; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Paljarvi T, 2005, ADDICTION, V100, P1851, DOI 10.1111/j.1360-0443.2005.01258.x; Paljarvi T, 2012, ADDICTION, V107, P323, DOI 10.1111/j.1360-0443.2011.03596.x; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Puljula J, 2007, ALCOHOL ALCOHOLISM, V42, P474, DOI 10.1093/alcalc/agm003; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Schermer CR, 2003, J TRAUMA, V54, P701, DOI 10.1097/01.TA.0000056158.25478.50; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Winqvist S, 2008, BRAIN INJURY, V22, P780, DOI 10.1080/02699050802339397; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	18	28	28	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	FEB	2014	21	2					293	298		10.1111/ene.12302			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	287MZ	WOS:000329547200020	24237603				2022-02-06	
J	Vo, NJ; Althoen, M; Hippe, DS; Prabhu, SJ; Valji, K; Padia, SA				Vo, Nghia-Jack; Althoen, Morgan; Hippe, Daniel S.; Prabhu, Somnath J.; Valji, Karim; Padia, Siddharth A.			Pediatric Abdominal and Pelvic Trauma: Safety and Efficacy of Arterial Embolization	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							ANGIOGRAPHIC EMBOLIZATION; INTERVENTIONAL RADIOLOGY; BLUNT TRAUMA; ORGAN INJURY; CHILDREN; COAGULOPATHY; MANAGEMENT	Purpose: Although transcatheter embolization is a well established technique to treat adults in the trauma setting, evidence is lacking in the pediatric population. This study assesses the safety and efficacy of arterial embolization for blunt abdominal and pelvic trauma in the pediatric population. Materials and Methods: A retrospective review of abdominal and pelvic angiograms in 97 pediatric patients with blunt trauma was conducted over an 11-year period. Abdominal angiography and embolization was performed for ongoing hepatic, I renal, splenic, or nonvisceral retroperitoneal injury. Pelvic angiography was performed in the setting of pelvic fracture with ongoing pelvic hemorrhage. Complications and clinical success rates of these procedures were assessed. Results: Of the 97 pediatric patients who underwent angiography for acute abdominal or pelvic trauma, 54 (56%) required embolization involving 62 separate sites. Injury severity score greater than 15 was present in 94% of patients. Targets of embolization included the pelvis (n = 39), liver (n = 8), kidney (n = 7), spleen (n = 6), and retroperitoneum (n = 2), Effective hemorrhage control was achieved in 47 patients (87%). Overall mortality rate was 22% (12 of 54), with most deaths related to traumatic brain injury. Five complications occurred in four patients (7%), including three major complications (hepatic abscess, bile leak, and Urinary incontinence). Conclusions: Angiography and embolization is relatively safe and potentially effective in the setting of abdominal and pelvic trauma in the pediatric population. Angiography with embolization should be considered in the treatment algorithm for this patient population.	[Vo, Nghia-Jack] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA; [Vo, Nghia-Jack] Seattle Childrens Hosp, Sect Pediat Intervent Radiol & Vasc & Intervent R, Seattle, WA USA; [Vo, Nghia-Jack] Univ Wisconsin, Madison, WI 53706 USA; [Althoen, Morgan; Prabhu, Somnath J.; Valji, Karim; Padia, Siddharth A.] Univ Wisconsin, Sect Intervent Radiol, Madison, WI 53706 USA		Vo, NJ (corresponding author), Med Coll Wisconsin, Sect Pediat Vasc & Intervent Radiol, Dept Pediat Imaging, 9000 W Wisconsin Ave,MS 721, Milwaukee, WI 53226 USA.	nvo@chw.org		Hippe, Daniel/0000-0003-2427-4404			Agolini SF, 1997, J TRAUMA, V43, P395, DOI 10.1097/00005373-199709000-00001; Bisharat N, 2001, J INFECTION, V43, P182, DOI 10.1053/jinf.2001.0904; Bize PE, 2012, J VASC INTERV RADIOL, V23, P751, DOI 10.1016/j.jvir.2012.02.009; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Christensen R., 2001, SEMIN PEDIATR SURG, P17; Dente CJ, 2009, J TRAUMA, V66, P1616, DOI 10.1097/TA.0b013e3181a59ad5; Glennie D, 2008, PEDIATR RADIOL, V38, P1180, DOI 10.1007/s00247-008-0966-y; Hamner CE, 2008, J PEDIATR SURG, V43, P916, DOI 10.1016/j.jpedsurg.2007.12.039; HANSEN ME, 1990, RADIOLOGE, V30, P331; Hendrickson JE, 2012, J PEDIATR-US, V160, P204, DOI 10.1016/j.jpeds.2011.08.019; Heran MKS, 2010, J VASC INTERV RADIOL, V21, P32, DOI 10.1016/j.jvir.2009.09.006; Johnson GE, 2013, J VASC INTERV RADIOL, V24, P363, DOI 10.1016/j.jvir.2012.12.006; Kiankhooy A, 2010, J TRAUMA, V68, P526, DOI 10.1097/TA.0b013e3181d3e5b7; Letoublon C, 2011, J TRAUMA, V70, P1032, DOI 10.1097/TA.0b013e31820e7ca1; Mayglothling JA, 2011, J EMERG MED, V41, P21, DOI 10.1016/j.jemermed.2008.10.012; Mendelson KG, 2007, SURG CLIN N AM, V87, P207, DOI 10.1016/j.suc.2006.09.016; Ohtsuka Y, 2003, PEDIATR SURG INT, V19, P29, DOI 10.1007/s00383-002-0889-x; Puapong D, 2006, J PEDIATR SURG, V41, P1859, DOI 10.1016/j.jpedsurg.2006.06.013; R Development Core Team, 2011, R LANG ENV STAT COMP; Sacks David, 2003, J Vasc Interv Radiol, V14, pS199; Schnuriger B, 2011, J TRAUMA, V70, P252, DOI 10.1097/TA.0b013e3181f2a92e; Sidhu MK, 2009, J VASC INTERV RADIOL, V20, P1115, DOI 10.1016/j.jvir.2009.07.021; Sidhu MK, 2009, PEDIATR RADIOL, V39, P506, DOI 10.1007/s00247-008-1082-8; Sweed Y., 1997, Harefuah, V132, P252; Tinkoff G, 2008, J AM COLL SURGEONS, V207, P646, DOI 10.1016/j.jamcollsurg.2008.06.342; Vane DW, 2002, J INTENSIVE CARE MED, V17, P230, DOI 10.1177/088506602237107; Velmahos GC, 2002, J TRAUMA, V53, P303, DOI 10.1097/00005373-200208000-00019; Yardeni D, 2004, J TRAUMA, V57, P404, DOI 10.1097/01.TA.0000044633.53328.F0	28	28	29	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	FEB	2014	25	2					215	220		10.1016/j.jvir.2013.09.014			6	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	AA2KU	WOS:000330924300008	24252774				2022-02-06	
J	Lang, KP; Veazey-Morris, K; Andrasik, F				Lang, Katie P.; Veazey-Morris, Katherine; Andrasik, Frank			Exploring the Role of Insomnia in the Relation Between PTSD and Pain in Veterans With Polytrauma Injuries	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mediation; insomnia; traumatic brain injury; pain; posttraumatic stress disorder; veteran	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; COMBAT VETERANS; SLEEP; WAR; IRAQ; AFGHANISTAN; PREVALENCE; VALIDATION	Background: Soldiers returning from Operation Enduring Freedom/Operation Iraqi Freedom experience polytrauma injuries including traumatic brain injury. Traumatic brain injury is often complicated by symptoms of insomnia, posttraumatic stress disorder (PTSD), and pain that can impact treatment and rehabilitation. Methods: The medical records of 137 veterans seen at a Veterans Affairs Medical Center Polytrauma clinic who sustained traumatic brain injury in combat were reviewed for this study. Demographic variables include age, sex, ethnicity, military branch, and service connection. Outcome measures include PTSD, pain, and insomnia. Results: Analyses revealed a high prevalence of PTSD, insomnia, and pain co-occurring in 51.8% of veterans. Increased PTSD symptomatology was significantly correlated with reports of more pain severity (r = 0.53), pain interference (r = 0.61), and insomnia (r = 0.67). Further analyses, controlling for service connection, indicated that insomnia partially mediated the relation between PTSD and both pain severity and interference. Conclusions: These results highlight the overlap and complexity of presenting complaints in veterans and help identify the role of sleep disturbances in complicating diagnosis and treatment of veterans. As sleep problems reduce pain tolerance and exacerbate other symptoms, such as cognitive deficits and irritability, failure to address sleep disturbances may compromise rehabilitation efforts, suggesting the importance of a multidisciplinary team approach to assessing and treating these veterans.	[Lang, Katie P.; Veazey-Morris, Katherine; Andrasik, Frank] Univ Memphis, Dept Psychol, Memphis, TN 38152 USA; [Veazey-Morris, Katherine] Memphis VA Med Ctr, Memphis, TN USA		Lang, KP (corresponding author), Univ Memphis, Dept Psychol, 202 Psychol Bldg, Memphis, TN 38152 USA.	klang1@memphis.edu		Andrasik, Frank/0000-0001-6625-479X	Memphis VA Medical Center Office of Research and Development	This work was supported by the Memphis VA Medical Center Office of Research and Development.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; ANDRASIK F, 1981, HEADACHE, V21, P218, DOI 10.1111/j.1526-4610.1981.hed2105218.x; Andrasik F., 2009, P 2 DEPL MENT HLTH S; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beecher H. K., 1959, MEASUREMENT SUBJECTI; Belleville G, 2011, J PSYCHOSOM RES, V70, P318, DOI 10.1016/j.jpsychores.2010.09.022; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bourbonnais Frances Fothergill, 2004, J Nurs Manag, V12, P194; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carskadon MA, 2000, PRINC PRACT SLEEP ME, V2, P13; Clark W., 1983, PAIN MEASUREMENT ASS, P15; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Defrin R, 2008, PAIN, V138, P450, DOI 10.1016/j.pain.2008.05.006; Ebben MR, 2009, J BEHAV MED, V32, P244, DOI 10.1007/s10865-008-9198-8; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gehrman PR., 2011, J AGGRESS MALTREAT T, V20, P904, DOI DOI 10.1080/10926771.2011.613448; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; INMAN DJ, 1990, J TRAUMA STRESS, V3, P429, DOI DOI 10.1007/BF00974782; Jackson P, 2013, VISN 09 DATA EXTRACT; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kobayashi I, 2007, PSYCHOPHYSIOLOGY, V44, P660, DOI 10.1111/j.1469-8986.2007.537.x; LAVIE P, 1979, AM J PSYCHIAT, V136, P175; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Litz BT, 1997, AM J PSYCHIAT, V154, P178; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P110; MELZACK R, 1968, P423; MIKULINCER M, 1989, PSYCHOL REP, V65, P567, DOI 10.2466/pr0.1989.65.2.567; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Moore BA, 2010, PSYCHOL TRAUMA-US, V2, P232, DOI 10.1037/a0019895; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nappi CM, 2010, BEHAV THER, V41, P237, DOI 10.1016/j.beth.2009.03.003; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Onen SH, 2001, J SLEEP RES, V10, P35, DOI 10.1046/j.1365-2869.2001.00240.x; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Otis JD, 2010, PSYCHOL SERV, V7, P126, DOI 10.1037/a0020512; Ouellet M, 2012, INT ENCY REHABILITAT; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Perlis ML., 2010, BEHAV TREATMENTS SLE; Poundja J, 2007, J PAIN SYMPTOM MANAG, V33, P720, DOI 10.1016/j.jpainsymman.2006.09.031; Preacher K.J., 2008, SAGE SOURCEBOOK ADV, P13, DOI DOI 10.4135/9781452272054.N2; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schwab KA, 2006, NEUROLOGY, V66, pA235; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Smith M. T., 2003, MEASURES FATIGUE SLE, V49, P184; Smith S, 2001, J SLEEP RES, V10, P229, DOI 10.1046/j.1365-2869.2001.00262.x; SUTKER PB, 1993, J SOC ISSUES, V49, P33, DOI 10.1111/j.1540-4560.1993.tb01180.x; Swanson LM, 2009, J TRAUMA STRESS, V22, P639, DOI 10.1002/jts.20468; Tan G, 2004, J PAIN, V5, P133, DOI 10.1016/j.jpain.2003.12.005; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1993, P ANN M INT SOC TRAU; Yetkin S, 2010, PSYCHIAT CLIN NEUROS, V64, P309, DOI 10.1111/j.1440-1819.2010.02084.x; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	69	28	29	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					44	53		10.1097/HTR.0b013e31829c85d0			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400010	23835878				2022-02-06	
J	Magen, I; Gozes, I				Magen, Iddo; Gozes, Illana			Davunetide: Peptide Therapeutic in Neurological Disorders	CURRENT MEDICINAL CHEMISTRY			English	Article						Activity-dependent neuroprotective protein (ADNP); Alzheimer's disease; Davunetide; NAP; neurodegenerative diseases; neurological disorders	DEPENDENT NEUROPROTECTIVE PROTEIN; FETAL ALCOHOL SYNDROME; FEMTOMOLAR-ACTING PEPTIDES; INDUCED LEARNING-DEFICITS; CLOSED-HEAD INJURY; MOUSE MODEL; NAP DAVUNETIDE; NEUROTROPHIC FACTOR; D-SAL; NEURODEGENERATIVE DISEASES	This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of Prof. Illana Gozes. The effects of NAP and its related peptides in models of neurodegenerative diseases and other neurological disorders will be described here in details. Possible mechanisms of NAP actions include anti-inflammatory effect, antioxidant activity, inhibition of protein aggregation and interaction with microtubules. In line with the fact that all of these features are characteristic to most neurological/neurodegenerative disorders, NAP was found to have beneficial effects on the behavioral manifestations associated with these disorders.	[Gozes, Illana] Tel Aviv Univ, Sackler Fac Med, Adams Super Ctr Brain Studies, IL-69978 Tel Aviv, Israel; [Gozes, Illana] Tel Aviv Univ, Sackler Fac Med, Lily & Avraham Gildor Chair Invest Growth Factors, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Elton Lab Neuroendocrinol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel		Gozes, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Lily & Avraham Gildor Chair Invest Growth Factors, IL-69978 Tel Aviv, Israel.	igozes@post.tau.ac.il		Magen, Iddo/0000-0002-3011-3175	Post-Doctoral Fellowship from Tel Aviv University; AMN Foundation; CFTAU Montreal Circle of Friends; Adams Super Center for Brain Studies and at Tel Aviv University; Joe and Grace Alter; Barbara and Don Seal; Oberfeld and the Adams families; Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology	Dr. Iddo Magen was partially supported by a Post-Doctoral Fellowship from Tel Aviv University. Professor Gozes (the Lily and Avraham Gildor Chair for the Investigation of Growth Factors) laboratory is supported by the AMN Foundation, CFTAU Montreal Circle of Friends, Joe and Grace Alter, Barbara and Don Seal, the Oberfeld and the Adams families, Adams Super Center for Brain Studies and at Tel Aviv University and the the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology. Professor Gozes served as a Director Founding Scientist at Allon Therapeutics Inc. that has been developing davunetide (NAP) and related compounds. As this paper was reviewed and processed several new finding accumulated in the field and these are subjects of current and future publications.	Aboonq MS, 2012, J MOL NEUROSCI, V46, P33, DOI 10.1007/s12031-011-9562-y; Ashur-Fabian O, 2003, PEPTIDES, V24, P1413, DOI 10.1016/j.peptides.2003.08.005; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Belokopytov M, 2011, ACTA OPHTHALMOL, V89, pE126, DOI 10.1111/j.1755-3768.2010.02041.x; Ben-David E, 2013, MOL PSYCHIATR, V18, P1054, DOI 10.1038/mp.2012.148; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Blat D, 2008, J MED CHEM, V51, P126, DOI 10.1021/jm070800l; Borozdin Wiktor, 2007, Hum Mutat, V28, P830, DOI 10.1002/humu.9502; Braitch M, 2010, NEUROIMMUNOMODULAT, V17, P120, DOI 10.1159/000258695; Brenneman DE, 2004, J PHARMACOL EXP THER, V309, P1190, DOI 10.1124/jpet.103.063891; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Brenneman DE, 1998, J PHARMACOL EXP THER, V285, P619; Busciglio J, 2007, CURR PHARM DESIGN, V13, P1091, DOI 10.2174/138161207780618957; Castorina A, 2012, J MOL NEUROSCI, V48, P674, DOI 10.1007/s12031-012-9755-z; Cattano D, 2008, NEUROSCI LETT, V440, P217, DOI 10.1016/j.neulet.2008.05.086; Chen LM, 2012, J NEUROCHEM, V120, P157, DOI 10.1111/j.1471-4159.2011.07275.x; Chen SZ, 2008, P NATL ACAD SCI USA, V105, P19962, DOI 10.1073/pnas.0807758105; Chen SY, 2005, DEV NEUROSCI-BASEL, V27, P13, DOI 10.1159/000084528; CHO MJ, 1993, SOC PSYCH PSYCH EPID, V28, P156, DOI 10.1007/BF00797317; Cosgrave AS, 2008, NEUROBIOL DIS, V30, P281, DOI 10.1016/j.nbd.2008.02.005; Cosgrave AS, 2009, J MOL NEUROSCI, V39, P9, DOI 10.1007/s12031-008-9169-0; Dangoor D, 2005, PEPTIDES, V26, P2579, DOI 10.1016/j.peptides.2005.06.005; Divinski I, 2004, J BIOL CHEM, V279, P28531, DOI 10.1074/jbc.M403197200; Divinski I, 2006, J NEUROCHEM, V98, P973, DOI 10.1111/j.1471-4159.2006.03936.x; Dresner E, 2012, J BIOL CHEM, V287, P40173, DOI 10.1074/jbc.M112.387027; Dresner E, 2011, EUR NEUROPSYCHOPHARM, V21, P355, DOI 10.1016/j.euroneuro.2010.06.004; Fernagut PO, 2007, SYNAPSE, V61, P991, DOI 10.1002/syn.20456; Fernandez-Montesinos R, 2010, J MOL NEUROSCI, V41, P114, DOI 10.1007/s12031-009-9300-x; Fitzgerald DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024364; Fleming SM, 2011, MOL CELL NEUROSCI, V46, P597, DOI 10.1016/j.mcn.2010.12.011; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Furman S, 2005, NEUROSCI LETT, V373, P73, DOI 10.1016/j.neulet.2004.09.077; Gennet N, 2008, HISTOL HISTOPATHOL, V23, P309, DOI 10.14670/HH-23.309; Gold M, 2012, NEUROPSYCH DIS TREAT, V8, P85, DOI 10.2147/NDT.S12518; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; Gozes I, 2002, J MOL NEUROSCI, V19, P167, DOI 10.1007/s12031-002-0028-0; Gozes I, 2000, ANN NY ACAD SCI, V921, P115; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; Gozes I, 2000, J MOL NEUROSCI, V14, P61, DOI 10.1385/JMN:14:1-2:061; Gozes I., 2012, NEUR M PLANN SOC NEU; Gozes I., 2013, HDB BIOL ACTIVE PEPT, p[1611, 1611]; GOZES I, 2007, HDB NEUROCHEMISTRY M, P673; Gozes I, 2007, PHARMACOL THERAPEUT, V114, P146, DOI 10.1016/j.pharmthera.2007.01.004; Gozes Illana, 2005, P251, DOI 10.1017/CBO9780511546310.016; Gozes I, 2005, CNS DRUG REV, V11, P353; Gozes Illana, 2005, Current Alzheimer Research, V2, P149, DOI 10.2174/1567205053585873; Gozes Illana, 2012, Front Endocrinol (Lausanne), V3, P134, DOI 10.3389/fendo.2012.00134; Gozes I, 2011, CURR PHARM DESIGN, V17, P3413, DOI 10.2174/138161211798072553; Gozes I, 2011, CURR PHARM DESIGN, V17, P1040, DOI 10.2174/138161211795589373; Gozes I, 2011, PEPTIDES, V32, P428, DOI 10.1016/j.peptides.2010.10.030; Gozes I, 2010, RSC DRUG DISCOV, V3, P108; Gozes I, 2008, J MOL NEUROSCI, V36, P115, DOI 10.1007/s12031-008-9105-3; Greggio S, 2011, NEUROBIOL DIS, V44, P152, DOI 10.1016/j.nbd.2011.06.018; Greggio S, 2009, NEUROBIOL DIS, V36, P435, DOI 10.1016/j.nbd.2009.08.008; Haro JM, 2011, BRIT J PSYCHIAT, V199, P194, DOI 10.1192/bjp.bp.110.082065; Holtser-Cochav M, 2006, J MOL NEUROSCI, V28, P303, DOI 10.1385/JMN:28:3:303; Idan-Feldman A., 2012, INT J ALZHEIMERS DIS, V2012, DOI DOI 10.1155/2012/493670; Idan-Feldman A, 2011, NEUROBIOL DIS, V44, P327, DOI 10.1016/j.nbd.2011.06.020; Incerti M, 2011, OBSTET GYNECOL, V117, P354, DOI 10.1097/AOG.0b013e3182051ca5; Incerti M, 2010, AM J PERINAT, V27, P743, DOI 10.1055/s-0030-1253558; Incerti M, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.03.050; Incerti M, 2010, OBSTET GYNECOL, V115, P350, DOI 10.1097/AOG.0b013e3181cb59da; Jarskog LF, 2013, NEUROPSYCHOPHARMACOL, V38, P1245, DOI 10.1038/npp.2013.23; Javitt DC, 2012, SCHIZOPHR RES, V136, P25, DOI 10.1016/j.schres.2011.11.001; Jehle T, 2008, GRAEF ARCH CLIN EXP, V246, P1255, DOI 10.1007/s00417-007-0746-7; Johnstone M, 2011, SCHIZOPHRENIA BULL, V37, P14, DOI 10.1093/schbul/sbq135; Jouroukhin Y, 2012, J MOL NEUROSCI, V48, P597, DOI 10.1007/s12031-012-9882-6; Katayama T, 2009, PHARMACOGENOMICS, V10, P1967, DOI 10.2217/PGS.09.147; Kumral A, 2006, BRAIN RES, V1115, P169, DOI 10.1016/j.brainres.2006.07.114; Lagreze WA, 2005, INVEST OPHTH VIS SCI, V46, P933, DOI 10.1167/iovs.04-0766; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Mandel S, 2008, J MOL NEUROSCI, V35, P127, DOI 10.1007/s12031-007-9013-y; Mandel S, 2007, J BIOL CHEM, V282, P34448, DOI 10.1074/jbc.M704756200; Mandel S, 2007, DEV BIOL, V303, P814, DOI 10.1016/j.ydbio.2006.11.039; Merenlender-Wagner A, 2010, PEPTIDES, V31, P1368, DOI 10.1016/j.peptides.2010.04.011; Morimoto BH, 2009, CHIM OGGI, V27, P16; Nakamachi T, 2008, REGUL PEPTIDES, V145, P88, DOI 10.1016/j.regpep.2007.09.025; Nakamachi T, 2006, PEPTIDES, V27, P1859, DOI 10.1016/j.peptides.2006.01.007; O'Roak BJ, 2012, SCIENCE, V338, P1619, DOI 10.1126/science.1227764; O'Roak BJ, 2012, NATURE, V485, P246, DOI 10.1038/nature10989; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Oz S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051458; Parnell SE, 2007, ALCOHOL CLIN EXP RES, V31, P2059, DOI 10.1111/j.1530-0277.2007.00524.x; Pascual M, 2007, J NEUROCHEM, V103, P557, DOI 10.1111/j.1471-4159.2007.04761.x; Pinhasov A, 2003, DEV BRAIN RES, V144, P83, DOI 10.1016/S0165-3806(03)00162-7; Piper M, 2012, PSYCHIAT CLIN N AM, V35, P571, DOI 10.1016/j.psc.2012.06.002; Quintana FJ, 2006, ANN NY ACAD SCI, V1070, P500, DOI 10.1196/annals.1317.069; Quraishe S, 2013, MOL PSYCHIATR, V18, P834, DOI 10.1038/mp.2013.32; Roberson R, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.10.005; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Rotstein M, 2006, J PHARMACOL EXP THER, V319, P332, DOI 10.1124/jpet.106.106898; Sari Y, 2009, NEUROSCIENCE, V158, P1426, DOI 10.1016/j.neuroscience.2008.11.021; Sari Y, 2006, BRAIN RES REV, V52, P107, DOI 10.1016/j.brainresrev.2006.01.004; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Shiryaev N, 2011, CURR PHARM DESIGN, V17, P2603, DOI 10.2174/138161211797416093; Smith-Swintosky VL, 2005, J MOL NEUROSCI, V25, P225, DOI 10.1385/JMN:25:3:225; Sokolowska P, 2011, NEUROSCIENCE, V173, P156, DOI 10.1016/j.neuroscience.2010.10.074; Spong CY, 2001, J PHARMACOL EXP THER, V297, P774; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Sudo H, 2011, HUM MOL GENET, V20, P763, DOI 10.1093/hmg/ddq521; Teuchner B, 2011, ACTA OPHTHALMOL, V89, P670, DOI 10.1111/j.1755-3768.2009.01828.x; Thimmasettappa T, 2007, J MOL NEUROSCI, V33, P268, DOI 10.1007/s12031-007-0066-8; Toso L, 2006, AM J OBSTET GYNECOL, V194, P1153, DOI 10.1016/j.ajog.2005.12.023; Toso L, 2006, AM J OBSTET GYNECOL, V194, P681, DOI 10.1016/j.ajog.2006.01.003; Toso L, 2007, AM J OBSTET GYNECOL, V196, P259, DOI 10.1016/j.ajog.2007.01.015; Vacic V, 2011, NATURE, V471, P499, DOI 10.1038/nature09884; Vink J, 2005, AM J OBSTET GYNECOL, V193, P825, DOI 10.1016/j.ajog.2005.02.101; Vink J, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.052; Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005; Vulih-Shultzman I, 2007, J PHARMACOL EXP THER, V323, P438, DOI 10.1124/jpet.107.129551; Wilkemeyer MF, 2004, J PHARMACOL EXP THER, V309, P1183, DOI 10.1124/jpet.103.063818; Yang MH, 2012, J PROTEOMICS, V75, P3617, DOI 10.1016/j.jprot.2012.04.017; Zaltzman R, 2005, PEPTIDES, V26, P1520, DOI 10.1016/j.peptides.2005.03.014; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1; Zemlyak I, 2009, J NEUROCHEM, V111, P1252, DOI 10.1111/j.1471-4159.2009.06415.x; Zemlyak I, 2009, EUR J PHARMACOL, V618, P9, DOI 10.1016/j.ejphar.2009.07.013; Zheng H, 2006, J NEURAL TRANSM-SUPP, P163; Zheng YP, 2010, BIOMED PHARMACOTHER, V64, P417, DOI 10.1016/j.biopha.2010.01.016; Zusev M, 2004, REGUL PEPTIDES, V123, P33, DOI 10.1016/j.regpep.2004.05.021	121	28	28	0	10	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	0929-8673	1875-533X		CURR MED CHEM	Curr. Med. Chem.		2014	21	23					2591	2598		10.2174/0929867321666140217124945			8	Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	AK7TE	WOS:000338629800004	24533805				2022-02-06	
J	Zhou, YF; Li, WT; Han, HC; Gao, DK; He, XS; Li, L; Song, JN; Fei, Z				Zhou, Yue-fei; Li, Wen-tao; Han, Hong-cheng; Gao, Da-kuan; He, Xiao-sheng; Li, Liang; Song, Jin-ning; Fei, Zhou			Allicin protects rat cortical neurons against mechanical trauma injury by regulating nitric oxide synthase pathways	BRAIN RESEARCH BULLETIN			English	Article						Traumatic brain injury; Nitric oxide synthase; ERIC; Akt	ISCHEMIA-REPERFUSION INJURY; BRAIN-INJURY; CEREBRAL-ISCHEMIA; NEUROPROTECTION; INHIBITION; KINASE; ERK; PHOSPHORYLATION; AMINOGUANIDINE; EXPRESSION	Allicin, a small molecule that is responsible for the typical smell and most of the functions of garlic, possesses a broad spectrum of pharmacological activities and is considered to have therapeutic potential in many pathologic conditions. In the present study, we investigated the potential protective effect of allicin in an in vitro model of traumatic brain injury (TBI) using primary cultured rat cortical neurons. We found that allicin treatment significantly reduced mechanical trauma-induced lactate dehydrogenase (LDH) release and inhibited apoptotic neuronal death in a dose-dependent manner. These protective effects were observed even if allicin treatment was delayed to 2 h after injury. Allicin significantly decreased the expression of inducible nitric oxide synthase (iNOS) and increased the phosphorylation of endothelial NOS (eNOS) but had no effect on neuronal NOS (nNOS) expression. Allicin-induced protection in cortical neurons was augmented by iNOS and nNOS antagonists and was partly reversed by blocking eNOS phosphorylation. In addition, allicin treatment inhibited the TBI-induced activation of ERIC and further enhanced the phosphorylation of Akt in TBI-injured neurons. The Akt inhibitor LY294002 attenuated the allicin-induced increase in eNOS expression and phosphorylation, whereas the ERIC inhibitor PD98059 had opposite effects on the expression of iNOS and eNOS. Pretreatment with LY294002 or PD98059 partly prevented or further enhanced allicin-induced neuroprotection, respectively. Collectively, these data demonstrate that allicin treatment may be an effective therapeutic strategy for traumatic neuronal injury and that the potential underlying mechanism involves Akt- and ERIC-mediated regulation of NOS pathways. (C) 2013 Elsevier Inc. All rights reserved.	[Zhou, Yue-fei; Gao, Da-kuan; He, Xiao-sheng; Li, Liang; Fei, Zhou] Fourth Mil Med Univ, Dept Neurosurg, Xijing Inst Clin Neurosci, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Li, Wen-tao; Song, Jin-ning] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, Xian 710061, Shaanxi, Peoples R China; [Han, Hong-cheng] Xian Cent Hosp, Dept Cadre Ward, Xian 710000, Shaanxi, Peoples R China		Fei, Z (corresponding author), Fourth Mil Med Univ, Dept Neurosurg, Xijing Inst Clin Neurosci, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.	jinnings@126.com; fmmuzhoufei@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30930093]; National Science & Technology Pillar Program [2012BAI11B02]; Research Foundation of PLA [2010gxjs078, AWS11J008]	The work was supported by the National Natural Science Foundation of China (No. 30930093), the National Science & Technology Pillar Program (No. 2012BAI11B02) and the Research Foundation of PLA (No. 2010gxjs078 and No. AWS11J008).	Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Asahi M, 2005, J CEREBR BLOOD F MET, V25, P722, DOI 10.1038/sj.jcbfm.9600070; Baek JA, 2009, NITRIC OXIDE-BIOL CH, V20, P122, DOI 10.1016/j.niox.2008.10.003; Barbosa VA, 2013, INT J CARDIOL, V167, P2983, DOI 10.1016/j.ijcard.2012.08.050; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Fu WG, 2013, J SURG RES, V183, P876, DOI 10.1016/j.jss.2013.01.044; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Ginter E, 2010, BRATISL MED J, V111, P452; Horev-Azaria L, 2009, EUR J NUTR, V48, P67, DOI 10.1007/s00394-008-0762-3; Hou YC, 1999, CURR PHARM DESIGN, V5, P417; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hunter R, 2005, ANN NY ACAD SCI, V1056, P234, DOI 10.1196/annals.1352.011; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lawson LD, 2005, J AGR FOOD CHEM, V53, P6254, DOI 10.1021/jf050536+; Liu HQ, 2012, BRAIN RES BULL, V89, P65, DOI 10.1016/j.brainresbull.2012.06.010; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Peng B, 2012, BRAIN RES, V1445, P92, DOI 10.1016/j.brainres.2012.01.033; Shioda N, 2009, INT REV NEUROBIOL, V85, P375, DOI 10.1016/S0074-7742(09)85026-5; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; Villmann C, 2007, NEUROSCIENTIST, V13, P594, DOI 10.1177/1073858406296259; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wang RM, 2013, HIPPOCAMPUS, V23, P634, DOI 10.1002/hipo.22126; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249; Zhao Xiao-gang, 2007, Chin J Traumatol, V10, P376; Zhou L, 2009, NITRIC OXIDE-BIOL CH, V20, P223, DOI 10.1016/j.niox.2009.03.001; Zhu JW, 2012, NEUROCHEM INT, V61, P640, DOI 10.1016/j.neuint.2012.06.021	38	28	30	1	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	JAN	2014	100						14	21		10.1016/j.brainresbull.2013.10.013			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AB0KG	WOS:000331480000003	24184006				2022-02-06	
J	De Nicola, AF; Coronel, F; Garay, LI; Gargiulo-Monachelli, G; Deniselle, MCG; Gonzalez, SL; Labombarda, F; Meyer, M; Guennoun, R; Schumacher, M				De Nicola, Alejandro F.; Coronel, Florencia; Garay, Laura I.; Gargiulo-Monachelli, Gisella; Gonzalez Deniselle, Maria Claudia; Gonzalez, Susana L.; Labombarda, Florencia; Meyer, Maria; Guennoun, Rachida; Schumacher, Michael			Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Progesterone; neuroprotection; steroid receptors; animal models	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MOTOR-NEURON DISEASE; AMYOTROPHIC-LATERAL-SCLEROSIS; CEREBRAL-ARTERY OCCLUSION; MOUSE MOTONEURON DISEASE; CENTRAL-NERVOUS-SYSTEM; BINDING-PROTEIN 25-DX; MULTIPLE-SCLEROSIS	Substantial evidence supports that progesterone exerts many functions in the central and peripheral nervous system unrelated to its classical role in reproduction. In this review we first discussed progesterone effects following binding to the classical intracellular progesterone receptors A and B and several forms of membrane progesterone receptors, the modulation of intracellular signalling cascades and the interaction of progesterone reduced metabolites with neurotransmitter receptors. We next described our results involving animal models of human neuropathologies to elucidate the protective roles of progesterone. We described: (a) the protective and promyelinating effects of progesterone in experimental spinal cord injury; (b) the progesterone protective effects exerted upon motoneurons in the degenerating spinal cord of Wobbler mouse model of amyotropic lateral sclerosis; (c) the protective and anti-inflammatory effects of progesterone in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis and after lysolecithin demyelination; (d) the progesterone prevention of nociception and neuropathic pain which follow spinal cord injury; and (e) the protective effect of progesterone in experimental ischemic stroke. Whenever available, the molecular mechanisms involved in these progesterone effects were examined. The multiplicity of progesterone beneficial effects has opened new venues of research for neurological disorders. In this way, results obtained in animal models could provide the basis for novel therapeutic strategies and pre-clinical studies.	[De Nicola, Alejandro F.; Garay, Laura I.; Gargiulo-Monachelli, Gisella; Gonzalez Deniselle, Maria Claudia; Labombarda, Florencia; Meyer, Maria] Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [De Nicola, Alejandro F.; Garay, Laura I.; Gonzalez Deniselle, Maria Claudia; Gonzalez, Susana L.; Labombarda, Florencia] Univ Buenos Aires, Fac Med, Dept Human Biochem, Buenos Aires, DF, Argentina; [Coronel, Florencia; Gonzalez, Susana L.] Inst Biol & Med Expt, Lab Nocicept & Neurophat Pain, RA-1428 Buenos Aires, DF, Argentina; [Guennoun, Rachida; Schumacher, Michael] INSERM, Unite Mixte Rech 788, Le Kremlin Bicetre, France; [Guennoun, Rachida; Schumacher, Michael] Univ Paris 11, Le Kremlin Bicetre, France		De Nicola, AF (corresponding author), Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	alejandrodenicola@gmail.com	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300	FONCYTFONCyT [PICT 2007 - 01044]; National Research Council of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [CONICET PIP 112-200801-00542]; University of Buenos AiresUniversity of Buenos Aires [20020100100089]; CONICET / INSERM	This work was supported by FONCYT PICT 2007 - 01044, the National Research Council of Argentina (CONICET PIP 112-200801-00542), the University of Buenos Aires (20020100100089) and by an international cooperative program between CONICET / INSERM.	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Arevalo M. A., 2009, BIOCHIM BIOPHYS ACTA, V1800, P1106; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Baastrup C, 2008, CNS DRUGS, V22, P455, DOI 10.2165/00023210-200822060-00002; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Boillee S, 2003, MOL NEUROBIOL, V28, P65, DOI 10.1385/MN:28:1:65; Boonyaratanakornkit V, 2008, STEROIDS, V73, P922, DOI 10.1016/j.steroids.2008.01.010; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Carreras Maria C., 2004, Molecular Aspects of Medicine, V25, P125, DOI 10.1016/j.mam.2004.02.014; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Coronel MF, 2011, J PAIN, V12, P71, DOI 10.1016/j.jpain.2010.04.013; Dai DH, 2003, J STEROID BIOCHEM, V87, P123, DOI 10.1016/j.jsbmb.2003.08.004; Dave KR, 2003, EXP NEUROL, V182, P412, DOI 10.1016/S0014-4886(03)00091-8; de la Puente B, 2009, PAIN, V145, P294, DOI 10.1016/j.pain.2009.05.013; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Deniselle MCG, 2005, EXP NEUROL, V195, P518, DOI 10.1016/j.expneurol.2005.06.015; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Diana V, 2010, EXP NEUROL, V225, P163, DOI 10.1016/j.expneurol.2010.06.008; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; Druckmann R, 2005, J STEROID BIOCHEM, V97, P389, DOI 10.1016/j.jsbmb.2005.08.010; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Coronel MF, 2011, PAIN MED, V12, P1249, DOI 10.1111/j.1526-4637.2011.01178.x; FRYE CA, 1994, BRAIN RES, V643, P194, DOI 10.1016/0006-8993(94)90025-6; Furuzawa-Carballeda J, 2007, AUTOIMMUN REV, V6, P169, DOI 10.1016/j.autrev.2006.10.002; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garay L, 2008, NEUROIMMUNOMODULAT, V15, P76, DOI 10.1159/000135627; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garay L, 2009, BRAIN RES, V1283, P177, DOI 10.1016/j.brainres.2009.04.057; Monachelli GG, 2011, ACTA NEUROL SCAND, V123, P60, DOI 10.1111/j.1600-0404.2010.01385.x; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Giatti S, 2010, NEUROCHEM INT, V56, P118, DOI 10.1016/j.neuint.2009.09.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gintzler A R, 2001, Prog Brain Res, V133, P83; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Deniselle MCG, 2012, J NEUROCHEM, V122, P185, DOI 10.1111/j.1471-4159.2012.07753.x; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Hantaz-Ambroise D, 2001, DIFFERENTIATION, V69, P100, DOI 10.1046/j.1432-0436.2001.690204.x; Henderson JT, 1996, J NEUROSCI, V16, P7574; Hosie AM, 2006, NATURE, V444, P486, DOI 10.1038/nature05324; Hu R, 2010, J NEUROSURG-SPINE, V13, P169, DOI 10.3171/2010.3.SPINE09190; Hubbard P., 2002, J ANAT, V200, P213; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Ikeda K, 2000, BRAIN RES, V858, P84, DOI 10.1016/S0006-8993(99)02427-0; KIMBRO KS, 1994, J MOL NEUROSCI, V5, P27, DOI 10.1007/BF02736692; LAAGE S, 1988, DEV NEUROSCI-BASEL, V10, P190, DOI 10.1159/000111969; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2008, NEUROSCI LETT, V447, P115, DOI 10.1016/j.neulet.2008.09.062; Leitner H, 2010, MED HYPOTHESES, V75, P229, DOI 10.1016/j.mehy.2010.02.028; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lin T, 2006, J NEUROSCI METH, V157, P187, DOI 10.1016/j.jneumeth.2006.04.014; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Losel RM, 2008, STEROIDS, V73, P929, DOI 10.1016/j.steroids.2007.12.017; Lopez A.D., 2012, MEASURING GLOBAL BUR; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; Martin WJ, 2001, J NEUROSCI, V21, P5321, DOI 10.1523/JNEUROSCI.21-14-05321.2001; Matute C, 2005, TRENDS NEUROSCI, V28, P173, DOI 10.1016/j.tins.2005.01.006; Maurice T, 2006, PHARMACOL BIOCHEM BE, V84, P581, DOI 10.1016/j.pbb.2006.07.009; McQualter JL, 2007, J NEUROCHEM, V100, P295, DOI 10.1111/j.1471-4159.2006.04232.x; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; Mensah-Nyagan AG, 2008, J STEROID BIOCHEM, V109, P286, DOI 10.1016/j.jsbmb.2008.03.002; Mensah-Nyagan AG, 2009, PSYCHONEUROENDOCRINO, V34, pS169, DOI [10.1016/j.psyneuen.2009.06.004, DOI 10.1016/j.psyneuen.2009.06.004, 10.1016/j.psyneue n.2009.06.004, DOI 10.1016/J.PSYNEUEN.2009.06.004]; Meyer M, 2012, NEUROSCIENCE, V201, P267, DOI 10.1016/j.neuroscience.2011.11.034; Meyer M, 2010, CELL MOL NEUROBIOL, V30, P123, DOI 10.1007/s10571-009-9437-8; MITSUMOTO H, 1982, BRAIN, V105, P811, DOI 10.1093/brain/105.4.811; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; National Institute of Neurological Disorders and Stroke, SPIN CORD INJ HOP RE; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; Onuki I, 2001, MICROSC RES TECHNIQ, V52, P731; Park HH, 2009, MOL MED REP, V2, P539, DOI 10.3892/mmr_00000133; PARSONS B, 1982, J NEUROSCI, V2, P1446; Paterson P Y, 1980, Prog Clin Biol Res, V49, P19; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Peng HY, 2009, PAIN, V143, P12, DOI 10.1016/j.pain.2008.12.023; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Qi YC, 2001, DEVELOPMENT, V128, P2723; Quadros PS, 2008, ENDOCRINOLOGY, V149, P3054, DOI 10.1210/en.2007-1133; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Santoro B, 2004, NEUROBIOL DIS, V17, P349, DOI 10.1016/j.nbd.2004.07.003; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Selye H., 1947, TXB ENDOCRINOLOGY; Siegenthaler MM, 2007, J NEUROTRAUM, V24, P1631, DOI 10.1089/neu.2007.0302; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Spence RD, 2012, FRONT NEUROENDOCRIN, V33, P105, DOI 10.1016/j.yfrne.2011.12.001; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Sun DM, 2003, INT IMMUNOL, V15, P261, DOI 10.1093/intimm/dxg023; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Tsuzaka K, 2001, MUSCLE NERVE, V24, P474, DOI 10.1002/mus.1029; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Watanabe M, 2004, GLIA, V46, P311, DOI 10.1002/glia.20006; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yates MA, 2010, J NEUROIMMUNOL, V220, P136, DOI 10.1016/j.jneuroim.2010.01.013; Yu HJ, 2010, NEUROSCI LETT, V476, P42, DOI 10.1016/j.neulet.2010.03.079; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	131	28	28	0	8	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	DEC	2013	12	8					1205	1218					14	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	284FD	WOS:000329300600015	24040821				2022-02-06	
J	Lee, YM; Odom, MJ; Zuckerman, SL; Solomon, GS; Sills, AK				Lee, Young M.; Odom, Mitchell J.; Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.			Does age affect symptom recovery after sports-related concussion? A study of high school and college athletes	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; sports; age; mild traumatic brain injury; ImPACT; post-concussion symptoms; trauma	TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; UNITED-STATES; NEUROCOGNITIVE PERFORMANCE; EPIDEMIOLOGY; MILD; DEPRESSION; MANAGEMENT; MODERATE; SCALE	Object. Sport-related concussions (SRCs) in high school and college athletes represent a significant public health concern. Research suggests that younger athletes fare worse symptomatically than older athletes after an SRC. Using reliable change index (RCI) methodology, the authors conducted a study to determine if there are age-related differences in number, severity, and resolution of postconcussion symptoms. Methods. Between 2009 and 2011, baseline measures of neurocognitive functions and symptoms in high school and college athletes were entered into a regional database. Seven hundred forty of these athletes later sustained an SRC. Ninety-two athletes in the 13- to 16-year-old group and 92 athletes in the 18- to 22-year-old group were matched for number of prior concussions, sex, biopsychosocial variables, and days to first postconcussion testing and symptom assessment. A nonparametric Mann-Whitney U-test was used to compare the severity of each of 22 symptoms comprising the Total Symptom Scale (TSS) at baseline and first postconcussion test. To obtain a family-wise p value of 0.05 for each test, the significance level for each symptom comparison was set at an alpha of 0.05/22 = 0.0023. The number of days to return to baseline TSS score was compared using the RCI methodology, set at the 80% confidence interval, equal to a change in raw score of 9.18 points on the TSS. Results. There was no statistically significant difference in symptom presence, symptom severity, and total symptoms between the age groups at baseline or at postconcussion testing. There was no statistically significant difference in return to baseline symptom scores between the age groups. Conclusions. Using RCI methodology, there was no statistically significant difference between younger and older athletes in return to baseline symptoms postconcussion.	[Lee, Young M.; Odom, Mitchell J.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37212 USA; [Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Nashville, TN 37212 USA		Zuckerman, SL (corresponding author), 1500 21st Ave South,Ste 4340, Nashville, TN 37212 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019				Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BROSHEK DK, 2012, J CHILD NEUROL; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Dick R, 2007, J ATHL TRAINING, V42, P221; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Powell JW, 1999, J ATHL TRAINING, V34, P277; RUTHERFORD WH, 1977, LANCET, V1, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Sosin DM, 1996, BRAIN INJURY, V10, P47; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	34	28	28	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	DEC	2013	12	6					537	544		10.3171/2013.7.PEDS12572			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics; Surgery	257EV	WOS:000327367300003	24063601	Bronze			2022-02-06	
J	Brogaard, B				Brogaard, Berit			Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						acquired synesthesia; autism spectrum disorder; drug-induced synaesthesia; left-hemisphere injuries; multisensory perception; savant syndrome; serotonin hypothesis; traumatic brain injury	AUDITORY-VISUAL SYNESTHESIA; STRUCTURAL CONNECTIVITY; SAVANT MEMORY; BRAIN INJURY; SYNAESTHESIA; COLOR; AUTISM; RELEASE; PREVALENCE; PERCEPTION	Though synesthesia research has seen a huge grow thin recent decades, and tremendous progress has been made in terms of understanding the mechanism and cause of synesthesia, we are still left mostly in the dark when it comes to the mechanistic commonalities (if any) among developmental, acquired and drug-induced synesthesia. We know that many forms of synesthesia involve aberrant structural or functional brain connectivity. Proposed mechanisms include direct projection and disinhibited feedback mechanisms, in which information from two otherwise structurally or functionally separate brain regions mix. We also know that synesthesia sometimes runs in families. However, it is unclear what causes its on set. Studies of psychedelic drugs, such as psilocybin, LSD and mescaline, reveal that exposure to these drugs can induce synesthesia. One neurotransmitter suspected to be central to the perceptual changes is serotonin. Excessive serotonin in the brain may cause many of the characteristics of psychedelic in toxication. Excessive serotonin levels may also play a role in synesthesia acquired after brain injury. In brain injury sudden cell death floods local brain regions with serotonin and glutamate. This neurotransmitter flooding could perhaps result in unusual feature binding. Finally, developmental synesthesia that occurs in individuals with autism may be a result of alterations in the serotonergic system, leading to a blockage of regular gating mechanisms. I conclude on these grounds that one commonality among at least some cases of acquired, developmental and drug-induced synesthesia may be the presence of excessive levels of serotonin, which increases the excitability and connectedness of sensory brain regions.	[Brogaard, Berit] Univ Missouri, Dept Philosophy, St Louis, MO 63121 USA; [Brogaard, Berit] Univ Missouri, Ctr Neurodynam, St Louis, MO 63121 USA		Brogaard, B (corresponding author), Univ Missouri, Dept Philosophy, St Louis, MO 63121 USA.	brogaardb@gmail.com					ABRAHAM HD, 1983, ARCH GEN PSYCHIAT, V40, P884; Afra P, 2009, PSYCHOL RES BEHAV MA, V2, P31; Aghajanian GK, 1997, NEUROPHARMACOLOGY, V36, P589, DOI 10.1016/S0028-3908(97)00051-8; Alstadhaug KB, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-121; Armel KC, 1999, NEUROCASE, V5, P293, DOI 10.1080/13554799908411982; Asher JE, 2009, AM J HUM GENET, V84, P279, DOI 10.1016/j.ajhg.2009.01.012; Banissy MJ, 2009, EXP BRAIN RES, V196, P565, DOI 10.1007/s00221-009-1888-0; BARKAI E, 1994, J NEUROPHYSIOL, V72, P72, DOI 10.1152/jn.1994.72.1.72; Baron-Cohen S, 2007, J CONSCIOUSNESS STUD, V14, P237; Baron-Cohen S, 2009, PHILOS T R SOC B, V364, P1377, DOI 10.1098/rstb.2008.0337; BARONCOHEN S, 1987, PERCEPTION, V16, P761, DOI 10.1068/p160761; BaronCohen S, 1996, PERCEPTION, V25, P1073, DOI 10.1068/p251073; Beauchamp MS, 2008, J NEUROSCI, V28, P13696, DOI 10.1523/JNEUROSCI.3872-08.2008; Behrendt RP, 2004, BEHAV BRAIN SCI, V27, P771, DOI 10.1017/S0140525X04000184; Bor D, 2007, NEUROCASE, V13, P311, DOI 10.1080/13554790701844945; Brang D, 2008, MED HYPOTHESES, V70, P903, DOI 10.1016/j.mehy.2007.09.007; Brang D, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001205; Brogaard B., 2013, GURU MAG, V11, P10; Brogaard B., 2012, COGNITION LANGUAGE E; Brogaard B., 2013, SENSORY INTEGRATION; Brogaard B., 2013, SENSORY BLENDINGS NE; Brogaard B, 2013, NEUROCASE, V19, P566, DOI 10.1080/13554794.2012.701646; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; Carhart-Harris RL, 2012, P NATL ACAD SCI USA, V109, P2138, DOI 10.1073/pnas.1119598109; Ceglia I, 2004, J NEUROCHEM, V91, P189, DOI 10.1111/j.1471-4159.2004.02704.x; Chandana SR, 2005, INT J DEV NEUROSCI, V23, P171, DOI 10.1016/j.ijdevneu.2004.08.002; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; Chugani DC, 1997, ANN NEUROL, V42, P666, DOI 10.1002/ana.410420420; Ciranna L, 2006, CURR NEUROPHARMACOL, V4, P101, DOI 10.2174/157015906776359540; Cott C, 2008, J SCI EXPLORATION, V22, P359; Cytowic R. E., 1997, SYNAESTHESIA CLASSIC, P17; Cytowic R. E, 1989, SYNESTHESIA UNION SE, DOI [10.1007/978-1-4612-3542-2, DOI 10.1007/978-1-4612-3542-2]; DeLong GR, 1999, NEUROLOGY, V52, P911, DOI 10.1212/WNL.52.5.911; DEVINSKY O, 1991, SEMIN NEUROL, V11, P100, DOI 10.1055/s-2008-1041211; Dixon MJ, 2004, COGN AFFECT BEHAV NE, V4, P335, DOI 10.3758/CABN.4.3.335; Dixon MJ, 2006, CORTEX, V42, P243, DOI 10.1016/S0010-9452(08)70349-6; Domino G., 1989, CREATIVITY RES J, V2, P17, DOI [10.1080/10400418909534297, DOI 10.1080/10400418909534297]; DORMAN C, 1991, BRAIN COGNITION, V15, P26, DOI 10.1016/0278-2626(91)90013-X; Dovern A, 2012, J NEUROSCI, V32, P7614, DOI 10.1523/JNEUROSCI.5401-11.2012; Eagleman DM, 2007, J NEUROSCI METH, V159, P139, DOI 10.1016/j.jneumeth.2006.07.012; Esterman M, 2006, J COGNITIVE NEUROSCI, V18, P1570, DOI 10.1162/jocn.2006.18.9.1570; Eysel UT, 1999, RESTOR NEUROL NEUROS, V15, P153; Ffytche Dominic H, 2007, Dialogues Clin Neurosci, V9, P173; Friedrichs H, 1940, PSYCHOL MESKALINRAUS; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; GLENNON RA, 1990, NEUROPSYCHOPHARMACOL, V3, P509; Gonzalez-Maeso J, 2008, NATURE, V452, P93, DOI 10.1038/nature06612; Gonzalez-Maeso J, 2007, NEURON, V53, P439, DOI 10.1016/j.neuron.2007.01.008; Grandin T., 1995, THINKING PICTURES MY; Grossenbacher PG, 2001, TRENDS COGN SCI, V5, P36, DOI 10.1016/S1364-6613(00)01571-0; Guillery RW, 2003, J COMP NEUROL, V463, P360, DOI 10.1002/cne.10738; Hanggi J, 2011, J NEUROSCI, V31, P5816, DOI 10.1523/JNEUROSCI.0964-10.2011; Harrison J, 2004, J AUTISM DEV DISORD, V34, P727, DOI 10.1007/s10803-004-5293-z; HIER DB, 1979, J AUTISM DEV DISORD, V9, P153, DOI 10.1007/BF01531531; Hintzen A., 2010, PHARM LSD; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hubbard Edward M, 2007, Curr Psychiatry Rep, V9, P193, DOI 10.1007/s11920-007-0018-6; Hubbard EM, 2006, CORTEX, V42, P184, DOI 10.1016/S0010-9452(08)70343-5; JACOBS L, 1981, ARCH NEUROL-CHICAGO, V38, P211, DOI 10.1001/archneur.1981.00510040037005; JACOME DE, 1979, NEUROLOGY, V29, P1050, DOI 10.1212/WNL.29.7.1050; Jancke L, 2009, EUR J NEUROSCI, V29, P1287, DOI 10.1111/j.1460-9568.2009.06673.x; Kadosh RC, 2009, PSYCHOL SCI, V20, P258, DOI 10.1111/j.1467-9280.2009.02286.x; Kamal Sahar Mohamed, 2010, J Exp Pharmacol, V2, P65; KEMNER C, 1995, BIOL PSYCHIAT, V38, P150, DOI 10.1016/0006-3223(94)00247-Z; Kim U, 1998, J NEUROSCI, V18, P9500; Klimesch W, 2011, BRAIN RES, V1408, P52, DOI 10.1016/j.brainres.2011.06.003; Kometer M, 2013, J NEUROSCI, V33, P10544, DOI 10.1523/JNEUROSCI.3007-12.2013; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; KRAMER K, 1994, DEV BRAIN RES, V78, P142, DOI 10.1016/0165-3806(94)90019-1; LaFay L., 1987, VIRGINIA PILOT, P31; Leboyer M, 1999, BIOL PSYCHIAT, V45, P158, DOI 10.1016/S0006-3223(97)00532-5; Lee HM, 2012, P NATL ACAD SCI USA, V109, P1820, DOI 10.1073/pnas.1121358109; LESSELL S, 1979, NEUROLOGY, V29, P1524, DOI 10.1212/WNL.29.11.1524; Loui P, 2011, J COGNITIVE NEUROSCI, V23, P1015, DOI 10.1162/jocn.2010.21500; Lythgoe MFX, 2005, NEUROLOGY, V64, P397, DOI 10.1212/01.WNL.0000150526.09499.3E; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Mattingley JB, 2001, NATURE, V410, P580, DOI 10.1038/35069062; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P993; Miller BL, 2000, BRIT J PSYCHIAT, V176, P458, DOI 10.1192/bjp.176.5.458; Miller BL, 1998, NEUROLOGY, V51, P978, DOI 10.1212/WNL.51.4.978; Milner B., 1973, NEUROSCIENCES 3RD ST, P75; Mueller S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067329; Mulvenna C, 2005, CURR BIOL, V15, pR399, DOI 10.1016/j.cub.2005.05.039; Neufeld J, 2012, NEUROPSYCHOLOGIA, V50, P1471, DOI 10.1016/j.neuropsychologia.2012.02.032; Newbury DF, 2009, AM J MED GENET A, V149A, P588, DOI 10.1002/ajmg.a.32704; Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002; Ornitz E.M., 1978, COGNITIVE DEFECTS DE, P24; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Pesenti M, 2001, NAT NEUROSCI, V4, P103, DOI 10.1038/82831; Pralong E, 2002, PROG NEUROBIOL, V67, P173, DOI 10.1016/S0301-0082(02)00017-5; Presti D. E., 2004, TEONANACATL, P89; Previc F., 2011, ALTERING CONSCIOUSNE, V2, P43; Ramachandran V, 2001, J CONSCIOUSNESS STUD, V8, P3; Ramachandran VS, 2001, P ROY SOC B-BIOL SCI, V268, P979, DOI 10.1098/rspb.2000.1576; Rich AN, 2002, NAT REV NEUROSCI, V3, P43, DOI 10.1038/nrn702; Ro T, 2007, ANN NEUROL, V62, P433, DOI 10.1002/ana.21219; Ro T, 2013, CEREB CORTEX, V23, P1724, DOI 10.1093/cercor/bhs166; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; Rogowska A, 2011, REV GEN PSYCHOL, V15, P213, DOI 10.1037/a0024078; Rothen N, 2012, NEUROSCI BIOBEHAV R, V36, P1952, DOI 10.1016/j.neubiorev.2012.05.004; Rothen N, 2010, PERCEPTION, V39, P718, DOI 10.1068/p6680; Rouw R, 2007, NAT NEUROSCI, V10, P792, DOI 10.1038/nn1906; Sacks OW, 2012, HALLUCINATIONS: RESEARCH AND PRACTICE, P133, DOI 10.1007/978-1-4614-0959-5_11; Sagiv N., 2011, INTELLECTICA, V55, P81; Sagiv N, 2006, PROG BRAIN RES, V155, P259, DOI 10.1016/S0079-6123(06)55015-0; SCHAIN RJ, 1961, J PEDIATR-US, V58, P315, DOI 10.1016/S0022-3476(61)80261-8; Schott GD, 2012, BRAIN, V135, P1947, DOI 10.1093/brain/awr314; Schroeder CE, 2005, CURR OPIN NEUROBIOL, V15, P454, DOI 10.1016/j.conb.2005.06.008; Scruggs JL, 2003, NEUROSCI LETT, V346, P137, DOI 10.1016/S0304-3940(03)00547-0; Shanon B, 2003, J CONSCIOUSNESS STUD, V10, P69; Shanon B, 2002, ANTIPODES MIND; Simner J, 2006, PERCEPTION, V35, P1024, DOI 10.1068/p5469; Sinke C, 2012, CONSCIOUS COGN, V21, P1419, DOI 10.1016/j.concog.2012.03.009; Snyder A, 2009, PHILOS T R SOC B, V364, P1399, DOI 10.1098/rstb.2008.0290; Snyder Allan W, 2003, J Integr Neurosci, V2, P149, DOI 10.1142/S0219635203000287; Takeuchi N, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/823285; Tammet Daniel, 2006, BORN BLUE DAY INSIDE; Terhune DB, 2012, HALLUCINATIONS: RESEARCH AND PRACTICE, P91, DOI 10.1007/978-1-4614-0959-5_7; Terhune DB, 2011, CURR BIOL, V21, P2006, DOI 10.1016/j.cub.2011.10.032; Thomas-Anterion C, 2010, PAIN, V150, P121, DOI 10.1016/j.pain.2010.04.010; Tomson SN, 2011, BEHAV BRAIN RES, V223, P48, DOI 10.1016/j.bbr.2011.03.071; Torres-Escalante JL, 2004, J NEUROSCI RES, V78, P268, DOI 10.1002/jnr.20247; Treffert D., 2006, EXTRAORDINARY PEOPLE; Treffert DA, 2009, PHILOS T R SOC B, V364, P1351, DOI 10.1098/rstb.2008.0326; Trudeau LE, 2004, J PSYCHIATR NEUROSCI, V29, P296; Veenstra-VanderWeele J, 2012, P NATL ACAD SCI USA, V109, P5469, DOI 10.1073/pnas.1112345109; Vollenweider FX, 1997, NEUROPSYCHOPHARMACOL, V16, P357, DOI 10.1016/S0893-133X(96)00246-1; Vollenweider FX, 1998, NEUROREPORT, V9, P3897, DOI 10.1097/00001756-199812010-00024; Walsh R, 2005, J CONSCIOUSNESS STUD, V12, P5; Ward J., 2012, NEUROSCI BIOBEHAV R, DOI [10.1016/j.neubiorev.2012.07.007, DOI 10.1016/J.NEUBI0REV.2012.07.007]; Ward J, 2008, BRIT J PSYCHOL, V99, P127, DOI 10.1348/000712607X204164; Ward J, 2013, ANNU REV PSYCHOL, V64, P49, DOI 10.1146/annurev-psych-113011-143840; Weiss PH, 2009, BRAIN, V132, P65, DOI 10.1093/brain/awn304; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whitaker-Azmitia PM, 2005, INT J DEV NEUROSCI, V23, P75, DOI 10.1016/j.ijdevneu.2004.07.022; WHITAKERAZMITIA PM, 1994, NEUROPSYCHOPHARMACOL, V11, P125, DOI 10.1038/npp.1994.42; Yaro C, 2007, Q J EXP PSYCHOL, V60, P681, DOI 10.1080/17470210600785208; Young RL, 2004, NEUROCASE, V10, P215, DOI 10.1080/13554790490495140; Yuan JY, 2009, APOPTOSIS, V14, P469, DOI 10.1007/s10495-008-0304-8; Zamm A, 2013, NEUROIMAGE, V74, P359, DOI 10.1016/j.neuroimage.2013.02.024	141	28	29	7	87	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 21	2013	7								657	10.3389/fnhum.2013.00657			13	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	238BV	WOS:000325916500001	24155703	Green Published, gold			2022-02-06	
J	Lobel, DA; Elder, JB; Schirmer, CM; Bowyer, MW; Rezai, AR				Lobel, Darlene A.; Elder, J. Bradley; Schirmer, Clemens M.; Bowyer, Mark W.; Rezai, Ali R.			A Novel Craniotomy Simulator Provides a Validated Method to Enhance Education in the Management of Traumatic Brain Injury	NEUROSURGERY			English	Article						Craniotomy; Curriculum; Education; Neurotrauma; Residency; Simulation; Traumatic brain injury	VIRTUAL-REALITY; CONSTRUCT-VALIDATION; TECHNICAL SKILL; COUNCIL	BACKGROUND: in a variety of surgical simulation-based technologies play an important role in resident training. The Congress of Neurological Surgeons (CNS) established an initiative to enhance neurosurgical training by developing a simulation-based curriculum to complement standard and clinical learning. OBJECTIVE: To enhance resident education in management of traumatic brain injury by the use of simulation-based training. METHODS: A course-based neurosurgical simulation curriculum was developed and offered at the 2012 CNS annual meeting. Within this curriculum, a trauma module was developed to teach skills necessary in the management of traumatic brain injury, including the performance of craniotomy for trauma. Didactic and simulator-based instruction were incorporated into the course. Written and practical pre- and posttests, as well as questionnaires, were used to assess the improvement in skill level and to validate the simulator as a teaching tool. RESULTS: Fourteen trainees participated in the didactic section of the trauma module. Average performance improved significantly in written scores from pretest (75%) to posttest (87.5%, P < .05). Eight participants completed the trauma craniotomy simulator. Incision planning, burr hole placement (P < .02), and craniotomy size (P < .05) improved significantly. Junior residents (postgraduate years 1-3) demonstrated the most improvement during the course. CONCLUSION: The CNS simulation trauma module provides a complementary method for residents to acquire necessary skills in the management of traumatic brain injury. Preliminary data indicate improvement in didactic and hands-on knowledge after training. Additional data are needed to confirm the validity of the simulator.	[Lobel, Darlene A.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA; [Elder, J. Bradley; Rezai, Ali R.] Ohio State Univ, Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA; [Schirmer, Clemens M.] Baystate Med Ctr, Div Neurosurg, Springfield, MA USA; [Schirmer, Clemens M.] Tufts Univ, Sch Med, Dept Neurosurg, Boston, MA 02111 USA; [Bowyer, Mark W.] Uniformed Serv Univ Hlth Sci, Norman M Rich Dept Surg, Bethesda, MD 20814 USA		Lobel, DA (corresponding author), Mayo Clin, Dept Neurol Surg, 200 1st St SW, Rochester, MN 55905 USA.	Darlene.a.lobel@hotmail.com		Schirmer, Clemens/0000-0003-1743-8781			Abboudi H, 2013, BJU INT, V111, P194, DOI 10.1111/j.1464-410X.2012.11270.x; Accreditation Council for Graduate Medical Education (ACGME), 2011, COMM PROGR REQ; Acosta E, 2007, STUD HEALTH TECHNOL, V125, P1; Alaraj A, 2013, NEUROSURGERY, V72, pA115, DOI 10.1227/NEU.0b013e3182753093; Dayal R, 2004, J VASC SURG, V40, P1112, DOI 10.1016/j.jvs.2004.09.028; Delorme S, 2012, NEUROSURGERY, V71, P32, DOI 10.1227/NEU.0b013e318249c744; Dumont TM, 2012, J NEUROSURG, V116, P483, DOI 10.3171/2011.9.JNS116; Faulkner H, 1996, ACAD MED, V71, P1363, DOI 10.1097/00001888-199612000-00023; Gallagher AG, 2005, ANN SURG, V241, P364, DOI 10.1097/01.sla.0000151982.85062.80; Ganju A, 2012, WORLD NEUROSURG; Ghobrial GM, NEUROSURGERY S1, V73, pS111; Kelly DC, 2012, UROLOGY, V79, P1068, DOI 10.1016/j.urology.2012.01.028; Khan MS, 2013, BJU INT, V111, P518, DOI 10.1111/j.1464-410X.2012.11204.x; Leiter JR, 2012, KNEE SURG SPORTS TRA; Lemole GM, 2007, NEUROSURGERY, V61, P142, DOI 10.1227/01.neu.0000279734.22931.21; Liss MA, 2012, J ENDOUROL, V26, P1629, DOI 10.1089/end.2012.0328; Mazzola CA, 2010, NEUROSURGERY, V67, P225, DOI 10.1227/01.NEU.0000372206.41812.23; Palter VN, 2013, ANN SURG, V257, P224, DOI 10.1097/SLA.0b013e31827051cd; Pflesser Bernhard, 2002, Comput Aided Surg, V7, P74; Plooy AM, 2012, GASTROINTEST ENDOSC, V76, P144, DOI 10.1016/j.gie.2012.03.246; Scerbo MW, 2010, P HUM FACT ERG SOC 5, V54, P2361; Sim P., 2000, THESIS U LEEDS; Singapogu RB, 2013, SURG ENDOSC, V27, P1653, DOI 10.1007/s00464-012-2648-y; Tedesco MM, 2008, J VASC SURG, V47, P1008, DOI 10.1016/j.jvs.2008.01.007; Wong GKC, 2007, NEUROSURGERY, V61, P564, DOI 10.1227/01.NEU.0000290904.46061.0D	25	28	29	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2013	73			1			57	65		10.1227/NEU.0000000000000116			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	300SG	WOS:000330483300012	24051884				2022-02-06	
J	Zemek, R; Clarkin, C; Farion, KJ; Vassilyadi, M; Anderson, P; Irish, B; Goulet, K; Barrowman, N; Osmond, MH				Zemek, Roger; Clarkin, Chantalle; Farion, Ken J.; Vassilyadi, Michael; Anderson, Peter; Irish, Brendan; Goulet, Kristian; Barrowman, Nick; Osmond, Martin H.			Parental Anxiety at Initial Acute Presentation Is Not Associated With Prolonged Symptoms Following Pediatric Concussion	ACADEMIC EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; EMERGENCY-DEPARTMENT; ABDOMINAL-PAIN; CHILDREN; IMPACT; INTERVENTION; EPIDEMIOLOGY	ObjectivesAnxiety modulates symptom perception in adults following concussion, prolonging the time to full recovery. The authors sought to determine whether parental anxiety was associated with persistent postconcussive symptoms (PCS) in their children following concussion. MethodsA prospective observational cohort with 98 children aged 5 to 17years following concussion participated from a tertiary pediatric emergency department (ED). The main exposure was parental anxiety at the time of acute presentation following pediatric concussion, measured using the self-administered, validated Spielberger State-Trait Anxiety Inventory-State Anxiety Scale (STAI-S). The primary outcome measured was presence of PCS in the child at 1month, per the validated Post-Concussive Symptom Inventory (PCSI). Secondary outcome measures included parental anxiety score over time, school absenteeism, and return to sports. Data were collected during the initial ED visit and at 3-day, 7-day, 2-week, 1-month, and 3-month follow-ups. ResultsOf 98 children enrolled, 27% (95% confidence interval [CI]=19% to 36%) developed PCS at 1month. No significant associations were detected between parental anxiety at the index visits and the number of previous pediatric concussions (p=0.73), sex (p=0.61), loss of consciousness (p=0.43), history of migraines (p=0.31), or history of anxiety diagnosed in the patients (p=0.09). A significant association was noted between patient diagnosis of attention deficit hyperactivity disorder (ADHD) and parental anxiety at the index visits (p=0.001). Parental anxiety at acute presentation was not associated with children's prolonged symptoms at 1month (p=0.63). Parental anxiety remained elevated in parents whose children had prolonged symptoms compared to those parents whose children's symptoms resolved (median=30, interquartile range [IQR]=22 to 44; and median=21, IQR=20 to 25, respectively; p<0.001). Initial parental anxiety presentation was not associated with school absenteeism (p=0.23) or not returning to sport or gym class (p=0.89). There were no significant effects involving ADHD alone (p=0.44) or together with baseline parental anxiety (p=0.36 for ADHD and p=0.55 for anxiety) using logistic regression analysis to examine potential predictive effects of child's ADHD combined with parental anxiety at the index visit on persistent symptoms at 1month. ConclusionsParental anxiety at time of acute presentation does not appear to be associated with prolongation of postconcussive symptoms in their children. However, parents of persistently symptomatic children remain significantly more anxious than those whose children's symptoms have resolved. Future research should attempt to reduce the familial burden of concussion through expectation management strategies.	[Zemek, Roger; Farion, Ken J.; Barrowman, Nick; Osmond, Martin H.] Childrens Hosp Eastern Ontario, Div Pediat Emergency Med, Toronto, ON, Canada; [Vassilyadi, Michael] Childrens Hosp Eastern Ontario, Div Neurosurg, Toronto, ON, Canada; [Anderson, Peter] Childrens Hosp Eastern Ontario, Div Neuropsychol, Toronto, ON, Canada; [Zemek, Roger; Farion, Ken J.; Barrowman, Nick; Osmond, Martin H.] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Vassilyadi, Michael] Univ Ottawa, Dept Surg, Ottawa, ON K1N 6N5, Canada; [Anderson, Peter] Univ Ottawa, Dept Psychol, Ottawa, ON K1N 6N5, Canada; [Irish, Brendan] Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada; [Zemek, Roger; Clarkin, Chantalle; Farion, Ken J.; Barrowman, Nick; Osmond, Martin H.] Childrens Hosp Eastern Ontario, Res Inst, Toronto, ON, Canada; [Goulet, Kristian] Eastern Ontario Concuss Clin, Ottawa, ON, Canada		Zemek, R (corresponding author), Childrens Hosp Eastern Ontario, Div Pediat Emergency Med, Toronto, ON, Canada.	rzemek@cheo.on.ca	Barrowman, Nick/AAL-3166-2020; Zemek, Roger/H-1039-2018; Meijer, Anna/K-5118-2016	Barrowman, Nick/0000-0002-4704-9595; Osmond, Martin/0000-0001-8275-8381	Academic Health Science Innovation Fund, Ontario, Canada	This study was funded by a grant from the Academic Health Science Innovation Fund, Ontario, Canada. The authors have no conflicts of interest or financial relationships relevant to this article to disclose.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barnes LLB, 2002, EDUC PSYCHOL MEAS, V62, P603, DOI 10.1177/0013164402062004005; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; Campo JV, 2007, ARCH PEDIAT ADOL MED, V161, P131, DOI 10.1001/archpedi.161.2.131; Carroll L J, 2011, CONCUSSION CRISIS AN; CASEY R, 1987, PEDIATRICS, V80, P159; Edmed S, 2012, PSYCHIAT RES, V200, P41, DOI 10.1016/j.psychres.2012.05.022; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emiroglu FNI, 2004, J CHILD NEUROL, V19, P332; Feldman JM, 2010, J NERV MENT DIS, V198, P272, DOI 10.1097/NMD.0b013e3181d61271; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; GARBER J, 1990, J AM ACAD CHILD PSY, V29, P648, DOI 10.1097/00004583-199007000-00021; GAUTHIER J, 1993, CAN J BEHAV SCI, V25, P559, DOI 10.1037/h0078881; Gennaro S, 1986, J Obstet Gynecol Neonatal Nurs, V15, P160; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; HATCHER JW, 1989, J PEDIATR PSYCHOL, V14, P335, DOI 10.1093/jpepsy/14.3.335; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Center for Injury Prevention and Control, 2010, TRAUMATIC BRAIN INJU; Ontario Injury Prevention Resource Centre, ONT INJ SPOTL; Parkinson GW, 1999, CLIN PEDIATR, V38, P219, DOI 10.1177/000992289903800403; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Rivara FP, 2012, ARCH PEDIAT ADOL MED, V166, P666, DOI 10.1001/archpediatrics.2011.1602; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; SESTI A, 2000, QUAL LIFE NEWSL, V25, P15; Spielberger CD., 1983, STATE TRAIT ANXIETY; Vincent, 2008, J INT NEUROPSYCH SOC, V1, P204; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Youngblut JM, 2006, J PEDIATR PSYCHOL, V31, P608, DOI 10.1093/jpepsy/jsj066; Zafonte R, 2011, JAMA-J AM MED ASSOC, V306, P79, DOI 10.1001/jama.2011.819; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	46	28	28	0	20	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	OCT	2013	20	10					1041	1049		10.1111/acem.12220			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	239KX	WOS:000326023700010	24127708	Bronze			2022-02-06	
J	Karch, D; Albers, L; Renner, G; Lichtenauer, N; von Kries, R				Karch, Dieter; Albers, Lucia; Renner, Gerolf; Lichtenauer, Norbert; von Kries, Ruediger			The Efficacy of Cognitive Training Programs in Children and Adolescents A Meta-analysis	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Article							TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; DEFICIT HYPERACTIVITY DISORDER; RANDOMIZED CLINICAL-TRIAL; MULTIMODAL TREATMENT; EXECUTIVE FUNCTIONS; WORKING-MEMORY; ADHD; REHABILITATION; INTERVENTIONS	Background: Cognitive therapies are intended to improve basic cognitive functions, whatever the cause of the deficiency may be. Children and adolescents with various cognitive deficits are treated with behavioral therapeutic and computer-supported training programs. We here report the first meta-analysis of the efficacy of such programs. Methods: We systematically searched the Medline, Embase, PsycINFO, PSYNDEX, and ERIC databases to find pertinent publications for a meta-analysis of cognitive training programs that are used in children and adolescents to improve attention, memory, and executive performance (primary goals) as well as behavior/psychopathology, intelligence, and school performance (secondary goals). The mean differences between the treatment and control groups are given here as standard deviation (SD) scores. Results: 1661 potentially relevant publications were found, including 22 studies that were considered in the meta-analysis, 17 of which were randomized controlled trials. The target variables were measured with more than 90 different testing techniques. The overall effects of cognitive training on attention (SD 0.18, 95% CI -0.11-0.47) and executive function (SD 0.17, 95% CI -0.12-0.46) were consistently small. A relatively strong effect was found on memory performance (0.65 SD, 95% [-0.12-1.42), albeit with marked heterogeneity (I-2 = 82%) owing to two studies. The largest effect was found in the area of behavior and psychopathology (SD 0.58, 95% CI 0.31-0.85), but this last figure is derived mainly from studies that lacked an active control group. Conclusion: Cognitive therapies for children and adolescents have generally favorable, but probably nonspecific effects on behavior. On the other hand, the specific effects, however, were weak overall. Therapeutic benefit has been demonstrated only for certain individual types of therapy for specific indications.	[Karch, Dieter] Children Ctr Maulbronn, Clin Pediat Neurol & Social Pediat, Maulbronn, Germany; [Albers, Lucia; von Kries, Ruediger] Univ Munich, Inst Sozaile Padiatrie & Jugendmed, D-81377 Munich, Germany; [Renner, Gerolf] Univ Educ Ludwigsburg, Fac Special Pedag, Ludwigsburg, Germany		von Kries, R (corresponding author), Univ Munich, Inst Sozaile Padiatrie & Jugendmed, Heigelhofstr 63, D-81377 Munich, Germany.	ruediger.kries@med.uni-muenchen.de					ABIKOFF H, 1991, J LEARN DISABIL, V24, P205, DOI 10.1177/002221949102400404; BANASCHEWSKI T, 2006, MOTORIK, V29, P57; Bangirana P, 2009, J DEV BEHAV PEDIATR, V30, P310, DOI 10.1097/DBP.0b013e3181b0f01b; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Boivin MJ, 2010, NEUROPSYCHOLOGY, V24, P667, DOI 10.1037/a0019312; Borenstein M., 2009, INTRO META ANAL; Boutron I, 2008, ANN INTERN MED, V148, pW60, DOI 10.7326/0003-4819-148-4-200802190-00008-w1; Braun J, PSYCHOL ERZIEHUNG UN, V47, P10; BROWN RT, 1986, J ABNORM CHILD PSYCH, V14, P481, DOI 10.1007/BF01260518; Buch SR, 2009, KOGNITIVE FORDERUNG; Bundesarztekammer, 2005, DTSCH ARZTEBL, V102, pA; Butler RW, 2008, J CONSULT CLIN PSYCH, V76, P367, DOI 10.1037/0022-006X.76.3.367; Chenault BM, 2004, EFFECTS PRIOR ATTENT; Cohen J, 1969, STAT POWER ANAL BEHA; Conners CK, 2001, J AM ACAD CHILD PSY, V40, P159, DOI 10.1097/00004583-200102000-00010; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Domsch H, 2009, PSYCHOL FORDER INTER; Dopfner M, 2004, EUR CHILD ADOLES PSY, V13, P117, DOI 10.1007/s00787-004-1011-9; Dopfner M., 1998, THERAPIEPROGRAMM KIN; Dreisorner T., 2006, KINDH ENTWICKL, V15, P255; FEHLINGS DL, 1991, J DEV BEHAV PEDIATR, V12, P223; G-BA, 2011, STELL AMB NEUR THER; Galbiati S, 2009, NEUROPSYCHOLOGY, V23, P40, DOI 10.1037/a0013409; Hedges LV., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.2307/1164588]; Jaeggi SM, 2011, P NATL ACAD SCI USA, V108, P10081, DOI 10.1073/pnas.1103228108; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kausch T, 2002, THESIS U TUBINGEN TU; Kline R.B., 2004, SIGNIFICANCE TESTING; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Kozulin A, 2010, RES DEV DISABIL, V31, P551, DOI 10.1016/j.ridd.2009.12.001; Lauth GW, 2006, KINDH ENTWICKL, V15, P229, DOI 10.1026/0942-5403.15.4.229; Lauth GW, 1996, Z KINDER JUG-PSYCH, V24, P164; Lauth GW, 2002, TRAINING AUFMERKSAMK; Lepach AC, 2009, KINDH ENTWICKL, V18, P105, DOI 10.1026/0942-5403.18.2.105; Lomas KM, 2002, THESIS HOWARD U WASH; MEICHENBAUM DH, 1971, J ABNORM PSYCHOL, V77, P115, DOI 10.1037/h0030773; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ross KA, 2011, DEV MED CHILD NEUROL, V53, P692, DOI 10.1111/j.1469-8749.2011.03976.x; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Sonntag W, 2004, Z PADAGOG PSYCHOL, V18, P101, DOI 10.1024/1010-0652.18.2.101; Sturm W, 2010, NEURO REHABIL, V16, P55; Thorell LB, 2009, DEVELOPMENTAL SCI, V12, P106, DOI 10.1111/j.1467-7687.2008.00745.x; Toplak ME, 2008, CLIN PSYCHOL REV, V28, P801, DOI 10.1016/j.cpr.2007.10.008; Tucha O, 2011, ADHD-ATTEND DEFICIT, V3, P271, DOI 10.1007/s12402-011-0059-x; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	49	28	31	2	48	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	SEP 27	2013	110	39					643	U23		10.3238/arztebl.2013.0643			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248UQ	WOS:000326730200001	24163706	Green Published			2022-02-06	
J	Aslaksen, PM; Orbo, M; Elvestad, R; Schafer, C; Anke, A				Aslaksen, P. M.; Orbo, M.; Elvestad, R.; Schafer, C.; Anke, A.			Prediction of on-road driving ability after traumatic brain injury and stroke	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						driving; neuropsychology; stroke; traumatic brain injury	NEUROPSYCHOLOGICAL ASSESSMENT; MEDICAL CONDITIONS; FITNESS; REHABILITATION; DRIVERS; TRAIL	Background and purpose: The aim of the study was to examine the predictive value of widely used standardized neuropsychological tests in a clinical setting for on-road driving performance in patients with cerebral stroke or traumatic brain injury (TBI), and to provide cut-off values for neuropsychological test results under which driving should not be recommended. Methods: Data from 78 patients who had undergone comprehensive driving assessment after stroke or TBI were retrospectively included in the analysis. Patients underwent medical examination, neuropsychological testing and on-road assessment. Medical data, demographic variables and neuropsychological performance were used as predictors in a stepwise logistic regression analysis with pass/fail after the on-road test as the dependent variable. Receiver operating characteristic curve analysis was employed to select cut-off values for the tests that were significant predictors for on-road performance. Results: Forty-three patients passed and 35 failed the on-road driving task. Logistic regression analysis revealed three significant neuropsychological tests (CalCap simple reaction time, Trail Making Test A, Grooved Pegboard) as predictors for on-road performance explaining 46% of the variance with an overall classification accuracy of 82.1%. Receiver operating characteristic curve analysis showed the following cutoff values: CalCap, 395 ms; Trail Making Test A, 46 s; Grooved Pegboard, 97.5 s. Conclusion: The results suggest that driving ability after brain damage and cerebral disease with no severe neurological deficits can be measured with a few distinctive neuropsychological tests together with medical examination and on-road assessment. Cut-off scores are a useful supplement to normative data/scaled scores.	[Aslaksen, P. M.; Orbo, M.; Elvestad, R.; Schafer, C.; Anke, A.] Univ Hosp North Norway, Dept Rehabil, Tromso, Norway; [Aslaksen, P. M.] Univ Tromso, Dept Psychol, Fac Hlth Sci, N-9037 Tromso, Norway; [Anke, A.] Univ Tromso, Dept Clin Med, Fac Hlth Sci, N-9037 Tromso, Norway		Aslaksen, PM (corresponding author), Univ Tromso, Dept Psychol, Fac Hlth Sci, N-9037 Tromso, Norway.	per.aslaksen@uit.no	Arbo, Marte/AAU-4163-2021; Orbo, Marte/AAA-2899-2021; Aslaksen, Per/J-6589-2019	Aslaksen, Per/0000-0002-9299-7260; Anke, Audny/0000-0002-2491-2560; Schafer, Christoph/0000-0002-4740-0429	University Hospital North Norway; University of Tromso, Norway	The authors wish to thank Morten Overvoll, Department of Psychology, University of Tromso, for his valuable assistance regarding ROC curve analyses. The study was funded by the University Hospital North Norway and the University of Tromso, Norway.	Akinwuntan AE, 2006, NEUROREHAB NEURAL RE, V20, P417, DOI 10.1177/1545968306287157; Alexandersen A, 2009, BRAIN INJURY, V23, P313, DOI 10.1080/02699050902788428; Bacon D, 2007, NEUROLOGY, V68, P1174, DOI 10.1212/01.wnl.0000259514.85579.e0; Barrash J, 2010, J INT NEUROPSYCH SOC, V16, P679, DOI 10.1017/S1355617710000470; Bliokas VV, 2011, BRAIN INJURY, V25, P471, DOI 10.3109/02699052.2011.559609; Cernich AN, 2010, CURR TREAT OPTION NE, V12, P412, DOI 10.1007/s11940-010-0085-6; Currie Z, 2000, BRIT MED J, V321, P990, DOI 10.1136/bmj.321.7267.990; Dawson JD, 2010, J AM GERIATR SOC, V58, P1090, DOI 10.1111/j.1532-5415.2010.02872.x; Devos H, 2011, NEUROLOGY, V76, P747, DOI 10.1212/WNL.0b013e31820d6300; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Gottesman RF, 2010, LANCET NEUROL, V9, P895, DOI 10.1016/S1474-4422(10)70164-2; Heaton R., 1980, MANUAL WISCONSIN CAR; Jacobson SC, 2011, BRAIN COGNITION, V77, P60, DOI 10.1016/j.bandc.2011.06.001; Marshall SC, 2007, TOP STROKE REHABIL, V14, P98, DOI 10.1310/tsr1401-98; MILLER EN, 1990, CALIFORNIA COMPUTERI; Ortoleva C, 2012, J HEAD TRAUMA REHAB, V27, P302, DOI 10.1097/HTR.0b013e3182236299; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rizzo M, 2011, JAMA-J AM MED ASSOC, V305, P1018, DOI 10.1001/jama.2011.252; RUFF RM, 1993, PERCEPT MOTOR SKILL, V76, P1219, DOI 10.2466/pms.1993.76.3c.1219; Sand KM, 2012, CEREBROVASC DIS EXTR, V2, P17, DOI 10.1159/000337016; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Soderstrom ST, 2006, SCAND J PSYCHOL, V47, P419, DOI 10.1111/j.1467-9450.2006.00550.x; SUNDET K, 1995, SCAND J PSYCHOL, V36, P47, DOI 10.1111/j.1467-9450.1995.tb00967.x; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WILSON B, 1987, ARCH PHYS MED REHAB, V68, P98; Withaar FK, 2000, J INT NEUROPSYCH SOC, V6, P480, DOI 10.1017/S1355617700644065	28	28	28	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	SEP	2013	20	9					1227	1233		10.1111/ene.12172			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	190WD	WOS:000322372400007	23560568				2022-02-06	
J	Kaushik, DK; Basu, A				Kaushik, Deepak Kumar; Basu, Anirban			A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Alzheimer's disease; central nervous system; cytokines; microglia; neuroinflammation; Parkinson's disease; toll-like receptors	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; AMYOTROPHIC-LATERAL-SCLEROSIS; TUMOR-NECROSIS-FACTOR; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; BACTERIAL-ENDOTOXIN EXPOSURE; AMYLOID-BETA-PEPTIDE; TOLL-LIKE RECEPTORS	Inflammation plays a critical role in the progression of neurodegenerative diseases. Microglia are the resident macrophages of the central nervous system (CNS) which actively take part in the neuronal development of CNS and are involved in clearance of pathogens as well as cellular debris from the system upon insult to this organization. Chronic activation of microglia in neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) as well as inflammatory conditions of CNS such as multiple sclerosis (MS) results in overall upregulation of pro-inflammatory cytokines and chemokines in the brain parenchyma. This compromises the neuronal health which further activates microglia by releasing death associated molecules such as neuromelanin, A peptides and cellular debris at the lesion site thereby forming a vicious cycle of disease advancement. Targeting microglial activation has proven to be a viable option in the treatment of inflammation related neurodegenerative diseases. This review will discuss the central position of inflammation and therapeutic strategies aiming to alleviate disease progression in some of the important inflammatory conditions of CNS.	[Kaushik, Deepak Kumar; Basu, Anirban] Natl Brain Res Ctr, Manesar 122051, Haryana, India		Kaushik, DK (corresponding author), Natl Brain Res Ctr, Manesar 122051, Haryana, India.	deepakkaushiik@gmail.com		Basu, Anirban/0000-0002-5200-2054	Life Science Research Board, Defence Research & Developmental Organization, Government of IndiaDefence Research & Development Organisation (DRDO) [DLS/81/48222/LSRB-213/EPB2010]; Indian Council of Medical Research (ICMR)Indian Council of Medical Research (ICMR); Department of Biotechnology (DBT)Department of Biotechnology (DBT) India	The work in the author's laboratory is funded by Life Science Research Board, Defence Research & Developmental Organization (DLS/81/48222/LSRB-213/EPB2010), Government of India. DKK is a recipient of Senior Research Fellowship from Indian Council of Medical Research (ICMR). AB is a recipient of the National Bioscience Award for Career Development-2010 from the Department of Biotechnology (DBT).	Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Almer G, 2002, NEUROLOGY, V58, P1277, DOI 10.1212/WNL.58.8.1277; Alvarez-Erviti L, 2011, NEUROSCI RES, V69, P337, DOI 10.1016/j.neures.2010.12.020; Badiola N, 2009, NEUROBIOL DIS, V35, P438, DOI 10.1016/j.nbd.2009.06.005; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Beraud D, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00080; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; BILLINGHAM RE, 1953, PROC R SOC SER B-BIO, V141, P392, DOI 10.1098/rspb.1953.0049; Bjorkqvist M, 2008, J EXP MED, V205, P1869, DOI 10.1084/jem.20080178; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Brambilla R, 2011, BRAIN, V134, P2736, DOI 10.1093/brain/awr199; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Caballol N, 2007, MOVEMENT DISORD, V22, pS358, DOI 10.1002/mds.21677; Hernandez-Romero MC, 2012, NEUROTOXICOLOGY, V33, P347, DOI 10.1016/j.neuro.2012.01.018; Carrasco E, 2002, PARKINSONISM RELAT D, V8, P407, DOI 10.1016/S1353-8020(02)00022-6; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Casper D, 2000, NEUROSCI LETT, V289, P201, DOI 10.1016/S0304-3940(00)01294-5; Centonze D, 2009, J NEUROSCI, V29, P3442, DOI 10.1523/JNEUROSCI.5804-08.2009; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Chechneva OV, 2011, NEUROBIOL DIS, V44, P63, DOI 10.1016/j.nbd.2011.06.004; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chiu IM, 2008, P NATL ACAD SCI USA, V105, P17913, DOI 10.1073/pnas.0804610105; Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275; Dibaj P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017910; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Eng LF, 1996, NEUROCHEM RES, V21, P511, DOI 10.1007/BF02527717; Eugenin EA, 2003, METHODS, V29, P351, DOI 10.1016/S1046-2023(02)00359-6; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje; Freeman TB, 2000, P NATL ACAD SCI USA, V97, P13877, DOI 10.1073/pnas.97.25.13877; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gao Z., 2012, NEUROL RES INT, V2011; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Gelinas DS, 2004, P NATL ACAD SCI USA, V101, P14657, DOI 10.1073/pnas.0404866101; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Gowing G, 2008, J NEUROSCI, V28, P10234, DOI 10.1523/JNEUROSCI.3494-08.2008; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Gris D, 2010, J IMMUNOL, V185, P974, DOI 10.4049/jimmunol.0904145; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Hebert SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI 10.1073/pnas.0710263105; Henderson APD, 2009, ANN NEUROL, V66, P739, DOI 10.1002/ana.21800; Henkel JS, 2009, J NEUROIMMUNE PHARM, V4, P389, DOI 10.1007/s11481-009-9171-5; Henkel JS, 2004, ANN NEUROL, V55, P221, DOI 10.1002/ana.10805; Hensley K, 2003, NEUROBIOL DIS, V14, P74, DOI 10.1016/S0969-9961(03)00087-1; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Herber DL, 2007, J NEUROIMMUNE PHARM, V2, P222, DOI 10.1007/s11481-007-9069-z; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Hoozemans JJM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-171; Huang Y, 2005, CELL MOL IMMUNOL, V2, P113; Huizinga R, 2012, GLIA, V60, P422, DOI 10.1002/glia.22276; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; Iadecola C, 1996, AM J PHYSIOL-REG I, V271, pR990, DOI 10.1152/ajpregu.1996.271.4.R990; Jack C, 2005, J NEUROSCI RES, V81, P363, DOI 10.1002/jnr.20482; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Johnston LC, 2008, MOL THER, V16, P1392, DOI 10.1038/mt.2008.113; Kaisho T, 2000, CRIT REV IMMUNOL, V20, P393; Kanneganti TD, 2006, J BIOL CHEM, V281, P36560, DOI 10.1074/jbc.M607594200; Kanwar JR, 2005, CURR MED CHEM, V12, P2947, DOI 10.2174/092986705774462833; Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640; Kaushik DK, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-68; Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270; Kaushik DK, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-57; Kaushik DK, 2011, FRONT BIOSCI-LANDMRK, V16, P2187, DOI 10.2741/3847; Kihara Y, 2009, P NATL ACAD SCI USA, V106, P21807, DOI 10.1073/pnas.0906891106; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kraft AD, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.02.015; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; Kuhle J, 2009, EUR J NEUROL, V16, P771, DOI 10.1111/j.1468-1331.2009.02560.x; Kurkowska-Jastrzebska I, 2004, INT IMMUNOPHARMACOL, V4, P1307, DOI 10.1016/j.intimp.2004.05.006; Kurkowska-Jastrzebska I, 2002, INT IMMUNOPHARMACOL, V2, P1213, DOI 10.1016/S1567-5769(02)00078-4; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Lautner Ronald, 2011, Int J Alzheimers Dis, V2011, P939426, DOI 10.4061/2011/939426; Lee DC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-56; Liang XB, 2008, ANN NEUROL, V64, P304, DOI 10.1002/ana.21437; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Ling ZD, 2004, NEUROSCIENCE, V124, P619, DOI 10.1016/j.neuroscience.2003.12.017; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Liu SR, 2012, J IMMUNOL, V188, P1098, DOI 10.4049/jimmunol.1101121; Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Long-Smith CM, 2009, PROG NEUROBIOL, V89, P277, DOI 10.1016/j.pneurobio.2009.08.001; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Ma L, 2003, GLIA, V43, P274, DOI 10.1002/glia.10261; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Martin R, 2012, BRIT J PHARMACOL, V166, P1708, DOI 10.1111/j.1476-5381.2012.01869.x; MATSUMOTO Y, 1986, J NEUROIMMUNOL, V12, P265; McGann JC, 2012, CURR OPIN NEUROBIOL; McGeer PL, 1998, ALZ DIS ASSOC DIS, V12, pS1; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MCGEER PL, 1987, CAN J NEUROL SCI, V14, P363, DOI 10.1017/S0317167100037756; McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Meissner F, 2010, P NATL ACAD SCI USA, V107, P13046, DOI 10.1073/pnas.1002396107; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357; Mills JH, 2012, J IMMUNOL, V188, P5713, DOI 10.4049/jimmunol.1200545; Minones-Moyano E, 2011, HUM MOL GENET, V20, P3067, DOI 10.1093/hmg/ddr210; Monk PN, 2006, NAT MED, V12, P885, DOI 10.1038/nm0806-885; Montgomery SL, 2011, AM J PATHOL, V179, P2053, DOI 10.1016/j.ajpath.2011.07.001; Moreau C, 2005, NEUROLOGY, V65, P1958, DOI 10.1212/01.wnl.0000188907.97339.76; Murphy AC, 2010, BRAIN BEHAV IMMUN, V24, P641, DOI 10.1016/j.bbi.2010.01.014; Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952; Nakajima K, 1998, GLIA, V24, P272, DOI 10.1002/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4; Napoli I, 2010, EXP NEUROL, V225, P24, DOI 10.1016/j.expneurol.2009.04.024; Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583; Nunez-Iglesias J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008898; Ogata A, 1997, J NEUROVIROL, V3, P141, DOI 10.3109/13550289709015803; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Pathak SK, 2004, J BIOL CHEM, V279, P55127, DOI 10.1074/jbc.M409885200; Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17; Penfield W., 1932, CYTOLOGY CELLULAR PA, V2, P482; Politis M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00096; Politis M, 2011, HUM BRAIN MAPP, V32, P258, DOI 10.1002/hbm.21008; Pollari E, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-74; Poloni M, 2000, NEUROSCI LETT, V287, P211, DOI 10.1016/S0304-3940(00)01177-0; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Qian L, 2006, J NEURAL TRANSM-SUPP, P367; Quintana A, 2009, J IMMUNOL, V183, P2079, DOI 10.4049/jimmunol.0900242; Ramaglia V, 2012, P NATL ACAD SCI USA, V109, P965, DOI 10.1073/pnas.1111924109; Ratchford JN, 2012, J NEUROL, V259, P1199, DOI 10.1007/s00415-011-6337-x; Rentzos M, 2007, AMYOTROPH LATERAL SC, V8, P283, DOI 10.1080/17482960701419232; RICHARDSON A, 1993, GLIA, V7, P25, DOI 10.1002/glia.440070107; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rus H, 2006, J NEUROIMMUNOL, V180, P9, DOI 10.1016/j.jneuroim.2006.07.009; Ryu JK, 2004, EXP NEUROL, V187, P150, DOI 10.1016/j.expneurol.2004.01.006; Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010; Samii A, 2004, LANCET, V363, P1783, DOI 10.1016/S0140-6736(04)16305-8; Sargsyan SA, 2005, GLIA, V51, P241, DOI 10.1002/glia.20210; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Simmons DA, 2007, GLIA, V55, P1074, DOI 10.1002/glia.20526; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Song M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-92; SOTREL A, 1991, NEUROLOGY, V41, P1117, DOI 10.1212/WNL.41.7.1117; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sta M, 2011, NEUROBIOL DIS, V42, P211, DOI 10.1016/j.nbd.2011.01.002; Stefanova N, 2011, AM J PATHOL, V179, P954, DOI 10.1016/j.ajpath.2011.04.013; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Tahara K, 2006, BRAIN, V129, P3006, DOI 10.1093/brain/awl249; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Tai YF, 2007, BRAIN RES BULL, V72, P148, DOI 10.1016/j.brainresbull.2006.10.029; Thomas M, 2004, CURR PHARM DESIGN, V10, P679, DOI 10.2174/1381612043453162; TOPPER R, 1993, EXP NEUROL, V123, P271, DOI 10.1006/exnr.1993.1159; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; van Loo G, 2006, NAT IMMUNOL, V7, P954, DOI 10.1038/ni1372; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Varvel NH, 2009, J CLIN INVEST, V119, P3692, DOI 10.1172/JCI39716; Venero JL, 2011, CELL DEATH DIFFER, V18, P1679, DOI 10.1038/cdd.2011.107; von Bernhardi R, 2010, J NEUROCHEM, V112, P1099, DOI 10.1111/j.1471-4159.2009.06537.x; Westin K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030525; Williams AH, 2009, SCIENCE, V326, P1549, DOI 10.1126/science.1181046; WILLIAMS KC, 1994, CLIN NEUROSCI, V2, P229; Wilms H, 2003, J NEUROIMMUNOL, V144, P139, DOI 10.1016/j.jneuroim.2003.08.042; Wilms H, 2003, NEUROBIOL DIS, V14, P417, DOI 10.1016/j.nbd.2003.07.002; Wilms H, 2003, FASEB J, V17, P500, DOI 10.1096/fj.02-0314fje; Yan Q, 2003, J NEUROSCI, V23, P7504; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com; Zhang Y, 2011, GENE THER, V18, P1139, DOI 10.1038/gt.2011.170; Zhao J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-150	186	28	29	0	25	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	SEP	2013	12	6					726	740		10.2174/18715273113126660170			15	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	263HD	WOS:000327797200005	24070095				2022-02-06	
J	Maxwell, WL				Maxwell, William L.			Damage to Myelin and Oligodendrocytes: A Role in Chronic Outcomes Following Traumatic Brain Injury?	BRAIN SCIENCES			English	Article						brain trauma; axonal injury; secondary axotomy; spreading depression; white matter loss		There is increasing evidence in the experimental and clinical traumatic brain injury (TBI) literature that loss of central myelinated nerve fibers continues over the chronic post-traumatic phase after injury. However, the biomechanism(s) of continued loss of axons is obscure. Stretch-injury to optic nerve fibers in adult guinea-pigs was used to test the hypothesis that damage to the myelin sheath and oligodendrocytes of the optic nerve fibers may contribute to, or facilitate, the continuance of axonal loss. Myelin dislocations occur within internodal myelin of larger axons within 1-2 h of TBI. The myelin dislocations contain elevated levels of free calcium. The volume of myelin dislocations increase with greater survival and are associated with disruption of the axonal cytoskeleton leading to secondary axotomy. Waves of Ca2+ depolarization or spreading depression extend from the initial locus injury for perhaps hundreds of microns after TBI. As astrocytes and oligodendrocytes are connected via gap junctions, it is hypothesized that spreading depression results in depolarization of central glia, disrupt axonal ionic homeostasis, injure axonal mitochondria and allow the onset of axonal degeneration throughout an increasing volume of brain tissue; and contribute toward post-traumatic continued loss of white matter.	[Maxwell, William L.] Univ Glasgow, Coll Med Vet Med & Biol Sci, Dept Human Anat, Glasgow G12 8QQ, Lanark, Scotland		Maxwell, WL (corresponding author), Univ Glasgow, Coll Med Vet Med & Biol Sci, Dept Human Anat, Glasgow G12 8QQ, Lanark, Scotland.	William.Maxwell@Glasgow.ac.uk					Aggarwal S, 2011, TRENDS CELL BIOL, V21, P585, DOI 10.1016/j.tcb.2011.06.004; Baltan S, 2009, NEUROSCIENTIST, V15, P126, DOI 10.1177/1073858408324788; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BORGERS M, 1977, LAB INVEST, V37, P1; Butt AM, 2004, EYE, V18, P1110, DOI 10.1038/sj.eye.6701595; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Hamilton N, 2008, GLIA, V56, P734, DOI 10.1002/glia.20649; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jahn O, 2009, MOL NEUROBIOL, V40, P55, DOI 10.1007/s12035-009-8071-2; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Llorens F, 2011, FASEB J, V25, P463, DOI 10.1096/fj.10-162792; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Maglione M, 2010, GLIA, V58, P1104, DOI 10.1002/glia.20991; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Narciso MS, 2001, AN ACAD BRAS CIENC, V73, P231, DOI 10.1590/S0001-37652001000200008; Nawaz S, 2009, J NEUROSCI, V29, P4794, DOI 10.1523/JNEUROSCI.3955-08.2009; Nualart-Marti A, 2013, BBA-BIOMEMBRANES, V1828, P69, DOI 10.1016/j.bbamem.2012.01.024; Quarles RH., 2006, BASIC NEUROCHEMISTRY, P51; Salameh A, 2013, BBA-BIOMEMBRANES, V1828, P147, DOI 10.1016/j.bbamem.2011.12.030; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Soldan MMP, 2012, SEMIN NEUROL, V32, P9, DOI 10.1055/s-0032-1306381; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Velumian AA, 2011, NEUROIMAGE, V56, P27, DOI 10.1016/j.neuroimage.2010.11.022; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412	44	28	29	0	0	MDPI AG	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2076-3425	2976-3425		BRAIN SCI	Brain Sci.	SEP	2013	3	3					1374	1394		10.3390/brainsci3031374			21	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V20QX	WOS:000214902200019	24961533	Green Published, gold, Green Accepted, Green Submitted			2022-02-06	
J	Yin, T; Lindley, TE; Albert, GW; Ahmed, R; Schmeiser, PB; Grady, MS; Howard, MA; Welsh, MJ				Yin, Terry; Lindley, Timothy E.; Albert, Gregory W.; Ahmed, Raheel; Schmeiser, Peter B.; Grady, M. Sean; Howard, Matthew A.; Welsh, Michael J.			Loss of Acid Sensing Ion Channel-1a and Bicarbonate Administration Attenuate the Severity of Traumatic Brain Injury	PLOS ONE			English	Article							SEVERE HEAD-INJURY; NEURONAL DEGENERATION; HIPPOCAMPAL-NEURONS; MYOCARDIAL-ISCHEMIA; ACTIVATED CURRENTS; FLUID PERCUSSION; OXIDATIVE STRESS; LACTIC-ACIDOSIS; CLINICAL-TRIAL; ASICS	Traumatic brain injury (TBI) is a common cause of morbidity and mortality in people of all ages. Following the acute mechanical insult, TBI evolves over the ensuing minutes and days. Understanding the secondary factors that contribute to TBI might suggest therapeutic strategies to reduce the long-term consequences of brain trauma. To assess secondary factors that contribute to TBI, we studied a lateral fluid percussion injury (FPI) model in mice. Following FPI, the brain cortex became acidic, consistent with data from humans following brain trauma. Administering HCO3- after FPI prevented the acidosis and reduced the extent of neurodegeneration. Because acidosis can activate acid sensing ion channels (ASICs), we also studied ASIC1a(-/-) mice and found reduced neurodegeneration after FPI. Both HCO3- administration and loss of ASIC1a also reduced functional deficits caused by FPI. These results suggest that FPI induces cerebral acidosis that activates ASIC channels and contributes to secondary injury in TBI. They also suggest a therapeutic strategy to attenuate the adverse consequences of TBI.	[Yin, Terry; Schmeiser, Peter B.; Welsh, Michael J.] Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Lindley, Timothy E.; Albert, Gregory W.; Ahmed, Raheel; Howard, Matthew A.; Welsh, Michael J.] Univ Iowa, Dept Neurosurg, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA; [Welsh, Michael J.] Univ Iowa, Howard Hughes Med Inst, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Grady, M. Sean] Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA		Welsh, MJ (corresponding author), Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA.	michael-welsh@uiowa.edu		Welsh, Michael/0000-0002-1646-6206; Howard, Matthew/0000-0003-3935-8889	Howard Hughes Medical InstituteHoward Hughes Medical Institute	This work was supported by Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Benson CJ, 2001, ANN NY ACAD SCI, V940, P96; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bourdeaux C, 2010, NEUROCRIT CARE, V13, P24, DOI 10.1007/s12028-010-9368-8; Bourdeaux CP, 2011, NEUROCRIT CARE, V15, P42, DOI 10.1007/s12028-011-9512-0; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; Deval E, 2010, PHARMACOL THERAPEUT, V128, P549, DOI 10.1016/j.pharmthera.2010.08.006; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; Faul M, 2010, TRAUMATIC BRAIN INJU; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Grunder Stefan, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P73; Gu L, 2010, NEUROSCI LETT, V479, P63, DOI 10.1016/j.neulet.2010.05.029; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Harrison FE, 2006, LEARN MEMORY, V13, P809, DOI 10.1101/lm.334306; Ishrat T, 2012, NEUROSCIENCE, V210, P442, DOI 10.1016/j.neuroscience.2012.03.008; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Joch M, 2007, MOL BIOL CELL, V18, P3105, DOI 10.1091/mbc.E05-11-1027; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Koseki H, 2009, SYNAPSE, V63, P805, DOI 10.1002/syn.20657; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; Krajewska M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024341; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Lehmann H, 2012, NEUROBIOL LEARN MEM; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; Picloplichko VI, 2006, P NATL ACAD SCI USA, V103, P11376, DOI 10.1073/pnas.0600768103; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; Sarkar S, 2011, FUNDAMENTAL NEUROPATHOLOGY FOR PATHOLOGISTS AND TOXICOLOGISTS: PRINCIPLES AND TECHNIQUES, P171; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sherwood TW, 2011, J NEUROSCI, V31, P9723, DOI 10.1523/JNEUROSCI.1665-11.2011; Sherwood TW, 2012, AM J PHYSL CELL PHYS; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Sun X, 2011, BRAIN RES, V1396, P77, DOI 10.1016/j.brainres.2011.04.011; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tsai YD, 2013, BRAIN INJURY, V27, P361, DOI 10.3109/02699052.2012.750738; Turner RJ, 2004, J AM COLL NUTR, V23, p534S, DOI 10.1080/07315724.2004.10719397; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Weng JY, 2010, J NEUROSCI, V30, P6548, DOI 10.1523/JNEUROSCI.0582-10.2010; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Wong HK, 2008, HUM MOL GENET, V17, P3223, DOI 10.1093/hmg/ddn218; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xiong ZG, 2008, CURR OPIN PHARMACOL, V8, P25, DOI 10.1016/j.coph.2007.09.001; Yagi J, 2006, CIRC RES, V99, P501, DOI 10.1161/01.RES.0000238388.79295.4c; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; Zhang BL, 2011, BRAIN RES, V1382, P165, DOI 10.1016/j.brainres.2011.01.065; Zhao XR, 2008, J NEUROTRAUM, V25, P1195, DOI 10.1089/neu.2008.0635; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47; Ziemann AE, 2008, NAT NEUROSCI, V11, P816, DOI 10.1038/nn.2132; Ziemann AE, 2009, CELL, V139, P1012, DOI 10.1016/j.cell.2009.10.029	80	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2013	8	8							e72379	10.1371/journal.pone.0072379			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	215RU	WOS:000324228800067	23991103	Green Published, gold			2022-02-06	
J	Tam, JW; Schmitter-Edgecombe, M				Tam, Joyce W.; Schmitter-Edgecombe, Maureen			The Role of Processing Speed in the Brief Visuospatial Memory Test - Revised	CLINICAL NEUROPSYCHOLOGIST			English	Article						BVMT-R; Visuospatial memory; Speed of processing; Executive function	TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; WORKING-MEMORY; MULTIPLE-SCLEROSIS; OLDER-ADULTS; PERFORMANCE; BATTERY; SCHIZOPHRENIA; VALIDATION; DEMENTIA	The Brief Visuospatial Memory Test - Revised (BVMT-R) is a commonly used, commercialized, assessment tool to measure visuospatial learning and memory abilities across research and clinical settings. In this study we evaluated the influence of processing speed and executive functioning on BVMT-R learning, memory, and percent retention scores. A total of 141 cognitively healthy older adults completed the BVMT-R along with measures of visuoconstructional abilities (BVMT-R copy), speeded processing (Symbol Digit Modalities Test-oral), and executive function (FAS). After controlling for age and visuoconstructional abilities, hierarchical regression models showed that the processing speed measure was a unique predictor of both BVMT-R learning and memory performances, while the executive function measure was not. The visuoconstructional measure was the only unique predictor of BVMT-R percent retention. The findings suggest that, when interpreting the BVMT-R learning and memory scores of patients who exhibit speeded processing deficits, the impact of slowed processing speed on performance should be considered.	[Tam, Joyce W.; Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA		Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			Life Science Discovery Fund of Washington State; NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB009675]; NSFNational Science Foundation (NSF) [DGE-0900781]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009675] Funding Source: NIH RePORTER	We would like to thank the members of the WSU Aging and Dementia Research Laboratory for their help in coordinating, collecting, and scoring the data. Portions of this research were presented at the 40th annual conference of the International Neuropsychological Society, Montreal, Quebec, Canada. This research was funded in part by grants from the Life Science Discovery Fund of Washington State; NIBIB (Grant #R01 EB009675); and NSF (Grant DGE-0900781). No financial or other relationships exist that could be interpreted as a conflict of interest pertaining to this manuscript.	Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 2006, J INT NEUROPSYCH SOC, V12, P549, DOI 10.1017/S1355617706060723; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; BENEDICT RHB, 1995, CLIN NEUROPSYCHOL, V0009, P00011; Brown LA, 2012, EXP AGING RES, V38, P1, DOI 10.1080/0361073X.2012.636722; Delis DC., 2001, DELIS KAPLAN EXECUTI; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Duff K, 2005, ARCH CLIN NEUROPSYCH, V20, P111, DOI 10.1016/j.acn.2004.03.003; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Folstein M., 2003, TELEPHONE INTERVIEW; Foster PS, 2010, COGN BEHAV NEUROL, V23, P19, DOI 10.1097/WNN.0b013e3181c20de7; Green MF, 2004, BIOL PSYCHIAT, V56, P301, DOI 10.1016/j.biopsych.2004.06.023; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Johnson AM, 2004, NEUROPSYCHOLOGIA, V42, P577, DOI 10.1016/j.neuropsychologia.2003.10.011; Lee T, 2012, NEUROPSYCHOLOGY, V26, P776, DOI 10.1037/a0030053; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Nuechterlein K. H, 2006, MATRIS CONSENSUS BAT; Perrotin A, 2006, ACTA PSYCHOL, V122, P58, DOI 10.1016/j.actpsy.2005.10.003; SACCUZZO DP, 1981, ARCH GEN PSYCHIAT, V38, P175; Salthouse T. A., 1993, J GERONTOL B-PSYCHOL, V48, P245; SALTHOUSE TA, 1991, PSYCHOL SCI, V2, P179, DOI 10.1111/j.1467-9280.1991.tb00127.x; SALTHOUSE TA, 1992, ACTA PSYCHOL, V79, P155, DOI 10.1016/0001-6918(92)90030-H; SALTHOUSE TA, 1992, J GERONTOL, V47, P121, DOI DOI 10.1093/GER0NJ/47.3.P121; Schmitter-Edgecombe M, 2011, J INT NEUROPSYCH SOC, V17, P853, DOI 10.1017/S1355617711000865; SLIWINSKI M, 1997, J GERONTOL B-PSYCHOL, V52, P308; Smerbeck AM, 2011, MULT SCLER J, V17, P449, DOI 10.1177/1352458510391689; Smith A., 1991, SYMBOL DIGIT MODALIT; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P83, DOI 10.1016/j.acn.2005.07.008; Yatham LN, 2010, BIPOLAR DISORD, V12, P351, DOI 10.1111/j.1399-5618.2010.00830.x; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	35	28	29	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG 1	2013	27	6					962	972		10.1080/13854046.2013.797500			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	197RA	WOS:000322867100005	23682755	Green Accepted			2022-02-06	
J	Deans, KJ; Minneci, PC; Lowell, W; Groner, JI				Deans, Katherine J.; Minneci, Peter C.; Lowell, Wendi; Groner, Jonathan I.			Increased morbidity and mortality of traumatic brain injury in victims of nonaccidental trauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Child abuse; nonaccidental trauma (NAT); traumatic brain injury (TBI); intentional injury; intentional trauma	ABUSIVE HEAD TRAUMA; DECOMPRESSIVE CRANIECTOMY; PHYSICAL ABUSE; OUTCOMES; MODEL	BACKGROUND: The purpose of this study was to determine if the morbidity and mortality associated with traumatic brain injury (TBI) are worse in children who experienced nonaccidental trauma (NAT) compared with TBI from other traumatic mechanisms. METHODS: We identified all pediatric patients admitted with the diagnosis of TBI between 2001 and 2010 in our institutional trauma registry with an Abbreviated Injury Scale (AIS) score greater than 1. Patients were divided into groups based on a nonaccidental (NAT) or accidental mechanism of injury. Need for gastrostomy tube insertion was used as a marker of more severe neurologic morbidity in survivors of TBI. Group comparisons were made using Fisher's exact tests. RESULTS: A total of 2,782 patients with TBI were included; 315 (11.3%) patients had TBI secondary to NAT. Overall mortality and AIS-specific mortality were higher in patients with TBI secondary to NAT. In comparison with patients with TBI secondary to accidental mechanisms, patients with TBI secondary to NAT were younger (mean, 1 year vs. 8 years), had longer intensive care unit stays (mean, 3 days vs. 1 day), and required gastrostomy tubes more often (6% vs. 1%, p < 0.0001). Even among the subgroup of patients with severe TBI, (AIS score 4 and 5), patients with NAT required gastrostomy tubes more often (5% vs. 2%, p = 0.014). CONCLUSION: Patients with TBI from NAT have increased morbidity and mortality compared with patients with TBI from accidental mechanisms; these differences are present at all levels of severity of injury. Patients with TBI from NAT represent a vulnerable group of pediatric trauma patients who are at increased risk for death and worse outcome and who will require greater short-and long-term medical resources. (J Trauma Acute Care Surg. 2013; 75: 157-160. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Deans, Katherine J.; Minneci, Peter C.] Nationwide Childrens Hosp, Ctr Surg Outcomes Res, Columbus, OH 43205 USA; [Lowell, Wendi; Groner, Jonathan I.] Nationwide Childrens Hosp, Trauma Program, Columbus, OH 43205 USA; [Deans, Katherine J.; Minneci, Peter C.; Groner, Jonathan I.] Ohio State Univ, Coll Med, Dept Surg, Columbus, OH 43210 USA		Groner, JI (corresponding author), Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.	Jonathan.groner@nationwidechildrens.org	Groner, Jonathan/E-3156-2011	Groner, Jonathan/0000-0002-0998-593X			Ashwal S, 2010, DEV NEUROSCI-BASEL, V32, P343, DOI 10.1159/000316801; Barr RG, 2012, P NATL ACAD SCI USA, V109, P17294, DOI 10.1073/pnas.1121267109; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Carroll Christopher P, 2010, Ann Adv Automot Med, V54, P233; Cuff S, 2007, J TRAUMA, V63, P172, DOI 10.1097/TA.0b013e31805c14b1; Finnie JW, 2012, J CLIN NEUROSCI, V19, P1159, DOI 10.1016/j.jocn.2011.12.019; Finnie JW, 2010, J CLIN NEUROSCI, V17, P237, DOI 10.1016/j.jocn.2009.07.001; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Leventhal JM, 2012, PEDIATRICS, V130, P847, DOI 10.1542/peds.2012-0922; Leventhal JM, 2012, PEDIATRICS, V129, P458, DOI 10.1542/peds.2011-1277; Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449	13	28	30	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2013	75	1					157	160		10.1097/TA.0b013e3182984acb			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	300EV	WOS:000330448100039	23940862				2022-02-06	
